<SEC-DOCUMENT>0001628280-21-003370.txt : 20210226
<SEC-HEADER>0001628280-21-003370.hdr.sgml : 20210226
<ACCEPTANCE-DATETIME>20210226085724
ACCESSION NUMBER:		0001628280-21-003370
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		111
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210226
DATE AS OF CHANGE:		20210226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mersana Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001442836
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38129
		FILM NUMBER:		21684017

	BUSINESS ADDRESS:	
		STREET 1:		840 MEMORIAL DRIVE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-498-0020

	MAIL ADDRESS:	
		STREET 1:		840 MEMORIAL DRIVE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MERSANA THERAPEUTICS INC
		DATE OF NAME CHANGE:	20080813
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mrsn-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:2da7fb72-9c95-4f34-a8ba-21eaa0b59775,g:bc62363b-ba21-41ff-8e10-87a9df40b55e,d:7157c5eacfe941de9505feeee920791e--><html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:mrsn="http://www.mersana.com/20201231" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrsn-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV80L2ZyYWc6ODc3ZDA5ZGJmYTQwNDI1ZmFkMDI1ZDc5MTE0ZDkyYTQvdGFibGU6M2ExNjYxM2Q4NWJkNGJhNGJkYzg3MTU4NGNlMTdhYzkvdGFibGVyYW5nZTozYTE2NjEzZDg1YmQ0YmE0YmRjODcxNTg0Y2UxN2FjOV8xNi0xLTEtMS0w_e9b44339-ada2-4935-859e-7a49ace95b6b">0001442836</ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV80L2ZyYWc6ODc3ZDA5ZGJmYTQwNDI1ZmFkMDI1ZDc5MTE0ZDkyYTQvdGFibGU6M2ExNjYxM2Q4NWJkNGJhNGJkYzg3MTU4NGNlMTdhYzkvdGFibGVyYW5nZTozYTE2NjEzZDg1YmQ0YmE0YmRjODcxNTg0Y2UxN2FjOV8xOC0xLTEtMS0w_59bff244-88c2-4891-969e-78510115dae5">2020</ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV80L2ZyYWc6ODc3ZDA5ZGJmYTQwNDI1ZmFkMDI1ZDc5MTE0ZDkyYTQvdGFibGU6M2ExNjYxM2Q4NWJkNGJhNGJkYzg3MTU4NGNlMTdhYzkvdGFibGVyYW5nZTozYTE2NjEzZDg1YmQ0YmE0YmRjODcxNTg0Y2UxN2FjOV8xOS0xLTEtMS0w_14382aa7-b874-44bb-90e6-5c7c945cdf14">FY</ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV80L2ZyYWc6ODc3ZDA5ZGJmYTQwNDI1ZmFkMDI1ZDc5MTE0ZDkyYTQvdGFibGU6M2ExNjYxM2Q4NWJkNGJhNGJkYzg3MTU4NGNlMTdhYzkvdGFibGVyYW5nZTozYTE2NjEzZDg1YmQ0YmE0YmRjODcxNTg0Y2UxN2FjOV8yMC0xLTEtMS0w_c9c23db8-a1ee-41b3-86b1-cb071664044d">false</ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xODk2L2ZyYWc6MDA1OGM3ZTBhOWQzNGNkZjk2MjE0M2ViMmM3Y2VkNjIvdGFibGU6NTRhNzg2MmU4NGYwNDJkYmFmMDNkYjkwMzcyNzZkNjQvdGFibGVyYW5nZTo1NGE3ODYyZTg0ZjA0MmRiYWYwM2RiOTAzNzI3NmQ2NF8yLTEtMS0xLTk2MzU_ca5868e3-45f4-4c03-b737-afa8296e37ae">mrsn:CollaborationMember</ix:nonNumeric><ix:nonNumeric contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xODk2L2ZyYWc6MDA1OGM3ZTBhOWQzNGNkZjk2MjE0M2ViMmM3Y2VkNjIvdGFibGU6NTRhNzg2MmU4NGYwNDJkYmFmMDNkYjkwMzcyNzZkNjQvdGFibGVyYW5nZTo1NGE3ODYyZTg0ZjA0MmRiYWYwM2RiOTAzNzI3NmQ2NF8yLTMtMS0xLTk2Mzc_e5d579e2-e0e3-4c3f-967d-42e52fdb1f5f">mrsn:CollaborationMember</ix:nonNumeric><ix:nonNumeric contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xODk2L2ZyYWc6MDA1OGM3ZTBhOWQzNGNkZjk2MjE0M2ViMmM3Y2VkNjIvdGFibGU6NTRhNzg2MmU4NGYwNDJkYmFmMDNkYjkwMzcyNzZkNjQvdGFibGVyYW5nZTo1NGE3ODYyZTg0ZjA0MmRiYWYwM2RiOTAzNzI3NmQ2NF8yLTUtMS0xLTk2Mzk_c90a21b1-f9fa-4812-916c-265bb8f37742">mrsn:CollaborationMember</ix:nonNumeric><ix:nonNumeric contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMy0wLTEtMS0xMjY3_a627f6f4-0dcd-4d57-a53d-d933bbc3fbaf">us-gaap:AccountingStandardsUpdate201409Member</ix:nonNumeric><ix:nonNumeric contextRef="i83018382077d46b8aefa5023352430ad_I20200101" format="ixt:booleantrue" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDYvZnJhZzphZjI4YmIxYjIwMjQ0MzJhOTIwYTBiYThjZmYwMzAwNy90YWJsZTpiZDllMmFmM2YxYjM0N2M2OWU2Y2QxNjZkZWU4ZGQxYi90YWJsZXJhbmdlOmJkOWUyYWYzZjFiMzQ3YzY5ZTZjZDE2NmRlZThkZDFiXzQtNC0xLTEtMA_90bd2b64-add4-4097-9685-ce4e5321468f">TRUE</ix:nonNumeric><ix:nonNumeric contextRef="i4df390ba859c457b82608a3b20950c08_I20200101" format="ixt:booleantrue" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDYvZnJhZzphZjI4YmIxYjIwMjQ0MzJhOTIwYTBiYThjZmYwMzAwNy90YWJsZTpiZDllMmFmM2YxYjM0N2M2OWU2Y2QxNjZkZWU4ZGQxYi90YWJsZXJhbmdlOmJkOWUyYWYzZjFiMzQ3YzY5ZTZjZDE2NmRlZThkZDFiXzUtNC0xLTEtNzQxMQ_e56fd037-5fed-45d1-b499-0ffb0ca66f72">TRUE</ix:nonNumeric><ix:nonNumeric contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMC0xLTEtMTkwMQ_def9574d-e21a-4369-9aec-5ccd94c4b5a5">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTAtMS0xLTE5MDM_e1131034-fc7f-40a3-8087-977f8547a400">us-gaap:OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i90755edba69e44b6969f908dafac0389_D20200101-20201231" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDgvZnJhZzo0NjRhZjJhZDIzYmM0MDA5ODFjNDdkZjMwMTZiYTYwZC90YWJsZTpjMGQxYjMxMjhiMGU0NDY3OTJiYWFlMGExM2MyNjc3Mi90YWJsZXJhbmdlOmMwZDFiMzEyOGIwZTQ0Njc5MmJhYWUwYTEzYzI2NzcyXzYtMS0xLTEtMA_65334f8c-b5a9-405a-a46b-71559cc2c13d">TRUE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrsn-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia8f204faa7704411a0850b074d255000_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="idc81d87920df4d46804f62d14d1675af_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i93de83dcf0d640bda59d5ec464074a69_I20210223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02a979a8932342d78dec04dc805709b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7a39af3ac91431f9135e7905754c66c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec68d7798d0041aaa3817b210b456dc3_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd854fec4ed47cb8bffad52078aa3ea_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bdd4a73857d40c8a50ac539b3fe1443_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d2fd67c849e42de89b7f83df7efdddd_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4dd90b55c3d4405a31378f2cf6c85a5_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1666e43922144352b571dcc6dc54780c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6957e6107783414c86d7d038c4de0d0d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie629a06a7eb44ce7b948b0a2eac6c15a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb028a17d03043db910b31d93f01ebd6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdd4c70c35274a40bc12395e93b9c793_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248321357d504cd6b2392e62a156b394_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i646b21abf1f34c91ad1c6c0474853466_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b30519d48b44dce8f3ebc341927841e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90519fa5579c4a0a830381b5fb35398f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id85be7739be4471886b92107ad654c16_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7763b300d146495ba1f6d378fcf527d4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i820a1679d0844c67ad4f922202689e57_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4018a4aefc7144ef90a07daed7e35438_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d51cce334c24c3384bbf0988c25c72b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i568856ae452c43d9a8f78d6db3cd490b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaf2a7f80adb41dba4f4492c90a549b8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c5ee7c8c32f480aaa50a43deb934371_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f1bc12c003c4e57a5f7a90f50d8d476_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4f7e8965da448198116af6c110f7faf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524d5f48af734daa921b6b627766b439_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6fd43849d3e4363a46139030c95a116_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8130fe63e6246718c8b705ebba7e9b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ee2fd134e6b4b6abbb327c32e4f4ded_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e5bfe19343142b3906779afeba94ec7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5d693db8b41458bb34eba574b8b961b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a6d0e47a36447d293b93e7ae49266ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b597f23a2c4b7ebe27542604c170b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c6e587f4aa4d3a87ad5a5bd3f7ef47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a63ce8628a6420f8f56fbf95c67ba5c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c8a68e376b84047b4655bd24fe4098b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d033197c1ce4359a4e3f0b33dee0964_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad9d949fa3384c24aed7832550cba9f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b785dd5a254889b46e8f92526bbb8a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic822eefabb4d4deb9631ece7d64d45df_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7587cbccc6c4451e9d3b098bfd5bc320_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e03a06a83b45da881a991b3fa64a37_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35ae40d344cb48109420ed8b520d73e7_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20d32d9d39084d6a842551c406380048_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i32e7573ef8fe419aa60a3e7c2573e532_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6249b32c3a3472199c99217268325e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4bce75e9484c55ab4f169eabc82fde_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc5954c2df24836829d0bdf041a7dc2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf326ed84a184b69aac5f187571380da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc059b98c5e4406eb2f908459f254117_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4e7d49b91dd454c97384848857e7904_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbf381469b4d49adacff9769db1f0076_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef7477d01eb42fa93cb54ff9d6cbd4f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9972585559044d9bb7fe57fd33d4126d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ca1a08f33fc491daa2aa0165f719267_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:ComputerEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67f598299c7a417cbd523207c78e819a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff1a309483c5420db7794218d82c68a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83018382077d46b8aefa5023352430ad_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4df390ba859c457b82608a3b20950c08_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic742200b058d41098d52ab5f0e3428b8_D20140601-20140630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-06-01</xbrli:startDate><xbrli:endDate>2014-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>mrsn:target</xbrli:measure></xbrli:unit><xbrli:context id="if4257918738749a69d4891f5d50d9d76_I20140630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a9c0faaca2d45558f08d2d44e3bcb4f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>mrsn:milestone</xbrli:measure></xbrli:unit><xbrli:context id="iff84fe17ddac4d30aa64382852adc5e5_D20150101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5291b03335245c7aa553dda74e5ae19_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc3fca032b454351a178597d5f40733b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i907e240893884fc3b84988f45bb0e42c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib969f2c036c54b3aa4e16d5cd4467eca_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fa45b03b28a4c988f4645fd9a126190_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbdaeaae5ace468d9fc696fd63746c47_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f3c590e11e5409186c16c2b7663f9fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c28bca56c544eb188d401c14dce4279_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c254ebe9d141308dc815c9e53ae58d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a0a25cb274a4de5addf0a574c9ee5aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87ac3e6acdfe4d5297fd46e985220155_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:RightsToFutureTechnologicalImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf1def552aea421892138747772fc31f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:JointResearchCommitteeServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb6492dc61484f73b5b8d09644054672_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:RightsToFutureTechnologicalImprovementsMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4931e025e0654175a346486558f333d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:JointResearchCommitteeServicesMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaed771792aa4f45820e1bdf461f9acc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e9a106d068b45588dee4fc2c9191449_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:SupplyAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b8df85e3b534d9680740bcea14c3648_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:SupplyAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99dca4a69ab24c5a872dd3a7062b04b4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:SupplyAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad77cfaea7c4367aa41179d395dd1fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c929a4e2c64380af7083035353ca9b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cfc255c5b5348df8b706ecee6e18fc5_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i753b8ff92fff46fea6569a01931d0c30_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26c601317048494e845d1196c42e27fb_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50edd11bfb47457a9112b1ae5cb86665_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>mrsn:agreement</xbrli:measure></xbrli:unit><xbrli:context id="icbf321584c2242ad97228b78ab55de05_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i084338c0a80d483dad529458b1964134_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f7873d325a04701833b6ce4c01cf715_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff6fad6dff742daae99d7c13a13b3a3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68908ae9c5064baa964d04f85fc17eaa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dd109ee0cb84c998131f728a303e54f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23577b731ce742d9a2dc95f75f3ed39e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LimitedServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9427fc34fbbb4872be93f51ea1a98758_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LimitedServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf844a9201846c6b8d71ce0fc4564a6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LimitedServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2c25c7d679e4207b7260e4df1988cd6_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:ServiceMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f85c6dbea4e41f68ef9f77064c9488c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c0a8934a1c6426dbdc36c02ecbace70_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c164faee42044c6bd0efd3f8e822986_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1ad11b4ad384e07aadaac9fb23dd498_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if421bb6d4ade4aa7875850e2e9e7ce5e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8269462beefc49e0bf40ee05af372ef6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32fd9e9a94794fe3a2242b4ca9bc78d0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6341208859442f9b6ef8af77034d83d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i352d06ba5fb848548eb58f8027ff894b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fc9df98ef2d477ba1138bc3dd081e76_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia12bcd4d127345a18bc09a7631d0e9ae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c176c12317e495abdb2f03744b1bffa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32e2e3e778ca460194f0dffe0a2edf27_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbc4ff85c1d24045ab6977cd50a5b2e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic52340d210a24378ae895de1817cdca3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id50ec1eca088483b9329538c98b03e04_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f480eeb670e4a4e820469036816203f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>mrsn:security</xbrli:measure></xbrli:unit><xbrli:context id="if61098ade0e347d582c1a9c5ca600ca2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09af4016cf924f80913d431c2607ec67_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3e5c95050104eaa8d8078a5e789e74b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47ab6eccf1b6445f80bc756361d8cff7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id53d0e5e5e574f9ea3bfac8d17355c76_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fc584d33c9d43799da46631af3ada8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0a28d50b8e94ad8a3d5ce0e83bf2a8c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i856895a9ae3d498cbd7a6e7e6aea88cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:ComputerEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd1dfdef8c0c4efbb4a9ef235c35a801_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:ComputerEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0af0080ba1dc4a0cb75af59f74d83190_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentLeasedAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7699dd1563a4628924b1afe47e1a4dd_D20190508-20190508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-08</xbrli:startDate><xbrli:endDate>2019-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i631efc7ffeaf4f04ac0f4957eaba56a9_I20190508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i163836ee7b6f4ffa9c0cb574b727c47f_D20190508-20190508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-08</xbrli:startDate><xbrli:endDate>2019-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc12f9880564eaaaf5cd6c44d035584_I20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90749e47b83a4ed7a4168ba3c7be4fbc_I20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie14bf80516a946eab284cdc6fa94ee65_I20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e2dcf3cdc3748e483ed1c6403bb6a16_I20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityTrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec2d0197c15d41c8a6bdc407bc838c19_I20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfaa9f81105a42f396f57538ca9bca0e_I20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6d2f0012515488e88c88d4beea20fbd_I20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityTrancheSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa8dbb46bbe744e985b2e0216ba5ac51_I20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b7d7299ce1c41e0b7319ee9be889c78_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i078da7f737c349af8b0fe34900888817_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21f9feecd548415ea57bfadff8075528_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mrsn:DebtCovenantPeriodAxis">mrsn:PrepaymentOccursPriorToAugust282021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d95ffd29d8a42f09d5833c466360f5c_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="mrsn:DebtCovenantPeriodAxis">mrsn:PrepaymentOccursBetweenAugust282021AndAugust282022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c584ca6ee79452785e1ad58cd890611_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mrsn:DebtCovenantPeriodAxis">mrsn:PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b8290917b104724b022253cb68344a8_I20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab9b2892056c4107bc99217b78b467ca_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia64de5de74d14ba6a2d99ac7e5b576e6_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram559PerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12e103ce06ac4a6899e2b020312d0789_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram774PerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if180f69d9ce245cf99704eb7f6351a59_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram559PerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41a996208e274d7a8e321ab0940d2cd2_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram774PerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13f8a6424f0a4cf9be7614ce49041c63_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i308407f9760646139e65cbbff6cda013_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia651b5389b414e8d9e7497b27b28db57_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06524015ee73497b86e333130cd09189_D20130101-20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id811a98ebc9446e780342c9c938b83b6_I20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2013-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i317cfb0a66ce420aba39052cc61dd3f7_D20191126-20191126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-26</xbrli:startDate><xbrli:endDate>2019-11-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i455788b289d34014a736e72b5a36e693_I20191126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87d8789f035d4fd5a4df293bbf1c1d7e_D20200302-20200302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-02</xbrli:startDate><xbrli:endDate>2020-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>mrsn:vote</xbrli:measure></xbrli:unit><xbrli:context id="ib6469fe4541e48b89a7a078c0ed5ffcf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:WarrantsAndShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i535686c256b94372ae4ce5f38fcb0825_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:WarrantsAndShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5e733a950fa45a997c912a1f02d01a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i140f6ca2a4144d20a6d857ac59d04d54_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie75edfebdd6e45ba9f9bfbf6f784bf06_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if65e9cab919646faac147bc5c615a4ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i303a7a474d1f41a5a7a7433b5d46bcc1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i659d9c80d2bc46cdb8692d3fccee5dd2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecb87f2b399c4ebca9aa9663b640aed4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5864a7879b4087ac73cb3bfcccd0e8_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61566b4dae604295b9e10906b8b19b74_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9335c4c8a544f7784ac7050e6f8525a_D20170601-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc230768a013428dbfb0b0e0a1cf01d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20cea58d91fe4a02bb07ac2b8a1f0791_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90de0efc2a4f4539a8da0eb8a4f579dd_D20200902-20200902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-02</xbrli:startDate><xbrli:endDate>2020-09-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c52f697f3447aca0d47be353863ce4_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aec4bf8702f430b91a2277849a9a314_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie39e122b84984208a83a60f26cebb72b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:InducementAwardProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d84e8019e7f46ad999a65d511d99d20_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23c524872861491cbbc5e13e4cf5d051_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id980ee2ed8d34feca1762482a2e75df0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i920acb3427774292827daa9726c45873_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15699193709b4c5198a5f460762ea356_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b2ee45dc2784fc396ead6a8bfd4ecb5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f6ea660b40844fe84f66bd5e5fe9ea5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79fb9930f6094104a456730528f5bc99_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f4688b8c44640b09f240cd0e1c92161_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad5bc870fab4400884a565359cfdf9a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fd03e26fc404cd7886d527bbebe9cee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25c2d7125bea4d40a3c4bd88341d03b4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ebb056de9f546e0a119ca21f8308e0c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e58426df2940999d78200d99d5eba5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf67d48970814a13815d8dec946856d1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95fd51f717da4b488c652bf7d8674730_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5593e7a34742298584e0cea80c0c50_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f6b9959fd5242cba1fd04a96cea57d3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e12adb838364036838eba86fa043b68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f8aac06008a4724ae9284b7cc253a25_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05268d4f6e994edd8ddff9186d1b7540_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7df3a8881d504e549decddca8cac8c76_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3d5650f067549778be0f063470fcbca_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6686ed562d224356b9709fed401426e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:OfficeSpaceCambridgeMaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib85365aea4d54cff875208fefeee96ef_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90755edba69e44b6969f908dafac0389_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:OfficeSpaceCambridgeMaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic059f7a3532745518966900be47d1c47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82697de2ab144693bec9626ce8bdb92c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1a16dd07ee341a0b4a2267c3b6bd737_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibacf6c67e9b24271b096b036df23e4a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jurisdiction"><xbrli:measure>mrsn:jurisdiction</xbrli:measure></xbrli:unit><xbrli:unit id="audit"><xbrli:measure>mrsn:audit</xbrli:measure></xbrli:unit><xbrli:context id="i2f999c2f67b946f6a6d1493212350a0f_D20190101-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6132787d773e482cbb6d82895b63d717_D20190801-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4114a3ad19d943caa2f08b5649e9e275_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementUpfrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a071cec119846ab9055589216a2b776_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementUpfrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1094fe6fc0a54ffaa7e6425e002d5fd9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementUpfrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i480e629817294830afafe0f1a51084b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4abde9e6537849859c77bdc8d4176754_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65bb47754a65456c89056c19e9b6a48d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7157c5eacfe941de9505feeee920791e_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDU2_68c3ae68-d884-4b3d-a26d-e81dd7276257">10-K</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDUx_b0ff835e-bac6-4a86-89db-bd6e33f3b01b">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8yMTk5MDIzMjU4NjU2_03f4c5fc-9ca3-464a-b6ac-9a6c57a77630"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8yMTk5MDIzMjU4NjU2_211c405e-44eb-496b-a4e9-156738d665d1">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric>.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDU5_a0c7206f-5818-4606-ad73-2069fca99b6d">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDY0_71ebdf02-c5c1-418e-b550-e9b2d2cfca14">001-38129</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDUz_9c6573b1-855e-4564-8d84-190ef0ed6906">Mersana Therapeutics, Inc.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6NjU4ZmExMzg3NDJmNDEzY2EzNDNjZWIyOGVjN2Y0MjIvdGFibGVyYW5nZTo2NThmYTEzODc0MmY0MTNjYTM0M2NlYjI4ZWM3ZjQyMl8wLTAtMS0xLTA_45d3379c-764d-4c7a-b90e-728272b0e185">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6NjU4ZmExMzg3NDJmNDEzY2EzNDNjZWIyOGVjN2Y0MjIvdGFibGVyYW5nZTo2NThmYTEzODc0MmY0MTNjYTM0M2NlYjI4ZWM3ZjQyMl8wLTItMS0xLTA_45f11b38-783e-49cc-a411-0045dbb717d5">04-3562403</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6NjU4ZmExMzg3NDJmNDEzY2EzNDNjZWIyOGVjN2Y0MjIvdGFibGVyYW5nZTo2NThmYTEzODc0MmY0MTNjYTM0M2NlYjI4ZWM3ZjQyMl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YjAwZDVlYWQ4MmQ0ZDAzOWUwYWQyMTg3MDAyMjhhNF80_afecccd3-db04-4352-b61a-911e8c996a2a">840 Memorial Drive</ix:nonNumeric> <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6NjU4ZmExMzg3NDJmNDEzY2EzNDNjZWIyOGVjN2Y0MjIvdGFibGVyYW5nZTo2NThmYTEzODc0MmY0MTNjYTM0M2NlYjI4ZWM3ZjQyMl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YjAwZDVlYWQ4MmQ0ZDAzOWUwYWQyMTg3MDAyMjhhNF83_02e7df54-0b82-4e03-8ad7-70663219aa93">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6NjU4ZmExMzg3NDJmNDEzY2EzNDNjZWIyOGVjN2Y0MjIvdGFibGVyYW5nZTo2NThmYTEzODc0MmY0MTNjYTM0M2NlYjI4ZWM3ZjQyMl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YjAwZDVlYWQ4MmQ0ZDAzOWUwYWQyMTg3MDAyMjhhNF8xMQ_298f3447-d63c-4c29-92ab-9d436b0fce3b">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6NjU4ZmExMzg3NDJmNDEzY2EzNDNjZWIyOGVjN2Y0MjIvdGFibGVyYW5nZTo2NThmYTEzODc0MmY0MTNjYTM0M2NlYjI4ZWM3ZjQyMl8zLTItMS0xLTA_505508f5-a699-4ef7-9dd0-6595f7de55bc">02139</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDQ5_aa2c4800-9374-4c85-86c6-9dc0abd74ee7">617</ix:nonNumeric>) <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDU0_37267912-9644-4d2f-9a95-2d19ce7e740c">498-0020</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6YmVhNWMzNTJlMDQwNDI0ODhjYjUyN2I1NmYxNmFiMTAvdGFibGVyYW5nZTpiZWE1YzM1MmUwNDA0MjQ4OGNiNTI3YjU2ZjE2YWIxMF8xLTAtMS0xLTA_3f9c8d26-9eae-4d42-9dfc-f9fc21cf054d">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6YmVhNWMzNTJlMDQwNDI0ODhjYjUyN2I1NmYxNmFiMTAvdGFibGVyYW5nZTpiZWE1YzM1MmUwNDA0MjQ4OGNiNTI3YjU2ZjE2YWIxMF8xLTEtMS0xLTA_42cfe384-6134-4c7a-a5f8-4a304161737f">MRSN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6YmVhNWMzNTJlMDQwNDI0ODhjYjUyN2I1NmYxNmFiMTAvdGFibGVyYW5nZTpiZWE1YzM1MmUwNDA0MjQ4OGNiNTI3YjU2ZjE2YWIxMF8xLTItMS0xLTA_f42947cc-d22d-444e-bd72-ace4e8a4f6dc">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NONE</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8yNzQ4Nzc5MDc0MDQy_b0aeb2ba-2133-4bbb-8884-6053f6f1bf3b">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDY1_68059b1d-a573-4167-a085-ab7418a73ae5">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDUw_83c78d7c-fc1c-4881-a4dd-55f48e7bdcb1">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDYy_2e4b433f-5d9d-401c-aabb-97e9d6325a64">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6MzIxYjhiNWRkZjI5NGYwNzg3MzZmYWQzM2NkNzc3MzAvdGFibGVyYW5nZTozMjFiOGI1ZGRmMjk0ZjA3ODczNmZhZDMzY2Q3NzczMF8wLTAtMS0xLTEzNjE_84428ac2-0d1a-40df-9a23-587c0572c6bb">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6MzIxYjhiNWRkZjI5NGYwNzg3MzZmYWQzM2NkNzc3MzAvdGFibGVyYW5nZTozMjFiOGI1ZGRmMjk0ZjA3ODczNmZhZDMzY2Q3NzczMF8xLTMtMS0xLTA_a8231a52-922b-41b8-83a9-1ea04eace66f">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6MzIxYjhiNWRkZjI5NGYwNzg3MzZmYWQzM2NkNzc3MzAvdGFibGVyYW5nZTozMjFiOGI1ZGRmMjk0ZjA3ODczNmZhZDMzY2Q3NzczMF8yLTMtMS0xLTA_f590057b-1246-42c7-94b0-c1099310fa96">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8yNzQ4Nzc5MDczNjEw_6a391c1b-99a8-4760-81ab-32836162f42e">&#9746;</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined by Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDYx_ab54f76b-d890-48f8-a6c7-761544df9290">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of June 30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates was $<ix:nonFraction unitRef="usd" contextRef="idc81d87920df4d46804f62d14d1675af_I20200630" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8yNjQx_fd3013ed-b006-4a11-8803-cadc1f830fe0">1,147,647,431</ix:nonFraction>, based on the last reported sale price of such stock on the Nasdaq Global Select Market as of such date.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of February&#160;23, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="i93de83dcf0d640bda59d5ec464074a69_I20210223" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8yNzc4_5bfc73d1-6bec-4345-9790-ff3a98fb4c7f">69,042,942</ix:nonFraction> shares of common stock outstanding at a par value $0.0001 per share.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMjk4NTM0ODg2Mzk0_30249dae-6cc0-4cc6-9dc9-71b32729207b" escape="true">Portions of the registrant&#8217;s definitive proxy statement that will be filed for the 2021 Annual Meeting of Stockholders are incorporated by reference in Part III.</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_10">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_13">FORWARD LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_13">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_16">ITEM 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_16">BUSINESS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_19">ITEM 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_19">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_19">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_22">ITEM 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_22">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_22">62</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_25">ITEM 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_25">PROPERTIES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_25">62</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_28">ITEM 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_28">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_28">62</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_31">ITEM 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_31">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_31">62</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_34">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_37">ITEM 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_37">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_37">63</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_40">ITEM 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_40">SELECTED FINANCIAL DATA</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_40">64</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_43">ITEM 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_43">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_43">65</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_67">ITEM 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_67">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_67">77</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_70">ITEM 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_70">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_70">78</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_175">ITEM 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_175">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_175">109</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_178">ITEM 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_178">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_178">109</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_181">ITEM 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_181">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_181">111</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_184">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_187">ITEM 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_187">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_187">112</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_190">ITEM 11 </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_190">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_190">112</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_193">ITEM 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_193">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_193">112</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_196">ITEM 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_196">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_196">112</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_199">ITEM 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_199">PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_199">112</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_202">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_205">ITEM 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_205">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_205">113</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_208">ITEM 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_208">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_208">113</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_211">EXHIBIT INDEX</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_211">114</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_214">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_214">117</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="i7157c5eacfe941de9505feeee920791e_13"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. The words &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; "on track," &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements include, among other things, statements about:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, cost, timing, progress and results of our current and future research and development activities and preclinical and clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the adequacy of our inventory of upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592 to support our ongoing clinical studies, as well as the outcome of planned manufacturing runs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of, and our ability to obtain and maintain, regulatory approvals for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unmet need of ovarian cancer and non-small cell lung cancer;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to quickly and efficiently identify and develop additional product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to advance any product candidate into, and successfully complete, clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position, including with respect to our trade secrets;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits of strategic partnership agreements and our ability to enter into selective strategic partnerships;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenues, capital requirements, the sufficiency of our current and expected cash resources and our need for additional financing; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of the ongoing COVID-19 pandemic.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the &#8220;Risk factors&#8221; section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we expect that the COVID-19 pandemic might adversely affect our preclinical and clinical development efforts, business operations and financial results, the extent of the impact and the value of and market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, physical distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements contained herein represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS SUMMARY</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to varying degrees of risk and uncertainty. Investors should consider the risks and uncertainties summarized below, as well as the risks and uncertainties discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our business is subject to the following principal risks and uncertainties:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred net losses since our inception, we have no products approved for commercial sale and we anticipate that we will continue to incur substantial operating losses for the foreseeable future.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a credit facility that requires us to meet certain operating covenants and place restrictions on our operating and financial flexibility.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully than, we do.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We only have two product candidates, upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592, in clinical studies. A failure of any of our product candidates in clinical development would adversely affect our business and may require us to discontinue development of other product candidates based on the same technology.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We can provide no assurance that our clinical product candidates will obtain regulatory approval or that the results of clinical studies will be favorable.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug discovery and development is a complex, time-consuming and expensive process that is fraught with risk and a high rate of failure. We can provide no assurance of the successful and timely development of new ADC products.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our ADC product candidates, conduct our clinical studies and commercialize our ADC product candidates.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a pharmaceutical manufacturer, our activities, including our interactions with healthcare providers, third party payors, patients and government officials, are, and will continue to be, subject to extensive regulation involving health care, anti-corruption, data privacy and security and consumer protection laws. Failure to comply with applicable laws could result in substantial penalties, contractual damages, reputational harm, diminished revenues and curtailment or restructuring of our operations.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely upon patents and other intellectual property rights to protect our technology. We may be unable to protect our intellectual property rights, and we may be liable for infringing the intellectual property rights of others.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to risks arising from the outbreaks of disease, such as epidemics or pandemics, including the ongoing COVID-19 pandemic.</span></div><div id="i7157c5eacfe941de9505feeee920791e_16"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need. We have leveraged over 20&#160;years of industry learning in the ADC field to develop proprietary and differentiated technology platforms that enable us to design ADCs that have improved efficacy, safety and tolerability relative to existing ADC therapies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative platforms, which include Dolaflexin and Dolasynthen, delivering our DolaLock payload, as well as Immunosynthen, delivering a novel stimulator of interferon genes, or STING, agonist, compose a highly efficient product engine that has enabled a robust discovery pipeline for us and our partners. Our ADCs in preclinical and clinical studies include </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first-in-class molecules that target multiple tumor types with high unmet medical need and have exhibited improved safety and efficacy compared to ADCs developed using first-generation technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a management team with extensive and relevant experience, including specific ADC experience, from prior work at leading pharmaceutical companies such as Millennium Pharmaceuticals, Inc., Takeda Pharmaceuticals, Biogen, Inc., Bayer AG, Tesaro, Inc., Vertex Pharmaceuticals Inc., Cubist Pharmaceuticals Inc. and Bristol Myers Squibb. We are supported by our board of directors and scientific advisory board, who offer complementary experience in drug discovery and development, as well as expertise in building public companies, management and business development. We believe that our highly differentiated platforms, together with the team we have assembled, position us well to discover and develop life-changing antibody-drug conjugates for patients fighting cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to become a leading oncology company by leveraging the potential of our innovative and differentiated ADC technologies and the experience and competencies of our management team to discover and develop promising ADC product candidates and to commercialize cancer therapeutics that address unmet medical needs or provide significant benefit to patients. Key components of our strategy to achieve this goal are as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Rapidly advance upifitamab rilsodotin (UpRi, XMT-1536).&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our lead product candidate, UpRi, is a first-in-class Dolaflexin ADC currently in a Phase 1 proof-of-concept clinical trial in patients with tumors likely to express NaPi2b, an antigen broadly expressed in ovarian cancer and non-small cell lung cancer, or NSCLC, adenocarcinoma. We expect to initiate a single-arm registration strategy in platinum-resistant ovarian cancer, UPLIFT, and a combination dose escalation study, UPGRADE, in earlier lines of platinum-resistant ovarian cancer in 2021. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Rapidly advance XMT-1592 through dose escalation.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Mersana&#8217;s second product candidate targeting NaPi2b-expressing tumors, XMT-1592, is an ADC created using our Dolasynthen platform. In the first half of 2020, we initiated a Phase 1 dose escalation study of XMT-1592 in ovarian cancer and NSCLC adenocarcinoma. We believe that we have a path to advance XMT-1592 through rapid dose escalation and clinical validation.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expand our ADC pipeline.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We intend to establish a leading position in the field of ADCs by continuing to advance platform innovations that further broaden the potential of our ADCs to deliver clinically meaningful benefit for cancer patients, by focusing on first-in-class targets and payloads, and by pursuing fast-to-market opportunities. We are advancing a new, potentially first-in-class ADC targeting B7-H4, XMT-1660, which leverages our Dolasynthen platform in IND-enabling studies. We have taken ADCs beyond cytotoxics by developing the Immunosynthen platform, an approach that may allow tumor-targeted activation of the innate immune system. Our first Immunosynthen STING-agonist ADC development candidate, XMT-2056, is in IND-enabling studies.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Attract and retain talented and experienced people.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;In addition to our team&#8217;s deep experience with ADC science, drug development and operational management, we believe that our accomplishments are a testament to the talent and commitment of our people. Our team is driven by a shared passion to advance therapies that make a significant difference in the lives of cancer patients. We will continue to cultivate the collaborative and passionate workplace culture that has allowed us to advance this mission.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Build strategic partnerships to maximize the value of our programs and platforms.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our platform technologies, and product discovery and development capabilities, drive the potential for multiple clinically meaningful opportunities for cancer patients. In order to preserve a disciplined drug development and commercialization focus, we may choose to enter into strategic partnerships that facilitate our ability to bring differentiated product candidates to more patients. Our current partnerships with Merck KGaA and Asana Biosciences exemplify different aspects of this strategy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pipeline is summarized in the chart below:</span></div><div style="margin-top:12pt;text-align:center"><img src="mrsn-20201231_g1.jpg" alt="mrsn-20201231_g1.jpg" style="height:261px;margin-bottom:5pt;vertical-align:text-bottom;width:550px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Background</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Traditional ADCs are a class of cancer biotherapeutics that combine the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drug payloads. Antibodies and payloads are chemically linked, allowing specific drug delivery to cancer cells targeted by the antibody. After ADCs enter a cell, the conjugated payload is released and kills the cell. Despite the promise of ADCs, companies in the field have faced certain challenges in developing product candidates that achieve the optimal therapeutic index, or the balance between efficacy and tolerability. These challenges are characterized as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Linker stability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Linkers must be stable in the bloodstream to ensure that free payload is not released into circulation prior to delivery into the tumor. Free payload in circulation causes toxicity. Efforts to design better linkers to increase stability have, in turn, reduced the efficiency of payload release once the ADC is internalized in the tumor cell, resulting in decreased efficacy.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Drug-to-antibody ratio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Increasing the number of payload molecules delivered per antibody internalization event increases potency. However, the drug-to-antibody ratio, or DAR, has typically been limited to three to four payload molecules per antibody due to aggregation, poor pharmacokinetics and loss of drug-like properties of the ADC at levels above this threshold. Other attempts to increase efficacy have involved the introduction of ultra-potent payloads, however these efforts appear to face safety and tolerability challenges, necessitating even further reduced DAR to maintain acceptable pharmacokinetics and drug-like properties.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Target antigen expression level</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Tumor cells typically require a threshold number of payload molecules to be internalized in order to kill the cell. Antigens with lower levels of expression have proven less desirable as targets for ADCs, as a result of fewer binding, internalization and payload delivery events to drive cell-killing activity. In turn, this has limited the number of cancers amenable to treatment with low-DAR ADC approaches, as the use of ADCs requires antigen targets to be highly expressed on tumor cells.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bystander effect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160; Once ADCs release their cytotoxic payload into targeted cells, the drug is often able to cross cell membranes, entering and potentially killing neighboring cells whether those cells are cancerous or not. This is known as the &#8216;bystander effect,&#8217; which is advantageous when bystander cells are cancerous, but toxic if the cytotoxic drug is able to enter adjacent healthy cells, leading to dose-limiting toxicities such as neutropenia, peripheral neuropathy, or ocular toxicity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Technologies and Platforms</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of ADCs is not a one-size-fits-all approach. In fact, a number of diverse factors impact the properties of an ADC, including payload, drug-to-antibody ratio, site of conjugation and homogeneity. For each target antigen, there is an optimal combination of these factors. Our novel and highly differentiated platforms are designed to allow us to optimize these properties for a given target and develop ADCs that best address patient needs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DolaLock Payload</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DolaLock payload is a proprietary auristatin cytotoxic drug and is a highly potent anti-tubulin agent selectively toxic to rapidly dividing cells. The DolaLock payload has been shown in preclinical studies to control the bystander effect by locking the cytotoxic drug inside cells after allowing a short period of diffusion throughout the tumor. As the drug diffuses through neighboring tissue, the DolaLock payload is metabolized to a form that is still highly potent but is no longer able to cross the cell membrane, effectively locking the drug inside cells and controlling the bystander effect for a safer and more effective cancer therapy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A common mechanism of resistance in cancer is the up-regulation of multi-drug resistance, or MDR, pumps, such as P-glycoproteins, or PgPs, which actively pump drugs out of cancer cells to help them survive. Once metabolized, our DolaLock payload cannot be pumped out by PgPs, thereby avoiding this resistance mechanism. In addition, our proprietary auristatin payload has also been shown in preclinical studies to cause immunogenic cell death and to stimulate the immune system through dendritic cell activation. Because of this, synergy with immuno-oncology agents such as PD-1 inhibitors has been observed in preclinical models. Our DolaLock payload with controlled bystander effect is designed to allow us to create ADCs that produce a highly potent, well-tolerated and specifically-targeted cancer therapy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 1. DolaLock Payload with Controlled Bystander Effect</span></div><div style="margin-top:12pt;text-align:center"><img src="mrsn-20201231_g2.jpg" alt="mrsn-20201231_g2.jpg" style="height:149px;margin-bottom:5pt;vertical-align:text-bottom;width:592px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dolaflexin Platform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Dolaflexin platform was designed to increase the efficacy, safety and tolerability of ADCs. Dolaflexin utilizes our proprietary Fleximer polymer, a biodegradable, highly biocompatible, water-soluble polymer able to carry multiple drug molecules. Instead of direct conjugation to an antibody, drug molecules are attached through an optimized, cleavable linker to the Fleximer scaffold, which is then conjugated to the antibody through a non-cleavable linker. Fleximer has demonstrated dramatically improved drug solubility, pharmacokinetics and immunogenicity, and an increased number of drug molecules carried by each ADC compared with traditional ADC therapies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we believe Dolaflexin has the potential to offer the following benefits relative to traditional ADCs:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Proprietary DolaLock Payload:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dolaflexin is loaded with our proprietary auristatin chemotherapeutic drug, which is a highly potent anti-tubulin agent selectively toxic to rapidly dividing cells, with the advantages of the DolaLock controlled bystander effect.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Higher Drug-to-Antibody Ratio:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Historically, ADCs have been limited to a DAR of 3-4. The Dolaflexin platform can deliver ADCs with DAR of about 10, allowing for greater efficacy while also maintaining pharmacokinetics and drug-like properties.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expanded Range of Addressable Tumor Targets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The higher DAR enabled by Dolaflexin results in more chemotherapeutic drug released into the tumor cell for every ADC internalized. As a result, Dolaflexin ADCs can have efficacy against tumor targets with lower levels of antigen expression where traditional ADCs have not been effective.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these advantageous characteristics of our Dolaflexin platform provide a substantial opportunity to develop clinically meaningful ADC therapies with potential to address a broader range of cancers than traditional ADC-based approaches. Our lead clinical candidate, UpRi, is a Dolaflexin ADC that targets NaPi2b. UpRi is currently in a proof-of-concept study in patients with ovarian cancer and NSCLC adenocarcinoma.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dolasynthen Platform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Dolasynthen platform enables an iterative approach to develop the right ADC for a given indication through customization and optimization. Dolasynthen utilizes a synthetic scaffold for precise control of DAR, from 2-24, and site-specific antibody bioconjugation. The platform is also able to homogeneously generate ADCs with precisely defined DARs for consistent drug delivery to cancer cells. The Dolasynthen scaffold has been precisely designed to provide optimal water solubility, charge balance, linker stability and DAR. We believe that Dolasynthen retains the favorable properties of Dolaflexin, including our proprietary DolaLock technology for a controlled bystander effect, with superior physicochemical and pharmacokinetic properties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Illustrated by our preclinical data, optimized Dolasynthen ADCs exhibit a broad therapeutic index as a cancer therapy. These data demonstrate the ability of the Dolasynthen platform to generate and identify the optimal ADC for a given target and antibody.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Dolasynthen offers the benefits of Dolaflexin, including the proprietary DolaLock payload, and has the potential to offer the following benefits relative to traditional ADCs:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Precise Control of DAR:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The optimal DAR may vary between different targets and antigens. Dolasynthen allows for precise DARs between 2-24, enabling optimization of the DAR for specific antigens and antibodies.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Site-Specific Bioconjugation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The site of scaffold bioconjugation to an antibody impacts the overall properties of that ADC. Dolasynthen enables site-specific bioconjugation allowing further ADC optimization.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Homogenous ADC Development:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The DAR and antibody bioconjugation is consistent throughout ADCs developed with the Dolasynthen platform allowing for consistent and precise drug delivery to targeted cancer cells.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Increased Hydrophilicity:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The precise optimization of the hydrophilic moiety on Dolasynthen ADCs allows for increased aqueous solubility and enhanced pharmacokinetic properties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second clinical candidate, XMT-1592, is a Dolasynthen ADC targeting NaPi2b-expressing tumors. In the first half of 2020 we initiated a Phase 1 dose escalation trial of XMT-1592 in ovarian cancer and NSCLC adenocarcinoma. XMT-1660, our B7-H4 targeted ADC, was selected as our next Dolasynthen ADC and is currently in IND-enabling studies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunosynthen STING-Agonist ADC Platform and Pipeline</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond  traditional cytotoxic payloads and into targeted stimulation of the innate immune system. Stimulator of Interferon Genes (STING) is a well-studied innate immune pathway capable of inducing anti-tumor immune activity. Through the tumor-targeted delivery of a novel STING agonist, ADCs created with our Immunosynthen platform have the potential to address the challenges of efficacy, delivery and tolerability posed by the intratumoral or intravenous injection of free STING agonist.  Our preclinical data show that the anti-tumor activity of Immunosynthen STING-agonist ADCs is driven by the targeted activation of the STING pathway in tumor-resident immune cells and in tumor cells, in a target dependent manner. STING pathway activation in both cell types within the tumor provides the potential for enhanced anti-tumor activity with a STING-agonist ADC compared to other innate immune approaches that activate only the immune cells.  Further, we have generated preclinical data across multiple, diverse targets by creating Immunosynthen ADCs based on a variety of antibodies directed to those targets and evaluating them in a range of tumor models. In each case we have demonstrated significant anti-tumor activity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including complete tumor regressions) after a single low, well-tolerated dose. Additional characterization has demonstrated increased cytokine expression and immune cell infiltration in the tumor micro environment, as well as the induction of immunological memory. We have demonstrated excellent tolerability and pharmacokinetic profile of Immunosynthen ADCs in non-human primates, after multiple intravenous doses and at exposures significantly higher than those required for robust efficacy in mice.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunosynthen ADCs have been designed to overcome the limitations of free STING agonists and to offer a highly differentiated approach from other innate immune activators due to the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Systemic Administration with Targeted Delivery:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ADCs have the convenience of systemic administration with potential to provide targeted delivery specifically to all tumor lesions, including metastatic sites.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Improved Therapeutic Index:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Conjugation of the STING agonist provides protection in the systemic circulation to minimize off-target effects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Enhanced Pharmacokinetic Properties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The prolonged pharmacokinetics of ADCs and active transport into tumor cells and tumor-resident immune cells can overcome pharmacokinetic and permeability issues of the free agonists, resulting in more robust and sustained activation of the innate immune response in the tumor.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Immunosynthen STING ADCs Provide Targeted Activation in Two Cell Types: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Because STING, unlike other innate immune pathways, can be activated in tumor cells and tumor-resident immune cells, target-dependent delivery can result in innate immune activation of both cell types, providing potent and robust anti-tumor responses and the induction of immunological memory.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 2. Immunosynthen ADCs Active Against Diverse Tumor Antigens and Tumor-Associated Antigens in Multiple Models After Single, Low IV Dose</span></div><div style="margin-top:12pt;text-align:center"><img src="mrsn-20201231_g3.jpg" alt="mrsn-20201231_g3.jpg" style="height:324px;margin-bottom:5pt;vertical-align:text-bottom;width:680px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are building a pipeline of Immunosynthen ADC candidates applicable to a broad range of clinical indications. Our first Immunosynthen ADC development candidate, XMT-2056, is in IND-enabling studies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our product candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our platforms to develop a robust pipeline of clinically meaningful cancer therapies. Our pipeline strategy focuses on targets that have been biologically validated (either as ADCs or through another modality), where the advantages of our platforms may lead to clinically superior therapeutic benefits, where we have the potential to achieve first-in-class status, and where fast-to-market opportunities are available. Our lead product candidate, UpRi, is in a Phase 1 proof-of-concept study with expansion cohorts in ovarian cancer and NSCLC adenocarcinoma. We expect to initiate a single-arm registration strategy in platinum-resistant ovarian cancer, UPLIFT, and a combination dose escalation study, UPGRADE, in ovarian cancer in 2021. Our next product candidate, XMT-1592, is in a Phase 1 dose escalation study.&#160;We are also advancing a potentially first-in-class B7-H4-targeted Dolasynthen ADC, XMT-1660, currently in IND-enabling studies and have nominated our first Immunosynthen development candidate, XMT-2056, currently in IND-enabling studies.&#160;In addition, our partners have multiple ADC product candidates leveraging our Dolaflexin technology in development.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Upifitamab rilsodotin (UpRi, XMT-1536): our NaPi2b-targeted Dolaflexin ADC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in NSCLC adenocarcinoma and ovarian cancer with limited expression in normal tissue. NaPi2b is a member of the SLC34 family of sodium-dependent transporters and plays an important role in maintaining phosphate homeostasis.&#160;There are currently no tests approved by the U.S. Food and Drug Administration, or FDA, to measure NaPi2b expression on tumor cells. Given the prevalence of its expression on epithelial ovarian and NSCLC adenocarcinoma tumors, our initial clinical studies of UpRi are being conducted without prospective identification of patients with NaPi2b-expressing tumors. Nonetheless, we have developed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an immunohistochemistry assay to measure NaPi2b expression which we intend to use retrospectively to confirm the broad prevalence of NaPi2b expression in our target patient populations while correlating those expression levels with the efficacy observed in such patients. We are currently collaborating with a third party to create and obtain regulatory approval for our assay as a commercial companion or complementary diagnostic.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we presented data from the UpRi Phase 1 dose escalation study establishing the maximum tolerated dose and showing encouraging clinical activity with confirmed responses and prolonged stable disease in heavily pretreated patients, without pre-selection for NaPi2b expression. Interim data from the expansion portion of the ongoing UpRi Phase 1 study were presented at the American Society of Clinical Oncology (ASCO) virtual meeting in May 2020. Updated interim data from the ovarian cancer cohort of the UpRi Phase 1 Expansion Study were presented at the European Society for Medical Oncology (ESMO) virtual meeting in September 2020, as well as at a virtual analyst and investor day in January 2021. These data showed clinically meaningful activity in heavily-pretreated patients with an objective response rate &gt;30% and complete responses in patients with ovarian cancer with higher NaPi2b expression.  While serious adverse events have been experienced in this heavily-pretreated population, the data showed that UpRi was generally well tolerated without the severe toxicities commonly seen with other ADCs such as neutropenia, ocular toxicities, or peripheral neuropathy. We continue to enroll ovarian cancer and NSCLC adenocarcinoma patients in the expansion portion of the Phase 1 study.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fourth quarter of 2020, data from the expansion portion of the Phase 1 study of UpRi in ovarian cancer were discussed with the FDA in order to inform the design and initiation of a single-arm registration strategy in platinum-resistant ovarian cancer, to be named UPLIFT. We plan to initiate UPLIFT to evaluate the safety and efficacy of UpRi in heavily-pretreated platinum-resistant ovarian cancer patients. Patients with one to four prior lines of therapy may enroll without regard to NaPi2b expression; however, the role of the biomarker will be evaluated retrospectively. Patients with three to four prior lines of therapy may enroll without prior bevacizumab treatment, accommodating differences in bevacizumab use in early disease.  The primary endpoint will be the objective response rate, or ORR, in the higher NaPi2b patient population and the secondary endpoints will be the ORR regardless of NaPi2b expression, as well as duration of response and safety. The single-arm registration strategy will be initiated as an amendment to the ongoing multinational, multi-center, open label study protocol leveraging expansion enrollment momentum.  We expect to enroll approximately 100 patients with higher NaPi2b expression and up to 180 patients overall. The single-arm registration strategy is intended to support a potential regulatory submission under the FDA's accelerated approval pathway.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect to initiate a combination dose escalation study, to be named UPGRADE, in earlier lines of ovarian cancer in 2021. UPGRADE is expected to evaluate the combination of UpRi with a variety of other agents, starting with a platinum chemotherapy. This study is designed to inform the lifecycle management strategy for UpRi in earlier lines of ovarian cancer, including platinum-sensitive disease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FDA granted Fast Track Designation for UpRi.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XMT-1592: our NaPi2b targeted Dolasynthen ADC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XMT-1592 was created using our Dolasynthen platform and also targets NaPi2b.&#160;XMT-1592 comprises the same proprietary NaPi2b antibody and potent auristatin DolaLock payload with controlled bystander effect as UpRi, with the additional features of homogeneous, site-specific bioconjugation and precise DAR. Preclinically, XMT-1592 has shown a differentiated profile particularly in NSCLC adenocarcinoma, where it was four times more efficacious than UpRi, consistent with higher tumor penetration, as described in below in Figure 2. Based on these preclinical data, we believe that XMT-1592 has the potential to provide us with a second opportunity to treat NSCLC adenocarcinoma patients. XMT-1592 is in a Phase 1 dose escalation study in patients with ovarian cancer and NSCLC adenocarcinoma. We plan to evaluate the clinical differentiation of Dolasynthen by leveraging our experience in NaPi2b to rapidly progress XMT-1592 through dose escalation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 3. XMT-1592 Shows Four-Fold Greater Efficacy in Lung Tumor Model</span></div><div style="margin-top:12pt;text-align:center"><img src="mrsn-20201231_g4.jpg" alt="mrsn-20201231_g4.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:277px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">       </span><img src="mrsn-20201231_g5.jpg" alt="mrsn-20201231_g5.jpg" style="height:265px;margin-bottom:5pt;vertical-align:text-bottom;width:278px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XMT-1660: our B7-H4 targeted Dolasynthen ADC candidate</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our early stage programs include XMT-1660, a potentially first-in-class B7-H4-targeted ADC development candidate, created with our Dolasynthen platform, addressing areas of high unmet medical need. The expression profile of B7-H4 is well suited for our unique DolaLock payload. B7-H4 can be expressed in two places: on tumor cells and on immunosuppressive tumor associated macrophages, or TAMs, which may lead to additional processing of the ADC and more payload in the tumor environment.&#160;DolaLock&#8217;s dual mechanisms of action with a direct cytotoxic effect as well as an immunostimulatory effect through dendritic cell activation and immunogenic cell death are well suited to the biology of the B7-H4 target. We have generated favorable efficacy and non-human primate tolerability data with both Dolaflexin and Dolasynthen ADCs targeting B7-H4. Our objective in 2021 is to rapidly progress XMT-1660 through IND-enabling studies and scale up manufacturing activities with third parties. B7-H4 provides significant opportunities for development in areas of high unmet need such as breast cancer, endometrial and ovarian cancer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 4. XMT-1660 Selected Based on Direct Comparison of Candidates in Multiple In Vivo Models</span></div><div style="margin-top:12pt;text-align:center"><img src="mrsn-20201231_g6.jpg" alt="mrsn-20201231_g6.jpg" style="height:322px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/><img src="mrsn-20201231_g7.jpg" alt="mrsn-20201231_g7.jpg" style="height:330px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XMT-2056: our First Immunosynthen ADC candidate</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our early stage programs also include XMT-2056, our first STING-agonist ADC development candidate, created using our Immunosynthen platform. The therapeutic rationale of an Immunosynthen ADC is to selectively deliver the STING agonist to tumor cells and tumor-resident immune cells in a target-dependent manner, while avoiding delivery to healthy tissues. Our preclinical studies have demonstrated that XMT-2056 has robust activity, resulting in complete tumor regressions in mouse models after a single intravenous low dose. In addition, preclinical studies have also shown excellent tolerability in multi-dose non-human primate, or NHP, studies after intravenous dosing, at exposure levels far exceeding those needed for complete responses in mouse models, which indicates a high preclinical therapeutic index. XMT-2056 is in IND-enabling studies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 5. XMT-2056 Shows Robust Activity in In Vitro and In Vivo Models</span></div><div style="margin-top:12pt;text-align:center"><img src="mrsn-20201231_g8.jpg" alt="mrsn-20201231_g8.jpg" style="height:247px;margin-bottom:5pt;vertical-align:text-bottom;width:340px"/><img src="mrsn-20201231_g9.jpg" alt="mrsn-20201231_g9.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:340px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ovarian cancer unmet need and epidemiology</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide, ovarian cancer had incidence of approximately 295,000 and caused an estimated 185,000 deaths in 2018.&#160;With a U.S. incidence of approximately 25,000 new cases (including fallopian tube and primary peritoneal cancers) and mortality of 14,000 in 2020, ovarian cancer was the second most common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States. The majority of ovarian malignancies (approximately 90%) are derived from epithelial cells. Diagnosis is made histologically, and evaluation is commonly performed following surgical removal of an ovary or fallopian tube or biopsies of the peritoneum. The ovarian cancer standard of care is characterized by initial surgery followed by platinum-containing chemotherapy followed by periods of either observation or maintenance. Nearly 85% of ovarian cancer patients typically relapse following initial treatment.&#160;Subsequent treatment depends on the depth and duration of response to initial platinum treatment. Ovarian cancer patients who progress within six months of completion of platinum-based therapy are considered to have platinum-resistant disease. Unmet medical need is significant for patients with platinum-resistant ovarian cancer as treatment options are mainly limited to single agent chemotherapies such as pegylated liposomal doxorubicin, topotecan and paclitaxel. Multiple Phase 3 studies of single agent chemotherapies in patients with platinum-resistant disease and one to three prior therapies have exhibited an overall response rate of 4-12% and median progression-free survival of 3-4 months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With targeted agents approved in platinum-resistant disease increasingly being prescribed in earlier lines of therapy, the unmet need is expected to remain severe. Bevacizumab in combination with chemotherapy is indicated to treat a subset of platinum-resistant ovarian cancer patients with no more than two prior therapies but it is not always well-tolerated and has shown no overall survival benefit. Use of bevacizumab in combination with platinum-containing chemotherapy in the frontline and platinum-sensitive recurrent settings mean an increasing number of platinum-resistant patients are pre-treated with bevacizumab and are not candidates for additional bevacizumab combination treatment. More recently, PARP inhibitors have been approved for heavily-pretreated ovarian cancer including platinum-resistant disease. However, they are predominantly used in a subset of patients with cancers harboring BRCA1 and BRCA2 mutations. Similarly, use of PARP inhibitors in earlier lines of recurrent platinum-sensitive maintenance and more recently frontline maintenance therapy following platinum-based chemotherapy means an increasing number of platinum-resistant patients are pre-treated with PARP inhibitors and are not candidates for additional PARP inhibitor therapy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NSCLC unmet need and epidemiology</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide, lung cancer had an incidence of approximately 2.1 million and caused an estimated 1.7 million deaths in 2018. With a U.S. incidence of approximately 230,000 new cases and over 130,000 deaths in 2020, lung cancer was the most deadly form of cancer in the United States. The five year survival rate is less than 20% on average.&#160;Approximately 95% of all lung cancers are classified as either small cell lung cancer or NSCLC.&#160;NSCLC can be further divided into squamous or non-squamous. The majority of non-squamous NSCLC is classified as adenocarcinoma. These histological distinctions are important for proper staging, treatment and prognosis. For patients with NSCLC, initial treatment is largely determined by the stage of disease. Surgical resection offers the best opportunity for long-term survival and cure in patients with resectable early-stage NSCLC. Locally-advanced NSCLC is treated by combinations of radiotherapy, immunotherapy, chemotherapy and surgery. The majority of patients present with inoperable disease.&#160;Metastatic NSCLC is managed with systemic chemotherapy and immunotherapy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standard of care is evolving for NSCLC with the introduction of immunotherapies for patients without oncogenic driver mutations and new targeted therapies for patients with EGFR, ALK, ROS-1, NTRK or BRAF mutations. For patients with metastatic disease without oncogenic driver mutations, frontline platinum-based chemotherapy is combined with or, depending on PD-L1 expression status, replaced by, immunotherapy using anti-PD-1 or anti-PD-L1 monoclonal antibodies. For patients with metastatic disease harboring oncogenic driver mutations, several generations of targeted agents are available with different resistance profiles. Frontline therapy is often followed by relapse and recurrence and treatment options for these patients are substantially more limited. The standard of care of docetaxel alone or in combination with targeted agents has an overall response rate of 14-23%, median progression-free survival of 3-4 months and median overall survival of 9-12 months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With PD-1 and PD-L1 inhibitors and next generation targeted therapies moving into frontline, the unmet need in recurrent lung cancer is expected to remain severe.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic partnerships</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic partnerships with leading biopharmaceutical companies to advance Fleximer ADC product candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our ADC platforms have broad applicability across a number of targets. We have used strategic partnering to accelerate bringing Fleximer ADCs to patients. Fleximer is our proprietary, biodegradable, highly biocompatible and water-soluble polymer that is able to carry multiple drug molecules, and it is a key component of our Dolaflexin platform. Since 2012, we have entered into strategic research and development partnerships with Merck KGaA and Asana BioSciences,&#160;LLC (by assignment from Endo Pharmaceuticals&#160;Inc.) to enable development of certain ADC product candidates utilizing Fleximer. In establishing each of these partnerships, our primary objectives were to collaborate with leading biopharmaceutical companies to validate the potential of ADC product candidates utilizing Fleximer, gain meaningful near-term funding and drive significant long-term value. Under each of our partnerships, we own the rights to any improvements to our ADC platform. The details of our material existing strategic partnerships are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck KGaA strategic research and development partnership</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, we entered into a collaboration agreement with Merck KGaA for the development and commercialization of ADC product candidates utilizing Fleximer for up to six target antigens. We formed a strategic partnership with Merck KGaA because of their expertise in oncology drug development. Under this agreement, we are responsible for generating ADC product candidates against Merck KGaA-selected target antigens. Merck KGaA received rights to select up to six target antigens, of which it has selected all six. Merck KGaA is responsible for generating antibodies against the target antigens, and we are responsible for generating Fleximer and our proprietary payloads and conjugating this to such antibodies to create the ADC product candidates. With respect to each target antigen selected by Merck KGaA, we granted Merck KGaA an exclusive, worldwide license under certain of our Fleximer ADC-related patents and know-how to develop, manufacture and commercialize ADC product candidates directed to such target antigen. Merck KGaA is then responsible for the further development and commercialization of these ADC product candidates. In addition, if Merck KGaA advances candidates, we are responsible for manufacturing these ADC product candidates for GLP toxicology studies and Phase&#160;1 clinical studies at Merck KGaA&#8217;s expense and Merck KGaA is responsible for all further manufacture of these ADC product candidates. Merck KGaA is required to pay its own costs in the development, commercialization and manufacture of these ADC product candidates and to reimburse us for our costs incurred in performing our research activities under this agreement. The most advanced product candidates in this partnership are in the lead optimization stage.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2020, we have received an upfront payment of $12&#160;million and milestone payments of $3&#160;million under this agreement. If products are successfully developed and commercialized against all six target antigens, we would be entitled </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to receive future development, regulatory and commercial milestones of up to $777&#160;million. We are entitled to receive tiered royalties in the low- to mid-single digit percentages on net sales of products targeting Merck KGaA&#8217;s target antigens during the applicable royalty term if products are successfully developed and commercialized by Merck KGaA under this agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, this agreement will expire upon the expiration of the last royalty term for a product under the agreement in all countries or, if Merck KGaA does not designate any ADC product candidates produced by us under the agreement as preclinical development candidates, upon the expiration of the last-to-expire research program. The royalty term means, on a product-by-product and country-by-country basis, the period commencing upon the first commercial sale of a product and ending upon the later to occur of: (i)&#160;the expiration of the last Mersana patent right that covers or claims the exploitation of such product in such country, or (ii)&#160;10 years from the date of first commercial sale of such product in such country. Upon the expiration of each royalty term for each product on a country-by-country basis, Merck KGaA&#8217;s exclusive license will convert to a perpetual, non-exclusive, royalty-free license with respect to such product in such country. Merck KGaA may terminate this agreement in its entirety or with respect to any target antigen for convenience upon 60&#160;days&#8217; prior written notice. Each party may terminate this agreement in its entirety upon an uncured material breach of the agreement by the other party.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asana Biosciences collaboration agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2012, we entered to a collaboration agreement with Asana Biosciences, or Asana, formerly part of Endo Pharmaceuticals, to develop next-generation ADCs. Under this agreement, Asana paid us an upfront fee for the right to utilize our Fleximer technology to develop novel ADC candidates against a single cancer target. We are responsible for conducting research and creating ADCs that are conjugates of our diverse, highly potent cytotoxic payloads, our Fleximer polymer and custom linkers, and Asana&#8217;s novel antibodies. In addition to providing novel antibodies, Asana is responsible for product development, manufacturing and commercialization of any Fleximer ADC products. Through December&#160;31, 2020, we have received an upfront payment of $0.8&#160;million and milestone payments of $3.3&#160;million under this agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic partnerships to access antibodies and develop new platforms to progress our proprietary pipeline</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is to progress our proprietary pipeline of ADCs. For this reason, we have partnered with biotechnology companies that have the capability to generate high quality antibodies or that have existing antibodies that we can license for inclusion in our ADCs. We have also entered into license agreements with biotechnology companies that own certain patent rights and related know-how that enable us to develop new ADC platforms. These strategic partnerships have facilitated the acceleration of our proprietary pipeline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recepta license for the NaPi2b antibody</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, we entered into a license agreement with Recepta Biopharma&#160;S.A., or Recepta, a Brazilian biopharmaceutical company, licensing Recepta&#8217;s NaPi2b antibody for use in UpRi and XMT-1592 and granting Recepta the exclusive right to commercialize UpRi and XMT-1592 in Brazil. Under this agreement, Recepta granted us an exclusive license and sub-license with respect to certain patents licensed by Recepta from Ludwig Institute for Cancer Research and technology owned by Recepta to develop and exploit products containing Recepta&#8217;s NaPi2b antibody, including UpRi and XMT-1592, worldwide for the diagnosis, prophylaxis and treatment of human cancer. We granted Recepta an exclusive license under our rights in such patents and technology and certain of our ADC-related patents and technology to commercialize any such products developed by us, including UpRi and XMT-1592, in Brazil. We are responsible for the worldwide development and commercialization of products under this agreement at our own expense in certain major markets, including at least one study site in our Phase&#160;3 clinical studies in Brazil. Recepta may conduct development activities in Brazil at its own expense after providing us the opportunity to first conduct such activities at Recepta&#8217;s expense. If a product is successfully developed and commercialized by Recepta in Brazil, we will use diligent efforts to enter into an agreement for the supply of such products to Recepta for sale in Brazil.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, we paid Recepta an upfront payment of $1&#160;million during the year ended December&#160;31, 2015 and are obligated to pay Recepta up to $65.5&#160;million in development, regulatory and commercial milestones and tiered royalties in the low-single digit percentages on net sales of products outside of Brazil until the expiration of the royalty term if products are successfully developed and commercialized. Through December 31, 2020, we have paid $1.9 million in milestone payments. We are entitled to receive tiered royalties in the low- to&#160;mid-single digit percentages on net sales of products in Brazil until the expiration of the royalty term if products are successfully developed and commercialized. The royalty term means, on a product-by-product and country-by-country basis, the period ending upon the later of (i)&#160;with respect to products commercialized by Mersana, the expiration of the last-to-expire Recepta patent that covers the product in such country (including the term of any applicable supplementary protection certificate) or with respect to products commercialized by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recepta, the expiration of the last-to-expire Mersana Patent that covers the product in Brazil (including the term of any applicable supplementary protection certificate) or (ii)&#160;10 years from the date of first commercial sale of such product in such country. Upon the expiration of each royalty term in each country for each applicable product, the exclusive licenses granted to each party under the agreement will become fully-paid up and royalty-free. This agreement will remain in effect until otherwise terminated as set forth below. We may terminate this agreement for convenience in its entirety or on a country-by-country basis (except with respect to Brazil) or product-by-product basis upon 180&#160;days&#8217; prior written notice for a termination in its entirety or upon 45&#160;days&#8217; prior written notice for a termination in part. Each party may terminate this agreement in its entirety upon bankruptcy or similar proceedings of the other party, upon a patent challenge by the other party or upon an uncured material breach of the agreement by the other party. However, if such breach only relates to one country, the agreement may only be terminated with respect to such country.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Synaffix commercial license agreement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, we entered into a commercial license agreement with Synaffix B.V., or Synaffix, to develop, manufacture and commercialize ADC targets using Synaffix&#8217;s proprietary site-specific conjugation technology for a total of six targets, including XMT-1592. At contract inception we designated the first target and paid an upfront, non-refundable license fee of $0.8 million. We are required to make milestone payments to Synaffix of up to an aggregate of $24.8 million in development and regulatory milestones and up to $20.0 million in one-time sales milestones based on the achievement of annual sales objectives for the first target. In addition, upon designation of additional targets, we will be obligated to pay in the range of $44.8 million to $62.0 million for issuance, development, regulatory and one time sales milestones. Through December 31, 2020, we have paid $0.8 million in milestone payments. Pursuant to the terms this license agreement, upon commencement of commercial sales of a product, if any, we are required to pay to Synaffix tiered royalties in the low-single digit percentages on net sales of the respective products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement remains in effect on a country-by-country and licensed product-by-licensed product basis until the expiration of the last-to-expire valid claim in a patent licensed under the agreement covering such product in such country. Upon the expiration of the agreement for each licensed product in each country, the licenses granted to us for such product in such country will become fully paid-up and perpetual. We may terminate the agreement in its entirety or on a licensed product-by-licensed product basis at any time. Either party may terminate the agreement, subject to a specified notice and cure period, for a breach by the other party of a material provision of the agreement or upon an insolvency-related event experienced by the other party.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate and currently have no plans to establish any cGMP compliant manufacturing facilities. We currently rely, and expect to continue to rely, on external Contract Manufacturing Organizations, or CMOs, for the manufacture of product to support our activities through regulatory approval and commercial manufacturing. We have personnel with pharmaceutical development and manufacturing experience who are responsible for the relationships with our CMOs. In the future, we expect to use these CMOs to manufacture commercial supply of our products, which will require these CMOs to increase scale of production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have qualified alternate suppliers in the event the current CMOs that we utilize are unable to scale production for commercial manufacturing. The Dolaflexin and Dolasynthen manufacturing processes involve readily available starting materials and use unit operations that are well-precedented in the field of chemical/pharmaceutical production. The current UpRi supply chain utilizes the same vendors that we could use for commercialization. The current XMT-1592 supply chain utilizes the same vendors that we could use for commercialization with the exception of components necessary for the Synaffix bioconjugation technology, where the identification of a commercially capable vendor is ongoing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, clinical and preclinical studies, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including imposition of a clinical hold, refusal to approve marketing applications, withdrawal of an approval, import/export delays, issuance of warning letters and other types of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal investigations and penalties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and approval in the United States</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our ADC product candidates are subject to regulation by the FDA as biologics. The FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Service Act, or PHS Act, and associated implementing regulations. The failure to comply with the FDCA, the PHS Act and other applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of enforcement-related letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal investigations and penalties brought by the FDA and the Department of Justice, or DOJ, or other governmental entities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biologic may not be marketed in the United States until it has been approved by the FDA. The steps before a biological product may be approved for marketing in the United States generally include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the submission to the FDA of an Investigational New Drug, or IND application which must take effect before human clinical studies may begin in the United States;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent Institutional Review Board, or IRB representing each clinical site before each clinical study may be initiated;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled clinical studies to establish the safety and efficacy of the proposed product for each indication, conducted in accordance with good clinical practice, or GCP, requirements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation and submission to the FDA of a Biologics License Application, or BLA;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA acceptance and review of the BLA, which might include an Advisory Committee review;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of any FDA inspections or audits of the sponsor, clinical research organizations and clinical study sites to assure compliance with GCP requirements and the integrity of the clinical data;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payment of user fees, if any, for FDA review of the BLA; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA approval of the BLA; and </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with any post-approval requirements, including a Risk Evaluation and Mitigation Strategy, or REMS, where applicable, and post-approval studies required by the FDA as a condition of approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing and approval process requires substantial time, effort and financial resources, and the receipt and timing of any approval is uncertain.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical studies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies include laboratory evaluation of the product candidate, as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and animal studies to assess the potential safety and efficacy of the product candidate for use in humans. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, are submitted to the FDA as part of an IND. Additional preclinical testing, such as toxicity studies, may continue after the IND is submitted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical studies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical studies involve the administration of the product candidate to human subjects under the supervision of qualified investigators in accordance with GCP requirements. GCP requirements include, among other things, conducting the study in accordance with a written protocol, maintaining the integrity of study data, obtaining informed consent from study subjects and approval and ongoing review of the study by an IRB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A protocol for each clinical study and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical study or places the study on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical study can begin.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical studies are typically conducted in three sequential phases prior to approval, which may overlap or be combined:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase&#160;1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;The product candidate is initially introduced into healthy human subjects or, in some cases, patients with the target disease (e.g.,&#160;cancer) or condition. In Phase&#160;1, the product candidate is typically tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase&#160;2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;The product candidate is administered to a limited patient population to preliminarily evaluate the efficacy of the product for specific targeted diseases, to identify possible adverse effects and safety risks and to determine dosage tolerance and optimal dosage.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase&#160;3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical study sites, in well-controlled clinical studies to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase&#160;4 clinical studies may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of products approved under accelerated approval regulations or when otherwise requested by the FDA in the form of post-market requirements or commitments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical studies at each phase of development may not be completed successfully within any specified period, or at all. Furthermore, the FDA, an IRB, the sponsor or the data monitoring committee, if applicable, may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Submission of a marketing application to the FDA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BLA pathway</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ADC product candidates must be licensed via FDA approval of a BLA under Section&#160;351 of the PHS Act on the basis of a demonstration that the product is safe, pure and potent. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review BLAs within ten months of the filing date for standard review or six months of the filing date for priority review. The review process is often significantly extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving the BLA, the FDA will inspect the facilities at which the biological product is manufactured and will not approve the product unless the facility is compliant with cGMPs. Additionally, the FDA will typically inspect one or more clinical study sites for compliance with GCP and integrity of the data supporting safety and efficacy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the approval process, the FDA also will determine whether to require post-approval testing, including Phase&#160;4 clinical studies and surveillance programs to monitor the effect of approved biologics after they are commercialized. In addition, the FDA will determine whether the biologic will require a REMS to ensure that the benefits of the product outweigh its risks, which could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of the FDA&#8217;s evaluation of the BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA will issue either an approval of the BLA or a Complete Response Letter, detailing the deficiencies in the submission and the additional testing or information required for reconsideration of the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase&#160;4 clinical studies, be conducted to further assess the product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast track, breakthrough therapy and priority review designations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are fast track designation, breakthrough therapy designation and priority review designation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First, the FDA may designate a product for &#8220;fast track&#8221; review if it is intended for the treatment of a serious or life-threatening disease or condition and it demonstrates the potential to address unmet medical needs for such disease or condition. For fast track products, sponsors may have greater interactions with the FDA, and the FDA may initiate review of sections of a fast track product&#8217;s BLA before the application is complete. This &#8220;rolling review&#8221; is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Second, the FDA may designate a product as a breakthrough therapy if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical studies in an efficient manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third, the FDA may designate a product for priority review if it treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. A priority designation is intended to direct overall attention and resources to the evaluation of such applications and shortens the FDA&#8217;s goal for taking action on a marketing application from ten months to six months from the filing date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accelerated approval pathway</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large studies to demonstrate a clinical or survival benefit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;4 or post-approval clinical studies to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-approval requirements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for certain supplemental applications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences of regulatory non-compliance or post-market problems with a product include, among other things:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning or other enforcement-related letters or holds on post-approval clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Such products may be promoted only for the approved indications and consistent with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars and exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, signed into law on March&#160;23, 2010, or the Health Care Reform Act, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products shown to be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biosimilar to, or interchangeable with, an FDA-licensed reference biological product. Biosimilarity requires a showing that the product is &#8220;highly similar&#8221; to the reference product notwithstanding minor differences in clinically inactive components and that there are no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reference biologic is entitled to 12&#160;years of exclusivity from the time of first licensure of the product. In addition, the first biological product submitted under the abbreviated approval pathway that is determined to be interchangeable with, not just biosimilar to, the reference product has exclusivity against other biologics submitting under the abbreviated approval pathway for the lesser of (i)&#160;one year after the first commercial marketing, (ii)&#160;18&#160;months after approval if there is no legal challenge, (iii)&#160;18&#160;months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologics&#8217; patents if an application has been submitted or (iv)&#160;42&#160;months after the application has been approved if a lawsuit is ongoing within the 42-month period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BPCIA is complex and continues to be interpreted and implemented by the FDA.&#160;In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Further, since the BPCIA was enacted as part of the overall Health Care Reform Act, current litigation challenges to that Act, discussed more in full below, could impact the validity of the BPCIA. As a result, there still remains significant uncertainty as to the ultimate impact, implementation and regulatory interpretation of the BPCIA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric studies and exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003, all applications for new active ingredients, new indications, new dosage forms, new dosing regimens or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred or inapplicable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Best Pharmaceuticals for Children Act, a product may be eligible for pediatric exclusivity, which, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued written request for such a study.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan drug designation and exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a product, including a biological product, as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, a disease for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales in the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product that receives the first FDA approval for a product for the indication for which it has orphan designation is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same product for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent term restoration</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patent claiming a new product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which permits a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of a BLA, plus the time between the submission date of a BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14&#160;years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. The United States Patent and Trademark Office, or USPTO, reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Approval or Clearance of Companion Diagnostics</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, we may seek approval or partner with a third-party to seek approval of a companion diagnostic for one or more of our ADC product candidates. In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and in vitro companion diagnostics. According to the guidance, for novel drugs and biologics, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the therapeutic products and in vitro companion diagnostic devices on issues related to co-development of the products. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA, in vitro diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA previously has required in vitro companion diagnostics intended to select the patients who will respond to a product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial is typically required for a PMA application and, in a small percentage of cases, the FDA may require a clinical study in support of a 510(k) submission. A manufacturer that wishes to conduct a clinical study involving the device is subject to the FDA&#8217;s investigational device exemption, or IDE, regulation. The IDE regulations distinguish between significant and non-significant risk device studies and the procedures for obtaining approval to begin the study differ accordingly. Also, some types of studies are exempt from the IDE regulations. A significant risk device presents a potential for serious risk to the health, safety, or welfare of a subject. Significant risk devices are devices that are substantially important in diagnosing, curing, mitigating, or treating disease or in preventing impairment to human health. Studies of devices that pose a significant risk require both FDA and an IRB approval prior to initiation of a clinical study. Many companion diagnostics are considered significant risk devices due to their role in diagnosing a disease or condition. Non-significant risk devices are devices that do not pose a significant risk to the human subjects. A non-significant risk device study requires only IRB approval prior to initiation of a clinical study.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, device manufacturers are also subject to FDA&#8217;s medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, and FDA&#8217;s correction and removal reporting regulations, which require that manufacturers report to the FDA corrections or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the Quality System Regulation, which covers the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and approval outside the United States</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions governing, among other things, clinical studies, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical studies or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union and other geographies, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries outside of the United States have a process that requires the submission of a clinical trial application, or CTA, much like the IND prior to the commencement of human clinical studies. In the European Union, for example, a CTA must be submitted for each clinical trial to the national health authority and an independent ethics committee in each country in which the company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#8217;s requirements, the clinical trial may proceed. In all cases, the clinical trials must be conducted in accordance with GCPs and other applicable regulatory requirements and ethical principles.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain regulatory approval of an investigational product under European Union regulatory systems, we must submit a marketing authorization application under either a centralized or decentralized procedure. The centralized procedure is compulsory for medicinal products produced by biotechnology. The application used to file the BLA in the United States is similar to that required in the European Union, with the exception of, among other things, region-specific document requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union also provides opportunities for market exclusivity. For example, upon receiving marketing authorization, innovative medicinal products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic or biosimilar application. There is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to be an innovative medicinal product, and products may not qualify for data exclusivity. Products receiving orphan designation in the European Union can receive ten years of market exclusivity, during which time no similar medicinal product for the same indication may be placed on the market. An orphan product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection, use, disclosure, transfer or other processing of personal data regarding individuals in the European Economic Area, including personal health data, is subject to the Regulation (EU) 2016/679 (General Data Protection Regulation, or GDPR), which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches and taking certain measures when engaging third-party data processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Economic Area, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical coverage, pricing and reimbursement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of pharmaceutical products depend in significant part on the availability and adequacy of third-party payor reimbursement. Third-party payors include government health administrative authorities, including authorities at the U.S. federal and state level, managed care providers, private health insurers and other organizations. Third-party payors are increasingly challenging the prices charged for, examining the medical necessity of and assessing the cost-effectiveness of medical products and services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of drugs and biologics have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies, or so called health technology assessments, to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or may instead adopt a system of direct or indirect controls on the profitability of the company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The downward pressure on healthcare costs in general, particularly prescription drugs and biologics, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for products may not allow favorable reimbursement and pricing arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare law and regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the United States, the activities of pharmaceutical companies are subject to extensive regulation and our activities could possibly be subject to challenge as a result. Laws and regulations that may affect our ability to operate (including certain laws that will apply if and when we have a product approved for marketing) include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal anti-kickback law, which prohibits, among other things, persons from soliciting, offering, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service, for which payment may be made, under federal healthcare programs such as Medicare and Medicaid;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal anti-kickback prohibition known as Eliminating Kickbacks in Recovery Act or EKRA, enacted in 2018, which prohibits certain payments related to referrals of patients to certain providers (recovery homes, clinical treatment facilities and laboratories) and applies to services reimbursed by private health plans as well as government health care programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal law known as HIPAA, which, in addition to privacy protections applicable to healthcare providers and other entities (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government regulation &#8211; Data privacy and security</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), prohibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">executing a scheme to defraud any healthcare benefit program (which may include private health plans) or making false statements relating to healthcare matters;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products for off-label use and regulates the distribution of samples;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the so-called &#8220;federal sunshine&#8221; law, which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with teaching hospitals, physicians, and certain non-physician practitioners  to the federal government for re-disclosure to the public ; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law analogues of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including private health plans, and state and local laws regulating interactions between pharmaceutical manufacturers and healthcare providers, requiring disclosure of such financial interactions or mandating adoption of certain compliance standards, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Violations of these laws can subject us to criminal, civil and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and reputational harm. Additionally, we may be required to curtail or restructure our operations. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our future operations and business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and operations could be affected by changes in healthcare spending and policy in the United States and elsewhere. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been and continue to be a number of significant legislative initiatives to contain healthcare costs. Federal and state governments continue to propose and pass legislation designed to reform delivery of, or payment for, health care, which include initiatives to reduce the cost of healthcare. For example, the Health Care Reform Act expanded health care coverage through Medicaid expansion and the implementation of the individual mandate for health insurance coverage and included changes to the coverage and reimbursement of drug products under government healthcare programs. Under the Trump administration, there have been ongoing efforts to modify or repeal all or certain provisions of the Health Care Reform Act. For example, tax reform legislation was enacted at the end of 2017 that eliminated the tax penalty established under Health Care Reform Act for individuals who do not maintain mandated health insurance coverage beginning in 2019. The Health Care Reform Act has also been subject to judicial challenge.&#160;The case </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas v. Azar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which challenges the constitutionality of the Health Care Reform Act, including provisions that are unrelated to healthcare reform but were enacted as part of the Health Care Reform Act, was argued before the Supreme Court in November 2020. Pending resolution of the litigation, all of the Health Care Reform Act but the individual mandate to buy health insurance remains in effect.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond the Health Care Reform Act, there have been ongoing health care reform efforts, including a number of recent actions. Some recent healthcare reform efforts have sought to address certain issues related to the COVID-19 pandemic, including an expansion of telehealth coverage under Medicare and accelerated or advanced Medicare payments to healthcare providers. Other reform efforts affect pricing or payment for drug products. For example, the Medicaid Drug Rebate Program has been subject to statutory and regulatory changes and the discount that manufacturers of Medicare Part D brand name drugs must provide to Medicare Part D beneficiaries during the coverage gap from 50% to 70%. A number of regulations were issued in late 2020 and early 2021. For example, effective January, 2022, revisions to the federal antikickback statute would remove protection for traditional Medicare Part D discounts offered by pharmaceutical manufacturers to PBMs and health plans. Some of these changes have been and may continue to be subject to legal challenge. For example, courts temporarily enjoined a new &#8220;most favored nation&#8221; payment model for select drugs covered under Medicare Part B that was to take effect on January 1, 2021 and would limit payment based on international drug price. The nature and scope of health care reform in the wake of the transition from the Trump administration to the Biden administration remains uncertain. President Biden has temporarily halted implementation of new rules issued immediately prior to the transition that had not yet taken effect (which include a number of health care reforms) to allow for review by the new administration. More generally, President Biden supported reforms to lower drug prices during his campaign for the presidency.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have also been efforts by federal and state government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation. Recently, there has been considerable public and government scrutiny of pharmaceutical pricing and proposals to address the perceived high cost of pharmaceuticals. There </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have also been recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around drug costs or limiting drug prices.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adoption of new healthcare reform legislation at the federal or state level could affect demand for, or pricing of, our product candidates if approved for sale. We cannot predict, however, the ultimate content, timing or effect of any healthcare reform legislation or action, or its impact on us, and healthcare reform could increase compliance costs and may adversely affect our future business and financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data privacy and security</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to privacy and security laws in the various jurisdictions in which we operate, obtain or store personally identifiable information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the United States, our operations may be affected by the Health Insurance Portability and Accountability Act of 1996 as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, collectively, HIPAA, which impose obligations on certain &#8220;covered entities&#8221; (healthcare providers, health plans and healthcare clearinghouses) and certain of their &#8220;business associate&#8221; contractors with respect to safeguarding the privacy, security and transmission of individually identifiable health information. Although we believe that we currently are neither a &#8220;covered entity&#8221; nor a &#8220;business associate&#8221; under the legislation, HIPAA may affect our interactions with customers who are covered entities or their business associates because HIPAA affects the ability of these entities to disclose patient health information to us. Various states also have laws that regulate the privacy and security of patient information and so may affect our business operations.&#160;For example, we are subject to the California Consumer Privacy Act, or CCPA, that became effective on January 1, 2020. The CCPA gives California consumers (defined to include all California residents) certain rights, including the right to ask companies to disclose the types of personal information collected, specific pieces of information collected by a company, the categories of sources from which such information was collected, the business purpose for collecting or selling the consumer&#8217;s personal information, and the categories of third parties with whom a company shares personal information. The CCPA also imposes several obligations on companies to provide notice to California consumers regarding a company&#8217;s data processing activities. Additionally, the CCPA gives California consumers the right to ask companies to delete a consumer&#8217;s personal information and it places limitations on a company&#8217;s ability to sell personal information, including providing consumers a right to opt out of sales of their personal information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, other data privacy and security regulations may apply.&#160;For example, the processing of personal data in the European Economic Area, or the EEA, is subject to the General Data Protection Regulation, or the GDPR, which took effect in May 2018. The GDPR increases obligations with respect to clinical trials conducted in the EEA, such as in relation to the provision of fair processing notices, exercising data subject rights and reporting certain data breaches to regulators and affected individuals, as well as how we document our relationships with third parties that process GDPR-covered personal data on our behalf. The GDPR also increases the scrutiny applied to transfers of personal data from the EEA (including from clinical trial sites in the EEA) to countries that are considered by the European Commission to lack an adequate level of data protection, such as the United States. Adoption of new healthcare reform legislation at the federal or state level could affect demand for, or pricing of, our product candidates if approved for sale. We cannot predict, however, the ultimate content, timing or effect of any healthcare reform legislation or action, or its impact on us, and healthcare reform could increase compliance costs and may adversely affect our future business and financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with data privacy and security regulation can require allocation of resources as well as changes in operations. Any failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages by data subjects, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have been adopted in foreign countries that impose similar obligations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek to protect the proprietary technology that we consider important to our business, including pursuing patents that cover our ADC platform, proprietary composition of matter, ADC product candidates and methods of using and manufacturing the same, as well as any other relevant inventions and improvements that are considered commercially important to the development of our business. We also rely on trade secrets, know how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend significantly on our ability to obtain and maintain patents and other proprietary protection for the technology, inventions and improvements we consider important to our business, and to defend our patents, preserve the confidentiality of our trade secrets and operate without infringing the patents and proprietary rights of third parties. Our policy is to seek to protect our proprietary and intellectual property position by, among other methods, filing U.S., international (under Patent Cooperation Treaty, or PCT) and foreign patent applications related to our proprietary technology, inventions and improvements that we consider to be important to the development and implementation of our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug or biological product may also be eligible for patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. In the future, if and when our drug candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those drugs, depending upon the length of the clinical studies for each drug and other factors. There can be no assurance that any of our pending patent applications will issue or that we will benefit from any patent term extension or favorable adjustments to the terms of any of our patents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our drug candidates and technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our pending patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Any issued patents that we may currently own or license or may receive in the future may be challenged, invalidated, circumvented or have the scope of their claims narrowed. For example, we cannot be certain of the priority of inventions covered by pending third party patent applications. If third parties prepare and file patent applications in the United States that also claim technology or therapeutics to which we have rights, we may have to participate in interference proceedings in the USPTO to determine priority of invention, which could result in substantial costs to us, even if the eventual outcome is favorable to us, which is highly unpredictable. In addition, because of the extensive time required for clinical development and regulatory review of a drug candidate we may develop, it is possible that, before any of our drug candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide. For more information regarding the risks related to our intellectual property, please see &#8220;Risk factors&#8212;Risks related to our intellectual property.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2021, we owned, in all of our patent portfolios, 21 issued U.S. patents, 12 pending non-provisional U.S. patent applications (including one allowed U.S. patent application), seven pending provisional U.S. patent applications, 95 issued foreign patents, five pending PCT patent applications and 102 pending foreign patent applications (including two allowed foreign patent applications) in a number of foreign jurisdictions, including, but being not limited to, Argentina, Australia, Brazil, Canada, China, Europe, Eurasia, Gulf Cooperation Council, Hong Kong, Israel, India, Indonesia, Iran, Japan, Mexico, Macau, Pakistan, New Zealand, Russia, South Korea, South Africa, and Taiwan. Our 10 issued U.S. patents covering our Fleximer ADC platform are projected to expire in 2032, excluding any additional term for patent term adjustments or patent term extensions; our two issued U.S. patents covering our Dolaflexin ADC platform are projected to expire in 2034 and 2038, excluding any additional term for patent term adjustments or patent term extensions; our additional nine issued U.S. patents are projected to expire between 2030 and 2037, excluding any additional term for patent term adjustments or patent term extensions; and any patent that may issue from our pending U.S. applications is projected to expire between 2037 and 2042, in each case, excluding any additional term for patent term adjustments or patent term extensions. In addition, we have exclusively in licensed four issued U.S. patents and one issued European patent for the NaPi2b antibody from Recepta. These in licensed issued U.S. and foreign patents are projected to expire in 2029, excluding any additional term for patent term adjustments or patent term extensions. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before they are granted. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes of patent protection may be granted on the same product candidate or technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio of our ADC platform, our ADC product candidates and components thereof and companion diagnostics are summarized below. Some of these portfolios are in very early stages and prosecution has yet to commence on most of the pending patent applications. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the USPTO may be narrowed (sometimes significantly) by the time they issue, if they issue at all. We expect this to be the case with respect to our pending patent applications referred to below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fleximer ADC platform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for our Fleximer ADC platform is directed to compositions of matter for the Fleximer ADCs, as well as methods of using and making these novel conjugates, compositions of matter for Fleximer drug conjugates prior to conjugation with the antibody or antibody fragment and methods of making the same, and compositions of matter for our proprietary auristatin compounds (and by extension our proprietary DolaLock feature) and conjugates thereof (e.g., to Fleximer and/or an antibody or antibody fragment). As of January 31, 2021, we owned 10 issued U.S. patents, one pending non-provisional U.S. patent application, 48 issued foreign patents, and three pending foreign patent applications  in a number of foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, Russia, South Korea, and Taiwan. Any U.S. or foreign patent issuing from the pending applications covering the Fleximer ADC platform is projected to expire in 2032, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dolaflexin ADC platform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for our Dolaflexin ADC platform is directed to compositions of matter for the Dolaflexin ADCs, as well as methods of using and making these novel conjugates, compositions of matter for Dolaflexin drug conjugates prior to conjugation with the antibody or antibody fragment and methods of making the same. As of January 31, 2021, we owned two issued U.S. patents, and one pending non-provisional U.S. patent application, 33 issued foreign patent, and 12 pending foreign patent applications in a number of foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, South Korea, Mexico, Russia, South Africa and Taiwan. Any U.S. or foreign patent issuing from the pending applications covering Dolaflexin ADC platform is projected to expire in 2034, and any U.S. or foreign patent issuing from the pending applications covering the method of making the Dolaflexin ADC is projected to expire in 2038, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UpRi ADC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for our NaPi2b ADC product candidate, UpRi, is directed to compositions of matter for our novel ADC based on exclusively in licensed NaPi2b antibody and our Dolaflexin platform, as well as methods of using, making these novel conjugates, methods of administration and companion diagnostics. As of January 31, 2021, we owned four pending non-provisional U.S. patent applications (including one allowed U.S. patent application), 37 pending foreign patent applications, and one pending PCT application directed to the composition of matter for UpRi, methods of using and making same, companion diagnostics for UpRi ADC and UpRi dosing regimens. We also intend to enter the national/regional phase of the pending PCT patent application in foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, South Korea, Macau, Mexico and South Africa. Any U.S. or foreign patent issuing from the pending applications covering UpRi is projected to expire in 2037, and any U.S. or foreign patent issuing from the pending applications covering UpRi companion diagnostics is projected to expire in 2038, excluding any additional term for patent term adjustments or patent term extensions, and any U.S. or foreign patent issuing from the pending applications covering the UpRi dosing regimens is projected to expire in 2039.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have exclusively in licensed four issued U.S. patents and one issued European patent for the novel NaPi2b antibody from Recepta, which Recepta licensed from Ludwig Institute for Cancer Research. These in licensed issued U.S. and European patents are projected to expire in 2029, excluding any additional term for patent term adjustments or patent term extensions. Recepta still owns one pending Brazilian patent application for the NaPi2b antibody, which is not licensed to us. A patent issuing from this Brazilian patent application is projected to expire in 2029.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dolasynthen ADC platform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for our novel Dolasynthen platform is directed to compositions of matter for the novel scaffold and ADCs thereof, as well as methods of using and making these novel conjugates and scaffolds. As of January 31, 2021, we owned one pending non-provisional U.S. patent application, 16 pending foreign patent applications, and one pending PCT patent application. We intend to enter the national/regional phase of the PCT patent applications in a number of foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, Russia, South Korea, and Taiwan. Any U.S. or foreign patent issuing from the pending applications covering the novel Dolasynthen platform is projected to expire between 2037 and 2039, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XMT-1592 ADC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for our site-specific NaPi2b ADC product candidate, XMT-1592, is directed to compositions of matter for our novel ADC based on exclusively in licensed NaPi2b antibody and our Dolasynthen platform, as well as methods of using, making these novel conjugates and administration of these novel conjugates. As of January 31, 2021, we owned one pending non-provisional U.S. patent application, one pending provisional application, three pending foreign patent applications and one pending PCT patent application. We intend to enter the national/regional phase of the PCT patent applications in a number of foreign jurisdictions, including, but mot limited to, Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, Russia, South Korea, and Taiwan.  Any U.S. or foreign patent issuing from the pending applications covering XMT-1592 is projected to expire in 2041, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XMT-1660 ADC </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for our site-specific B7-H4  ADC product candidate, XMT-1660, is directed to compositions of matter for our novel ADC based on our novel B7-H4 antibody and our Dolasynthen platform, as well as methods of using, making these novel conjugates and administration of these novel conjugates. As of January 31, 2021, we owned one pending provisional application, Any U.S. or foreign patent issuing from the pending applications covering XMT-1660 is projected to expire in 2042, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immunosynthen ADC platform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for our novel Immunosynthen platform is directed to compositions of matter for the novel STING agonists, as well as methods of using and methods of making these novel payloads. As of January 31, 2021, we owned one pending non-provisional U.S. patent application, five pending provisional U.S. patent applications, two pending foreign patent applications and two pending PCT patent applications related to the Immunosynthen platform. We intend to enter the national/regional phase of the PCT patent applications in a number of foreign jurisdictions, including, but mot limited to, Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, Russia, South Korea, and Taiwan. Any U.S. or foreign patent issuing from the pending applications is projected to expire between 2040 and 2041, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors and non-competition, non-solicitation, confidentiality and invention assignment agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot guarantee, however, that we will have executed such agreements with all applicable employees and contractors, or that these agreements will afford us adequate protection of our intellectual property and proprietary information rights. With respect to the building of our proprietary compound library, we consider trade secrets and know-how to be our primary intellectual property. Trade secrets and know-how can be difficult to protect. In particular, we anticipate that with respect to this technology platform, these trade secrets and know-how will over time be disseminated within the industry through independent development and public presentations describing the methodology. For more information regarding the risks associated with our trade secrets, please see &#8220;Risk factors&#8212;Risks related to our intellectual property&#8212;Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and biopharmaceutical industries, and the oncology subsector, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. Any product candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. While we believe that our proprietary ADC platforms and scientific expertise provide us with competitive advantages, a wide variety of institutions, including large biopharmaceutical companies, specialty biotechnology companies, academic research departments and public and private research institutions, are actively developing potentially competitive products and technologies. These competitors generally fall within the following categories:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New cancer treatments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;Many global pharmaceutical companies, as well as medium and small biotechnology companies, are pursuing new cancer treatments whether small molecules, biologics or ADCs. Any of these treatments could prove to be superior clinically to our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC platforms:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;Although Dolaflexin, Dolasynthen and the new platform initiatives we have underway are highly differentiated and proprietary, many companies continue to invest in innovation in the ADC field including new payload classes, new conjugation approaches and new targeting moieties. Any of these initiatives could lead to a platform that has superior properties to ours. We are also aware of multiple companies with ADC technologies that may be competitive to our platforms, including Daiichi Sankyo, ImmunoGen, Gilead (Immunomedics), Pfizer and SeaGen. These companies or their partners, including Astellas, AstraZeneca, AbbVie, Genentech/Roche and Takeda, may develop product candidates which compete in the same indications as our current and future product candidates. We expect to compete on improved efficacy, safety and tolerability compared to other product candidates and if our products are not demonstrably superior in these respects compared to other approved therapeutics, we may not be able to compete effectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Accelerated merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical study sites and patient registration for clinical studies and acquiring technologies complementary to, or necessary for, our programs. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, more convenient or less expensive than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of our products&#8217; entry. We believe the factors determining the success of our programs will be the efficacy, safety and tolerability of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2021, we had 110 full time employees, including 76 with M.D., Ph.D. or other advanced degrees. Of these full time employees, 87 are engaged in research and development and 23 are engaged in general and administrative activities. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunity for equity ownership, development programs that enable continued learning and growth, and a robust employment package that promotes wellness across all aspects of their lives, including healthcare, retirement planning, and paid time off. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facilities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Cambridge, Massachusetts. We occupy approximately 35,000 square feet of office and laboratory space that we lease in the multi-tenant building in which our corporate headquarters are located. We have an option to extend the lease term for an additional five years thereafter. We believe that this office and laboratory space is sufficient to meet our current needs and that suitable additional space will be available as and when needed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 2001 as a Delaware corporation. Our principal executive offices are located at 840 Memorial Drive, Cambridge, MA 02139, and our telephone number is 617-498-0020. Our internet site is www.mersana.com. We routinely make available important information free of charge, including copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. We recognize our website as a key channel of distribution to reach public investors and as a means of disclosing material non-public information to comply with our disclosure obligations under SEC Regulation FD. Information contained on our website shall not be deemed incorporated into, or to be part of this Annual Report on Form 10-K, and any website references are not intended to be made through active hyperlinks.</span></div><div id="i7157c5eacfe941de9505feeee920791e_19"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following risk factors and other information included in this Annual Report on Form 10-K should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to development and approval of our ADC product candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure of a discovery program or product candidate may occur at any stage of preclinical or clinical development, and, because our and our partner&#8217;s discovery programs and our product candidates are in early stages of preclinical or clinical development, there is a relatively higher risk of failure and we or our partners may never succeed in generating revenue from such discovery programs or product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our early encouraging clinical results for UpRi, our lead product candidate, our early encouraging preclinical results for XMT-1592 and the early results of any other current or future product candidates, are not necessarily predictive of the results of our ongoing or future discovery programs or clinical studies. Promising results in preclinical studies and early encouraging clinical results of a drug candidate may not be predictive of similar results in later-stage preclinical studies or in humans during clinical studies. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical studies after achieving positive results in early-stage development, including early-stage clinical studies, and we cannot be certain that we will not face similar setbacks. These companies&#8217; setbacks have been caused by, among other things, preclinical findings made while clinical studies were underway or safety or efficacy observations made in preclinical studies and clinical studies, including previously unreported adverse events.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical studies that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. In addition, clinical trial results for one of our product candidates or for competitor products utilizing similar technology, may raise concerns about the safety or efficacy of other products in our pipeline. If the results of our ongoing or future clinical studies are inconclusive with respect to the efficacy of our product candidates or if we do not meet the clinical endpoints with statistical significance or if there are safety concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates. There can be significant variability in safety or efficacy results between different clinical studies of the same product candidate due to numerous factors, including changes in study procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical study protocols and the rate of dropout among clinical study participants. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical studies nonetheless failed to obtain FDA approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternatively, even if we obtain regulatory approval, that approval may be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical studies to obtain approval or be subject to additional post-marketing testing requirements to maintain regulatory approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a risk evaluation and mitigation strategy (REMS) program. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim, &#8220;top-line&#8221; or preliminary data from our clinical studies. Positive preliminary data may not be predictive of such trial&#8217;s subsequent or overall results. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have only two ADC product candidates, UpRi and XMT-1592 in clinical studies. A failure of any of our product candidates in clinical development would adversely affect our business and may require us to discontinue development of other ADC product candidates based on the same technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UpRi and XMT-1592 are currently our only clinical-stage development product candidates. While we have certain other preclinical programs in development and we intend to develop other product candidates, including XMT-1660 and XMT-2056, it will take additional investment and time for such programs to reach the clinical stage of development. In addition, we have other product candidates in our current pipeline that are based on the same platforms as UpRi and XMT-1592. If either product candidate fails in development as a result of any underlying problem with our platforms, then we may be required to discontinue development of the product candidates that are based on the same technologies. If we were required to discontinue development of UpRi or XMT-1592, or if UpRi or XMT-1592 were to fail to receive regulatory approval or were to fail to achieve sufficient market acceptance, we could be prevented from or significantly delayed in achieving profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Events that may delay or prevent successful commencement, enrollment or completion of clinical studies of our product candidates could result in increased costs to us as well as a delay in obtaining, or failure to obtain, regulatory approval, or cause us to suspend or terminate a clinical trial, which could prevent us from commercializing our product candidates on a timely basis, or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that clinical studies, including our ongoing Phase&#160;1b clinical study and anticipated additional clinical studies for UpRi, our lead product candidate, and our ongoing Phase 1 does escalation study of XMT-1592, will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of testing, and other events may cause us to temporarily or permanently cease a clinical study. Events that may prevent successful or timely commencement, enrollment or completion of clinical development include, among others:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays by us in reaching a consensus with regulatory agencies on study design;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching, or failing to reach, agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical study sites;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in obtaining required Institutional Review Board, or IRB, or Ethics Committee, or EC, approval at each clinical study site;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges in recruiting and enrolling suitable patients to participate in clinical studies that meet the criteria of the protocol for the clinical study;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of a clinical hold by regulatory agencies or IRBs or ECs for any reason, including safety concerns or after an inspection of clinical operations or study sites;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by CROs, other third parties or us to adhere to clinical study requirements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to perform in accordance with the FDA&#8217;s good clinical practices, or GCP, or applicable regulatory guidelines in other countries;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate quantity or quality of a product candidate or other materials necessary to conduct clinical studies, including, for example, delays in the testing, validation, manufacturing or delivery of the product candidates to the clinical sites;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients not completing participation in a study or not returning for post-treatment follow-up, including as a result of the ongoing COVID-19 pandemic;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical study sites or patients dropping out of a study;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety issues, including occurrence of serious adverse events, or SAEs, in clinical studies that are associated with the product candidates that are viewed to outweigh their potential benefits or unforeseen safety issues in our ongoing preclinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements or guidance that require amending or submitting new clinical protocols; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical study.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays, including delays caused by the above factors, can be costly and could negatively affect our ability to complete a clinical study. If we or our partners are not able to successfully complete clinical studies, we or they will not be able to obtain regulatory approval and will not be able to commercialize our product candidates or our partners&#8217; product candidates based on our technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An inability to enroll sufficient numbers of patients in our clinical studies could result in increased costs and longer development periods for our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical studies require sufficient patient enrollment, which is a function of many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and nature of the patient population;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the nature and complexity of the study protocol, including eligibility criteria for the study;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of clinical study sites and the proximity of patients to those sites;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">standard of care in the diseases under investigation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commitment of clinical investigators to identify eligible patients;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing studies or trials; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Challenges in recruiting and enrolling suitable patients to participate in clinical studies that meet the criteria of the protocol for clinical studies could increase costs and result in delays to our current development plan for UpRi, our lead product candidate, XMT-1592 or any other current or future product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek a Breakthrough Therapy Designation or Fast Track Designation by the FDA for any of our ADC product candidates, and we may be unsuccessful. If we are successful, the designation may not actually lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that any ADC product candidate would receive marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FDA granted Fast Track Designation for UpRi for the treatment of patients with platinum-resistant high-grade serous ovarian cancer who have received up to three prior lines of systemic therapy or patients who have received four prior lines of systemic therapy regardless of platinum status. We may seek a Breakthrough Therapy Designation for UpRi, or we may seek Breakthrough Therapy Designation or Fast Track Designation for XMT-1592 or any of our product candidates. Fast Track Designation may be available if a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effects observed early in clinical development. Drugs that receive Breakthrough Therapy Designation or Fast Track Designation by the FDA may also be eligible for accelerated approval and/or priority review if they satisfy the criteria for those programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has broad discretion whether or not to grant Breakthrough Therapy Designation or Fast Track Designation. Even if we receive Breakthrough Therapy Designation or Fast Track Designation for a product candidate, such designation may not result in a faster development process, review or approval compared to conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if any of our product candidates receives Breakthrough Therapy Designation or Fast Track Designation, the FDA may later decide that the drugs no longer meet the conditions for qualification and rescind the designation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain orphan drug designation for our ADC product candidates, and even if we do, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek orphan drug designation status for one of our current or future product candidates, and we may be unsuccessful. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In Europe, orphan drug designation entitles a party to a number of incentives, such as protocol assistance and scientific advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor. Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the European Medicines Agency or the FDA from approving another marketing application for the same drug and indication for a set time period, except in limited circumstances. Even if we obtain orphan drug exclusivity for a drug, that exclusivity may not effectively protect the drug from competition because different drugs can be approved for the same condition, or the drug may be used off-label. Even after an orphan drug is approved, the FDA can subsequently approve another drug for the same condition if the FDA concludes that the other drug is clinically superior. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek orphan drug designation for applicable indications for our current or future product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development, regulatory review and approval by the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If we or our partners are ultimately unable to obtain regulatory approval for our ADC product candidates, our business will be substantially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preclinical studies and clinical studies of our product candidates are subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and, if approved, market any such product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These government regulations relate to, among other things, development, clinical studies, manufacturing and commercialization. In order to obtain regulatory approval for the commercial sale of any product candidates, we or our partners must demonstrate through extensive preclinical studies and clinical studies that the product candidate is safe and effective for use in each target indication.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following the commencement of clinical studies and depends upon numerous factors. Of the large number of drugs in development in the United States, only a small percentage will successfully complete the FDA regulatory approval process and will be commercialized. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development and preclinical studies and clinical studies, we cannot be assured that any of our product candidates will be successfully developed or commercialized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval of or the decision not to approve an application. Regulatory approval has not been obtained for any product candidate based on our technologies, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. In addition, we may gain regulatory approval for UpRi, our lead product candidate, or XMT-1592, or any other current or future product candidates in some but not all of the territories in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which we seek approval or some but not all of the target indications, resulting in limited commercial opportunity for the approved product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applications for our or our partners&#8217; product candidates could be delayed or could fail to receive regulatory approval for many reasons, including, but not limited to the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the number, design or implementation of our clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical studies of our product candidates may not meet the level of statistical or clinical significance required by the FDA or comparable foreign regulatory authorities for marketing approval or may otherwise not be sufficient to support the submission of a new drug application or biologics license application, or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may not accept data generated at our preclinical studies and clinical study sites;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may require us to conduct additional preclinical studies and clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any third-party service providers may be unable to demonstrate compliance with current Good Manufacturing Practices, or cGMPs, to the satisfaction of the FDA or comparable foreign regulatory authorities, which could result in delays in or prevent regulatory approval or require us to withdraw or recall products and interrupt commercial supply of our products; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors, many of which are beyond our control, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may conduct clinical trials for ADC product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to conduct clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles. If the foreign data is the sole basis for a marketing application, then the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful and the FDA must be able to validate the data through an on-site inspection, if necessary. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly, time-consuming and could delay or permanently halt our development of the applicable product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accelerated approval by the FDA, even if granted for UpRi, XMT-1592- or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek approval of UpRi, XMT-1592 and any of our other current and future product candidates using the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. As a condition of approval, the FDA requires that a sponsor of a product receiving accelerated approval perform a post-marketing confirmatory clinical trial or trials. These confirmatory trials must be completed with due diligence. In addition, the FDA currently requires as a condition for accelerated approval preapproval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate full FDA approval. Accelerated approval may also be withdrawn if, among other things, a confirmatory trial required to verify the predicted clinical benefit of the product fails to verify such benefit or if such trial is not conducted with due diligence.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain regulatory approval in jurisdictions outside the United States, we will not be able to market our products in those jurisdictions.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to market our product candidates, including UpRi, our lead product candidate, and XMT-1592, each, if approved, in international markets either directly or through partnerships. Such marketing will require separate regulatory approvals in each market and compliance with numerous and varying regulatory requirements. The approval procedures vary from country to country and may require additional testing that we are not required to perform to obtain regulatory approval in the United States. Moreover, the time required to obtain approval in countries outside the United States may differ from that required to obtain FDA approval. In addition, in many countries outside the United States, a drug must be approved for reimbursement before it can be approved for sale in that country. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We or our partners may not obtain foreign regulatory approvals on a timely basis, if at all. We or our partners may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. If we or any existing or future partner are unable to obtain regulatory approval for UpRi, XMT-1592, or any of our other current or future product candidates in one or more significant foreign jurisdictions, then the commercial opportunity for such product candidate and our financial condition will be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval for our ADC product candidates, such products will be subject to ongoing regulatory review, which may result in significant additional expense. Additionally, our ADC product candidates, if approved, could be subject to labeling and other restrictions, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to conditions of approval, or contain requirements for potentially costly post-marketing testing and surveillance to monitor safety and efficacy. In addition, if the FDA or any other governing regulatory body approves any of our product candidates, the manufacturing, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP, for any clinical studies that we conduct post-approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with an approved drug, including adverse events of unanticipated severity or frequency, or with manufacturing operations or processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA or any other governing regulatory body to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies of the FDA or any other governing regulatory body may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or not able to maintain regulatory compliance, we may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ADC product candidates or ADCs developed or commercialized by our competitors may cause undesirable side effects or have other properties that delay or prevent regulatory approval of our ADC product candidates or limit their commercial potential.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates or ADCs being developed or commercialized by our partners or competitors could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in a more restrictive label or the denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims. Further, clinical studies by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates or those of our competitors may only be uncovered with a significantly larger number of patients exposed to the drug. SAEs deemed to be caused by our product candidates or those of our competitors, either before or after receipt of marketing approval, could have a material adverse effect on the development of our product candidates and our business as a whole.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or others identify undesirable side effects caused by our product candidates or those of our competitors either before or after receipt of marketing approval, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our clinical studies may be put on hold;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to obtain regulatory approval for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw or limit their approvals of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a contraindication, black box warnings or additional warnings;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may require development of a REMS with Elements to Assure Safe Use as a condition of approval or post-approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may decide to remove such product candidates from the marketplace;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to regulatory investigations and government enforcement actions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could substantially increase commercialization costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our third-party collaborators are unable to successfully develop and commercialize any required companion diagnostics for our product candidates or engage a third party to do so, or we or they experience significant delays in doing so, we may not realize the full potential of our ADC product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a companion diagnostic is required for the label for UpRi, our lead product candidate, XMT-1592, or any of our other current or future product candidates, therefore conditioning our ability to market such product candidates on the commercial availability of an approved companion diagnostic, we may seek approval for our validated assay as a companion diagnostic or we may contract with third parties to create and obtain approval for a companion diagnostic. To be successful in developing and commercializing such a companion diagnostic, we need to address a number of scientific, technical and logistical challenges. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have little experience in the development and commercialization of diagnostics and may not be successful in developing and commercializing appropriate diagnostics to pair with UpRi, XMT-1592, or any of our other current or future product candidates. Companion diagnostics are subject to regulation by the FDA and equivalent foreign regulatory authorities as medical devices and require separate regulatory approval prior to commercialization. Given our limited experience in developing and commercializing diagnostics, we may rely in part or in whole on third parties for their design, manufacture and commercialization. We, our collaborators or such third parties may encounter difficulties in developing and obtaining approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility or clinical validation. Any delay or failure by us, our collaborators or such third parties to develop or obtain regulatory approval of the companion diagnostics could delay or prevent approval of our product candidates. If we, or any third parties that we may contract with to assist us, are unable to successfully develop and commercialize companion diagnostics for our product candidates, or experience delays in doing so:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the development of UpRi, XMT-1592, and our other current or future product candidates, may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may not receive marketing approval if safe and effective use of a therapeutic product candidate depends on the availability of an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostic; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not realize the full commercial potential of any product candidates that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, our business would be harmed, possibly materially.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, third-party collaborators may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics in the clinical community. If such companion diagnostics fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales of our product candidates, if approved. In addition, any diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our partners may fail to discover and develop additional potential product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our partners&#8217; research programs to identify new product candidates will require substantial technical, financial and human resources, and we or our partners may be unsuccessful in our or their efforts to identify new product candidates. If we or our partners are unable to identify suitable additional product candidates for preclinical and clinical development, our or their ability to develop product candidates and our ability to obtain revenues from commercializing our products or to receive royalties from our partners&#8217; sales of their products in future periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our financial position and need for additional capital</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred net losses since our inception, we have no products approved for commercial sale and we anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or sustain profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception. Our net loss was $88.0&#160;million for the year ended December&#160;31, 2020. As of December&#160;31, 2020, we had an accumulated deficit of $280.4 million. We do not know when or whether we will become profitable. To date, we have not commercialized any products and therefore have never generated any revenues from the sale of products, and we do not expect to generate any product revenues in the foreseeable future. Our losses have resulted principally from costs incurred in our discovery and development activities. Our net losses may fluctuate significantly from quarter to quarter and year to year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted most of our financial resources to research and development, including our clinical and preclinical development activities. To date, we have financed our operations primarily through the sale of equity securities, the receipt of funds through strategic partnerships with third parties and our credit facility. The amount of our future net losses will depend, in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">part, on the rate of our future expenditures. We have not completed pivotal clinical studies for any product candidate and only have one product candidate in a clinical study. It will be several years, if ever, before we have a product candidate ready for commercialization. Even if we obtain regulatory approval to market a product candidate, our future revenues would depend upon the size of the market or markets in which our product candidates received such approval and our ability to achieve sufficient market acceptance, reimbursement from third-party payors and adequate market share for our product candidates in those markets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing net losses for at least the next several years. We expect our expenses will increase substantially in connection with our ongoing activities, as we:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct clinical development of upifitamab rilsodotin (UpRi, XMT-1536), our lead product candidate, XMT-1592, and any other current or future product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approval for UpRi, XMT-1592, and any other current or future product candidates, if our development efforts are successful;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add personnel to support our product development efforts;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our research and development efforts for new product opportunities; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to operate as a public company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required by the United States Food and Drug Administration, or FDA, or any equivalent foreign regulatory authority to perform clinical studies or preclinical studies in addition to those we currently expect to conduct, or if there are any delays in completing the clinical studies of UpRi, XMT-1592, or any other current or future product candidates, our expenses could increase.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must succeed in developing our product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We may not succeed in these activities, and we may never generate revenue from product sales or strategic partnerships in an amount sufficient to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, discover or develop other product candidates or continue our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents were $255.1&#160;million as of December&#160;31, 2020. We have utilized substantial amounts of cash since our inception and expect that we will continue to expend substantial resources for the foreseeable future developing UpRi, our lead product candidate, XMT-1592, and any other current or future product candidates. These expenditures may include costs associated with research and development, conducting preclinical studies and clinical studies, potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling products approved for sale, if any, and potentially acquiring new technologies. In addition, other unanticipated costs may arise. Because the outcome of our planned and anticipated clinical studies is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Our costs will increase if we experience any delays in our clinical studies for UpRi, XMT-1592 or any other current or future product candidates, including delays in enrollment of patients. We also incur costs associated with operating as a public company, hiring additional personnel and expanding our facilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of researching and developing UpRi, XMT-1592 and any other current or future product candidates and conducting preclinical studies and clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of, and the costs involved in, obtaining regulatory approvals for UpRi, XMT-1592 and any other current or future product candidates if preclinical studies and clinical studies are successful;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing UpRi, XMT-1592 and any other current or future product candidates for clinical studies in preparation for regulatory approval and in preparation for commercialization;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities for UpRi, XMT-1592 and any other current or future product candidates, if any product candidates are approved for sale, including manufacturing, marketing, sales and distribution costs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of sales of, or royalties on, our future products, if any, or products developed by our partners.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our currently available funds will be sufficient to fund our operations through at least the next twelve months following the filing of our Annual Report on Form 10-K. Our operating plan, however, may change as a result of many factors currently unknown to us and we may need additional funds sooner than planned. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for one or more of our product candidates or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or ADC product candidates on unfavorable terms to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional capital through a variety of means, including through private and public equity offerings and debt financings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of such equity or convertible debt securities may include liquidation or other preferences that are senior to or otherwise adversely affect the rights of our common stockholders. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such as incurring future debt, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness, each of which could adversely impact our ability to conduct our business and execute our operating plan. If we raise additional funds through strategic partnerships with third parties, we may have to relinquish valuable rights to our technologies, including our&#160;platforms, or product candidates, or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts for UpRi, our lead product candidate, XMT-1592, or any other current or future product candidates, or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a credit facility that requires us to meet certain operating and financial covenants and place restrictions on our operating and financial flexibility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2020, we entered into a second amendment to our existing loan and security agreement, or the Credit Facility, with Silicon Valley Bank, or SVB, pursuant to which we may borrow, at our option, up to $25.0 million through April 30, 2022. We also may be able to borrow, at our option, an additional $5.0 million, if we reach certain development milestone events. &#160;The Credit Facility is secured by substantially all of our assets, except for our intellectual property, which is subject to a negative pledge, and certain other customary exclusions, which ensures that SVB&#8217;s rights to repayment would be senior to the rights of the holders of our common stock in the event of liquidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility includes customary covenants including covenants requiring us to maintain our corporate existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. Additionally, we are restricted in our ability to transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets and agree to a change in control.&#160;Upon the occurrence of an event of default, which includes our failure to satisfy our payment obligations under the Credit Facility, the breach of certain of the covenants under the Credit Facility, or the occurrence of a material adverse change in our business, SVB is entitled to increase the applicable interest rate, accelerate amounts due under the Credit Facility and dispose the collateral as permitted under applicable law. Any declaration by SVB of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on specific product candidates. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to properly assess potential product candidates could result in our focus on product candidates with low market potential, which would harm our business and financial condition. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through partnering, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our reliance on third parties</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we rely on third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party contract manufacturers to manufacture our preclinical and clinical study product supplies, and we lack the internal resources and the capability to manufacture any product candidates on a clinical or commercial scale. The facilities used by our contract manufacturers to manufacture the active pharmaceutical ingredient and final drug product must be acceptable to the FDA and other comparable foreign regulatory agencies pursuant to inspections that would be conducted after we submit our marketing application or relevant foreign regulatory submission to the applicable regulatory agency. There can be no assurance that our preclinical and clinical development product supplies will be sufficient, uninterrupted or of satisfactory quality or continue to be available at acceptable prices. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or applicable foreign regulatory agencies, they will not be able to secure or maintain regulatory approval for their manufacturing facilities. Any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMP. We have no direct control over our contract manufacturers&#8217; ability to maintain adequate quality control, quality assurance and qualified personnel. In the event that any of our manufacturers fails to comply with regulatory requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. Our reliance on contract manufacturers also exposes us to the possibility that they, or third parties with access to their facilities, will have access to and may appropriate our trade secrets or other proprietary information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a delay or inability to initiate or continue clinical studies of product candidates under development;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in submitting regulatory applications, or delay or failure to receive regulatory approvals, for product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of the cooperation of an existing or future strategic partner;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement to cease distribution or to recall batches of our product candidates; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, adverse publicity, and civil and criminal enforcement and sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, or our third-party manufacturers, may be unable to successfully scale-up manufacturing of our ADC product candidates in sufficient quality and quantity, which would delay or prevent us from developing our ADC product candidates and commercializing approved products, if any.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to conduct clinical studies of our product candidates and commercialize any approved product candidates, we, or our manufacturing partners, will need to manufacture them in large quantities. We, or our manufacturing partners, may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we, or any manufacturing partners, are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical studies of that product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. We have evaluated which third-party manufactures to engage for scale-up to commercial supply of our product candidates, including UpRi, our lead product candidate and XMT-1592, and we have begun transfer and scale-up of certain manufacturing activities. If we are unable to obtain or maintain third-party manufacturing for commercial supply of our product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct preclinical studies and clinical studies for UpRi and XMT-1592 and if such third parties do not properly and successfully perform their obligations to us, we may not be able to obtain regulatory approvals for UpRi, XMT-1592, or any other current or future ADC product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designed the Phase&#160;1 clinical studies for UpRi, our lead product candidate, and XMT-1592, and we intend to design any future clinical studies for any future unpartnered product candidates that we may develop if preclinical studies are successful. However, we rely on CROs and other third parties to assist in managing, monitoring and otherwise carrying out many of these studies. As a result, we have less direct control over the conduct, timing and completion of these clinical studies and the management of data developed through clinical studies than would be the case if we were relying entirely upon our own staff. These CROs and other third parties are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. We compete with many other companies for the resources of these third parties. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with whom we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical studies, resulting in the preclinical studies or clinical studies being delayed or unsuccessful.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third parties on whom we rely generally may terminate their engagements at any time, and having to enter into alternative arrangements would delay development and commercialization of our product candidates. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have staffing difficulties;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fail to comply with contractual obligations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience regulatory compliance issues;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">undergo changes in priorities or become financially distressed; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">form relationships with other entities, some of which may be our competitors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable foreign regulatory authorities require compliance with regulations and standards, including GCP, for designing, conducting, monitoring, recording, analyzing and reporting the results of clinical studies to assure that the data and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">results are credible and accurate and that the rights, integrity and confidentiality of study participants are protected. Although we rely, and intend to continue to rely, on third parties to conduct our clinical studies, they are not our employees, and we are responsible for ensuring that each of these clinical studies is conducted in accordance with its general investigational plan, protocol and other requirements. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these third parties do not successfully carry out their duties under their agreements, if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to clinical study protocols or to regulatory requirements, or if they otherwise fail to comply with clinical study protocols or meet expected deadlines, the clinical studies of our product candidates may not meet regulatory requirements. The FDA enforces GCP regulations through periodic inspections of clinical study sponsors, principal investigators and study sites. If we or our CROs fail to comply with applicable GCPs or other regulatory requirements, the clinical data generated in our clinical studies may be deemed unreliable, third parties may need to be replaced, we may be subject to negative publicity, fines and civil or criminal sanctions, and preclinical development activities or clinical studies may be extended, delayed, suspended or terminated. If any of these events occur, we may not be able to obtain regulatory approval of our product candidates on a timely basis or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on strategic partnerships with other companies to assist in the research, development and commercialization of our ADC platforms and ADC product candidates. If our existing partners do not perform as expected, this may negatively affect our ability to commercialize our ADC product candidates, generate revenues through technology licensing, or otherwise negatively affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established strategic partnerships and intend to continue to establish strategic partnerships with third parties to research, develop and commercialize our platforms and existing and future product candidates. We entered into a collaboration agreement with Merck KGaA for the development and commercialization of other product candidates. For certain of these programs, we will depend on our partners to design and conduct their clinical studies. As a result, we may not be able to conduct these programs in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations. In addition, if any of these partners withdraw support for these programs or proposed products or otherwise impair their development or experience negative results, our business and our product candidates could be negatively affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners may terminate their agreements with us for cause under certain circumstances or at will in certain cases and discontinue use of our technologies. In addition, we cannot control the amount and timing of resources our partners may devote to products utilizing or incorporating our technology. Moreover, our relationships with our partners may divert significant time and effort of our scientific staff and management team and require effective allocation of our resources to multiple internal and collaborative projects. Our partners may fail to perform their obligations under the collaboration agreements or may not perform their obligations in a timely manner. If conflicts arise between our partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. If any of our partners terminate or breach our agreements with them, or otherwise fail to complete their obligations in a timely manner, it may have a detrimental effect on our financial position by reducing or eliminating the potential for us to receive technology access and license fees, milestones and royalties, reimbursement of development costs, as well as possibly requiring us to devote additional efforts and incur costs associated with pursuing internal development of product candidates. Furthermore, if our partners do not prioritize and commit sufficient resources to programs associated with our product candidates or collaboration product candidates, we or our partners may be unable to commercialize these product candidates, which would limit our ability to generate revenue and become profitable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners may separately pursue competing products, therapeutic approaches or technologies to develop treatments for the diseases targeted by us or our partners. Competing products, either developed by the partners or to which the partners have rights, may result in the withdrawal of partner support for our product candidates. Even if our partners continue their contributions to the strategic partnerships, they may nevertheless determine not to actively pursue the development or commercialization of any resulting products. Additionally, if our partners pursue different clinical or regulatory strategies with their product candidates based on our platforms or technologies, adverse events with their product candidates could negatively affect our product candidates utilizing similar technologies.&#160;Any of these developments could harm our product development efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To date, we have depended on a small number of partners for a substantial portion of our revenue. The loss of any one of these partners could result in a material decline in our revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have strategic partnerships with a limited number of companies. To date, a substantial portion of our revenue has resulted from payments made under agreements with our strategic partners, and we expect that a portion of our revenue will continue to come from strategic partnerships. The loss of any of our partners, or the failure of our partners to perform their obligations under their agreements with us, including paying license or technology fees, milestone payments, royalties or reimbursements, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could have a material adverse effect on our financial performance. Payments under our existing and future strategic partnerships are also subject to significant fluctuations in both timing and amount, which could cause our revenue to fall below the expectations of securities analysts and investors and cause a decrease in our stock price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in establishing and maintaining additional strategic partnerships, which could adversely affect our ability to develop and commercialize products, negatively impacting our operating results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to strategically evaluate our partnerships and, as appropriate, we expect to enter into additional strategic partnerships in the future, including potentially with major biotechnology or biopharmaceutical companies. We face significant competition in seeking appropriate partners for our product candidates, and the negotiation process is time-consuming and complex. In order for us to successfully partner our product candidates, potential partners must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Even if we are successful in our efforts to establish strategic partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. Any delay in entering into strategic partnership agreements related to our product candidates could delay the development and commercialization of such candidates and reduce their competitiveness even if they reach the market. If we are not able to generate revenue under our strategic partnerships when and in accordance with our expectations or the expectations of industry analysts, this failure could harm our business and have an immediate adverse effect on the trading price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to establish and maintain additional strategic partnerships related to our unpartnered product candidates, we will bear all of the risk and costs related to the development of any such product candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise, such as regulatory expertise, for which we have not budgeted. If we were not successful in seeking additional financing, hiring additional employees or developing additional expertise, our cash burn rate would increase or we would need to take steps to reduce our rate of product candidate development. This could negatively affect the development of any unpartnered product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to commercialization of our ADC product candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future commercial success depends upon attaining significant market acceptance of our ADC product candidates, if approved, among physicians, patients and health care payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for UpRi, our lead product candidate, XMT-1592, or any other current or future product candidates that we may develop or acquire in the future, the product candidate may not gain market acceptance among physicians, health care payors, patients and the broader healthcare community. Market acceptance of any approved products depends on a number of factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and safety of the product, as demonstrated in clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the indications for which the product is approved and the label approved by regulatory authorities for use with the product, including any warnings that may be required on the label;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians and patients of the product as a safe and effective treatment;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, safety and efficacy of treatment in relation to alternative treatments;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate reimbursement and pricing by third-party payors and government authorities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse side effects; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Perceptions of any product are influenced by perceptions of competitors&#8217; products that are in the same class of drugs or have a similar mechanism of action. As a result, adverse public perception of our competitors&#8217; products may negatively impact the market acceptance of our product candidates. Market acceptance is critical to our ability to generate significant revenue and become profitable. Any therapeutic candidate, if approved and commercialized, may be accepted in only limited capacities or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not at all. If any approved products are not accepted by the market to the extent that we expect, we may not be able to generate significant revenue and our business would suffer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The incidence and prevalence for target patient populations of our drug candidates have not been established with precision. If the market opportunities for our drug candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The precise incidence and prevalence of epithelial ovarian cancer and non-squamous NSCLC with NaPi2b expression are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our drug candidates, are based on estimates. The total addressable market opportunity for UpRi or XMT-1592 for the treatment of epithelial ovarian cancer and non-squamous NSCLC with NaPi2b expression will ultimately depend upon, among other things, the diagnosis criteria included in the final label for UpRi or XMT-1592, if our drug candidates are approved for sale for these indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients who can be treated with our drug candidates may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our drugs, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of products. To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales and marketing organization.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we expect to build a focused sales and marketing infrastructure to market UpRi, our lead product candidate, XMT-1592, and any other current or future product candidates in the United States and certain foreign jurisdictions, if and when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our products on our own include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of sales personnel to obtain access to physicians;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of adequate numbers of physicians to prescribe any future products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish our own sales, marketing and distribution capabilities and enter into arrangements with third parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute certain of our product candidates outside of the United States or may be unable to do so on terms that are favorable to us. We likely will have limited control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement may be limited or unavailable in certain market segments for our ADC product candidates, which could make it difficult for us to sell our products profitably.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, sales of any of our product candidates, if approved, will depend, in part, on the extent to which the costs of our products will be covered by third-party payors, such as government health programs, commercial insurance and managed health care organizations. These third-party payors decide which drugs will be covered and establish reimbursement levels for those drugs. The containment of health care costs has become a priority of foreign and domestic governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. Cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower than anticipated product revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse pricing limitations may hinder our ability to recoup our investment in UpRi, our lead product candidate, XMT-1592, or any other current or future product candidates, even if such product candidates obtain marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. Further, there is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our products. If reimbursement is not available or is available only to limited levels, we may not be able to commercialize certain of our products. In addition, in the United States, third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement of new drugs. As a result, significant uncertainty exists as to whether and how much third-party payors will reimburse patients for their use of newly approved drugs, which in turn will put pressure on the pricing of drugs. Manufacturers further may be required to offer price concessions to achieve sales or favorable coverage.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Price controls may be imposed in foreign markets, which may adversely affect our future profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, including member states of the European Union, the pricing of prescription drugs is subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In such countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. We cannot be sure that such prices and reimbursement will be acceptable to us or our strategic partners. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the potential profitability of our product candidates in those countries would be negatively affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The impact of health care reform legislation and other changes in the health care industry and in health care spending on us is currently unknown and may adversely affect our business model.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue prospects could be affected by changes in health care spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care availability, the method of delivery or payment for health care products and services could negatively impact our business, operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the United States, there have been ongoing government efforts at the federal and state levels to reform the provision or control the cost of health care.&#160;There have been a number of legislative and regulatory changes to the healthcare system, such as the enactment and subsequent modification of the Health Care Reform Act,&#160;that could affect our future results of operations or the commercial success of our products, if approved.&#160;See &#8220;Business-Government regulation - Healthcare reform&#8221;. We continue to evaluate the effect that healthcare reform efforts may have on our business, but expect that healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if approved. Healthcare reform efforts to contain or reduce costs of health care may adversely affect:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for any products for which we may obtain regulatory approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain coverage and reimbursement approval for a product;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the ultimate content, timing or effect of any such reforms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted that affect health care spending. The Budget Control Act of 2011, includes provisions to reduce the federal deficit. The Budget Control Act, as amended, resulted in the imposition of 2% reductions in Medicare payments to providers which began in April 2013, and will remain in effect through 2030 (except May 1, 2020 to March 31, 2021) unless additional Congressional action is taken. Any significant spending reductions affecting Medicare, Medicaid&#160;or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could&#160;have an adverse impact on our results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully than, we do.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. Many third parties compete with us in developing various approaches to cancer therapy. They include pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. Any treatments developed by our competitors could be superior to our product candidates. It is possible that these competitors will succeed in developing technologies that are more effective than our platforms or product candidates or that would render our platforms obsolete or noncompetitive. We anticipate that we will face increased competition in the future as additional companies enter our market and scientific developments surrounding other cancer therapies continue to accelerate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of multiple companies with ADC technologies that may be competitive to our platforms, including Astellas, AstraZeneca, Daiichi Sankyo, ImmunoGen, Immunomedics, Pfizer and SeaGen. These companies or their partners, including AbbVie, Genentech and Takeda, may develop product candidates which compete in the same indications as our current and future product candidates. We expect to compete on improved efficacy, safety and tolerability compared to other product candidates and if our products are not demonstrably superior in these respects compared to other approved therapeutics, we may not be able to compete effectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, conducting clinical studies, obtaining regulatory approval and marketing than we do. In addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Smaller or early-stage companies may also prove to be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant competitors, particularly through strategic partnerships with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to our programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our product candidates are approved and commercialized, we may face competition from biosimilars. The route to market for biosimilars was established with the passage of the Health Care Reform Act in March 2010. The Health Care Reform Act establishes a pathway for the FDA approval of follow-on biologics and provides twelve years data exclusivity for reference products. The BPCIA is complex and continues to be interpreted and implemented by the FDA.  In addition, government proposals have sought to reduce the 12-year reference product exclusivity period.  Further, since the BPCIA was enacted as part of the overall Health Care Reform Act, current litigation challenges to that Act, discussed more in full below, could impact the validity of the BPCIA.  As a result, there still remains significant uncertainty as to the ultimate impact, implementation and regulatory interpretation of the BPCIA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the European Medicines Agency has issued guidelines for approving products through an abbreviated pathway, and biosimilars have been approved in Europe. If a biosimilar version of one of our potential products were approved in the United States or Europe, it could have a negative effect on sales and gross profits of the potential product and our financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our current and potential future product candidates, we believe that our ability to compete effectively and develop products that can be manufactured cost-effectively and marketed successfully will depend on our ability to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our technology platforms;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and maintain intellectual property protection for our technologies and products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain required government and other public and private approvals on a timely basis;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain key personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize effectively;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain reimbursement for our products in approved indications;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comply with applicable laws, regulations and regulatory requirements and restrictions with respect to the commercialization of our products, including with respect to any changed or increased regulatory restrictions; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into additional strategic partnerships to advance the development and commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our intellectual property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or protect intellectual property rights related to our technology and ADC product candidates, or if our intellectual property rights are inadequate, we may not be able to compete effectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain protection with respect to our intellectual property and proprietary technology. We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our&#160;platforms and our product candidates, including UpRi and XMT-1592. The patent position of biopharmaceutical companies is generally uncertain because it involves complex legal and factual considerations and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights is highly uncertain. The standards applied by the United States Patent and Trademark Office, or USPTO, and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in patents. In addition, changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The patent prosecution process is expensive, complex and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. It is also possible that we fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found. We may be unaware of prior art that could be used to invalidate an issued patent or prevent our pending patent applications from issuing as patents.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent applications that we own or in-license may fail to result in issued patents, and even if they do issue as patents, such patents may not cover our platforms and product candidates in the United States or in other countries. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. For example, even if patent applications we license or own do successfully issue as patents and even if such patents cover our platforms and product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not provide adequate protection or exclusivity for our ADC platform or product candidates, prevent others from designing around our claims or otherwise provide us with a competitive advantage. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If patent applications we own or have in-licensed with respect to our platforms or our product candidates fail to issue as patents, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity, it could dissuade companies from collaborating with us. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patents or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful development and commercialization of any product candidate. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be initiated by the USPTO or a third-party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20&#160;years after it is filed. Various extensions may be available; however, the life of a patent and the protection it affords is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, our owned or in-licensed patents protecting such candidates might expire before or shortly after such candidates are commercialized. If we encounter delays in obtaining regulatory approvals, the period of time during which we could market a drug under patent protection could be further reduced. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from similar or generic products. The launch of a generic version of one of our products in particular would be likely to result in an immediate and substantial reduction in the demand for our product, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law, which could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switch the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file&#160;a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. These provisions also allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. The USPTO developed additional regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and, in particular, the first-to-file provisions, only became effective on March&#160;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any loss of patent protection could have a material adverse impact on our business. We may be unable to prevent competitors from entering the market with a product that is similar to or the same as our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering UpRi, our lead product candidate, XMT-1592, and any other current or future ADC product candidates could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign authority.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering UpRi, our lead product candidate, XMT-1592, or any other current or future product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">counterclaims alleging invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be, among other things, an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description or non-enablement. Grounds for an unenforceability assertion could be, among other things, an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, inter partes review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g.,&#160;opposition proceedings). Such proceedings could result in revocation, cancellation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our licensors, our patent counsel and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Any such loss of patent protection could have a material adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under any license, strategic partnership or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our ADC product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, in part, on license, collaboration and other agreements. We may need to obtain additional licenses from others to advance our research or allow commercialization of our product candidates and it is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. The licensing or acquisition of third party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to use. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our existing licenses and collaboration agreements, including our license with Recepta Biopharma S.A., or Recepta, for intellectual property covering the NaPi2b antibody in UpRi and XMT-1592,  and our license with Synaffix B.V, or Synaffix, for intellectual property covering components included in the Dolasynthen platform, impose, and any future licenses, collaborations or other agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, including, in the case of our agreement with Recepta, the license for the rights covering the NaPi2b antibody in UpRi and XMT-1592, and in the case of our agreement with Synaffix, the license for the rights covering components in the Dolasynthen platform. Any of the foregoing could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Disputes may arise regarding intellectual property subject to a licensing, collaboration or other agreements, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation related issues;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering the technology that we license from third parties. For example, pursuant to our license agreement with Recepta, Ludwig Institute for Cancer Research&#160;Ltd., a co-owner of the intellectual property, retains control of such activities. Therefore, we cannot be certain that these patents and applications will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If our licensors fail to obtain or maintain such intellectual property, or lose rights to such intellectual property, the rights we have licensed and our exclusivity may be reduced or eliminated and our right to develop and commercialize any of our products that are subject to such licensed rights could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, our rights to our in-licensed patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such in-licensed patents and patent applications. If one or more of such joint owners breaches such inter-institutional or operating agreements, our rights to such in-licensed patents and patent applications may be adversely affected. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate and our business, financial condition, results of operations and prospects could suffer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property or to defend against intellectual property claims, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors and other third parties may infringe our patents or misappropriate or otherwise violate our owned and in-licensed intellectual property rights. To counter infringement or unauthorized use, litigation or other intellectual property proceedings may be necessary to enforce or defend our owned and in-licensed intellectual property rights, to protect our trade secrets or to determine the validity and scope of our own intellectual property rights or the proprietary rights of others. Such litigation or proceedings can be expensive and time consuming, and any such claims could provoke defendants to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Many of our current and potential competitors have the ability to dedicate substantially greater resources to litigate intellectual property rights than we can and have more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. Even if resolved in our favor, litigation or other intellectual property proceedings could result in substantial costs and diversion of management attention and resources, which could harm our business and financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in a litigation or other proceeding, a court or administrative judge may decide that a patent owned by or licensed to us is invalid or unenforceable, or a court may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or other proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation and other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. During the course of any patent or other intellectual property litigation or other proceeding, there could be public announcements of the results of hearings, rulings on motions and other interim proceedings or developments and if securities analysts or investors regard these announcements as negative, the perceived value of our product candidates, programs or intellectual property could be diminished. Accordingly, the market price of our common stock may decline. Any of the foregoing could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement or misappropriation may prevent or delay our development and commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability and the ability of our strategic partners to develop, manufacture, market and sell product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, derivation and post grant review proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing and may develop our product candidates. As the biopharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we, our customers, licensees or parties indemnified by us are employing their proprietary technology without authorization or have infringed upon, misappropriated or otherwise violated their intellectual property or other rights, regardless of their merit. For example, we may be subject to claims that we are infringing the patent, trademark or copyright rights of third parties, or that our employees have misappropriated or divulged their former employers&#8217; trade secrets or confidential information. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates, that we failed to identify. For example, applications filed before November&#160;29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until issued as patents. Except for certain exceptions, including the preceding exceptions, patent applications in the United States and elsewhere are generally published only after a waiting period of approximately 18&#160;months after the earliest filing, and sometimes not at all. Therefore, patent applications covering our platforms or our product candidates could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platforms, our product candidates or the use or manufacture of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we believe a third party&#8217;s claims against us are without merit, a court of competent jurisdiction could hold that such third party&#8217;s patent is valid, enforceable and cover aspects of our product candidates, including the materials, formulations, methods of manufacture, methods of analysis, or methods for treatment, in which case, such third party would be able to block our ability to develop and commercialize the applicable technology or product candidate until such patent expired or unless we obtain a license and we may be required to pay such third-party monetary damages, which could be substantial. Such licenses may not be available on acceptable terms, if at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property and it could require us to make substantial licensing and royalty payments. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may also obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our technologies or one or more of our product candidates. Defending against claims of patent infringement, misappropriation of trade secrets or other violations of intellectual property could be costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle at an early stage, such litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. In the event of a successful claim of infringement against us, in addition to potential injunctive relief, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face a claim of misappropriation if a third party believes that we inappropriately obtained and used trade secrets of such third party. If we are found to have misappropriated a third party&#8217;s trade secrets, we may be prevented from further using such trade secrets, limiting our ability to develop our product candidates, we may be required to obtain a license to such trade secrets which may not be available on commercially reasonable terms or at all and may be non-exclusive, and we may be required to pay damages, which could be substantial. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world where we expect there to be significant markets for our products could be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. In addition, our intellectual property license agreements may not always include worldwide rights. For example, certain U.S. and foreign issued patents and patent applications are licensed to us by Recepta on a worldwide basis, except that Recepta retains exclusive rights in such patents and patent applications in Brazil. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our licensed and owned patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing as patents, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our platform technology and discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants and outside scientific advisors, contractors and partners. We cannot guarantee that we have entered into such agreement with each party that may have or have had access to our trade secrets or proprietary technology and processes. Additionally, our confidentiality agreements and other contractual protections may not be adequate to protect our intellectual property from unauthorized disclosure, third-party infringement or misappropriation. We may not have adequate remedies in the case of a breach of any such agreements, and our trade secrets and other proprietary information could be disclosed to our competitors or others may independently develop substantially equivalent or superior proprietary information and techniques or otherwise gain access to our trade secrets or disclose such technologies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, some courts outside and within the United States sometimes are less willing to protect trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our licensors, employees, consultants, advisors or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our and our licensors&#8217; employees, including our senior management, consultants or advisors are currently, or previously were, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, including members of our senior management, executed proprietary rights, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Any of the foregoing may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our owned or in-licensed U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and patent applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and non-U.S. patent agencies. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make ADC products that are similar to any product candidates we may develop or utilize similar ADC-related technology but that are not covered by the claims of the patents that we license or may own in the future;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our license partners or current or future strategic partners, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our license partners or current or future strategic partners, might not have been the first to file patent applications covering certain of our or their inventions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may harm our business; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file&#160;a patent in order to maintain certain trade secrets or know how, and a third party may subsequently file&#160;a patent covering such intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our business and industry</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our ADC product candidates, conduct our clinical studies and commercialize our ADC product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and biopharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on members of our senior management, including Anna Protopapas, our President and Chief Executive Officer. The loss of the services of any of our senior management could impede the achievement of our research, development and commercialization objectives. Also, each of these persons may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, sales and marketing personnel will also be critical to our success. We conduct our operations at our facility in Cambridge, Massachusetts, in a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors, may be employed or have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we seek to advance our product candidates through clinical studies and commercialization, we will need to expand our development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our development efforts and clinical studies effectively and hire, train and integrate additional management, administrative and, if necessary, sales and marketing personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company or disrupt our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a pharmaceutical manufacturer, our activities, including our interactions with healthcare providers, third party payors, patients and government officials, are, and will continue to be, subject to extensive regulation involving health care, anti-corruption, data privacy and security and consumer protection laws.&#160;Failure to comply with applicable laws could result in substantial penalties, contractual damages, reputational harm, diminished revenues and curtailment or restructuring of our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities may now or in the future be directly or indirectly subject to various federal and state laws related to health care, anti-corruption, data privacy and security consumer protection. If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws include, but are not limited to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal anti-kickback law, which prohibits, among other things, persons from offering, soliciting, receiving or providing any remuneration, directly or indirectly, to induce, either the referral of an individual for,  or the purchasing or ordering of a good or service, for which payment may be made under federal health care programs such as the Medicare and Medicaid;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal anti-kickback prohibition known as Eliminating Kickbacks in Recovery Act or EKRA, enacted in 2018, which prohibits certain payments related to referrals of patients to certain providers (recovery homes, clinical treatment facilities and laboratories) and applies to services reimbursed by private health plans as well as government health care programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal law known as HIPAA, which, in addition to privacy protections to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program (which may include private health plans) or making false statements relating to healthcare matters;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDCA, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products for off-label use and regulates the distribution of samples;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the so-called &#8220;federal sunshine&#8221; law, which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with teaching hospitals, physicians and certain non-physician practitioners to the federal government for re-disclosure to the public;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the privacy, security and breach provisions of HIPAA, which impose obligations on certain &#8220;covered entities&#8221; (healthcare providers, health plans and healthcare clearinghouses) and certain of their &#8220;business associate&#8221; contractors with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state laws and regulations, including state security breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure and protection of health-related and other personal information.  </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Foreign Corrupt Practices Act, a United States law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals); and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law analogues of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including private health plans, state privacy laws, state consumer protection laws, and state laws regulating interactions between pharmaceutical manufacturers and healthcare providers, requiring disclosure of such financial interactions or mandating adoption of certain compliance standards, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the regulatory approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the health care laws mentioned above, among other foreign laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable health care laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal health care programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal health care programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our ADC product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates or products that we may develop;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical study participants;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to study participants or patients;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decline in our stock price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We currently carry product liability insurance covering our clinical studies in the amount of $10&#160;million in the aggregate. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. In such instance, we might have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our third-party contract manufacturers must comply with environmental, health and safety laws and regulations, and failure to comply with these laws and regulations could expose us to significant costs or liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations, we could be held liable for any resulting damages and any such liability could exceed our assets and resources. We could also incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with respect to the operations of our third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire assets or form strategic alliances in the future, and we may not realize the benefits of such acquisitions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire additional technologies and assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire assets with promising markets or technologies, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not be able to realize the benefit of acquiring such assets if we are unable to successfully integrate them with our existing technologies. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot be assured that, following any such acquisition, we will achieve the expected synergies to justify the transaction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of our strategic partners, third-party collaborators or other contractors or consultants, may fail or suffer security breaches, which could adversely affect our business, including through&#160;material disruptions of our programs or business operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal information technology systems and those of our current or future strategic partners, third party collaborators and other contractors and consultants are vulnerable to service interruptions or security breaches, including from cyber-attacks, computer viruses, ransomware, malware, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If a failure, accident or security breach were to occur and cause interruptions in our operations or the operations of those third parties with which we contract, it could result in a material disruption of our programs and our business operations. We could lose access to our trade secrets or other proprietary information or experience other disruptions, which could require a substantial expenditure of resources to remedy. For example, the loss of clinical study data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in our information systems and networks, including personal information of our employees or others. Outside parties may attempt to penetrate our systems or those of the third parties with which we contract or to coerce or fraudulently induce our employees or employees of such third parties to disclose sensitive information to gain access to our data. The number and complexity of these threats continue to increase over time. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, such risks cannot be eliminated. Furthermore, there can be no assurance that we, or those third parties with which we contract, will promptly detect any such disruption or security breach, if at all. Additionally, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become more sophisticated. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities, our competitive position and the market perception of the effectiveness of our security measures could be harmed, our credibility could be damaged and the further development of our product candidates could be delayed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our common stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our stock price is volatile, our stockholders could incur substantial losses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and may continue to be volatile. The market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this &#8220;Risk Factors&#8221; section, and others beyond our control, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results and timing of preclinical studies and clinical studies of our current or future product candidates, including UpRi and XMT-1592;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical studies of our competitors&#8217; products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to adequately protect our trade secrets;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms on which we raise additional capital or our ability to raise it;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement or termination of any strategic partnership or licensing arrangement;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments, including actions with respect to our products or our competitors&#8217; products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated fluctuations in our financial condition and operating results;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports by securities analysts about us or our competitors or our industry;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions and departures of key personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the passage of legislation or other regulatory developments affecting us or our industry;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us (including pursuant to the pre-funded warrants described below), our insiders or our other stockholders;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">speculation in the press or investment community;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in market conditions for biopharmaceutical stocks; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in general market and economic conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market has historically experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. As a result of this volatility, stockholders may not be able to sell their common stock at or above the price for which they paid for their shares. As we operate in a single industry, we are especially vulnerable to these factors to the extent that they affect our industry or our products, or to a lesser extent our markets. Furthermore, as a result of this volatility, we may not be able to maintain compliance with listing requirements of the Nasdaq Stock Market. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management&#8217;s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and are able to exercise significant influence over matters subject to stockholder approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our executive officers, directors and stockholders who own more than 5% of our outstanding common stock, together with their respective affiliates, beneficially owned a significant amount of our common stock, including shares subject to outstanding options and warrants that are exercisable within 60&#160;days after such date. Accordingly, these stockholders are able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of our board of directors and approval of significant corporate transactions. This concentration of ownership could have the effect of entrenching our management or board of directors, delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material and adverse effect on the fair market value of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not expect to pay any cash dividends for the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our operations. In addition, our credit facility contains terms and any future debt financing arrangement may contain additional terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our amended and restated certificate of incorporation, our amended and restated by-laws and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation, amended and restated by-laws and Delaware law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. Our amended and restated certificate of incorporation and by-laws include provisions that:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create a classified board of directors whose members serve staggered three-year terms;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specify that special meetings of our stockholders can be called only by our board of directors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit stockholder action by written consent;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that our directors may be removed only for cause;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specify that no stockholder is permitted to cumulate votes at any election of directors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expressly authorize our board of directors to have discretion to modify, alter or repeal our amended and restated by-laws; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated by-laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our amended and restated certificate of incorporation, amended and restated by-laws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses and certain tax credit carryforwards may be subject to certain limitations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded no income tax benefit for the net operating losses incurred in each year, due to the uncertainty of realizing a benefit from those items. The Company has incurred net operating losses (NOLs) since its inception. As of December&#160;31, 2020, the Company had federal NOLs of approximately  $250.4 million and state NOLs of approximately $184.8 million. Of the $250.4 million of federal NOLs, $34.2 million expire at various dates through 2037. The remaining $216.2 million of federal NOLs do not expire. The state NOLs will expire at various dates through 2040. As of December&#160;31, 2020, the Company had Federal and State research and development tax credit carryforwards of approximately $4.6 million and $1.5 million, respectively, which expire at various dates through 2040. Under the 2017 Tax Act, federal NOLs incurred in 2019 and in future years may be carried forward indefinitely, but the deductibility of such federal NOLs is limited. It is uncertain if and to what extent various states will conform to the 2017 Tax Act. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, under Section 382 of the Internal Revenue Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes to offset its post-change income or taxes may be limited. Our past issuances of stock and other changes in our stock ownership may have resulted in ownership changes within the meaning of Section 382 of the Code; accordingly, our pre-change NOLs may be subject to limitation under Section 382. If we determine that we have not undergone an ownership change, the Internal Revenue Service could challenge our analysis, and our ability to use our NOLs to offset taxable income could be limited by Section 382 of the Code. Future changes in our stock ownership, some of which are outside of our control, could result in ownership changes under Section 382 of the Code further limiting our ability to utilize our NOLs. Our NOLs may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs. The Company has determined that ownership changes have occurred since our inception and that certain NOLs and research and development tax credit carryforwards will be subject to limitation.&#160;We may also have incurred subsequent ownership changes. Furthermore, our ability to utilize our NOLs is conditioned upon our attaining profitability and generating U.S. federal taxable income. We have incurred net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future; thus, we do not know whether or when we will generate the U.S. federal taxable income necessary to utilize our NOLs. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation designates the state or federal courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, subject to limited exceptions, the state or federal courts within the State of Delaware will be exclusive forums for (1)&#160;any derivative action or proceeding brought on our behalf, (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3)&#160;any action asserting a claim against us arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated by-laws or (4)&#160;any other action asserting a claim against us that is governed by the internal affairs doctrine. Any person or entity that purchases or otherwise acquires any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General risk factors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business is subject to risks arising from the outbreaks of disease, such as epidemics or pandemics, including the ongoing COVID-19 pandemic.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization, or the WHO, declared the COVID-19 outbreak a pandemic and recommended containment and mitigation measures worldwide. On March 13, 2020, the U.S. President announced a National Emergency relating to the disease. The widespread infection in the United States and abroad has caused significant volatility and uncertainty in U.S. and international markets, which could result in a prolonged economic downturn that may disrupt the Company&#8217;s business, including by adversely affecting our ability to conduct financings on terms acceptable to us, if at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may be adversely affected, delayed or interrupted, including, for example, site initiation, patient recruitment and enrollment, availability of clinical trial materials, and data analysis. Some patients and clinical investigators may not be able to comply with clinical trial protocols and patients may choose to withdraw from our studies or we may have to pause enrollment or we may choose to or be required to pause enrollment and or patient dosing in our ongoing clinical trials in order to preserve health resources and protect trial participants, which could delay our clinical trials or impact the strength or validity of our clinical trial data. It is unknown how long these pauses or disruptions could continue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently rely on third parties to, among other things, manufacture raw materials, manufacture our product candidates for our clinical trials, shipping of investigation drugs and clinical trial samples, perform quality testing and supply other goods and services to run our business. If any such third party in our supply chain for materials are adversely impacted by restrictions resulting from the coronavirus pandemic, including staffing shortages, raw material supplies, production slowdowns or disruptions in delivery systems, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our clinical trials and conduct our research and development operations.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have requested that most of our personnel work remotely, restricted on-site staff to only those personnel and contractors who must perform essential activities that must be completed on-site and limited the number of staff in any given research and development laboratory. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees and contractors conducting research and development activities may not be able to access our laboratory for an extended period of time as a result of the closure of our offices and the possibility that governmental authorities further modify current restrictions. As a result, this could delay timely completion of preclinical activities, including completing Investigational New Drug (IND)-enabling studies or our ability to select future development candidates, and initiation of additional clinical trials for other of our development programs</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health regulatory agencies globally may experience disruptions in their operations as a result of the coronavirus pandemic. The U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory agencies may have slower response times or be under-resourced to continue to monitor our clinical trials and, as a result, review, inspection, and other timelines may be materially delayed. It is unknown how long these disruptions could continue, were they to occur. Any prolongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates. For example, regulatory authorities may require that we not distribute a product candidate lot until the relevant agency authorizes its release. Such release authorization may be delayed as a result of the coronavirus pandemic and could result in delays to our clinical trials.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trading prices for our common shares and other biopharmaceutical companies have been highly volatile as a result of the coronavirus pandemic. As a result, we may face difficulties raising capital through sales of our common shares or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the coronavirus could materially and adversely affect our business and the value of our common shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve rapidly. The ultimate impact of the coronavirus pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the ultimate geographic spread of the disease, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19, the timing, availability, efficacy, adoption and distribution of vaccines or other preventative treatments and other actions taken to contain coronavirus or address its impact in the short and long term, among others. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We, or the third parties upon whom we depend, may be adversely affected by serious disasters.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any unplanned event, such as a flood, fire, explosion, earthquake, extreme weather condition, medical epidemic, power shortage, telecommunication failure or other natural or human-made accidents or incidents that result in us being unable to fully use our facilities, or the facilities of third-parties with which we contract, may have a material and adverse effect on our ability to operate our business and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our current or future product candidates or the interruption of our business operations for a substantial period of time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the amounts of insurance that we maintain will be sufficient to satisfy any damages and losses in the event a serious disaster or similar event occurs. If our facilities, or the manufacturing facilities of our third-party contract </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs and commercialization efforts may be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div id="i7157c5eacfe941de9505feeee920791e_22"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i7157c5eacfe941de9505feeee920791e_25"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;PROPERTIES.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Cambridge, Massachusetts. We occupy approximately 35,000 square feet of office and laboratory space that we lease in a multi-tenant building in which our corporate headquarters are located. We have an option to extend the lease term for an additional five years thereafter. We believe that this office and laboratory space is sufficient to meet our current needs, and that suitable additional space will be available as and when needed.</span></div><div id="i7157c5eacfe941de9505feeee920791e_28"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this Annual Report on Form 10-K, we do not believe we are party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div id="i7157c5eacfe941de9505feeee920791e_31"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i7157c5eacfe941de9505feeee920791e_37"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Information Regarding the Trading of Our Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades under the symbol &#8220;MRSN&#8221; on the Nasdaq Global Select Market. As of February&#160;23, 2021, there were approximately 26 holders of record of shares of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. Any future determination to pay cash dividends will be made at the discretion of our board of directors and will depend on restrictions and other factors our board of directors may deem relevant. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph and related information shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, or SEC, for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, nor shall such information be incorporated by reference into any future filing under the Exchange Act or Securities Act of 1933, as amended, or the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the performance of our common stock to the Nasdaq Composite Index and to the Nasdaq Biotechnology Index from June 28, 2017 (the first date that shares of our common stock were publicly traded) through December&#160;31, 2020, which was the last trading day of the year. The comparison assumes $100 was invested in our common stock and in each of the foregoing indices after the market closed on June 28, 2017, and it assumes reinvestment of dividends, if any. The stock price performance included in this graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-top:12pt;text-align:center"><img src="mrsn-20201231_g10.jpg" alt="mrsn-20201231_g10.jpg" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:450px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;SELECTED FINANCIAL DATA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read the following selected financial data together with our financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K and the information under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; We have derived the statement of operations data for the&#160;years ended December&#160;31, 2020, 2019 and 2018 and the balance sheet data as of December&#160;31, 2020 and 2019 from our audited financial statements included elsewhere in this Annual Report on Form 10-K. The historical statement of operations data for the years ended December&#160;31, 2017 and 2016 and the historical balance sheet data as of December&#160;31, 2018, 2017 and 2016 have been derived from audited financial statements not included in this Annual Report on Form&#160;10-K. All financial information presented has been consolidated and reflects the operations of Mersana Therapeutics Inc. and its wholly-owned subsidiaries.&#160;Our historical results are not necessarily indicative of results expected in any future period.&#160;The selected historical financial information in this section is not intended to replace our consolidated financial statements and the related notes thereto.</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except<br/>share and per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statements of Operations Data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,249&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,992&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,045)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,208)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,257)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,707)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,700)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders &#8212; basic and diluted(1)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,045)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,208)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,257)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,707)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,700)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders &#8212; basic and diluted(1)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.43)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.79)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.22)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.82)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders &#8212; basic and diluted(1)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,485,205&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,492,113&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,032,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,022,733&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,266,758&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,790&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,297&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital(2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,399&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,541&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,087&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,619)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">See Note&#160;2 to our financial statements appearing elsewhere in this Annual Report on Form 10-K for further details on the calculation of basic and diluted net loss per share applicable to common stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">We define working capital as current assets less current liabilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Annual Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Annual Report, they may not be predictive of results or developments in future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in the Annual Report on Form 10-K, including those risks identified under Part II, Item 1A. Risk Factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span></div><div id="i7157c5eacfe941de9505feeee920791e_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need. We have leveraged over 20&#160;years of industry learning in the ADC field to develop proprietary and differentiated technology platforms that enable us to design ADCs to have improved efficacy, safety and tolerability relative to existing ADC therapies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our innovative platforms which include Dolaflexin and Dolasynthen, delivering our DolaLock payload, as well as Immunosynthen, delivering a novel stimulator of interferon genes, or STING, agonist, compose a highly efficient product engine that has enabled a robust discovery pipeline for us and our partners. Our ADCs in preclinical and clinical studies include first-in-class molecules that target multiple tumor types with high unmet medical need and have exhibited improved safety and efficacy compared to ADCs developed using first-generation technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to become a leading oncology company by leveraging the potential of our innovative and differentiated ADC technologies and the experience and competencies of our management team to identify, acquire and develop promising ADC product candidates and to commercialize cancer therapeutics that are improvements over existing treatments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upifitamab rilsodotin (UpRi, XMT-1536), our first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. The NaPi2b antigen is broadly expressed in NSCLC adenocarcinoma and ovarian cancer with limited expression in normal tissue.&#160;We are actively recruiting and dosing patients with ovarian cancer and NSCLC adenocarcinoma, where a majority of patients express NaPi2b in a Phase 1 clinical trial. We expect to initiate a single-arm registration strategy in platinum-resistant ovarian cancer, UPLIFT, and a combination dose escalation study, UPGRADE, in ovarian cancer in 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XMT-1592 was created using our Dolasynthen platform and also targets NaPi2b.&#160;XMT-1592 comprises the same proprietary NaPi2b antibody and potent auristatin DolaLock payload with controlled bystander effect as UpRi, with the additional features of homogeneous, site-specific bioconjugation and precise DAR. XMT-1592 is in a Phase 1 dose escalation study in patients with ovarian cancer and NSCLC adenocarcinoma.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our early stage programs include, XMT-1660, a potentially first-in-class B7-H4-targeted DolaLock ADC, as well as XMT-2056, a STING-agonist ADC developed using our novel Immunosynthen platform. Our objective in 2021 is to rapidly progress these candidates through IND-enabling studies and scale up manufacturing activities with third parties. These development candidates provide significant opportunities for development in areas of high unmet need such as breast cancer, NSCLC and ovarian cancer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have established strategic research and development partnerships with Merck KGaA and Asana Biosciences for the development and commercialization of additional ADC product candidates against a limited number of targets selected by our partners based on our Dolaflexin platform. We believe the potential of our ADC technologies, supported by our world class management team and protected by our robust intellectual property portfolio, will allow us to discover and develop life-changing antibody-drug conjugates for patients fighting cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, our operations have focused on building our platforms, identifying potential product candidates, producing drug substance and drug product material for use in preclinical studies, conducting preclinical and toxicology studies, manufacturing clinical study material and conducting clinical studies, establishing and protecting our intellectual property, staffing our company and raising capital. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations primarily through our strategic partnerships, private placements of our convertible preferred stock and public offerings of our common stock. In April 2020, we sold approximately 10.9 million shares of common stock pursuant to an at-the-market, or the ATM, equity offering program and received net proceeds of $63.0 million. In addition, in June 2020, we sold 9.2 million shares of common stock in a follow-on offering and received net proceeds of $164.0 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant cumulative operating losses. Our net losses were $88.0&#160;million, $28.2 million and $64.3&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $280.4&#160;million. We expect to continue to incur significant expenses and operating losses over the next several years. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue clinical development activities for our lead product candidates, UpRi and XMT-1592;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop a companion or complementary diagnostic for the NaPi2b biomarker;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complete IND-enabling studies for our preclinical development candidates XMT-2056 and XMT-1660;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue activities to discover, validate and develop additional product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;&#160;and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional research, development and general and administrative personnel.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Impact of COVID-19 on Our Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">We are continuing to monitor the impact of the COVID-19 pandemic on our operations and ongoing clinical and preclinical development, as well as discovery efforts. Mitigation activities to minimize COVID-19-related operation disruptions are ongoing and include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In line with guidance from the U.S. Centers for Disease Control and Prevention (CDC) and the Commonwealth of Massachusetts, we have implemented work from home measures for all non-laboratory employees and have suspended all business travel. We have also prioritized laboratory activities and implemented staggered schedules in the interest of safety and efficiency for laboratory-based employees. We will continue to modify and adapt our measures to align with guidance as the pandemic evolves.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently enrolling patients at investigational sites in different geographic areas across the United States, Canada and Australia in the UpRi Phase 1 study and within the United States in the XMT-1592 Phase 1 dose escalation study. We are in the process of initiating additional clinical sites both inside and outside the United States to increase enrollment, which could additionally mitigate potential regional impacts from COVID-19. Consistent with FDA guidance, we issued an administrative letter to allow for remote patient monitoring and remote testing, when possible. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To the best of our knowledge, our contract manufacturing partners continue to operate their manufacturing facilities at or near normal levels, and we have not experienced any COVID-related delays in our manufacturing to date. We believe we have sufficient inventory of UpRi and XMT-1592 to support our ongoing clinical studies. We have planned manufacturing runs to address all currently anticipated future needs. At this time, and subject to further COVID-19 implications, we do not anticipate any disruptions to our clinical supply.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the coronavirus pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted. While the pandemic did not materially affect our financial results and business operations in the year ended December 31, 2020, we are unable to predict the impact that COVID-19 will have on our financial position and operating results in future periods due to numerous uncertainties. Management is actively monitoring this situation and the possible effects on our financial condition, operations, suppliers, industry, and our employees. For additional information about risks and uncertainties related to the COVID-19 pandemic that may impact our business, our financial condition or our results of operations, see &#8220;Part I, Item 1A&#8212;Risk Factors&#8221; in this Annual Report on Form 10-K.</span></div><div id="i7157c5eacfe941de9505feeee920791e_49"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from the sale of products. All of our revenue has been generated from strategic partnerships.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, we entered into an agreement with Merck KGaA for the development and commercialization of ADC product candidates utilizing Fleximer for up to six target antigens. Merck KGaA is responsible for generating antibodies against the target antigens and we are responsible for generating Fleximer and our proprietary payloads and conjugating this to the antibody to create the ADC product candidates. Merck KGaA has the exclusive right to and is responsible for the further development and commercialization of these ADC product candidates. In May 2018, we entered into a supply agreement with Merck KGaA for the supply of materials that could be used for IND-enabling studies and clinical trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, we recognized revenue of $0.8&#160;million, $2.1 million and $2.4 million, respectively, related to the Merck KGaA agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, we entered into collaboration agreements with Takeda for the development and commercialization of XMT-1522, a HER2-targeted ADC, and up to seven ADC product candidates utilizing Fleximer. The Company&#8217;s collaboration agreements with Takeda were terminated during the first quarter of 2019. We recognized the remaining deferred revenue of $40.0 million related to the termination of the Takeda agreements in the first quarter of 2019. We do not expect to have any further revenue related to these agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have provided limited services to Asana BioSciences. We recorded no revenue for the year ended December&#160;31, 2020, an immaterial amount of revenue for the year ended December&#160;31, 2019 and revenue of $0.8 million for the year ended December&#160;31, 2018, related to those services. In addition, we recognized revenue of $1.5 million related to a milestone achieved during the third quarter of 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, we expect substantially all of our revenue to be generated from our collaboration agreements with Merck KGaA and Asana BioSciences. Given the uncertain nature and timing of clinical development, we cannot predict when or whether we will receive further milestone payments or any royalty payments under these collaborations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our revenue recognition policy, see the notes to consolidated financial statements included in this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include our drug discovery efforts, manufacturing, and the development of our product candidates, which consist of:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, and stock-based compensation expense;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of funding research and development performed by third parties that conduct research, preclinical activities, manufacturing and clinical studies on our behalf;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory supplies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility costs, including rent, depreciation and maintenance expenses; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upfront and milestone payments under our third-party licensing agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Costs of certain activities, such as manufacturing, preclinical and clinical studies, are generally recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain development activities, such as clinical studies, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations and information provided to us by the third parties with whom we contract.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials and manufacturing costs.&#160;We expect that our total future research and development costs will continue to increase over current levels, depending on the progress of our clinical development programs. There are numerous factors associated with the successful development and commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at our current stage of development. Additionally, future commercial and regulatory factors beyond our control may impact our clinical development programs and plans.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our research and development costs have been external costs, which we track on a program-by-program basis following nomination as a product candidate. We have not historically tracked all of our internal research and development expenses on a program-by-program basis as they are deployed across multiple projects under development. The following table summarizes our external research and development expenses, by program, following nomination as a clinical candidate for the years ended December&#160;31, 2020, 2019 and 2018. All external research and development expenses not attributable to the UpRi, XMT-1592 and XMT-1522 programs are captured within preclinical and discovery costs. These costs relate to XMT-1592 prior to its designation in early 2020, as well as preclinical development candidates XMT-1660 and XMT-2056, additional earlier discovery stage programs and certain unallocated costs. We terminated the development of XMT-1522 in the first quarter of 2019. Our internal research and development costs are primarily personnel-related costs, stock-based compensation costs, and facility costs, including depreciation, and lab consumables. </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UpRi external costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XMT-1592 external costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XMT-1522 external costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical and discovery costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,883&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,517&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development costs</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,036&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,040&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,915&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our product candidates is highly uncertain. As such, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of our product candidates. We are also unable to predict when, if ever, we will generate revenue from commercialization and sale of any of our product candidates that obtain regulatory approval. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of preclinical studies and IND-enabling studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment in and completion of clinical studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing the product candidates, if and when approved, whether alone or in collaboration with others; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued acceptable safety profile of the drugs following approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development, manufacture or commercialization of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other employee-related costs, including stock-based compensation, for personnel in executive, finance, accounting, business development, legal operations, information technology and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future to support continued research and development activities, including increased costs related to the hiring of additional personnel, fees to outside consultants and patent costs, among other expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of interest income earned on cash equivalents and marketable securities. Interest expense is related to the credit facility that we entered into on May 9, 2019 and amended in August 2020, with Silicon Valley Bank. These borrowings bear a floating per annum rate interest, as well as a final payment of 5.5% of the amounts drawn, that is being recorded as interest expense over the term through the maturity date using the effective-interest method. Also included in interest expense is the amortization of the deferred financing costs and the accretion of debt discount relating to the credit facility.</span></div><div id="i7157c5eacfe941de9505feeee920791e_52"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of&#160;Years Ended December&#160;31, 2020 and 2019</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the&#160;years ended December&#160;31, 2020 and 2019, together with the changes in those items:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,295)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,619&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,802)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(359)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,927)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,045)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,208)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,837)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $0.8 million during the year ended December&#160;31, 2020, compared to $42.1 million during the&#160;year ended December&#160;31, 2019, a decrease of $41.3 million, primarily as a result of the termination of the Takeda agreements and the recognition of the remaining deferred revenue of $40.0 million in early 2019. Additionally, revenue of $2.1 million was recognized in connection with the Merck KGaA Agreement and Merck KGaA Supply Agreement in the year ended December 31, 2019. During the year ended December 31, 2020, $0.8 million was recognized as a result of completion of research services associated with a target included in the Merck KGaA Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was $67.0 million for the year ended December&#160;31, 2020, compared to $55.0 million for the year ended December&#160;31, 2019. The overall increase of $12.0 million was primarily attributable to the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $9.2 million related to manufacturing, clinical and regulatory activities for UpRi;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $4.3 million related to employee compensation, primarily due to an increase in headcount supporting the growth of our research and development activities, and the increase in valuation of stock-based awards granted to employees;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $1.8 million related to XMT-1592 clinical and regulatory expenses;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $1.7 million related to manufacturing for preclinical and discovery stage programs including XMT-1660 and XMT-2056;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $1.3 million related to other research services and supplies costs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $1.1 million related to advancement of companion diagnostic development efforts for the NaPi2b biomarker; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.4 million related to milestones paid for in-licensed technologies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increased costs were partially offset by the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of  $5.2 million related to preclinical development and manufacturing activities for XMT-1592;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of  $1.7 million related to the development and manufacturing activities for XMT-1522; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $0.9 million to support partner programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase as we continue our clinical development UpRi and XMT-1592 and continue to advance our preclinical product candidate pipeline and invest in improvements in our ADC technologies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense was $21.9 million for the year ended December&#160;31, 2020, compared to $17.3 million for the year ended December&#160;31, 2019. The overall increase of $4.6 million was primarily attributable to the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $2.8 million related to consulting and professional fees;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $1.3 million related to employee compensation, primarily due to the increase in valuation of stock-based awards granted to employees; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.5 million in facility-related costs as a result of the amendment of our lease in March 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expense will increase in the future to support continued research and development activities. These increases will likely include legal, auditing and filing fees, additional insurance premiums and general compliance and consulting expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net was $0.1 million and $2.0 million for the years ended December&#160;31, 2020 and 2019, respectively. Other income consists primarily of interest income on cash equivalents and short-term marketable securities. Interest expense was related to our outstanding borrowings under the credit facility.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2019 and 2018</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December&#160;31, 2019 and 2018, together with the changes in those items:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,875)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,926)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,208)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,257)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,049&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $42.1 million during the year ended December&#160;31, 2019, compared to $10.6 million during the&#160;year ended December&#160;31, 2018, a increase of $31.5 million, primarily as a result of the termination of the Takeda agreements and the recognition of the remaining deferred revenue of $40.0 million in early 2019. Additionally, revenue of $2.1 million was recognized in connection with the Merck KGaA Agreement and Merck KGaA Supply Agreement in the year ended December&#160;31, 2019. This compares to the revenue recognized during the year ended December&#160;31, 2018 for support of partner programs with Takeda, Merck KGaA and Asana BioSciences of $9.1 million and recognition of a milestone of $1.5 million achieved upon completion of a GLP toxicology study by Asana BioSciences.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was $55.0 million for the year ended December&#160;31, 2019, compared to $59.9 million for the year ended December&#160;31, 2018. The overall decrease of $4.9 million was primarily attributable to the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decrease of $13.5 million related to the development and manufacturing activities for XMT-1522; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decrease of $9.0 million related to manufacturing activities for UpRi.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreased costs were partially offset by the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase of approximately $8.3 million related to preclinical development and manufacturing activities for XMT-1592;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase of approximately $3.0 million related to UpRi clinical and regulatory expenses;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase of approximately $3.0 million related to research efforts to further platform development and evaluate potential product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase of $1.8&#160;million related to employee compensation, including stock-based compensation expense;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase of $0.8 million related to advancement of companion diagnostic development efforts for the NaPi2B biomarker; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase of $0.6 million related to a milestone paid upon dosing of the first patient in the expansion cohort of the UpRi clinical trial.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase as we continue our clinical development UpRi and XMT-1592 and continue to advance our preclinical product candidate pipeline and invest in improvements in our ADC technologies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense was $17.3 million for the year ended December&#160;31, 2019, compared to $16.3 million for the year ended December&#160;31, 2018. The overall increase of $0.9 million was primarily attributable to the increase in stock-based compensation expense.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expense will increase in the future to support continued research and development activities. These increases will likely include legal, auditing and filing fees, additional insurance premiums and general compliance and consulting expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net was $2.0 million and $1.4 million for the years ended December&#160;31, 2019 and 2018, respectively. Other income consists primarily of interest income on cash equivalents and short-term marketable securities, which increased $0.6 million due to higher investable balances for the year ended December&#160;31, 2019. Interest expense of $0.2 million was related to our outstanding borrowings under the credit facility.</span></div><div id="i7157c5eacfe941de9505feeee920791e_55"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations primarily with the proceeds from our initial public offering, our follow-on public offerings in 2019 and 2020, and use of our at-the-market, or ATM, equity offering program in 2020. Our follow-on public offering was completed on March 5, 2019 and resulted in net proceeds of $92.2 million. On July 2, 2018, we established an ATM, or the 2018 ATM, pursuant to which we were able to offer and sell up to $75.0 million of our common stock from time to time at prevailing market prices. In April 2020, we sold approximately 10.9 million shares of common stock and received net proceeds of $63.0 million pursuant to our 2018 ATM. In addition, in June 2020, we sold 9.2 million shares of common stock in a follow-on public offering and received net proceeds of approximately $164.0 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we terminated the 2018 ATM and established a new ATM, or the 2020 ATM, pursuant to which we are able to sell up to $100.0 million of our common stock from time to time at prevailing market prices. As of December&#160;31, 2020, we had not sold any shares under the 2020 ATM and had $100.0 million of availability under the program.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2019, we entered into a term-loan agreement which was subsequently amended on August 28, 2020. Pursuant to the amendment, we may be subject to certain conditions, borrow term loans in an aggregate amount of up to $30.0 million, of which $5.2 million were funded upon execution of the amendment. These proceeds were used to repay the existing balance and satisfy our existing obligations to Silicon Valley Bank, or SVB. No additional amounts have been drawn since the initial draw of $5.2 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had cash and cash equivalents of $255.1 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the&#160;years ended December&#160;31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,696)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,744)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,216)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,293)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in cash, cash equivalents and restricted cash</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,743&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,043&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $74.7 million for the&#160;year ended December&#160;31, 2020 and primarily consisted of a net loss of $88.0 million adjusted for changes in our net working capital and other non-cash items including stock-based compensation of $7.2 million and depreciation of $1.0 million. Net cash used in operating activities was $67.7 million for the year ended December&#160;31, 2019 and primarily consisted of a net loss of $28.2 million adjusted for non-cash items including </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock-based compensation of $4.9 million and depreciation of $1.2 million, as well as change in our net working capital and the decrease in deferred revenue of $41.4 million primarily related to the Takeda agreements. Net cash used in operating activities was $55.2 million for the year ended December&#160;31, 2018 and primarily consisted of a net loss of $64.3 million adjusted for non-cash items including stock-based compensation of $3.9 million and depreciation of $1.3 million, as well as change in our net working capital and the decrease in deferred revenue of $6.2 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by (Used in) Investing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $37.0&#160;million during the year ended December&#160;31, 2020 compared to net cash used in investing activities of $27.3&#160;million during the&#160;year ended December&#160;31, 2019. Net cash provided by investing activities for the&#160;year ended December&#160;31, 2020 consisted primarily of maturities of marketable securities. Net cash used in investing activities for the year ended December&#160;31, 2019 consisted primarily of purchases of marketable securities, partially offset by maturities of marketable securities. Net cash provided by investing activities for the year ended December&#160;31, 2018 consisted primarily of maturities of marketable securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $230.4&#160;million during the year ended December&#160;31, 2020 compared to net cash provided by financing activities of $97.7&#160;million during the&#160;year ended December&#160;31, 2019. During the year ended December&#160;31, 2020 cash provided by financing activities consisted primarily of $164.0 million related to the follow-on public offering in May 2020 and the proceeds from the use of the 2018 ATM of $63.0 million in April 2020 as well as proceeds from exercise of stock options of $3.1 million. During the year ended December&#160;31, 2019 cash provided by financing activities consisted primarily of the proceeds from our follow-on public offering of our common stock and issuance of debt. During the year ended December&#160;31, 2018 cash provided by financing activities consisted primarily of the proceeds from the exercise of stock options.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our cash expenditures to increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate clinical studies of, and seek marketing approval for our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our currently available funds will be sufficient to fund our current operating plan commitments for approximately the next two years. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical studies for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, prioritization and number of our research and development programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we obtain;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical study costs under future collaboration agreements, if any;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of securing manufacturing arrangements for clinical and commercial production; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting preclinical testing and clinical studies is a time-consuming, expensive and uncertain process that takes many&#160;years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve drug sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many&#160;years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, strategic partnerships and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. We currently have access to an additional line of credit under the credit facility with SVB, along with funds to potentially be earned in connection with our agreements with Merck KGaA and Asana BioSciences, if development activities are successful under those agreements. Future additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through additional strategic partnerships or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i7157c5eacfe941de9505feeee920791e_58"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant contractual obligations as of payment due date by period at December&#160;31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than<br/>1 Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1 to 3<br/>Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3 to 5<br/>Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than<br/>5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease commitments(1)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,739&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,929&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,140&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt obligations(2)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,074&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,796&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents future minimum lease payments under our non-cancelable operating and finance leases, which expire through February&#160;2024. The minimum lease payments above do not include any related common area maintenance charges or real estate taxes.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents future debt principal plus interest and final payments under our term-loan, which is payable in full on November 1, 2024. Refer to footnote 8 in the Notes to the Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements in the normal course of business with third parties to assist us with preclinical, clinical, manufacturing, and other products and services for operating purpose. Certain of these agreements provide for termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to the parties with whom we contract upon termination, primarily to reimburse them for their unrecoverable outlays incurred prior to cancellation and for wind-down activities. The exact amounts of such obligations are dependent on the timing of termination and the exact terms of the relevant agreement and cannot be reasonably estimated. At December&#160;31, 2020, we had cancellable open purchase orders of $59.8 million in total under material agreements for preclinical, clinical, manufacturing, and other products and services for operating purposes. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December&#160;31, 2020, assuming we would not cancel these agreements. The actual amounts we expect to pay in the future to the third parties under such agreements may differ from the cancellable open purchase order amounts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, we entered into a license agreement with Recepta Biopharma S.A., or Recepta, as amended, for the NaPi2b antibody. Under this agreement, we paid Recepta an upfront payment of $1.0&#160;million and are obligated to pay Recepta up to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$65.5&#160;million in development, regulatory and commercial milestones and tiered royalties in the low-single digit percentages on net sales of products outside of Brazil until the expiration of the royalty term. Upon the expiration of each royalty term in each country for each applicable product, the exclusive licenses granted to each party under the agreement will become fully-paid up and royalty-free. We have made $1.9 million in development milestone payments to date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, we entered into a license agreement with Synaffix B.V., or Synaffix, to develop, manufacture and commercialize ADC targets using Synaffix&#8217;s proprietary technology for a total of six targets. At contract inception we designated the first target and paid an upfront, non-refundable license fee of $0.8 million. During the year ended December 31, 2020, we designated the next target and paid an upfront non-refundable reservation fee of $0.3 million. We are required to make milestone payments to Synaffix of up to an aggregate of $24.8 million in development and regulatory milestones, up to $20.0 million in one-time sales milestones based on the achievement of annual sales objectives for the first target. In addition, upon designation of additional targets, we will be obligated to pay in the range of $44.8 million to $62.0 million for issuance, development, regulatory and one time sales milestones. Finally, pursuant to the terms this license agreement, upon commencement of commercial sales of a product, if any, we are required to pay to Synaffix tiered royalties in the low-single digit percentages on net sales of the respective products. We have made $0.8 million in development milestone payments to Synaffix to date.</span></div><div id="i7157c5eacfe941de9505feeee920791e_61"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable Securities and Exchange Commission rules.</span></div><div id="i7157c5eacfe941de9505feeee920791e_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgements and Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management's discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the financial statements prospectively from the date of change in estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our most critical accounting policies are those relating to revenue recognition, accrued research and development expenses as discussed in the notes to consolidated financial statements included in this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration agreements which are within the scope of Accounting Standards Update 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or Topic 606, under which we license rights to our technology and certain of our product candidates and perform research and development services for third parties.&#160;The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, we perform the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation.&#160;We only apply the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised good or services in our arrangement typically consist of license rights to our intellectual property and research and development services.&#160;We also have optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#160;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.&#160;Promised goods or services are considered distinct </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.&#160;In assessing whether promised good or services are distinct, we consider factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.&#160;The consideration may include both fixed consideration or variable consideration.&#160;At the inception of each arrangement that includes variable consideration and at each reporting period, we evaluate the amount of potential payment and the likelihood that the payments will be received.&#160;We utilize either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method better predicts the amount expected to be received.&#160;If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, we evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is not probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestone payments that are not within our control or the licensee&#8217;s control, such as regulatory approvals, are not included in the transaction price.&#160;At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.&#160;We must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;We utilize key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.&#160;Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts we would expect to receive for each performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance obligations consisting of licenses and other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&#160;We evaluate the measure of progress each reporting period and, if necessary, adjusts the measure of performance&#160;and related revenue recognition.&#160;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the elements of our collaboration agreements that represent joint operating activities in accordance with ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. We consider the guidance in ASC Topic 606 in determining the appropriate treatment for the transactions between us and our collaborative partners and the transactions between us and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, we will recognize our share of the net sales on a gross basis if we are deemed to be the principal in the transactions with customers, or on a net basis if we are instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us&#160;monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our expenses related to research and development activities based upon our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period.&#160;If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrued or prepaid expense balance accordingly.&#160;Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period.&#160;To date, there have been no material differences from our estimates to the amounts actually incurred. Significant judgement is, at times, involved in making the above estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the Notes to Consolidated Financial Statements for a description of recent accounting pronouncements applicable to our business.</span></div><div id="i7157c5eacfe941de9505feeee920791e_67"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk-related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents and marketable securities are invested in U.S. Treasury obligations, commercial paper and corporate bonds. However, we believe that due to the short-term duration of our investment portfolio and low-risk profile of our investments,&#160;an immediate 100 basis points change in interest rates would not have a material effect on the fair market value of our investments portfolio.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently not exposed to market risk related to changes in foreign currency exchange rates, but we may contract with vendors that are located Asia and Europe and may be subject to fluctuations in foreign currency rates at that time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics, Inc.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_73">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_73">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_76">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_76">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_82">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_82">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_88">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_88">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_94">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_94">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_97">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i7157c5eacfe941de9505feeee920791e_97">85</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Mersana Therapeutics, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Mersana Therapeutics, Inc. (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, and stockholders&#8217; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 26, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of ASU No. 2016-02</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for leases in 2019 due to the adoption of Accounting Standards Update (ASU) No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 842), and the related amendments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accrued Preclinical, Manufacturing and Clinical Expenses</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s accrual for preclinical, manufacturing and clinical expenses totaled $9.9 million at December 31, 2020. As discussed in Note 2 to the consolidated financial statements, the Company is required to estimate accruals for preclinical, manufacturing and clinical expenses based on certain information, including actual costs incurred or level of effort expended, as provided by its vendors. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.<br/><br/>Auditing the Company&#8217;s accrual for preclinical, manufacturing and clinical expenses was complex and judgmental, as the amounts are based on various estimates from third-party vendors, as well as other inputs estimated by members of management, such as the number of active sites, patient enrollment, and project timelines. Furthermore, due to the duration of the Company&#8217;s ongoing research and development activities and the timing of invoicing received from third parties, the actual amounts incurred are not typically known by the date the financial statements are issued.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><br/>How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/>We obtained an understanding, evaluated the design, and tested the operating effectiveness of the controls over the Company&#8217;s process for recording accrued preclinical, manufacturing and clinical expenses. These procedures included controls over management&#8217;s review of inputs used, as well as the completeness and accuracy of the underlying data, in estimating the accrual.<br/><br/>To test the accruals for preclinical, manufacturing and clinical expenses, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in the estimates and evaluating the various estimates and other inputs noted above that are used by management to estimate the amounts recorded. We corroborated the progress of research and development activities through discussion with the Company&#8217;s research and development personnel that oversee the research and development projects. We also inspected the Company&#8217;s contracts with third parties and any pending change orders to assess the impact on amounts recorded. Additionally, we reviewed information received by the Company directly from certain sites and other third parties, which included third parties&#8217; estimates of costs incurred to date. We also performed analytical procedures over fluctuations in accruals by vendor, study, or other significant work order throughout the period subject to audit and inspected subsequent invoices received from third parties to assess the impact to the accrual.</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2013.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;26, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMy0xLTEtMS0w_397b906e-ffe8-490d-bef5-cf558891cee4">255,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMy0zLTEtMS0w_2b5dbf07-eeab-466a-967e-352355a51499">62,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfNC0xLTEtMS0w_469b7b7a-84f2-4cdb-97fa-456ce5cb2f82">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfNC0zLTEtMS0w_1bc0d1b5-44e9-4bdd-85d7-376623d9a0d6">37,439</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfNi0xLTEtMS0w_716cb704-48c9-4312-9c25-cf62203002d9">3,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfNi0zLTEtMS0w_11f9cdbc-5cdb-43bf-9045-de4c75a1c473">1,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfNy0xLTEtMS0w_2cea4faf-0480-467d-a232-f6ca3de6e1ed">258,580</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfNy0zLTEtMS0w_c116f3eb-0437-4aa5-809e-04c22f7a70c8">101,326</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfOC0xLTEtMS0w_f68bc53c-766b-409e-9901-6f0e14c01ab3">1,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfOC0zLTEtMS0w_eba99c4e-c1f0-4cfc-9f81-5a874ee17d2e">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfOS0xLTEtMS0w_6c6ad973-921a-4332-a840-dde8351a995b">10,936</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfOS0zLTEtMS0w_7e7f83e1-bbd7-4bb3-bf54-29fbbd1211f7">2,598</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTAtMS0xLTEtMA_0302bd55-a959-4330-8ece-20ad4f011f95">2,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTAtMy0xLTEtMA_9ffacb72-a1c2-48de-bf63-054c8cb31955">1,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTEtMS0xLTEtMA_79f22742-6ef3-4cef-b53a-e504ec73ffeb">273,399</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTEtMy0xLTEtMA_c1576349-5652-4157-93f5-552a14d468a9">107,541</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTQtMS0xLTEtMA_1bdcf7db-53c0-4b41-8ee0-ef4432cda1b9">8,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTQtMy0xLTEtMA_885881fc-c9c5-4fc9-87b8-7cc0e735d3ca">7,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTUtMS0xLTEtMA_67e95e1c-cbe8-45c3-aa83-c2e388d8f9d3">16,146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTUtMy0xLTEtMA_c5ec44c4-8e86-405e-975d-8920a083f553">8,986</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTYtMS0xLTEtMA_30e868e7-e13d-4058-ad0d-c407ac397bd0">3,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTYtMy0xLTEtMA_4fff1323-de4a-4a51-96e9-6a6a010dec82">4,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTctMS0xLTEtMA_a58ab0db-10e3-4647-92d8-701edbbb60ba">1,437</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTctMy0xLTEtMA_7eb441b0-06bd-49c2-b5bd-baeaea5c9be7">2,219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTgtMS0xLTEtMA_07810ece-e9f0-4efc-837f-cace4bc0ed71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTgtMy0xLTEtMA_5c727d6a-18e7-4f36-8508-add2883092d4">667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTktMS0xLTEtMA_a467565b-4e95-4b4e-8fae-05a59738d96b">93</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTktMy0xLTEtMA_f989d3c5-a969-482f-89b8-a1fb4ac1c4c1">87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjAtMS0xLTEtMA_54518462-cff5-4386-949c-c969b2daec07">30,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjAtMy0xLTEtMA_ad6078b0-ac2c-43a1-96aa-f47bacf9652c">24,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjEtMS0xLTEtMA_367f5ea6-fe1a-47c6-ab33-44775cbf0220">10,158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjEtMy0xLTEtMA_9d54b997-629f-49c1-a327-4cfad4568482">677</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjItMS0xLTEtMA_6223fb32-8888-4913-8c76-bf8c71ac671c">4,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjItMy0xLTEtMA_640e0225-aa56-4d61-bcb3-4ce4f01e08bc">4,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjMtMS0xLTEtMA_81c35f54-ffa4-432d-9f4b-16e0d45c8e0f">174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjMtMy0xLTEtMA_b3a47996-3117-4ad0-9266-deba15d39f7c">275</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjQtMS0xLTEtMA_c9b1f0c7-d596-4077-bfa5-f89915a6f041">45,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjQtMy0xLTEtMA_3c269f2a-656f-40d9-a76e-5ce379d9f80a">29,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments (Note&#160;14)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjUtMS0xLTEtMA_555b1f9c-5b86-4c9e-b376-4d26a0d1db14"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjUtMy0xLTEtMA_6fd4cca6-313e-448c-9c9b-fb31c557e739"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NDE_4a496eaa-47a4-4939-9b5a-e490d80e177d"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NDE_cb34589c-be3d-4b2b-81f2-7b0e0492a621">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NTQ_8df6ab6b-b791-404b-9aef-4f22dc1e9fbe"><ix:nonFraction unitRef="shares" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NTQ_af12a50a-e8f2-4972-bc59-ea2e835c40de">25,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NTg_c592db1b-419a-4b4e-93ad-c9c3c759707a"><ix:nonFraction unitRef="shares" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NTg_ea4ba233-60f3-4956-a5a6-4952ae67ae2d"><ix:nonFraction unitRef="shares" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NTg_f0392792-a464-40a3-b769-8ff325c49672"><ix:nonFraction unitRef="shares" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NTg_ff171ddd-b2d9-4a18-8ae5-445152809ea8">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMS0xLTEtMA_0977ccb6-99bb-43c5-89fa-070bd3a255d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMy0xLTEtMA_426b5b48-4d7e-4836-a490-5e73f4657c92">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyMTk_20775a18-c636-4185-8b66-3ac39a14f4b3"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyMTk_2fe0355d-87f7-47ec-94cd-b339c9677f79">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyMzM_04b884c4-8713-405a-801c-867245c9747b"><ix:nonFraction unitRef="shares" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyMzM_93463672-45fd-46ac-a66a-7c6d82409192">175,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyNDY_1a307504-d77c-473c-9d80-9ce0bd821149"><ix:nonFraction unitRef="shares" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyNDY_37009d98-7f93-428b-bf19-dd8905809113">68,841,288</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyNTk_08d08fd9-bbaf-4a87-a1b8-25d92bf71216"><ix:nonFraction unitRef="shares" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyNTk_26a9b5e9-5cb1-4e7e-97fc-b26ef0213e97">45,388,023</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at December&#160;31, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMS0xLTEtMA_65a39135-9672-4334-98f8-b7f398b13be9">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMy0xLTEtMA_619d4473-273e-4d16-a7d3-8806fb59dcd8">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjktMS0xLTEtMA_8225c0ce-22f0-422c-abbc-e4a37004ab73">508,499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjktMy0xLTEtMA_74d45e6b-a062-47a7-b43d-a93dc09659ba">270,662</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzAtMS0xLTEtMA_f9e4d836-a33d-459f-869b-47aa319b6cb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzAtMy0xLTEtMA_1858cb8b-a6e2-4412-94e4-8b4412f57700">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzEtMS0xLTEtMA_69f98de1-4274-4652-be9b-f49b5bb7ab99">280,419</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzEtMy0xLTEtMA_941ecc06-a726-4b9d-921e-4d317c7e44fd">192,374</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzItMS0xLTEtMA_ca9a6b9d-2ae3-48f4-888e-b2e033fc336d">228,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzItMy0xLTEtMA_2f96a947-5784-45af-a1e3-e6cbd999c464">78,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzMtMS0xLTEtMA_e6a37a01-9de3-48b6-a559-ef4f6929e2f6">273,399</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzMtMy0xLTEtMA_4decd5aa-84bb-4d75-998e-9486921b53f7">107,541</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMy0xLTEtMS0w_2934b57a-13b9-44f0-aaf4-0803eeab415f">828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMy0zLTEtMS0w_514b8cc3-be51-4d8c-82e1-170aa4c26c94">42,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMy01LTEtMS0w_f171fa6b-e941-4029-b527-30e1a8ad8cf2">10,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNS0xLTEtMS0w_c24163c3-fd4a-493b-b4f9-2c17d92dd64c">67,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNS0zLTEtMS0w_98c3e726-be26-4cd1-9a45-49da9597c929">55,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNS01LTEtMS0w_93d7e373-724a-4f8e-91ba-ec314e8d8db0">59,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNi0xLTEtMS0w_ddb6edf8-56e0-4f29-be54-f475ff0e5e89">21,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNi0zLTEtMS0w_51cfb76c-3483-4ad6-83e2-fb7690c544dc">17,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNi01LTEtMS0w_4db375aa-9ff3-4333-b901-921b2db08494">16,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNy0xLTEtMS0w_a955a95e-1c11-47d4-af4d-004dade37cdb">88,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNy0zLTEtMS0w_aebc18c4-173a-4597-a40e-7f472add6cbd">72,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNy01LTEtMS0w_d7c3c3ce-e63f-4384-b19d-e08434ceaba0">76,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfOS0xLTEtMS0w_f10b5885-834f-4263-a228-2b3cac386fc7">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfOS0zLTEtMS0w_beaab818-27ab-44ad-a56a-6aad8a682e8a">2,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfOS01LTEtMS0w_dc2a02da-4e21-4878-b5b1-5213ef9aa5d3">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTAtMS0xLTEtMA_7d421056-18c0-4e7b-b0e0-04d9dd93de37">359</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTAtMy0xLTEtMA_c186571e-5064-4961-9f98-58ecf3e9fd68">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTAtNS0xLTEtMA_3099b994-34e9-44d1-a564-dc75a10684d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTEtMS0xLTEtMA_64953a36-884f-42ae-9176-43f50150a867">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTEtMy0xLTEtMA_f4147e2d-00a4-4c3c-a9ba-a8c30557051f">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTEtNS0xLTEtMA_ec729c48-c0d6-453b-ae69-0b57e3854c8b">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTItMS0xLTEtMA_17161cb7-205f-446f-ace3-cf0668283708">88,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTItMy0xLTEtMA_283a4b33-998d-4716-a5d2-501eb218bfbd">28,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTItNS0xLTEtMA_609f3089-0564-4cbd-8a7d-c450fa504b6f">64,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTQtMS0xLTEtMA_42841011-73b2-4f72-a7b3-e9942ecbcfc8">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTQtMy0xLTEtMA_f5afdc6f-0d3c-43e1-a9e7-5a63bb89924d">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTQtNS0xLTEtMA_4b39ce9f-800d-4666-93f1-d232689e8a23">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTUtMS0xLTEtMA_7e5622e2-2ea6-455a-92c2-d418930511c8">88,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTUtMy0xLTEtMA_452b047c-cb6b-423b-9816-0efcae384732">28,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTUtNS0xLTEtMA_6ef44be1-e5cd-4f5d-999a-fdee280db1dd">64,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss&#160;attributable to common stockholders &#8212; basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTYtMS0xLTEtMA_4fefbec9-9f58-4f83-a860-3cce38a92fc2"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTYtMS0xLTEtMA_da11df87-9f5d-4815-b4f8-a60a8cdf82cf">88,045</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTYtMy0xLTEtMA_9c50153f-d8ae-44a3-b07f-894a2e3bac5e"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTYtMy0xLTEtMA_e267b2ad-c2d1-4d41-8f9a-39da94136155">28,208</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTYtNS0xLTEtMA_72226ed4-d7f6-44e5-8e25-b9bb2d24178c"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTYtNS0xLTEtMA_eb45d924-d4e8-401d-8708-1c2254951935">64,257</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share&#160;attributable to common stockholders &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTctMS0xLTEtMA_797167d9-1132-4e39-86b3-c05529cfebff">1.43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTctMy0xLTEtMA_c8c86b27-95f7-4da3-a4e9-1fa9b3f02a7a">0.65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTctNS0xLTEtMA_69332cfd-8935-40a6-91a1-42ac1b399c71">2.79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTgtMS0xLTEtMA_6620217c-4379-47e5-8d1c-82982e55d3c9">61,485,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTgtMy0xLTEtMA_57856849-2449-43c2-bcd7-fb18717cdf8c">43,492,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTgtNS0xLTEtMA_52c15fa8-d028-4f63-95d1-d8919f190b20">23,032,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_88"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Stockholders' Equity</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec68d7798d0041aaa3817b210b456dc3_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMi0xNC0xLTEtMA_397c36c8-8b53-4724-b0ad-c9b593aafab3">22,765,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec68d7798d0041aaa3817b210b456dc3_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMi0xNi0xLTEtMA_27182357-007e-45e1-9fee-806699770953">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dd854fec4ed47cb8bffad52078aa3ea_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMi0xOC0xLTEtMA_e69f1352-e0d4-48f3-9d70-e9d1ee41ab03">168,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bdd4a73857d40c8a50ac539b3fe1443_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMi0yMC0xLTEtMA_f0e8e665-9da2-4ec0-86ca-831ede3821bf">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d2fd67c849e42de89b7f83df7efdddd_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMi0yMi0xLTEtMA_38c8681d-c8d1-47ba-8fad-cf9e712b2553">97,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4dd90b55c3d4405a31378f2cf6c85a5_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMi0yNC0xLTEtMA_fbcef075-565a-48cc-96c5-5bce4d12b90c">69,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMy0wLTEtMS0xMjY3_a627f6f4-0dcd-4d57-a53d-d933bbc3fbaf">Cumulative effect adjustment for adoption of ASC 606</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1666e43922144352b571dcc6dc54780c_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNS05LTEtMS0xMjQz_4a536200-85e4-411f-97a2-60e2aa9c5402">2,031</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6957e6107783414c86d7d038c4de0d0d_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNS0xMS0xLTEtMTI0Mw_cf94fcff-7c0a-4fd1-8131-350fadf68372">2,031</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie629a06a7eb44ce7b948b0a2eac6c15a_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNi0xNC0xLTEtMA_06700e6a-a3bd-462a-8a65-60b13d5da59e">427,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb028a17d03043db910b31d93f01ebd6_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNi0xOC0xLTEtMA_c13b868b-ba33-4603-856c-fa377206c5a4">918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNi0yNC0xLTEtMA_0a3d26c7-55bf-4cb7-9c5c-2e453d0a7d76">918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under ESPP</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie629a06a7eb44ce7b948b0a2eac6c15a_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNS0xLTEtMS0xMjYw_38bac3f8-65bb-4b24-839b-1cab614cdb21">42,186</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb028a17d03043db910b31d93f01ebd6_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNS01LTEtMS0xMjYw_e2d33f4d-60d6-4a75-baf1-72e4fff4a4f9">146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNS0xMS0xLTEtMTI2MA_935d17e3-9b50-45d4-9d1a-def079f0bfb6">146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb028a17d03043db910b31d93f01ebd6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNy0xOC0xLTEtMA_0f01ccf0-62e5-4af6-b8c5-c1040c98f11c">3,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNy0yNC0xLTEtMA_2beb0078-121b-4132-946d-ce3cccc3008b">3,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdd4c70c35274a40bc12395e93b9c793_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfOC0yMC0xLTEtMA_a625604d-9b6e-4a45-8908-b66ddb6f8eb4">141</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfOC0yNC0xLTEtMA_22728f53-06bc-441f-9c12-6edc05bc8768">141</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i248321357d504cd6b2392e62a156b394_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfOS0yMi0xLTEtMA_ee645848-a9d8-4eb9-9a0d-ab4e098a5dd3">64,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfOS0yNC0xLTEtMA_34e84fc5-7458-4988-861a-7567fb378073">64,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i646b21abf1f34c91ad1c6c0474853466_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMTQtMS0xLTA_183f3634-2525-438d-b280-ee1c7b3a4ed6">23,234,472</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646b21abf1f34c91ad1c6c0474853466_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMTYtMS0xLTA_22c2a04d-7d51-4e58-a236-044189705498">3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b30519d48b44dce8f3ebc341927841e_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMTgtMS0xLTA_0bb9c8f3-37c8-4028-bf22-ad8b1efda02f">172,966</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90519fa5579c4a0a830381b5fb35398f_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMjAtMS0xLTA_41930f4b-2c42-4ca9-8dde-747520d1f0fb">8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id85be7739be4471886b92107ad654c16_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMjItMS0xLTA_4c982d0c-7ca2-4ea9-bec2-1b56f0ea3009">164,166</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMjQtMS0xLTA_96d161f6-c4b8-455e-b1cf-5de8a5031568">8,795</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under public offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMC0xLTEtMTMwNi90ZXh0cmVnaW9uOmNhNDMzZDQ1NTAxMTQ0OWZhMjQ5NTBlYWIzYjZhNzNiXzEwOTk1MTE2Mjc4NjU_91ea28bb-9c7b-44c0-a678-aa6ec8886db2">5,587</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7763b300d146495ba1f6d378fcf527d4_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMS0xLTEtMTI3OQ_e9939700-acdc-44f6-8b37-3e0e00f0add8">24,437,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7763b300d146495ba1f6d378fcf527d4_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMy0xLTEtMTI3OQ_ade2ab05-996e-49b1-bc53-abe641a2f0ee">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtNS0xLTEtMTI3OQ_679592e2-dd34-4552-9ed1-5e3c9983b002">92,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMTEtMS0xLTEyNzk_a19c81f6-dfe6-4163-a15d-3f75ebdf9de9">92,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options and warrants</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7763b300d146495ba1f6d378fcf527d4_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="mrsn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTItMTQtMS0xLTA_a6946407-6511-4ee9-8271-931034211c2a">150,978</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231" decimals="-3" name="mrsn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTItMTgtMS0xLTA_361cc9d7-a3bc-4a8b-ab36-004471ddace7">175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="mrsn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTItMjQtMS0xLTA_addbe289-835e-4635-bcc7-190da84276b9">175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7763b300d146495ba1f6d378fcf527d4_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTMtMTQtMS0xLTA_a9fe16f6-06f2-4e84-a941-4c070b4ef8c1">140,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTMtMTgtMS0xLTA_b3080a56-a039-4565-be68-faf24e6fae89">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTMtMjQtMS0xLTA_35eae489-f876-4939-baee-e1282f30fff8">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock in exchange for common stock warrant</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7763b300d146495ba1f6d378fcf527d4_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTMtMS0xLTEtMTI4NA_f99eb669-328f-49ed-91ca-e78257ae3f72">2,575,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTMtNS0xLTEtMTI4NA_cb6bdf41-e745-4a55-a661-b56729219e31">8,986</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTMtMTEtMS0xLTEyODQ_871b29d3-3568-4e3a-b274-a5c08b45e714">8,986</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock warrant in exchange for retirement of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTQtNS0xLTEtMTI4OQ_084a347b-87cd-4b05-9617-1bb0cc0ca9d2">8,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTQtMTEtMS0xLTEyODk_25df6c10-5167-416f-9784-4d68de4951cf">8,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTQtMTgtMS0xLTA_0f25585c-39f1-4406-b805-624249d1fdcc">4,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTQtMjQtMS0xLTA_b68a9d4b-61b5-4035-bd33-3ee577e60893">4,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820a1679d0844c67ad4f922202689e57_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTUtMjAtMS0xLTA_492fa8b2-b4ae-402f-a4a3-06216e6061da">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTUtMjQtMS0xLTA_b4862353-e60f-4246-8052-6cc4dd98d5f4">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4018a4aefc7144ef90a07daed7e35438_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTYtMjItMS0xLTA_b1c72efc-b206-4e9e-ae62-10082d476030">28,208</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTYtMjQtMS0xLTA_6c5b9f79-388a-4c91-a975-df75649215ab">28,208</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d51cce334c24c3384bbf0988c25c72b_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTctMTQtMS0xLTA_0bdc6e67-174c-4635-aa9d-155e323f7d8a">45,388,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d51cce334c24c3384bbf0988c25c72b_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTctMTYtMS0xLTA_b8b4b6ce-7b5f-40c9-9551-c6a431a06560">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i568856ae452c43d9a8f78d6db3cd490b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTctMTgtMS0xLTA_bbbe5a15-20b6-4828-9f23-0cca02c3947b">270,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf2a7f80adb41dba4f4492c90a549b8_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTctMjAtMS0xLTA_72722719-7523-40b3-a257-35f0b5f1a9b6">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c5ee7c8c32f480aaa50a43deb934371_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTctMjItMS0xLTA_61f8abe0-988a-4343-9017-c9cc4b5e127b">192,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTctMjQtMS0xLTA_42e50cc2-ded5-4e79-84f2-8e69eb2e6004">78,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock from at-the-market transactions, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i1f1bc12c003c4e57a5f7a90f50d8d476_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMC0xLTEtMTMxNy90ZXh0cmVnaW9uOmFmY2U3YzhhMzk5ZDQ5N2I4MzkzODNmNDA4Y2RlZDg0XzEwOTk1MTE2Mjc4NzU_c3d613f4-5059-4595-953b-0a3844203012">2,176</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4f7e8965da448198116af6c110f7faf_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMS0xLTEtMTMxNw_c71e49b5-dc87-4298-9269-fe0f96642ca7">10,900,599</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4f7e8965da448198116af6c110f7faf_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMy0xLTEtMTMxNw_9b67ce55-dfac-4468-a710-431019015e55">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524d5f48af734daa921b6b627766b439_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktNS0xLTEtMTMxNw_2f3b6eb3-5488-4592-8e87-a36027d3df8f">62,976</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f1bc12c003c4e57a5f7a90f50d8d476_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMTEtMS0xLTEzMTc_42782688-bab3-42a9-9528-efdac30e4bd5">62,977</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under public offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ie6fd43849d3e4363a46139030c95a116_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMC0xLTEtMTMxNy90ZXh0cmVnaW9uOmMxN2IxODhlNzJmMjQwZWM5ZmYxODg3MDRlODY5MmI1XzEwOTk1MTE2Mjc4Njc_02220df8-a5c3-4453-ac39-12870102c163">10,809</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8130fe63e6246718c8b705ebba7e9b6_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMS0xLTEtMTMxNw_db668d04-4e77-4472-bd87-5ac4e6f23341">9,200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8130fe63e6246718c8b705ebba7e9b6_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMy0xLTEtMTMxNw_556c997e-ce88-4ebb-a7f9-d013dba24017">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ee2fd134e6b4b6abbb327c32e4f4ded_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtNS0xLTEtMTMxNw_71ebf8a0-d0fe-479f-986b-39cafb2b2e6e">163,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6fd43849d3e4363a46139030c95a116_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMTEtMS0xLTEzMTc_60b87019-77d7-4f65-9414-dc0130da529d">163,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common stock warrant in exchange for common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e5bfe19343142b3906779afeba94ec7_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="mrsn:StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjEtMS0xLTEtNDczNw_c7f6f2b3-d2e4-47a1-8434-0fa0b46a586a">2,574,971</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e5bfe19343142b3906779afeba94ec7_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMTQtMS0xLTA_42c65cb1-eb7f-4e12-982d-325e624b1ae5">697,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d693db8b41458bb34eba574b8b961b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMTgtMS0xLTA_db8869a7-8e46-4443-8361-31928d2b12ca">3,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMjQtMS0xLTA_3459b1ce-03f8-41ae-a9cd-ef2a21285577">3,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under ESPP</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e5bfe19343142b3906779afeba94ec7_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMTQtMS0xLTA_fa978c78-701e-458e-8cc1-feae85d3aaf1">80,267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d693db8b41458bb34eba574b8b961b_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMTgtMS0xLTA_7735c943-8674-42ed-8f81-4c65c021050d">561</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMjQtMS0xLTA_4d26fac7-a76b-4b63-8ce3-a413383f45cc">561</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d693db8b41458bb34eba574b8b961b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjMtMTgtMS0xLTA_d63a5fa5-37e5-4e1a-9104-350918169903">7,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjMtMjQtMS0xLTA_8dacc272-1723-40ee-a86c-4fb12a8b8215">7,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a6d0e47a36447d293b93e7ae49266ad_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjQtMjAtMS0xLTA_d6ca5ea6-4d8e-4d54-a35a-1d3bb13ff5ed">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjQtMjQtMS0xLTA_dcd19b99-aa94-45ae-a65e-077e13a2d08c">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1b597f23a2c4b7ebe27542604c170b4_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjUtMjItMS0xLTA_48a244c8-bde2-4c3c-83b2-d9b7d0b30511">88,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjUtMjQtMS0xLTA_3b9c7222-0482-4dc4-8d46-ef355d32e0d8">88,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08c6e587f4aa4d3a87ad5a5bd3f7ef47_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjYtMTQtMS0xLTA_37a265b2-285c-4266-9fdd-9fdc20d4364c">68,841,288</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c6e587f4aa4d3a87ad5a5bd3f7ef47_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjYtMTYtMS0xLTA_9ff36b1f-7fa2-4d73-9385-73bfb79e6442">7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a63ce8628a6420f8f56fbf95c67ba5c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjYtMTgtMS0xLTA_d00a768c-b853-4499-a50b-1f23e1b9e00b">508,499</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c8a68e376b84047b4655bd24fe4098b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjYtMjAtMS0xLTA_12b3eb6b-e3dc-486c-873b-1711e9f8a20e">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d033197c1ce4359a4e3f0b33dee0964_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjYtMjItMS0xLTA_ac8dfa9a-6123-4306-8bf3-f3e6401075ab">280,419</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjYtMjQtMS0xLTA_65568de9-7988-486c-af01-0465b0d2b04c">228,087</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_94"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMy0xLTEtMS0w_049c112d-fa33-4c64-8c2d-87acd5e4bd7f">88,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMy0zLTEtMS0w_fbd940f2-9a9b-475f-a8ab-641e634f1da6">28,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMy01LTEtMS0w_42305e81-3ce3-4cda-b737-317f9b0903c0">64,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNS0xLTEtMS0w_5f19e4cb-b814-4d1b-8337-4e3b74211d4d">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNS0zLTEtMS0w_792443f0-5b0d-409b-b593-fb6637a791a5">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNS01LTEtMS0w_e98489fc-c353-453e-a72c-5d19aee12a82">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNi0xLTEtMS0w_7e8b3576-aa54-4cad-939c-cb25f185cbf7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNi0zLTEtMS0w_3ac09d43-d9e8-4cdf-94e1-2ed4df6778f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNi01LTEtMS0w_6a9d7f81-349f-4aba-8d35-7241f1715325">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of premiums and discounts on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNy0xLTEtMS0w_176dcf22-8bd2-423c-bba3-265032e619f1">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNy0zLTEtMS0w_7dfd3638-f6c0-40a9-ac27-899ad30ccf9f">222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNy01LTEtMS0w_38923ce2-0286-4462-b77e-61a660f61370">296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfOC0xLTEtMS0w_719af26a-2505-4920-b6d1-94441fd417df">7,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfOC0zLTEtMS0w_38f30105-bd30-4fb5-8568-7153cb8a49b8">4,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfOC01LTEtMS0w_22fd9378-ccb8-49c0-b910-abba8011a1b3">3,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in deferred rent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="mrsn:ChangeInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfOS0xLTEtMS0w_88f0d6d8-3ee7-4c45-b27b-1c71e83b56ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="mrsn:ChangeInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfOS0zLTEtMS0w_e7c69d57-7d7e-4223-a23a-731bb88c7553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" name="mrsn:ChangeInDeferredRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfOS01LTEtMS0w_bae8bd95-632e-4ad9-8add-adbed41837c6">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTAtMS0xLTEtMA_ab0c6583-3f06-4e8c-87f2-409cb69aa7db">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTAtMy0xLTEtMA_5278acbe-d2fc-4d41-b679-b99d711af8ff">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTAtNS0xLTEtMA_8dac751f-f9f0-42c8-ab15-cc74946d2bdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTItMS0xLTEtMA_50c3ccb4-7c8f-4a38-8496-ef6407af9427">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTItMy0xLTEtMA_97add20b-1acc-4cef-a6ab-e04a96f9fc1b">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTItNS0xLTEtMA_3795139c-f6f9-4042-85c3-0b6a5ddaa4d7">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTMtMS0xLTEtMA_e148f0f4-596f-4ddd-8c1d-cd1891996d2b">1,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTMtMy0xLTEtMA_c4453125-156f-494d-8505-93410b1d32cb">2,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTMtNS0xLTEtMA_0c3afe5e-c585-475b-87d6-85d503c94acf">1,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTQtMS0xLTEtMA_7df6d328-e7b9-4878-8694-80a759eda946">700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTQtMy0xLTEtMA_024ee368-ec64-49e5-817a-e7db8acfdd7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTQtNS0xLTEtMA_8d01c592-e953-419c-b2e6-eb11b8a82bde">1,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTUtMS0xLTEtMA_bd1514ad-52c9-499e-9c0f-0ec1669a4563">942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTUtMy0xLTEtMA_2cd1893e-924a-478e-8a16-ea793e589c18">3,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTUtNS0xLTEtMA_e0fa1f26-2500-4100-8717-09440506930b">7,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTYtMS0xLTEtMA_24b06f70-a869-4864-96a1-ffa5bbbdcca5">7,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTYtMy0xLTEtMA_7ba7852e-4700-43a6-a8b0-0f57dc211c41">3,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTYtNS0xLTEtMA_265df0a1-d8ee-47c8-8e24-3825ca57b09b">5,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mrsn:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTctMS0xLTEtMA_9ae975b3-814a-44c1-8bf0-3afd85609b6d">1,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mrsn:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTctMy0xLTEtMA_5d6f33f9-8c92-4da8-adaf-cd26c3ad43b3">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="mrsn:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTctNS0xLTEtMA_e02dec5b-fa4a-40bb-abda-540649f466bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mrsn:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTgtMS0xLTEtMA_c9d8f926-6667-43be-bd81-7b6fe225209a">1,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mrsn:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTgtMy0xLTEtMA_1e12f55b-bca6-42d7-bf1c-14dfee5717e4">1,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="mrsn:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTgtNS0xLTEtMA_d6e1b3b4-04c0-482e-a0ee-f11269ec1d07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTktMS0xLTEtMA_9833f83f-8680-48e2-a249-625ad2e4988b">828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTktMy0xLTEtMA_573fd2c1-74c9-45e8-a520-d714dabdeb9c">41,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTktNS0xLTEtMA_1678dd38-a016-41d7-865a-7cd44ec859a3">6,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjAtMS0xLTEtMA_fa8871ec-44ac-4166-81fb-80f66cc14454">74,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjAtMy0xLTEtMA_239e5845-f773-43ef-b381-56a970b74640">67,744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjAtNS0xLTEtMA_80df4c7d-a830-49a3-938b-0b3471c4c8ff">55,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjMtMS0xLTEtMA_2add0451-6464-4111-bb9e-156d45028e5e">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjMtMy0xLTEtMA_36ca8ca5-23af-4b01-a38c-0dd0b49e15d1">27,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjMtNS0xLTEtMA_25752e22-aad6-435a-855c-91afd3f00da3">88,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjQtMS0xLTEtMA_e3fd6c31-a567-4840-8853-6eed9df6fd64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjQtMy0xLTEtMA_4c1c9a5a-1194-461c-a16f-b734673241a0">53,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjQtNS0xLTEtMA_22aa3b16-bfb0-4012-841d-a8a7c9d8ef02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjUtMS0xLTEtMA_c02e0dd4-fdf0-4a14-a9c2-9baa6f814f01">473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjUtMy0xLTEtMA_c9100b94-b6c7-4c8b-a633-5c1a02f949ed">605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjUtNS0xLTEtMA_05f39e92-b7ba-4601-a93f-892c9a5d76a2">1,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjYtMS0xLTEtMA_5fd46126-16ff-4e8e-9e35-7801b0cc9f7f">37,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjYtMy0xLTEtMA_06fab1e9-1078-4ef8-b059-4a772a2c64b7">27,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjYtNS0xLTEtMA_74c6c311-c9b5-4c05-b124-0d1c7ac28680">87,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from public offering of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6fd43849d3e4363a46139030c95a116_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjktMS0xLTEtMA_223f6bbe-60b7-42b8-b373-3b29afdd86b0">163,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9d949fa3384c24aed7832550cba9f3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjktMy0xLTEtMA_37e68094-c948-4677-8ebd-970c29ee83aa">92,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b785dd5a254889b46e8f92526bbb8a_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjktNS0xLTEtMA_d38182c9-263c-4dd2-98a0-6e863594bded">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from use of ATM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f1bc12c003c4e57a5f7a90f50d8d476_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzAtMS0xLTEtMA_00f5e768-9622-4b7e-a4ae-92fe605f3a9e">63,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic822eefabb4d4deb9631ece7d64d45df_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzAtMy0xLTEtMA_f22cef49-10dc-4876-9cc6-51b4828bfeab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7587cbccc6c4451e9d3b098bfd5bc320_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzAtNS0xLTEtMA_d9995ac8-86b0-4d3e-b15a-6dfb535c411e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzItMS0xLTEtMA_02e15d39-a4ab-4135-a7b7-b5a89863d5a4">3,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzItMy0xLTEtMA_cd211479-1d67-4e6d-b68f-222ba4f5fcb2">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzItNS0xLTEtMA_aa4eff63-1288-4116-ace8-671da827483c">918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from purchases of common stock under ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzMtMS0xLTEtMA_dcc08f80-54d8-4fe6-9129-a0bafc16cb20">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzMtMy0xLTEtMA_1931d47a-533b-439d-bdbf-0379190b07c9">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzMtNS0xLTEtMA_0b59dcff-7dd8-46fb-933f-4ab11ba42fe0">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of debt, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" name="mrsn:ProceedsFromDebtNetIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzQtMS0xLTEtMA_87d5738e-d23d-44db-8497-84598868517d">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:ProceedsFromDebtNetIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzQtMy0xLTEtMA_348d8e9c-4fa1-4da9-880d-dc3684718dd8">4,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="mrsn:ProceedsFromDebtNetIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzQtNS0xLTEtMA_4c8d7ef9-9d94-48e5-9f9b-120819572241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments under capital lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzUtMS0xLTEtMA_823fef5f-9781-4604-970e-c56a9f33e025">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzUtMy0xLTEtMA_811253ee-dfec-4293-9b7a-e7a047472be2">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzUtNS0xLTEtMA_a4d05385-3b65-4f24-9533-6ceca11d5ab1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzYtMS0xLTEtMA_35caeab8-a8b3-4cbf-9976-c6405717dcc0">230,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzYtMy0xLTEtMA_6a228e53-7643-4e7d-a884-72c937aa677c">97,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzYtNS0xLTEtMA_fb6d62d8-6c39-4c5a-a60d-b0be3d682f6d">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzgtMS0xLTEtMA_891d4e09-a9a0-4909-a6f5-efecf6b6c373">192,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzgtMy0xLTEtMA_9c52ea8f-bf80-4dc8-bd8e-bbf1be903b18">2,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzgtNS0xLTEtMA_d3696c53-d402-45ac-84c2-d876577bf7f1">33,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzktMS0xLTEtMA_2bac1b5b-7196-471f-bbcc-f2b4c1d2a17f">62,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzktMy0xLTEtMA_caaf17e8-7a00-46b6-89f6-10d280c12043">60,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4dd90b55c3d4405a31378f2cf6c85a5_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzktNS0xLTEtMA_c81e6179-30eb-4c7b-ae42-36683981235a">26,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDAtMS0xLTEtMA_e08d9a8a-d81d-4c17-a867-096cc6963752">255,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDAtMy0xLTEtMA_d62a4882-0243-4dc4-a71f-6606d748c4c5">62,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDAtNS0xLTEtMA_cef9a415-90d1-47cf-bc35-e8dcffc242d3">60,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of common stock retired in exchange for issuance of common stock warrant</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDMtMS0xLTEtMA_8520cfcd-a756-43af-9fcf-72151e49f8bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDMtMy0xLTEtMA_22604557-3029-4dc2-910c-c3062d313f54">8,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDMtNS0xLTEtMA_51232025-d869-4d6a-a0bf-f650db9e8d66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDUtMS0xLTEtMA_3347f690-74dc-48af-b563-86b1f089f68a">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDUtMy0xLTEtMA_df46cf87-d10d-48d5-a2d5-ce96e48d3824">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDUtNS0xLTEtMA_415ea4f0-836e-4ae6-b258-9c2e52789682">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt financing costs in accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDYtMS0xLTEtMA_496b288b-756d-40c4-8f6d-8a8d96ed83b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDYtMy0xLTEtMA_91039759-4fea-422c-b337-81495403c519">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDYtNS0xLTEtMA_0aec3520-1dc0-4222-914d-d43e7221f585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDctMS0xLTEtMA_d25d81a3-47ff-42c8-a96c-8c9827e5cdce">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDctMy0xLTEtMA_65db3ea6-6ac5-4733-8d06-7d1ec230f85d">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDctNS0xLTEtMA_f6c6d5d2-97e3-445e-aa66-a083ee667976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDgtMS0xLTEtMA_9a651351-6140-4946-9de4-db7a32eb9256">9,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDgtMy0xLTEtMA_1e3c8a31-d01a-4db6-b03d-cdbf113cb623">4,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDgtNS0xLTEtMA_efa3f95d-700b-4b79-ad35-3995d0352ba6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDktMS0xLTEtMA_6411baf5-340a-4536-935c-21b6cb7afd27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDktMy0xLTEtMA_8e32069c-efa4-4b1a-9476-d6ed42ecf6c5">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDktNS0xLTEtMA_090894e1-9db0-45e6-b6ec-402c367f5dfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="mrsn:AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNTAtMS0xLTEtMA_b4b07ac4-bb5e-4c2b-857e-8b371fd9a8f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="mrsn:AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNTAtMy0xLTEtMA_d5994ac1-b754-42b9-9bf9-73a87e736986">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mrsn:AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNTAtNS0xLTEtMA_b4fd13b3-b36c-40bf-91e7-fee2baad9959">2,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_97"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i7157c5eacfe941de9505feeee920791e_100"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzU3MzQ_6642e7d0-b6fe-40f2-8af4-22653f337753" continuedAt="i47165f229a794698a61c30934ce8bfa2" escape="true">Nature of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i47165f229a794698a61c30934ce8bfa2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with significant unmet need. The Company has leveraged 20 years of industry learning in the ADC field to develop proprietary and differentiated technology platforms that enable it to design ADCs to have improved efficacy, safety and tolerability relative to existing ADC therapies. The Company&#8217;s innovative platforms, which include Dolaflexin and Dolasynthen, each delivering its DolaLock payload, as well as Immunosynthen, delivering a novel stimulator of interferon genes (STING) agonist, provide an efficient product engine that has enabled a robust discovery pipeline for the Company and its partners. The Company&#8217;s product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company's early stage programs include a potentially first-in-class B7-H4-targeted DolaLock ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform, the most advanced of which is XMT-2056.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UpRi, an ADC utilizing the Company&#8217;s Dolaflexin platform and targeting NaPi2b, an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma, is currently in the expansion portion of a Phase 1 study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592 uses one of the Company&#8217;s new platforms, Dolasynthen, and also targets NaPi2b. In the first half of 2020, the Company initiated the Phase 1 dose escalation study of XMT-1592 .</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, the need for additional capital, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and reimbursement for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on third party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since inception. The Company&#8217;s net loss was $<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIzMjA_d33962b0-1104-4de7-b728-e0da4d79fdbb">88,045</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIzMjQ_93f6c0b2-5797-4db5-b757-70a576643127">28,208</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIzMzE_385e3260-3057-4a17-99c7-cb29af35bf91">64,257</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The Company expects to continue to incur operating losses for at least the next several years.&#160;As of December&#160;31, 2020, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzI1MzE_02917592-2f66-4fa0-8ffd-764745cf5a75">280,419</ix:nonFraction>. The future success of the Company is dependent on, among other factors, its ability to identify and develop its product candidates and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative operating cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="ia4e03a06a83b45da881a991b3fa64a37_D20200401-20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIxOTkwMjMyNjQ5Njk_7e94b48b-dca8-4a83-bcd6-5d0ee4cd8d49">10,900,599</ix:nonFraction> shares of common stock and received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia4e03a06a83b45da881a991b3fa64a37_D20200401-20200430" decimals="-3" format="ixt:numdotdecimal" name="mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIxOTkwMjMyNjQ5OTE_643964b3-1a9a-4c31-b4e8-06cfc3f041ff">62,976</ix:nonFraction>. In addition, in June 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i35ae40d344cb48109420ed8b520d73e7_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIxOTkwMjMyNjUwMzk_771c5c1c-7751-4a70-ab31-bccf9f074b78">9,200,000</ix:nonFraction> shares of common stock and received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i35ae40d344cb48109420ed8b520d73e7_D20200601-20200630" decimals="-3" format="ixt:numdotdecimal" name="mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIxOTkwMjMyNjUwMTQ_7624e36d-b11f-4d83-9364-aab745055c5f">163,990</ix:nonFraction>. The Company believes that its currently available funds will be sufficient to fund the Company&#8217;s operations through at least the next twelve months from the issuance of this Annual Report on Form 10-K. Management&#8217;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management&#8217;s estimates, the Company may need to seek additional funding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). All dollar amounts, except per share data in the text and tables herein, are stated in thousands unless otherwise indicated.</span></div></ix:continuation><div id="i7157c5eacfe941de9505feeee920791e_103"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTY0_00db374b-c73b-49af-a9b6-c5374c67aba4" continuedAt="ic03743e6fd4f4766ba187b609b1ef1a8" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ic03743e6fd4f4766ba187b609b1ef1a8" continuedAt="ia6913ef5bc6342b291113333df0bd410"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTUy_08305847-7449-4073-b5bf-0718003bef61" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include those of the Company and its wholly owned subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="ia6913ef5bc6342b291113333df0bd410" continuedAt="i500691f0441046d9bab7cb18e3b9ce1d"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTYw_c275427c-c9a8-4a57-ac66-63fa2e4030ba" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company's management evaluates its estimates which include, but are not limited to, management's judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTY1_658f4aec-d363-457a-8fb2-ac075329d648" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess performance. The Company views its operations and manages its business as a single operating segment, which is the business of discovering and developing ADCs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTYx_45bf10d6-de2c-4e8e-b020-a2a98f8a9640" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, bonuses, benefits, travel and stock-based compensation expense;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of preclinical and clinical studies and related services;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of acquiring, developing and manufacturing ADC product candidates, clinical study materials and other research and development materials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees and costs related to regulatory filings and activities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with collaboration agreements and license fees and milestone payments related to license agreements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with creating and obtaining approval for the NaPi2b companion or complementary diagnostic biomarker;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities, maintenance of facilities, insurance and other supplies; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other costs associated with clinical, preclinical, discovery and other research activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for certain development activities, such as clinical studies and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued preclinical, manufacturing and clinical expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTY4_352a6a82-9041-4e8d-87ee-af3cdddab82a" continuedAt="i56b44d6f1a824afcaa27ce999b3013a1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements which are within the scope of Accounting Standards Update (ASU) No. 2014-9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606), under which the Company licenses rights to its technology and certain of the Company&#8217;s product candidates and performs research and development services for third parties.&#160;The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i500691f0441046d9bab7cb18e3b9ce1d" continuedAt="ia613b8c07ce84482a455a08333421f43"><ix:continuation id="i56b44d6f1a824afcaa27ce999b3013a1" continuedAt="i00fe967274f740d28e32fadb88d930e0"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development costs; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised good or services in the Company&#8217;s arrangement typically consist of license rights to the Company&#8217;s intellectual property and research and development services.&#160;The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#160;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.&#160;Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.&#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.&#160;The consideration may include both fixed consideration and variable consideration.&#160;At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received.&#160;The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method better predicts the amount expected to be received.&#160;If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not included in the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.&#160;The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="ia613b8c07ce84482a455a08333421f43" continuedAt="ie50598d1ae374504b079192aadefba97"><ix:continuation id="i00fe967274f740d28e32fadb88d930e0"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract.&#160;The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.&#160;Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance&#160;and related revenue recognition.&#160;If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:durday" name="mrsn:RevenueCollectionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzEwOTk3_2b328fb5-76ee-4bb2-818f-2cfefced88f5">30</ix:nonNumeric>-day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company adopted the provisions of Topic 606, using the modified retrospective transition method. Under this method, the Company recorded the cumulative effect of initially applying the new standard to all contracts in process as of the date of adoption. This standard applied to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The adoption of the new revenue recognition guidance resulted in increases of $<ix:nonFraction unitRef="usd" contextRef="i20d32d9d39084d6a842551c406380048_I20180101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzEwOTk1MTE3MDEyNTg_ce5e19cf-1118-4e2c-9acd-9f2cba08ef96"><ix:nonFraction unitRef="usd" contextRef="i20d32d9d39084d6a842551c406380048_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzEwOTk1MTE3MDEyNTg_f4bfe9d0-5dc7-43fa-b14a-ef99df54246e">2,031</ix:nonFraction></ix:nonFraction> in deferred revenue and accumulated deficit as of January 1, 2018. For the years ended December 31, 2019 and 2018, revenue was not materially impacted as compared to the Company&#8217;s prior revenue recognition methodology under ASC 605 Revenue Recognition.</span></div></ix:continuation><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTY5_7da5da03-476d-4322-9ce5-810a9d524b77" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company considers the guidance in ASC Topic 606 in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTUz_d1a4ddab-85eb-4cb0-bdc1-a178d808a914" continuedAt="i49d5feb729f84c8faee6888570f54d45" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;820) establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="ie50598d1ae374504b079192aadefba97" continuedAt="i75c6e5bfffcd458b8f32fec5c30e52a6"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i49d5feb729f84c8faee6888570f54d45">Level&#160;3&#8212;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</ix:continuation></span></div><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTQ3_07aa6c1b-ef6c-471a-9776-582812451cf8" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.</span></div></ix:nonNumeric><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzI3NDg3NzkxMTYzNTI_262fb467-eaee-438d-a5c9-0b545572fc20" escape="true"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTU0_68c9165e-a97c-42af-a2e4-e17e232f49bd" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzItMS0xLTEtMA_e4187f8f-d2cd-4c12-9b0c-02477d80a0e0">62,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzItMy0xLTEtMA_49bbe73a-98e3-45b1-97e4-096968706c0c">255,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzItNS0xLTEtMA_576901ca-d20b-4e56-b8fe-820f9840379f">59,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzItNy0xLTEtMA_9d214014-31da-467f-ac67-0861e06bdb80">62,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash included in other assets, noncurrent</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzMtMS0xLTEtMA_49553b36-34f8-4a12-9775-1c3600ab1327">321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzMtMy0xLTEtMA_a67fc646-7f24-4d0a-b6e8-75d63facb526">321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzMtNS0xLTEtMA_c4fa0523-8931-4820-8ef8-84f17526b468">371</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzMtNy0xLTEtMA_0d10f18d-4152-46cf-b0ed-79c0c99d64ad">321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzQtMS0xLTEtMA_946e6e95-d1bd-48fb-8d46-445672e971fc">62,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzQtMy0xLTEtMA_237a725c-39e9-402f-88cb-6fd9f2380402">255,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzQtNS0xLTEtMA_630f8067-999b-45c0-b1ab-e90e6c3370fb">60,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzQtNy0xLTEtMA_49df72f7-aaa4-45be-be8f-8828fb8cac18">62,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTU1_f3b91ec8-5f81-44f2-ac67-bddee5d4b4d1" continuedAt="i593beb68b7ac468eaa77ac34c40086a3" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term marketable securities consist of investments in debt securities with maturities greater than three months and less than one year from the balance sheet date. The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Amortization and accretion of discounts and premiums are recorded as interest income within other income. Prior to the adoption of ASU 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, unrealized gains and losses on available-for-sale securities were included in other accumulated comprehensive loss as a component of stockholders&#8217; equity until realized. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net, based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis. Fair value is determined based on quoted market prices.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i593beb68b7ac468eaa77ac34c40086a3">In accordance with the adoption of ASU 2016-13, the Company is required to determine whether any portion of the unrealized loss for any available-for-sale debt security is due to a credit loss, and if so, to measure the amount of the credit loss. The Company reviews each of its available-for-sale marketable securities for unrealized losses (declines in fair value below its amortized cost basis) at each balance sheet date presented in its financial statements and whenever events or changes in circumstances indicate that the amortized cost basis of an asset may not be recoverable.</ix:continuation> </span></div><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTU2_7c729b69-2d76-4b2d-9471-8d384885a05e" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded other assets of $<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzE1NTQ0_253b1a35-05e4-4b9a-9eb5-c5ddd819476c">2,153</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzE1NTUx_19412005-b6e3-4f06-bc3b-bf97ffad3633">1,453</ix:nonFraction> as of December&#160;31, 2020 and 2019, respectively, comprised of $<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainageDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzIxOTkwMjMyOTEyOTA_41b617a4-9421-4e4f-85a8-98ffb49d48f0">1,832</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainageDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzIxOTkwMjMyOTEyOTg_3c89851c-db92-4d62-96a4-45324fe11251">1,132</ix:nonFraction>, respectively, held by a service provider, and restricted cash of $<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:SecurityDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzE1NjQz_bcc43262-56c6-4e14-a2bd-c876919f9d6d">321</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:SecurityDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzE1NjUw_e60f1e99-4b2a-4e6d-918f-422ac60db6e3">321</ix:nonFraction> at the end of each period held as a security deposit for a standby letter of credit related to a facility lease.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTQ4_70e94979-d81e-4449-8263-81fbfab92faa" continuedAt="ie60ef155a55740dd8d057c3063d5f34c" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Stock-based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC 718). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the initial public offering and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption.&#160;The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i75c6e5bfffcd458b8f32fec5c30e52a6" continuedAt="i14f5e9208e0f42368b41b0f623ac65c3"><ix:continuation id="ie60ef155a55740dd8d057c3063d5f34c"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be <ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzE3OTMw_4b7bf8c8-3edd-4908-a5c5-2386f4a83267">zero</ix:nonFraction> as the Company has never paid dividends and has no current plans to do so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of each restricted stock unit, or RSU, at its grant date based on the closing market price of the Company&#8217;s common stock on that date. For stock-based compensation subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based compensation on a straight-line basis over the requisite service period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records forfeitures as a cumulative adjustment in the period in which they occur.</span></div></ix:continuation><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTU3_47b775f2-4a6e-4359-a191-b105cac45d4f" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding and <ix:nonFraction unitRef="shares" contextRef="i32e7573ef8fe419aa60a3e7c2573e532_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzE4NzE4_7d03c01b-8fb1-41b9-a11c-8a53714649a2">2,575,000</ix:nonFraction> Exchange Warrants (as defined in footnote 9) outstanding during the period, without further consideration for potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, stock options, unvested restricted stock units (RSUs) and warrants to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTQ5_a63330c0-410f-4dc5-934f-a72e9d18b636" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6249b32c3a3472199c99217268325e2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzItMS0xLTEtMA_39948aa8-453c-4b2c-bc5c-4173eaaa7083">6,112,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a4bce75e9484c55ab4f169eabc82fde_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzItMy0xLTEtMA_045b1f33-bd9e-46ac-9df6-b62fe1d20289">4,720,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bc5954c2df24836829d0bdf041a7dc2_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzItNS0xLTEtMA_b225f70f-5614-440d-9a42-5794ffbf20dd">3,746,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf326ed84a184b69aac5f187571380da_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzMtMS0xLTEtMA_eb569eec-4306-42b5-9bfe-e4a2d65d27de">716,767</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc059b98c5e4406eb2f908459f254117_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzMtMy0xLTEtMA_5c072ace-32df-445a-af6c-4b22f0d247ae">447,336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4e7d49b91dd454c97384848857e7904_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzMtNS0xLTEtMA_ece8c530-cefb-4899-951f-45001b541c42">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbf381469b4d49adacff9769db1f0076_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzQtMS0xLTEtMA_a9513788-7865-44a7-b915-337d74d845e5">39,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icef7477d01eb42fa93cb54ff9d6cbd4f_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzQtMy0xLTEtMA_cee28e86-ca8b-434c-90f1-91b148fde6fb">39,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9972585559044d9bb7fe57fd33d4126d_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzQtNS0xLTEtMA_f52e0dcb-346e-4314-8ba6-786e44c154d1">110,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzUtMS0xLTEtMA_a2e930b2-e452-4be4-ba78-0f3a3c24afce">6,869,189</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzUtMy0xLTEtMA_7538765d-9962-4a7f-add5-bc34eda4fa15">5,207,582</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzUtNS0xLTEtMA_891fa20c-5fc4-4caa-924a-fc79f153e1bf">3,856,932</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTU4_2d274e95-d06f-42ce-b284-361d2e211de7" continuedAt="i060348c94a204947b8e44c1c121a7e2d" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, less accumulated depreciation. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="mrsn:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTY2_8aa8546e-9a23-4a3e-b75f-b09ff3bdeb20" continuedAt="iffa6751b850146d894067e03c08e488e" escape="true">Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="iffa6751b850146d894067e03c08e488e"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment, office equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2ca1a08f33fc491daa2aa0165f719267_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZToyZGU3MDA0YWM2NjY0ZmM2YmQ1MzUzMWRjMmE2ZWU3My90YWJsZXJhbmdlOjJkZTcwMDRhYzY2NjRmYzZiZDUzNTMxZGMyYTZlZTczXzAtMS0xLTEtMA_590a1b41-3610-4baa-a7ae-a2b1d54fc23e">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67f598299c7a417cbd523207c78e819a_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZToyZGU3MDA0YWM2NjY0ZmM2YmQ1MzUzMWRjMmE2ZWU3My90YWJsZXJhbmdlOjJkZTcwMDRhYzY2NjRmYzZiZDUzNTMxZGMyYTZlZTczXzEtMS0xLTEtMA_2445719e-26dc-4bfb-88a3-b98c2ea8295f">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iff1a309483c5420db7794218d82c68a9_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZToyZGU3MDA0YWM2NjY0ZmM2YmQ1MzUzMWRjMmE2ZWU3My90YWJsZXJhbmdlOjJkZTcwMDRhYzY2NjRmYzZiZDUzNTMxZGMyYTZlZTczXzItMS0xLTEtMA_f409363b-512f-4916-9820-e7e3f296a34a">Shorter of useful life or life of lease</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the statement of operations. There were no material sales of assets during the&#160;years ended December&#160;31, 2020, 2019 and 2018.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i14f5e9208e0f42368b41b0f623ac65c3" continuedAt="ibd7bc6f3550442e99616b46c997b0994"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i060348c94a204947b8e44c1c121a7e2d">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If an impairment review is performed to evaluate an asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the asset to its carrying value. If the carrying amount of the asset exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not recognize impairment charges during the&#160;years ended December&#160;31, 2020, 2019 and 2018.</ix:continuation></span></div><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTUw_d678a4bc-9527-47c6-85b7-c6abc5d775f0" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with ASC 842, the Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use lease assets (ROU assets), current portion of lease obligations and long-term lease obligations on the Company&#8217;s consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#8217;s consolidated balance sheets. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheets for leases with an original term of twelve months or less.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&#160;Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="mrsn:PatentCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTY3_d0db52ef-75c4-4c92-8955-b2a57b40593b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTYz_4350717d-a1ca-4df1-95dc-1901c56f101e" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides for deferred taxes using an asset and liability approach.&#160;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.&#160;The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160;Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is more likely than not to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="ibd7bc6f3550442e99616b46c997b0994"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTU5_099eeec3-b7fe-4c10-b676-c6a8f5ffbcde" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) comprises net loss and other comprehensive loss. For the years ended December&#160;31, 2020, 2019 and 2018, other comprehensive income (loss) consisted of changes in unrealized income and loss on marketable securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTYy_143179f6-5623-47dc-b682-f5991a4a5dea" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-balance Sheet Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzI1NTU1_ef7bcf64-e265-4d05-b9d1-4077207b1971">no</ix:nonFraction> financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company has not experienced any credit losses and does not believe this it is subject to any significant concentrations of credit risk from these financial instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTUx_4a68fde6-c400-44f8-95ef-eb25304c908d" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. This guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The guidance per ASU 2018-18 is to be adopted retrospectively to the date of initial application of Topic 606. The Company adopted the new standard effective January 1, 2020. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. Historically, U.S. GAAP delayed recognition of the full amount of credit losses until the loss was probable of occurring. Under this ASU, the income statement will reflect an entity&#8217;s current estimate of all expected credit losses. The measurement of expected credit losses will be based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down of the security. This ASU is effective for annual periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company adopted the new standard effective January 1, 2020 using the modified retrospective method. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as part of its initiative to reduce complexity in the accounting standards. The amendments in ASU 2019-12 eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes. The amendments in ASU 2019-12 are effective for the fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.</span></div></ix:nonNumeric></ix:continuation><div id="i7157c5eacfe941de9505feeee920791e_109"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE3NDMx_411c2d8b-15ad-4b71-bbb8-b0423385165a" continuedAt="i92d3d52a237c4b19988212bea9719c58" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i92d3d52a237c4b19988212bea9719c58" continuedAt="i2b5f61ba4192416e8591d2ec9fc1e8a6"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck KGaA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Company entered into a Collaboration and Commercial License Agreement with Merck KGaA (the Merck KGaA Agreement). Upon the execution of the Merck KGaA Agreement, Merck KGaA paid the Company a nonrefundable technology access fee of $<ix:nonFraction unitRef="usd" contextRef="ic742200b058d41098d52ab5f0e3428b8_D20140601-20140630" decimals="-3" format="ixt:numdotdecimal" name="mrsn:CollaborativeArrangementsUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI5Mw_b11ab5b5-84e2-4244-bf57-8c4393e3dc4a">12,000</ix:nonFraction> for the right to develop ADCs directed to <ix:nonFraction unitRef="target" contextRef="if4257918738749a69d4891f5d50d9d76_I20140630" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:CollaborativeArrangementsExclusiveTargetsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI3NDg3NzkwODgwMjU_24768b4e-a8fa-4c03-bcaf-e18f48dbafa3">six</ix:nonFraction> exclusive targets over a specified period of time. <ix:nonFraction unitRef="usd" contextRef="if4257918738749a69d4891f5d50d9d76_I20140630" decimals="-3" format="ixt-sec:numwordsen" name="mrsn:CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzM5Mw_07ffabb0-ae04-4b0a-b286-108bda8440eb">No</ix:nonFraction> additional fees are due when a target is designated and the commercial license to the target is granted. Merck KGaA will be </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i2b5f61ba4192416e8591d2ec9fc1e8a6" continuedAt="i4174537a823044439f0615f87745cb78"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsible for the product development and marketing of any products resulting from this collaboration. All <ix:nonFraction unitRef="target" contextRef="i7a9c0faaca2d45558f08d2d44e3bcb4f_I20171231" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:CollaborationArrangementsTargetsDesignatedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzYyOQ_a9063808-a9e3-4823-8471-8dabe2f5bda5">six</ix:nonFraction> targets were designated prior to 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merck KGaA Agreement, the Company and Merck KGaA develop research plans to evaluate Merck KGaA's antibodies as ADCs incorporating the Company's technology. The Company receives reimbursement for its efforts under the research plans. The goal of the research plans is to provide Merck KGaA with sufficient information to formally nominate a development candidate and begin IND-enabling studies or cease development on the designated target.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the payments received for research and development activities performed on behalf of Merck KGaA, the Company could be eligible to receive up to a total of $<ix:nonFraction unitRef="usd" contextRef="if4257918738749a69d4891f5d50d9d76_I20140630" decimals="-3" format="ixt:numdotdecimal" name="mrsn:CollaborationArrangementsMaximumAggregateMilestones" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEzMDM_7693a0b7-510f-41bc-adaa-128dc5300b53">780,000</ix:nonFraction> in future milestones related to all targets under the Merck KGaA Agreement, plus low to mid single digit royalties on the commercial sales of any resulting products during the applicable royalty term. The total milestones are categorized as follows: development milestones $<ix:nonFraction unitRef="usd" contextRef="if4257918738749a69d4891f5d50d9d76_I20140630" decimals="-3" format="ixt:numdotdecimal" name="mrsn:CollaborationArrangementsDevelopmentMilestones" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE1Nzk_193ecf41-03a8-487a-9f8f-ee45aaa60ef8">84,000</ix:nonFraction>; regulatory milestones $<ix:nonFraction unitRef="usd" contextRef="if4257918738749a69d4891f5d50d9d76_I20140630" decimals="-3" format="ixt:numdotdecimal" name="mrsn:CollaborationArrangementsRegulatoryMilestones" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2MDU_3017be48-d8a4-48c8-b777-fb8e4dfc341c">264,000</ix:nonFraction>; and sales milestones $<ix:nonFraction unitRef="usd" contextRef="if4257918738749a69d4891f5d50d9d76_I20140630" decimals="-3" format="ixt:numdotdecimal" name="mrsn:CollaborationArrangementsSalesMilestones" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2MzA_f90532be-8ad5-4d97-b0e3-4c1e6d8a17f6">432,000</ix:nonFraction>. There are <ix:nonFraction unitRef="milestone" contextRef="if4257918738749a69d4891f5d50d9d76_I20140630" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2NDQ_f4deca6e-c1bc-47bd-bec8-7e272cfba055">six</ix:nonFraction> individual development milestones per target, payable upon the completion of various activities from the delivery of ADCs meeting defined specifications, through the dosing in a Phase&#160;3 clinical trial. There are <ix:nonFraction unitRef="milestone" contextRef="if4257918738749a69d4891f5d50d9d76_I20140630" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE4NTk_6801086c-dfdc-4326-8820-6b3a22aa2774">five</ix:nonFraction> regulatory milestones, which are payable upon regulatory approvals for a first indication in each of the U.S., European Union and Japanese markets and regulatory approvals for both a second and a third indication in the United States. There are <ix:nonFraction unitRef="milestone" contextRef="if4257918738749a69d4891f5d50d9d76_I20140630" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:CollaborationArrangementIndividualCommercialMilestonesTargetNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzIxMDc_c010eedd-3ce9-4d0d-b2b2-11e8752292d6">three</ix:nonFraction> individual commercial milestones, which are payable upon the attainment of certain defined thresholds for annual net sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2018, the Company had received $<ix:nonFraction unitRef="usd" contextRef="iff84fe17ddac4d30aa64382852adc5e5_D20150101-20171231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzIyNzQ_f9a6006a-1249-45cf-a924-868d8983b889">3,000</ix:nonFraction> related to development milestones under the Merck KGaA Agreement. There have been <ix:nonFraction unitRef="usd" contextRef="if5291b03335245c7aa553dda74e5ae19_D20200101-20201231" decimals="-3" format="ixt-sec:numwordsen" name="mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzIzNTk_7207dcba-c74f-4895-a049-815cf6920cfd"><ix:nonFraction unitRef="usd" contextRef="icc3fca032b454351a178597d5f40733b_D20190101-20191231" decimals="-3" format="ixt-sec:numwordsen" name="mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzIzNTk_9ebca646-f932-498f-834c-01b687c4836a">no</ix:nonFraction></ix:nonFraction> additional milestone payments in the years ended December&#160;31, 2019 or 2020. The next potential milestone payment the Company will be eligible to receive will be a development milestone of $<ix:nonFraction unitRef="usd" contextRef="i907e240893884fc3b84988f45bb0e42c_I20201231" decimals="-3" name="mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI1MzM_3aa0a45b-07cb-4b3f-bd7e-b779eba5f474">500</ix:nonFraction> on Merck KGaA's designation of a preclinical development candidate for any target. Revenue will be recognized when achievement of the milestone is considered probable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Merck KGaA Agreement will expire upon the expiration of the last royalty term for a product under the Merck KGaA Agreement, after which time, Merck KGaA will have a perpetual, royalty-free license, or if Merck KGaA does not designate any ADC product candidates produced by the Company under the Merck KGaA Agreement as preclinical development candidates, upon the expiration of the last to expire research program. Merck KGaA may terminate the Merck KGaA Agreement in its entirety or with respect to any target for convenience upon <ix:nonNumeric contextRef="if5291b03335245c7aa553dda74e5ae19_D20200101-20201231" format="ixt-sec:durday" name="mrsn:CollaborationArrangementsPriorWrittenTerminationNoticeDuration" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzMyNjc_613a94d1-14a4-49e6-9970-305682e663e2">60</ix:nonNumeric> days' prior written notice. Each party may terminate the Merck KGaA Agreement in its entirety upon bankruptcy or similar proceedings of the other party or upon an uncured material breach of the Merck KGaA Agreement by the other party. However, if such breach only relates to one target, the agreement may only be terminated with respect to such target.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a Supply Agreement with Merck KGaA (the Merck KGaA Supply Agreement). Under the terms of the Merck KGaA Supply Agreement, the Company will provide Merck KGaA preclinical non-GMP ADC Drug Substance and clinical GMP Drug Substance for use in clinical trials associated with one of the antibodies designated under the Merck KGaA Agreement. The Company receives fees for its efforts under the Merck KGaA Supply Agreement and reimbursement equal to the supply cost. The Company may also enter into future supply agreements to provide clinical supply material should Merck KGaA pursue clinical development of any other candidates nominated under the Merck KGaA Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Analysis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following performance obligations under the Merck KGaA Agreement: (i)&#160;exclusive license and research services for <ix:nonFraction unitRef="target" contextRef="ib969f2c036c54b3aa4e16d5cd4467eca_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:CollaborationArrangementsTargetsDesignatedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzQ0ODM_37852444-aa91-4453-9cc8-2300f04cef4d">six</ix:nonFraction> designated targets, (ii)&#160;rights to future technological improvements and (iii)&#160;participation of project team leaders and providing joint research committee services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded that each license for a designated target is not distinct from the research services performed related to the designated target as Merck KGaA cannot obtain the benefit of the license without the related research services.&#160;Each license for a designated target and the related services performance obligation is considered distinct from every other license for a designated target and related services performance obligation as each research plan is pursued independent of every other research plans for other designated targets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i4174537a823044439f0615f87745cb78" continuedAt="i483cbd520f044c38b25bd2822cb8e413"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the expected value approach to estimate the amount of consideration related to the payment of fees associated with development and research services.&#160;The Company utilizes the most likely amount approach to estimate any development and regulatory milestone payments to be received.&#160;As of the date of initial application of Topic 606, there were <ix:nonFraction unitRef="usd" contextRef="i5fa45b03b28a4c988f4645fd9a126190_I20180101" decimals="-3" format="ixt-sec:numwordsen" name="mrsn:MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzU1NzQ_8db1d302-673b-44c4-8cf9-991d2fdab491">no</ix:nonFraction> milestones payments that had not already been received, included in the estimated transaction price.&#160;The Company considered the stage of development and the remaining risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Merck KGaA.&#160;The milestone payment amounts were fully constrained, as a result of the uncertainty whether any of the associated milestones would be achieved.&#160;The Company has determined that any commercial milestones and sales based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation or in the case of certain variable consideration to one or more performance obligations.&#160;The estimated standalone selling prices for performance obligations, that include a license and research services, were developed using the estimated selling price of the license and an estimate of the overall effort to perform the research service and an estimated market rate for research services. The estimated standalone selling price of the licenses was established based on comparable transactions.&#160;The estimated standalone selling price for the rights to future technological improvements was developed based on the estimated selling prices of a license or rights received, as well as considering the probability that additional technology would be made available or the probability the counterpart would utilize the technology. The estimated standalone selling price for the joint research committee services was developed using an estimate of the time and costs incurred to participate in the committees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. As of December&#160;31, 2019, the total transaction price for the Merck KGaA Agreement was $<ix:nonFraction unitRef="usd" contextRef="icbdaeaae5ace468d9fc696fd63746c47_I20191231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:RevenueTransactionPriceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzc3MzI_57a8edb0-02f1-47a3-8cd6-c265df250637">21,500</ix:nonFraction>. During 2020, the Company revised its estimate for fees associated with research and development activities under the Merck KGaA Agreement to $<ix:nonFraction unitRef="usd" contextRef="i907e240893884fc3b84988f45bb0e42c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:ReimbursableExpenseResearchAndDevelopmentEstimated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzc4OTQ_2ab12ef9-f6f5-4bc5-8779-87139bd89934">6,325</ix:nonFraction>, a decrease of $<ix:nonFraction unitRef="usd" contextRef="if5291b03335245c7aa553dda74e5ae19_D20200101-20201231" decimals="-3" sign="-" name="mrsn:RevenueTransactionPriceIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzc5MTI_963e7205-e29a-4f80-ae34-8a9beede51c6">175</ix:nonFraction>. The revised total transaction price for the Merck KGaA Agreement is $<ix:nonFraction unitRef="usd" contextRef="i907e240893884fc3b84988f45bb0e42c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:RevenueTransactionPriceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzc5ODQ_d941b058-48e9-4f2d-a75f-96928538a101">21,325</ix:nonFraction>. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="i907e240893884fc3b84988f45bb0e42c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:RevenueTransactionPriceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzgwMTM_37d816a7-d49a-4689-aae5-71444411c774">21,325</ix:nonFraction> was allocated to the performance obligations as follows: approximately $<ix:nonFraction unitRef="usd" contextRef="i5f3c590e11e5409186c16c2b7663f9fc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:RevenueTransactionPriceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzgwODc_396e0d59-1d8e-47f1-84e6-cbc39f05a5f1">3,941</ix:nonFraction> for each of the license and corresponding research and development services units of account for the first and second designated targets; $<ix:nonFraction unitRef="usd" contextRef="i1c28bca56c544eb188d401c14dce4279_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:RevenueTransactionPriceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzgyMjg_946cc233-fb0a-4d4b-8998-ad00ba19b776">3,439</ix:nonFraction> for each of the license and corresponding research and development services units of account for the third and sixth designated target; $<ix:nonFraction unitRef="usd" contextRef="i60c254ebe9d141308dc815c9e53ae58d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:RevenueTransactionPriceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzgzNjc_174406a7-5ab6-43be-979f-82a4fe02f284">3,152</ix:nonFraction> for the license and corresponding research and development services unit of account for the fourth designated target; $<ix:nonFraction unitRef="usd" contextRef="i2a0a25cb274a4de5addf0a574c9ee5aa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:RevenueTransactionPriceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzg0ODg_93bc15a5-0304-4655-b7bb-e136ca8b346a">2,746</ix:nonFraction> for the license and corresponding research and development services unit of account for the fifth designated target; $<ix:nonFraction unitRef="usd" contextRef="i87ac3e6acdfe4d5297fd46e985220155_I20201231" decimals="-3" name="mrsn:RevenueTransactionPriceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzg2MDg_eaa0383c-dde2-45f3-b078-b70b7581104f">425</ix:nonFraction> for rights to future technological improvements; and $<ix:nonFraction unitRef="usd" contextRef="iaf1def552aea421892138747772fc31f_I20201231" decimals="-3" name="mrsn:RevenueTransactionPriceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzg2NjQ_a482a80b-a415-46ae-8cb3-a31eb035aab9">242</ix:nonFraction> for joint research committee services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is recognizing revenue related to the exclusive license and research and development services performance obligation over the estimated period of the research and development services using a proportional performance model.&#160;The Company measures proportional performance based on the costs incurred relative to the total costs expected to be incurred.&#160;To the extent that the Company receives fees for the research services as they are preformed, these amounts are recorded as deferred revenue. Revenue related to future technological improvements and joint research committee services will be recognized ratably over the performance period (which in the case of the joint research committee services approximate the time and cost incurred each period), which are <ix:nonNumeric contextRef="ieb6492dc61484f73b5b8d09644054672_I20201231" format="ixt-sec:duryear" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk0ODI_95aa9262-5e41-48f0-b177-b271b0fa6103">10</ix:nonNumeric> and <ix:nonNumeric contextRef="i4931e025e0654175a346486558f333d9_I20201231" format="ixt-sec:duryear" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk0ODk_a0d3867f-1a35-4887-b181-512ae4930e5a">5</ix:nonNumeric> years, respectively.&#160;The Company is continuing to reassess the estimated remaining term at each subsequent reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company has completed its research service obligations associated with <ix:nonFraction unitRef="target" contextRef="i907e240893884fc3b84988f45bb0e42c_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI3NDg3NzkwODc5ODY_998496f5-a9ab-44a1-9351-5ea6bc978a78">four</ix:nonFraction> of the <ix:nonFraction unitRef="target" contextRef="i907e240893884fc3b84988f45bb0e42c_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:CollaborationArrangementsTargetsDesignatedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI3NDg3NzkwODc5OTQ_df7b0e2a-60f1-4cab-b8a9-553d611033ec">six</ix:nonFraction> designated targets. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded collaboration revenue of $<ix:nonFraction unitRef="usd" contextRef="if5291b03335245c7aa553dda74e5ae19_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk2OTc_d7e49ed7-21c4-4aec-8091-c4b6bfb858d8">828</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="icc3fca032b454351a178597d5f40733b_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk3MDE_9cb552b0-01b3-475a-a67f-764cba35d3cb">853</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idaed771792aa4f45820e1bdf461f9acc_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk3MDg_d3c8e32b-68c3-4ebc-a3d6-ceef47f74b20">2,444</ix:nonFraction>, respectively, related to its efforts under the Merck KGaA Agreement. During the year ended December&#160;31, 2019, the Company recognized collaboration revenue and corresponding research and development expense of $<ix:nonFraction unitRef="usd" contextRef="i6e9a106d068b45588dee4fc2c9191449_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk5MDY_d0afa709-2677-4ec5-9fe4-9c8fe9bf4b4c">1,280</ix:nonFraction> related to the Merck KGaA Supply Agreement. There were <ix:nonFraction unitRef="usd" contextRef="i5b8df85e3b534d9680740bcea14c3648_D20200101-20201231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk5NjQ_0f5b5743-e72d-4765-aca2-b783ca726451"><ix:nonFraction unitRef="usd" contextRef="i99dca4a69ab24c5a872dd3a7062b04b4_D20180101-20181231" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk5NjQ_9bdc25e8-fba5-400e-a295-a665de89d993">no</ix:nonFraction></ix:nonFraction> amounts recognized during the years ended December&#160;31, 2020 and 2018 related to the Merck KGaA Supply Agreement.&#160;There was <ix:nonFraction unitRef="usd" contextRef="i3ad77cfaea7c4367aa41179d395dd1fc_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AccountsReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI3NDg3NzkwODgwNTQ_09dd17d2-c6d6-4340-8d70-1c197a5923d0"><ix:nonFraction unitRef="usd" contextRef="i61c929a4e2c64380af7083035353ca9b_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AccountsReceivableNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI3NDg3NzkwODgwNTQ_ce2709f0-934a-4f13-9e05-075882f5cd95">no</ix:nonFraction></ix:nonFraction> balance in accounts receivable related to the Merck KGaA Agreement and Merck KGaA Supply Agreement as of either December&#160;31, 2020 or December&#160;31, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company had recorded $<ix:nonFraction unitRef="usd" contextRef="i3ad77cfaea7c4367aa41179d395dd1fc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEwMjUz_b7a244f6-b087-4423-8a8a-50ca9fedbad8">3,987</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i61c929a4e2c64380af7083035353ca9b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEwMjYw_c98b2252-86ef-48e6-ac4c-341a5a3815f3">4,815</ix:nonFraction>, respectively, in deferred revenue related to the Merck KGaA Agreement and Merck KGaA Supply Agreement that will be recognized over the remaining performance period.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i483cbd520f044c38b25bd2822cb8e413" continuedAt="i86b0c034943649e29b9356fe33b7fc68"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda XMT-1522 Strategic Partnership</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the Company entered into a Development Collaboration and Commercial License Agreement with Takeda&#8217;s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. for the development and commercialization of XMT-1522 (the XMT-1522 Agreement). Under the XMT-1522 Agreement, Takeda was granted the exclusive right to commercialize XMT-1522 outside of the United States and Canada. Under the XMT-1522 Agreement, the Company was responsible for conducting certain Phase 1 development activities for XMT-1522, including the ongoing Phase 1 clinical trial, at its own expense. The parties agreed to collaborate on the further development of XMT-1522 in accordance with a global development plan (Post-Phase 1 Development). On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the XMT-1522 Agreement upon <ix:nonNumeric contextRef="i5cfc255c5b5348df8b706ecee6e18fc5_D20190102-20190102" format="ixt-sec:durday" name="mrsn:CollaborationArrangementsDurationToTermination" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzExMzQy_72901367-fb35-4ccb-91a1-9e27b415ab2e">30</ix:nonNumeric> days&#8217; prior written notice. The XMT-1522 Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the XMT-1522 Agreement as of March 31, 2019. Under the XMT-1522 Agreement, the Company and Takeda shared equally all agreed Post-Phase 1 Development costs through the date of termination and for a period of <ix:nonNumeric contextRef="i5cfc255c5b5348df8b706ecee6e18fc5_D20190102-20190102" format="ixt-sec:durday" name="mrsn:CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzExNzA0_b18d9d03-8d84-4388-ba1a-408252dff85b">30</ix:nonNumeric> days after the effective termination date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Strategic Research and Development Partnership</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Company entered into a Research Collaboration and Commercial License Agreement with Takeda&#8217;s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (the 2014 Agreement). The 2014 Agreement was amended in January 2015 and amended and restated in January 2016 (the 2016 Restated Agreement). The agreements provided Takeda with the right to develop ADCs directed to a total of <ix:nonFraction unitRef="target" contextRef="i753b8ff92fff46fea6569a01931d0c30_I20160131" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:CollaborativeArrangementsExclusiveTargetsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEyMTk1_d560d95f-74c6-46ba-9aa8-204f3b2f6314">seven</ix:nonFraction> exclusive targets, designated by Takeda, over a specified period of time. On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the 2016 Restated Agreement upon <ix:nonNumeric contextRef="i26c601317048494e845d1196c42e27fb_D20190102-20190102" format="ixt-sec:durday" name="mrsn:CollaborationArrangementsDurationToTermination" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEyNDIz_e0ca131a-f96b-45a4-8f93-23fe1228783e">45</ix:nonNumeric> days&#8217; prior written notice. The 2016 Restated Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the 2016 Restated Agreement as of March 31, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Analysis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaboration agreements with Takeda were terminated following receipt of written notices during the first quarter of 2019. As there are no further performance obligation, the Company recognized the remaining deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i50edd11bfb47457a9112b1ae5cb86665_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEyODk2_8db1a47a-ab71-4053-b0b5-652cf9c1639c">39,965</ix:nonFraction> related to the termination of the Takeda agreements in the first quarter of 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the termination of the agreements, the Company had identified <ix:nonFraction unitRef="agreement" contextRef="icbf321584c2242ad97228b78ab55de05_I20181231" decimals="INF" name="mrsn:RevenueRemainingPerformanceObligationNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEzMDUy_366b1273-21ee-424e-89af-8a3398d927e3">14</ix:nonFraction> performance obligations in the agreements. The Company concluded that the license related to each of the designated targets was not distinct from the research services performed related to each of the designated targets as Takeda could not have obtain the benefit of the license without the related research services. Each license to a designated target and the related service performance obligation was considered distinct from every other license to a designated target and related services performance obligation as each research plan was pursued independent of the any other research plans for other designated targets. Further, the material rights provided were determined to be distinct from the other performance obligations in the arrangement as they were options in the contract Takeda agreements and not required for Takeda to obtain the benefit of the other promised goods or services in the arrangement. Similarly, the Company concluded that the XMT-1522 license and the related research and development services, including the Phase 1 development and the transfer of certain materials and know-how related to the Company's manufacturing processes, were <ix:nonFraction unitRef="agreement" contextRef="i084338c0a80d483dad529458b1964134_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:RevenueRemainingPerformanceObligationNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE0MjIy_c0c54887-b057-4678-a683-7310d14be4cf">one</ix:nonFraction> performance obligation. The license to the Company's intellectual property was not determined to be distinct from the research and related development services that the Company was obligated to perform. For the years ended December&#160;31, 2019 and 2018, the Company recorded total revenue of $<ix:nonFraction unitRef="usd" contextRef="i6f7873d325a04701833b6ce4c01cf715_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE0NTA1_04c326c5-bff7-4377-8606-1a23261526f2">39,965</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4ff6fad6dff742daae99d7c13a13b3a3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE0NTEy_56805ace-0506-4796-ba31-f5cdb132c3d6">5,868</ix:nonFraction>, respectively, related to its efforts under the 2016 Restated Agreement and the XMT-1522 Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the Post-Phase 1 Development activities under the XMT-1522 Agreement represented joint operating activities in which both parties were active participants and of which both parties were exposed to significant risks and rewards that are dependent on the commercial success of the activities. Accordingly, the Company accounted for the Post-Phase 1 Development activities in accordance with ASC 808. For the years ended December&#160;31, 2019 and 2018, the Company was billed approximately $<ix:nonFraction unitRef="usd" contextRef="i68908ae9c5064baa964d04f85fc17eaa_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE1MzM2_08baf852-9a48-4194-8b41-b272e3ecaab9">200</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7dd109ee0cb84c998131f728a303e54f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE1MzQz_4156d651-dbfe-4280-a735-9089c0c0bb89">8,046</ix:nonFraction>, respectively, from Takeda representing Post-Phase 1 Development costs incurred by Takeda. These amounts have been reflected as research and development costs in the consolidated statement of operations. The Company did not perform any Post-Phase 1 Development activities or incur any associated costs prior to January 1, 2018. During the years ended December&#160;31, 2019 and 2018, the Company billed Takeda $<ix:nonFraction unitRef="usd" contextRef="i68908ae9c5064baa964d04f85fc17eaa_D20190101-20191231" decimals="-3" name="mrsn:CollaborationArrangementsCostsBilled" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE1NzQy_e25b87c7-8cbd-4705-8af8-962ba609df77">195</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7dd109ee0cb84c998131f728a303e54f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:CollaborationArrangementsCostsBilled" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE1NzQ5_6d1f5797-89d1-40c9-9d51-3eb6bcfa0108">3,746</ix:nonFraction>, respectively, related to ASC 808 costs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i86b0c034943649e29b9356fe33b7fc68"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contract Assets and Liabilities</span></div><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE3NDMy_da197391-941c-4596-86ea-c5318f219977" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our contract assets and liabilities during the years ended December&#160;31, 2020 and December&#160;31, 2019:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTo4YWE3ODViZDE1MDk0YThkODljZTFiNDU2YjM5N2UxZS90YWJsZXJhbmdlOjhhYTc4NWJkMTUwOTRhOGQ4OWNlMWI0NTZiMzk3ZTFlXzItMS0xLTEtMA_ff0a8257-b2f5-4105-9189-2641b7819975">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTo4YWE3ODViZDE1MDk0YThkODljZTFiNDU2YjM5N2UxZS90YWJsZXJhbmdlOjhhYTc4NWJkMTUwOTRhOGQ4OWNlMWI0NTZiMzk3ZTFlXzItNy0xLTEtMA_8129ac9d-2535-456a-a28f-0c97be2ae35f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTo4YWE3ODViZDE1MDk0YThkODljZTFiNDU2YjM5N2UxZS90YWJsZXJhbmdlOjhhYTc4NWJkMTUwOTRhOGQ4OWNlMWI0NTZiMzk3ZTFlXzQtMS0xLTEtMA_a11d06c0-602b-47ed-a98c-6a2678f758c0">4,815</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="mrsn:ContractWithCustomerLiabilityIncrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTo4YWE3ODViZDE1MDk0YThkODljZTFiNDU2YjM5N2UxZS90YWJsZXJhbmdlOjhhYTc4NWJkMTUwOTRhOGQ4OWNlMWI0NTZiMzk3ZTFlXzQtMy0xLTEtMA_5d208387-0557-4553-b328-3383d2927e13">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="mrsn:ContractWithCustomerLiabilityDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTo4YWE3ODViZDE1MDk0YThkODljZTFiNDU2YjM5N2UxZS90YWJsZXJhbmdlOjhhYTc4NWJkMTUwOTRhOGQ4OWNlMWI0NTZiMzk3ZTFlXzQtNS0xLTEtMA_92c9f8f7-78bf-4612-b0bc-b5843d68a10c">828</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTo4YWE3ODViZDE1MDk0YThkODljZTFiNDU2YjM5N2UxZS90YWJsZXJhbmdlOjhhYTc4NWJkMTUwOTRhOGQ4OWNlMWI0NTZiMzk3ZTFlXzQtNy0xLTEtMA_f2b79b1d-7b5f-484d-bc34-a43b47154347">3,987</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplOGU3NmFiNjRhNWE0MmUxODVmYTA5MzNlNjZkNjk3Yy90YWJsZXJhbmdlOmU4ZTc2YWI2NGE1YTQyZTE4NWZhMDkzM2U2NmQ2OTdjXzItMS0xLTEtMA_29863b2b-0755-495c-9e34-7c3c586907e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplOGU3NmFiNjRhNWE0MmUxODVmYTA5MzNlNjZkNjk3Yy90YWJsZXJhbmdlOmU4ZTc2YWI2NGE1YTQyZTE4NWZhMDkzM2U2NmQ2OTdjXzItNy0xLTEtMA_91a9039f-d232-43f9-a4cc-33f00398249e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplOGU3NmFiNjRhNWE0MmUxODVmYTA5MzNlNjZkNjk3Yy90YWJsZXJhbmdlOmU4ZTc2YWI2NGE1YTQyZTE4NWZhMDkzM2U2NmQ2OTdjXzQtMS0xLTEtMA_1ccfd1cf-3e89-4391-b6b4-c910a888ad08">46,196</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="mrsn:ContractWithCustomerLiabilityIncrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplOGU3NmFiNjRhNWE0MmUxODVmYTA5MzNlNjZkNjk3Yy90YWJsZXJhbmdlOmU4ZTc2YWI2NGE1YTQyZTE4NWZhMDkzM2U2NmQ2OTdjXzQtMy0xLTEtMA_cfdd45be-a979-49ff-a71d-cf183d6c74ca">210</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:ContractWithCustomerLiabilityDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplOGU3NmFiNjRhNWE0MmUxODVmYTA5MzNlNjZkNjk3Yy90YWJsZXJhbmdlOmU4ZTc2YWI2NGE1YTQyZTE4NWZhMDkzM2U2NmQ2OTdjXzQtNS0xLTEtMA_8715d932-c205-4863-8ab6-de4b37d6f0b1">41,591</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplOGU3NmFiNjRhNWE0MmUxODVmYTA5MzNlNjZkNjk3Yy90YWJsZXJhbmdlOmU4ZTc2YWI2NGE1YTQyZTE4NWZhMDkzM2U2NmQ2OTdjXzQtNy0xLTEtMA_0ff86efc-f987-442f-ae0c-b50fb8788bb1">4,815</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue recognized in the period from:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in the contract liability at the beginning of the period</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplYzU1ZWMyYmY3YjI0OGRiYmZhNzE3ZDJmMDc2MmIwYi90YWJsZXJhbmdlOmVjNTVlYzJiZjdiMjQ4ZGJiZmE3MTdkMmYwNzYyYjBiXzMtMS0xLTEtMA_2d6dafd9-4530-48d9-b1d6-330171b51840">828</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplYzU1ZWMyYmY3YjI0OGRiYmZhNzE3ZDJmMDc2MmIwYi90YWJsZXJhbmdlOmVjNTVlYzJiZjdiMjQ4ZGJiZmE3MTdkMmYwNzYyYjBiXzMtMy0xLTEtMA_2308572c-2760-4b4e-92da-15d7ef100d7c">41,591</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplYzU1ZWMyYmY3YjI0OGRiYmZhNzE3ZDJmMDc2MmIwYi90YWJsZXJhbmdlOmVjNTVlYzJiZjdiMjQ4ZGJiZmE3MTdkMmYwNzYyYjBiXzQtMS0xLTEtMA_1b71e2e3-c1f2-4069-ad7c-e540c7222afb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplYzU1ZWMyYmY3YjI0OGRiYmZhNzE3ZDJmMDc2MmIwYi90YWJsZXJhbmdlOmVjNTVlYzJiZjdiMjQ4ZGJiZmE3MTdkMmYwNzYyYjBiXzQtMy0xLTEtMA_64b3d8de-44c8-41ea-a3ff-972ebf355414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided limited services for a collaboration partner, Asana BioSciences. For the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded revenue of $<ix:nonFraction unitRef="usd" contextRef="i23577b731ce742d9a2dc95f75f3ed39e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2MzIw_e57e701c-043c-4407-b56e-32e0b18dfb87">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i9427fc34fbbb4872be93f51ea1a98758_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2MzI0_d68f884c-7f52-4bcb-84a4-96fa62b137f3">25</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4bf844a9201846c6b8d71ce0fc4564a6_D20180101-20181231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2MzMx_5a538a7d-4865-4cbe-9b83-7982f1fb3c7b">782</ix:nonFraction>, respectively, related to these services. In addition, during the year ended December&#160;31, 2018, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ib2c25c7d679e4207b7260e4df1988cd6_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2NDQ5_b53a5a96-48a3-400b-8874-616adcdf3035">1,500</ix:nonFraction> related to a milestone achieved upon the completion of a GLP toxicology study by Asana BioSciences. The next potential milestone the Company is eligible to receive is $<ix:nonFraction unitRef="usd" contextRef="i7f85c6dbea4e41f68ef9f77064c9488c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:CollaborationArrangementsMilestonePaymentReceivableNextMilestone" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2NjE5_8b24e752-0b96-42fe-ac14-e0371401b0d4">2,500</ix:nonFraction> upon dosing the fifth patient in a Phase 1 clinical study by Asana BioSciences. As of December&#160;31, 2020, the Company considered this next milestone to be fully constrained as there is considerable judgment involved in determining whether it is probable that a significant revenue reversal would occur. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestone is outside the control of the Company and there is a high level of uncertainty in achieving this milestone, as this would require initiation of clinical trials by the collaboration partner. The Company reevaluates the probability of achievement of a milestone subject to constraint at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_115"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90ZXh0cmVnaW9uOjZkNWUzZWQ1YTRmZjRmYjFiOGFhYmYxZTRiMzRjY2YzXzkyMA_be7cbfa1-b2bd-4cf5-a9b5-f736ce4626de" continuedAt="icbbff6d099324599934231c69e669cfb" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="icbbff6d099324599934231c69e669cfb"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90ZXh0cmVnaW9uOjZkNWUzZWQ1YTRmZjRmYjFiOGFhYmYxZTRiMzRjY2YzXzkyMQ_e4111f83-68ea-4659-abdc-e7c6362569ec" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents information about the Company's assets and liabilities regularly measured and carried at a fair value and indicates the level within fair value hierarchy of the valuation techniques utilized to determine such value as of December&#160;31, 2019. The Company had no marketable securities as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in&#160;Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c0a8934a1c6426dbdc36c02ecbace70_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtMS0xLTEtMjM5Mg_99d5a03a-2066-425b-a32b-5b50540f86c3">11,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c164faee42044c6bd0efd3f8e822986_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtMy0xLTEtMjM5Mg_271d37bb-65c7-4a7a-88d4-58193b0fb099">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ad11b4ad384e07aadaac9fb23dd498_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtNS0xLTEtMjM5Mg_c6775e1b-c4c3-4010-a097-905bf1650827">11,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if421bb6d4ade4aa7875850e2e9e7ce5e_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtNy0xLTEtMjM5Mg_8abc9dbb-2c25-4d2f-91f4-84e978e7dee5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8269462beefc49e0bf40ee05af372ef6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtMS0xLTEtMjM5Mg_58ebef5f-1726-4008-bd73-a9defc89666e">12,010</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32fd9e9a94794fe3a2242b4ca9bc78d0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtMy0xLTEtMjM5Mg_fa868cc7-ddc8-4382-8b66-a3f62393415c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6341208859442f9b6ef8af77034d83d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtNS0xLTEtMjM5Mg_7c7560d3-61e7-443e-a7b5-8a879b03bbf8">12,010</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i352d06ba5fb848548eb58f8027ff894b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtNy0xLTEtMjM5Mg_fad453c9-c016-4fa5-b3b3-541bfd8606ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc9df98ef2d477ba1138bc3dd081e76_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtMS0xLTEtMA_6481c3ba-104a-490e-b96e-f03c0406fd5d">13,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia12bcd4d127345a18bc09a7631d0e9ae_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtMy0xLTEtMA_656ca187-60e4-4b9c-a76c-80e3682d4e3f">13,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c176c12317e495abdb2f03744b1bffa_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtNS0xLTEtMA_5018afe9-cf76-4999-9bd2-bd8cb31796bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e2e3e778ca460194f0dffe0a2edf27_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtNy0xLTEtMA_9731f3e8-ffe1-4fbb-abd6-b340c7f61bfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc4ff85c1d24045ab6977cd50a5b2e9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtMS0xLTEtMA_4a0af7cc-fe6c-410a-9b22-78e8df163e23">37,439</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic52340d210a24378ae895de1817cdca3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtMy0xLTEtMA_123e5d03-be14-4d67-a1cd-c1d967cf788c">13,489</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50ec1eca088483b9329538c98b03e04_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtNS0xLTEtMA_fbc88610-c26c-470f-8c15-b6a56597c32a">23,950</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f480eeb670e4a4e820469036816203f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtNy0xLTEtMA_0187ea21-7bf6-45fc-90ae-c1fadd0042fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in valuation techniques or transfers between fair value measurement levels during the&#160;years ended December&#160;31, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the consolidated balance sheets for prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the carrying value of the Company&#8217;s outstanding borrowing under the Credit Facility (as defined below) approximated fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. The Credit Facility is discussed more detail in Note 8, &#8220;Debt&#8221;.</span></div></ix:continuation><div id="i7157c5eacfe941de9505feeee920791e_121"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90ZXh0cmVnaW9uOjYxNjA5ZGRlMTUzOTQyZDE5NzhjMDEzNGZkYWNjZTBiXzcwNA_bfcb501f-ba21-41de-9ca5-185c0443fa31" continuedAt="id9c329fa57844de8b1c5d97ceba39e50" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="id9c329fa57844de8b1c5d97ceba39e50"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90ZXh0cmVnaW9uOjYxNjA5ZGRlMTUzOTQyZDE5NzhjMDEzNGZkYWNjZTBiXzcwNQ_fe429c53-5156-45cd-b037-53ddbedcd385" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes marketable securities held at December&#160;31, 2019. The Company had <ix:nonFraction unitRef="security" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90ZXh0cmVnaW9uOjYxNjA5ZGRlMTUzOTQyZDE5NzhjMDEzNGZkYWNjZTBiXzI3NDg3NzkwNzA4ODM_5c33644e-6d87-48d2-bccf-707b7a6713d4">no</ix:nonFraction> marketable securities as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if61098ade0e347d582c1a9c5ca600ca2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItMS0xLTEtMjQxMQ_a2c22dd8-e1b1-4203-91bb-016ffde1a1e5">11,940</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if61098ade0e347d582c1a9c5ca600ca2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItMy0xLTEtMjQxMQ_e891bc38-5056-4ffe-85b6-537cac8762a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if61098ade0e347d582c1a9c5ca600ca2_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItNS0xLTEtMjQxMQ_44c8a3f2-32d1-4668-b75d-f0f24fe6f081">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if61098ade0e347d582c1a9c5ca600ca2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItNy0xLTEtMjQxMQ_0d700def-2b81-471f-b32b-d7e81d3d268c">11,940</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09af4016cf924f80913d431c2607ec67_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtMS0xLTEtMjQxMQ_8450b1a3-c3b6-4e5a-9882-b9c608849754">11,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09af4016cf924f80913d431c2607ec67_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtMy0xLTEtMjQxMQ_8eb10710-836a-497a-bd9a-1b7e98933572">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09af4016cf924f80913d431c2607ec67_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtNS0xLTEtMjQxMQ_a2996fdb-b777-4791-bd4c-4bc4c7d0bb74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09af4016cf924f80913d431c2607ec67_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtNy0xLTEtMjQxMQ_22761fbf-72fd-4cb5-8a4e-9ae022b1aef8">12,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e5c95050104eaa8d8078a5e789e74b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItMS0xLTEtMA_4350601d-2e24-47f1-bd13-e8c11b04f24a">13,484</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e5c95050104eaa8d8078a5e789e74b_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItMy0xLTEtMA_60f9e5ef-632d-476a-ae52-30caec249d8a">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e5c95050104eaa8d8078a5e789e74b_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItNS0xLTEtMA_b6ea261b-49b1-43c3-a7ce-2ca671774377">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e5c95050104eaa8d8078a5e789e74b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItNy0xLTEtMA_a8ccf4d2-be96-44b9-8d13-fae174ab926f">13,489</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtMS0xLTEtMA_73cbdee1-9208-4f0b-ae7a-e59273f14acb">37,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtMy0xLTEtMA_1b8f58cc-d03e-4f4a-94eb-b105aafef63d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtNS0xLTEtMA_5cd01bba-df30-4df1-8ac6-8fdceacebe70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtNy0xLTEtMA_226b2bf3-5f1c-4321-9cae-18d5fdb0d846">37,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="i7157c5eacfe941de9505feeee920791e_127"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90ZXh0cmVnaW9uOjcxZTI3ZjZkYTYzYTQzYjFhMzJhMDY2YTUwZjlkYzdjXzM1Nw_4e28ac1f-9356-488a-826d-9577dec46165" continuedAt="i5eb1ec06c5774b58b49f1b8b045e7007" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i5eb1ec06c5774b58b49f1b8b045e7007" continuedAt="ie931382e2c574c46806c7697cea37847"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90ZXh0cmVnaW9uOjcxZTI3ZjZkYTYzYTQzYjFhMzJhMDY2YTUwZjlkYzdjXzM1OA_e1250a25-adff-42db-9a85-ad3f441d6cf9" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following as of December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47ab6eccf1b6445f80bc756361d8cff7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzEtMS0xLTEtMA_64f8c98f-cd85-487e-82d7-db97b551cfeb">6,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53d0e5e5e574f9ea3bfac8d17355c76_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzEtMy0xLTEtMA_c1bf44f1-46d5-4770-82c0-fa641f76b56c">6,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc584d33c9d43799da46631af3ada8e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzItMS0xLTEtOTk2Mw_9f994b6b-45fe-4570-ba04-9f36e7fc5462">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0a28d50b8e94ad8a3d5ce0e83bf2a8c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzItMy0xLTEtOTk2Mw_8f291f4d-c67d-482d-af70-0c0f7e5d2d56">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856895a9ae3d498cbd7a6e7e6aea88cf_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzItMS0xLTEtMA_c25065ed-5fe9-4415-9d0a-d63e74e233e7">959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd1dfdef8c0c4efbb4a9ef235c35a801_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzItMy0xLTEtMA_c52c4c02-8b4a-48da-8a72-56ca6a9bc2c5">1,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzQtMS0xLTEtMA_10ff1a8b-0481-4cef-9619-a7dd9ee2169d">9,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzQtMy0xLTEtMA_01b2a37a-25a8-49b8-a199-809aca0e3869">9,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzUtMS0xLTEtMA_b28c4b3f-f28f-48a8-b4f3-7107f755573c">7,635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzUtMy0xLTEtMA_77c68546-c05a-42bf-8490-fe57b6043564">7,209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzYtMS0xLTEtMA_0dd7cc56-126f-40df-a274-9bf8e4f2e4d6">1,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzYtMy0xLTEtMA_54a67d31-5752-4969-947c-f91c8f7b0197">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie931382e2c574c46806c7697cea37847">The Company recorded assets under finance leases of $<ix:nonFraction unitRef="usd" contextRef="i0af0080ba1dc4a0cb75af59f74d83190_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90ZXh0cmVnaW9uOjcxZTI3ZjZkYTYzYTQzYjFhMzJhMDY2YTUwZjlkYzdjXzE1MQ_dfd53fc1-4b30-46ae-85f2-debd28cd6bd4">429</ix:nonFraction> as laboratory equipment during the year ended December&#160;31, 2019. Financing leases are discussed in more detail in Note 11 &#8220;Leases&#8221;. Depreciation expense for the&#160;years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90ZXh0cmVnaW9uOjcxZTI3ZjZkYTYzYTQzYjFhMzJhMDY2YTUwZjlkYzdjXzMzMA_c9721486-32dd-48c7-969c-de18b80f85c0">1,010</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90ZXh0cmVnaW9uOjcxZTI3ZjZkYTYzYTQzYjFhMzJhMDY2YTUwZjlkYzdjXzMzNA_4e0391eb-8145-42bb-a7f4-93fed4d6c320">1,245</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90ZXh0cmVnaW9uOjcxZTI3ZjZkYTYzYTQzYjFhMzJhMDY2YTUwZjlkYzdjXzM0MQ_99bb81e7-cc49-4bce-a2bf-5e7851645c80">1,257</ix:nonFraction>, respectively.</ix:continuation></span></div><div id="i7157c5eacfe941de9505feeee920791e_130"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90ZXh0cmVnaW9uOjc0YjlkNGI3MDk2MTRhOGQ4Y2QyMDFkZGM4MjAzMjczXzg1_1bf1de78-52df-4d4c-845a-d22917f45d15" continuedAt="i10a266de075448cf80607c5fb185bee2" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i10a266de075448cf80607c5fb185bee2"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90ZXh0cmVnaW9uOjc0YjlkNGI3MDk2MTRhOGQ4Y2QyMDFkZGM4MjAzMjczXzg2_7c2440c6-4f7c-4580-a889-acca76aad102" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following as of December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical, manufacturing and clinical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:AccruedPreclinicalAndClinicalExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzEtMS0xLTEtOTk0NQ_90a4afa8-1eae-41b0-ab8e-adf900d78f68">9,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:AccruedPreclinicalAndClinicalExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzEtMy0xLTEtOTk0NQ_1a5a5d45-1e00-41d4-a2ff-75c37659175e">4,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzEtMS0xLTEtMA_93fe9cb7-9b3e-4c52-9b04-f1648b488ca6">5,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzEtMy0xLTEtMA_816a4221-f8c3-4e23-b763-710a98d51eb0">4,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzMtMS0xLTEtMA_9185b452-15f5-406b-abc3-ecc0e9da46a7">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzMtMy0xLTEtMA_105916b9-24a6-4427-8559-2824bafe49b7">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzQtMS0xLTEtMA_1f4f23b9-73bb-4944-9483-4648a86f9c44">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzQtMy0xLTEtMA_102a2bd2-4fdf-4165-8fa9-58fb8322d683">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzUtMS0xLTEtMA_b5825ec0-d2d4-419c-ac77-c58d0f6321d3">16,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzUtMy0xLTEtMA_dc1fb010-3820-4c01-a05b-5214509b0770">8,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i7157c5eacfe941de9505feeee920791e_133"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQ2NzY_38154782-22a9-48c7-9043-b5baaf7bfdd9" continuedAt="i42a47505cded4d65934e19a5eab8c437" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i42a47505cded4d65934e19a5eab8c437" continuedAt="i89a7800bdc0b4881a221d21e5293722b"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2019, the Company entered into a loan and security agreement (the Original Agreement) with Silicon Valley Bank (SVB) pursuant to which the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="ic7699dd1563a4628924b1afe47e1a4dd_D20190508-20190508" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzM0OQ_deff9dea-9aec-4e1f-a8f9-0e6d5a6d8b20">5,000</ix:nonFraction>. The Original Agreement accrued interest at a floating per annum rate equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="i631efc7ffeaf4f04ac0f4957eaba56a9_I20190508" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQ5NA_ea3f85cf-608a-49e1-b569-7d5cef73a817">4.0</ix:nonFraction>% and (ii) <ix:nonFraction unitRef="number" contextRef="i163836ee7b6f4ffa9c0cb574b727c47f_D20190508-20190508" decimals="4" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzUwNg_0e28cf32-3876-44e3-a0f4-3db8217a9589">1.50</ix:nonFraction>% below the Prime Rate. The Original Agreement had an interest-only period through August 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2020 (the Effective Date), the Company entered into a second amendment (the Amendment) to its existing loan and security agreement (as amended prior to the Amendment, the Existing Credit Facility) with SVB. Pursuant to the Amendment, the Company can borrow term loans in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i6bc12f9880564eaaaf5cd6c44d035584_I20200828" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyMTk_c71511a9-a2fc-4638-a156-64aca4386178">30,000</ix:nonFraction> (the Amended Credit Facility), at its option, (i) up to $<ix:nonFraction unitRef="usd" contextRef="i90749e47b83a4ed7a4168ba3c7be4fbc_I20200828" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyMzE_3865a729-f943-421f-b465-a2db561783f6"><ix:nonFraction unitRef="usd" contextRef="ie14bf80516a946eab284cdc6fa94ee65_I20200828" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyMzE_6468deb8-7865-41e6-9867-c79f4f5b5906"><ix:nonFraction unitRef="usd" contextRef="i7e2dcf3cdc3748e483ed1c6403bb6a16_I20200828" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyMzE_c13eb810-263d-4b86-86d8-ea83cf8d5925"><ix:nonFraction unitRef="usd" contextRef="iec2d0197c15d41c8a6bdc407bc838c19_I20200828" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyMzE_f0c86795-eed1-460c-b330-f14eb7cfe7d0"><ix:nonFraction unitRef="usd" contextRef="icfaa9f81105a42f396f57538ca9bca0e_I20200828" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyMzE_f72fcc4d-6011-4a3f-a6fa-629f29b87e67">25,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> in up to five principal advances through April 30, 2022, and (ii) an additional $<ix:nonFraction unitRef="usd" contextRef="ie6d2f0012515488e88c88d4beea20fbd_I20200828" decimals="INF" format="ixt:numdotdecimal" name="mrsn:LineOfCreditFacilityAccordianFeatureIncreaseLimit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyNDM_a2d2d967-212c-40a7-b21a-ed79a7c2f277">5,000</ix:nonFraction> in one principal advance, if the Company reaches certain development milestone events, as described in the Amendment, through April 30, 2022. The Company drew $<ix:nonFraction unitRef="usd" contextRef="i6bc12f9880564eaaaf5cd6c44d035584_I20200828" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyNjA_7ed8928a-1294-4120-b5bc-612857228fde">5,200</ix:nonFraction> upon execution of the Amendment, the proceeds of which were used to repay the Company&#8217;s existing balance and satisfy its obligations to SVB, including the final payment obligation under the Existing Credit Facility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Facility bears interest at a floating per annum rate equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="iaa8dbb46bbe744e985b2e0216ba5ac51_I20200828" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2Mzg3NDM_624c5dfd-a095-4494-b01e-a7f5aac8bbd6">4.25</ix:nonFraction>% and (ii) <ix:nonFraction unitRef="number" contextRef="i5b7d7299ce1c41e0b7319ee9be889c78_D20200828-20200828" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2Mzg3NTA_d40a9fef-6abe-487a-ab53-ce57ace389fb">1.00</ix:nonFraction>% above the Prime Rate, as defined. The Company is obligated to make monthly interest-only payments on each outstanding term loan commencing on the first calendar day of the month following the funding date of such term loan, and continuing on the first calendar day of each month thereafter through May 31, 2022. The interest only period may be extended through January 31, 2023 upon the achievement of a regulatory milestone, as described in the Amendment. Following the interest-only period, the Company will be required to repay the outstanding principal balance under the term loans in equal monthly payments plus interest in arrears to SVB through November 1, 2024 (the Maturity Date).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to make a final payment to SVB equal to <ix:nonFraction unitRef="number" contextRef="i078da7f737c349af8b0fe34900888817_D20200828-20200828" decimals="3" name="mrsn:FinalPaymentAsPercentageOfOriginalPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEyOTQ_e479e020-aa65-4cbc-8d52-6f010d796a64">5.5</ix:nonFraction>% of the principal amount of the Term Loans then extended to the Company. This final payment is accreted under the effective interest method over the life of each term loan. The term loans are secured by substantially all of the Company&#8217;s assets, except for its intellectual property which is subject to a negative pledge, and certain other customary exclusions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Company&#8217;s option, it may prepay the outstanding principal balance of any term loans in whole but not in part, subject to a prepayment fee of: (a) <ix:nonFraction unitRef="number" contextRef="i21f9feecd548415ea57bfadff8075528_D20200828-20200828" decimals="3" name="mrsn:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzE4MDY_6f74f7c1-565e-4e9e-b8b4-48e82afa02c3">3.0</ix:nonFraction>% of the term loans then extended to the Company if the prepayment occurs on or prior to August 28, 2021, (b) <ix:nonFraction unitRef="number" contextRef="i1d95ffd29d8a42f09d5833c466360f5c_D20200828-20200828" decimals="3" name="mrsn:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzE5MTM_9505049f-bf75-49bf-adf4-74b8e04941d2">2.0</ix:nonFraction>% of the term loans then extended to the Company if the prepayment occurs after August 28, 2021 but on or prior to August 28, 2022, or (c) <ix:nonFraction unitRef="number" contextRef="i3c584ca6ee79452785e1ad58cd890611_D20200828-20200828" decimals="3" name="mrsn:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzIwNDU_37f181ad-761e-4d21-bca9-9caaa34aa8f5">1.0</ix:nonFraction>% of the term loans then extended to the Company if the prepayment occurs after August 28, 2022 but before November 1, 2024. The Amended Credit Facility includes customary affirmative and restrictive covenants applicable to the Company. Affirmative covenants include, among others, covenants requiring the Company to maintain its corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The Amendment removed the requirement for the Company to maintain a minimum liquidity ratio. The restrictive covenants include, among others, requirements relating to the Company&#8217;s ability to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i89a7800bdc0b4881a221d21e5293722b"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets and agree to a change in control, in each case subject to certain customary exceptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s payment obligations under the Amended Credit Facility are subject to acceleration upon the occurrence of specified events of default, which include, but are not limited to, the occurrence of a material adverse change in the Company&#8217;s business, operations, or financial or other condition. Amounts outstanding upon the occurrence of an event of default are payable upon SVB&#8217;s demand and shall accrue interest at an additional rate of <ix:nonFraction unitRef="number" contextRef="i078da7f737c349af8b0fe34900888817_D20200828-20200828" decimals="3" name="mrsn:DebtInstrumentAdditionalRateInEventOfDefault" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzM4MDc_6c0254f4-583f-4a89-b3ee-0468e1af89f3">5.0</ix:nonFraction>% per annum of the past due amount outstanding. As of December&#160;31, 2020, the Company was in compliance with all covenants under the Credit Facility. As such, as of December&#160;31, 2020, the classification of the loan balance as stated on the balance sheet was based on the timing of defined future payment obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unamortized issuance costs under the Existing Credit Facility were $<ix:nonFraction unitRef="usd" contextRef="i4b8290917b104724b022253cb68344a8_I20200828" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzI3NDg3NzkwODk2MDQ_2cd1f404-deb0-4eaa-b7f5-37d083c40d6e">139</ix:nonFraction> as of the date of the Amendment. The Company incurred debt issuance costs paid to the lender in connection with the Amended Credit Facility of $<ix:nonFraction unitRef="usd" contextRef="i6bc12f9880564eaaaf5cd6c44d035584_I20200828" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQxMTU_16ea74ec-fef9-4ad1-a4b0-c1e5026f2171">17</ix:nonFraction>. The Company recorded such costs, including the settlement of the final payment obligation under the Existing Credit Facility as a discount from the carrying value of the term loans which are amortized as interest expense using the effective-interest method over the term of the Amended Credit Facility.</span></div><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQ2Nzc_bc1eae38-65d4-4936-aaaf-1735632cde8d" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i6bc12f9880564eaaaf5cd6c44d035584_I20200828" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQ0NTQ_7ed8928a-1294-4120-b5bc-612857228fde">5,200</ix:nonFraction> outstanding under the Amended Credit Facility and the debt consisted of the following:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo1OTgzMDdjMzhlZTM0YThmODE0ZmQ1YzAwNDk4NmNhNi90YWJsZXJhbmdlOjU5ODMwN2MzOGVlMzRhOGY4MTRmZDVjMDA0OTg2Y2E2XzEtMS0xLTEtMA_d254a229-e9bc-4cce-9308-fbf41392e95f">5,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term-debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo1OTgzMDdjMzhlZTM0YThmODE0ZmQ1YzAwNDk4NmNhNi90YWJsZXJhbmdlOjU5ODMwN2MzOGVlMzRhOGY4MTRmZDVjMDA0OTg2Y2E2XzItMS0xLTEtMA_81961f97-9f50-4b28-98a1-cadd3a4ab150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:DebtInstrumentCarryingAmountNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo1OTgzMDdjMzhlZTM0YThmODE0ZmQ1YzAwNDk4NmNhNi90YWJsZXJhbmdlOjU5ODMwN2MzOGVlMzRhOGY4MTRmZDVjMDA0OTg2Y2E2XzMtMS0xLTEtMA_2e0636e0-03a1-4b79-ad97-09c03cca7ca9">5,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt financing costs, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo1OTgzMDdjMzhlZTM0YThmODE0ZmQ1YzAwNDk4NmNhNi90YWJsZXJhbmdlOjU5ODMwN2MzOGVlMzRhOGY4MTRmZDVjMDA0OTg2Y2E2XzQtMS0xLTEtMA_e063e3de-98cf-4e16-a5d7-22c7ed9da948">246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion related to final payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo1OTgzMDdjMzhlZTM0YThmODE0ZmQ1YzAwNDk4NmNhNi90YWJsZXJhbmdlOjU5ODMwN2MzOGVlMzRhOGY4MTRmZDVjMDA0OTg2Y2E2XzUtMS0xLTEtMA_b12bbe98-12ac-49b1-9f31-6d60194de022">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo1OTgzMDdjMzhlZTM0YThmODE0ZmQ1YzAwNDk4NmNhNi90YWJsZXJhbmdlOjU5ODMwN2MzOGVlMzRhOGY4MTRmZDVjMDA0OTg2Y2E2XzYtMS0xLTEtMA_16f920aa-7cd7-40b3-bc22-e9601a1b5f60">4,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQ2Nzg_bf1197f3-c45b-4663-8187-9e0163069d1d" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the estimated future principal payments due are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo2NWY5MzJkYjI1N2E0MzAwYTA5M2ZlYzcxMWM3YTVjZS90YWJsZXJhbmdlOjY1ZjkzMmRiMjU3YTQzMDBhMDkzZmVjNzExYzdhNWNlXzAtMS0xLTEtMA_00778e70-7cca-403f-a812-260abd09eca6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo2NWY5MzJkYjI1N2E0MzAwYTA5M2ZlYzcxMWM3YTVjZS90YWJsZXJhbmdlOjY1ZjkzMmRiMjU3YTQzMDBhMDkzZmVjNzExYzdhNWNlXzEtMS0xLTEtMA_346d5a09-c042-4686-abca-21b371333c63">1,213</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo2NWY5MzJkYjI1N2E0MzAwYTA5M2ZlYzcxMWM3YTVjZS90YWJsZXJhbmdlOjY1ZjkzMmRiMjU3YTQzMDBhMDkzZmVjNzExYzdhNWNlXzItMS0xLTEtMA_183fbe2f-c16c-43d7-9ad5-77d7ea6742f0">2,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo2NWY5MzJkYjI1N2E0MzAwYTA5M2ZlYzcxMWM3YTVjZS90YWJsZXJhbmdlOjY1ZjkzMmRiMjU3YTQzMDBhMDkzZmVjNzExYzdhNWNlXzMtMS0xLTEtMA_0e1d102b-63eb-45d2-a824-eaadd100e555">1,907</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo2NWY5MzJkYjI1N2E0MzAwYTA5M2ZlYzcxMWM3YTVjZS90YWJsZXJhbmdlOjY1ZjkzMmRiMjU3YTQzMDBhMDkzZmVjNzExYzdhNWNlXzQtMS0xLTEtMA_b01776db-c342-426e-a7b5-26e5a64894f1">5,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020 and 2019, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQ2MjM_db40e32c-99d0-4a5a-85e4-562f500af9cb">340</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzI1NzY_285c7ad0-2a85-4140-88a8-afa9518fb4df">214</ix:nonFraction>, respectively, of interest expense related to the Existing Credit Facility and Amended Credit Facility, as applicable.</span></div></ix:continuation><div id="i7157c5eacfe941de9505feeee920791e_139"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzI3NzI_6fab9757-ab5b-4937-a47f-c01f0a3d971e" continuedAt="i4444b09bd5fa41288f8dfca0f769a376" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i4444b09bd5fa41288f8dfca0f769a376" continuedAt="i28f26199bc7449bbab6e3c1268fe346a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company has <ix:nonFraction unitRef="shares" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzkwMDg_7d1fe851-c55d-44ca-93e8-866f1b7a4060">25,000,000</ix:nonFraction> shares of authorized preferred stock. <ix:nonFraction unitRef="shares" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzkwMTI_beba5002-8267-4acb-99b7-dbe921363515">No</ix:nonFraction> shares of preferred stock have been issued.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At-the-market equity offering program</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company established an at-the-market (ATM) equity offering program (the 2018 ATM) pursuant to which it could offer and sell up to $<ix:nonFraction unitRef="usd" contextRef="iab9b2892056c4107bc99217b78b467ca_I20180731" decimals="INF" format="ixt:numdotdecimal" name="mrsn:StockIssuanceProgramAuthorizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMyNTY_9420ea46-347d-49ff-b275-f59491d3704f">75,000</ix:nonFraction> of its common stock from time to time at prevailing market prices. In April 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="ia64de5de74d14ba6a2d99ac7e5b576e6_D20200401-20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMyNjg_1b77f4bf-9e5d-418b-ab3e-14799e60b60f">8,938,599</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i12e103ce06ac4a6899e2b020312d0789_D20200401-20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMyNzk_02406985-736a-4f87-94fe-b7b304934014">1,962,000</ix:nonFraction> shares of common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="if180f69d9ce245cf99704eb7f6351a59_I20200430" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMyOTA_d7bd0bf1-48a2-40d0-901c-8930e35edcea">5.59</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="i41a996208e274d7a8e321ab0940d2cd2_I20200430" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMyOTc_16f90fa7-3aea-4dcc-a494-b77a53b31074">7.74</ix:nonFraction> per share, respectively, to raise </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i28f26199bc7449bbab6e3c1268fe346a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia4e03a06a83b45da881a991b3fa64a37_D20200401-20200430" decimals="-3" format="ixt:numdotdecimal" name="mrsn:ProceedsFromIssuanceOfCommonStockGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMzMDQ_fb177ff2-7009-42fa-87b2-30b7f2ba2d31">65,153</ix:nonFraction> through the 2018 ATM facility. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering were approximately $<ix:nonFraction unitRef="usd" contextRef="ia4e03a06a83b45da881a991b3fa64a37_D20200401-20200430" decimals="-3" format="ixt:numdotdecimal" name="mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMzMTY_ec1ff238-990a-447b-8f87-10a417f9cd43">62,976</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company terminated the 2018 ATM and established a new ATM equity offering program (the 2020 ATM) pursuant to which it is able to sell up to $<ix:nonFraction unitRef="usd" contextRef="i13f8a6424f0a4cf9be7614ce49041c63_I20200531" decimals="INF" format="ixt:numdotdecimal" name="mrsn:StockIssuanceProgramAuthorizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMzMjg_0cc83433-15e2-4179-80d9-4efb82b43e9d">100,000</ix:nonFraction> of its common stock from time to time at prevailing market prices. As of December&#160;31, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="i308407f9760646139e65cbbff6cda013_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzgwMTM_79f43833-13df-418b-9d57-a387cc3e0b1a">no</ix:nonFraction>t sold any shares under the 2020 ATM.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Follow-on offering</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i35ae40d344cb48109420ed8b520d73e7_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMzNjM_96fc0899-3279-4695-b60c-a5b618a67e3e">9,200,000</ix:nonFraction> shares of common stock, in an underwritten public offering price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia651b5389b414e8d9e7497b27b28db57_I20200630" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMzNzQ_0809e642-bbae-41b5-8a94-c547d9761e08">19.00</ix:nonFraction> per share. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering were $<ix:nonFraction unitRef="usd" contextRef="i35ae40d344cb48109420ed8b520d73e7_D20200601-20200630" decimals="-3" format="ixt:numdotdecimal" name="mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMzOTU_63588bb1-53bc-45c8-bd19-8fd2030c4bcd">163,990</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a 2013 Series&#160;A-1 Preferred Stock issuance, the Company granted to certain investors warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i06524015ee73497b86e333130cd09189_D20130101-20131231" decimals="INF" format="ixt:numdotdecimal" name="mrsn:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzQwNDM_5e26d2a4-002a-4ab5-b7a3-881bddc6c62b">129,491</ix:nonFraction> shares of common stock. The warrants have a $<ix:nonFraction unitRef="usdPerShare" contextRef="id811a98ebc9446e780342c9c938b83b6_I20131231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzQwOTE_b11f4329-ba94-4b09-b844-da1f2b3f61ad">0.05</ix:nonFraction> per share exercise price and a contractual life of <ix:nonNumeric contextRef="i06524015ee73497b86e333130cd09189_D20130101-20131231" format="ixt-sec:duryear" name="mrsn:ContractualLifeOfWarrants" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzQxNDY_2e5ff118-4a48-4ed0-b7c2-03892426dc19">10</ix:nonNumeric> years. The fair value of these warrants was recorded as a component of equity at the time of issuance. As of December&#160;31, 2020 and 2019 there were warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzQyOTA_1fb03d57-b99e-466d-8e99-3e27cac65aad"><ix:nonFraction unitRef="shares" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzQyOTA_410e7d40-d55d-4bab-ad9f-21fa6d5b7329">39,474</ix:nonFraction></ix:nonFraction> shares of common stock. During the year ended December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2Mzg0NTQ_97521a81-d919-4b67-8e1e-49f5d90633c6">no</ix:nonFraction> exercises of warrants in exchange for shares of common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange warrants</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 26, 2019, the Company entered into an exchange agreement with entities affiliated with Biotechnology Value Fund, L.P. (the Exchanging Stockholders), pursuant to which the Exchanging Stockholders exchanged an aggregate of <ix:nonFraction unitRef="shares" contextRef="i317cfb0a66ce420aba39052cc61dd3f7_D20191126-20191126" decimals="INF" format="ixt:numdotdecimal" name="mrsn:ClassOfWarrantOrRightSharesExchangedForWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzYwODY_7f7715e3-9603-4fcd-b4e6-be1d21ac8105">2,575,000</ix:nonFraction> shares of common stock for warrants (the Exchange Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i455788b289d34014a736e72b5a36e693_I20191126" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzYwOTc_929e6a3d-2b52-472c-94ec-0a26aa549328">2,575,000</ix:nonFraction> shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, merger or consolidation, change of control, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i455788b289d34014a736e72b5a36e693_I20191126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzYxMDg_5beec896-57a2-49e6-a412-2f612afec5d1">0.0001</ix:nonFraction> per share.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification Topic 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. While outstanding, the Exchange Warrants were classified as equity in accordance with Accounting Standards Codification Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. On March 2, 2020, the Exchanging Stockholders exercised the Exchange Warrants in full on a net cashless exercise basis, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="i87d8789f035d4fd5a4df293bbf1c1d7e_D20200302-20200302" decimals="INF" format="ixt:numdotdecimal" name="mrsn:WarrantsExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzYxMTc_ac1e3871-41d2-4f19-a5ad-2ae1d3746817">2,574,971</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="i6e5bfe19343142b3906779afeba94ec7_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:NumberOfVotesPerCommonShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzgwMDY_1fb9348e-075d-4d0e-aae3-c862dc357e47">one</ix:nonFraction> vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors (the Board).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019 there were <ix:nonFraction unitRef="shares" contextRef="ib6469fe4541e48b89a7a078c0ed5ffcf_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzI3MQ_ad609bab-211f-4b0f-a106-a153978214bb">6,869,189</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i535686c256b94372ae4ce5f38fcb0825_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzI3OA_3edd7a2d-d33c-4057-906a-4b89f350d596">7,782,582</ix:nonFraction>, respectively, shares of common stock reserved for the exercise of outstanding stock options and warrants.</span></div><div style="margin-bottom:6pt"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzI3NzM_007ff899-e751-47fb-8eab-a042f21786ea" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5e733a950fa45a997c912a1f02d01a3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzEtMS0xLTEtMA_45e4c7dd-8d2d-4284-b7f1-f21d6aafbbf1">6,112,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i140f6ca2a4144d20a6d857ac59d04d54_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzEtMy0xLTEtMA_0477efca-048a-4436-a2c4-96afdf3418e9">4,720,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie75edfebdd6e45ba9f9bfbf6f784bf06_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzItMS0xLTEtMA_f29f7aa6-75d4-4a9e-bc29-b32b0bdd675a">716,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if65e9cab919646faac147bc5c615a4ad_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzItMy0xLTEtMA_4f73774b-5296-40bf-a468-7425e727adcb">447,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i303a7a474d1f41a5a7a7433b5d46bcc1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzQtMS0xLTEtMA_4bc34b8c-0267-4834-9e22-ae52525194aa">39,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i659d9c80d2bc46cdb8692d3fccee5dd2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzQtMy0xLTEtMA_13537a23-7c30-44ca-a986-98bf8d702245">39,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32e7573ef8fe419aa60a3e7c2573e532_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzUtMS0xLTEtMjkyMQ_0722d0f7-fdf4-40a9-821a-2df80c9fbe8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecb87f2b399c4ebca9aa9663b640aed4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzUtMy0xLTEtMjkyMQ_92964fa2-ceaf-44ac-a40c-65aba61c742e">2,575,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzUtMS0xLTEtMA_4c26605b-71a6-49f4-81f7-cc5c247dc85e">6,869,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzUtMy0xLTEtMA_31e89c53-d1a8-4410-a490-eaa001478b21">7,782,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="i7157c5eacfe941de9505feeee920791e_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDA0Njg_e8c0aefb-4c0e-43cd-8767-6e4cbc4a7d98" continuedAt="ic68c9f054b0c40edbaa0034b6f433fdd" escape="true">Stock Options</ix:nonNumeric></span></div><ix:continuation id="ic68c9f054b0c40edbaa0034b6f433fdd" continuedAt="i7ed5cc9ae31d43b8ab798e37fa9961d7"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2017, there were <ix:nonFraction unitRef="shares" contextRef="i7a5864a7879b4087ac73cb3bfcccd0e8_I20170630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2Xzc0_deae96ea-267c-438f-8c64-9936d036bf54">3,141,625</ix:nonFraction> options outstanding under the Company&#8217;s 2007 Stock Incentive Plan.&#160;The 2007 Plan expired in June 2017. Any cancellations under the 2007 Stock Incentive Plan will increase the options available under the 2017 Stock Incentive Plan as described below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017 the Company&#8217;s shareholders approved the 2017 Stock Incentive Plan (the 2017 Plan or the Plan).&#160;Under the 2017 Plan initially, up to <ix:nonFraction unitRef="shares" contextRef="i61566b4dae604295b9e10906b8b19b74_I20170630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzQ3Mw_a0897695-15c1-4acf-9c40-fab6dd763086">2,255,000</ix:nonFraction> shares of common stock may be granted to the Company's employees, officers, directors, consultants and advisors in the form of options, restricted stock units (RSUs) or other stock-based awards. The number of shares of common stock issuable under the Plan will be cumulatively increased annually by <ix:nonFraction unitRef="number" contextRef="ic9335c4c8a544f7784ac7050e6f8525a_D20170601-20170630" decimals="2" name="mrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2Xzc3NQ_49fed797-c4d1-4172-a698-58f00cd2c7f5">4</ix:nonFraction>% of the outstanding shares or such lesser amount specified by the Board. The terms of the awards are determined by the Board, subject to the provisions of the Plan. As of December&#160;31, 2020 there were <ix:nonFraction unitRef="shares" contextRef="idc230768a013428dbfb0b0e0a1cf01d9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2Xzk2Mg_26055e30-5013-4de6-beea-4ada838d49a6">1,288,072</ix:nonFraction> shares available for future issuance under the Plan, including <ix:nonFraction unitRef="shares" contextRef="i20cea58d91fe4a02bb07ac2b8a1f0791_D20200101-20200101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwMjg_f6f3dda5-2163-4bd7-bfb2-8aa05563db60">1,815,520</ix:nonFraction> shares automatically added to the Plan on January 1, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement awards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted its senior vice president of regulatory affairs an option to purchase up to <ix:nonFraction unitRef="shares" contextRef="i90de0efc2a4f4539a8da0eb8a4f579dd_D20200902-20200902" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2Mzk5MzY_4847fb9e-353c-4352-8e97-7dc7f9307f48">120,000</ix:nonFraction> and its senior vice president and chief medical officer an option to purchase <ix:nonFraction unitRef="shares" contextRef="id1c52f697f3447aca0d47be353863ce4_D20201130-20201130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDM1MTc_eae36241-d8c0-419b-8ee3-26b454978b7f">200,000</ix:nonFraction> shares of common stock on September 2, 2020 and November 30, 2020, respectively, as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). No underwriters were involved in this issuance of securities. The securities were issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, relating to transactions by an issuer not involving any public offering. These options are subject to terms substantially the same as the 2017 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to incentive stock options, the exercise price per share will equal the fair market value of the common stock on the date of grant, as determined by the Board, and the vesting period is generally <ix:nonNumeric contextRef="i1aec4bf8702f430b91a2277849a9a314_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDAzNjc_43c8be6c-2c9a-4f0e-af7f-08ab69426253">four years</ix:nonNumeric>. Nonqualified stock options will be granted at an exercise price established by the Board at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Options granted under the Plan expire no later than <ix:nonNumeric contextRef="ie39e122b84984208a83a60f26cebb72b_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDA0MDM_d402661f-291c-4baa-9d53-ba6478b6cbc6">10</ix:nonNumeric> years from the date of grant. The Board may accelerate vesting or extend the expiration of granted options in the case of a merger, consolidation, dissolution, or liquidation of the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option activity</span></div><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUzMzM_91a220a3-5c80-45d2-915b-872d2de94a86" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity under the Plan is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzEtMS0xLTEtMA_4b0a6901-6063-454a-9bc7-ba817acf36b8">4,720,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzEtMy0xLTEtMA_3d713b54-b9ab-490b-98de-1b9c333cdf1d">5.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzEtNS0xLTEtMA_0e370cde-7be4-409f-b016-3ed72f7fa331">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzEtNy0xLTEtMA_aff5f378-65b5-46f6-bf46-6f6ff94e238f">9,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzItMS0xLTEtMA_9281e346-5141-4af8-9767-c4d5c4cd19c5">2,359,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzItMy0xLTEtMA_413c46a4-e7c0-4832-8007-ba031f3bef5e">11.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzMtMS0xLTEtMA_feb8a6d9-2f74-429f-bedd-533037a705c6">697,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzMtMy0xLTEtMA_3777704d-d574-42f5-bc68-9ce587a1be5a">4.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzQtMS0xLTEtMA_91ce5c8c-73a6-49f3-b3e8-bc1ff9c2a31a">269,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzQtMy0xLTEtMA_38435f48-eca2-40eb-9c86-5a43360fd0ef">7.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzUtMS0xLTEtMA_6cf85b33-00dc-4d73-bed5-4daae24c7e10">6,112,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzUtMy0xLTEtMA_19624c62-7e06-443d-a160-b3f967921bb7">7.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzUtNS0xLTEtMA_89020839-e028-429d-8ac8-f92e419ced16">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzUtNy0xLTEtMA_81c6224d-521f-4eed-b79e-dc56d96195de">114,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzctMS0xLTEtMA_32b2726a-a8e8-45db-85f4-219d0917fc93">3,147,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzctMy0xLTEtMA_ed9f5328-b6d5-40b7-b7ba-7d1746bdca66">5.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzctNS0xLTEtMA_2652d27a-9e38-43ac-921a-9431c4fa0a23">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzctNy0xLTEtMA_45696417-101d-46c7-9dbe-e2610988e8ee">67,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2020, 2019 and 2018, was $<ix:nonFraction unitRef="usdPerShare" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzE5NDM_a90862ca-9d13-40b9-a464-b37fd5aa1d52">7.99</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzE5NDc_f646ed90-8147-4796-9100-e1186d51a041">2.47</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzE5NTQ_40336abe-cf15-4c6f-8f7b-63dd16a843c7">8.78</ix:nonFraction> per share, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i7ed5cc9ae31d43b8ab798e37fa9961d7" continuedAt="ib9810326570c4835a738926337adb0b8"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from the exercise of stock options was $<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzIwMzU_5cb4afb0-0270-4604-acc3-5a43fe785a94">3,138</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzIwMzk_d11ab878-1652-4ed8-a9b9-bd1c0c8c93d1">175</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzIwNDY_1d1d82d1-2d38-485c-8462-7476143e703c">918</ix:nonFraction> for the&#160;years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2019, the Company issued RSUs with service conditions to employees. The awards cliff-vest <ix:nonNumeric contextRef="i6d84e8019e7f46ad999a65d511d99d20_D20190701-20190731" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDA0MzQ_5455a285-64c7-4454-80f7-28b0d14a99a8">two years</ix:nonNumeric> after the grant date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i23c524872861491cbbc5e13e4cf5d051_D20200101-20200131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDA4NTk_9b1ce19f-7990-47fc-b96b-2c271ab8bab6">324,932</ix:nonFraction> RSUs with a service condition to employees for which the vesting term is annually over <ix:nonNumeric contextRef="i23c524872861491cbbc5e13e4cf5d051_D20200101-20200131" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzI3NDg3NzkwODY3MDc_04420e4a-9b85-4ba4-a83a-1fea6491550c">four years</ix:nonNumeric>.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Vesting of these awards is contingent on the fulfillment of the service conditions during the vesting term.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUzMzQ_4ec488ee-77d2-48a9-bcca-da19c78f161a" escape="true"><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of the RSU activity under the 2017 Plan is as follow:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id980ee2ed8d34feca1762482a2e75df0_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzEtMS0xLTEtMA_d4020e76-901d-4edb-9ec6-1103f83c5507">447,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i920acb3427774292827daa9726c45873_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzEtMy0xLTEtMA_96fd78d5-c537-41c6-b980-758543f2e745">1.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id980ee2ed8d34feca1762482a2e75df0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzEtNS0xLTEtMA_a9cd5af7-dd71-4bcf-8526-fce193948d73">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id980ee2ed8d34feca1762482a2e75df0_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzEtNy0xLTEtMA_6ca54ac7-e59b-4552-8034-29f625015c31">4.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzItMS0xLTEtMA_704e2125-bf70-44db-82d1-2da9e185e7b3">361,932</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzItNy0xLTEtMA_f0728717-46a4-4824-9b12-1bb4f9045653">8.14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzMtMS0xLTEtMA_b91a3c55-a7d2-4ce2-9382-8c28db75dfc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzMtNy0xLTEtMA_16fe5b08-6629-442e-9a8b-69e4b72f3794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzQtMS0xLTEtMA_3280f831-8889-40c3-b341-819260fdc8f6">92,501</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzQtNy0xLTEtMA_6ef0c4fa-e65f-4f4d-b885-68d5e59600c9">4.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15699193709b4c5198a5f460762ea356_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzUtMS0xLTEtMA_5accc3ca-5923-4b16-9042-a3d52c8bcf12">716,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzUtMy0xLTEtMA_978a3574-b6d7-493e-9bad-f377b5458142">1.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15699193709b4c5198a5f460762ea356_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzUtNS0xLTEtMA_c7601e83-6ded-41cd-9bcb-d1056f191362">19,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15699193709b4c5198a5f460762ea356_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzUtNy0xLTEtMA_8e974a5b-64ac-45ad-b227-203f1f5439c2">6.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the provisions of ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to account for all stock-based awards to employees and non-employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement date for employee awards is generally the date of grant. Stock-based compensation expense is recognized over the requisite service period, which is generally the vesting period, using the straight-line method.</span></div><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUzMzU_4aa4c116-d932-4fbc-9b65-a21a13b29e4b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense by award type included within the Company&#8217;s consolidated statement of operations and comprehensive loss:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2ee45dc2784fc396ead6a8bfd4ecb5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzItMS0xLTEtMA_0a650dd2-d0b2-4063-adc0-6723a7e099de">5,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6ea660b40844fe84f66bd5e5fe9ea5_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzItMy0xLTEtMA_bf46bf1f-2efc-4be1-abb3-20fa8edbddbc">4,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79fb9930f6094104a456730528f5bc99_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzItNS0xLTEtMA_affbb04c-5e2b-481f-8954-629434cd776a">3,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzMtMS0xLTEtMA_6b06778e-1079-4b03-88d0-6c9ecfa71e74">1,187</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i920acb3427774292827daa9726c45873_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzMtMy0xLTEtMA_92da8cbb-ac08-4c5a-b95e-3be5c0b9b4a7">410</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4688b8c44640b09f240cd0e1c92161_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzMtNS0xLTEtMA_5bd47072-c1ab-46ef-802c-c6369de369b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad5bc870fab4400884a565359cfdf9a1_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzQtMS0xLTEtMA_5bc4301c-ba14-4862-bc77-a1e93c56d391">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd03e26fc404cd7886d527bbebe9cee_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzQtMy0xLTEtMA_4723b473-85c5-43fe-86a9-2caf281ef372">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25c2d7125bea4d40a3c4bd88341d03b4_D20180101-20181231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzQtNS0xLTEtMA_fd6a9e4a-5944-4e89-886c-ff1ca7673bab">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in Total operating expenses</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzUtMS0xLTEtMA_fb72395d-09bf-40eb-ac47-c0717ab522a7">7,172</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzUtMy0xLTEtMA_a4d4bfad-a201-4ced-a92d-4c0eff9be989">4,872</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzUtNS0xLTEtMA_fffed89b-f031-4685-b500-588a8d5524cf">3,884</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUzMzA_7595cc98-99d1-443b-9297-416f26cd9cc4" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense as reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ebb056de9f546e0a119ca21f8308e0c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzItMS0xLTEtMA_c8c47da3-14c7-4002-bb21-3de72f8b395d">3,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95e58426df2940999d78200d99d5eba5_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzItMy0xLTEtMA_b3010e27-0ec3-45f8-9f37-5b62f007cfcd">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf67d48970814a13815d8dec946856d1_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzItNS0xLTEtMA_180836ee-5bb0-488e-9bd1-97cdb20a1ccd">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95fd51f717da4b488c652bf7d8674730_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzMtMS0xLTEtMA_5c9a0057-fc97-4dc7-b373-404fe281f1bd">3,331</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e5593e7a34742298584e0cea80c0c50_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzMtMy0xLTEtMA_c8c6cf8f-5631-4e74-8cbc-474d980c921d">2,627</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6b9959fd5242cba1fd04a96cea57d3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzMtNS0xLTEtMA_b7d57c60-a140-4d93-bc2e-c39c5a8c693f">2,096</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in Total operating expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzQtMS0xLTEtMA_6bf42767-4b67-43ea-b876-e1f984de8a09">7,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzQtMy0xLTEtMA_4f2827ac-4654-4841-a95b-552edd74ab57">4,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzQtNS0xLTEtMA_65865d20-a7e3-4f5d-8b4a-84d7f1cc2d82">3,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i3e12adb838364036838eba86fa043b68_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzMwOTE_840e2ce8-e80e-4bf0-9dad-0d85fb822ca3">19,487</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i15699193709b4c5198a5f460762ea356_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzMwOTg_2ab33739-a470-4255-9ba5-7eef0208a61c">2,699</ix:nonFraction> of unrecognized compensation expense related to unvested stock options and unvested RSUs, respectively, that is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i4b2ee45dc2784fc396ead6a8bfd4ecb5_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzMyNzM_cdef84ff-976e-4f5a-a43e-cfe3c8ee1671">2.8</ix:nonNumeric> years and <ix:nonNumeric contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzMyODA_dc93618f-ea1c-4174-83b1-9b6777213c88">2.3</ix:nonNumeric> years, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="ib9810326570c4835a738926337adb0b8"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUzMzE_26a1c5fd-179a-4a28-863d-418cdf60eb8c" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black&#8211;Scholes option pricing model with the following weighted average assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzItMS0xLTEtMA_be92030b-5d6f-4be2-9a91-379f156788f4">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzItMy0xLTEtMA_51ae310e-2803-4480-b1c8-04a50dcb0890">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzItNS0xLTEtMA_116075cb-da1a-468e-99b0-52c80f5cb8b5">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzMtMS0xLTEtMA_2771388c-830c-41af-b510-93c729dc93e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzMtMy0xLTEtMA_cfcebf60-b6eb-4708-83a0-5a3fffb12ece">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzMtNS0xLTEtMA_ea44508d-341f-4ebf-a24d-58e42cb9c094">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzQtMS0xLTEtMA_6e0568c0-b640-42f3-88a4-faa6db5d1fb6">6.05</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzQtMy0xLTEtMA_63a775ff-ff29-4657-997b-43f96b09bcb5">5.99</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzQtNS0xLTEtMA_fd25a718-e479-4dcd-b672-6cdf29e9e857">6.07</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzUtMS0xLTEtMA_1d301375-2e58-4111-b5b5-869bc5f06aed">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzUtMy0xLTEtMA_1ee98d5e-5217-44e9-a01b-ee1f1988f736">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzUtNS0xLTEtMA_90030ede-bd7c-4736-947f-cd3285b9db7d">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility for the Company&#8217;s common stock is determined based on the historical volatility of comparable publicly traded companies. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected term of the option. <ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzI3NDg3NzkwODY4NDQ_624dcd3e-9736-47d7-b546-5e70cbf4c1be">No</ix:nonFraction> dividend yield was assumed as the Company has not historically and does not expect to pay dividends on its common stock. The expected term of the options granted is based on the use of the simplified method, in which the expected term is presumed to be the mid-point between the vesting date and the end of the contractual term.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs is determined based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2017, the Board adopted and the Company's stockholders approved the 2017 employee stock purchase plan (the 2017 ESPP). The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="i6f8aac06008a4724ae9284b7cc253a25_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDA5MDY_48739e36-fa3e-47d1-a759-e4226a8f206b">225,000</ix:nonFraction> shares of common stock for issuance under the 2017 ESPP. During the years ended December&#160;31, 2020 and 2019 the Company issued <ix:nonFraction unitRef="shares" contextRef="iad5bc870fab4400884a565359cfdf9a1_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUxNTQ_5e430825-b931-443a-a447-1dbc931855a4">80,267</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0fd03e26fc404cd7886d527bbebe9cee_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUxNjE_d3b6989d-cd38-4435-b5f7-f0fabe2836c0">140,073</ix:nonFraction> shares, respectively, under the 2017 ESPP. As of December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i05268d4f6e994edd8ddff9186d1b7540_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUyMjg_5228a16c-0317-459b-94f6-d5ccba4e8e0a">644,818</ix:nonFraction> shares available for issuance, including <ix:nonFraction unitRef="shares" contextRef="i7df3a8881d504e549decddca8cac8c76_D20200101-20200101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUyNjU_b4ce882e-a8bc-404c-8174-1f15c582af9f">450,000</ix:nonFraction> shares automatically added to the 2017 ESPP on January 1, 2020.</span></div></ix:continuation><div id="i7157c5eacfe941de9505feeee920791e_145"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEzMDk_55eaafae-8f65-437d-83ef-8f57f06229fe" continuedAt="ifc1460c36e124a43910bde52e99515ea" escape="true"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEzMDk_64e75a3e-feb7-481f-9843-7f2e7ce58f4f" continuedAt="idbbba7a7ca9c4d7289f9f3a342e34d80" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ifc1460c36e124a43910bde52e99515ea" continuedAt="i17c56ca7a1e44ddeb9d4fd62d81045a7"><ix:continuation id="idbbba7a7ca9c4d7289f9f3a342e34d80" continuedAt="i27710993586d47a3a135ec2615703b23"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for its office space in Cambridge, MA and operating and finance leases for certain equipment. In March 2020, the Company entered into the Seventh Amendment to the office space lease to extend the term of the lease through March 2026 and to provide the Company with a tenant improvement allowance of $<ix:nonFraction unitRef="usd" contextRef="if3d5650f067549778be0f063470fcbca_D20200301-20200331" decimals="-3" name="mrsn:TenantImprovementAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEwOTk1MTE2MzExMDY_4191d81b-78fb-4b12-994d-579f39b852e0">172</ix:nonFraction>. The current rate per square foot that is in place through March 2021 (the original expiration date of the lease) did not change. After March 2021, there are predetermined fixed escalations of the rate as outlined in the amendment. The Company has an option to extend the lease term for an additional <ix:nonNumeric contextRef="i6686ed562d224356b9709fed401426e2_I20201231" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEwOTk1MTE2MzExMTY_1ee1b0b7-7413-4426-b322-4afdb4333046">five years</ix:nonNumeric>. The Company&#8217;s exercise of this option was not considered reasonably certain as of December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extension is accounted for as a lease modification. The Company assessed the lease classification of the amended office space lease at the modification date and determined that the amended office space lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been remeasured based on the present value of remaining lease payments over the remaining extended lease term, using the incremental borrowing rate applicable as of the lease modification date. The Company determined the appropriate incremental borrowing rate by using a synthetic credit rating which was estimated based on an analysis of outstanding debt of companies with similar credit and financial profiles. Since the operating lease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred, such non-lease components were not included in the right-of-use asset and liability and are reflected as an expense in the period incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the modification in March 2020, the Company recorded an increase of $<ix:nonFraction unitRef="usd" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="mrsn:LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEwOTk1MTE2MzM0MjA_41f0dbd9-854b-479f-8479-b292946c157b"><ix:nonFraction unitRef="usd" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="mrsn:LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEwOTk1MTE2MzM0MjA_b63eb185-668c-4294-9647-7198c14a41ca">9,980</ix:nonFraction></ix:nonFraction> to its right-of-use (ROU) asset and lease liabilities in the first quarter of 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the office lease, the Company had a letter of credit agreement for the benefit of its landlord in the amount of $<ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:SecurityDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzcwMA_2e17b439-78f7-44fa-8c27-2fe3093d801b"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:SecurityDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzcwMA_7dbec876-98f5-40a8-b899-3261b0f49540">321</ix:nonFraction></ix:nonFraction> as of each December&#160;31, 2020 and 2019, collateralized by a money market account.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2019, the Company entered into finance leases for certain equipment. The Company recorded assets under finance leases of $<ix:nonFraction unitRef="usd" contextRef="ib85365aea4d54cff875208fefeee96ef_I20190331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzkxNg_8c3e142b-c959-4b69-9797-45e79ee8c2ec">429</ix:nonFraction> as property and equipment.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i17c56ca7a1e44ddeb9d4fd62d81045a7" continuedAt="i2b618808b45248d3bc13e6bd84d2f8e3"><ix:continuation id="i27710993586d47a3a135ec2615703b23" continuedAt="i6581ad86e8a744889b3d4ef4085fe452"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEzMTA_b33d9777-00aa-4ed2-b0c7-025bd2c2e353" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzEtMS0xLTEtMA_0d04072d-0eaf-4d86-aa01-3a7d3a341dee">2,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzItMy0xLTEtMzU3MQ_f31b959a-55f8-4074-8c05-41f31145b889">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzQtMS0xLTEtMA_aa9406e7-ed39-431e-b14b-62ba1a259420">176</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzUtMy0xLTEtMzU3MQ_a99feb67-a65e-45db-bfb2-ab979e3094a2">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzUtMS0xLTEtMA_b11c4638-5030-4cbf-b2d2-dd36e374df40">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzYtMy0xLTEtMzU3MQ_0a1ac474-29b5-43c6-a035-1b4ddaedbbf2">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="mrsn:FinanceLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzYtMS0xLTEtMA_769b88ea-226f-4146-8913-6d046f2210c9">197</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="mrsn:FinanceLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzctMy0xLTEtMzU3MQ_da832422-74f2-46a8-b6cf-94cceb62c2c1">95</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="mrsn:LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEzMTE_35bac52c-369a-49cb-944a-f8eb8678ab76" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzItMS0xLTEtMA_0314e3d1-9430-4004-b2a0-c3acd95898b0">10,936</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzMtMy0xLTEtMzYxNw_c2efb34d-978a-499c-8bd8-15acc9d523e8">2,598</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzMtMS0xLTEtMA_aa3838fe-fa3e-495a-9927-d94f13419409">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzQtMy0xLTEtMzYxNw_ef813497-8143-48a3-8d74-a6c0fbd46edd">2,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzQtMS0xLTEtMA_9dcc0ea1-5bc5-45db-a796-f024eec551ed">10,158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzUtMy0xLTEtMzYxNw_d664ce3f-c38a-4e33-a197-0d2cbfb8363a">677</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzctMS0xLTEtMA_e0985af8-38c0-4577-94e1-c04d1cf8cd28">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzgtMy0xLTEtMzYxNw_b9572e06-190d-4546-90b8-2198b492aaaa">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzgtMS0xLTEtMA_52ffc5fd-3e04-4628-bfe7-c5537c1aa582">176</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMy0xLTEtMzYxNw_825d4a74-45a5-4b2f-9c2d-f9ed2bdba86a">75</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMC0xLTEtMTkwMQ_def9574d-e21a-4369-9aec-5ccd94c4b5a5">Other liabilities, current</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMS0xLTEtMA_ffcde58d-7d6d-4966-9f32-ab04995a2c3d">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTMtMS0xLTM2MTc_421bcc04-0a5e-4321-839e-b6ff72ab62d6">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTAtMS0xLTE5MDM_e1131034-fc7f-40a3-8087-977f8547a400">Other liabilities</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTEtMS0xLTA_ebe0c502-698c-4cff-9109-18ce906d691a">174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzExLTMtMS0xLTM2MTc_6949e5c7-1943-4dd8-a1b7-9751422f2e3f">275</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEzLTEtMS0xLTA_934dd616-5479-4fc5-87d5-fc78feccadc0">5.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE0LTMtMS0xLTM2MTc_ca5b4113-0647-4571-a556-bdd5a84fb2b5">1.3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE0LTEtMS0xLTA_20c62bc3-3965-4e89-bab1-18a90c492cc4">2.9</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE1LTMtMS0xLTM2MTc_29383c9b-6a03-4bdd-9116-f947684f5d2e">3.7</ix:nonNumeric> years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE3LTEtMS0xLTA_e13f5a5b-17b5-4ebc-b80f-afbeaac9e908">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE4LTMtMS0xLTM2MTc_3ef0b83a-c342-4ea2-9dba-5afc9de64037">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE4LTEtMS0xLTA_47129f92-276d-4de5-96ff-b02066178ac8">6.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE5LTMtMS0xLTM2MTc_2cfd960d-3df1-4ffb-b8c0-4fed1cf290f3">6.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="mrsn:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEzMTI_52ed4b6f-af1d-4d67-a369-64e993ecfc2b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpiMjcwYTU5MDYyOWU0ZGE5YTJjYjFjNzRmNDliNzU4Yy90YWJsZXJhbmdlOmIyNzBhNTkwNjI5ZTRkYTlhMmNiMWM3NGY0OWI3NThjXzItMS0xLTEtMA_faa73348-0d6a-4463-86ff-d4f441e96b85">2,394</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpiMjcwYTU5MDYyOWU0ZGE5YTJjYjFjNzRmNDliNzU4Yy90YWJsZXJhbmdlOmIyNzBhNTkwNjI5ZTRkYTlhMmNiMWM3NGY0OWI3NThjXzMtMy0xLTEtMzYzMw_5403cf56-84eb-4698-9d20-e261740ccdfc">2,271</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpiMjcwYTU5MDYyOWU0ZGE5YTJjYjFjNzRmNDliNzU4Yy90YWJsZXJhbmdlOmIyNzBhNTkwNjI5ZTRkYTlhMmNiMWM3NGY0OWI3NThjXzMtMS0xLTEtMA_7724fe4c-1c16-4a03-bd9c-21ed3c132b2e">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpiMjcwYTU5MDYyOWU0ZGE5YTJjYjFjNzRmNDliNzU4Yy90YWJsZXJhbmdlOmIyNzBhNTkwNjI5ZTRkYTlhMmNiMWM3NGY0OWI3NThjXzQtMy0xLTEtMzYzMw_790eb70d-cddf-439e-b6d0-cef50cd5db70">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpiMjcwYTU5MDYyOWU0ZGE5YTJjYjFjNzRmNDliNzU4Yy90YWJsZXJhbmdlOmIyNzBhNTkwNjI5ZTRkYTlhMmNiMWM3NGY0OWI3NThjXzQtMS0xLTEtMA_6f9ad9af-9996-442d-8281-90fb23f4fe3f">116</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpiMjcwYTU5MDYyOWU0ZGE5YTJjYjFjNzRmNDliNzU4Yy90YWJsZXJhbmdlOmIyNzBhNTkwNjI5ZTRkYTlhMmNiMWM3NGY0OWI3NThjXzUtMy0xLTEtMzYzMw_3a83463f-6ff8-47d8-84ae-84fb2c8c2b5e">87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense was $<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzExNjA_2dd8ccd2-ac4e-4f4f-860b-c72cbe0293a7">2,644</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzExNjQ_eb8622bb-a43d-4ac0-bf9e-f6fc5a1020a7">2,160</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzExNzE_ede04e51-6d64-47b2-9592-29bbe964c705">1,994</ix:nonFraction> for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i2b618808b45248d3bc13e6bd84d2f8e3"><ix:continuation id="i6581ad86e8a744889b3d4ef4085fe452"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEzMTM_35e6d661-51da-4e5f-8e1f-5f0de42bdfe2" escape="true"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzI3NDg3NzkwNzUxNDI_e3cfbd66-8938-460e-8bed-ca86f52748c3" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2020 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzEtMS0xLTEtMA_d2e2c8df-1063-4ab1-ab03-cbeaacdfc4a0">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzEtMy0xLTEtMA_adc36016-0c9d-4c37-8be6-9320fc2149b3">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzItMS0xLTEtMA_bfbaf7f8-f96c-40aa-8c57-4ba9813c762e">2,843</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzItMy0xLTEtMA_8a956c62-2373-45c7-950b-f79b835f1bca">84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzMtMS0xLTEtMA_7a6e3a5e-b1f6-41cb-8063-04a3fa909b01">2,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzMtMy0xLTEtMA_ce7015b3-5987-4e32-be80-ac64fe16c76f">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzQtMS0xLTEtMA_cbcf834d-3c1d-462a-9afd-1e4bbd20b33f">3,016</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzQtMy0xLTEtMA_527b7e7f-dd2a-41b6-8dd6-3752518eb798">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzUtMS0xLTEtMA_bfaf6923-871d-4c0f-b917-0cd1f691130e">3,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzUtMy0xLTEtMA_16150950-7cf7-4cad-b375-11f6051d1df3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzYtMS0xLTEtMA_3bf31fab-0622-4dda-b908-9bad4ef3b45c">15,447</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzYtMy0xLTEtMA_8c27b3d2-5103-4ae2-ac59-c1228e6d0298">292</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzctMS0xLTEtMA_c3b704c1-7943-4fd5-aebe-0f3fc276bb36">3,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzctMy0xLTEtMA_c88f3761-aa5a-415a-9f3f-85e86c7c09ae">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzgtMS0xLTEtMA_f1f44037-322b-4779-960c-bac3b9aca7ce">11,593</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzgtMy0xLTEtMA_bb370b8f-75de-4e70-a764-551206d287ba">267</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i7157c5eacfe941de9505feeee920791e_151"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzUyOTY_ec4dd1f6-9409-4331-9e9f-30c0872df186" continuedAt="i5c254323f9094021ab1f11e4926817d2" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i5c254323f9094021ab1f11e4926817d2" continuedAt="i2059e379b5b544d4ac8dc66fc696a151"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded no income tax benefit for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items.</span></div><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzUyOTQ_16f8ce5c-b776-4a08-8773-4410d2d940b3" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations as of December&#160;31, 2020, 2019 and 2018 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax computed at federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzEtMS0xLTEtMA_91a2e3fb-ced6-4b12-885d-b46adf525f9c">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzEtMy0xLTEtMA_2d816d60-3df2-4c03-9b3f-0f1cccd84be1">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzEtNS0xLTEtMA_a00d2b59-8300-4ad0-a03e-efa7a3b23361">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzItMS0xLTEtMA_bafd8184-df70-4760-b1ff-fac7fcdecee3">6.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzItMy0xLTEtMA_d1ed3f83-223f-46e8-88db-b95295d32b6b">6.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzItNS0xLTEtMA_764ae225-39af-4f11-93ba-fbd0523a5bc1">6.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzMtMS0xLTEtMA_4f166475-f25e-4466-b987-9fd26162e255">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzMtMy0xLTEtMA_06852f6e-49ae-4284-82ae-5c25e0dd5316">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzMtNS0xLTEtMA_2e77973c-38e7-4ccf-825d-16513b508fb3">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzUtMS0xLTEtMA_76985d85-d5e2-4ea3-89e1-9208b02373bf">3.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzUtMy0xLTEtMA_aefec750-dae8-4a71-a44c-b85015ec2106">10.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzUtNS0xLTEtMA_5fe6d889-cd8b-4dff-a7ea-60333958ce22">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of ownership shift</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzctMS0xLTEtMA_6d3289bf-43ae-4737-b023-013e0423c2e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzctMy0xLTEtMA_915ad3bd-4c1f-44f1-8cc6-cf4119e176ad">53.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzctNS0xLTEtMA_699af40e-4387-49bf-a0ce-52fd9e04cb99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzgtMS0xLTEtMA_680730d2-1509-4040-be76-9f845ab1d168">32.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzgtMy0xLTEtMA_d1c6f3bb-59a0-49c4-b315-c6f41e1da6b3">17.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzgtNS0xLTEtMA_a1a14acd-12b7-45ef-b07f-1351c25883aa">32.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzktMS0xLTEtMA_10367bca-a368-477d-b176-aad56ecbfd30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzktMy0xLTEtMA_653571e2-33cf-4b6b-a5c5-a8ef36172b8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzktNS0xLTEtMA_aef2f091-40ed-472e-b4c2-9e4f869e6ab4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i2059e379b5b544d4ac8dc66fc696a151" continuedAt="i0491046ff56a4996a0c36770a68263ac"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzUyOTU_7edc8060-f11c-482e-8961-18eb654edad3" continuedAt="i3b3db1d956a94dc8bc560396524e8642" escape="true">Significant components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2020 and 2019 are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="i3b3db1d956a94dc8bc560396524e8642"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzItMS0xLTEtMA_2a96eb46-14aa-43ed-8eae-2fdc013866e2">64,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzItMy0xLTEtMA_24b3cd6d-4b81-43d5-a230-b4cde96b3c49">40,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzMtMS0xLTEtOTA1NQ_1ff7c594-0344-460c-80f1-ea7a45bb8477">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzMtMy0xLTEtOTA1NQ_7d132c55-1f5c-4479-b3c4-ea9f8e6e3bd5">2,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzMtMS0xLTEtMA_b6a588bb-8707-4789-ac30-f96b6f7cd9c4">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzMtMy0xLTEtMA_3e52cacf-99fe-498f-aa20-6f2c4c22f19e">2,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:DeferredTaxAssetsLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzQtMS0xLTEtMA_7ee65625-b345-4c64-9bd3-1f217e3884dd">3,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="mrsn:DeferredTaxAssetsLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzQtMy0xLTEtMA_ee3bc1f4-06ed-41df-8a6f-c83604a0862a">791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:DeferredTaxAssetsLicensedTechnology" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzUtMS0xLTEtMA_eb3ceaef-08d2-468e-ad02-b8a906d70340">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:DeferredTaxAssetsLicensedTechnology" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzUtMy0xLTEtMA_b3ca37fe-945b-4546-ac17-50d343865866">1,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzYtMS0xLTEtMA_5e839349-818f-440c-95fb-d53b9f124f1d">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzYtMy0xLTEtMA_a2062309-5a05-4291-b7e5-2ffc42e0eb4c">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="mrsn:DeferredTaxAssetsDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzgtMS0xLTEtMA_35de98e6-e3c3-4352-9253-32b8d19845e7">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="mrsn:DeferredTaxAssetsDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzgtMy0xLTEtMA_c03bb0aa-0235-438a-b5c1-109b36c35bec">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzEwLTEtMS0xLTA_78a70890-7501-4144-954a-79d14ebc2bd6">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzEwLTMtMS0xLTA_a0a0b73c-5736-471c-a872-96d8bd31ea85">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzExLTEtMS0xLTA_cb2d0d52-7bcc-49cd-a581-9b7bda14919e">80,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzExLTMtMS0xLTA_2b4b086c-e951-42e6-b59b-5846d6a5a2b4">49,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzEyLTEtMS0xLTA_3d49ffe2-73c1-45b8-8e25-30ace11619b2">77,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzEyLTMtMS0xLTA_23b0e30d-c043-4e6b-95d0-d8c6dca15a3f">48,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzEzLTEtMS0xLTA_4aa58354-63a0-4b17-a5df-43c155cda54b">2,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzEzLTMtMS0xLTA_09141fff-05af-435b-b41a-229bc6cfcf52">710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzE1LTEtMS0xLTA_2e5299b8-bfc9-400b-a2c8-29535d077c9e">2,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzE1LTMtMS0xLTA_174db9f1-544f-4fc2-b818-5715192ef819">710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzE2LTEtMS0xLTA_df674b5f-1f72-4747-bd71-7b5da7d1fe95">2,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzE2LTMtMS0xLTA_8ed65a59-2db2-4dd6-81e6-4ba1a2931227">710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzE3LTEtMS0xLTA_f6fec491-cfae-4581-bf44-bacb55e835d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzE3LTMtMS0xLTA_bae7778c-8726-4acd-a9bd-1f368da91ba6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net operating losses (NOL) since inception. At December&#160;31, 2020, the Company had Federal and State net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ic059f7a3532745518966900be47d1c47_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzgzMw_21912ffa-374c-4641-a6fc-60f113d9bd67">250,367</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i82697de2ab144693bec9626ce8bdb92c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzg0MA_fdb0456b-f10a-4cb1-90dc-644a519e7f75">184,781</ix:nonFraction>, respectively. Of the $<ix:nonFraction unitRef="usd" contextRef="ic059f7a3532745518966900be47d1c47_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzg2NQ_09311830-0e95-4caa-b9bb-8e007529ea9b">250,367</ix:nonFraction> of Federal net operating loss carryforwards, $<ix:nonFraction unitRef="usd" contextRef="ic059f7a3532745518966900be47d1c47_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:OperatingLossCarryforwardsSubjectToExpiration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzkxMw_cddcc1d6-6df4-408e-b2d5-60407f9a0976">34,149</ix:nonFraction> expire at various dates through 2037. The remaining $<ix:nonFraction unitRef="usd" contextRef="ic059f7a3532745518966900be47d1c47_I20201231" decimals="-3" format="ixt:numdotdecimal" name="mrsn:OperatingLossCarryforwardsNotSubjectToExpiration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzk2OQ_b3b8ba86-4879-4416-b663-42c0a5220921">216,218</ix:nonFraction> of Federal net operating loss carryforwards do not expire. The State net operating loss carryforwards expire at various dates through 2040. At December&#160;31, 2020, the Company had Federal and State research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ia1a16dd07ee341a0b4a2267c3b6bd737_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzEyMjA_8503cf4f-1de2-4a1e-8df5-645967389058">4,582</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ibacf6c67e9b24271b096b036df23e4a4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzEyMjc_c0e8a528-da73-4bf8-92ae-1598b7ff190c">1,482</ix:nonFraction>, respectively, which expire at various dates through 2040.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC 740, management of the Company has evaluated the evidence bearing upon the reliability of its deferred tax assets. Based on the weight of available evidence, both positive and negative, management has determined that it is more likely than not that the Company will not realize the benefits of all of these assets. Accordingly, the Company recorded a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzE2ODI_88ab5ab7-e72c-4cf1-a9ba-6b031023f725">77,375</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzE2ODk_63849cda-75f5-412f-acd7-a4c4d27e90d2">48,889</ix:nonFraction> at December&#160;31, 2020 and December&#160;31, 2019, respectively. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzE3NTc_64137311-a8b2-4d63-ba97-edf153e768ff">28,468</ix:nonFraction> and decreased by $<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzE3NzQ_830723ac-fa1f-4432-8de0-b3198ab4da4a">5,051</ix:nonFraction> during the years ended December&#160;31, 2020 and 2019, respectively, primarily as a result of the Company&#8217;s 382 limitation and net operating losses generated during the periods, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the NOLs and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&#160;382 due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section&#160;382, as well as similar state provisions. These ownership changes may limit the amount of NOLs and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. If a change in control as defined by Section&#160;382 has occurred at any time since the Company&#8217;s formation, utilization of its NOLs or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could then be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOLs or research and development tax carryforwards before their utilization. The Company has determined that ownership changes have occurred through November 4, 2019 and that certain NOLs and research and development tax credit carryforwards will be subject to limitation. The amounts presented do not include NOLs or research and development tax credit carryforwards that will expire unused due to ownership changes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the accounting guidance in ASC 740 related to accounting for uncertainty in income taxes. The Company&#8217;s reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i0491046ff56a4996a0c36770a68263ac"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. As of December&#160;31, 2020 and 2019, the Company had <ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzM4MzM_42af5a13-1214-4c7e-b048-941d2d266524"><ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzM4MzM_a42ea398-5e79-4db1-a279-242cf375330f">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to uncertain tax positions would be classified as income tax expense in the accompanying statements of operations. As of December&#160;31, 2020 and 2019, the Company had <ix:nonFraction unitRef="usd" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzQ2NzQ_5e6e2355-319f-4b4d-ad4f-7d04bc44f909"><ix:nonFraction unitRef="usd" contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzQ2NzQ_d3afdf2f-bb0c-4df9-a14a-c2832539f1de">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States federal tax jurisdiction and <ix:nonFraction unitRef="jurisdiction" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:IncomeTaxesNumberOfStateJurisdictions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzQ4MzA_af92174d-4327-4817-82c4-0d1d882007cc">two</ix:nonFraction> state jurisdiction. The Company did not have any foreign operations during the&#160;years ended December&#160;31, 2020, 2019 and 2018. The statute of limitations for assessment by the Internal Revenue Service and state tax authorities is closed for tax&#160;years prior to 2016, although carryforward attributes that were generated prior to tax&#160;year 2015 may still be adjusted upon examination to the extent utilized in a future period. There are <ix:nonFraction unitRef="audit" contextRef="i02a979a8932342d78dec04dc805709b8_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="mrsn:IncomeTaxesNumberOfAuditsInProgress" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzUyNDY_b0b1c915-5552-4f3b-a1fd-9318f1eba1a1">no</ix:nonFraction> federal or state audits currently in progress.</span></div></ix:continuation><div id="i7157c5eacfe941de9505feeee920791e_157"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzg0NA_8ab2045b-b440-4ef6-a5b6-e02371da7007" continuedAt="ifa94f6d05dfc4e2e8c81aa0c7bf60346" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifa94f6d05dfc4e2e8c81aa0c7bf60346">The Company has a defined contribution plan established under Section&#160;401(k)&#160;of the Internal Revenue Code (401(k)&#160;Plan), which covers substantially all employees. Employees who have attained the age of <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" format="ixt-sec:duryear" name="mrsn:DefinedContributionPlanEligibleAgeToParticipate" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzEwOTk1MTE2Mjg2NjM_92e53b3d-1b70-453c-a59e-7b4a22979b67">21</ix:nonNumeric> are eligible to participate in the 401(k)&#160;Plan with no service requirement. Employees may contribute up to <ix:nonFraction unitRef="number" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="2" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzEwOTk1MTE2Mjg2Nzg_54697ab4-cdc3-47f8-919f-cabd78ed0775">75</ix:nonFraction>% of eligible pay on a pre&#8211;tax basis up to the federal annual limits. For the year ended December&#160;31, 2018 and the period from January 1, 2019 to July 31, 2019, the Company matched the employees&#8217; contributions at <ix:nonFraction unitRef="number" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzU1MA_2f5bef14-a40e-406b-8029-92ba20fac1f0"><ix:nonFraction unitRef="number" contextRef="i2f999c2f67b946f6a6d1493212350a0f_D20190101-20190731" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzU1MA_484961b8-ff24-4fcb-8f68-454637ddec25">50</ix:nonFraction></ix:nonFraction>% on the first <ix:nonFraction unitRef="number" contextRef="i2f999c2f67b946f6a6d1493212350a0f_D20190101-20190731" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzU2Ng_255c23d0-da2d-426b-9435-d99a8cd60f87"><ix:nonFraction unitRef="number" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzU2Ng_e6a9b497-0a5e-461e-8166-01e2323d3d84">6</ix:nonFraction></ix:nonFraction>% up to $<ix:nonFraction unitRef="usd" contextRef="i2f999c2f67b946f6a6d1493212350a0f_D20190101-20190731" decimals="-3" name="mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzU3NQ_b0fafd8c-a2dd-402d-b8fb-0beb94fcdc20"><ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" name="mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzU3NQ_e54cd50c-812d-4dde-b529-89dd86639394">6</ix:nonFraction></ix:nonFraction>. For the period from August 1, 2019 to December&#160;31, 2019 and for the year ended December&#160;31, 2020, the Company matched the employees&#8217; contributions at <ix:nonFraction unitRef="number" contextRef="i6132787d773e482cbb6d82895b63d717_D20190801-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzEwOTk1MTE2Mjg3MTc_1fbb44c7-f445-448b-bfd7-587e2bbd01dc">100</ix:nonFraction>% on the first <ix:nonFraction unitRef="number" contextRef="i6132787d773e482cbb6d82895b63d717_D20190801-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzEwOTk1MTE2Mjg3Mjg_74611bc6-5f27-4a9c-8b3e-b7898e0ff4c5">4</ix:nonFraction>% up to $<ix:nonFraction unitRef="usd" contextRef="i6132787d773e482cbb6d82895b63d717_D20190801-20201231" decimals="-3" name="mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzEwOTk1MTE2Mjg3Mzc_a6d9d190-772b-4c9c-8428-213b2d1f69fd">7</ix:nonFraction>. For the&#160;years ended December&#160;31, 2020, 2019 and 2018, the Company recorded expense of $<ix:nonFraction unitRef="usd" contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzc2OQ_77d84b1a-589f-4396-809b-c0e914d275e7">486</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzc3Mw_544654b6-24ed-4fad-8a59-793d9ee32e53">404</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzc4MA_fd3e20ea-e3bb-4795-8647-ba81e085ad2b">332</ix:nonFraction>, respectively, related to its contribution to its 401(k)&#160;Plan.</ix:continuation></span></div><div id="i7157c5eacfe941de9505feeee920791e_163"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:CommitmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzU5Mw_9d790256-f27a-404c-b569-55c4f26bbfe8" continuedAt="id6f17b42c22e45bda8bd76cbab85c011" escape="true">Commitments</ix:nonNumeric></span></div><ix:continuation id="id6f17b42c22e45bda8bd76cbab85c011"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded research and development expense related to non-refundable upfront payments of $<ix:nonFraction unitRef="usd" contextRef="i4114a3ad19d943caa2f08b5649e9e275_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzEwOTk1MTE2MzA3NTU_df68e3b1-6893-4bf7-a604-1a529440112e">250</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i6a071cec119846ab9055589216a2b776_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzEwOTk1MTE2MzA3NjI_ab1ef77b-d78a-469b-a3a6-b4def556fbe4">750</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i1094fe6fc0a54ffaa7e6425e002d5fd9_D20180101-20181231" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzEwOTk1MTE2MzA3Njc_117f5b42-8b7b-487c-ab76-1a5516fe06be">0</ix:nonFraction>, respectively. Further milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i480e629817294830afafe0f1a51084b4_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzQ2MA_49a4ec26-d263-47fa-b868-2ad27af2f4ef">750</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i4abde9e6537849859c77bdc8d4176754_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzQ2NA_c5a3c767-364d-40c2-adc1-b0678074e80b">600</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i65bb47754a65456c89056c19e9b6a48d_D20180101-20181231" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzQ3MQ_05deef8f-8a67-4117-a5e0-1bf4f7d56028">0</ix:nonFraction>, respectively, were also recorded as research and development expense during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 for the Company&#8217;s future obligations related to leases as of December&#160;31, 2020.</span></div></ix:continuation><div id="i7157c5eacfe941de9505feeee920791e_172"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90ZXh0cmVnaW9uOmJiYWJmYWNlOWIwYjQwMmM5ZDc3YjVhZjBlZmJiNDQ0XzQxOA_35271693-9936-4380-9580-114faa2411ea" continuedAt="i8c6ee62c493f413bb651bba37868c8d2" escape="true">Selected Quarterly Financial Data (unaudited)</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8c6ee62c493f413bb651bba37868c8d2" continuedAt="i39c325223fe946e39d2a202c373d8f37"><ix:nonNumeric contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90ZXh0cmVnaW9uOmJiYWJmYWNlOWIwYjQwMmM5ZDc3YjVhZjBlZmJiNDQ0XzQxOQ_c8908743-5317-4a30-a0f8-8bc3dd9dcfd7" continuedAt="i0ae7969c122a461a89dd7ed07ccb5388" escape="true">The following table contains selected quarterly financial information for 2020 and 2019. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.</ix:nonNumeric></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i39c325223fe946e39d2a202c373d8f37"><ix:continuation id="i0ae7969c122a461a89dd7ed07ccb5388"><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzItMS0xLTEtMA_d6c2d97d-64cc-44c0-9212-f58307666258">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzItMy0xLTEtMA_2575a3cb-13e6-468e-b7c9-336299c595ac">796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzItNS0xLTEtMA_dbd2d01c-0b86-4ed9-99c9-c0085c3a0308">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzItNy0xLTEtMA_d82eb61a-2a9a-4d7d-abe4-a1b2c6e5930d">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzQtMS0xLTEtMA_da473221-3134-4ba8-9efb-a12b0d6d396c">12,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzQtMy0xLTEtMA_617aea2b-d4e1-4cf8-9c5b-24f4876298ec">15,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzQtNS0xLTEtMA_c96e0cb1-6d23-44db-95b8-25783a12111a">16,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzQtNy0xLTEtMA_2167672d-efd7-4d08-844a-59570224c0e1">22,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzUtMS0xLTEtMA_976a3f5d-c1f5-4cf1-a9f2-bb6bce436fb7">4,936</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzUtMy0xLTEtMA_06739b95-fd65-4da1-8df8-f4d0dc73a5ac">5,171</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzUtNS0xLTEtMA_0b2daf9e-c274-4894-827e-94d956bccca3">5,881</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzUtNy0xLTEtMA_49fbbcc7-17d2-4e09-a6c6-9fc11e05efe4">5,914</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzYtMS0xLTEtMA_1a29cd15-f7ef-47af-ac1a-02935bc5d36d">17,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzYtMy0xLTEtMA_a55e562d-48ab-4dcb-a396-8291516b1350">20,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzYtNS0xLTEtMA_3478ece6-e9e9-437a-bba7-0afd89abd137">22,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzYtNy0xLTEtMA_f809f4cc-d4e4-421d-aa65-6bedae338e7d">28,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzgtMS0xLTEtMA_b0da3bf2-b22e-4f29-9290-be59105882df">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzgtMy0xLTEtMA_15ac2f8c-9c77-4ebf-8141-c319e42e6d6d">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzgtNS0xLTEtMA_f8c9aa55-7e56-416f-b72c-b45b37916bcf">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzgtNy0xLTEtMA_35286672-e1be-4469-8e8b-78bccc016c05">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzktMS0xLTEtMA_c2d62c84-4b32-45bc-b654-5408198111e8">88</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzktMy0xLTEtMA_4d51eb6d-db0c-4b99-8f39-e61fd5770833">87</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzktNS0xLTEtMA_16ab3239-b80f-400f-a111-94334237f521">92</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzktNy0xLTEtMA_76c444e4-cb9b-4b0b-bd80-4e62d8f99d39">92</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEwLTEtMS0xLTA_66e32295-6e10-4801-b358-3cfc481a4d69">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEwLTMtMS0xLTA_bc9d4f64-890c-44a7-83cc-494e722c5f0c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEwLTUtMS0xLTA_dff8d3f4-4238-4e6f-8247-7410f0987099">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEwLTctMS0xLTA_ef5fdf75-a0ba-4c03-868b-2f9606344084">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzExLTEtMS0xLTA_81cd85b4-c3a3-42e1-a3f9-c8e51bdc5507">16,926</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzExLTMtMS0xLTA_0c3e672d-e554-47d8-8676-5dd750e3fb29">19,786</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzExLTUtMS0xLTA_94eac668-36a4-4097-b294-08f387227704">22,489</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzExLTctMS0xLTA_0e071e15-1424-48fc-b77e-0cd915a7ca2d">28,844</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share&#160;attributable to common stockholders &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTEtMS0xLTA_84a383a7-e0d3-4da0-af12-3ec028787908"><ix:nonFraction unitRef="usdPerShare" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTEtMS0xLTA_8a197d38-a37e-4eed-a887-18ed2de69bd5">0.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTMtMS0xLTA_117d7c0e-949a-496a-8fa8-7710ed891591"><ix:nonFraction unitRef="usdPerShare" contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTMtMS0xLTA_6e045b78-3ee1-4fb4-9891-2a4b0897eaf9">0.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTUtMS0xLTA_48f9304e-9240-4051-9ba3-27132d2549cc"><ix:nonFraction unitRef="usdPerShare" contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTUtMS0xLTA_4a73b6a2-2cd5-4191-b1fe-b3897e05a1d2">0.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTctMS0xLTA_180bfda3-5f95-4fa6-876f-4b1d6fa2229a"><ix:nonFraction unitRef="usdPerShare" contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTctMS0xLTA_589a38d6-4691-4ede-9f57-b445304a9e9d">0.42</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in net loss per share attributable to common stockholders &#8212; basic and diluted</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzE0LTEtMS0xLTA_96cd2b07-5ba6-469d-9265-80590f8afe5f">47,988,630</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzE0LTMtMS0xLTA_73ae3563-cbbb-40f9-b693-a32779faae32">60,748,225</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzE0LTUtMS0xLTA_c10fdfcf-3c6c-432d-ac15-23ab38af3d65">68,419,192</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzE0LTctMS0xLTA_46a4d361-f546-4112-9b6f-d1b73fdf54db">68,630,078</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzItMS0xLTEtMA_3b33072c-59af-41ab-9fd1-d58ecee9a431">41,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzItMy0xLTEtMA_2603a8a4-df9d-4d22-aca0-7d0411eb45a9">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzItNS0xLTEtMA_a3cf249d-38bf-4e7d-84f4-090b49a57e80">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzItNy0xLTEtMA_1a770c62-c615-4b00-877b-66c337a6bf7a">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzQtMS0xLTEtMA_8735421c-e11f-4751-ab2c-81d0829d230b">15,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzQtMy0xLTEtMA_8cda0394-74c3-407c-8d89-0bd0b845727f">13,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzQtNS0xLTEtMA_e22c99c9-5972-415f-9d91-ab309883b219">13,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzQtNy0xLTEtMA_ef0ecd48-2b1f-40f7-977d-16459790fb30">12,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzUtMS0xLTEtMA_76644ec3-b8db-41b8-9148-a4d926066d23">4,443</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzUtMy0xLTEtMA_1e9d1d65-75da-4489-9465-95f5a8354cfb">4,192</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzUtNS0xLTEtMA_801f0bfa-67e2-41d5-8094-af8075e40b01">4,436</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzUtNy0xLTEtMA_41b4a25f-bd20-4932-8dfd-3b91fcd83395">4,212</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzYtMS0xLTEtMA_369878ab-929f-4373-b39d-82eeb93f0485">19,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzYtMy0xLTEtMA_72a00342-2617-4347-986b-2079f5693f30">17,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzYtNS0xLTEtMA_d1984f4c-c080-4844-bc68-e09481376894">18,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzYtNy0xLTEtMA_8e479d30-fb00-477c-bc8b-fee4b4281ffe">16,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzgtMS0xLTEtMA_a53e81ad-f034-4901-a901-e2911aadd322">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzgtMy0xLTEtMA_b7cc49e7-0fbf-45e2-aebd-563bcf0f0cb7">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzgtNS0xLTEtMA_1ed81ad8-2dab-4052-9147-57154ed0cca3">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzgtNy0xLTEtMA_e4473318-63c4-4cf8-b728-c68ac33a3fe6">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzktMS0xLTEtMA_5460374a-6cce-4af2-853e-286dbb2cb03a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzktMy0xLTEtMA_c0c77a2d-9486-4b99-a75d-34535215b703">40</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzktNS0xLTEtMA_763b074f-790f-49fd-895e-2aeb7b3d365c">107</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzktNy0xLTEtMA_8a481093-e884-4de8-8627-9fd2f5fbfef5">87</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEwLTEtMS0xLTA_b0b08799-1cae-4684-83cd-d739ef15815a">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEwLTMtMS0xLTA_40b9d884-08de-42c2-9f31-818684beb7ca">685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEwLTUtMS0xLTA_bc3cdee2-68f1-4267-887b-19771831187c">501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEwLTctMS0xLTA_1c822946-6be5-4615-af86-efa482e7134f">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzExLTEtMS0xLTA_0a622733-5316-47a6-bbfe-24f66a410b18">21,901</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzExLTMtMS0xLTA_c30a4ab2-a8d4-413c-9c03-6efa700608f4">17,071</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzExLTUtMS0xLTA_f8474488-cc5e-43dd-8a79-ebe1a5c0dbab">16,792</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzExLTctMS0xLTA_29f2eadd-f56c-4ab6-8f95-3430060150f4">16,246</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share&#160;attributable to common stockholders &#8212; basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTEtMS0xLTM5MDE_18f1298c-9653-400b-8d67-2dcf05489615">0.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTMtMS0xLTM5MDE_2fe6706b-cfaf-4069-83bf-61b55cea03ee">0.36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTUtMS0xLTM5MDE_1151aca8-3eda-457c-9f72-3da0ef0b3fc9">0.35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTctMS0xLTM5MDE_7e45bbe5-56a3-476c-8f7c-0e84e64d4a7f">0.34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share&#160;attributable to common stockholders &#8212; diluted</span></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEzLTEtMS0xLTM5MjU_9279dcbd-0e38-4465-96c9-8d3116461a23">0.70</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEzLTMtMS0xLTM5MjU_81222265-720e-4e95-b95f-e0cd06395182">0.36</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEzLTUtMS0xLTM5MjU_90cac7b3-60db-4b16-b32c-9675e583ea80">0.35</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEzLTctMS0xLTM5MjU_51811e06-5946-45fe-be28-95ebb3c9c07f">0.34</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in net income (loss) per share attributable to common stockholders &#8212; basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTEtMS0xLTA_f369487b-4687-4211-b817-fe31a4111bf7">30,299,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTMtMS0xLTA_c2925879-e315-4da2-94ce-073e7aa80155">47,708,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTUtMS0xLTA_c75b34a5-5a34-4e53-98cd-d50892ec705b">47,833,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTctMS0xLTA_5ef5e447-8442-4147-8bfd-8e25da196a0a">47,886,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in net income (loss) per share attributable to common stockholders &#8212; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzE1LTEtMS0xLTM5Mjg_fc859e63-005d-47d6-9b98-2993d29a0c95">31,461,696</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzE1LTMtMS0xLTM5Mjg_1397243e-973c-4b30-a61f-a2ff8ec65bc3">47,708,085</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzE1LTUtMS0xLTM5Mjg_eb5bbff9-6664-432b-965f-b099d8641cff">47,833,607</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzE1LTctMS0xLTM5Mjg_f1b07f56-efe6-41ff-8cbb-2854e779872d">47,886,144</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i7157c5eacfe941de9505feeee920791e_178"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2020, the end of the period covered by this Annual Report on Form 10-K. Based upon such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2020. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control &#8212; Integrated Framework. Based on our assessment, our management has concluded that, as of December&#160;31, 2020, our internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2020 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report which is included herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended December&#160;31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Mersana Therapeutics, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Mersana Therapeutics, Inc.&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Mersana Therapeutics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2020 consolidated financial statements of the Company and our report dated February 26, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 26, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="i7157c5eacfe941de9505feeee920791e_187"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;10 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</span></div><div id="i7157c5eacfe941de9505feeee920791e_190"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 11&#160;will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated here by reference.</span></div><div id="i7157c5eacfe941de9505feeee920791e_193"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</span></div><div id="i7157c5eacfe941de9505feeee920791e_196"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</span></div><div id="i7157c5eacfe941de9505feeee920791e_199"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2021 Annual Meeting of Stockholders and is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="i7157c5eacfe941de9505feeee920791e_205"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15.&#160;&#160;&#160;&#160;EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a list of the consolidated financial statements included herein, see Index to the Consolidated Financial Statements in this Annual Report on Form 10-K, which is incorporated into this Item by reference.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Schedules</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No financial statement schedules have been submitted because they are not required or are not applicable or because the information required is included in the consolidated financial statements or the notes thereto.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Exhibit Index immediately before the signature page of this Annual Report on Form 10-K. The exhibits listed in the Exhibit Index are filed or incorporated by reference as part of this Annual Report on Form 10-K.</span></div><div id="i7157c5eacfe941de9505feeee920791e_208"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT&#160;INDEX</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description&#160;of&#160;Exhibit</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465917044267/a17-17109_1ex3d1.htm">Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465917044267/a17-17109_1ex3d1.htm">Current Report on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465917044267/a17-17109_1ex3d1.htm">Form 8-K, File No. 001-38129, filed on July 10, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465917044267/a17-17109_1ex3d2.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465917044267/a17-17109_1ex3d2.htm">Current Report on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465917044267/a17-17109_1ex3d2.htm">Form 8-K, File No. 001-38129, filed on July 10, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-4_1.htm">Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-4_2.htm">Third Amended and Restated Investor Rights Agreement, dated as of June 15, 2016, by and among Mersana Therapeutics, Inc. and the Stockholders listed therein (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465919068163/tm1924038d1_ex4-1.htm">Form of Exchange Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K, File No. 001-38129, filed on November 27, 2019).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020001726/mrsn-20191231ex44aee8769.htm">Description of Registrant&#8217;s Common </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020001726/mrsn-20191231ex44aee8769.htm">Stock (incorporated by reference to Exhibit 4.4 to the Company's Form 10-K, File No. 001-38129, filed on February 28, 2020)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020001726/mrsn-20191231ex44aee8769.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917004050/a2232415zex-10_1.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form S-1/A, File No. 333-218412, filed on June 16, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_2.htm">Commercial Lease, dated February 24, 2009, between Mersana Therapeutics, Inc. and Rivertech Associates II, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm">Seventh</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm"> Lease Extension and Modification </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm">Agreement to the Lease Between Rivertech Associates II LLC and Mersana Therapeutics, Inc.,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm"> dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm">10,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm">2020,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm"> by and between Mersana Therapeutics, Inc. and Rivertech Associates II LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q, File No. 001-38129, filed on May </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm">8,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm">2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_4.htm">Collaboration and Commercial License Agreement, dated June 23, 2014, by and between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_5.htm">Amendment 1 to the Collaboration and Commercial License Agreement, dated June 1, 2016, by and between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_6.htm">Amendment 2 to the Collaboration and Commercial License Agreement, dated August 12, 2016, by and between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_7.htm">Amendment 3 to the Collaboration and Commercial License Agreement, dated February 28, 2017, by and between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837018007081/mer-20180630ex10176898a.htm">Amendment 4 to Collaboration and Commercial License Agreement dated May 15, 2018, by and between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q, File No. 001-38129, filed on August 14, 2018).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_8.htm">License, Development and Commercialization Agreement, dated July 9, 2015, by and between Mersana Therapeutics, Inc. and Recepta Biopharma S.A. (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837019010082/mrsn-20190930ex101faeead.htm">First Amendment to the License, Development and Commercialization Agreement, dated August 19, 2019, by and between Mersana Therapeutics, Inc. and Recepta Biopharma S.A. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q, File No. 001-38129, filed on November 6, 2019).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_9.htm">Agreement Regarding LICR Technology, dated July 9, 2015, by and between Ludwig Institute for Cancer Research, Recepta Biopharma S.A. and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_10.htm">Collaboration Agreement, dated as of July 25, 2012, by and between Adimab, LLC and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.10 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_11.htm">Amendment Number One to the Collaboration Agreement, dated February 21, 2013, by and between Adimab, LLC and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_12.htm">Amendment Number One, to the Collaboration Agreement dated June 17, 2014, by and between Adimab, LLC and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.12 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837017006537/mer-20170630ex101c250d6.htm">Second Amendment to Amended and Restated Research Collaboration and Commercial License Agreement, as amended, dated August 2, 2017 by and between Mersana Therapeutics, Inc. and Millennium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q, File No. 001-38129, filed on August 11, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837017008761/mer-20170930ex101b7addc.htm">Third Amendment to the Amended and Restated Research Collaboration and Commercial License Agreement, as amended, dated October 30, 2017 by and between Mersana Therapeutics, Inc. and Millennium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q, file No. 001-38129, filed on November </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837017008761/mer-20170930ex101b7addc.htm">13, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465919068163/tm1924038d1_ex10-1.htm">Exchange Agreement, dated November 26, 2019, by and between Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P. and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K, File No. 001-38129, filed on November 27, 2019).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837019004673/mrsn-20190331ex10210c080.htm">Loan and Security Agreement, dated May 8, 2019, by and between Silicon Valley Bank and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q, File No. 001-38129, filed on May 9, 2019).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837019007600/mrsn-20190630ex102e61657.htm">First Amendment to the Loan and Security Agreement, dated June 21, 2019 by and between Silicon Valley Bank and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 10-Q, File No. 001-38129, filed on August 8, 2019).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">Second</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> Amendment to</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> Loan and Security Agreement, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">28,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">2020,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">Mersana</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">Therapeutics,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">Inc.,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">Silicon</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">Valley</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">Bank</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> (incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> to the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">Current Report on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">8-K,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> File No. 001-38129, filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">September</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">3,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465920102013/tm2030113d1_ex10-1.htm">2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_16.htm">Amended and Restated&#160;Offer&#160;Letter, by and between Mersana Therapeutics, Inc. and Anna Protopapas, dated March 17, 2017 (incorporated by reference to Exhibit 10.16 to the Company's Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.22&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">Offer</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">Letter,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm"> by and between Mersana Therapeutics, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">Dirk</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">Huebner,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm"> dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">November</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">5,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">2018</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm"> (incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm"> to the Company's Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">10-Q,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm"> File No. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">001-38129,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm"> filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">May</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">8,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex102c455ed.htm">2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.23&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm">Offer Letter, by and between Mersana Therapeutics, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm">Brian</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm">DeSchuytner,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm"> dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm">June</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm">10,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm">2019</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm"> (incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm"> to the Company&#8217;s Form 10-Q, File No. 001-38129, filed on May </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm">8,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm">2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.24&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_19.htm">2007 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.19 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.25&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_20.htm">Form of Incentive Stock Option under the 2007 Stock Incentive Plan (incorporated by reference to Exhibit 10.20 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.26&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_21.htm">Form of Nonqualified Stock Option under the 2007 Stock Incentive Plan (incorporated by reference to Exhibit 10.21 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.27&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917004050/a2232415zex-10_22.htm">2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.22 to the Company&#8217;s Form S-1/A, File No. 333-218412, filed on June 16, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.28&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917004050/a2232415zex-10_23.htm">Form of Incentive Stock Option under the 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.23 to the Company&#8217;s Form S-1/A, File No. 333-218412, filed on June 16, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.29&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917004050/a2232415zex-10_24.htm">Form of Nonqualified Stock Option under the 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.24 to the Company&#8217;s Form S-1/A, File No. 333-218412, filed on June 16, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.30&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917004050/a2232415zex-10_25.htm">2017 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.25 to the Company&#8217;s Form S-1/A, File No. 333-218412, filed on June 16, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.31&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917004050/a2232415zex-10_26.htm">2017 Cash Bonus Plan (incorporated by reference to Exhibit 10.26 to the Company&#8217;s Form S-1/A, File No. 333-218412, filed on June 16, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit21110kfy2020q4.htm">Subsidiaries of Mersana Therapeutics, Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit23110kfy2020q4.htm">Consent of Ernst&#160;&amp; Young&#160;LLP.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit31110kfy2020q4.htm">Certification pursuant to Section 302 of Sarbanes Oxley Act of 2002 by Chief Executive Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit31210kfy2020q4.htm">Certification pursuant to Section 302 of Sarbanes Oxley Act of 2002 by Principal Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1**</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit32110kfy2020q4.htm">Certification of periodic financial report pursuant to Section 906 of Sarbanes Oxley Act of 2002 by Chief Executive Officer and Principal Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following financial and related information from Mersana Therapeutics, Inc.&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, formatted in Inline eXtensible Business Reportable Language (iXBRL) includes: (i) the Consolidated Balance Sheet; (ii) the Consolidated Statement of Operations and Comprehensive Loss; (iii) the Consolidated Statement of Changes in Stockholders' Equity; (iv) the Consolidated Statement of Cash Flows; and, (v) Notes to Consolidated Financial Statements.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, formatted in Inline XBRL (contained in Exhibit 101).</span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Indicates a management contract or compensatory plan.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been submitted separately to the Securities and Exchange Commission.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="i7157c5eacfe941de9505feeee920791e_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7157c5eacfe941de9505feeee920791e_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics, Inc.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 26, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Anna Protopapas</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anna Protopapas</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on dates indicated.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signature</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;ANNA PROTOPAPAS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director (Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anna Protopapas</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;BRIAN DESCHUYTNER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Finance &amp; Product Strategy (Principal Financial Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brian DeSchuytner</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;ASHISH MANDELIA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President, Controller (Principal Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ashish Mandelia</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;DAVID MOTT</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman of the Board</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Mott</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;KRISTEN HEGE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristen Hege, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;ANDREW A. F. HACK</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Andrew A. F. Hack, M.D., Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;LAWRENCE M. ALLEVA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawrence M. Alleva</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;WILLARD H. DERE, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Willard H. Dere, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;MARTIN H. HUBER, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 26, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin H. Huber, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>exhibit21110kfy2020q4.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3621aaede3f945d1b1cdc267123ad05f_32"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries of the Registrant</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.294%"><tr><td style="width:1.0%"></td><td style="width:44.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State of Incorporation or Organization</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mersana Securities Corp.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit23110kfy2020q4.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i29635ad9cdbe41d9a58d2a2ce727ba0c_32"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 23.1</font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-3 No. 333-238140) of Mersana Therapeutics, Inc. and in the related Prospectus,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-236775) pertaining to the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan and the Mersana Therapeutics, Inc. 2017 Employee Stock Purchase Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-230159) pertaining to the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan and the Mersana Therapeutics, Inc. 2017 Employee Stock Purchase Plan, </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-222845) pertaining to the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-219388) pertaining to the Mersana Therapeutics, Inc. 2007 Stock Incentive Plan, as amended, the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan and the Mersana Therapeutics, Inc. 2017 Employee Stock Purchase Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of our report dated February&#160;26, 2021, with respect to the consolidated financial statements of Mersana Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Mersana Therapeutics, Inc. included in this Annual Report (Form 10-K) of Mersana Therapeutics, Inc. for the year ended December&#160;31, 2020.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                                                                                                            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Boston, Massachusetts </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February&#160;26, 2021</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit31110kfy2020q4.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i446c22d44fa94332a363084a08435f1d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Anna Protopapas, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K of Mersana Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report), that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:18pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 26, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anna Protopapas</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anna Protopapas<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit31210kfy2020q4.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i97887e40ddc44d4386bf96273f804a55_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brian&#160;DeSchuytner, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K of Mersana Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report), that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-9pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 26, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian&#160;DeSchuytner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brian DeSchuytner</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Finance &#38; Product Strategy</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit32110kfy2020q4.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i972c4aaaf5204c23966173802f395e0c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this Annual Report on Form 10-K of Mersana Therapeutics, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the company, hereby certifies, pursuant to Section&#160;1350 of Chapter 63 of Title 18, United States Code, that to the best of her or his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 26, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anna Protopapas</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anna Protopapas<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 26, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian&#160;DeSchuytner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian DeSchuytner<br>Senior Vice President, Finance &#38; Product Strategy<br>(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mrsn-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2da7fb72-9c95-4f34-a8ba-21eaa0b59775,g:bc62363b-ba21-41ff-8e10-87a9df40b55e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrsn="http://www.mersana.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.mersana.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrsn-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrsn-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrsn-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrsn-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.mersana.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentation" roleURI="http://www.mersana.com/role/NatureofBusinessandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentationDetails" roleURI="http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails" roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails">
        <link:definition>2406402 - Disclosure - Summary of significant accounting policies - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails" roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails">
        <link:definition>2407403 - Disclosure - Summary of significant accounting policies - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesOtherAssetsDetails" roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails">
        <link:definition>2408404 - Disclosure - Summary of significant accounting policies - Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Stock Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesNetlosspershareDetails" roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails">
        <link:definition>2410406 - Disclosure - Summary of significant accounting policies - Net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>2411407 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesRisksDetails" roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRisksDetails">
        <link:definition>2412408 - Disclosure - Summary of significant accounting policies - Risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails" roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails">
        <link:definition>2413409 - Disclosure - Summary of significant accounting policies - Recently Issued Accounting Pronouncement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.mersana.com/role/CollaborationAgreements">
        <link:definition>2114103 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.mersana.com/role/CollaborationAgreementsTables">
        <link:definition>2315302 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsMerckKGaADetail" roleURI="http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail">
        <link:definition>2416410 - Disclosure - Collaboration Agreements - Merck KGaA (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsMerckKGaAAccountingAnalysisDetails" roleURI="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails">
        <link:definition>2417411 - Disclosure - Collaboration Agreements - Merck KGaA - Accounting Analysis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsMerckKGaAAccountingAnalysisDetails_1" roleURI="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails_1">
        <link:definition>2417411 - Disclosure - Collaboration Agreements - Merck KGaA - Accounting Analysis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails" roleURI="http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails">
        <link:definition>2418412 - Disclosure - Collaboration Agreements - Takeda XMT-1522 Strategic Partnership (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedastrategicRDpartnershipDetails" roleURI="http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails">
        <link:definition>2419413 - Disclosure - Collaboration Agreements - Takeda strategic R &amp; D partnership (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaAccountingAnalysisDetails" roleURI="http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails">
        <link:definition>2420414 - Disclosure - Collaboration Agreements - Takeda - Accounting Analysis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsContractAssetsandLiabilitiesDetails" roleURI="http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails">
        <link:definition>2421415 - Disclosure - Collaboration Agreements - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsOtherRevenueDetails" roleURI="http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails">
        <link:definition>2422416 - Disclosure - Collaboration Agreements - Other Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.mersana.com/role/FairValueMeasurements">
        <link:definition>2123104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.mersana.com/role/FairValueMeasurementsTables">
        <link:definition>2324303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.mersana.com/role/FairValueMeasurementsDetails">
        <link:definition>2425417 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.mersana.com/role/MarketableSecurities">
        <link:definition>2126105 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.mersana.com/role/MarketableSecuritiesTables">
        <link:definition>2327304 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://www.mersana.com/role/MarketableSecuritiesDetails">
        <link:definition>2428418 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.mersana.com/role/PropertyandEquipment">
        <link:definition>2129106 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.mersana.com/role/PropertyandEquipmentTables">
        <link:definition>2330305 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.mersana.com/role/PropertyandEquipmentDetails">
        <link:definition>2431419 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.mersana.com/role/AccruedExpenses">
        <link:definition>2132107 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesTables" roleURI="http://www.mersana.com/role/AccruedexpensesTables">
        <link:definition>2333306 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.mersana.com/role/AccruedExpensesDetails">
        <link:definition>2434420 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.mersana.com/role/Debt">
        <link:definition>2135108 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.mersana.com/role/DebtTables">
        <link:definition>2336307 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.mersana.com/role/DebtNarrativeDetails">
        <link:definition>2437421 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtComponentsDetails" roleURI="http://www.mersana.com/role/DebtComponentsDetails">
        <link:definition>2438422 - Disclosure - Debt - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtFuturepaymentsDetails" roleURI="http://www.mersana.com/role/DebtFuturepaymentsDetails">
        <link:definition>2439423 - Disclosure - Debt - Future payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.mersana.com/role/StockholdersEquity">
        <link:definition>2140109 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.mersana.com/role/StockholdersEquityTables">
        <link:definition>2341308 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityPreferredStockDetails" roleURI="http://www.mersana.com/role/StockholdersEquityPreferredStockDetails">
        <link:definition>2442424 - Disclosure - Stockholders' Equity Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails" roleURI="http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails">
        <link:definition>2443425 - Disclosure - Stockholders' Equity At-the-market Equity and Follow On Offering Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityWarrantsDetails" roleURI="http://www.mersana.com/role/StockholdersEquityWarrantsDetails">
        <link:definition>2444426 - Disclosure - Stockholders' Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityExchangeWarrantsDetails" roleURI="http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails">
        <link:definition>2445427 - Disclosure - Stockholders' Equity - Exchange Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonstockDetails" roleURI="http://www.mersana.com/role/StockholdersEquityCommonstockDetails">
        <link:definition>2446428 - Disclosure - Stockholders' Equity - Common stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptions" roleURI="http://www.mersana.com/role/StockOptions">
        <link:definition>2147110 - Disclosure - Stock Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsTables" roleURI="http://www.mersana.com/role/StockOptionsTables">
        <link:definition>2348309 - Disclosure - Stock Options (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsPlansNarrativeDetails" roleURI="http://www.mersana.com/role/StockOptionsPlansNarrativeDetails">
        <link:definition>2449429 - Disclosure - Stock Options - Plans Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsInducementNarrativeDetails" roleURI="http://www.mersana.com/role/StockOptionsInducementNarrativeDetails">
        <link:definition>2450430 - Disclosure - Stock Options - Inducement Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsActivityUnderStockOptionPlanDetails" roleURI="http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails">
        <link:definition>2451431 - Disclosure - Stock Options - Activity Under Stock Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsRestrictedStockUnitsDetails" roleURI="http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails">
        <link:definition>2452432 - Disclosure - Stock Options - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsStockBasedCompensationExpenseDetails" roleURI="http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails">
        <link:definition>2453433 - Disclosure - Stock Options - Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsFairValueAssumptionsDetails" roleURI="http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails">
        <link:definition>2454434 - Disclosure - Stock Options - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsEmployeeStockPurchasePlanDetails" roleURI="http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails">
        <link:definition>2455435 - Disclosure - Stock Options - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.mersana.com/role/Leases">
        <link:definition>2156111 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.mersana.com/role/LeasesTables">
        <link:definition>2357310 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDescriptionDetails" roleURI="http://www.mersana.com/role/LeasesDescriptionDetails">
        <link:definition>2458436 - Disclosure - Leases - Description (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2459437 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalbalancesheetinformationDetails" roleURI="http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails">
        <link:definition>2460438 - Disclosure - Leases - Supplemental balance sheet information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalcashflowinformationDetails" roleURI="http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails">
        <link:definition>2461439 - Disclosure - Leases - Supplemental cash flow information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureminimumleasepaymentsDetails" roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails">
        <link:definition>2462440 - Disclosure - Leases - Future minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureminimumleasepaymentsDetails_1" roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1">
        <link:definition>2462440 - Disclosure - Leases - Future minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.mersana.com/role/IncomeTaxes">
        <link:definition>2163112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.mersana.com/role/IncomeTaxesTables">
        <link:definition>2364311 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationDetails" roleURI="http://www.mersana.com/role/IncomeTaxesReconciliationDetails">
        <link:definition>2465441 - Disclosure - Income Taxes - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofdeferredtaxassetsDetails" roleURI="http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails">
        <link:definition>2466442 - Disclosure - Income Taxes - Components of deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNetoperatinglosscarryforwardsDetails" roleURI="http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails">
        <link:definition>2467443 - Disclosure - Income Taxes - Net operating loss carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTaxcreditcarryforwardDetails" roleURI="http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails">
        <link:definition>2468444 - Disclosure - Income Taxes - Tax credit carryforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesValuationallowanceDetails" roleURI="http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails">
        <link:definition>2469445 - Disclosure - Income Taxes - Valuation allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.mersana.com/role/EmployeeBenefitPlan">
        <link:definition>2170113 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://www.mersana.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2471446 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://www.mersana.com/role/Commitments">
        <link:definition>2172114 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsLicenseagreementsDetails" roleURI="http://www.mersana.com/role/CommitmentsLicenseagreementsDetails">
        <link:definition>2473447 - Disclosure - Commitments - License agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnaudited" roleURI="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnaudited">
        <link:definition>2174115 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedTables" roleURI="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>2375312 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedQuarterlyFinancialDataUnauditedDetails" roleURI="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails">
        <link:definition>2476448 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mrsn_AmendedCreditFacilityTrancheFiveMember" abstract="true" name="AmendedCreditFacilityTrancheFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" abstract="false" name="FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_WarrantsAndShareBasedPaymentsMember" abstract="true" name="WarrantsAndShareBasedPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_LeasesTable" abstract="true" name="LeasesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_LaboratoryEquipmentLeasedAssetMember" abstract="true" name="LaboratoryEquipmentLeasedAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_InducementAwardProgramMember" abstract="true" name="InducementAwardProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_ContractWithCustomerLiabilityIncrease" abstract="false" name="ContractWithCustomerLiabilityIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_AmendedCreditFacilityTrancheOneMember" abstract="true" name="AmendedCreditFacilityTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" abstract="true" name="CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" abstract="false" name="CollaborationArrangementsMilestonePaymentReceivableNextMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard" abstract="false" name="AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_IncreaseDecreaseInOperatingLeaseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" abstract="true" name="LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" abstract="true" name="ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_AtMarketEquityOfferingProgram2020ATMMember" abstract="true" name="AtMarketEquityOfferingProgram2020ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_ProceedsFromIssuanceOfCommonStockGross" abstract="false" name="ProceedsFromIssuanceOfCommonStockGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_PatentCostsPolicyTextBlock" abstract="false" name="PatentCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" abstract="false" name="FinalPaymentAsPercentageOfOriginalPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_CollaborativeArrangementsUpfrontPayment" abstract="false" name="CollaborativeArrangementsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_PrepaymentOccursPriorToAugust282021Member" abstract="true" name="PrepaymentOccursPriorToAugust282021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_ChangeInDeferredRent" abstract="false" name="ChangeInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" abstract="true" name="CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" abstract="false" name="CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" abstract="false" name="LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentOfficeEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsRegulatoryMilestones" abstract="false" name="CollaborationArrangementsRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" abstract="false" name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrsn_LesseeFinanceLeasesAbstract" abstract="true" name="LesseeFinanceLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsCostsBilled" abstract="false" name="CollaborationArrangementsCostsBilled" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" abstract="false" name="StockIssuanceDiscountsAndCommissionsOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member" abstract="true" name="PrepaymentOccursBetweenAugust282021AndAugust282022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_StockIssuanceProgramAuthorizedAmount" abstract="false" name="StockIssuanceProgramAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_LeasesSupplementalCashFlowInformationAbstract" abstract="true" name="LeasesSupplementalCashFlowInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_RevenueTransactionPriceIncreaseDecrease" abstract="false" name="RevenueTransactionPriceIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_AccruedPreclinicalAndClinicalExpensesCurrent" abstract="false" name="AccruedPreclinicalAndClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_JointResearchCommitteeServicesMember" abstract="true" name="JointResearchCommitteeServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" abstract="false" name="CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsSalesMilestones" abstract="false" name="CollaborationArrangementsSalesMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_DebtCovenantPeriodDomain" abstract="true" name="DebtCovenantPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" abstract="false" name="CollaborationArrangementIndividualCommercialMilestonesTargetNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" abstract="false" name="DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" abstract="false" name="StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" abstract="true" name="LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsMaximumAggregateMilestones" abstract="false" name="CollaborationArrangementsMaximumAggregateMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_FinanceLeaseTotalCostAbstract" abstract="true" name="FinanceLeaseTotalCostAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_IncomeTaxesNumberOfStateJurisdictions" abstract="false" name="IncomeTaxesNumberOfStateJurisdictions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets" abstract="false" name="LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" abstract="true" name="ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" abstract="false" name="MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_TenantImprovementAllowance" abstract="false" name="TenantImprovementAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_WeightedAverageDiscountRateAbstract" abstract="true" name="WeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsDurationToTermination" abstract="false" name="CollaborationArrangementsDurationToTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" abstract="true" name="LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated" abstract="false" name="ReimbursableExpenseResearchAndDevelopmentEstimated" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_StockIncentivePlan2007Member" abstract="true" name="StockIncentivePlan2007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" abstract="false" name="CollaborationArrangementsPriorWrittenTerminationNoticeDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsDevelopmentMilestones" abstract="false" name="CollaborationArrangementsDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_RevenueTransactionPriceAmount" abstract="false" name="RevenueTransactionPriceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_IncomeTaxesNumberOfAuditsInProgress" abstract="false" name="IncomeTaxesNumberOfAuditsInProgress" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_WarrantsExercisedInPeriod" abstract="false" name="WarrantsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_RevenueCollectionPeriod" abstract="false" name="RevenueCollectionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member" abstract="true" name="PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_RightsToFutureTechnologicalImprovementsMember" abstract="true" name="RightsToFutureTechnologicalImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" abstract="true" name="LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_LicenseAgreementUpfrontPaymentsMember" abstract="true" name="LicenseAgreementUpfrontPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" abstract="false" name="CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_AtMarketEquityOfferingProgram774PerShareMember" abstract="true" name="AtMarketEquityOfferingProgram774PerShareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_LesseeOperatingLeasesAbstract" abstract="true" name="LesseeOperatingLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_ServiceMilestoneMember" abstract="true" name="ServiceMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_ExistingCreditFacilityMember" abstract="true" name="ExistingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit" abstract="false" name="LineOfCreditFacilityAccordianFeatureIncreaseLimit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_RevenueRemainingPerformanceObligationNumber" abstract="false" name="RevenueRemainingPerformanceObligationNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_AmendedCreditFacilityTrancheFourMember" abstract="true" name="AmendedCreditFacilityTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" abstract="true" name="CollaborationAndCommercialLicenseAgreementMerckKgaaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_DebtInstrumentAdditionalRateInEventOfDefault" abstract="false" name="DebtInstrumentAdditionalRateInEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrsn_DeferredTaxAssetsLicensedTechnology" abstract="false" name="DeferredTaxAssetsLicensedTechnology" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" abstract="false" name="StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_LicenseAgreementMilestonePaymentsMember" abstract="true" name="LicenseAgreementMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_OfficeSpaceCambridgeMaMember" abstract="true" name="OfficeSpaceCambridgeMaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_ContractWithCustomerLiabilityDecrease" abstract="false" name="ContractWithCustomerLiabilityDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_AmendedCreditFacilityTrancheTwoMember" abstract="true" name="AmendedCreditFacilityTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_ContractualLifeOfWarrants" abstract="false" name="ContractualLifeOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" abstract="false" name="CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_DebtInstrumentPrepaymentFeePercent" abstract="false" name="DebtInstrumentPrepaymentFeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" abstract="false" name="ClassOfWarrantOrRightSharesExchangedForWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_LeasesLineItems" abstract="true" name="LeasesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_AtMarketEquityOfferingProgram2018ATMMember" abstract="true" name="AtMarketEquityOfferingProgram2018ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_DeferredTaxAssetsDepreciation" abstract="false" name="DeferredTaxAssetsDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsTargetsDesignatedNumber" abstract="false" name="CollaborationArrangementsTargetsDesignatedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" abstract="false" name="CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" abstract="false" name="StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_SupplyAgreementMerckKgaaMember" abstract="true" name="SupplyAgreementMerckKgaaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_CollaborationAgreementsAbstract" abstract="true" name="CollaborationAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_CollaborativeArrangementsExclusiveTargetsNumber" abstract="false" name="CollaborativeArrangementsExclusiveTargetsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_AmendedCreditFacilityTrancheThreeMember" abstract="true" name="AmendedCreditFacilityTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_ProceedsFromDebtNetIssuanceCosts" abstract="false" name="ProceedsFromDebtNetIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_AtMarketEquityOfferingProgram559PerShareMember" abstract="true" name="AtMarketEquityOfferingProgram559PerShareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" abstract="true" name="DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_DefinedContributionPlanEligibleAgeToParticipate" abstract="false" name="DefinedContributionPlanEligibleAgeToParticipate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" abstract="false" name="CollaborationArrangementsDevelopmentMilestonesPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" abstract="false" name="ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" abstract="false" name="CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_AmendedCreditFacilityTrancheSixMember" abstract="true" name="AmendedCreditFacilityTrancheSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_DebtInstrumentCarryingAmountNoncurrent" abstract="false" name="DebtInstrumentCarryingAmountNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" abstract="false" name="LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mrsn_NumberOfVotesPerCommonShare" abstract="false" name="NumberOfVotesPerCommonShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_AmendedCreditFacilityMember" abstract="true" name="AmendedCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" abstract="true" name="ChangeInContractAssetsAndLiabilitiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" abstract="true" name="LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_DebtCovenantPeriodAxis" abstract="true" name="DebtCovenantPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_StockIncentivePlan2017Member" abstract="true" name="StockIncentivePlan2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_ExchangeWarrantsMember" abstract="true" name="ExchangeWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mrsn_LimitedServicesMember" abstract="true" name="LimitedServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mrsn-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2da7fb72-9c95-4f34-a8ba-21eaa0b59775,g:bc62363b-ba21-41ff-8e10-87a9df40b55e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.mersana.com/role/Cover" xlink:type="simple" xlink:href="mrsn-20201231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fb3c5934-e46a-41d1-9fe7-f15980bf3b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4aa77951-95dc-44ce-aedb-c808259eab35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fb3c5934-e46a-41d1-9fe7-f15980bf3b8f" xlink:to="loc_us-gaap_CommonStockValue_4aa77951-95dc-44ce-aedb-c808259eab35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_75380a28-3cc1-4cd3-99b3-3b06eadb8b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fb3c5934-e46a-41d1-9fe7-f15980bf3b8f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_75380a28-3cc1-4cd3-99b3-3b06eadb8b39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2698758e-0bbc-4782-ac04-4538288751ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fb3c5934-e46a-41d1-9fe7-f15980bf3b8f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2698758e-0bbc-4782-ac04-4538288751ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0698adf2-7882-4e24-8e7c-ee9040333e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fb3c5934-e46a-41d1-9fe7-f15980bf3b8f" xlink:to="loc_us-gaap_PreferredStockValue_0698adf2-7882-4e24-8e7c-ee9040333e3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_35f76664-100a-4879-ad75-5151dee13a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fb3c5934-e46a-41d1-9fe7-f15980bf3b8f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_35f76664-100a-4879-ad75-5151dee13a33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_80b59158-14e8-4d2e-84a6-d75fc3a283fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b1354597-57d2-4edd-ada0-eef60b0fade8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_80b59158-14e8-4d2e-84a6-d75fc3a283fd" xlink:to="loc_us-gaap_AccountsPayableCurrent_b1354597-57d2-4edd-ada0-eef60b0fade8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5553f417-6de2-47eb-9ee4-767bbf0af035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_80b59158-14e8-4d2e-84a6-d75fc3a283fd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5553f417-6de2-47eb-9ee4-767bbf0af035" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_148451dd-c488-4a7d-b046-499b2b48d50d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_80b59158-14e8-4d2e-84a6-d75fc3a283fd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_148451dd-c488-4a7d-b046-499b2b48d50d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7bb247b7-dac4-45f5-b93b-43cd84fd0028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_80b59158-14e8-4d2e-84a6-d75fc3a283fd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7bb247b7-dac4-45f5-b93b-43cd84fd0028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_df0387ba-4d17-4434-b280-ca8bc6dea451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_80b59158-14e8-4d2e-84a6-d75fc3a283fd" xlink:to="loc_us-gaap_LongTermDebtCurrent_df0387ba-4d17-4434-b280-ca8bc6dea451" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_36ae5686-21f9-491a-9499-19916426389a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_80b59158-14e8-4d2e-84a6-d75fc3a283fd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_36ae5686-21f9-491a-9499-19916426389a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d5d1fa3e-95f0-4756-8ddd-2a1274cd9790" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9317a58f-2401-4a0f-b56e-80e960619611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5d1fa3e-95f0-4756-8ddd-2a1274cd9790" xlink:to="loc_us-gaap_LiabilitiesCurrent_9317a58f-2401-4a0f-b56e-80e960619611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7ce58f2a-e251-4cb8-927b-96462970d2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5d1fa3e-95f0-4756-8ddd-2a1274cd9790" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7ce58f2a-e251-4cb8-927b-96462970d2ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_be004f8d-2e51-4f0f-aa0a-b2ae1eb1e269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5d1fa3e-95f0-4756-8ddd-2a1274cd9790" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_be004f8d-2e51-4f0f-aa0a-b2ae1eb1e269" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9fac3a30-7795-40c5-82b8-6394e6cd8a10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d5d1fa3e-95f0-4756-8ddd-2a1274cd9790" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9fac3a30-7795-40c5-82b8-6394e6cd8a10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d1703be3-1c3d-4fc3-adcc-5b22fa38a60a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4232d0d8-4e11-4a6b-b355-1ef68ccc645b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d1703be3-1c3d-4fc3-adcc-5b22fa38a60a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4232d0d8-4e11-4a6b-b355-1ef68ccc645b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2c2b0df5-acdd-43c4-993b-1e0db107dc57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d1703be3-1c3d-4fc3-adcc-5b22fa38a60a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2c2b0df5-acdd-43c4-993b-1e0db107dc57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7af8097c-c6bb-4197-8ae6-0f17a4392239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d1703be3-1c3d-4fc3-adcc-5b22fa38a60a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7af8097c-c6bb-4197-8ae6-0f17a4392239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_38e231e5-5d97-46a4-9f77-6afb06daf6ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bf98fe48-ea53-4a3a-a92d-c771a52617cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_38e231e5-5d97-46a4-9f77-6afb06daf6ff" xlink:to="loc_us-gaap_AssetsCurrent_bf98fe48-ea53-4a3a-a92d-c771a52617cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_24cc8cef-2723-4672-bc99-4c1a786e842c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_38e231e5-5d97-46a4-9f77-6afb06daf6ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_24cc8cef-2723-4672-bc99-4c1a786e842c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_de3aaf20-19dd-4bf2-b497-d8338d5bd49e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_38e231e5-5d97-46a4-9f77-6afb06daf6ff" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_de3aaf20-19dd-4bf2-b497-d8338d5bd49e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0dc7bf93-8dd8-4b5f-9c15-b64f89e613b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_38e231e5-5d97-46a4-9f77-6afb06daf6ff" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0dc7bf93-8dd8-4b5f-9c15-b64f89e613b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e9967f4-1411-4099-b264-a95146136324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7c94c56d-ee11-482d-87d2-24e086a899f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e9967f4-1411-4099-b264-a95146136324" xlink:to="loc_us-gaap_Liabilities_7c94c56d-ee11-482d-87d2-24e086a899f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2738f758-7c2c-48da-bcd6-08dc8ba872bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e9967f4-1411-4099-b264-a95146136324" xlink:to="loc_us-gaap_StockholdersEquity_2738f758-7c2c-48da-bcd6-08dc8ba872bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_22c39701-6f36-4edb-b36b-9b4594538eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1e9967f4-1411-4099-b264-a95146136324" xlink:to="loc_us-gaap_CommitmentsAndContingencies_22c39701-6f36-4edb-b36b-9b4594538eed" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ff9bed0-0796-45ec-be12-5f3ae83e324c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9f73b923-26bd-4bb9-ad2a-ad5972c2068d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3ff9bed0-0796-45ec-be12-5f3ae83e324c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9f73b923-26bd-4bb9-ad2a-ad5972c2068d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6e6c4839-c38c-4ec9-a105-8902f2288916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3ff9bed0-0796-45ec-be12-5f3ae83e324c" xlink:to="loc_us-gaap_OperatingExpenses_6e6c4839-c38c-4ec9-a105-8902f2288916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_17f2a21a-2dcc-40e5-8dfb-6a1afe7b54e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3ff9bed0-0796-45ec-be12-5f3ae83e324c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_17f2a21a-2dcc-40e5-8dfb-6a1afe7b54e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cc292474-fbc9-4fbe-aa76-73c0eb12cdaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_636dbeea-efcf-4afd-bca3-5f381c3fd6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cc292474-fbc9-4fbe-aa76-73c0eb12cdaa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_636dbeea-efcf-4afd-bca3-5f381c3fd6a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_aa4df15f-62d2-4f10-abab-2a47a86f5ff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cc292474-fbc9-4fbe-aa76-73c0eb12cdaa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_aa4df15f-62d2-4f10-abab-2a47a86f5ff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3609c39c-77d6-4ab0-a461-edec0472bc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_19fd4611-a9ad-4c0c-a50b-4611959df9f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3609c39c-77d6-4ab0-a461-edec0472bc6c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_19fd4611-a9ad-4c0c-a50b-4611959df9f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_613e043c-3d5a-4b7b-8c43-8e34dbc23b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3609c39c-77d6-4ab0-a461-edec0472bc6c" xlink:to="loc_us-gaap_NetIncomeLoss_613e043c-3d5a-4b7b-8c43-8e34dbc23b4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_61818766-0dc7-45db-9ccd-c294f2c3181b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_69318baa-675b-4ff5-8cb5-c4902fea28bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_61818766-0dc7-45db-9ccd-c294f2c3181b" xlink:to="loc_us-gaap_InterestExpense_69318baa-675b-4ff5-8cb5-c4902fea28bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6b36c4cc-3af5-4d53-9346-d8087bc2d952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_61818766-0dc7-45db-9ccd-c294f2c3181b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6b36c4cc-3af5-4d53-9346-d8087bc2d952" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0f50b1f-5944-4fce-be85-0804f1e55b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_01c5120e-8e45-4e86-8c80-1adfa61cacab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0f50b1f-5944-4fce-be85-0804f1e55b7e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_01c5120e-8e45-4e86-8c80-1adfa61cacab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromDebtNetIssuanceCosts_3494b46f-99e6-4849-b0f4-8e70611c1cbd" xlink:href="mrsn-20201231.xsd#mrsn_ProceedsFromDebtNetIssuanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0f50b1f-5944-4fce-be85-0804f1e55b7e" xlink:to="loc_mrsn_ProceedsFromDebtNetIssuanceCosts_3494b46f-99e6-4849-b0f4-8e70611c1cbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_5281712d-5a7e-4034-82ee-2bb63a0c1efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0f50b1f-5944-4fce-be85-0804f1e55b7e" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_5281712d-5a7e-4034-82ee-2bb63a0c1efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_175b6aab-42c8-4f45-b525-143a9f847795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0f50b1f-5944-4fce-be85-0804f1e55b7e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_175b6aab-42c8-4f45-b525-143a9f847795" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_33dbf9ae-754f-4306-a4ae-8d0d557afbbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0f50b1f-5944-4fce-be85-0804f1e55b7e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_33dbf9ae-754f-4306-a4ae-8d0d557afbbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a16ba86e-467f-42fb-bab5-ae509a95551f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f141a719-6770-4a76-9282-5971faf4da05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a16ba86e-467f-42fb-bab5-ae509a95551f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f141a719-6770-4a76-9282-5971faf4da05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5300c707-16d8-4d68-8b2b-a601db40d6aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a16ba86e-467f-42fb-bab5-ae509a95551f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5300c707-16d8-4d68-8b2b-a601db40d6aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6537060-6661-4f95-a4c8-74472211ebba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a16ba86e-467f-42fb-bab5-ae509a95551f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f6537060-6661-4f95-a4c8-74472211ebba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5772faf4-1505-41a1-ad6c-9218c604829b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5772faf4-1505-41a1-ad6c-9218c604829b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9ce6fe11-c386-4c4a-b7c1-571915ef05b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9ce6fe11-c386-4c4a-b7c1-571915ef05b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_77bb110a-0cac-45fc-961d-f514767370ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_77bb110a-0cac-45fc-961d-f514767370ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_dbc749df-a037-483a-9160-e90da514e83f" xlink:href="mrsn-20201231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_dbc749df-a037-483a-9160-e90da514e83f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6bcb98e9-c8c5-43f1-9383-9874101510fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6bcb98e9-c8c5-43f1-9383-9874101510fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0cd21483-f4f6-4645-b644-fbefeb73812d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0cd21483-f4f6-4645-b644-fbefeb73812d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_0de10ca2-da8f-4899-8f0b-6ef5e51be448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_0de10ca2-da8f-4899-8f0b-6ef5e51be448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7ea31bce-1f43-4033-abde-58e0ecf2a993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_us-gaap_ProfitLoss_7ea31bce-1f43-4033-abde-58e0ecf2a993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_39feceb4-5099-4cb1-ac61-c81d4c7b76d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_us-gaap_ShareBasedCompensation_39feceb4-5099-4cb1-ac61-c81d4c7b76d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets_411da1ed-8233-4804-942e-9f374473fd30" xlink:href="mrsn-20201231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets_411da1ed-8233-4804-942e-9f374473fd30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2ded5b11-2608-4ada-ab3c-6b877e02310c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2ded5b11-2608-4ada-ab3c-6b877e02310c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2ac9db67-b809-44c8-88f5-375777afee7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2ac9db67-b809-44c8-88f5-375777afee7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ChangeInDeferredRent_4e8ff34f-97af-4883-9753-6c4b69e633ff" xlink:href="mrsn-20201231.xsd#mrsn_ChangeInDeferredRent"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_mrsn_ChangeInDeferredRent_4e8ff34f-97af-4883-9753-6c4b69e633ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_82077f8b-ecc2-4047-bff1-9c8460881295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_82077f8b-ecc2-4047-bff1-9c8460881295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d7c32d7f-33b0-49c6-961e-79eeffa30043" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_677010f7-f581-4f20-a70a-30ffb5b4f704" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d7c32d7f-33b0-49c6-961e-79eeffa30043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec858a49-f21c-45b7-b94d-f156031c3664" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a651e4b5-41e3-4af6-a48c-525161d73f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec858a49-f21c-45b7-b94d-f156031c3664" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a651e4b5-41e3-4af6-a48c-525161d73f23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_d5ee4831-5ec3-4a2f-9222-e78ceb2d2b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec858a49-f21c-45b7-b94d-f156031c3664" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_d5ee4831-5ec3-4a2f-9222-e78ceb2d2b98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_efa3a5fa-175c-4fc8-a2bd-6193d181b635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec858a49-f21c-45b7-b94d-f156031c3664" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_efa3a5fa-175c-4fc8-a2bd-6193d181b635" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="mrsn-20201231.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca3c81b6-b131-4f44-b4f6-a2916449856f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3c0572f-be59-48c6-89f4-46cea4c7ab60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca3c81b6-b131-4f44-b4f6-a2916449856f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a3c0572f-be59-48c6-89f4-46cea4c7ab60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a95de0d2-9a82-42ad-833e-12ac42784153" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca3c81b6-b131-4f44-b4f6-a2916449856f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a95de0d2-9a82-42ad-833e-12ac42784153" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dfdda2ea-e8be-4f32-a712-841e0465d1f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainageDeposit_41d1a465-a201-49af-8377-ff604e506c9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainageDeposit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_dfdda2ea-e8be-4f32-a712-841e0465d1f7" xlink:to="loc_us-gaap_RetainageDeposit_41d1a465-a201-49af-8377-ff604e506c9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_9e59654b-ab87-4e44-b202-47dfbdd8d57c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_dfdda2ea-e8be-4f32-a712-841e0465d1f7" xlink:to="loc_us-gaap_SecurityDeposit_9e59654b-ab87-4e44-b202-47dfbdd8d57c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesNetlosspershareDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRisksDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesRisksDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRisksDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreements"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/CollaborationAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsTables"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsMerckKGaADetail"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_0bd1afe2-4239-4743-8986-f3a0c16442b3" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsMaximumAggregateMilestones"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_9fc84efd-7470-4a79-a208-27c72531b6d8" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestones"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_0bd1afe2-4239-4743-8986-f3a0c16442b3" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_9fc84efd-7470-4a79-a208-27c72531b6d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_a256d183-e0af-4fee-9a63-d549c2667fb4" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsRegulatoryMilestones"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_0bd1afe2-4239-4743-8986-f3a0c16442b3" xlink:to="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_a256d183-e0af-4fee-9a63-d549c2667fb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSalesMilestones_75c70009-9a91-49e9-8c2c-5c7cc8d16492" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsSalesMilestones"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_0bd1afe2-4239-4743-8986-f3a0c16442b3" xlink:to="loc_mrsn_CollaborationArrangementsSalesMilestones_75c70009-9a91-49e9-8c2c-5c7cc8d16492" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails_1" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsMerckKGaAAccountingAnalysisDetails_1"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsTakedastrategicRDpartnershipDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsTakedaAccountingAnalysisDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsOtherRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="mrsn-20201231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2ae40639-0f18-427f-89c7-943cc50e9174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4355fd1f-4cff-421b-97b8-cd975941fbaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2ae40639-0f18-427f-89c7-943cc50e9174" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4355fd1f-4cff-421b-97b8-cd975941fbaf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mrsn-20201231.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0cb0fcbd-4878-4362-a9f4-e3c079cb4a2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_025d6149-650a-4c3b-b0b1-41e4c370c9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0cb0fcbd-4878-4362-a9f4-e3c079cb4a2b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_025d6149-650a-4c3b-b0b1-41e4c370c9cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d8d9451d-809b-4a0c-b050-46118cd3e6f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0cb0fcbd-4878-4362-a9f4-e3c079cb4a2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d8d9451d-809b-4a0c-b050-46118cd3e6f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58c4a58c-f4bd-42f8-b4e3-a03023b1198d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0cb0fcbd-4878-4362-a9f4-e3c079cb4a2b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_58c4a58c-f4bd-42f8-b4e3-a03023b1198d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="mrsn-20201231.xsd#PropertyandEquipment"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/PropertyandEquipment" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#PropertyandEquipmentTables"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/PropertyandEquipmentTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3482d9c3-11b3-44a6-953d-4ceb1c10178a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_b603d80d-1bd8-4d74-bdf7-ee014f7de6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3482d9c3-11b3-44a6-953d-4ceb1c10178a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_b603d80d-1bd8-4d74-bdf7-ee014f7de6c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4c09e6a2-df76-431e-b793-d6137ddd86cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3482d9c3-11b3-44a6-953d-4ceb1c10178a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4c09e6a2-df76-431e-b793-d6137ddd86cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedExpenses" xlink:type="simple" xlink:href="mrsn-20201231.xsd#AccruedExpenses"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/AccruedExpenses" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedexpensesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#AccruedexpensesTables"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/AccruedexpensesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3d23aa95-846c-432a-abe7-2bd0688b4b88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4e3cc0af-5986-496b-9965-3d09a2d577cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3d23aa95-846c-432a-abe7-2bd0688b4b88" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4e3cc0af-5986-496b-9965-3d09a2d577cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_28346eb2-2ed3-4c1e-853e-4cbf17735c86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3d23aa95-846c-432a-abe7-2bd0688b4b88" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_28346eb2-2ed3-4c1e-853e-4cbf17735c86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_51605d2a-82a3-41f0-95c4-37aa2fb9cf2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3d23aa95-846c-432a-abe7-2bd0688b4b88" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_51605d2a-82a3-41f0-95c4-37aa2fb9cf2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent_65c632ef-9cec-4618-9ed7-d7180165963e" xlink:href="mrsn-20201231.xsd#mrsn_AccruedPreclinicalAndClinicalExpensesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3d23aa95-846c-432a-abe7-2bd0688b4b88" xlink:to="loc_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent_65c632ef-9cec-4618-9ed7-d7180165963e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/Debt" xlink:type="simple" xlink:href="mrsn-20201231.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#DebtTables"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/DebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#DebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/DebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtComponentsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#DebtComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/DebtComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9eb2d583-fa78-4059-bb89-7b443c688d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_f8dfbc75-56f2-46bf-b12a-a3a2dfab3fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_9eb2d583-fa78-4059-bb89-7b443c688d2a" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_f8dfbc75-56f2-46bf-b12a-a3a2dfab3fcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_501992a7-65d3-4112-a545-eecbfb936177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_9eb2d583-fa78-4059-bb89-7b443c688d2a" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_501992a7-65d3-4112-a545-eecbfb936177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent_0bcbe3e1-2841-4882-9864-b1764b6d58b6" xlink:href="mrsn-20201231.xsd#mrsn_DebtInstrumentCarryingAmountNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_9eb2d583-fa78-4059-bb89-7b443c688d2a" xlink:to="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent_0bcbe3e1-2841-4882-9864-b1764b6d58b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d234bebe-75ee-4c28-97ac-166a6c4177fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent_c27cd19d-0095-4ca0-9649-cab83e65bf38" xlink:href="mrsn-20201231.xsd#mrsn_DebtInstrumentCarryingAmountNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_d234bebe-75ee-4c28-97ac-166a6c4177fe" xlink:to="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent_c27cd19d-0095-4ca0-9649-cab83e65bf38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_93c0346f-519d-4eab-be65-658af1ab4644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_d234bebe-75ee-4c28-97ac-166a6c4177fe" xlink:to="loc_us-gaap_LongTermDebtCurrent_93c0346f-519d-4eab-be65-658af1ab4644" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtFuturepaymentsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#DebtFuturepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/DebtFuturepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4519e569-6b7c-46f4-90ba-bc00e6c11b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d711d527-769a-4e28-a82a-c4f9e612e73c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_4519e569-6b7c-46f4-90ba-bc00e6c11b02" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d711d527-769a-4e28-a82a-c4f9e612e73c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0ad5b8bd-ea9c-4f9c-9213-291221a654b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_4519e569-6b7c-46f4-90ba-bc00e6c11b02" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0ad5b8bd-ea9c-4f9c-9213-291221a654b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4bc61a49-c53f-466e-a792-208d54a850df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_4519e569-6b7c-46f4-90ba-bc00e6c11b02" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4bc61a49-c53f-466e-a792-208d54a850df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5a838de2-d61c-4a62-9dd8-7c6e35ad189b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_4519e569-6b7c-46f4-90ba-bc00e6c11b02" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5a838de2-d61c-4a62-9dd8-7c6e35ad189b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockholdersEquityWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityExchangeWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityCommonstockDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityCommonstockDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockholdersEquityCommonstockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptions" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptions"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockOptions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsTables"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockOptionsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsPlansNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsPlansNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockOptionsPlansNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsInducementNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsInducementNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockOptionsInducementNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsActivityUnderStockOptionPlanDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsRestrictedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsFairValueAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsEmployeeStockPurchasePlanDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/Leases" xlink:type="simple" xlink:href="mrsn-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesDescriptionDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesDescriptionDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/LeasesDescriptionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeaseCost_d31ef85b-13ed-4c89-9f5e-364f6f681068" xlink:href="mrsn-20201231.xsd#mrsn_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_e913232d-1af1-4474-b21c-1e71b9a71e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrsn_FinanceLeaseCost_d31ef85b-13ed-4c89-9f5e-364f6f681068" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_e913232d-1af1-4474-b21c-1e71b9a71e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ef7ec621-3c91-4e34-8fb4-c26f06291e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrsn_FinanceLeaseCost_d31ef85b-13ed-4c89-9f5e-364f6f681068" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ef7ec621-3c91-4e34-8fb4-c26f06291e71" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesSupplementalbalancesheetinformationDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesSupplementalcashflowinformationDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesFutureminimumleasepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_97473d9e-3d9b-4dde-94b2-528eaf174d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_7f390393-5ad1-45a9-9001-511a5e36ec48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_97473d9e-3d9b-4dde-94b2-528eaf174d80" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_7f390393-5ad1-45a9-9001-511a5e36ec48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_df193ed0-788d-48f6-a0d5-454e347775c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_97473d9e-3d9b-4dde-94b2-528eaf174d80" xlink:to="loc_us-gaap_FinanceLeaseLiability_df193ed0-788d-48f6-a0d5-454e347775c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ab682a0-4c0b-423e-9f77-b8a69bd30023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2f9e0096-52aa-4af4-8698-cbfdb7190bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ab682a0-4c0b-423e-9f77-b8a69bd30023" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2f9e0096-52aa-4af4-8698-cbfdb7190bdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_77a950a2-cd00-4c0a-971f-4b942fd09ef9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ab682a0-4c0b-423e-9f77-b8a69bd30023" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_77a950a2-cd00-4c0a-971f-4b942fd09ef9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e2a8c280-2ecd-4350-847f-c5534e397f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ab682a0-4c0b-423e-9f77-b8a69bd30023" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e2a8c280-2ecd-4350-847f-c5534e397f9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0bdb8c5c-72f4-42df-8c2b-d851a7ed8a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ab682a0-4c0b-423e-9f77-b8a69bd30023" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0bdb8c5c-72f4-42df-8c2b-d851a7ed8a56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6e75f9e2-ca79-4890-92ff-110fa2e2ca14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7ab682a0-4c0b-423e-9f77-b8a69bd30023" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6e75f9e2-ca79-4890-92ff-110fa2e2ca14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesFutureminimumleasepaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5d3f9ef1-6837-4814-8f41-8260179d69e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_943540cd-1cde-4a8b-a7cb-296a262985f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5d3f9ef1-6837-4814-8f41-8260179d69e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_943540cd-1cde-4a8b-a7cb-296a262985f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3a8785bf-2f2c-48f7-b032-c2cb2d7b868f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5d3f9ef1-6837-4814-8f41-8260179d69e3" xlink:to="loc_us-gaap_OperatingLeaseLiability_3a8785bf-2f2c-48f7-b032-c2cb2d7b868f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_203e48b0-cad6-47d8-83a4-a36677197a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_9bebbaaa-2dcd-4288-99a6-f7379e133c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_203e48b0-cad6-47d8-83a4-a36677197a27" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_9bebbaaa-2dcd-4288-99a6-f7379e133c24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_02416a20-8a3f-4b0c-95be-e2a44a1e4172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_203e48b0-cad6-47d8-83a4-a36677197a27" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_02416a20-8a3f-4b0c-95be-e2a44a1e4172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0ad1f4ee-985d-4aec-880f-1bfe39e8a457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_203e48b0-cad6-47d8-83a4-a36677197a27" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0ad1f4ee-985d-4aec-880f-1bfe39e8a457" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2f0b3e7e-80ff-4bbf-84ca-ee649ce863f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_203e48b0-cad6-47d8-83a4-a36677197a27" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2f0b3e7e-80ff-4bbf-84ca-ee649ce863f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_f12a10b1-7614-453f-9649-1323017d3588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_203e48b0-cad6-47d8-83a4-a36677197a27" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_f12a10b1-7614-453f-9649-1323017d3588" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesReconciliationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/IncomeTaxesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_12d128e0-3535-4ed0-a71c-6756733e3905" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1e4b91d5-634f-4260-a41c-cd5369d27461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_12d128e0-3535-4ed0-a71c-6756733e3905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1e4b91d5-634f-4260-a41c-cd5369d27461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cce72339-9271-4066-ac90-a8bc5dba25bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_12d128e0-3535-4ed0-a71c-6756733e3905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cce72339-9271-4066-ac90-a8bc5dba25bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1820775b-e8d2-4cce-9a55-fec8d6ecc5f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_12d128e0-3535-4ed0-a71c-6756733e3905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1820775b-e8d2-4cce-9a55-fec8d6ecc5f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_67cfff23-edee-4a8f-9dc5-80d8e6bb6359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_12d128e0-3535-4ed0-a71c-6756733e3905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_67cfff23-edee-4a8f-9dc5-80d8e6bb6359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9aca5e97-0f1f-47e7-b2cc-57ba3c2963cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_12d128e0-3535-4ed0-a71c-6756733e3905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9aca5e97-0f1f-47e7-b2cc-57ba3c2963cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_ccc0f5eb-2308-4a5a-b3bc-eee6b2e2a304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_12d128e0-3535-4ed0-a71c-6756733e3905" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_ccc0f5eb-2308-4a5a-b3bc-eee6b2e2a304" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesComponentsofdeferredtaxassetsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ab35e9bb-1206-41f8-a0d0-8826180ae053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f8b9bfc6-1d09-42a4-9415-779f55ef5e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_ab35e9bb-1206-41f8-a0d0-8826180ae053" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f8b9bfc6-1d09-42a4-9415-779f55ef5e18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_61288f01-1bcf-45a0-95cf-3c37ac9059a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_ab35e9bb-1206-41f8-a0d0-8826180ae053" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_61288f01-1bcf-45a0-95cf-3c37ac9059a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_51bb75c4-ebbc-4cc7-93c8-04f9347e0f77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7855ef7b-1ddd-4c5d-8ded-443d715cb202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_51bb75c4-ebbc-4cc7-93c8-04f9347e0f77" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7855ef7b-1ddd-4c5d-8ded-443d715cb202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_578501c7-afac-40be-9916-33d8e9216817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_51bb75c4-ebbc-4cc7-93c8-04f9347e0f77" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_578501c7-afac-40be-9916-33d8e9216817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e31bc1f3-22fc-444d-b444-6f2eced0c760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1ccbe4a2-6fcd-4ca3-a805-03de99138a06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e31bc1f3-22fc-444d-b444-6f2eced0c760" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1ccbe4a2-6fcd-4ca3-a805-03de99138a06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e90e116b-861e-4b4d-ab75-ab486f3c9de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e31bc1f3-22fc-444d-b444-6f2eced0c760" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e90e116b-861e-4b4d-ab75-ab486f3c9de9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_218379a7-bd48-442e-a660-9a1b3cc827fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e31bc1f3-22fc-444d-b444-6f2eced0c760" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_218379a7-bd48-442e-a660-9a1b3cc827fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsLicensedTechnology_84aca762-105b-4f62-a042-ef73aa6cca90" xlink:href="mrsn-20201231.xsd#mrsn_DeferredTaxAssetsLicensedTechnology"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e31bc1f3-22fc-444d-b444-6f2eced0c760" xlink:to="loc_mrsn_DeferredTaxAssetsLicensedTechnology_84aca762-105b-4f62-a042-ef73aa6cca90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_6b0cba68-6570-4786-91c6-6b952484f94f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e31bc1f3-22fc-444d-b444-6f2eced0c760" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_6b0cba68-6570-4786-91c6-6b952484f94f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsLeaseLiabilities_9ff583cc-bcae-4778-9eb5-6ca4c72a104a" xlink:href="mrsn-20201231.xsd#mrsn_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e31bc1f3-22fc-444d-b444-6f2eced0c760" xlink:to="loc_mrsn_DeferredTaxAssetsLeaseLiabilities_9ff583cc-bcae-4778-9eb5-6ca4c72a104a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsDepreciation_12e9f9ec-2f04-420a-b48a-a30c69564415" xlink:href="mrsn-20201231.xsd#mrsn_DeferredTaxAssetsDepreciation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e31bc1f3-22fc-444d-b444-6f2eced0c760" xlink:to="loc_mrsn_DeferredTaxAssetsDepreciation_12e9f9ec-2f04-420a-b48a-a30c69564415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_84e14fa4-420d-4fdb-bbd8-e2b1b390ae52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e31bc1f3-22fc-444d-b444-6f2eced0c760" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_84e14fa4-420d-4fdb-bbd8-e2b1b390ae52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_134302e3-48f4-4920-be5c-3d48675418a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1c5c68e9-6b02-4aaf-83b2-5b2c06c8ee70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_134302e3-48f4-4920-be5c-3d48675418a4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1c5c68e9-6b02-4aaf-83b2-5b2c06c8ee70" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesNetoperatinglosscarryforwardsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesTaxcreditcarryforwardDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesValuationallowanceDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mrsn-20201231.xsd#EmployeeBenefitPlan"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/EmployeeBenefitPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#EmployeeBenefitPlanDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/EmployeeBenefitPlanDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/Commitments" xlink:type="simple" xlink:href="mrsn-20201231.xsd#Commitments"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/Commitments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CommitmentsLicenseagreementsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CommitmentsLicenseagreementsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/CommitmentsLicenseagreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SelectedQuarterlyFinancialDataUnaudited"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mrsn-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2da7fb72-9c95-4f34-a8ba-21eaa0b59775,g:bc62363b-ba21-41ff-8e10-87a9df40b55e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.mersana.com/role/Cover" xlink:type="simple" xlink:href="mrsn-20201231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/Cover" xlink:type="extended" id="i292c058592d4418d97e4e997db56624d_Cover"/>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i1ad89f29c0be42e9846496315758539f_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ie437bd2c0989433faac217ea63501f4b_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="ibd6a24122ae448b1a58a388187f0c11e_ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i00c2f6cbcd2c429bb6dbb40210039aa6_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1ad4bbec-3fed-456f-b42d-b8094367a85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1ad4bbec-3fed-456f-b42d-b8094367a85d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7ed39717-99cd-4712-b128-40bf115e1adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_SharesOutstanding_7ed39717-99cd-4712-b128-40bf115e1adb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_99b43405-04d0-4e07-9cce-7835aaba0eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockholdersEquity_99b43405-04d0-4e07-9cce-7835aaba0eeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_37b006ec-98c5-4172-983a-ee629ebcbeac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_37b006ec-98c5-4172-983a-ee629ebcbeac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1bd1c81e-9a1e-4997-bce5-db90447a165b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1bd1c81e-9a1e-4997-bce5-db90447a165b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c4ffb9bf-f641-4bd2-abdf-19a710fde761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c4ffb9bf-f641-4bd2-abdf-19a710fde761" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_d55a432c-cb22-4fde-9fe6-d35eb90f45ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_d55a432c-cb22-4fde-9fe6-d35eb90f45ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_adf9b331-569f-4b28-89eb-b6eb224cecb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_adf9b331-569f-4b28-89eb-b6eb224cecb5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_591b499c-429b-4d9a-b381-0c2d70c74330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_591b499c-429b-4d9a-b381-0c2d70c74330" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4adde04b-451b-4713-9984-a91a7dac56fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4adde04b-451b-4713-9984-a91a7dac56fc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_a4e92e75-db97-4f53-bf13-621582a998b1" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_a4e92e75-db97-4f53-bf13-621582a998b1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_a307a1d0-2b2d-4672-9681-9a2eb305cd87" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_a307a1d0-2b2d-4672-9681-9a2eb305cd87" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_45b37879-b12f-4d6b-8863-0cb1aff3d705" xlink:href="mrsn-20201231.xsd#mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_45b37879-b12f-4d6b-8863-0cb1aff3d705" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_e2e79980-aa00-44ce-adbe-243aef32f2ac" xlink:href="mrsn-20201231.xsd#mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_e2e79980-aa00-44ce-adbe-243aef32f2ac" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_026e4464-8715-4e6f-a1f3-9495696fc39f" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_026e4464-8715-4e6f-a1f3-9495696fc39f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3fae1406-0ef2-4890-bc89-c4991f6c5de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3fae1406-0ef2-4890-bc89-c4991f6c5de1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6e238a4f-57a5-444d-8401-f54606febe72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6e238a4f-57a5-444d-8401-f54606febe72" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_80703997-88c4-4500-b371-c6827e4957a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_NetIncomeLoss_80703997-88c4-4500-b371-c6827e4957a1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f43effbd-f120-49ea-b919-b0b54d170d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_53a144d3-4dca-4a2a-84be-6f46cb04b7c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_1cd3cc78-75e7-434f-9947-0eb08f561c9f" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_1cd3cc78-75e7-434f-9947-0eb08f561c9f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_143d7ec5-e61b-489b-8f4b-8394c6693b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1ad4bbec-3fed-456f-b42d-b8094367a85d" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_143d7ec5-e61b-489b-8f4b-8394c6693b82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cc943287-3743-4f96-b4ef-37a9781ad680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1ad4bbec-3fed-456f-b42d-b8094367a85d" xlink:to="loc_us-gaap_StatementTable_cc943287-3743-4f96-b4ef-37a9781ad680" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a5cbfd3-50bf-4c6a-8999-4df91d440be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cc943287-3743-4f96-b4ef-37a9781ad680" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a5cbfd3-50bf-4c6a-8999-4df91d440be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a5cbfd3-50bf-4c6a-8999-4df91d440be0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a5cbfd3-50bf-4c6a-8999-4df91d440be0" xlink:to="loc_us-gaap_EquityComponentDomain_6a5cbfd3-50bf-4c6a-8999-4df91d440be0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56943108-cc68-49bc-99a5-61ae4fd10b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a5cbfd3-50bf-4c6a-8999-4df91d440be0" xlink:to="loc_us-gaap_EquityComponentDomain_56943108-cc68-49bc-99a5-61ae4fd10b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0566ceb4-b86c-47f9-b14c-f606422acae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56943108-cc68-49bc-99a5-61ae4fd10b46" xlink:to="loc_us-gaap_CommonStockMember_0566ceb4-b86c-47f9-b14c-f606422acae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5b4affe6-6d10-4c0a-aac8-88cb18ce99b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56943108-cc68-49bc-99a5-61ae4fd10b46" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5b4affe6-6d10-4c0a-aac8-88cb18ce99b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_248ab8e4-4700-455c-8573-bb6d9b3d7367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56943108-cc68-49bc-99a5-61ae4fd10b46" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_248ab8e4-4700-455c-8573-bb6d9b3d7367" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ea25b38d-68b3-4c1f-a08b-5dddb3ba812c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56943108-cc68-49bc-99a5-61ae4fd10b46" xlink:to="loc_us-gaap_RetainedEarningsMember_ea25b38d-68b3-4c1f-a08b-5dddb3ba812c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f851f967-654c-433b-90c7-d85e25632402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cc943287-3743-4f96-b4ef-37a9781ad680" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f851f967-654c-433b-90c7-d85e25632402" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f851f967-654c-433b-90c7-d85e25632402_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f851f967-654c-433b-90c7-d85e25632402" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f851f967-654c-433b-90c7-d85e25632402_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4126ab83-b40e-46b9-8925-bc5c4683f7ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f851f967-654c-433b-90c7-d85e25632402" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4126ab83-b40e-46b9-8925-bc5c4683f7ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_45c222a7-bbdb-49e2-8091-86539332d5c9" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4126ab83-b40e-46b9-8925-bc5c4683f7ff" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_45c222a7-bbdb-49e2-8091-86539332d5c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_3bc39e41-fc33-4579-9bbe-0b6ad75ec6d9" xlink:href="mrsn-20201231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4126ab83-b40e-46b9-8925-bc5c4683f7ff" xlink:to="loc_mrsn_PublicStockOfferingMember_3bc39e41-fc33-4579-9bbe-0b6ad75ec6d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7a742a9-b5dc-4dad-ac01-dcd8c91383d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cc943287-3743-4f96-b4ef-37a9781ad680" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7a742a9-b5dc-4dad-ac01-dcd8c91383d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c7a742a9-b5dc-4dad-ac01-dcd8c91383d7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7a742a9-b5dc-4dad-ac01-dcd8c91383d7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c7a742a9-b5dc-4dad-ac01-dcd8c91383d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_92741f29-ebdc-40f2-a34b-612740be4412" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7a742a9-b5dc-4dad-ac01-dcd8c91383d7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_92741f29-ebdc-40f2-a34b-612740be4412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_968fccf9-b393-46fa-a91e-585ec4e8f7e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_92741f29-ebdc-40f2-a34b-612740be4412" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_968fccf9-b393-46fa-a91e-585ec4e8f7e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="i10a013ccf64e4fafb8ebd4bbdce2c8d8_ConsolidatedStatementsofStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e5ebe0bc-c4e4-4de9-80e9-6ec2ea9515d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_37d694a8-dc05-43ef-8eea-10bc97d617eb" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e5ebe0bc-c4e4-4de9-80e9-6ec2ea9515d7" xlink:to="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_37d694a8-dc05-43ef-8eea-10bc97d617eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_abd1d164-7abd-4b32-b502-a2c182645c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e5ebe0bc-c4e4-4de9-80e9-6ec2ea9515d7" xlink:to="loc_us-gaap_StatementTable_abd1d164-7abd-4b32-b502-a2c182645c08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_16426e29-cfaa-4ec5-aa9d-fb32fcf49183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_abd1d164-7abd-4b32-b502-a2c182645c08" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_16426e29-cfaa-4ec5-aa9d-fb32fcf49183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16426e29-cfaa-4ec5-aa9d-fb32fcf49183_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16426e29-cfaa-4ec5-aa9d-fb32fcf49183" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16426e29-cfaa-4ec5-aa9d-fb32fcf49183_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_52648d6e-422c-4a46-934d-17ddb87dc6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16426e29-cfaa-4ec5-aa9d-fb32fcf49183" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_52648d6e-422c-4a46-934d-17ddb87dc6b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_0a867401-cf3a-4634-8555-cb2c5f9318c9" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_52648d6e-422c-4a46-934d-17ddb87dc6b9" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_0a867401-cf3a-4634-8555-cb2c5f9318c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_85fec31d-6fea-4496-bd52-85d8024a801f" xlink:href="mrsn-20201231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_52648d6e-422c-4a46-934d-17ddb87dc6b9" xlink:to="loc_mrsn_PublicStockOfferingMember_85fec31d-6fea-4496-bd52-85d8024a801f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i78f0eb936072418f868c8c7da7fb813e_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8a71a6dc-cc7a-4cb2-8f6a-7e3ae152b032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8a71a6dc-cc7a-4cb2-8f6a-7e3ae152b032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1c7d94eb-1552-4297-a25a-ea751900ef52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8a71a6dc-cc7a-4cb2-8f6a-7e3ae152b032" xlink:to="loc_us-gaap_ProfitLoss_1c7d94eb-1552-4297-a25a-ea751900ef52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8a71a6dc-cc7a-4cb2-8f6a-7e3ae152b032" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1aec49b7-a417-4c80-beb4-6ca0dbd3749b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1aec49b7-a417-4c80-beb4-6ca0dbd3749b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0f0168d6-95a7-4c39-89a4-0fcd7c48cde0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0f0168d6-95a7-4c39-89a4-0fcd7c48cde0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_023fc69d-6e2a-4446-ba5c-d9b43d3d2dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_023fc69d-6e2a-4446-ba5c-d9b43d3d2dce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0d604d02-b569-424d-b26a-ed7cba20c84d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_ShareBasedCompensation_0d604d02-b569-424d-b26a-ed7cba20c84d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ChangeInDeferredRent_b0b2e8a7-52c3-4917-bd3b-0d170d967ee0" xlink:href="mrsn-20201231.xsd#mrsn_ChangeInDeferredRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_mrsn_ChangeInDeferredRent_b0b2e8a7-52c3-4917-bd3b-0d170d967ee0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_281b0135-52be-4c98-add8-b6ad8d250258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_281b0135-52be-4c98-add8-b6ad8d250258" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a819c7f6-0eb4-4ddc-b31f-7e49ead7b8df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a819c7f6-0eb4-4ddc-b31f-7e49ead7b8df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ade355ab-a6bd-48c1-8b86-f5bac83f9891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ade355ab-a6bd-48c1-8b86-f5bac83f9891" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_791583b4-d4cc-422b-9c5a-c81e9722929a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_791583b4-d4cc-422b-9c5a-c81e9722929a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8a055e61-f7cb-4ea0-8e00-4b629ecb93d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8a055e61-f7cb-4ea0-8e00-4b629ecb93d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e3218fe9-c83d-4d24-a6f6-9ce5d5e2eaaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e3218fe9-c83d-4d24-a6f6-9ce5d5e2eaaf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets_57708536-0737-4e30-9f34-e00592b89cad" xlink:href="mrsn-20201231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets_57708536-0737-4e30-9f34-e00592b89cad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_c81c3934-cc71-4ca1-86bd-2e397b1ab95b" xlink:href="mrsn-20201231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_c81c3934-cc71-4ca1-86bd-2e397b1ab95b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bfbbfc9f-0936-4af1-b196-cb0f56a2bef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bfbbfc9f-0936-4af1-b196-cb0f56a2bef7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c089fe3-cfea-463d-b26b-dda8d265148c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c089fe3-cfea-463d-b26b-dda8d265148c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869cc459-ebf0-4df8-ba47-5905c766da88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869cc459-ebf0-4df8-ba47-5905c766da88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d6fe13c9-9b81-46ae-bf3d-5701b178dbde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869cc459-ebf0-4df8-ba47-5905c766da88" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d6fe13c9-9b81-46ae-bf3d-5701b178dbde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_808a6e8c-e3f4-4f83-a3b7-44a83d97da90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869cc459-ebf0-4df8-ba47-5905c766da88" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_808a6e8c-e3f4-4f83-a3b7-44a83d97da90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dca49033-9a7a-4971-a8cc-e854071b500c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869cc459-ebf0-4df8-ba47-5905c766da88" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dca49033-9a7a-4971-a8cc-e854071b500c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e28a2426-b508-41f6-bacd-3ddfdf37e391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869cc459-ebf0-4df8-ba47-5905c766da88" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e28a2426-b508-41f6-bacd-3ddfdf37e391" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7e9cff16-28d0-457f-ae6c-64305ff56f08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7e9cff16-28d0-457f-ae6c-64305ff56f08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6b828f0a-ba70-4ef3-9f7c-446ca2588703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6b828f0a-ba70-4ef3-9f7c-446ca2588703" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_35cc7743-5eb4-40f0-9c69-dd5a4232f4ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_35cc7743-5eb4-40f0-9c69-dd5a4232f4ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromDebtNetIssuanceCosts_d0c68223-61f8-4bfd-88ce-8fabbf639d9a" xlink:href="mrsn-20201231.xsd#mrsn_ProceedsFromDebtNetIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:to="loc_mrsn_ProceedsFromDebtNetIssuanceCosts_d0c68223-61f8-4bfd-88ce-8fabbf639d9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f97531fe-f946-48b4-a0ac-a4181d44b45f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f97531fe-f946-48b4-a0ac-a4181d44b45f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99d7a712-9a2a-4d38-8c5e-ba775ff4c70a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99d7a712-9a2a-4d38-8c5e-ba775ff4c70a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ee060b78-a4fd-41af-af30-60f517b62889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ee060b78-a4fd-41af-af30-60f517b62889" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1fb9aa1e-b08e-42b1-a3b9-11adbdaf86d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1fb9aa1e-b08e-42b1-a3b9-11adbdaf86d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1c7ef963-ffba-4ccb-8ceb-a5e1580b72db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_6d862dd9-d6ff-4cb5-b68e-21c017b2c0ca" xlink:href="mrsn-20201231.xsd#mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_6d862dd9-d6ff-4cb5-b68e-21c017b2c0ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_776ee780-df82-4c55-9cae-f18c2c7ea01b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_776ee780-df82-4c55-9cae-f18c2c7ea01b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_42da3455-8625-4f0a-9e0b-5080b0657ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_42da3455-8625-4f0a-9e0b-5080b0657ef7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_8202fdee-57ee-4052-81fc-922fde6ac169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_us-gaap_InterestPaidNet_8202fdee-57ee-4052-81fc-922fde6ac169" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_08d9ef93-a5b3-4580-88f7-18460277d7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_08d9ef93-a5b3-4580-88f7-18460277d7b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_1d9513c4-683d-4de6-a062-3db803e9b7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_1d9513c4-683d-4de6-a062-3db803e9b7b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard_beddd81c-9d9b-4354-a36c-967efa299921" xlink:href="mrsn-20201231.xsd#mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard_beddd81c-9d9b-4354-a36c-967efa299921" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1ce38ff1-d80f-4ca2-b8bc-69b4f2cfdb2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_StatementTable_1ce38ff1-d80f-4ca2-b8bc-69b4f2cfdb2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cdbf410e-0216-4726-a2ec-b131abf423a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1ce38ff1-d80f-4ca2-b8bc-69b4f2cfdb2a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cdbf410e-0216-4726-a2ec-b131abf423a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cdbf410e-0216-4726-a2ec-b131abf423a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cdbf410e-0216-4726-a2ec-b131abf423a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cdbf410e-0216-4726-a2ec-b131abf423a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bb39b48-2744-4a89-868f-3a64d65c6f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cdbf410e-0216-4726-a2ec-b131abf423a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bb39b48-2744-4a89-868f-3a64d65c6f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_8db712da-d9ff-4a68-a6df-1c5dd3c42b9e" xlink:href="mrsn-20201231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bb39b48-2744-4a89-868f-3a64d65c6f55" xlink:to="loc_mrsn_PublicStockOfferingMember_8db712da-d9ff-4a68-a6df-1c5dd3c42b9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_daa8f394-f31b-48a6-a1fd-58e902a09830" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bb39b48-2744-4a89-868f-3a64d65c6f55" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_daa8f394-f31b-48a6-a1fd-58e902a09830" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="mrsn-20201231.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended" id="ibb51a5df75f641f2940f23995dbf2c0d_NatureofBusinessandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended" id="ic03b6052a0604c64bcb41b03be771aad_NatureofBusinessandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d1ed68a0-5bfd-47f8-aaec-c775ab7d654a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb589f71-7aec-4b6d-8de2-1a9ae9c056a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d1ed68a0-5bfd-47f8-aaec-c775ab7d654a" xlink:to="loc_us-gaap_NetIncomeLoss_eb589f71-7aec-4b6d-8de2-1a9ae9c056a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c95bbe5d-1faa-40c4-8ba1-9a1efdeaf249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d1ed68a0-5bfd-47f8-aaec-c775ab7d654a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c95bbe5d-1faa-40c4-8ba1-9a1efdeaf249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_73415da5-0501-4d15-bacf-583380d10a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d1ed68a0-5bfd-47f8-aaec-c775ab7d654a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_73415da5-0501-4d15-bacf-583380d10a59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_875e62cc-14e7-4e0d-a05b-6c33f91bbcb9" xlink:href="mrsn-20201231.xsd#mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d1ed68a0-5bfd-47f8-aaec-c775ab7d654a" xlink:to="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_875e62cc-14e7-4e0d-a05b-6c33f91bbcb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_8334d530-1980-4bc2-82f4-37a334036f74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d1ed68a0-5bfd-47f8-aaec-c775ab7d654a" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_8334d530-1980-4bc2-82f4-37a334036f74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b8f31cb4-904a-4867-a665-f6aa58578f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_8334d530-1980-4bc2-82f4-37a334036f74" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b8f31cb4-904a-4867-a665-f6aa58578f7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b8f31cb4-904a-4867-a665-f6aa58578f7e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b8f31cb4-904a-4867-a665-f6aa58578f7e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b8f31cb4-904a-4867-a665-f6aa58578f7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86580de5-5b62-4f28-a61f-85f101d1e735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b8f31cb4-904a-4867-a665-f6aa58578f7e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86580de5-5b62-4f28-a61f-85f101d1e735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_98ab34c5-f89a-4f15-b531-d52be22fe8dc" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86580de5-5b62-4f28-a61f-85f101d1e735" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_98ab34c5-f89a-4f15-b531-d52be22fe8dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_e54043db-fca5-44bf-9051-2f3923fd5a74" xlink:href="mrsn-20201231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86580de5-5b62-4f28-a61f-85f101d1e735" xlink:to="loc_mrsn_PublicStockOfferingMember_e54043db-fca5-44bf-9051-2f3923fd5a74" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="icbc57aadabcc45eb96af82471c9d3b44_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i54e1d2a2bbd04150a07cf8b93a34ca5a_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="ia0b61e68a1e248119e65c094aa316521_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails" xlink:type="extended" id="i38e0e04a108d4368bcbc8042a8912ae8_SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1152528a-d18b-419c-84f6-e6a31b3a551d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueCollectionPeriod_241d6561-b94d-48b4-b948-9f7d846ddcf8" xlink:href="mrsn-20201231.xsd#mrsn_RevenueCollectionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1152528a-d18b-419c-84f6-e6a31b3a551d" xlink:to="loc_mrsn_RevenueCollectionPeriod_241d6561-b94d-48b4-b948-9f7d846ddcf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3497a23b-ca14-455b-9c93-1ab58487e9b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1152528a-d18b-419c-84f6-e6a31b3a551d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3497a23b-ca14-455b-9c93-1ab58487e9b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a5800a8e-e24e-4339-9f65-01c1440e06ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1152528a-d18b-419c-84f6-e6a31b3a551d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a5800a8e-e24e-4339-9f65-01c1440e06ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_06cab2b9-9749-4f25-85f6-44400d7a408b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1152528a-d18b-419c-84f6-e6a31b3a551d" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_06cab2b9-9749-4f25-85f6-44400d7a408b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_56af90fc-a414-452f-a518-f603b853a80d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_06cab2b9-9749-4f25-85f6-44400d7a408b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_56af90fc-a414-452f-a518-f603b853a80d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_56af90fc-a414-452f-a518-f603b853a80d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_56af90fc-a414-452f-a518-f603b853a80d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_56af90fc-a414-452f-a518-f603b853a80d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_514cb4e2-cc29-4910-bad3-4f69b8cd8773" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_56af90fc-a414-452f-a518-f603b853a80d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_514cb4e2-cc29-4910-bad3-4f69b8cd8773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_18632c2d-b096-499c-a0d7-65269800a43b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_514cb4e2-cc29-4910-bad3-4f69b8cd8773" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_18632c2d-b096-499c-a0d7-65269800a43b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails" xlink:type="extended" id="iea50a124a3b2418c9e6f3a12a94c984e_SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesOtherAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails" xlink:type="extended" id="ieb5aab4f7fb54457bb2b410819296ada_SummaryofsignificantaccountingpoliciesOtherAssetsDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended" id="i5286358991f24b118d16be25789567c4_SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesNetlosspershareDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails" xlink:type="extended" id="i2eeb30b90d52437b9db4eaa64c4eab43_SummaryofsignificantaccountingpoliciesNetlosspershareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b927d7d-d8e7-4858-b4f3-70c6c842eca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_500e8d48-5f9a-4aa3-bd83-579179a86371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b927d7d-d8e7-4858-b4f3-70c6c842eca2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_500e8d48-5f9a-4aa3-bd83-579179a86371" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_bc4f4374-a6f7-4681-8a83-443b8f3545aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_500e8d48-5f9a-4aa3-bd83-579179a86371" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_bc4f4374-a6f7-4681-8a83-443b8f3545aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_476be8c1-e2bb-4b1f-b333-68777ba9a15b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b927d7d-d8e7-4858-b4f3-70c6c842eca2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_476be8c1-e2bb-4b1f-b333-68777ba9a15b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f15cc5f-0951-4745-9976-00a549c8f18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b927d7d-d8e7-4858-b4f3-70c6c842eca2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f15cc5f-0951-4745-9976-00a549c8f18b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f585cdae-17aa-483f-abf7-508b7bcd5a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f15cc5f-0951-4745-9976-00a549c8f18b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f585cdae-17aa-483f-abf7-508b7bcd5a35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f585cdae-17aa-483f-abf7-508b7bcd5a35_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f585cdae-17aa-483f-abf7-508b7bcd5a35" xlink:to="loc_us-gaap_EquityComponentDomain_f585cdae-17aa-483f-abf7-508b7bcd5a35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_195a85ba-d1fe-4d27-bdfa-c0a2f6626922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f585cdae-17aa-483f-abf7-508b7bcd5a35" xlink:to="loc_us-gaap_EquityComponentDomain_195a85ba-d1fe-4d27-bdfa-c0a2f6626922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExchangeWarrantsMember_0db0fd8a-408a-4f04-a714-14b24a047af8" xlink:href="mrsn-20201231.xsd#mrsn_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_195a85ba-d1fe-4d27-bdfa-c0a2f6626922" xlink:to="loc_mrsn_ExchangeWarrantsMember_0db0fd8a-408a-4f04-a714-14b24a047af8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2135c80c-efb2-4653-8a44-1f9b558b31f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f15cc5f-0951-4745-9976-00a549c8f18b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2135c80c-efb2-4653-8a44-1f9b558b31f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2135c80c-efb2-4653-8a44-1f9b558b31f8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2135c80c-efb2-4653-8a44-1f9b558b31f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2135c80c-efb2-4653-8a44-1f9b558b31f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a161ada8-4d7e-46a7-a84e-bbedcdd5f4ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2135c80c-efb2-4653-8a44-1f9b558b31f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a161ada8-4d7e-46a7-a84e-bbedcdd5f4ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d8cffe6b-8680-4306-a4bd-451c906d1456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a161ada8-4d7e-46a7-a84e-bbedcdd5f4ee" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d8cffe6b-8680-4306-a4bd-451c906d1456" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_19e9716c-749f-43ed-9c46-7cb99bb7f16c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a161ada8-4d7e-46a7-a84e-bbedcdd5f4ee" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_19e9716c-749f-43ed-9c46-7cb99bb7f16c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_07d8fea2-0abb-46ce-8e1f-ed4726319945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a161ada8-4d7e-46a7-a84e-bbedcdd5f4ee" xlink:to="loc_us-gaap_WarrantMember_07d8fea2-0abb-46ce-8e1f-ed4726319945" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended" id="i926e43f2aa1d481a9edc0afaa9b76de6_SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e99bd8e-2a74-4a83-beea-bea91cca3c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c7b39575-c968-42db-9afd-08a75d057972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e99bd8e-2a74-4a83-beea-bea91cca3c15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c7b39575-c968-42db-9afd-08a75d057972" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_2a86a81c-90f8-49b6-8ada-97bf99d3eac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e99bd8e-2a74-4a83-beea-bea91cca3c15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_2a86a81c-90f8-49b6-8ada-97bf99d3eac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_efb6f281-3fbd-4879-ad22-c1be528b93bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e99bd8e-2a74-4a83-beea-bea91cca3c15" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_efb6f281-3fbd-4879-ad22-c1be528b93bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_54904b65-8430-4b1d-9f93-3e4d43445921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_efb6f281-3fbd-4879-ad22-c1be528b93bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_54904b65-8430-4b1d-9f93-3e4d43445921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_54904b65-8430-4b1d-9f93-3e4d43445921_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_54904b65-8430-4b1d-9f93-3e4d43445921" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_54904b65-8430-4b1d-9f93-3e4d43445921_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fcf7c04f-f6d0-461d-987e-aa800a5841f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_54904b65-8430-4b1d-9f93-3e4d43445921" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fcf7c04f-f6d0-461d-987e-aa800a5841f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember_e41b2ae3-307b-4b62-b431-32538c1973cf" xlink:href="mrsn-20201231.xsd#mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fcf7c04f-f6d0-461d-987e-aa800a5841f3" xlink:to="loc_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember_e41b2ae3-307b-4b62-b431-32538c1973cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentMember_469f4075-cb6f-42fb-a22e-c6358ec62d25" xlink:href="mrsn-20201231.xsd#mrsn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fcf7c04f-f6d0-461d-987e-aa800a5841f3" xlink:to="loc_mrsn_LaboratoryEquipmentMember_469f4075-cb6f-42fb-a22e-c6358ec62d25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d5d0a40c-a344-44dd-9470-9fe4f07e8826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fcf7c04f-f6d0-461d-987e-aa800a5841f3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d5d0a40c-a344-44dd-9470-9fe4f07e8826" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRisksDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesRisksDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRisksDetails" xlink:type="extended" id="i31083bd506ad426a812876896c7978cd_SummaryofsignificantaccountingpoliciesRisksDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails" xlink:type="extended" id="i80fe26c92e6948e88e3222071f9354ce_SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d9c1754a-00ca-459b-ad08-4a04b65fa9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_efb39ea4-d509-42c2-92f1-16559d7858a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d9c1754a-00ca-459b-ad08-4a04b65fa9b7" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_efb39ea4-d509-42c2-92f1-16559d7858a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e12ccf5-519b-4f49-9415-0bbe65e15e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d9c1754a-00ca-459b-ad08-4a04b65fa9b7" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e12ccf5-519b-4f49-9415-0bbe65e15e9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f0a7dc86-6570-41ae-85d9-cd93b607468e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e12ccf5-519b-4f49-9415-0bbe65e15e9e" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f0a7dc86-6570-41ae-85d9-cd93b607468e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_f0a7dc86-6570-41ae-85d9-cd93b607468e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f0a7dc86-6570-41ae-85d9-cd93b607468e" xlink:to="loc_us-gaap_TypeOfAdoptionMember_f0a7dc86-6570-41ae-85d9-cd93b607468e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1dc6b308-00fe-4e95-9af9-4f41e6b4d843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f0a7dc86-6570-41ae-85d9-cd93b607468e" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1dc6b308-00fe-4e95-9af9-4f41e6b4d843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201818Member_703b38ac-ed29-4a6f-b04c-9299286e676d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1dc6b308-00fe-4e95-9af9-4f41e6b4d843" xlink:to="loc_us-gaap_AccountingStandardsUpdate201818Member_703b38ac-ed29-4a6f-b04c-9299286e676d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_8e6f4627-7a77-495e-9efd-16d9047c47c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1dc6b308-00fe-4e95-9af9-4f41e6b4d843" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_8e6f4627-7a77-495e-9efd-16d9047c47c6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreements"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CollaborationAgreements" xlink:type="extended" id="i1823141a7da241d3894d02f15ef57c9e_CollaborationAgreements"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsTables"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTables" xlink:type="extended" id="i1361bcf690a749faa1b9de337938537c_CollaborationAgreementsTables"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsMerckKGaADetail"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail" xlink:type="extended" id="i3556c3f9598a4174ba364032cba76a2d_CollaborationAgreementsMerckKGaADetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsUpfrontPayment_86541135-a3c2-472e-b138-96f58eb0ad48" xlink:href="mrsn-20201231.xsd#mrsn_CollaborativeArrangementsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborativeArrangementsUpfrontPayment_86541135-a3c2-472e-b138-96f58eb0ad48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_d9b157df-040c-4633-a768-d8b1759b3c22" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_d9b157df-040c-4633-a768-d8b1759b3c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_c409dcad-ba16-4e27-a8bf-9b1fb6888f0f" xlink:href="mrsn-20201231.xsd#mrsn_CollaborativeArrangementsExclusiveTargetsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_c409dcad-ba16-4e27-a8bf-9b1fb6888f0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_74072102-eab3-403f-b744-2c37600b3686" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_74072102-eab3-403f-b744-2c37600b3686" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_01c8f910-71f7-46ad-af98-865ccd7902b0" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsMaximumAggregateMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_01c8f910-71f7-46ad-af98-865ccd7902b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_d663bc92-385a-4f68-a5cd-118bd9109e68" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_d663bc92-385a-4f68-a5cd-118bd9109e68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_de05b8a8-0d72-4691-9c53-164e963967c2" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_de05b8a8-0d72-4691-9c53-164e963967c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSalesMilestones_0cefb589-bf9a-415d-9d92-64ff2cdde59f" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsSalesMilestones_0cefb589-bf9a-415d-9d92-64ff2cdde59f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_75e1bda1-108a-4208-9515-5eeb4ad6a227" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_75e1bda1-108a-4208-9515-5eeb4ad6a227" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_7c44e617-bf4f-45c7-97cf-04d0ffd6182a" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_7c44e617-bf4f-45c7-97cf-04d0ffd6182a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_966f038e-984b-43fd-80ff-b96897856ff5" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_966f038e-984b-43fd-80ff-b96897856ff5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_ef4b73d3-d28c-4989-9b33-439120837727" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_ef4b73d3-d28c-4989-9b33-439120837727" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_f6db066d-afd5-4071-b62e-febcf49a2ca7" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_f6db066d-afd5-4071-b62e-febcf49a2ca7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_b9055f49-064e-4417-ae1e-69205a92cbf0" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_b9055f49-064e-4417-ae1e-69205a92cbf0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7fc5ce4-4914-424a-a45b-fbad1e1ef672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7fc5ce4-4914-424a-a45b-fbad1e1ef672" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_38f6b56c-5f8c-478a-9e5c-cc123c09268c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7fc5ce4-4914-424a-a45b-fbad1e1ef672" xlink:to="loc_us-gaap_TypeOfArrangementAxis_38f6b56c-5f8c-478a-9e5c-cc123c09268c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38f6b56c-5f8c-478a-9e5c-cc123c09268c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_38f6b56c-5f8c-478a-9e5c-cc123c09268c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_38f6b56c-5f8c-478a-9e5c-cc123c09268c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5189f532-851c-4fb8-b418-0d224225b89f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_38f6b56c-5f8c-478a-9e5c-cc123c09268c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5189f532-851c-4fb8-b418-0d224225b89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_ebc8e0f8-2f30-4d98-9594-2b2f774a27b7" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5189f532-851c-4fb8-b418-0d224225b89f" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_ebc8e0f8-2f30-4d98-9594-2b2f774a27b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails" xlink:type="extended" id="ie064256365ad4ce6867a067037a789a3_CollaborationAgreementsMerckKGaAAccountingAnalysisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_c4aa532b-b241-4cc2-ab9d-8a652a289bad" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_c4aa532b-b241-4cc2-ab9d-8a652a289bad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_6f73eee4-99d7-4704-813a-4b4f8fc11e60" xlink:href="mrsn-20201231.xsd#mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_6f73eee4-99d7-4704-813a-4b4f8fc11e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueTransactionPriceAmount_1dbde409-89a3-4232-9be2-61a14a07624f" xlink:href="mrsn-20201231.xsd#mrsn_RevenueTransactionPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_RevenueTransactionPriceAmount_1dbde409-89a3-4232-9be2-61a14a07624f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_5d9bc5e8-58a5-4287-b0ed-bd0a1170f2fe" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_5d9bc5e8-58a5-4287-b0ed-bd0a1170f2fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated_760c1f3f-e92c-4d0f-a1d5-109184785fc9" xlink:href="mrsn-20201231.xsd#mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated_760c1f3f-e92c-4d0f-a1d5-109184785fc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueTransactionPriceIncreaseDecrease_f681276e-5b1a-4b42-afe3-0eafe2badce0" xlink:href="mrsn-20201231.xsd#mrsn_RevenueTransactionPriceIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_RevenueTransactionPriceIncreaseDecrease_f681276e-5b1a-4b42-afe3-0eafe2badce0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bada9fe1-1793-4712-befe-8215e15fd347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bada9fe1-1793-4712-befe-8215e15fd347" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0b79410c-2844-491f-a2e6-25b0115290d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0b79410c-2844-491f-a2e6-25b0115290d2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_b6e740d8-c7cb-4c41-b804-66fb771de508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_AccountsReceivableNet_b6e740d8-c7cb-4c41-b804-66fb771de508" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_669d52c8-433b-454f-836f-9d34b7cbc80a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_ContractWithCustomerLiability_669d52c8-433b-454f-836f-9d34b7cbc80a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b426f4b3-fe3b-46a4-9211-a7d254639c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b426f4b3-fe3b-46a4-9211-a7d254639c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_85867946-3b20-4b45-be65-a4de05848452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:to="loc_us-gaap_TypeOfArrangementAxis_85867946-3b20-4b45-be65-a4de05848452" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85867946-3b20-4b45-be65-a4de05848452_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_85867946-3b20-4b45-be65-a4de05848452" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85867946-3b20-4b45-be65-a4de05848452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_050d728d-e0ac-4190-8378-1d3635d273be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_85867946-3b20-4b45-be65-a4de05848452" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_050d728d-e0ac-4190-8378-1d3635d273be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_29b2d40f-11bb-4720-8e26-0eb000598ba5" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_050d728d-e0ac-4190-8378-1d3635d273be" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_29b2d40f-11bb-4720-8e26-0eb000598ba5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_89af59e4-8ac3-44a4-a798-c9402db7e2bd" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_29b2d40f-11bb-4720-8e26-0eb000598ba5" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_89af59e4-8ac3-44a4-a798-c9402db7e2bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SupplyAgreementMerckKgaaMember_ef03cd09-ed62-4ac2-8831-c8b073f94e12" xlink:href="mrsn-20201231.xsd#mrsn_SupplyAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_29b2d40f-11bb-4720-8e26-0eb000598ba5" xlink:to="loc_mrsn_SupplyAgreementMerckKgaaMember_ef03cd09-ed62-4ac2-8831-c8b073f94e12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5a3fcfde-4606-4f30-96e2-acae353af210" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:to="loc_srt_ProductOrServiceAxis_5a3fcfde-4606-4f30-96e2-acae353af210" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a3fcfde-4606-4f30-96e2-acae353af210_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5a3fcfde-4606-4f30-96e2-acae353af210" xlink:to="loc_srt_ProductsAndServicesDomain_5a3fcfde-4606-4f30-96e2-acae353af210_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5a3fcfde-4606-4f30-96e2-acae353af210" xlink:to="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_b8f83cf6-1730-4995-a255-fce614dad50d" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_b8f83cf6-1730-4995-a255-fce614dad50d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_db66a824-06c7-40df-ac10-b17a426d6246" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_db66a824-06c7-40df-ac10-b17a426d6246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_343a18c5-690d-4079-a176-9b94d4a171e6" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_343a18c5-690d-4079-a176-9b94d4a171e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_bbc99fdd-8de3-4b4e-9ae8-ae685acf6483" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_bbc99fdd-8de3-4b4e-9ae8-ae685acf6483" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RightsToFutureTechnologicalImprovementsMember_f861c75c-565a-489f-b90c-9878fbd19029" xlink:href="mrsn-20201231.xsd#mrsn_RightsToFutureTechnologicalImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_RightsToFutureTechnologicalImprovementsMember_f861c75c-565a-489f-b90c-9878fbd19029" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_JointResearchCommitteeServicesMember_bcbbf643-18a2-4852-ab16-e504e3881fae" xlink:href="mrsn-20201231.xsd#mrsn_JointResearchCommitteeServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_JointResearchCommitteeServicesMember_bcbbf643-18a2-4852-ab16-e504e3881fae" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails_1" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsMerckKGaAAccountingAnalysisDetails_1"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails_1" xlink:type="extended" id="i598d84297bc447d692a7e520958f0150_CollaborationAgreementsMerckKGaAAccountingAnalysisDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_c4aa532b-b241-4cc2-ab9d-8a652a289bad" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_c4aa532b-b241-4cc2-ab9d-8a652a289bad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_6f73eee4-99d7-4704-813a-4b4f8fc11e60" xlink:href="mrsn-20201231.xsd#mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_6f73eee4-99d7-4704-813a-4b4f8fc11e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueTransactionPriceAmount_1dbde409-89a3-4232-9be2-61a14a07624f" xlink:href="mrsn-20201231.xsd#mrsn_RevenueTransactionPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_RevenueTransactionPriceAmount_1dbde409-89a3-4232-9be2-61a14a07624f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_5d9bc5e8-58a5-4287-b0ed-bd0a1170f2fe" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_5d9bc5e8-58a5-4287-b0ed-bd0a1170f2fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated_760c1f3f-e92c-4d0f-a1d5-109184785fc9" xlink:href="mrsn-20201231.xsd#mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated_760c1f3f-e92c-4d0f-a1d5-109184785fc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueTransactionPriceIncreaseDecrease_f681276e-5b1a-4b42-afe3-0eafe2badce0" xlink:href="mrsn-20201231.xsd#mrsn_RevenueTransactionPriceIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_RevenueTransactionPriceIncreaseDecrease_f681276e-5b1a-4b42-afe3-0eafe2badce0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bada9fe1-1793-4712-befe-8215e15fd347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bada9fe1-1793-4712-befe-8215e15fd347" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0b79410c-2844-491f-a2e6-25b0115290d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0b79410c-2844-491f-a2e6-25b0115290d2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_b6e740d8-c7cb-4c41-b804-66fb771de508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_AccountsReceivableNet_b6e740d8-c7cb-4c41-b804-66fb771de508" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_669d52c8-433b-454f-836f-9d34b7cbc80a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_ContractWithCustomerLiability_669d52c8-433b-454f-836f-9d34b7cbc80a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_85867946-3b20-4b45-be65-a4de05848452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:to="loc_us-gaap_TypeOfArrangementAxis_85867946-3b20-4b45-be65-a4de05848452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85867946-3b20-4b45-be65-a4de05848452_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_85867946-3b20-4b45-be65-a4de05848452" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85867946-3b20-4b45-be65-a4de05848452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_050d728d-e0ac-4190-8378-1d3635d273be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_85867946-3b20-4b45-be65-a4de05848452" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_050d728d-e0ac-4190-8378-1d3635d273be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_29b2d40f-11bb-4720-8e26-0eb000598ba5" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_050d728d-e0ac-4190-8378-1d3635d273be" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_29b2d40f-11bb-4720-8e26-0eb000598ba5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_89af59e4-8ac3-44a4-a798-c9402db7e2bd" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_29b2d40f-11bb-4720-8e26-0eb000598ba5" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_89af59e4-8ac3-44a4-a798-c9402db7e2bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SupplyAgreementMerckKgaaMember_ef03cd09-ed62-4ac2-8831-c8b073f94e12" xlink:href="mrsn-20201231.xsd#mrsn_SupplyAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_29b2d40f-11bb-4720-8e26-0eb000598ba5" xlink:to="loc_mrsn_SupplyAgreementMerckKgaaMember_ef03cd09-ed62-4ac2-8831-c8b073f94e12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5a3fcfde-4606-4f30-96e2-acae353af210" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:to="loc_srt_ProductOrServiceAxis_5a3fcfde-4606-4f30-96e2-acae353af210" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a3fcfde-4606-4f30-96e2-acae353af210_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5a3fcfde-4606-4f30-96e2-acae353af210" xlink:to="loc_srt_ProductsAndServicesDomain_5a3fcfde-4606-4f30-96e2-acae353af210_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5a3fcfde-4606-4f30-96e2-acae353af210" xlink:to="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_b8f83cf6-1730-4995-a255-fce614dad50d" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_b8f83cf6-1730-4995-a255-fce614dad50d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_db66a824-06c7-40df-ac10-b17a426d6246" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_db66a824-06c7-40df-ac10-b17a426d6246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_343a18c5-690d-4079-a176-9b94d4a171e6" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_343a18c5-690d-4079-a176-9b94d4a171e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_bbc99fdd-8de3-4b4e-9ae8-ae685acf6483" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_bbc99fdd-8de3-4b4e-9ae8-ae685acf6483" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RightsToFutureTechnologicalImprovementsMember_f861c75c-565a-489f-b90c-9878fbd19029" xlink:href="mrsn-20201231.xsd#mrsn_RightsToFutureTechnologicalImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_RightsToFutureTechnologicalImprovementsMember_f861c75c-565a-489f-b90c-9878fbd19029" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_JointResearchCommitteeServicesMember_bcbbf643-18a2-4852-ab16-e504e3881fae" xlink:href="mrsn-20201231.xsd#mrsn_JointResearchCommitteeServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_JointResearchCommitteeServicesMember_bcbbf643-18a2-4852-ab16-e504e3881fae" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails" xlink:type="extended" id="ib43168d04a7c43279f5acf63fad10753_CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0bd3123-c0ab-4754-9d87-da4aeaf9a3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDurationToTermination_737fd822-92e2-474b-bc42-aae47a0e8e65" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDurationToTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0bd3123-c0ab-4754-9d87-da4aeaf9a3cf" xlink:to="loc_mrsn_CollaborationArrangementsDurationToTermination_737fd822-92e2-474b-bc42-aae47a0e8e65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_a8c168d9-d45d-412d-8b45-a87468404892" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0bd3123-c0ab-4754-9d87-da4aeaf9a3cf" xlink:to="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_a8c168d9-d45d-412d-8b45-a87468404892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95c219d7-1f0e-498f-8b1b-df4e4328dc97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0bd3123-c0ab-4754-9d87-da4aeaf9a3cf" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95c219d7-1f0e-498f-8b1b-df4e4328dc97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_746a18af-50f1-4a24-9d63-77e6fd74aa18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95c219d7-1f0e-498f-8b1b-df4e4328dc97" xlink:to="loc_us-gaap_TypeOfArrangementAxis_746a18af-50f1-4a24-9d63-77e6fd74aa18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_746a18af-50f1-4a24-9d63-77e6fd74aa18_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_746a18af-50f1-4a24-9d63-77e6fd74aa18" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_746a18af-50f1-4a24-9d63-77e6fd74aa18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_056e0bb5-4d7d-4a52-985c-83e3d2756c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_746a18af-50f1-4a24-9d63-77e6fd74aa18" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_056e0bb5-4d7d-4a52-985c-83e3d2756c6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_00eec4a9-e6c2-4431-a379-f8c95a2d1620" xlink:href="mrsn-20201231.xsd#mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_056e0bb5-4d7d-4a52-985c-83e3d2756c6b" xlink:to="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_00eec4a9-e6c2-4431-a379-f8c95a2d1620" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsTakedastrategicRDpartnershipDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails" xlink:type="extended" id="ica70caf9f59d40e5a542e9444c3aed28_CollaborationAgreementsTakedastrategicRDpartnershipDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2832d39d-e3f9-4a75-a7fc-083b041a2c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_c94032f4-5437-4af9-8894-53828f02b838" xlink:href="mrsn-20201231.xsd#mrsn_CollaborativeArrangementsExclusiveTargetsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2832d39d-e3f9-4a75-a7fc-083b041a2c0c" xlink:to="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_c94032f4-5437-4af9-8894-53828f02b838" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDurationToTermination_68517c3a-4ead-4e6e-b716-14ab58d2db1a" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDurationToTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2832d39d-e3f9-4a75-a7fc-083b041a2c0c" xlink:to="loc_mrsn_CollaborationArrangementsDurationToTermination_68517c3a-4ead-4e6e-b716-14ab58d2db1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_027de6ae-f159-4919-8401-bd47aa7281be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2832d39d-e3f9-4a75-a7fc-083b041a2c0c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_027de6ae-f159-4919-8401-bd47aa7281be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bc5c9f1f-df1f-40c4-b5e2-7d3c695b79c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_027de6ae-f159-4919-8401-bd47aa7281be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bc5c9f1f-df1f-40c4-b5e2-7d3c695b79c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bc5c9f1f-df1f-40c4-b5e2-7d3c695b79c5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bc5c9f1f-df1f-40c4-b5e2-7d3c695b79c5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bc5c9f1f-df1f-40c4-b5e2-7d3c695b79c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb577006-bd48-4446-a3cf-56bd76826a18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bc5c9f1f-df1f-40c4-b5e2-7d3c695b79c5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb577006-bd48-4446-a3cf-56bd76826a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_d840cdc9-18a9-4a74-843d-445a51dbe44a" xlink:href="mrsn-20201231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb577006-bd48-4446-a3cf-56bd76826a18" xlink:to="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_d840cdc9-18a9-4a74-843d-445a51dbe44a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsTakedaAccountingAnalysisDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails" xlink:type="extended" id="i87fadd5be8e14aefadc26b955a871295_CollaborationAgreementsTakedaAccountingAnalysisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c22b6324-ba34-4f58-9113-db673dfb8423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c22b6324-ba34-4f58-9113-db673dfb8423" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueRemainingPerformanceObligationNumber_ec4d8c77-178f-4f32-88f6-5c43e348ed5a" xlink:href="mrsn-20201231.xsd#mrsn_RevenueRemainingPerformanceObligationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:to="loc_mrsn_RevenueRemainingPerformanceObligationNumber_ec4d8c77-178f-4f32-88f6-5c43e348ed5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4078e6af-03f2-49b6-8e32-70a5d54a19c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4078e6af-03f2-49b6-8e32-70a5d54a19c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9965dd05-5d89-48b8-972f-f9582a666976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9965dd05-5d89-48b8-972f-f9582a666976" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsCostsBilled_d6b14e92-d2af-479d-96c3-24b028450d26" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsCostsBilled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:to="loc_mrsn_CollaborationArrangementsCostsBilled_d6b14e92-d2af-479d-96c3-24b028450d26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_17c2477f-ee17-4779-b594-abf5c403a0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_17c2477f-ee17-4779-b594-abf5c403a0fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a05c124a-368a-47fa-9826-7408a24099e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_17c2477f-ee17-4779-b594-abf5c403a0fb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a05c124a-368a-47fa-9826-7408a24099e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a05c124a-368a-47fa-9826-7408a24099e0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a05c124a-368a-47fa-9826-7408a24099e0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a05c124a-368a-47fa-9826-7408a24099e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73f896a6-2936-45e3-b6ee-15135e325940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a05c124a-368a-47fa-9826-7408a24099e0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73f896a6-2936-45e3-b6ee-15135e325940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_ce27a9d9-9314-4daa-b2ce-74d1d9fef5f5" xlink:href="mrsn-20201231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73f896a6-2936-45e3-b6ee-15135e325940" xlink:to="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_ce27a9d9-9314-4daa-b2ce-74d1d9fef5f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_5989d1da-b590-4f50-8e88-e64d7c5ceb11" xlink:href="mrsn-20201231.xsd#mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73f896a6-2936-45e3-b6ee-15135e325940" xlink:to="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_5989d1da-b590-4f50-8e88-e64d7c5ceb11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a546fa99-521f-4c05-99b2-b5b0b97efe83" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_17c2477f-ee17-4779-b594-abf5c403a0fb" xlink:to="loc_srt_ProductOrServiceAxis_a546fa99-521f-4c05-99b2-b5b0b97efe83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a546fa99-521f-4c05-99b2-b5b0b97efe83_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a546fa99-521f-4c05-99b2-b5b0b97efe83" xlink:to="loc_srt_ProductsAndServicesDomain_a546fa99-521f-4c05-99b2-b5b0b97efe83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e15b318-69c4-45d2-9c53-9fe8b796a85a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a546fa99-521f-4c05-99b2-b5b0b97efe83" xlink:to="loc_srt_ProductsAndServicesDomain_9e15b318-69c4-45d2-9c53-9fe8b796a85a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_e820c5b2-5af5-4e31-a518-aa94c4ba36c9" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e15b318-69c4-45d2-9c53-9fe8b796a85a" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_e820c5b2-5af5-4e31-a518-aa94c4ba36c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsContractAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails" xlink:type="extended" id="i49ba0e80689145e5afa47b457e946e10_CollaborationAgreementsContractAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsOtherRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails" xlink:type="extended" id="ibfc8b48a3b0c478487af58fe4844ccd6_CollaborationAgreementsOtherRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c90ef024-ddcc-419b-9056-37984898d0af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_673a7780-4f28-47bf-9f32-920c96a0dc79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c90ef024-ddcc-419b-9056-37984898d0af" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_673a7780-4f28-47bf-9f32-920c96a0dc79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_9c0464ac-9ceb-4b2b-b7e5-efd7f462d9ac" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c90ef024-ddcc-419b-9056-37984898d0af" xlink:to="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_9c0464ac-9ceb-4b2b-b7e5-efd7f462d9ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7c99c30-b887-466c-ad22-dcddceee2c64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c90ef024-ddcc-419b-9056-37984898d0af" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7c99c30-b887-466c-ad22-dcddceee2c64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fc8116ba-3ca8-433b-9fa9-0e6ff4073691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7c99c30-b887-466c-ad22-dcddceee2c64" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fc8116ba-3ca8-433b-9fa9-0e6ff4073691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc8116ba-3ca8-433b-9fa9-0e6ff4073691_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc8116ba-3ca8-433b-9fa9-0e6ff4073691" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fc8116ba-3ca8-433b-9fa9-0e6ff4073691_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c1ecfa2e-fb80-4be5-b047-753bbd82d4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc8116ba-3ca8-433b-9fa9-0e6ff4073691" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c1ecfa2e-fb80-4be5-b047-753bbd82d4b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_e3b18546-78a8-41d2-a55f-b9feea9d6710" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c1ecfa2e-fb80-4be5-b047-753bbd82d4b3" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_e3b18546-78a8-41d2-a55f-b9feea9d6710" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dd029b6a-0f97-4b81-b5a3-13c670f55893" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7c99c30-b887-466c-ad22-dcddceee2c64" xlink:to="loc_srt_ProductOrServiceAxis_dd029b6a-0f97-4b81-b5a3-13c670f55893" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dd029b6a-0f97-4b81-b5a3-13c670f55893_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dd029b6a-0f97-4b81-b5a3-13c670f55893" xlink:to="loc_srt_ProductsAndServicesDomain_dd029b6a-0f97-4b81-b5a3-13c670f55893_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a2aff60d-68a7-4e73-afd6-f5df5d1f4a16" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dd029b6a-0f97-4b81-b5a3-13c670f55893" xlink:to="loc_srt_ProductsAndServicesDomain_a2aff60d-68a7-4e73-afd6-f5df5d1f4a16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LimitedServicesMember_77bde099-bd05-490d-8dcb-3c1677a4f3d8" xlink:href="mrsn-20201231.xsd#mrsn_LimitedServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a2aff60d-68a7-4e73-afd6-f5df5d1f4a16" xlink:to="loc_mrsn_LimitedServicesMember_77bde099-bd05-490d-8dcb-3c1677a4f3d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ServiceMilestoneMember_a54f8ad4-b5bb-4cdb-beb2-d79373e1058a" xlink:href="mrsn-20201231.xsd#mrsn_ServiceMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a2aff60d-68a7-4e73-afd6-f5df5d1f4a16" xlink:to="loc_mrsn_ServiceMilestoneMember_a54f8ad4-b5bb-4cdb-beb2-d79373e1058a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="mrsn-20201231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/FairValueMeasurements" xlink:type="extended" id="i7cbc84e12fb74d32a72d2c9064b80dea_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.mersana.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i62b40128e611409d984dc943bfba0421_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.mersana.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ibad7422637f14da0ad61d7db41be757f_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c1027950-2372-455b-9628-17b4b1188e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_246e37ed-f29b-492e-8438-b96cad6d3e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c1027950-2372-455b-9628-17b4b1188e59" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_246e37ed-f29b-492e-8438-b96cad6d3e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_df71e624-8a2a-4276-9419-f0b372647a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c1027950-2372-455b-9628-17b4b1188e59" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_df71e624-8a2a-4276-9419-f0b372647a8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c879c6a8-a9ae-4e10-8976-86cb1fdfc2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c1027950-2372-455b-9628-17b4b1188e59" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c879c6a8-a9ae-4e10-8976-86cb1fdfc2f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db3e419d-4d05-469d-a30b-e216715bf90f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c879c6a8-a9ae-4e10-8976-86cb1fdfc2f5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db3e419d-4d05-469d-a30b-e216715bf90f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_db3e419d-4d05-469d-a30b-e216715bf90f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db3e419d-4d05-469d-a30b-e216715bf90f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_db3e419d-4d05-469d-a30b-e216715bf90f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_872a1ea3-426d-4c93-a37e-5ac570c6bf1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db3e419d-4d05-469d-a30b-e216715bf90f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_872a1ea3-426d-4c93-a37e-5ac570c6bf1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_20784418-74e3-45fa-9aee-d7fa0ce36092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_872a1ea3-426d-4c93-a37e-5ac570c6bf1a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_20784418-74e3-45fa-9aee-d7fa0ce36092" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a51cdea-18a0-45b7-bf6d-18ac1389df70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c879c6a8-a9ae-4e10-8976-86cb1fdfc2f5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a51cdea-18a0-45b7-bf6d-18ac1389df70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a51cdea-18a0-45b7-bf6d-18ac1389df70_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a51cdea-18a0-45b7-bf6d-18ac1389df70" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a51cdea-18a0-45b7-bf6d-18ac1389df70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c9eebb-4b4b-488a-9dfe-7808f7a0a2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a51cdea-18a0-45b7-bf6d-18ac1389df70" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c9eebb-4b4b-488a-9dfe-7808f7a0a2be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_902e17ec-1d25-49f6-8fcf-cd2c951d28c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c9eebb-4b4b-488a-9dfe-7808f7a0a2be" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_902e17ec-1d25-49f6-8fcf-cd2c951d28c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_79aa2221-3a85-40d9-aa59-8fad84e39d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c9eebb-4b4b-488a-9dfe-7808f7a0a2be" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_79aa2221-3a85-40d9-aa59-8fad84e39d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a6bf54e2-3232-4971-ac21-f954d059be4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c9eebb-4b4b-488a-9dfe-7808f7a0a2be" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a6bf54e2-3232-4971-ac21-f954d059be4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8403a4d4-4fcd-4b08-a907-b228dc393fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c879c6a8-a9ae-4e10-8976-86cb1fdfc2f5" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_8403a4d4-4fcd-4b08-a907-b228dc393fbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8403a4d4-4fcd-4b08-a907-b228dc393fbf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8403a4d4-4fcd-4b08-a907-b228dc393fbf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8403a4d4-4fcd-4b08-a907-b228dc393fbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0683d5aa-d228-43e9-b7e8-c5fd571f7f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8403a4d4-4fcd-4b08-a907-b228dc393fbf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0683d5aa-d228-43e9-b7e8-c5fd571f7f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_3ffe52a8-f094-4f0f-9610-01bf4c880981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0683d5aa-d228-43e9-b7e8-c5fd571f7f5a" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_3ffe52a8-f094-4f0f-9610-01bf4c880981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_faf8e0b1-427f-4f4c-95ed-9957b8f70f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0683d5aa-d228-43e9-b7e8-c5fd571f7f5a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_faf8e0b1-427f-4f4c-95ed-9957b8f70f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c630380e-5183-454b-b053-e396315ce198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0683d5aa-d228-43e9-b7e8-c5fd571f7f5a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c630380e-5183-454b-b053-e396315ce198" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mrsn-20201231.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/MarketableSecurities" xlink:type="extended" id="i3a193a3532e94e228c6ce613d094e70f_MarketableSecurities"/>
  <link:roleRef roleURI="http://www.mersana.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/MarketableSecuritiesTables" xlink:type="extended" id="i66e1217d45e14f3dbd47da486e73aa53_MarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.mersana.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="if545f895ef0447cab815fc7a643d79c4_MarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1552985-ee7d-42ba-a4bd-ccf0b9db0d17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_32d8da3c-19ab-434a-aea8-1c5fa0e2007b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1552985-ee7d-42ba-a4bd-ccf0b9db0d17" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_32d8da3c-19ab-434a-aea8-1c5fa0e2007b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9009907a-f90f-4cfd-b445-892e1fe9f605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1552985-ee7d-42ba-a4bd-ccf0b9db0d17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9009907a-f90f-4cfd-b445-892e1fe9f605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5d12a8fa-dc0c-4e9a-9a25-d397aef39bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9009907a-f90f-4cfd-b445-892e1fe9f605" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5d12a8fa-dc0c-4e9a-9a25-d397aef39bb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ea43a35f-57e1-46a0-9f98-ac15fc09f4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9009907a-f90f-4cfd-b445-892e1fe9f605" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ea43a35f-57e1-46a0-9f98-ac15fc09f4c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c2e09d34-c8f9-4290-a940-a125bf8fabb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9009907a-f90f-4cfd-b445-892e1fe9f605" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c2e09d34-c8f9-4290-a940-a125bf8fabb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c62b039d-f04e-4294-bc20-bbbb1d2c519a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9009907a-f90f-4cfd-b445-892e1fe9f605" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c62b039d-f04e-4294-bc20-bbbb1d2c519a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bdbedf90-16f2-44a5-a81f-1abed8528596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1552985-ee7d-42ba-a4bd-ccf0b9db0d17" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bdbedf90-16f2-44a5-a81f-1abed8528596" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_cd7d12ca-58c8-4f68-8751-d4ad07d2c14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bdbedf90-16f2-44a5-a81f-1abed8528596" xlink:to="loc_us-gaap_FinancialInstrumentAxis_cd7d12ca-58c8-4f68-8751-d4ad07d2c14d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd7d12ca-58c8-4f68-8751-d4ad07d2c14d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_cd7d12ca-58c8-4f68-8751-d4ad07d2c14d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cd7d12ca-58c8-4f68-8751-d4ad07d2c14d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97dbda75-01bb-4e9d-8285-92d1a2a0d237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_cd7d12ca-58c8-4f68-8751-d4ad07d2c14d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97dbda75-01bb-4e9d-8285-92d1a2a0d237" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_f110fbac-1340-460c-9232-2b8a3d66df3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97dbda75-01bb-4e9d-8285-92d1a2a0d237" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_f110fbac-1340-460c-9232-2b8a3d66df3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c17bbee3-5980-4a4a-8d50-d71fe2ae21ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97dbda75-01bb-4e9d-8285-92d1a2a0d237" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c17bbee3-5980-4a4a-8d50-d71fe2ae21ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_81f542a0-95fb-497a-8023-7008b0e34da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97dbda75-01bb-4e9d-8285-92d1a2a0d237" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_81f542a0-95fb-497a-8023-7008b0e34da4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="mrsn-20201231.xsd#PropertyandEquipment"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/PropertyandEquipment" xlink:type="extended" id="ib308cff3526a44debe2e3d5783fab3e2_PropertyandEquipment"/>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#PropertyandEquipmentTables"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/PropertyandEquipmentTables" xlink:type="extended" id="i5dffd1a5cef449fbbad62988a5b27850_PropertyandEquipmentTables"/>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="i977aaa039b804a5fa2bb8439fc55292b_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_56cea2dc-0652-4218-b9eb-907569c80158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_56cea2dc-0652-4218-b9eb-907569c80158" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_70df3d53-9ecc-416a-b9ee-22cfb8322a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_70df3d53-9ecc-416a-b9ee-22cfb8322a2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_bb022617-554b-443f-a0e4-faf15d856dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_bb022617-554b-443f-a0e4-faf15d856dc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3dec144c-a603-4c59-a622-ef16e9f61315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3dec144c-a603-4c59-a622-ef16e9f61315" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0ffca154-df76-454f-946b-2d5095c16ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:to="loc_us-gaap_Depreciation_0ffca154-df76-454f-946b-2d5095c16ec7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943aaefb-1ac7-443a-aa9e-2c7333281000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943aaefb-1ac7-443a-aa9e-2c7333281000" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0177c445-f984-4e1b-bf6e-dd40f849f815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943aaefb-1ac7-443a-aa9e-2c7333281000" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0177c445-f984-4e1b-bf6e-dd40f849f815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0177c445-f984-4e1b-bf6e-dd40f849f815_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0177c445-f984-4e1b-bf6e-dd40f849f815" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0177c445-f984-4e1b-bf6e-dd40f849f815_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04edb278-51c2-4470-8d2e-8d027a08674c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0177c445-f984-4e1b-bf6e-dd40f849f815" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04edb278-51c2-4470-8d2e-8d027a08674c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentMember_af3b9eb0-a0d8-4471-84ca-d724958263e7" xlink:href="mrsn-20201231.xsd#mrsn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04edb278-51c2-4470-8d2e-8d027a08674c" xlink:to="loc_mrsn_LaboratoryEquipmentMember_af3b9eb0-a0d8-4471-84ca-d724958263e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8a4d1bea-e6c0-420d-bcbe-918be69aeece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04edb278-51c2-4470-8d2e-8d027a08674c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8a4d1bea-e6c0-420d-bcbe-918be69aeece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember_cb163b43-8dc3-424c-98a1-bb1e4ea1c4f2" xlink:href="mrsn-20201231.xsd#mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04edb278-51c2-4470-8d2e-8d027a08674c" xlink:to="loc_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember_cb163b43-8dc3-424c-98a1-bb1e4ea1c4f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentLeasedAssetMember_a2dcfa72-18c8-43d0-8128-554dc7beb3c2" xlink:href="mrsn-20201231.xsd#mrsn_LaboratoryEquipmentLeasedAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04edb278-51c2-4470-8d2e-8d027a08674c" xlink:to="loc_mrsn_LaboratoryEquipmentLeasedAssetMember_a2dcfa72-18c8-43d0-8128-554dc7beb3c2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedExpenses" xlink:type="simple" xlink:href="mrsn-20201231.xsd#AccruedExpenses"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/AccruedExpenses" xlink:type="extended" id="ifac0ef30cfc14480978625aa6544aae9_AccruedExpenses"/>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedexpensesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#AccruedexpensesTables"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/AccruedexpensesTables" xlink:type="extended" id="ibcbe04da39e648628b0fae3164e8ba73_AccruedexpensesTables"/>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#AccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/AccruedExpensesDetails" xlink:type="extended" id="i701a2cee03b14dea9877f724607bc6b0_AccruedExpensesDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/Debt" xlink:type="simple" xlink:href="mrsn-20201231.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/Debt" xlink:type="extended" id="i541dea99622f4fb2bc681817cf2f33ab_Debt"/>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#DebtTables"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/DebtTables" xlink:type="extended" id="i87f76f9629144bdd8ad87d31451b8814_DebtTables"/>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/DebtNarrativeDetails" xlink:type="extended" id="iea84d2eeaee14514a480a8268d99fd9d_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_0c1ff9f8-d409-4caf-8985-72a1c22360e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_0c1ff9f8-d409-4caf-8985-72a1c22360e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f6b2179-fc41-41b7-9d03-01edfac5e897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f6b2179-fc41-41b7-9d03-01edfac5e897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_17701832-df10-46d5-b95c-964f2e50a897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_17701832-df10-46d5-b95c-964f2e50a897" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5ffb3167-6ef1-4fdd-9daf-db56d5db1c05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5ffb3167-6ef1-4fdd-9daf-db56d5db1c05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit_4bd9be75-3e34-4451-9478-858956ebe0c2" xlink:href="mrsn-20201231.xsd#mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit_4bd9be75-3e34-4451-9478-858956ebe0c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_643b26ac-0abc-4d03-8471-2396bc1ab19d" xlink:href="mrsn-20201231.xsd#mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_643b26ac-0abc-4d03-8471-2396bc1ab19d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentPrepaymentFeePercent_75967a1d-2b21-4e27-b02a-a1762de05cf0" xlink:href="mrsn-20201231.xsd#mrsn_DebtInstrumentPrepaymentFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_mrsn_DebtInstrumentPrepaymentFeePercent_75967a1d-2b21-4e27-b02a-a1762de05cf0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_c177d25a-fe9c-4ad7-91e5-309059ca53be" xlink:href="mrsn-20201231.xsd#mrsn_DebtInstrumentAdditionalRateInEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_c177d25a-fe9c-4ad7-91e5-309059ca53be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_cef1fdb0-f78c-4036-b6b1-de9765fc0a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_cef1fdb0-f78c-4036-b6b1-de9765fc0a7f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_8cd6f777-13bf-49ab-8585-4ca0f6bd4fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_8cd6f777-13bf-49ab-8585-4ca0f6bd4fe7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f7506af7-0e66-44df-a59a-5b2b1c943e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f7506af7-0e66-44df-a59a-5b2b1c943e9a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7b3045b3-302e-42ac-8385-285e163f1185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:to="loc_us-gaap_DebtInstrumentAxis_7b3045b3-302e-42ac-8385-285e163f1185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7b3045b3-302e-42ac-8385-285e163f1185_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7b3045b3-302e-42ac-8385-285e163f1185" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7b3045b3-302e-42ac-8385-285e163f1185_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7b3045b3-302e-42ac-8385-285e163f1185" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExistingCreditFacilityMember_c84e54d2-5349-484f-8c44-96e040737be8" xlink:href="mrsn-20201231.xsd#mrsn_ExistingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_ExistingCreditFacilityMember_c84e54d2-5349-484f-8c44-96e040737be8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityMember_354d8e63-9bd6-4280-a8a6-72667c2f0855" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityMember_354d8e63-9bd6-4280-a8a6-72667c2f0855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheOneMember_3305a53f-d07a-4119-a578-2f0a6a1bc68f" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityTrancheOneMember_3305a53f-d07a-4119-a578-2f0a6a1bc68f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheTwoMember_0419ef0d-91b2-4e09-ae19-47009e35476b" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityTrancheTwoMember_0419ef0d-91b2-4e09-ae19-47009e35476b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheThreeMember_cb11ea56-7473-45ac-a77c-b2164e06ecf3" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityTrancheThreeMember_cb11ea56-7473-45ac-a77c-b2164e06ecf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheFourMember_183eae8d-a89b-42f8-9165-49ca6d52ce72" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityTrancheFourMember_183eae8d-a89b-42f8-9165-49ca6d52ce72" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheFiveMember_327144a5-2a36-470e-9487-3fc33f5315e1" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityTrancheFiveMember_327144a5-2a36-470e-9487-3fc33f5315e1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheSixMember_de21b35b-3fde-4d50-a903-27e19579819b" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityTrancheSixMember_de21b35b-3fde-4d50-a903-27e19579819b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_9bd39932-e304-4552-895f-45344b71a85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:to="loc_us-gaap_VariableRateAxis_9bd39932-e304-4552-895f-45344b71a85a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_9bd39932-e304-4552-895f-45344b71a85a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_9bd39932-e304-4552-895f-45344b71a85a" xlink:to="loc_us-gaap_VariableRateDomain_9bd39932-e304-4552-895f-45344b71a85a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_168293cc-e204-4571-ae7a-158a2a724da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_9bd39932-e304-4552-895f-45344b71a85a" xlink:to="loc_us-gaap_VariableRateDomain_168293cc-e204-4571-ae7a-158a2a724da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_0083dae7-7f21-43c8-b6b5-7dcace70bb59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_168293cc-e204-4571-ae7a-158a2a724da5" xlink:to="loc_us-gaap_PrimeRateMember_0083dae7-7f21-43c8-b6b5-7dcace70bb59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_82d7f98d-33c2-4731-b2b4-571cff847285" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:to="loc_srt_RangeAxis_82d7f98d-33c2-4731-b2b4-571cff847285" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82d7f98d-33c2-4731-b2b4-571cff847285_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_82d7f98d-33c2-4731-b2b4-571cff847285" xlink:to="loc_srt_RangeMember_82d7f98d-33c2-4731-b2b4-571cff847285_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0891f58-60b1-49d1-a18b-7c8f6ca7d943" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_82d7f98d-33c2-4731-b2b4-571cff847285" xlink:to="loc_srt_RangeMember_c0891f58-60b1-49d1-a18b-7c8f6ca7d943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ffcf8a5f-a348-49aa-9154-06018f148e0d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c0891f58-60b1-49d1-a18b-7c8f6ca7d943" xlink:to="loc_srt_MinimumMember_ffcf8a5f-a348-49aa-9154-06018f148e0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5f8fbeec-ebca-4738-94e0-b67fbe870075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:to="loc_us-gaap_CreditFacilityAxis_5f8fbeec-ebca-4738-94e0-b67fbe870075" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5f8fbeec-ebca-4738-94e0-b67fbe870075_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_5f8fbeec-ebca-4738-94e0-b67fbe870075" xlink:to="loc_us-gaap_CreditFacilityDomain_5f8fbeec-ebca-4738-94e0-b67fbe870075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_59dd1f34-7c66-4106-9587-23140e4749f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_5f8fbeec-ebca-4738-94e0-b67fbe870075" xlink:to="loc_us-gaap_CreditFacilityDomain_59dd1f34-7c66-4106-9587-23140e4749f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_459f1556-53f0-4ea5-be80-6fb6fddb1170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_59dd1f34-7c66-4106-9587-23140e4749f5" xlink:to="loc_us-gaap_LineOfCreditMember_459f1556-53f0-4ea5-be80-6fb6fddb1170" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodAxis_99986596-1eae-4e1e-8c09-22ca67d471a1" xlink:href="mrsn-20201231.xsd#mrsn_DebtCovenantPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:to="loc_mrsn_DebtCovenantPeriodAxis_99986596-1eae-4e1e-8c09-22ca67d471a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodDomain_99986596-1eae-4e1e-8c09-22ca67d471a1_default" xlink:href="mrsn-20201231.xsd#mrsn_DebtCovenantPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mrsn_DebtCovenantPeriodAxis_99986596-1eae-4e1e-8c09-22ca67d471a1" xlink:to="loc_mrsn_DebtCovenantPeriodDomain_99986596-1eae-4e1e-8c09-22ca67d471a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodDomain_1e4cc801-42a8-4531-ac90-928f39929806" xlink:href="mrsn-20201231.xsd#mrsn_DebtCovenantPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mrsn_DebtCovenantPeriodAxis_99986596-1eae-4e1e-8c09-22ca67d471a1" xlink:to="loc_mrsn_DebtCovenantPeriodDomain_1e4cc801-42a8-4531-ac90-928f39929806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursPriorToAugust282021Member_6a4c1cd0-5e3d-4653-961e-6bb2e2431da6" xlink:href="mrsn-20201231.xsd#mrsn_PrepaymentOccursPriorToAugust282021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_DebtCovenantPeriodDomain_1e4cc801-42a8-4531-ac90-928f39929806" xlink:to="loc_mrsn_PrepaymentOccursPriorToAugust282021Member_6a4c1cd0-5e3d-4653-961e-6bb2e2431da6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member_4c5efa11-be94-40b1-80bf-20b67f40f219" xlink:href="mrsn-20201231.xsd#mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_DebtCovenantPeriodDomain_1e4cc801-42a8-4531-ac90-928f39929806" xlink:to="loc_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member_4c5efa11-be94-40b1-80bf-20b67f40f219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member_568eabfc-116d-4968-b774-2b5e44bc4eab" xlink:href="mrsn-20201231.xsd#mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_DebtCovenantPeriodDomain_1e4cc801-42a8-4531-ac90-928f39929806" xlink:to="loc_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member_568eabfc-116d-4968-b774-2b5e44bc4eab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtComponentsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#DebtComponentsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/DebtComponentsDetails" xlink:type="extended" id="i0a24b14051c74a719fef74d098e9e37e_DebtComponentsDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtFuturepaymentsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#DebtFuturepaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/DebtFuturepaymentsDetails" xlink:type="extended" id="ie5961942c8aa42849ba733f67b81ad49_DebtFuturepaymentsDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockholdersEquity" xlink:type="extended" id="i8b63dd576ffe4abb926fd91a49526815_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockholdersEquityTables" xlink:type="extended" id="iaa52353595ad41df9b076c886d2436b6_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended" id="i855f3f30cbe146a9b804ddfe2ac79c7c_StockholdersEquityPreferredStockDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails" xlink:type="extended" id="i9b55b5ad9b3f4e09bf6c0fdcc612074a_StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceProgramAuthorizedAmount_528b2e66-3da3-40d8-b2d6-e69fc9d76585" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuanceProgramAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_mrsn_StockIssuanceProgramAuthorizedAmount_528b2e66-3da3-40d8-b2d6-e69fc9d76585" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eb85b6e8-d33b-45a7-a845-fda8f9a240c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eb85b6e8-d33b-45a7-a845-fda8f9a240c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_ddb1edf5-501e-461b-a26c-72f4180a866d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_ddb1edf5-501e-461b-a26c-72f4180a866d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromIssuanceOfCommonStockGross_a388dc02-eb53-4af3-8b0c-8c366001b376" xlink:href="mrsn-20201231.xsd#mrsn_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_mrsn_ProceedsFromIssuanceOfCommonStockGross_a388dc02-eb53-4af3-8b0c-8c366001b376" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_fdcc73bd-8824-4596-bdf0-0e7b02e6d92f" xlink:href="mrsn-20201231.xsd#mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_fdcc73bd-8824-4596-bdf0-0e7b02e6d92f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_196c66b0-bac2-4b86-8ed7-4c53e3ba2285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_us-gaap_SharesIssued_196c66b0-bac2-4b86-8ed7-4c53e3ba2285" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ed574ddf-3a6f-4c9d-b377-f5000067a25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ed574ddf-3a6f-4c9d-b377-f5000067a25a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ba770555-bc82-46c6-a220-ee62e23c5e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ed574ddf-3a6f-4c9d-b377-f5000067a25a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ba770555-bc82-46c6-a220-ee62e23c5e2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ba770555-bc82-46c6-a220-ee62e23c5e2f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba770555-bc82-46c6-a220-ee62e23c5e2f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ba770555-bc82-46c6-a220-ee62e23c5e2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90af832f-ee62-4d70-abfb-0ec3f818da20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba770555-bc82-46c6-a220-ee62e23c5e2f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90af832f-ee62-4d70-abfb-0ec3f818da20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_b51a50e3-1341-44e8-b9d0-71fa7137e2fb" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90af832f-ee62-4d70-abfb-0ec3f818da20" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_b51a50e3-1341-44e8-b9d0-71fa7137e2fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram559PerShareMember_0acb20d0-ff95-4dc1-b249-fac118f8ec26" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram559PerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_b51a50e3-1341-44e8-b9d0-71fa7137e2fb" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram559PerShareMember_0acb20d0-ff95-4dc1-b249-fac118f8ec26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram774PerShareMember_f3c17848-108b-4159-a14b-f238fd89d2e4" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram774PerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_b51a50e3-1341-44e8-b9d0-71fa7137e2fb" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram774PerShareMember_f3c17848-108b-4159-a14b-f238fd89d2e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_8fe4fa8e-424b-49ca-ba83-dbf03e7d017f" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2020ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90af832f-ee62-4d70-abfb-0ec3f818da20" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_8fe4fa8e-424b-49ca-ba83-dbf03e7d017f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_f189639c-87ad-4bb2-8fac-ae1641e684b5" xlink:href="mrsn-20201231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90af832f-ee62-4d70-abfb-0ec3f818da20" xlink:to="loc_mrsn_PublicStockOfferingMember_f189639c-87ad-4bb2-8fac-ae1641e684b5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockholdersEquityWarrantsDetails" xlink:type="extended" id="i95e76e5a1a4f4361a14fb15b423ec2dd_StockholdersEquityWarrantsDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityExchangeWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails" xlink:type="extended" id="i7bdec558913f4310bf9f7d2db9edd737_StockholdersEquityExchangeWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9c82d68b-6a56-4049-8c1b-b73747f19034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_f3d02b2f-46db-4c86-8b7c-b37a965cf264" xlink:href="mrsn-20201231.xsd#mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9c82d68b-6a56-4049-8c1b-b73747f19034" xlink:to="loc_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_f3d02b2f-46db-4c86-8b7c-b37a965cf264" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5ed60622-12ae-4ae2-862f-95a1ddaae15b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9c82d68b-6a56-4049-8c1b-b73747f19034" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5ed60622-12ae-4ae2-862f-95a1ddaae15b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5fa2c573-d15b-4438-83d2-636a5f069fa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9c82d68b-6a56-4049-8c1b-b73747f19034" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5fa2c573-d15b-4438-83d2-636a5f069fa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsExercisedInPeriod_248f93cc-6763-41e2-9cd4-f8fd2724df0a" xlink:href="mrsn-20201231.xsd#mrsn_WarrantsExercisedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9c82d68b-6a56-4049-8c1b-b73747f19034" xlink:to="loc_mrsn_WarrantsExercisedInPeriod_248f93cc-6763-41e2-9cd4-f8fd2724df0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_22607b15-6355-49a1-bfbd-6e9f77a0d8bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9c82d68b-6a56-4049-8c1b-b73747f19034" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_22607b15-6355-49a1-bfbd-6e9f77a0d8bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3d9d4b50-a7ab-4810-9938-804ae5aaff20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_22607b15-6355-49a1-bfbd-6e9f77a0d8bb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3d9d4b50-a7ab-4810-9938-804ae5aaff20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d9d4b50-a7ab-4810-9938-804ae5aaff20_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3d9d4b50-a7ab-4810-9938-804ae5aaff20" xlink:to="loc_us-gaap_EquityComponentDomain_3d9d4b50-a7ab-4810-9938-804ae5aaff20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b97116fc-79c5-4d42-ae5c-1245d0ff2b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3d9d4b50-a7ab-4810-9938-804ae5aaff20" xlink:to="loc_us-gaap_EquityComponentDomain_b97116fc-79c5-4d42-ae5c-1245d0ff2b81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExchangeWarrantsMember_64fce0db-1d85-4a3f-a30f-871846cb1922" xlink:href="mrsn-20201231.xsd#mrsn_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b97116fc-79c5-4d42-ae5c-1245d0ff2b81" xlink:to="loc_mrsn_ExchangeWarrantsMember_64fce0db-1d85-4a3f-a30f-871846cb1922" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_83d485ef-5dab-4972-b838-11f3b1c53d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b97116fc-79c5-4d42-ae5c-1245d0ff2b81" xlink:to="loc_us-gaap_CommonStockMember_83d485ef-5dab-4972-b838-11f3b1c53d31" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityCommonstockDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityCommonstockDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockholdersEquityCommonstockDetails" xlink:type="extended" id="i4c34575ef0664666ab0dc09d03f6fd69_StockholdersEquityCommonstockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_31af6024-df30-4bd7-b363-45c320a37fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NumberOfVotesPerCommonShare_7b65ff8e-8ce2-4b93-94f7-124e388cdc5d" xlink:href="mrsn-20201231.xsd#mrsn_NumberOfVotesPerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_31af6024-df30-4bd7-b363-45c320a37fa3" xlink:to="loc_mrsn_NumberOfVotesPerCommonShare_7b65ff8e-8ce2-4b93-94f7-124e388cdc5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_09d93a7c-a331-49ad-bcbb-d348cc6c0f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_31af6024-df30-4bd7-b363-45c320a37fa3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_09d93a7c-a331-49ad-bcbb-d348cc6c0f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_32890835-c29c-4a4d-8075-098f9cf6ad18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_31af6024-df30-4bd7-b363-45c320a37fa3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_32890835-c29c-4a4d-8075-098f9cf6ad18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_06970bb6-a731-44e7-af4d-364a03ba5ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32890835-c29c-4a4d-8075-098f9cf6ad18" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_06970bb6-a731-44e7-af4d-364a03ba5ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_06970bb6-a731-44e7-af4d-364a03ba5ef7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_06970bb6-a731-44e7-af4d-364a03ba5ef7" xlink:to="loc_us-gaap_EquityComponentDomain_06970bb6-a731-44e7-af4d-364a03ba5ef7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f907e9a1-e717-4b6c-961f-b58d62e124c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_06970bb6-a731-44e7-af4d-364a03ba5ef7" xlink:to="loc_us-gaap_EquityComponentDomain_f907e9a1-e717-4b6c-961f-b58d62e124c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_46e9479d-2712-4836-9578-844d4a4adc4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f907e9a1-e717-4b6c-961f-b58d62e124c9" xlink:to="loc_us-gaap_CommonStockMember_46e9479d-2712-4836-9578-844d4a4adc4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsAndShareBasedPaymentsMember_2bdb9802-e356-488b-82e8-47600e2e36fc" xlink:href="mrsn-20201231.xsd#mrsn_WarrantsAndShareBasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f907e9a1-e717-4b6c-961f-b58d62e124c9" xlink:to="loc_mrsn_WarrantsAndShareBasedPaymentsMember_2bdb9802-e356-488b-82e8-47600e2e36fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_f80ecfe3-0b22-4513-91ef-125f336b2ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_WarrantsAndShareBasedPaymentsMember_2bdb9802-e356-488b-82e8-47600e2e36fc" xlink:to="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_f80ecfe3-0b22-4513-91ef-125f336b2ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_471f6319-3b47-4a57-bca8-a6f4601a734a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_WarrantsAndShareBasedPaymentsMember_2bdb9802-e356-488b-82e8-47600e2e36fc" xlink:to="loc_us-gaap_WarrantMember_471f6319-3b47-4a57-bca8-a6f4601a734a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExchangeWarrantsMember_5234dbfe-fb90-4ef5-bece-b113c9fc8851" xlink:href="mrsn-20201231.xsd#mrsn_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_WarrantsAndShareBasedPaymentsMember_2bdb9802-e356-488b-82e8-47600e2e36fc" xlink:to="loc_mrsn_ExchangeWarrantsMember_5234dbfe-fb90-4ef5-bece-b113c9fc8851" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e0bfd190-20c0-48e7-8a6b-161ae6b33a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32890835-c29c-4a4d-8075-098f9cf6ad18" xlink:to="loc_us-gaap_AwardTypeAxis_e0bfd190-20c0-48e7-8a6b-161ae6b33a38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0bfd190-20c0-48e7-8a6b-161ae6b33a38_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e0bfd190-20c0-48e7-8a6b-161ae6b33a38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0bfd190-20c0-48e7-8a6b-161ae6b33a38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_782794d7-d5e1-4803-aa5b-9bab0afabe91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e0bfd190-20c0-48e7-8a6b-161ae6b33a38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_782794d7-d5e1-4803-aa5b-9bab0afabe91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_42b61e82-aa6b-4226-9d95-d39be44be0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_782794d7-d5e1-4803-aa5b-9bab0afabe91" xlink:to="loc_us-gaap_EmployeeStockOptionMember_42b61e82-aa6b-4226-9d95-d39be44be0bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bc07e141-f803-4b04-bcd9-6f9a34667157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_782794d7-d5e1-4803-aa5b-9bab0afabe91" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bc07e141-f803-4b04-bcd9-6f9a34667157" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptions" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptions"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockOptions" xlink:type="extended" id="i3ee793e14a424b6180459ba76c4b96e5_StockOptions"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsTables"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockOptionsTables" xlink:type="extended" id="ic2431eb3457c4c8094de35fe8876ca5b_StockOptionsTables"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsPlansNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockOptionsPlansNarrativeDetails" xlink:type="extended" id="i69068b939b204e0392927f12204c46d9_StockOptionsPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3566f998-fd9a-4a55-8381-72578659a2e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3566f998-fd9a-4a55-8381-72578659a2e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e7de667b-24a0-4a38-8b96-f56876ff21dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e7de667b-24a0-4a38-8b96-f56876ff21dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_49f0d872-783b-4062-b2c0-58381e79743b" xlink:href="mrsn-20201231.xsd#mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:to="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_49f0d872-783b-4062-b2c0-58381e79743b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50972c95-7ea6-4aee-afd4-8fd12cc5be60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50972c95-7ea6-4aee-afd4-8fd12cc5be60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1ff38097-9ca8-4fc8-a676-43f8874560fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1ff38097-9ca8-4fc8-a676-43f8874560fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e8fe5a9-c186-4102-9638-ad5f15e66419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e8fe5a9-c186-4102-9638-ad5f15e66419" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3ddc3df9-c4b0-4eb5-a5f4-2e985f7223e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e8fe5a9-c186-4102-9638-ad5f15e66419" xlink:to="loc_us-gaap_PlanNameAxis_3ddc3df9-c4b0-4eb5-a5f4-2e985f7223e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3ddc3df9-c4b0-4eb5-a5f4-2e985f7223e7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3ddc3df9-c4b0-4eb5-a5f4-2e985f7223e7" xlink:to="loc_us-gaap_PlanNameDomain_3ddc3df9-c4b0-4eb5-a5f4-2e985f7223e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fe29a054-034d-4369-8a1c-b997d638f8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3ddc3df9-c4b0-4eb5-a5f4-2e985f7223e7" xlink:to="loc_us-gaap_PlanNameDomain_fe29a054-034d-4369-8a1c-b997d638f8d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIncentivePlan2007Member_79824dc2-deff-4670-992f-d75196c7be75" xlink:href="mrsn-20201231.xsd#mrsn_StockIncentivePlan2007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fe29a054-034d-4369-8a1c-b997d638f8d5" xlink:to="loc_mrsn_StockIncentivePlan2007Member_79824dc2-deff-4670-992f-d75196c7be75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIncentivePlan2017Member_61117b81-f286-4c33-8358-955bc442432a" xlink:href="mrsn-20201231.xsd#mrsn_StockIncentivePlan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fe29a054-034d-4369-8a1c-b997d638f8d5" xlink:to="loc_mrsn_StockIncentivePlan2017Member_61117b81-f286-4c33-8358-955bc442432a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_18c8f744-d339-41e1-a7e9-4d36aae6e3a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e8fe5a9-c186-4102-9638-ad5f15e66419" xlink:to="loc_us-gaap_AwardTypeAxis_18c8f744-d339-41e1-a7e9-4d36aae6e3a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18c8f744-d339-41e1-a7e9-4d36aae6e3a4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_18c8f744-d339-41e1-a7e9-4d36aae6e3a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18c8f744-d339-41e1-a7e9-4d36aae6e3a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aeab6232-236a-48c2-ab7d-382ce0e89afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_18c8f744-d339-41e1-a7e9-4d36aae6e3a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aeab6232-236a-48c2-ab7d-382ce0e89afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_542282f6-a87d-451c-9e09-993e6f005f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aeab6232-236a-48c2-ab7d-382ce0e89afd" xlink:to="loc_us-gaap_EmployeeStockMember_542282f6-a87d-451c-9e09-993e6f005f1d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsInducementNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsInducementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockOptionsInducementNarrativeDetails" xlink:type="extended" id="iea218be362b8482ea9f5c025a12146bd_StockOptionsInducementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc4c192-7512-4ef7-b0c8-2fc3231baac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_08a22224-6198-43e6-a0f5-810613796daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc4c192-7512-4ef7-b0c8-2fc3231baac0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_08a22224-6198-43e6-a0f5-810613796daa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7552fb9f-6a34-453f-8612-e9868f3a44c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc4c192-7512-4ef7-b0c8-2fc3231baac0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7552fb9f-6a34-453f-8612-e9868f3a44c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_059ac89d-95c4-4aba-b168-90f9c1eb04ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc4c192-7512-4ef7-b0c8-2fc3231baac0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_059ac89d-95c4-4aba-b168-90f9c1eb04ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_784b2122-3626-4672-b09c-9042cbb05dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc4c192-7512-4ef7-b0c8-2fc3231baac0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_784b2122-3626-4672-b09c-9042cbb05dbf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4c8a9ed5-4c60-43b1-8b73-b40583f613ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_784b2122-3626-4672-b09c-9042cbb05dbf" xlink:to="loc_us-gaap_PlanNameAxis_4c8a9ed5-4c60-43b1-8b73-b40583f613ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4c8a9ed5-4c60-43b1-8b73-b40583f613ae_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4c8a9ed5-4c60-43b1-8b73-b40583f613ae" xlink:to="loc_us-gaap_PlanNameDomain_4c8a9ed5-4c60-43b1-8b73-b40583f613ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2d81774c-fe8d-4ceb-a40e-0af4c37f982a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4c8a9ed5-4c60-43b1-8b73-b40583f613ae" xlink:to="loc_us-gaap_PlanNameDomain_2d81774c-fe8d-4ceb-a40e-0af4c37f982a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_InducementAwardProgramMember_3636e6b7-d121-4a51-9682-1b433d66e968" xlink:href="mrsn-20201231.xsd#mrsn_InducementAwardProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2d81774c-fe8d-4ceb-a40e-0af4c37f982a" xlink:to="loc_mrsn_InducementAwardProgramMember_3636e6b7-d121-4a51-9682-1b433d66e968" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04c280e9-3ce4-4442-93b6-62b404d1045c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_784b2122-3626-4672-b09c-9042cbb05dbf" xlink:to="loc_srt_RangeAxis_04c280e9-3ce4-4442-93b6-62b404d1045c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_04c280e9-3ce4-4442-93b6-62b404d1045c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_04c280e9-3ce4-4442-93b6-62b404d1045c" xlink:to="loc_srt_RangeMember_04c280e9-3ce4-4442-93b6-62b404d1045c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3764775-d49d-4f7b-94a3-2ef75b6567d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_04c280e9-3ce4-4442-93b6-62b404d1045c" xlink:to="loc_srt_RangeMember_d3764775-d49d-4f7b-94a3-2ef75b6567d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3626193b-3a2e-4c2c-9019-72c040e2fb39" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d3764775-d49d-4f7b-94a3-2ef75b6567d9" xlink:to="loc_srt_MaximumMember_3626193b-3a2e-4c2c-9019-72c040e2fb39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_81226d86-a316-43b3-84c2-d18ea425c0d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_784b2122-3626-4672-b09c-9042cbb05dbf" xlink:to="loc_us-gaap_AwardTypeAxis_81226d86-a316-43b3-84c2-d18ea425c0d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81226d86-a316-43b3-84c2-d18ea425c0d0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_81226d86-a316-43b3-84c2-d18ea425c0d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81226d86-a316-43b3-84c2-d18ea425c0d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cded65af-29fb-4e42-882f-a4ab4c7e57fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_81226d86-a316-43b3-84c2-d18ea425c0d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cded65af-29fb-4e42-882f-a4ab4c7e57fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4bf70ff1-49f9-4185-aa5f-8c33447bdc93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cded65af-29fb-4e42-882f-a4ab4c7e57fb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4bf70ff1-49f9-4185-aa5f-8c33447bdc93" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsActivityUnderStockOptionPlanDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails" xlink:type="extended" id="if40e028205994a60abd1fe1304a610f0_StockOptionsActivityUnderStockOptionPlanDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails" xlink:type="extended" id="i0d7806cc53514e1ab0abe7c244e0cc7d_StockOptionsRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da4457a8-061f-45c1-8d17-cb459f18c464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d5cc8ec7-37f0-4294-a717-9c7dddcc4fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da4457a8-061f-45c1-8d17-cb459f18c464" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d5cc8ec7-37f0-4294-a717-9c7dddcc4fde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da4457a8-061f-45c1-8d17-cb459f18c464" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e83a6b08-b5e8-41a5-b2ab-b9e06c98589a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e83a6b08-b5e8-41a5-b2ab-b9e06c98589a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_98331413-2a02-4486-a360-619aa3d0004a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_98331413-2a02-4486-a360-619aa3d0004a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_609d11af-a914-4a04-af22-387eecfe4431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_609d11af-a914-4a04-af22-387eecfe4431" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2ff08e85-2199-45ed-a2c6-0c72e8a907d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2ff08e85-2199-45ed-a2c6-0c72e8a907d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_61024ef9-229e-4734-b3c6-54e00a6b87e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_53e6515b-dc8f-4989-b69f-53fd6b40ad23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_53e6515b-dc8f-4989-b69f-53fd6b40ad23" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b3cb182e-3b36-4b04-a208-a78a67dd4d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_53e6515b-dc8f-4989-b69f-53fd6b40ad23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b3cb182e-3b36-4b04-a208-a78a67dd4d0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6231da3f-5da3-4b23-b324-3cbc5f03c2b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_53e6515b-dc8f-4989-b69f-53fd6b40ad23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6231da3f-5da3-4b23-b324-3cbc5f03c2b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d510aec8-5318-4799-b0c3-00e8bafda6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d510aec8-5318-4799-b0c3-00e8bafda6f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_765ee68c-8204-41d7-bf03-6c0af0880d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_765ee68c-8204-41d7-bf03-6c0af0880d57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_187439ac-ebde-4b05-9fdb-8f53dc0161a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_187439ac-ebde-4b05-9fdb-8f53dc0161a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_16d81226-7bed-416c-bd9a-00570922fa8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_16d81226-7bed-416c-bd9a-00570922fa8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_33ccb4f6-43d6-445f-9850-b3e6d547f1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b065600-7ecb-421f-8e0f-e6ab37d8c3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da4457a8-061f-45c1-8d17-cb459f18c464" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b065600-7ecb-421f-8e0f-e6ab37d8c3ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_26446752-2aaa-4ba2-8f92-8ce8785747b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b065600-7ecb-421f-8e0f-e6ab37d8c3ed" xlink:to="loc_us-gaap_AwardTypeAxis_26446752-2aaa-4ba2-8f92-8ce8785747b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26446752-2aaa-4ba2-8f92-8ce8785747b8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_26446752-2aaa-4ba2-8f92-8ce8785747b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26446752-2aaa-4ba2-8f92-8ce8785747b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe644284-3910-4ab5-96c3-77e9400214dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_26446752-2aaa-4ba2-8f92-8ce8785747b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe644284-3910-4ab5-96c3-77e9400214dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ea9bce71-8a21-4e23-af7e-a5399e0adf17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe644284-3910-4ab5-96c3-77e9400214dc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ea9bce71-8a21-4e23-af7e-a5399e0adf17" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails" xlink:type="extended" id="i51862695999043d0aed3d187b6eeb18b_StockOptionsStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12db8ea6-ee7b-480e-83f8-a9760619500f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_26854449-1444-4d03-8e5b-45a7f661cb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12db8ea6-ee7b-480e-83f8-a9760619500f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_26854449-1444-4d03-8e5b-45a7f661cb17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ea0875f2-d6e9-40f3-910f-5e0d923c7174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12db8ea6-ee7b-480e-83f8-a9760619500f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ea0875f2-d6e9-40f3-910f-5e0d923c7174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_19ad4765-0414-4a7b-a047-7c749bb771b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12db8ea6-ee7b-480e-83f8-a9760619500f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_19ad4765-0414-4a7b-a047-7c749bb771b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23818e41-9b2f-4e14-bde3-e4d3351dc9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12db8ea6-ee7b-480e-83f8-a9760619500f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23818e41-9b2f-4e14-bde3-e4d3351dc9e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_55b8a11c-c78c-429b-b9c7-b75c154023f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23818e41-9b2f-4e14-bde3-e4d3351dc9e6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_55b8a11c-c78c-429b-b9c7-b75c154023f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_55b8a11c-c78c-429b-b9c7-b75c154023f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_55b8a11c-c78c-429b-b9c7-b75c154023f4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_55b8a11c-c78c-429b-b9c7-b75c154023f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1cdc74d4-e68a-4558-ad77-51b7381a4322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_55b8a11c-c78c-429b-b9c7-b75c154023f4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1cdc74d4-e68a-4558-ad77-51b7381a4322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7bf1e987-85e0-4b6e-a16e-0d306714111c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1cdc74d4-e68a-4558-ad77-51b7381a4322" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7bf1e987-85e0-4b6e-a16e-0d306714111c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dc328422-efb8-4eb4-98b5-31ea8f2e5ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1cdc74d4-e68a-4558-ad77-51b7381a4322" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dc328422-efb8-4eb4-98b5-31ea8f2e5ea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8bb9e804-1a7a-4f1e-bd89-a63264cf045f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23818e41-9b2f-4e14-bde3-e4d3351dc9e6" xlink:to="loc_us-gaap_AwardTypeAxis_8bb9e804-1a7a-4f1e-bd89-a63264cf045f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8bb9e804-1a7a-4f1e-bd89-a63264cf045f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8bb9e804-1a7a-4f1e-bd89-a63264cf045f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8bb9e804-1a7a-4f1e-bd89-a63264cf045f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d0e6d01-07ae-4e00-bbc8-a89803747644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8bb9e804-1a7a-4f1e-bd89-a63264cf045f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d0e6d01-07ae-4e00-bbc8-a89803747644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fb55e2ac-b3e3-4fe4-acbc-4d4771be1b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d0e6d01-07ae-4e00-bbc8-a89803747644" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fb55e2ac-b3e3-4fe4-acbc-4d4771be1b1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c9518085-b100-4e08-b05d-278101b4871c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d0e6d01-07ae-4e00-bbc8-a89803747644" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c9518085-b100-4e08-b05d-278101b4871c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f769a0c4-bb98-47f4-92b4-65727ee8c9d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d0e6d01-07ae-4e00-bbc8-a89803747644" xlink:to="loc_us-gaap_EmployeeStockMember_f769a0c4-bb98-47f4-92b4-65727ee8c9d3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails" xlink:type="extended" id="ia20cfffe566b47c0a41f11a2eb633710_StockOptionsFairValueAssumptionsDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails" xlink:type="extended" id="i22416f79a33748ef819f8bc3868f836e_StockOptionsEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805df2c-039a-4a42-8bf0-82a37b188465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_98a7a611-3a60-4d94-b649-14d7cee2cc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805df2c-039a-4a42-8bf0-82a37b188465" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_98a7a611-3a60-4d94-b649-14d7cee2cc15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8f480586-6e48-4b58-8bbe-653c3d902c0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805df2c-039a-4a42-8bf0-82a37b188465" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8f480586-6e48-4b58-8bbe-653c3d902c0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d3081741-4b89-435a-9782-80ae77a9c3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805df2c-039a-4a42-8bf0-82a37b188465" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d3081741-4b89-435a-9782-80ae77a9c3b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_451bd0c3-cc0c-453e-b41a-4e042c5aa239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805df2c-039a-4a42-8bf0-82a37b188465" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_451bd0c3-cc0c-453e-b41a-4e042c5aa239" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04a4bab5-39ad-4fd9-afb2-3759daf1c2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805df2c-039a-4a42-8bf0-82a37b188465" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04a4bab5-39ad-4fd9-afb2-3759daf1c2c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_60b4909a-f719-471c-9d73-3a460c10dde0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04a4bab5-39ad-4fd9-afb2-3759daf1c2c5" xlink:to="loc_us-gaap_AwardTypeAxis_60b4909a-f719-471c-9d73-3a460c10dde0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60b4909a-f719-471c-9d73-3a460c10dde0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_60b4909a-f719-471c-9d73-3a460c10dde0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60b4909a-f719-471c-9d73-3a460c10dde0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e72292d6-fd4a-49bf-8166-291b1ac04121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_60b4909a-f719-471c-9d73-3a460c10dde0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e72292d6-fd4a-49bf-8166-291b1ac04121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_105baaea-f9bb-42b0-a156-acea7eba419f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e72292d6-fd4a-49bf-8166-291b1ac04121" xlink:to="loc_us-gaap_EmployeeStockMember_105baaea-f9bb-42b0-a156-acea7eba419f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/Leases" xlink:type="simple" xlink:href="mrsn-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/Leases" xlink:type="extended" id="i5c41bd952d27441894bfd3fc6a532aec_Leases"/>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/LeasesTables" xlink:type="extended" id="icc7e3836154345e5939f937f5461ed1a_LeasesTables"/>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesDescriptionDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesDescriptionDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/LeasesDescriptionDetails" xlink:type="extended" id="i55f1362abeb04520bbdbed7841eb0e8b_LeasesDescriptionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:href="mrsn-20201231.xsd#mrsn_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_TenantImprovementAllowance_f1503a16-6172-45b7-ac6d-c67f3b79bce0" xlink:href="mrsn-20201231.xsd#mrsn_TenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_mrsn_TenantImprovementAllowance_f1503a16-6172-45b7-ac6d-c67f3b79bce0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_76228236-e482-44a7-a9bb-a33da6029763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_76228236-e482-44a7-a9bb-a33da6029763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_3ec30fa6-4980-4784-9edf-ebadee844758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_3ec30fa6-4980-4784-9edf-ebadee844758" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability_77aa3661-fcc4-4570-bfe3-6394ff77d03e" xlink:href="mrsn-20201231.xsd#mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability_77aa3661-fcc4-4570-bfe3-6394ff77d03e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets_3bb0f198-9172-4c91-9ed7-96e57fe028f2" xlink:href="mrsn-20201231.xsd#mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets_3bb0f198-9172-4c91-9ed7-96e57fe028f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_5e603712-48f7-4ee4-ad96-65d8acfd8525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_us-gaap_SecurityDeposit_5e603712-48f7-4ee4-ad96-65d8acfd8525" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_1efbe26a-925b-4d81-9976-1867f2232022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_1efbe26a-925b-4d81-9976-1867f2232022" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesTable_b6ff1989-8af6-4cab-8781-2fef50633107" xlink:href="mrsn-20201231.xsd#mrsn_LeasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_mrsn_LeasesTable_b6ff1989-8af6-4cab-8781-2fef50633107" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5142c87c-7420-4e7e-a38e-122523c2a39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrsn_LeasesTable_b6ff1989-8af6-4cab-8781-2fef50633107" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5142c87c-7420-4e7e-a38e-122523c2a39d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5142c87c-7420-4e7e-a38e-122523c2a39d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5142c87c-7420-4e7e-a38e-122523c2a39d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5142c87c-7420-4e7e-a38e-122523c2a39d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_882a7ffe-b90c-48c4-b8bf-9accadb71e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5142c87c-7420-4e7e-a38e-122523c2a39d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_882a7ffe-b90c-48c4-b8bf-9accadb71e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OfficeSpaceCambridgeMaMember_f70faf51-4e35-43ab-8fde-f25974bfdf7b" xlink:href="mrsn-20201231.xsd#mrsn_OfficeSpaceCambridgeMaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_882a7ffe-b90c-48c4-b8bf-9accadb71e18" xlink:to="loc_mrsn_OfficeSpaceCambridgeMaMember_f70faf51-4e35-43ab-8fde-f25974bfdf7b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended" id="ie4ef454f606e4a45ae36aea1b7fc815f_LeasesComponentsofLeaseExpenseDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesSupplementalbalancesheetinformationDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails" xlink:type="extended" id="i37b355af58c9429f935fb7e0fcb5ebac_LeasesSupplementalbalancesheetinformationDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesSupplementalcashflowinformationDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails" xlink:type="extended" id="i1fdb2b6894d24c3396109b90e1c64853_LeasesSupplementalcashflowinformationDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesFutureminimumleasepaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails" xlink:type="extended" id="i32807205f95a4ff68f7806026d2a722c_LeasesFutureminimumleasepaymentsDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/IncomeTaxes" xlink:type="extended" id="i4515bb8b2413437d81bd04f75c03fff1_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/IncomeTaxesTables" xlink:type="extended" id="i59393e927c81462ba2e2fcc23aadb5af_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesReconciliationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/IncomeTaxesReconciliationDetails" xlink:type="extended" id="i5d38fd84dcaa410fb8624fd2926aaf76_IncomeTaxesReconciliationDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesComponentsofdeferredtaxassetsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails" xlink:type="extended" id="i2b60bf6f1355485bacd613deb0439187_IncomeTaxesComponentsofdeferredtaxassetsDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesNetoperatinglosscarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails" xlink:type="extended" id="i829ddf99632546769704883e9afbcbbf_IncomeTaxesNetoperatinglosscarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_f08cdda0-4339-49a1-8780-f8ce45adb426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_5c681653-dbd3-4249-b549-f9e85068525c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f08cdda0-4339-49a1-8780-f8ce45adb426" xlink:to="loc_us-gaap_OperatingLossCarryforwards_5c681653-dbd3-4249-b549-f9e85068525c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLossCarryforwardsSubjectToExpiration_c0d923c7-881c-42ca-b80d-29f422b69de9" xlink:href="mrsn-20201231.xsd#mrsn_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f08cdda0-4339-49a1-8780-f8ce45adb426" xlink:to="loc_mrsn_OperatingLossCarryforwardsSubjectToExpiration_c0d923c7-881c-42ca-b80d-29f422b69de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_c787b972-39ea-421b-8578-94d1b32a2530" xlink:href="mrsn-20201231.xsd#mrsn_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f08cdda0-4339-49a1-8780-f8ce45adb426" xlink:to="loc_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_c787b972-39ea-421b-8578-94d1b32a2530" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_45b3c570-497e-48df-a314-ecca6bfca24a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f08cdda0-4339-49a1-8780-f8ce45adb426" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_45b3c570-497e-48df-a314-ecca6bfca24a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e77eb1eb-88fb-4469-8bee-1556c3adad23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_45b3c570-497e-48df-a314-ecca6bfca24a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e77eb1eb-88fb-4469-8bee-1556c3adad23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e77eb1eb-88fb-4469-8bee-1556c3adad23_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e77eb1eb-88fb-4469-8bee-1556c3adad23" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e77eb1eb-88fb-4469-8bee-1556c3adad23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8d4d520b-0126-4334-957a-c9f4ff139e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e77eb1eb-88fb-4469-8bee-1556c3adad23" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8d4d520b-0126-4334-957a-c9f4ff139e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3e25a59b-9f48-4e53-b490-959e5c6ef564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8d4d520b-0126-4334-957a-c9f4ff139e56" xlink:to="loc_us-gaap_DomesticCountryMember_3e25a59b-9f48-4e53-b490-959e5c6ef564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f1ce0d87-98e8-4996-a722-ca38b71032fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8d4d520b-0126-4334-957a-c9f4ff139e56" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f1ce0d87-98e8-4996-a722-ca38b71032fa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesTaxcreditcarryforwardDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails" xlink:type="extended" id="ibde4ef9dd1684891af68dfe1beb59be0_IncomeTaxesTaxcreditcarryforwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_ccc6c96f-3e97-40df-98dd-1b05f42e5121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2048df1c-8f5f-422e-a8d8-7271690d26a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ccc6c96f-3e97-40df-98dd-1b05f42e5121" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2048df1c-8f5f-422e-a8d8-7271690d26a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_87c415b9-829a-429f-8c49-4a664b6bda82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ccc6c96f-3e97-40df-98dd-1b05f42e5121" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_87c415b9-829a-429f-8c49-4a664b6bda82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_317f38c7-e708-4d74-9219-378508c6efe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_87c415b9-829a-429f-8c49-4a664b6bda82" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_317f38c7-e708-4d74-9219-378508c6efe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_317f38c7-e708-4d74-9219-378508c6efe0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_317f38c7-e708-4d74-9219-378508c6efe0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_317f38c7-e708-4d74-9219-378508c6efe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0a071278-2335-4039-822a-59ee5dec9b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_317f38c7-e708-4d74-9219-378508c6efe0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0a071278-2335-4039-822a-59ee5dec9b99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_344c30bb-505e-4c78-80c0-8344ac484551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0a071278-2335-4039-822a-59ee5dec9b99" xlink:to="loc_us-gaap_DomesticCountryMember_344c30bb-505e-4c78-80c0-8344ac484551" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_d22e9804-ec94-4453-b235-355982175417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0a071278-2335-4039-822a-59ee5dec9b99" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_d22e9804-ec94-4453-b235-355982175417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_8289d4ed-151d-4d88-a381-2cb49b4bf715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_87c415b9-829a-429f-8c49-4a664b6bda82" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_8289d4ed-151d-4d88-a381-2cb49b4bf715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_8289d4ed-151d-4d88-a381-2cb49b4bf715_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_8289d4ed-151d-4d88-a381-2cb49b4bf715" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_8289d4ed-151d-4d88-a381-2cb49b4bf715_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_77fe9dd5-5dfc-4de4-88e8-ffae83ae9a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_8289d4ed-151d-4d88-a381-2cb49b4bf715" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_77fe9dd5-5dfc-4de4-88e8-ffae83ae9a6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_9c83b493-a325-42e5-9760-21b7deefed9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_77fe9dd5-5dfc-4de4-88e8-ffae83ae9a6b" xlink:to="loc_us-gaap_ResearchMember_9c83b493-a325-42e5-9760-21b7deefed9e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesValuationallowanceDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails" xlink:type="extended" id="i87cb67ef0cf345418e19e43e12ef9fed_IncomeTaxesValuationallowanceDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mrsn-20201231.xsd#EmployeeBenefitPlan"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/EmployeeBenefitPlan" xlink:type="extended" id="ia1243798e37443d1b2bed87678c1dc77_EmployeeBenefitPlan"/>
  <link:roleRef roleURI="http://www.mersana.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#EmployeeBenefitPlanDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" id="i2c3b89eeded242bf8f6ec379d890278e_EmployeeBenefitPlanDetails"/>
  <link:roleRef roleURI="http://www.mersana.com/role/Commitments" xlink:type="simple" xlink:href="mrsn-20201231.xsd#Commitments"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/Commitments" xlink:type="extended" id="i00e6b4608d5347c78971d47abc737698_Commitments"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CommitmentsLicenseagreementsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CommitmentsLicenseagreementsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CommitmentsLicenseagreementsDetails" xlink:type="extended" id="id787bf19ca994a59884018268acee33c_CommitmentsLicenseagreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_31233505-8c1c-47aa-a9b2-94fff2cb8448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_5382b2b9-370a-41f1-8c4b-3a1348b7aec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_31233505-8c1c-47aa-a9b2-94fff2cb8448" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_5382b2b9-370a-41f1-8c4b-3a1348b7aec1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2e8352e0-1c08-42a1-adc4-d40570ba9315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_31233505-8c1c-47aa-a9b2-94fff2cb8448" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2e8352e0-1c08-42a1-adc4-d40570ba9315" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_531cddb8-3814-47ee-be5b-0a1e552ced21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2e8352e0-1c08-42a1-adc4-d40570ba9315" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_531cddb8-3814-47ee-be5b-0a1e552ced21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_531cddb8-3814-47ee-be5b-0a1e552ced21_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_531cddb8-3814-47ee-be5b-0a1e552ced21" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_531cddb8-3814-47ee-be5b-0a1e552ced21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0b68188e-adc0-4164-baac-78b1c8c8a361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_531cddb8-3814-47ee-be5b-0a1e552ced21" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0b68188e-adc0-4164-baac-78b1c8c8a361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAgreementUpfrontPaymentsMember_850b2e5a-3b82-442e-95fd-b287c77aa75a" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAgreementUpfrontPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0b68188e-adc0-4164-baac-78b1c8c8a361" xlink:to="loc_mrsn_LicenseAgreementUpfrontPaymentsMember_850b2e5a-3b82-442e-95fd-b287c77aa75a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAgreementMilestonePaymentsMember_b4cb6df6-e6f3-4f48-9cf8-c4661431f3d5" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAgreementMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0b68188e-adc0-4164-baac-78b1c8c8a361" xlink:to="loc_mrsn_LicenseAgreementMilestonePaymentsMember_b4cb6df6-e6f3-4f48-9cf8-c4661431f3d5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SelectedQuarterlyFinancialDataUnaudited"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended" id="ic91225d6a25c42bda0b262f51b33dfc0_SelectedQuarterlyFinancialDataUnaudited"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended" id="i94f50fed419149e7ae46f2402ca13b1d_SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:roleRef roleURI="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" id="ida35cd8888784ec3a40283ce309ba306_SelectedQuarterlyFinancialDataUnauditedDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mrsn-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2da7fb72-9c95-4f34-a8ba-21eaa0b59775,g:bc62363b-ba21-41ff-8e10-87a9df40b55e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0ccf67a1-7d74-4761-9a00-d0a6ec6f8bde_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1467b0d3-f48a-4de8-a619-a88c72b469f1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_4bbfffd0-1887-4889-981e-8848849f41a7_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck KGaA</link:label>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_label_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Commercial License Agreement Merck Kgaa [Member]</link:label>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_documentation_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the Collaboration and Commercial License Agreement with Merck KGaA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" xlink:to="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_ba1f22db-d185-465f-843f-11b052574476_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e9b447ef-39e8-48d2-bde6-4d36b19e9ad0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1a057d6d-b030-4708-b349-a8765ee4c4fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_f4e45180-ec26-4781-b4d6-3d66f172fc96_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bd1cbc9a-8718-48a9-abee-b6ee9357c5ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_447e8df1-d66b-4820-bb12-511f58865012_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e2641a8c-0154-4773-84b5-11afae2c555b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_55497747-29e5-4b1b-a396-12cd350c6b1a_terseLabel_en-US" xlink:label="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_label_en-US" xlink:label="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract Assets And Liabilities [Roll Forward]</link:label>
    <link:label id="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_documentation_en-US" xlink:label="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract Assets And Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" xlink:href="mrsn-20201231.xsd#mrsn_ChangeInContractAssetsAndLiabilitiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" xlink:to="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_b8765b4d-8e35-4724-b95b-ddc02e4a06dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_de67896a-4c14-4b1b-8437-40cee3a6cd2b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_61a7e815-c389-4d6f-a4ae-35f721dd46fe_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2064cce9-858f-4c7d-9a43-1b05e84d31f1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_508ff3eb-dae4-48f5-ae82-e0e3a58d4285_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8429936-ee40-4e41-85fa-2d7f434f90f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_fe15f84e-70f3-435b-96c6-ef42625b945e_terseLabel_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Off-balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_35892d01-a896-416d-8957-625eac74d149_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_84e640e1-030b-4575-8354-7ead17f24414_terseLabel_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and warrants</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_label_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options and Warrants Exercised</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_documentation_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued as a result of the exercise of stock options and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:to="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8a85dc96-3186-4816-b32e-ef44bd17508e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_88557b99-3ac4-4e15-acbb-bcb94ec20bea_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_62dae119-aedb-4054-8438-a11e30fa4143_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_eb3fab14-f755-4cd0-9486-114a1e3f69b0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LaboratoryEquipmentLeasedAssetMember_b8e129f4-96c5-4a8a-bd6d-c552152c0848_terseLabel_en-US" xlink:label="lab_mrsn_LaboratoryEquipmentLeasedAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment , under finance lease</link:label>
    <link:label id="lab_mrsn_LaboratoryEquipmentLeasedAssetMember_label_en-US" xlink:label="lab_mrsn_LaboratoryEquipmentLeasedAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment Leased Asset [Member]</link:label>
    <link:label id="lab_mrsn_LaboratoryEquipmentLeasedAssetMember_documentation_en-US" xlink:label="lab_mrsn_LaboratoryEquipmentLeasedAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to laboratory equipment under finance leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentLeasedAssetMember" xlink:href="mrsn-20201231.xsd#mrsn_LaboratoryEquipmentLeasedAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LaboratoryEquipmentLeasedAssetMember" xlink:to="lab_mrsn_LaboratoryEquipmentLeasedAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_ae9ecb1d-762c-4fcc-bf83-bc689454a59c_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next potential milestone payment eligible to receive</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Milestone Payment Receivable, Next Milestone</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the next potential milestone the company will be eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" xlink:to="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_4f4064ac-d6d9-4fd7-8718-d1cfe43fd094_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in the balances of our contract assets and liabilities and recognized revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_225daf52-3d90-46a8-a187-57255d1aab72_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8f38d963-fd51-466a-9adc-4e4018edb59d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cc8ca6a5-3fab-4ead-b7c3-354881f938b3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_3fe816f2-6d5e-4da0-8ecf-d64b11590c3a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_c9899218-4664-4d51-a42a-2769b50f16f9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_471b396a-226c-41e8-ab72-f4dc15ea934c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7ddc452c-d956-4f12-85ec-0dc7b94e8cc7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments (Note&#160;14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_155e67ec-3287-4afc-88a6-64e2c26c2c91_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution by employee (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4fddc40e-9c00-497f-9ebb-9f73994ccf19_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_d7ca798b-6418-455d-b047-45ca2e4fbcd5_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_97e54d6b-8f65-4794-9ba0-1af5fa769568_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a557b740-e8d2-4077-bc7d-4bce5a5076a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637f1163-90fc-4492-8a00-7f91259bfed5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_4e8173f9-5067-45ba-af31-9d812a8b00f5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_12e551bd-3c6b-440f-98d1-902d22fe79d1_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c0d0f9d8-b7ae-451b-8501-31888592c8f3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9ed4328f-35e3-4395-8e92-1ef1248b9637_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_1943f39d-d47d-4e89-98b3-89dd56919cc1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ContractWithCustomerLiabilityIncrease_dad7c5bb-dea8-4d91-8541-af50721b0334_terseLabel_en-US" xlink:label="lab_mrsn_ContractWithCustomerLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, additions</link:label>
    <link:label id="lab_mrsn_ContractWithCustomerLiabilityIncrease_label_en-US" xlink:label="lab_mrsn_ContractWithCustomerLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Increase</link:label>
    <link:label id="lab_mrsn_ContractWithCustomerLiabilityIncrease_documentation_en-US" xlink:label="lab_mrsn_ContractWithCustomerLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in obligation to transfer good or service to customer for which consideration has been received or is receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractWithCustomerLiabilityIncrease" xlink:href="mrsn-20201231.xsd#mrsn_ContractWithCustomerLiabilityIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ContractWithCustomerLiabilityIncrease" xlink:to="lab_mrsn_ContractWithCustomerLiabilityIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2f65cb7c-dd83-49e0-8bc0-1b1e6d4dec38_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_fbba099e-44ee-4c11-afe3-2f914be03601_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_05b2c98b-8670-4809-8ba0-4c82d07a6c1f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_802de605-afd8-43c7-a054-f84ef0905b7a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_852e6f1c-65ee-4b7d-9479-6e8a60fcae79_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8d9ed683-0fb5-48ca-a1e4-2c8bae57dd31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9f547e12-9869-4ef1-bc07-4179bb6571ac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_bbddbdfc-637a-4b4f-96a4-b4aa503be3c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_511ad12f-cd20-4f0a-ada2-53d43df066c8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_5aae1163-918e-43da-9605-da6cfc5bc94d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e8062de8-e133-4053-904d-e041fc0a4834_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d494a74-0179-44ac-9389-7138a70dec13_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ca272a3-4b28-4fd8-af97-de87328b2fe3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5784c13e-15f1-4693-874f-fc7ecae277a6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_b2b6e3bc-0bcf-4aaf-a1f1-af205225e680_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheFiveMember_2cbdd475-7a42-42b4-afe1-455ed56933d4_terseLabel_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Five</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheFiveMember_label_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Five [Member]</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheFiveMember_documentation_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheFiveMember" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AmendedCreditFacilityTrancheFiveMember" xlink:to="lab_mrsn_AmendedCreditFacilityTrancheFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_08bb0c14-d346-41b3-9f4a-dfe04a605296_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_bc2d65b3-db52-4d29-bae0-114ae733b247_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_c68be42f-ef0c-4d48-af2a-3155eac24527_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_de8e3cb0-3d21-4a05-95b1-7e4e4f55961d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at December&#160;31, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_RevenueTransactionPriceIncreaseDecrease_fadcd633-94fe-4283-8c25-bad19d847a4c_negatedLabel_en-US" xlink:label="lab_mrsn_RevenueTransactionPriceIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in fees expected to be received for research and development activities</link:label>
    <link:label id="lab_mrsn_RevenueTransactionPriceIncreaseDecrease_label_en-US" xlink:label="lab_mrsn_RevenueTransactionPriceIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Transaction Price, Increase (Decrease)</link:label>
    <link:label id="lab_mrsn_RevenueTransactionPriceIncreaseDecrease_documentation_en-US" xlink:label="lab_mrsn_RevenueTransactionPriceIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in transaction price during the period due to change in fees expected to be received for research and development activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueTransactionPriceIncreaseDecrease" xlink:href="mrsn-20201231.xsd#mrsn_RevenueTransactionPriceIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_RevenueTransactionPriceIncreaseDecrease" xlink:to="lab_mrsn_RevenueTransactionPriceIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_be265095-f63f-4d21-9b7e-a2e6a08e62f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_65097991-492f-4fee-a681-bbe20c32f52c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_0a8b4a18-4a00-4743-be38-2192f6db5005_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_570ede9f-e287-4a12-a863-8b218dfe4e95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_164937e7-f293-4f81-b809-caae018fb6c7_terseLabel_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrant in exchange for common stock (in shares)</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_label_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares Of Common Stock Warrants In Exchange For Common Stock Exercised</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_documentation_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued during period and exercise of common stock warrant in exchange for common stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" xlink:to="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1d3161be-6f57-467c-9a12-16266c151320_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_295eca74-c03b-4d54-83b2-831db724871e_terseLabel_en-US" xlink:label="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock issuance, net of issuance costs</link:label>
    <link:label id="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_label_en-US" xlink:label="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Net Of Stock Issuance Costs</link:label>
    <link:label id="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_documentation_en-US" xlink:label="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net proceeds from the additional capital contribution to the entity after deducting fees, commissions and other expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:href="mrsn-20201231.xsd#mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:to="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2578d6e5-6f28-4f4a-8260-712afb078e22_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_51a8d7f9-f353-4ec9-8d8c-236bd2bb5e12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_ecff5306-588d-4bf9-bb36-afe617ed3f8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments under capital lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_558feaf7-87c7-49e8-998e-14f6398de991_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets_fc62676e-8a84-4b26-bfbb-162d3aecdf89_negatedLabel_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets_label_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Assets</link:label>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets_documentation_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in operating lease assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets" xlink:href="mrsn-20201231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets" xlink:to="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member_66ba9b35-3542-475a-9091-525241ac6438_terseLabel_en-US" xlink:label="lab_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment occurs between August 28, 2021 and August 28, 2022</link:label>
    <link:label id="lab_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member_label_en-US" xlink:label="lab_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Occurs Between August 28, 2021 And August 28, 2022 [Member]</link:label>
    <link:label id="lab_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member_documentation_en-US" xlink:label="lab_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the prepayment occurs between August 28, 2021 and August 28, 2022.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member" xlink:href="mrsn-20201231.xsd#mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member" xlink:to="lab_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b76abd3a-fad2-480c-8a27-29b0ae6e5903_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised_f4804faa-fd3b-483c-8522-2585bc0059f1_terseLabel_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of warrant (in shares)</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares, Warrants Exercised</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of stock issued as a result of the exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheThreeMember_73256e4f-e159-4c00-bc87-6793a5afa931_terseLabel_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Three</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheThreeMember_label_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Three [Member]</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheThreeMember_documentation_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheThreeMember" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AmendedCreditFacilityTrancheThreeMember" xlink:to="lab_mrsn_AmendedCreditFacilityTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_adadf3e7-0611-4269-a149-0ddbb0a71d12_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_687d1729-d77a-473b-b388-28f1c51a1200_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_0c49cad5-eef6-44ec-980f-be581e917a49_terseLabel_en-US" xlink:label="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targets</link:label>
    <link:label id="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_label_en-US" xlink:label="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements, Exclusive Targets, Number</link:label>
    <link:label id="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_documentation_en-US" xlink:label="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of exclusive targets entity provided right to develop under terms of agreement as of balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber" xlink:href="mrsn-20201231.xsd#mrsn_CollaborativeArrangementsExclusiveTargetsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber" xlink:to="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AmendedCreditFacilityMember_eb07d458-33b7-47f1-84ec-27c7375804ae_terseLabel_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityMember_label_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility [Member]</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityMember_documentation_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityMember" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AmendedCreditFacilityMember" xlink:to="lab_mrsn_AmendedCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_c5d1d08f-ce4b-49c1-ac93-8a0b6e57abe1_verboseLabel_en-US" xlink:label="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of milestone payments, which had not been received, included in the estimated transaction price</link:label>
    <link:label id="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_label_en-US" xlink:label="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Not Received, Included in Estimated Transaction Price</link:label>
    <link:label id="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_documentation_en-US" xlink:label="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of milestone payments, which had not been received, included in the estimated transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" xlink:href="mrsn-20201231.xsd#mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" xlink:to="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b6b26e9c-60a0-45c8-81fc-b58cd839fd16_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0048e51a-08e7-4b1a-8801-4145d20ae29b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3d1b9431-4464-4665-9c2c-bddae6a0e2cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of outstanding potentially dilutive securities excluded from calculation of diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember_3455e130-9ac6-48a5-8231-cc9a674ba12a_terseLabel_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At market equity offering program (2018 ATM)</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember_label_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program (2018 ATM) [Member]</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember_documentation_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market equity offering program to offer and sell common stock from time to time at prevailing market prices.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember" xlink:to="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_11530018-8c30-4af6-b68b-41739b5f92f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_e849f1d8-d41c-4f76-951a-92e265d5fb1c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_426ec575-487d-4021-aff1-264ce53ce745_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract_070171e0-c480-4351-8924-7bdc207c5715_terseLabel_en-US" xlink:label="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term:</link:label>
    <link:label id="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WeightedAverageRemainingLeaseTermAbstract" xlink:href="mrsn-20201231.xsd#mrsn_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_91b95258-c3df-44a3-a742-9c80a5f06d09_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7da34ddc-38a6-4e3d-9d9a-fe62d6b2b6bf_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_bfdc1c3a-c0e9-430c-8b16-d5aefe285292_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DeferredTaxAssetsLicensedTechnology_e611877c-f3f5-41ea-822c-253db816c1cb_terseLabel_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsLicensedTechnology" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed technology</link:label>
    <link:label id="lab_mrsn_DeferredTaxAssetsLicensedTechnology_label_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsLicensedTechnology" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Licensed Technology</link:label>
    <link:label id="lab_mrsn_DeferredTaxAssetsLicensedTechnology_documentation_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsLicensedTechnology" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from licensed technology.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsLicensedTechnology" xlink:href="mrsn-20201231.xsd#mrsn_DeferredTaxAssetsLicensedTechnology"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DeferredTaxAssetsLicensedTechnology" xlink:to="lab_mrsn_DeferredTaxAssetsLicensedTechnology" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cb1f7901-b70a-409c-9250-3bc5fcd9044a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5edc55e9-aa66-4962-b85c-88c3bdf21e88_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_da92c317-f819-4e33-a449-fb8cda8be789_terseLabel_en-US" xlink:label="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated useful life of property and equipment</link:label>
    <link:label id="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_label_en-US" xlink:label="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]</link:label>
    <link:label id="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_documentation_en-US" xlink:label="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:href="mrsn-20201231.xsd#mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ae16b9b8-ff19-4ecf-a758-4b60affd16a4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fb7b02ff-ff9d-40d4-bd14-48742ddb2ce6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_2ac100a6-3b10-42f4-a806-d4fa48ed0090_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_7de2d8ba-2820-48c4-8e6b-f5ee16c878f2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders &#8212; basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsCostsBilled_7923ba93-4479-4558-a20c-d23b1bb1d2e8_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsCostsBilled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 808 costs billed to Takeda</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsCostsBilled_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsCostsBilled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Costs Billed</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsCostsBilled_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsCostsBilled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of costs billed during the period under terms of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsCostsBilled" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsCostsBilled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsCostsBilled" xlink:to="lab_mrsn_CollaborationArrangementsCostsBilled" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b5d30ba4-145f-4044-b768-ab4745452777_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_974899ef-71b5-46ac-a371-9879a9d6cb9a_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_75724083-0f91-49a8-8f3d-48294e86c51e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c2779a15-2957-4b71-8873-242e73daea39_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_1f3f01ee-1b4d-4453-9e85-29a33550cb52_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of shared development costs following effective termination date</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Shared Development Costs Effective Following Termination Date, Period</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time following effective termination date in which development costs were equally shared with counterparty under the terms of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" xlink:to="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram774PerShareMember_8039e9dd-6ae2-4462-bfec-15c36658403a_terseLabel_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram774PerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program, 7.74 per Share</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram774PerShareMember_label_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram774PerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program, 7.74 per Share [Member]</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram774PerShareMember_documentation_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram774PerShareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program, 7.74 per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram774PerShareMember" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram774PerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AtMarketEquityOfferingProgram774PerShareMember" xlink:to="lab_mrsn_AtMarketEquityOfferingProgram774PerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_ddbe4590-821b-468e-87bd-6e6d00d15b62_negatedLabel_en-US" xlink:label="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock in exchange for common stock warrant</link:label>
    <link:label id="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_label_en-US" xlink:label="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Retired During Period, Exchanged for Common Stock Warrant, Value</link:label>
    <link:label id="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_documentation_en-US" xlink:label="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity impact of the value of stock that has been retired in exchange for common stock warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" xlink:href="mrsn-20201231.xsd#mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" xlink:to="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_9f5360b7-0994-4dc6-b34e-ae76a864f996_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5196b0c3-5a33-40f4-a2d9-940e3925c0d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4eb98730-f27e-47c5-8ad8-1fd23b164376_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_fdaaa31b-9e68-4674-b257-8e6fd11bdd5d_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck KGaA Agreement and Merck KGaA supply agreement</link:label>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_label_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Commercial License Agreement And Supply Agreement Merck Kgaa [Member]</link:label>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_documentation_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the Collaboration and Commercial License Agreement with Merck KGaA and the Supply Agreement with Merck KGaA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" xlink:to="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5043cdc8-797c-4463-bd8e-49488e14aa1b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from public offering of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability_d96e5618-8b8c-4da3-83ae-c7859001aaaa_terseLabel_en-US" xlink:label="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in lease liabilities</link:label>
    <link:label id="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease Modification, Increase (Decrease) In Operating Lease Liability</link:label>
    <link:label id="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in present value of lessee's discounted obligation for lease payments from operating lease due to lease modification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability" xlink:href="mrsn-20201231.xsd#mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_50e6ec72-a68e-45ce-8efa-b64c40a79395_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_1ec7d7d5-b619-4b2a-8d20-70c9283ef8ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_cfba9d91-1c1c-4409-8716-581fe17978ad_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest or penalties related to uncertain tax position</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_bd930655-6c8d-4285-8847-6fe92c3ab1dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6a7761f6-c48c-4044-a278-8c4ed1fa7e3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0f928190-4e06-4cfd-b724-f3775424513f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_59d563c0-f923-46a9-ac7d-b23b58f8d84b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_b0a4fc70-248f-42e0-b3d4-c7ca358d1cc0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheOneMember_a7e9c241-f5d0-4c0d-b64b-afd7c891fa95_terseLabel_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche One</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheOneMember_label_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche One [Member]</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheOneMember_documentation_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheOneMember" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AmendedCreditFacilityTrancheOneMember" xlink:to="lab_mrsn_AmendedCreditFacilityTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c51f3756-6c99-4efa-96f4-a0573f3412fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_396ab02f-7030-4fbe-84af-8ba7db65a9f6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4158c9df-fa3e-4ea9-89d8-a235c8dafb8d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_d167310b-4f23-41c9-a12b-44b09f1a356a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_cfa77890-baf7-4d93-9b7f-f1ba257767c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_56deee31-c248-4f0c-8dba-f676bd08fe7c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_ac116392-73d2-4f8b-b9fe-f43259aba9cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f2eb28cf-fe81-4dca-846e-93a887322ef1_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_be3ad276-880b-4fac-8670-5030fd8b76bd_terseLabel_en-US" xlink:label="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance, Discounts And Commissions On Transaction</link:label>
    <link:label id="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_e0909dfa-01da-482d-a76b-ccd234af300b_verboseLabel_en-US" xlink:label="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_label_en-US" xlink:label="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance, Discounts And Commissions On Transaction</link:label>
    <link:label id="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_documentation_en-US" xlink:label="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and commissions deducted from cash proceeds received on stock transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:to="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsDurationToTermination_8c7b4cfc-642f-45f5-84be-24268000195d_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDurationToTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time until agreement terminated</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDurationToTermination_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDurationToTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Duration to Termination</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDurationToTermination_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDurationToTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time before which agreement will be terminated due to counter party serving prior written notice, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDurationToTermination" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDurationToTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsDurationToTermination" xlink:to="lab_mrsn_CollaborationArrangementsDurationToTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b1e2ca69-d5bd-4fe6-940d-44c1bd04daec_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_e1d101cb-f795-45d4-ac62-b18a183d1792_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember_7b2deb45-845b-4fe4-aea5-b4f3cc1cc851_terseLabel_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program (2020 ATM)</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember_label_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program (2020 ATM) [Member]</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember_documentation_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program (2020 ATM)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2020ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember" xlink:to="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c7027ac5-46aa-4240-9162-533634cbc4f4_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_4ded541d-4304-4789-8747-e0fe03f29a4e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_10c21f6c-0ee3-447a-8be6-d0274f2ee246_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6f65cf0c-f560-4033-8ec6-2b0e2f17d9c6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_be8173dc-191e-4d19-bc28-073968063e5a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_a753f0a4-5f72-466c-8a63-767b52837e6d_terseLabel_en-US" xlink:label="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares exchanged for warrants (in shares)</link:label>
    <link:label id="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_label_en-US" xlink:label="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Shares Exchanged for Warrants</link:label>
    <link:label id="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_documentation_en-US" xlink:label="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares exchanged for warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" xlink:href="mrsn-20201231.xsd#mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" xlink:to="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d9736e26-5f14-4af3-a954-2d2a761bc4f5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a797a2b4-bde2-49ae-86d1-cac97696f0c0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_45b201be-e120-46e0-94ac-55c14372cc7d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6b8f428d-8283-4ca4-865c-894d27d5503e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ee4d8cfa-4b74-4af0-8e49-09b40e9b02f6_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_329f5b7b-0bc9-4511-98c4-435e6ec5d6cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e370bf80-e49f-4236-8115-16a70ce9a487_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_49dded29-cf35-4def-acb5-e514f24aa6f8_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3027a06a-2a9d-4eb5-b552-c54d72be8d93_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_831a189d-d365-499c-9fe3-f072da8fdf98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of marketable securities from cost basis to fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_4f4bd457-8a2c-45da-abc5-50ad12781d94_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_RevenueTransactionPriceAmount_9b28b539-6a3c-429e-a7fe-6fbc8f9bb9f8_verboseLabel_en-US" xlink:label="lab_mrsn_RevenueTransactionPriceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_mrsn_RevenueTransactionPriceAmount_label_en-US" xlink:label="lab_mrsn_RevenueTransactionPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Transaction Price, Amount</link:label>
    <link:label id="lab_mrsn_RevenueTransactionPriceAmount_documentation_en-US" xlink:label="lab_mrsn_RevenueTransactionPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price which represents the amount of consideration the entity expects to receive for transfer of goods and services. Amount is net of estimated fees associated with research and development activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueTransactionPriceAmount" xlink:href="mrsn-20201231.xsd#mrsn_RevenueTransactionPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_RevenueTransactionPriceAmount" xlink:to="lab_mrsn_RevenueTransactionPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_fc0648ec-8528-4893-9de2-f9a664d4daf4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_d0f9b23f-3682-49cc-91a8-66ffdc30bd8a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DebtCovenantPeriodDomain_dd9a201f-ca49-4b91-865a-58464452908d_terseLabel_en-US" xlink:label="lab_mrsn_DebtCovenantPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Period [Domain]</link:label>
    <link:label id="lab_mrsn_DebtCovenantPeriodDomain_label_en-US" xlink:label="lab_mrsn_DebtCovenantPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Period [Domain]</link:label>
    <link:label id="lab_mrsn_DebtCovenantPeriodDomain_documentation_en-US" xlink:label="lab_mrsn_DebtCovenantPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodDomain" xlink:href="mrsn-20201231.xsd#mrsn_DebtCovenantPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DebtCovenantPeriodDomain" xlink:to="lab_mrsn_DebtCovenantPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d9682b64-de08-47fd-bf52-dfa5b34aa9ff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ececff03-15f4-4a7a-bb78-db9f1a2e1b80_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_68009dc6-9208-4b96-8a6e-707cbb2f4fa1_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_74a695fe-25e3-430d-9e54-3da79fcabc61_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4613a7b3-826c-4e42-8def-2770cf8a89d0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_f76f45e5-10aa-43f0-9242-834c03ef6041_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_8e1684f3-e16d-47ff-87b2-586c539b00dd_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and corresponding research and development services, fourth target</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_label_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Related Research And Development Services Target Four [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the license and corresponding research and development services for fourth target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" xlink:to="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_RevenueCollectionPeriod_71b73995-14e8-446d-ac47-81dce73bfa15_terseLabel_en-US" xlink:label="lab_mrsn_RevenueCollectionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billing term</link:label>
    <link:label id="lab_mrsn_RevenueCollectionPeriod_label_en-US" xlink:label="lab_mrsn_RevenueCollectionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Collection Period</link:label>
    <link:label id="lab_mrsn_RevenueCollectionPeriod_documentation_en-US" xlink:label="lab_mrsn_RevenueCollectionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which entity receives payment upon billing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueCollectionPeriod" xlink:href="mrsn-20201231.xsd#mrsn_RevenueCollectionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_RevenueCollectionPeriod" xlink:to="lab_mrsn_RevenueCollectionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_23878496-e909-41c1-938f-0a9f6df91a2e_terseLabel_en-US" xlink:label="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional rate in event of default</link:label>
    <link:label id="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_label_en-US" xlink:label="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Additional Rate in Event of Default</link:label>
    <link:label id="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_documentation_en-US" xlink:label="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the additional percentage of rate in event of default under debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentAdditionalRateInEventOfDefault" xlink:href="mrsn-20201231.xsd#mrsn_DebtInstrumentAdditionalRateInEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DebtInstrumentAdditionalRateInEventOfDefault" xlink:to="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_f8058ee0-c8c0-45e6-a764-e5800d6661d3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9bd52919-146f-43e3-a972-aa43d23a3b4a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_59776e7e-3586-4098-92b0-eefb18ac046e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1c42e664-9d4d-48b8-ac39-155998d1d549_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_da2a2d68-6f3d-426f-9813-f45f57f646ee_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_21e76b85-7d23-4564-bee2-5227d07f6b4e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborativeArrangementsUpfrontPayment_20ffd17e-5f3d-4717-8037-a51a5e4ca7fe_terseLabel_en-US" xlink:label="lab_mrsn_CollaborativeArrangementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_mrsn_CollaborativeArrangementsUpfrontPayment_label_en-US" xlink:label="lab_mrsn_CollaborativeArrangementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements, Upfront Payment</link:label>
    <link:label id="lab_mrsn_CollaborativeArrangementsUpfrontPayment_documentation_en-US" xlink:label="lab_mrsn_CollaborativeArrangementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of upfront payment received during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsUpfrontPayment" xlink:href="mrsn-20201231.xsd#mrsn_CollaborativeArrangementsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborativeArrangementsUpfrontPayment" xlink:to="lab_mrsn_CollaborativeArrangementsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_66b47b13-d4df-4fc3-aef8-ab52b35e7091_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_272ee008-e466-483d-863a-03aa236a5e91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_82d8b622-5cab-454d-a15d-f6baea57361c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8465f2fc-0ff2-4113-a1d1-ad9e107d771f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_80fb7616-88fe-4241-9fab-4a4eefb883dd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Off-balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_a117f954-ebd2-4b82-830c-833969e3de91_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future minimum payments on finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsSalesMilestones_27f29e96-bcc8-4a6b-a08d-da418dc289e4_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsSalesMilestones_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Sales Milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsSalesMilestones_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum sales milestone amount the company is entitled to receive under terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSalesMilestones" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsSalesMilestones" xlink:to="lab_mrsn_CollaborationArrangementsSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_9ae408a8-e471-493d-8b06-467231f8d477_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_940870ca-e2f6-428a-beaf-6f354caecb64_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_736468d1-9459-4e54-9f31-96fc6eb02033_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior written notice for termination period</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Prior Written Termination Notice, Duration</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time before which prior written notice needs to be served for termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" xlink:to="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_c7a8b414-98d0-43bf-b0a0-dd2260f6c5cc_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_06fe28df-5ab6-4da0-ac57-143d34d7b7ee_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_abc6331b-68c5-4028-b8e0-7e0a1bbed951_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LeasesTable_ea674070-71b0-4a81-8eff-996447bdfb10_terseLabel_en-US" xlink:label="lab_mrsn_LeasesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Table]</link:label>
    <link:label id="lab_mrsn_LeasesTable_label_en-US" xlink:label="lab_mrsn_LeasesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Table]</link:label>
    <link:label id="lab_mrsn_LeasesTable_documentation_en-US" xlink:label="lab_mrsn_LeasesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesTable" xlink:href="mrsn-20201231.xsd#mrsn_LeasesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LeasesTable" xlink:to="lab_mrsn_LeasesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_c43692a0-52d9-4c43-988f-c7f8b3e9f184_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4f673499-d25f-499a-885c-f9e96fc01cdd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average amortization period of unrecognized stock compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_fc03a28e-9139-416b-9663-098ba4253d88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ea71e152-1dfe-4c4c-a468-bf1dd16dd4b9_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DeferredTaxAssetsLeaseLiabilities_b6b6d08c-5e70-4fb2-980e-e2632adb7f6e_terseLabel_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_mrsn_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_mrsn_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsLeaseLiabilities" xlink:href="mrsn-20201231.xsd#mrsn_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_mrsn_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_365e6f95-b1bc-453a-a4ed-8c7ee19df2b2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount_4899a784-c4ed-43eb-be31-4b9e2839b968_terseLabel_en-US" xlink:label="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual amount employer contributes per employee</link:label>
    <link:label id="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount_label_en-US" xlink:label="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Employer Contribution Per Employee, Amount</link:label>
    <link:label id="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount_documentation_en-US" xlink:label="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual amount the employer contributes per employee to a defined contribution plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" xlink:href="mrsn-20201231.xsd#mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" xlink:to="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_921229dc-8280-4f50-a233-5b3c6db92726_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule for number of common stock reserved for exercise of outstanding stock options and warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_cc09a273-cc9b-41b5-aceb-8e6edd973199_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3c4375ee-6723-4c71-b049-9cab73a1cfbb_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts included in the contract liability at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1bf4639e-d4c5-4f59-b54a-ffce569681c8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_35a65791-eb3a-4a00-8f7f-f3a828b64643_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from purchases of common stock under ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a8d955c4-e519-4f3c-805f-ddcd43161d06_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e7118d20-ee3c-4c30-97a6-0bd0ab54ec98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Prices in&#160;Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DeferredTaxAssetsDepreciation_c3c2e0fb-f020-4ba5-82b5-a20478d72e7f_terseLabel_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_mrsn_DeferredTaxAssetsDepreciation_label_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Depreciation</link:label>
    <link:label id="lab_mrsn_DeferredTaxAssetsDepreciation_documentation_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsDepreciation" xlink:href="mrsn-20201231.xsd#mrsn_DeferredTaxAssetsDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DeferredTaxAssetsDepreciation" xlink:to="lab_mrsn_DeferredTaxAssetsDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_86fbee78-8f3b-48ca-891a-27248ab6521e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_b316c9d1-3509-4e5b-9aee-3d2658aff363_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5e6d43f8-3d7c-4031-a280-4cf11b683b5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ccafea6d-f665-4b1b-a11a-f7f2339a5e07_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_78b30ca7-d951-4abd-bfb8-dcc5b7bc8a37_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_da25434c-0db2-4edd-bac6-886e4b9e83ae_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ef45f7ec-e184-4789-82aa-b088ade979b0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_7041e611-587d-4055-9369-ce80ab12aa77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected quarterly financial data (unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_fe0124d2-c2bb-407a-a339-f230406dedb8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_c396d184-f4de-4e78-88a8-97d3b7b0e9ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_11909306-6080-4d92-a38d-da688ac4c6df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_b2aa9c81-959c-42f8-bc9f-9f898c72b92d_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold to date (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_804fd420-1c86-4de0-aab3-dbf28d50f35d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_89eaf685-fc56-44ba-ac1a-4c3fe4026c92_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_06845cf4-9bb0-42be-bce3-84efc9edb296_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions_76b793b5-9edf-46da-874a-8ee8742ce9c6_verboseLabel_en-US" xlink:label="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of state jurisdictions in which entity files income tax returns</link:label>
    <link:label id="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions_label_en-US" xlink:label="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes, Number of State Jurisdictions</link:label>
    <link:label id="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions_documentation_en-US" xlink:label="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of state jurisdictions in which entity files income tax returns.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncomeTaxesNumberOfStateJurisdictions" xlink:href="mrsn-20201231.xsd#mrsn_IncomeTaxesNumberOfStateJurisdictions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_IncomeTaxesNumberOfStateJurisdictions" xlink:to="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_23904d66-9969-4a34-ab42-f0677e8639eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d4fc44cd-6e03-4f9f-b18a-20aa6408f4ab_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_f6213328-67fb-489f-b517-df8f8e84530f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_4990696e-6542-4222-bc36-117e6802c92c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_dbee5279-3a1d-47e8-ae74-763b73ce4875_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments with off-balance sheet risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:to="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_2c55124b-fc00-4043-91be-2bd1a5b005b5_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of development milestone payment received</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Development Milestones Payment Received</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the development milestone payment received by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" xlink:to="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAgreementMilestonePaymentsMember_2af2cf74-77ad-4aec-813d-22c74c2b243e_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAgreementMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payments</link:label>
    <link:label id="lab_mrsn_LicenseAgreementMilestonePaymentsMember_label_en-US" xlink:label="lab_mrsn_LicenseAgreementMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payments [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAgreementMilestonePaymentsMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAgreementMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAgreementMilestonePaymentsMember" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAgreementMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAgreementMilestonePaymentsMember" xlink:to="lab_mrsn_LicenseAgreementMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6ea205d0-756b-4c16-b28f-8279e67f4388_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones_8751bb79-8b46-4f08-9617-9c293b7f7b25_totalLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Maximum Aggregate Milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate milestone the Company is entitled to receive under terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsMaximumAggregateMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:to="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_64b83a53-0e0b-4f8f-b138-4b309c2d1484_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of ownership shift</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_4f09e356-5e04-4640-8469-9b9cdbd904d7_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next potential development milestone payment eligible to receive</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Development Milestones Payment Receivable, Next Milestone</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the next potential development milestone the company will be eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" xlink:to="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a53b8be2-2241-46a3-9f96-ecebcb3417f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9d4838fe-0584-4a5f-bb70-a94ebaa774d8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_fdf179de-eab4-4c67-90dd-fb277c4ad5cd_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_ae0e560c-26b0-492b-872e-8592fbfde5c1_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b84f627f-0d4b-4ea9-be00-37506cdcfac5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_70ab4c27-b3ec-471d-8cd9-6439e2858b02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted stock unit activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_WarrantsAndShareBasedPaymentsMember_ca9abb76-b289-42df-a7c1-3944954df688_terseLabel_en-US" xlink:label="lab_mrsn_WarrantsAndShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and share-based payment awards</link:label>
    <link:label id="lab_mrsn_WarrantsAndShareBasedPaymentsMember_label_en-US" xlink:label="lab_mrsn_WarrantsAndShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Share Based Payments [Member]</link:label>
    <link:label id="lab_mrsn_WarrantsAndShareBasedPaymentsMember_documentation_en-US" xlink:label="lab_mrsn_WarrantsAndShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and share-based payment awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsAndShareBasedPaymentsMember" xlink:href="mrsn-20201231.xsd#mrsn_WarrantsAndShareBasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_WarrantsAndShareBasedPaymentsMember" xlink:to="lab_mrsn_WarrantsAndShareBasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8d78d7c1-40dd-407d-9b34-32ccce59cdb5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_8964fdc7-fa4c-4433-a0ea-a1fec65f8acb_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_13e82892-8d9d-4b2b-b225-46d75844091e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from the exercise of stock options (in dollars)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LesseeOperatingLeasesAbstract_13380c67-73c6-4a6e-bd33-d90235ef056c_terseLabel_en-US" xlink:label="lab_mrsn_LesseeOperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_mrsn_LesseeOperatingLeasesAbstract_label_en-US" xlink:label="lab_mrsn_LesseeOperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Leases [Abstract]</link:label>
    <link:label id="lab_mrsn_LesseeOperatingLeasesAbstract_documentation_en-US" xlink:label="lab_mrsn_LesseeOperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingLeasesAbstract" xlink:href="mrsn-20201231.xsd#mrsn_LesseeOperatingLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LesseeOperatingLeasesAbstract" xlink:to="lab_mrsn_LesseeOperatingLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract_a6962ea9-a929-4263-a16a-cf1469e0abb0_terseLabel_en-US" xlink:label="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract_documentation_en-US" xlink:label="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Supplemental Cash Flow Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract" xlink:href="mrsn-20201231.xsd#mrsn_LeasesSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract" xlink:to="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_PrepaymentOccursPriorToAugust282021Member_7021a595-a301-45f3-be85-007ee28002b6_terseLabel_en-US" xlink:label="lab_mrsn_PrepaymentOccursPriorToAugust282021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment occurs prior to August 28, 2020</link:label>
    <link:label id="lab_mrsn_PrepaymentOccursPriorToAugust282021Member_label_en-US" xlink:label="lab_mrsn_PrepaymentOccursPriorToAugust282021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Occurs Prior To August 28, 2021 [Member]</link:label>
    <link:label id="lab_mrsn_PrepaymentOccursPriorToAugust282021Member_documentation_en-US" xlink:label="lab_mrsn_PrepaymentOccursPriorToAugust282021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the prepayment occurs prior to August 28, 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursPriorToAugust282021Member" xlink:href="mrsn-20201231.xsd#mrsn_PrepaymentOccursPriorToAugust282021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_PrepaymentOccursPriorToAugust282021Member" xlink:to="lab_mrsn_PrepaymentOccursPriorToAugust282021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_PublicStockOfferingMember_ba83e05f-28e8-4328-875d-e49544160b0f_terseLabel_en-US" xlink:label="lab_mrsn_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_mrsn_PublicStockOfferingMember_label_en-US" xlink:label="lab_mrsn_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_mrsn_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_mrsn_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember" xlink:href="mrsn-20201231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_PublicStockOfferingMember" xlink:to="lab_mrsn_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54b38cdd-e150-4fa9-b3db-80f12ba1672c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_984ebb84-f1be-431d-a353-126777aa12ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34c25682-873e-404f-ade3-26d13adcfa59_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_7cf2ca3e-7fd1-4444-b9f1-20657058e5b8_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adopted</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3c1cb34b-3728-47ff-a9da-fdc540e911af_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e3ca9c09-c27b-47f1-b8e7-0148200ab6a6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock_5ec71111-c3db-48f2-ad57-07234a6abcdf_terseLabel_en-US" xlink:label="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental balance sheet information related to leases</link:label>
    <link:label id="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock_label_en-US" xlink:label="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating And Finance Lease, Supplemental Balance Sheet Information [Table Text Block]</link:label>
    <link:label id="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock_documentation_en-US" xlink:label="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tabular disclosure of supplemental balance sheet information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" xlink:href="mrsn-20201231.xsd#mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" xlink:to="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_dec0e77f-997d-4777-969c-3a9c5788d523_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_f3dcf38a-81b8-4055-a900-e5b06240707d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_60310e9c-169e-4f52-9d1c-9a8be9f1c43b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_1f031631-9f9f-4270-9277-0ee55acefc87_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_a9454e13-5987-434e-ba0c-2bff1b6c3660_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_c77714f2-a29d-4fb4-aff9-d991302605f9_terseLabel_en-US" xlink:label="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XMT-1522 agreement</link:label>
    <link:label id="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_label_en-US" xlink:label="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Collaboration And Commercial License Agreement Takeda [Member]</link:label>
    <link:label id="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_documentation_en-US" xlink:label="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the Development Collaboration and Commercial License Agreement for the development and commercialization of XMT-1522 with Takeda Pharmaceutical Company Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:href="mrsn-20201231.xsd#mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:to="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent_45496ec2-adb3-4ee8-919d-5b85274fd020_terseLabel_en-US" xlink:label="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt, net of current portion</link:label>
    <link:label id="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent_label_en-US" xlink:label="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount, Noncurrent</link:label>
    <link:label id="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent_documentation_en-US" xlink:label="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, classified as noncurrent. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent" xlink:href="mrsn-20201231.xsd#mrsn_DebtInstrumentCarryingAmountNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent" xlink:to="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_dd5ba56a-ac4d-47d6-8964-ec1e213e895a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_e8f3e7d1-7ff9-4bcd-86cb-36d8efb064dc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsRegulatoryMilestones_7e895580-5878-4cb4-a525-e83e78edb3c7_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsRegulatoryMilestones_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Regulatory Milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsRegulatoryMilestones_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum regulatory milestone amount the company is entitled to receive under terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsRegulatoryMilestones" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsRegulatoryMilestones" xlink:to="lab_mrsn_CollaborationArrangementsRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_745f9f40-578d-4101-a561-3cf0f8227665_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_f3f22f20-f238-44c4-b647-92af0cef6a89_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_b0734af6-6480-4ecc-8795-2f69f042ebe8_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_74d52e4f-fc88-4b71-86d7-2f06431621ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of income tax rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fb65140c-e3ed-428b-b3cc-34c92976f371_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember_d23a4ebc-ba0d-4683-9cb5-5c8558024447_terseLabel_en-US" xlink:label="lab_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment, office equipment and software</link:label>
    <link:label id="lab_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment Office Equipment And Software [Member]</link:label>
    <link:label id="lab_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to computer equipment, office equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember" xlink:href="mrsn-20201231.xsd#mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="lab_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_853d40c8-23bf-4538-8854-7f91e5a5e1d8_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana BioSciences</link:label>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_label_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Commercial License Agreement Asana Bio Sciences [Member]</link:label>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_documentation_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the Collaboration and Commercial License Agreement with Asana BioSciences, an existing partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" xlink:to="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LesseeFinanceLeasesAbstract_4cf04dea-779d-4977-af30-93c8073de4b0_terseLabel_en-US" xlink:label="lab_mrsn_LesseeFinanceLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases:</link:label>
    <link:label id="lab_mrsn_LesseeFinanceLeasesAbstract_label_en-US" xlink:label="lab_mrsn_LesseeFinanceLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Abstract]</link:label>
    <link:label id="lab_mrsn_LesseeFinanceLeasesAbstract_documentation_en-US" xlink:label="lab_mrsn_LesseeFinanceLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeFinanceLeasesAbstract" xlink:href="mrsn-20201231.xsd#mrsn_LesseeFinanceLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LesseeFinanceLeasesAbstract" xlink:to="lab_mrsn_LesseeFinanceLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_50c2c378-1370-4e7b-9629-86d58d9d4426_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_13851797-26dd-48d3-bf2b-4a623640bd0c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationAgreementsAbstract_6c9367e9-56d5-448f-9823-023fa0163b32_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements</link:label>
    <link:label id="lab_mrsn_CollaborationAgreementsAbstract_label_en-US" xlink:label="lab_mrsn_CollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements</link:label>
    <link:label id="lab_mrsn_CollaborationAgreementsAbstract_documentation_en-US" xlink:label="lab_mrsn_CollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationAgreementsAbstract" xlink:to="lab_mrsn_CollaborationAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_e65494b5-86ba-44a8-b60e-287c420024e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b66be2fc-1f64-42b2-b018-e95227da7ce7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_508391bf-8b0f-492e-aedd-e2eb8918cee9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0e79926a-737f-45c8-a8cf-cdacdb5da71b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_68a18d44-263d-4edd-935e-836fc173a677_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_e8c81ced-abcf-4011-bf33-57b2e0115a72_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_a2134e22-40ca-4f36-b138-d1a06ac91603_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit for security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_4fea433b-38a0-4f02-bcb0-a933e505a9e5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_86036555-2911-48b0-a40b-36a9a36da2fa_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_faaede74-c82b-447b-952f-02a9284ef1da_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and corresponding research and development services, fifth target</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_label_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Related Research And Development Services Target Five [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the license and corresponding research and development services for fifth target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" xlink:to="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_330930f0-9d7e-403f-97ee-f47fb4ac6f8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock-based compensation expense by award type</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9e2dbc05-a2eb-41a0-acaa-c9ca73806106_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_5bdf97fa-a378-4f08-b6e0-e6380ce2e742_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual development milestones per target</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement Individual Development Milestones Target Number</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual development milestones per target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" xlink:to="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c68d7dca-1ab4-4665-a255-d2b18f000d78_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_WarrantsExercisedInPeriod_af6022ad-2f2f-4ad6-9a09-fb96899bfff9_terseLabel_en-US" xlink:label="lab_mrsn_WarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common upon exercise of warrant (in shares)</link:label>
    <link:label id="lab_mrsn_WarrantsExercisedInPeriod_label_en-US" xlink:label="lab_mrsn_WarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Exercised In Period</link:label>
    <link:label id="lab_mrsn_WarrantsExercisedInPeriod_documentation_en-US" xlink:label="lab_mrsn_WarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of stock issued as a result of the exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsExercisedInPeriod" xlink:href="mrsn-20201231.xsd#mrsn_WarrantsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_WarrantsExercisedInPeriod" xlink:to="lab_mrsn_WarrantsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_78e09d93-1171-41ac-afea-3e485b003bc5_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember_31df3748-071f-4ebb-a9e1-8a50f62178b7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation, Share-based Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:to="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_d901d8cd-40ce-4cc0-9a25-65382c46ae0e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c5edd11e-bfdf-4ddc-a01e-4911c6236d39_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_10bc4195-0cd3-4e12-bb93-ebcb6dac957b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_9dc571ed-05b4-4f19-a53c-5c7f39b11470_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a20af1f2-a802-40b5-900b-b78f19cd00ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram559PerShareMember_d2a83085-aac4-4134-b9c7-90c93754c28c_terseLabel_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram559PerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program, 5.59 per Share</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram559PerShareMember_label_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram559PerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program, 5.59 per Share [Member]</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram559PerShareMember_documentation_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram559PerShareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program, 5.59 per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram559PerShareMember" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram559PerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AtMarketEquityOfferingProgram559PerShareMember" xlink:to="lab_mrsn_AtMarketEquityOfferingProgram559PerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_b2bf9984-0625-4d39-bdf0-0e18a073c081_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and related research and development services, including phase 1 development and transfer certain materials and know how</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_label_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Related Research And Development Services And Development And Transfer [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and related research and development services, including Phase 1 development and transfer certain materials and know how related to the Company's manufacturing processes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" xlink:to="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4a57d9f4-ae37-4877-b21e-0b937ddba08a_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization of premiums and discounts on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_eda10596-1152-4b6a-a637-0ef6a8ff767e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_78553f5e-5908-4609-83c1-97a14d42fefa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ddee7584-cd15-4977-bace-e8ccfcaef3c8_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ed69e000-2227-4dc4-b437-2cc1a9294cc5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4de4568b-2ee4-4568-8753-1ca8ba0191a6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_a8c99595-a402-49b3-821e-5c522b38d70e_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual commercial milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement Individual Commercial Milestones Target Number</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual commercial milestones per target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" xlink:to="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bc14c3b2-aebf-4707-ae3d-29519af2569b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8e83184d-15ad-4f4c-8718-39aef9e58230_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_caeec5d0-f8d5-416e-a495-afa003394173_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b32e55e8-db11-40ed-b4dc-42dba48bd946_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_29a78814-8878-465f-abc6-bce8eccc1c46_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual regulatory milestones per target</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement Individual Regulatory Milestones Target Number</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual regulatory milestones per target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" xlink:to="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_f3f64265-fe34-490e-92e2-634c411289f7_terseLabel_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="mrsn-20201231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ProceedsFromIssuanceOfCommonStockGross_ad0637ab-9f80-494d-87d6-df2428f634af_terseLabel_en-US" xlink:label="lab_mrsn_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, gross</link:label>
    <link:label id="lab_mrsn_ProceedsFromIssuanceOfCommonStockGross_label_en-US" xlink:label="lab_mrsn_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Gross</link:label>
    <link:label id="lab_mrsn_ProceedsFromIssuanceOfCommonStockGross_documentation_en-US" xlink:label="lab_mrsn_ProceedsFromIssuanceOfCommonStockGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The gross proceeds from the additional capital contribution to the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromIssuanceOfCommonStockGross" xlink:href="mrsn-20201231.xsd#mrsn_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ProceedsFromIssuanceOfCommonStockGross" xlink:to="lab_mrsn_ProceedsFromIssuanceOfCommonStockGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c2845b14-1e62-469c-8535-37fbc66bb22a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheSixMember_7132aea6-c9e9-42f7-a98f-01a10a268fa2_terseLabel_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Six</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheSixMember_label_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Six [Member]</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheSixMember_documentation_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheSixMember" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AmendedCreditFacilityTrancheSixMember" xlink:to="lab_mrsn_AmendedCreditFacilityTrancheSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_847d1788-e105-48e5-bf41-20b10003c518_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2dd70210-a5d9-4306-8ccc-a9c1919549f4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_c85e488d-17b0-48ff-9a10-105c05d5ba02_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_OfficeSpaceCambridgeMaMember_e47d7045-4f8e-47c4-901e-5c86e32044c3_terseLabel_en-US" xlink:label="lab_mrsn_OfficeSpaceCambridgeMaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space, Cambridge, MA, Leased</link:label>
    <link:label id="lab_mrsn_OfficeSpaceCambridgeMaMember_label_en-US" xlink:label="lab_mrsn_OfficeSpaceCambridgeMaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Cambridge Ma [Member]</link:label>
    <link:label id="lab_mrsn_OfficeSpaceCambridgeMaMember_documentation_en-US" xlink:label="lab_mrsn_OfficeSpaceCambridgeMaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space in Cambridge, MA under operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OfficeSpaceCambridgeMaMember" xlink:href="mrsn-20201231.xsd#mrsn_OfficeSpaceCambridgeMaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_OfficeSpaceCambridgeMaMember" xlink:to="lab_mrsn_OfficeSpaceCambridgeMaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c0c53af4-b87a-48ce-bc01-24dc63f28906_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_26c6cce9-ea7e-438b-87a8-31180ede0c77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted average assumptions for estimating fair value of option awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_5de142de-99de-486b-9122-0346bbdc8d30_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage employer matches of the employee's percentage contribution matched</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_83b95876-1a17-4e4b-a867-0ca08e93d7fb_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ad4fc2f9-39ac-4e8c-acff-701b6443457f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_59aebe6a-1736-44e3-8c21-4f8876a72540_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_58f8f004-9c47-49cb-9ec8-8c57f9ebf04c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_072fef5e-fb6e-4def-9d5a-424e6c95fd05_terseLabel_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and warrants (in shares)</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_label_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Options and Warrants Exercised</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_documentation_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock issued as a result of the exercise of stock options and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:to="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22339033-6ef3-4708-9633-63dc4e683978_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_92edd5af-243f-4e53-8717-25d2606a315f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d6652e28-7f29-4462-b1e9-6bf5d0cd94ff_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_958f6537-0083-47f4-af51-df3580950999_terseLabel_en-US" xlink:label="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental cash flow information related to leases</link:label>
    <link:label id="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_label_en-US" xlink:label="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating And Finance Lease, Supplemental Cash Flow Information [Table Text Block]</link:label>
    <link:label id="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_documentation_en-US" xlink:label="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tabular disclosure of supplemental cash flows information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:href="mrsn-20201231.xsd#mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:to="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_02b2606d-109a-417d-bf13-f66ae672b017_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting for Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_eea7f536-19b7-4b43-94fe-7551518e2a1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a67fdcbb-008f-4deb-9e98-5a86ab5a6785_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect adjustment for adoption of ASC 606</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_f7bb1b0c-0f27-4d8e-ab58-aa60a0d23b10_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_80d21b87-974c-44a6-9e7c-268e2ef8ec9a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesAbstract_ab90dd48-6668-4517-bfd8-1347dd02ba7a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract" xlink:to="lab_us-gaap_MarketableSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_58ff752a-58cb-42e1-bf3c-729578e6fd48_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_73c84ede-50a7-4dc0-af14-88b0fde2ed3e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5ace1cb6-0d14-400d-b914-b67838ca0f0a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_8a549957-503e-47a9-a6a8-90a68116a6d3_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_f20fb510-e07f-4351-b27c-4f9bc8b907a0_negatedLabel_en-US" xlink:label="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock in exchange for common stock warrant (in shares)</link:label>
    <link:label id="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_label_en-US" xlink:label="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Retired During Period, Exchanged For Common Stock Warrant, Shares</link:label>
    <link:label id="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_documentation_en-US" xlink:label="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock that have been retired in exchange for common stock warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" xlink:href="mrsn-20201231.xsd#mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" xlink:to="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_ab208212-03d8-45cd-8f27-98bcb1a5422c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_24b99c42-72ce-479e-bf05-d6b447614b73_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt financing costs, net of accretion</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f80a7498-58ea-451a-bf9a-300c505a283b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_b2de6193-4ebb-407f-952e-70831349efc1_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value adjustment</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIssuanceProgramAuthorizedAmount_7c283c67-923b-4314-bf89-83d4f78ab749_terseLabel_en-US" xlink:label="lab_mrsn_StockIssuanceProgramAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of shares authorized to be offered and sold</link:label>
    <link:label id="lab_mrsn_StockIssuanceProgramAuthorizedAmount_label_en-US" xlink:label="lab_mrsn_StockIssuanceProgramAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Program, Authorized Amount</link:label>
    <link:label id="lab_mrsn_StockIssuanceProgramAuthorizedAmount_documentation_en-US" xlink:label="lab_mrsn_StockIssuanceProgramAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of common stock shares authorized to be issued under the program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceProgramAuthorizedAmount" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuanceProgramAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIssuanceProgramAuthorizedAmount" xlink:to="lab_mrsn_StockIssuanceProgramAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_TenantImprovementAllowance_826aa6a7-b701-4136-9cde-ce3ff7f02ba5_terseLabel_en-US" xlink:label="lab_mrsn_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_mrsn_TenantImprovementAllowance_label_en-US" xlink:label="lab_mrsn_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance</link:label>
    <link:label id="lab_mrsn_TenantImprovementAllowance_documentation_en-US" xlink:label="lab_mrsn_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of allowance granted and reimbursable by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenants occupancy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_TenantImprovementAllowance" xlink:href="mrsn-20201231.xsd#mrsn_TenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_TenantImprovementAllowance" xlink:to="lab_mrsn_TenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_42d673e3-ba46-4909-ac4e-af7dc31fd739_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a3f7814a-b25e-46c3-ae21-3c23e882d23d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_91007383-2c44-4bed-a738-b0a00f7a37fe_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_592e03a7-ae0f-4f41-a811-b93d0201a547_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DebtInstrumentPrepaymentFeePercent_848ace10-71d3-4706-9c75-bb088179ea84_terseLabel_en-US" xlink:label="lab_mrsn_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee percentage</link:label>
    <link:label id="lab_mrsn_DebtInstrumentPrepaymentFeePercent_label_en-US" xlink:label="lab_mrsn_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Percent</link:label>
    <link:label id="lab_mrsn_DebtInstrumentPrepaymentFeePercent_documentation_en-US" xlink:label="lab_mrsn_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of prepayment fee under debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentPrepaymentFeePercent" xlink:href="mrsn-20201231.xsd#mrsn_DebtInstrumentPrepaymentFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DebtInstrumentPrepaymentFeePercent" xlink:to="lab_mrsn_DebtInstrumentPrepaymentFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_24d639a0-d4b4-4529-b762-80097efdce3a_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b03eb999-f1c7-4804-8e2a-5a225f056d32_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_461e6c22-cb82-4caa-b8af-195f2509854f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_d59445bb-201b-4db2-a888-ed0d98f0ceba_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other assets, noncurrent</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_WeightedAverageDiscountRateAbstract_6309e369-1365-42ee-8521-5d901f2253e5_terseLabel_en-US" xlink:label="lab_mrsn_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate:</link:label>
    <link:label id="lab_mrsn_WeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_mrsn_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_mrsn_WeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_mrsn_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WeightedAverageDiscountRateAbstract" xlink:href="mrsn-20201231.xsd#mrsn_WeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_WeightedAverageDiscountRateAbstract" xlink:to="lab_mrsn_WeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_be6a0ec4-ed10-4eb4-96f1-002a3a94bb70_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_448a87bc-f0fe-429b-9e14-1cd1fa18560d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_5e44ba90-c6f5-431d-8e65-e56a2c0e6c0b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carry-forwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_244e2266-3906-4276-a507-66eb1aaef88c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_cbc3c4cb-40c6-444f-9852-839832a7c1e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3523411a-8357-45e1-ab38-3fccf1d8e978_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares used in net loss per share attributable to common stockholders &#8212; basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_991aff8b-c36c-44e2-8412-b06ea956421a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheFourMember_c4a4004c-95d8-4098-908e-a77b1420b6da_terseLabel_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Four</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheFourMember_label_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Four [Member]</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheFourMember_documentation_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheFourMember" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AmendedCreditFacilityTrancheFourMember" xlink:to="lab_mrsn_AmendedCreditFacilityTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_07f642b5-ba60-40a2-90a5-46ec45b5f4e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7e95d1c6-079d-4de8-b28c-2b230914524e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f97f8f8b-52e6-428e-911a-1e6511775cc1_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets_7e7076b6-c6f0-429a-b9ce-84993fb3b64e_terseLabel_en-US" xlink:label="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in right-of-use asset</link:label>
    <link:label id="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets_label_en-US" xlink:label="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease Modification, Increase (Decrease) In Right-of-use Assets</link:label>
    <link:label id="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets_documentation_en-US" xlink:label="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) in lessee's right to use underlying asset under operating lease due to lease modification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets" xlink:href="mrsn-20201231.xsd#mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets" xlink:to="lab_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d93fcf72-59c8-46a1-8e31-2a58e2abc948_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_18a2dee7-9baf-4146-9c33-0b02e15f6839_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_e0cc6cae-e6ac-4d41-9c19-0ce0770155f5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ac73546c-b74d-4066-a9c0-498313364816_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_8b047d27-2f9e-419a-be05-85312d6443d9_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_9726d72b-f8c3-4102-a34f-e53dd2c427e6_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued_6e0d152f-fbb2-4ebf-bb2b-6b85f248d746_terseLabel_en-US" xlink:label="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares into which warrant issued during period may be converted</link:label>
    <link:label id="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued_label_en-US" xlink:label="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Securities Called by Warrants or Rights, Number Issued</link:label>
    <link:label id="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued_documentation_en-US" xlink:label="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities into which the class of warrant or right issued during the period may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" xlink:href="mrsn-20201231.xsd#mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" xlink:to="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_701aa133-16ad-4370-a3af-38e3f7e6b4c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_NumberOfVotesPerCommonShare_8baa2a9f-5fa2-4c5d-a5db-c4826fd02d1c_terseLabel_en-US" xlink:label="lab_mrsn_NumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per common share</link:label>
    <link:label id="lab_mrsn_NumberOfVotesPerCommonShare_label_en-US" xlink:label="lab_mrsn_NumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Per Common Share</link:label>
    <link:label id="lab_mrsn_NumberOfVotesPerCommonShare_documentation_en-US" xlink:label="lab_mrsn_NumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of votes for each shares held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NumberOfVotesPerCommonShare" xlink:href="mrsn-20201231.xsd#mrsn_NumberOfVotesPerCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_NumberOfVotesPerCommonShare" xlink:to="lab_mrsn_NumberOfVotesPerCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_857b7d4c-4459-4188-9d49-13fe98e8c692_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_2f9e2c1f-2ac2-421b-8a5d-8611f47b8222_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d83e4532-2567-4e81-b45a-1aa5d50eaff6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets regularly measured and carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_e74aed39-7b77-4a17-ada3-916828c05307_terseLabel_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future principal payments</link:label>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_label_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_99d94e7d-802b-4f30-b068-acf2d98b6580_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestones_a65e506b-5ada-4c89-9cad-09f5bda05e8a_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestones_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Development Milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestones_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum development milestone amount the company is entitled to receive under terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestones" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsDevelopmentMilestones" xlink:to="lab_mrsn_CollaborationArrangementsDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_f9d3864d-bc11-47fc-92f9-b2023b5553b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a4124aff-cb83-4ddb-a9bd-a3569b037b96_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_c5d2964b-6bff-4d58-bdda-2a94639bd28c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_07c159f8-cc42-4e80-bd97-9281808509bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_7e95cae3-e5c2-43ed-b23c-d422d03e1d11_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_1754a22c-dbca-4ef6-8d23-3ae1023fb727_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb27cadf-0f49-4e37-90d8-566fba0c1db2_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares of common stock used in net income (loss) per share attributable to common stockholders &#8212; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_cf015bd4-e63b-4ac6-a355-c392e09f777b_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ed91aa39-a225-414a-9ac7-c2ba0c8176bf_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_eb2e0928-4cdb-49ec-865d-60cf5f1e3ef0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities measured and carried at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_97d8c825-dd0f-4e28-bd16-795b9caab71f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_dba6221a-66a2-4c32-abd1-f82075c34993_terseLabel_en-US" xlink:label="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Restated Tokeda agreement and XMT-1522 agreement</link:label>
    <link:label id="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_label_en-US" xlink:label="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And Commercial License Agreement Takeda2016 Restated Agreement And Development Collaboration And Commercial License Agreement Takeda [Member]</link:label>
    <link:label id="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_documentation_en-US" xlink:label="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the 2016 Restated Research Collaboration and Commercial License Agreement with Takeda Pharmaceutical Company Limited. Also includes the Development Collaboration and Commercial License Agreement for the development and commercialization of XMT-1522 with Takeda Pharmaceutical Company Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:href="mrsn-20201231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:to="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_JointResearchCommitteeServicesMember_1a35dc22-69b4-4b5b-bd95-440b9d3c3204_terseLabel_en-US" xlink:label="lab_mrsn_JointResearchCommitteeServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint research committee services</link:label>
    <link:label id="lab_mrsn_JointResearchCommitteeServicesMember_label_en-US" xlink:label="lab_mrsn_JointResearchCommitteeServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Research Committee Services [Member]</link:label>
    <link:label id="lab_mrsn_JointResearchCommitteeServicesMember_documentation_en-US" xlink:label="lab_mrsn_JointResearchCommitteeServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents joint research committee services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_JointResearchCommitteeServicesMember" xlink:href="mrsn-20201231.xsd#mrsn_JointResearchCommitteeServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_JointResearchCommitteeServicesMember" xlink:to="lab_mrsn_JointResearchCommitteeServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f69dc42c-f25b-4dc9-98ae-b0d7d7fa2a0a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5124b626-b4ef-4c7d-8acb-e116a7910cd4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4bd15bfc-55b9-48a5-840d-82b34b52ca44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2d838d52-0ed7-4fa2-a950-414b03273200_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_418b5913-2d27-4142-a22c-564030123192_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_dcb22f42-1f7f-4cc1-a39b-dd980d8c0f79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cbb72b0c-8b42-47a9-8b79-210aafe217b1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ContractWithCustomerLiabilityDecrease_39cb1f94-d6f9-4a9e-b784-1e8f07c3bcf4_terseLabel_en-US" xlink:label="lab_mrsn_ContractWithCustomerLiabilityDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, deductions</link:label>
    <link:label id="lab_mrsn_ContractWithCustomerLiabilityDecrease_label_en-US" xlink:label="lab_mrsn_ContractWithCustomerLiabilityDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Decrease</link:label>
    <link:label id="lab_mrsn_ContractWithCustomerLiabilityDecrease_documentation_en-US" xlink:label="lab_mrsn_ContractWithCustomerLiabilityDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of decrease in obligation to transfer good or service to customer for which consideration has been received or is receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractWithCustomerLiabilityDecrease" xlink:href="mrsn-20201231.xsd#mrsn_ContractWithCustomerLiabilityDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ContractWithCustomerLiabilityDecrease" xlink:to="lab_mrsn_ContractWithCustomerLiabilityDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_5767c6d1-0acb-4c20-a17a-fae75826d04f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_RevenueRemainingPerformanceObligationNumber_53b0abd9-a562-493d-9898-2ee2986fe19c_terseLabel_en-US" xlink:label="lab_mrsn_RevenueRemainingPerformanceObligationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mrsn_RevenueRemainingPerformanceObligationNumber_label_en-US" xlink:label="lab_mrsn_RevenueRemainingPerformanceObligationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Number</link:label>
    <link:label id="lab_mrsn_RevenueRemainingPerformanceObligationNumber_documentation_en-US" xlink:label="lab_mrsn_RevenueRemainingPerformanceObligationNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueRemainingPerformanceObligationNumber" xlink:href="mrsn-20201231.xsd#mrsn_RevenueRemainingPerformanceObligationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_RevenueRemainingPerformanceObligationNumber" xlink:to="lab_mrsn_RevenueRemainingPerformanceObligationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a8a2f1f2-4527-4706-9ab0-1802b878a699_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_1419a14d-4e90-4a61-83c5-3c9848cb2d72_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock warrant in exchange for retirement of common stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_fda56b26-376b-4f43-96f9-c3004a84d6c1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock under ESPP</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6b0deba8-5aea-4598-962b-b4cfb7dc43a1_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in Total operating expenses</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_cbdf40fb-c988-4ef2-ab48-a3c066a1ca93_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_baa0f169-873d-4ccd-86d8-228fec259275_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_43aeb6be-ed40-41aa-a4bc-23d50e675edc_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4699a0ee-7a38-4f74-ade5-1c21b039b4ff_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 175,000,000 shares authorized; 68,841,288 and 45,388,023&#160;shares issued and outstanding at December&#160;31, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ContractualLifeOfWarrants_3645ec48-fc4e-4a72-93df-fc7f9738984b_terseLabel_en-US" xlink:label="lab_mrsn_ContractualLifeOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual life of warrants</link:label>
    <link:label id="lab_mrsn_ContractualLifeOfWarrants_label_en-US" xlink:label="lab_mrsn_ContractualLifeOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Life of Warrants</link:label>
    <link:label id="lab_mrsn_ContractualLifeOfWarrants_documentation_en-US" xlink:label="lab_mrsn_ContractualLifeOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The contractual life of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractualLifeOfWarrants" xlink:href="mrsn-20201231.xsd#mrsn_ContractualLifeOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ContractualLifeOfWarrants" xlink:to="lab_mrsn_ContractualLifeOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_55985f0f-9215-4072-ba29-4cd62149834f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_b8dc0f0b-040e-41b1-8d07-3378914d2f56_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201818Member_22e2943f-183c-4365-829d-ccbe00d4aed7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201818Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2018-18</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201818Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201818Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2018-18 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201818Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201818Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201818Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_015ecc02-16c0-4e45-b341-b1f9b11a5e05_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_f4690135-0c3b-4e25-ab8d-2b3e9c1bae80_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_9971ee3b-773d-4b90-ba41-d630c81b10fa_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term-debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_08c10236-813d-41fe-9c7f-9726fd4e8de2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_b393b78d-5bab-4816-a479-545bb31aeacd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6501a65b-eb40-4bdd-9aa9-6169c069f070_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_5f10b011-1588-40d1-8f39-efc7c432807f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_61b4c50c-90c5-4c3b-8f5b-4de986ed989f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3a8b2d91-5cb4-4af2-bcef-1885776b35d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_cf92c4ea-8af5-4104-86a1-10fe53caee5f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements, estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress_e7480cc4-e64c-4492-b217-17ebe85bd11a_terseLabel_en-US" xlink:label="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of federal or state audits in progress</link:label>
    <link:label id="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress_label_en-US" xlink:label="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes, Number of Audits in Progress</link:label>
    <link:label id="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress_documentation_en-US" xlink:label="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of federal and (or) state audits in progress.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncomeTaxesNumberOfAuditsInProgress" xlink:href="mrsn-20201231.xsd#mrsn_IncomeTaxesNumberOfAuditsInProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_IncomeTaxesNumberOfAuditsInProgress" xlink:to="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_839c3d12-b3d0-47bc-86ba-07286bcc4464_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6043c06f-6b11-4bf4-9717-f28015928452_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5d3fd9b1-47c3-4aaa-a2b7-3bd71b88ef39_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1953b30a-683c-4e93-8b85-d785228f2e20_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_e70a2840-84dd-4950-8404-a69e8e287044_terseLabel_en-US" xlink:label="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative annual increase in number of shares issuable, percentage</link:label>
    <link:label id="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_label_en-US" xlink:label="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Percentage Of Outstanding Stock Maximum, Cumulative Annual Increase</link:label>
    <link:label id="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_documentation_en-US" xlink:label="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares that may be cumulatively issued annually in accordance with the plan, as a percentage of outstanding capital stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" xlink:href="mrsn-20201231.xsd#mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" xlink:to="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_4bb7fb80-1354-498e-a678-e196790ad2be_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6b8f1ae8-e1ea-401f-a0ef-9e6618cc8cef_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a3a5f4a7-db3b-4d45-b966-6ee561bb9e64_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_08ef775f-995d-4362-bfff-c160a01fd2ac_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_162cbd47-1540-482c-8923-8d37ff3f2bbe_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_dd03c78d-eb80-476f-9a86-b69dbc3f68fe_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ProceedsFromDebtNetIssuanceCosts_b9d85b95-ec96-45f9-8279-21115347a1d4_terseLabel_en-US" xlink:label="lab_mrsn_ProceedsFromDebtNetIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt, net of issuance costs</link:label>
    <link:label id="lab_mrsn_ProceedsFromDebtNetIssuanceCosts_label_en-US" xlink:label="lab_mrsn_ProceedsFromDebtNetIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Debt, Net Issuance Costs</link:label>
    <link:label id="lab_mrsn_ProceedsFromDebtNetIssuanceCosts_documentation_en-US" xlink:label="lab_mrsn_ProceedsFromDebtNetIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Debt, Net Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromDebtNetIssuanceCosts" xlink:href="mrsn-20201231.xsd#mrsn_ProceedsFromDebtNetIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ProceedsFromDebtNetIssuanceCosts" xlink:to="lab_mrsn_ProceedsFromDebtNetIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAgreementUpfrontPaymentsMember_104c389a-f326-4bcc-b2ce-83a096a9075e_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAgreementUpfrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Upfront Payments</link:label>
    <link:label id="lab_mrsn_LicenseAgreementUpfrontPaymentsMember_label_en-US" xlink:label="lab_mrsn_LicenseAgreementUpfrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Upfront Payments [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAgreementUpfrontPaymentsMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAgreementUpfrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Upfront Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAgreementUpfrontPaymentsMember" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAgreementUpfrontPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAgreementUpfrontPaymentsMember" xlink:to="lab_mrsn_LicenseAgreementUpfrontPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_bc85020b-9b57-4350-a7cd-b93a6cea610e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_58e44979-988e-4b7f-9ce4-71b358f729e2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3c1c6563-9418-40ab-bfb9-493c152d2dba_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d55ae5f0-abfd-48d4-91c2-cd36ab5ac661_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6577b681-9515-46b9-adf6-2a42fc9503ef_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIncentivePlan2017Member_5a8952f8-ea03-453e-9f56-6dd1e81ee461_terseLabel_en-US" xlink:label="lab_mrsn_StockIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Plan</link:label>
    <link:label id="lab_mrsn_StockIncentivePlan2017Member_label_en-US" xlink:label="lab_mrsn_StockIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2017 [Member]</link:label>
    <link:label id="lab_mrsn_StockIncentivePlan2017Member_documentation_en-US" xlink:label="lab_mrsn_StockIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to 2017 Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIncentivePlan2017Member" xlink:href="mrsn-20201231.xsd#mrsn_StockIncentivePlan2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIncentivePlan2017Member" xlink:to="lab_mrsn_StockIncentivePlan2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_554f5010-83b6-44f8-ab63-efa12207b22b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e710ba06-0bc4-45c4-8cfa-45115fba7397_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c8f4f002-e24b-40a8-a2ff-4adf3aaedd11_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0bec9ea4-b18f-4dfa-ab33-2705c7db8683_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c96bb2d4-b197-4a08-8a5d-6bdedb53ce3c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f3652ae6-148d-4641-ab99-4876e0f6a72c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_9e1402c5-7336-44f7-b748-8b804a944476_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d0380bab-f6d2-4b0f-a1d6-1d9842b11114_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_884b3c0c-ff00-402e-a8de-69ef4092fb43_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_eba1624d-bbbd-4b05-85e3-abf747d93c2c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LimitedServicesMember_b5423545-ed88-4e8c-9b19-abf331ac1370_terseLabel_en-US" xlink:label="lab_mrsn_LimitedServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited services</link:label>
    <link:label id="lab_mrsn_LimitedServicesMember_label_en-US" xlink:label="lab_mrsn_LimitedServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Services [Member]</link:label>
    <link:label id="lab_mrsn_LimitedServicesMember_documentation_en-US" xlink:label="lab_mrsn_LimitedServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LimitedServicesMember" xlink:href="mrsn-20201231.xsd#mrsn_LimitedServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LimitedServicesMember" xlink:to="lab_mrsn_LimitedServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_82020e7b-64d2-4ae5-8c9a-b17186b7cb9a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_1dfb4b35-97f5-4db8-96fe-f986821c2ec3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_cde80e53-6826-4ea0-801b-7ab0e756c713_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_0c38cc1b-819c-4309-a0a9-f83b533b7229_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_465809d2-0456-4235-827b-e9718d1518de_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_30b77a62-83b7-49f0-b6aa-594ea7095063_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, liability, noncurrent, statement of financial position</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_5b2fc034-4a37-400f-a5b7-a7e2fb138c6f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_24a3098a-f055-4c0f-9cb2-79e81a15c7c0_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_c34f95ba-34e1-4d24-bbb7-944db6c6f989_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and corresponding research and development services, first and second targets</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_label_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Related Research And Development Services Targets One And Two [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the license and corresponding research and development services for the first and second designated targets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" xlink:to="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_363a5f39-74d8-4373-a9ec-adf48f2cd79b_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_410bfacb-7463-47db-bf64-4d650aa0830a_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8971a84d-d358-458d-a5cc-29870f857545_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_4d4570d9-f9f2-4793-a2e4-5c2658a85b3b_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of additional fees receivable when target is designated and commercial license to target is granted</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Additional Payment to Obtain a Development and Commercial License</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of additional fees receivable when a target is designated and the commercial license to the target is granted under terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" xlink:to="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_dbe1e65b-c582-40ee-a970-591bd7a34e28_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_cd87f83b-cb47-4e68-b44b-71f1a1ca6dd2_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b386e345-0485-4515-8c13-ba865c6a7de5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9eda3ece-2f84-4144-8e25-9d84d84ad960_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2388d5e6-1c4a-4317-a401-06a1969ec29e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_FinanceLeaseCost_d2caaa22-f5bd-4291-a971-f2c4cc275bbf_totalLabel_en-US" xlink:label="lab_mrsn_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease cost</link:label>
    <link:label id="lab_mrsn_FinanceLeaseCost_label_en-US" xlink:label="lab_mrsn_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_mrsn_FinanceLeaseCost_documentation_en-US" xlink:label="lab_mrsn_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of finance lease cost recognized by lessee for lease contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeaseCost" xlink:href="mrsn-20201231.xsd#mrsn_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_FinanceLeaseCost" xlink:to="lab_mrsn_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_603cb04d-05c7-4729-95e7-27d973afb48b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f77a186a-e46c-4fd2-9f87-c0b8ad58f544_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_899dd732-2add-421d-8eae-caafddb6979c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b4035a84-5b18-4305-aa43-0d947080c357_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d448eb23-937d-44a1-8714-d7161ebec96f_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_eec28169-22c8-4dbe-9d54-7102a6bf2b65_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9a95c7fb-23ba-4bd8-9150-5bfaa2c8ee27_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_1d9234d1-6661-404d-93d0-cb3e76e25d89_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_fa773ef4-0f30-4b2c-b24e-e45817b7cf3c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_PatentCostsPolicyTextBlock_83698da6-2744-4379-9f7d-81b231b6a55c_terseLabel_en-US" xlink:label="lab_mrsn_PatentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs</link:label>
    <link:label id="lab_mrsn_PatentCostsPolicyTextBlock_label_en-US" xlink:label="lab_mrsn_PatentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs [Policy Text Block]</link:label>
    <link:label id="lab_mrsn_PatentCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_mrsn_PatentCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for patent costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PatentCostsPolicyTextBlock" xlink:href="mrsn-20201231.xsd#mrsn_PatentCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_PatentCostsPolicyTextBlock" xlink:to="lab_mrsn_PatentCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_159ae1eb-80c6-4bd3-836b-a883bfea8a38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_0cd1f2b4-f7a4-4b5f-8f34-aee8b7d3fe9c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion related to final payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DebtCovenantPeriodAxis_cfe8ca52-4a29-40e2-8364-2226c590a435_terseLabel_en-US" xlink:label="lab_mrsn_DebtCovenantPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Period [Axis]</link:label>
    <link:label id="lab_mrsn_DebtCovenantPeriodAxis_label_en-US" xlink:label="lab_mrsn_DebtCovenantPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Period [Axis]</link:label>
    <link:label id="lab_mrsn_DebtCovenantPeriodAxis_documentation_en-US" xlink:label="lab_mrsn_DebtCovenantPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodAxis" xlink:href="mrsn-20201231.xsd#mrsn_DebtCovenantPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DebtCovenantPeriodAxis" xlink:to="lab_mrsn_DebtCovenantPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_18bde5ee-2283-408c-9087-7eae0ad49e5e_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of service obligations completed of designated targets</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Targets Designated, Service Obligations Completed, Number</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Targets Designated, Service Obligations Completed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" xlink:to="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_11c13b06-303c-4f10-8513-5d704eb3278e_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_288f52a2-4149-4ae4-9874-0e6716bc1cca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, existence of option to extend</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8482f97b-a656-4961-b791-138266fdbd0e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9a1a7ff6-4143-4fd7-9746-3d54a2d50c5f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_SupplyAgreementMerckKgaaMember_4ad7eb1c-57c4-41bb-a0ce-276baa13d804_terseLabel_en-US" xlink:label="lab_mrsn_SupplyAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck KGaA supply agreement</link:label>
    <link:label id="lab_mrsn_SupplyAgreementMerckKgaaMember_label_en-US" xlink:label="lab_mrsn_SupplyAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement Merck Kgaa [Member]</link:label>
    <link:label id="lab_mrsn_SupplyAgreementMerckKgaaMember_documentation_en-US" xlink:label="lab_mrsn_SupplyAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the Supply Agreement with Merck KGaA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SupplyAgreementMerckKgaaMember" xlink:href="mrsn-20201231.xsd#mrsn_SupplyAgreementMerckKgaaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_SupplyAgreementMerckKgaaMember" xlink:to="lab_mrsn_SupplyAgreementMerckKgaaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b288cab5-e316-4a3f-9087-4848f5e06a11_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_9f2c1501-ac52-40a8-9b4a-9ef7f2ed5a07_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carry forwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_21332c5f-fc33-4ad9-b8f8-7831a111c20d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of significant components of net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_973e2d52-6d23-430a-9196-207017bf0a80_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4e8d6ae8-8eb8-4a75-bafb-e78f7b133cbc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIncentivePlan2007Member_8f0287f2-d290-48d7-b70b-af96a0e95721_terseLabel_en-US" xlink:label="lab_mrsn_StockIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Plan</link:label>
    <link:label id="lab_mrsn_StockIncentivePlan2007Member_label_en-US" xlink:label="lab_mrsn_StockIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2007 [Member]</link:label>
    <link:label id="lab_mrsn_StockIncentivePlan2007Member_documentation_en-US" xlink:label="lab_mrsn_StockIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to 2007 Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIncentivePlan2007Member" xlink:href="mrsn-20201231.xsd#mrsn_StockIncentivePlan2007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIncentivePlan2007Member" xlink:to="lab_mrsn_StockIncentivePlan2007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_da866b10-9f4c-4d36-9e9b-077354da451c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fab66843-b26c-40b8-998b-7b839d34b7c5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_8a5650c0-cfde-414f-b7f4-13ba2b337064_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_RightsToFutureTechnologicalImprovementsMember_758380dd-bbd1-4a7f-8339-d72ea0e4dc48_terseLabel_en-US" xlink:label="lab_mrsn_RightsToFutureTechnologicalImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights to future technological improvements</link:label>
    <link:label id="lab_mrsn_RightsToFutureTechnologicalImprovementsMember_label_en-US" xlink:label="lab_mrsn_RightsToFutureTechnologicalImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights To Future Technological Improvements [Member]</link:label>
    <link:label id="lab_mrsn_RightsToFutureTechnologicalImprovementsMember_documentation_en-US" xlink:label="lab_mrsn_RightsToFutureTechnologicalImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents rights to future technological improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RightsToFutureTechnologicalImprovementsMember" xlink:href="mrsn-20201231.xsd#mrsn_RightsToFutureTechnologicalImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_RightsToFutureTechnologicalImprovementsMember" xlink:to="lab_mrsn_RightsToFutureTechnologicalImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_318dd155-806c-4a9e-a2ba-733eb09ebe68_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2bc5b5af-fbd9-453a-8d80-1070ace0d4d4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock into which warrants may be converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_37259f62-ce89-44dd-93ea-802b415efeea_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0c4ee57-23d4-4566-9806-2badee211525_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9768d21f-7abe-49df-93e7-c0084a403c4c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_a85a6214-9080-4864-be5c-275c7964c5cc_negatedLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainageDeposit_51a0c44e-fa6a-4a01-aa39-3169140524a8_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainageDeposit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held by service provider</link:label>
    <link:label id="lab_us-gaap_RetainageDeposit_label_en-US" xlink:label="lab_us-gaap_RetainageDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retainage Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainageDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainageDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainageDeposit" xlink:to="lab_us-gaap_RetainageDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LeasesLineItems_4a7ad286-4fb9-4fc3-9b98-51e9a03915be_terseLabel_en-US" xlink:label="lab_mrsn_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_mrsn_LeasesLineItems_label_en-US" xlink:label="lab_mrsn_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_mrsn_LeasesLineItems_documentation_en-US" xlink:label="lab_mrsn_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesLineItems" xlink:href="mrsn-20201231.xsd#mrsn_LeasesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LeasesLineItems" xlink:to="lab_mrsn_LeasesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_126fd450-8984-4136-8102-81ca87bd50f6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_00a978a1-c56a-42ee-aeb4-66d015e41e0e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_c0f74910-20a7-448f-a99f-72d8f71ffd62_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_bac25d58-6558-4b2f-8ff0-9b8fd987e225_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ChangeInDeferredRent_bfe80f4e-45d4-4c91-b0fa-8980c9a3a7f5_terseLabel_en-US" xlink:label="lab_mrsn_ChangeInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred rent</link:label>
    <link:label id="lab_mrsn_ChangeInDeferredRent_label_en-US" xlink:label="lab_mrsn_ChangeInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Deferred Rent</link:label>
    <link:label id="lab_mrsn_ChangeInDeferredRent_documentation_en-US" xlink:label="lab_mrsn_ChangeInDeferredRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of change in deferred rent during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ChangeInDeferredRent" xlink:href="mrsn-20201231.xsd#mrsn_ChangeInDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ChangeInDeferredRent" xlink:to="lab_mrsn_ChangeInDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_59068c02-6f9e-4dcd-bc1e-ca712255d5f6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock under ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_6bd11545-38ea-462e-80e7-d9160821d6f7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_36e47934-7629-461d-a233-af62e8905665_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock-based compensation expense as reflected in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_a7f79640-4cb0-4e27-8653-8d3f9b73da88_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c1b3dcc3-69c8-4fb0-8de3-8e89213be716_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_ceaa94da-ed5b-4daa-bd7b-4dd11423defc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_2f4cb7fe-6366-4c51-9668-5a9689f2fce8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated_d0569b60-62e9-4d15-bc42-cde9871957d2_terseLabel_en-US" xlink:label="lab_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of research and development fees expected to be received</link:label>
    <link:label id="lab_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated_label_en-US" xlink:label="lab_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursable Expense, Research and Development, Estimated</link:label>
    <link:label id="lab_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated_documentation_en-US" xlink:label="lab_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amount of research and development expenses received or expected to be received included in transaction price (performance obligation).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated" xlink:href="mrsn-20201231.xsd#mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated" xlink:to="lab_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_7e5eb76f-cb06-487e-b5a1-b6c17f5ebe42_terseLabel_en-US" xlink:label="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards not subject to expiration</link:label>
    <link:label id="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:label id="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws not subject to expiration dates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="mrsn-20201231.xsd#mrsn_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_2ce04a88-0005-42d7-a8ae-4bc0c50a4617_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit expenses</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_2030f525-490b-4245-b96a-edf39e68e3ee_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a27aee29-9dcc-44d0-88a1-253b27010038_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_77fc6f78-6e6d-42a9-b65d-0d168e2fd9e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt financing costs in accrued expenses</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_e3252cf9-41a6-4a04-88c5-fc15b480c502_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6a0dbcbd-f244-404b-b919-ad76e8947ac4_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d758ecfe-3d44-404c-b5b7-4a0c41e278f9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_6ef547a0-10cc-48b2-ba8c-493d85f9fbbe_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_e443d36a-e6b0-458e-a803-29a5c4221865_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard_79ebe39a-2bda-4cb5-868b-d3bfc8ba522f_negatedLabel_en-US" xlink:label="lab_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606</link:label>
    <link:label id="lab_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard_label_en-US" xlink:label="lab_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Retained Earnings, Deferred Revenue Upon Adoption Of New Accounting Standard</link:label>
    <link:label id="lab_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard_documentation_en-US" xlink:label="lab_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To Retained Earnings, Deferred Revenue Upon Adoption Of New Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard" xlink:href="mrsn-20201231.xsd#mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard" xlink:to="lab_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_a06195d9-0d3f-4fa1-b045-244a4b8ceffd_terseLabel_en-US" xlink:label="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Restated Tokeda agreement</link:label>
    <link:label id="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_label_en-US" xlink:label="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And Commercial License Agreement Takeda2016 Restated Agreement [Member]</link:label>
    <link:label id="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_documentation_en-US" xlink:label="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the 2016 Restated Research Collaboration and Commercial License Agreement with Takeda Pharmaceutical Company Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" xlink:href="mrsn-20201231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" xlink:to="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_89ecda97-28c8-464c-948e-4bfc24b650f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_4f45c78d-034c-490f-8104-f1a3464d54c0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected recognition period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheTwoMember_d52130b9-2a19-43aa-be1e-e0f1dcdf8e7d_terseLabel_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Two</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheTwoMember_label_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Two [Member]</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityTrancheTwoMember_documentation_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheTwoMember" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AmendedCreditFacilityTrancheTwoMember" xlink:to="lab_mrsn_AmendedCreditFacilityTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ad88ddba-99a6-4426-95a5-590970d6c0d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4dba09c5-6747-4593-99d5-7a5854c59c65_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_79c3a2b0-9268-4714-a5fe-aa59ff2daba0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d1ddd04b-3118-48a4-80d5-9723d7874200_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8c0be671-e1fa-4370-a235-bbbf905a044b_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_f6612794-dd2b-44fb-b497-b99e9f12e267_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ad99db1a-3a78-4d33-bcf7-8f8aca95699b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future minimum payments under operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f7f34799-ce4c-49a5-b813-657611d2560e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9bec978f-55c4-4858-a97e-bbbb394c26c9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares of common stock used in net income (loss) per share attributable to common stockholders &#8212; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_21e7c306-d5be-41fd-85be-174ca4628722_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spread (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_674fe866-2bca-47af-b1e7-0c38021fc046_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0339c3e5-dcfc-4289-80e5-f785668924fb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber_fddbb74e-2654-4440-8463-2995dc2946b1_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targets designated</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Targets Designated, Number</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targets designated as of balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber" xlink:to="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member_dd47ef10-d42a-4c34-b784-ad3746630bde_terseLabel_en-US" xlink:label="lab_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment occurs after August 28, 2022 but on or prior to August 28, 2022</link:label>
    <link:label id="lab_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member_label_en-US" xlink:label="lab_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Occurs After August 28, 2022 But Before November 1, 2024 [Member]</link:label>
    <link:label id="lab_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member_documentation_en-US" xlink:label="lab_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the prepayment occurs after August 28, 2022 but before November 1, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member" xlink:href="mrsn-20201231.xsd#mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member" xlink:to="lab_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_bbbb77b9-d2a8-4602-ac67-a11f68831d0d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_32afd0f1-42b6-4cd9-84f0-cf793be91b62_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_56c63e4e-cd8a-426b-95c4-ad4f0bbe126f_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_c2ea255c-0708-437c-8d51-ece04a432675_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_573d0354-e8ff-4d52-a345-90095aad0ac8_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_5b39d3aa-ec8d-4fe3-aef3-b1b040844360_terseLabel_en-US" xlink:label="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock retired in exchange for issuance of common stock warrant</link:label>
    <link:label id="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_label_en-US" xlink:label="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Common Stock Retired in Exchange For Issuance of Common Stock Warrant</link:label>
    <link:label id="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_documentation_en-US" xlink:label="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fair value of common stock retired in exchange for issuance of common stock warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:href="mrsn-20201231.xsd#mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:to="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9cc38689-2dfa-4810-b736-aaaa0de9ddce_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_911719b3-473d-4596-aef6-e9f585160834_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_961be68a-c419-439a-9eba-0c6f0152f9bd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f9b9245a-7bef-42e2-bffb-982729c0d43f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash per statement of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent_871bab99-6621-4bc7-8850-ce4d5108efc0_terseLabel_en-US" xlink:label="lab_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical, manufacturing and clinical expenses</link:label>
    <link:label id="lab_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent_label_en-US" xlink:label="lab_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preclinical And Clinical Expenses Current</link:label>
    <link:label id="lab_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for preclinical, manufacturing and clinical expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent" xlink:href="mrsn-20201231.xsd#mrsn_AccruedPreclinicalAndClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent" xlink:to="lab_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9b486d47-7d8b-4bf1-aada-cb3692b3183b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_eac582c8-7752-430b-8ab8-89735b486d14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated future payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_996d9896-79ab-478d-b6d4-f326ee091649_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8be746e7-4f84-47cc-8c22-3ef3e15cec4e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialDataAbstract_ae090298-a70b-4aa7-b996-3ed0ff2146b9_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialDataAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialDataAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialDataAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialDataAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3f8bf585-dd8d-4eaa-975b-e4faa1395d3d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_064eba33-fa96-40fa-8d0a-0eac4c799760_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e90f7170-372a-4d26-b64f-5c3b0aea06e8_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_f1272ff3-01f8-4101-a55d-69fca65a1ebb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities, current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f501c37f-11b9-4a67-b9b5-9617d101fcfc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_b04035ee-2c68-44ef-a0f0-dec359e68d85_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_726c7fca-fd90-4d16-a615-e956e0297502_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ca397d89-a255-4670-9aff-61eabb1403d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_51b09bd4-df7d-416f-81c5-7dbd8a2c18e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ServiceMilestoneMember_fc81c546-3d8e-41c7-84a0-8529a9354a53_terseLabel_en-US" xlink:label="lab_mrsn_ServiceMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone</link:label>
    <link:label id="lab_mrsn_ServiceMilestoneMember_label_en-US" xlink:label="lab_mrsn_ServiceMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Milestone [Member]</link:label>
    <link:label id="lab_mrsn_ServiceMilestoneMember_documentation_en-US" xlink:label="lab_mrsn_ServiceMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service milestones represented by the achievement of specific activities as defined in the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ServiceMilestoneMember" xlink:href="mrsn-20201231.xsd#mrsn_ServiceMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ServiceMilestoneMember" xlink:to="lab_mrsn_ServiceMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_23ccfc90-4c80-431d-8bce-9e15e5830708_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_bc4672c1-08e2-4f63-8d0d-dda2eb629da4_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_be6683b3-a9f3-49da-b437-36f4debbf943_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ef49a62d-fae7-4aa0-99d5-f0951afc65d4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsAbstract_cf912ad9-ba29-4139-b4ed-62ed519e892c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_91f1c8c1-1e2b-4cfa-a06c-85571980270f_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_4f662b24-4437-4ba2-a744-b467e21cf5aa_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized in the period from:</link:label>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Asset and Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:to="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_4429629b-2bc8-40a5-b77f-54d2b7012a2e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_ec03ceec-263b-456f-909c-6153cdcc4423_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_bd264f47-6dee-43e1-947f-531ded9c07d6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, balance at end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ExistingCreditFacilityMember_f5fb45f6-8d32-45c8-b701-6bfe20496587_terseLabel_en-US" xlink:label="lab_mrsn_ExistingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Credit Facility</link:label>
    <link:label id="lab_mrsn_ExistingCreditFacilityMember_label_en-US" xlink:label="lab_mrsn_ExistingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Credit Facility [Member]</link:label>
    <link:label id="lab_mrsn_ExistingCreditFacilityMember_documentation_en-US" xlink:label="lab_mrsn_ExistingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExistingCreditFacilityMember" xlink:href="mrsn-20201231.xsd#mrsn_ExistingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ExistingCreditFacilityMember" xlink:to="lab_mrsn_ExistingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1e01e452-cc44-4418-a8de-23e384fe0705_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_38a9705a-8319-4e88-9861-42d10c8c4cf7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0507eeeb-f6c3-42e4-befa-2337307b613d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1a3e0ac0-3e4a-4d16-96e3-075a45d6296e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ecd9a161-561c-42d9-931c-21592d5e8ff6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5e1f48c4-ecce-4229-814a-a230d7981fb4_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_84a24e73-b372-4186-9fbe-79b57aa52985_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a1c5356a-9a6b-4ec2-99fb-9aeb35a16743_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_692483f6-2985-40ab-99eb-a76ae89ab1e6_terseLabel_en-US" xlink:label="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final payment as percentage of original principal amount</link:label>
    <link:label id="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_label_en-US" xlink:label="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment as Percentage of Original Principal Amount</link:label>
    <link:label id="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_documentation_en-US" xlink:label="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the final payment as percentage of original principal amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" xlink:href="mrsn-20201231.xsd#mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" xlink:to="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceAbstract_a1404937-d975-4bba-9c3b-979298471fa1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceAbstract_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceAbstract" xlink:to="lab_us-gaap_ValuationAllowanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e991e335-b93d-4977-8638-926ce8ba1fbc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_a0346871-eaa8-4054-af18-060a6febb381_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_3a2dd81c-54c8-4655-bfe9-bd1ab4d6a512_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration_6a4b4ef4-1be3-4923-a15a-15bb6f6e1a19_terseLabel_en-US" xlink:label="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards subject to expiration</link:label>
    <link:label id="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:label id="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws subject to expiration dates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="mrsn-20201231.xsd#mrsn_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e4e79d3b-05b6-4c78-903d-7edf63884c0d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_fafa739c-7233-4fa9-be17-7f5db6dec69d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_InducementAwardProgramMember_88302441-15b5-48fd-a9a8-d5b036d47778_terseLabel_en-US" xlink:label="lab_mrsn_InducementAwardProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Award Program</link:label>
    <link:label id="lab_mrsn_InducementAwardProgramMember_label_en-US" xlink:label="lab_mrsn_InducementAwardProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Award Program [Member]</link:label>
    <link:label id="lab_mrsn_InducementAwardProgramMember_documentation_en-US" xlink:label="lab_mrsn_InducementAwardProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Award Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_InducementAwardProgramMember" xlink:href="mrsn-20201231.xsd#mrsn_InducementAwardProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_InducementAwardProgramMember" xlink:to="lab_mrsn_InducementAwardProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_FinanceLeaseTotalCostAbstract_4fb7b8f1-09c6-4912-9007-001a17a9976b_terseLabel_en-US" xlink:label="lab_mrsn_FinanceLeaseTotalCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease cost:</link:label>
    <link:label id="lab_mrsn_FinanceLeaseTotalCostAbstract_label_en-US" xlink:label="lab_mrsn_FinanceLeaseTotalCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Total Cost [Abstract]</link:label>
    <link:label id="lab_mrsn_FinanceLeaseTotalCostAbstract_documentation_en-US" xlink:label="lab_mrsn_FinanceLeaseTotalCostAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Total Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeaseTotalCostAbstract" xlink:href="mrsn-20201231.xsd#mrsn_FinanceLeaseTotalCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_FinanceLeaseTotalCostAbstract" xlink:to="lab_mrsn_FinanceLeaseTotalCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_75a59cd9-e793-41b9-a055-624e960da04a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, liability, current, statement of financial position</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f02abc17-0fb4-4be9-ae30-651205d5597c_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dcc7ca40-d44a-4c5d-a597-96d3931ac164_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_72da9fcc-a8c8-4c97-992f-807136c75c37_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb94c260-49bd-448b-8e2e-2f8dd8f1501a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_80000248-8027-49cc-9fc8-a8d197263e45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_061d3c70-7105-4ec2-a568-423018202900_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_add99e7e-3a24-4c3a-8cab-4a8210cd6623_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07b81450-d491-43a1-9b8e-3011485379a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_8b6becdb-fba8-425b-86fe-da42083c5295_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ecba9867-abd8-4fe7-b347-8c1df4b38a5f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ce47ad1a-002e-4dbb-9a02-4ff442c9f128_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_15b26bc0-8916-4276-a766-93e19ef725bf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b056e608-9c3c-4c83-ae25-52ba6b6fd7ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit_00e970c2-831d-475e-9ec3-10f5a2e16b4f_terseLabel_en-US" xlink:label="lab_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, increase limit</link:label>
    <link:label id="lab_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit_label_en-US" xlink:label="lab_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Accordian Feature, Increase Limit</link:label>
    <link:label id="lab_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit_documentation_en-US" xlink:label="lab_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Accordian Feature, Increase Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit" xlink:href="mrsn-20201231.xsd#mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit" xlink:to="lab_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate_4a9c2874-2774-4b3f-b7a8-293fc211870e_terseLabel_en-US" xlink:label="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible age to participate</link:label>
    <link:label id="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate_label_en-US" xlink:label="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligible Age to Participate</link:label>
    <link:label id="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate_documentation_en-US" xlink:label="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum age for employees to be eligible to participate in defined contribution plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DefinedContributionPlanEligibleAgeToParticipate" xlink:href="mrsn-20201231.xsd#mrsn_DefinedContributionPlanEligibleAgeToParticipate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DefinedContributionPlanEligibleAgeToParticipate" xlink:to="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_1eceaa25-79a4-4097-80c1-4236dba9e2c2_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and corresponding research and development services, third and sixth target</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_label_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Related Research And Development Services Target Three And Six [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the license and corresponding research and development services for third and sixth designated target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" xlink:to="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ExchangeWarrantsMember_6e845dcb-c7d4-4cc1-b973-52012e360ff7_terseLabel_en-US" xlink:label="lab_mrsn_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange warrants</link:label>
    <link:label id="lab_mrsn_ExchangeWarrantsMember_label_en-US" xlink:label="lab_mrsn_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Warrants [Member]</link:label>
    <link:label id="lab_mrsn_ExchangeWarrantsMember_documentation_en-US" xlink:label="lab_mrsn_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security, two, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount with an exercise price of $0.0001 per share. Referred to as the "Exchange Warrants".</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExchangeWarrantsMember" xlink:href="mrsn-20201231.xsd#mrsn_ExchangeWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ExchangeWarrantsMember" xlink:to="lab_mrsn_ExchangeWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_747ec778-c779-469b-a007-df50076fe59c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0922dff6-2a0e-49b4-a09f-962d2811bbc6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d23555d9-88f0-4c52-ae19-d95afef66c20_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_67ab2ee3-7f59-4b2a-ae20-6d6757e65e9f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax computed at federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ec4b8e7e-43e8-4367-9f95-07bde7524b5d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4ace70ac-75a4-4e4d-aa94-a67088ed96c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_a27e390e-e6de-415e-92d0-3d1be3fa8d35_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_a04da2d9-c3e4-4ba5-b3ae-94dc3146c756_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_336171d1-2567-4ec4-98d4-d6f4c7196e69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LaboratoryEquipmentMember_3c61b27f-e1f6-4e2f-9c0c-9cc981cb191a_terseLabel_en-US" xlink:label="lab_mrsn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_mrsn_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_mrsn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_mrsn_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_mrsn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentMember" xlink:href="mrsn-20201231.xsd#mrsn_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LaboratoryEquipmentMember" xlink:to="lab_mrsn_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_33a4812f-5845-47f5-a878-0fc1529f7979_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5e45a1a0-1508-4766-811d-9e9d46ac74e0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_8aa25f57-acdc-4b67-9cd9-366c0198aff2_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_18067c94-196c-4824-b997-2d839d616e13_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mrsn-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2da7fb72-9c95-4f34-a8ba-21eaa0b59775,g:bc62363b-ba21-41ff-8e10-87a9df40b55e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.mersana.com/role/Cover" xlink:type="simple" xlink:href="mrsn-20201231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9a4c8ac3-c139-4a2b-8453-a67d49c38ad4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_DocumentType_9a4c8ac3-c139-4a2b-8453-a67d49c38ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_b95efb4e-691f-48fe-932d-6dad512d97b0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_DocumentAnnualReport_b95efb4e-691f-48fe-932d-6dad512d97b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fcd74193-fc26-4963-818a-2cf125998d82" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_DocumentPeriodEndDate_fcd74193-fc26-4963-818a-2cf125998d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5d1f2e34-0324-487a-ae1a-aed2c9ba909c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_CurrentFiscalYearEndDate_5d1f2e34-0324-487a-ae1a-aed2c9ba909c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_28a604b7-8d6f-41c0-b5eb-dc76df6bf700" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_DocumentTransitionReport_28a604b7-8d6f-41c0-b5eb-dc76df6bf700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a4ecd504-8a59-4905-a105-9a391812c1b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityFileNumber_a4ecd504-8a59-4905-a105-9a391812c1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_919f7965-73b6-4567-9a6b-51bfa1a8c96d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityRegistrantName_919f7965-73b6-4567-9a6b-51bfa1a8c96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e5016185-99db-42c9-afb7-a855a2e1845b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e5016185-99db-42c9-afb7-a855a2e1845b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e25c0754-6303-4c75-b322-f1ef6d794239" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityTaxIdentificationNumber_e25c0754-6303-4c75-b322-f1ef6d794239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_45745c27-d9b3-4908-94e2-7f9fd6811028" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityAddressAddressLine1_45745c27-d9b3-4908-94e2-7f9fd6811028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_da4501f9-4b2c-43c5-8b44-fad6879e0d2e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityAddressCityOrTown_da4501f9-4b2c-43c5-8b44-fad6879e0d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_24b14651-b9c5-4fa5-8f07-e1a810ecf4f6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityAddressStateOrProvince_24b14651-b9c5-4fa5-8f07-e1a810ecf4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_07146928-b4b8-4213-bd16-fdd303e6d558" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityAddressPostalZipCode_07146928-b4b8-4213-bd16-fdd303e6d558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9261b0ea-51d4-41a2-8ab3-fcd6e36368b7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_CityAreaCode_9261b0ea-51d4-41a2-8ab3-fcd6e36368b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_502d723e-9a67-4329-93a9-24c5973cd09b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_LocalPhoneNumber_502d723e-9a67-4329-93a9-24c5973cd09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9aa2955e-a0ed-4358-a543-a8326b52ad40" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_Security12bTitle_9aa2955e-a0ed-4358-a543-a8326b52ad40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e04628a1-2038-46b6-9060-3bbcfbdf1470" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_TradingSymbol_e04628a1-2038-46b6-9060-3bbcfbdf1470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_52f724e0-f0ce-4bb2-8d3e-aeede9357471" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_SecurityExchangeName_52f724e0-f0ce-4bb2-8d3e-aeede9357471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_49877754-9186-411a-a697-a67c43f95441" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_49877754-9186-411a-a697-a67c43f95441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_79ab7b3f-49ee-4c93-823f-bed05e75a85c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityVoluntaryFilers_79ab7b3f-49ee-4c93-823f-bed05e75a85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ff83813a-369d-4be4-a52c-091570052678" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityCurrentReportingStatus_ff83813a-369d-4be4-a52c-091570052678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c6bcee30-69c7-43ec-83d1-7354ca57d0e1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityInteractiveDataCurrent_c6bcee30-69c7-43ec-83d1-7354ca57d0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6e7dd3cb-572c-408e-b18b-5e04c71e2db6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityFilerCategory_6e7dd3cb-572c-408e-b18b-5e04c71e2db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_65785163-aa48-451f-83d4-3b482bb68113" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntitySmallBusiness_65785163-aa48-451f-83d4-3b482bb68113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_08e75dcc-fd00-4beb-9796-925eb517887b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityEmergingGrowthCompany_08e75dcc-fd00-4beb-9796-925eb517887b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1a385430-a006-4c64-bb9d-cda8a5782dd5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1a385430-a006-4c64-bb9d-cda8a5782dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_cef3cb7f-fd0f-4699-8fe8-07e466bcb863" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityShellCompany_cef3cb7f-fd0f-4699-8fe8-07e466bcb863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_655c6673-6636-4d2c-b4a0-f97ce3959aac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityPublicFloat_655c6673-6636-4d2c-b4a0-f97ce3959aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ae38f51e-e4d8-4c58-ba65-63b748914b64" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ae38f51e-e4d8-4c58-ba65-63b748914b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b7b65f3c-0e51-4ec9-874c-64439951612e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b7b65f3c-0e51-4ec9-874c-64439951612e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ee0584cb-df71-42d4-b375-eee84942c9b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_EntityCentralIndexKey_ee0584cb-df71-42d4-b375-eee84942c9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c3bf7483-4e8b-4a9d-b5df-b8aa8ade112d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_DocumentFiscalYearFocus_c3bf7483-4e8b-4a9d-b5df-b8aa8ade112d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_eee9694d-3583-45ae-b9bf-07d995561a15" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_eee9694d-3583-45ae-b9bf-07d995561a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_bcba7605-404e-40d7-9ed1-34e591c23f08" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_74a15bca-ade0-4b00-aeaa-1af3ace5f4e3" xlink:to="loc_dei_AmendmentFlag_bcba7605-404e-40d7-9ed1-34e591c23f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2ecea817-314c-41bb-ad5a-7b0e8ca5c7fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3c30120f-936e-4d6d-a7e5-fd63c4320d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ecea817-314c-41bb-ad5a-7b0e8ca5c7fa" xlink:to="loc_us-gaap_AssetsAbstract_3c30120f-936e-4d6d-a7e5-fd63c4320d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_01caeb89-0953-407f-a918-c4e357cd2688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3c30120f-936e-4d6d-a7e5-fd63c4320d1c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_01caeb89-0953-407f-a918-c4e357cd2688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8bcc306a-d55e-45b5-b12e-67369b97b86b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_01caeb89-0953-407f-a918-c4e357cd2688" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8bcc306a-d55e-45b5-b12e-67369b97b86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d7b875e9-d052-41fa-b895-cf9721a8e703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_01caeb89-0953-407f-a918-c4e357cd2688" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d7b875e9-d052-41fa-b895-cf9721a8e703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f664dd7e-1d89-4d3f-9991-fa33722bd130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_01caeb89-0953-407f-a918-c4e357cd2688" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f664dd7e-1d89-4d3f-9991-fa33722bd130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a3d71d5d-fe67-4fe0-b9c3-a3e23cbbc452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_01caeb89-0953-407f-a918-c4e357cd2688" xlink:to="loc_us-gaap_AssetsCurrent_a3d71d5d-fe67-4fe0-b9c3-a3e23cbbc452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dfe584fb-da1e-4fc6-9b34-712b810f27ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3c30120f-936e-4d6d-a7e5-fd63c4320d1c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dfe584fb-da1e-4fc6-9b34-712b810f27ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_008c64a5-f5ce-4958-8479-9ea0199c26b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3c30120f-936e-4d6d-a7e5-fd63c4320d1c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_008c64a5-f5ce-4958-8479-9ea0199c26b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7505ff5b-3382-4c9e-84db-7a6b6a6b5eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3c30120f-936e-4d6d-a7e5-fd63c4320d1c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7505ff5b-3382-4c9e-84db-7a6b6a6b5eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a74c73c6-9c2d-442e-9db4-4ee0a288f08b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3c30120f-936e-4d6d-a7e5-fd63c4320d1c" xlink:to="loc_us-gaap_Assets_a74c73c6-9c2d-442e-9db4-4ee0a288f08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3098b0a5-7116-482f-bf86-48bf5e37a217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ecea817-314c-41bb-ad5a-7b0e8ca5c7fa" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3098b0a5-7116-482f-bf86-48bf5e37a217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3098b0a5-7116-482f-bf86-48bf5e37a217" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_299b66a0-0f97-4e57-b4cb-6d84edf84725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:to="loc_us-gaap_AccountsPayableCurrent_299b66a0-0f97-4e57-b4cb-6d84edf84725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b2e65fcb-77cb-4796-869d-c0892d69f5e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b2e65fcb-77cb-4796-869d-c0892d69f5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ee4efa9d-0729-42d8-b425-43823f382a17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ee4efa9d-0729-42d8-b425-43823f382a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_58c8ddfa-8ecf-419e-9378-a3b0d7ab893f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_58c8ddfa-8ecf-419e-9378-a3b0d7ab893f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c1bd3397-0977-4dd0-95bb-a104ee7a2c66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:to="loc_us-gaap_LongTermDebtCurrent_c1bd3397-0977-4dd0-95bb-a104ee7a2c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_71e6b30b-5279-49dc-8beb-1a8fde05dbab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_71e6b30b-5279-49dc-8beb-1a8fde05dbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3ac47c29-1a1c-4560-9093-fb7cc1e3c2bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:to="loc_us-gaap_LiabilitiesCurrent_3ac47c29-1a1c-4560-9093-fb7cc1e3c2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_efca8854-7ff5-47b0-9cf5-173ac2a8d1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_efca8854-7ff5-47b0-9cf5-173ac2a8d1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_52a51f93-85d6-4b6d-8d84-a57d96ec21e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_52a51f93-85d6-4b6d-8d84-a57d96ec21e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a29527c5-4453-4414-a346-72ae9fe675f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a29527c5-4453-4414-a346-72ae9fe675f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_882345e1-f9fc-4ff8-a326-187843871a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:to="loc_us-gaap_Liabilities_882345e1-f9fc-4ff8-a326-187843871a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_13ff1562-0849-4b06-95bb-2cbede249cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e08dff1b-49aa-4b71-90eb-c79e67ea33af" xlink:to="loc_us-gaap_CommitmentsAndContingencies_13ff1562-0849-4b06-95bb-2cbede249cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a3fe84e8-34a2-495b-9451-5d36cdcb2682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3098b0a5-7116-482f-bf86-48bf5e37a217" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a3fe84e8-34a2-495b-9451-5d36cdcb2682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a218f5d4-2417-4c97-9214-a86335b21805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a3fe84e8-34a2-495b-9451-5d36cdcb2682" xlink:to="loc_us-gaap_PreferredStockValue_a218f5d4-2417-4c97-9214-a86335b21805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0a9bd7b5-f689-4fa2-8753-c11bd9be0d44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a3fe84e8-34a2-495b-9451-5d36cdcb2682" xlink:to="loc_us-gaap_CommonStockValue_0a9bd7b5-f689-4fa2-8753-c11bd9be0d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_da464d11-6f09-48c6-b648-4fd33312f63f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a3fe84e8-34a2-495b-9451-5d36cdcb2682" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_da464d11-6f09-48c6-b648-4fd33312f63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1eb6d247-60ab-4977-a0e4-9a46d06c5d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a3fe84e8-34a2-495b-9451-5d36cdcb2682" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1eb6d247-60ab-4977-a0e4-9a46d06c5d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3f1a6dc1-3ff9-4c50-9578-c173db3c5f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a3fe84e8-34a2-495b-9451-5d36cdcb2682" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3f1a6dc1-3ff9-4c50-9578-c173db3c5f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_74d673bb-ac53-45dc-b351-64c69d68b7ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a3fe84e8-34a2-495b-9451-5d36cdcb2682" xlink:to="loc_us-gaap_StockholdersEquity_74d673bb-ac53-45dc-b351-64c69d68b7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae67375c-b103-468b-b085-da989c494a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3098b0a5-7116-482f-bf86-48bf5e37a217" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae67375c-b103-468b-b085-da989c494a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1a4e7f46-6731-4e67-80eb-e5f4c76458a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_08eb1640-c666-4457-b491-cd355ba2b9e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1a4e7f46-6731-4e67-80eb-e5f4c76458a0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_08eb1640-c666-4457-b491-cd355ba2b9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6b57ebf6-1957-4407-9cc7-ccb0fc22f12a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08eb1640-c666-4457-b491-cd355ba2b9e8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6b57ebf6-1957-4407-9cc7-ccb0fc22f12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_99f7ea8e-ff19-4c45-854d-08663945b1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08eb1640-c666-4457-b491-cd355ba2b9e8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_99f7ea8e-ff19-4c45-854d-08663945b1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0f7613e4-3bef-46d6-9e07-302fe4e88e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08eb1640-c666-4457-b491-cd355ba2b9e8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0f7613e4-3bef-46d6-9e07-302fe4e88e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_04f80eca-80de-43fb-8a9f-ebefa01daa10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08eb1640-c666-4457-b491-cd355ba2b9e8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_04f80eca-80de-43fb-8a9f-ebefa01daa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ea6bb813-25b5-410a-b6d7-ef28d2145cf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08eb1640-c666-4457-b491-cd355ba2b9e8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ea6bb813-25b5-410a-b6d7-ef28d2145cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ef30b475-8fb1-4434-91c3-9231a1f006f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08eb1640-c666-4457-b491-cd355ba2b9e8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ef30b475-8fb1-4434-91c3-9231a1f006f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2451b07f-23bc-4c0f-abeb-ad2a61d872b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08eb1640-c666-4457-b491-cd355ba2b9e8" xlink:to="loc_us-gaap_CommonStockSharesIssued_2451b07f-23bc-4c0f-abeb-ad2a61d872b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2b4561c3-7895-4264-a731-170825109f74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_08eb1640-c666-4457-b491-cd355ba2b9e8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2b4561c3-7895-4264-a731-170825109f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_755a287c-c1f4-496f-b0e2-3d9b177ff233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_88375173-59a5-45fc-9fa0-737182e13e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_755a287c-c1f4-496f-b0e2-3d9b177ff233" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_88375173-59a5-45fc-9fa0-737182e13e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_5e82309b-85e6-4c56-9455-9e0ff318f7da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_755a287c-c1f4-496f-b0e2-3d9b177ff233" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_5e82309b-85e6-4c56-9455-9e0ff318f7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2e4b913f-49bd-4bc5-adde-1a970c1d38d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_755a287c-c1f4-496f-b0e2-3d9b177ff233" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2e4b913f-49bd-4bc5-adde-1a970c1d38d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_396f76ba-36be-4507-a902-216451edf02b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2e4b913f-49bd-4bc5-adde-1a970c1d38d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_396f76ba-36be-4507-a902-216451edf02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0651ad22-bd41-44e9-be20-72440f7b7e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2e4b913f-49bd-4bc5-adde-1a970c1d38d4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0651ad22-bd41-44e9-be20-72440f7b7e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_26ac44e4-00ea-4495-b7cd-5ac6c59e7a47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2e4b913f-49bd-4bc5-adde-1a970c1d38d4" xlink:to="loc_us-gaap_OperatingExpenses_26ac44e4-00ea-4495-b7cd-5ac6c59e7a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ef64d1a6-843b-4ab4-be0c-c61c54529ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_755a287c-c1f4-496f-b0e2-3d9b177ff233" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ef64d1a6-843b-4ab4-be0c-c61c54529ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_da07d958-ce41-4c8e-8700-375e582ac66f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ef64d1a6-843b-4ab4-be0c-c61c54529ef7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_da07d958-ce41-4c8e-8700-375e582ac66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7d620867-f749-4a2b-bb69-d715e333bf46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ef64d1a6-843b-4ab4-be0c-c61c54529ef7" xlink:to="loc_us-gaap_InterestExpense_7d620867-f749-4a2b-bb69-d715e333bf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4274c0fe-1288-4ab6-90d0-fb4ebe42598c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ef64d1a6-843b-4ab4-be0c-c61c54529ef7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4274c0fe-1288-4ab6-90d0-fb4ebe42598c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a1a77676-20af-459a-9cc4-7a3a2a979888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_755a287c-c1f4-496f-b0e2-3d9b177ff233" xlink:to="loc_us-gaap_NetIncomeLoss_a1a77676-20af-459a-9cc4-7a3a2a979888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1de334aa-cbce-4dc2-a8ba-6b3a9bfc6df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_755a287c-c1f4-496f-b0e2-3d9b177ff233" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1de334aa-cbce-4dc2-a8ba-6b3a9bfc6df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_22b64e7f-c2e5-4408-9228-f115057eeca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1de334aa-cbce-4dc2-a8ba-6b3a9bfc6df8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_22b64e7f-c2e5-4408-9228-f115057eeca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_de303a85-070a-4441-abe4-f79ad9348589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_755a287c-c1f4-496f-b0e2-3d9b177ff233" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_de303a85-070a-4441-abe4-f79ad9348589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2a2927e1-c6f4-466d-897a-d6fd927fdf9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_755a287c-c1f4-496f-b0e2-3d9b177ff233" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2a2927e1-c6f4-466d-897a-d6fd927fdf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2cb41643-db91-4259-beaa-b86739d76a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_755a287c-c1f4-496f-b0e2-3d9b177ff233" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2cb41643-db91-4259-beaa-b86739d76a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_644bca70-c459-4145-85c5-4dedd763ac65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_755a287c-c1f4-496f-b0e2-3d9b177ff233" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_644bca70-c459-4145-85c5-4dedd763ac65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_d111222c-471b-4021-abb6-e9ac5d47133c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_755a287c-c1f4-496f-b0e2-3d9b177ff233" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_d111222c-471b-4021-abb6-e9ac5d47133c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_18fb25e8-dfa0-4620-8b23-841db3c2423d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cc943287-3743-4f96-b4ef-37a9781ad680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_18fb25e8-dfa0-4620-8b23-841db3c2423d" xlink:to="loc_us-gaap_StatementTable_cc943287-3743-4f96-b4ef-37a9781ad680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a5cbfd3-50bf-4c6a-8999-4df91d440be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc943287-3743-4f96-b4ef-37a9781ad680" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a5cbfd3-50bf-4c6a-8999-4df91d440be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56943108-cc68-49bc-99a5-61ae4fd10b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a5cbfd3-50bf-4c6a-8999-4df91d440be0" xlink:to="loc_us-gaap_EquityComponentDomain_56943108-cc68-49bc-99a5-61ae4fd10b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0566ceb4-b86c-47f9-b14c-f606422acae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56943108-cc68-49bc-99a5-61ae4fd10b46" xlink:to="loc_us-gaap_CommonStockMember_0566ceb4-b86c-47f9-b14c-f606422acae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5b4affe6-6d10-4c0a-aac8-88cb18ce99b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56943108-cc68-49bc-99a5-61ae4fd10b46" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5b4affe6-6d10-4c0a-aac8-88cb18ce99b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_248ab8e4-4700-455c-8573-bb6d9b3d7367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56943108-cc68-49bc-99a5-61ae4fd10b46" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_248ab8e4-4700-455c-8573-bb6d9b3d7367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ea25b38d-68b3-4c1f-a08b-5dddb3ba812c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56943108-cc68-49bc-99a5-61ae4fd10b46" xlink:to="loc_us-gaap_RetainedEarningsMember_ea25b38d-68b3-4c1f-a08b-5dddb3ba812c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f851f967-654c-433b-90c7-d85e25632402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc943287-3743-4f96-b4ef-37a9781ad680" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f851f967-654c-433b-90c7-d85e25632402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4126ab83-b40e-46b9-8925-bc5c4683f7ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f851f967-654c-433b-90c7-d85e25632402" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4126ab83-b40e-46b9-8925-bc5c4683f7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_45c222a7-bbdb-49e2-8091-86539332d5c9" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4126ab83-b40e-46b9-8925-bc5c4683f7ff" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_45c222a7-bbdb-49e2-8091-86539332d5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_3bc39e41-fc33-4579-9bbe-0b6ad75ec6d9" xlink:href="mrsn-20201231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4126ab83-b40e-46b9-8925-bc5c4683f7ff" xlink:to="loc_mrsn_PublicStockOfferingMember_3bc39e41-fc33-4579-9bbe-0b6ad75ec6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7a742a9-b5dc-4dad-ac01-dcd8c91383d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc943287-3743-4f96-b4ef-37a9781ad680" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7a742a9-b5dc-4dad-ac01-dcd8c91383d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_92741f29-ebdc-40f2-a34b-612740be4412" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c7a742a9-b5dc-4dad-ac01-dcd8c91383d7" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_92741f29-ebdc-40f2-a34b-612740be4412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_968fccf9-b393-46fa-a91e-585ec4e8f7e1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_92741f29-ebdc-40f2-a34b-612740be4412" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_968fccf9-b393-46fa-a91e-585ec4e8f7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1ad4bbec-3fed-456f-b42d-b8094367a85d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cc943287-3743-4f96-b4ef-37a9781ad680" xlink:to="loc_us-gaap_StatementLineItems_1ad4bbec-3fed-456f-b42d-b8094367a85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1ad4bbec-3fed-456f-b42d-b8094367a85d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7ed39717-99cd-4712-b128-40bf115e1adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_SharesOutstanding_7ed39717-99cd-4712-b128-40bf115e1adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_99b43405-04d0-4e07-9cce-7835aaba0eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockholdersEquity_99b43405-04d0-4e07-9cce-7835aaba0eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_37b006ec-98c5-4172-983a-ee629ebcbeac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_37b006ec-98c5-4172-983a-ee629ebcbeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1bd1c81e-9a1e-4997-bce5-db90447a165b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1bd1c81e-9a1e-4997-bce5-db90447a165b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c4ffb9bf-f641-4bd2-abdf-19a710fde761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c4ffb9bf-f641-4bd2-abdf-19a710fde761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_d55a432c-cb22-4fde-9fe6-d35eb90f45ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_d55a432c-cb22-4fde-9fe6-d35eb90f45ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_adf9b331-569f-4b28-89eb-b6eb224cecb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_adf9b331-569f-4b28-89eb-b6eb224cecb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_591b499c-429b-4d9a-b381-0c2d70c74330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_591b499c-429b-4d9a-b381-0c2d70c74330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4adde04b-451b-4713-9984-a91a7dac56fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4adde04b-451b-4713-9984-a91a7dac56fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_a4e92e75-db97-4f53-bf13-621582a998b1" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_a4e92e75-db97-4f53-bf13-621582a998b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_a307a1d0-2b2d-4672-9681-9a2eb305cd87" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_a307a1d0-2b2d-4672-9681-9a2eb305cd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_45b37879-b12f-4d6b-8863-0cb1aff3d705" xlink:href="mrsn-20201231.xsd#mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_45b37879-b12f-4d6b-8863-0cb1aff3d705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_e2e79980-aa00-44ce-adbe-243aef32f2ac" xlink:href="mrsn-20201231.xsd#mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_e2e79980-aa00-44ce-adbe-243aef32f2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_026e4464-8715-4e6f-a1f3-9495696fc39f" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_026e4464-8715-4e6f-a1f3-9495696fc39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3fae1406-0ef2-4890-bc89-c4991f6c5de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_3fae1406-0ef2-4890-bc89-c4991f6c5de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6e238a4f-57a5-444d-8401-f54606febe72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6e238a4f-57a5-444d-8401-f54606febe72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_80703997-88c4-4500-b371-c6827e4957a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_NetIncomeLoss_80703997-88c4-4500-b371-c6827e4957a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f43effbd-f120-49ea-b919-b0b54d170d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_SharesOutstanding_f43effbd-f120-49ea-b919-b0b54d170d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_53a144d3-4dca-4a2a-84be-6f46cb04b7c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_us-gaap_StockholdersEquity_53a144d3-4dca-4a2a-84be-6f46cb04b7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_1cd3cc78-75e7-434f-9947-0eb08f561c9f" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4b144f91-f643-42bd-a457-5f2902eca283" xlink:to="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_1cd3cc78-75e7-434f-9947-0eb08f561c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_143d7ec5-e61b-489b-8f4b-8394c6693b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1ad4bbec-3fed-456f-b42d-b8094367a85d" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_143d7ec5-e61b-489b-8f4b-8394c6693b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_fa1fb213-80ea-45d3-a200-bb403577deb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_abd1d164-7abd-4b32-b502-a2c182645c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fa1fb213-80ea-45d3-a200-bb403577deb5" xlink:to="loc_us-gaap_StatementTable_abd1d164-7abd-4b32-b502-a2c182645c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_16426e29-cfaa-4ec5-aa9d-fb32fcf49183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_abd1d164-7abd-4b32-b502-a2c182645c08" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_16426e29-cfaa-4ec5-aa9d-fb32fcf49183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_52648d6e-422c-4a46-934d-17ddb87dc6b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16426e29-cfaa-4ec5-aa9d-fb32fcf49183" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_52648d6e-422c-4a46-934d-17ddb87dc6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_0a867401-cf3a-4634-8555-cb2c5f9318c9" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_52648d6e-422c-4a46-934d-17ddb87dc6b9" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_0a867401-cf3a-4634-8555-cb2c5f9318c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_85fec31d-6fea-4496-bd52-85d8024a801f" xlink:href="mrsn-20201231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_52648d6e-422c-4a46-934d-17ddb87dc6b9" xlink:to="loc_mrsn_PublicStockOfferingMember_85fec31d-6fea-4496-bd52-85d8024a801f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e5ebe0bc-c4e4-4de9-80e9-6ec2ea9515d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_abd1d164-7abd-4b32-b502-a2c182645c08" xlink:to="loc_us-gaap_StatementLineItems_e5ebe0bc-c4e4-4de9-80e9-6ec2ea9515d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_37d694a8-dc05-43ef-8eea-10bc97d617eb" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e5ebe0bc-c4e4-4de9-80e9-6ec2ea9515d7" xlink:to="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_37d694a8-dc05-43ef-8eea-10bc97d617eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mrsn-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a5803d85-35c2-4831-bfed-e2ddb3baca89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1ce38ff1-d80f-4ca2-b8bc-69b4f2cfdb2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5803d85-35c2-4831-bfed-e2ddb3baca89" xlink:to="loc_us-gaap_StatementTable_1ce38ff1-d80f-4ca2-b8bc-69b4f2cfdb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cdbf410e-0216-4726-a2ec-b131abf423a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ce38ff1-d80f-4ca2-b8bc-69b4f2cfdb2a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cdbf410e-0216-4726-a2ec-b131abf423a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bb39b48-2744-4a89-868f-3a64d65c6f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cdbf410e-0216-4726-a2ec-b131abf423a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bb39b48-2744-4a89-868f-3a64d65c6f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_8db712da-d9ff-4a68-a6df-1c5dd3c42b9e" xlink:href="mrsn-20201231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bb39b48-2744-4a89-868f-3a64d65c6f55" xlink:to="loc_mrsn_PublicStockOfferingMember_8db712da-d9ff-4a68-a6df-1c5dd3c42b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_daa8f394-f31b-48a6-a1fd-58e902a09830" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8bb39b48-2744-4a89-868f-3a64d65c6f55" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_daa8f394-f31b-48a6-a1fd-58e902a09830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ce38ff1-d80f-4ca2-b8bc-69b4f2cfdb2a" xlink:to="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8a71a6dc-cc7a-4cb2-8f6a-7e3ae152b032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8a71a6dc-cc7a-4cb2-8f6a-7e3ae152b032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1c7d94eb-1552-4297-a25a-ea751900ef52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8a71a6dc-cc7a-4cb2-8f6a-7e3ae152b032" xlink:to="loc_us-gaap_ProfitLoss_1c7d94eb-1552-4297-a25a-ea751900ef52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8a71a6dc-cc7a-4cb2-8f6a-7e3ae152b032" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1aec49b7-a417-4c80-beb4-6ca0dbd3749b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1aec49b7-a417-4c80-beb4-6ca0dbd3749b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0f0168d6-95a7-4c39-89a4-0fcd7c48cde0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0f0168d6-95a7-4c39-89a4-0fcd7c48cde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_023fc69d-6e2a-4446-ba5c-d9b43d3d2dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_023fc69d-6e2a-4446-ba5c-d9b43d3d2dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0d604d02-b569-424d-b26a-ed7cba20c84d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_ShareBasedCompensation_0d604d02-b569-424d-b26a-ed7cba20c84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ChangeInDeferredRent_b0b2e8a7-52c3-4917-bd3b-0d170d967ee0" xlink:href="mrsn-20201231.xsd#mrsn_ChangeInDeferredRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_mrsn_ChangeInDeferredRent_b0b2e8a7-52c3-4917-bd3b-0d170d967ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_281b0135-52be-4c98-add8-b6ad8d250258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_281b0135-52be-4c98-add8-b6ad8d250258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a819c7f6-0eb4-4ddc-b31f-7e49ead7b8df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a819c7f6-0eb4-4ddc-b31f-7e49ead7b8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ade355ab-a6bd-48c1-8b86-f5bac83f9891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ade355ab-a6bd-48c1-8b86-f5bac83f9891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_791583b4-d4cc-422b-9c5a-c81e9722929a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_791583b4-d4cc-422b-9c5a-c81e9722929a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8a055e61-f7cb-4ea0-8e00-4b629ecb93d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8a055e61-f7cb-4ea0-8e00-4b629ecb93d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e3218fe9-c83d-4d24-a6f6-9ce5d5e2eaaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e3218fe9-c83d-4d24-a6f6-9ce5d5e2eaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets_57708536-0737-4e30-9f34-e00592b89cad" xlink:href="mrsn-20201231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets_57708536-0737-4e30-9f34-e00592b89cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_c81c3934-cc71-4ca1-86bd-2e397b1ab95b" xlink:href="mrsn-20201231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_c81c3934-cc71-4ca1-86bd-2e397b1ab95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bfbbfc9f-0936-4af1-b196-cb0f56a2bef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_94088c12-6e2e-47c1-9008-7416fe48982f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_bfbbfc9f-0936-4af1-b196-cb0f56a2bef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c089fe3-cfea-463d-b26b-dda8d265148c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_393a317e-87f2-454c-8311-204530d3366a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c089fe3-cfea-463d-b26b-dda8d265148c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869cc459-ebf0-4df8-ba47-5905c766da88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869cc459-ebf0-4df8-ba47-5905c766da88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d6fe13c9-9b81-46ae-bf3d-5701b178dbde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869cc459-ebf0-4df8-ba47-5905c766da88" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d6fe13c9-9b81-46ae-bf3d-5701b178dbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_808a6e8c-e3f4-4f83-a3b7-44a83d97da90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869cc459-ebf0-4df8-ba47-5905c766da88" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_808a6e8c-e3f4-4f83-a3b7-44a83d97da90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dca49033-9a7a-4971-a8cc-e854071b500c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869cc459-ebf0-4df8-ba47-5905c766da88" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_dca49033-9a7a-4971-a8cc-e854071b500c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e28a2426-b508-41f6-bacd-3ddfdf37e391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869cc459-ebf0-4df8-ba47-5905c766da88" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e28a2426-b508-41f6-bacd-3ddfdf37e391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7e9cff16-28d0-457f-ae6c-64305ff56f08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7e9cff16-28d0-457f-ae6c-64305ff56f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6b828f0a-ba70-4ef3-9f7c-446ca2588703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6b828f0a-ba70-4ef3-9f7c-446ca2588703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_35cc7743-5eb4-40f0-9c69-dd5a4232f4ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_35cc7743-5eb4-40f0-9c69-dd5a4232f4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromDebtNetIssuanceCosts_d0c68223-61f8-4bfd-88ce-8fabbf639d9a" xlink:href="mrsn-20201231.xsd#mrsn_ProceedsFromDebtNetIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:to="loc_mrsn_ProceedsFromDebtNetIssuanceCosts_d0c68223-61f8-4bfd-88ce-8fabbf639d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f97531fe-f946-48b4-a0ac-a4181d44b45f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f97531fe-f946-48b4-a0ac-a4181d44b45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99d7a712-9a2a-4d38-8c5e-ba775ff4c70a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6e72e09c-1ff0-4536-b819-3ae9d4d0c83a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_99d7a712-9a2a-4d38-8c5e-ba775ff4c70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ee060b78-a4fd-41af-af30-60f517b62889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ee060b78-a4fd-41af-af30-60f517b62889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1fb9aa1e-b08e-42b1-a3b9-11adbdaf86d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1fb9aa1e-b08e-42b1-a3b9-11adbdaf86d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1c7ef963-ffba-4ccb-8ceb-a5e1580b72db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1c7ef963-ffba-4ccb-8ceb-a5e1580b72db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f0b31ef-0222-454d-8e88-11351e74d18f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_6d862dd9-d6ff-4cb5-b68e-21c017b2c0ca" xlink:href="mrsn-20201231.xsd#mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_6d862dd9-d6ff-4cb5-b68e-21c017b2c0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_776ee780-df82-4c55-9cae-f18c2c7ea01b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_776ee780-df82-4c55-9cae-f18c2c7ea01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_42da3455-8625-4f0a-9e0b-5080b0657ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_42da3455-8625-4f0a-9e0b-5080b0657ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_8202fdee-57ee-4052-81fc-922fde6ac169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_us-gaap_InterestPaidNet_8202fdee-57ee-4052-81fc-922fde6ac169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_08d9ef93-a5b3-4580-88f7-18460277d7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_08d9ef93-a5b3-4580-88f7-18460277d7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_1d9513c4-683d-4de6-a062-3db803e9b7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_1d9513c4-683d-4de6-a062-3db803e9b7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard_beddd81c-9d9b-4354-a36c-967efa299921" xlink:href="mrsn-20201231.xsd#mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7db544c2-cfaf-4a2e-866f-39dedf99fbd2" xlink:to="loc_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard_beddd81c-9d9b-4354-a36c-967efa299921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="mrsn-20201231.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2087ff9b-f9e1-444e-91e1-da044e28e26a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_f6b8ae97-c0de-4c7c-a904-a6d15c6c46d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2087ff9b-f9e1-444e-91e1-da044e28e26a" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_f6b8ae97-c0de-4c7c-a904-a6d15c6c46d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_996b2744-4ef0-4afa-ab36-0b6192294b8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_8334d530-1980-4bc2-82f4-37a334036f74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_996b2744-4ef0-4afa-ab36-0b6192294b8c" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_8334d530-1980-4bc2-82f4-37a334036f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b8f31cb4-904a-4867-a665-f6aa58578f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_8334d530-1980-4bc2-82f4-37a334036f74" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b8f31cb4-904a-4867-a665-f6aa58578f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86580de5-5b62-4f28-a61f-85f101d1e735" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b8f31cb4-904a-4867-a665-f6aa58578f7e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86580de5-5b62-4f28-a61f-85f101d1e735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_98ab34c5-f89a-4f15-b531-d52be22fe8dc" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86580de5-5b62-4f28-a61f-85f101d1e735" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_98ab34c5-f89a-4f15-b531-d52be22fe8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_e54043db-fca5-44bf-9051-2f3923fd5a74" xlink:href="mrsn-20201231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86580de5-5b62-4f28-a61f-85f101d1e735" xlink:to="loc_mrsn_PublicStockOfferingMember_e54043db-fca5-44bf-9051-2f3923fd5a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d1ed68a0-5bfd-47f8-aaec-c775ab7d654a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_8334d530-1980-4bc2-82f4-37a334036f74" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d1ed68a0-5bfd-47f8-aaec-c775ab7d654a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb589f71-7aec-4b6d-8de2-1a9ae9c056a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d1ed68a0-5bfd-47f8-aaec-c775ab7d654a" xlink:to="loc_us-gaap_NetIncomeLoss_eb589f71-7aec-4b6d-8de2-1a9ae9c056a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c95bbe5d-1faa-40c4-8ba1-9a1efdeaf249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d1ed68a0-5bfd-47f8-aaec-c775ab7d654a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c95bbe5d-1faa-40c4-8ba1-9a1efdeaf249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_73415da5-0501-4d15-bacf-583380d10a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d1ed68a0-5bfd-47f8-aaec-c775ab7d654a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_73415da5-0501-4d15-bacf-583380d10a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_875e62cc-14e7-4e0d-a05b-6c33f91bbcb9" xlink:href="mrsn-20201231.xsd#mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_d1ed68a0-5bfd-47f8-aaec-c775ab7d654a" xlink:to="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_875e62cc-14e7-4e0d-a05b-6c33f91bbcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c6220560-9d56-41c1-bf68-326d5048f547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a07fb274-3d51-4d43-b990-91310c265606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c6220560-9d56-41c1-bf68-326d5048f547" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a07fb274-3d51-4d43-b990-91310c265606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_7c34939c-5b5f-46fa-9931-1aa6f9dad6d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_7c34939c-5b5f-46fa-9931-1aa6f9dad6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_61c767b9-108e-443c-bdbf-fee8d72f8f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_UseOfEstimates_61c767b9-108e-443c-bdbf-fee8d72f8f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_cbc1ac91-3931-4b2c-ab43-278fd99738e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_cbc1ac91-3931-4b2c-ab43-278fd99738e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2e9ff15a-9c05-4422-8a90-53d01df1d701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2e9ff15a-9c05-4422-8a90-53d01df1d701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1ec06541-72ef-49fd-b1f1-28d4ca7afbf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1ec06541-72ef-49fd-b1f1-28d4ca7afbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_75f5b24a-172b-4e66-8dd9-e7a80b8d39f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_75f5b24a-172b-4e66-8dd9-e7a80b8d39f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8fff607c-2feb-43e0-b840-56c99e402c51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8fff607c-2feb-43e0-b840-56c99e402c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7cc116cd-6820-4c91-993a-0ba80decdc0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7cc116cd-6820-4c91-993a-0ba80decdc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_5d918d6f-1274-47fb-b8be-eb3f92b83fae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_5d918d6f-1274-47fb-b8be-eb3f92b83fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_877b9ce1-a27d-4270-ba8b-02628cc9afb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_877b9ce1-a27d-4270-ba8b-02628cc9afb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c0c24964-24e9-4533-b14a-2a185421e614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c0c24964-24e9-4533-b14a-2a185421e614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_e2bc3018-9121-492a-869a-00cfe58feb68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_e2bc3018-9121-492a-869a-00cfe58feb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8c3990ac-c8b6-412f-ac58-d211372b2914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8c3990ac-c8b6-412f-ac58-d211372b2914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_13d88d21-c9f7-42ee-b524-18a34caa1411" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_13d88d21-c9f7-42ee-b524-18a34caa1411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PatentCostsPolicyTextBlock_daf24d9f-4ab4-44be-b2f9-32ac16ee0192" xlink:href="mrsn-20201231.xsd#mrsn_PatentCostsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_mrsn_PatentCostsPolicyTextBlock_daf24d9f-4ab4-44be-b2f9-32ac16ee0192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_942c4085-85f8-432b-b943-746430e952aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_942c4085-85f8-432b-b943-746430e952aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2e4b18ce-2fef-4084-9830-f8fc6d2bc62c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2e4b18ce-2fef-4084-9830-f8fc6d2bc62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_fdb3b331-4fdf-489d-8e47-fdeec7b17a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_fdb3b331-4fdf-489d-8e47-fdeec7b17a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7e6504d2-8309-4c8e-a631-45821a96f40b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c45d9a6f-a764-4701-869e-8ce3313e892f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7e6504d2-8309-4c8e-a631-45821a96f40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2d4d472a-3c71-4d65-b3d4-74e2f9989415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_713ffcff-662c-4b11-b215-6ea9f5b51455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2d4d472a-3c71-4d65-b3d4-74e2f9989415" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_713ffcff-662c-4b11-b215-6ea9f5b51455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_1c6c5d03-c789-4ca5-9b84-18b8d7e1c6cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2d4d472a-3c71-4d65-b3d4-74e2f9989415" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_1c6c5d03-c789-4ca5-9b84-18b8d7e1c6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_53e83092-f0d4-4560-bbc6-3f30dac7f7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2d4d472a-3c71-4d65-b3d4-74e2f9989415" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_53e83092-f0d4-4560-bbc6-3f30dac7f7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_acb147cf-cfb1-464f-ba92-690884f3d7d2" xlink:href="mrsn-20201231.xsd#mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2d4d472a-3c71-4d65-b3d4-74e2f9989415" xlink:to="loc_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_acb147cf-cfb1-464f-ba92-690884f3d7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3e8473a0-292c-4a47-9df6-1c141ee7af98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_06cab2b9-9749-4f25-85f6-44400d7a408b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3e8473a0-292c-4a47-9df6-1c141ee7af98" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_06cab2b9-9749-4f25-85f6-44400d7a408b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_56af90fc-a414-452f-a518-f603b853a80d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_06cab2b9-9749-4f25-85f6-44400d7a408b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_56af90fc-a414-452f-a518-f603b853a80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_514cb4e2-cc29-4910-bad3-4f69b8cd8773" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_56af90fc-a414-452f-a518-f603b853a80d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_514cb4e2-cc29-4910-bad3-4f69b8cd8773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_18632c2d-b096-499c-a0d7-65269800a43b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_514cb4e2-cc29-4910-bad3-4f69b8cd8773" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_18632c2d-b096-499c-a0d7-65269800a43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1152528a-d18b-419c-84f6-e6a31b3a551d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_06cab2b9-9749-4f25-85f6-44400d7a408b" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1152528a-d18b-419c-84f6-e6a31b3a551d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueCollectionPeriod_241d6561-b94d-48b4-b948-9f7d846ddcf8" xlink:href="mrsn-20201231.xsd#mrsn_RevenueCollectionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1152528a-d18b-419c-84f6-e6a31b3a551d" xlink:to="loc_mrsn_RevenueCollectionPeriod_241d6561-b94d-48b4-b948-9f7d846ddcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3497a23b-ca14-455b-9c93-1ab58487e9b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1152528a-d18b-419c-84f6-e6a31b3a551d" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3497a23b-ca14-455b-9c93-1ab58487e9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a5800a8e-e24e-4339-9f65-01c1440e06ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1152528a-d18b-419c-84f6-e6a31b3a551d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a5800a8e-e24e-4339-9f65-01c1440e06ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_765928cf-bade-4e7d-aefe-01181b54b11f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_4e616757-9c10-4012-8361-d46dfea09ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_765928cf-bade-4e7d-aefe-01181b54b11f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_4e616757-9c10-4012-8361-d46dfea09ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ddb8c678-d921-4217-afda-a7755df51698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_4e616757-9c10-4012-8361-d46dfea09ed1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ddb8c678-d921-4217-afda-a7755df51698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_ec33faf8-fb02-42d8-afe3-f4a248e533e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_4e616757-9c10-4012-8361-d46dfea09ed1" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_ec33faf8-fb02-42d8-afe3-f4a248e533e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc813c30-234e-4003-b32f-8df2287be42a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_4e616757-9c10-4012-8361-d46dfea09ed1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc813c30-234e-4003-b32f-8df2287be42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dfbb0637-4980-49eb-a225-587453520a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_7b26f92f-02fc-48b1-8f05-c00d47234f88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dfbb0637-4980-49eb-a225-587453520a6a" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_7b26f92f-02fc-48b1-8f05-c00d47234f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2853bfda-a19f-487e-9555-5919498074bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_7b26f92f-02fc-48b1-8f05-c00d47234f88" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2853bfda-a19f-487e-9555-5919498074bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainageDeposit_c8443a74-77fa-4203-9f11-b7277193e423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainageDeposit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_7b26f92f-02fc-48b1-8f05-c00d47234f88" xlink:to="loc_us-gaap_RetainageDeposit_c8443a74-77fa-4203-9f11-b7277193e423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_76f1014c-b821-491f-84de-b10b76f28cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_7b26f92f-02fc-48b1-8f05-c00d47234f88" xlink:to="loc_us-gaap_SecurityDeposit_76f1014c-b821-491f-84de-b10b76f28cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_337a74a3-5088-4030-8d14-87f5e3e33353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30f099fe-47c2-4341-aa99-59959c2151e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_337a74a3-5088-4030-8d14-87f5e3e33353" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30f099fe-47c2-4341-aa99-59959c2151e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesNetlosspershareDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f1d17f43-be0d-41a5-bc23-3e10f9d84a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f15cc5f-0951-4745-9976-00a549c8f18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f1d17f43-be0d-41a5-bc23-3e10f9d84a4d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f15cc5f-0951-4745-9976-00a549c8f18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f585cdae-17aa-483f-abf7-508b7bcd5a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f15cc5f-0951-4745-9976-00a549c8f18b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f585cdae-17aa-483f-abf7-508b7bcd5a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_195a85ba-d1fe-4d27-bdfa-c0a2f6626922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f585cdae-17aa-483f-abf7-508b7bcd5a35" xlink:to="loc_us-gaap_EquityComponentDomain_195a85ba-d1fe-4d27-bdfa-c0a2f6626922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExchangeWarrantsMember_0db0fd8a-408a-4f04-a714-14b24a047af8" xlink:href="mrsn-20201231.xsd#mrsn_ExchangeWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_195a85ba-d1fe-4d27-bdfa-c0a2f6626922" xlink:to="loc_mrsn_ExchangeWarrantsMember_0db0fd8a-408a-4f04-a714-14b24a047af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2135c80c-efb2-4653-8a44-1f9b558b31f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f15cc5f-0951-4745-9976-00a549c8f18b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2135c80c-efb2-4653-8a44-1f9b558b31f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a161ada8-4d7e-46a7-a84e-bbedcdd5f4ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2135c80c-efb2-4653-8a44-1f9b558b31f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a161ada8-4d7e-46a7-a84e-bbedcdd5f4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d8cffe6b-8680-4306-a4bd-451c906d1456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a161ada8-4d7e-46a7-a84e-bbedcdd5f4ee" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d8cffe6b-8680-4306-a4bd-451c906d1456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_19e9716c-749f-43ed-9c46-7cb99bb7f16c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a161ada8-4d7e-46a7-a84e-bbedcdd5f4ee" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_19e9716c-749f-43ed-9c46-7cb99bb7f16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_07d8fea2-0abb-46ce-8e1f-ed4726319945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a161ada8-4d7e-46a7-a84e-bbedcdd5f4ee" xlink:to="loc_us-gaap_WarrantMember_07d8fea2-0abb-46ce-8e1f-ed4726319945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b927d7d-d8e7-4858-b4f3-70c6c842eca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f15cc5f-0951-4745-9976-00a549c8f18b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b927d7d-d8e7-4858-b4f3-70c6c842eca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_500e8d48-5f9a-4aa3-bd83-579179a86371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b927d7d-d8e7-4858-b4f3-70c6c842eca2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_500e8d48-5f9a-4aa3-bd83-579179a86371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_bc4f4374-a6f7-4681-8a83-443b8f3545aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_500e8d48-5f9a-4aa3-bd83-579179a86371" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_bc4f4374-a6f7-4681-8a83-443b8f3545aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_476be8c1-e2bb-4b1f-b333-68777ba9a15b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b927d7d-d8e7-4858-b4f3-70c6c842eca2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_476be8c1-e2bb-4b1f-b333-68777ba9a15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7bc84f8f-5cb5-4dbc-bd4f-a0fe2eaaa2ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_efb6f281-3fbd-4879-ad22-c1be528b93bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bc84f8f-5cb5-4dbc-bd4f-a0fe2eaaa2ee" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_efb6f281-3fbd-4879-ad22-c1be528b93bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_54904b65-8430-4b1d-9f93-3e4d43445921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_efb6f281-3fbd-4879-ad22-c1be528b93bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_54904b65-8430-4b1d-9f93-3e4d43445921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fcf7c04f-f6d0-461d-987e-aa800a5841f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_54904b65-8430-4b1d-9f93-3e4d43445921" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fcf7c04f-f6d0-461d-987e-aa800a5841f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember_e41b2ae3-307b-4b62-b431-32538c1973cf" xlink:href="mrsn-20201231.xsd#mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fcf7c04f-f6d0-461d-987e-aa800a5841f3" xlink:to="loc_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember_e41b2ae3-307b-4b62-b431-32538c1973cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentMember_469f4075-cb6f-42fb-a22e-c6358ec62d25" xlink:href="mrsn-20201231.xsd#mrsn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fcf7c04f-f6d0-461d-987e-aa800a5841f3" xlink:to="loc_mrsn_LaboratoryEquipmentMember_469f4075-cb6f-42fb-a22e-c6358ec62d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d5d0a40c-a344-44dd-9470-9fe4f07e8826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fcf7c04f-f6d0-461d-987e-aa800a5841f3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d5d0a40c-a344-44dd-9470-9fe4f07e8826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e99bd8e-2a74-4a83-beea-bea91cca3c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_efb6f281-3fbd-4879-ad22-c1be528b93bc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e99bd8e-2a74-4a83-beea-bea91cca3c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c7b39575-c968-42db-9afd-08a75d057972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e99bd8e-2a74-4a83-beea-bea91cca3c15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c7b39575-c968-42db-9afd-08a75d057972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_2a86a81c-90f8-49b6-8ada-97bf99d3eac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e99bd8e-2a74-4a83-beea-bea91cca3c15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_2a86a81c-90f8-49b6-8ada-97bf99d3eac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRisksDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesRisksDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_840f7482-7abc-4812-947a-55f5ed52d4bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_e1efb847-0b17-4c12-9518-f01859f82efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_840f7482-7abc-4812-947a-55f5ed52d4bc" xlink:to="loc_us-gaap_RisksAndUncertaintiesAbstract_e1efb847-0b17-4c12-9518-f01859f82efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_0a871fc9-1b4b-4520-88f1-4543953311c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_e1efb847-0b17-4c12-9518-f01859f82efa" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_0a871fc9-1b4b-4520-88f1-4543953311c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_31f98374-f3dd-404c-a54c-4d94d9a51b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e12ccf5-519b-4f49-9415-0bbe65e15e9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_31f98374-f3dd-404c-a54c-4d94d9a51b0a" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e12ccf5-519b-4f49-9415-0bbe65e15e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f0a7dc86-6570-41ae-85d9-cd93b607468e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e12ccf5-519b-4f49-9415-0bbe65e15e9e" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f0a7dc86-6570-41ae-85d9-cd93b607468e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1dc6b308-00fe-4e95-9af9-4f41e6b4d843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f0a7dc86-6570-41ae-85d9-cd93b607468e" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1dc6b308-00fe-4e95-9af9-4f41e6b4d843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201818Member_703b38ac-ed29-4a6f-b04c-9299286e676d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1dc6b308-00fe-4e95-9af9-4f41e6b4d843" xlink:to="loc_us-gaap_AccountingStandardsUpdate201818Member_703b38ac-ed29-4a6f-b04c-9299286e676d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_8e6f4627-7a77-495e-9efd-16d9047c47c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1dc6b308-00fe-4e95-9af9-4f41e6b4d843" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_8e6f4627-7a77-495e-9efd-16d9047c47c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d9c1754a-00ca-459b-ad08-4a04b65fa9b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e12ccf5-519b-4f49-9415-0bbe65e15e9e" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d9c1754a-00ca-459b-ad08-4a04b65fa9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_efb39ea4-d509-42c2-92f1-16559d7858a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d9c1754a-00ca-459b-ad08-4a04b65fa9b7" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_efb39ea4-d509-42c2-92f1-16559d7858a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_2bcc249a-cb79-4481-b8e4-d94f39f325d6" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c1802f1e-ad57-4870-9542-2be8d6702fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_2bcc249a-cb79-4481-b8e4-d94f39f325d6" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c1802f1e-ad57-4870-9542-2be8d6702fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_f30a8cbc-ebe4-4901-8413-6c0d54fe47b8" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_688690a3-68f6-4110-85ed-5bb7ba9d646b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_f30a8cbc-ebe4-4901-8413-6c0d54fe47b8" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_688690a3-68f6-4110-85ed-5bb7ba9d646b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsMerckKGaADetail"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_d85a32ec-b870-488f-9510-3d35bd5bd4be" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7fc5ce4-4914-424a-a45b-fbad1e1ef672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_d85a32ec-b870-488f-9510-3d35bd5bd4be" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7fc5ce4-4914-424a-a45b-fbad1e1ef672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_38f6b56c-5f8c-478a-9e5c-cc123c09268c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7fc5ce4-4914-424a-a45b-fbad1e1ef672" xlink:to="loc_us-gaap_TypeOfArrangementAxis_38f6b56c-5f8c-478a-9e5c-cc123c09268c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5189f532-851c-4fb8-b418-0d224225b89f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_38f6b56c-5f8c-478a-9e5c-cc123c09268c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5189f532-851c-4fb8-b418-0d224225b89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_ebc8e0f8-2f30-4d98-9594-2b2f774a27b7" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5189f532-851c-4fb8-b418-0d224225b89f" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_ebc8e0f8-2f30-4d98-9594-2b2f774a27b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7fc5ce4-4914-424a-a45b-fbad1e1ef672" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsUpfrontPayment_86541135-a3c2-472e-b138-96f58eb0ad48" xlink:href="mrsn-20201231.xsd#mrsn_CollaborativeArrangementsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborativeArrangementsUpfrontPayment_86541135-a3c2-472e-b138-96f58eb0ad48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_d9b157df-040c-4633-a768-d8b1759b3c22" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_d9b157df-040c-4633-a768-d8b1759b3c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_c409dcad-ba16-4e27-a8bf-9b1fb6888f0f" xlink:href="mrsn-20201231.xsd#mrsn_CollaborativeArrangementsExclusiveTargetsNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_c409dcad-ba16-4e27-a8bf-9b1fb6888f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_74072102-eab3-403f-b744-2c37600b3686" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_74072102-eab3-403f-b744-2c37600b3686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_01c8f910-71f7-46ad-af98-865ccd7902b0" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsMaximumAggregateMilestones"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_01c8f910-71f7-46ad-af98-865ccd7902b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_d663bc92-385a-4f68-a5cd-118bd9109e68" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_d663bc92-385a-4f68-a5cd-118bd9109e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_de05b8a8-0d72-4691-9c53-164e963967c2" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsRegulatoryMilestones"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_de05b8a8-0d72-4691-9c53-164e963967c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSalesMilestones_0cefb589-bf9a-415d-9d92-64ff2cdde59f" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsSalesMilestones"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsSalesMilestones_0cefb589-bf9a-415d-9d92-64ff2cdde59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_75e1bda1-108a-4208-9515-5eeb4ad6a227" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_75e1bda1-108a-4208-9515-5eeb4ad6a227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_7c44e617-bf4f-45c7-97cf-04d0ffd6182a" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_7c44e617-bf4f-45c7-97cf-04d0ffd6182a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_966f038e-984b-43fd-80ff-b96897856ff5" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_966f038e-984b-43fd-80ff-b96897856ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_ef4b73d3-d28c-4989-9b33-439120837727" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_ef4b73d3-d28c-4989-9b33-439120837727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_f6db066d-afd5-4071-b62e-febcf49a2ca7" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_f6db066d-afd5-4071-b62e-febcf49a2ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_b9055f49-064e-4417-ae1e-69205a92cbf0" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e66dcbfe-e37b-4f93-850a-f1528e0ab96e" xlink:to="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_b9055f49-064e-4417-ae1e-69205a92cbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_14c8c6f7-d2a8-4215-9a86-08b3a7e5c8e6" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_14c8c6f7-d2a8-4215-9a86-08b3a7e5c8e6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b426f4b3-fe3b-46a4-9211-a7d254639c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_b426f4b3-fe3b-46a4-9211-a7d254639c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_85867946-3b20-4b45-be65-a4de05848452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:to="loc_us-gaap_TypeOfArrangementAxis_85867946-3b20-4b45-be65-a4de05848452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_050d728d-e0ac-4190-8378-1d3635d273be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_85867946-3b20-4b45-be65-a4de05848452" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_050d728d-e0ac-4190-8378-1d3635d273be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_29b2d40f-11bb-4720-8e26-0eb000598ba5" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_050d728d-e0ac-4190-8378-1d3635d273be" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_29b2d40f-11bb-4720-8e26-0eb000598ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_89af59e4-8ac3-44a4-a798-c9402db7e2bd" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_29b2d40f-11bb-4720-8e26-0eb000598ba5" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_89af59e4-8ac3-44a4-a798-c9402db7e2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SupplyAgreementMerckKgaaMember_ef03cd09-ed62-4ac2-8831-c8b073f94e12" xlink:href="mrsn-20201231.xsd#mrsn_SupplyAgreementMerckKgaaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_29b2d40f-11bb-4720-8e26-0eb000598ba5" xlink:to="loc_mrsn_SupplyAgreementMerckKgaaMember_ef03cd09-ed62-4ac2-8831-c8b073f94e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5a3fcfde-4606-4f30-96e2-acae353af210" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:to="loc_srt_ProductOrServiceAxis_5a3fcfde-4606-4f30-96e2-acae353af210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5a3fcfde-4606-4f30-96e2-acae353af210" xlink:to="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_b8f83cf6-1730-4995-a255-fce614dad50d" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_b8f83cf6-1730-4995-a255-fce614dad50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_db66a824-06c7-40df-ac10-b17a426d6246" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_db66a824-06c7-40df-ac10-b17a426d6246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_343a18c5-690d-4079-a176-9b94d4a171e6" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_343a18c5-690d-4079-a176-9b94d4a171e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_bbc99fdd-8de3-4b4e-9ae8-ae685acf6483" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_bbc99fdd-8de3-4b4e-9ae8-ae685acf6483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RightsToFutureTechnologicalImprovementsMember_f861c75c-565a-489f-b90c-9878fbd19029" xlink:href="mrsn-20201231.xsd#mrsn_RightsToFutureTechnologicalImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_RightsToFutureTechnologicalImprovementsMember_f861c75c-565a-489f-b90c-9878fbd19029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_JointResearchCommitteeServicesMember_bcbbf643-18a2-4852-ab16-e504e3881fae" xlink:href="mrsn-20201231.xsd#mrsn_JointResearchCommitteeServicesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_daa71570-8772-48ff-b113-3bcd0328c197" xlink:to="loc_mrsn_JointResearchCommitteeServicesMember_bcbbf643-18a2-4852-ab16-e504e3881fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a4bbc95f-a680-48a1-95ca-bd3fd0163f73" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_c4aa532b-b241-4cc2-ab9d-8a652a289bad" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_c4aa532b-b241-4cc2-ab9d-8a652a289bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_6f73eee4-99d7-4704-813a-4b4f8fc11e60" xlink:href="mrsn-20201231.xsd#mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_6f73eee4-99d7-4704-813a-4b4f8fc11e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueTransactionPriceAmount_1dbde409-89a3-4232-9be2-61a14a07624f" xlink:href="mrsn-20201231.xsd#mrsn_RevenueTransactionPriceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_RevenueTransactionPriceAmount_1dbde409-89a3-4232-9be2-61a14a07624f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_5d9bc5e8-58a5-4287-b0ed-bd0a1170f2fe" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_5d9bc5e8-58a5-4287-b0ed-bd0a1170f2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated_760c1f3f-e92c-4d0f-a1d5-109184785fc9" xlink:href="mrsn-20201231.xsd#mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated_760c1f3f-e92c-4d0f-a1d5-109184785fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueTransactionPriceIncreaseDecrease_f681276e-5b1a-4b42-afe3-0eafe2badce0" xlink:href="mrsn-20201231.xsd#mrsn_RevenueTransactionPriceIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_mrsn_RevenueTransactionPriceIncreaseDecrease_f681276e-5b1a-4b42-afe3-0eafe2badce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bada9fe1-1793-4712-befe-8215e15fd347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bada9fe1-1793-4712-befe-8215e15fd347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0b79410c-2844-491f-a2e6-25b0115290d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0b79410c-2844-491f-a2e6-25b0115290d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_b6e740d8-c7cb-4c41-b804-66fb771de508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_AccountsReceivableNet_b6e740d8-c7cb-4c41-b804-66fb771de508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_669d52c8-433b-454f-836f-9d34b7cbc80a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_cb7a86a4-342d-48c6-b913-f7c253540a38" xlink:to="loc_us-gaap_ContractWithCustomerLiability_669d52c8-433b-454f-836f-9d34b7cbc80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails_1" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsMerckKGaAAccountingAnalysisDetails_1"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_5ee059ba-d387-48f4-9a8a-b875dfda7e67" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95c219d7-1f0e-498f-8b1b-df4e4328dc97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_5ee059ba-d387-48f4-9a8a-b875dfda7e67" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95c219d7-1f0e-498f-8b1b-df4e4328dc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_746a18af-50f1-4a24-9d63-77e6fd74aa18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95c219d7-1f0e-498f-8b1b-df4e4328dc97" xlink:to="loc_us-gaap_TypeOfArrangementAxis_746a18af-50f1-4a24-9d63-77e6fd74aa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_056e0bb5-4d7d-4a52-985c-83e3d2756c6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_746a18af-50f1-4a24-9d63-77e6fd74aa18" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_056e0bb5-4d7d-4a52-985c-83e3d2756c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_00eec4a9-e6c2-4431-a379-f8c95a2d1620" xlink:href="mrsn-20201231.xsd#mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_056e0bb5-4d7d-4a52-985c-83e3d2756c6b" xlink:to="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_00eec4a9-e6c2-4431-a379-f8c95a2d1620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0bd3123-c0ab-4754-9d87-da4aeaf9a3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95c219d7-1f0e-498f-8b1b-df4e4328dc97" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0bd3123-c0ab-4754-9d87-da4aeaf9a3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDurationToTermination_737fd822-92e2-474b-bc42-aae47a0e8e65" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDurationToTermination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0bd3123-c0ab-4754-9d87-da4aeaf9a3cf" xlink:to="loc_mrsn_CollaborationArrangementsDurationToTermination_737fd822-92e2-474b-bc42-aae47a0e8e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_a8c168d9-d45d-412d-8b45-a87468404892" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e0bd3123-c0ab-4754-9d87-da4aeaf9a3cf" xlink:to="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_a8c168d9-d45d-412d-8b45-a87468404892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsTakedastrategicRDpartnershipDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_f691dd8e-1632-41ac-80f6-6772fc1977c5" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_027de6ae-f159-4919-8401-bd47aa7281be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_f691dd8e-1632-41ac-80f6-6772fc1977c5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_027de6ae-f159-4919-8401-bd47aa7281be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bc5c9f1f-df1f-40c4-b5e2-7d3c695b79c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_027de6ae-f159-4919-8401-bd47aa7281be" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bc5c9f1f-df1f-40c4-b5e2-7d3c695b79c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb577006-bd48-4446-a3cf-56bd76826a18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bc5c9f1f-df1f-40c4-b5e2-7d3c695b79c5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb577006-bd48-4446-a3cf-56bd76826a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_d840cdc9-18a9-4a74-843d-445a51dbe44a" xlink:href="mrsn-20201231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb577006-bd48-4446-a3cf-56bd76826a18" xlink:to="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_d840cdc9-18a9-4a74-843d-445a51dbe44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2832d39d-e3f9-4a75-a7fc-083b041a2c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_027de6ae-f159-4919-8401-bd47aa7281be" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2832d39d-e3f9-4a75-a7fc-083b041a2c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_c94032f4-5437-4af9-8894-53828f02b838" xlink:href="mrsn-20201231.xsd#mrsn_CollaborativeArrangementsExclusiveTargetsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2832d39d-e3f9-4a75-a7fc-083b041a2c0c" xlink:to="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_c94032f4-5437-4af9-8894-53828f02b838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDurationToTermination_68517c3a-4ead-4e6e-b716-14ab58d2db1a" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsDurationToTermination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2832d39d-e3f9-4a75-a7fc-083b041a2c0c" xlink:to="loc_mrsn_CollaborationArrangementsDurationToTermination_68517c3a-4ead-4e6e-b716-14ab58d2db1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsTakedaAccountingAnalysisDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_6277679d-c653-4420-96bf-89fb707518dc" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_17c2477f-ee17-4779-b594-abf5c403a0fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_6277679d-c653-4420-96bf-89fb707518dc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_17c2477f-ee17-4779-b594-abf5c403a0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a05c124a-368a-47fa-9826-7408a24099e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_17c2477f-ee17-4779-b594-abf5c403a0fb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a05c124a-368a-47fa-9826-7408a24099e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73f896a6-2936-45e3-b6ee-15135e325940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a05c124a-368a-47fa-9826-7408a24099e0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73f896a6-2936-45e3-b6ee-15135e325940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_ce27a9d9-9314-4daa-b2ce-74d1d9fef5f5" xlink:href="mrsn-20201231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73f896a6-2936-45e3-b6ee-15135e325940" xlink:to="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_ce27a9d9-9314-4daa-b2ce-74d1d9fef5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_5989d1da-b590-4f50-8e88-e64d7c5ceb11" xlink:href="mrsn-20201231.xsd#mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_73f896a6-2936-45e3-b6ee-15135e325940" xlink:to="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_5989d1da-b590-4f50-8e88-e64d7c5ceb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a546fa99-521f-4c05-99b2-b5b0b97efe83" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_17c2477f-ee17-4779-b594-abf5c403a0fb" xlink:to="loc_srt_ProductOrServiceAxis_a546fa99-521f-4c05-99b2-b5b0b97efe83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e15b318-69c4-45d2-9c53-9fe8b796a85a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a546fa99-521f-4c05-99b2-b5b0b97efe83" xlink:to="loc_srt_ProductsAndServicesDomain_9e15b318-69c4-45d2-9c53-9fe8b796a85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_e820c5b2-5af5-4e31-a518-aa94c4ba36c9" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e15b318-69c4-45d2-9c53-9fe8b796a85a" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_e820c5b2-5af5-4e31-a518-aa94c4ba36c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_17c2477f-ee17-4779-b594-abf5c403a0fb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c22b6324-ba34-4f58-9113-db673dfb8423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_c22b6324-ba34-4f58-9113-db673dfb8423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueRemainingPerformanceObligationNumber_ec4d8c77-178f-4f32-88f6-5c43e348ed5a" xlink:href="mrsn-20201231.xsd#mrsn_RevenueRemainingPerformanceObligationNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:to="loc_mrsn_RevenueRemainingPerformanceObligationNumber_ec4d8c77-178f-4f32-88f6-5c43e348ed5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4078e6af-03f2-49b6-8e32-70a5d54a19c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4078e6af-03f2-49b6-8e32-70a5d54a19c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9965dd05-5d89-48b8-972f-f9582a666976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9965dd05-5d89-48b8-972f-f9582a666976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsCostsBilled_d6b14e92-d2af-479d-96c3-24b028450d26" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsCostsBilled"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_23d1bc82-035e-4575-9f90-a791468129ad" xlink:to="loc_mrsn_CollaborationArrangementsCostsBilled_d6b14e92-d2af-479d-96c3-24b028450d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_04bcc61b-5693-4643-a48c-01b772388e16" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_40bbd98d-e3df-4303-87ef-df0ff7899942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_04bcc61b-5693-4643-a48c-01b772388e16" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_40bbd98d-e3df-4303-87ef-df0ff7899942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_638f8f26-a93c-475c-bfae-cf67c5ee3430" xlink:href="mrsn-20201231.xsd#mrsn_ChangeInContractAssetsAndLiabilitiesRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_04bcc61b-5693-4643-a48c-01b772388e16" xlink:to="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_638f8f26-a93c-475c-bfae-cf67c5ee3430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2545d527-6c7d-40e0-aec0-0b2e5215be3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_638f8f26-a93c-475c-bfae-cf67c5ee3430" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2545d527-6c7d-40e0-aec0-0b2e5215be3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractWithCustomerLiabilityIncrease_2e849087-3e79-4da2-89fb-d7537b5507f0" xlink:href="mrsn-20201231.xsd#mrsn_ContractWithCustomerLiabilityIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_638f8f26-a93c-475c-bfae-cf67c5ee3430" xlink:to="loc_mrsn_ContractWithCustomerLiabilityIncrease_2e849087-3e79-4da2-89fb-d7537b5507f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractWithCustomerLiabilityDecrease_6fbc22db-8951-4ceb-a6cd-ff4887418882" xlink:href="mrsn-20201231.xsd#mrsn_ContractWithCustomerLiabilityDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_638f8f26-a93c-475c-bfae-cf67c5ee3430" xlink:to="loc_mrsn_ContractWithCustomerLiabilityDecrease_6fbc22db-8951-4ceb-a6cd-ff4887418882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_28c4b196-5b13-4769-967f-ade6fa1fd618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_638f8f26-a93c-475c-bfae-cf67c5ee3430" xlink:to="loc_us-gaap_ContractWithCustomerLiability_28c4b196-5b13-4769-967f-ade6fa1fd618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_f158e85d-00b5-486a-841e-a69242eccfcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_04bcc61b-5693-4643-a48c-01b772388e16" xlink:to="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_f158e85d-00b5-486a-841e-a69242eccfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_69b6e29e-035c-405b-995f-5551be8e0c20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_f158e85d-00b5-486a-841e-a69242eccfcf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_69b6e29e-035c-405b-995f-5551be8e0c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_40339952-2a32-4b1e-8bd2-6be252ef3fe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_f158e85d-00b5-486a-841e-a69242eccfcf" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_40339952-2a32-4b1e-8bd2-6be252ef3fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CollaborationAgreementsOtherRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_005ef5d4-5ba4-408a-8d9d-d4e2065ba532" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7c99c30-b887-466c-ad22-dcddceee2c64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_005ef5d4-5ba4-408a-8d9d-d4e2065ba532" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7c99c30-b887-466c-ad22-dcddceee2c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_fc8116ba-3ca8-433b-9fa9-0e6ff4073691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7c99c30-b887-466c-ad22-dcddceee2c64" xlink:to="loc_us-gaap_TypeOfArrangementAxis_fc8116ba-3ca8-433b-9fa9-0e6ff4073691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c1ecfa2e-fb80-4be5-b047-753bbd82d4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_fc8116ba-3ca8-433b-9fa9-0e6ff4073691" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c1ecfa2e-fb80-4be5-b047-753bbd82d4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_e3b18546-78a8-41d2-a55f-b9feea9d6710" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c1ecfa2e-fb80-4be5-b047-753bbd82d4b3" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_e3b18546-78a8-41d2-a55f-b9feea9d6710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dd029b6a-0f97-4b81-b5a3-13c670f55893" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7c99c30-b887-466c-ad22-dcddceee2c64" xlink:to="loc_srt_ProductOrServiceAxis_dd029b6a-0f97-4b81-b5a3-13c670f55893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a2aff60d-68a7-4e73-afd6-f5df5d1f4a16" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dd029b6a-0f97-4b81-b5a3-13c670f55893" xlink:to="loc_srt_ProductsAndServicesDomain_a2aff60d-68a7-4e73-afd6-f5df5d1f4a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LimitedServicesMember_77bde099-bd05-490d-8dcb-3c1677a4f3d8" xlink:href="mrsn-20201231.xsd#mrsn_LimitedServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a2aff60d-68a7-4e73-afd6-f5df5d1f4a16" xlink:to="loc_mrsn_LimitedServicesMember_77bde099-bd05-490d-8dcb-3c1677a4f3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ServiceMilestoneMember_a54f8ad4-b5bb-4cdb-beb2-d79373e1058a" xlink:href="mrsn-20201231.xsd#mrsn_ServiceMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a2aff60d-68a7-4e73-afd6-f5df5d1f4a16" xlink:to="loc_mrsn_ServiceMilestoneMember_a54f8ad4-b5bb-4cdb-beb2-d79373e1058a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c90ef024-ddcc-419b-9056-37984898d0af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7c99c30-b887-466c-ad22-dcddceee2c64" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c90ef024-ddcc-419b-9056-37984898d0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_673a7780-4f28-47bf-9f32-920c96a0dc79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c90ef024-ddcc-419b-9056-37984898d0af" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_673a7780-4f28-47bf-9f32-920c96a0dc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_9c0464ac-9ceb-4b2b-b7e5-efd7f462d9ac" xlink:href="mrsn-20201231.xsd#mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c90ef024-ddcc-419b-9056-37984898d0af" xlink:to="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_9c0464ac-9ceb-4b2b-b7e5-efd7f462d9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="mrsn-20201231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a63e99d7-28ed-4350-b4e4-f543559a84c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_bbce4634-c80c-4e67-99d7-4c74d0875ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a63e99d7-28ed-4350-b4e4-f543559a84c9" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_bbce4634-c80c-4e67-99d7-4c74d0875ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_be164828-5360-4a1d-81b9-2325befadefb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_aadf8dae-e76c-4fc2-bcea-6735adad0a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_be164828-5360-4a1d-81b9-2325befadefb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_aadf8dae-e76c-4fc2-bcea-6735adad0a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b25c31ab-3405-4bfa-a97b-8df5790af10c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c879c6a8-a9ae-4e10-8976-86cb1fdfc2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b25c31ab-3405-4bfa-a97b-8df5790af10c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c879c6a8-a9ae-4e10-8976-86cb1fdfc2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db3e419d-4d05-469d-a30b-e216715bf90f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c879c6a8-a9ae-4e10-8976-86cb1fdfc2f5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db3e419d-4d05-469d-a30b-e216715bf90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_872a1ea3-426d-4c93-a37e-5ac570c6bf1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_db3e419d-4d05-469d-a30b-e216715bf90f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_872a1ea3-426d-4c93-a37e-5ac570c6bf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_20784418-74e3-45fa-9aee-d7fa0ce36092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_872a1ea3-426d-4c93-a37e-5ac570c6bf1a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_20784418-74e3-45fa-9aee-d7fa0ce36092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a51cdea-18a0-45b7-bf6d-18ac1389df70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c879c6a8-a9ae-4e10-8976-86cb1fdfc2f5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a51cdea-18a0-45b7-bf6d-18ac1389df70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c9eebb-4b4b-488a-9dfe-7808f7a0a2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6a51cdea-18a0-45b7-bf6d-18ac1389df70" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c9eebb-4b4b-488a-9dfe-7808f7a0a2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_902e17ec-1d25-49f6-8fcf-cd2c951d28c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c9eebb-4b4b-488a-9dfe-7808f7a0a2be" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_902e17ec-1d25-49f6-8fcf-cd2c951d28c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_79aa2221-3a85-40d9-aa59-8fad84e39d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c9eebb-4b4b-488a-9dfe-7808f7a0a2be" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_79aa2221-3a85-40d9-aa59-8fad84e39d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a6bf54e2-3232-4971-ac21-f954d059be4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0c9eebb-4b4b-488a-9dfe-7808f7a0a2be" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a6bf54e2-3232-4971-ac21-f954d059be4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_8403a4d4-4fcd-4b08-a907-b228dc393fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c879c6a8-a9ae-4e10-8976-86cb1fdfc2f5" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_8403a4d4-4fcd-4b08-a907-b228dc393fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0683d5aa-d228-43e9-b7e8-c5fd571f7f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_8403a4d4-4fcd-4b08-a907-b228dc393fbf" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0683d5aa-d228-43e9-b7e8-c5fd571f7f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_3ffe52a8-f094-4f0f-9610-01bf4c880981" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0683d5aa-d228-43e9-b7e8-c5fd571f7f5a" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_3ffe52a8-f094-4f0f-9610-01bf4c880981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_faf8e0b1-427f-4f4c-95ed-9957b8f70f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0683d5aa-d228-43e9-b7e8-c5fd571f7f5a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_faf8e0b1-427f-4f4c-95ed-9957b8f70f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_c630380e-5183-454b-b053-e396315ce198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0683d5aa-d228-43e9-b7e8-c5fd571f7f5a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_c630380e-5183-454b-b053-e396315ce198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c1027950-2372-455b-9628-17b4b1188e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c879c6a8-a9ae-4e10-8976-86cb1fdfc2f5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c1027950-2372-455b-9628-17b4b1188e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_246e37ed-f29b-492e-8438-b96cad6d3e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c1027950-2372-455b-9628-17b4b1188e59" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_246e37ed-f29b-492e-8438-b96cad6d3e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_df71e624-8a2a-4276-9419-f0b372647a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c1027950-2372-455b-9628-17b4b1188e59" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_df71e624-8a2a-4276-9419-f0b372647a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mrsn-20201231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_489337df-9a63-4f2d-b5bd-fc502fef1897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_34b8634b-8943-494d-be74-886929b62df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_489337df-9a63-4f2d-b5bd-fc502fef1897" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_34b8634b-8943-494d-be74-886929b62df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_4c4ce1a8-9895-45e8-b505-2a0ec6481d70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3e0f2a76-54ab-4798-8fd0-201ad118887b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_4c4ce1a8-9895-45e8-b505-2a0ec6481d70" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_3e0f2a76-54ab-4798-8fd0-201ad118887b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_b2c03a5d-f310-446d-86bf-bf452ca73c33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bdbedf90-16f2-44a5-a81f-1abed8528596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_b2c03a5d-f310-446d-86bf-bf452ca73c33" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bdbedf90-16f2-44a5-a81f-1abed8528596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_cd7d12ca-58c8-4f68-8751-d4ad07d2c14d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bdbedf90-16f2-44a5-a81f-1abed8528596" xlink:to="loc_us-gaap_FinancialInstrumentAxis_cd7d12ca-58c8-4f68-8751-d4ad07d2c14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97dbda75-01bb-4e9d-8285-92d1a2a0d237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_cd7d12ca-58c8-4f68-8751-d4ad07d2c14d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97dbda75-01bb-4e9d-8285-92d1a2a0d237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_f110fbac-1340-460c-9232-2b8a3d66df3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97dbda75-01bb-4e9d-8285-92d1a2a0d237" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_f110fbac-1340-460c-9232-2b8a3d66df3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c17bbee3-5980-4a4a-8d50-d71fe2ae21ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97dbda75-01bb-4e9d-8285-92d1a2a0d237" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c17bbee3-5980-4a4a-8d50-d71fe2ae21ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_81f542a0-95fb-497a-8023-7008b0e34da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97dbda75-01bb-4e9d-8285-92d1a2a0d237" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_81f542a0-95fb-497a-8023-7008b0e34da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1552985-ee7d-42ba-a4bd-ccf0b9db0d17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bdbedf90-16f2-44a5-a81f-1abed8528596" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1552985-ee7d-42ba-a4bd-ccf0b9db0d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_32d8da3c-19ab-434a-aea8-1c5fa0e2007b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1552985-ee7d-42ba-a4bd-ccf0b9db0d17" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_32d8da3c-19ab-434a-aea8-1c5fa0e2007b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9009907a-f90f-4cfd-b445-892e1fe9f605" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1552985-ee7d-42ba-a4bd-ccf0b9db0d17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9009907a-f90f-4cfd-b445-892e1fe9f605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5d12a8fa-dc0c-4e9a-9a25-d397aef39bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9009907a-f90f-4cfd-b445-892e1fe9f605" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5d12a8fa-dc0c-4e9a-9a25-d397aef39bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ea43a35f-57e1-46a0-9f98-ac15fc09f4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9009907a-f90f-4cfd-b445-892e1fe9f605" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ea43a35f-57e1-46a0-9f98-ac15fc09f4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c2e09d34-c8f9-4290-a940-a125bf8fabb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9009907a-f90f-4cfd-b445-892e1fe9f605" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c2e09d34-c8f9-4290-a940-a125bf8fabb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c62b039d-f04e-4294-bc20-bbbb1d2c519a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9009907a-f90f-4cfd-b445-892e1fe9f605" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c62b039d-f04e-4294-bc20-bbbb1d2c519a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="mrsn-20201231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d7c0b1d1-3497-4e99-9afc-ca158d6b484f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51297a6e-56b7-4f20-8a94-8f2d2b581d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d7c0b1d1-3497-4e99-9afc-ca158d6b484f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_51297a6e-56b7-4f20-8a94-8f2d2b581d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_49694e73-33ad-4cba-aebd-8fac678843b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_abf7383b-9cc3-4b0f-8ca8-ce6e11e66b62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_49694e73-33ad-4cba-aebd-8fac678843b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_abf7383b-9cc3-4b0f-8ca8-ce6e11e66b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fbf75d14-6bd1-4396-974d-3f5bb11ca624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943aaefb-1ac7-443a-aa9e-2c7333281000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fbf75d14-6bd1-4396-974d-3f5bb11ca624" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943aaefb-1ac7-443a-aa9e-2c7333281000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0177c445-f984-4e1b-bf6e-dd40f849f815" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943aaefb-1ac7-443a-aa9e-2c7333281000" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0177c445-f984-4e1b-bf6e-dd40f849f815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04edb278-51c2-4470-8d2e-8d027a08674c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0177c445-f984-4e1b-bf6e-dd40f849f815" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04edb278-51c2-4470-8d2e-8d027a08674c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentMember_af3b9eb0-a0d8-4471-84ca-d724958263e7" xlink:href="mrsn-20201231.xsd#mrsn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04edb278-51c2-4470-8d2e-8d027a08674c" xlink:to="loc_mrsn_LaboratoryEquipmentMember_af3b9eb0-a0d8-4471-84ca-d724958263e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8a4d1bea-e6c0-420d-bcbe-918be69aeece" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04edb278-51c2-4470-8d2e-8d027a08674c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8a4d1bea-e6c0-420d-bcbe-918be69aeece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember_cb163b43-8dc3-424c-98a1-bb1e4ea1c4f2" xlink:href="mrsn-20201231.xsd#mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04edb278-51c2-4470-8d2e-8d027a08674c" xlink:to="loc_mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember_cb163b43-8dc3-424c-98a1-bb1e4ea1c4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentLeasedAssetMember_a2dcfa72-18c8-43d0-8128-554dc7beb3c2" xlink:href="mrsn-20201231.xsd#mrsn_LaboratoryEquipmentLeasedAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_04edb278-51c2-4470-8d2e-8d027a08674c" xlink:to="loc_mrsn_LaboratoryEquipmentLeasedAssetMember_a2dcfa72-18c8-43d0-8128-554dc7beb3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943aaefb-1ac7-443a-aa9e-2c7333281000" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_56cea2dc-0652-4218-b9eb-907569c80158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_56cea2dc-0652-4218-b9eb-907569c80158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_70df3d53-9ecc-416a-b9ee-22cfb8322a2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_70df3d53-9ecc-416a-b9ee-22cfb8322a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_bb022617-554b-443f-a0e4-faf15d856dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_bb022617-554b-443f-a0e4-faf15d856dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3dec144c-a603-4c59-a622-ef16e9f61315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3dec144c-a603-4c59-a622-ef16e9f61315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0ffca154-df76-454f-946b-2d5095c16ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32bc11d3-f026-49d4-adec-97dbe813e39d" xlink:to="loc_us-gaap_Depreciation_0ffca154-df76-454f-946b-2d5095c16ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedExpenses" xlink:type="simple" xlink:href="mrsn-20201231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0fb848c0-4840-438b-9db1-a569b3070e9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e8aa46f5-fc1d-4d18-853f-aa397256885d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0fb848c0-4840-438b-9db1-a569b3070e9f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e8aa46f5-fc1d-4d18-853f-aa397256885d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedexpensesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#AccruedexpensesTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/AccruedexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_db780297-6bac-4318-a8ec-b2811298d055" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_d7ba47bb-2b78-40ce-a289-d288f2886f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_db780297-6bac-4318-a8ec-b2811298d055" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_d7ba47bb-2b78-40ce-a289-d288f2886f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_88fb03a2-5858-4304-a342-393e1b0e0e46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent_9685ef15-2d49-497e-a735-56922f8fd785" xlink:href="mrsn-20201231.xsd#mrsn_AccruedPreclinicalAndClinicalExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_88fb03a2-5858-4304-a342-393e1b0e0e46" xlink:to="loc_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent_9685ef15-2d49-497e-a735-56922f8fd785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_33d4e303-720a-4bf8-97ab-e07f95bf8bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_88fb03a2-5858-4304-a342-393e1b0e0e46" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_33d4e303-720a-4bf8-97ab-e07f95bf8bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_c6315145-f1b3-4e65-add4-2b7933b3b914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_88fb03a2-5858-4304-a342-393e1b0e0e46" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_c6315145-f1b3-4e65-add4-2b7933b3b914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c8b56687-5c23-4a1f-939e-eb21ac9493fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_88fb03a2-5858-4304-a342-393e1b0e0e46" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c8b56687-5c23-4a1f-939e-eb21ac9493fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fe948041-41db-4fd9-a46d-2da987dbd1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_88fb03a2-5858-4304-a342-393e1b0e0e46" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fe948041-41db-4fd9-a46d-2da987dbd1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/Debt" xlink:type="simple" xlink:href="mrsn-20201231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2bc1d57b-4728-4e1d-a75d-7feec4f12ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_8e8db406-74b5-4915-9c6a-b7ad0509044a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2bc1d57b-4728-4e1d-a75d-7feec4f12ccf" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_8e8db406-74b5-4915-9c6a-b7ad0509044a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9fddbd81-8e71-41b6-9467-d9f1ed49617a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_323ca69f-78e8-4333-842c-071b1aaeb68e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9fddbd81-8e71-41b6-9467-d9f1ed49617a" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_323ca69f-78e8-4333-842c-071b1aaeb68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a7c3444c-1515-44f8-a6cb-fd8aaf3dfc50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9fddbd81-8e71-41b6-9467-d9f1ed49617a" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a7c3444c-1515-44f8-a6cb-fd8aaf3dfc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bc8f73bb-2cce-43d4-9170-bd62bfc056f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bc8f73bb-2cce-43d4-9170-bd62bfc056f1" xlink:to="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7b3045b3-302e-42ac-8385-285e163f1185" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:to="loc_us-gaap_DebtInstrumentAxis_7b3045b3-302e-42ac-8385-285e163f1185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7b3045b3-302e-42ac-8385-285e163f1185" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExistingCreditFacilityMember_c84e54d2-5349-484f-8c44-96e040737be8" xlink:href="mrsn-20201231.xsd#mrsn_ExistingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_ExistingCreditFacilityMember_c84e54d2-5349-484f-8c44-96e040737be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityMember_354d8e63-9bd6-4280-a8a6-72667c2f0855" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityMember_354d8e63-9bd6-4280-a8a6-72667c2f0855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheOneMember_3305a53f-d07a-4119-a578-2f0a6a1bc68f" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityTrancheOneMember_3305a53f-d07a-4119-a578-2f0a6a1bc68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheTwoMember_0419ef0d-91b2-4e09-ae19-47009e35476b" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheTwoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityTrancheTwoMember_0419ef0d-91b2-4e09-ae19-47009e35476b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheThreeMember_cb11ea56-7473-45ac-a77c-b2164e06ecf3" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheThreeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityTrancheThreeMember_cb11ea56-7473-45ac-a77c-b2164e06ecf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheFourMember_183eae8d-a89b-42f8-9165-49ca6d52ce72" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheFourMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityTrancheFourMember_183eae8d-a89b-42f8-9165-49ca6d52ce72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheFiveMember_327144a5-2a36-470e-9487-3fc33f5315e1" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheFiveMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityTrancheFiveMember_327144a5-2a36-470e-9487-3fc33f5315e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityTrancheSixMember_de21b35b-3fde-4d50-a903-27e19579819b" xlink:href="mrsn-20201231.xsd#mrsn_AmendedCreditFacilityTrancheSixMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c11bcdaf-4485-4b4a-8aa1-f8f08b9b8107" xlink:to="loc_mrsn_AmendedCreditFacilityTrancheSixMember_de21b35b-3fde-4d50-a903-27e19579819b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_9bd39932-e304-4552-895f-45344b71a85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:to="loc_us-gaap_VariableRateAxis_9bd39932-e304-4552-895f-45344b71a85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_168293cc-e204-4571-ae7a-158a2a724da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_9bd39932-e304-4552-895f-45344b71a85a" xlink:to="loc_us-gaap_VariableRateDomain_168293cc-e204-4571-ae7a-158a2a724da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_0083dae7-7f21-43c8-b6b5-7dcace70bb59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_168293cc-e204-4571-ae7a-158a2a724da5" xlink:to="loc_us-gaap_PrimeRateMember_0083dae7-7f21-43c8-b6b5-7dcace70bb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_82d7f98d-33c2-4731-b2b4-571cff847285" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:to="loc_srt_RangeAxis_82d7f98d-33c2-4731-b2b4-571cff847285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c0891f58-60b1-49d1-a18b-7c8f6ca7d943" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_82d7f98d-33c2-4731-b2b4-571cff847285" xlink:to="loc_srt_RangeMember_c0891f58-60b1-49d1-a18b-7c8f6ca7d943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ffcf8a5f-a348-49aa-9154-06018f148e0d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c0891f58-60b1-49d1-a18b-7c8f6ca7d943" xlink:to="loc_srt_MinimumMember_ffcf8a5f-a348-49aa-9154-06018f148e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5f8fbeec-ebca-4738-94e0-b67fbe870075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:to="loc_us-gaap_CreditFacilityAxis_5f8fbeec-ebca-4738-94e0-b67fbe870075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_59dd1f34-7c66-4106-9587-23140e4749f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_5f8fbeec-ebca-4738-94e0-b67fbe870075" xlink:to="loc_us-gaap_CreditFacilityDomain_59dd1f34-7c66-4106-9587-23140e4749f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_459f1556-53f0-4ea5-be80-6fb6fddb1170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_59dd1f34-7c66-4106-9587-23140e4749f5" xlink:to="loc_us-gaap_LineOfCreditMember_459f1556-53f0-4ea5-be80-6fb6fddb1170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodAxis_99986596-1eae-4e1e-8c09-22ca67d471a1" xlink:href="mrsn-20201231.xsd#mrsn_DebtCovenantPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:to="loc_mrsn_DebtCovenantPeriodAxis_99986596-1eae-4e1e-8c09-22ca67d471a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodDomain_1e4cc801-42a8-4531-ac90-928f39929806" xlink:href="mrsn-20201231.xsd#mrsn_DebtCovenantPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_DebtCovenantPeriodAxis_99986596-1eae-4e1e-8c09-22ca67d471a1" xlink:to="loc_mrsn_DebtCovenantPeriodDomain_1e4cc801-42a8-4531-ac90-928f39929806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursPriorToAugust282021Member_6a4c1cd0-5e3d-4653-961e-6bb2e2431da6" xlink:href="mrsn-20201231.xsd#mrsn_PrepaymentOccursPriorToAugust282021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_DebtCovenantPeriodDomain_1e4cc801-42a8-4531-ac90-928f39929806" xlink:to="loc_mrsn_PrepaymentOccursPriorToAugust282021Member_6a4c1cd0-5e3d-4653-961e-6bb2e2431da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member_4c5efa11-be94-40b1-80bf-20b67f40f219" xlink:href="mrsn-20201231.xsd#mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_DebtCovenantPeriodDomain_1e4cc801-42a8-4531-ac90-928f39929806" xlink:to="loc_mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member_4c5efa11-be94-40b1-80bf-20b67f40f219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member_568eabfc-116d-4968-b774-2b5e44bc4eab" xlink:href="mrsn-20201231.xsd#mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_DebtCovenantPeriodDomain_1e4cc801-42a8-4531-ac90-928f39929806" xlink:to="loc_mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member_568eabfc-116d-4968-b774-2b5e44bc4eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4ddb78d5-25b0-402d-94d5-0cc9265fe025" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_0c1ff9f8-d409-4caf-8985-72a1c22360e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_0c1ff9f8-d409-4caf-8985-72a1c22360e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f6b2179-fc41-41b7-9d03-01edfac5e897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f6b2179-fc41-41b7-9d03-01edfac5e897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_17701832-df10-46d5-b95c-964f2e50a897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_17701832-df10-46d5-b95c-964f2e50a897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5ffb3167-6ef1-4fdd-9daf-db56d5db1c05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5ffb3167-6ef1-4fdd-9daf-db56d5db1c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit_4bd9be75-3e34-4451-9478-858956ebe0c2" xlink:href="mrsn-20201231.xsd#mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit_4bd9be75-3e34-4451-9478-858956ebe0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_643b26ac-0abc-4d03-8471-2396bc1ab19d" xlink:href="mrsn-20201231.xsd#mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_643b26ac-0abc-4d03-8471-2396bc1ab19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentPrepaymentFeePercent_75967a1d-2b21-4e27-b02a-a1762de05cf0" xlink:href="mrsn-20201231.xsd#mrsn_DebtInstrumentPrepaymentFeePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_mrsn_DebtInstrumentPrepaymentFeePercent_75967a1d-2b21-4e27-b02a-a1762de05cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_c177d25a-fe9c-4ad7-91e5-309059ca53be" xlink:href="mrsn-20201231.xsd#mrsn_DebtInstrumentAdditionalRateInEventOfDefault"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_c177d25a-fe9c-4ad7-91e5-309059ca53be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_cef1fdb0-f78c-4036-b6b1-de9765fc0a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_cef1fdb0-f78c-4036-b6b1-de9765fc0a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_8cd6f777-13bf-49ab-8585-4ca0f6bd4fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_8cd6f777-13bf-49ab-8585-4ca0f6bd4fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f7506af7-0e66-44df-a59a-5b2b1c943e9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee1d0826-419c-4181-ac67-513f098242d2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f7506af7-0e66-44df-a59a-5b2b1c943e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtComponentsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#DebtComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/DebtComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5f72fd72-d200-403b-b6eb-473bba7642cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_60661ec5-38dd-4c8d-9202-01b9d3dbd1b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f72fd72-d200-403b-b6eb-473bba7642cf" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_60661ec5-38dd-4c8d-9202-01b9d3dbd1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7a79ac70-4973-4210-aa9c-4c06b8de2245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f72fd72-d200-403b-b6eb-473bba7642cf" xlink:to="loc_us-gaap_LongTermDebtCurrent_7a79ac70-4973-4210-aa9c-4c06b8de2245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent_ecb4e820-3c77-4e42-83a4-0539d94b26f4" xlink:href="mrsn-20201231.xsd#mrsn_DebtInstrumentCarryingAmountNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f72fd72-d200-403b-b6eb-473bba7642cf" xlink:to="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent_ecb4e820-3c77-4e42-83a4-0539d94b26f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_01c51b2c-89dc-45c1-9444-cba9d8ce751d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f72fd72-d200-403b-b6eb-473bba7642cf" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_01c51b2c-89dc-45c1-9444-cba9d8ce751d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_f27c87b6-181e-4c6d-8b8a-5493271dbcb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f72fd72-d200-403b-b6eb-473bba7642cf" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_f27c87b6-181e-4c6d-8b8a-5493271dbcb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_27a8b8f3-a409-41a7-8fd4-db2a7fd445ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5f72fd72-d200-403b-b6eb-473bba7642cf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_27a8b8f3-a409-41a7-8fd4-db2a7fd445ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtFuturepaymentsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#DebtFuturepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/DebtFuturepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d8bcfdfd-b8f3-4236-99d7-b9b6ac687ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_35f6ccc4-a613-4365-b195-f79a3afba5fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d8bcfdfd-b8f3-4236-99d7-b9b6ac687ce7" xlink:to="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_35f6ccc4-a613-4365-b195-f79a3afba5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d0352e2e-61c6-4c3f-832c-cbedd1243cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_35f6ccc4-a613-4365-b195-f79a3afba5fa" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d0352e2e-61c6-4c3f-832c-cbedd1243cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_922df9f3-5580-466b-82ac-2051ba0c6ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_35f6ccc4-a613-4365-b195-f79a3afba5fa" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_922df9f3-5580-466b-82ac-2051ba0c6ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f6709b8c-1a1e-4038-aa26-6a8da6648945" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_35f6ccc4-a613-4365-b195-f79a3afba5fa" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f6709b8c-1a1e-4038-aa26-6a8da6648945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c3b41ba8-9340-45bc-bc3d-8f498d25ba0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_35f6ccc4-a613-4365-b195-f79a3afba5fa" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c3b41ba8-9340-45bc-bc3d-8f498d25ba0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1e462afa-4b06-4721-bfe0-960812f71414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_35f6ccc4-a613-4365-b195-f79a3afba5fa" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1e462afa-4b06-4721-bfe0-960812f71414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_4a0a1e5f-a527-4f84-a87b-fa8866a6f9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d8bcfdfd-b8f3-4236-99d7-b9b6ac687ce7" xlink:to="loc_us-gaap_InterestExpenseDebt_4a0a1e5f-a527-4f84-a87b-fa8866a6f9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4212f49c-43ce-43f7-b1eb-d1ba1e5a4197" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_55a3cdbb-08ac-4448-ad96-25364b384944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4212f49c-43ce-43f7-b1eb-d1ba1e5a4197" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_55a3cdbb-08ac-4448-ad96-25364b384944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_cccaea76-0de1-4b92-8844-c0d92f12f618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_ee269037-55ff-4895-8f2b-995378185e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_cccaea76-0de1-4b92-8844-c0d92f12f618" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_ee269037-55ff-4895-8f2b-995378185e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockholdersEquityPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2e85f069-b846-46bc-8286-7d3121d3478f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0485ca3e-1ac0-466b-ac04-cc93421fbdbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2e85f069-b846-46bc-8286-7d3121d3478f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0485ca3e-1ac0-466b-ac04-cc93421fbdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7399b02b-8f27-47f9-b7ab-1df5e6b56e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2e85f069-b846-46bc-8286-7d3121d3478f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7399b02b-8f27-47f9-b7ab-1df5e6b56e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5aa5fdc1-e97d-4ba3-a228-4eca334dea5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ed574ddf-3a6f-4c9d-b377-f5000067a25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5aa5fdc1-e97d-4ba3-a228-4eca334dea5c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ed574ddf-3a6f-4c9d-b377-f5000067a25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ba770555-bc82-46c6-a220-ee62e23c5e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ed574ddf-3a6f-4c9d-b377-f5000067a25a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ba770555-bc82-46c6-a220-ee62e23c5e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90af832f-ee62-4d70-abfb-0ec3f818da20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ba770555-bc82-46c6-a220-ee62e23c5e2f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90af832f-ee62-4d70-abfb-0ec3f818da20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_b51a50e3-1341-44e8-b9d0-71fa7137e2fb" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90af832f-ee62-4d70-abfb-0ec3f818da20" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_b51a50e3-1341-44e8-b9d0-71fa7137e2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram559PerShareMember_0acb20d0-ff95-4dc1-b249-fac118f8ec26" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram559PerShareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_b51a50e3-1341-44e8-b9d0-71fa7137e2fb" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram559PerShareMember_0acb20d0-ff95-4dc1-b249-fac118f8ec26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram774PerShareMember_f3c17848-108b-4159-a14b-f238fd89d2e4" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram774PerShareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_b51a50e3-1341-44e8-b9d0-71fa7137e2fb" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram774PerShareMember_f3c17848-108b-4159-a14b-f238fd89d2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_8fe4fa8e-424b-49ca-ba83-dbf03e7d017f" xlink:href="mrsn-20201231.xsd#mrsn_AtMarketEquityOfferingProgram2020ATMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90af832f-ee62-4d70-abfb-0ec3f818da20" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_8fe4fa8e-424b-49ca-ba83-dbf03e7d017f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_f189639c-87ad-4bb2-8fac-ae1641e684b5" xlink:href="mrsn-20201231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90af832f-ee62-4d70-abfb-0ec3f818da20" xlink:to="loc_mrsn_PublicStockOfferingMember_f189639c-87ad-4bb2-8fac-ae1641e684b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ed574ddf-3a6f-4c9d-b377-f5000067a25a" xlink:to="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceProgramAuthorizedAmount_528b2e66-3da3-40d8-b2d6-e69fc9d76585" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuanceProgramAuthorizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_mrsn_StockIssuanceProgramAuthorizedAmount_528b2e66-3da3-40d8-b2d6-e69fc9d76585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eb85b6e8-d33b-45a7-a845-fda8f9a240c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eb85b6e8-d33b-45a7-a845-fda8f9a240c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_ddb1edf5-501e-461b-a26c-72f4180a866d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_ddb1edf5-501e-461b-a26c-72f4180a866d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromIssuanceOfCommonStockGross_a388dc02-eb53-4af3-8b0c-8c366001b376" xlink:href="mrsn-20201231.xsd#mrsn_ProceedsFromIssuanceOfCommonStockGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_mrsn_ProceedsFromIssuanceOfCommonStockGross_a388dc02-eb53-4af3-8b0c-8c366001b376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_fdcc73bd-8824-4596-bdf0-0e7b02e6d92f" xlink:href="mrsn-20201231.xsd#mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_fdcc73bd-8824-4596-bdf0-0e7b02e6d92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_196c66b0-bac2-4b86-8ed7-4c53e3ba2285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_59af1bcf-e0a0-4100-a2b7-4bfef6141974" xlink:to="loc_us-gaap_SharesIssued_196c66b0-bac2-4b86-8ed7-4c53e3ba2285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockholdersEquityWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_7b236d86-2128-4de9-9024-470fbefe95f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued_c228ad1c-f21e-4635-b20e-42c2ab5a499a" xlink:href="mrsn-20201231.xsd#mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7b236d86-2128-4de9-9024-470fbefe95f6" xlink:to="loc_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued_c228ad1c-f21e-4635-b20e-42c2ab5a499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_59c3eee8-79b6-406d-af1f-e6b7c498d68e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7b236d86-2128-4de9-9024-470fbefe95f6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_59c3eee8-79b6-406d-af1f-e6b7c498d68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractualLifeOfWarrants_3e2138d8-e4e3-4cf0-9ee4-648b6f860ea6" xlink:href="mrsn-20201231.xsd#mrsn_ContractualLifeOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7b236d86-2128-4de9-9024-470fbefe95f6" xlink:to="loc_mrsn_ContractualLifeOfWarrants_3e2138d8-e4e3-4cf0-9ee4-648b6f860ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_36d8db5a-d923-4085-8966-6b487f52eedf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7b236d86-2128-4de9-9024-470fbefe95f6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_36d8db5a-d923-4085-8966-6b487f52eedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised_24e550b6-179d-4287-a9e8-4764cad9c08f" xlink:href="mrsn-20201231.xsd#mrsn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7b236d86-2128-4de9-9024-470fbefe95f6" xlink:to="loc_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised_24e550b6-179d-4287-a9e8-4764cad9c08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityExchangeWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e5f982ab-7b57-4f4a-b358-d5111b359b74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_22607b15-6355-49a1-bfbd-6e9f77a0d8bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e5f982ab-7b57-4f4a-b358-d5111b359b74" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_22607b15-6355-49a1-bfbd-6e9f77a0d8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3d9d4b50-a7ab-4810-9938-804ae5aaff20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_22607b15-6355-49a1-bfbd-6e9f77a0d8bb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3d9d4b50-a7ab-4810-9938-804ae5aaff20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b97116fc-79c5-4d42-ae5c-1245d0ff2b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3d9d4b50-a7ab-4810-9938-804ae5aaff20" xlink:to="loc_us-gaap_EquityComponentDomain_b97116fc-79c5-4d42-ae5c-1245d0ff2b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExchangeWarrantsMember_64fce0db-1d85-4a3f-a30f-871846cb1922" xlink:href="mrsn-20201231.xsd#mrsn_ExchangeWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b97116fc-79c5-4d42-ae5c-1245d0ff2b81" xlink:to="loc_mrsn_ExchangeWarrantsMember_64fce0db-1d85-4a3f-a30f-871846cb1922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_83d485ef-5dab-4972-b838-11f3b1c53d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b97116fc-79c5-4d42-ae5c-1245d0ff2b81" xlink:to="loc_us-gaap_CommonStockMember_83d485ef-5dab-4972-b838-11f3b1c53d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9c82d68b-6a56-4049-8c1b-b73747f19034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_22607b15-6355-49a1-bfbd-6e9f77a0d8bb" xlink:to="loc_us-gaap_ClassOfStockLineItems_9c82d68b-6a56-4049-8c1b-b73747f19034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_f3d02b2f-46db-4c86-8b7c-b37a965cf264" xlink:href="mrsn-20201231.xsd#mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9c82d68b-6a56-4049-8c1b-b73747f19034" xlink:to="loc_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_f3d02b2f-46db-4c86-8b7c-b37a965cf264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5ed60622-12ae-4ae2-862f-95a1ddaae15b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9c82d68b-6a56-4049-8c1b-b73747f19034" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5ed60622-12ae-4ae2-862f-95a1ddaae15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5fa2c573-d15b-4438-83d2-636a5f069fa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9c82d68b-6a56-4049-8c1b-b73747f19034" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5fa2c573-d15b-4438-83d2-636a5f069fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsExercisedInPeriod_248f93cc-6763-41e2-9cd4-f8fd2724df0a" xlink:href="mrsn-20201231.xsd#mrsn_WarrantsExercisedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9c82d68b-6a56-4049-8c1b-b73747f19034" xlink:to="loc_mrsn_WarrantsExercisedInPeriod_248f93cc-6763-41e2-9cd4-f8fd2724df0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityCommonstockDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockholdersEquityCommonstockDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockholdersEquityCommonstockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_c7c3f810-1c28-43a9-9f7b-f6ffab848b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_32890835-c29c-4a4d-8075-098f9cf6ad18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c7c3f810-1c28-43a9-9f7b-f6ffab848b82" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_32890835-c29c-4a4d-8075-098f9cf6ad18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_06970bb6-a731-44e7-af4d-364a03ba5ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32890835-c29c-4a4d-8075-098f9cf6ad18" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_06970bb6-a731-44e7-af4d-364a03ba5ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f907e9a1-e717-4b6c-961f-b58d62e124c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_06970bb6-a731-44e7-af4d-364a03ba5ef7" xlink:to="loc_us-gaap_EquityComponentDomain_f907e9a1-e717-4b6c-961f-b58d62e124c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_46e9479d-2712-4836-9578-844d4a4adc4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f907e9a1-e717-4b6c-961f-b58d62e124c9" xlink:to="loc_us-gaap_CommonStockMember_46e9479d-2712-4836-9578-844d4a4adc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsAndShareBasedPaymentsMember_2bdb9802-e356-488b-82e8-47600e2e36fc" xlink:href="mrsn-20201231.xsd#mrsn_WarrantsAndShareBasedPaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f907e9a1-e717-4b6c-961f-b58d62e124c9" xlink:to="loc_mrsn_WarrantsAndShareBasedPaymentsMember_2bdb9802-e356-488b-82e8-47600e2e36fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_f80ecfe3-0b22-4513-91ef-125f336b2ae1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WarrantsAndShareBasedPaymentsMember_2bdb9802-e356-488b-82e8-47600e2e36fc" xlink:to="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_f80ecfe3-0b22-4513-91ef-125f336b2ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_471f6319-3b47-4a57-bca8-a6f4601a734a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WarrantsAndShareBasedPaymentsMember_2bdb9802-e356-488b-82e8-47600e2e36fc" xlink:to="loc_us-gaap_WarrantMember_471f6319-3b47-4a57-bca8-a6f4601a734a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExchangeWarrantsMember_5234dbfe-fb90-4ef5-bece-b113c9fc8851" xlink:href="mrsn-20201231.xsd#mrsn_ExchangeWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WarrantsAndShareBasedPaymentsMember_2bdb9802-e356-488b-82e8-47600e2e36fc" xlink:to="loc_mrsn_ExchangeWarrantsMember_5234dbfe-fb90-4ef5-bece-b113c9fc8851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e0bfd190-20c0-48e7-8a6b-161ae6b33a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32890835-c29c-4a4d-8075-098f9cf6ad18" xlink:to="loc_us-gaap_AwardTypeAxis_e0bfd190-20c0-48e7-8a6b-161ae6b33a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_782794d7-d5e1-4803-aa5b-9bab0afabe91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e0bfd190-20c0-48e7-8a6b-161ae6b33a38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_782794d7-d5e1-4803-aa5b-9bab0afabe91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_42b61e82-aa6b-4226-9d95-d39be44be0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_782794d7-d5e1-4803-aa5b-9bab0afabe91" xlink:to="loc_us-gaap_EmployeeStockOptionMember_42b61e82-aa6b-4226-9d95-d39be44be0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bc07e141-f803-4b04-bcd9-6f9a34667157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_782794d7-d5e1-4803-aa5b-9bab0afabe91" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bc07e141-f803-4b04-bcd9-6f9a34667157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_31af6024-df30-4bd7-b363-45c320a37fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_32890835-c29c-4a4d-8075-098f9cf6ad18" xlink:to="loc_us-gaap_ClassOfStockLineItems_31af6024-df30-4bd7-b363-45c320a37fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NumberOfVotesPerCommonShare_7b65ff8e-8ce2-4b93-94f7-124e388cdc5d" xlink:href="mrsn-20201231.xsd#mrsn_NumberOfVotesPerCommonShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_31af6024-df30-4bd7-b363-45c320a37fa3" xlink:to="loc_mrsn_NumberOfVotesPerCommonShare_7b65ff8e-8ce2-4b93-94f7-124e388cdc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_09d93a7c-a331-49ad-bcbb-d348cc6c0f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_31af6024-df30-4bd7-b363-45c320a37fa3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_09d93a7c-a331-49ad-bcbb-d348cc6c0f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptions" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptions"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1aa786b8-8702-4d5a-be21-100a8576995a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a80a2957-295c-4b32-b35b-4e46f8f30077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1aa786b8-8702-4d5a-be21-100a8576995a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a80a2957-295c-4b32-b35b-4e46f8f30077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a13a2688-9e31-477f-9958-8fb932449800" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_71ebcd4c-8f28-4517-8ec4-488a477d988f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a13a2688-9e31-477f-9958-8fb932449800" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_71ebcd4c-8f28-4517-8ec4-488a477d988f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_cc8656b1-38d6-4e3f-bd22-e1ea9bb58771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a13a2688-9e31-477f-9958-8fb932449800" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_cc8656b1-38d6-4e3f-bd22-e1ea9bb58771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b977f940-ebc4-4bd7-9692-2131ef8d4f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a13a2688-9e31-477f-9958-8fb932449800" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b977f940-ebc4-4bd7-9692-2131ef8d4f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2933d853-e18e-4868-b2eb-e6b825285c04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a13a2688-9e31-477f-9958-8fb932449800" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2933d853-e18e-4868-b2eb-e6b825285c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5e13f9d4-35d1-4c08-8421-04652da3d048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a13a2688-9e31-477f-9958-8fb932449800" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5e13f9d4-35d1-4c08-8421-04652da3d048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsPlansNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10a4d52f-69b5-4127-9f3b-2fe4ac6c3bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e8fe5a9-c186-4102-9638-ad5f15e66419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10a4d52f-69b5-4127-9f3b-2fe4ac6c3bcd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e8fe5a9-c186-4102-9638-ad5f15e66419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3ddc3df9-c4b0-4eb5-a5f4-2e985f7223e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e8fe5a9-c186-4102-9638-ad5f15e66419" xlink:to="loc_us-gaap_PlanNameAxis_3ddc3df9-c4b0-4eb5-a5f4-2e985f7223e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fe29a054-034d-4369-8a1c-b997d638f8d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3ddc3df9-c4b0-4eb5-a5f4-2e985f7223e7" xlink:to="loc_us-gaap_PlanNameDomain_fe29a054-034d-4369-8a1c-b997d638f8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIncentivePlan2007Member_79824dc2-deff-4670-992f-d75196c7be75" xlink:href="mrsn-20201231.xsd#mrsn_StockIncentivePlan2007Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fe29a054-034d-4369-8a1c-b997d638f8d5" xlink:to="loc_mrsn_StockIncentivePlan2007Member_79824dc2-deff-4670-992f-d75196c7be75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIncentivePlan2017Member_61117b81-f286-4c33-8358-955bc442432a" xlink:href="mrsn-20201231.xsd#mrsn_StockIncentivePlan2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fe29a054-034d-4369-8a1c-b997d638f8d5" xlink:to="loc_mrsn_StockIncentivePlan2017Member_61117b81-f286-4c33-8358-955bc442432a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_18c8f744-d339-41e1-a7e9-4d36aae6e3a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e8fe5a9-c186-4102-9638-ad5f15e66419" xlink:to="loc_us-gaap_AwardTypeAxis_18c8f744-d339-41e1-a7e9-4d36aae6e3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aeab6232-236a-48c2-ab7d-382ce0e89afd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_18c8f744-d339-41e1-a7e9-4d36aae6e3a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aeab6232-236a-48c2-ab7d-382ce0e89afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_542282f6-a87d-451c-9e09-993e6f005f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aeab6232-236a-48c2-ab7d-382ce0e89afd" xlink:to="loc_us-gaap_EmployeeStockMember_542282f6-a87d-451c-9e09-993e6f005f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e8fe5a9-c186-4102-9638-ad5f15e66419" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3566f998-fd9a-4a55-8381-72578659a2e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3566f998-fd9a-4a55-8381-72578659a2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e7de667b-24a0-4a38-8b96-f56876ff21dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e7de667b-24a0-4a38-8b96-f56876ff21dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_49f0d872-783b-4062-b2c0-58381e79743b" xlink:href="mrsn-20201231.xsd#mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:to="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_49f0d872-783b-4062-b2c0-58381e79743b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50972c95-7ea6-4aee-afd4-8fd12cc5be60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_50972c95-7ea6-4aee-afd4-8fd12cc5be60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1ff38097-9ca8-4fc8-a676-43f8874560fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d03a51c-d6b0-44ad-84ad-14e4a4b5de15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1ff38097-9ca8-4fc8-a676-43f8874560fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsInducementNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsInducementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsInducementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39b371b7-62bd-40ec-8c08-2abe2d1acff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_784b2122-3626-4672-b09c-9042cbb05dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39b371b7-62bd-40ec-8c08-2abe2d1acff8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_784b2122-3626-4672-b09c-9042cbb05dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4c8a9ed5-4c60-43b1-8b73-b40583f613ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_784b2122-3626-4672-b09c-9042cbb05dbf" xlink:to="loc_us-gaap_PlanNameAxis_4c8a9ed5-4c60-43b1-8b73-b40583f613ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2d81774c-fe8d-4ceb-a40e-0af4c37f982a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4c8a9ed5-4c60-43b1-8b73-b40583f613ae" xlink:to="loc_us-gaap_PlanNameDomain_2d81774c-fe8d-4ceb-a40e-0af4c37f982a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_InducementAwardProgramMember_3636e6b7-d121-4a51-9682-1b433d66e968" xlink:href="mrsn-20201231.xsd#mrsn_InducementAwardProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2d81774c-fe8d-4ceb-a40e-0af4c37f982a" xlink:to="loc_mrsn_InducementAwardProgramMember_3636e6b7-d121-4a51-9682-1b433d66e968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04c280e9-3ce4-4442-93b6-62b404d1045c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_784b2122-3626-4672-b09c-9042cbb05dbf" xlink:to="loc_srt_RangeAxis_04c280e9-3ce4-4442-93b6-62b404d1045c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3764775-d49d-4f7b-94a3-2ef75b6567d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_04c280e9-3ce4-4442-93b6-62b404d1045c" xlink:to="loc_srt_RangeMember_d3764775-d49d-4f7b-94a3-2ef75b6567d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3626193b-3a2e-4c2c-9019-72c040e2fb39" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d3764775-d49d-4f7b-94a3-2ef75b6567d9" xlink:to="loc_srt_MaximumMember_3626193b-3a2e-4c2c-9019-72c040e2fb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_81226d86-a316-43b3-84c2-d18ea425c0d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_784b2122-3626-4672-b09c-9042cbb05dbf" xlink:to="loc_us-gaap_AwardTypeAxis_81226d86-a316-43b3-84c2-d18ea425c0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cded65af-29fb-4e42-882f-a4ab4c7e57fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_81226d86-a316-43b3-84c2-d18ea425c0d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cded65af-29fb-4e42-882f-a4ab4c7e57fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4bf70ff1-49f9-4185-aa5f-8c33447bdc93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cded65af-29fb-4e42-882f-a4ab4c7e57fb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4bf70ff1-49f9-4185-aa5f-8c33447bdc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc4c192-7512-4ef7-b0c8-2fc3231baac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_784b2122-3626-4672-b09c-9042cbb05dbf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc4c192-7512-4ef7-b0c8-2fc3231baac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_08a22224-6198-43e6-a0f5-810613796daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc4c192-7512-4ef7-b0c8-2fc3231baac0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_08a22224-6198-43e6-a0f5-810613796daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7552fb9f-6a34-453f-8612-e9868f3a44c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc4c192-7512-4ef7-b0c8-2fc3231baac0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7552fb9f-6a34-453f-8612-e9868f3a44c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_059ac89d-95c4-4aba-b168-90f9c1eb04ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2bc4c192-7512-4ef7-b0c8-2fc3231baac0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_059ac89d-95c4-4aba-b168-90f9c1eb04ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsActivityUnderStockOptionPlanDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_595afa1b-dac5-43a1-87a8-d6e28f26b9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638e1ee7-33db-4be7-a19b-ca6190ca4f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_595afa1b-dac5-43a1-87a8-d6e28f26b9d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638e1ee7-33db-4be7-a19b-ca6190ca4f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e9a02429-2fc3-4414-a082-8f2551cdde78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638e1ee7-33db-4be7-a19b-ca6190ca4f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e9a02429-2fc3-4414-a082-8f2551cdde78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d4f24d4-f802-4b08-bc18-fc05f05e1074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638e1ee7-33db-4be7-a19b-ca6190ca4f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0d4f24d4-f802-4b08-bc18-fc05f05e1074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5d287c5a-e71c-4aad-adb5-65e44ad36410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638e1ee7-33db-4be7-a19b-ca6190ca4f39" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5d287c5a-e71c-4aad-adb5-65e44ad36410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e72ed89a-7963-45f7-bbd7-6b449dba4025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638e1ee7-33db-4be7-a19b-ca6190ca4f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e72ed89a-7963-45f7-bbd7-6b449dba4025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ac1b43e7-452a-4c98-8cd6-12e67e07ca7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638e1ee7-33db-4be7-a19b-ca6190ca4f39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ac1b43e7-452a-4c98-8cd6-12e67e07ca7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9f39bd48-9abc-4905-b412-59c585ef54d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_595afa1b-dac5-43a1-87a8-d6e28f26b9d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9f39bd48-9abc-4905-b412-59c585ef54d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210591c7-816c-41b0-9d6f-079261b2c8ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_595afa1b-dac5-43a1-87a8-d6e28f26b9d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210591c7-816c-41b0-9d6f-079261b2c8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3b29db3c-6b26-4e04-b5c8-bdb57cf4ec58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210591c7-816c-41b0-9d6f-079261b2c8ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3b29db3c-6b26-4e04-b5c8-bdb57cf4ec58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_51723aac-8a6b-4685-b654-89444006b4fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210591c7-816c-41b0-9d6f-079261b2c8ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_51723aac-8a6b-4685-b654-89444006b4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9038d232-2c2f-44da-9e29-62bc0ca76947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210591c7-816c-41b0-9d6f-079261b2c8ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9038d232-2c2f-44da-9e29-62bc0ca76947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_fdb15dec-1415-426f-9a3c-beb71e8c4fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210591c7-816c-41b0-9d6f-079261b2c8ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_fdb15dec-1415-426f-9a3c-beb71e8c4fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bc9c733b-3917-4ee9-8151-effdfaa95069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_210591c7-816c-41b0-9d6f-079261b2c8ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bc9c733b-3917-4ee9-8151-effdfaa95069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2436c7a1-35bc-45ce-87ee-581d9d5f2576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_595afa1b-dac5-43a1-87a8-d6e28f26b9d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2436c7a1-35bc-45ce-87ee-581d9d5f2576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_200a9c45-738d-483b-8bfa-37107bbf2f66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_595afa1b-dac5-43a1-87a8-d6e28f26b9d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_200a9c45-738d-483b-8bfa-37107bbf2f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_49db813c-a337-402b-a03d-14913568c049" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_200a9c45-738d-483b-8bfa-37107bbf2f66" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_49db813c-a337-402b-a03d-14913568c049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_366a0669-75f7-49fe-8767-13bb27c7892b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_200a9c45-738d-483b-8bfa-37107bbf2f66" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_366a0669-75f7-49fe-8767-13bb27c7892b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_905ad884-6f1a-449d-b84b-9bfb020512b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_200a9c45-738d-483b-8bfa-37107bbf2f66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_905ad884-6f1a-449d-b84b-9bfb020512b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9838f893-8a2c-447c-b3a4-732b066cbff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_200a9c45-738d-483b-8bfa-37107bbf2f66" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9838f893-8a2c-447c-b3a4-732b066cbff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5b08ceba-cb43-4116-88cb-1d120b9f9b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_200a9c45-738d-483b-8bfa-37107bbf2f66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5b08ceba-cb43-4116-88cb-1d120b9f9b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0a81bde0-334d-4fe1-90f4-288792fad8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_200a9c45-738d-483b-8bfa-37107bbf2f66" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0a81bde0-334d-4fe1-90f4-288792fad8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fdb68de-9888-481c-885f-4decc9163380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b065600-7ecb-421f-8e0f-e6ab37d8c3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fdb68de-9888-481c-885f-4decc9163380" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b065600-7ecb-421f-8e0f-e6ab37d8c3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_26446752-2aaa-4ba2-8f92-8ce8785747b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b065600-7ecb-421f-8e0f-e6ab37d8c3ed" xlink:to="loc_us-gaap_AwardTypeAxis_26446752-2aaa-4ba2-8f92-8ce8785747b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe644284-3910-4ab5-96c3-77e9400214dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_26446752-2aaa-4ba2-8f92-8ce8785747b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe644284-3910-4ab5-96c3-77e9400214dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ea9bce71-8a21-4e23-af7e-a5399e0adf17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe644284-3910-4ab5-96c3-77e9400214dc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ea9bce71-8a21-4e23-af7e-a5399e0adf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da4457a8-061f-45c1-8d17-cb459f18c464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b065600-7ecb-421f-8e0f-e6ab37d8c3ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da4457a8-061f-45c1-8d17-cb459f18c464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d5cc8ec7-37f0-4294-a717-9c7dddcc4fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da4457a8-061f-45c1-8d17-cb459f18c464" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d5cc8ec7-37f0-4294-a717-9c7dddcc4fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_da4457a8-061f-45c1-8d17-cb459f18c464" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e83a6b08-b5e8-41a5-b2ab-b9e06c98589a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e83a6b08-b5e8-41a5-b2ab-b9e06c98589a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_98331413-2a02-4486-a360-619aa3d0004a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_98331413-2a02-4486-a360-619aa3d0004a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_609d11af-a914-4a04-af22-387eecfe4431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_609d11af-a914-4a04-af22-387eecfe4431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2ff08e85-2199-45ed-a2c6-0c72e8a907d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2ff08e85-2199-45ed-a2c6-0c72e8a907d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_61024ef9-229e-4734-b3c6-54e00a6b87e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_61024ef9-229e-4734-b3c6-54e00a6b87e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_53e6515b-dc8f-4989-b69f-53fd6b40ad23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_53e6515b-dc8f-4989-b69f-53fd6b40ad23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b3cb182e-3b36-4b04-a208-a78a67dd4d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_53e6515b-dc8f-4989-b69f-53fd6b40ad23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b3cb182e-3b36-4b04-a208-a78a67dd4d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6231da3f-5da3-4b23-b324-3cbc5f03c2b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_53e6515b-dc8f-4989-b69f-53fd6b40ad23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_6231da3f-5da3-4b23-b324-3cbc5f03c2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_423fb937-fd61-4ed1-8d5d-0c2c7e9d3767" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d510aec8-5318-4799-b0c3-00e8bafda6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d510aec8-5318-4799-b0c3-00e8bafda6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_765ee68c-8204-41d7-bf03-6c0af0880d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_765ee68c-8204-41d7-bf03-6c0af0880d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_187439ac-ebde-4b05-9fdb-8f53dc0161a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_187439ac-ebde-4b05-9fdb-8f53dc0161a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_16d81226-7bed-416c-bd9a-00570922fa8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_16d81226-7bed-416c-bd9a-00570922fa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_33ccb4f6-43d6-445f-9850-b3e6d547f1cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e69a5fb4-66d4-4fbb-a58b-ef9a980240ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_33ccb4f6-43d6-445f-9850-b3e6d547f1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1b11b8b-b11f-4c78-8fdc-15c92af80f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23818e41-9b2f-4e14-bde3-e4d3351dc9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1b11b8b-b11f-4c78-8fdc-15c92af80f26" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23818e41-9b2f-4e14-bde3-e4d3351dc9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_55b8a11c-c78c-429b-b9c7-b75c154023f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23818e41-9b2f-4e14-bde3-e4d3351dc9e6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_55b8a11c-c78c-429b-b9c7-b75c154023f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1cdc74d4-e68a-4558-ad77-51b7381a4322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_55b8a11c-c78c-429b-b9c7-b75c154023f4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1cdc74d4-e68a-4558-ad77-51b7381a4322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7bf1e987-85e0-4b6e-a16e-0d306714111c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1cdc74d4-e68a-4558-ad77-51b7381a4322" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7bf1e987-85e0-4b6e-a16e-0d306714111c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dc328422-efb8-4eb4-98b5-31ea8f2e5ea4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1cdc74d4-e68a-4558-ad77-51b7381a4322" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_dc328422-efb8-4eb4-98b5-31ea8f2e5ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8bb9e804-1a7a-4f1e-bd89-a63264cf045f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23818e41-9b2f-4e14-bde3-e4d3351dc9e6" xlink:to="loc_us-gaap_AwardTypeAxis_8bb9e804-1a7a-4f1e-bd89-a63264cf045f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d0e6d01-07ae-4e00-bbc8-a89803747644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8bb9e804-1a7a-4f1e-bd89-a63264cf045f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d0e6d01-07ae-4e00-bbc8-a89803747644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fb55e2ac-b3e3-4fe4-acbc-4d4771be1b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d0e6d01-07ae-4e00-bbc8-a89803747644" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fb55e2ac-b3e3-4fe4-acbc-4d4771be1b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c9518085-b100-4e08-b05d-278101b4871c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d0e6d01-07ae-4e00-bbc8-a89803747644" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c9518085-b100-4e08-b05d-278101b4871c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f769a0c4-bb98-47f4-92b4-65727ee8c9d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d0e6d01-07ae-4e00-bbc8-a89803747644" xlink:to="loc_us-gaap_EmployeeStockMember_f769a0c4-bb98-47f4-92b4-65727ee8c9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12db8ea6-ee7b-480e-83f8-a9760619500f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23818e41-9b2f-4e14-bde3-e4d3351dc9e6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12db8ea6-ee7b-480e-83f8-a9760619500f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_26854449-1444-4d03-8e5b-45a7f661cb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12db8ea6-ee7b-480e-83f8-a9760619500f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_26854449-1444-4d03-8e5b-45a7f661cb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ea0875f2-d6e9-40f3-910f-5e0d923c7174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12db8ea6-ee7b-480e-83f8-a9760619500f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ea0875f2-d6e9-40f3-910f-5e0d923c7174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_19ad4765-0414-4a7b-a047-7c749bb771b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_12db8ea6-ee7b-480e-83f8-a9760619500f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_19ad4765-0414-4a7b-a047-7c749bb771b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0e31630-1176-40b5-8ae7-8fd8b137acd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_00b8aa1f-9834-402e-90a3-be0691c7ead1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0e31630-1176-40b5-8ae7-8fd8b137acd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_00b8aa1f-9834-402e-90a3-be0691c7ead1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a7a8ef0d-30b9-41e5-8614-2f94ff3e1922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0e31630-1176-40b5-8ae7-8fd8b137acd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a7a8ef0d-30b9-41e5-8614-2f94ff3e1922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f91012fa-eeb4-44ef-b524-4233a438adf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0e31630-1176-40b5-8ae7-8fd8b137acd4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f91012fa-eeb4-44ef-b524-4233a438adf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba46fd87-53d7-44b9-b6b3-d28e2f09641f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0e31630-1176-40b5-8ae7-8fd8b137acd4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ba46fd87-53d7-44b9-b6b3-d28e2f09641f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#StockOptionsEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_01e27c62-d4ac-4154-b620-540f04e379dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04a4bab5-39ad-4fd9-afb2-3759daf1c2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_01e27c62-d4ac-4154-b620-540f04e379dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04a4bab5-39ad-4fd9-afb2-3759daf1c2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_60b4909a-f719-471c-9d73-3a460c10dde0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04a4bab5-39ad-4fd9-afb2-3759daf1c2c5" xlink:to="loc_us-gaap_AwardTypeAxis_60b4909a-f719-471c-9d73-3a460c10dde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e72292d6-fd4a-49bf-8166-291b1ac04121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_60b4909a-f719-471c-9d73-3a460c10dde0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e72292d6-fd4a-49bf-8166-291b1ac04121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_105baaea-f9bb-42b0-a156-acea7eba419f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e72292d6-fd4a-49bf-8166-291b1ac04121" xlink:to="loc_us-gaap_EmployeeStockMember_105baaea-f9bb-42b0-a156-acea7eba419f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805df2c-039a-4a42-8bf0-82a37b188465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04a4bab5-39ad-4fd9-afb2-3759daf1c2c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805df2c-039a-4a42-8bf0-82a37b188465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_98a7a611-3a60-4d94-b649-14d7cee2cc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805df2c-039a-4a42-8bf0-82a37b188465" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_98a7a611-3a60-4d94-b649-14d7cee2cc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8f480586-6e48-4b58-8bbe-653c3d902c0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805df2c-039a-4a42-8bf0-82a37b188465" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_8f480586-6e48-4b58-8bbe-653c3d902c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d3081741-4b89-435a-9782-80ae77a9c3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805df2c-039a-4a42-8bf0-82a37b188465" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d3081741-4b89-435a-9782-80ae77a9c3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_451bd0c3-cc0c-453e-b41a-4e042c5aa239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c805df2c-039a-4a42-8bf0-82a37b188465" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_451bd0c3-cc0c-453e-b41a-4e042c5aa239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/Leases" xlink:type="simple" xlink:href="mrsn-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a2f3291b-0d7f-4de6-b578-8f4bea4a508a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_c585186a-8493-46b3-813b-dbd5bb8adb5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2f3291b-0d7f-4de6-b578-8f4bea4a508a" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_c585186a-8493-46b3-813b-dbd5bb8adb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_1c4a7558-528c-49e8-b169-cff324f32cae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2f3291b-0d7f-4de6-b578-8f4bea4a508a" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_1c4a7558-528c-49e8-b169-cff324f32cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0d72accf-a209-4c59-95fb-81bfc08ce5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_b5d129dc-4be9-49d9-b101-31d806477275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d72accf-a209-4c59-95fb-81bfc08ce5d9" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_b5d129dc-4be9-49d9-b101-31d806477275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock_d39b859a-5b4e-4e83-a0b2-3e3fdf9d5210" xlink:href="mrsn-20201231.xsd#mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d72accf-a209-4c59-95fb-81bfc08ce5d9" xlink:to="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock_d39b859a-5b4e-4e83-a0b2-3e3fdf9d5210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_f7d210e9-5c59-4cc4-a5a0-3b1578b68a91" xlink:href="mrsn-20201231.xsd#mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d72accf-a209-4c59-95fb-81bfc08ce5d9" xlink:to="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_f7d210e9-5c59-4cc4-a5a0-3b1578b68a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f50ff040-9f7f-4ecb-8c69-1ddce63b3ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d72accf-a209-4c59-95fb-81bfc08ce5d9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f50ff040-9f7f-4ecb-8c69-1ddce63b3ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_c81b2784-c95c-4503-85ec-03116313a9e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d72accf-a209-4c59-95fb-81bfc08ce5d9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_c81b2784-c95c-4503-85ec-03116313a9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesDescriptionDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesDescriptionDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesDescriptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6da1fcc2-394f-42bf-a398-7c537dfffaa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesTable_b6ff1989-8af6-4cab-8781-2fef50633107" xlink:href="mrsn-20201231.xsd#mrsn_LeasesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6da1fcc2-394f-42bf-a398-7c537dfffaa6" xlink:to="loc_mrsn_LeasesTable_b6ff1989-8af6-4cab-8781-2fef50633107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5142c87c-7420-4e7e-a38e-122523c2a39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesTable_b6ff1989-8af6-4cab-8781-2fef50633107" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5142c87c-7420-4e7e-a38e-122523c2a39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_882a7ffe-b90c-48c4-b8bf-9accadb71e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5142c87c-7420-4e7e-a38e-122523c2a39d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_882a7ffe-b90c-48c4-b8bf-9accadb71e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OfficeSpaceCambridgeMaMember_f70faf51-4e35-43ab-8fde-f25974bfdf7b" xlink:href="mrsn-20201231.xsd#mrsn_OfficeSpaceCambridgeMaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_882a7ffe-b90c-48c4-b8bf-9accadb71e18" xlink:to="loc_mrsn_OfficeSpaceCambridgeMaMember_f70faf51-4e35-43ab-8fde-f25974bfdf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:href="mrsn-20201231.xsd#mrsn_LeasesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesTable_b6ff1989-8af6-4cab-8781-2fef50633107" xlink:to="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_TenantImprovementAllowance_f1503a16-6172-45b7-ac6d-c67f3b79bce0" xlink:href="mrsn-20201231.xsd#mrsn_TenantImprovementAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_mrsn_TenantImprovementAllowance_f1503a16-6172-45b7-ac6d-c67f3b79bce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_76228236-e482-44a7-a9bb-a33da6029763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_76228236-e482-44a7-a9bb-a33da6029763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_3ec30fa6-4980-4784-9edf-ebadee844758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_3ec30fa6-4980-4784-9edf-ebadee844758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability_77aa3661-fcc4-4570-bfe3-6394ff77d03e" xlink:href="mrsn-20201231.xsd#mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability_77aa3661-fcc4-4570-bfe3-6394ff77d03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets_3bb0f198-9172-4c91-9ed7-96e57fe028f2" xlink:href="mrsn-20201231.xsd#mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets_3bb0f198-9172-4c91-9ed7-96e57fe028f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_5e603712-48f7-4ee4-ad96-65d8acfd8525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_us-gaap_SecurityDeposit_5e603712-48f7-4ee4-ad96-65d8acfd8525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_1efbe26a-925b-4d81-9976-1867f2232022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_7120a1db-c860-4274-9569-5bea0036387d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_1efbe26a-925b-4d81-9976-1867f2232022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f21ce9c1-a317-4f9f-99cd-4a16ce7ef141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_724714a6-328a-4022-b785-a2f1ab40b3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f21ce9c1-a317-4f9f-99cd-4a16ce7ef141" xlink:to="loc_us-gaap_OperatingLeaseCost_724714a6-328a-4022-b785-a2f1ab40b3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeaseTotalCostAbstract_092441e7-aab7-491a-b993-c86909a5bd03" xlink:href="mrsn-20201231.xsd#mrsn_FinanceLeaseTotalCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f21ce9c1-a317-4f9f-99cd-4a16ce7ef141" xlink:to="loc_mrsn_FinanceLeaseTotalCostAbstract_092441e7-aab7-491a-b993-c86909a5bd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_825bd2c7-7018-4e0e-95e8-5fc720d047d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_FinanceLeaseTotalCostAbstract_092441e7-aab7-491a-b993-c86909a5bd03" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_825bd2c7-7018-4e0e-95e8-5fc720d047d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_c66330db-5269-4711-95d9-0e37ee181697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_FinanceLeaseTotalCostAbstract_092441e7-aab7-491a-b993-c86909a5bd03" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_c66330db-5269-4711-95d9-0e37ee181697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeaseCost_7f14188a-7cc3-400c-a69a-24a2a3ec9a7e" xlink:href="mrsn-20201231.xsd#mrsn_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_FinanceLeaseTotalCostAbstract_092441e7-aab7-491a-b993-c86909a5bd03" xlink:to="loc_mrsn_FinanceLeaseCost_7f14188a-7cc3-400c-a69a-24a2a3ec9a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesSupplementalbalancesheetinformationDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6819fbb3-e834-4862-bad6-e334fc018761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingLeasesAbstract_2f9db940-8a79-4823-9c1b-ca544b6a2be1" xlink:href="mrsn-20201231.xsd#mrsn_LesseeOperatingLeasesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6819fbb3-e834-4862-bad6-e334fc018761" xlink:to="loc_mrsn_LesseeOperatingLeasesAbstract_2f9db940-8a79-4823-9c1b-ca544b6a2be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3584b8ed-587a-441a-8447-69e5e9ee9a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeOperatingLeasesAbstract_2f9db940-8a79-4823-9c1b-ca544b6a2be1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3584b8ed-587a-441a-8447-69e5e9ee9a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_62458125-e3d5-4b0f-a5e2-695a71238bd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeOperatingLeasesAbstract_2f9db940-8a79-4823-9c1b-ca544b6a2be1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_62458125-e3d5-4b0f-a5e2-695a71238bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5d4f7d7b-a83f-47d6-bf8f-f2b2915d3255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeOperatingLeasesAbstract_2f9db940-8a79-4823-9c1b-ca544b6a2be1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5d4f7d7b-a83f-47d6-bf8f-f2b2915d3255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeFinanceLeasesAbstract_9db57360-7b79-41a0-9e46-e636d86fc0f2" xlink:href="mrsn-20201231.xsd#mrsn_LesseeFinanceLeasesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6819fbb3-e834-4862-bad6-e334fc018761" xlink:to="loc_mrsn_LesseeFinanceLeasesAbstract_9db57360-7b79-41a0-9e46-e636d86fc0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_6828b376-ba3f-45fc-b0e6-0411f52847df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeFinanceLeasesAbstract_9db57360-7b79-41a0-9e46-e636d86fc0f2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_6828b376-ba3f-45fc-b0e6-0411f52847df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_3f1744cd-f590-428d-af19-fdf591977592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeFinanceLeasesAbstract_9db57360-7b79-41a0-9e46-e636d86fc0f2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_3f1744cd-f590-428d-af19-fdf591977592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_30ab215f-0748-4d2f-9384-b2c4bdc62efc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeFinanceLeasesAbstract_9db57360-7b79-41a0-9e46-e636d86fc0f2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_30ab215f-0748-4d2f-9384-b2c4bdc62efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_7228681f-b9c6-47f8-aede-5d889e5775d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeFinanceLeasesAbstract_9db57360-7b79-41a0-9e46-e636d86fc0f2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_7228681f-b9c6-47f8-aede-5d889e5775d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WeightedAverageRemainingLeaseTermAbstract_eac31c36-90d0-4b0f-8994-ea0e7619d1f2" xlink:href="mrsn-20201231.xsd#mrsn_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6819fbb3-e834-4862-bad6-e334fc018761" xlink:to="loc_mrsn_WeightedAverageRemainingLeaseTermAbstract_eac31c36-90d0-4b0f-8994-ea0e7619d1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5f42f5bb-8a52-430a-a4df-effb96ef93a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WeightedAverageRemainingLeaseTermAbstract_eac31c36-90d0-4b0f-8994-ea0e7619d1f2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5f42f5bb-8a52-430a-a4df-effb96ef93a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_eb18a1ea-6d0f-4658-8acf-3d51b419d4ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WeightedAverageRemainingLeaseTermAbstract_eac31c36-90d0-4b0f-8994-ea0e7619d1f2" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_eb18a1ea-6d0f-4658-8acf-3d51b419d4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WeightedAverageDiscountRateAbstract_c78375a0-bd5b-4c61-b866-7256bf7c9d81" xlink:href="mrsn-20201231.xsd#mrsn_WeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6819fbb3-e834-4862-bad6-e334fc018761" xlink:to="loc_mrsn_WeightedAverageDiscountRateAbstract_c78375a0-bd5b-4c61-b866-7256bf7c9d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b1121448-6840-4234-87d4-745d4dea8711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WeightedAverageDiscountRateAbstract_c78375a0-bd5b-4c61-b866-7256bf7c9d81" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b1121448-6840-4234-87d4-745d4dea8711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_2b62dc1c-7b31-4758-ba46-e9f170def529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WeightedAverageDiscountRateAbstract_c78375a0-bd5b-4c61-b866-7256bf7c9d81" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_2b62dc1c-7b31-4758-ba46-e9f170def529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_ab13e5f3-1f07-4a5f-9785-e914a14b9d67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6819fbb3-e834-4862-bad6-e334fc018761" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_ab13e5f3-1f07-4a5f-9785-e914a14b9d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_988525d1-894b-4e9c-a82a-30067df4f0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6819fbb3-e834-4862-bad6-e334fc018761" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_988525d1-894b-4e9c-a82a-30067df4f0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesSupplementalcashflowinformationDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_210e6505-6681-4315-bf1f-3254778022c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract_4b4b2991-9715-4fb9-a0ea-51fa26feeff7" xlink:href="mrsn-20201231.xsd#mrsn_LeasesSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_210e6505-6681-4315-bf1f-3254778022c3" xlink:to="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract_4b4b2991-9715-4fb9-a0ea-51fa26feeff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_949ee07e-be0f-4067-9913-abbb2f40906d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract_4b4b2991-9715-4fb9-a0ea-51fa26feeff7" xlink:to="loc_us-gaap_OperatingLeasePayments_949ee07e-be0f-4067-9913-abbb2f40906d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_c5d93707-6bd0-4016-b4f1-1b38497b2d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract_4b4b2991-9715-4fb9-a0ea-51fa26feeff7" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_c5d93707-6bd0-4016-b4f1-1b38497b2d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_eef26fac-1233-499e-b22e-c612e362dc5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract_4b4b2991-9715-4fb9-a0ea-51fa26feeff7" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_eef26fac-1233-499e-b22e-c612e362dc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesFutureminimumleasepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_80407754-4377-411b-9dd0-d00ea90449d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_26fff621-3891-46c2-96e7-81c0e3acb9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80407754-4377-411b-9dd0-d00ea90449d9" xlink:to="loc_us-gaap_LeaseCost_26fff621-3891-46c2-96e7-81c0e3acb9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e6956590-9c09-491e-8815-e14933d75039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80407754-4377-411b-9dd0-d00ea90449d9" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e6956590-9c09-491e-8815-e14933d75039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c594816c-3f9e-4a82-9eb0-b2e7aa5dc336" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e6956590-9c09-491e-8815-e14933d75039" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c594816c-3f9e-4a82-9eb0-b2e7aa5dc336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c697f816-a027-4cf3-8043-8d229394e9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e6956590-9c09-491e-8815-e14933d75039" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c697f816-a027-4cf3-8043-8d229394e9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_64c71680-da98-44d1-b9e6-3ab6e12a83f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e6956590-9c09-491e-8815-e14933d75039" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_64c71680-da98-44d1-b9e6-3ab6e12a83f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_81112210-4743-43fd-9079-ed9b602cf9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e6956590-9c09-491e-8815-e14933d75039" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_81112210-4743-43fd-9079-ed9b602cf9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_840168ea-38ea-45c1-a6b2-47978d44838f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e6956590-9c09-491e-8815-e14933d75039" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_840168ea-38ea-45c1-a6b2-47978d44838f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fb236b3f-59fe-4d6e-bf7c-c3d65a2adbfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e6956590-9c09-491e-8815-e14933d75039" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fb236b3f-59fe-4d6e-bf7c-c3d65a2adbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51479e93-34ef-46f3-8104-2cb646173046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e6956590-9c09-491e-8815-e14933d75039" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51479e93-34ef-46f3-8104-2cb646173046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d619659b-5691-44b5-97ed-e6395525cf13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e6956590-9c09-491e-8815-e14933d75039" xlink:to="loc_us-gaap_OperatingLeaseLiability_d619659b-5691-44b5-97ed-e6395525cf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_7d94aea0-35aa-424b-adb2-de6b9b95fed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80407754-4377-411b-9dd0-d00ea90449d9" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_7d94aea0-35aa-424b-adb2-de6b9b95fed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_63e9a53b-bbd9-4008-bcdd-efc8efd5b4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_7d94aea0-35aa-424b-adb2-de6b9b95fed8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_63e9a53b-bbd9-4008-bcdd-efc8efd5b4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_fbb1eeb1-2aeb-412f-b9f2-b96b7da8a942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_7d94aea0-35aa-424b-adb2-de6b9b95fed8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_fbb1eeb1-2aeb-412f-b9f2-b96b7da8a942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_963c885c-3ed9-4c7a-aad6-9bd18735bcab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_7d94aea0-35aa-424b-adb2-de6b9b95fed8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_963c885c-3ed9-4c7a-aad6-9bd18735bcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c0c4d677-bb07-455a-97fb-c64f94f8d03d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_7d94aea0-35aa-424b-adb2-de6b9b95fed8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c0c4d677-bb07-455a-97fb-c64f94f8d03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_0d2f2320-f405-48a0-99bc-881e034a80b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_7d94aea0-35aa-424b-adb2-de6b9b95fed8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_0d2f2320-f405-48a0-99bc-881e034a80b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_79d744e8-c9c1-4bc5-be31-6c033142cb38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_7d94aea0-35aa-424b-adb2-de6b9b95fed8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_79d744e8-c9c1-4bc5-be31-6c033142cb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_23f60cad-9cf4-48db-a485-fd1ee6e2c62d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_7d94aea0-35aa-424b-adb2-de6b9b95fed8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_23f60cad-9cf4-48db-a485-fd1ee6e2c62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_92f813e4-08cd-4643-86b2-8ec643deb4ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_7d94aea0-35aa-424b-adb2-de6b9b95fed8" xlink:to="loc_us-gaap_FinanceLeaseLiability_92f813e4-08cd-4643-86b2-8ec643deb4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1" xlink:type="simple" xlink:href="mrsn-20201231.xsd#LeasesFutureminimumleasepaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1ce7ad5a-a517-4254-88ca-22dc2e80bb48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_800d5fc1-08b9-4248-acfc-3fef2583131a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1ce7ad5a-a517-4254-88ca-22dc2e80bb48" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_800d5fc1-08b9-4248-acfc-3fef2583131a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_171e02ef-4400-4b1a-b3ad-687f6fe5a079" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b6f3c4be-6857-47ce-b07e-3136a070f44d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_171e02ef-4400-4b1a-b3ad-687f6fe5a079" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b6f3c4be-6857-47ce-b07e-3136a070f44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e4e80ad6-1f54-4ccd-906d-d5c24cf56c91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_171e02ef-4400-4b1a-b3ad-687f6fe5a079" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e4e80ad6-1f54-4ccd-906d-d5c24cf56c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesReconciliationDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cb4f01df-d123-439e-8388-7bb47efe3e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_d3b875f5-1f26-4252-ab2c-30eb904c3d0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cb4f01df-d123-439e-8388-7bb47efe3e75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_d3b875f5-1f26-4252-ab2c-30eb904c3d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7f13c4bf-faa7-4d96-a914-b35e3b704d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_d3b875f5-1f26-4252-ab2c-30eb904c3d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7f13c4bf-faa7-4d96-a914-b35e3b704d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0f8cc216-4f00-4f5e-8f0d-60f03a4abb2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_d3b875f5-1f26-4252-ab2c-30eb904c3d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0f8cc216-4f00-4f5e-8f0d-60f03a4abb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_755d9df5-b55f-49ea-8837-deef30d25630" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_d3b875f5-1f26-4252-ab2c-30eb904c3d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_755d9df5-b55f-49ea-8837-deef30d25630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1b7420c6-5470-49b0-a2f0-bd1f7c012769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_d3b875f5-1f26-4252-ab2c-30eb904c3d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1b7420c6-5470-49b0-a2f0-bd1f7c012769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_249f62be-14f0-467d-a4ed-0e7774f854e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_d3b875f5-1f26-4252-ab2c-30eb904c3d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_249f62be-14f0-467d-a4ed-0e7774f854e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c0a64de3-518f-4d9e-8d83-c50708db0c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_d3b875f5-1f26-4252-ab2c-30eb904c3d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c0a64de3-518f-4d9e-8d83-c50708db0c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e740aa40-dd32-4836-a566-29b7078aa26c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_d3b875f5-1f26-4252-ab2c-30eb904c3d0a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e740aa40-dd32-4836-a566-29b7078aa26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesComponentsofdeferredtaxassetsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c774bd80-8c73-43a6-8901-b0d00adfa4da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6cae4840-6c67-4cf7-a8da-4620c3fc5cc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c774bd80-8c73-43a6-8901-b0d00adfa4da" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6cae4840-6c67-4cf7-a8da-4620c3fc5cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6cae4840-6c67-4cf7-a8da-4620c3fc5cc4" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_124c082b-94ce-4710-8bb4-390351564941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_124c082b-94ce-4710-8bb4-390351564941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_0a4b271a-71ea-4bb8-afae-491ac1afc71b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_0a4b271a-71ea-4bb8-afae-491ac1afc71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_b5e2645a-89e7-48b1-844c-d3482a1e295d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_b5e2645a-89e7-48b1-844c-d3482a1e295d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsLeaseLiabilities_a583c79a-b384-4570-9083-f7041ac0d91c" xlink:href="mrsn-20201231.xsd#mrsn_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:to="loc_mrsn_DeferredTaxAssetsLeaseLiabilities_a583c79a-b384-4570-9083-f7041ac0d91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsLicensedTechnology_25081a76-11ca-4196-a1d7-34292d4408c6" xlink:href="mrsn-20201231.xsd#mrsn_DeferredTaxAssetsLicensedTechnology"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:to="loc_mrsn_DeferredTaxAssetsLicensedTechnology_25081a76-11ca-4196-a1d7-34292d4408c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3e4f308b-7866-4902-8647-547a76ba080b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3e4f308b-7866-4902-8647-547a76ba080b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsDepreciation_23e60cfd-0a5b-4725-b23f-1e2872dd2079" xlink:href="mrsn-20201231.xsd#mrsn_DeferredTaxAssetsDepreciation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:to="loc_mrsn_DeferredTaxAssetsDepreciation_23e60cfd-0a5b-4725-b23f-1e2872dd2079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_c00fc51b-fde1-4bef-b331-1f25a96339da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_c00fc51b-fde1-4bef-b331-1f25a96339da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4cfe65eb-4fe3-46cf-bddc-ee362df9fc7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4cfe65eb-4fe3-46cf-bddc-ee362df9fc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_975192a5-8d5f-4f79-9c84-d6acbb1e72a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_975192a5-8d5f-4f79-9c84-d6acbb1e72a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ded016ed-0297-4b96-a3e3-0552618ae602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a87effe8-a569-4e98-9f4c-30efbd0f2f3f" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_ded016ed-0297-4b96-a3e3-0552618ae602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_37897e2f-c097-4339-bc51-0ae840785a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6cae4840-6c67-4cf7-a8da-4620c3fc5cc4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_37897e2f-c097-4339-bc51-0ae840785a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1f051009-73ad-4b7f-b825-b4032ad292ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_37897e2f-c097-4339-bc51-0ae840785a03" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1f051009-73ad-4b7f-b825-b4032ad292ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c65e12d1-bea5-4d00-8ef6-dd04e0920531" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_37897e2f-c097-4339-bc51-0ae840785a03" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_c65e12d1-bea5-4d00-8ef6-dd04e0920531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b3c70d4b-66f8-4b61-b4d6-f7310407322f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6cae4840-6c67-4cf7-a8da-4620c3fc5cc4" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b3c70d4b-66f8-4b61-b4d6-f7310407322f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesNetoperatinglosscarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_85377e0e-41ae-4faf-a4a9-f5e8472f7845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_45b3c570-497e-48df-a314-ecca6bfca24a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_85377e0e-41ae-4faf-a4a9-f5e8472f7845" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_45b3c570-497e-48df-a314-ecca6bfca24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e77eb1eb-88fb-4469-8bee-1556c3adad23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_45b3c570-497e-48df-a314-ecca6bfca24a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e77eb1eb-88fb-4469-8bee-1556c3adad23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8d4d520b-0126-4334-957a-c9f4ff139e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e77eb1eb-88fb-4469-8bee-1556c3adad23" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8d4d520b-0126-4334-957a-c9f4ff139e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3e25a59b-9f48-4e53-b490-959e5c6ef564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8d4d520b-0126-4334-957a-c9f4ff139e56" xlink:to="loc_us-gaap_DomesticCountryMember_3e25a59b-9f48-4e53-b490-959e5c6ef564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f1ce0d87-98e8-4996-a722-ca38b71032fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8d4d520b-0126-4334-957a-c9f4ff139e56" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f1ce0d87-98e8-4996-a722-ca38b71032fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_f08cdda0-4339-49a1-8780-f8ce45adb426" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_45b3c570-497e-48df-a314-ecca6bfca24a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_f08cdda0-4339-49a1-8780-f8ce45adb426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_5c681653-dbd3-4249-b549-f9e85068525c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f08cdda0-4339-49a1-8780-f8ce45adb426" xlink:to="loc_us-gaap_OperatingLossCarryforwards_5c681653-dbd3-4249-b549-f9e85068525c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLossCarryforwardsSubjectToExpiration_c0d923c7-881c-42ca-b80d-29f422b69de9" xlink:href="mrsn-20201231.xsd#mrsn_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f08cdda0-4339-49a1-8780-f8ce45adb426" xlink:to="loc_mrsn_OperatingLossCarryforwardsSubjectToExpiration_c0d923c7-881c-42ca-b80d-29f422b69de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_c787b972-39ea-421b-8578-94d1b32a2530" xlink:href="mrsn-20201231.xsd#mrsn_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f08cdda0-4339-49a1-8780-f8ce45adb426" xlink:to="loc_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_c787b972-39ea-421b-8578-94d1b32a2530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesTaxcreditcarryforwardDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_09a80e9b-e1d1-4e30-b8a8-0046621e47f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_87c415b9-829a-429f-8c49-4a664b6bda82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_09a80e9b-e1d1-4e30-b8a8-0046621e47f1" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_87c415b9-829a-429f-8c49-4a664b6bda82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_317f38c7-e708-4d74-9219-378508c6efe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_87c415b9-829a-429f-8c49-4a664b6bda82" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_317f38c7-e708-4d74-9219-378508c6efe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0a071278-2335-4039-822a-59ee5dec9b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_317f38c7-e708-4d74-9219-378508c6efe0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0a071278-2335-4039-822a-59ee5dec9b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_344c30bb-505e-4c78-80c0-8344ac484551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0a071278-2335-4039-822a-59ee5dec9b99" xlink:to="loc_us-gaap_DomesticCountryMember_344c30bb-505e-4c78-80c0-8344ac484551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_d22e9804-ec94-4453-b235-355982175417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0a071278-2335-4039-822a-59ee5dec9b99" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_d22e9804-ec94-4453-b235-355982175417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_8289d4ed-151d-4d88-a381-2cb49b4bf715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_87c415b9-829a-429f-8c49-4a664b6bda82" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_8289d4ed-151d-4d88-a381-2cb49b4bf715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_77fe9dd5-5dfc-4de4-88e8-ffae83ae9a6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_8289d4ed-151d-4d88-a381-2cb49b4bf715" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_77fe9dd5-5dfc-4de4-88e8-ffae83ae9a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_9c83b493-a325-42e5-9760-21b7deefed9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_77fe9dd5-5dfc-4de4-88e8-ffae83ae9a6b" xlink:to="loc_us-gaap_ResearchMember_9c83b493-a325-42e5-9760-21b7deefed9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_ccc6c96f-3e97-40df-98dd-1b05f42e5121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_87c415b9-829a-429f-8c49-4a664b6bda82" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_ccc6c96f-3e97-40df-98dd-1b05f42e5121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2048df1c-8f5f-422e-a8d8-7271690d26a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_ccc6c96f-3e97-40df-98dd-1b05f42e5121" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2048df1c-8f5f-422e-a8d8-7271690d26a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#IncomeTaxesValuationallowanceDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ad010c1e-ede0-47ed-bdb9-87183d219005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6b3a0774-6f21-42d7-9270-3ed0fc754dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ad010c1e-ede0-47ed-bdb9-87183d219005" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6b3a0774-6f21-42d7-9270-3ed0fc754dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceAbstract_b138b8ad-d9ba-4309-a37e-3a489f85820f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6b3a0774-6f21-42d7-9270-3ed0fc754dbd" xlink:to="loc_us-gaap_ValuationAllowanceAbstract_b138b8ad-d9ba-4309-a37e-3a489f85820f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1104daf2-e1b6-4d3a-b3d0-3656c5b32260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_b138b8ad-d9ba-4309-a37e-3a489f85820f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1104daf2-e1b6-4d3a-b3d0-3656c5b32260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ca033db1-5817-45e1-a59c-96af8c3480a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_b138b8ad-d9ba-4309-a37e-3a489f85820f" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ca033db1-5817-45e1-a59c-96af8c3480a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_bf4c7821-5bc8-4163-94aa-8da16736cdc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_b138b8ad-d9ba-4309-a37e-3a489f85820f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_bf4c7821-5bc8-4163-94aa-8da16736cdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ad3cdc3-b740-4d3a-9f75-fd363f73fe12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_b138b8ad-d9ba-4309-a37e-3a489f85820f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ad3cdc3-b740-4d3a-9f75-fd363f73fe12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncomeTaxesNumberOfStateJurisdictions_4d03a6f9-8bf9-497c-a326-f23ad685fe90" xlink:href="mrsn-20201231.xsd#mrsn_IncomeTaxesNumberOfStateJurisdictions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6b3a0774-6f21-42d7-9270-3ed0fc754dbd" xlink:to="loc_mrsn_IncomeTaxesNumberOfStateJurisdictions_4d03a6f9-8bf9-497c-a326-f23ad685fe90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncomeTaxesNumberOfAuditsInProgress_74a18ec0-c7e7-4b44-98fa-f2413a8b4f64" xlink:href="mrsn-20201231.xsd#mrsn_IncomeTaxesNumberOfAuditsInProgress"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6b3a0774-6f21-42d7-9270-3ed0fc754dbd" xlink:to="loc_mrsn_IncomeTaxesNumberOfAuditsInProgress_74a18ec0-c7e7-4b44-98fa-f2413a8b4f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mrsn-20201231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7b5899ba-aa0b-4ddd-9909-09e5130d7c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_cea15731-5a2b-4596-bc43-be16510a5188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7b5899ba-aa0b-4ddd-9909-09e5130d7c19" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_cea15731-5a2b-4596-bc43-be16510a5188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e1754c2-171a-4b8a-a499-68f8da96594e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DefinedContributionPlanEligibleAgeToParticipate_c943d4bb-480a-4790-8fa4-c22f4a287155" xlink:href="mrsn-20201231.xsd#mrsn_DefinedContributionPlanEligibleAgeToParticipate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e1754c2-171a-4b8a-a499-68f8da96594e" xlink:to="loc_mrsn_DefinedContributionPlanEligibleAgeToParticipate_c943d4bb-480a-4790-8fa4-c22f4a287155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_191d1625-be64-4779-a562-5d2ddcd6db82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e1754c2-171a-4b8a-a499-68f8da96594e" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_191d1625-be64-4779-a562-5d2ddcd6db82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_af7a8bc8-729f-4fd4-9ccb-b42aa21270a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e1754c2-171a-4b8a-a499-68f8da96594e" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_af7a8bc8-729f-4fd4-9ccb-b42aa21270a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_056aced7-8cf4-47ea-9915-598489bc1a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e1754c2-171a-4b8a-a499-68f8da96594e" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_056aced7-8cf4-47ea-9915-598489bc1a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount_a99800b8-a441-4560-a8cc-0cae7745b719" xlink:href="mrsn-20201231.xsd#mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e1754c2-171a-4b8a-a499-68f8da96594e" xlink:to="loc_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount_a99800b8-a441-4560-a8cc-0cae7745b719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_4e0f51bf-87a1-4202-8305-14e1608234ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e1754c2-171a-4b8a-a499-68f8da96594e" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_4e0f51bf-87a1-4202-8305-14e1608234ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/Commitments" xlink:type="simple" xlink:href="mrsn-20201231.xsd#Commitments"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_09168107-73ac-429b-9fbc-a30ff3a43bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_6670bdcb-f183-4bee-a22d-59edd3f61fdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_09168107-73ac-429b-9fbc-a30ff3a43bd3" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_6670bdcb-f183-4bee-a22d-59edd3f61fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CommitmentsLicenseagreementsDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#CommitmentsLicenseagreementsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CommitmentsLicenseagreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f489091a-1b73-40c6-9b84-125b1e4f5aa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2e8352e0-1c08-42a1-adc4-d40570ba9315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f489091a-1b73-40c6-9b84-125b1e4f5aa3" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2e8352e0-1c08-42a1-adc4-d40570ba9315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_531cddb8-3814-47ee-be5b-0a1e552ced21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2e8352e0-1c08-42a1-adc4-d40570ba9315" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_531cddb8-3814-47ee-be5b-0a1e552ced21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0b68188e-adc0-4164-baac-78b1c8c8a361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_531cddb8-3814-47ee-be5b-0a1e552ced21" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0b68188e-adc0-4164-baac-78b1c8c8a361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAgreementUpfrontPaymentsMember_850b2e5a-3b82-442e-95fd-b287c77aa75a" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAgreementUpfrontPaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0b68188e-adc0-4164-baac-78b1c8c8a361" xlink:to="loc_mrsn_LicenseAgreementUpfrontPaymentsMember_850b2e5a-3b82-442e-95fd-b287c77aa75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAgreementMilestonePaymentsMember_b4cb6df6-e6f3-4f48-9cf8-c4661431f3d5" xlink:href="mrsn-20201231.xsd#mrsn_LicenseAgreementMilestonePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_0b68188e-adc0-4164-baac-78b1c8c8a361" xlink:to="loc_mrsn_LicenseAgreementMilestonePaymentsMember_b4cb6df6-e6f3-4f48-9cf8-c4661431f3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_31233505-8c1c-47aa-a9b2-94fff2cb8448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2e8352e0-1c08-42a1-adc4-d40570ba9315" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_31233505-8c1c-47aa-a9b2-94fff2cb8448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_5382b2b9-370a-41f1-8c4b-3a1348b7aec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_31233505-8c1c-47aa-a9b2-94fff2cb8448" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_5382b2b9-370a-41f1-8c4b-3a1348b7aec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SelectedQuarterlyFinancialDataUnaudited"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_d9d07a63-29be-4f29-b336-37d24f45ad4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_80cd5419-9212-4b70-ae02-a03562164c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_d9d07a63-29be-4f29-b336-37d24f45ad4c" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_80cd5419-9212-4b70-ae02-a03562164c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9470312a-087e-47c8-ad83-f19db5cff1c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_fca9117b-5b65-4f22-a050-dfdcaa29d440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9470312a-087e-47c8-ad83-f19db5cff1c0" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_fca9117b-5b65-4f22-a050-dfdcaa29d440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="simple" xlink:href="mrsn-20201231.xsd#SelectedQuarterlyFinancialDataUnauditedDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3235afa1-7d31-4da8-8217-6a7e85ac0de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3235afa1-7d31-4da8-8217-6a7e85ac0de0" xlink:to="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b5fa4682-163c-49a2-86e6-d2cae46c8f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b5fa4682-163c-49a2-86e6-d2cae46c8f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1ee3319d-d359-4cb9-894a-024139868616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1ee3319d-d359-4cb9-894a-024139868616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6082d8a7-29c4-447a-9c81-c5317068963c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ee3319d-d359-4cb9-894a-024139868616" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6082d8a7-29c4-447a-9c81-c5317068963c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cbdbfe19-e14d-4362-b9f4-c6b7131f7abc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ee3319d-d359-4cb9-894a-024139868616" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cbdbfe19-e14d-4362-b9f4-c6b7131f7abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ffbdc694-ef14-4d10-b4f2-7b2287327b29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:to="loc_us-gaap_OperatingExpenses_ffbdc694-ef14-4d10-b4f2-7b2287327b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4b901821-b7b4-4f5f-a69e-6ea939dbccc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4b901821-b7b4-4f5f-a69e-6ea939dbccc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_223d6c5b-17e1-43f0-9190-74cae2142868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4b901821-b7b4-4f5f-a69e-6ea939dbccc2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_223d6c5b-17e1-43f0-9190-74cae2142868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d670f9b4-5c76-4380-9e3a-28fbc4834daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_4b901821-b7b4-4f5f-a69e-6ea939dbccc2" xlink:to="loc_us-gaap_InterestExpense_d670f9b4-5c76-4380-9e3a-28fbc4834daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c0996772-4324-4045-bd32-e4c9cce4afcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c0996772-4324-4045-bd32-e4c9cce4afcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_90944ced-731c-44db-b5f4-a5a332fb8d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:to="loc_us-gaap_NetIncomeLoss_90944ced-731c-44db-b5f4-a5a332fb8d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7db5d747-9260-4b4f-90f2-d8e05cba985b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:to="loc_us-gaap_EarningsPerShareBasic_7db5d747-9260-4b4f-90f2-d8e05cba985b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_97b6e7cc-0adf-4f19-a97b-eaec52a66ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:to="loc_us-gaap_EarningsPerShareDiluted_97b6e7cc-0adf-4f19-a97b-eaec52a66ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_217e68a6-1edc-40ed-b7ba-281aad860e33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_217e68a6-1edc-40ed-b7ba-281aad860e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a5aa77d0-b6cc-4242-8046-aa3136e8463e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a5aa77d0-b6cc-4242-8046-aa3136e8463e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a27283e7-5633-4ebe-adf8-6a07134f52c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_c90ae28d-5245-4e58-8537-53c7d2d99e55" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_a27283e7-5633-4ebe-adf8-6a07134f52c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>mrsn-20201231_g1.jpg
<TEXT>
begin 644 mrsn-20201231_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *6!74# 2(  A$! Q$!_\0
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M94D>XK0KRCP7_P G!?$;_KUT_P#]%"@#U>BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !5"WUW3[K6+K2HKR*34;5$EFM@WSHK9VDCT./Y>M7Z\H\+_\
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M4 %%%% 'E&C_ /)RWB#_ +%^'_T:*]7KRC1_^3EO$'_8OP_^C17J] !1110
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MP3_;"Z1H6D:/;?97LY[FU9(KEI=[K<1K&DP"(L( D4_/LP0#Z*HHHH ****
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MUV<+INHMI.H7BZ5>-:6%T)O(,=Q<B+RH/WG&Z1U4@AL[2#0!ZC1110 4444
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M-V[D$#!S6EX)^,7A3XA:D^G:/?72ZBMHFH+9ZEIMUI\TMLS;1/$EQ'&TD>[
M+H"H+*"1N&0#M:*\^TGX^>!=<UZVTFRUIY9KNZDL;6\:PN4L;JX3=OAAO&C$
M$KC:_P J2$Y5@!P:XSX1_'J\\=0^&!K>H:3I.HZOKFLZ9!IL&FW$C7R69EV^
M7+YI6%E2,.QD#!\%5"DC ![I17ENB_M.?#?Q ^FFPUZ>6VU"[&GV]^^E7D=D
MUT20(&N6A$22DC 1G#'(XY&=*;XM:!H>J>/VUGQ/IT.G^%C:F]C:RF@?3Q+
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M^W^"?AB&UO+:9]?U.UNT6.:VU;Q-J5]$RK(D@^2>X=1\R+D@9(RIRK,#WE%
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M3.+O38Y8=-6\U*ZNX=.23 D6UAFE>.WRH"_NE7Y?E^Z<5Z!10 4444 %%%%
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M- &K165_PE6B?]!BP_\  I/\:/\ A*M$_P"@Q8?^!2?XT :M%97_  E6B?\
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M%J('M)&C5A"Q<;E,NR/$C'<,-7M'_"5:)_T&+#_P*3_&N%\3_#SX;>+=:O\
M5KV]-M?ZA"EO?2:3XBNM.6]1 503I;SQK,0K%<N&.WY<X % 'S%\-?"NO_\
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MT\/ZF=4U7Q/K]Q8V:V4GG7D<EP#')$FW=(K*,JR@@CI7U'_PE6B?]!BP_P#
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MH7$D-YJ%O"9H663]V%>>!50Y)VL37TS_ ,)5HG_08L/_  *3_&C_ (2K1/\
MH,6'_@4G^- 'R9\*?#/B'P?X%_9JU#6O#FNVZ>'M1UB'5H$TVXN;FR,T%Y%$
M7A1&DV%BH\S;MPRDD!@3-X@^%_BO6?"_QD-IH%]/,GQ$MM?M].FB,7]KVD M
M7=8B^ X8(V,'!9,9S7U;_P )5HG_ $&+#_P*3_&C_A*M$_Z#%A_X%)_C0!X5
MKRWOQ>^+WA_Q+HOA_7-.T?PYX<U6*[O-8TNXTZ2YGNTC6*UCBGC220IY3.6
M*#>H#%N*Y;P_X%UV/]G3]G32YO#VHK?Z5XDT>YO[)[*02V:1M*7DE0KF,*2"
M68#!(KZ>_P"$JT3_ *#%A_X%)_C1_P )5HG_ $&+#_P*3_&@#R32?#>I1_&S
MXWZB^EW2VNH:%I$%C=M;L$N62&\$B1/C#E2R9"DX)7/45T7[,>D7^@?L^?#_
M $[4[*XT[4+71[>*>TNXFBEB<+RKHP!4CT(KN?\ A*M$_P"@Q8?^!2?XT?\
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M_C0!JUY1^SK_ ,B[XG_[&.]_FE>A?\)5HG_08L/_  *3_&O+OV?=?TRS\/\
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MT5E?\)5HG_08L/\ P*3_ !H_X2K1/^@Q8?\ @4G^- &K165_PE6B?]!BP_\
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MT5E?\)5HG_08L/\ P*3_ !H_X2K1/^@Q8?\ @4G^- &K165_PE6B?]!BP_\
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M/WP]_P"A7M?^^Y/_ (JC_AG[X>_]"O:_]]R?_%5Z%10!Y[_PS]\/?^A7M?\
MON3_ .*H_P"&?OA[_P!"O:_]]R?_ !5>A44 >>_\,_?#W_H5[7_ON3_XJC_A
MG[X>_P#0KVO_ 'W)_P#%5Z%10!Y[_P ,_?#W_H5[7_ON3_XJC_AG[X>_]"O:
M_P#?<G_Q5>A44 >=_P##/?P\\PO_ ,(Q;9QC_62X_+=BG?\ #/WP]_Z%>U_[
M[D_^*KT*B@#SW_AG[X>_]"O:_P#?<G_Q5'_#/WP]_P"A7M?^^Y/_ (JO0J*
M//?^&?OA[_T*]K_WW)_\51_PS]\/?^A7M?\ ON3_ .*KT*B@#SW_ (9^^'O_
M $*]K_WW)_\ %4?\,_?#W_H5[7_ON3_XJO0J* //?^&?OA[_ -"O:_\ ?<G_
M ,51_P ,_?#W_H5[7_ON3_XJO0J* //?^&?OA[_T*]K_ -]R?_%4?\,_?#W_
M *%>U_[[D_\ BJ]"HH \]_X9^^'O_0KVO_?<G_Q5'_#/WP]_Z%>U_P"^Y/\
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M'O\ T*]K_P!]R?\ Q5>A44 >>_\ #/WP]_Z%>U_[[D_^*H_X9^^'O_0KVO\
MWW)_\57H5% 'GO\ PS]\/?\ H5[7_ON3_P"*H_X9^^'O_0KVO_?<G_Q5>A44
M >>_\,_?#W_H5[7_ +[D_P#BJ/\ AG[X>_\ 0KVO_?<G_P 57H5% 'GO_#/W
MP]_Z%>U_[[D_^*H_X9^^'O\ T*]K_P!]R?\ Q5>A44 >>_\ #/WP]_Z%>U_[
M[D_^*H_X9^^'O_0KVO\ WW)_\57H5% 'GO\ PS]\/?\ H5[7_ON3_P"*IK_L
M]_#R3;GPQ;#:<C;+*/Y-S]*]$HH \]_X9^^'O_0KVO\ WW)_\51_PS]\/?\
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MO0J* //?^&?OA[_T*]K_ -]R?_%4?\,_?#W_ *%>U_[[D_\ BJ]"HH \[?\
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M^'O_ $*]K_WW)_\ %5Z%10!Y[_PS]\/?^A7M?^^Y/_BJ/^&?OA[_ -"O:_\
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M<G_Q5>A44 >>_P##/WP]_P"A7M?^^Y/_ (JC_AG[X>_]"O:_]]R?_%5Z%10
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MPEINH^(+**;34U34/$>HW5S,LJ;&G\R>61A; 8/V5RS(7D9'R,RU/"7P NO
M<VDMH_@C1Q;Z+,%LK&7Q!J$MG'=;"BZG%;2RO%'@,<H4,V7D(E8J#* ?2-%-
MCW!%#D,^.2HP"?89XIU !1110 4444 %%%% !1110 4444 %%?#G[-OBW5/@
MWX@U+5M4NWG^'7C#Q=JFFSO(<)HVIK=2+#*3VBG4+&2> Z*20#76_"'Q_?\
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M43PVMGH,^G7EQ:)\MO<:A<+*5ELU7AG6*))"N7X1P/IT*%Q@ 8&!QTH"A<8
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M7_T+.L?^ $O_ ,31_P *[\5_]"SK'_@!+_\ $T <]170_P#"N_%?_0LZQ_X
M2_\ Q-'_  KOQ7_T+.L?^ $O_P 30!SU%=#_ ,*[\5_]"SK'_@!+_P#$T?\
M"N_%?_0LZQ_X 2__ !- '/45T/\ PKOQ7_T+.L?^ $O_ ,31_P *[\5_]"SK
M'_@!+_\ $T <]170_P#"N_%?_0LZQ_X 2_\ Q-'_  KOQ7_T+.L?^ $O_P 3
M0!SU%=#_ ,*[\5_]"SK'_@!+_P#$T?\ "N_%?_0LZQ_X 2__ !- '/45T/\
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M^ $O_P 30!SU%=#_ ,*[\5_]"SK'_@!+_P#$T?\ "N_%?_0LZQ_X 2__ !-
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M]<'YC^ KZ9^&OPUT_P"&^CM;6Q^T7DV&N;MUPTA'0 =E'84 =A1110 4444
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MX]A_PHGPPO\ JVU.';^YB\K4)5\FT/WK),'Y;8\_NN@^7&/+CV>AT4 >>?\
M"B?#"_ZMM3AV_N8O*U"5?)M#]ZR3!^6V//[KH/EQCRX]G5>)O!^D>+]'33-5
ML_/LXY8IXA'(\+PR1L'C>-T*M&RLH(92"*V:* . N/@AX9N)I9L:A%*S$1O%
M?RJ;>!CE[:/#?+ ^6S&..1C&Q-M+4OV=_!FJ6_D2VU\D22(;=8;^6/[+"K!C
M;1;6&R GDQCC[N,;(]OIE% 'GI^!/A5<^5'?VVT[(/L]]*GV:W/W[6+!^2!L
MG,8XY&,;$VA^!/A5<^5'?VVT[(/L]]*GV:W/W[6+!^2!LG,8XY&,;$V^A44
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M-4_\ 8__ (J@#U>BO*/^%3>-/^BJ:I_X Q__ !5'_"IO&G_15-4_\ 8__BJ
M/5Z*\H_X5-XT_P"BJ:I_X Q__%4?\*F\:?\ 15-4_P# &/\ ^*H ]7HKRC_A
M4WC3_HJFJ?\ @#'_ /%4?\*F\:?]%4U3_P  8_\ XJ@#U>BO*/\ A4WC3_HJ
MFJ?^ ,?_ ,51_P *F\:?]%4U3_P!C_\ BJ /5Z*\H_X5-XT_Z*IJG_@#'_\
M%4?\*F\:?]%4U3_P!C_^*H ]7HKRC_A4WC3_ **IJG_@#'_\51_PJ;QI_P!%
M4U3_ , 8_P#XJ@#U>BO*/^%3>-/^BJ:I_P" ,?\ \51_PJ;QI_T535/_  !C
M_P#BJ /5Z*\H_P"%3>-/^BJ:I_X Q_\ Q5'_  J;QI_T535/_ &/_P"*H ]7
MHKRC_A4WC3_HJFJ?^ ,?_P 51_PJ;QI_T535/_ &/_XJ@#U>BO*/^%3>-/\
MHJFJ?^ ,?_Q5'_"IO&G_ $535/\ P!C_ /BJ /5Z*\H_X5-XT_Z*IJG_ ( Q
M_P#Q5'_"IO&G_15-4_\  &/_ .*H ]7HKRC_ (5-XT_Z*IJG_@#'_P#%4?\
M"IO&G_15-4_\ 8__ (J@#U>BO*/^%3>-/^BJ:I_X Q__ !5'_"IO&G_15-4_
M\ 8__BJ /5Z*\H_X5-XT_P"BJ:I_X Q__%4?\*F\:?\ 15-4_P# &/\ ^*H
M]7HKRC_A4WC3_HJFJ?\ @#'_ /%4?\*F\:?]%4U3_P  8_\ XJ@#U>BO*/\
MA4WC3_HJFJ?^ ,?_ ,51_P *F\:?]%4U3_P!C_\ BJ /5Z*\H_X5-XT_Z*IJ
MG_@#'_\ %4?\*F\:?]%4U3_P!C_^*H ]7HKRC_A4WC3_ **IJG_@#'_\51_P
MJ;QI_P!%4U3_ , 8_P#XJ@#U>BO*/^%3>-/^BJ:I_P" ,?\ \51_PJ;QI_T5
M35/_  !C_P#BJ /5Z*\H_P"%3>-/^BJ:I_X Q_\ Q5'_  J;QI_T535/_ &/
M_P"*H ]7HKRC_A4WC3_HJFJ?^ ,?_P 51_PJ;QI_T535/_ &/_XJ@#U>BO*/
M^%3>-/\ HJFJ?^ ,?_Q5'_"IO&G_ $535/\ P!C_ /BJ /5Z*\H_X5-XT_Z*
MIJG_ ( Q_P#Q5'_"IO&G_15-4_\  &/_ .*H ]7HKRC_ (5-XT_Z*IJG_@#'
M_P#%4?\ "IO&G_15-4_\ 8__ (J@#U>BO*/^%3>-/^BJ:I_X Q__ !5'_"IO
M&G_15-4_\ 8__BJ /5Z*\H_X5-XT_P"BJ:I_X Q__%4?\*F\:?\ 15-4_P#
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M !5'_"IO&G_15-4_\ 8__BJ /5Z*\H_X5-XT_P"BJ:I_X Q__%4?\*F\:?\
M15-4_P# &/\ ^*H ]7HKRC_A4WC3_HJFJ?\ @#'_ /%4?\*F\:?]%4U3_P
M8_\ XJ@#U>BO*/\ A4WC3_HJFJ?^ ,?_ ,51_P *F\:?]%4U3_P!C_\ BJ /
M5Z*\H_X5-XT_Z*IJG_@#'_\ %4?\*F\:?]%4U3_P!C_^*H ]7HKRC_A4WC3_
M **IJG_@#'_\51_PJ;QI_P!%4U3_ , 8_P#XJ@#U>BO*/^%3>-/^BJ:I_P"
M,?\ \51_PJ;QI_T535/_  !C_P#BJ /5Z*\H_P"%3>-/^BJ:I_X Q_\ Q5'_
M  J;QI_T535/_ &/_P"*H ]7HKRC_A4WC3_HJFJ?^ ,?_P 51_PJ;QI_T535
M/_ &/_XJ@#U>BO*/^%3>-/\ HJFJ?^ ,?_Q5'_"IO&G_ $535/\ P!C_ /BJ
M /5Z*C@1XX8TDD,SJH#2$ %CCDX' S[44 24444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !5/5M8LM!T^6^U"ZCL[2(9>69L >WN?
M;O5NOCCXQ?$BX\?>)9ECE8:/:.4M(<_*<<&0^I;]!@4 >N:Y^U)HME,8],TN
MZU-1_P M9'$"GZ<,?S K(_X:R_ZE7_RH_P#VJOGRB@#Z#_X:R_ZE7_RH_P#V
MJC_AK+_J5?\ RH__ &JOGRB@#Z#_ .&LO^I5_P#*C_\ :J/^&LO^I5_\J/\
M]JKY\HH ^@_^&LO^I5_\J/\ ]JH_X:R_ZE7_ ,J/_P!JKY\HH ^@_P#AK+_J
M5?\ RH__ &JC_AK+_J5?_*C_ /:J^?** /H/_AK+_J5?_*C_ /:J/^&LO^I5
M_P#*C_\ :J^?** /H/\ X:R_ZE7_ ,J/_P!JH_X:R_ZE7_RH_P#VJOGRB@#Z
M#_X:R_ZE7_RH_P#VJC_AK+_J5?\ RH__ &JOGRB@#Z#_ .&LO^I5_P#*C_\
M:J/^&LO^I5_\J/\ ]JKY\HH ^@_^&LO^I5_\J/\ ]JH_X:R_ZE7_ ,J/_P!J
MKY\HH ^@_P#AK+_J5?\ RH__ &JC_AK+_J5?_*C_ /:J^?** /H/_AK+_J5?
M_*C_ /:J/^&LO^I5_P#*C_\ :J^?** /H/\ X:R_ZE7_ ,J/_P!JH_X:R_ZE
M7_RH_P#VJOGRB@#Z#_X:R_ZE7_RH_P#VJC_AK+_J5?\ RH__ &JOGRB@#Z#_
M .&LO^I5_P#*C_\ :J/^&LO^I5_\J/\ ]JKY\HH ^@_^&LO^I5_\J/\ ]JH_
MX:R_ZE7_ ,J/_P!JKY\HH ^@_P#AK+_J5?\ RH__ &JC_AK+_J5?_*C_ /:J
M^?** /H/_AK+_J5?_*C_ /:J/^&LO^I5_P#*C_\ :J^?** /H/\ X:R_ZE7_
M ,J/_P!JH_X:R_ZE7_RH_P#VJOGRB@#Z#_X:R_ZE7_RH_P#VJC_AK+_J5?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW37,,ID=RH;9&8U"@#[Q+4>,/B%\0O#,/P<M];-AH^N:UXH33-;ATM5FM;B
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#IOAE-)!\1/#319#'4
M8%./[I<!OT)K[@KY2_9T\%RZ]XS35Y(S]@TO]X6(X:4@A%'TSN_ >M?5M !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#XY7V)10!\=_\ "@?'G_0"_P#)RW_^.4?\*!\>?] +_P G+?\ ^.5]B44
M?'?_  H'QY_T O\ R<M__CE'_"@?'G_0"_\ )RW_ /CE?8E% 'QW_P *!\>?
M] +_ ,G+?_XY1_PH'QY_T O_ "<M_P#XY7V)10!\=_\ "@?'G_0"_P#)RW_^
M.4?\*!\>?] +_P G+?\ ^.5]B44 ?'?_  H'QY_T O\ R<M__CE'_"@?'G_0
M"_\ )RW_ /CE?8E% 'QW_P *!\>?] +_ ,G+?_XY1_PH'QY_T O_ "<M_P#X
MY7V)10!\=_\ "@?'G_0"_P#)RW_^.4?\*!\>?] +_P G+?\ ^.5]B44 ?'?_
M  H'QY_T O\ R<M__CE'_"@?'G_0"_\ )RW_ /CE?8E% 'QW_P *!\>?] +_
M ,G+?_XY1_PH'QY_T O_ "<M_P#XY7V)10!\=_\ "@?'G_0"_P#)RW_^.4?\
M*!\>?] +_P G+?\ ^.5]B44 ?'?_  H'QY_T O\ R<M__CE'_"@?'G_0"_\
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M)W8_^#F*C_A,_BO_ -$[L?\ P<Q5ZO10!Y1_PF?Q7_Z)W8_^#F*C_A,_BO\
M]$[L?_!S%7J]% 'E'_"9_%?_ *)W8_\ @YBH_P"$S^*__1.['_P<Q5ZO10!Y
M1_PF?Q7_ .B=V/\ X.8J/^$S^*__ $3NQ_\ !S%7J]% 'E'_  F?Q7_Z)W8_
M^#F*C_A,_BO_ -$[L?\ P<Q5ZO10!Y1_PF?Q7_Z)W8_^#F*C_A,_BO\ ]$[L
M?_!S%7J]% 'E'_"9_%?_ *)W8_\ @YBH_P"$S^*__1.['_P<Q5ZO10!Y1_PF
M?Q7_ .B=V/\ X.8J/^$S^*__ $3NQ_\ !S%7J]% 'E'_  F?Q7_Z)W8_^#F*
MC_A,_BO_ -$[L?\ P<Q5ZO10!Y1_PF?Q7_Z)W8_^#F*C_A,_BO\ ]$[L?_!S
M%7J]% 'E'_"9_%?_ *)W8_\ @YBH_P"$S^*__1.['_P<Q5ZO10!Y1_PF?Q7_
M .B=V/\ X.8J/^$S^*__ $3NQ_\ !S%7J]% 'E'_  F?Q7_Z)W8_^#F*C_A,
M_BO_ -$[L?\ P<Q5ZO10!Y1_PF?Q7_Z)W8_^#F*C_A,_BO\ ]$[L?_!S%7J]
M% 'E'_"9_%?_ *)W8_\ @YBH_P"$S^*__1.['_P<Q5ZO10!Y1_PF?Q7_ .B=
MV/\ X.8J/^$S^*__ $3NQ_\ !S%7J]% 'E'_  F?Q7_Z)W8_^#F*C_A,_BO_
M -$[L?\ P<Q5ZO10!Y1_PF?Q7_Z)W8_^#F*C_A,_BO\ ]$[L?_!S%7J]% 'E
M'_"9_%?_ *)W8_\ @YBH_P"$S^*__1.['_P<Q5ZO10!Y1_PF?Q7_ .B=V/\
MX.8J/^$S^*__ $3NQ_\ !S%7J]% 'E'_  F?Q7_Z)W8_^#F*C_A,_BO_ -$[
ML?\ P<Q5ZO10!Y1_PF?Q7_Z)W8_^#F*C_A,_BO\ ]$[L?_!S%7J]% 'E'_"9
M_%?_ *)W8_\ @YBH_P"$S^*__1.['_P<Q5ZO10!Y1_PF?Q7_ .B=V/\ X.8J
M/^$S^*__ $3NQ_\ !S%7J]% 'E'_  F?Q7_Z)W8_^#F*C_A,_BO_ -$[L?\
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M!Y1_PF?Q7_Z)W8_^#F*C_A,_BO\ ]$[L?_!S%7J]% 'E'_"9_%?_ *)W8_\
M@YBH_P"$S^*__1.['_P<Q5ZO10!Y1_PF?Q7_ .B=V/\ X.8J/^$S^*__ $3N
MQ_\ !S%7J]% 'E'_  F?Q7_Z)W8_^#F*C_A,_BO_ -$[L?\ P<Q5ZO10!Y1_
MPF?Q7_Z)W8_^#F*C_A,_BO\ ]$[L?_!S%7J]% 'E'_"9_%?_ *)W8_\ @YBH
M_P"$S^*__1.['_P<Q5ZO10!Y1_PF?Q7_ .B=V/\ X.8J/^$S^*__ $3NQ_\
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M_1.['_P<Q5ZO10!Y1_PF?Q7_ .B=V/\ X.8J/^$S^*__ $3NQ_\ !S%7J]%
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M)W8_^#F*C_A,_BO_ -$[L?\ P<Q5ZO10!Y1_PF?Q7_Z)W8_^#F*C_A,_BO\
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M2O+S4E8V\\=Q;)Y_RAAY*M*,C_6@^88RQA<1B4@@>N4 %%%% !1110 4444
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M)M4L([Y_#*ZK%/>6X>,2;2GRN<*0<[!P0>E>FT %%%% !1110 4444 %%%%
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M-_&:#6/&EKX4U?PQKWA#6[VR>_L8=96U=;N*-@)-CVT\RADW)E7*GYA@'G'
M_P##4ND>+OA_HOBNST?QIX?\-ZGJ%G;V>L1VVG?Z3))<+"8=DDLC*N\E78HI
M(5C&QX)YSP3\&]2TW]HKPIXNTGX;WGA/P_;VFI0ZGJ&M:M!>ZK=7,RH5DN)!
M<SO)'\NU#YKL#ORJ+@M7T_X(^-8?V2OAGX+?1=OB71]7TZZOK'[5!^YCBOC+
M(V_?L;"<X5B3T&3Q0!ZMXD_:(TS0YO$\EGX8\1>(=(\,.T>M:QI45L;:RD1
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M:/\ AJ3Q7_T#]'_[\R__ !VO':* /8O^&I/%?_0/T?\ [\R__':/^&I/%?\
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M1D$$$9X(K2KX5_97U.[^ OA'P?XHN;F63X=^.+RYLM6\V3*:3JWVV:&WN?\
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M!+PKXXT'5]+:ZTFUCQJ&B1V^$U,W<> T(_UB/Y@ D9A][<#7T-_PA/CA>GQ
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M..O4 \IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:X_\ 9O_ (F@"'2?V8_"NB?"GPWX%M+W6(H/#<[W>D:U'=+'J-G.SR,9%D5
MA/[UUVLA4J<,K5O^'OA#;:9XNM_%&M>(M:\8Z[9V[VMA=:TUNJV,;G,OE16T
M,,89\*&=E+X4 ,!P<;_AJ#X>?]!:X_\  &;_ .)H_P"&H/AY_P!!:X_\ 9O_
M (F@":Z^ EK:W^N3^&/%_B;P-;:V[3W]AH,MJ8)+A]WF7""XMY6AD?<-QA9
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M^.5E?\-0?#S_ *"UQ_X S?\ Q-'_  U!\//^@M<?^ ,W_P 30!J_\*!\!_\
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M_P#$T?\ #4'P\_Z"UQ_X S?_ !- &K_PH'P'_P! +_R<N/\ XY1_PH'P'_T
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M_P# &;_XF@#U>BO*/^&H/AY_T%KC_P  9O\ XFC_ (:@^'G_ $%KC_P!F_\
MB: /5Z*\H_X:@^'G_06N/_ &;_XFC_AJ#X>?]!:X_P# &;_XF@#U>BO*/^&H
M/AY_T%KC_P  9O\ XFC_ (:@^'G_ $%KC_P!F_\ B: /5Z*\H_X:@^'G_06N
M/_ &;_XFC_AJ#X>?]!:X_P# &;_XF@#U>BO*/^&H/AY_T%KC_P  9O\ XFC_
M (:@^'G_ $%KC_P!F_\ B: /5Z*\H_X:@^'G_06N/_ &;_XFC_AJ#X>?]!:X
M_P# &;_XF@#U>BO*/^&H/AY_T%KC_P  9O\ XFC_ (:@^'G_ $%KC_P!F_\
MB: /5Z*\H_X:@^'G_06N/_ &;_XFC_AJ#X>?]!:X_P# &;_XF@#U>BO*/^&H
M/AY_T%KC_P  9O\ XFC_ (:@^'G_ $%KC_P!F_\ B: /5Z*\H_X:@^'G_06N
M/_ &;_XFC_AJ#X>?]!:X_P# &;_XF@#U>BO*/^&H/AY_T%KC_P  9O\ XFC_
M (:@^'G_ $%KC_P!F_\ B: /5Z*\H_X:@^'G_06N/_ &;_XFC_AJ#X>?]!:X
M_P# &;_XF@#U>BO*/^&H/AY_T%KC_P  9O\ XFC_ (:@^'G_ $%KC_P!F_\
MB: /5Z*\H_X:@^'G_06N/_ &;_XFC_AJ#X>?]!:X_P# &;_XF@#U>BO*/^&H
M/AY_T%KC_P  9O\ XFC_ (:@^'G_ $%KC_P!F_\ B: /5Z*\H_X:@^'G_06N
M/_ &;_XFC_AJ#X>?]!:X_P# &;_XF@#U>BO*/^&H/AY_T%KC_P  9O\ XFC_
M (:@^'G_ $%KC_P!F_\ B: /5Z*\H_X:@^'G_06N/_ &;_XFC_AJ#X>?]!:X
M_P# &;_XF@#U>BO*/^&H/AY_T%KC_P  9O\ XFC_ (:@^'G_ $%KC_P!F_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ&^-?QBC\3^%/"GB5-($,%FOBW7Y; Z5IIM58W%JHM)Q&&?>[7"LK!EQQM%
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M0/,UG2S:/)=S717)N"KK WF2%BCOG(+&@#ZMHKXN^&/PN\.>(O@-\1=3GO\
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M^RKK%[KW[.?P]O\ 4;J:^O9M(A\RXN'+R.0, LQY)P!R>30!ZM1110 4444
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MI9<HHX)1"1WV+Z"NEHH CN+>*Z@D@GC2:&12CQR*&5E(P00>H([57T?1M/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"#.+_XFC_A:GCK_HE5_P#^#.+_ .)KU>B@#RC_ (6IXZ_Z)5?_ /@SB_\
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M_P"B57__ (,XO_B:/^%J>.O^B57_ /X,XO\ XFO5Z* /*/\ A:GCK_HE5_\
M^#.+_P")H_X6IXZ_Z)5?_P#@SB_^)KU>B@#RC_A:GCK_ *)5?_\ @SB_^)H_
MX6IXZ_Z)5?\ _@SB_P#B:]7HH \H_P"%J>.O^B57_P#X,XO_ (FC_A:GCK_H
ME5__ .#.+_XFO5Z* /*/^%J>.O\ HE5__P"#.+_XFC_A:GCK_HE5_P#^#.+_
M .)KU>B@#RC_ (6IXZ_Z)5?_ /@SB_\ B:/^%J>.O^B57_\ X,XO_B:]7HH
M\H_X6IXZ_P"B57__ (,XO_B:/^%J>.O^B57_ /X,XO\ XFO5Z* /*/\ A:GC
MK_HE5_\ ^#.+_P")H_X6IXZ_Z)5?_P#@SB_^)KU>B@#RC_A:GCK_ *)5?_\
M@SB_^)H_X6IXZ_Z)5?\ _@SB_P#B:]7HH \H_P"%J>.O^B57_P#X,XO_ (FC
M_A:GCK_HE5__ .#.+_XFO5Z* /*/^%J>.O\ HE5__P"#.+_XFC_A:GCK_HE5
M_P#^#.+_ .)KU>B@#RC_ (6IXZ_Z)5?_ /@SB_\ B:/^%J>.O^B57_\ X,XO
M_B:]7HH \H_X6IXZ_P"B57__ (,XO_B:/^%J>.O^B57_ /X,XO\ XFO5Z* /
M*/\ A:GCK_HE5_\ ^#.+_P")H_X6IXZ_Z)5?_P#@SB_^)KU>B@#RC_A:GCK_
M *)5?_\ @SB_^)H_X6IXZ_Z)5?\ _@SB_P#B:]7HH \H_P"%J>.O^B57_P#X
M,XO_ (FC_A:GCK_HE5__ .#.+_XFO5Z* /*/^%J>.O\ HE5__P"#.+_XFC_A
M:GCK_HE5_P#^#.+_ .)KU>B@#RC_ (6IXZ_Z)5?_ /@SB_\ B:/^%J>.O^B5
M7_\ X,XO_B:]7HH \H_X6IXZ_P"B57__ (,XO_B:/^%J>.O^B57_ /X,XO\
MXFO5Z* /*/\ A:GCK_HE5_\ ^#.+_P")H_X6IXZ_Z)5?_P#@SB_^)KU>B@#R
MC_A:GCK_ *)5?_\ @SB_^)H_X6IXZ_Z)5?\ _@SB_P#B:[7Q#\0O#?A60QZK
MK%K:S#DP[M\@_P" +EOTK _X7[X#_P"@[_Y)S_\ QN@#)_X6IXZ_Z)5?_P#@
MSB_^)H_X6IXZ_P"B57__ (,XO_B:U?\ A?W@/_H._P#DG<?_ !NC_A?W@/\
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M._@6XD"+KR G^_;3(/S* 5V.DZS8:[:+=:=>07UNW EMY ZY],CO[4 >:_\
M"U/'7_1*K_\ \&<7_P 31_PM3QU_T2J__P#!G%_\37J]% 'E'_"U/'7_ $2J
M_P#_  9Q?_$T?\+4\=?]$JO_ /P9Q?\ Q->KT4 >4?\ "U/'7_1*K_\ \&<7
M_P 31_PM3QU_T2J__P#!G%_\37J]% 'E'_"U/'7_ $2J_P#_  9Q?_$T?\+4
M\=?]$JO_ /P9Q?\ Q->KT4 >4?\ "U/'7_1*K_\ \&<7_P 31_PM3QU_T2J_
M_P#!G%_\37J]% 'E'_"U/'7_ $2J_P#_  9Q?_$T?\+4\=?]$JO_ /P9Q?\
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M $2J_P#_  9Q?_$T?\+4\=?]$JO_ /P9Q?\ Q->KT4 >4?\ "U/'7_1*K_\
M\&<7_P 31_PM3QU_T2J__P#!G%_\37J]% 'E'_"U/'7_ $2J_P#_  9Q?_$T
M?\+4\=?]$JO_ /P9Q?\ Q->KT4 >4?\ "U/'7_1*K_\ \&<7_P 31_PM3QU_
MT2J__P#!G%_\37J]% 'E'_"U/'7_ $2J_P#_  9Q?_$T?\+4\=?]$JO_ /P9
MQ?\ Q->KT4 >4?\ "U/'7_1*K_\ \&<7_P 31_PM3QU_T2J__P#!G%_\37J]
M% 'E'_"U/'7_ $2J_P#_  9Q?_$T?\+4\=?]$JO_ /P9Q?\ Q->KT4 >4?\
M"U/'7_1*K_\ \&<7_P 31_PM3QU_T2J__P#!G%_\37J]% 'E'_"U/'7_ $2J
M_P#_  9Q?_$T?\+4\=?]$JO_ /P9Q?\ Q->KT4 >4?\ "U/'7_1*K_\ \&<7
M_P 31_PM3QU_T2J__P#!G%_\37J]% $=O(\EO&\D9AD906C)!VG'(R.#BBI*
M* "BBB@ HKP76/VDF^$7C#Q+H'Q1%K:;86U/PU?:3;2*NL6N50VJ1N[[KQ)"
M%*A@&#JP"C)K,^)WQL^)_P +?@[X2\2:AH.A3^+=<UR"UDT"-)E2WMY8I91:
M^;YAS<#RPAEQLW,<1D#) /HVBO)?BI\<CX3^!L7CGP[9Q:I>ZIIXN](M[@D1
M/NM7NM[XP2J0QR2%006$>W*YW#E?B1\5/B-X9^ 8^*.E:CX76"/0+759-'O-
M#N96>62-&=1.MZFU<N< QD@#!)ZT ?0E%<A\//\ A,+C3X[[Q/K.B:G%=6\4
ML$.DZ/-8F(L,G<TEU-O'( P%Z=\\5/&%U\0;SQ99Z7X5M]'TK1A:-<W7B#68
M&O5,N[:MM';1SPONQ\YD9MH&  3G !W5%?/UO^T9KEY\-[62+2M-_P"$XN/%
M;^"(\2.^FO?([J]VN#YA@V1R2^7G=QLW9^>N@L/BYK/@_P 1^,?#GCC^S;V^
MT30O^$FM=2TBWDM(;NR&]9%:*264QR1R1D9\Q@RNI^7D4 >PT5X9\ OBMKOQ
M4MM#O;SX@_#_ %2YFT^.^U3PSX?L7-]9%XQ^[:3[?)L*2,JL6BYP1P2".<M_
MVD?$7BC_ (F?AK4/!9-Q?M'H_@;4KI8=;UFS28Q-/',]RBQ-(4F9$,+C"+E_
MF.T ^EJ*** "BBB@ HHHH **** "BBB@ HHHH **\U^ ?Q*U/XI^$=5U35H+
M2WN+77-0TQ%LT94,4$[1H2&9CN(49.<9Z 5R7PY_:<TZX^&__"3^/[NST/S_
M !+>^'K/[%:SNLTD3R^4FT>8V]DA;T!88 R0" >[T5QWAKXO>$_%5GKUS:ZH
MUFN@<ZM%K%K-ILU@IB\T2317*1ND93+!V 4A6P?E.."7]I33?$7Q4^'7AGPR
MSSV/B(7DUT^J:3>64S01VK30S6WGI&'1F7!=0ZX[@D&@#VZBO+=#^/7AA?"^
MF:A?>(5UZ;4KV\M;-=!T"^::X-O(ZRA+-!-,5BVA7EQLR5/R[U%;/_"[O!1\
M%P>*AK:MH]Q=BPA*V\QN9+HN8Q;+;!/.,^\$>4$W\'Y: .YHKQ+XC?M&VFG>
M";?6O!TD%]=IXCT_0[ZSU>RN+:>U\^9$<202"*6-]C[EW#!R#@BNL\1?'SP+
MX5UN]TO4M9DCFL'ACO[F'3[F>ST]I2 @NKJ.-H;?.03YKK@$,< @T >@T5Q'
MB[XS>$_!.I#3]1O+RXOOLOVY[?2=*N]2>&WS@2RBVBD\I"0<,^ VUL9VG"ZQ
M\:/!NBZ3X?U&36/ML'B$%M(BTJUFO[B_41^8S0P0(\CJJ#<Q"X48W8S0!VU%
M<2OQH\%-X#E\9?V_ OAZ%S#)</'(LB3!MI@,)7S1-N^7R=N_<0-N3BN7\&_'
M:/QU\<M0\'Z6A&D67AZ/4IA?:=<V5_%=-<,GEO%.$94,>QAF,$[@02"* /7J
M*** "BBB@ HHKRO]E_XJ:M\;/@?X?\9:Y;V=KJFH2WB2PZ>CI"!#>30+M#LS
M<K$I.6/)/0<4 >J45\W?!?\ ;"T?6_@-\.O&7Q(O+30]>\8SWUI9V6D:?=3)
M<SP3SJ(H8T$KF1DA&U,EG=@J LRK7J.A_'KP'X@\)Z_XEBU]+#2?#\CQ:PVL
MVTVFS:<ZJ&*W$%RD<D1*LI&Y1N# C.10!Z!17@6D_M267C']H+P;X$\.)+_9
MNJ:)J6JW\>MZ+?:9J$?DM;"VDCCN4B8PR>9.-_ELK&)@K HPK6\*_M-^#KCP
M+X1U2Z\2OXNO=?L9+^U;PIX6U.62Z@238]PNGQK<7$,(9E0M(2-S ;LL!0![
M/17GEW^T%X M/A[HGC;_ (2!;KP_KDD<&EM96L]S=7TSL5$$-K&C3O,"'W1+
M&73RY-ZKL;'#^.?VG;,:7\/-1\#S6VIVVN>/;3P?JL.JV5Q;75AO64S1O;R>
M5+!.NR-@)4^ZZMM*LIH ][HKR_5?VF/AQHOB*\T>[U^5'L;]-+O=133+N32[
M.\;9BVGOUB-K#+F2,%))58%T! + &QX\_:&\"_#?5-0T[6M0U%[K3+5;W4AI
M.AW^IIIT#!F62Z>U@D6W4JCL#*5RJEN@S0!Z117!>,/CGX*\#KH/V_5Y;Z?7
MD,VE6>@V%SJ]U>Q!-[3106D<LC1!2"90NP;ERWS#+9/CUX!C^&]CX\'B2WE\
M,7SQPVMS#%))-/.[[%MDMU4S-<;\H8 GFAU92@8$  [^BO$?A3^T5'\6/CIX
MU\):6B_V#H.C:=>C[9IUU8:E%=3RW*R17$-P$>,!(8G56C4E9 V65E->W4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445Y9K7Q8O]'_:%T_P
M1)%9KH$OA>YUV>Y:-S<+)%.L> 0V-FUB2-I.>_:@#U.BO)+/]JSX7W]IIUY%
MXAN%L-31FL+Z;2+V*VO6523%!,T(26;@KY*$R;P4V[QMK8_X: \!Q^%-=\1W
M&M26&EZ#<1VNJ?VAI]S:W%E)(4$8EMY(UE4-YJ$,4Q@YS@$@ ]#HKR^+]I3P
M!-?-IZZAJG]J^5'<1:6WA_41>W,+EPLT%N8/-GB_=/F2-65<<D9&=JQ^-'@S
M5++PC=VFMI/;^+)6@T=T@E/VF159G0C9^[90C@B3:05*GGB@#MJ*XKQ!\9O!
MWA:/Q9)JFLBT3PJEO)K+&VF86JSC,1^5#OW _P &['?%-\*?&CPAXT\0#1-+
MU&X.IO;?;8(;W3KFS^U6^<>=;M-&BSQY(^>(LN"#G!!H [>BO/;'X_>!-2UV
MWTJWUJ1WN;XZ9;WS6%RNGSW8S^XCO3&+=Y,JP"+(264J 2,4GB+X_>!O"NIW
M]EJ6K7$?]G31V]_>P:9=SV5C(^W"7%U'$T,)^="1(Z[0P)P#F@#T.BN=TOX@
M:!K&M>(])MM04:AX=,8U2&>)X?LPDC,B,6=0&4J"=RDKP>>#7)_\-)?#]I-'
MAAU6^O+O6-,CUG3[*ST2^N+FYLW9E69(8X3(5.PG[N0,,< @D ].HKQ3XA?M
M,:/X?\._#O7?#OF^(-(\6:U%8K=6FF7=SLM_G\XA(HRPG!38(6 ?(?Y#Y;@9
MNC_M4Z5IWCCXE:1XL=K*Q\,WT<<$VFZ/>W)BM3;QR--=M$DBPC<S ,_EKA6Z
M[6( /?:*X_Q5\6O"G@]=&^WZFUS-K.6TVUTFTFU&YO$"%VDBAMDDD:,*,F0+
MM&5R1N&<^^^/G@'3?!>F>+;GQ'#'X?U*[6QM[P0RM_I#;L0N@3?&X*,"KA2I
M&#@\4 >@45R?@KXI>'/B!>ZG9:/=W0U'3#']LT_4=/N;"Z@#KN1FAN(TDVL
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M>/=6O-1L[?3YI;R*UN)[M$N%MU4R2)F2-OD4G:VX C)'V310!\6_%#1_$7Q
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M@@4[<YQ@UZ5)\/\ 0YO&T/BR:WN+G7((6@MY+B]GEAME8*',,#.8HG8* 71
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M/^@%_P"3EO\ _'*/^% ^//\ H!?^3EO_ /'* //:*]"_X4#X\_Z 7_DY;_\
MQRC_ (4#X\_Z 7_DY;__ !R@#SVBO0O^% ^//^@%_P"3EO\ _'*/^% ^//\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#H8_#7_@')_A0!ZO17E']B?&/_ *&/PU_X!R?X4?V)\8_^AC\-?^ <G^%
M'J]%>4?V)\8_^AC\-?\ @')_A1_8GQC_ .AC\-?^ <G^% 'J]%>4?V)\8_\
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M?V)\8_\ H8_#7_@')_A1_8GQC_Z&/PU_X!R?X4 >KT5Y1_8GQC_Z&/PU_P"
M<G^%']B?&/\ Z&/PU_X!R?X4 >KT5Y1_8GQC_P"AC\-?^ <G^%']B?&/_H8_
M#7_@')_A0!ZO17E']B?&/_H8_#7_ (!R?X4?V)\8_P#H8_#7_@')_A0!ZO17
ME']B?&/_ *&/PU_X!R?X4?V)\8_^AC\-?^ <G^% 'J]%>4?V)\8_^AC\-?\
M@')_A1_8GQC_ .AC\-?^ <G^% 'J]%>4?V)\8_\ H8_#7_@')_A1_8GQC_Z&
M/PU_X!R?X4 >KT5Y1_8GQC_Z&/PU_P" <G^%']B?&/\ Z&/PU_X!R?X4 >KT
M5Y1_8GQC_P"AC\-?^ <G^%']B?&/_H8_#7_@')_A0!ZO17E']B?&/_H8_#7_
M (!R?X4?V)\8_P#H8_#7_@')_A0!ZO17E']B?&/_ *&/PU_X!R?X4?V)\8_^
MAC\-?^ <G^% 'J]%>4?V)\8_^AC\-?\ @')_A1_8GQC_ .AC\-?^ <G^% 'J
M]%>4?V)\8_\ H8_#7_@')_A1_8GQC_Z&/PU_X!R?X4 >KT5Y1_8GQC_Z&/PU
M_P" <G^%']B?&/\ Z&/PU_X!R?X4 >KT5Y1_8GQC_P"AC\-?^ <G^%']B?&/
M_H8_#7_@')_A0!ZO17E']B?&/_H8_#7_ (!R?X4?V)\8_P#H8_#7_@')_A0!
MZO17E']B?&/_ *&/PU_X!R?X4?V)\8_^AC\-?^ <G^% 'J]%>4?V)\8_^AC\
M-?\ @')_A1_8GQC_ .AC\-?^ <G^% 'J]%>4?V)\8_\ H8_#7_@')_A1_8GQ
MC_Z&/PU_X!R?X4 >KT5Y1_8GQC_Z&/PU_P" <G^%']B?&/\ Z&/PU_X!R?X4
M >KT5Y1_8GQC_P"AC\-?^ <G^%']B?&/_H8_#7_@')_A0!ZO17E']B?&/_H8
M_#7_ (!R?X4?V)\8_P#H8_#7_@')_A0!ZO17E']B?&/_ *&/PU_X!R?X4?V)
M\8_^AC\-?^ <G^% 'J]%>4?V)\8_^AC\-?\ @')_A1_8GQC_ .AC\-?^ <G^
M% 'J]%>4?V)\8_\ H8_#7_@')_A1_8GQC_Z&/PU_X!R?X4 >KT5Y1_8GQC_Z
M&/PU_P" <G^%']B?&/\ Z&/PU_X!R?X4 >KT5Y1_8GQC_P"AC\-?^ <G^%']
MB?&/_H8_#7_@')_A0!ZO17E']B?&/_H8_#7_ (!R?X4?V)\8_P#H8_#7_@')
M_A0!ZO17E']B?&/_ *&/PU_X!R?X4?V)\8_^AC\-?^ <G^% 'J]%>4?V)\8_
M^AC\-?\ @')_A1_8GQC_ .AC\-?^ <G^% 'J]%>4?V)\8_\ H8_#7_@')_A1
M_8GQC_Z&/PU_X!R?X4 >KT5Y1_8GQC_Z&/PU_P" <G^%']B?&/\ Z&/PU_X!
MR?X4 >KT5Y1_8GQC_P"AC\-?^ <G^%']B?&/_H8_#7_@')_A0!ZO17E']B?&
M/_H8_#7_ (!R?X4?V)\8_P#H8_#7_@')_A0!ZO17E']B?&/_ *&/PU_X!R?X
M4?V)\8_^AC\-?^ <G^% 'J]%>4?V)\8_^AC\-?\ @')_A1_8GQC_ .AC\-?^
M <G^% 'J]%>4?V)\8_\ H8_#7_@')_A1_8GQC_Z&/PU_X!R?X4 >KT5Y1_8G
MQC_Z&/PU_P" <G^%']B?&/\ Z&/PU_X!R?X4 >KT5Y1_8GQC_P"AC\-?^ <G
M^%']B?&/_H8_#7_@')_A0!ZO17E']B?&/_H8_#7_ (!R?X4?V)\8_P#H8_#7
M_@')_A0!ZO17E']B?&/_ *&/PU_X!R?X4?V)\8_^AC\-?^ <G^% 'J]%>4?V
M)\8_^AC\-?\ @')_A1_8GQC_ .AC\-?^ <G^% 'J]%>4?V)\8_\ H8_#7_@'
M)_A1_8GQC_Z&/PU_X!R?X4 >KT5Y1_8GQC_Z&/PU_P" <G^%']B?&/\ Z&/P
MU_X!R?X4 >KT5Y1_8GQC_P"AC\-?^ <G^%']B?&/_H8_#7_@')_A0!ZO17E'
M]B?&/_H8_#7_ (!R?X4?V)\8_P#H8_#7_@')_A0!ZO17E']B?&/_ *&/PU_X
M!R?X4?V)\8_^AC\-?^ <G^% 'J]%>4?V)\8_^AC\-?\ @')_A1_8GQC_ .AC
M\-?^ <G^% 'J]%>4?V)\8_\ H8_#7_@')_A1_8GQC_Z&/PU_X!R?X4 >KT5Y
M1_8GQC_Z&/PU_P" <G^%']B?&/\ Z&/PU_X!R?X4 >KT5Y1_8GQC_P"AC\-?
M^ <G^%']B?&/_H8_#7_@')_A0!ZO17E']B?&/_H8_#7_ (!R?X4?V)\8_P#H
M8_#7_@')_A0!ZO17E']B?&/_ *&/PU_X!R?X4?V)\8_^AC\-?^ <G^% 'J]%
M>4?V)\8_^AC\-?\ @')_A1_8GQC_ .AC\-?^ <G^% 'J]%,A\P0QB8JTNT;R
M@(4MCG /;-% #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M('A;PK<>'7\+^,+^YOEU'4IYTN](-X<7:I;I$R7(7+/&#+%\S;6X&: -:_\
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MOQ7_ -!#1_\ O]+_ /&J/^&6_%?_ $$-'_[_ $O_ ,:KZDHH ^6_^&6_%?\
MT$-'_P"_TO\ \:H_X9;\5_\ 00T?_O\ 2_\ QJOJ2B@#Y;_X9;\5_P#00T?_
M +_2_P#QJC_AEOQ7_P!!#1_^_P!+_P#&J^I** /EO_AEOQ7_ -!#1_\ O]+_
M /&J/^&6_%?_ $$-'_[_ $O_ ,:KZDHH ^74_9:\4EAOU'2%7N5EE)_]%UZ+
MX _9UTGPM=Q7^JS_ -LWL>&2-H]L,;>NW)W'Z_E7KM% !1110 4444 %%%%
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MIL%U =!UFXT.Z^U(J[YX0A9DVL<H=XP3@]>!754 >4?\*!_ZJ#XW_P#!O_\
M84?\*!_ZJ#XW_P#!O_\ 85ZO10!Y1_PH'_JH/C?_ ,&__P!A1_PH'_JH/C?_
M ,&__P!A7J]>=>)OCIX>\+6WQ"FN(;^X'@:VANM42WB4EA+#YRK%N<!FV8)R
M0.0,]< &;_PH'_JH/C?_ ,&__P!A1_PH'_JH/C?_ ,&__P!A7IFDZE%K6DV6
MH0*ZPW<"3HL@ 8*RA@#@GG!JW0!Y1_PH'_JH/C?_ ,&__P!A1_PH'_JH/C?_
M ,&__P!A7J]% 'E'_"@?^J@^-_\ P;__ &%'_"@?^J@^-_\ P;__ &%>KT4
M>4?\*!_ZJ#XW_P#!O_\ 84?\*!_ZJ#XW_P#!O_\ 85ZO10!Y1_PH'_JH/C?_
M ,&__P!A1_PH'_JH/C?_ ,&__P!A7J](S!%+,0J@9)/04 >4_P#"@?\ JH/C
M?_P;_P#V%'_"@?\ JH/C?_P;_P#V%=%J7QF\%:3.T-QX@MV=>OV=7F'YHI%4
MO^%_> _^@[_Y)W'_ ,;H RO^% _]5!\;_P#@W_\ L*/^% _]5!\;_P#@W_\
ML*U?^%_> _\ H._^2=Q_\;H_X7]X#_Z#O_DG<?\ QN@#*_X4#_U4'QO_ .#?
M_P"PH_X4#_U4'QO_ .#?_P"PK6_X7[X#_P"@[_Y)S_\ QNNC\.^//#_BS(TG
M5K:\DZ^4K;9,>NPX;'X4 <-_PH'_ *J#XW_\&_\ ]A1_PH'_ *J#XW_\&_\
M]A7J]% 'E'_"@?\ JH/C?_P;_P#V%'_"@?\ JH/C?_P;_P#V%>KT4 >4?\*!
M_P"J@^-__!O_ /84?\*!_P"J@^-__!O_ /85ZO10!Y1_PH'_ *J#XW_\&_\
M]A1_PH'_ *J#XW_\&_\ ]A7J]% 'E'_"@?\ JH/C?_P;_P#V%'_"@?\ JH/C
M?_P;_P#V%>KT4 >4?\*!_P"J@^-__!O_ /84?\*!_P"J@^-__!O_ /85ZO10
M!Y1_PH'_ *J#XW_\&_\ ]A1_PH'_ *J#XW_\&_\ ]A7J]% 'E'_"@?\ JH/C
M?_P;_P#V%'_"@?\ JH/C?_P;_P#V%>KT4 >4?\*!_P"J@^-__!O_ /84?\*!
M_P"J@^-__!O_ /85ZO10!Y1_PH'_ *J#XW_\&_\ ]A1_PH'_ *J#XW_\&_\
M]A7J]% 'E'_"@?\ JH/C?_P;_P#V%'_"@?\ JH/C?_P;_P#V%>KT4 >4?\*!
M_P"J@^-__!O_ /84?\*!_P"J@^-__!O_ /85ZO10!Y1_PH'_ *J#XW_\&_\
M]A1_PH'_ *J#XW_\&_\ ]A7J]% 'E'_"@?\ JH/C?_P;_P#V%'_"@?\ JH/C
M?_P;_P#V%>KT4 >4?\*!_P"J@^-__!O_ /84?\*!_P"J@^-__!O_ /85ZO10
M!Y1_PH'_ *J#XW_\&_\ ]A1_PH'_ *J#XW_\&_\ ]A7J]% 'E'_"@?\ JH/C
M?_P;_P#V%'_"@?\ JH/C?_P;_P#V%>KT4 >4?\*!_P"J@^-__!O_ /84?\*!
M_P"J@^-__!O_ /85ZO10!Y1_PH'_ *J#XW_\&_\ ]A1_PH'_ *J#XW_\&_\
M]A7J]% 'E'_"@?\ JH/C?_P;_P#V%'_"@?\ JH/C?_P;_P#V%>KT4 >4?\*!
M_P"J@^-__!O_ /84?\*!_P"J@^-__!O_ /85ZO10!Y1_PH'_ *J#XW_\&_\
M]A1_PH'_ *J#XW_\&_\ ]A7J]% 'E'_"@?\ JH/C?_P;_P#V%'_"@?\ JH/C
M?_P;_P#V%>KT4 >4?\*!_P"J@^-__!O_ /84?\*!_P"J@^-__!O_ /85ZO10
M!Y1_PH'_ *J#XW_\&_\ ]A1_PH'_ *J#XW_\&_\ ]A7J]% 'E'_"@?\ JH/C
M?_P;_P#V%'_"@?\ JH/C?_P;_P#V%>KT4 >4?\*!_P"J@^-__!O_ /84?\*!
M_P"J@^-__!O_ /85ZO10!Y1_PH'_ *J#XW_\&_\ ]A1_PH'_ *J#XW_\&_\
M]A7J]% 'E'_"@?\ JH/C?_P;_P#V%'_"@?\ JH/C?_P;_P#V%>KT4 >4?\*!
M_P"J@^-__!O_ /84?\*!_P"J@^-__!O_ /85ZO10!Y1_PH'_ *J#XW_\&_\
M]A1_PH'_ *J#XW_\&_\ ]A7J]% 'E'_"@?\ JH/C?_P;_P#V%'_"@?\ JH/C
M?_P;_P#V%>KT4 >4?\*!_P"J@^-__!O_ /84?\*!_P"J@^-__!O_ /85ZO10
M!Y1_PH'_ *J#XW_\&_\ ]A1_PH'_ *J#XW_\&_\ ]A7J]% 'E'_"@?\ JH/C
M?_P;_P#V%'_"@?\ JH/C?_P;_P#V%>KT4 >4?\*!_P"J@^-__!O_ /84?\*!
M_P"J@^-__!O_ /85ZO10!Y1_PH'_ *J#XW_\&_\ ]A1_PH'_ *J#XW_\&_\
M]A7J]% 'E'_"@?\ JH/C?_P;_P#V%'_"@?\ JH/C?_P;_P#V%>KT4 >4?\*!
M_P"J@^-__!O_ /84?\*!_P"J@^-__!O_ /85ZO10!%:P_9;:*'S))?+0)YDK
M;G; QDGN314M% !1110 45\>_ O4KGPC^TAXZO)+F;^QO%'C/6-!DB9V$,=[
M#;6MU;-C[H9HQ>+V)P@&>E2^$?%%[J7[3^K>.A*T\>H^ =5O]+AG9FBCLX;^
MWBM]HSPLBP^><=YS^ !]>T5X-I_QY\077PA^#?BI[/31J'C+5M,L=0C6*3RH
MH[E7,AB&_*L-HQN+#U!KQ/6&UW['XKCT74[73A-\>;2*475I).LCE[!H2P6:
M/*+(JLR'[V!AD(W4 ?<M%?+7CCXW>(_ /BCXI+H?AWPS=Z_INK>&=-%S]CDM
MWU-KR-%8SNKECMW%8SSL4X(?'/6ZQ\0/%^@>(=2\"^-FT74GUCPQ?:EINJ:'
M:2VB+) H6>"2*2:4G D1ED##/(*@T >\45\9_"CX_?\ "(_#WX2>!;3Q+X2\
M&R'PA;ZQ>ZYXOEW0K&Q:**"&$3P%Y69&8DR *J]"6%?0'P!^+R_&/P;?7[OI
MLU_I.I3:/>W.C7'GV-S-$%/GV[Y)\J171U!)*[MI+8W$ ],HKY)EM/A_=?M1
M_&/_ (3CP9_PEC+#HGV1O^$2N-<\@?97W\Q6\OE;OEZ[=VWC.TXK:3XJ\8?
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M^+M)\4>'_P!I:V\;:?X.U3Q1H;>$6T9FTFYL4DCN#>";!6YN(?EV+U&>2/?
M!+X;\?ZUX"^+^J^ O%VO?V]I;Z&WB/3=>O8(H+B*&.01W$-QY*)$VTE75U1/
ME)!R>:T=!_:,T76KKP[)/H'B#1=!\23?9]#\0ZE;PI9:B[<PA0LK31><H+1^
M=''N&.Y /+77PE\0_&+QAXQ\3^)M/D\'VU]X5N?".CZ9-<Q3W4<<Y8SW4YA=
MHU8G8%1)'^52203BLN/P-X]\<>%/AEX$UOP>=!@\*:CI]WJNO-?VTME>)8,
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MRX\ :9J7@?6;&?P_?6]WJ.K:]XUO-1TLFU(V/8VR7Q8NY 9/.A1(UW!E;[I
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M  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B_ /_ $*NG_\ ?L_XT?\ "B_
M/_0JZ?\ ]^S_ (T ;W_"=^&O^AATK_P-B_\ BJ/^$[\-?]##I7_@;%_\56#_
M ,*+\ _]"KI__?L_XT?\*+\ _P#0JZ?_ -^S_C0!O?\ "=^&O^AATK_P-B_^
M*H_X3OPU_P!##I7_ (&Q?_%5@_\ "B_ /_0JZ?\ ]^S_ (T?\*+\ _\ 0JZ?
M_P!^S_C0!O?\)WX:_P"AATK_ ,#8O_BJ/^$[\-?]##I7_@;%_P#%5@_\*+\
M_P#0JZ?_ -^S_C1_PHOP#_T*NG_]^S_C0!O?\)WX:_Z&'2O_  -B_P#BJ/\
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M^AATK_P-B_\ BJ/^$[\-?]##I7_@;%_\56#_ ,*+\ _]"KI__?L_XT?\*+\
M_P#0JZ?_ -^S_C0!O?\ "=^&O^AATK_P-B_^*H_X3OPU_P!##I7_ (&Q?_%5
M@_\ "B_ /_0JZ?\ ]^S_ (T?\*+\ _\ 0JZ?_P!^S_C0!O?\)WX:_P"AATK_
M ,#8O_BJ/^$[\-?]##I7_@;%_P#%5@_\*+\ _P#0JZ?_ -^S_C1_PHOP#_T*
MNG_]^S_C0!O?\)WX:_Z&'2O_  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B
M_ /_ $*NG_\ ?L_XT?\ "B_ /_0JZ?\ ]^S_ (T ;W_"=^&O^AATK_P-B_\
MBJ/^$[\-?]##I7_@;%_\56#_ ,*+\ _]"KI__?L_XT?\*+\ _P#0JZ?_ -^S
M_C0!O?\ "=^&O^AATK_P-B_^*H_X3OPU_P!##I7_ (&Q?_%5@_\ "B_ /_0J
MZ?\ ]^S_ (T?\*+\ _\ 0JZ?_P!^S_C0!O?\)WX:_P"AATK_ ,#8O_BJ/^$[
M\-?]##I7_@;%_P#%5@_\*+\ _P#0JZ?_ -^S_C1_PHOP#_T*NG_]^S_C0!O?
M\)WX:_Z&'2O_  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B_ /_ $*NG_\
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M  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B_ /_ $*NG_\ ?L_XT?\ "B_
M/_0JZ?\ ]^S_ (T ;W_"=^&O^AATK_P-B_\ BJ/^$[\-?]##I7_@;%_\56#_
M ,*+\ _]"KI__?L_XT?\*+\ _P#0JZ?_ -^S_C0!O?\ "=^&O^AATK_P-B_^
M*H_X3OPU_P!##I7_ (&Q?_%5@_\ "B_ /_0JZ?\ ]^S_ (T?\*+\ _\ 0JZ?
M_P!^S_C0!O?\)WX:_P"AATK_ ,#8O_BJ/^$[\-?]##I7_@;%_P#%5@_\*+\
M_P#0JZ?_ -^S_C1_PHOP#_T*NG_]^S_C0!O?\)WX:_Z&'2O_  -B_P#BJ/\
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M^AATK_P-B_\ BJ/^$[\-?]##I7_@;%_\56#_ ,*+\ _]"KI__?L_XT?\*+\
M_P#0JZ?_ -^S_C0!O?\ "=^&O^AATK_P-B_^*H_X3OPU_P!##I7_ (&Q?_%5
M@_\ "B_ /_0JZ?\ ]^S_ (T?\*+\ _\ 0JZ?_P!^S_C0!O?\)WX:_P"AATK_
M ,#8O_BJ/^$[\-?]##I7_@;%_P#%5@_\*+\ _P#0JZ?_ -^S_C1_PHOP#_T*
MNG_]^S_C0!O?\)WX:_Z&'2O_  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B
M_ /_ $*NG_\ ?L_XT?\ "B_ /_0JZ?\ ]^S_ (T ;W_"=^&O^AATK_P-B_\
MBJ/^$[\-?]##I7_@;%_\56#_ ,*+\ _]"KI__?L_XT?\*+\ _P#0JZ?_ -^S
M_C0!O?\ "=^&O^AATK_P-B_^*H_X3OPU_P!##I7_ (&Q?_%5@_\ "B_ /_0J
MZ?\ ]^S_ (T?\*+\ _\ 0JZ?_P!^S_C0!O?\)WX:_P"AATK_ ,#8O_BJ/^$[
M\-?]##I7_@;%_P#%5@_\*+\ _P#0JZ?_ -^S_C1_PHOP#_T*NG_]^S_C0!O?
M\)WX:_Z&'2O_  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B_ /_ $*NG_\
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M  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B_ /_ $*NG_\ ?L_XT?\ "B_
M/_0JZ?\ ]^S_ (T ;W_"=^&O^AATK_P-B_\ BJ/^$[\-?]##I7_@;%_\56#_
M ,*+\ _]"KI__?L_XT?\*+\ _P#0JZ?_ -^S_C0!O?\ "=^&O^AATK_P-B_^
M*H_X3OPU_P!##I7_ (&Q?_%5@_\ "B_ /_0JZ?\ ]^S_ (T?\*+\ _\ 0JZ?
M_P!^S_C0!O?\)WX:_P"AATK_ ,#8O_BJ/^$[\-?]##I7_@;%_P#%5@_\*+\
M_P#0JZ?_ -^S_C1_PHOP#_T*NG_]^S_C0!O?\)WX:_Z&'2O_  -B_P#BJ/\
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M^AATK_P-B_\ BJ/^$[\-?]##I7_@;%_\56#_ ,*+\ _]"KI__?L_XT?\*+\
M_P#0JZ?_ -^S_C0!O?\ "=^&O^AATK_P-B_^*H_X3OPU_P!##I7_ (&Q?_%5
M@_\ "B_ /_0JZ?\ ]^S_ (T?\*+\ _\ 0JZ?_P!^S_C0!O?\)WX:_P"AATK_
M ,#8O_BJ/^$[\-?]##I7_@;%_P#%5@_\*+\ _P#0JZ?_ -^S_C1_PHOP#_T*
MNG_]^S_C0!O?\)WX:_Z&'2O_  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B
M_ /_ $*NG_\ ?L_XT?\ "B_ /_0JZ?\ ]^S_ (T ;W_"=^&O^AATK_P-B_\
MBJ/^$[\-?]##I7_@;%_\56#_ ,*+\ _]"KI__?L_XT?\*+\ _P#0JZ?_ -^S
M_C0!O?\ "=^&O^AATK_P-B_^*H_X3OPU_P!##I7_ (&Q?_%5@_\ "B_ /_0J
MZ?\ ]^S_ (T?\*+\ _\ 0JZ?_P!^S_C0!O?\)WX:_P"AATK_ ,#8O_BJ/^$[
M\-?]##I7_@;%_P#%5@_\*+\ _P#0JZ?_ -^S_C1_PHOP#_T*NG_]^S_C0!O?
M\)WX:_Z&'2O_  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B_ /_ $*NG_\
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M  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B_ /_ $*NG_\ ?L_XT?\ "B_
M/_0JZ?\ ]^S_ (T ;W_"=^&O^AATK_P-B_\ BJ/^$[\-?]##I7_@;%_\56#_
M ,*+\ _]"KI__?L_XT?\*+\ _P#0JZ?_ -^S_C0!O?\ "=^&O^AATK_P-B_^
M*H_X3OPU_P!##I7_ (&Q?_%5@_\ "B_ /_0JZ?\ ]^S_ (T?\*+\ _\ 0JZ?
M_P!^S_C0!O?\)WX:_P"AATK_ ,#8O_BJ/^$[\-?]##I7_@;%_P#%5@_\*+\
M_P#0JZ?_ -^S_C1_PHOP#_T*NG_]^S_C0!O?\)WX:_Z&'2O_  -B_P#BJ/\
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M^AATK_P-B_\ BJ/^$[\-?]##I7_@;%_\56#_ ,*+\ _]"KI__?L_XT?\*+\
M_P#0JZ?_ -^S_C0!O?\ "=^&O^AATK_P-B_^*H_X3OPU_P!##I7_ (&Q?_%5
M@_\ "B_ /_0JZ?\ ]^S_ (T?\*+\ _\ 0JZ?_P!^S_C0!O?\)WX:_P"AATK_
M ,#8O_BJ/^$[\-?]##I7_@;%_P#%5@_\*+\ _P#0JZ?_ -^S_C1_PHOP#_T*
MNG_]^S_C0!O?\)WX:_Z&'2O_  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B
M_ /_ $*NG_\ ?L_XT?\ "B_ /_0JZ?\ ]^S_ (T ;W_"=^&O^AATK_P-B_\
MBJ/^$[\-?]##I7_@;%_\56#_ ,*+\ _]"KI__?L_XT?\*+\ _P#0JZ?_ -^S
M_C0!O?\ "=^&O^AATK_P-B_^*H_X3OPU_P!##I7_ (&Q?_%5@_\ "B_ /_0J
MZ?\ ]^S_ (T?\*+\ _\ 0JZ?_P!^S_C0!O?\)WX:_P"AATK_ ,#8O_BJ/^$[
M\-?]##I7_@;%_P#%5@_\*+\ _P#0JZ?_ -^S_C1_PHOP#_T*NG_]^S_C0!O?
M\)WX:_Z&'2O_  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B_ /_ $*NG_\
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M  -B_P#BJ/\ A._#7_0PZ5_X&Q?_ !58/_"B_ /_ $*NG_\ ?L_XT?\ "B_
M/_0JZ?\ ]^S_ (T ;W_"=^&O^AATK_P-B_\ BJ/^$[\-?]##I7_@;%_\56#_
M ,*+\ _]"KI__?L_XT?\*+\ _P#0JZ?_ -^S_C0!O?\ "=^&O^AATK_P-B_^
M*H_X3OPU_P!##I7_ (&Q?_%5@_\ "B_ /_0JZ?\ ]^S_ (T?\*+\ _\ 0JZ?
M_P!^S_C0!O?\)WX:_P"AATK_ ,#8O_BJ/^$[\-?]##I7_@;%_P#%5@_\*+\
M_P#0JZ?_ -^S_C1_PHOP#_T*NG_]^S_C0!O?\)WX:_Z&'2O_  -B_P#BJ/\
MA._#7_0PZ5_X&Q?_ !58/_"B_ /_ $*NG_\ ?L_XT?\ "B_ /_0JZ?\ ]^S_
M (T ;W_"=^&O^AATK_P-B_\ BJ/^$[\-?]##I7_@;%_\56#_ ,*+\ _]"KI_
M_?L_XT?\*+\ _P#0JZ?_ -^S_C0!W2L&4,IR#R"**;%&D,:1QHL<: *J*,!0
M.@ ]** 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-_:5I_S]0_\ ?P?XT?VE:?\ /U#_ -_!_C7G/_#-'PV_Z%L?^!MS_P#'*/\
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M-_:5I_S]0_\ ?P?XT?VE:?\ /U#_ -_!_C7G/_#-'PV_Z%L?^!MS_P#'*/\
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M-_:5I_S]0_\ ?P?XT?VE:?\ /U#_ -_!_C7G/_#-'PV_Z%L?^!MS_P#'*/\
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M-_:5I_S]0_\ ?P?XT?VE:?\ /U#_ -_!_C7G/_#-'PV_Z%L?^!MS_P#'*/\
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M-_:5I_S]0_\ ?P?XT?VE:?\ /U#_ -_!_C7G/_#-'PV_Z%L?^!MS_P#'*/\
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M-_:5I_S]0_\ ?P?XT?VE:?\ /U#_ -_!_C7G/_#-'PV_Z%L?^!MS_P#'*/\
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M-_:5I_S]0_\ ?P?XT?VE:?\ /U#_ -_!_C7G/_#-'PV_Z%L?^!MS_P#'*/\
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M-_:5I_S]0_\ ?P?XT?VE:?\ /U#_ -_!_C7G/_#-'PV_Z%L?^!MS_P#'*/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ[XI%*.OJ",$5\0_$#P/>^ ?$EQIMTC&(,6M[@CY9H\\,/?U'8YH YNBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OHS]E&\FDT[Q':L3]
MGBE@E0=MS!PWZ(M?.L<;2R*B*7=CA549))Z "OK[X%^ YO _@_\ TU/+U*^?
MSYDSS&,81#[@9)]R: /1J*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (2FE9TNM6@4](XYXR!_WU&3^M1_\,M^%/\ H(:Q_P!_HO\ XU7L5% 'CO\
MPRWX4_Z"&L?]_HO_ (U1_P ,M^%/^@AK'_?Z+_XU7L5% 'CO_#+?A3_H(:Q_
MW^B_^-4?\,M^%/\ H(:Q_P!_HO\ XU7L5% 'CO\ PRWX4_Z"&L?]_HO_ (U1
M_P ,M^%/^@AK'_?Z+_XU7L5% 'CO_#+?A3_H(:Q_W^B_^-4?\,M^%/\ H(:Q
M_P!_HO\ XU7L5% 'CO\ PRWX4_Z"&L?]_HO_ (U1_P ,M^%/^@AK'_?Z+_XU
M7L5% 'CO_#+?A3_H(:Q_W^B_^-4?\,M^%/\ H(:Q_P!_HO\ XU7L5% 'CO\
MPRWX4_Z"&L?]_HO_ (U1_P ,M^%/^@AK'_?Z+_XU7L5% 'CO_#+?A3_H(:Q_
MW^B_^-4?\,M^%/\ H(:Q_P!_HO\ XU7L5% '$^#_ (.^%_!5PMS96)GO5^[=
M7;>8Z_3L#[@ UVU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS\2_^BK-_P""&#_XJC_A7/Q+_P"BK-_X(8/_ (JO5Z* /*/^%<_$O_HJS?\
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M@_\ BJ]7HH \H_X5S\2_^BK-_P""&#_XJC_A7/Q+_P"BK-_X(8/_ (JO5Z*
M/*/^%<_$O_HJS?\ @A@_^*H_X5S\2_\ HJS?^"&#_P"*KU>B@#RC_A7/Q+_Z
M*LW_ ((8/_BJ/^%<_$O_ **LW_@A@_\ BJ]7HH \H_X5S\2_^BK-_P""&#_X
MJC_A7/Q+_P"BK-_X(8/_ (JO5Z* /*/^%<_$O_HJS?\ @A@_^*H_X5S\2_\
MHJS?^"&#_P"*KU>B@#RC_A7/Q+_Z*LW_ ((8/_BJ/^%<_$O_ **LW_@A@_\
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MS\2_^BK-_P""&#_XJC_A7/Q+_P"BK-_X(8/_ (JO5Z* /*/^%<_$O_HJS?\
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M@_\ BJ]7HH \H_X5S\2_^BK-_P""&#_XJC_A7/Q+_P"BK-_X(8/_ (JO5Z*
M/*/^%<_$O_HJS?\ @A@_^*H_X5S\2_\ HJS?^"&#_P"*KU>B@#RC_A7/Q+_Z
M*LW_ ((8/_BJ/^%<_$O_ **LW_@A@_\ BJ]7HH \H_X5S\2_^BK-_P""&#_X
MJC_A7/Q+_P"BK-_X(8/_ (JO5Z* /*/^%<_$O_HJS?\ @A@_^*H_X5S\2_\
MHJS?^"&#_P"*KU>B@#RC_A7/Q+_Z*LW_ ((8/_BJ/^%<_$O_ **LW_@A@_\
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M ]EHKS+Q-\6M7A\:Z1X-\->%5U3Q/=:9_;-[!J^HBQM]-M2QC7S98HY]TC2
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M^$* );J\GO96EN)Y)Y&.2\KEB?Q-0T44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 /AFDMY \3M&XZ,A((_&O5/A
M?\=]6\+ZA!::U=S:GHSD(QG8O+ /[RL>2!_=/8<8KRBB@#] X9H[B&.6)UDB
MD4,CJ<A@1D$4^N&^"-Y-??"OP_).276)XAG^ZDC(O_CJBNYH **** "BBB@
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M&^L9KOQI<_%)O'.CQ_$ZWU9;?3[$SW?]D0Z&,HUM(WD[C X:25KWR_+$H&"
MK5#XP\-V'B+6/'-Y%XKT.!=<\8Z)K4*R-<YBMK-(A+(_[GB(F-MLXS">\BX.
M/L0:79KC%I ,0_9Q^[7B+^YT^[[=*!I=FN,6D Q#]G'[M>(O[G3[OMTH \=T
M/4-(\2?M))XHT[7+&YMY/#C:"EBOFBZ>5;DW'GJI0*UN44@3!BK-\H)->V57
MBL+6WDCDBMH8Y(X_)1E0 K&.B ]EX''2K% !1110 4444 %%%% $=Q;QW=O+
M!*N^*12CKZ@C!%?$/Q \#WO@'Q)<:;=(QB#%K>X(^6://##W]1V.:^XJRO$7
MA?2?%M@;/5[&*^M\Y"R @J?56'*GW!% 'P=17U1<?LO^$II6=+K5H%/2..>,
M@?\ ?49/ZU'_ ,,M^%/^@AK'_?Z+_P"-4 ?+=%?4G_#+?A3_ *"&L?\ ?Z+_
M .-4?\,M^%/^@AK'_?Z+_P"-4 ?+=%?4G_#+?A3_ *"&L?\ ?Z+_ .-4?\,M
M^%/^@AK'_?Z+_P"-4 ?+=%?4G_#+?A3_ *"&L?\ ?Z+_ .-4?\,M^%/^@AK'
M_?Z+_P"-4 ?+=%?4G_#+?A3_ *"&L?\ ?Z+_ .-4?\,M^%/^@AK'_?Z+_P"-
M4 ?+=%?4G_#+?A3_ *"&L?\ ?Z+_ .-4?\,M^%/^@AK'_?Z+_P"-4 ?+=%?4
MG_#+?A3_ *"&L?\ ?Z+_ .-4?\,M^%/^@AK'_?Z+_P"-4 ?+=%?4G_#+?A3_
M *"&L?\ ?Z+_ .-4?\,M^%/^@AK'_?Z+_P"-4 ?+=%?4G_#+?A3_ *"&L?\
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M_!C)_C1_PS/X,]=5_P#!C)_C0!ZO17E'_#,_@SUU7_P8R?XT?\,S^#/75?\
MP8R?XT >KT5Y1_PS/X,]=5_\&,G^-'_#,_@SUU7_ ,&,G^- 'J]%>4?\,S^#
M/75?_!C)_C1_PS/X,]=5_P#!C)_C0!ZO17E'_#,_@SUU7_P8R?XT?\,S^#/7
M5?\ P8R?XT >KT5Y1_PS/X,]=5_\&,G^-'_#,_@SUU7_ ,&,G^- 'J]%>4?\
M,S^#/75?_!C)_C1_PS/X,]=5_P#!C)_C0!ZO17E'_#,_@SUU7_P8R?XT?\,S
M^#/75?\ P8R?XT >KT5Y1_PS/X,]=5_\&,G^-'_#,_@SUU7_ ,&,G^- 'J]%
M>4?\,S^#/75?_!C)_C1_PS/X,]=5_P#!C)_C0!ZO17E'_#,_@SUU7_P8R?XT
M?\,S^#/75?\ P8R?XT >KT5Y1_PS/X,]=5_\&,G^-'_#,_@SUU7_ ,&,G^-
M'J]%>4?\,S^#/75?_!C)_C1_PS/X,]=5_P#!C)_C0!ZO17E'_#,_@SUU7_P8
MR?XT?\,S^#/75?\ P8R?XT >KT5Y1_PS/X,]=5_\&,G^-'_#,_@SUU7_ ,&,
MG^- 'J]%>4?\,S^#/75?_!C)_C1_PS/X,]=5_P#!C)_C0!ZO17E'_#,_@SUU
M7_P8R?XT?\,S^#/75?\ P8R?XT >KT5Y1_PS/X,]=5_\&,G^-'_#,_@SUU7_
M ,&,G^- 'J]%>4?\,S^#/75?_!C)_C1_PS/X,]=5_P#!C)_C0!ZO17E'_#,_
M@SUU7_P8R?XT?\,S^#/75?\ P8R?XT >KT5Y1_PS/X,]=5_\&,G^-'_#,_@S
MUU7_ ,&,G^- 'J]%>4?\,S^#/75?_!C)_C1_PS/X,]=5_P#!C)_C0!ZO17E'
M_#,_@SUU7_P8R?XT?\,S^#/75?\ P8R?XT >KT5Y1_PS/X,]=5_\&,G^-'_#
M,_@SUU7_ ,&,G^- 'J]%>4?\,S^#/75?_!C)_C1_PS/X,]=5_P#!C)_C0!ZO
M17E'_#,_@SUU7_P8R?XT?\,S^#/75?\ P8R?XT >KT5Y1_PS/X,]=5_\&,G^
M-'_#,_@SUU7_ ,&,G^- 'J]%>4?\,S^#/75?_!C)_C1_PS/X,]=5_P#!C)_C
M0!ZO17E'_#,_@SUU7_P8R?XT?\,S^#/75?\ P8R?XT >KT5Y1_PS/X,]=5_\
M&,G^-'_#,_@SUU7_ ,&,G^- 'J]%>4?\,S^#/75?_!C)_C1_PS/X,]=5_P#!
MC)_C0!ZO17E'_#,_@SUU7_P8R?XT?\,S^#/75?\ P8R?XT >KT5Y1_PS/X,]
M=5_\&,G^-'_#,_@SUU7_ ,&,G^- 'J]%>4?\,S^#/75?_!C)_C1_PS/X,]=5
M_P#!C)_C0!ZO17E'_#,_@SUU7_P8R?XT?\,S^#/75?\ P8R?XT >KT5Y1_PS
M/X,]=5_\&,G^-'_#,_@SUU7_ ,&,G^- 'J]%>4?\,S^#/75?_!C)_C1_PS/X
M,]=5_P#!C)_C0!ZO17E'_#,_@SUU7_P8R?XT?\,S^#/75?\ P8R?XT >KT5Y
M1_PS/X,]=5_\&,G^-'_#,_@SUU7_ ,&,G^- 'J]%>4?\,S^#/75?_!C)_C1_
MPS/X,]=5_P#!C)_C0!ZO17E'_#,_@SUU7_P8R?XT?\,S^#/75?\ P8R?XT >
MKT5Y1_PS/X,]=5_\&,G^-'_#,_@SUU7_ ,&,G^- 'J]%>4?\,S^#/75?_!C)
M_C1_PS/X,]=5_P#!C)_C0!ZO17E'_#,_@SUU7_P8R?XT?\,S^#/75?\ P8R?
MXT >KT5Y1_PS/X,]=5_\&,G^-'_#,_@SUU7_ ,&,G^- 'J]%>4?\,S^#/75?
M_!C)_C1_PS/X,]=5_P#!C)_C0!ZO17E'_#,_@SUU7_P8R?XT?\,S^#/75?\
MP8R?XT >KT5Y1_PS/X,]=5_\&,G^-'_#,_@SUU7_ ,&,G^- 'J]%>4?\,S^#
M/75?_!C)_C1_PS/X,]=5_P#!C)_C0!ZO17E'_#,_@SUU7_P8R?XT?\,S^#/7
M5?\ P8R?XT >KT5Y1_PS/X,]=5_\&,G^-'_#,_@SUU7_ ,&,G^- 'J]%>4?\
M,S^#/75?_!C)_C1_PS/X,]=5_P#!C)_C0!ZO17E'_#,_@SUU7_P8R?XT?\,S
M^#/75?\ P8R?XT >KT5Y1_PS/X,]=5_\&,G^-'_#,_@SUU7_ ,&,G^- 'J]%
M>4?\,S^#/75?_!C)_C1_PS/X,]=5_P#!C)_C0!ZO17E'_#,_@SUU7_P8R?XT
M?\,S^#/75?\ P8R?XT >KT5Y1_PS/X,]=5_\&,G^-'_#,_@SUU7_ ,&,G^-
M'J]%1PPK;PQQ)D)&H5=Q). ,#D\G\:* )**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;SRQ2V6QWC!VLRB1L,1D;CCJ:\L$_P 3_'_@?XPQ>#]0O_$-]H_Q1NXWT?\
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ME_MN?%-_!GAS0_$<Q\):$;B+6M=FTS:!+>[?+,=I<;R3D'=L P.3GCZ2\*^
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MG)9[BU\N0OL+K'$,_6_P6\47OC;X.>!/$6IN)-1U?0;#4+EU4*&EEMXY'.
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MWTJ_FOM1OU_M:X3[+:R7=VD=I++$)-]WO5Q@R%FD"D>B_L[>)/&&A_M0>(/
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61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>mrsn-20201231_g10.jpg
<TEXT>
begin 644 mrsn-20201231_g10.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ?D"8$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8PW8W+G'3</6@#H**Q/"WCCPYXYM9KGPWX@TOQ!;POY<LVEWL=RD;8SM8HQ
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MH8<$?2@">BBB@ HK/U[Q#I7A729]4UO4[/1],M]OG7M_.D$,>Y@J[G<A1EF
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MGB3Q9H?A^ZFC\V.#5-2AMG=,D;@KL"1D$9'H:Q?^&A/A9_T4OP?_ .#ZU_\
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M'-<TW7[*.4PO<Z7=QW,:R  E"R$@-AE..N"/6@#9HHKA]1^.GPWT?4+FPO\
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M TJ*** "BN!D_: ^%T,C1R?$CPBCJ2K*VNVH((Z@CS*;_P -"?"S_HI?@_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M48R?5B<L6/)))/)K9OK&VU.RN+.\MXKNTN(VAFMYT#QR(PPRLIX(()!!X(-
M'X;_ /!/K]O[Q%\ _'&D>#O%^KW.J_#+495M&BNY#(='9B LT)/*Q@XWQ@[<
M$L!N'/[G9SR.17P'X=_X(R_!ZQ\0W^HZUKOB/6+.6ZDEMM+AFCM8(8F<E(F(
M5I'VJ0NX.N<9Q7U_\3O$]O\  _X%^)M>M(WEM_"OA^XN;>*>5I6?[/;L8U9V
M)9B=B@DDDYR30!^=?_!2O_@HQK7A_P 3:E\)/A7JLFDRV),&O>(K-RMP)N]M
M;N.4V]'<?-NRH(VG=\(? S]DWXM_M0W=Y=^"_#=SJUI',1=ZU?3+!:K(>6!F
MD(WOR"57<WS D8.:X'P3X;U/XN?%#0M %R\NK^)M8@LOM4N78S7$RH7;U^9\
MFOZ6OAO\/-"^$_@71/"'AJR33]$TBV2UMH5'.U1RS'^)V.69CR223UH _#7Q
M[_P2N_:%\":'-JJ^&+/Q'#!'YDL&@WZ7%PHQD@1':[D=,(&/H".:XG]EW]M#
MXC_LF^*H1I=]<:CX968KJ'A34)7^RR#/S[%/^IE_VU'4#<&&17]$M?C+_P %
MD_@3IG@'XN>&OB!HUHEG%XP@G348X5PAO8"F9CV#2)*F?4QLQY)- 'ZV_"?X
MI>'_ (U?#O0O&OA>[^V:)K%N)X'(PZ')5XW'9T8,K#L5-?D'_P %J_\ DZ;P
MM_V)EK_Z77U>Y?\ !$KXH7.I>#?B%X NIV>+2KJWU:QC8YVK.&28#T :*,X]
M7)[FO#?^"U?_ "=-X6_[$RU_]+KZ@#X.T'6KSPUKFG:O82&"_L+B.[MY1_!)
M&X96_ @5_3S\._&5I\1O /AOQ78<66N:;;ZE",YPDT2R 9]@V*_G7^)'PW_L
MO]GOX0>.H8L1:O\ VKI5PRCCS+>[+J6]RMQ@>T?M7[!?\$G_ (F_\+!_8_T3
M3II?,O?"]]<Z+*6.6*!A-%QZ".=4'^Y0!\R_\%N_B8)M8^&_P^@EY@@GUV[C
MSP=[>3 ?P\NX_P"^J_+BOIC_ (*(_$27XN?ME^/);1VN[?3[U- LHX_F_P"/
M=1"ZKZYF$K?\"KSW]J3X?Q?"GXZ>(O!T04#0X[.P=EZ/)'9PJ[_5F#-^- '[
M^_LG?\FL_!O_ +$S1O\ TAAK^;;5O^0K>_\ 79__ $(U_23^R=_R:S\&_P#L
M3-&_](8:_FVU;_D*WO\ UV?_ -"- 'UH_P#P2A_:256(\'6#D#(5=;L\GVYD
MKQ#XQ?LW_%+]G#4+ >/?">H>%Y+ALVEYYB2PNZX.$GA9D+#@X#9%?TLU\2?\
M%=/%_A+2_P!DO5= UF[LSXFU2]LY-#LI&4W!DCN$:69%ZA5A\U2_0>8%S\P!
M /(?^"3_ .VUXA^(.L7/P@\?:O-K5]%:O=Z!JE](TES(J<RVTDA)+X7YT)Y"
MHX)("@?IS7\_G_!,.UO;G]N#X;&R#YB>^DF91PL7V&X#;O0$''U(K]QOCQ\5
MK+X'?!OQ?X[O]K0Z'I\ES'$YP)IL;88L_P"W(R)_P*@#\;?^"M7QR_X6E^TW
M-X8LKCS=%\$V_P#9B!6RANWP]RP]P=D1]X:\._8Y^.#?L\_M&^#/&4DK1Z5#
M=BTU0#HUE-^[F)'?:K;P/[R+69\#OA_JO[3?[1WAOPY>337E]XHUKSM2NOXS
M&SF:ZF^H02M]17HW_!1?X"P? #]J+Q%INEV2V/AO6E36M*AB7;''%+D21J.@
M"3+*H4=%"T ?T%QR)-&LD;*Z, RLIR"#T(-?,/\ P4T_Y,<^)_\ UQL?_2^V
MJK_P31^.G_"[_P!E7PY]LN?/U[PS_P 2#4-QRY\E5\ASW.Z%HLL>K!_0U:_X
M*:?\F.?$_P#ZXV/_ *7VU 'X2?"GX6^(OC5\0-)\%^$[2.^\0:HTBVMO+,D*
MN4C>1LNY"CY48\GM7TE_PZ?_ &DO^A0T_P#\'=I_\<KFO^":MU#8_MN?#*>X
MFCMX5FO=TDK!5'^@7(Y)K]^/^$LT/_H,Z?\ ^!4?^- '\YOQP_9*^+7[-\=K
M=^//"%UHUA<2^5!J4,T5S;-)C(7S8F958@$A6()P<#@U]Y?\$G/VUO$WB3QD
M?@WXYUBXUR*ZMI+CP]?WTK2W$3Q)N>U+L<LGEJ[KGE?+(Z$!?9?^"JW[0/PY
MM?V8_$7@3^W]-U?Q=KDUJMCIMG,D\L'E744CS2;2?* 6-U!."Q; S\V/SY_X
M);^$=1\4?MJ>![BRBE-MHZ7FHWLT:DB*(6TD8+'L&DDC3_@= 'ZA?\%5/^3'
M/'W_ %VTW_TOMZ_,O_@D_P#\GM>$/^O+4?\ TDEK]-/^"JG_ "8YX^_Z[:;_
M .E]O7YE_P#!)_\ Y/:\(?\ 7EJ/_I)+0!^CW_!3G]K?5OV9?A+IFE^$YQ:>
M,O%DDUM:WN,M96\:KYTZ?]-,R1JN>FXMU6OR.^"'[,OQ:_;!\3:M=>%["?7I
MXY0^J:]J]YMB21\D&6:0EG<X)PNYN^.]?>__  6X^&^K7^C_  W\<VL,D^D:
M<]UI=ZRC*P/+Y;PL?0-Y<@SZA1W%?,7[ _\ P4";]D"'6O#VM>')/$/A'5[I
M;V0V,JQW=I,$",Z!OED#*JC82O*@ANH( [XC_P#!)WX]_#OPK=ZZMCHGB>&T
MB,\]KH-^TMRJ!2S$1R1Q[R /NIN8]@:\]_8Y_;(\6_LH_$"QNK2^N;WP5=7"
MC6?#[.6AFB) >6-2<),HY5AC. #D$BOU\^&O_!3/]GKXE-!"GCA/#-]+C_1?
M$EN]EMS_ 'IB#"/^_E<8W_!*W]G7QUJFI>*8'UC4K;6KF6^0V&L(;1/,=G(A
M,:?<!.!EFP .: /M#3=1MM8TZUO[*9;FSNHEG@FC.5DC8!E8>Q!!KX!_X*7?
M\% [[X#_ /%L_AW=)%XXN[<2ZEJP 8Z5"Z_(D8/'GN#NR?N*00,L"OW9X9T#
M3_A[X*TK1+)I1I6AZ?%90M.^^3R88PBEF[G:HR>]?S1?%[XA7OQ>^*WBOQE>
M[VN]>U2>^\MCN*+)(2D8]E4JH'HHH Z;X6_!'XK_ +6'C34!X7TC5/&>M.XF
MU'5;NX^1&;^.>YF8*&.#@,VYMIP#BO<O$7_!);]HC0='>_AT+2-9=$+M9:=J
MT9G &<@!]@8X&<*23G YXK]A_P!EGX%Z7^SK\#?"W@S3K:.&ZM[1)M3G5<-<
MWKJ#/*QZG+Y R3A55>@%>LT ?S>?!O\ :!^*G[('Q"F;0K[4-!O;*ZV:IX:U
M-9%MIV4X:.XMV(^;'&[AU[$5^]7[+_[16@?M0?"'2O&^A?Z.\O\ H^HZ<S;G
ML;M0#)"Q[CY@RMW5E.!G ^$_^"T_P)TQ?#_A/XMZ=:)!JPO1H>JR1+@W$;1N
M]O(_NAB=-W4B11T48\X_X(J_%"YT?XQ>,/ 4T[?V=K>E?VC#"3E1<V\BKP.Q
M,<KY]?+'H* /0O\ @N5_R"O@W_UVU;_T&SKX/_8[_:4U']EGXX:-XO@,LVC2
M'[%K5C'_ ,O-D[#> .[J0'7I\R =":^\/^"Y7_(*^#?_ %VU;_T&SK\PT\ Z
MW-\/Y/&D5FTOAZ'4AI,]TG/DW#1^8BOZ;U#X/^PW3C(!_3MX>\0:=XLT'3M;
MT>\BU#2=1MX[NTNX#E)H74,CJ?0J0?QK\N_^"YW_ #1/_N-_^V%:'_!'O]K+
M^TM/N/@?XEO<W-JLE[X:EF;EXN6GM1GNO,BC^Z9.R@5G_P#!<[_FB?\ W&__
M &PH [7_ ((C_P#)%_B'_P!C!'_Z3)7Z/U^<'_!$?_DB_P 0_P#L8(__ $F2
MOT?H *I:UK5CX<T>^U;4[J.QTVQ@DNKFZF;:D,2*6=V/8  D_2KM?%7_  5P
M^)EQX!_9'O-+LW:.?Q5JEMH[2(<%8<//)^#"#8?9S0!^=/[;W_!0?Q=^TSXF
MU'1/#^H7GA[X90NT-MI=N[1/J* _ZV[P?GW8R(S\JC'!;+'G?@S_ ,$X_CK\
M;O#UKK^D>%H]'T*[57MK[7KI;03H<8=(SF0I@@AMF&'W2:N_\$T_@5IOQX_:
MHT6QURU6^T'0;:77;VTD7*3B)D6)&[%3-)$2#D,H8=Z_?]5"J !@#@ 4 ?SN
M?'3]@OXU?L[Z&^O>*/"OG>'XB!+J^D7"7<$&3@&3:=T8R0-SJ%R0,YXKWK]@
M/_@I-XD^%?BO2O _Q-UN?6_ %]*MM%J>I2M+<:.Q^5&$A.6@S@,K9V#E<8*M
M^T5_86VJV-S97MO%=V=S&T,]O.@>.6-@0RLIX(()!!Z@U_.5^V=\%[7X _M,
M>.?!>G(T>CVMVMSIRL2=MM/&LT: GD[!)LR>I0T ?T>*P=0RD,I&01T-?S;_
M +8G_)U_QA_[&W5/_2J2OV\_X)Y_%"Y^+7[(?P_U:_G:YU.SM7TFZDD.69K:
M1H5)/<F-8V)]6K\0_P!L3_DZ_P",/_8VZI_Z524 >B^"/^":/Q]^(G@W1/%&
MA^%[&YT;6;*&_LYGU>UC9X94#HQ5G!!*D<'FMO\ X=/_ +27_0H:?_X.[3_X
MY7Z@?LJ?M,?"#P[^S+\*M+U7XK>"-,U.S\,:=;W5E>>(K.*:"1;= R.C2!E8
M$$$$9!%>J?\ #6/P0_Z+)\/_ /PJ+'_X[0!\L?\ !+;]DGXE_LPW_P 2)?B#
MH]OI2:U%IZV1@OH;G>8C<%\^6QVX\Q.O7-??E9_A_P 1:5XLT:TU?1-3L]9T
MF\3S+:_T^=)X)D_O)(A*L/<&M"@ HHKR7]J+]HC0_P!F'X.ZQXWUG;/-"/L^
MFZ?NVM>WC@^5"/;@LQ[*K'G&* /DO_@K%^V1_P *P\%-\(_"E]L\5>(K;.KW
M$#_-8Z>W!CR.DDPR/:/<>-ZFOSD_8#_Y/)^$_P#V&D_] :KWPI^$_C/]M;X@
M_$OQ[XBO;B6TTG3+[Q'KVK[>#(D,CP6R=AO9 H7^&-&Q]T T?V _^3R?A/\
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M''FW-V')7W"6Y!]I/>@#ZE_X(J?\G3>*?^Q,NO\ TNL:]5_X+G?\T3_[C?\
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MZ?\ VDO^A0T__P '=I_\<K]Y+6ZAOK:*XMY4GMYD$D<L;!E=2,A@1U!'>I:
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MROU?_8"^#GBGX"_LQ>'?!OC*RCT_7[.YO))K>&X2=562X=T^="5.58=ZM?\
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MQ#>^;XQ\(0)'"\K9DO=.&%CDYZM&<1M[>63DL:^1?^"U?_)TWA;_ +$RU_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAFW_ /1!H _,[QAX7\:_LE_'JXTV6:32?%_A'4UEMKR$$*Y1@\4R9^]&Z[6
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MEF@#%HU ZL\32HO^TPH _/7_ ((I:A;6_P"T=XPM9&5;FX\+2&$'&6"W5N6
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M^TNX/NLT2_\  *9_P5U^&8\#?M;7>M01;+3Q5I=MJFY1\OG(#;R#Z_N5<_\
M73WKYA^&/A?4OC=\9?"/AJXN)KN]\0:K9Z:]PYRX1G2,L3Z*G.?1: /LK]KC
MX;_\*M_X)L_LYZ5)%Y5W>7SZO<Y&&,EU!)<8;W59%7_@->H?\$,?^:V?]P3_
M -OZZ[_@M590:;\"OAK9VL2P6UOKC111(,!$6U<*H]@ *Y'_ ((8_P#-;/\
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M_P#Z M?K1^V!^S9IO[4OP1UCP?<B*#5T'VS1KZ0?\>MZBGRR3_<;)1O]ESW
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M^Q,NO_2ZQKUK_@N9!NM?@O-GA'UE-OU%B?\ V7]:\E_X(J?\G3>*?^Q,NO\
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MVLVS:/J+J.!<PY>%F/\ >>)F7Z05]R?\$WO^3)?A;_UY7'_I7/6A^WS\%_\
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M !J]8ZA:ZE$9;.YANX@VTO!(' /7&0>O(_.@"Q1110 5^5?_  7._P":)_\
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MTIU_-9^UC_R=-\9/^QSUG_TNFH _H(_9E_Y-M^%'_8I:3_Z1Q5Z77FG[,O\
MR;;\*/\ L4M)_P#2.*C]I+XPVWP#^!?C+QW<%/,TBP=[6.3I+=-A+>,^S2L@
M/L30!^-'_!5/XY?\+>_:FU32+.X\W1/!L7]B6X4_*;A26NGQZ^:3&?:%:^TO
M^"8/C#X/? ?]F>T?7_BAX(TCQ7XDO)-4U&SOO$5G#<6Z@^7!$ZM(&4A$#[2
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MA-<6]W;H4G5$D*['D5ONNAR!CG&<\5]5_P#!;#_DY+P;_P!BE#_Z675?2O\
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M/@V[\J#51K%_>:/?R#_CUO48>6V?[K LC?[+MCG%>/?\%L/^3DO!O_8I0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M510!\B_\$P?@#KGP#_9M-IXITB;1/$^M:M<ZA>6=T )H5&V&)6P3QMBW@?\
M33WKX _;<_8W^-?Q"_:J^(OB+PY\.=:U?0]0U!9;6^MXU,<J^3&,C+>H(_"O
MVYHH \Z_9O\ #^H^$_V=_A=HFKVDEAJVF^%M+LKRTF&'AFCM(DD1O=64@_2O
MPDU+]@?]H2;4;IT^%'B!D:5F!$2<@D_[5?T044 %%%% 'B'[:5]XUA_9M\8V
M'P\T.^U_Q;K%M_95I;Z>N9(EF^267.1MVQ&0@_WMM?DY^RK_ ,$[_BOJG[0G
M@C_A/?A_JFA^#[74$OM2NK^-1"T<(,HB.&)/F,BQ_P# Z_=*B@ HHHH _)3_
M (*=?L->/?&_[0$7CGX;>$+WQ'9^(+%&U-=/528;R'$99@2,!XQ$1ZE7-/\
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M/E ]"TA!'96K]L** *6B:+8>&]&L-)TNTBL-,L(([6UM8%VQPQ(H5$4=@%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M35#:AX>O)5>1$.!YL3@#S(MQVEMH*G 8#*D@'T;1110 4444 %%%% !1110
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M DC*N23M!8@9.<4 =91110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHGPM_89^'/BWQ'>+8:'H_@C3[R[G;DA%M(SA1_$Q.%"CDD@#DU\;_M=?!O\
MX4+_ ,$J?!'A&6#[/J<.HV%WJ2D8;[7.)99@WJ59R@]D'I6;^VYXGO-'_P""
M6/[/^E6SRQPZO!HD5TR,0CQ1Z<\@1L=<NL; 'O'GMP >C>&_VYOVFOVD7O\
M5O@1\$-*;P=;SM'#JGBBYP;C;G@,9X$+$C!5"^S=@M_%7HW[.O[>VN^(OC!_
MPIWXW^!F^&OQ)G.;#RB38WORE@BEF;#-M;:RLZ/@@,&P&\<^"_[6GQ]^&/PE
M\(>%?#O[)6MW.BZ3I=O;6UU#).JW*A!F?Y;?&9"3(3W+D]Z\A_:PU_\ :'_:
M@\3> O$<?[-OB?P=K_A&X>>WU"SAN)Y)@7CD12?*0C8\>X<G&]O6@#[L_P""
M@7[6/B+]D7X:^'/$GAO1]+UFZU/5QI\D6J"38J>3))N&QE.<H!R>YKP&^_X*
M$?M!_$;QO+J_P=^"G_"1_"==0%A::M?:9>,]\OF^6TPF1U5%R#T1Q&"=^2.+
M/_!:J8W'[//P_E,;1&3Q&K&.089<VDQP1ZBOM[X#^%[7P3\$O .@V4<<5OI^
MA65NHB4*&*P(&; [L<L3W))H ^>/VJOVW?$OPT^*6B?!_P"$O@J/Q_\ %748
M!<S6L[,+6R0J64-@IN)4%R2Z*JX)//'DWC;]LG]KS]G.PB\4?%SX+^&;KP5Y
MJBZN=!N2)+;>P 1I$N9PG) !=,$D#<2:F_;*_9L^-O@O]J"U_:(^!-M'KFJ/
M9QP:EI?R/,"D0A;]T[#S8WB5%VH=X*D@#AAR*_\ !5:6WCG\$?M'_ J\TRVO
M$\J^ACMV"RID9#65V 2N0#_K#]#0!]_>"?CYX/\ ''P-M/BU;7YM/!TVER:K
M+<W2X:VBC#><K@9^9"CJ0,\J<9KXU\._MY?M"_M+7FKW/[/OP6TZY\)V=PUJ
MFN^*KH*&8 ')'G0J'P5)C1I-NX9)%?5/AO4O@E\0/V;);S1XO#B_!FYL)99X
M+:!+/3X8 2\JR1J%$15@=RD @YS7R/X5_P""D/PW^'NFCP#^SQ\$O%/C71M-
MDD%M!I,$D,+O([.64;)IL,S$_.@/M@ 4 2>'?^"BGQA^"_Q<\/>"/VEOAGIO
MA6SUJ2.&#7-(9DCB5F5#,3YTT<RJS OL=2@;..BGZH_;1^/6K_LT_L^ZYX^T
M+3['5-2L+BUB2VU#?Y+"6=(V)V,IX#$CFORR_P""C7QF^,?QE\,^!]1^(OPC
M/PO\/P7=R-*^V3,]Y-*R1^8KAMK!0 AYB7ZFOO\ _P""L'_)DOB__K]T[_TK
MBH \JTO_ (* ?'?]H'1=.C_9_P#@_:>)+BVTZU.O:]JI:+3XM0>W22XM[?S)
MHE_=NQ W2,3@?+@@MN?LV_\ !1+QKK'QW@^#/QW\"6_@GQG>R"&RN=/1XH?,
M*%TCDCDD?_6  +(CD%B!@9R/:O\ @G7X7M/"G[&7PP@M8HXS=Z>VH3,BX,DD
MTKR%F/<X8#Z*!T%?*G_!1JW2U_;W_9AOX1Y=W)J&G1M*O!*IJB%1GV+M^= '
MV_\ M0?M*>&?V5_A7=>-/$D<UX/.6TL--MB!+>W+!BL:D\*,*S,QZ*I."< _
M)^C_ +3G[;7Q:\-VOBKP)\#/"^E^'+I5NK-=:NQ]INH3@K@274)VE3G<47<"
M"IKZ-_;,E^!NE_#&'6OCM86>I>'["X_T&WG$CSRW#+]R!$8,SD*>^  22 ":
M^=;+_@J5XB\=1K%\)?V;_&7C"RQL@NF#11(HX!(AAE4 8 QO ]Z .Q_8]_;^
MU[XQ?%C5/A%\5?!D?@7XDV,4DB16_F)#<-& TD7E2%G1PA\P?.X90QR,#=]K
MU^0'P=\4?$#QE_P5R\%:S\2_"5MX(\57=G<-)H]K*)!'"-&N1$6(=OF* 9R0
M1Z#I7Z_T %%%% 'Y:_\ !,O_ )/D_:-_Z[7_ /Z<S7ZE5^6O_!,O_D^3]HW_
M *[7_P#Z<S7ZE4 ?DS^W-\4])^"7_!3OP!XYUV*YGTK0]"MKJ>*S0--)_P ?
MBA4!(&2S <D#GDUZAXC_ &NOVT)_#\GCS0_V?='T_P !K$UZEOJ#M<:B;;[V
MYHEN8Y<[>>(!ZX(KBOVK/#=CXN_X*Y?!_3-1MX[NS:STZ9X)EW(_E274H# \
M$90<'@U^I77@\B@#Y^_8M_:\TC]L#X:W.O6NFMH6N:7<+::KI32^:L4A7<DD
M;X&Z-QG&0""K#G&3Q'[7G[>B_ /QMI'PV\#>$I_B'\4=61)(M)MV;R[97)V;
MP@+N[!21&,87YBP&,^ ?\$?X8]-^*O[2&GVR+#9Q:C9+'$HP%"3WZJ![ '%>
M$_"_XQ^/?#O[?'QK\?\ A7X5:A\6?$$6HZE8QVD;2&33(3=>4CY6-R"(HA".
MF%+#H<4 ?3_B/]KK]L7X,:6WB_XE? ?P_+X(A82WO]A76ZZLX<X)8I=3;< 9
MW-'M&>2.@^T?@9\;?#'[0WPSTGQQX2N))M)U!6!BN%"SV\JG:\4J@G:ZGW((
MP02""?C>^_;@_:.U2QN+.\_8_P!<N;2XC:&:&62X9)$8$,K V_(()!'O5;_@
MD7\._B+\*;#XGZ'XU\&Z[X1TJYNK._TN+5[>2-"Y$R3!2P&XA5@R1UP,T <Y
M??\ !5;QT?%'Q*\$:-\/;+Q'X^L-?.C>%-+TNVN9C=1QR70GGN$5RS[%AA^5
M"N3(QR IQ]#_ +*_[1?Q:\1^!_B!KO[07@FT^&]KX419A?+:W%L+B%8GDF?R
MY&?<$55.]&()8@ %:^6_^":/A>UU#]NK]H;7IHXY+C3+G4+> NH)0S:BY9E/
M8XB*Y'9B.YK])_BAI_A35/A[K]OXZ6R?P>;1WU4:B^RW^SJ-S&0Y&%&,_A0!
M\,>'?V\OVA?VEKS5[G]GWX+:=<^$[.X:U37?%5T%#, #DCSH5#X*DQHTFW<,
MDBJGAW_@HI\8?@O\7/#W@C]I;X9Z;X5L]:DCA@US2&9(XE9E0S$^=-',JLP+
M['4H&SCHIC\*_P#!2'X;_#W31X!_9X^"7BGQKHVFR2"V@TF"2&%WD=G+*-DT
MV&9B?G0'VP *^7O^"C7QF^,?QE\,^!]1^(OPC/PO\/P7=R-*^V3,]Y-*R1^8
MKAMK!0 AYB7ZF@#]3?VT?CUJ_P"S3^S[KGC[0M/L=4U*PN+6)+;4-_DL)9TC
M8G8RG@,2.:^7/"?[>7[07[2VEV*_ ;X4:1J7V&QMO[?U[77:*R2_>$/-!;!Y
MH\A&.WEG8C!*@$,?5?\ @K!_R9+XO_Z_=._]*XJ] _8%\(:=X+_8]^%EKIL4
M4:WFC0ZG.T?62:X'G2,Q[G+X]MH'0"@#QW]G_P#X* >*[CXV1?!K]H#P+!\.
MO'UXP73[JQ8_8;IVSLCPSR??P521)'5V^7@]?I_X^?'3PU^SG\+M6\<^*Y9%
MTVQ"HEO;@&>ZF<XCAC!(RS'\  Q/ )KX+_X+4:3;Z'8_"/QQ8%+3Q+8ZC<6T
M-V@Q*44),G/<(ZY'H7/J:QO^"S'B;4];A^!?AV.UNIH=2:[OY;")F47$Y%M'
M&@']\"250<$CS/?D [[PK^V!^V'\<-(3Q=\,O@-X?M_!DA:2U;7;L^==QYP/
M+9[FWWC!)WK'M)7@]C[%^R/^W,/COXMU?X;^.O"UQ\/OBQHRN]UHUQN$-PBD
M;FBW?,& 8$H<Y4[E9AG;Y/IO[;G[1FBZ;::?8?L>ZW9V-I$D%O;PR7"QQ1JH
M544"WP    /:O$M8G^.OQC_;<^%'Q;N_@!XF\!-I=[86&J2P6\TB2VHN&666
M1S&F,0RNASGY5 Z"@#Z^_;,_;&\3?LV_%;X2>%M#T72=4L_&-V;>[FU 2^9"
MHG@CS'L<#.)6/(/(%?6]?F5_P57_ .3DOV9?^PFW_I99U^FM 'R1\#/VQO$W
MQ2_;5^)_P9U#1=)M-"\*VEW<6M_;"7[5,T5S;1*'W.5P1.Q. .0*^(OVY?&7
MQMO/VUOA5/K?@+2;#6=*\01KX'M8KV-DUJ--24VK3D3D1F1A&#N,>-QSMQQZ
M_P#L>G/_  5G_:%Q_P! S4__ $OL*M_\%#/^3^OV4/\ L,Z=_P"G6&@#W+XB
M?M,?&7X+_L;>)/B=\0/ >A^'_B!I=_##'H2W/VBT:WDN88E=FBG?DB1S@/U4
M<5Z;\/?VD-/NOV4M$^,_CI[70;*;1$U?4!:AC'&2/N1AB68EL*JY))8#O7FO
M_!53_DQSQ]_UVTW_ -+[>OD?]K3Q%>Z3_P $F?@3I]J72WU6?38+IE^ZT:6U
MS*$/U>-&_P" 4 >I>%_VXOVH_P!I.:\UGX%_!315\$P3-%%J/B:?Y[@H>@<W
M$"$G&UE0/M)QO[UZ=^RW^WMK/Q$^+UY\&_C!X+7X=_%&!6,$$+,;:]94,C(J
ML6*'RP74[W5U!(;H#]#?LW^%=/\ !/[/_P .M$TN***RM- LE7R1A78PJSO[
MEF9F)[EB:/$W[._P[\8_%;1?B5K'AF&\\;Z-%'#8:L9YD>%$9V0;%<(Q!D?E
ME)YQTP* /!OVK?VW/$?PS^*VC?!_X1>"D^('Q2U&$7,EM<EEMK.,J64. R[B
M5!<DNBJN"6YX\D\;?MD_M>?LYV$7BCXN?!?PS=>"O-475SH-R1);;V "-(ES
M.$Y( +I@D@;B34W[97[-GQM\%_M06O[1'P)MH]<U1[..#4M+^1Y@4B$+?NG8
M>;&\2HNU#O!4D <,.17_ (*K2V\<_@C]H_X%7FF6UXGE7T,=NP65,C(:RNP"
M5R ?]8?H: /T2^#_ ,5-#^-WPS\/>.?#<DDFC:U;"X@$RA9(R"5>-P"0&1U9
M3@D94X)KL:X'X%^(OA[XL^%VB:I\+5TF+P3<(SV4.BVJ6MO%EB73R55?+<,6
MW*0"#G(KOJ "O'_VQ/\ DU#XP_\ 8I:I_P"DLE>P5X_^V)_R:A\8?^Q2U3_T
MEDH ^:/^"0]\^F?L7ZW>1JKO;Z_J$JJW0E;> @'\J\_^%W_!5;XD?%_P>-$\
M'_"NV\6?%Z[O[@0Z9IBS+I]EIZ10%;FX9GR=TLDB8WHHVC+ E0W<?\$F?^3'
M?$O_ &&=3_\ 2:&N%_X(@^%[2'P3\3_$?E1M?7&HVFGB4K\ZQQQ-(5![ F49
M]=H]!0!8U3_@HI^T)^S?XTTBW_:)^$6F:5X9U.5E2ZT $2J!@MY<@N9HI"@8
M?NR58C^*OT;;Q9HZ^%?^$F;4K=- ^Q?VB=1=]L(MMGF>:6/1=GS9]*^.?^"P
M5C#=?L>W$LJ!I+;7K&6)B/NL?,0G_OEV'XUS?QV\3:AH/_!'?1KFSDD%Q<^#
M?#]B\R\[8I6M8I ?8HS)_P "H RH?^"@GQQ_:.\7:OI_[-/PEL=9\-Z;,8)?
M$7B9F5),]'&9H4C/\0C+2.5P2HS@=3\(?^"@/CK0?CAI?PC_ &BOA]:_#[Q-
MK#I'IFJ:9(S64SR-MB7!>4%7<%!(DC -PP')'J'_  37\*Z?X5_8O^'*V$42
MOJ%M-J-U)&.99I)W)+'N0 J?1 .U>J_%7]G?X=_&[5_#NJ>-O#,.NW_AZ1Y=
M,GDGFB-NSE&8_NW4-S&A^;.,<8R: /1Z*** "BBB@#SWX\Z]\1/#/PTU#4/A
M9X9L?%WC..2$6NDZA<)!#*AD42$NTD8&U"Q'S#IWZ5^3_P#P3S\<?'SP]\3/
MBV?AO\.M'\4RZAJ]D?%*WU_%"-,/G7>!%NN(]_WKC[N__5KZC/[15^:O_!(G
M_DJ?[3W_ &&;#_T?J5 '!_MS?%/2?@E_P4[\ >.==BN9]*T/0K:ZGBLT#32?
M\?BA4!(&2S <D#GDUZAXC_:Z_;0G\/R>/-#_ &?='T_P&L37J6^H.UQJ)MOO
M;FB6YCESMYX@'K@BN*_:L\-V/B[_ (*Y?!_3-1MX[NS:STZ9X)EW(_E274H#
M \$90<'@U^I77@\B@#Y^_8M_:\TC]L#X:W.O6NFMH6N:7<+::KI32^:L4A7<
MDD;X&Z-QG&0""K#G&3Q'[7G[>B_ /QMI'PV\#>$I_B'\4=61)(M)MV;R[97)
MV;P@+N[!21&,87YBP&,^ ?\ !'^&/3?BK^TAI]LBPV<6HV2QQ*,!0D]^J@>P
M!Q7A/PO^,?CWP[^WQ\:_'_A7X5:A\6?$$6HZE8QVD;2&33(3=>4CY6-R"(HA
M".F%+#H<4 ?3_B/]KK]L7X,:6WB_XE? ?P_+X(A82WO]A76ZZLX<X)8I=3;<
M 9W-'M&>2.@^T?@9\;?#'[0WPSTGQQX2N))M)U!6!BN%"SV\JG:\4J@G:ZGW
M((P02""?C>^_;@_:.U2QN+.\_8_URYM+B-H9H99+ADD1@0RL#;\@@D$>]5O^
M"1?P[^(OPIL/B?H?C7P;KOA'2KFZL[_2XM7MY(T+D3),%+ ;B%6#)'7 S0!^
MA]?"O_!9+_DT>S_[&:R_]%7%?=5?"O\ P62_Y-'L_P#L9K+_ -%7% 'Q[:^'
M?$/_  3WU[X&?'SPI#<7W@#QGX9TL:_8JY(,TMG#)=0,3T+D&>(GHZL,;5P?
MV2\%^,='^(7A/2/$OA^^CU+1=5MH[NTNHC\LD;C(/L>Q!Y!!!Y%>&_#CX0Z!
M\>/V"OAUX&\30>=I6K>!-'B,B@>9!(+&$QS1D]'1PK#W'.02*^2O^"??Q>\0
M?LK_ !RU[]EKXGS^3";UV\-WLAQ%YS_,$C)_Y97"D.@[2$KC<YP ._X)6_\
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M;XF>)/@?<_"KXX?#<>!O'3ZC:ZII]YI;>9IM_;QEUD"MYD@#*67[KN#DYV'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUNDRJV,9 8'!P3S[UH1QI#&L<:JB* JJHP !T % 'YF?$3_E-9X!_P"P8/\
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M_MA0ZIX[FU+7_@!KEOY5A'965O\ Z$Y1-_SJBLTL<JL=KODQR<9(P*W[5O\
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MCX?W'Q)\<^--"T_PEXB\>:O'>_\ "-:9)'+%I=I"ACMXB\8VL^&<G;QR.A)
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M_P %</@GH/P_OKWP3JE[XM\6R0LEAHXTNYMPLY&$,SRHJ[ <$["Q(X KO_\
M@GS<?''7?A'=>)/CAK5W>:AJTZR:1IE]8V]M-:6@4GS)/+C1MTC,?E?)543&
M-Q%>VZ+\#_AQX;UK^V=(^'_A?2]7WB3^T++1;:&XW#HWF*@;(]<UVU !7PK_
M ,%DO^31[/\ [&:R_P#15Q7W55#6=!TSQ'9BTU;3K35+4,'$%Y LR;AG!VL"
M,\GGWH \Y_9._P"36?@W_P!B9HW_ *0PU\]_\%./V2;CXV_#F#X@^#X)(_B-
MX-C-S UID3WMHIWO$I7DR(<R1XYSO4#+\?:=I:0:?:PVMK#';6T*+'%#"@5(
MT P%4#@    "IJ /R7_X(KZO=^(/BM\8=4OYC<7]]9VMS<3$ %Y'GE9FP..2
M2>*O^$)O^&U/^"K=[K9Q>^"_AODV['F,K9OLB*GH=]Y(TH]5!],U^H6B^$="
M\-S32Z1HNG:7+.,2R65I'"TF#GYBH&>O>ET7PCH7AN6>72-%T_2I9\"5[*UC
MA,F.1N*@9ZGKZT :U?$'_!6_X'_\+0_9G;Q396_FZSX)N?[14J,N;.3$=RH]
M@/+D/M":^WZBNK6&^M9K:YACN+:9&CEAE4,CJ1@JP/!!!P0: /S^\,Z7)_P4
M@_X)M6&CI>QGQWH_EVPFN9,+_:=F,*9#_P!-H'!)QP9B?X:\K_9F_P""DU[^
MR[X<LO@]\>O!6OZ9?^&8UL;74+>$&X2W7B))H9&7*JN LD;$,@7"\;F_4?0_
M#.C^&89(M'TFQTF*1MSQV-LD*NV,9(4#)JKXJ\!^&?'5O';^)?#ND^(8(SE(
MM5L8KE5SUP)%(% 'PG\3/^"ROPST_1+FV^'OA[Q!XJ\43)Y=@EY:+;VGFMPN
M\^89&Y(^54^;&-RYS71_\$M/V:?%GP@\&>+_ !YX^M)=,\5>.;F*X_LVXC\N
M:VMXS(P:1,#8\CS.2A^Z%3H20/K'PC\$?AU\/[P7?A;P#X7\-78SB?2-&MK6
M3D 'YHT!Y 'Y5VM 'XM>$_VFO"_[*/\ P4F^-_C'Q;8:OJ.F7%UJNF)%HL,4
MLPD>\B<$B22-=N(FYW9R1QZ?3]Y_P6N^#$=K*UIX1\=SW('[N.:SLHT8^A87
M3$#\#7W%??#3PAJ5Y-=WGA71+NZF8O+//IT+N['J68KDGW--MOAAX-LYTGM_
M"6AP3(<K)'IL*LI]00O% 'Y:-H/Q4_X*L?'#PMK/B#PG?>!O@?H1\Q#.7"S1
M,RF7RI65?.GEV*NY!MC4#N/G^K_^"GOQFA^!_P"R7JNCZ6Z6>I^*-OAVQAA^
M7R[=E/V@@#HHA5DXZ&1:^PJRM<\*Z)XH6%=9T>PU9823$+ZU28)G&=NX'&<#
MIZ4 ?/'_  3B^"O_  I+]D_PC:7,'D:SKR'7]0R,-YEP%,:D=BL(A4CU4U]-
M]>#R*2.-8HU1%"(HPJJ, #T%.H _)3X%3']AW_@IUXA^'LV;+P3XWF^S6*](
M@EPWFV)'KLE+6^?]IZ]F_P""A_[(OC35/'V@_M _!N*63Q[X>,4NH:?;?--=
M+!@Q31)_RT=5!1X_XTV@ D$-]VZIX/T'7-0AOM2T33=0OH %BN;JTCEDC )8
M!68$C!)/'<UL4 ?G?X5_X*Z?#KQ3X%U'1/B!9>(?AKXU-I+974EG8FZBM[@Q
ME?,BYWJP;D)(ORG +-R:^'8_VUOC%H/@WQW\.?!/CC7OB)X(N+!X1K>M:6_]
MH6%H<"1T822-"I3*$N[!0<KL.#7[A>,/@WX!^(5P;CQ3X'\-^)9V 4RZQI%O
M=L0,8&9$)XP/RK5\.^"?#OA'39=/T+0-+T6PF),EKIUG'!$^>N510#U]* /C
M[_@E#X8^&GA/]GX+X.\6:=XG\5ZLZW_B+R3Y=Q:RA0J6[1,!((X\D!B,,S.R
MG# #[<KQOX=_LA_"GX2_%?4OB'X/\*V_A_Q#J%F]G.MF[+;!7=7=DASMC8E%
M'R!1C/')KV2@#E_BA\.='^+GP[\0^#-?B:72-;LI+*XV'#*&'#J>S*<,#ZJ*
M_+'X*_''X@_\$L?&&K?#/XK>&=0U_P"&MY>-=:;K&EKN"LV 9+9G(1E95R\)
M965AGC)W?KM5+6-$T[Q%ILVGZK86NIV$PQ+:WD*S1./1E8$'\10!\0>,O^"Q
MGP.T/P_-=:%;^(/$NJ^63#IZV/V52^2 'ED.%'&25#<'H3Q7FW[%/P)^(G[1
MW[2MY^T_\7=,DT2UCD,GA_2+J!HS(?+V0LB, 1#%&1M<C+OALG!)^^M'^ GP
MR\/:D=1TKX<^$],U L'-W9Z':Q2EAT.]8P<CZUW= 'YZ?\%+?@OXVT'XD_#W
M]H_X=Z?<:UJW@SRH=3TZWB\QA;PRO.DQ51N9/WDJ28R0K*> &([30_\ @KM\
M +_P1'K&HZEK&EZWY.^7PZ=,FFN!)@Y1)57R6&1@,77.1D#D#[7KA;[X#_#3
M4M875KSX=^%+K5%.Y;Z?1+9YP3SD.4W=AW[4 ? /[$_@KQG^U1^V)KO[47BG
M0Y_#_A2!)8O#T-T"#/F$VT:Q\#>D<)?=)C!D;Y<_-M?^T)_RF*^#W_8,M?\
MT&\K],T58U554*JC 51@ >E9MQX7T:\UB'5Y](L9M6A 6*^DMD:>,#. LA&X
M=3T/<T <]\;O^2+^/O\ L7]0_P#2:2OC7_@BI_R:SXI_['.Z_P#2&QK[[G@C
MNH9(9HUEAD4H\<BAE92,$$'J"*IZ)X>TKPU:O:Z1IEGI5L[F1H;&W2%"Y !8
MA0!G  S["@#\V_\ @L9_R/W[-O\ V$]2_P#1NFU]D_MK?\FC_%[_ +%F^_\
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MHP%48 'I3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4GCO0!V'P:_;#^+/PB^/FF?!;]I;3]-&H:ZP&A^,-+"Q6URS?*BL%5597<;
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M_!1G]GS6]7NX[#2=-31;V\NYCA(88]7F>1V]E523]*^VO^&_/V>?^BL>'_\
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M51P.0_X*V:;#K'Q^_9QL+E%DM[J]E@D1AD,K75HI!'<8-?I_0!\3_P#!/O\
M;2\7_';Q%XP^&?Q1TNWT[XC>$PSS2V\8B^T)'+Y,PDC!*K)'(4!*?*0XP!CG
MAOVQ?V\/'W[-7[8FB^&-/B_MWP=+H N3X=@M(S->7TJ74=NHEVF15,ZV^0IS
M@' ).#S?[*_[C_@KM\=DC^17TR_W!> <W%BQ_7FJ/[3FCP:Y_P %?O@U;7*A
MHTM-.N0",_-%)=2K_P"/(* .B\5:5_P41GT&X\<0^(_#.E&.-[H>"=,M[6:Y
MC0+N,2J]O()&P, >>S9X!R:]Z_X)]_MB77[7'PTU:?7M/M]+\8>';F.TU.*T
MR(IE="8IU4\IN*2J4R<&,D'!P/J>OS(_X)#Q);_&+]I*&-=D2:C:*JCH +B^
M % 'HG[4O[<_CUOCG'\!?V?M!MM;\?95+_6+H+)%9OM\QD16.SY$P7DD)53E
M=I85RWC:3]O?]G_PW<>.M4\7>$OB9I&GK]LU/0[*RB\R*% 3(0%MH&*! ,^6
MY8<D*<$GG?\ @F+:#4_VR?VE-7U@!O$L5[<1%I #(!)J$QG ../FCC!Q[>E?
MIY)&DT;1R*KHP*LK#((/4$4 >-_LG_M-Z%^U=\([/QEH\']G7BRM::GI+RB1
M[*Y7!*%L#<I4JRM@9##@$$#XP_X)A_\ )WG[3W_83F_].%S4/_!(!QI/Q6_:
M'T+30#H-O?VQM]O"H%GO$3 [93_T$5-_P3#_ .3O/VGO^PG-_P"G"YH ]F_;
M>_;HUGX)>,-#^%/PNT"/Q5\5=?2/RHY09(K(2L5B!0$;Y6()"DA5 #-D'%>>
MZEX3_P""AGA?P_)XK_X3KPCXCNHXO.E\(P6EL9MHPVQ2+5%9^6!"R\X&&8XQ
MR7PDM!K?_!9[XASZZ ][I]E/)IXF 8KBTMHX]O''[AV/T)]<U^GU 'S5^P_^
MV58_M<>!]2DO--C\.^-M"E6WUC1E<E02/EFC#?,$8JXVMDJ5()/!/CW[4W[:
M7Q*U;X]Q_ ']GC3;2\\:HN-4UZZC25+%MH=@@?,:B-2"[N'&3L"[ASYQ^R6(
M_#O_  5H^.>EZ.BKIEU9Z@]Q'&-JJYN+61FP.XD9A_P(U)_P3!4:I^U[^TOJ
MNLC=XG%_*A9U!=5>_G,X!Z@;TBX]AZ"@#I/%'Q"_;*_9!T=/&_Q*U3PW\7O
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MMXHWE:=U4*TL@ 9R!RQP ,GKP /:I*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /S/_P""BWPT\;_#O]JCX;?M$Z!X6NO&GAS08K1=1L[6-I6MGMYY
M'RX5241UE&U\$*ZDGJN?0%_X*JZ?\0-*:P^%7P>\?>+?&DO[F*QN=/CCM8)N
M1^^EBD<@*1D_*. <E><?>%% 'Y._L*^!_B3\)/\ @HIXI'Q2TRZ3Q%XFT:[E
MNM1M8G>R>ZN3!?,@E5?+X".I .T,FT$X&?0?CYX7UF\_X*X_"35X-(OIM*AT
MVV66^CMG:!"!>9#.!M'4=3W%?I#10 5^;W_!*7POK/A_XQ?M&3:II%]IL-UJ
M5LT$EY;/$LH%Q?$E"P&[@CIZBOTAHH _,CX\_#GXB?L-_M;ZI^T!\/?#%UXR
M^'OB;S&\1Z58AF>W:5@\X<*"44R*)4EP5#$JV,C=-\5O^"@'B/\ :Z^'^L?#
M;X$_#;Q1'JNL6LEGK.N:O"D<&EVY4^?\T3. 2FY=S%3S\JEB!7Z8T4 ?#7_!
M'OP_JGAO]EO6;75M-O-+NF\57<@AO8'A<J;:U ;:P!QD'GV-?<M%% 'P3_P6
M%^$OB7XC? ?PWJOAO2+K6CX>U<W%]!91F26.WDB9#+L')56" XS@-D\ D,M/
MVM;S]L3]CGXZVR>!-6\-ZQH_A=H9(9BTPO9IH)LB'"*3@Q#CK\Z\>OWS10!\
M@_\ !*G1=0\/_L=Z#9ZI876FW:ZE?LUO=PM%( 9R02K 'FO)O^"T/AG6/$WP
MQ^',6CZ3?:M)%K%PTB6-L\Q0&$ $A0<"OT7HH \$_:X_9QC_ &HOV<-0\%"9
M;365CBO])N)6*I%>Q*=@?'\+!GC/!P') R!7Q]\$?V^_%?[(/@BT^&/[0'PR
M\6QW?AE%T^RUO2[>.9;BW7*Q*QD=(W"C:BR)(0R@<9!+?IY10!^8-KXW^.7_
M  4)_:"\+:GX3M/%WP@^#7AZ3-SJ27L^GS7J%E,PWQE?,E=0$55++&"23\QS
M^GO3BEHH *_-3]C?PMK6F_\ !4CX_P"J7FD7]KIES9ZN(+V:V=(92=2LR KD
M;6R 2,'H#7Z5T4 ,FACN(9(I8UEBD4J\;@%64C!!!ZBOPB_;X_8I\1_ 'XO7
MD/@S1M4U+X>>(Y#J6G0Z?!).EK(N0]NX4'!C,AV$_P $@&20U?O!10!\,_\
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M?&GB7P?XI\$ZUX[^#^KWCWNFZSHL?FM"P&T2#^%7=%C$D3E.4#*2!\WZM44
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M_'PH.?U(HH I:+K%IXBT>QU6PE,UC?0)<P2%&0M&ZAE)5@"#@C@@$=ZNT44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R.%(5*QHL8+%B%&,D
MG)/U))-/HHH :(U5F8* S=6QR<4ZBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_8[U7X,^%]2^)WC*PFTWQ5XDMA:V&GW *RVFGEED+2*?NO*ZHVT\JJ+T+,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,_M2?%BW\"Z7X+U;0[N:TFNQ=WES%)&!& 2,+SDYKV+_ (8I^ G_ $2'P?\
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M>*F_X)>>+_!U[ILMOXY\37#>*;72Y4V7$;Q&$P6[ ]'>.WZ'!!GP<$&O$_\
M@GK^WSX5_9&^'OC+P)\0M(UQ9%U234K-;&V5Y!,8TBEMY%=T,; PIC/&2^<8
MY_9^O(_B)^R3\&_BOXA;7O%?PYT'5]:=@\M^]L(YIR!@&5D*F3@ ?/G@ =J
M/S!_X)F^ -=_:"_;3\0?&G4+&2#1M,O-0UB>=E+1/?7GF*D"L1RRB9Y..GEK
MG&X9_9JL;PAX,T'X?^'[70O#.C6&@:-:@B&PTVW2"%,G)(50!DGDGJ2<FMF@
M HHHH Y?XI?\DR\7?]@>\_\ 1+T?"W_DF7A'_L#V?_HE*/BE_P DR\7?]@>\
M_P#1+T?"W_DF7A'_ + ]G_Z)2@#J**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E
M_BE_R3+Q=_V![S_T2]'PM_Y)EX1_[ ]G_P"B4H^*7_),O%W_ &![S_T2]'PM
M_P"29>$?^P/9_P#HE* .HHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .7^*7_),O
M%W_8'O/_ $2]'PM_Y)EX1_[ ]G_Z)2CXI?\ ),O%W_8'O/\ T2]'PM_Y)EX1
M_P"P/9_^B4H ZBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?XI?\DR\7?]@>\_
M]$O1\+?^29>$?^P/9_\ HE*/BE_R3+Q=_P!@>\_]$O1\+?\ DF7A'_L#V?\
MZ)2@#J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#E_BE_R3+Q=_V![S_P!$O1\+
M?^29>$?^P/9_^B4H^*7_ "3+Q=_V![S_ -$O1\+?^29>$?\ L#V?_HE* .HH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** .7^*7_),O%W_8'O/_1+T?"W_DF7A'_L
M#V?_ *)2CXI?\DR\7?\ 8'O/_1+T?"W_ ))EX1_[ ]G_ .B4H ZBBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH Y?XI?\DR\7?]@>\_\ 1+T?"W_DF7A'_L#V?_HE
M*/BE_P DR\7?]@>\_P#1+T?"W_DF7A'_ + ]G_Z)2@#J**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]Z^+OV+;ZX_9U^-?Q!_9EUF>0Z;92/XE\$37#$^=ID[DR0*3U,;D^Y83GH*
M/MBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E_BE_P DR\7?]@>\
M_P#1+T?"W_DF7A'_ + ]G_Z)2CXI?\DR\7?]@>\_]$O1\+?^29>$?^P/9_\
MHE* .HHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$G_!+_\ 9Q\3:H]_)X".GNZA3#INI7-O#QW"+)@'Z5E?\.G_ -FW_H4-0_\
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M^)'_  6NAM?%=Y9_#_X;_P!NZ#9R$C5-4OGADNHAPSB%8SY0ST+,3C&5!.
M?J)17S;^QK^W)X1_;"T._73[*7PYXLTM1)J&@7,PF*1LV%EBE"KYJ9P"=JE2
M0",%2WTE0 4444 <O\4O^29>+O\ L#WG_HEZ/A;_ ,DR\(_]@>S_ /1*4?%+
M_DF7B[_L#WG_ *)>CX6_\DR\(_\ 8'L__1*4 =11110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OR7_:Z_P"">OQ3^&GQDUSXN_ J9I=.O)+C4KBSM+M(+O3FD5C<J!(0
MLL+[I/D!)VL4*$#)_6BH+ZQ@U.QN+.ZC$MM<1M%+&20&1@01QZ@F@#\-OV:/
MV2/CI^V!\,/!>@S:O'H7P0TJ^N9K6ZGDB*B4R/Y[QP(?,EEW%U!DPHR0" 3G
M[=_X*!?LX?%#Q9\!?AW\'O@=X5EU+PEIN%U)1J=K;$16Z(EK$YFE0R;F9W;
M/S1J3SBOLGX9?"WPM\&_!]KX6\&Z1'H>@6KR20V4,CNJ,[%W.79FY8D]>]=5
M0!^&_P ./V)?VV_@^M^O@C0=7\*B_*&Z_LGQ3IT!GV9V;]MUSC<V,],FOK+]
MA_X8_M@>%?CQ:7_QGO/$,_@A;"Y21=2\26M]%YQ4>7^ZCG=B<YYV\5^BU% '
MY]?\%&/^"??B7X[>*K'XH_"Z:,>.+2&*"[TIYUMFO/+.8IH9F8*DJ#"X8@%5
M4A@5PWSAJW[)W[9/[9'B;PYI/Q?EGTGP[HS-$-4U9K...V4X#NL%N0T\C!0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !17&?&7XJ:1\$OA;XF\<ZZ^W3=$LGNG3=M:9QQ'$I_O.Y5![L*\=_8;_
M &MKC]JKP'K$^O:1#X;\::'>"'4M'A#J%AE7S+:95<E@KID<GK&QX!% 'TK1
M17YW_P#!3;]KCXM_"KQ=X?\ A?\ #'2;_3KCQ#9"8:_9VCS75U(SLGV:SP"
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M$3T/_H#:?_X"Q_X5\E_\$YO^0K^TE_V5/5__ $):W_V_OVU+;]DGX=01Z/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/V.3\(O ?_"T_%5CY?C#Q+; :=;SKA[#3VPP.#TDEP&/<($'!+"OT"I%4*H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ***\/\ B9^VY\#/@_JD^F>*?B3H]IJ5NQ2>RL_,OIX6!P5D2W21D;GHP!H
M]PHKR#X3_M=?!SXX7R6'@OX@Z/J^I2#,>GN[6UU(,9^6&94=L#KA3CO7K] !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!R_Q2_Y)EXN_[ ]Y_P"B
M7H^%O_),O"/_ &![/_T2E'Q2_P"29>+O^P/>?^B7H^%O_),O"/\ V![/_P!$
MI0!U%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '+_%+_ ))EXN_[ ]Y_Z)>CX6_\DR\(_P#8'L__ $2E'Q2_Y)EX
MN_[ ]Y_Z)>CX6_\ ),O"/_8'L_\ T2E '44444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#FI:A]AU".9OW>G7XPL5TI/'E.NP,W0H8WSA.?VMK\\?^"LO['O_  L[P/\
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M"_;A_8M^+'P:^.WB'XU_!^'4+_1]4GN-3NFT?]Y>:=+,K?:E>+&9(7+RGA6
M5F5@  6_7VOR^C_X*@^+-)^-WC;X7?&30=!\+:)!#J&D"_T^UN5FBNPK+#)(
M7E<&&0=P@_UB-NV@T >-?L'_ /!3:Q_9S\%Z-\-?&/A8W/A.WNI777=-E/VF
MV$LC.QDA((E 9C]TJ0HZ,>OZH?&;X2^$_P!K;X,1^'=0U2YD\):Y]CU)+W2)
M%5[B%72>,H[*P"N O.,X/&#S7XG?$+QA\,KS]@/X6>'8GLKGXKV>NWL[_9HP
M;BVT]I;@LL\@' 9C"RH3G^(#'7]F_P!BGPMK'@O]E'X7Z/K\<L&JV^BPF6"=
M=LD0?+I&P[%495QU&* /SU_X*R_!7P7\!?A'\'/"_@;0;?0M)COM2=UBRTD\
MACM\R2R,2TCGU8G@ #   _0']A7_ ),_^$G_ &+]O_*OC7_@N-_R*OPD_P"O
MW4O_ $7;U]E?L*_\F?\ PD_[%^W_ )4 ?G[_ ,%.O@/\8_C?^UGITWA3X?:]
MK>C6NFV6DV&I6MF7LRY:29F>3[B*'F969RH&WDXQ7/?&.;]MS]CVVT_XB^*O
MB#>:OI,UVD=PJ:G_ &A9PR-DK%-;NH5%;YES&,9&-P)7/U'^T-_P4PU3]G7]
MI]/AOXD\!06GA2.YM'E\1&\DDDDL9E4M<1Q",9*$N"H)YC8=:P/^"G_[67PL
M\3_LJ7OA+PQXQT3Q;K7B:YM#;P:->QW36T44Z3O++L)\O_5A,-AB7.!\K8 .
M5_:Z_::C_::_X)AVWC.WMAI]_>:Y9Z;K-E"3Y<-U$Q=U7.24)$;KDD@.H)R#
M7J/_  1IACB_9*U!D0*TGBB\=R/XCY%L,G\ !^%?-/PD_9Y\2:U_P2*^(,WV
M*=KS4=;;Q7IMK@EGM;?[/'(X7KDI!<$>H"'H178?\$GOVLOAO\*_@?XL\(^.
MO%NF^%KVRUB35K<ZE+Y0N+>2&)2L?]]U>)OE&6.\8!H \3^'K-H/_!8"Y^R-
MLW>/]34[>.)FG#C\G85^W]?B9^PEIMU^T1_P4FU7XA65M(=$M=5U;Q/<2,FW
MRXYC,MNI]&WSQ\=2%;T-?MG0 5B^*_&6C>!].CO]<ODT^TDE$"RNK,"Y!8#Y
M0>RM^5;51S6\5PH66-)5!SM=01G\: /'_B!\=/ FK^ _$EA9^(89[NZTVY@A
MB$4H+NT3*HY7N2*[SX6_\DR\(_\ 8'L__1*57^)^FVD?PU\6LMK"K+I%V0PC
M (/DO[58^%O_ "3+PC_V![/_ -$I0!U%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCXVOI;+2$G2UC6WA,LL\SY*QHHZL0K'D@ *230!Z'17PK_P^2^ G_/GXP_\
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M[(W @XP/@+^SK;?M;?M*#PIX!TZ]T'P,DWGW%W=R>?/9Z;&0IEE?&TSR<84
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD$$"#U9B HKXM^&^L7/[=?[5>C?$RSM+B'X*?#$SQ^'KJZB:/^W-6?"O<*K
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M9L L17T)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <O\4O\ DF7B[_L#WG_HEZ/A;_R3+PC_ -@>
MS_\ 1*4?%+_DF7B[_L#WG_HEZ/A;_P DR\(_]@>S_P#1*4 =11110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7?!'BBU^U:/JT!B<KCS(7!RDL9/1T8*P/J.<C(K\8OA3XZ\;_P#!+7]K*_\
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MJ**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;6;9%KFM7BXSYD&C3!?I\X4_I0!]<^*/$VE^"_#6J^(-;O$T_1]+M9;V\NY
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M,4F]'!7=R, $9//- 'SKXR_X+4_"?2/,C\.>$O%/B&5<@27"06<+>F&,CO\
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MD $&M_P4 _;@^-G[./Q:T_P]X'\'V4GAN33H[E=7O]-GNA=S,S!U5T=578%
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M44 %%%% !7BG[4'[)'@/]K#PG#I7BZUE@U&Q#G3-:LF"W5D[ 9VYX=#M7<C
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M,DYP2!0!^O/CSQ)??&S]GGQ)>_!7Q7IEUK&K:;-#HNMVMR&A28C!Q(N=CCD
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MF^\1%6#?V;H< LX3C^%Y7+NP/^R$/O7T-_P]&_9B_P"BF?\ E U3_P"1J/\
MAZ-^S%_T4S_R@:I_\C4 >4?MJ_!'P'\#O!OP#TCP)X5T[PS8M\4]%\P6<7[V
M<A9\&65LO(1D\NQ-?H#7YG?M>?MB?"']H[4O@;X=^'7BT^(]9M?B1I%[-:KI
MEY;%80SQEMTT**?FD08!)YZ=:_3&@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6G_QBC_@D_\ \F2^$/\ K]U'_P!*Y:^P* /C_P#X:M_:2_Z- U#_ ,+BT_\
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M>$?^P/9_^B4H^*7_ "3+Q=_V![S_ -$O1\+?^29>$?\ L#V?_HE* .HHHHH
M**** "BBB@ HHHH **** "BBB@ HKB_BI\9_ _P2\//K?CGQ/I_AK3P#L:\E
MQ),1U6*,9>1O]E 3[5^<'[0'_!: R-<:1\&O"Y9F)C7Q!XB3DGIF*U4_B#(W
MU3M0!^HNMZ[IOAG2[C4]8U"UTK3;9=\]Y?3K##$OJSL0%'N37QO\</\ @J[\
M#OAS#?Z9HFH7WC_5@C1!=!A'V4.01S<2%5*_[4>\5\+Z!^R/^UE^W'J,&O\
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M-*U+3M3EA&#A)I)GD7=G )1V'<?W: /'?"G_  1)^(.HLC^*/B+X=TC><O\
MV9;W%^PR>?OB')Q[]>_>L+3_ /@F)H%G^V/9?!;4_'6I7NG2>$O^$EDU6TL8
M[>4O]H,)B",S@#"D[LGKTKWY_P#@H!X[_9WU.U?X@>-/A=\<?!DTJQRZKX!U
MVU36+0,P&YK0.!(!S\J+CC+2"NN^'GQ6\)?&?_@ISHWB?P5KUEXAT6X^%F/M
M%G*&,3_;2QBD7K'( ZY1@&&1D4 4+7_@BC\%T@47/B[QY--SN>*]LHU//&%-
MJV/SI+S_ ((H_!AX2+7Q=X[AFSPTUY92+^0M5_G7Z#44 ?FEJW_!$'P7-O\
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M?A[^UY\%_BGY2^&?B9X<OKB3E+.:]6VN6^D,VR3_ ,=KUU6#J&4AE(R".AH
M6BJ^H2O!I]S(AVND3,IQT(!(K\V?V-?V?/&O[3WP#T?XAZ_^T;\8-*U34KF[
M26UTOQ/*ENOESO&-JG.,A>G3TQ0!^EU%?'__  [\US_HY[XX?^%5)_A1_P .
M_-<_Z.>^.'_A52?X4 ?8%%?!OP2\.^+?@?\ \%!!\-+GXJ^./B!X;N_ ;ZRT
M7B[6)+W9.;L1@JK':N!'P0,_,PS@XK[RH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ K-\1^)=)\'Z'>:SKNIVFCZ19QF6
MYOKZ98885'=G8@ ?6OF+]K#_ (*,?#;]F..ZT>&=?&/CI 570=-F&VW?''VJ
M;D1?[N&?I\N#FOS9V_M)_P#!4CQQG]Y'X3M;C_;M="TO^9EE /\ MR8/9>@!
M]%?M8?\ !8!(VNO"_P "[;[3<,3"_BZ_M\J#G'^BV[#YCZ/*,?[!X->6? '_
M ()F_%C]J#7AX]^-.N:IX;TR_<3RR:HS3:U?J?1),^2N. 9.1QB,CFOO#]D_
M_@G/\-?V8X[36);=?&/CI &;7M2A&VW?'/V6'D1#_:^9^3\V#BOJZ@#S?X(?
MLZ_#[]G7PV-%\!^&[71HF ^T7>/,NKMA_%-,V6<YR<$X&> !Q7I%9FO>)M'\
M*V+7NMZK8Z/9J"6N+^Y2",8ZY9R!4/A/QGX?\>:0NJ^&==TWQ%I;.T8OM)O(
M[J NOWEWQDKD=QGB@#9HKX1^,7_!7_X3_#3Q+K'A[1]!\0>+M3TRYDM)9[=(
MK>R>1&*L%E=RY 8'YA'@]037F'PJ_P""PVO_ !4^./@_PG:_"NWM-%US4H--
MD2'49+J]C\UPGFJ1&BD)G<5*]%/S#K0!^GM1W%Q%:0O-/*D,,8W/)(P55'J2
M>E?*W_!0C3?V@M6^'_AZW^ DES'=/>R#6?[-N(H+WRM@\KRWD(PF[=NVD-G9
MVW5\!6__  3-_:N^-4T=QX^\016A+;BWBSQ+)?R@'DD"+SN?8D?A0!^O_C[P
MKHOQ<^&'B'PY>WI;0/$6E7%C->6,RY$$T3(TD;\KD!B03D<=Z_'#QY\9/A%\
M)_#]SX?^'W[1/Q_\02:9 UKI=KH^L&STI&0$(@+%"L0( S'&>.@K]0OV-?V:
MKG]EWX%VW@+5/$'_  E,YNY[R:4Q%;>+S=N88D8D^6-N>>K.YP,XK\]_'G[+
M_P"SUI/[9MSH,(A\.?"WP+:?VKXUOM4U20V\EU,2UOIL)+9R1M^527($JCE*
M /"?V+/$UU\2/C5IG@J3QU\5/#&M>,KN634M>\+^*6B-U=!9)!+/#Y6Y^-P9
MVE8\LW0D#MOVE?@+\9_V0_C=I7P^^%/Q \=W.C>-";_2AI^LS6DM]>X"W"R"
M)T1Y@50EL9*O'U-?7_P__;._9D^%]TTWPH^#?B6^LUS#)XB\(>"T"%,J"7FD
M9)F7)&<@GVZ9F^/7Q<^&G[=WP=NK7X8>)FL_C#X-N%\1^'])OX6L]5CO+;+O
M%'&X_>%D5AB,L X0M]V@#Y)\+_\ !*#]HGXQ:Q-K_P 0-7L-!O;UA)=7GB+5
M7U#4)C@ ,WE^9N. !\\@( ]L5S7P_P#B-\4_^"9?Q>U7P'X\T7^W/ >K%DU3
M0IOWMAJMJWR-<VK.-NXID$$#</DD (&W]@OV8/CG8?M&_ _POX[LO+CGO[<)
M?VJ'_CVO$^2>+'4 ."1GJI4]Z@_:8_9G\(?M3?#BX\*^*K?9*NZ73=6A0&XT
MZ?&!)&3U!X#(>&'!Y ( *'[,_A7X(7G@?3O&?P=\->'+'2M40R)?Z781Q7 )
M^_%(V-ZLIRI0GY>F*]JK\,?A#\5/B1_P2W_:.U#PCXOM9[[PE=2J=2T^%B8+
MZV)Q'?VA; W@#OC.UHVP1E?O/]H+_@K!\)OA'8VL/A43?$;7+VRBO88=-D$-
MI"LB!T$\S E'VD$H$9AT;:: /MNOG?X_?M\?!G]G7[1::]XGCU?Q!#D'0-!V
MW=V&'\+X(2(^TC*?K7YC:U^TC^UG^WYJMQHG@NSU*R\/.QCEL?"Z-8V,:G^&
MYO&8$Y'57DP><)VKWKX _P#!%NRM/LVI_&#Q2;Z3ASH'AQBD7KMDN7&YO0A%
M7IPYH \H^*?_  5!^.?[2&O'PC\'?#MUX6BNR4B@T.%K[5YTZ$F4+B,=#F-5
M*_WR*]2_8I_X)M?%31?C)H'Q?^+'B"31]0L+G^T!IWVTW>IW<NT@"XFR552#
M\PW.Q&5(7.:_1CX6_!?P-\$]!&C>!O"VF^&;# WK8P@23$=&ED.7D;_:=B?>
MNTH **** "BBB@ HHHH **** "BBB@ HHHH **** /C[_@I9\'_B[\5OA3HL
M_P )=8U""\T2[DO-0T72[Q[:XU"/:-C1LK#>T94D1D_-O)&650?E/]E7_@J+
M-:1M\+_VD; ZII;[M.EUZ_L]\L0^ZT6H0,/WB_PE]N[CYE;)8?K;7RG^V7_P
M3Z\$_M6:;-JULL/A;XAQ1_Z/KUO%\MS@8$=T@_UB\ !_OK@8) VD \VL?^"5
M?PKU'XR>%_BGX!\7WVC>&8;VWUJ+1]+9+BWF9&$B&VN=^8XF(4XP_&0I7(V^
MP_'_ /X* ?"S]FSXIZ-X$\82:LNH7T"7-Q>65GYMO81.S*CRG<&.=I.(U<@<
MXK\S/A#^T-\:_P#@F7\3)/ GCG2+F_\ "+2F270KB0M!+&6YNM/GZ#/7 ^4G
M(=5;E?O3XK? _P""W_!4+X6V/C+PQK?V7Q':P?9K/7+=?])L6Y;[+>6Y/*AF
M)VY!YW(VUCN /L#PSXFTCQGH-CKF@ZE:ZQH]]$)K6^LI5EAF0]&5E."/\*TZ
M_%OX!V7[3'[ _P"T1HO@#_A']2\0^&];U&..73+..2ZTW482X62XMI,8BD5/
MF+':5 'F+MQ7[24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%,EE2&-Y)'6.- 69V. H'4D^E #Z9-,EO$\LKK'$BEF=S@*!R23V%?
M#'[4?_!6#X=?!O[9H?@(1?$7Q9'F,R6LN-+MGZ?/./\ 6D==L60>074UV_\
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MV.VR_P"^7^RBOVWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,NEZ[I\^FW36[[)!'+&48J>Q ;C@CV- 'Q-XB^(7_!/;PP[K=VGP\G9"5/\
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M2/YLPA+/+.X& TDKEG<XZ;F..U '!_MA?LD^&OVMOAI+H>IB/3_$=B'FT37
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M?5HVR#C]TJR/%GA/1O'?AS4- \0Z9:ZSHNH1&&ZL;R,212H>Q!_,'J" 1R*
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M +N[LG(^Y-$>4/!P>5;!*DCFO2J "BBB@ HHHH **** "BBB@ HHHH ****
M"BN*^)7QJ\!?!VWM)_&_B_1_"Z7;B.W&IW:1-*<X^52<D#/) P.Y%>3?MS3_
M !?U3]GJ5O@.[7/B&\NH?/N--F477V!E8N]JY(&\MY7S YV%BO.#0!=_:6_;
MD^%?[+ENUOXFUAM2\2%0T?AS1]L]Z0>C."P6)<<YD9<C.T-TJ&U\4Z#_ ,%
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M/+ ".JX+#&*_0CPOXPT'QQI::EX<UO3=?TY_NWFEW<=S"WT="0?SH V****
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MXY9B3P.>* .PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#3/%.CW>DZSIUKJVEW:&*XLKZ%9H9D/\+HP(8>Q% &=X7^('A?QMHJZOX?\
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M/]GNQT;]F73/@[XLU*?Q;IR:&=$O[R4F-YXV4J=G)*!0<)R2H5><BO /"O\
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MGB_Q'!-J%TENXVR)!;6L<FURI8 DG.3\T9PP_53_ (1/0_\ H#:?_P" L?\
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M *\Z_:!^!OA[]HOX4:YX%\21?Z'J$68+I5!DL[A>8IX_]I6[=P64\,:]%HH
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MGD# <@KUW-T !^D5<M\4OASI/Q>^'?B'P7KOG_V1KEG)97+6TFR558?>5NS
MX(R"..01Q74T4 ?C[\2/^"+?Q \,7!U#X<^/-+\0>2WF10:DDFFW2^@1U,B,
MPXY)3\.E9VBZU^UI^SWX+UWX<>-[W4I[_P ?HGA7PI8:KJT=_<B[EEC66XMY
M%=V2&.!I$)W *\\+ ?*V/V2SCD\"OR\C_:T^'FN?M;>)?C9XRO[C5=&\+A_"
MOPZ\-Z1!]JOM3FR5N;R&($##%F59'*AA*%R6CQ0!F?&;X\_&O]A;4]%^"OPL
M\ 6MYX-T'1K41ZS<:+<7AU:XE3S+FYW(P509FE79@D%3S@@#Y@^!W[8'[0G[
M.[2>#O!^AFWBUK4I-3M?#EUH,DI\Q\;TMH^'$9VCY5/&"1@DD_I:O[;'QHOL
M7VF_LD^,YM#8;A->ZI':WF#N*_Z*T);/R\C/&?IGQW]H_P#:$\+?M.>$;/5/
M"5MJ_@#]H3X6W?\ PDFF^%_%-D;34)8X@KW4" G$JM&F_P L'>WD@%0": /K
M_P",T7Q9\=_LJWQ\"K'X5^+&I:-:S);M*$-K<-Y;7,"2-PC[?-C5ST;!ROWA
M^9/A_P#X)0_M%_&#4EU7XC^)K#1IV/[V;7M7DU2^YZX\LNI_&45^M/P/^+6D
M_'7X3^&/'>B,/L&M6:W'E;MQ@E^[+"Q_O)(KH?=:[F@#Y;_8H_8-T']CB'7+
MR#Q'=^*?$.LQQP7-[);BVA2)"6"1Q!FQ\Q)+%CT&,<Y^GUM84N'N%AC6=P%:
M4* S = 3U(J6B@ HKB/BI\;/ GP0T/\ M?QWXJTWPS9$$Q_;9L2S8ZB*(9>0
M^R*3[5^=/[0G_!:"%5N-(^#7AIIY22@\0^(H\*.V8;93D^H:1ATY0T ?J;17
MY#_LE_ K]JKX\?'GPE\7O'?B+Q!X>T33;Z.]>^UN=X)+NW#;GMK:S& L<J_*
M?E2/:Y(W8VG]>* /F_\ ;*_8E\/_ +9&G^%HM6\0ZAX<N] GF>&>RC659(I=
MGFHR,0-W[M-K9XYX.:Z;]G?]CWX7?LQ::L7@SP]&-69-EQKVH8GU"?US*0-B
MGND85>.F:]JHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[7_  [I/BS29]+UO2[/
M6-,G&V:SU"W2>&0>C(X(/XBM&B@#XO\ C-_P2;^!WQ/\^[T*PO/A[JTF6$V@
MRYMBW^U;R94#VC*5\6^-/^"7?[1'[/>LOX@^%'B7_A(O)Y2Z\.W[Z7J04<_-
M$S@$?[*R.3Z5^T5% 'Q[_P $Y/''[0?B[PAXI@^.NCZE9KI]Q#%H]_K>G_8K
MZXR'\Y63:N]%Q$5D*\EV^9L?+]A444 %%?G;_P %"/V$/B[\>OBQI_Q#^'GB
MFWN!96*6T.BW=])9S63J22ULX&SYR<MDH0>[#I\O1_$3]O3]F(&'4H?&E[IM
MO_K&U*R37K7:.QN0)=H_W9!0!^V=%?CQX+_X+7_$70W-OXR^'F@:Z\1V-_9\
M\^FRY'!W;_.&?HH^E>Y>$O\ @MA\+]0VKXC\#^*=$D;^*Q-O>QK]27C;'T4T
M ?HK6+XT\9:-\//">K>)?$5_%I>B:7;O=7=W,?ECC49)]2>P Y)( R37R=I/
M_!6W]G34<?:-?UC2\[?^/O1IVQGK_JP_3O\ IFL;]M;Q;I7[1$G[./PYT#51
MJ/@KXG>(/[1O;NR=E%YIUFL<LD73(W>:#R 5:,9&010 WP_XP_:(_;>5M;\&
M:ROP$^#TS,-/U.6R6ZUW6(LX$JJ3B)&ZAE92,\&0<UN2?L._%;05?4/"_P"U
M9\0TUU?WB?\ "0.-1LF<%B 8'?:JD$#&".^#P!]AV5E;Z;9P6EI!':VMO&L4
M,$*!$C11A551P    !Z5\+_'G_@KO\-?A%XPUOPMH?AO6O&>L:/<R6=S-&\=
MG9>=&2KHLK;G;:P*D^7@XR"PP: .W^#'[4GCSP7\5K'X-?M#:38:/XOU)3_P
MCOBS2<C2_$&W *#./+FSCY<+DD#:A*!_JC7O$&E^%=)N=4UK4K/1],MEWSWM
M_.D$,2^K.Y"J/<FOPO\ VIO^"CWC#]JK1]-T:'P3I/ANWTB^36;*]LY)KG4;
M.:$$B1)P550%R6_=]@>, UN>"?V,_P!J']M^'2_%WB[Q!./#FH(MU9ZMXJU5
MI(VB89#6]M&6*@@\#8BG/7J: /LS]H'_ (*_?"_X<K=:;\/K6?XBZXN46YCS
M;:;&W3)E8;I,'LB[3C[XZUY7^PW^T)^U1^TU^T38^*]1GD3X6@RIJD?V!8-)
MCB"-B*W)&YY0^W!#,P_B.WBO<_@#_P $F_@]\(_LVH>*89?B5K\8#&36$"6"
ML.Z6JDJ1[2M(/I7VE8V-MI=G!9V=O%:6D"".*"! D<:@8"JHX  ["@">BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /D;_@J=\4/^%;
M?L>>)K:*7RK[Q-/!H,&#R1(3),/H88I1_P "KSG_ ((S_"__ (17]G/6_&,\
M.R[\5:N_E28^_:VP\I/_ "*;FO#/^"V7Q,?5/'GP\^'=I(SC3[*76+F&/G=)
M._E1 C^\%ADP/23WK]+/V<_AFOP;^!'@3P6$"3:/I%O;W..C7&P-.WXRLY_&
M@#T:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "OF7]J[]OSX:?LLM-HFJWEUJ_C.2V,L.C:5"LTD!9<QO.
M6=5122#C=N(Y"D8KZ:K\(=2U;PGIO_!13XH7/QN@62P_M;6DM_[1C:2WCG(D
M%@TBD$F+;Y6PD8&8R?E!H ^WOV._^"JWA/XK6^C^%?B?<CPYX^O;EH$O8[3R
MM*N"SD0HK^8[(Y! .\!<_P 7.*_0"OR8_9,_X)Z?#[]K']E/X=>)-5OKWPUK
M5E<ZI;WMYHL<0EOT^U/Y0E+J1F/'#8SM;!X"X^Z?VJOBEXD_9B_9BN=;\(VS
M>*_$>F+8Z79?VLC7$MU(\D< DD6+89)#G<0H4%NP'% %G]J;]LGP!^R+I6B7
M?C)=3O[G6)GBM=-T6**6Y*HN7E*R21@1J2JYW9RXP#SCTGX3_$K3/C%\-_#O
MC;1H+NVTK7+-+VVAOD5)T1AP'"LR@_1B/>OP1_:R^&OQMCL/#_Q6^-TUQ'K7
MB^>>"TL-1^2[@AA"-AH  MNG[WY8^"/F)49R?VE_85_Y,_\ A)_V+]O_ "H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY!![B@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^"OQ@^)7_">>+_!%MK'B-HDBEF>YFCBGV#:C2Q(X21@H"Y8'( !S@8]5\&^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OCO\
M;6_87^&'[2W]J^)9K]O#GQ!TW3I)GOM,>-GNHXHP4%S ?OA1M4,"K %06("B
MOL2OQ&^/7P1^*_[ ?[1WB+QUX(T2XU'P-JWVQ;>^AMFFM#97()DM+@)S&4R
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M5K44 9/_  B>A_\ 0&T__P !8_\ "K5CH]AI;.UG8VUHSC#&"%4)^N!5RB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /A/_@JA^R#
M_P +Q^&(^(/AJQ\WQOX3MV:6.)<R7^GC+218_B>,EI$'H9% )85SG_!)7]KW
M_A9?@4_"/Q/?;_$_AJWW:1-,WS7FG+@"/)ZO#D+C^X5X^1C7Z'=>#R*_$_\
M;H^!^N?L*_M1:%\6/ARATWP[J=\=2TTQ+B*SNQS<6; ?\LW5F(7@%'91]PF@
M#]L:*\Y_9[^.&A?M%?"/0/'?A]P+;4H?W]J6W/9W"\2P/[JV1GN-K#AA7HU
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEN[S3[>YF?\ M>107>-6;  P!DU]B_%+_DF7B[_L#WG_ *)>CX6_\DR\(_\
M8'L__1*4 >$?"/\ X)P_!+X)_$+2?&GAK1M377=+9WM)+O4Y94C9D9"VS(!.
MUFZY'.:^GZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ,EE2&-Y)'6.- 69V. H'4D^E?
MB9^R)')^UA_P4WN_'$ZM<Z7:ZI?>)SN!RD$)V68Y_NNUJ/\ @-?IS^WA\4?^
M%0_LE_$;7(I?)OI]-;2[,@X;SKHB!67W42%_^ &OD#_@B1\+_L?A/XA_$.XA
M^>^NX=$LY&&"$B7S9L>H8RP_C'0!^GE%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!R_Q2_Y)EXN_[ ]Y_P"B7H^%O_),O"/_ &![
M/_T2E'Q2_P"29>+O^P/>?^B7H^%O_),O"/\ V![/_P!$I0!U%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $5S;0WEO+;W$23P2H8Y(I%#
M*ZD8*D'@@CM7X?\ [1WPU\2?\$UOVP=(\;^"8W7PI>W#ZAHZLQ\J2W) N=.D
M//"AMH/)VM&WWAQ^XM>,?M;_ +-VD_M2?!76/!M_Y=OJ>/M>CZA(,FSO4!\M
M_7:<E&'=7;'." #N/A'\4]!^-GPWT#QMX9N?M6C:Q;+<19(WQMT>)P.CHP9&
M'8J:Z^OQL_X)F_M(ZM^S1\;=6^!GQ$\S2=*U74FM$BO&P-,U93Y>/39-A4)'
M&X1D<%C7[)T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% '+_ !2_Y)EXN_[ ]Y_Z
M)>CX6_\ ),O"/_8'L_\ T2E'Q2_Y)EXN_P"P/>?^B7H^%O\ R3+PC_V![/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,?%M^'\;^';<"QN+A_GU.Q7 !R?O2Q#"MW*[6Y(<@ ^_**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *_'C_@LU\19_&7QP\#?#?3-UTVC6'VA[>(Y+7=W( J8_O!(HB/\ KK[U
M^PV<<G@5^(OP7'_#8/\ P5-D\1N/MFB0Z_-K8D^\OV*Q&+3/L3%;*1_M4 ?L
M/\%_AW;_  D^$?@[P9;!?+T/2K:P9E_CD2,!W^K-N8^YKM*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?XI?\ ),O%W_8'
MO/\ T2]'PM_Y)EX1_P"P/9_^B4H^*7_),O%W_8'O/_1+T?"W_DF7A'_L#V?_
M *)2@#J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB/J5A8V\DK2>5#&$11EB23M5<GJ<<T ?;=%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?XI?\
M),O%W_8'O/\ T2]'PM_Y)EX1_P"P/9_^B4H^*7_),O%W_8'O/_1+T?"W_DF7
MA'_L#V?_ *)2@#J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *^2O^"JG_ "8YX^_Z[:;_ .E]O7UK7R5_P54_Y,<\??\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***X?XX_$JW^#OP>\9>-KDKLT/2Y[Q$?I)*J'RH_JS[5_
MX%0!^/7[3D[_ +8W_!3:#P;;NUSI%OJ]OX97:2=EK:DM>L/HPNF&/_KU^W4,
M*6\211(L<2*%5$& H'  '85^//\ P1I^&MQXW^.GC7XFZJ&NCH=D8([B7JU[
M>.2S@]R(XY0?^NH]17[$T %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 <O\4O^29>+O^P/>?\ HEZ/A;_R3+PC_P!@>S_]
M$I1\4O\ DF7B[_L#WG_HEZ/A;_R3+PC_ -@>S_\ 1*4 =11110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7AG[;'P1UW]HG]
MFOQ7X#\-3V5MK>HM:26[ZA(T<),5U%*P9E5B,JC <'G'UKW.B@#XWT^\_;FT
MW3[:SBT/X(M%;Q+$I>34R2%  S^]Z\58_MG]NK_H _ __OYJ?_QVOL"B@#\D
M/VOOV(?VE_VAM0E\>>(/"/PWB\0:?9,LZ^"[B[CN]31 "BLDS,LDB@$+@JQ!
M"Y;"@5O^"0O[4&@_#SQ!K_PC\6,=+U'Q'J8O=,U"Z8JLMYL6-[63/W7;8NS/
MWFW+U*@_KQ7Y=_\ !4+]@A[P:A\;?AK8-'J$&;KQ)I-FN#(!R;Z(#^,=9 .H
M&_J&) /U$HKX,_X)H_MYK\?/#L7P[\<WZCXBZ3!_HMY.V#K-L@^_GO.@^^.K
M ;^?GV_>= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!R_Q2_Y)EXN_P"P/>?^B7H^
M%O\ R3+PC_V![/\ ]$I1\4O^29>+O^P/>?\ HEZ/A;_R3+PC_P!@>S_]$I0!
MU%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 451OM=TW2[RRM+W4+6TN[UBEK!/.J/.PQD(I.6(R
M.GJ*O4 %%%% !1110 4444 %%%% '+_%+_DF7B[_ + ]Y_Z)>CX6_P#),O"/
M_8'L_P#T2E'Q2_Y)EXN_[ ]Y_P"B7H^%O_),O"/_ &![/_T2E '44444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%>:?M*?&"V^ GP+\9^.[AD\S2=/=[6.3I+=/B.W0^
MS2L@/L30!^27[:&M7G[97_!1"P^'>CSL^F:??P>%;>2(Y$:QN6O9L=,HQGR>
MZQ+7[5Z+H]GX=T>QTK3K=+33[&".UMK>,?+'$BA44>P  _"OR/\ ^"-/PANO
M&7Q9\9?%O6$>Z71X6L;2ZFY,E]<_--(#_>6+(/\ U\"OU]H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,G_KG_<% 'ZHT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y:?\
M%K/CAY-EX,^$NGS_ +R=CK^JHA_@&Z*V0XZY;SF(/]Q#Z5^H&K:I::'I=YJ5
M_<):6%G"]Q<7$APL<:*69B?0 $_A7XC_  )TZ\_X* _\%%KCQ7JUN\WAJ"_;
M7+F"496+3[4JEK;L.GS$0(PXSN=O6@#]1OV%_@;_ ,,^_LQ^#O#5Q;_9]:N+
M?^U=6#+AOM<X#NK>Z+LB^D8KWVBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *\._:W_:ITS]D?P!IWBS6/#FI^(;*]OUTX+IK1KY4C([J7+G@$1OR >0!
MWKW&N,^,'PC\-?'3X=ZQX*\6V7VW1-3CV2!"%DB8'*2QM@[75@"#CJ.01D4
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MKW"@,H)Z991W%=;^V;_P3/\ "_[47B0^,M%UIO!?C5XTCNK@6PGM;\*,*TJ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-/_@I
MO_P3]?QG'?\ QB^&>G$>)+=3<:_HUFN&OE49-U"HZS #+*/O@9'S@[_TLHH
M_/'_ ()I_P#!0A/B]I]E\+?B-J*KXYM(Q'I6JW#_ /(8B5?]6Y/_ "\*!U_Y
M: 9^\#G]#J_)S_@I5^P/=>"=4NOCC\);66R@@E^WZYI>FY22PE5M_P!OM]O*
MJ"-S@?<(WCY=VWZ"_P""=?\ P4 L_P!I#08/!'C6[AL_B;IT/RR,0B:U"HYE
MC'02J!ET'7EUXW! #[AHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+:VMXAA(HD4*BK[!0 /I0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** .7^*7_),O%W_8'O/_1+T?"W_DF7
MA'_L#V?_ *)2CXI?\DR\7?\ 8'O/_1+T?"W_ ))EX1_[ ]G_ .B4H ZBBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** &R1I-&T<BJZ,"K*PR"#U!%?D!_P %!OV"
M]4^ /B1OC9\&DN-.T&VN5OKW3],W)+H4X8,+B#;R(-W) _U9/]S[G[ U'<6\
M5Y;RP3Q)/!*I22.10RNI&""#P01VH ^.O^"?W[?6E_M1>'(?#'B>:#3?BAIT
M&;BWX2/58U'-Q .F['+QCI]X?+]W[)K\;OV\_P!@_7?V8_%@^,WP;:\LO#%M
M="]FM]/8B?P_/NR)(R.?L^>A_@S@_+@U]D_L!_M_:3^U)X?B\->)I;?2?B?I
M\.9[882+5(U'-Q /[W=XQTZCY?N@'V11110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%>2_M)?M+>&?V7_!^E^(?$VG:UJ\>
MJ:G%I%G8:!:I<74UQ(CNH57=!TC;^+))  .: /6J*^/_ /AY-H?_ $0OXX?^
M$A'_ /)%'_#R;0_^B%_'#_PD(_\ Y(H ^P**^/F_X*4:$BEF^!GQO50,DGPC
M'@?^3%>^_ 'XZ>'OVC_A;I7CWPO#?VVCZBTR)!J<2Q7$;1R-&P=49EZJ2,,1
M@CZ4 >B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[_L#WG_HEZ/A;_R3+PC_ -@>S_\ 1*4 =11110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX%_;M_X)C:5\=I+[QS\-
M4M/#_C]MTUYI[8BL]8;J23TBG/\ ?^ZQ^]@DN/OJB@#\8_V5?^"AWQ _9(\3
M?\*M^-FF:K?^&].D%HR7R'^U-% QM"[O]="!@A2>%(*-@!6_7OP%\0/#GQ0\
M*V'B7PGK-IKVA7R;X+VS?<C>H/=6!X*L 0<@@&O*?VJ/V-O '[67AG[)XDM/
M[/\ $-M&5T[Q'9(!=VAZA3_STCR3F-N.205;YA^4NN>#?VBO^"6?Q ;5=,N6
MNO"5W.%^W0H\^C:H/X4GCR/*EQQSM<?-L8C)(!^Z-%?FAX[_ ."MFC>./V6/
M$VI^#;W_ (0/XQ6B6HATN^A2Z1MUS$DTEL[J8Y0(V<[74,.3M(7=7LNE? _]
MKC5-+L[P?M2Z?&+B%)@A\"Z>=NY0<9V>] 'V517Q_P#\*!_:Y_Z.HT__ ,(3
M3_\ XBC_ (4#^US_ -'4:?\ ^$)I_P#\10!]@45\K?L!_%CX@_$G0/BAI?Q&
M\21>+-9\(^,KSP_%JL=A#9^;'"J+GRXE50"VYAQGYL$G KZIH **** "BBB@
M HHJKJ6J6>BV$]]J%W!8V4"EYKFYD6..-1U+,Q  ]S0!:HKXP^.G_!5SX*?"
M3[19:!?3_$;7(\J+?02/L@;MONF^0K[QB3Z5\/>+O^"@O[3W[6VLS>&_A=H]
M[H%I)\ILO!UK)+=JA/#37A&Z/_?7RAZT ?K/\8/VD/AG\!;$W/CSQGI?A]]F
M]+.67S+N5?5+=,R./<*17P'\;/\ @M=86;SV/PI\$OJ##*IK'B9S'%GU6VB;
M<P]"TBGU6N"^#_\ P1S^(?Q OAKOQ?\ %\?AO[2_G7%G:2?VCJ4I/7S)B?+1
MO]H-+]*^_P#X'_L%_!/X!B&?P_X-MM2UF/!_MK7L7UWN'\2EQMC/'_+-4H _
M,".U_;3_ &[B'9_$,?A6[Y#.PT71_+/(P!L\]1ZXD:O;_A+_ ,$1U'D7/Q,^
M(1;_ )Z:;X6@Q^5S,/\ VC^-?JG10!\U?#?_ ()R_L]_#/RI;/X=V.MWB<FZ
M\0N^H%CZ^7*3&#]$%>>?\%$]#T[P[X<_9_LM*T^UTRS3XIZ-MM[.%8HU^68<
M*H ' 'Y5]L5YQ\=OV>_ W[27A&V\->/M)?5M*M;Q;^!(KF2W>.94= P:-@?N
MR.,'CGV% 'H]%?'_ /PZ?_9M_P"A0U#_ ,'=W_\ '*/^'3_[-O\ T*&H?^#N
M[_\ CE 'UKJW_(*O?^N+_P#H)KY*_P""3_\ R9+X0_Z_=1_]*Y:/^'3_ .S;
M_P!"AJ'_ (.[O_XY7T;\(/A#X6^!/@'3_!G@S3VTSP_8M(\-O).\S;I)&D<E
MW)8DLQZGCH.!0!V=<YK_ ,-_"/BO?_;?A;1=8WG+?VAI\,^[G/.]3W /X5T=
M% 'A7BS]A?X >-%8:C\)O#,1;.YM,LQ8,<]\VY0Y]Z\9\6?\$?\ ]GWQ%YAT
MZV\1^%RQRO\ 9>K&0)SG ^T)+D=N3T]^:^VZ* /RY\9?\$/M,DCDD\)_%.[M
MG .RWUG2EF#>@,D<B8[<[#]*\:OO^"8/[4WP5NGO/A_K]O?N&WK)X4\12:?/
MQW(E\GGCLQ^M?M710!^)O_#0O[=O[/.X>(+3Q9=Z=!_K'UW0EU&V./6Z$;'\
MI*[_ .'/_!;CQ/8^7!X[^'&EZLOW7NM!O)+-Q_M>7*)0Q]MRC^5?KG7GGQ#_
M &>/AC\6/,/B_P  ^'_$$\G6ZO-/C:X'TF WC\&% 'SC\.?^"MWP \;^5%JN
MIZQX*NGXV:WIS-'N]I(#(H'NVW\*^H/ /QD\"?%2W\[P=XQT/Q.NW<RZ7J$4
M[I_O*K%E/L0*^3OB)_P1]^!'B_S9=!77O!%RW*+IM^;B -_M)<"1B/977^E?
M+WQ!_P""+OQ&\*7']H?#OQ_I.OO"WF11WR2:9=+Z!&4R*6]RR?ATH _8.BOQ
M*_X3;]NS]DGC4T\77NC6_#MJ,*Z]8[!T!G'F^6OT=3V]J],^&?\ P6XUNT\J
MW^(7PYLM0' DOO#MVUNP]_)EWAC_ -M%H _6FBOE7X5_\%-_V??BD((O^$Q_
MX1'4)<?Z'XIA-ELSZS9:#_R)7T[H^MZ=XBT^&_TJ_M=3L)AF.ZLYEEB<>JLI
M(/X4 7:*^6O^"@7Q:\??"WP/\/+;X=>((O"^N>*/&5CX??5)+&&\\F*9)<D1
MRJRGYE0GC.!@$9K$_P"% _M<_P#1U&G_ /A":?\ _$4 ?8%%?'__  H']KG_
M *.HT_\ \(33_P#XBHKKX#_M<6MK-,?VI]/81HS[?^$$T_G S_<H ^Q:*^<_
M^"?OQ@\5?'7]EOPQXN\::@FJ^(KF>\AN+U+>.#S1'<R(A*1JJ [0!\JCIZYK
MZ,H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBL3QIXUT+X=>%]1\2>)M5MM%T/3HC-=7UV^V.-1_,DX
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M[_L#WG_HEZ/A;_R3+PC_ -@>S_\ 1*4 =11110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX;K_ *M&\Q\'^])@]U[5]Q>$O!>@> =$AT?PUHFG^'])A_U=CIEJEO"ON$0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <O\4O^29>+O\
ML#WG_HEZ/A;_ ,DR\(_]@>S_ /1*4?%+_DF7B[_L#WG_ *)>CX6_\DR\(_\
M8'L__1*4 =11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!\O\ _!2[PIK7C3]C/QWI7A_2;W6]3D>PD2RT^!IYG5+V!G*HH+'"@DX'
M !/:N2T/_@HSH^FZ+I]G+\#/C<TMO;QQ,4\(H02J@''^D=.*^S:* /C_ /X>
M3:'_ -$+^.'_ (2$?_R11_P\FT/_ *(7\</_  D(_P#Y(K[ HH ^-O\ @FO9
M:S-HGQH\1:IX:UOPQ;^)/'^H:O86NO6+6ER8)51U)1O3=@E21D$ G%?9-%%
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ME_2VGX60D]%8*Y[*<9KZYH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Y?XI?\DR\7?\ 8'O/_1+T?"W_ ))EX1_[ ]G_ .B4
MH^*7_),O%W_8'O/_ $2]'PM_Y)EX1_[ ]G_Z)2@#J**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K/U[P_IGBK1[O2-:TZUU;2KR,Q7%
MC?0K-#,AZJZ,"&'L16A10!^9_P"U-_P1WT3Q)]L\0?!>^C\/:DV9'\,ZE(S6
M4IZD03'+1'T5MRY.,H!7@/PB_;P^/7[$/BJ/P%\6]#U+7M$M<(=*UYBM[;Q=
M UK='<)(^. 2Z$#"E>M?M=7#?%[X(^!_CQX5D\/>.O#MGX@TX[C']H3$MNQ&
M"\,@P\;?[2D'\* .7_9Y_:R^&G[3NA_;?!.OQS7\<>^ZT2\Q#?VG;YXLG*Y.
M-ZED_P!JO8:_';]HC_@E7\1?@7KG_"<? G6=2\0VEC)]H@L[:8PZW8X[Q,FT
M3X_V-K\@!&Y-=#^S)_P5\UOPG>1>%/CQI5Q>I;O]G;Q'96WEWENP."+JVP ^
M#U9 K#'W'- 'ZT45S/P[^)GA7XM>&;;Q#X.U^Q\1Z-<?<N["8.H/=6'5&'=6
M 8=P*Z:@ HHHH **** "BBB@ HHHH **** "BBB@ I,XY/ K'\8>,M"^'WAN
M_P#$'B75K30]$L8_-N;Z^E$<4:].2>Y.  .22 ,DU^0G[8/_  46\7_M0^(?
M^%5_ ^SU2W\.:E)]B,UG$XU+7">"BJ/FBA(S\OWF7._ )0 'M?[>7_!4BT\$
M_P!H?#[X-7T.I>(SNM]0\40XD@L3T,=MVDE]7Y5>VYON<'^PS_P3'U'QUJ%M
M\4?CO;W,MO=2?;K3PUJ+,US?.QW>??%OF"DG/EGYF/W\#Y6]C_83_P""8.D_
M!1M/\=?$^*VU[QXN)K32N);/2&Z@GM+./[WW5/W<D!Z_0*@"*VMH;.WBM[>)
M(((D$<<4:A510,!0!P !VJ6BB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .7^
M*7_),O%W_8'O/_1+T?"W_DF7A'_L#V?_ *)2CXI?\DR\7?\ 8'O/_1+T?"W_
M ))EX1_[ ]G_ .B4H ZBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ KY[_::_88^%O[4EK+<>(=)_LGQ0$VP^)-)"Q7BX
MZ"3C;,OLX) SM*YS7T)10!^'GQ%_9)_:._X)]>)KGQIX UB^U/P[!\\FO>'0
MS)Y2Y.+VS.["CDG<'C''S9KZ8_9K_P""R7ASQ(MIHOQCTG_A&=2.(_\ A(=)
MC>6QD/\ >EAYDB^J[QG)^45^E=?)7[2/_!,[X0?M!?:M3M=._P"$#\62Y;^V
M-!B5(Y7/>>VX23G))78Y/5Z /I[PKXNT3QUH-KK?AW5[+7-'NEWP7VGSK-#(
M/9E)!K7K\0O$O[*/[5?[!FLW7B+P!J.HZEH,;>;+J/A-VN8)$'0W5BP).!U+
M(Z+_ 'N]>V_ ?_@M,BQP:9\8/"+K*N$;7/#0R#VS);2-QZDH_KA!TH _5"BO
M,/@]^TU\+OCY:K+X$\:Z7KLY7>U@LOE7D8]6MY LBC@\E<<'FO3Z "N7\<?%
M+P7\,8;27QCXNT'PG%>,RVTFN:G#9+,R@%@AE9=Q&1G'3(KJ*^'?VUO"&B>/
M?VS?V5M \1Z5:ZWHM[)KJ7-A?1"6&91;PL RG@X*@_A0!]&_\-8_!#_HLGP_
M_P#"HL?_ ([1_P -8_!#_HLGP_\ _"HL?_CM9/\ PQ3\!/\ HD/@_P#\%,7^
M%'_#%/P$_P"B0^#_ /P4Q?X4 :W_  UC\$/^BR?#_P#\*BQ_^.UZ7IFJ6>M:
M;:ZAIUW!?Z?=Q+/;W5K(LD4T; ,KHZDAE((((."#7R=^U+^R/\%O"W[-?Q2U
MG1_A=X6TW5;#PSJ%S:7EMID22P2I;NR.K 9# @$'VIOP4_:>^&/[/7[&GPEN
MO'/B[3])N%\+6+QZ8LGFWT_[E<>7;KESGCYL;1GD@<T ?7M?.G[4W[=GPS_9
M5L9;?6K_ /MSQ<R;K?PSICJURV1\K2G[L*=.7Y(^ZK8KX!^/?_!63XC_ !HU
M0^#_ ((>'K[PW;WS&WANHX?M>M7>>,1(@9821G[F]QU#BM_]EG_@DEKWC?4(
M_&GQ]O[JTCNI/M3>'([DO?W;,=Q:[GR?+W=2JDN<G+(1B@#Q>ZU#]H/_ (*K
M?$WR(4^Q^$M/G'[M2\6C:.IZ%SR99BI/]YSDX"KT_4K]DO\ 8?\  '[)>B!M
M&@_MOQ=<1>7?^)KZ,?:)0<%DB7D0Q9'W5))P-S-@&O;/!7@?P_\ #CPS9>'O
M"^CV>@Z)9)L@L;&(1QH.YP.I)Y+'DDDDDUN4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '+_%+_ ))EXN_[ ]Y_Z)>CX6_\DR\(_P#8'L__ $2E
M'Q2_Y)EXN_[ ]Y_Z)>CX6_\ ),O"/_8'L_\ T2E '44444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^/\ \4?VW/VGOVJ/!/B2WM+"XL? J65Q)K$?A?1W6T6U5"91/<MO8)LR"#(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTJWTYKWRO*$[1QA2X3)V@D$XR<>IKMJ* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_HE7_EQ6W_Q- 'I]%>8?\)]\2?^B5?^7%;?_$T?\)]\2?\ HE7_ )<5M_\
M$T >GT5YA_PGWQ)_Z)5_Y<5M_P#$T?\ "??$G_HE7_EQ6W_Q- 'I]%>8?\)]
M\2?^B5?^7%;?_$T?\)]\2?\ HE7_ )<5M_\ $T >GT5YA_PGWQ)_Z)5_Y<5M
M_P#$T?\ "??$G_HE7_EQ6W_Q- 'I]%>8?\)]\2?^B5?^7%;?_$T?\)]\2?\
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M^+7B;4O#-KX8?3;G[,U[K]G93GRU??"Y;>OS XS@<CGWK+_X3[XD_P#1*O\
MRXK;_P")KF/'ES\2?&T&BQ_\*V^Q?V;JMOJ>?[=MI/,\HGY.V,YZ\X]#0![M
M17F'_"??$G_HE7_EQ6W_ ,31_P )]\2?^B5?^7%;?_$T >GT5YA_PGWQ)_Z)
M5_Y<5M_\31_PGWQ)_P"B5?\ EQ6W_P 30!Z?17F'_"??$G_HE7_EQ6W_ ,31
M_P )]\2?^B5?^7%;?_$T >GT5YA_PGWQ)_Z)5_Y<5M_\31_PGWQ)_P"B5?\
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M_P#+BMO_ (F@#T^BO,/^$^^)/_1*O_+BMO\ XFC_ (3[XD_]$J_\N*V_^)H
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M$^^)/_1*O_+BMO\ XF@#T^BO,/\ A/OB3_T2K_RXK;_XFC_A/OB3_P!$J_\
M+BMO_B: /3Z*\P_X3[XD_P#1*O\ RXK;_P")H_X3[XD_]$J_\N*V_P#B: /3
MZ*\P_P"$^^)/_1*O_+BMO_B:/^$^^)/_ $2K_P N*V_^)H ]/HKS#_A/OB3_
M -$J_P#+BMO_ (FC_A/OB3_T2K_RXK;_ .)H ]/HKS#_ (3[XD_]$J_\N*V_
M^)H_X3[XD_\ 1*O_ "XK;_XF@#T^BO,/^$^^)/\ T2K_ ,N*V_\ B:/^$^^)
M/_1*O_+BMO\ XF@#4\:>)M2TGXD> =+M+GRK#5);Q;N+RU/FB.$,G)&1@\\$
M>]=W7A/B*Y^)/B#QAX6UW_A6WD?V&]P_V?\ MVV;S_-C"8W<;<8ST.?:NG_X
M3[XD_P#1*O\ RXK;_P")H ]/HKS#_A/OB3_T2K_RXK;_ .)H_P"$^^)/_1*O
M_+BMO_B: /3Z*\P_X3[XD_\ 1*O_ "XK;_XFC_A/OB3_ -$J_P#+BMO_ (F@
M#T^BO,/^$^^)/_1*O_+BMO\ XFC_ (3[XD_]$J_\N*V_^)H ]/HKS#_A/OB3
M_P!$J_\ +BMO_B:/^$^^)/\ T2K_ ,N*V_\ B: /3Z*\P_X3[XD_]$J_\N*V
M_P#B:/\ A/OB3_T2K_RXK;_XF@#T^BO,/^$^^)/_ $2K_P N*V_^)H_X3[XD
M_P#1*O\ RXK;_P")H ]/HKS#_A/OB3_T2K_RXK;_ .)H_P"$^^)/_1*O_+BM
MO_B: /3Z*\P_X3[XD_\ 1*O_ "XK;_XFC_A/OB3_ -$J_P#+BMO_ (F@#T^N
M$F\3:DOQPM_#XN<:0V@->FW\M>9A<;-V[&[[O&,X]JR_^$^^)/\ T2K_ ,N*
MV_\ B:YB2Y^),GQ*B\6_\*VQY>E'3/L?]NVW.9?,W[_TQC\: /=J*\P_X3[X
MD_\ 1*O_ "XK;_XFC_A/OB3_ -$J_P#+BMO_ (F@#T^BO,/^$^^)/_1*O_+B
MMO\ XFC_ (3[XD_]$J_\N*V_^)H ]/HKS#_A/OB3_P!$J_\ +BMO_B:/^$^^
M)/\ T2K_ ,N*V_\ B: /3Z*\P_X3[XD_]$J_\N*V_P#B:/\ A/OB3_T2K_RX
MK;_XF@#T^BO,/^$^^)/_ $2K_P N*V_^)H_X3[XD_P#1*O\ RXK;_P")H ]/
MHKS#_A/OB3_T2K_RXK;_ .)H_P"$^^)/_1*O_+BMO_B: /3Z*\P_X3[XD_\
M1*O_ "XK;_XFC_A/OB3_ -$J_P#+BMO_ (F@#T^BO,/^$^^)/_1*O_+BMO\
MXFC_ (3[XD_]$J_\N*V_^)H ]/HKS#_A/OB3_P!$J_\ +BMO_B:/^$^^)/\
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M$J_\N*V_^)H_X3[XD_\ 1*O_ "XK;_XF@#T^BO,/^$^^)/\ T2K_ ,N*V_\
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M$J_\N*V_^)H_X3[XD_\ 1*O_ "XK;_XF@#T^BO,/^$^^)/\ T2K_ ,N*V_\
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MO_+BMO\ XF@#T^BO,/\ A/OB3_T2K_RXK;_XFC_A/OB3_P!$J_\ +BMO_B:
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M$J_\N*V_^)H_X3[XD_\ 1*O_ "XK;_XF@#T^BO,/^$^^)/\ T2K_ ,N*V_\
MB:/^$^^)/_1*O_+BMO\ XF@#T^L'Q]J=SHO@7Q'J%E)Y-Y::;<W$,FT-L=(F
M93@@@X('!&*X[_A/OB3_ -$J_P#+BMO_ (FLOQ3XD^)/B7PSJ^D?\*P^S?VA
M9S6GG?\ "06S>7YB%=V,#.,YQD4 >B^ =3N=:\"^'-0O9/.O+O3;:XFDVA=[
MO$K,<  #))X Q6]6-X,T>;P[X/T+2;EHWN+&P@M96B)*%DC525) .,CC(%;-
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7<C-A(EDCE<+(W8-@$D ,20*^Q* "BBB@ HHHH **** "BBB@ HHHH ****
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M!X(!H W:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1EL@'P;_ ,%-?@G^SG\.O@CX2U/X<1:'I/BJ:[BCL(=#O1.=0L2C%Y) ';>
M0A$QY).,G-=C^SO_ ,%<OASX!^'_ ,/_  -XDT#Q.8]'T>STR\U[9#*!+'"B
M,_E!]QC!!Y!+%1G;GBOECX@?LZ_#C]FK]NWPA\//%FH7NL> 8;K3Y=4O=3V1
M+*LWS9;9C;""45^<[5<YZ5]Y?\%,/V;O@]!^RMK'BVS\/Z#X4US1! VC7^CV
ML-J;EGD1?LQ$8 E5D+$#G;C<, -D ^X_"WBC2?&WAO3=?T*_AU31M2MTNK2\
MMVW)-$XRK#\#WY'>M6OAG_@CG?:U=_LCSQZFTC6%OXBO(M+\QB<6_EPLP4'H
MOG--T[EJ^YJ "BBB@ HHHH **** "BBB@ HHHH **** "BN9^)OC9?AK\.?$
M_BU]/N-6CT/3+C4FL;0@2SK#&TA1<\9(7_\ 7TKXQ_89_P""G&G_ +17B>Z\
M%^/K6Q\+>+;JYD?17MV(M;V)F)6VRQXF4<#M(!P W! /E+]N[Q18?$C_ (*3
MZ5X0^*.HS:;\-M%O--T\JTICBAM)HH9II-P^X)'D(:0<A5'/R#&C_P %5O@Y
M\!_AGX;\"W7PU@T71O%5S,8YM-T.X#I/8",D3R*&(!#A K\%][Y+;>/OK]K3
M]@GX??M<7%AJFMS7WA_Q18Q?9XM:TO9ODAR2(I48$.H+,1T()/.,BORY\,?
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M,LFC+J5FDEM"6D4QFWN8G9BI<G:'4KM8J"HY8 '%?\$T?V2?@1^TM\"_%?\
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MW@NSOUU+P]+HTUQ+/;D^3++;7<44,R^Q6>3'LP]* /V%HHHH **** "BBB@
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M!]I2/JO.5;C:6!*\95?I2@"OI^GVVDV%M8V5O%:6=M$L,%O"@2.*-0 JJHX
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MQS]CW]L+PK^UQ\/QJFEE-,\3V*JFLZ!))F2UD/\ &G=XF(.U_P #@@BO._\
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M\&@#8^#'QG\*?'SX?:;XR\&ZDNHZ1>K@@X$MO* -\,J9^21<\CZ$$@@GXO\
MV[O@3^UC\3/BU8:U\+/$/V/PG9VAM+&ST+76TRYB\P+Y[W&YD#EB!C:QPJ#
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M+_\ X27QMJD8AO=:>'RECA!#>1 F253< 22<L5!.  !]1444 %%%% !1110
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M?GED!)"26I=P?[K\X(8#[6N+>*Z@D@GC2:&12CQR*&5E(P00>H([5^2WD/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%0WEY!I]K-=74\=M;0H9)9IG")&H&2S,>  .<FN#\)_M"?"[X@>()/#WAOX
MB>%]?UH;A_9^FZQ!-.V!EMJ*Y+ #J5SCO0!^<7QP_:L^-_[97Q\UCX2_L\7U
MQH7AW1FE$^K6-R;.:Y6,A)+B6YSNCBWG:BI@MD$Y) 7+_96_: ^/O[,_[6VA
M?!/XQ:GJFO:?KMQ%9"#5[TWS1>:"MO<VUPQ+&/< I7=MQN&T,O'F?A'2_C/_
M ,$QOVE-<DT[P1>>+M U!7L(9%M96MM5M6D#0M'-&K;)@0N5Y()8$$$&H]#T
M_P"-G_!3W]I;5?&GAZ:Q\!7OA>RAMDODN9H%TB+?*88ED0&5IF=IVW #^/[H
M % 'WO\ \%-OV4Y/CU\'U\6>&[9O^$_\&J][9-;@B:ZM1\TT (Y+#'F)WW*0
M/OFNL_X)[_M51_M1? RTN-2N5?QMX?":=KD>1NE<+^[NL>DJJ2>V]9 . *_-
MZ'XI_M!_\$U?CYI^E>-]=U'Q+X<N66XGLI-0EO+#5;0MB22W:7F.4>N%8,%W
M J>?IC1_@-XW_9[_ &__  KXV^#>BRZQ\,/B5$UUJ5M#\EK96\FV2YWM]V,(
M62:+IG/E+GD$ _2FJ\&GVMK=7-S#;0PW-T5:>:.,*\I5=JER!EL  #/0#%6*
M* "BBB@ HHHH **** "BBB@ HHHH ***J:IJUEH>G7&H:E>6^GV%NADFNKJ5
M8HHE'5F9B ![F@">XN([6"2:9UBAC4N[L<!5 R23Z8K\AOB9^VA^T9^V-\5-
M?\-?LYV^IV/A'2B5CDT=8X+B>+<56XGN92/*+D$J@9.!_$037Z3P_%[X:?'K
M1O$?@[PC\1_#FMZI>V%S9M#H^K0SW$8:-D,BJC%B%W9W $>]?DQ^P;^TM_PP
M5\;/&W@'XI:5/I>F:E<16>J7$<1DETVY@+A)=J\R0LLK9VY."K+GD$ W/A9_
MP4F^/'[,'Q$;PC\;=/OO$NGV\BI?6&L0+#JEJA'$D,P $@Q\PW[@PZ,N=U?0
M7[?GPWT7]J#X'>&_VD_@WJ/VW7_"T:WGVS3\K<26<;[V##JDUL^7VG! \SJ=
MM>5?\%'OB5\+_P!L#XB?!WPA\+]6M_$WC"[U V$^K:?:NZ06\[QJB.Q +[6W
MR;1G: Y.W=SPW["_Q,\8?L9?M>7?P3\<(T>B:]J*:+J.GR-O@2ZD 6UNHL\;
M9-\8)XW1R D950 #]-/V*_VFK']JCX&:3XH#Q1>(K7%AKME'@>3>(HW,%[)(
M")%] VW.5->\U^<7P7_9Y^(7[(O_  4&N]+\!:'<:C\'?&EI)>71!VVVGP*2
M=K,>!)!*X5%Y+1RXZDE?T=H KVNGVMC)<R6UM#;R74GG3O%&%,LFU5WN0/F;
M:JC)YPH':K%%% !1110 4444 %%%% !1110 4444 %9GB;Q)IO@WPWJNOZS=
M)8Z1I=K+>WEU)G;##&A=W..P52?PJ?5M8L- TZ?4-4OK;3;" ;I;J[E6**,=
M,LS$ #ZUXI\;K[0/VG/V=?B7X4^'/B_1/$VK7VBW-O"-$U2"Y'G;3LC=D8A0
M[+L)/8F@#\Y_&?[;O[4O[6GBK7Y/@9H^M:3X,TJ7:D.@V,<EQLR?+:XG92?,
M8 GRT(&.,-C<=/\ 9Q_X*U>/?A[XP_X1/X]V$FK6$=Q]EN=4%B+34]-<':WG
M0JJK(J]UVJXY.6/RUG?\$O/VS/"_[.'_  DOPK^)1;PQ9WVJO?0:K=1,$M;O
MRTAE@N!C<@Q"F&(PI#!L9S5;]OF#P1^V3^UMX&\-_!C4--U[Q1J6G26NI:M8
MY-I-*BM)"'D488I&K!I!D*I4$_(0 #Z;_P""D_P#M/V@/@SH?QO^&EXE]XE\
M*VZZG::EI,F6OM-SYI:-UY+1']ZO.0/,'4BO>/V'/VG[7]JCX%Z9XAFDB3Q3
MI^-/UZUC 79=*!^\"]DD7#CL,LO\)KX*_P""4?[0OB/X9_&#4_V>_&BS0V-Y
M+=)96-[G?INHPAFG@ [*ZI)E>F]!CEVS[?\ !K]E?XA_LO\ _!0#4Y_AYI@;
MX,>*K*2\U'S'\NVLH\DB <<RQS']VH'^KD(R!O8 'Z$U0T?0=,\.VLEMI6G6
MFF6\LTES)#9P+"CRR,7DD(4 %F8EBW4DDFK]% !1110 4444 %%%% !1110
M4444 %%%5-3U:RT6S>[U&\M["TC^_/=2K'&OU9B * ,_QMXOTWX?^#==\3ZQ
M*8=)T6QGU&[D49*Q11EW('<X4X'>OQZE_:(_:\_;E\4^)];^$CZMH7A;1&RF
MEZ%?Q62P*P)1&F=D:XF95)(!(ST500*_5SX@Z/H/[0WP8\8^&=&U[3]1L-?T
MJZTM=0T^Y2XBB>6)E5MR$@[2RMCVK\B_^"?O[4=S^Q/\9O$GPS^)EL^D>'=2
MO_LNHR3(0^E7T9*+,WK$PX8^FQQP"& .^_9H_P""JOCWX6>-#X'_ &@;6YU"
MP@G^R7&JS6?D:II;@X/GQJH\U!W^42#DY?A:[[_@HE\-;SX=^,/!?[7GP?NH
M)WMY;:35;G3V$D%PC )!=$J<-'(C>1)SR&C]6->^_MT?L*^'?VNO!P\2>&VL
M]/\ B):VPDT[5XBODZG%MRL$[#[RD8V2<E<]U)%?&W_!,OXSWMGXN\2?LM?%
M&RENO#FO17ME!I6I AK&[17-S:D'E%=5E.,_+(@QRY- 'ZE? GXRZ'^T!\*/
M#WCOP\^;#5K<2- S O;3#Y987_VD<,OOC(X(KOJ_/?\ X)__  <^*O[+O[1/
MQ0^%EUIMUJ7PF4+J5EKEP=D0E? @>/L[O&"DJJ/E:%3D#&[]"* (+.QMM-@\
MBTMXK6'>TGEPH$7<S%F; [EF))[DD]ZGHHH **** "BBB@ HHHH **** "BB
MB@ KC/C)\5M%^!_PO\1^.O$+.NDZ):FYE6,9>5LA8XU_VG=D09XRPSQ6OXP\
M=>'/AYHSZOXIU_3/#FEJVTWNK7<=M#NP2%WN0,\'CKQ7S5^V VB?M>_L>_$+
M1_A5XFTOQIJ,,5O>);Z#J$5R7:&=)C"ZHQ(9DC?:IP2P7% 'P2_[07[:W[7'
M]J^-?AY!KNG^$K"X80VGAGRK:"+;SY2LQ$ETX!&X?/U^Z!@5WG[*7_!6GQ/X
M9\4Q>#/CY";FS$WV1O$:VGV>]L) VTBZA4 .H/!*JKK@DAST/^"9/_!0#P5\
M)?A__P *H^)-ROAJVL;B:XTK6WB8P,)'+R0S[02C!RQ5R,$':2NT;O,/VHO!
M^B?MW_MG^(8O@4L6IF'PXUY?7\<#1P:A>6ZMN920,;P8(0[8!< YP0U 'M?[
M=7@?4?V6_C]X._:M^%HBN] U:YC.M163AK>>21>7++D&*ZBR-PX$@W9RZU^E
M'PQ^(VA_%SX?Z#XR\-W0O-$UJT2[MI.-P!ZHP[.K JR]F4CM7Y:?\$ROB>GQ
MG\&^.?V6OB9'-?Z)<Z=/-I:761-:*K@36Z[N5*.RS1\?(R/[ >]?\$T?AY\6
M_@'XP^*?PG\6:5//X"T.]\[2]=ERD3SOM.( ?OI+$4D('$; @_,YH ^^*KZ?
MI]KI-C#9V-M#9V<"A(K>WC$<<:CH%4# 'L*L44 %%%% !1110 4444 %%%%
M!1110 445S?CKXD^$_AAI(U3Q?XETGPQI[':MSJ][';([==JER-S>PR: .9_
M:,^.6C_LX_!SQ%X^UJ-KF#3(0(+.,X:YN'8)%$#VW.PRV.!D]J_**&X_;5_;
M$\,ZI\7O#FO:UI?ARWEFDT_3-!U>33$E\K*NMI C@RE<,NYB69@R@L<BOO/]
MLCP7I?[;W[*6O:;\+/$VC>+-0L;F'4K,:5?Q3QS3Q DV[,K81V1V #8^8KG
MY'Y^_!G]O3XU?LB?!&_^&=]\-95;13,EAJ>M6=Q;/I1FD=L3(4Q(/-9RNXKR
M<9(P  ?:G_!+7]K;Q9^T?X#\4:!XYF.H^)/"<MLO]JM&$>ZMYA($$H P9%:%
MP6P-P*YR02?"_P!K3PGJO_!/_P#:^T#X_P#@RRD;P+XIN7AUW3;8;4$LGS7,
M'H/- \Z//22-N@4 ^'_ O]@']HOXB?!6?Q_X2\5Q^';3Q /[1AT1M7N+2XU8
M(6\N5@B^7D[G,9D8?>)RH;)]%_8U^,OB#]I:'QC^RG\<[K4=8;4[2XCTO4M5
M)DU'2[ZVRS1NS_,Q0H7&XD@Q,IRK84 _6KPEXKTGQUX7TKQ%H5['J.C:I;1W
MEI=1'Y98G4,K>W!Z'D=#6K)&DT;1R*KHP*LK#((/4$5\/_\ !+[PS\6_A9X;
M\>_#+X@Z'/;>'O"VK-;Z-JDS865F)::. 'EX3E95<<9E8=>%^XJ (;.SM].L
MX+2T@CM;6"-8HH(4")&BC"JJC@    #IBIJ** "BBB@ HHHH **** "BBB@
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M\G6/'&I1+_;&O;/O=#Y$.>5A4_BQ&YNP7Z3HHH **** "BBB@ HHHH ****
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M?]A3XXWW[1G[+OA7Q/K-P)O$*I+IFJ30_*6N(7*>8<=&=/+D..,N< "ORI^
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MC:YKX>_#;PM\)_#-OX=\'Z#8^'=%@)9+.PA$:;CU9N[,>[$DGUKI: "BBB@
MHHHH **** "BBB@ HHHH **** "OQ7U.3QY_P5<_:J\0>%T\6#PSX#\/K<75
MC"T;30VMK'*(4E$ =1+/(74LQ88!8 @*%KZE^#_[7GQ \!_MY^-_A#\:+R&/
M3_$-VH\,2QIY=K!_SZI%G^">/ .23YR@=2U>M_LT_P#!/[PA^S;\8/%_Q"TW
M5]0OM0UB>X2PL5/D6VGV<L@?R"JG]\00 &;@!5PN1NH _._X.^%?&'_!/O\
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M3MG:<<'MFOSX_9-_:W\=G]JCXD_ SX\3PC7=0OYI='*IY=LA$8_T6$'GR9(
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M(^&?@O\ M]?#C1_BQXG^$6G)X@G8VUZVH610R3Q$!BDHV_:(L\!CGH5."I
M/E/_ ()>_#W7OC+^U/X^_:"O-'_L+PY)/J$EM'&I$4EY=REFBC)QN6-&?<?5
MD]3C]9JH:#H&F>%M'L](T;3K72=*LXQ#;6-C"L,,*#HJ(H 4>P%7Z "BBB@
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M9:_1G]C']E]?V3?@[#X/;Q#=>(KZ>X:_O9I"1;1SNJADMT/*1_*.IRQRQQG
M_.35 MY_P6D3RFV!?$L.3CNM@NX?B0?SH ]?_P""T'PC\3ZQH_@+XE:)%<W.
ME^'3/::@UMN+61D:-XI^/NJ60J6['R^>17"77_!9JXU3X$76@77@::;XBW&G
M-I[:D+E/L#R,A0W)3&[/.[RL8SQN KZ._:R_X*;>#/@3\3M,^'^FZ*OCR1;G
MR/%"6[ADM(6!5H(Q]V2?D$H?E &PG<QV?0W@G]FWX-:=>6'BS0OA7X9T?4IT
M2[@N#H$5M<P%P'!V,@:)QGD8#*<CCF@#YA_X))?LO:]\%?AGK_C7Q98RZ7K7
MB]H!:Z;=1E)[:SAWE6<'E6D:0MM(X5$/? ^^:** "BBB@ HHHH **** "BBB
M@ HHHH ***\*_;=UWXC^&?V9_&>J_"UTB\3V=MYSRJA:XCM!_KWMQT\U4RP)
MSP&P-VV@#F_^"AG[26J_LQ?LZ7OB#P]Y:>)=5O8]&TVXE0.MM+(DCM-M/!*Q
MQ2%<\;BN01D'\T_#_P#P3D\?_&S]FW4OCYJ7CR.^\1ZA:7&MII%]$\\][#&6
M+-)=M)\LK!&*KL8?=!9<G;]F>";K1O\ @JS^Q79Z#K>L+HOC31M0M?[3N8H!
M(;>\BROV@197*S0/+CD ,[#G8<_0,_[*>G:#^R5J?P/\'>(=5T2TFTF?3[;5
M[BX,TZM(2[E\C&QV9@R(%&UV"[3@T ?'G_!-7]IKPHW[+OB#PA\:O&6AP:!;
MZC)I6FP>)K^,-<6<D"M);!)#EXD+'L0!(%R % ^>?VE/V,?%?[-'B2R^,_P#
MUN?Q)\.Q,=0T[7/#UR+J;2.3E7="WF0@97S>5(RLF.K_ $=X=_X(J^%IO@[%
M!K7B_5+;XFR6WFO>6CQOID%P1Q%Y1C#O&#P6W*Q/(P/EKS?_ ()!_$#Q1X _
M:$\;?!S5)V?2&M;J>6SR72VU"UF2-G0]%#*75N/F*Q^E ''?%#_@K!X@^-'[
M-^L_#77/ -C/XHUNV73[C6K>Y/V=U+*3*MJ4)$IQP ^ Q##H%K[M_P""7?[/
MOB'X!?LW>7XKMI=.UWQ'J+ZQ)ILZ[9+.)HXXXD=>SE8]Y!Y&\*0"IKZ+TOX*
M?#S1/$A\0Z=X"\,V&OEMQU6UT>WCNBWKYJH&S^-=I0 4444 %%%% !1110 4
M444 %%%% !1110 5\;?\%//VK-<_9H^#>F6GA&?[#XL\57,EG:ZAM!:S@C4-
M/*F<CS/GC49'&\MU45Z5^W9#\2)/V8?&,OPMU*33?$EM!]HE:U4_:I+-<FX2
MW8'*2[,D,,M\I"X9@1\I>&O#>E_\%:OV:/ JZMXB7P_X^\#ZFMOKTZ0"5Y(G
MCVO(B9&#.L<;@_=#QR#! H ^4O'W_!.GXGZ#^SF/CUJGBJUU+4YK6+7[[39)
M)6O8X)=KB8W#'YY0'#LO&,-AF(P?OW]@O]K#0O%G[*_AU/C#X^\/6FN//=:5
M&WB?5K>&XU.V1@JLZS.#*<-Y9.#NV<Y)->E?M%?LNZKXP_8UNO@[X!\07EC<
M6.G6]G8R:C.)&OHK?:5MIY2.%<(!E< 84?<RI^/_ !M_P18L-+^"\EYH'C34
M;_XE6=F;F6WG2/\ LV[E5=S01*$$D>3\JNS-GC*C/ !^IMK<0W5K#/;21S6T
MB*\4D3!D92,@J1P01T(K\R_^"BG_  37F\47EY\4O@]I3'79)/.UGPS8I@W3
M$Y-S;*/^6F>6C'WOO+\V0T?_  19^-VN^(-'\9_#/5;N2]TK18H=3TGS26:V
M61V2:($]$W;&"]BSGOQ^GM 'D?[*?AGXD>#_ ($>%]*^*^LPZWXS@@Q<31_,
M\4?_ "SBEDR1-*B\-(,9/][&]O7*** "BBB@ HHHH **** "BBB@ HHHH **
M*^2/^"E/Q+^+7P?^".F^+OA?<16EOIFK03:[,L/F3I;A@8\9X\DR!5D&,D.H
MX7?0!Q__  5;_:H\1?L__"WP_P"'/!U[+I'B+Q?+<1G5;<E9K2TA">;Y3?P2
M,98U##D#?C!P1\+?%S_@F?XR^&'[,\/QHN_&-KJ6IK;6^J:IH@MV62VCF9<,
MMR9#YLBF1"PVK_%AFP-WWQX[^#_@7_@JE\%?A7XU36;CP\NGW3R7JV:K+/"&
M0+>67/"OYD<161@?E ;:0U>D?M3?LJWGQ;_9.?X2>"M=N-#;3X+2.P%Y<O)'
M=QVP&RWN9#N=D.U3GJ'1#R 00#R_]AS]L7PA??LL^"8/BW\2/#UEXED6YL=N
MO:I"EQ=6\<[Q1O,)&SRH"EF^]M))/)K[:L[RWU&S@NK2>.ZM9T62*>%PZ2(1
MD,K#@@CD$5^87Q<_X(U^%?#_ ,#[V_\ "?BK6+KQ_I-@]W(U\8_L6H.B%GC6
M,)NBW8(0[VQD;L]1H_\ !%7XP:YXC\(>.OA[J=S)=Z5X?:VOM*WY;[.LYE$T
M6[LNY%95]6DH 9_P4,_X)GW/C+5)_B7\&]+7_A(+B8/J_AJU*Q"Z=FYN;?)"
MK)DY=<@-RPPV0WW1^S9X1\=>!?@GX6T/XD>(8_%'B^SM0EYJ$:G_ (#&SGF5
MD7"F0@%]N3R<GTVB@ HHHH **** "BBB@ HHHH **** "BBB@ K\[?\ @K9^
MUAXJ^$.C>&_AQX*U";1=2\26\MWJ.IVKF.XCM0PC2*)P<IO;?N88("  _,:]
M$_X*6_&?XN? 'P?X'\:?#YX$\+Z?K,;^(1Y1:20;E,,4A_AMY#O1R,'<8QGY
ML4SXK?LT?#K_ (*6^'?A+\4(-?O-,T>&WD:ZBLE0SW$#X+VK.<B.2*9&4MAN
MK\<@@ ^ /VE_^":/C']EGX+Z=\3W\9VNKWEG/;_VK96=NUN^FRR,JH\,WF$S
M 2E5W;4()! (SC[?^&_QB^$/[3'[&G@KP9\>O'?AJ+Q+K6FA;B+4=7@AOHIH
MY9(H+L%FS',RJKY/WMY!!#$'U?\ ;:_9/U?]I#X!Z7X"\*^)9M"ETR\M94BO
M9GE@O(HQY96X<YD<JI,@))W,@W9)#+\@?M._\$B_"/PY^ FM>+/ WB76;CQ'
MX;TY]1OHM6>)[>_AAC+S[%5 T3[59E&YAQM/7< #YZ\9?#'XW?\ !,+XQ1^*
MO#ES)?>&IG\NUUZ&)I-,U6V)R(+I <(Q&/E)!!&Z-C@-6W^U)^W)XB_X* >&
M_!/PP\-_#)[+7#JD=X4M;LWDMS<B*2,)$/+7RX\2.S%B< #) 4D_7'_!'[XG
M:E\5/V?_ !3X'\4;=:TWPQ>16UFM]'YJ_9)T9A V[(959'P#T# =  /M_P &
M_"7P-\.;BXG\)^#/#_AB>XSYTNC:5!:-+DY.XQHI/([T <_^S1\*[CX(_ /P
M-X&O+A;J^T;3(X+J6/E#.<O*%]5#LP!] *],HHH **** "BBB@ HHHH ****
M "BBB@ HHKX:_P""C/[0GQ9_9G\7?"OQIX;\N;X9V]^4UNTAC_>74Y##R9G/
M1&A+F/ XD0LV2$P >:?\%7_VF/&6E^+O"WP*\"W\FDS^(K6*?5+JVE,4MPL\
MSP0VOF _(A*,7Q]X,HSC<&^5_P!JS_@GKXP_8I\$^&?B+8^.X]8D%]%;7$VF
MP26,^FW3(7C:%_,+2+E&&_Y&!V_+R<?HI\6OV.?AQ^W1XX^&GQGC\1WB: NE
M(SQ:7^[DU*'?YMNIE!W0LC/*KX!?HH*%<C=_;U_9!UK]K?P9X.T31O%3Z%#I
M&KQSW=K<$O!<0/B.24CJTT2%BF3@[Y 2"P( .$N/'GP7_;"_9=\$>"?B]X^\
M+V7CG6M%LKL[M4MHKZSU!H1MG12PV2-G/EG&X/MQ@BO@&XT7X[_\$K_C,^H0
M1M<:!=R>5]K".^D:[;@DJKX^Y* 3P2'0DX)4Y;V_]M/_ ()5>$_@Q\#M1\>_
M#W7=9N+KP_$DVIV.LRQ2K<P[E5I(V2--CKNW$'((!Q@CGZ._X)6_$B]^.W[)
MMUH/C6*+Q#%X=U-]$C_M&$3I/9B**6))-X(<IO9!GHJ)0!\+?M/?M5^)_P#@
MI/XE^'G@7P;\-WTW4[.:5DA2[^V2RRRA%=C)Y:"*% F68\=SC;7[._!_P'_P
MJSX3^#?!OVG[:?#^CVFEFYQCS3#"L9?';)7./>K'@OX6^#/AO',GA'PCH7A9
M)O\ 6KHNFPV8DYS\WEJN?QKIZ "BBB@ HHHH **** "BBB@ HHHH **** "O
MRS_X*/?'SX@?%;]HG1_V8_AWJ+Z/!>-:VFJNDIA^V7%RJR+'*Z_,($B=&91]
M[<V0V%%>M?\ !23XR?%[]G3QK\*OB-X8OFE^&NFWOE:OI%N"GVBX;<"EPW.Z
M.2$NJ<81U+'+%,:Z_L;^"?VFOVC/"7[3^C^+[R/P_?V5AJT-AIX\J>>\@ 6-
MGES^[54CC1XP-VY&&10!^>7[0G[+/Q,_X)P>+_!?C31O&D5U)=RL+75M*#V[
M1SQ[6>"6-B=\; ]"2K@,& Z']F?!?QV^'?CN?0=.?Q?X4F\9M#%='0(]6MI;
MZUN'A^=5AW^8K 2,O0'#$=Z\"_;T_8A\3?M>>-?AK)8^+?[*\+:7+-!JUC*H
M/V>-QO-S",9>5MBQ;6.!E",#?GXB_;N_X)M6?[*O@>Q^(O@#Q+JVI:+:74-O
M?0:JT?VNTD<XCGCEB1 5WX7&T,I*D%LG !^RWB;PSI7C+P_J&AZYI]OJNCZA
M"UO=65U&'BFC88*L#U%?DOX\_P"";/Q;^!/[4WA;5_@+?7$>@WU\9;'6I)?^
M0$ "9(KLG.^+9N )!\P?(06/S?>'_!/WXT:S\>/V5O"'B3Q'-]JU^+SM.O;H
MC!N'@D9%E/JS($+'NQ;ITKZ+H @L4N8[&W2\ECGNUC432PQF-'? W,JEF*@G
M) )./4]:GHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *SO$7B+3/"6@ZAK6M7T&F:3I\#W
M-U>7+A(X8U&69B>@ %:-?!?_  67\3:SH?[+.E:?ISR1:=K'B*WM=29.CQ+%
M-,D;>QDB1OK&* ,_7_\ @M%\(=+\6OIUAX:\4:QHL<IC;6(8H8Q( <;XXGD#
M%2.1NV'V%?1?[2OP/T3]LS]G"?1?+DLKK4+2/5="N]0MG@FLKK9NB,B, R9#
M%'4C(5VXR!7QM\'[7]F+X'_L&^ ?B]X@\%:;XIUV&>-UD>-&U&ZUI)&)@WDC
M:B%"VT_+Y:!MK$_-R$7_  6B^(NDZ]9WNN_"C2H?"]X!+;P++<PW,L>>62=\
MH_!ZB/% 'M?_  2O_:,U.\T?6?@#X]\RQ\;>"6DBL8;P_O9+1'V20=>6@?@?
M[#+CA":]R_X*/^&[KQ5^Q-\4K*SC:6:.RM[XJ@R?+M[N"XD/T"1,3["OAW]J
M[6-.\32>"OVVO@+/(DEC>Q6OB:SD0)+:W"[8U-RBDX#HP@DP<,KQ$$AR:_3'
MX._%+PQ^TM\&-'\6:9'%>Z%XAL2ES8W&)/+8@I/;2CH2K;T/8XST(H _!G]F
MKX,_$[]K?5-(^%?AZ^N4\'Z7=OJEW+-G[#I9E"I)<.!C=(RH%1<Y.#C:"YK]
MX/V?/V?/"'[-/PYLO!_@^R\FUB_>75[* ;B^G( ::9@.6..G10    !5GX'_
M  %\$_LZ^"D\+>!M(72M-\UIY79C)-<2,>7ED/+G& ,]  !@"O0J "BBB@ H
MHHH **** "BBB@ HHHH **** ,?Q=XOT3P%X;O\ 7_$>JVNBZ+81F:YOKV41
MQ1*.Y)]3@ =22 .37RS:?\%7/V<;KQ#_ &9_PEE_!"9/+74IM(N!;'L#G9O
M]RH]\"OF?_@M5\1M8_M[X;_#[[9-I_ABZBDU:\95)CFE$GE(6 Y;RUWMM_Z:
M#OC'I?CS_@C_ /"/Q)\(XX_A]J>H6/BM;-9['7KB^-S;:@^S*F5!\H1^/FB
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MP-?E=^RU^SW\2OVT]=T#P/;:G>0> O"V\S7]P"UII,4TK2R"-> TTC%B%ZG
MR0JY'[MZ#K7@_P#:0^#=O?VZQ:[X,\6Z60T4HXE@E4J\;@'Y6'S*1U5E/<4_
MX-?!GPG\ _A_IW@[P9IBZ9H]F,_WI;B0XW32OU>1L<D^@ P   !/@Q\&/"GP
M#^'VF^#?!NFKIVD62Y).&EN)2!OFE?'SR-CD_0    =Q110 4444 %%%% !1
M110 4444 %%%% !7-_$+XC>&?A/X2OO$_B[6K30-"LEW37EX^U1Z*HZLQZ!5
M!8G@ FNDK\?_ /@K5X\O_''[4?@3X7:OJ[:!X'LX;*>::1OW227,S)+=L._E
MQ@*,]-KX^\: /J70_P#@K]\ =:\61:-))XETNUDD$8UJ^TQ%LAGHQVRM*%]S
M'QWXKU/]LC]G71_VP_V>;K3-,GM+K5EA75_#.JQ2*T1GV90"0<&*5#M)&1AE
M;DJ*^7OVU/\ @FM\)?!O[+^M>)OA[I$VB^(O"ED+\WK7LLW]HPICSA,'8KN*
M;G!0+\P QM.!V_\ P1S^)U_XT_9IU/P[J-Q-<R>%]8>UM7E8MLM98TD1 3V5
MS+QV!4"@"3_@EC^TY=_$'P#?_"+QB\MMX]\" VJ0WF1//8HWE@,#SO@;$3#L
M#'U)-87_  6J\.W>H?L[^$=6@C:2WTWQ(BW!49V++;S!6/MN4+]6%<5_P4(^
M&6N_LJ_'_P +?M2?#JVVV\EZD'B*SC^6-IF&TLX XCN(]T;''#@-]YQ7W#J.
MG^ ?VVOV;Q%(TFH>"_&.G+(DD3!)[=@P8$'D+-%*G0Y 9""",@@'XV?LL_LW
M_$G]O;Q9H-CK6KWT'P[\'VD.F2:K*/W5E;( 1:VJXVF9AR3SC(9L_*K?N3\,
M_AGX:^#W@C2_"/A'2X='T+38O+@MX1U[L[MU9V.2S'DDDFCX9_#/PU\'O!&E
M^$?".EPZ/H6FQ>7!;PCKW9W;JSL<EF/)))-=30 4444 %%%% !1110 4444
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M"C0]#T[PSHUCI&D6-OINEV,*V]K9VL8CBAC485%4<   # J]0 4444 %%%%
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M'X>_L.?\%&M,N_"M[?#P?X<N8+^ZLK*7[3<6N^ F:S5F8%\AL?.V0),,>":
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M,;_@F[^RS\/?VQ-0^(_B;XJ:A?\ B/Q#;W<<C6"WSP.YGWN]U(R$,Y9P5&"
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M,^"<7A^_N(;[Q3JEP=1UFYMV+1><5"K%&2 2B(H&2.6+'@$ ?1M%% !1110
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M+OQ2\8>++T%VUR*"QTF%A]IOYA; K'&#ZYY8\* 2?2OT^^/G@6X^)WP/\?\
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MXPQ( /EK_@JI^S3\)]#_ &:[OQKIGA[1/!_BC1[NUAL)-)M(K0WXDE5'MV1
M ^$+R#C*^4<$#=F#]A_X%:?^U1_P3AL? _CW[1_97]LW3Z/?0L#/:+'-E9(B
MP(!#M<)C&-K,.]>1> _^"2/QF\<ZYI-E\6OB%;P^#=+8(EM::I/?W CP,I;I
M(@CB!P%W'IC.UL8K]6/ O@?1?AKX-T?PMX<L8]-T/2;9+2TM8QPB*,<GNQY)
M8\DDD\F@!/ 7@?1_AIX+T7PIX?MFM-$T>TCLK.%I&D*1H,*"S$DGW-;]%% !
M1110 4444 %%%% !1110 4444 %%%% !7Q'_ ,%.OV,KO]I#X>V?BSPC:?:/
M'OA>)_+M4'SZE9GYG@'K(K9=!W+.O5QC[<HH _ +]AG]H+2OAI^U9X0\0_%6
MYEN=.TZP;0+?4-03S&T@!#'"Q!&0L?,>>JJY[+BOO/\ X*W^#/ACXP_9MMOB
M&]]I/_"7V]Q;QZ!J5G,C2:I"\JK+ K*?WL:H[RYYVE."-Q![_P#:X_X)C^ ?
MVEM8N?%.D7C>!?&]QEKF_M+<2VM\W]Z>'*_/_P!-$8$Y)8-Q7S7\,?\ @B5J
M$/BF*?X@?$"RF\/PR[FL] MY/M%T@/W3)( (L]R _MZT >E_LD?LXZ1^UU_P
M3O\ A_X:^(BW,=KIVK7%QI&HVK 74=O'=R!E5F!PK S1=P $/51C] _#N@6/
MA3P_IFB:7!]FTS3;:.SM8=[/Y<4:!$7<Q).% &22>*9X8\,Z7X+\.Z9H.B6,
M.FZ/IMO':6EG N$AB10JJ![ "M2@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH _-+_@HE_P3Q\5>.O'S?&+X/(TGB5S'/J>CVT_D7+W$> EW:OD#?A5W
M+D'*!ERQ(KQNZM?VXOVMO"]K\)/%&@:IHOAQY(X]2UC7-(_LQ9DB8,&GF909
M0"%;$0)<J#SR:_9&O"/VT/AW\4OBI\#=5\,_"C6]/T/6[YA'=R7DCQ23VN#O
MABE4'RV;@9(P1D97.: /S5_X*F?LL^$OV>=)^$>K^%9EMM0?3ET*]&1'+>M9
MPPI'>;5Z.1P[#C)C[Y)^_=?_ &:_#7[:_P"SO\%[WXFQ71UBVTS3-:N+BW;R
MYY'EM8VN;=FQD)(3\V,$%5(((KY"^"__  2U^+/Q*^(&DZY^T1XKFOO#^C[8
MX],GUB34[N[B1LK )"Q6&$]\-NQP%4G</U=@@CM88X88UBAC4(D<:A550,
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M:907"$*1&H() RQ *G])* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7G7C?\ 9_\  WQ"^)/@WQ[K6BQ3^*O"<S3:=J"?*^"CJ(Y/[Z*S
M^8H/W74$$98-Z+10!Y)^TQ^S/X0_:F^'%QX5\56^R5=TNFZM"@-QIT^,"2,G
MJ#P&0\,.#R 1^2GPD\1?&G_@FC^TZG@BYT:\\2:7K=S'$^B6*L\.NPLVR.XL
M^.)AT'&0<HX]/W&K.O\ P[I6J:IINI7NF6=WJ.F-(]C=SP*\MJSKL<QN1E-R
M\'!&1P: !M.LM:_LN_O=+B-Y:G[3;?:XD>:SD:,HQ5AG:^UW0E3T9AD@UHT4
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5YUX(_9_P# WPY^)GB_QYX=T6+3/$'BM(5U22'B.1HR[%U3HK.7
MR^.&**2,Y)]%HH ^+_\ @H%_P3]TS]I_0Y?%?A2*WTOXGV$.(Y3B.+5HU'$$
MQZ!P.$D/3A6^7!7YY_X)8?M)?$[0OB%<_ #Q;X=U?5M,TM9A'--&1/X=,>=T
M4Y?&("WRJ#RK, H(.!^JU9UEX=TK3=6U'5;33+.UU/4O+^VWD,"I-<^6NV/S
M' R^U20,DX'2@"2WT73[35+S4H+&VAU&\2..YNXXE66=8]WEAW RP7<V,]-Q
MQUJ[110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%4;W7--TV817>H6MK*1N"33*C8]<$].*O4 %%%% !1110 4444
M %%%% !115:^U*TTR-9+RZAM$8[0T\@0$^F2: +-%5[+4+74H3+:7,-U$#M+
MPR!USZ9'?FK% !1110 44UW6-69F"JHR68X 'K5.SUW3=2F\JTU"UNI<;O+A
MG5VQZX!H O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4;
MC7--L[D6UQJ%K!<<?N9)E5^>G!.: +U%%% !1110 4444 %%%% !1110 454
MOM6LM+V&]O+>T#YV^?*J;L=<9//45)9WUOJ$(FM9XKF$G DA<.IQ[B@">BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO/
M?C-^T!\/OV>]!M=8^(7B:V\-V%U*8;=I8Y)I)G R0D<2L[8'7"\9&>HKQ?\
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M/Q/^R/\ "^/XD6WQ#L]9%E=0PW$5K:R6,\+R-M5H7\QM^"1_=."3VK[_ /\
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M!$> ZK*&!QN5@1G&<_;G_!:+4KO3/V<O!\EG=36DC>*X5+P2%"1]CNN,@]*
M/T!9@JDDX Y)-,M[B*ZA2:&1)HG&5DC8,K#U!'6OQ#_9=^ OQM_;I^$UIX53
MQN?"WPK\)O+:A[CS9%OKR65KA]T:L/.=1*HRS!478%&2Q/'Z]:?&3_@ES^T!
M86D.M^?;2QQWBI:R.=-UFS+D.CQL.&RK*>-R'!4\@D _?"H;J\@L8Q)<3QV\
M9(7=*X49/09/>OF7]IS]L[3OA-^R%9?%OPZGVB\\3VMJGAV&Y3(%Q<PF5#*N
M?^6:+(Q'<Q[>^:_-S]GO]C'XJ_\ !1"SUSXE>+_B))8V?VM[:'4-5B>\ENIU
M4%UCB#HL<2[E7Y2 .0%^6@#]PZ*_%'X&_&;XG_\ !.W]JBW^%'CC7)-5\$/>
M06=[9O</+9QVTVWR[VVW?ZHJ&#,H R%92,@$?5G_  6BU*[TS]G+P?)9W4UI
M(WBN%2\$A0D?8[KC(/2@#] J*^,?^"25]<ZA^Q[ITUU<2W,O]LWP\R9R[8WK
MQDU\)?\ !7G7M3T[]KIX;34;NUB_L"R/EPSLBYS+S@&@#]G_ !SXD/@WP3X@
MU];<7;:5I]Q?"W+[!)Y43/MW8.,[<9P<9K\Y/^"=_P"V5\2OVK/VO/$TGB_5
M%@T*V\)7<UEX>T]3%96S?;;)0^W)+OAF&]R3\S 8!Q7M_P"WU\ /$OQ__9CT
M&/P[KEKHK^'8O[;O&NY)5^T01V4FZ-=@.6.?XL"OR._9$_9M\5?M2?$G4O"G
MA'7[/PYJ5GI,FJ275[)*B-$DT,90&-2<EID/3'RGVH _5K_@IA^QMX]_:V_X
M5Q_P@\VCQ?\ "/\ ]I?;/[6NG@SY_P!E\O9M1L_ZA\YQCBOH3]DWX6ZS\%?V
M=? _@CQ UJ^LZ-9-;W+64ADA+&5V^5B 2,,.PK\[?^"NMCK'PX^'/[-GA]M4
ME%]INE:A875Q:3.JSR0PZ<A;/!()!(SSS7VU^PGXABTG]AOX=ZWJUT_V>TT6
M:ZNKF4EV$:2RLS'N< '\J /I.HK>ZAO(A+!+'/&20'C8,,@X(R/>OPWUSXC?
M&/\ X*A_M$7'A'0M:FT;PJ#/<VNF22M%9:=IZL%\VX6/_6R$,BY.<L^T;5Z7
M_C!^PE\=/V(M:\->*?AMXDU7Q/<W]Q]E6X\(6=PEU%.%+B.2!-_F1LJMURIV
MD,HR,@'[?5#=WEOI\!FNIX[:%>#),X51GIR:^3_&'[3OQ#\&_P#!/S5/BKXA
M\+7/AGXE6.G+!<:;J%B\7E7;W"6RW'E-R$_>+,%/ ^Z>E?F9^S)^S[;_ +=N
MOZ]JOQ%^/46B>*([D)%8:RWVS4+\,N?,C\V9!L4X7";L8QA1M) /WHSGD<BE
MK\COA-^QG^U9^R1^T!&GPSG/BCP5;W$4MQ<R:C%9:;J<# ;TEM9)BRR ;ERH
M8J0"&YK]<%)902"I(Z'J* %HHHH _*#_ (+E?\A7X-_]<=6_]"LZ^O\ _@F7
M_P F.?##_KC??^E]S7R!_P %RO\ D*_!O_KCJW_H5G7U_P#\$R_^3'/AA_UQ
MOO\ TON: /J"H6O+=;I;9IXQ<LN]82XWE?4#KBOYU_V3/%_Q<U+XO6WA;X9:
M[/;>+O%=I+HL-]<W+_Z'$Q66:=6R=C+'"YW@%@NXJ-VTCU_]L#_@G;X[_9?\
M%0?$VY\=Q^,@;R*+4;N..6"ZMII"0DF]G8R+N 7=D-EAQCD '[GT5\7_ /!*
MCX^^)/CC^SK=P>++^XU?6?#6IMI@U*ZD,DUS;F-)(C(YY9UW,F3R0JDDG)KX
ME_:@_:6^*'[;G[3C?!_X:ZO=:=X5_M-],TZQMYFMH[IH@WG7=RZ#<T8V2.%.
M0J*#MW9R ?M+#=0W#2"*6.4QML<(P.QO0XZ'GI4M?B3\:?\ @F=\7/V4_"MC
M\0O!GB^;Q'J=G<113Q^%X+BWO[5I&"H\6PEI%WE5.-I&X'!&<?I;^PI\2?B;
M\1O@9:O\7/#.K>'O&.FSFRDFU;3WLY-0A"J8[C8P&&.2K<#YD)P,XH ^B:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBO$_C)^VC\%_@#XD3P_X[\<V
MVBZVT2S&QCL[F[E1&Y4N((GV9'(W8R,'O0![917RU:_\%/OV9;RXCAC^)T:O
M(=H,NB:E&OXLUN ![DU]":]\0O#7AGP//XRU/6[*T\*P6BW[ZLTH-OY# %9
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M7Z75_/M'%'\%?^"D2P:*!9V6C_$CR((TZ);&_P!OE\=O*8KQVH _H)K\E?\
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MH6$ZC.'1;9[@ _\  K=3^% '[Q5R?Q7^)FB?!KX<>(?&WB*9H=&T6T:ZG\L
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M_P!NKQ5X-\9_\*<^&^JW&B74,$<FNZMI[E;LR2J'CM8G7YH_D*LS+ACO500
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MS:^T?5=0D9[IHT95EMI7;ER-P92W("N"2 H !^E]%%% !1110 4444 %%%%
M!1110 4444 %%%% !17S]\2OV^O@'\(?%]]X7\5?$.VL-=L7\NZM+?3[R[\E
M\ E&:"%U##/*YR.]<M_P]&_9B_Z*9_Y0-4_^1J /JJBOE7_AZ-^S%_T4S_R@
M:I_\C4?\/1OV8O\ HIG_ )0-4_\ D:@#ZJHKY:M?^"GW[,MY<1PQ_$Z-7D.T
M&71-2C7\6:W  ]R:^G--U*TUK3;34+"YBO;&[B2>WN8'#QRQLH975AP5((((
MZ@T <M\6?C!X/^!O@VZ\4^-]<M]!T6W(7SI\L\KG.(XT4%I'.#A5!/!/0&O
MK/\ ;.^(/C"%-3\$_LU>.M<\-R',6HZM<VVE23IVDC@E)9E(Y!SR,>M9/@GP
MS!^U!^V1XZ\7>)X1J'A#X3W4?AWPWI-Q\\']J;!)=WCH>#(A**I.>-AX*BNN
M\3?\%(_V</".O7NCZE\3+87]G*T,ZVFEWUU&'4D$"2*!D;!!^ZQH W/@W^V/
MX1^*GBY_!.K:5KGPX^(21^9_PBWB^S^QW,ZXR7MVR5F7&2-IW$ G;@9KWNOS
MI_:R_:__ &5?V@OAA=VUK\2?L7CG1U;4?"^N6^AZG%=6%_&-\6R7[,"JNRJK
M#.,$'JJD=[\(?^"J_P #M4^&'ABY\=^-UT3QD]A$-7L4T:_E6.Z"XD*M' R;
M6(+  G 8#M0!]LT5\J_\/1OV8O\ HIG_ )0-4_\ D:M'P[_P4H_9M\4:U9Z5
M8?$VV%Y=R+%%]KTN^M8RS$  R2P*B\GJS 4 ?3-%%5[^_MM+L;F]O;B.TL[:
M-IIKB9PB1HH)9F8\   DD^E %BBOERX_X*=?LS6MX]J_Q.B:1'V%H]&U%TS[
M.MN5(]P<5]$>"_&NA?$7PKIOB7PUJEOK.A:E%YUI?6K;HY5R1QZ$$$$'D$$$
M B@#FOVA/^2!?$O_ +%G4_\ TEDK^>7]FOX\:U^S;\9- \=Z*6D-C+LO;,-M
M6\M'P)H6_P!Y>A/1@K=5%?T-?M"?\D"^)?\ V+.I_P#I+)7X _LW_LWZC^T?
MI_Q'M-",DGB/P[H)UO3[.,9^V,DT:R08_O,CMMQU95'0F@#^A[P#XZT;XG>"
MM$\5^';M;[1-8M8[RTG7NC#.".S#D%>H((/(K\2_#/\ REPF_P"RF7?_ *5R
M5[#_ ,$?_P!K$^'?$%Q\$?$UWLT[4Y'N_#LDS8$-U@M-;9/02 %U''SJXY,@
MKQ[PS_REPF_[*9=_^E<E '[J5^7/_!:SXY?9=)\&_":PN,27;'7M513SY:EH
M[9#[%O.8CUC0U^H4\\=K#)--(L4,:EWDD8*JJ!DDD] !7X*^=/\ \% /^"AT
M9(DN-!UK7  IR/+T>U'_ (Z6@B/_  .3U- &U_P2I^-DOP9_:FM_#&J.]II7
MC&/^Q;F&;*^7> EK9F4_Q;]T7MYQK]U*_#W_ (*L?"&?X(_M46?C70$;3+'Q
M/#%JUI-;#8(+Z JDP3'0@K%+]9:_7C]F_P",-I\?/@;X.\=VI0-J]@DEU''T
MBNERD\?T657 ]@* /B#_ (*W?MA>+/A/=Z#\+? ^J7'A^]U33SJFK:I9.4N/
ML[2/%%!%(#F/)BE9B,-@( 0"P/SG\.?^"1?Q@^*W@NP\7ZIXG\/Z+<ZS;I?0
M6FI3SSW+)(%96F9$(5BK$X!8C@'!SCZ?_P""KW[&7BKXV1Z%\2? FG2Z[K6B
MV1T[4='M4!N)K4.\J2Q#J[(SN"@RQ#C X-?%_P &O^"EWQW_ &=;&U\)7SVO
MB'2])"VJ:5XHLW^T6D:C B$BE)!@8 #EMH  &!B@"IX%^,7QF_X)M_'Q_">M
M7]Q<:9I]Q&VJ>'%NC-I^H6K@$20;AA&*$%9%"L" &'#+7ZH_\%"]4MM<_80^
M(VHV<@FL[S3+2XAD'1D>Y@93^((KY\^"O_!3'X&?'OQIIEK\4OAOI?A3Q5<;
M;6WUS4;:WU"TSDA5:X:-9(02QQE2HR<L.M?17_!1F"*U_8=^)T,$:101V%LD
M<<:A551=P   <  4 ?C1^RU^QIXX_:Z;Q0G@N_T.SD\/1V\ERFLW,L)E\XR!
M!'LB<$_NFSN*]1U[>J?$;]AG]I[]E[P]_P )I:7]S)8Z7&99[[PAK4S2V$2
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MHL]P'5L' RNT]Z /SN_X(G_\G)>,O^Q2F_\ 2RUK]GZ_&#_@B?\ \G)>,O\
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MTB#0+?3W:]OU@?SDGN'8;2.F)%Y^M?H=X"T>X\/>!?#NE7@5;NQTVVMI@AR
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MX[M=.M[?5[*V@M38WJSDLDCLV0!QPPKR/]JC_@F3\5;'X^:G\4/@??07)O\
M4GUN*U6^6ROM.O&?S'\MW*HR&0LR_,, [2,#) //OVQOV ?$/P9^ ^J_$SXA
M_&/4O'OBB&YMK>"TNED=#)+*JO\ OII7=SLW-PJ_=]J^AO\ @B7(I^ WCQ ?
MG7Q+N(]C:PX_D?RKS_Q/^P9^U1^U!X-O]0^-?Q!A74]*M'?0/#7FP,DMT%P#
M,;=5ACR./,&]CDY(&2?>_P#@F7^S+\3_ -ES0_'&@^/M/TV"PU.YM[ZQGL+Y
M9V\P*R2JP X&!&0?9O:@#[<HHHH _)7_ (+C?\C5\)/^O+4O_1EO7W!_P3Q_
MY,M^%7_8,;_T?+7B'_!3C]C?XC_M4:YX NO =MIUQ%HUM>17?VZ]6W(:1HBF
MW(YX1J^FOV1?AGK?P;_9O\">"_$D<,6N:/9-!=);RB2,,97;AAUX84 >:?\
M!4?_ ),3^)O_ '#/_3I:5\X?\$/;=%\$_%:<#]X^HV"'Z+%,1_Z$:^Q/VX/A
M#XB^/'[+OC7P+X4CMYM?U7[%]F2ZF$49\J]@F?+'I\D;?CBO(/\ @F7^RKX]
M_99\*>.;#QW;V-O<:O>VT]J+&[$X*I&ZMD@<<L* /FG_ (+C?\C5\)/^O+4O
M_1EO7:_';3[Z^_X(T>$'L]QBM],T>:Z503F+[0B\^P9D/X5WG_!3C]C?XC_M
M4:YX NO =MIUQ%HUM>17?VZ]6W(:1HBFW(YX1J^C_@E\#VTG]DWPS\*O'EE;
MW)7P\-&U:UBDWQL&0HX5Q['AAT."* /R5_8%_9U^*OQW\*^*I/AI\;K[X:C3
M;V);[2;'4;NW,V^/]W.RP.H(.UU!(_@->E_%[_@GKXNUCQ9IFC?%+]JOPY?>
M)!;>;86?C#5YY+GR7<C,*W$N[:61ON]U/I5O5/\ @FO^TE^S5\0[W7?@/XJ7
M4K*7<D$]KJ$=C=M#G<(KB*8B*3&!W*D@'"]!H_#G_@EW\9OCA\58O%_[1'B4
M+9"1&O(SJ0O=1O$7I"C)F.*/MD-\H/RKW ![Y^VQX)G^&O\ P2PD\*7.IPZU
M-HNF:'8'4+;/E7 CN[5 Z9_A( Q[8KS_ /X(?V<<?P[^*-V!^]EU6SB8_P"R
MD+D?J[5]6_MM_ W6_C5^RKXB^'?@>TLTU.Y^PI96LT@MX$CAN87*@XPH"1G
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M\'^./@._PAO[6XC\&?V7;Z1'#;S%9H88 @@*N0?F0Q1D$@@E>01D5Z310!\
M?\.5/@A_T-/Q _\ !C8__(=>T_LM_L _#;]DGQ7JWB3PC?>(-4U?4;+^SWGU
MR[AE\J R)(RH(H8Q\S1QDDY/RC&.<_2U% 'R=^T5_P $TOA3^TO\2[KQUXBU
M'Q-I&N7<$4-U_8EY!'%/Y:!$=EE@D(8(JK\I PHXSDGXG_:Q_P""</PR^$VL
M?#OP/\/-:\6:S\2?'&K+9V5IJU[:RVUM:)S<74JQVR-M0$?Q#@.>=A%?L37Q
M[\:/V-_BCXR_:;G^,7@7XQVO@_45TN/2K"WO/#L.HFP@"@2)&96*C>^]]P4,
M/,9<X)R >SW_ .S#X)U3]F^/X)7-M<#P:NEPZ8?L[B.?]V5=9MP&/,\Q1(20
M06SD$$BOS6_;"_X)I?#W]FG1?"'C73M5\7:KX"CUB&R\6^=<VSWEI:2LJI<0
M,MNJC:V5(96R7C QR:^Q/^% _M<_]'4:?_X0FG__ !%8?CC]DK]IWXD>$=7\
M+^)?VF-+U70=6MVM;RSE\#6*B6-A@C<JAE/<,I!! (((!H [_P#9-_8/^%O[
M+NO7WC#P-JFNZ[>:SIRVB7VKWL,Z"U=DE_=>3%&"'*1G)S]T8QDYR_VBO^":
M7PI_:7^)=UXZ\1:CXFTC7+N"*&Z_L2\@CBG\M B.RRP2$,$55^4@84<9R3[-
M^S;\*=5^!_P1\*>!-9\2'Q9>Z';-:C5#;^1OB#L8HPFYL".,I&.>0@Z=*]+H
M ^ 5_P""*OP/5@3XH\?L >AU&RP?_).OK7QC^S[X/\<? =_A#?VMQ'X,_LNW
MTB.&WF*S0PP!! 5<@_,ABC()!!*\@C(KTFB@#X _X<J?!#_H:?B!_P"#&Q_^
M0Z]I_9;_ & ?AM^R3XKU;Q)X1OO$&J:OJ-E_9[SZY=PR^5 9$D94$4,8^9HX
MR2<GY1C'.?I:B@ K)\6?\BKK/_7E-_Z+:M:J&O6<FH:'J-K" 99[:2)-QP-S
M*0/U- 'XB_\ !'K_ )/ 3_L7[[^<5=__ ,%;OV5)?AOX^M?C3X4MVMM'UZY5
M-6^RY4V>I#E9QC[HE"YR.DBDDY<5Z?\ \$\_V OBU^S?^T(OB_QG9Z5!HPTF
MYL]UGJ"S/YCE-OR@=/E/-?HC\4_AKH7QB^'FO>"_$MK]KT76;5K6X3C<N>5=
M#V=&"LI[,H- '\^OPU^)&K_%W]LSX=>+M?=)=:U+Q9HC7<R# ED2>WC,A'8M
MLW''&2<5^VO[=OQP_P"&?_V8?&7B.VN/L^M75O\ V3I+*<-]KN 45U]T7?+_
M -LZ_.GX6_\ !*?XV?#GX^>$-<ECT.^\.Z%XEL[U[Z/4 KS6L-TCF01D9!*+
MG;UYQ7U)_P %,/V8_C)^U-?>#M$\"VFFOX4T>.6\N6O-06!IKQSL V$'A(UX
M/_39O2@#\L?V;/"OQRM=</CGX,>'=?O=0TUGLSJVCZ8+L6[.F'3+(RABC>F<
M-[UZM\;-)_;+^,G@\:?\2/#'C76] TV4ZEMN] 6-8'2-P9-R1*PPC/GG'-?K
MA^Q#^SW-^S-^SKX>\':@D(\0,TM_J\EN^]'NI6R0&[[4$<>>XC%>\,H=2K ,
MI&"#T- 'Y"_\$6_CI_8?CKQ5\*=0N-MKKD/]KZ8C'@74*A9D4=R\6UOI;U]%
M_MR?\%&/%/[)'Q4M?"%E\/K#6+6\TV'4;75;S4)%$JL[HZ^6J<%6C(^\>,'O
MBOGNU_X)J_&WX-_M2+X\^&=GH\WAS1_$!U'24FU18':S,F[[.ZD< QLT1]1G
MUK[J_;._8U\/?MA> [/3[VZ_L#Q/I;-+I6M+")6AW ;X9%R-T;87(!R"H([@
M@'6^&X_AC^U]\(_#?BC4O#NA>,-%U:R2>./4;2*Z-L[ >9$"P)1T<%3C!!4U
M^3/_  52_9K^%_[._CSP>/AW&ND7.MVUS/J/A]+EIDM0C1B*90Y+(LA:48)Q
M^Z.T#!J]!_P3I_:_^#-Q?6_@&_NA;32%7E\*>+!IZW &0'97EA)R/49P<5TG
MPK_X)$_%[XD>-EU?XP:_;Z'ISS"2_E_M#^T=4NP,9"L"R#(&-[.2O'RMTH ^
MC_AAK6J:]_P1MO[G5WDENH_!VKVL;R'),$4UQ% /H(D11[ 5\\?\$1_^2T?$
M/_L7X_\ TI2OTH^,?P7&H_LJ^*?A;X%L+>S$GAJ71-(LWDV1I^Y\N-6<Y]LL
M<D\DU^3VA_\ !*O]I[PS-)-H[Z;I4TB['DL?$'DLRYS@E<9&: /VH\8^--"^
M'OAN^\0>)-5M-$T:QC,MQ>WLHCC10,]3U)[ <D\"OP:_9]L+O]J7_@H=I6MV
M-K(EMJGC&7Q1<+M_U%K'<M=,&/0?*H3/JP'>O5H_^"4?[3'CRX@MO$_B/1XK
M2)\B35]>GN@F?O,BJC\X'MG(Y[C]#?V*_P!A7PO^Q]H=[<0WI\2>--4C6._U
MR6$1!8P<B"!,DI'D G))<@$]%50#A_\ @K)\</\ A5/[+]UX=LKCR=:\:S_V
M3&%.&%J 'NF'L5VQ'_KO7Y:?LS^'?VD_!UM/XT^"WAOQ.EMJD363ZQI.CBZ2
M:-) 6C5WC88#J,X[KSTK[S_X**?L9_'7]JKXU6>I>&K'23X.T73X[/35NM36
M)W=OWD\I0CY26(3W$2FONWX!_"JT^"'P7\'>!;/:4T338K:61.DL^-TTG_ Y
M&=O^!4 ?AK^T9H'[57Q+T&WU_P",'AGQ;?:3X=CED34-2T1;>.SCD*!RSI&O
MRDHG7@8K[C_X(O?'3_A(OAQXF^%>H7&Z\\/3_P!J::C'DV<[8E51Z)-\Q][@
M5^AWC#PKIWCKPGK7AO5X?M&E:O936%W#_?BE0HX_)C7Y<?LD_P#!/[X^_LQ?
MM,:%XPBM]'O/#-O=2V.H-%J:A[G3Y,HS>61U VRA<_>0"@#P3_@K'\,;[P#^
MUYK&O-&Z:;XJM;?5+.8=-Z1+#*H/J'BW8[!U]:_6'X4?M8>'_BC^S%)\5M&B
MFUNYT_2'NM2T+3 ;B\BO(XB7MO+0%@Q8?*2!E65NAK5_:D_9:\(?M7?#MO#/
MBA'M;JW=I],UBV4&XL)R,;ES]Y#P&0\, .A"L/RZU;_@E_\ M/\ P1\175U\
M,M=74D8XCU#PUKQTFYD0'Y0ZR/'M;DG =@/6@#W\_P#!8/P5XP^ _C=-4T&]
M\+?$2/2Y;>QTG<;BVO+B0>4K1S!05",V]E<*0JG:6-?.7_!'/X7WOBS]IRZ\
M7B!QI7A32II)+C'R_:+A3!'']2C3M_VS-4+'_@E'^TM\1+W5-:\4+I=AJTJ-
M<RS:_KHNKJ\EP3MWQ>;ER0!N=@.>M>B_\$ZOB!\:_P!G7X^6OP!U7X?PPV.K
MWTEYJ,6HVOV:YM$5!YETER@*S1A4&T'<K$JJNN[- '[ U\7?\%;/AG??$+]D
M:]O]/B::?POJMOKDL:?>,"I)#*?HJS[S[(:^T:@OK&VU2QN+*\MXKNSN(VAF
MMYD#QR(P(964\$$$@@]<T ?EK_P19^.N@Z7H_B_X5:IJ-O8:Q=ZB-:TJ&X<(
M;TM"D4Z1YZNHAB;:.2"Q PK8_2CXH?$OP_\ !_P'K/B_Q1?QZ=HNE6[3S2R'
M!; ^5$'\3L<*JCDD@5^8'[27_!'GQ'I_BJX\1?!#5;6737E^T1Z!J5TUO<V3
MYR%@G/RNH/3>59<#ECS7EH_X)N_M<?%:XLM-\:74L6FVLNR&7Q+XI6]A@7@;
MT2.24@8)X"@\=!0!]6_L+_\ !2SQM^T]\6H/ .N^ =-5I+>XO9=:TBYDB2S@
MC&5,D+A]^6:./(=?F<':!T^3/^"QNBWVG_M:6]]<(_V34/#UI):R$?*55Y49
M0?4,I)'^T/6OTO\ V+?V)?#/['WA.\BM;H>(/%^J;?[3UZ2#RBR#E8(DR=D2
MGGJ2QY/10L_[:/[&7A[]L'P+:6%Y=_V%XHTEGETG6TB$GE;A\\,BY&Z)\*2
M005!'<, >J?!+Q5H_CCX/^"]=T":*?1[[2+66V:$Y55\I1L]05(*D'D%2#R*
M_$__ (*A:U8?$#]MSQ!9>&]NI74$5EI$HM3O,MXL85HQZLI98R!T*D=0:]&T
MS]@S]M/X.PWOACP-X@O(_#L\K%V\.^+!:6CEEYD$<DD3*3@*2$!/'4#-?0G[
M$'_!+&Y^$/CBQ^(GQ7U&QUCQ%I\@N=,T:Q=I8+:XSD3S2,!YDBGE5 P&&[<Q
M P <;_P6FLIM-^&_P2M+E_-N+>2]BDD'\3+#; G\Q7U5_P $P[=+;]AGX9*G
M\4>H.<^K:C<D_P ZXC_@IQ^R?X__ &J-#\ 6O@.WL+B71KF\EN_MUV+<!9%B
M";<CGE&KVW]BOX3Z_P# W]F/P1X'\41V\6O:3'<K<I:S"6,%[N:5<,.ORR+0
M!^1-K;)=?\%8RC]!\5GD_%=1+#]0*_2__@JI_P F.>/O^NVF_P#I?;U\UV7_
M  3W^+T'[>[?%AK+2?\ A$#XYDU_S?[17SOLINC*#Y>,[MI^[7V9^W5\&_$G
MQ^_9C\5>!_"45O-KVHR6;0)=3"&,B.[BE?+'I\J-0!\I?\$0_P#DEGQ+_P"P
MS;_^B#7Q9^U!K]CX4_X*0>)-;U-5;3=-\:6MY=*P)!BCDA=P0.2-JGI7Z8?\
M$S?V6O'?[+?@;QII?CJWL;>[U748;FV%C="<%%BVG) X.:_,_P#:?\'VWQ"_
MX*0>)/"U[--;V>N>-+73)YK?'F1QS20QLRY!&X!B1D$9H _?/^U++^R_[2^U
MP_V?Y/VC[5Y@\KRMN[?NZ;<<YZ8K\)_^"?O_ !57_!1OPYJ6C'R;%M3U>_5H
MP<+;FVNB!]"'5?\ @5>N^./V"_VQ?#NE2_#+P[XSNO%/PS;_ $>'RO$ M;46
M_9)()7#JOK&F]<],]:^MO^">O[ A_9,L=4\2>*;ZSU?Q[J\*VS&R!:#3[<'<
M8HW8!F9V"EVP!\B@#@E@#\X/VRS_ ,*^_P""D'B#5/$<3?V=;^)=/U67>I(D
MM,02Y&.2-@(X]".M?O-8:A:ZII]M?6=Q'=65S$LT-Q"P9)(V 964C@@@@@^]
M?)/[=W_!/S2OVN;:RU[1]2@\-^/]-@-O#?3QEK:]ASE89]HW#:2Q5U!(W,"K
M<8^&+?\ 87_;:\/^'Y/ .FZUJ"^#&#VYM[/Q>J:?Y1.&41&56$;;B2NSGG(R
M<$ \O\5WEO\ %K_@IM]I\'.EY;7_ ,0K=K6YM3N1UCND\R=3W7Y'DSTQSTK]
M%O\ @H'\#?@/\?KS38/%_P 4_#_P[^(VEH+2UNIKZW>X:)_G6":U:17=,ON4
M@@C>3G#8,?[!/_!-RT_9?U5O&WC+4;3Q#X_:)H;4608VFF(ZX?RV8!GD8$J7
M(&%) '))A_;\_P"";J_M0:U'XY\%ZI9Z'XZ2!;>[AU#<+748T&(RSJI9)%'R
M[L$$!0<;<T ?$OCK_@E1^T-\&[J77?"%U8>)!9!IHKOPWJ;6MZBJ,DA)/+.[
M ^ZC,3VR>*]V_P""5O[;GQ$^)7Q*N/A;X\UBX\66DNG2WFG:I?GS+RW>(@M'
M)+C=(K*Q.YR6!4 '!P.<7X _\%"3X;/@H^);C_A'?LWV+SWUVR.8?N[?.S]H
MZ=^N#CVKZ9_X)]_\$]?^&3IM2\6^*M4M=:\=ZE:BS5;#=]FT^W+*[HC, 9'9
ME3+E1@+@<$D@'PO_ ,%DO^3N+/\ [%FR_P#1MQ7ZE?&[_DQGQ]_V3G4/_39)
M7R#_ ,%%/V"/BQ^TI\?K?Q;X*L]*GT=-%MK$M>:@L#^:DDK,-I'3#KS7Z WG
M@"+Q-\'9_!&LDI!J&@MHU[Y)R0LEOY,FT_0G% 'Y3_\ !$=A_P +J^(2Y&X^
M'T('?_CY3_&O+O\ @KAI]Y9_MH:W+=%C!=Z5I\UKD=(A"$./4;TD_'-=5I/_
M  37_:P^"_CJ^;X=WXM%FCDM/^$BT#Q"EAYMN6!PX+I*,X5MH!P5X.0#7V]^
MUC^P+>?M3_!?P&EUJUKI/Q7\,Z1!:MJ4S--;7C^4@FAED WE?,4LLF"1EOE.
MXX /&M-_8-_:8U70[75[3]KG6I=+N;=;J&Z77=4\MH64,KAO.QM*D'/I5+]@
MW]BFQ^'O[0N@_$;2/CGX+^(45G%=FXL=!O//N9O.MY(\MAR>&<,=PS\OK7F=
MK^Q_^W5H/@M_AKI^LW*^"&C:V\FW\26ZVPA/RF)26$RQD,WR !2,@CH#]B?\
M$_\ _@G[#^R7!J/B7Q-J%IKGC_4X/LK2V0)MK"WR&,43,H9F9E!9R!PJ@ 8)
M8 ^S:*** "BBB@ HHHH **** "BBB@ HHHH **** /B[XM?\$G?@W\8/B1X@
M\::AJWB[2-1UR[>^N[;2;^V6W\YSND=1+;R,-S$L1NQDG&!Q7(_\.5/@A_T-
M/Q _\&-C_P#(=??]% 'P!_PY4^"'_0T_$#_P8V/_ ,AT?\.5/@A_T-/Q _\
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M&3U]36U9_P#!)C]H_P ?WUNGBWQ/HMM:Q-CSM5UJ>]=%.-QC54;)]B5SCJ*
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M0^,?C/X:\42V6C1"V75]6T<6T=O')( J,Z1J,%V &[NW'6OWV^&W@33OA?\
M#[PYX0TE=NFZ'I\&GP<8++&@7<?<XR3W)-4_C!\-=/\ C%\+?%7@G5,"RUW3
MIK%I"N3$SJ0D@'JC;6'NHH ^-/\ @CQ\=/\ A/\ X!ZAX!O[C?JO@RZVP*Q^
M9K&<L\?UVR"9?8;!7P%_P4'\&ZG\#_VY/$^KK R1WVHP>*--E?A9A(1(Q!]!
M,LJ?\ KZN_8/_8;^/W[+7[0FG^)M5L=';PO>6\VFZPEKJJN[0. RNJX&2LB1
MMZX##O7V=^UY^QSX1_:\\%0:7K<CZ1K^G%GTK7K:,/+:LV-R,I(\R)L#*9'0
M$$'F@"PW[6'A_7?V6-1^,_A&UF\406^DF\71M/!N+B.ZVC_195C!*%'8!SCY
M5!?[O-?&GQ._X*S^ _BM^RCX^TR/1]0\._$'5=,ET>+193YT3"Y0Q23QW"J
M5169L,JMD  'J/$+C_@FG^U?\#]:NW^&VL-=1R'B^\*>)?[,DE7.!O$DD)!P
M3QD@<X)[X=G_ ,$E_P!H_P 66FKZWK4&CV>K;6N?LVJ:TL]W?2GDJ)(_,3>3
MGYI'49[XYH [[_@BK\+[W5OC)XP\>R0.-)T;23ID<Q&%:YN)$; /?;'$^0.F
M]<]1G]C*_)S_ ()?_%CXP?#+XM#]GK6? D-KHT'VK4]0:_LVLKW35'69G"_O
MU9_+1=P).Y KA% K]8Z /A7_ (+)?\FCV?\ V,UE_P"BKBO./^"/'PO\&>./
MV>_%M[XC\(Z%X@O(O%$L,=QJFFPW,B(+2U(0,ZDA<DG'3)-?2'_!13]GWQ=^
MTI\ ;?PEX*AM)]836K:^*WEP($\I(Y58[B.N77BOSFT3_@EY^U1X:MGM](O;
M/2K=W\QH;'Q(849L ;B%P"< #/L* /TE_:>_9E^!-]\#_&%SXD\%^%?#=K9Z
M9/-'K=KIT%G<6<BH2C1RHJMG>%^3.'.%(.<5^97_  2!\6:WHO[7%MH^GR2G
M2=9TF[CU.%22FR-#)'(P]1(JJ#V\PC^(UM77_!+/]J3QCY5CKNM:;+9APX.J
M^(Y9X4;INVA7.<$\A?6OOS]A']@G2OV0M'O]5U._M_$7C_58Q!=:G;QLL-K!
MD-]G@W?,5+*&9R 6PO V\@'P_P#\%M/^2^^!?^Q9'_I5/7KW[?.BWVJ?\$M_
M@U<VB.UOIL/AVZO"HR%B.FO""?0>9-&/J170?\%+/V'_ (H?M0_%;POK_@:T
MTRXT_3]%%C.U]?+ PE\^5\ $<C#CFOL#PU\%;'7?V8O#OPM\=6$-]:_\(O9:
M+JMJC[EWQV\:,4<=U=-RL.05!'2@#Y+_ ."*_BK1[W]G?Q7X=MYHEUO3_$<E
MY=VP/SF*:W@6*4CT)AD3_MG63_P6V\5:1;_!GP%X;DEC.O76OG488<_.+:*V
MECD;'8%YXASUP<=#7BWB[_@EG\?_ (#^/)M;^!_BQM3M3N2VO+#5?[*U)(CR
M8YLLJ,. /E<AL9*KT$_@'_@E;\<?C=\08?$7QX\5/8VA9/MDUUJO]IZI/&.1
M%&P+QHN"0"7(7LA% 'U/_P $?]!U#1_V/8+F]1D@U37;Z\L]W>$".$D>WF0R
M5^?7[$K!?^"FN@EB /\ A(-:'/O;WE?N/X-\'Z/\/_"FD^&O#]C'IFB:5;):
M6=I%G;'&@P!D\D^I/).2>37Y)?';_@F5\=O"O[06L^-?A!)#>V5YJTVJZ;?6
M&KI8WFG&61F*,9&0_)N(RA;<ON2* .F_X+C:???VM\(;X[FTTP:G"N =J2[K
M8MD]BR[<>NP^E8O[,G[&_P ?/BI\"_"7B;P3^TOJWAWPU>VQ^S:/9ZOJ$<=C
MM=D>'9'*%4JRL" !7U7I/[&GBKXV?L0Z;\+OC;K,LGCVVNKC4+?7WO#J4]M<
M--*\3O(Q_>825HV7=C:< C (^0_#/[$W[;/[/<>I^'/AOXASX?O)27DT77H8
MK<D@CS52X*-&Y &60!NG)QP 7/!O_!/Z_P!1_:$T[6=4_:7\'^*O'6C:]:SZ
MA:W&I/<:L\]O,G[MP\AD\S]V$&[T [50_P""VVEWD/QQ\ :B[,;"X\.-;PKV
M$D=S*TA_$2Q_D*]O_8:_X)CZ]\+?B9;_ !2^+VIVNI>);21KK3]*MIVNMET^
M[=<7,S##R#)8!<_,0Q;(Q7U)^V5^R;HW[77PK_X1R]NQI&N6$QO-(U?RO,^S
MS;<,K#@F-Q@, >RGDJ!0!N_LA>)-,\6?LM?"?4-(EBEL_P#A&=/ML0G*QR0P
M)#+']4DC=#[J:Y/0OV_?@MK_ ,8KCX80>([I/%T>JOHL5N=-GDBN+I9#&526
M-63&X'YF*C ))%?G5HO[ W[:'PAM;SPSX)\03VOA^\D8S_V!XJ^RVC$C:7,;
MM&P)  )"9Z>E?37[ W_!,V[_ &>_&,/Q'^(VI6>J>,+>)UTW3-/9I(+!I%*O
M*\A \R78Q4 #:NYCECM*@'S+_P %L/\ DY+P;_V*4/\ Z675?JW^SC;I:_L\
M_"^",8CC\+:6B_06D0%?$W_!2C]AGXI?M0?&3P[XD\#6FF3Z98Z!'I\S7U\L
M#B87$\A 4CD;9%Y^M?>/PD\.7O@[X4^#- U%474-*T6RL;E8VW*)8H$1P#W&
M5/- 'XF?![_E*T/^RC:G_P"E-Q7W5_P6>_Y-0T3_ +&VS_\ 26[KROX>_P#!
M/;XO>&_V[A\5;VSTE?"/_"87NM>8FHJTWV:6:5T/EXSNPZ\5]0_\%'?V=_&'
M[3/P'TWPIX)ALY]7@U^WU!UO;@0)Y*07",=Q'7,B\?6@#S?_ ((S6RP?LF:H
MXZS>*KR0\8Y^SVJ_R45\=_\ !9[_ ).OT3_L4K/_ -*KNOT3_P""=?[/OB[]
MFOX W'A+QK#:0:P^M7-\%L[@3IY3QQ*IW =<HW%?.G_!1W]@WXK?M,_'C3?%
M?@BTTN?2(- M]/=KV_6!_.2>X=AM(Z8D7GZT :W_  4ZT6^U3_@GK\/[FT1V
MM]-O=&NKPJ,A8C92P@GT'F31CZD5<_X(K^*M'O?V=_%?AVWFB76]/\1R7EW;
M _.8IK>!8I2/0F&1/^V=?9-Q\)M*\;? VW^'GC&PCO\ 3;K1(=,U"V#9&5B5
M24;LRLH96'(*@CI7Y;^+O^"6?Q_^ _CR;6_@?XL;4[4[DMKRPU7^RM22(\F.
M;+*C#@#Y7(;&2J]  >T_\%MO%6D6_P &? 7AN26,Z]=:^=1AAS\XMHK:6.1L
M=@7GB'/7!QT-2_L!Z#J&C_\ !,#XB7-ZC)!JEMX@O+/=WA%IY)(]O,ADKQCP
M#_P2M^./QN^(,/B+X\>*GL;0LGVR:ZU7^T]4GC'(BC8%XT7!(!+D+V0BOT]\
M4_"NST_]G[7?AYX-T^#3[7_A'+K1M+LPVV--UN\<:EC[D98Y)R2<F@#\I?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !3&AC:9)3&IE0%5<@;@#C(!]#@?D*?10 4444 %%%% !1110 4444 %
M%%% !1110 5^6WQ"_P"">WQ>\2?MW'XJV5GI+>$?^$PLM:\Q]159OLT4T3N?
M+QG=A&XK]2:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.IF=&=-F_P"9B78MC;C#$C]9:** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH :SJN S ;C@9/4^E>9?#?]H/P]
M\3OB/\2O!>G6.J66I> ;BVMM4N=0BCCMIFG61D,#+(Q8 1$G<JXW+USQ@_MA
M_#7P=\2/@=K!\<'Q$-$T$_VYCPM(ZW_FPH^WRPJMN/SG 8;0<,<!<C\Q/A/^
MS[X@UKQ]X%D^,DWQ&F^'?QD;?91Z?J\DUQYT65LUU7$)\X&V"L) $VJQ;Y0K
M@ 'ZT_&[XZ>#?V=_ =SXO\<:I_9FD12+!&$C,DUQ,P)6*)!RSG!/H "20 2/
MAN/_ (+&:7:_$^:34OAYXBL_A>^F13V]RVGJNJ"5Y=HG?,_E&W8?*-ISN'WC
MTJI_P5"@L/#?Q>_9A'BZ.:Z^%>G:F8]2-P6E5U6:U\WSCR7S"N>>2/,QU->S
M>%U\-?$3_@H%XNC@.F^(O"VJ?"BTB A*7%I<V[7Q&!C*LA'''% 'TW\*_BIX
M7^-7@73/&'@[58]8T'4%+0W"*5(8$AD=6 *LI!!4C(Q76UX;^R?^R?H7[(_A
M/6_#WA[7]8UFPU2__M!HM3:/9!)L5#Y8101E54$L3G8O3G/E_P"UC;_M(_%[
MQ])\+OA5;6W@KP+-91/JWCVYD:.4^9NWP0$'=D*.?+4MD@%T!Y /:OAI^TYX
M&^+GQ3\;> O"]Y<:CJWA QKJ5TL8^R%V)4I'(&RQ5E96X !4X)KUBOR__P""
M5/@&+X4_M/?M$>#(+R348?#\J:6EY*@1IA#=31[RH)P3MSC)QFOJ3_@I%\5K
M_P"$?[(7C34-)N7L]7U,0Z-:W$>0R>?(%E((Z'R?-P1R#@T 8_Q+_P""HGP!
M^&7BJX\/S^(KW7KVUF\BYET*R-S!"PR&'FDJKXQSL+=?KCWGX-_'+P/^T!X1
M3Q+X#U^WU[2M_E2-&K)+!( "8Y8W 9&P0<,!D$$9!!KRC]A3]GWPO\(_V8?!
MMM!HEF=5U_2+?4M:NIH%>6ZEN(UE9)&(Y1 P0+T 7IDDGYN^&^FV'[(O_!4R
M\\ ^'+==+\$?$O1A>QZ8A*P6LX2:1"BC@#S;>=%'11/@< 4 ??'Q/^*GA/X,
M^#[SQ3XTURU\/Z%:X#W5R3\S'[J(H!9W.#A5!)P>.*^:?"/_  5;_9Y\6>*(
M]%/B+4=%$LBQ1:CJVG/#:.QZ9<$E!G^)PH'<@<UY%^UA9Q?M+?\ !1_X3?!C
M62UUX'T&P;6-2TXDJD\QCEG8/CJK)%;Q^H$CX(W&OK?]I#]FOPA\;O@7K?@J
MY\/V$?DV$G]BM;VR1MI]RJ$PM#M V -@%1@%20>": /9(9H[B&.6)UEBD4,D
MB$%64C(((ZBGU\9_\$GOC!>?%+]E"QT[4IC-J'A*^DT,2.Q+O;JB2P$^RI+Y
M8]HA7V90!Y!^S3^U)X-_:L\*:IXA\%Q:I%8:=>_8)AJENL+^9Y:OP%=LC#CG
M/K7K]?)/[+_[4'PF\1_L\_$CXB_#KX;_ /"#>&O"GVN\U'2;#3K2R>[>"T$[
M,JP$(6* *"Q'0=JY=O\ @JOX(U[PIH5SX'\">+O'?BW58)KEO"^D6HEN+"-)
MWA!N7CWA"Y0,H4,=KJ3C<,@'V]17RG^S/_P4.\%?M$>/I? -SX?UOP)X[2)Y
M5T?7(U FV+N=$88.]4!8JZJ=H)&<&NX\3?M;>'?!W[3_ (>^"6L:-JEEK&OV
MGVO3M8<1_89P4D(3.[<&+1.F-OWL>HH ]THJIJVJ6NAZ7>:E?SI:V-G"]Q//
M(<+'&BEF8^P )_"O!O@A^VQX*^,OP:\2_%.XM+_P5X)T*Z>UGU+Q!Y:"38J%
MF01LQ(S(B@#EF.T GB@#Z$HKX4;_ (*J:?K2W6K^$?@E\1O%G@BS=UN?$UII
MQ$"!206&T,N."?G=#Z@5]-?L]_M)>!?VG/!(\2^!]2:Z@C817EC=)Y=U92D9
M\N9,G!QT*DJ<'!- 'J-%?(7Q8_X*,:%X3^)&K^ OA[\/?%?QA\3Z,634XO"]
MJTL%K(I 9"Z*[$J<JQ"8!&,DY U_@+_P4%\'_&3XG?\ "MM:\+^)?AMX_9&:
M'1?$]GY+3E4+E%/W@VQ6;#JN0.,GB@#Z#\7?$;PQX#NM%MO$&N66DW6M7T6F
MZ;;W$H$MY<2,$2.)/O,<L,X& .3@<UT=?D;^WC^T)]L_;=^$-W_P@OBJ+_A
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M):<JA<HI^\&V*S8=5R!QD\4 ?0?B[XC>&/ =UHMMX@URRTFZUJ^BTW3;>XE
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M?DVNV1QUXKY]\,_\%2M%N'L=4\7_  C\?>!_ FH21I:^,+[3FDL-KXVR2,%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[7_P#'[2W[/OBGP+#-':ZI=1I<Z;<39V1W<3!X]Q[*Q!0G!PKDX-?('[/_\
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M?^"C/[*_AKXH?!VRU:'Q%X6U::ZTS3=2CAANIMC!)T $CIORD<B_.<[-N,D
M 'WOX<\.Z;X1T#3M$T:RAT[2=/MTM;6T@7:D42*%50/0 "OSM^%.G6WP3_X*
M\>,?"OAL"P\/>+=&:\N-,MB!"DQMTN2Q0< ^8DK#T$Q X-=/X7_X*^?#S2_!
M\4'Q!\,^*/#_ ,0+.$0ZAH4>G [[E>&$9=EV@L,X<*5SCG&34_8<^%GCSXP?
MM+>-?VH/B+X?G\*1:O UGX=T>[!680E4C$A!"G:D,2H&*CS#(S  8R <]^R[
MIT'Q<_X*E?';Q5XCB6]OO"?GV6DQS\BW\N5+5)$4]"(HVZ=Y2>IK[F^/'P(\
M)_M'?#NZ\%^,K66XTB>:*X$ELXCGADC<,KQN0=I(RI..5=AWKX@^,^G^*/V%
M/VU-:^/%IX:U+Q5\*?&EI]GU]M,0/+ITS%-Y([?/$LBLVU6\QDW \U'\?/\
M@H?_ ,-+>#U^&/[-VE>+-2\>^()(D;5;>!K)M+A616>02*^Y&^4*7R%568[L
MX% %K_@KAX-L/AW^Q+\.?"^E-</IFC>)M/L+4W4IEE\J/3[U$#.>6(4 9]J^
M?] ^)UQ^T=^UA\)KG]H_1-0\/_#'5+,/X,T2X)33I#N$<#SY'[Q973YF.-VZ
M+.(B*]S_ ."G7P_\1>$_V"?A;X9U74]0\8>(]-\0Z?'J.J2R2W4UU.+"]\V4
MLV7*ER<%N<;17T5^UY^RK:_M3?LTV6B6T<=OXOTBSCOM NWPNRX$0S"S=DE
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M_P /_P!EC1_$-_XTU"YA:XUZ;3D6+3X0^3Q(&4 D ,\@"JI."2?E /J+X/\
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MBH8LC%@5Y! !]U?%S]E?P)\:?B/X(\=:_;WL/B7PA.)].O-.N/(9BLB2HLI
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MD?%I[1HS"UNV@S&,H1@J5\G&,<8Z8J#_ (*.? ?QSJVO?#OXX?#"PEUKQ?X
MNA+-I,*;WN+59!*&5!\S[6#*R+DE93@<<YD/_!8SX3CPGY]SX:\50>,1&$/A
MG[(I8W!P/+$V[&W<?O%0V/X,_+0!QO\ P3=\#^,K'Q9\>_"^I^ O&/PV^'OB
M@27NBV>N:9/:+9>8\L>R-I$53((I(@=IR1"I[5P?P@^*GQP_X)DZ3JW@3Q?\
M()_&GP_CU&6\@\2:('2/YPH9_/6-T((52$E"./F&<  ?47[(<G[2'Q)^%?Q!
M\4_$CQ!/X7U7Q&LY\'Z1=:;;QOHVY9"D[HT.\J&:,*DN[Y8R2IW@UX_\$_\
M@I%J?P'L]4\ ?M2:;XBT_P =Z9=RM%JZZ:C)?0,YQ\J! 0#G:Z HRXYR.0#T
MS]F+]H']FK]J/X['QUX=TF?0/C2UD83'K#R07-Q"D;(PC5)6@FQ'G/&_:H)
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MQ9_P5]^'6H>#Y8/ 'AOQ1KWQ!O8S!IV@S:< 4N6!"^85=MP4_P *;BW3C)(
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ME4%BLV1]TT ?;'B?PKI/C+PQJ7AW6;"&_P!%U&V>SN;.504DB9=I7'T/X5\
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MG\,^*="^(_AFWCTJ:TAT[S&OO+4)$X!92KL ,@_*3R&(.!Q/[,GB#QU\1O\
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M3=]W/W1UH ]!HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\GTO\
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MBBB@ HHHH *@CLK>&ZEN4@B2XE $DRH [XX&3U.*GHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\B;O+"LP^;RT4@,<8XH X[_@CWJ5WJ7A?XPF[NIKHIXE55,TA?:-C<#)XK]
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MKXB^(_B!JNH2?"?P3=_8-%\/V=RT,<I9G6-CCE2R1&21AAB710VU<#T;XO\
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M9\"_#'X7:K\0O@BVK^ /'GA"TDU>VN++5;B472PH7E4F1V97**V"A )X((/
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MJ2OM+X#? [P[^SK\--/\#>%7OI-%L9)I8FU"999MTDC2-E@J@\L<<5A?$?\
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M$@@'BG_!$^[M[OPK\7WMXQ!$^KVDB0C_ )9HT<VT?IC\*\D_8O\  &H?$_\
MX)G_ +0_A[2K:6]U*;4FN;>VA&9)7@AM9PBCN3Y6 .^<5^DOP-_93\$_L[^+
M?&^N^#6U*S_X2ZZ%W?:9+,ALX7#R.H@C5!Y:KYKJ!D_+@=A4O[-/[+G@W]E/
MPIJGA[P7+JDMAJ-[]OF.J7"S/YGEJG!5%P,(.,>M 'E?_!,'XGZ+\0/V0_!V
MFV%[#)JWAR.33-2LE<>; RRN8RR]0KQE6!Z'D=0:W_%G[9MKI7[7WAGX#^'O
M#B>*;[4+;S]5U2WU'RQH^%DD99(_+8,1&BM@LG^L4=37*?$[_@F!\*/'7C*_
M\4^']2\2?#;6+X[KD>$KY+:VD8G+-Y3(VW/HA5<\XZY],_9K_8T^&_[+$>HS
M^$;2]OM<U$%;S7]:N!<7TZ%MVPNJJJKG!(55R0"V2!0!\F^']>LO!/\ P6D\
M:'6YUTU/$6A6]IILEQ\BW$IL++:JD\$DV\JCU9=HYXKVG_@J=\1M"\&_L?>+
MM'U"^ACU?Q#]GL=-L3(!+.PN(I'8+UVHB,2<8Z#JPKN_VGOV'/AA^UC<6%_X
MPM=0L==L8?LT&LZ-<+#<B')81-O5T=0S$C<I().",G/G'@;_ ()7_!_PKIGB
M"/5[OQ!XPU?6+)]/.LZU=I)<6<+KM/V?$85&V\;R&(!(! )% %+X9_\ *(^\
M_P"R9ZM_Z27%?-/@WX[>)_@!_P $B/#FK^$)Y+'6]6U^ZT:/4H5R]DDEQ<N\
MJG^%ML10-V+@CD C](M%^ /AG0?@#)\'K:2_/A.31;C02\DRFZ^S31O&YW[<
M;\2-@[?3BN<\+?L??#;PS^SW)\%Y=.N=<\#2&5FM]4GWS;GE,NX2($*LKG*L
MN","@#YI^ __  3#^$7C7X?^&_''Q"U?7/B=X@U[3X-4O;^[UB5;>1I4$A"-
M&1(RC=C<TA)P3QG \5_9O7X<Z;_P5FN-+^%MO8VG@S3]-N=/M!I[EX))8[$"
M9D<DE_W@D^;)W8SD@BOH_1_^"3GP[T>&;2U^(GQ*D\)R,6;PV-<CCM'SG*NJ
M0C<O)Z8/J3W]6\,_L'_"?P'\5O!_C_PEIEYX4U7PO8_V?:6FE3JEK/&1*K-.
MK*S2NPF<,[-N.%.<C- 'S?\ $":+3/\ @L]\.Y+J:.!+GPTZQ-(P4,S6=ZBK
MSW+# '<D"N5_X*E>"= T_P#:B^"'CGX@:3-JGPRNHTT+6L2RQQHB7#R-EHF5
MU;9.SC:06\HCG!%?6W[4?[!_PS_:VU;2=7\7'6-+UK38#:IJ6A7,<,TL&XL(
MI/,CD5E5F8CY006;GFNRA_9?\!7'P#TKX/ZYITGBKP=IMG'90KK#J]QA 0DG
MF(J;)%!X9 I':@#QR'_@F[^R7<>'UUV+P/92:(UO]K&I+XGU$VQAV[O,\S[5
MMV8YW9QBO*OV</"/P#^,/P]_:"T+]GWX>:UX9O;C0KWPU+KU_?3RV6H&:.98
M/)\VZD/)4.<HI"LN3\V*Z9O^"0?PM"FPC\=?$2+PTS;WT)=6@^SLV[=T\C[O
M [9[[J^N?A+\'_"/P,\$6?A+P3HT.B:':EG$,9+-)(V-TDCL2SN<#+,2< #H
M   ?'?\ P1_^)FF:A\ =2^'5Q(+'Q9X5U6Z^U:7<8CG\F5]PDV'YL!RZ'CY2
MH!QD5PG_  5<^)VAZA\6/@7X#L[V&ZUVPUZ/4[^")@S6J/)"D0?'W6?YVV]<
M*#T(S]#_ !V_X)Q?"_XV^.I?&T%WKO@/Q;<,7N]2\*W26_VMCU>1&1AO/=EV
MDGEMU9^F_P#!+OX*Z;I.C6ZKK]QJ6GZLNLOKEQ?I)?WLZXVB>0QX*#&=JJHR
M2>IS0!]=5Q/QP\'7'Q$^"_CWPM:+ON];T"_TV%0P7,DUN\:C)( Y8=>*[:B@
M#X+_ ."0?Q,TV^^ >H_#:[D6P\7>$]5NENM*N,)<>3))O\S8><"1I$;CY2H!
MZC.1_P %AOB-I]Q\)_"OPJTN5=2\:^(]<MYX=(ML23B% ZJ2HY4O*\:IQ\V'
MQ]TU[/\ '3_@G/\ "KXW^-)?&2OK7@?Q;-N:?5?"=TEHUS(3GS)4*,I<G.67
M:S9Y)J;X!?\ !/'X5_ /Q@/&$/\ :_C+QBIW1:WXHNENI8&(P6C5455;T8AF
M&3AN30!\\_\ !5[PS-X+_80^%7AZY97N-)UW2K"5E.06BTN\0D'N,K7Z'>$N
M/"NC <#[%#_Z+6O/?VDOV:?"/[5'@:Q\)^,Y-2BTNSU*/5(VTNX6&3SDBEB&
M2R,-NV9^,=<<UZAI]G'IMC;6D6XQ6\:Q)N.3M4 #/Y4 ?GG^QA_RDH_:>_[:
M_P#I5'7Z*5Y!\./V7/!OPM^,WC;XG:-+JC>)/%V[^T5NKA7MQEPY\M @*\J.
MI->OT ?G3^T8H;_@L!\ PP!'_",H>?9]5KZ,_P""AW_)EOQ5_P"P8O\ Z/BK
MJ_&'[+G@WQM^T)X4^,NHRZHOB[PW9"PLDAN%6U,8,Y^="A)/^DR<AA_#Z<]?
M\7?A;HWQJ^&^N^"/$#72:-K, M[EK*01S!0RM\K$$ Y4=C0!Y+_P3Q_Y,M^%
M7_8,;_T?+7SI^SK_ ,I@?CY_V++?^AZ57W+\(OA;HWP5^&^A>"/#[73Z-HT!
MM[9KV023%2S-\S  $Y8]A7(>#_V7/!O@G]H3Q7\9=.EU1O%WB2R-A>I-<*UJ
M(R8#\B! 0?\ 1H^2Q_B]> #XT_9=URU_9^_X*6?'3P3XI8:.WCJYDU/1KB\<
M*ETTD[W$2(Y/)=9Y /5HROWN*^O_ -LKXN:'\&OV;O'FLZS?0VLMSI-S8:?!
M(R[[J[FB:.*-%)^;YF!.,X56)X!I?VD/V0?AK^U-I]G'XTTN9-4L>+/7-+D%
MO?VZY)V+)M(9,DG:X9022 #S7BWA+_@E#\)M)\2V6K^*-=\7_$1;%\VNG>)=
M226U10055E2-2PR.5W!3T*D4 ><?LH^!-3\$_P#!)/XD3:G ]L^N^'/$>L01
M2 AO(>RDCC;'HRQ!QZJX/>O6O^"3_P#R9+X1_P"OW4?_ $KEKZ=\9> ])\<?
M#S7/!5Y&UKH6L:5/H\T=CMB:.WEA:%A'P0I",<<8&!Q6!\!O@=X=_9U^&FG^
M!O"KWTFBV,DTL3:A,LLVZ21I&RP50>6..* /BW]L_P#Y24?LP_\ ;+_TJDI?
M^"TB>7\(?AK=,0L,7B<!V/;-O(?Y*:^M/B/^RYX-^*7QF\$_$[69=47Q)X1V
M_P!G+:W"I;G#EQYB%"6Y8]"*U/VA/V>?!W[37P[F\&^-;:XETYITNH+FSD$=
MQ:3J"%EB8@@-M9UY!!#$$4 >-_\ !3ZYAO/V"_B/<6\J3P2II<D<L;!E=3J=
MH0P(X(([UZ)^Q1Q^R/\ "''_ $+-C_Z*6N#\%?\ !.?X9^!_@/XT^$EOJ_BB
M_P#"WBR\M[V^>]O8#<QR0R1.GE,D"JH)A3.5)([U]!?#7P!IGPK\ >'_  ?H
MK7#Z3H=E%86K73AY3'&H5=S  $X'7 H ^$/^<T?_ '+/_MC7IGQL_P""6/PH
M^//Q2U_Q[K_B#QE9ZQK4J2W$&FWMHENI6-(QL5[5V P@ZL><U[3_ ,,N>#?^
M&D/^%W>;JG_"9?8OL'E_:%^R>7Y7E?ZO9G.WONZUZ_0!\'?$/_@GSX<^!_[&
M_P ;O"?PWN_$FO7OB*RM[]H-5N(996>SD$RI%Y44?W@K @Y)X ]#YG^P)^RC
M^R_^TO\ L_Z-JFJ^#8-3\<:>&M-?B&N7\4JS!VV2F)+@!5D3:P*J%SN Y4@?
MI[7R!\4/^"7WPE\>^,KWQ7H-]XB^&^N7A+3-X2O4MK=V)R[>4T;;=W<(57/.
M.N0#Q_XD_!G]C7X&_'[P'\.8/A1JWB#QSK5U$UO!H.MWDS:?(9%$+3B2]4*"
M<OWPJ%B,$9M?M%<_\%@/@'G_ *%E?_0]5KZ+_9R_8-^%W[-'B"Y\2:%!J?B#
MQ;<!U;Q#XCNEN;M _P!\)M1$7=R"P7<02"Q!-=7XP_9<\&^-OVA/"GQEU&75
M%\7>&[(6%DD-PJVIC!G/SH4))_TF3D,/X?3D ZKXW?\ )%_'W_8OZA_Z325\
M.?\ !/#P9=?$;_@FCX]\*6./MVM_V[IUON.!YLML$3)]-S"OT%\3>'[;Q9X;
MU71+TR"SU*TELIS$VU_+D0HVTX.#ACCBN%_9Y_9[\+_LR_#T>#/"$FH2Z0+N
M6]W:E.LLOF2;=WS*JC'RCM0!\K?\$?\ XF:9J'P!U+X=7$@L?%GA75;K[5I=
MQB.?R97W"38?FP'+H>/E*@'&17"?\%7/B=H>H?%CX%^ [.]ANM=L->CU._@B
M8,UJCR0I$'Q]UG^=MO7"@]",_0_QV_X)Q?"_XV^.I?&T%WKO@/Q;<,7N]2\*
MW26_VMCU>1&1AO/=EVDGEMU9^F_\$N_@KINDZ-;JNOW&I:?JRZR^N7%^DE_>
MSKC:)Y#'@H,9VJJC))ZG- 'UU7YM_P#!6KQ=;_#_ .+W[+7BB[4O::)KM[J<
MRJNXE(;C3)& '?A37Z25X]\=OV5? O[1?B?P%K?C*&\NI?!MY)>6-I%(@MK@
MN\#NEQ&R-YB'[.@*\9!8=Z /1+?QWX=NO!B>+HM<L&\+O:?;QK'VA1:_9]N[
MS?,SMVXYSFO@?_@F:DOQ2_:#_:*^-%I:S0^&=>U=K32KB5=GG*T\DS#']Y8_
MLY/O)]:[K5O^"27PAU'5KC[/XA\;:5X9GG:X?PO9ZL@L Y;("AHF8*.G+%N!
M\U?6WP[^''AKX2^#].\+>$='MM"T&P39!9VJX49Y+,3RS$\EF)))))- 'Y>_
MLX_#E_\ @IY\3OB/XI^+WC+7%T70+^.+3?!.G78MX[6.0OMW(0P10L84E0&=
M@Q+\<Y?_  4N_9Y^ ?[,/P:T+0/ ^@VVG^/M7U6*??+?375Y]BCCE$DC>8[>
M6A<QKP%#$'&=K8^P/B=_P3,^&GCKXD7OCO0->\5_#;Q%J$K37LGA+4%MHYW8
M[I'VLC%&8X)VL%SSMR<U8M_^"8GP2'@KQ#H>H6NMZ[J>N^3]L\5:OJ N=7_=
MR)(!',R;8\E &VH-P)!R,8 *?Q0_:3^'/P3_ &>O@YHGQ+\,7GB+PKXVT>QT
MZ686T,UA @MX"S7'F." %?>-JL?W;$8(&>)^*_\ P2=^!?BK2;CQ+X/UC4/A
MS(L)OH-0L=0%QIL8V[Q,1*20@^]E)5 '3 KZ>\0?LQ^!/&?P-TSX3^)["?Q+
MX5TVT@M+5M0F_P!*C$*;(9!,@4B15&-PQD9!R"0?FE?^"0_PY5(].;XC?$:7
MPPI&=#DU6'R&4'=LXA "[N>%S[YYH \U_9+^,?C/XI_\$[OVBM/\7:M<^)(_
M#>BZSIVG:W=,7::#^S)&\KS#\S[#\P+9;$JCH *T_P!DW]H7PW^S5_P3/\*^
M*/%OAS4_$V@W6K7VF3VFFP0S#][<S_ZY974>6=I4_>Y91C!K[8T;]G/P)X7^
M!^J?";0-(_L+P=J6FW6F7$-B^)F2XB:.60R-N+2D,?G;)X'8 5F?#_\ 95^'
MW@#X#R?!Y-.FUWP-*LZS6>LRB5Y1+(9&RZA<$,<JRX*D @Y&: /G3Q%_P3+_
M &;_ -HCPG8>,/!4=YX4MM9MEO;6^\-WNZV<,N03#+O10.A5-F"".#FN9_X)
M>>/O%]G\2/C#\(M2\6S?$#PCX-N%CTK7&?S(X\32QE4<ECLD"[@NYE7RVV\$
MD]-<_P#!(OX<0O<6NB_$+XB:!H-R[-+HMIJT1M]K'YD7,/0KQ\^X^I-?3_P%
M_9U\!_LU^#SX<\":,--M)7\ZZN97,MS=R8QOED/+$#H.%&3@#- '2>'OBAX-
M\7>(M5T#0O%NA:UKNDLZ:AI>GZE#/=6;(^QQ-$C%HR'&TA@,'CK73UXK\)?V
M2? _P7^+OCGXC^'Y=6?Q#XQGGN-26\N4D@#37!G?RU" J-Y.,D\5[50 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>mrsn-20201231_g2.jpg
<TEXT>
begin 644 mrsn-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFLVWD]* '4=\4S=ZG
MI[X_STK/U;6+#1+1KK4KJ.WAZ9<C)/L.Y_\ K4 :61C.>*7OBN+\._$;2?$V
MM2:=9I,KHI=7D7 8#^78UV ;G'/)'M_G_P"M0!)14>X=%'/0?K2]>_YG&: '
MT4SH?O8]\_Y]*=N'^- "T4F?T]J6@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)[?EQ2]J8QP>V
M0,YQ^ H 7(/0Y/4<56NKJ"VC:2XF2*,?>9CCK7G7B#XFRV\\UII5L!Y;%#-/
MTXX^[7G>H:Q?ZQ*9K^ZDE;.0"3A?H.W/^>E 'JFM?$K2[/,5BIO)N[ XC'X_
MC7(2_$74K@-%<V5I+"_#1$'!'/ZUR5M;W%Y*(;2&65CP%C4G^7^?Z;A\#ZZ+
M8R_9T9P,F)9%W=.AY]Z )-OAK5LB-Y-*N&_A?YXS5&[\-ZC:)YJ1+=1=1- P
M88_.LR:&:W=HYXWC<9SO4C^GT_*IK34+O3I ]I/)">I ;@^Q'>@"L',4BL.&
M7@9'3_(/^>:V-(\4ZMI&X03(T9.?)8?+GCI]:L_V[8ZB-FL:=&[=!/!\K]>,
MCOVXIH\.P:BN_1M1CN,CB&4[)/UZT =OX=\>P:Q<QVES;M!<N?E*\HQZX]O_
M *]=JA/ SG^O^>M>6>"O#UU;:R]U>VS1K N$W#JQST_^M7ID;9Y/?KQ]/TQ0
M!=0583KP#G]>M5D&1SZ=35E1GH.O_P"O_/TH D7@<$?7'%.[]32>X^HXI10
MM%%% !VI,_YQ1G_.*,_7\J %HIN[(X(Y''>CKW//M0 ZDR,9II91SD#![U4N
M-5T^UQ]HO;>'C_EI,JG^= %W<,9_&C=[5S\GC#24?;$]Q<M_T[VTD@)^J@C]
M32C6M4FQ]ET"["GHUPZ1C\@2?TH W\\9QQZB@L!GV/K6"?\ A)ICR-.M5Z=6
ME(_E[4G]AZI<C%UK]R$/5+=%C^HR.: -YI%12S$*!W;@5G7&OZ3;;O,U&W##
M^$2 G\AFJ*>$=)#[YUN+L]?]*N&DQ^!Z5GZ]K_AOP9 $:V@-T_$=K @9V/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MI#TYZ=\T 'IS29_VAVHZ>V?:D+^_Z?E0 N?]H=Z7/OW]*:7]<CFF[B/7CWH
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MZ5NP'D<X..IJND7/3GCI5@/# ,RR)&/]IMO/^?YT 7HL[E[8YJV@P,8]N?\
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M$X*Q;8A^@S^M6K;PGI$)R;5IV'>XE>7]&)'Z5LJO.!U]:F1!CV_/T_S_ )-
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M^/?\<UZ;X@T2+7[(V<TKQKN#;D.#]*BO+N3P_;0<*]G%&$<,<2#MD9ZX!Z4
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M@D.XJ.^T_I5S0I)I-&MY;MCOVDEF.,KV/MQ596OO$,K16$GV>P!VR7)'S/\
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M*/B/X[U[PYXCCL;#R8K<PJZNR;MWKC/IBF>&OB!K6H^%-:N;KRFNK0J8W6/
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MYN-1G;9N_AC!./PS_*@#O8(8[:..*(+'$@"JHZ #@8^E.# >QP.3_GVJN][
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M;>,9SQCI^=+[CKR!WI<<>@/:EH 08[#';I2T44 %%%% !1110 4444 %%%%
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M_CBG^!#(^@B29F,C2R;BQ]S_ $K,N[O4+*06^GZ8UU(1EG+;57\:VO#]Z_\
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MZ8]?:EI#SQV[T )WZC.>F>]0.,*<#_/I_GT]ZGSQUSQV]*BD&?I^GO\ R_\
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M1V ]AFGZIJ4VK7BR7$[S*B@ OT]ZLZ/I:3Q-J%\3'IT'#/T,AX^5??\ E^%
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M_P"3[4 '\.>V.,\#\:SKN?S9=H.5!V\]ZN3OY<+-WQ_G_/\ *LL9!ZG(Y/\
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MBVN=-^U31I)"8S)AQGC&>]<0-(T_Q5ILES#$=/\ /X5X3@[>_'3G% '4] .
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MM=ML7V;P>?3.*]'6"+4-.:"X4/&XVL,<&@"EKGB:TT:SC?F>28@111XW,?\
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MDYS^.:-HST_04 <MXGCQX;OL#I%_6O&NV3T_S_3/YU[EXM0#POJ!..(2>?\
M/T_*O#N>G?@?CS_G\: &G[I)'7T/^??_ #FNV\3_ /(H:6 >=R=_]@C^=<3U
M3Z\?Y_ _I7;>)R?^$2TL>K)C_OC_ /50!Q8[XXSV_P _3^?I5S2C_P 3BS]I
M@<?B:IKCL>.@_/\ S^7Y6]*YU:T]/-7^8_\ K?K[4 >OCEB1Z\_Y_P ]:DB3
MVSZ@4Q1G.1R">M7(D'X?Y_QH 5(0/\]?\\_G5+5=6ATF)?,&^9AE4'\_I6U'
M%WR?P_"N'\:0S1ZNDA0^2\8"MCC(Z_SH T=/\6P3W"17$'DESA6W9_"NM1 !
MG.?3'^?85Y!!$TMS&D8+.S  "O7+52MM$K'+*@!X]J +: 9!_#_/ZU.J\#Z8
MYY]/\_G4"D<[?P_S_GI4ZGD<8Y_P_P _YX )>IY&>U Z9SFDS@=N!^%.H **
M** "BBB@ I#_ )/I2TAH 3'7Z]LC_/6HR#Z\D^OO4G!&!CT'/:FD9)]?3]*
M,[4;V#3;&>]N6VQ0IN8@=OI7A7B7Q%=>(M0-Q)E85/[F+L!S^O\ GTKWR]MH
M;RVDMYU#Q2KM8'H0<UY7J/PVFMM1=X+B-=-'S,SGYT4=?J1CB@#E=%TA;_=<
MW4@AL8.9I3@#C^$>I/3\:9K6K"_=((4\BP@&V"#IQTR?? J77-9CO%CL[!##
MIT'$:9Y<]V;US4.CZ5<ZI?I%!'OV_,[,/E7CJ: 'Z!HUQK-Z45=L"',K\\=?
MUKU*UM(K&U2WMD"1H, >OO63HD,FD)]BNPJ-(=R.O1CC^?%= HR>G;(H S;S
MP]I.I _:[""5CWVX/YCO7/WOPOT:Y)-O)-;$C)"G<">/7GO6WK.LO92K!;*C
M,1N)//J*T]&OGU&S$SIL8'!Q_.@#RV_^$NJ1$O974$X[!OW9KU'PWIKZ7H%G
M87&UY(D"MMZ9ST]ZU G& O'T_P ^E2+'Z_\ Z^E #K8JLH!X## ]JT>HZG'?
MCM_^K_/I0*<C'X8_S_G]*L02\;7Z]O?_ #_2@"I/"T3Y8=>A J$!G(VC/TYK
M5DD54+R<*.23Q[UDRW<L^[RR8H^Q_B- %^VMO+RS]>PZXJMJA+7$*X&,-U&:
MI^6F3D$^I+>_7_/I36BRP9696' YR!0 YVVHS=.,]?PK&<;U;/(.<]NM:P<G
M]W)PS=QT/_U^E9\MJR%D(R#QD&@#,_LR/(5I':,$[4W<"HM$TJ :S=:?<M(5
MDVSVX9B.#PQ'N#5N#0I9WQ-/*(!T4\?K3-1\/W+QI<07,DMQ9\P(/E)7^)?J
M0!SZB@#O+6%K:U2!I&DVC;N8<G_/^<U2G+&9BQS3]%NX[S28)HY_/#*<N1AL
M]P1V(JQ/;>805.&'ZT 9XSWJS:(6EW8X'6@6C]R!ZU=BC$*X'4=2?\^HH IZ
MH3Y$<79V4,/4?Y_E5#KR?Q_S^%7]6!$2..BO]<=O\*H]QCH.G^?RH R97:67
M=Z'C'3]*C[X'IQ^532PM&Y!7*]B/Z?Y[UFZC=R6T:Q6Z>9>7'R01XZGU^@ZT
M .T<F\\2W=SC,5M"8$STW$@M_(?G71]S[G^=4-'TM=*L(X-V^4\R/W+'J:T!
MSSSZGVH 9(,QMUR5/Z?_ *J=:2G8O.<<]?\ /]:CF?;"Q[XZ5%;$@+CT% &Y
M X/''X]ZNHW'U[G\:S("<\?_ *_\\UH0G&#Z'U_SZ_H: +(^F/04HIJ]NF?R
MIPZ4 +1110 4444 %%%% !1110 4444 (3@4'C_ZYI>U-/ [# ./:@#R>.6.
MR^+NO+-(J>;"C*6/^RM=ED$\<]3P?\_Y]:XCQ1I4$_Q<BBN$'EWMEP3V*CC'
MY5DZ[J&J^%[@:;:7<GV<@21NW) ] ?PH ]%NQFU(!'45G8)_A'X5%X8U.36M
M"5[G:902C8Z'I@U.\;1OM9<'MD?K0 9YZ^_\ZC959<,HP>N13Q[<=^O^?\F@
M!G;"+G/0#ZT -5 V%V]L >M8WB)M$T:S:":'_2;B,@;1DKGO[5U5M:B/#-]X
MC(]JY3QYH:7-H-3$@5H%VLIZ$?Y/\J .C\-6>FZII^GZC:.WFVZ^664;=V.Q
M%5/B78:E>:9"MDCRQHY,B)GD8X/TK8\%Z,FC^'8HU;<TF)68\<G_  KH2<
MCITS@?Y_S[4 >=?#C2]4MM/N_M<<D4+D-%&XQSW..U==ST(P:V!QR!CZ#_/M
M5::W60Y7@XY_SWH H_C1S@5(;>53TY'O3DMG8C(P/YT 1+&7;;CKUX[5B7OP
MXTF\U/[:QE4LVYHP>&/^?Y5UD$*QKQU[G//^?\*DR/3Z\?T_"@"K+91S:;)9
M8VQ.ACXXX(K!TRQ73+,6BL76$E=Q[X(KII"1&S#J!GD=_>N-\.ZI+JEC)-.
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M@_K2T %%%% !1110 4444 %%%% "$XI#G(&>:4G _KZ4T]<]_3/^?2@ SNZ
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M>M=*C?*/Z_YZ4 65.<'FG>PX_"HE//?/J?\ /^<&I!TQC/\ 2@!U%(,]Z6@
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M: .MZ8!Y&.0!_GW_ ,]5(^;^?^?\]Z3.1G.>._Y$_P"?Z4UY!$C2.=J@$Y/
M'?\ EB@!V[MUX]>,X_\ UUA^(]9_L..SNI9UCM3/LFSSE2#SGV/\Z@LO%)U3
M5&M]/LY9[5?E:XSM7/\ L^M-\6:'#J^CW#W%L\\D41:)(QDANW&<$T 1WWC_
M $2SL1<I<>=EMJI&,GCN,]O\:I6_CBXU0>9I&CR7$2\,SR!=I],5GW7AB?QA
MX;T^<VXTV[B4KY<@XQP,G'3UKHO!_A5O#-C+')*LDTC98@?*./I0!JV-\;BS
M1[B$V\K#)C/.T_6N7@U#28=9FMK2*6WEE<F0.A 8^HKMSM)^8<C/0]NO]37/
M^*](GO=+/V, 7$#B6,*/O$=OYT /.=N>?P['^E>6ZCXQUF/7I!')LBBEV"$+
MQC/2O1=+NIKFRB-S"\,VWYUD7!'K^%-ET339[Q;N2RB,X_B9<\^_OT_*@"9$
M6ZM8Y)$VL4!(]./_ -7YTTV"C(WMQ_G^M6_Y=OI_]:C\.?Z_YYH @6SA3ELM
MS@Y]O\_YQ7.^/[K[%X0N8T/[RY*PH ,EB374DXSUX)ZUQ?B,?V[X[T/0$^:.
M!_M4^!G&.E 'HGA;3ETKPSIMDH_U<"D\8P3R?YUL4T#' & .WM3J "BBB@ H
MHHH **** "D]CSV/%+2'IC&: &GTZ9Z\_P"?6JMQ"DL3(Z*ZD8((R"/\_P">
M*M_CC\:B<=?QX_7^E &!_9MKIUK*EI$L"D$_+GCKS_*LS1M,BTJU\M3F1SN9
MF^\2:9K%_=2>+(-+B?; D6^0 <L3T'M7%^.=5U*VUI;>":2&W504\LE=QQR?
M2@#TG&3DCG_/_P!:N+\8^%KS6+N.ZM#N*KL,;$#'^%:>@ZM<W&BV[W2#SF7Y
MBW&?3C%:T-VKR;74 ]L<C_/7\Z ,OP_8#PWH:QWMP@(;>[[L!<]L_E4^IV$6
MNVR+%(P^8,LR,>/QJ'6]+FU6]L87;-FIW2C/WF'0?K6TD8C1(XP H P !]?Z
M?Y[ &3IOAJQT]Q(F]YL?ZQF.3G_)JY>:5::B-MQ'YF"=N\YQ_GFO,K_7M:3Q
M+(HGE5EFVK"IXZXZ=Z]6A:1K>-I!AF12V>QX_P _XT 5-$TR'P_-,UDC&.4_
M-&6Z'U'OS5^#Q582:H=/D:2&8CY/,7 ;Z>_'Z4<Y'0<\9[?YYX__ %UF:OH5
MOKD2)("L@/RL.".F>: ->Q\2V6H:C/:6B/+Y)PTJ#Y-P/3/K45_X8LM7OEN[
M\-+M4*D9?Y1^%7]'TFUTBRCMK>)51!@X R3Q^9KSGXC:[JUCK$5K;3R06X0,
MK)QO/UH ])M--MK. 16L?EQ@\*N0!^ K+N]+L])6?480(SG?*<\,/6D\%7UW
MJ7ANWGO<F4@@,R_> Z&MF]LXKZSFMIQOAE!5@3V/]?\ "@#'1TD570@J?3_/
MM^E/.!G(Y]__ *]4M,\-7VDM+&M_YMJ!^Z5Q\R^V:)=6M+>\:UN94BF'5"W3
M/\Z .?\ &^N7VDVT$=FVPR$[I !D#I@4_P $ZU=ZO83?;#O:)P%DVXSQ[>G%
M;=Y'IVJ6_EW(BGCZX)SS[>E9[:UHFBP?9K7:.WEQC)S_ )]: -JXN([:!I9'
M"HHR3GVYK%TO4O[6$MPJ$1B3:C?W@/\ Z].NH1JL 6<-Y;\E,D?@:N6MLD$:
M11H%51\H &!0!>MO_K=.O^>*U81@?AC^?^-4;=,' ]?RK1A3Y0,'\J +<8.?
M3_/^?\]9@>./R%1(,#^N?_K?C4HZ8X], ].* %'4\TM%% !1110 4444 %%%
M% !1110 TX'&?2HI%!X/^?\ /]:E_ISC/--<#:V!_G_/\Z ,34M+MM3A\NY3
M=@_*1P5/J#VKD/L5Q<:R-*>\EN+.V82,KXZ]@?7_ .M7?73""&29ONHA8_@"
M?Z5QOAM3+;2WSG)NI&D)/89&/Z4 ;(  "C[H&/H/\XKSW77N3K%S]J)R&(3G
M^'M_^NM:]\67*7LBVT,1AC8K\_5L?R[UK)J$-_;Q7#VD3YY7>N2OKUH FT)I
MGT6U-P6\TJ3ENN.V:=J6JI8%(XXS-=R_ZN)>?Q/M_A5@7</V=YF/RQKN(] /
M_P!59&BQ&7S-8O<!YB2"QX1!T% $%MX=:ZEDN+^3:92"T<1VK[9]>*UDT'3D
M 7[)&?=ER:MV]Q!=#]Q*D@7@E3G'^?Z5Y_?:E>RZE-(]S(CJ^ JL1MQT&/\
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M&Y?]F0#^H'Z4 )<^&K!H)HXXW5F4@'S&.#^?\Z\YN[&>SG:&2%U93Z8S[U[
MV,D#G'>H'BB?[RJWOC)H Y+P=IL\4DEY,GEHR;5##&1W/TZ?K79(00,M^OY_
MUJ+!) ..HX_S]/\ /:1>F3WY- %F-LX[?Y[?Y_G4P/ [#V'^?I5=#W/KS_C4
MZ>G&<8'M0 X>H&!].U.I._IFEH **** "BBB@ I#R*6B@!I[\CTH*Y)ZX-.[
MTWCKP!0!"R!AV]L?2HC'Z5;QGKGT^M,*#'.??_/XF@#D/$/A4ZM=+/%.L3$
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MC/K[_P"<?SH 9#%A1P./\_RJ[&F/;/\ C2)%@\\?7_/L:G5.G&/I_GT_SS0
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MA->L'U'0[RSC8+)+%M7/<_Y_E7BK^$O$"%E?3)L].&!]>^>10!A#))![]?\
M/X"NW\3X_P"$1TLXSRG'_ #_ /7K#B\*:V\BK_9\B[S]Y\ #W/\ GO7:>(M#
MGNO#<%I;?/+;[2%R!N &/ZT >9+@CD9XY)_7]<U>TD%M6M1A<^<O0>__ -;^
M53#PYJ[$'^SY02/;_/\ G\]#0_#.J?VM;O-;-##$X9F?MCVH ]+0?-CWXYK1
MMP?T[_Y_G56*/YN!]<C]*O0* .>F.O\ G_/YT 7%X_G7&>-M6=+F.PBPH4!R
MP/.>V/RKME P2>/K7*^+?#MQJ$ZW]HNZ4*%9<C+?3\Z .1T_6[ZRNED^T.Z
MC<KG.?>O3X9%FB1QT89]:\\T[PMJ5Q=(+B#R8@06+=_R_&O1(XUBA6-!P@P.
M!VH >!U]NP-/09('7^M(O/KC\ZF12 .W^?\ ]7Z?B /0<#/?K^0/^?\ .)@/
MSSR>E,4 >V/?%/Q@8/8<\=J %'3TQV%+24M !1110 4444 %%%% !1VXHHH
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MP^S77[R/'3=W%#:CK5QE8=/6 $_?D<<?A56719KE3+=WCR7(_P!6RC"(?84
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M /4:>%&!S^/K_G-*/E'TZBE&?Z9- !W_ /KT8';M2T4 %%%% !1110 4444
M%%%% !1110 4A&:6B@!OX=\TP]A[_C_GK3SCIP .QI#R<>O;/^?\YH K.#],
MX'^?QJ+OFK1'/O\ Y_S^/Y1LO';CI_G_ #UH A51D#\.!4R#(Y';^G_U_P"5
M 3&1TX.>/\_Y_"I0.V.3Z=O_ -5 #&'MD]>/\_YX]*KR+VZ\C%6R..F#U _S
M]!_^NF.F<^F?Z_X?RH RY(SCCGC (/\ GZ_XU7:''&,#_/\ G\36H\9[CCWJ
M,Q_G0!FF+YL@_K0(?PK0\E<XP/\ ZW^?\\TX0@#MU[4 4TB QV ]?3K5R./
M7CGL*<D9]/RJ9(^1W_S_ )_*@!T8^7K_ )Y_S_\ KIQ&3C]/\]>W_P"LT\<
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M<X[Y%1N9CP7)_#'^?_K5L-!S[BH6M\\8R,=C_G_./:@#'\DGJ<G'<T[RN?\
MZ^*T_LV3DKDGD\CUI1;''"CWZ>U &%J<]S':*-[M;JX,B@X)7_.*M:MJ%U+I
M3K$"$X+A< E.I'Y4:[;D6:3,,QQ2!G0_QC_]=+K%HSZ8SQ_*B[6*=,J.H_SZ
M4 .2ZENK2-4.V,K\J@]NU-6#H<9]R/K5NTB6:TB>.,JK*,#' Z582#';M_\
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M#'/(/6@!P&.@]AQTI<#''':D ]OK2CI0 M%%% !1110 4444 %%%% !1110
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M =L^M68X".W3MC_#_/6@!D$/'/ISZ5HQ)QZ4Q(]OIQT_S_GJ:M(A'^?\]_\
M/% $B+@<=_I_G_\ 54G&, \9['VI N!TP?;M3N: %HHZ# HH **** "BBB@
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MI_G\Z0KGVST_'_)_ST *9B)[=?QS1Y)'49R/;G_/]:M[<]/J.:4(/3OT]/\
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M8EWL ><8]/RJ.TU&&^N)((M^^-$=MPQ@.N1_.@"]CT],#-!&?Y<B@>N<YI:
M$Y]:.??K2T4 )BDQQT'3!IU% "?KS1^/7D>M+10 G/L,]:,=NU+10 4444 %
M%%% !1110 4444 %%%% !56^M8+VU>"YC62,C)4DC/Y'VJU5:^NX+"TEN;F5
M8X8T+.S'H/\ .: .'T[2ECTCPK]F5[::60/-(H);/DODG/0T^]U?6HH+15<
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M>0#WST_.F+XGLW=4CANV\S<L96(_.5ZX^E $FM6<UR+,I!]IABDS)!N WC&
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M^([TQ_$%H+B>U5)3-&CLJ%/O[<9Q_GUH Y+28FO+:1+6!+B<^2TZA5V; #R
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M2!ANN.QX]\]:O?\ "3Z<+Q;:23$C$*>/E#$<*34MEKUI?3QPPK.OF[O+=HR
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MDK!L#'\!&#C(Z,#6J^O68:;;YCQPQ^;(ZIE0I&X?F#_^ND7Q!;/%,WEW.Z,
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MZU<@\36=TRQQK.CN753)&0-ZY)7ZCFH=.\303:?')=I)%(83(<QD*X'7;ZT
M5(-#N(/W<-D(=M_YQD4@"1.?Q_\ UUG)H6KLEUNL5C\ZVV,B,-I<.".Y)SZF
MNBF\26=O##+-'/&DO(9HL8!(P3Z4YO$-BEXUN1*-LOE&3RSL#=AGUQ0!SUW'
M=:6;VY>,1W,ES'/:H7'[T^6J&/ZG!'Y5NSZ3./#+6",9+AD^9BV-S'DFF?\
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MZ\D9]ZLG0[A)S=^6!/\ ;?,,F_GRSP1GT]JUM'U4:OI,-Z8)(1(,['7K]/\
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MZE/)X=>_GC4S(COA""&*YQT)_P BN>N=6U"]TVXMA=P.TEFD^^)?]5N;!0T
M6=:\.74MS'/8(LX,DLCAF4;6<@]^HXK:EL)-1T'[!>2*DKQ;)'A& K>P^M4=
M7%WIOA)!;W:031&(-)L^7:74=.W6LR2^U&SU+4[R.ZAGBA2 R+C_ %N1R >@
M'TH V9O#K3O(7OY,7"JMR%0#S=O<?W>IK2N]/CO1;!F=!;RK(H'J.@K L_$%
M_=:ZT!1/)$[1&(X!  ^]UR?7&.E6=8U.ZM=1CLX;JWMU\AY=\HY8C P,]/\
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M%%% !1110 4444 %%%% "'_/%4Y[!)[R&Y9F#1QN@7CG<.?QXJ[VI,>G'TH
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M?K]<5I#&!CICC%&. /3MB@#G[CPQ!/=QW3S%I=BI-))$KEPI)!Y''7M4G]@
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MMG//4]ZGT_3KBR6"-KUY8X4,:J4 !&!C/T K2X!]*!MSQCO0 M%%% !1110
M4444 %-;GCK[4O<#-1RN$7<Q V]2<4 4;^>]C(%K%$4QEI)'QC\!^=9FDZEJ
M=YJ\T<VS[.$W+L!YYQW[59^;6Y59BZ6"'IT\W_['^=7K6P$%[/,=IW[550.%
M '^)H NCGOUYI1U[TF,=OZ_C3J "D[]:6DSR<D<"@!D@#AD.2&!!'2L@>';<
M01(EW=JT);RY%<;D4_PC@\>W6M=N21GG\/\ />N,CU"YT]$+:B\P&H>7<(Z
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M[=LGZ8H Z6^T2SU"[-Q/YFYH3 P5L!DSGGZ')%0?\(Y:>6PDGN9)F9"L[O\
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M_P!:/L$'=7/_  *D^P0YSM?/7[W- $TB1S1&.159&&"I QV%,$%N(RFR,*P
M(P,$8%,_L^ =G_[[I#IUL1R''&3\Q% $GV>V^T&?RHO/88WX&:KW&G6MU>K<
MS*LC+&8P&&1@FI#IEMV$F?\ ?-(=,MQVD]OWAH )K.SG;=)!"S8P"5Y ^O\
MG'X4RUL+>!+@LWG-<-F5GQ\W& ..V!3_ .S+?MYF?3>?\:/[+M\\"0?60T /
M%I:"1)?(A+H,*V!P.G%(EG9)+YB6\(=B26"CG--_LNW(Z/\ 0N:3^RK8?\]/
MJ9&H <ME9(K*MM %;[P"=>?\_P"35D.O3('XU3.D6W]U^G_/0_Y[TAT:U.>)
M.3_ST/\ C]: +PD7CYAU]<T>8I_B'T!YK/\ [%LR3\KY]Y&_QH_L6S/.V4_]
MM#^5 %_S$'\2_P#?7>D\T<_, #R#5'^P[//27_OX:4:+9*.8V;./OOD?K0 D
M^J01_NXR9IC_  1C)_\ K?\ UZCM[.:[G6ZONO\ RSB!R$!SR?>M"&W@@7;#
M'&@[!%'X5+SC)[>_%  !QQQQU'2E(!ZC-'UYYXI>@H **** "BBB@ HHH[4
M-&<8^;_"EY]!^=-"X)V_GGI3L?3KD<4 '-'/H/SHQQT'7Z4A48^[^ H 7/L:
M,_3MWI-H[+T-(% [=/>@!2>#_0TN>?6F[.!QC\>G%(8U/48SVS^E #L@\$C\
M#2\^_3M33&O<G\Z3RX_3 /X?A0 [(SR<<^W^?>@D=P#VIHC7/3'XXQ2>4N.1
MCM]Z@!^1UXZ]31QT^4=O\*9Y29R1R!ZG-'DIT QSV8\4 /W>ASGIBC(ZC'KG
M.*9Y,?'R\9QWI!"A''?GK0!)D9QGOZTF5/X^_K3#!&0>,#USBD-M&<_>_ T
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M>:A'WE_/%9_]A61YQ(0>_FMZ?6C^PK+IME]_WK4 :.].F['_  *FLZ$'YAD
M]JH?V%9=,2]/^>IX_6E_L.SSG9(<]C(<?SH DN=4MK?<&?<W38OS$_A5017.
MJ-F=6@M 1MC)^:3_ 'O\*OPV-K;\PV\<9[;5YJR%YZ8XQ^% #50*BJJX51@"
MG\$4<9/Y<4=_?UH ,"EHHH **** $QSG^M,,,1+9B0EQ\WRCYOK4E)CGI]:
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M10 4444 %%%% !1110 4444 '08%)@4M% "8XQ_6C'^<TM% "8&,=O>EHHH
M.@P**** "BBB@ HHHH *3 QBEHH .^:0 "EHH *3 I:* $(!ZBEHHH 3 I:*
M* "DP*6B@ HHHH **** "BBB@ HHHH **** "BBB@!",_P#ZZ6BB@ H[T44
M)@4M%% !28_SFEHH 3 ]*7OFBB@ HHHH **** $P/3K2T44 '04444 %%%%
M!WS28'/O2T4 %%%% !T&!1WS110 F*7H,"BB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "CO110 =Z*** "D(!ZTM% !1110 F!1CK[^]+10
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M=[J&@S-;_9[6YN05*R9)7:W##I6KXNO)+/1%ECN)+<-.B-)&"6VD\X'KCVH
MW\C_ /71GUXXSUKCM/U:[MX=0DCFFO;*$*89KS]U\QX;+-C@>M2V7B\W$;/)
M;Q_N;M;>9XFR@W 88'TY H ZS/'7..*,_P"37+76K2WE_8^6"D":B8%<-_K<
M(V3^?\J5O$MP%GO8[)'TR"8P/(7PQP<$@=, \?G0!T^[Z?G2YY[<'UKF+_Q/
M)8:I';R0P&)I5BQYP\WYNC;1T%4O$&M7\ND:JUE;J+:V8PM-YN'+=R![4 =H
M,<8/&.@I:BMR3;Q9R?W:YS]*EH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "D(R.F?:EI&Z?RXH P?$.FWU]%'+I]T\5S#RH!P&Z<$5
MC'_A)M9:*SEC-A"/];(K<O[#TS76W%W;V\L<<LJQM)D(K-C.,=J=/=6]K%YT
M\J11C&68@"@#CO(\0^&YG2T634K9QE!(WS(<?RI/^$>\07-JU^^I2QZD6W+"
M#\@_V:Z^UOK>]B\RUFCD3IE6SS3'U6P%R+9[N$39QY9<9^E $.BW%]<V"-J-
MN(KC."N<@^X_6M(D=\#ZBC.5W*<Y'7%!^Z<<'GUH ;O4GAAD]@>:J:AJ4>G0
MB5K:>9?2"/<0!WZ]*YVU\)SV^I1W#?8MHDW?+YH;K[MBNIN<M:S!1DLC8'KQ
M0!1TO7;;5E#P07,:N,HTT84/UZ<UH--"F2947:0O.!@G_P"M7*&"ZLM&\/3O
M:S-]DDS,B+EE!!&<#_/-4Y[*ZU.VN6:PG6.?5HI DBX)C Y)'I]?QH ['^T+
M(JC?:8=KG:GS#!]A^M237-O 5$\T:%SQN.,_A7*W&@0_:?$$D>FH?,MU^SX0
M?>V'[OH<X_&HI+86]XTNJ:9/?1RV4<4($?F;& .Y<=LGG/2@#L)+JWB.)9D0
MGGE@#S3;JZBL[2:YG;;%&I9CGH.<UR.DZ#.-<TMM2MO-^SZ8$W2_,JR;EX^N
M,UJ^)K:_U"&UTVR 432AI9'4E51><$#UZ4 :EGJ=K?Z?#?POM@D&06&.IZ'T
M-++J-E%9R737$9@B!WLI!QC_ #TKB[O2-5CTS4]*GA\^.:YBN8F@0JF&<;QC
MMCG@UI7NA_\ $QU>&VLE%K/IJJJA0$:3+?ANQB@#;&JQ3R6@MD\^&Y)W2*P^
M08SR.OMQ4S:G9?:5M_M"-,[;=B?,0<?YYKDXK<R_V#+;Z?-;16PD^T;HC%M/
ME$9_IFL[0,-<61DD-O,4E6V86I7S&8'[S]&]?>@#T-+FWDD:))D:1?O*",K1
M'=VLTOEQRQL^,E003CZ#ZFN$T73;A+BTCFAG2ZM4D\TBW"*25QS)_%DG/K5K
M3M#DM-,\./'8F*ZCNB;AMF&VDMG=['B@#N!D#IR?\\TZFXR/KGK3J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0CC
M!/7UJEJEC%J6GSVDP^252#Z]JN'DXR3GT-)GN#^M '@6K^ =<TZ\>.*T>XAW
M81XQG(^E=/X$\!WEKJ4>IZHGE+%\T4>><],GZ5ZHSHG5@"3T)I=P*%ATZYH
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M HP#U!XR<\C)YZ5TO&"<\<]Z.O3&1Q0!S\?A>#[>ES<74UQY898T<+A=W!Y
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ3K8GU6SMK0JT4KRQR$YSE!G@T^/Q)I\MVL"R/EG,22&,^6S]U#=,\>M9_\
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MX7Z\444 (.>1TS_*FE 77< 6'()&<=/RHHH > >YZ48XQ_6BB@!>^:.@HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>mrsn-20201231_g3.jpg
<TEXT>
begin 644 mrsn-20201231_g3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (H!(0# 2(  A$! Q$!_\0
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M<$-D8X/H30!UM)F@=*R-0\4Z3INO:;HMS?10ZKJ(<VMJV=\P12S8X[!2?PH
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M4 %%%% !1110 5R?Q,N+ZT\(7TUAX@L?"DB -+K6H!#'9Q?QR?/\FX+DC?\
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M DHK-EU[3H)/*DU"V23IM:90?YU;2594#1R!E/1E.0: )Z*BW=^Q%+SU_3-
M$E%1[CU/%.4YYQB@!U%%% !1110 4444 %%%% !1110 4444 %%%% &#XN\%
M^'_'VDR:1XFT73]>TMF#M9ZE;)/"S#."5<$$C)_.F>$? _A[X?:,FD^&-$T_
MP]I<;,ZV>FVJ6\08G)(50!DDD_C7044 ,['.?4UR7CCX1^"/B<UL_BWPEHGB
M9[;(A;5K"*X,8/7;O4X_"NQI* *EA86VD6$-G96\=K:6ZB.*"% B1J!@ *.
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M.&5A@C('6M2B@#F/ _PU\*_#2QFLO"?AO2O#5I-(99(-)M([9'? &XA ,G
MS[5TL;;L\8I])0 M%%% !1110 4444 %%%% !1110 4444 -:N#^.G_))?$W
M_7H?_0A7>-7!_'3_ ))+XF_Z]#_Z$*TI_''U,ZGP2.]7[HK#\6^.- \#V<=U
MK^L6.CP2MLC:\N%B\UO[J!C\Q]ADUM;L >M?-7Q8\9?$G_A*-6%M\-].\0:/
MH]XJ:>+V+S9;E2B,9$)X7<Q9,X.WR\\YP,RUL>L:3\<O >L7T-C!XFL8+N=]
MD$%W+]G:9O[L8?&X^RYKNUY;T%<__P (WX7UJ2(MIFE74T!$B,L,;/&P(.00
M,CGTJ_J7B33-(U"PL;V_AMKR^9EM89' :4K@D*.^,B@9K45R]G\2?"^H7FIV
MEMKUE/<Z8K->1K*"8%'4M]*JGXN>#8_#/_"0MXET_P#L02>4;[S1Y>_/W?K0
M!V5%4['4+?5+.&ZM)DGMIE#QRQG<K*>A!]*R(?'6ER?$";P<&F.M0Z7'J[#9
M^[\AY7B'S?WMT;<>F* .CHHHH **** "BBB@ HHHH **** "BBO*-0_:*\/Z
M?\44\!MI6OOKKHTJ[+#,#1*ZH90^[[H9E&?>@#U>BDI: "D/2EHH X72_@I\
M/M$\6R>*=.\$Z#8^(W9F;5K?3HDNF9OO'S N[)[G-=JJ[0..?3%24M %/4M/
MM=8T^YLKVWBO+.XC:*:WN$#QR*1@J5/!!':N:\#_  D\%?#22\?PGX2T7PR]
MWC[0VDV,5L9<9QN* 9QD]?4UV-)0 U6I]%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %4-;TJ/7-)OM.FEN((KN%X&EM)FAF0,I4E'4AE8 \
M,#D'D5?HH \2'[)_AW_H<?B,!_V.^I?_ !ZC_AD_PZ.1XQ^(W_A;ZE_\>KVV
MB@#YU7]A?X=1^*)O$B:KXV7Q!/!]FEU0>+K\7,D62=AD\W<5Y/&<<T_PS^P[
M\/O!MO<P:%J_CC1HKF9KF>.Q\7W\(EE8Y9VVRC+$DG)YYKZ&I: /$O\ AD_P
MX?\ F<?B-_X6VI?_ !ZE_P"&3_#O_0X_$;_PMM2_^/5[910!Y)X=_9MT/PMK
MMCJ]OXI\=7<]G*LR0:AXMO[FW<CL\3RE77V(Q7JVW@<8 Z5+10 4444 %%%%
M !1110 4444 %%%% !7+_$C7;CPWX)UC4+73KC5)XHL):6N?-D+$+\I'(/S9
MSVQ745&WRD\XS0!\S_#?]G_P'XQU/68/&OPHT-]=TV6(#4;^U^V3ONC5U;[1
M*N6<;ADJ2 0><U[WX+\%Z;X!T9M+T@3I9>:TJQ2S-((\@#:F?NJ,<*.!DU\R
M>-X;_P 5?'CXA6KZ+J7BJTTV2RC@1-;.FQ66ZSA<QJ #Y@8L7+=BQ':OK'3X
MRMA;+M,1$:C9NW;>!P3W^M 'QA\0_C%\4/"OQ@^,&GWVK6MK:6/A3[7HUMI[
M.\=KNN%C2=MX'[W:P8]@<@'%8<7Q.\<RZS_P@;>+]3^S)>SSC6%E(N=J6L,@
MA+YR1N=CU[XKZ_UCX,^$O$.NZUJ^I:3'>7NLZ8='OGD=L36IY,?!X^HP?>N<
MD_99^&\GA6#P^=!/V"&[^VHPNIA,)=H7=YF_<?E4#!.,#I0!\C>$_P!ICXA>
M)+70O$UUK4Z3V3^%;.6QC)6"\&HK:BXD=!P3F=V''&!7UUXM_:>\">!]>U#1
M]6EUZ*\L6VSM;^&M2N(1\H.1+' R,,'J&(J\_P"SC\/&\3:/KR^'((K_ $F.
M**U\N1UC58D"19C#;6* #!()&!7:^*%/_",ZMSG_ $.;_P! - #/!WB[2_'G
MA?2?$6B70OM'U2UCO;2X",GF12*&1L, 1D$<$9K9KQ_]CU?^,5OA&<_\RMIW
M_I.E>P4 %%%% !1110 4444 %%%% !1110 4444 %%%(6Q0 M%-#9;%.H **
M** "BBB@ HHHH **** "BBB@ HHHH *:QZ4ZFMZT ?+/[0]U-J'Q\T#1&M7U
M2R/AV2Z:PN=26RM5?[05\T$N-\N.,8^[DU[[\,[<6/@31H%M8[-4AQ]GAG$Z
MI\QX#@G=7SY^U!>6-]\8?#FB:A<6MC&=%DNH[J.U:XO-_G%=NT,-L>/XO7BO
M?/A'!;VOPYT*"VG:Y@6#"RM$8RWS'G:2<?G0!<D^&?A*;Q*?$,GAS3'UW_H)
M-:H9^5VGY\9Z$BG1_#?PK'HMUI">'M-72KJ4SSV8MD\J60XRS+C!/ YKI**
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M - 'FO['W_)JOPC_ .Q6T[_TG2O7Z\@_8^_Y-5^$?_8K:=_Z3I7K] !1110
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M]>,_7FI** /,/C]^SSX1_:0\"R^%_%MGYMMO$T-Q%A98) " RGMU-<]^S/\
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M7O?PW\+ZEX/\&:7I6KZQ+K^IV\*K<ZC,NUIY,?,V.V3VKJ** "BBB@ HHHH
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M<8D4D'^5>07%AK/A'P_I'BX>)KS4+NXFC-S;2E#!*LA^XJ@<8[8YKJOA&?\
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M-=_N C:98RE%E)QM,TDIQTW,W>OO:R^&?A33;G4KBU\-:3;SZD&6\>*SC4W
M;E@Y Y!/4'K5<_"7P:WAU= /A;2#H8?S1I_V*/R0^<[MN,9]^M 'B/P)^,7B
MO0_V>?AO=WO@CQ9X]U"_TP//=Z2+9FCVX"^:9YXSE@>, ]#G%7/A?XXOO'7[
M6.NW>H>#]<\&RP^";2);37A;B65?M]P=Z^3+(-N21R0<@\5]$65A!IMK#:VL
M$=M;0J$CAA4*B@=  .@KR*S!'[8VJ?\ 8AVG_IPN: /9J*** "BBB@ HHHH
M**** &LVVJ]U?06N/.GBA)Z>8X7^=3R5\P?M]:5HUC\'6\5:@UY'+H]]8DR6
MU]-;_N#=Q>:I". <H6&3ZT =E\,3_P )M\?/B%XL#"6RTI+?PW;$<KOC!GD=
M3[BY4$C^Y[5[A7D?[+?@U?!GP8T.$JRW%\9-0E,C%F82N6C)).2?+\L9/I7K
ME !1110 44C,%Y)P*QO$'C+0O"JQG6=7L]+$GW#=S+'N^F30!L,VWKTKQ#P_
M8V^N_&2WUV>%9(]0M;KR-RY!CCDB"-]3N-=[XT\1I?>#=^BW<<\VJD6EE<6[
MAUW.=H<$=@>?PK-&EQ:+\1_"=C NV*#1[J,+_P!M(* /1:6DI: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@!,4FT#IQ3J* ,7Q'X.T?Q=;Q0ZO80W\<
M3;T$R[MI]14'AOP#H'A&::71],M["288D:% "P'3-=!10 ;?SHVXZ4M-W#..
M] &'XN\%Z=XTT]+6_5P8W\R*:%MLD3>JMV-8>@_"6QTG5X-3O=1O];O+<$6[
MZA*9!#D8RH/?'>NY# ]*-PH \ZU#X'Z/?7]U(+Z_M]/NY?.N--AF*P2MW)'O
MQGZ5T^G>#;'2_$$^JVX9));9+7RA]Q47&,#\!6]N%&X4 <#-\&])DT6VT^.Z
MN[=K:]:_AN(GQ(DC')P?3BM[2O!-AI?]LK\\Z:M(TEPLAR#D$$?J:Z#-&X'O
M0!YWI?P1TG3=0M96OM0N[&TE\ZVTZXF+01-G((7V[5U'AWPC:>&[C59K=W=M
M1NGNY=YR S$DX_.MS</6@L!U.!0!C>+/"]OXPT*?2KN1X[>?B3RS@E?2I]0\
M/V>I:'/I,L8^R2PF J!T4C''TK1W"ES0!Y[>?!VWF;2Y+;6]1L9]/M/L:302
M89HP20#SVW5J^%?AKI_AB\N+Y[BYU34KA/+DO+Y_,?9_='H/;VKK<T;A@'J*
M /.;CX(Z;Y]P+'5M4TJQN'+S6-I.4B8D_-QVS7:Z%X?LO#>EV^G:?"+>TMUV
M(B]A6CN'UI-Z^M #J*:KANAR*6@!:*** "F=S3Z8S'G H ^./VA/VIO'OPM^
M.#^'K&WMH-)\N46-G+9-*^J/]@\V(B8'$0:Y(@Y'&-U?7>C7$U]H]C<7,7D7
M$T"221CG8Q4$C/L:^1/&4B:O^T)\3+6ZM-/U&.TEL!&FNZP;81 V4+$6Z"1?
MW>223@_,6YKZ_P!,XL;8 *H\I>$;*]!T/<>] '*_&'X=Q_%;X:Z_X6EG^S#4
MK9H5E9=P5L?*2,\C.*^<-%_8]\6>&M*BOM*U'2;/6H;^:6'35W_8HH988XI"
M&QG>?*!QMQ7V)10!\>Z+^P]?^';S0](MM;@G\-(-%GU*:1"MP\^F)#Y7EIR
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M[4$"ZB8U^T"U!$0DQ\VS<<XSZT :-%-7A1WIU !1110 4444 %%%% !1110
M4444 %%%% #6K@_CI_R27Q-_UZ'_ -"%=XU<'\=/^22^)O\ KT/_ *$*TI_'
M'U,ZGP2.]7[HKS[]H+79_#/P5\9:K;"R:>UTV61!J*EK?('\8 .5KT%?NBN-
M^,?@V?XB?"_Q+X:M6B2XU2RDM8VG7<@9AP2/2LRUL>&?L@^$O"?A;7M5/AF^
MCE:[L_/N+=/#KZ:=Q=<N7,C;CD_=]\]J^IJ^8_@(OQ&\$_&R?P=X\\3KKL<_
MAV34K-$08 CN(8V8D#.1YF.>N<U],7#F."1AU521^5 Q^:6OSZ\._'#7H='\
M2:M=^(-<M_$NL:3-=6]I<A392+]LMXGDA&W,9C$NT $9WYYQD2^%_&'BO5/%
M%]\,[GQ5JKZ"OBFWLTU'SRMVL3Z;97+1^;][!DGD/7.&QT % 'W_ %XW:_\
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M4=,O(-0L+E?,AN;60212+ZJPX(K0H **** &MVS7$_&*&.3P#>EXU<B>UP6
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M_DUP'@_6+30['Q1=7<PBB76KH#G)8^8<*H[D^@H [JXN4M(GEF=8XD&XLQP
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M^M)"8%OC'^\\L_PY]*S]#^$_@[PWKDNL:7X;T^QU24DO=0P@.<]>>WX5UM%
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ML[-2CNC9LI4;1*&VD9SZUXK\(_AW\<?&WPVT&>^\5V.C64ML&B\JYNA<E,D
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M\IM5@5Q]5+Y'XBL/QI^TUX&\&ZM8:6+^;7=1O;>2[BM]"@>_80HRJ[MY(;:
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M7A?5H]=\/Z?J,6\QW4"2KY@^;!&>?>M6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C;J<]*DJ*1EC5F;"
M@<DDX H ^#?C_P#$K7_A[\>/'=SX4EUJ& K$VJ^7K%K96WFPZ='<$HLEK(S'
MR%'.[KQBON;P_=-J&B:==,23-;1R99@3\R@\D 9_*OAC]IR3Q+KWQFDCL]#T
MGQ!H<NXV'R6<L$LJV0-N\[.X.4O .HX50:^Z- 6==%T\72HEQ]GC$BQ?<#;1
MD#';- &A1110!X1X[_:DM? _Q4D\+2>'Y;K2K.[LK#4]9%V$^R7%YL%L@AV$
MR!C(@)W#&>^*]@\4?\BUJP[_ &.;_P! -?/WQ*_9?UWQO\8;W6H-4TV+PKK&
MHZ7JFI),TGVV.:P,30I" A0JS0KN+,, G&:[/XE? :P\2+X@UF3QCXZL))X)
M)6L].\375O:IB,C:D*MM5>.@]30!\O\ [*?_  3I^%FI>"OA1\5I9];_ .$A
MDTC3M5-NMS']F\\Q(^[;Y>[K_M5^@/\ $#P#BO$OV3=$CO?V:?@M?-<WD;VG
MABP988;ADB?-JJXD0<,!G(ST(![5Z<W@VW^QBV_M'52OVL7GF&^D+[A_!NSG
MR_\ 8Z4 >1?&3X>ZGK'Q*BURU\(0^*;)]$FL2IO3;-#,TB,C\*=V%5A^-2?#
M[PM\9/!OA+3K+[?X<N8(58II\UK-]HA4NS!6G\[#\'&=@Z5Z_-X6@N6UAC>Z
MB@U((L@2[<>5L7&8N?W>>^WK4L/A^*&\AN5NKPM';BV$;7#%"HS\Q7."W/WN
MM 'R7XX^-7BO1?$'BM->\7KX7UW39;,:;X:L2DRWRNP#[24RQ(ST(KWCP_\
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M9I:\DN?C1X<:UUM8?B;X*6>1LZ<S:M;[8UV 8D^;GYL^O%6O^%U>$O[7A?\
MX63X-^P"U*O'_:]OO\[C# [ON]: /4:*\CA^,WA\6=BLGQ.\$FZ2Y+7,@U:W
MVO!N.%7YN&VX_&I+GXT>&F&KB'XE^"QYFW^S]VKV_P"Z]=_S<_K0!ZQ17,^$
M?B!X;\8?Z-I'B?1M>OH8E>XCTN^BG*] 6(1B0,^M=-0 UNM<'\=/^22^)O\
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M[&+4O_DBO,/@/^S7X#\5:1XQEUC3M6O);+Q=K%A;>9K^HJ4MH;MTA08G&0J
M $\^I->I_M0?%N_^$_PTNKC04CG\47V8=-AD9=H8#YI6!/*)D9QG[PKQK6OC
M5\0M/TOX5ZO8^(M.N[WQ.FFI#X9M[0//?>8$:\F=O^6:HGF.",CY0.I H ]@
M7]D'X5GKH>I<?]3%J7_R10W[(/PK7D:'J7_A1:E_\D5[,IR*Y[X@>,+/P#X/
MU/7KYE$-I%E58@>9(Q"QQC/=G95'^]0!\U:;^S7X#F_:8UWPX^G:L= A\)V%
M_%:'7]1V+</=W2.X/GYR5C08SCY>E>H_\,?_  K_ .@%J7_A1:E_\D5\W6O[
M1OQ?U;X9Z7K7GKITSWNIK?WMK81W36S18:UMV3=P#G:S=.":^ROA7XNF\>?#
MCPWXBFC$$VIV4=R\:\A2RY(H X7_ (9!^%>/^0'J7X^(M2_^2*\M^-'[-?@3
MPWXH^%%MI6GZM:V^K>*UL-05-?U$B:W-C=R%"3.<#?&AR,'Y1S7UE-(8XW*J
M68 D 8YKX8U#]I'XB^ -/U'3O&]]/H/C*ZBCFM(Y[**XM8X6E5))H/)=VD*;
MD7#*IS(/0T ?0R_L@_"ML_\ $CU+_P *+4O_ )(IW_#(/PK'(T/4L_\ 8Q:E
M_P#)%;7[//BZX\9_#>UO;OQ+;^*[I)YX)-1@LWM"VR5U"O$R@JZ@!3QR02,@
MYKTL]* /E;]H?]F/X?\ A#X#?$36]$TW5;/6-.T"^NK*XC\0:BSQS) [(P!G
M()! X(-?27A*1G\*Z,TC,SM90[BQR2?+7K7S1HOQXU_Q1\?M9T >,-/TJTMK
MV;3+;0+O3)-DY6W#!OM6S;OWG=MS]W Z\5VW[._CCQ;JOC#Q[X6\6:Q;:Y-H
M3VI@NXK46KN9/-W@1]XQL3:_?YO2@#W@=!2/V]*5?NBB@#\Q?BQ^R/\ %OQ5
M\4_%6I^&?!>D>&+&]U*XG75H;R2XNKH-,S"4+(S1H6'4;#@,<8X(^^_@/X;U
M;PA\(/"^CZZ\DFKV=H(KEI@@8ON)YV*J]".@%=_M'/'6D"@4 .HHHH *I:U$
MTVCWL:*7=H'557J25/%7:\M_:2\8ZKX)^&%S>Z/=C3KN:YBM3?E0PM5<D&4@
MD#Y?K0!R?[,OP-\/Z/\ L\_#FQ\2> ])@\06^A6<=_%J&E0_:%F$:AQ(63.[
M.<YYKT__ (4_X#_Z$GPY_P""FW_^(KE_V=?&.J>,O!.J-J]\-5FTW7=0TF'4
M%4#[7#!,8XY?0[E&<@FO5Z /G;XT? S0=0\=?!Z;1_ >DRV-GXI>;53:Z3#L
M2V.G7B@RX7[GF-$.>-Q6O65^#_@/;_R)/AP_]PFW_P#B*\P\=W7B>\_:2\)^
M'O#_ (GO+2UDMY=7U:S*Y@6TBQ'L7G[[22Q'Z!J]\!- ')-\(/ 8_P"9)\.9
M_P"P3;__ !%>7?LU_ SP_H_PJAMO$7@/28-4_M?5I"E_I4)E\IM1N6A/S+G:
M8RA7_9(K1_:>\4>+O!VF^&=3\.ZU'I=B=5@MKZ VXD>X5W VAB?E&,]*XZT_
M:.U'6_VR;7P%#-]A\,VUK+;&*6-@]Y="/S/,4XQL&X+R?O*>,<T >Y?\*?\
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M^"/P-\/:;>?$;^VO >DPK<>+KR>P^UZ5#A[4Q0!#'E/N9#XQQP:]0_X4_P"
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MD#%7:02*2!\BG.#A2 ?27A?PCHO@O3VL="TRWTNT9_,,5NFT,Q &3ZG  ^@
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MA&!YDCEW;ZLS%C[FI=6T.QU[39]/U*TAO[&X79+;W"!T<>A!J_10!QT7P?\
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M5[#PQX7^&OBS5?!OAN%?*N[/2WGM[RZD4,\T;JF<!66,C)&8S7ZP44 ?CO\
M\$R?AK\8_@/^T9 ?$?PS\9Z=X9URRDTZYFN+*>"SMI,JZ3R[EVG:$90>H\SC
MJ:_8BBB@ HHHH **** "BBB@ KG/B)X-M?B)X'USPS>SS6UGJUI+9S2V^-ZJ
MZE25R",@'N*Z.B@#YVLOV/;&?1KJR\0>._$OB>Y_LIM&L+^Z-M!-IULRA2(?
M(B09( Y8$\"N \7?L4'PK\*_$WA3PB;SQ+>^,]1L&U+4;^:VLC9)"1YDZ")$
M!9D#*549)?TR*^R** /"/B9^REH_Q0\/^%=#O=<OM-TC0[>*#['96UJ?M 0
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MKZXM85MK>.*,;8XU"J/0 8 J:B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?'OA#6+_ $ZRL=8TV^O9T+VL=LZRMM Y(VYVC'KB@#K,BEIBY'TI] !1110
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M['NCZKHG[.W@^UU>*:"X^R@I!-]^*,G*J1V.* /::6D7/>EH **** "BBB@
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MQQ''HGQ2^,$6E?%:Z2308?">GWNCVM]<F"WFGD\S[5*,$9=0L/?C/3FN O\
M39_%F@_"[PW=:KJDWA5O'VHZ?8R^>4>XTV-;@11;N\6Q53_:7N,T ?H/N'%<
M%XX^.7@_X=>,/#OAC7=1>TUC7F*V,2P.ZM@XRS 80$X +8R2!U-8^FV?B_X?
MZYI?AKPMX(T&+X=VP56OY-=ECN;=227VVY@8-C@\R#.>U?*_Q(\57GQ8\2?%
M?6+'P/XJ\2"Q9=.\.ZMHMC%+;0R6DJRNQ=YE(S/ O13QGK0!]^;AQ0K!AD<C
MUKY"^(4[_';X4?#GQA%-HNLVEO!(=0\+^(=2.GPWDH"H[>:H9A)&T;X&TYW=
MJY[QSI^D^-O /@+QOIF@:/>>#K+2&9_ ?B#56L6A4*&\Z!UW&210I0*0 V\\
MB@#[>W"EW"OCF23PI\5?BSHNE>-;?^S/ :^%+:]T'1]0N6@A:=I)1,2<C<R*
ML6/FZ8/>N'O+DR:#X3\)ZAJEZ/A)-X[NM,-Q+(VR73HXIVMX6ER"(@Z18;OQ
MZT ?<^N>*+70;K38)K>^N&O[@6T;6=G).L;'',A0$1KS]YL"M?<..:^1O&6D
M>%/!OBKX6:7X%U!SI"^,$6:UM[EI8(&*PDQH>ZD$-U;EC]!Y/\=?&<.L>)M1
M\6:'X:T^"^TSQ1!IJ>(=0\0R1ZJC+<+&Z1V2PE3#M8@9<<$\T ?>.G^/-&U/
MQAJ7ABWN';6-.@CN+B$Q,%5'.%(;&#T[5O[A7R7X-^'/@K1_VO?&=^FE64&O
MC2K6^LFDF97:=V.YE!;YB2.E>(>"?#OCWQQH-GXD@T'PC:_$&34/M)\3W_C&
M6#48G$@WQM9FWP 4W+LW'[W6@#[V^*WQ MOA;X"UKQ5>6LE[;:7;/<O!"P5W
M"@D@$\#I6Y%KELN@C5IV,%J+;[2Y;^%-NX_I7YW^,M*\'^)/V=/B!XO\7Z@L
M/Q5;4=0MII$NW^T*R3R1PP+'C_5M$L8/R]#G(KZ6_:8^(%UX/^ >E:5I-M<7
M^O\ B(VNEV=A9H'GE#+NDV*2 ?D1AR1UH ]5^%/QF\*_&KP_-K/A2^DO;&&9
MK=VF@>%PP/\ =8 X(Y!Z$$$<&NWW"OCWX%^*H_ O[03>'(_"GB+P7X?\2:3"
MEG;Z_:16_FWEK"L9*;)7!/E1#.2.:X.S^'.DZ?\ L_K\2 ][/XRM-;#6VIS7
M3L\"^=M\I1D#9ACP<_6@#[?M?'6CWGC2^\*Q7#G6K.U2\FA,;!5B8@ [L8/)
M'%3^&O%-KXJM[B:VM[ZV6"=K=EO[.2V9F7&2JN 67GAAP:^;?#_PS\!V/[:.
MOWMQI=G;:N^CPW]JTLS*SSLZ[G4%N3R>.:\ C\107,^CZ9XFT;6/&/AE]9UZ
M6YTJQD7F91:"!V9Y(QA=TG ;^(\4 ?I3D4;A7YYZIX-U[P'\#_AWHFFZ3I_]
MG>)O$$]SJ]A>:P]M 8#YDL%O/=*LNPKB-#@$$C&>])JG@'Q3I.E7EH5T7PCX
M,U/6=,C@TCPGXF?4VMYR9Q-(':)"F]?+&.?N4 ?H;N'XUXMXR_:Z\ >!?$VM
M:'J">(9[G12O]HW&GZ!=W5M:[AD&2:.,HHP>I-<U\+_ ^D?";]IC5_#7A>!K
M#0[WPZM]-9F9G4SK+&@D&XGD@G/UKQGQ1IOB#6/BO\?K'2_B%H7@_3YC"MS:
MZGIXGEN1Y(_U<AF39TQ]UJ /NK2]4M-:TZVO["XCN[*YC66&XA8,DB,,AE(X
M((JW7E7[+NO1>)OV?_ M];Z3)H=N^E6XCL)'+F)0BX&X@9P.^!]*]47F@!:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK<8IU% &9+H>FS
MZO#JDFGVKZG#&T,5\T*&9$8@LBOC(!*C(![#TK,U[X<^$_%6L66KZUX8T?5]
M4L@!:WU]8133P88L-CLI9<$D\'KS72;1Z4N!0!C6OA+1+!M/-KH^GV[:?&T-
MHT=JBFWC;&5C('R X&0,=!3+CP7X?NK'4;*;0].EL]2):]MWM$:.Z)&"9%QA
MR0 ,G/%;>T<5YIXV^/&D>!?$#Z?=:)KU[:VQ07^K6-FLEE8;@#F:0N"H"D,<
M*>#^% '1>*/ACX.\;1V:>(?">AZ^ED"+5=2TZ&Y$ .,A-ZG:.!T]!6E)X7T:
M0:9NTFR8:7C[!FV0_9/EV_NN/DXX^7''%-\1>*M/\,^&[C7+V4C3X(A*61<L
MP. H4>I) 'UKEOA[\:+'Q]K%UI#^']?\,ZM# +H67B"T6WDEA+;?,0*[97=D
M=1R* .RU;0].U^V6WU6PMM1@5Q*L5W$LJ!QT8!@0"/6DUC0]-\16GV35+"UU
M*U\Q)!!>0K*F]&#(VU@1D, 0>Q -37FJ6>F1![RZ@M5P3F>4(..O)^M11ZWI
MLLT4":A:M-,NZ.-9E+.O7*C/(QW% $47AS2K=;U8M*LXUO3FZ"6Z#[0<8^?C
MYN/6L_6/ASX4\1:=IEAJ?A?1M2LM.*FQMKO3XI(K4J,*8U92$P.!C&*TKSQ)
MI.FW(@N]3L[6=@/W4UPB-CL<$YK$^('CI_!MKI0L[$:IJ&I7L5I;VOG>7N4L
M/,?=@_<CW/C'.W'&<T <]\8/@O;^/O FN:1H?V30-5U)8Q->1P!/M(3.V.=E
M&YDY(Q7$_"']GO5?"7Q#@\47^F>"_"JVMJ]LMAX$L&M8KO=WN-RC=CL/4"O6
MOA_XZC\<^$=/UF2&/3I+WS ENTH<_)(R'!P,_=ST[ULQ>(](FOOL4>IV;WF2
MIMUN$,@(ZC;G.: .<L_@O\/M.\0#7;7P-X<M=<$GG#4H=)@6X$G][S FX'WS
M6_\ \(SI"VU];_V59_9[]F>[B^S)MN6;[QD&,,3DYSUK7P*,4 4VTRSDTX6!
MM(&L/+\K[,8AY6S&-NW&,8XQTKG_  ?\*?!/@&ZFNO#'A#0O#US,GERSZ5IL
M-L[KD':QC4$C(!P?2NLP*,4 %+110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %4-4TVRUS3[FPU&R@O[&X1HIK6YC62*5#P592
M""".H-7Z3 H RM2\-Z3K&AR:-?Z797FCRQB)]/N($D@=1T4QL-I''3':LK1_
MAGX0\-V,EGI'A71-+M)86MI+>STZ&*-XF)+1E54 H222.G)KJMH]*1A\O'TH
M S#X;TEQ8YTNS/\ 9YW6F;=/]'.,9CX^4_2HO^$4T4_VH/['L,:L,:@/LR?Z
M6"FS$W'S_+\OS9XXKB-?^/>E>&_$QTJZT/Q!+8QS+;7&O0V*MIUM(?X9)"X8
M$9'13]X5T_Q$\?6/PT\+SZYJ%K>WL"2Q0+;:?$))Y9))!&BHI8 DLP'4=: %
M\,_#/PAX'AO(?#GA;1= AO %N8],T^&W6;&<;PBC=U/7UK:TG1K#0=/@L-,L
MK?3K&%=D5M:1+'%&OHJJ  /I7-?#[XA2>/K>[F?PMXB\," J GB"S2W:7/=-
MLCYQCGZBNFO]6LM+7=>7MO:+C.ZXE5!C..YH CTK1-.T.&:'3;"VTZ&61II$
MM85B5Y#@%R% RQP,GVJE'X)\/0R>8FA:8LGVIKS<EI&"+AL[I<X^^<MENIR:
MOQ:YI\UTMJE_:R73+O$*S*7*^NW.<5%<>(M*LKS[+/JEE;W/ $$LZ+(2>G!.
M>: %_P"$?TM;ZZO?[.M/MEW&L-S<"!?,FC&=J.V,LHW-P>!N/K6/IOPK\&:+
MI\=AIWA'0["RCG%TMM:Z;#'$LP.1(%"@!Q_>ZU!XZ\?-X0ET2WM; :G>:E<%
M/)\[R]D*C,DN=ISM!7COGK5CX=^.8O'G@GP_X@,*Z>^K64=ZMFTH=D5U#8!P
M,XSUQ0!\[^*OV1_$&L:]XJ)M_ ^OVNN7;7"Z]XBL)+C6;%61%V02;2JA=N5
MXR2:]XNO@WX3U[0=&TSQ5H.F>,VTR%88KG7K&*\DX&"V9%.">^*Z:W\1Z5?7
M7V:WU2RN+D$CR8KA&?CV!S6FO/:@##T_P7X=TNUTZULM"TVRMM-W?88;>T2-
M;7)Y\H ?)G_9Q5ZVT>PL;Z\O+:RMX;R\*_:+B.)5DFVYV[V RV 3U]:OX%%
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M]T=,=!Z5H-X3T-H-+A.C:>8M+(:PC^S(1:$+M!B&/DPIQ\N..*V=H':C ]*
M(CMD0H0'!&"#WJIH^BZ=X?LQ9:786VFVF6806D*QQAB<D[5 &2:OD >U<A\1
MOB5I_P -]/MI[NTOM3N[R7R+33-+B$UU=/@DB-"5!(4%CR. : (=6^#7@#7[
M>VMM3\$>'-1@MW>6&*ZTF"18F8Y9E#(<%CR2.M.UKX.^ O$AL&U?P5X=U3^S
MXQ%9F\TJ"7[/&,82/<AVJ,#@8Z4OPW^*&F_$[2[J[L;34-+NK.<VMWIVJ0"*
MYMI  VUT#$#Y64\$]:YO6OVB=#T/Q)+ILNA^()]-@NUL)_$5O9(VFPSEQ'Y;
MR;]P.\A/N]2* .P\4?#?PEXVL[.T\0^%]'UZTLN+:#4M/BN$AX ^174A> !Q
MZ"K5YX(\.ZAX9'AV[T'3+KP\L:PC2IK.-[4(I!51$1MP,# QQ@5POC+]HC0_
M!NL7UG-HFOZE8Z?@:CK&FV:RV5@2 V)G+@KA65CA3PPKU&.XCD@68./)9=X8
M\#'K0!@Z?\/_  OHUCI]EI_AK2;"STV3SK*WM[&)([9\YWQ*%PC9YR,&JEW\
M)? ^H:Y/K-UX.T"YUB8@RZA+I<#7#D,&!:0KN." >3U K;_X232?WX&J68-O
MS+_I"?(#W;GC\:F_MBQ2Q^W->VPLB-WVCS5$>/7=G% &=?>!?#>I>(+/7[SP
M_I=WKEFHCMM2FLXVN85SD!)"NY1DD\'O61J7P7^'^KZ\VNWW@;PY>:TT@E.I
M7&DV[W)<'(;S"F[/OFNHT_6+#6(W>POK>]5#AFMY5D ]C@\5YSX/^-Q\6>,;
M31_['6VLKV&]NK6_^U;A)!!)"BOMVC&_S<]>-O?- '377PG\$:AKUQK=UX.T
M&YUFYC,4^H3:9"T\J%=A5I"NY@5^7!/3BMNX\/:5>75A<SZ;:37-@2;2:2!6
M>WR,'82,KQZ4MYK^F:;#%+=:C:6T,G"233JBM]"3S5NSNX+ZW6:WFCN(6Y62
M)@RGZ$4 4]0T33=5NK.ZN]/M;RYLG,EM+/ KO Q&"R$C*DCC(J'_ (1+0CHY
MTK^QM/\ [,+[S9?9H_)W9SG9C&<\]*V=H]*-HZXH P-2\"^&]:URQUO4/#^E
M7VM6(VVNHW-G')<0#T20KN7\"*\8^,'[-MSXH\7Z5K?AS2_"%_96L,R2^'O%
M5BTFFF60H3<+%&N#+\F"S#IBOH;:/2C% 'D'PC^ ]IX-\ ZCX=\26NCZM::I
M=R7<VBV]FITNVW,6\J&%EP$!/0CM76Z)\'_ GA>-XM'\$^'M)CD=)7CL=*@A
M5G3.QB%09(RV#VR:[+ ]*,#&.U %!=)L5U0ZG]BMQJ31>2;SR5\XQY!V;\9V
MY .,]JY?7_@G\//%>L2:IK7@/PUJ^IR8+WU_I%O-,Q'3+LA8_G7;T8H CM[>
M.UMXX88UABC4*D: !5 Z  =!4M%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-+?SQ3JX_XJ?$*P
M^&'@V^U_4K>\NK:(K'Y.GQ^9.Q8X&T9]Z .NW]AUH5\G']*^8/A[X%^%OQVU
MK77U'P]XEGUK390LLGB.>:WD(<!U9!$ZJ5PPQQ7O7@GP+8_#^QFL].NKZ:T8
M@I!=S>:(1Z(<9Q]2>E '3T4W<*-PH =13=PQD<TNX?2@!:*3=2T %%%% !11
M10 4444 -)KP;XP?&/P=J7B27X>7_B[0]"C&QM:EU+58+4K"<,8 LCAB70XR
M!P&ZU[UMK"U#P-X>U:ZDN;W0=+N[F3[TUQ9QR.>, EB"3Q0!P'QL\6:%#\*]
M;LK:?3]9:*W@#VPNMP@C=ALFD\LEE0;<AO\ 9KA_@+JMN_Q0N;:/QIIOQ*N)
M=)C#ZUIMXMR+)5.!;DH2FWC@GYVSN;))-?0O]@Z?F4_8;7]Z@CD_<K\ZCHK<
M<@9/'O4>D>&=*\/[_P"S-+LM.\S[_P!DMTBW?7:!F@#R#XQ>!=$^(?QI\ Z1
MXAL(]5TG^SM2F>QN!N@E8-; >8AX<?,>"".E>2V'P@\,>"O UGXBT^R_XJ"R
M\;Q6=GJ4TA>>TM?[5$/V:%B<QP^5\GEKA<=J^QVM(I+A9FB1ID!5)"HW*#C(
M![9P/RJ(Z7:M'Y;6T)CW^9L* C>#G=C'7/.?6@#X9\:1^%OB+\9-;\.>)?"O
MAN;6AXE5K7Q)XAU/3EN(;940K%';R2?:2NXL54)M))[U]/>6GBSXQD(N-/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK$D&<8QF@#]"._';GI7C?[8R_P#&+GQ+_P"P--_2O)_@/\0O$.N?'W6+>_\
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M_#>VTGQKJVBZ;KMW<V]S96KD1[8K9I 0,]25KZ#KQCXR?\EH^"G_ &$M0_\
M2)Z /8X8S'$BEB[*H&X]3QUKAO&UQX@M?%.@6VFZXEA::C-)$\;622E=L9?(
M)/?&*[WTKB_&G_(X>"O^ONX_]$/0!V4:E8U#-N8#!;&,GUI](.E+0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %5[Z1H;29U.&5&89Z9 [U8JKJ<GDZ
M?<R%0X6)CM/0\'B@#\]M4_;\\=^'?BE!X9O].L]9M[G5A8QS^'81=")&EV@R
MDA=N >>N,&OT)L9OM%I#(QPSHK'/'49K\[M'_:$^&MKK6KR0^#O#-CK,6)E6
M&65));PZJEJ4($G+;&:3'J/2OT,L;R/^QK>ZEVPQ^0LK9X5!MR?P% %/4/".
MBZK!<076EVMS%<N))XY(@1(PZ%L]:(?!^B6ZV*Q:5:(+$EK4+$O[D]ROI7!1
M?M-?#NZ\*ZMXDM->CO=(TV[BL9+BW&\232L%C2/'WRQ90,=<TJ_M,?#]GT-4
MUM9%UA!);NBY"*79,R'^#YD=>>ZGTH ]%@T33[74KB_@LX8[ZX&);A$ =P.F
M3U->4_MC C]ESXF8/_,'F/7Z5U'AOXW>$/%WCC4O">EZD)]9T]I8Y8]N%9HG
MV2JC?Q%'X('0BN7_ &Q6_P",6_B7SD?V--S^5 'L4$>(T/L#^E35'"P\M.?X
M14E !1110 4444 %%%% !1110 4444 %%%% !1110 4W=[4N>U5;^^@TRQN+
MNZE6WM;>-II9G.%15&23Z  9H ^7/V\/C[X1^$.E^ [77[UDO)/$=EJ MXTW
M,8(9,NWICG^=?37A?Q%I_B[P]I^MZ3<K>:9J$"7%O<(#B2-AE6&?:OB+]J#X
M4Z?^TU-X0\7^)K%X?#:^(K'2-)MP-DMS;RRL)IG/4!NBCT7/\5?;_AS0;#PO
MH5CI&EVR6>G64*P6]O']V-%& H]@* -*BBB@ HHHH **** "BBB@ HHHH **
M** &MUK@_CI_R27Q-_UZ'_T(5WC5P?QT_P"22^)O^O0_^A"M*?QQ]3.I\$CN
MO2O@C]O;X5^,O''Q:T>]\(^ -6\23II<4+:JFJBWL8L2RDQM%NRS<@YVX((Y
MK[WP3CTKY%_:F^'?Q<\0>._$TG@>W2ZTS7?"]OI=O(VOBP-I=13W#O*(SR<K
M+&-RXZ>U9EK8U/V!? /C3P!X-\26OC;3TL+Z6ZB:(+:0P!E"MDYC8[^<<G%?
M4H[=Z\2_9XL?&MYXL^(7B?Q78QZ59ZU/9G3;"'5UU!(EBB99,%0 N6(. .:H
M_M9?%?QC\+-%\,7'AJTA2SO=;LK"]U&20%HUEDV[%0]2?7M0,]ZV^K9[TOH>
MU?#?C[]JWQQX1\6:KJ%O<P3Z7+XBU'PI;:;)$-EN]O#-(ESN'S%B8>03CD\5
M/H'QT^).I:S:?#^X\211ZMJ.H6OE^((K51)%#+9V\[)L(*D[I7 ./N[>IR2
M?<"_UKQ'X"_\EB_:"_[&FS_]-%C69\+OVLO"7_"E_ OB3XD>*M%\*ZQKUCY_
MEWEP(%F9<!VC#'. 2/SJ']E?QEH?C[X@_'?7?#FJVNM:/=^*;4P7UG()(I N
ME62MM8=<,I'U% 'T31110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7!?'C_DC_BO_KR;^8KO:X'X],%^#OBLL0!]B;K]10!J_"G_ ))?X/\
M^P-9_P#HA*ZFN4^%#JWPO\'88'_B3V?0_P#3!*ZN@ HHHH *1FVC.,TM(>:
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M._;%=+X;T>WT'1;6PM&+6T*8C)QR"2>WUH U**** "LOQ3_R+.K_ /7G-_Z
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MLI[J=A''$I=F)XXKR1-);4O%OA77]3@C:[U6\F=$= =EN(&\I2#T.T*3[YH
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MZ@9XGJG[)7@76/%>J:W=QWTRW[7$[6!N3]FBN9E*R7*1]%E(9AN'/S&J=O\
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M2(-#^);V5NH$46CP?-W9O,E)/XG)KT:@!*6BB@ HHHH **** "BBB@ HHHH
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MB>VTNVM9+?4K=H)-T<2H3M8#@[>#Z5Z10 444F: %HI,TF[VH AU#_CPN?\
MKDW\C7E/[)O_ "0#PO\ []Y_Z63UZ5XCU>ST71+V[O[F*SM(XFWSSN%1<C R
M3[D5Y)^QWXBTS6/@/X?AL;ZWNY+=[L3+#*',9-W,0#CID$&@#V^BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "HI)!&KNW"J,D^U2U!/,L,<CR$!%4DD]AWH ^8?C;\:H=>;5="
MT.\\+SV-U:R6<MSJT=T)HG92K81;9@0,_P![G%?0/P_L4T_P/HMK%>?;TCMD
M47(0KYG'4 \@5\I?&];/XG>)-=NO"Z:AXM@_L>2UT:;P?JC+%::D&(VW"P.
M"'ZF3Y1T-?6/@&VU.R\&Z-;ZRROJD=K&MP5  W@<]* #QQX)TSXA>%[[0-9B
M:2PO% ?RFVNC Y5E/9E(!!]0*\NN/V0?!,_A>UT87FN0O#>2WS:I'?XO9I)5
MC6022[?F5EAB!&!D(*]QHH \KA_9M\'6WCZR\66\=Y;7=JL06QBGQ9NT4/DQ
M2/'CEECPH.>U=;XH\-Z4?#>KN=+L]_V28Y-NF?N'GI73UE^*?^19U?\ Z\YO
M_0#0!YG^Q[_R:O\ ",_]2MIW_I.E>P5Y!^Q]_P FJ_"/_L5M._\ 2=*]?H *
M*** "BBB@ I,BANE9'BBXU>ST.[ET*TAOM45/W,%P^Q';W.1B@#7# ]#7E'[
M3WCS6_AY\&O$.I^%EAF\5-;M%I5O+DM+<,,(%4#YFR1QP/4CK61\)_C]?>)/
MA#%X[\8:7:Z%;W85K*WM)?,>X+9 0#))8D#@>_I4L>GW=O!>?$KQU?Z?H=U!
M QT^#5)0EGI$'.&?) \PCEF)R,XX P #Y[_X)*1>-E^#?B6?Q7IBVFGW&HK-
MIMTXQ+< [_-!_P!E3MV_[QKK_C9\.M9^(WQ>:?2)(WM;F5;:&620A#)'$"XZ
M=!@C\*G_ &-_B1%XL^ ?A_0=$UW2]6U5E,4B:=*KO81[FW--@G:>F/K[5['X
MA"^&O$7A*RL-(U"YM=-DE>6>&U>127B*[BP')+')/O0!Z7I\+6UA;1.<ND:H
M<=,@8-6JBC;>BL 0",X/4?6I: "BBB@ HHHH **** "BBB@ HHHH *\9_:<\
M=>./AOX/AU[P@NEO%%-%!<IJ&[),LR1J5P#TW\U[-7C/[7/_ "1/4/\ K_T_
M_P!+(: /4_#::G'HMJ-9-NVJ;/\ 2&M<^66[[<]JTZ** "BBB@ IKX')X%.J
M.9!(A1AD,,&@#X]^,EK#<>.;R3P\?%TVO/J-KL%O]E^PM^_C\S),H;;LWY.,
MCL#TKZ[T^.1;&W\W D$:[@#GG S7Q!\0GO=!^+6LQ6/A1EEL=8L8=.TDVMW*
MVJPRR1":<2J<?('=^#A=GS< U]PVC%K6$&/RCL7Y#SC@<4 -U+5;/1;&6\O[
MJ&SM(AEYIW"(H]R:H2>-?#\*6#OK5@B:A_QZ,UP@$_\ N<_-^%>3?M>>$?$G
MC#X5QP>&[./4KBUU*TN[C3YHC*EQ#'.C.IC'+@ $[><XQBOG'QM\(?&WB;P?
MX?1_ 8LK^]T.73=*MM/A;RM%NS<,_G9;+0!E9>21C&.U 'W=9^)M(U#5+C3+
M;4[6?4;<;IK6.96DC'3)4'(YKRW]L@_\8M_$O_L#3?TKRSX%_#/Q'X?^.^KW
M6H^')K.XAU/6;NZ\0N@5;ZVN+IGMXP^,O\K*VW)V[<<8IW[64?QE7X"_$4ZG
M<^!6\-G3YO-6TM[T7?D9'"EGV;\8Y(QF@#ZRA_U:?[HJ2H(#^[C^F.GM4] !
M1110 4444 %%%% !1110 4444 )N''-9^N:U8>'=,N-1U*ZCL[*W7?+-(V %
M'\S[#DUY+JG[5/A;0_B!J/A/4=.UJRNK!%FGNY]-F6W6-LA9"Y7 4E2 <X)%
M6M-T>\^+&H0^)?%=J^F^&+%O/TW1+L;-Y'(N+E3WQ\RHW"\$C<,T ?$?[?7A
M7PO\:/$7@_Q#XPUQ/"<9OX+.QTYH&>[FT]RQDN9,<(,J %Y]<\X'W;\ _"NG
MZ/\ #_0KK3V:6Q;3H(--\QMS1V2HHB4GN2H4GWKRGXZ?!NS^,>OZ3X@FBA@L
M7FATFV^T6RL[@ESY@!' ]/I7T7X+\.Q^$O"FCZ)$V^/3K2*U1@, A%"].W2@
M"JGP[\.QZ]_;:Z1;)JNX.;H*=^[USFNEHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** &M7!_'3_DDOB;_KT/\ Z$*[QJX/XZ?\DE\3?]>A_P#0A6E/
MXX^IG4^"1WB_=%>-?M!?'WPY\*['[!>>(;#1=99$NA_:EE<36X@+,"Q:.-E!
MRIZGM7L?48KYF_;&^*&E:#IMCX<U*WOHHHY[;5II[BVD32[Z%'<26<UT1Y2;
M@!D.PX(K,M;&O^R;XFT/XA77C7QCI/BS3O%%QJUQ:K<_V3:RQ6UOY4;*@4NJ
M[B0220.HKZ&KYX_9!L5GL?%GB.P72=-\/ZY>1SZ=H.BWT%W;:?&JL" \!,>7
M)!PO Q7T/0,\#O/VHH8?%7B:WB\-W5UX<\/M=VUYJL,R;X[BV5C(IB)!V97:
M&SR2O'<<SIW[95SJD=MID'@V0>+M0>"33M*DN@(Y[::-)(Y3+M^7Y7&1M."#
MUZUA^)/V*]9USXB:_J%MXAM].T+5-1U#5)9(3(+J9[J&5#;R '8T2M(' QG*
M+4&E_LF_$#2=2TOQ2FL:!)XLT3[+9Z="T<WV22S@BCC_ 'G.?,.QCD$#D4 ?
M2OPF^(^G_%KX=Z%XNTR.6"SU6V6X2&8 /'G^%L$C(^M>?? 5A_PN+]H+_L:;
M/_TT6-5_"_[)GANU^&'@WPKKFH:Y<2^';(VRW&D:Y>Z:LI;!8LMO*F[D#&[.
M.W6LO]E#P?8> _'WQVT/2WO9+&U\46HC;4+V:\G.[2K)CNEF9G;EC]YC@<=!
M0!]&T444 %%%% !1110 4444 %%%% !1110 4444 %(W2EI&Z4 >(_M56,%U
MX3\(O/!%*W_"7Z, SH&(!NTR,GL:2X@/Q?\ BM;Z;$%'@WP<ZRSJ@_=W6H$%
M43T*QKYF1ZLA[5\^?\%3?VD-<^"OAOP7IFBZ9#//=ZE#J8O;@$JCV\@=$ Z$
MDKSGL:^G/V8[1(/@5X1N/L%SIMU?627EU%>9\\SN,L9">2Q[YH ]5'3K7F/[
M0_CX^ ?A_)=+9B]:ZF6UV%]FT$$YS@\_+TKT>>XCLX))IW6.*-2[NYP% ')-
M>6_$#0X_B7X;OKW4XF71;5=]G;ME3*_3SFQSC&0![G/:@#4^ WCT_$+P#9WQ
MLQ9-;C[,T:OO!V#:"#@=0,UZ/7)_#'PQIOA7P?IEKIEJ+6&2!)F4,6W.R@D\
MGN3764 %(<]J6D/M0!Y;\7/C[I7P?U#2K+5-!U_4SJ;B*WETNVCE0R$X"$M(
MN#^%>D:==?;K&"X$4D'G('\N4 .N1T8 GG\:\;_:8&;OX<9''_"26_\ ,5ZW
MXA\06/A70[W5M2N%M;&TB,LLKG  % 'B7[:2W&L?"!?#FEVT.I>(=2U73GL=
M)FD,:W?D7D,\J,P!*IY<3Y;!P,\'I7.?L9^'-;U"XU_XAWOAO1?"&D>(H(;>
MRT?1KY[D1FWFG21W+11@$D]!G@5Z'\.M#OO%UY?_ !&\16KVUY?6S)H^GW P
MUA9D94E3]V1Q@MGYADKP.*?^R;_R0#PO_OWG_I9/0!ZZ.@[4M%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %5[G*PS,J>:VTXC)^]QTJQ3&_/% 'Q)XK_9C^('QD\62:K;Z'X=^#
M9CN)!%K6ESR7VHR)N/SE-L2(S=>K8SU-?9/A?29]#T#3]/NM0EU2YMH5BDO9
MQAYF ^\?>OFSX[?M+^)O@5\8'@DTR;Q%X2N=-24VUG"':PD#X:>=U&8HL Y:
M0A17TIX=U8ZYH=AJ!18C=0K+M20.HR,\,"0?J* -2BFEOEST^M49-<L(;<32
M7]M'"S^6LK2J%+?W<YZ^U &A67XI_P"19U?_ *\YO_0#5AM4M5OELS<Q"[9=
MZV^\;ROJ%ZD56\49_P"$7U?/_/G-_P"@&@#S7]C[_DU7X1_]BMIW_I.E>OUY
M!^Q]_P FJ_"/_L5M._\ 2=*]?H **** "BBFL<"@!6^Z:\J_::^)NL_!_P"!
M_BSQ;H-BFHZMIEE)-!#(,J&"DAB/X@.NT<FO4MQYKYZ^*7C#_A.O$5Y#;Z9?
M:]X2\'S1W&I6NFPM*VHWPPZ6Z@ [U3*,P&0<E3G!% 'A/_!,/6/$/QF^'[ZM
MXWTYA:>%WCM/#P,9C@96#F20*?O.,*-WHQ]:^MOCQ<WJ?#F^M-+W2:G=%8H(
M%4,SY/(P?:O+/V._B UG^S_H>F7GAW4]'O\ 3XDMHK:\MV0W3MNYB&/F48Y(
MZ=Z]OL]$U.)9]7N/(N==9,11R$^3 O\ <7'?U;OSSB@#Q[]C?PWJ.DZ3X@N]
M0T_[)%<FW^S2>6JAU DW8Q[D5]&]:Y'X8Z'K'AOPW%IFK"U+6_$3VI;Y@22<
MYKKJ %HHHH **** "BBB@ HHHH **** "BDJ"XO([6"2:5Q'%&A=V;H% R3]
M!0!8KQG]KG_DB>H?]?\ I_\ Z60UUG@WXV>"/B%K5SI/AWQ+IVK:C;9\ZWMI
MU=TQUR <]*\3_; \2:WKGB+0_AKIVK:)X?L]4TFYUZ;4-88@%[.YM2D28XRQ
MDS_P&@#ZFHK@?@7X\OOB7\+]&\0ZBMNM[="59/LF?*8I*\>Y<]CMS^-=]0 4
M444 %17(5H7#*77:<J._'2I::_3GD4 ?-EO\//B#<>.HK_P@DG@G1$NBTW]L
M7/VH2+ORVRT"C&X9PWG<9S@XQ7T?"&6)!(P:0##,HQGU..U?+VI?&OQ+\/?C
M!KN@3>(?#M_I-UJ,*Q&^$^=.\P*!#+*O[N,LS (&()+*!U%?4$,A:%&.TDJ"
M2G3IVH GHKC_ (L?$BQ^$WP^UOQ3J*M+#I\#/' GWKB4\1Q+ZL[E5'NPKP74
M/VT;RW\'Z'K\7AM#&VC'7M8MY9"KVUMYK1A4&>7RC9!STH ^JJ\:_;(_Y-;^
M)?\ V!IOZ5G?#/\ :.O/'WQ&O='?1([70'OM0T[3]067=)+-:3-')O7/ ;8S
M#CTKD_VN/CU\-M6_9[^(VAV/Q \,7>M2Z;-;)IL&KV[W#39 \L1A]Q;/&,9H
M ^GX?]6G^Z*?4,#9C3Z"IJ "BBB@ HHHH **** "BBD8X%  >GI7/^,O'&D^
M ]'?4=7N?*B!VQQ(-TLSGA41>[$X ^O.!7Q7_P % /VY/$W[-/Q"\,^'O"\R
MR37L7GW4#VJ2 )G P64G)/IZ5]%?"3PY+X@T/1/B5XYU"/4M:O-.AN[995\J
MVTR*2,/A8S@+)AOF<C=R1G'% 'Y^> _"NN>._P#@H\GB37?$MO:V/VF.]_LV
MZ,QD:/Y@EJR[-H88+$9(&1R<\?IRP?QY>$#='X>MVP<<&ZD4]/\ <!'XXKY@
MTO6M7\4_M ,DEH397MTL,LL=FL;- ,D?.%! //.:^SX(8[>%(HD6.-!M5$&
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MDPAW_P#': ._WXSQ2+)QR,&OC'XC?M176M?$ZXL=,^(EY\+?#<&C+=VTVL:
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MKW.O"/V;=:U.3Q+X_P! U+74\1_V1<6GE7]O=/<1,LL;-M#,2 PQ@@=#7N]
MSE-2^%7A#5]<AUF[\.Z=-JL*21I=M;KY@608<9'7(]:YX?LU_#-?#-WX?'@^
MP&D75S]KFMAO :7CYMV[<.@Z''%7YOCOX MO%%SX=F\46,.KV_F"6&0LJ!D4
MLZ"0C87558E VX!22.#6?'^TK\-9M!N-9C\40R6$$ZVSE+:=I#(P!4+$$WL"
M&!#*I!!!!Q0!W^DZ-9Z#IMKI]A;QVEE;((X8(AA(U X 'I7CGP$7_B\/[0.>
M3_PE-G_Z:+&O8=!U_3O%&CV>K:3>0ZAIMW&)K>ZMVW)*AZ,I[BO'O@*P/QA_
M:!_[&FS_ /318T >XT444 %%%% !1110 444E "T4FX>M)O7UH 2:9+>-I)'
M6.-1EF8X 'K6-H/C;0?%+2II&JVNI/$,NMM*'*C..<5@?&#XH^&/AGX1U&\\
M075FY^SNT6ES.IEO"!_JTCZN3Z &OSZ_X)__ +0/BGXK>+O'^E>!_ASX:\-W
MUQ<S:C)J\ENT<-I#)*#]G^49)!8;4P1\O(XH _3B\O[;3[=I[J>.VA7K),X5
M1^)KRO6OVC-#:^FTSPGIVH>-]93Y6@TB+,41]9)6("K[J&^E5;?]G9/$UXE]
M\1/$E_XVG'33Y6\C3E_V6MH\1RCW=2:]2T_2=+\*Z0EII]G:Z5IMNORV]M$L
M42 >B@  4 ?F;\"? OQP\3?M_:U=^/(TDTZS*7U[:RR^;;K;%B;95X&YEP1R
M.H-?IQJ&J6FDVDD]W.D$*#)9C_+UKX<^&_Q^UW5/VO?%$EIX(N5@UJWBT>WN
MI+F'R@T,LF)3A\E2&'3FOL/3?!)N+N/4==N?[4OD.8XNEO!_N)TS_M$9H \!
M_:0T3Q%\1-0TC5-&L[B#2D,=I')*YC,LC2':RKZ9(P?:O?\ X6Z'=>&_A[H&
MFWZ!+ZVM4CF .?GQSSWK+^+VL:=IFEZ0MY?VUFW]JV<@$\RH=JRC+<GH!UKN
M+6ZAN[>.:WECGA<!DDC8,K#U!'6@"POW12T@H)QUH 6FR1K+&R,,JPP1ZBC<
M",YXK*\6>(K;PKX9U35[JX@MH;.WDF,ES((T!"D@$GU- 'A_P;\!^']$_:*^
M+US9:9#:RV=S8>1(I;]V)+"%GQD]RS$_6NN\2>,M5^(&L3^%O!,I@MX6\O5/
M$17=';^L47]^3'?("\=<\?+WPU\;>)OB%\2-%E/C;PZ(/BM*9=2L_#MSNO\
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M&N;=)"H] 2#5^UM8K.W2"")((8QM2.-0JJ.P '05-10 4444 %%%% !1110
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MX#_#S0=!\2Z'X3OM/T_9J-KK6BR:BQD)&T*4N(MFT9R"#G/;%7/V4;+7]/\
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MQ L@BA^XN>PKY)_:R\5>$]'^(VH:??V>HPW]SI*RW%_;ZC';*@0Y4(&D5MS
M!2P&W!()ZBOJKX9M8R> M!?38Y8K%K1#"EPVZ0#'<]S0!U%%%% 'C]]^T=IM
MG\7I_!(TB[FAM;J&QNM71AY,-Q+!YT<97'(*X&<\$XQ7=^+]?TVW\/ZQ#-J-
MK%,MI,&C:=01\AX(S7G&I?LXQWGQDF\90:]+:Z9>7D.HWVBK;H5GN(;?R8V\
MS[P'1B!U(J'XT?L^?##5-$\4^++WX2^'_%OB9[26X9FTVU-Y=2!, ^9+@;@
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M6J:YI5W+)"N=L>Y[PG:,]*C\;:-+XW\*P:%-^S'XLT^"UD\ZUGT_4M'AFMI
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M:3Q+XDU'0M%OCJ-EX:OY[:33H)2CH,(( Y 5VP"]>TV?A_2;$C[-IME;\?\
M+*!%_+ KPJX_:3^%>H)J9:[\;!=2$?F&+PUK(V!.5\O%M\F<\XZU,O[2WPN&
MH&\^T^-3*;); J?#&L[-BDD-M^S8WY8_/UZ>E 'JGBKX5>#_ !MJ$5]KNA6>
MI7B)Y:S29W%?3@C(^M=+9V]MI]G;VEK&D-M BQ1QIP%51@*/H !7S_8_M&?"
MO3Y-*DBN_&Y.FPM!#O\ #.M,'5B"3)FV^<\#!/2J=Q^TM\(-!T59+O5/&5GI
M^FW,FI-=77A_64"9<RN9':W_ -6"3P3@*,=!0!])JVU3D@8X)S2%AN;)X'O7
MSO)^T=\*;S3]2@%]XW\C4YA=220^&]:!!R&_=L+?Y5.!P.,5/??M*?"S4)-4
M>6Y\:J=0MS;2B/POK*A%(QE +;Y&_P!H<T ?00<>V::&R1\RD'I[U\_G]I+X
M6-J%G>&Y\;&2UM9+1%/AC6=C*^W+,OV;#-\HPQY'/K5";]J#X/>&;?1)KS5O
M&%I!IUQMMY;SP_K"B22;,:HY:WQ(6+@*I_B(QS0!]([AC.0>?7CZ4>8.?F'%
M?/'_  T5\*OLS0?:O&^QKW[<3_PC.M;O,QC;G[-]SC[O2ENOVC/A7>-K1>\\
M<+_:QC,^SPUK2[-BA1Y>+;]WP.=O4T ?0RO\Q!(SC/6DW@LOS<'D8-> 1_M+
M?"Z.^DNQ=>-?,DM4LRO_  B^L[-B[L$+]FP&^8Y;J>/2J/\ PU%\'_"MIH\]
MUJOC"UM]+CCLX9K[P]K 60MB-!(S6_[QV+  MDEB.] 'T=YAS]X8/2D:3&?F
M YQR>/I7SM;_ +1'PJM['3[5;OQR8K*[^V1%O#>M%F?<6PY^S_,F2?E/%.NO
MVBOA5=VM_;O=>-PE[=)=R%/#.M*RNL@<!"+;Y5R!E1P1D4 ?1(D'<CISSTH\
MS=P&&:^>K[]H_P"%>H3:E+)=>-E;4+=;:7R_#.LJ%4$X*8MOD;D\CGI45U^U
M-\(]$FBU>\U3Q?:);6G]G>9=>'-82';)(@!;=;X,A8*H8\_-@=: /HG?TP<Y
MSWI1("/O#&<9'K7SS:_M(?"VT7346[\;.+ R,F_PSK+>87))$G^C?/[9Z4R3
M]HKX52VLD#7?CC:]ZU^6_P"$:UK<)"<[0?L^0G^QTQ0!]$>8.26 "]>:7S/<
M?GTKYUOOVAOA3J$&O127?CE5UG_CX,?AO6E,?R!/W1%O^[X4'Y<<Y/>C5OVJ
MOA'IOVS4K_4O%EE!+;"SEEG\-ZO'$BMA5(S;X5B2 #UR10!]$K+NP,C<><9[
M>HI1)WR,9QUZU\]V?[27PMLI-(=+KQLQTN$PPB3PSK+!QMVYD!MOG..Y[TRW
M_:,^%=O9Z=;+=^."EC=?;(V;PUK19GVLNUS]F^9,,?E/&0/2@#Z%\WY@,CKZ
MTH<Y89Y'I_A7SO<?M%?"NZM[N%KSQTBW-RETQC\-ZTK*R$$*I%O\J_*,J.#S
M4LO[6?PF\-7FI:]=ZEXJM(YXH8IY+WPSJXMXU0L%(#6^U"2^">_'M0!]#TM4
M]'U2#6])LM1M?,^RW<"7$7G1-$^QU#+N1@&4X(RK $="*N4 %%%% #6K@_CI
M_P DE\3?]>A_]"%=XW6N#^.G_))?$W_7H?\ T(5I3^./J9U/@D=ZOW17BO[7
M%I)=_"F+=J<&DZ9%J=M+J=Q.ZIFT!;S54LK#<1C'%>T!L8%?('[<WQTTSPU=
M:9X(O_ _C75I5^SZY:>(?#]E%+:6EPCR*@=I'5"PVDE6.,,*S+6QL_L%65Y;
M^&/$$[W]CJ>FW"6!MKRSF63[2XA82S?*JX1VPRC'3N:^J:^0?^"<QT&3P)K9
MT<:I++:K8Z=+=:I<V4CR100LD"A+6:14"KQ\V">O-?7U PKRCX_?$3Q#X*TW
MP]IWA3[##K^OZK#IMO=ZG"TUO;[V 9VC5E+X#= PZ=:]7K@?B]\*5^*6DZ;%
M!J\V@:MIE]%J%CJ4$*S&&5&!&4;Y6!P,@T 9WP1^+@^(?POT/7]<DL],U.Y0
MI<1K($C:1>&*!CG;GW->/:+\.=+^-6N?M&:#<:I)9VL_BRPN([^RD0M%)'I5
MBRL"00<$?I7J%C^RI\-6\':!H/B/PII/C-='B:."[UVQCN9<N078%P=NXJ"0
M/05X3\,7'PI^)7QU\'>#O@E>>)O";Z_;*UMH#:?;6< ?2[0O"8IYH^I)8X4@
M[^N<T =2W[!OA?Q/JVI:QX_\5:UXM\1W%O#;PZI]H6VEMH8PP 4( /XNI!Z5
MQNM?\$ZH;)D?P;\1=1B$A)2+Q([WRL.I \IX>/Y5Z]-\5O%\]T;E_P!G#Q6U
MP8#;&4ZAH^[RCC*9^U_=X'%06_Q(\3V;:68/V:O%$1TO=]BVWVC#[/N7:VS_
M $OY<@X.* /G3Q9^S1XR\#^']4FN?!/A_P 3645M*7U*TUV^BE#!"?E@\X\\
M9^]QCO7S]\ ?@'%\"_'7@CQC(C?$K_A*M.:\;0=,MFGGL]]N9OWB>8-^W/).
M.F:_0AOB!XB>R:S;]F7Q,UJ;@W?DF]T;9YQ!4R8^U_>()&?>N?T41^';JZN-
M+_9'U33Y[J-HII+:30T:16&&5B+KD$$C% $6F_%CQOH^U=(^#]UI!VY58]$"
M'']XE7&!7@GQ>\=>)_&'BCQGJ'C#Q4OP\U70M)^V:)HY@)-]*MOYBA,D\LW'
M'K7T=XT^/VK>!](O?%.O_L\>*;.SL[46TUXUYI#LD+,$V?+=%BI)48%68_&6
MM(NEJ/V8/$6-+C$5CF\T4_9TV[<)_I?RC;QQVH YWP?XJ^+6N^$])N=3\(ZC
M?":WB.(?$,,$3DJ#R/LQ(/MFNBLU^(%F\LG_  I/19Y%PTDEUXZW'IQD&UP.
M/:KEO\1O$MK9QVD7[-'B>.VCG^U+$M]HP59O^>@'VO[WO2W'Q*\47?\ :OG?
MLU^*)#JH47V^^T8_:0J[ '_TOYL+QSVH \'_ &F5O=8\5^!+/XL:/_PA/@T6
MVIR^9X/ODN)FGVV_DK(?*&%^]@XYY]*[+]F&/XP7'PATR/PKJ^@6?A\SSKI\
M_B"RDN;J6'>=CMLEC!^7!X'->E1?%'Q9!=-=1_LW>*DN'MELVE6_T<,85SMC
M)^U_=&YL#W-1V/Q,\3Z/9Z5:VG[-?BBVM]+41V,:7^C*+90A0!/]+^7Y21QV
M.* ,3XI?#_XZ>(/AOX@MK[X@>%M0\ZU>+[#I&@36S3Y'^K#-=288\C./PKQ7
M]G;P-K?C?XG17>A^%M6^!EKH_AJ33M1OK>2-FU&X:XA92=Z8 PC'IFO:(?CU
M?7WBBZ\&)^SMXGDU;38[?7)=/^UZ0!&)9)%BGS]JVEBT4@X.1M]Q6[<?$GQ/
M=-J33?LU>*)3J6S[9NOM&/VC8,)O_P!+^; Z9Z4 ;/\ PI7QAN*_\+E\3%L;
MMH%MG![_ .JZ4UO@'K-["K3?&WQ\)9QA?LMW8K$W'\(-J3^M9T?Q4\6PWQO$
M_9N\5+=FW6T,PO\ 1]_DJ25CS]K^Z"S<>YJO#\1?$MO%I$47[-/BB*/23FP1
M+[1@+;Y2GR#[7\ORL1QV- 'SOX#^%?C'6M=\+?#W7O -YI>B:)K5Q<3^/,1Q
MW&H(UT\@#.J@[F# 9S^':OK?2/V:?AAHTCS)H*7,Z_ZR:]O9ICSW(9RH/X"N
M,/CSQ";9+<_LS>)_(2]745C^W:-@7"MN67'VO[X/.>M,USXQ>(-)TG7-2U+]
MG'Q2ED\)N=2D:]T=A(D0+;G N\MM )[T 9O[1G[*D_Q&OM"N/ 3:'X5O++RQ
M<3+!)')-"LA8H3%(F5.2#D$\GFO<?A;X8MO 'P]\.^'(?L4,5A:);QI9Y$/R
MC^ ,S''XGZUY'X?^.WB;7[+3O$6F?L\>+)H;[3X?LUVNH:0I>U8;XU&;L$+A
MLX/K3[7XA^)+&#2H;?\ 9G\301:5_P >*1WNC*+;@C]V!=_+P3TH ^@OMD.T
M,)4VEM@.X8)SC'USQ7-_$+X?>&/BEX>;1/%5DFIZ6)%F>W:XDB&X @$E&4]S
MP3BO(/\ A87B3[#%9C]FCQ0MK'=B_2%;[1@JW D\P2@?:_O;_FSUSS5JY^*G
MBV\6\6?]F[Q5*+S;]HWW^CGS=IRN[_2^<$G&?6@#UKP'X%\._#/0X=!\-6BZ
M9IL(,B6OVAY=H)Z@NS-C\<5T"WD+-&%F1O,R5PP.[Z5X')\5/%O]H'4'_9O\
M5&\-M]B-P=0T?<8-Q;R\_:_NY)..G-<W_P +TN_#OB[PSX77]G/Q-::T;*ZN
M=(M$N](&RWB:(3E&%UM4!I8N,@G=QGF@#Z?^T0["XECV;MF[<,;LXQGUSVIS
M742;]TT8\L9;+#Y1VS7SVGQ$\2QV!LD_9H\3K9_:S?>0+W1MGV@R>;YN/M?W
MO,^;/7/-+=?$7Q->?VEY_P"S5XIE.I*J7A:_T;-PJDE0_P#I?S8).,^M 'T(
MUQ&&V^8N_;NQD?=]?I2"ZC;8!(A+_<.X?-ZX]:\";XH>+&OC>']F[Q5]J-J;
M(S?;]'W>03DQ9^U_=SVZ4D'Q.\56QT\Q?LV>*8SIX=;3;?Z,/(#$%MG^E\9P
M.GI0![[]KBVEC,@4-L)W#&[.,?G3EN(V9E$BLR_>4$9'X5\]S?$;Q-<6+6<O
M[-/BB2U:Z^W&%K[1MIG\SS/,Q]K^]O&[/KS5/X>_M$:UXOM1XG\.? #Q4UMJ
MTC+)J"WVDQF4QR-$Q8&Z#':RL.G;B@#Z5I:0=!2T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56OY
M&AL[B2,J)$C9E+_=S@XS[59J.:)9D>-U#(PVLK#((/6@#\LOB%^U1\0?$WCB
M]MM6TWX6>*#87\MI;G1].GU:YC16.%E"W*8(QRIXSFOTN^'M_<:IX-T:[N8H
MX9YK5'>.* P*I(Z",DE1[9->?7?['?P1O[R>[N/A/X1GN9Y&EEEDTF$L[DDE
MB=O))YKU?2-*L]#TZVL-/M8K*RMT\N&WA4*D:CH% Z"@"[1110 W:<YK'\77
MEA9>'[W^T+Z'3X)HF@\^=@%4LI K:KP7]K7PO?>(M#\)W$6@2^*-.T_6$N+W
M2X51V9=K 2;7(!"G\?FH ]#^"?@8_#3X0^#/";:A'JIT32+73S?0IL2X\J-4
M\P+DX!QG&3UKMMHKS;]F_P .:EX1^!?@?1M6LVTV_L])MH9+%R";8K&H\HE2
M1\O3@D<<5Z30 ;17E>O6NA^+/C7X)U2V\2V2ZAX;BU&)]*'S2S?:(XER#GC;
MLR>#G/:O5:\,\-_#=-2_:4U_Q7>Z)'9VND64=GI<ODJ-\S[FGF##DEE:->?^
M>= 'N6VD.%ZT+RN:'[<9H IWFLV&GW5K;7%W#!<W3^5!$[@-(VTMA1W. 3^%
M<U\-?">A_#71_P#A$-(OGN&@FN=1:*YD5IE^TW,L[$X ^7?(X''0#KUKROXZ
M?"^76?CI\&?%NF:)]LOM-UV0WM^JC=#;?8;E0"3SM+M&..^*XK]G[P)\2-"_
M:T^(7B7Q?I+BVUS2XX_MZ7&^W41W$ODI&N?E_="/<,?>W'O0!]=X%,DD2%6=
MR%51DL3P*DK"\<1V[>$=:%U8R:E;&SE\VS@ ,DR[3E%SW(XH Y>XT?PCXC\=
MZ1\24UM7N-!T^\TA'CG3[,$N)('DW\9W VZ8Y'5N#V[ZVFBNH8YH762&50Z.
MIR&!&01^%?%W@CX/Q>-/@#\0EU'P*VD:EJ<T=U!X<:V5(;<Q[Q"J@<,X#N2W
M?(YXKZP^%]A<:9\-_"=G=Q-!<V^DVD4L3=4=84# _0@T =/@5EZMXDTO06MU
MU&_M[)[EQ'"LSA2[$\ 9K5KY?_:\\/?\)1KOA+2HO!DNKO>2!+K7EMUF.FVR
MMN81@\AWP5!'3=G/% 'LGPQTOPO\.-#T_P !:-JPNGTR)RD-Q,K3[6D9R6P!
MW<]O2N[X-?$OPO\ A3XAT7]K"XUR?PK?V\#7U]+]L98FM?LKQ6BQ2[]^_P Q
MC&XV[?X.>V?ME3V].* !L*I)X^M>5>/=-T;QAXN\$^*4\26-M:>"-5N+N\5B
M&#F6TFM@F[(V$&8')SG&.^:]/OEWV-P/+\[,;#R_[W'3\:^$[SX5:C>6/CWR
M/AWK6DZ'?2Z>]S86GV>.99H;F%B8<28D1=A=LD9VD '- 'W-I6L6.N6,=YI]
MS'>6LGW9HFRI_&KN!7F7[.=IKUG\(=$A\1V3:?JB^;NMWBCC?9YC;"RQDJ"5
MVG@_K7IHZ"@"IJFI6FBV<E[?7,=I:PC+S3,%51[FN!^%^A:;\-;SQ#HEQKMI
M>:GK6O:AKL=LOR2(ES*90FTDY*@]>_I7CW_!0CP+\0/B-\*UT7P=ITFI:>1)
M-?6]M/Y<\CKM,*@9 9<[MP)YXK.U;PK+XL_:G\+7UYX%GT=-,\K4;K78X%D>
M[O/LTD20^8#E8T65\GU"@ @D@ ^NMRTO%, .[[OXT2,PC8HNX[<CW/I0!YU\
M7?#MAXZAT6P;7+73)]!UK3O$=PLHW'R;><2;2,C;NV$;CT]#7=Z3K%CK=C'>
M6%U%>6LGW9H6W*?QKX./P:^(6L?$CXW7OC;PIJ6LVOB/PYY8&F7RKYK1S3^3
M%;[G4(QC\O() W$G/.:^A?V0_!.I^"O NN1WUG?:?:7FM7-Y8VNH.#,(6(VL
MP!(7/IGM0![PQ5>M4-:U[3O#UBUYJ5W%8VJG:9IFVJ#Z9J_R!SS7B'[7'AV]
M\2?#G38+/2M4U4PZK'.Z:24\V("&8+(RNRAT#%05R>6!QQD &]X$TG2/"?CS
MQGKS>([*Z_X3C4+:^L;9<(RB*SAMBH)/SY,);( ZXKU.O@W4/A]\1H_B7\/-
M9U3P!:^)PUEI41DF2*-[!X[M9)'&"0C(,RG!P3D FOO!<[5R,''- #JBNH3<
M6\D8;874KN],CK4M% 'QO<_\$Z=+UCQU'XGU_P 33>([J'4!?VRZA"/W#"3>
MH7RRN<< 9STK[!M;?[/;Q1#G8H7\ABIZ* "FG-.HH C(P<>U><_M%>"]2^)'
MP0\9^%]'\C^U=6TZ2UMEN)/+0N<8!/85Z.PSBODO]M35-5L=:T<+?ZS862:3
M?2V#:,9][WZ^7Y>?*!^8<;<^IQWH ^L85VK@GG&.*EJAH[73Z;9M=C%RT2F0
M#LV.:T* $KS;]I#P;J'Q&^!?COPGI#6XU;6=&N;*T6YE$:&1T*KN;L,GK7I5
M>"?M4>$4\:1>$]#@-W;ZCK&I1V/VZUE>-K:W+#SG!7HP5OESCF@#V_2X6M["
MUA?!:.%%)!SD@ 5;JKIMFNGV<%LA9DB0(&8Y/ QR>YJW0 E>?_'[P=J'Q$^"
M/CWPKH_DG5M9T.\L+59I-B>;+"R)N;L,D<UZ#7RUJ6H>)_AW^T'\3-2T_P#M
MOQ8(O!B7]CI<T[-$]T+B3;%%N.U,@*,#US0!])^'K=K'0]/M)2IFM[>.&3:<
M@,J@']:T1AJ^9/V#_$'B?7/A[XN7Q8^IW&KP^)KMC/J<90F-@A55![+@CCBO
MII>] "G&*\M_:&\!ZI\2O!.EZ3HP@>\M?$6C:G()Y=@\FVU"">4_79&V!W.!
M7J74'%?*/A"2#Q1^U%XHT_1?$.NV\=K;W$%_<74\P6>=XV"QP*?E"PA@0W'S
M1\4 ?5JNK="#]*7BO#_V3;74K'P+X@M-2O=1U":W\0744=SJDKR3N@6+!+-R
M1R:]P7I0 <5YE^T)X(U'XE?#L:'HOD-J"ZQI-\5FE"#RK?4+>>0Y]=D;8'<X
M%>F-7Q9XUUR2;XQ?$EO#6K>(6O-'T74&O%6:;-U<-;R>7;VJ'C$>0VX8^:,8
MS0!]GQR+(,AE(!_A.:EKY;_88O-4D\.^)K?4-1OM62.]BDCGN//"(6MXBT8\
MU5.X-G<0",GKG-?4M #=PSBO.?V@?!>H_$;X7W_A_1O);49;W3K@+-($4)#?
M03OD_P"Y&V/4X%>B/GM7R-XJUBXL?V@=;FT;5-?D6;3M2MM0M-EPZVS+&S).
MH*[#&"N%"DDEEP* /KB.2.5CL=7(Z[3TJ2OFC]B_4+JXL?$MM._]HQ03Q&/5
MO+GB:YW1([!TE1<.K,0=N1P.<Y%?3% "5YM^T)X*U+XC?"G6/#NCB$ZE=36<
MD0FD"*1'=0ROD_[J-^.*]*KXD\9?$OQ=<?MDO9:S!XBT7P5'H>JV,7V>,^3^
M[:$_:U9"<EEW;<_,#T'- 'VO'(KKPP89QD'-/XKYJ_8JN&U3P_XFU2&_U-]'
MO-0']G:=JT\DMQ!$D21[WW_=,K(TV 3_ *SG!R!]*B@ KS;]H3P7J/Q(^$.O
M^&M'\E]4ODA\E9Y-BG9/&[9/T4UZ2>ASTKXF\?>/O'.J?ME6&ESP>(-'\*KI
M&K:?;_9X2T1D40$7893@Y!( .""O YH ^UTD23[C!NW!S3J^5_V+6U:WNO$U
MB^OZAXCT:WCM=M]?V\L)-P88R^1( =YR2^,C>6YS7U.HP* '4E+2-TH 3K7"
M?'3_ ))+XF_Z]#_,5W5<5\:K66\^%?B.&WB>>9[4A8XU+,QR. !UK2GI./J9
MSUBT=IM+ 8KP+X^?L;:!^T'XNL?$&K^,/%VAS6EHMHEGHE_'#;, [-O:-XV#
M-\Y&?0"O?U^[3JS+6QY3\ ?V>='_ &>M'U+3=&UC5-7@OI4E9M36V#(5!&%,
M,,>0<_Q9KU:BB@84444 ,D8*I9CM ')/05XW\#9_"]W\0/BQJ/A_Q?IWB.;6
M-;BO+FSLC\^GM%9P6QB<Y.3F MGC[V.U>H>+K2>_\*ZQ:VP)N)[*:*(#J6:-
M@!^=?*/[)>CZA-\58KU-+OM.L]%\*KH>I27=K);K)?+?7$C*N\#S/ED1MZY7
MGKF@#[$VBC:*,TM ";12' IU-;/:@#Q;]J[Q)X*A^&%_X6\6>--+\%OKR!;:
MZU,G:?*EC=R%R,X^4=?XA7K'AWQ!IOBO1;+5]'O8=1TR\B6:WNH&W)*C#*LI
M[@@BO*OVJ%U;4OAYIWA_2H[OS/$6L6VDW%S9QLS6T#AW>1L=%_=A2?\ :KUC
M1-%LO#NDV6EZ=;1VEA8PI;V\$:X6.-5"JH'8  "@"_M%&T4M% ";14-W-%:6
MTL\TBQ0Q*7>1SA5 &23[5/7'?%[PG:^.OAGXBT2\^TFVNK.0,MG*T;O@;@F5
MY*L0%([@D=Z .(L;SPII'C?7OC=-XQTO_A$=6T*RT=+DMB%&MKFZ9I/-S@@M
M,5QC@H>3FO9MRA<]J_+SXA>#O'DO[%O@3PI9_#[Q%?\ A_3K*[N)H]/6)#'<
MB]E\D2PNZRD(HW#:C9#U^FFBWEQJ6CV=U<V,VFS31*[V5P4,D+$<HQ4E<CIP
M2/>@#0P*-HH'04M #6PO:O.OB3X\\'W?V_X=7WBG3M+\3:_I\]K:V4\G[T^9
M$R[@G?&<XSSBO17Z<].]?&OQRUK3/$W[3&C^!CH5QH.F-+;:IK/B2#1;F5M2
MFC#"WMDFBB8#:78EF( VXSS0!])_#*[T;0=%TSP';:W:ZGK7AK3+2SO(82 Z
MA(E0.4R=H;&0">]=QM%?+O[/OP\/@7]J?XS/;6%]%I][':3)>78=A<.44M^\
M8?,0<C@G  ':OJ*@ VBC:*6B@"KJ=_:Z3IUS>WLZ6MG;QM+--(<*B*,DD^@
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MR?-C R ?7B_='.:6D'04M !1110 4444 %%%% !1110 4444 %%%% !1110
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M/R!CW..,^E:7\;OB+<^(OB=X=DG2&^\%Z1JMZUY):EXVF9I6L%*J"6Q"T+D
M'.#W- 'UE!;1VX<11K$&;)"+C)[FIQ7RS\ ?CEX\\6?L]>,O$&MVDFH>*-'N
MYH;4K;K&+A!'$RL "0<%G/7MBN&;XY?$N[T:ST[2_%\6J3WFI:3"VNII006_
MV@1>?%Y><$@NW?C&#B@#[>;M5%-+T^&Z:Z6SMEN&)#3"-0Y)ZY;&2:\Y^#/B
MKQ!XD^#46H^(+U;C6XQ=12WD4'E[BCL%<(.G 'Y5\6^&_%7C/6O ^K6MWX]U
M2Y:V\1:-=/J[))<6\L4DL0X63:T+,6#O'MPI!&>,T ?H];VL%DA2W@C@4DL5
MC4*,GN<5-N&XC.#WKXDD_:B\=V=C;VEC.-9U^UM=>EN;+[+AF-NMN;4GL,^9
M(<9YKEM/^//COP3J7CKQ<_C.;QGHFA'3)KQDL3%'.LMHT?EQ1#.P^?)$21UQ
M0!^@OMT]JA%G!YSS"%%G8;6DV ,P]"?2N<^%=UJNI?#O0;W7)?/U.[MA<RML
MV8\PEU7';"LH_"NKH KVMG!9KMMX8X$)+%8U"@D]>E6:2EH *JW%E;W,P>:"
M.5E4J#(@)VG&1SVX'Y5:I* *EAIEGIJ,MG:P6JL<D0QA03ZG%6Q]:*6@!*@D
MMHI+E)7B1I$4A79<L <9 /X"K%)0!7M[."S5EAAC@5F+,(T"@D\D\=ZL"EHH
M *2EHH ;2=1@]*?24"!:6DI:!A1110 4444 %<]\0O'&E?#3P/KOBO7)9(=(
MT:SEOKIXDWN(XU+-M7N< X%;[5^=?_!9#XXV/ASX2:5\,HC%/JWB&>._G0LZ
MO!;1295Q\NU@SJR8SD8S0![A_P $\_VE+[]I+X)SZAKFJ6FH>)M*OY+.Z\D!
M9O(SF"251P&<!N@ .TX'%?4U?A=_P2D^.B?"K]I"/0-3U&ZM]!\56S6)MQ*J
M6WVL%6AEFW,!\JK*H/)S)@#FOW1H **** "BBB@ HHHH 8W7%9UOX@TVXO'L
MXKZW>[0E3"L@W CJ"/6M%A\V:_.75['PO;^'?'NI6=I#_P +/M_BC/)I\UM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF8&]G9&6=^!^Y"F#.5<7"\UL_#G0=!^%V@:;<W;2:SXZU>Q@?4+X2F_U#4)
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MTFTE\/\ @75?'<UY>:7($URWMM1N+:V58S(&MUEAM))&ZD,Z;2!D5]2_M*?
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MWJ7C22\MXYTM?#6E7&H/%O4,$G>)#';N,X*S.FT@@X/%9L/[,LOA/Q3K6L>
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MR6I?R86DDVLP(V[?]9@GY>#UQ0!]O75U#96[SW$T<$$8R\DK!54>I)Z5S/\
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M#XK>$?B5X0FB^)I\>V>G^);B;2_#LFEV.D1S6%M;76J6\)$;2GS'=//9C(V
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M$DB)/']F06J !@?,5<NRJ3G H ]\N[N"PM9KJYFCM[:%&DEFE8*B*!DL2>
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M\+V&L1>()]-\'WWAZUMA971GLVOXY;N.9V^9R+A(2"%\QOGROS_=] !1110
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M[?3KQ4-_\3O#6F:'XDUBYU%H].\.3/;ZI-]FE/V>1$1V&T+N?"R(<H".?8T
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M[6&WBM9IG=O*5VSF-0,*<YQQUJ;X3_M$>*;&W\1^&OB/H-]KOC_0=5-C<_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"&=_VG?^CN?_,:Z7_\<H_X9W_:=_Z.Y_\ ,:Z7_P#'*^AO /Q$\/\ Q.T
MZSX;OS?6*W$MI*)();>:">)RDL,L,JK)%(C @HZJP[BNDH ^5?\ AG?]IW_H
M[G_S&NE__'*\J^(FE_M.^ ?CM\(_AQ_PT]]N_P"$_P#[7_XF?_" :7']@^PV
MJS_ZK)\W?NV_>7;C/S=*^_Z\%\5?$?X'>)/%FG>/=2U)=6\0_#G7+OPU8W-A
M%>SS6VJ74*QW%I#;P*?M<K1X!54EV[6QM*M@ X__ (9W_:=_Z.Y_\QKI?_QR
MC_AG?]IW_H[G_P QKI?_ ,<KZ1\'^,-&\?>&['7_  _J$6J:/?(7@NH<@, Q
M4@@@$$,"I4@$$$$ BMF@#Y5_X9W_ &G?^CN?_,:Z7_\ '*U?A-HGQB^&_P ?
M=(\.?$+XS?\ "T=%UOPSJNH0VO\ PBUGI'V2>UNM-C5]T)9GRMY(,$@#'0G&
M/?O%_BS2? ?A36/$NO78L-$T>SEO[VZ9&?RH8D+NVU06;"J>%!)Z $UYM-\8
M/AK>?V=\1;Q-<LKBR270].GU'P[JMG<W(O##,\-M:20+)=%_L<+ QQN0(C@@
M;L@'L%%8G@GQKHGQ&\*Z9XE\.:A'JNB:E")[6[B#*)%R1T8!E(((*L 0000"
M*VZ "OG3]N#6/BI8?"^"P^&?P_T7XBP:M+)8Z]INM6\EQ&MD\9!81Q31R-SQ
M\FX^@SBOHNO!_P!KC]F_7_VEO".BZ'H?Q(OOAT+&]-U<R6EHUTE\FPJ(I8Q-
M$&4$YPVX'TH ^/?^"<MBVA_M#:O9:C<^ H/$*:?<0W>CC_A(T\06&3&YC2+4
MP$5#A"Y7+'"\U^G5?*G[+O[&7BC]G/Q<NHW/Q'T'Q!HGV:2%]+TSX>Z;HLLD
MC8VR-=0$RMMQ]TD@YYZ5]5T %%%% 'F6H?LY^"-2^)/_  F\]E>'56OK?59;
M5;Z464U]!"88+M[?=L,J1MM#8_A0G)12/3:*@OKZVTNSGN[RXBM+2!#)+/.X
M1(U R69CP !W- 'PY_P3AUKXIV?[&/P\B\-^#?!^JZ*O]H^1>:IXMNK&XD_X
MF-T6WPIIDRIAMP&)&R #P3M'TK_PDGQO_P"B>?#_ /\ "\OO_E-5/]D7X26'
MP+_9W\(^"-+\4VWC73]-6Z:'7;.)8HKH374T^559)  IE*\.<[<\9P/8: /*
MO^$D^-__ $3SX?\ _A>7W_RFH_X23XW_ /1//A__ .%Y??\ RFKU6B@#PJ]^
M+'QAL?'VC>$9/AOX'.I:KIE]JL$J^.KSR5BM9;2*16/]CY#%KV+: ""%?)&
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M&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-7JM% 'E7_"2?&_\
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M>"/A_P"'/AWI_B6P\0ZCX.T>RT6\:VD02AH($AWR0J[&(MLSM).,XR<9KOZ
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MZX\%3R^!?$5OXHT.YU?4]0:^MKN.Y47-U>S7<\>Z,  +)<.H4\A0H))Y/>T
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M-^*W@OXA7VHV7A?Q7HWB&\TUMMY!IE]%</!\S+\X1B0-R.N>F58=0: / /\
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M&W](:* /F?\ 8W\+ZGHNN?%35+JV\0W>FZMJ5@]CXC\7Z2VF:OJ:Q6$,+K+
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MU:QUN_U?7M7\3Q>*;/Q=>:]>36XNM1N[6WDM[>.<) L8A2*5E$<21XXP1SD
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MMA8H)YQYDH1B[ !,*&KZJH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ%?R76O:IX?L%MX;6-;^;3POVJ2&2:XC1D#L8T4L))75A&C\9Q=?_8IA\/\
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MXQUN746L=)O)KNUTVU+O)':Q2RQQLP\V:YE.(T&Z<@+QD^]T %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>mrsn-20201231_g4.jpg
<TEXT>
begin 644 mrsn-20201231_g4.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MPH_"@ X]*./2C\*/PH ,#THX]*/PH_"@ X]*,#TH_"C\* #CTHX]*/PH_"@
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M;*<P77BS3()0,[)!M/Y$T >;<_I1S^E=UJ?PPO;;29M1TS4[/58H 3(ML?F
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MQK-/I>G:1=Z7?"(R12^<[YP?<D5D^#?#>E:Y:^(-(N;</K%LK-:SK*PSM)!
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MI.U%+[T 'X4?@:2C\* %_ T?@:3\*/PH 7\#1^!I/PH_"@!?P-'X&D_"C\*
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MHXI: $HI?SH^N<T )^-%+[T>WI0 GM2_KBD^E+0 G3ZT44OM0 E+_2D_&B@
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M '^D_P#BJZVB@#DO^%8^#O\ H"I_W^D_^*H_X5EX._Z J?\ ?Z3_ .*KK:*
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M._Z J?\ ?^7_ .*KK:* .2_X5CX._P"@*G_?^7_XJC_A6/@[_H"I_P!_Y?\
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M6/@[_H"I_P!_Y?\ XJC_ (5CX._Z J?]_P"7_P"*KK:* .2_X5EX._Z J?\
M?Z3_ .*H_P"%9>#O^@*G_?Z3_P"*KK:* .2_X5CX._Z J?\ ?Z3_ .*H_P"%
M9>#O^@*G_?\ E_\ BJZVB@#DO^%9>#O^@*G_ '^D_P#BJ/\ A6/@[_H"I_W^
MD_\ BJZVB@#DO^%8^#O^@*G_ '^D_P#BJ/\ A67@[_H"Q_\ ?Z3_ .*KK:*
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M])_\51_PK+P=_P! 5/\ O])_\576T4 <E_PK'P=_T!4_[_R?_%4?\*Q\'?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %1W'_'M+_N'^525'<?\ 'M+_ +A_E0!QOPC_ .26Z%_U
MP/\ Z$:[:N)^$?\ R2W0O^N!_P#0C7;4 %%%% !1110 4444 %%%% !1110
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M+^VBE R4>0 C\* ,B[\,W<<\!TF_2"WBMEMUMIX1(D>WI(GHV./0X%9E_P"
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MQ)(9I-PP&0CMZT ?0]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<-JM_XB34;I(/ EG>6X<A9Y+N-3(/4@J:[FO%]
M7T#Q1JOBJ_TNXL]1:PN]16XN+M9L1M9HH*Q)SD$G<#]: .^^'VBZCH7A@6VI
MI!%/)/),((.4A#-D(#[9KJJY/X=6&IZ=X42'5$FB<S2-#!/)ODAB+$JC'N0/
M<UUE !1110 5'<?\>TO^X?Y5)4=Q_P >TO\ N'^5 '&_"/\ Y);H7_7 _P#H
M1KMJXGX1_P#)+="_ZX'_ -"-=M0 4444 %%%9%S=:Q#=QPI%8%9G(C+.X. ,
M\\4 :]%16_GF%?M(C$O\0C)*_K4M !7DWBVVGOO$M]-:123QQE$=XU+!3@#'
M'>NYUK4I[FY&BZ6<W<G^NE'2!/4^]2S:;!I/AYK:W' 92S'J[;ADGWH Q/ &
M;1+RPN5:&Z#A_*<8;;@<\\UVU9.M:,-15+BW?R+^ [H9AZ^A]0:;HNLF]+V=
MW&8-0AXEB/<?WAZB@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH HZE?
M3V*(T-C-=EB05BZK7+>,7U-=.M]5M9;BU7&R:$MC;GH?Z5V]17-O%=V[P3H'
MC<893W% '->"#?R:?-/?FY9Y&W1M+T*^U=#9W,ES$SR6TD!#$!7ZD>M3HBQQ
MK&BA54 *!V IU "$!@01D'@BO*)(]-3Q5)H*7DR^$Y+K;-&JXA6\X/V?S,\(
MV0Q7IDXSSBO4[F$7-M) 7=!(I4LAPPSZ&LT^&-(/ALZ ;53IY0J8\\\G.[/7
M=GG/K0!Y[XL_XE7Q/CUNW4JFD:7#-*D8P/L_FNL@Q[*2P'JM+KTK:U\1]!U(
M2!["SU-;*V"YP[F)VD8^N/D /UKOH_"^G+=&YE$L\K60L7:9]V^(9X/OR>:B
MM/!VD65CI=I#'((],F,\&7R=Y!!+>O4]: ,;4].L!\4- C^PVVUM.O"R^2N"
M=T//2NF_M.&"^73TL[H $*'2V;RQ_P " QBI)M)M9]9M=5=6^U6T4D,9W<;7
M*EN/^ "KU 'GLFE)8_&+2[@W-Q<2W%C=,3,^=@W)A5 X &?3GN33+S2=:TN[
M\1>(U;1;R!I?/$-Q TDGE1K]P/NPIX/8\UVTVCVD^MVNKNK?:[:)XHSNX"MC
M/'X"LZ?P;I4\]VW^D1PWDGFW-O',RQ3-W)7W[XQGO0!3NK&UUW3#JUAIUI<:
MA=V2*D=ZQ*QHPR!CMU[8S7$:&+K5-5\.:9:-%-%9:3+\VH(9$6=)3&YV@C<>
M, ]A7I-WX8L+F]^V1F>TN#"(&>VD,>^,=%('IDX[C-(_A32_LUG%;Q/;-9 B
MWE@<JR _>Y[Y[YSF@#/\#3*+?5; VL%O<65\T<XM@1$[%5;<@).T$$?+G@YH
MK<TG1[/1;5X+-& DD,LCNVYY'/5F)ZG@44 7Z*** "BBB@ J)K6W>X2=X(VF
M0860H"R_0]JEHH AN+2VNPHN;>*8*<J)$#8^F:EV+LV;1MQC;CC%+10!#!:6
MUKN^SV\4.XY;RT"Y_*DFL[6YD22>VAE=/N,Z!BOTS4]% ",JLA1E!4C!4C@B
MHK>UM[1"EM!%"I.2(T"@G\*FHH *\G^,?_(>\!#_ *C*_P#H25ZQ7D_QC_Y#
MO@(<'_B<KQZ_,E 'K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>,:O-XJO\ Q3?Z(9-9BCN=2#//$I$45BB@_NV'
M 9CN!]Q7I/C/5'T7PAJ6I).\#6\)<2(@<K] 2 :Q(M+\7:E;P7UKXNCA@N(D
MEC1K%20"H(S^= %SX='5V\)QG5S=;_.D^SB\_P!<(=WR;_\ :Q6KXC\3:7X5
MTM[_ %2Y6&, [%R-TA SA1W-3:)::E96'E:IJ(O[C<3YPB$>1Z8%9/C_ $RS
MO?"&J7,]G%/<VUE/Y#N@9HRR\[?0G H 9=>/]+L_!]CXBEAN3'?A1:VJ(&FE
M9NB@9 S^-06OQ+T2?PYJ6L7$5W9?V;)Y-U:W$8$R2$X5< D$DD8Y[\XKA;Z"
M>W^'7P[U=K:66UTNXBFNU5<LB8(W;?;Z5F:O:W?B'1_&GB#3+*::QFU&UEA!
MC(,Z1,-S!2.1CG\#Q0!ZQX7\;67B:ZN;-;*^T^^ME61[:]B".4;[KC!/!KH[
MC_CVE_W#_*O-?"=[%XE^*.JZ[IJ2G3H]+AM//>,H&EW%B!GK@&H;OP=\3VEN
M)8_B#$D)9F5/LB_*O4#I0!O?"/\ Y);H7_7 _P#H1KMJXGX1_P#)+="_ZX'_
M -"-=M0 4444 %4+W_D(Z=_UT?\ ] -7ZH7W_(1T[K_K'_\ 030!?K$UO5Y+
M;R[&P7S-1N.(U[(/[S>@%3ZWJZZ5;*(T,UW,=L$*]6;_  J/1-':R#WEXPEU
M&?F63^[_ +*^@% $VC:1'I-LR[S+<2G?-,W5VJ2[TFTO7+3J[$]<.0*O44 0
M6UI%:(RQ;L,<G<Q/\ZS]:T;^T!'<VTGDW\',,H_]!/L:UZ* ,C1M9^W[[6Z0
MPZA#Q+$?YCU%:]9&M:-]O,=W:R>1J$',4H[_ .R?44:-K/\ : >WN4\B_A.)
M83_,>HH UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRCX
MQ_\ (=\!<9_XG*_^A)7J]>3_ !CYU[P$._\ ;*_^A)0!ZQ1110 4444 %%%%
M !1110 4444 %%%% !12$@=2!]:3S$_OK^= #J*;YB?WU_.G4 %%%% !1110
M 4444 %%%% ',?$33KS5_ &LV%A"TUU/;E8XU(RQ].:P-+^%.GC2+(7.I:['
M<"!/-1=3E 5MHR  >!FO1J\UL_BQI>G^)->TKQ)?Q6QM+O9:M'!(P:/ X) /
MS YS0!VV@Z'!X?T[[%;SW4Z;BV^YF,K\_P"T>:TR PP0"#U!K.T/7],\2:?]
MNTFZ%S:[BGF!&7D=>& -:5 ";%V;-HVXQC'% 557:% 7T XI:* $5%0850H]
M ,4RX_X]I?\ </\ *I*CN/\ CVE_W#_*@#C?A'_R2W0O^N!_]"-=M7$_"/\
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M_&/_ )#O@(9'_(93C_@25ZQ7D_QC_P"0[X"&1_R&4XQ_M)0!ZQ1110 4444
M%%%% !1110 4444 %%%% &)XN9E\+WI4D'9U!QWKQ_[3/_SWE_[[->O^,/\
MD5K[_<_K7CE &GHMQ,=:L@9I"#*O!<^M>V5X=HG_ "'++_KLO\Z]QH ****
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M*7>1S@*!R37.:1\1/"^N:DNGV.IJ]Q)S$KHR"4>J$C#?A6_J6FV>KZ?-8:A
MMQ:S#;)$_1AUP:\?\5P/I/Q)\(R:K9PZ=X<L9S!ILMI\S%SC:LF3\HX[9[T
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M4\5^)O!L-_X5O=&6#5HF5[ABPD)9.!E!T_&@#Z*HHHH **** "BBB@ HHHH
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MRG_H24 >L4444 %%%% !1110 4444 %%%% !1110!A>,/^16OO\ <_K7CO\
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M3C_@24 >KT444 %%%% !1110 4444 %%%% !1110!A>,/^16OO\ <_K7CO\
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MFVBVN8SE<Y)X./>NCKAO 6KZL^JZ]X>UB\^WSZ5,@CO/+"&5&&1N X!%=S0
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MV(/TR* -W_A--"_Y_/\ QTU<T[Q!IVJSM#93^8ZKN(P1Q58>#M Q_P @U/\
MOIO\:YOP?#';^,]5@A0)'&&55]!NH Z7QA_R*U]_N?UKQSZ?A_G\J]B\8?\
M(K7W^Y_6O'?\_P __K_E0!>T3_D.67_79?Y__JKW&O#]%_Y#EE_UV7^?^?RK
MW"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;QQX:N_$6G6;Z;<QP
M:EIUTEY:M*I*%UZ!L=C74T4 <AX*\,ZGI5WJVL:[/;R:MJDJO*EL#Y42J,!5
MSR?QKKZ** "BBB@ HHHH **** "N1\3^&+W7O%GAN\#P?V;ID[7$T;D[F?&%
MP,8/Z5UU% !1110 4444 %%%% !1110!3U:UDO='O;6(J))H'C0MTR00,UQ5
MK\-VO/ &@Z!JFHW-K<:8RR^982#F13D?>4Y Z]*]!HH X'P'X$U'PKKFMWU[
MK%S>1WDV8E>4-O']^0;1\_;@XQ7?444 %%%% !1110 4444 >:>*?#OC;5?%
MRW]K#H=WIMJ!]DMK^27:K]Y"JX!;MSG':N@\1:-K7B/X<7NDW/V*/5[NU\MQ
M$S"$/QT)YQ^==710!2TBUDL=&LK24J9(($C;;TR !5VBB@ HHHH **** "FR
M%Q&QC +X^4$\9IU% 'E>D^'OB'8>(I=7N+;PU=W,\F'N9I)FECB)^XG90!Z#
MGOFJ.L?"SQ#>7NJ6-O=Z6=+U.]%W)?31L;R#D':A]L<<]Z]BHH ;&GEQJF<[
M0!D]Z*=10 4444 %%%% !1168GB'29==DT2.^B;4XX_,>W7)95]3VH TZ*Q-
M<\7^'_#;QIK&JV]F\OW$D)R1ZX'./>KXU6P;3/[2%W#]AV;_ #]WR;?7- %R
MBL/0_&/A[Q)+)%H^JP7<D8W,B9! ]<$#CWINK^-/#>@WT=EJFL6UM<R8*QN3
MGGIG'3\: -ZBJEUJEA9::VHW-W#%9JF\S,V%V^N>]4=#\5Z#XE$AT;4X+SRO
MOB,G(_ \T ;->3_&,9UWP%P3_P 3E/\ T)*]8KR?XQC.N^ N"?\ B<I_Z$E
M'K%%%% !1110 4444 %%%% !7!_$/_CXTL?[9_F*[RN#^(G_ !\:9_OG^8H
M[L?='TK@_"V?^$ZUGZO_ .A"N\'2N#\+?\CUK&.>7_\ 0A0!T'C#_D5K[_<_
MK7CO^?Y__7_.O8O&'_(K7W^Y_6O'?I^'^?RH OZ)_P ARR_Z[+_/_/YU[A7A
MVB?\ARR_Z[+_ #__ %5[C0 4444 %%%% !1110 4444 %%%% !1110 4444
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M +VT9_.GT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\G^,?\ R'O 7_897C_@25ZQ7D_Q
MC_Y#O@(9'_(93C'^TE 'K%%%% !1110 4444 %%%% !7!_$/_CXTP?[9_F*[
MRN#^(?\ Q\:7_OG^8H [L?='TK@_"W_(]:SWY?M_M"N\'W1]*X/PM_R/6L^Q
M?I_O4 =!XP_Y%:^_W/ZUX[_G^?\ ]?\ .O8_&'_(K7W^Y_6O'/I^'^?RH OZ
M)_R'++_KLO\ /_/YU[A7AVB?\ARR_P"NR_S_ /U5[C0 4444 %%%% !1110
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MY5>Z^#GBJ]V?:OB-=S;#E=]N3C_R)0![(.G-<'X6_P"1YU@X/5__ $(5S_\
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M<KTW0K"YTO0[.RO+UKZYAC"2W3C!E;^\>3_.@#0HHHH **** "BBB@ HHHH
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M%\32/I6H0G-C=-NCD5AV;M^0(]:[SX6:)K?AWP1;Z9KNP7$+L(T1MVU,\#-
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MP_#75?$T\^K_ !+\2*BPKN^Q03 ")>OS'HHZ\ 'ZU:^#-@FL^&_$NC79>_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .@A%_WP: /0OM$/_/:/_OH4?:(?^>T?_?0KSW_A6D__ $$(O^^#1_PK2?\
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MP]O]JO1Z ///B7_K]._W'_I7!_Y_S^E=Y\2_]?IW^X_]*X/_ #_G]* #_/\
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M)_*M#5O#US+JJZKI-TEO>!=KB095Q[U6/AW5M5NX7UV\@>VA.X009PQ]\@4
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MN'!*12J[!>N 1T_SZ5H>)M6@UK66O+99%C9 N)  >/H30!<L=#T&XL8)KCQ
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M6/R@0OEX[_6LC_A6^F?\_=W^:_X4 >945Z;_ ,*WTS_G[N_S7_"C_A6^F?\
M/W=_FO\ A0!YE17IO_"M],_Y^[O\U_PH_P"%;Z9_S]W?YK_A0!YE17IO_"M]
M,_Y^[O\ -?\ "C_A6^F?\_=W^:_X4 >945Z;_P *XTS_ )^KK\U_PH_X5QIG
M_/U=?FO^% 'F5'T_S_GBO3/^%<:9_P _5U^:_P"%+_PKC3/^?N[_ #7_  H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%5=2OX=+TZ>]GSY<*[F ZGV'O53P_K]KXBTXWEJDD:ARC)* &4CUP30!JT5A
MZGXEBT_5(]-BL;R]NF3S"ELH.U<XR<D5;TS6K75IKR*VWDVD@BE+# W8R0/I
M0!HT444 %%%% !1574;U=-TZXO6BDE6%"Y2,99L>E302^=!'+M*[U#!3U&?6
M@"2BBB@ HK-UG6H-%BMY)XW<3SI H3&06. >>U:7;F@ HHHH **** "BBB@
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MX:91O0KUZ#IBHM*37?$=A)K$>MR6:R,WV:W1 4"J2!NSU)Q6K?Z/<7'C*SU
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=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mrsn-20201231_g5.jpg
<TEXT>
begin 644 mrsn-20201231_g5.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /.0!QTQ
M],_Y_P#KC\3!QR/0GC\_Z_E^:CMQGZ^^.OUYS]#2#'!)R,<DCJ,<G\B?U_$
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MZXY^O_Z\_F??( N.>1WYX]?\_P OQ3!QR/0GC\_Z_E^8,<9 _'Z__M?3G\3
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M/Y_TY_$_@O)'3J"<'_/X?G^"<<8X],]AU_\ K?\  ?R7GCJ#[CIT_ED?]\T
M'?CGZ]^?_KG\C^"8XYZ$8S^?].?Q/X ]!\OI[= /\?P/N <?3TR.G?\ ^M_P
M'\@!>2.G4$X/^?P_/\#OQS]>_/\ ]<_D?P?##)<7$<,0)ED<*@')R> /Y?\
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MJQ%X_P"$MT<8Z8;IC'O[?G6#XI\#ZEX4BAN)GAN;.8XCN(#E2>N/QP!]/IR
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M"PCU"Z@G:5K-_P#EHA48'Z&J?A_QL=5UNWL])\%:5]MW?(P=@8R ,DG;\N*
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M+3)K5_LQ>U,EPY99 3N/WL'HO!XXKD?"OA]M9\7V>CSHVSSL7(&>$7[W(Z9
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M'K2]#@<8.!QGN0/Y _A[T8&>I(!^]^7/Y#^O<4F?EY'(&<=.W3]/\\8 #''
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MFE[\>O'?O_\ 6'Z=S2=N#T'?\,<_E_G& !<<E<#TQ^0_S_\ 7- ;H2>F.O\
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M_2K/B3QSJ/BBVACOK6Q1XF#B>&(K(Q XR2<>_P"'UQS/;UI>G/M^?^3C_)%
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M2#'']T?RX_Q_K]0 '('?I_3_ !/UW>_![_CG/^?7^?<TH)R-WX\^PSU]U/\
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MU';W'^!_(?BB_P /M@_3[O\ CBCD]>I'/N><_KG_ "3@)R">/7GO_D?U]\
M.@'\A['_  /Z_B?U'K_G_/ZAXSSCKU'7Z_U^I_!2=I/L2??J?\#^ON2 &<]S
M@_Y_EC_(H_STX_S_ )^A[>G&?T_I^E)^M !QCD?@?US^?Z_D<CG/(&?\_P"?
MYT=!R1ZDG\?\_P">%Z' XYX!_P _3\OQH 0XZ9P,X]NA'^/Y"@GKSC/KV_\
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M \W_ .%*>'.]WJ7_ '\3_P")^M'_  I3PY_S]ZCZG]XG_P 3[FO2** /-_\
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M]ZC_ -_$_P#B?<TG_"E/#?\ S]ZC_P!_$_\ B:])HH \V_X4IX;_ .?O4?\
MOXG_ ,31_P *4\.?\_>H_P#?Q/\ XGV%>DT4 >;_ /"E/#F<_:]2_&1/_B?:
MD_X4IX;[7>H\=/WB?_$UZ310!YM_PI3PY_S]ZE_W\3_XFC_A2GAO&/M>H_\
M?Q/_ (G_ #BO2:* /-_^%*^'/^?O4>N?]8G_ ,31_P *4\-C&+O4>.G[Q/\
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MW_V?>O2:* /-O^%*>&SUNM1[_P#+1/\ XGW/YTO_  I3PWG/VO4L_P#71/\
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MC[5J..F/,3_XFD/P1\-$DFZU D]?G3_XBO2J* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?CO_ )+KX#_W9/ZUZY7D?CO_ )+KX#_W9/ZT >N4444 %%%% !1110 4444
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M)_6@#URBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU\!_[LG]: /7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)?Q6#OIEM%<70(V1RR>6I]<G!_E7,:#XC\3ZOJ-Q#+HUA#;VER;:YD6\)8$
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M NYL=3CJ: ,[0O@_X+T%5,>EB[F'66\;S"?P^Z/P%=HMG:I;&W2WB6$C!C"
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M002PR/,8_P *C/'UKIM$\$>*/&>L^5XO\0K>:9H=X8O(C7_7NH!R>/?OD]:
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MB_* I88_+%;]O&\-ND<DS3.HP9&&"U9>I_\ (Q:)_P!=)?\ T6U;- !1110
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M8_\ "0:0WVRW*QR2[SY@^7]VPY].:Z"*6.>)9(G5XVZ,IR#0 ^BBB@ HHHH
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M?CO_ )+KX#_W9/ZUZY7D?CO_ )+KX#_W9/ZT >N4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M #>HZ_G70^#470?C)XC\/V.8]+DM4N8[9?N1/QG:.W>@#U:O(_'?_)=? ?\
MNR?UJ[K/QHL=%UN]TR3P_JT[VDS0M+%&"KD<9'M7$R^-[?QM\:?!MQ!IUY9"
MW+H5NEP6R&.1[4 ?0M%%% !1110 4444 %%%% !13))8X4WRR)&H_B9L"HTO
M;21PB74+,>BK("30!/7&^*OB1IG@^Z\G4[#4=G&V:-$*-GL,N"3^%;FO>)M&
M\,V+7>KW\-M$.@9OF8^@'4FO"?#$WA?XG_$+Q!?>*+QI+9!G3K6:9HE\K)!;
M@C! V\9_BH SM9U*^^-_Q'M=.T]9X=&MAGY^/+3^)V ) 8]!]*]?OOAM//\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G\9Q^(-,^)]KKNB>$WU9!I_P!FF<G*MER0%S]UAS^#
M5ZQ7G?C;P#X-\3:ZM_KNJO:W:PK&$6]2+Y06(.#SZ_E0!;\(^(O$6JZPT&J^
M#7T>W$187#'.3_=Z5W->+> ?#_AWPS\7K[3]&O9+U#IP>.03B01<X96P,$\
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M" 9 YZ; >"?K7A,GQ$\=:((]6U9=:32YB'LS*L8$O<*_R\!O;\,T >H_&/Q
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M#/!;A+FY^T29),FS;^F:L4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &?KNHG1] U#4EC$AM+=Y@A. VU2<9_"O.7T7P/\
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MW("R9]#V/3BNYN;2WO(Q'<Q+*@8, PXR.E<CK_@."[+7&ED03'DQ'[C?3TH
MLZS)K]E<:C?1W,8T]+?=$..&X[>N<_G6%)X@URQBTV\NM2B>WNB'98T&Y5XS
MGCT-5(?$5[I\$^BZY!-+ P*-AL2+GT)ZTVV_X12>Z@B6'47+.%"NXVG)[\=*
M /0SKNGKI*ZFT^+5L?/M)P3VQC-06GBK1KZZCMK:[+S2'"KY3C/XD5E>+DM+
M3P<UO:*HA5T 6/D#G/-<AI%XE[XMTV2*W$ 1D4K&OIU)XH ]=J)[J"-BKS(K
M#L3@T3,S0.(742%2%)YP>U>2W&R#7YH_$DSSLJ<F%N=V!CF@#TB?Q)I\&K0:
M<7+33=&7E1Z9KS;Q;(T?B'4$B=V65@)!@ $C''O6EX=U[1M)TQY)XA-=I,QB
M4+EE&/7M6-JLT^O:K]LBLFA%PX1=H)#-TZXZT >@>#IK:U\+0[YU4!WW%\+@
MYZ5C>+;KPW<PW$T-RK:@RX#1 L&QV/;\:AL_AY>R*HO+Y(TY^2/+8Y_*MA/!
M.DZ;;M.]M<:A(H_U>X9;Z#C^= 'FVG:A<PW]O+&KR-!*)0F"1D8XZ>V*Z>^U
M+Q%XBLVLETO%N^.%A('U#'I71:%:_8-0NC_8,\2W$XV.0N(TP/?L<UTUW%/)
M;E+698),C#E-P_*@#ROP[X)N-5:62:3R(HG,;;R2Q(Z@5Z%I7A;2]) :* 23
M=Y9?F;_ZWX4NG:5?V,[,^HK)&\C2.GDX))]\ULT 8FLV>K7P\BV6S%NLD<BF
M21@V5(;! 4CJ*T[/[7Y'^FB$39/^J8E<=NH%6** ,>Z\-:?>7#3S&Y+EMPQ<
M. I]0,\5I6MLEG;K#&7*KT+N6/YGFIJ* (KBV@NX3#<1++&>JN,@U4AT+2K>
M998=/MTD4Y5EC (K0HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BF
M&6,'!=0<XY-/[4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XI\3H-7U[QY<:
M/;:M=V<5GH37]M!!)L$TP=A@^O _3ZU[77EOQ*\6'2]=@M]*T"WU/6+"RDOG
MN)SA;6 Y5C[DXZ4 <]\*$L(?'$(MM9N=7^T:.EQODG+FUD)^>-ATZ]. :]SK
MRWX=WFE6?BBXTR'PY;:9=7MA#?QSP9(F1E!88_APQ/%>I4 %%%% !1110 45
M6OM0L],M6NK^Z@M8$^])-($4?B>*+'4+/4[5;FPNH;J!NDD+AU/XB@"S7D?C
MO_DNO@/_ '9/ZUZY7D?CO_DNO@/_ '9/ZT >N4444 %%%% !1110!DZ]H=IK
M-A(DT :94)B<<,K8X_R:\N_X177ERW]G397G('X_YQ7L]% '@TZ7MNYAN$EC
M(^\KDC^=2:;"+B[6-KM+/CB5VP,_6O:]0T^WU.T>VN4#(XQGN/H>U<XWP]T@
MH0KW"MV8,./TH PHO"&K7$2O;:S%(AZ%9F(JIJW@W6((Q<S2K=-N5"0Q9N>!
MU[5I3> -0LW,FF:@,CH,E&/XBLC4-4\3Z+,MM=WLR-MRN&!R/\^M '5Z-X!L
M+,++?_Z5-P=A^XI^G>M6X\+:9<2^8RS*=VX*DS*JGV .!7':=\0+VUMHX[NU
M^T]?WI;#-S]*O2?$I-P\O3SC'\3\Y_"@#MK.TCL;801%R@)(+N6//N:GKD[?
MX@:3)"AF$T<A7++L) /IGO5H>-]"*D_:\8Z HP)_2@#HJ*YJV\<Z+<SK%YKQ
M[NCR+M7\ZU&U[25B,IU&VV 9)\T4 :-%9MGK^EZA,8K6\CD<+N(![<?XUH@@
MC(.10 M%037EK;MMGN88F/0/(%/ZU*DB21B1'5D(R&4Y!_&@!U%9EWXATFPG
M,%S>Q1R 9*DU=BNH)HEECE0HPR#N[4 344UW2-"\C*JJ,EF. *@@U*QNI!';
MWMO*Y&0L<JL<?0&@"S139)$B0O(ZHHZLQP!4<-Y:W+%8+F&5@,D(X8C\J )J
M*0D*,L0 .I-9UYK^EZ?,(;J\BCD(S@GM_G^5 &E17&ZYX[M+:W7^RY4GF)YR
MIV@5F6?Q'G17%W9B1L_+Y9QQ_G% 'HM%>?-\2),?+IR[O=^*KW7Q"OY;618K
M%(69<+(&)VGU_P ^U 'I-0W=U#96LES.VV*,98UY5IWBCQ))<F.WFENI&7&P
MIOQ[^WU]ZLZI!XNO=/FDOTE%LHW,F5_EUH ]!T[7-/U4N+.??L^\2"/7U^E7
MFFB4$F11@9/->0Z!X>U'59IEMY&M=J_,S$C.>W'^>*WQ\.+EV)GU)&Z_PD_S
MH U]:\91:7?BVB$$PXW'<>,_0&K(\:Z*L$;R78WL@+*BDX..E<7JG@NYL;M8
MK=I;A" 2R0GCUZ'_ #FNHTWP+I0LH)+E99)B@9\L5&2.>* .;U?Q/8W>MQW,
M=B9(XV)<F1E,HQ@?3!Y_ 5Z;;R"6UBD P'0-CTR*XK4O"5H-5A^S:/.UJ#^]
M*2@!AMP,#/'.*[>)!'"D:C 50 /3% #Z*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@""\NX+"SFN[F01P0H9)'/15')->)^/-4\$^+;I=1TWQM'I6HFV:TF<(72>$
M\[6'&.IY_P#K5[/JUE!J.CWEE=,4M[B%XI&!P0K @\U\X:SX2\)>$)I)-+\4
M:3?2 $?9;VV%PS'^Z"AX- '>_"FV\/PZS+(GBL:]K1M5A3";5@@3 "J#GVYK
MUZO%_A!JEU>ZS)'-X'M-(C6 E;^"W:/<<_=RW7->T4 %%%% !1110!Y=\18E
MU?XB>"]"NQYFG2R2SRP'[LK*!C<.X&/UJ+P*J:1\8/%VA6*"+3?*CN5@1<*C
MG;G'H.:Z3QQX1O==NM)U?1[F&#5]*E,D/GJ3'*IQE6Q].ON:;X+\(7VDZOJW
MB'7)X)M9U1AY@M\^7$@Z(N>3T% &3K'QGTK1M9O-,FT+7)I+69HFDAMU9&(.
M,J=W2O-?$_Q.T[5?B=X7UV+2=5CATX,)()80)),Y^X-W/6OI2O)/'1/_  O3
MP'U^[)_6@"3_ (7UHQZ>'/$1_P"W5?\ XJC_ (7UHW_0N>(O_ 5?_BJ]7HH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6LLZSR6T+S)]V1HP67Z'K0!S/PST:YT'X>:187B&.Y6+?(AZJ6)./UKK:**
M/*O$>I_#ZW\9:M;^)=&BAU!K4$7EXA=+@8X$><@-SVP:\\N-!UF;X$V\]S;7
M+6EKJQN8864EUM3@9P.<9+'\<U](W%G:W>W[3;0S;3E?,C#8/MFIMJA-@4;<
M8QCC% 'BGADZ3>?&#2;CP7%$NEQZ61J;6Z%8]Y!V@]M^=OY&O;*@M[.UM PM
MK:&$,<D1H%S^53T >??&C2[K5?AM?1VD3RO"Z3,B#)*J>3^ K@-".DW_ ,0O
M!,O@U%W0V/\ Q-3 I4+\O(D./O9SUKZ J"WL[6T+FVMH82YRYCC"[OKCK0!X
M]\0O$WA3Q%INL:=K%M=6>N:5N6PCE9@\DA^ZT84X<9 ZYXKTGP1-JL_@K29=
M;3;J+6ZF88 /MD#H<8K7EL;2>9)IK6"25/NN\8++]":L4 %>5^-T'B'XM^$_
M#LI#65LK:A.F?O,N=H(^H'7U->J5$;:W:X6X:"(SJ-JRE!N ] >M 'G'QACF
MMK3P[K*0&2VTS4XYKG:N2B8QNQZ#Z5GZ)=6_BWXY2ZYI+&YTJQTT0F\0?(TA
M.0H)Z]3^5>MNBR(4=0RD8((R#4=O:V]I'Y=M!%"F<[8T"C/T% $M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD.O6'@I=*U_3[FTGLI"D7GA0&C/(VX].>M>A44 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7QGH@\1>$-2TS'[R6(F(X^[(OS*?P(%</?>*YM9^$FF6T#,FKZNZZ5M!^9)
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M75#=".[2W9_,:S28B(GZ>GM7I%K:P65K%:VT2Q00H$CC08"J.@%2T4 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV]R'8N,863CY>.21TY]*T='\;:I'JNJ:;XITN'3YK*S^W"2";S$>+G//J,4
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M;:U9PBR;6?+'H %!)JEX?\=>&_%-W):Z-J7VJ:--[KY$B8'KEE H Z$*H)(
MR>IQ2T44 %(0",$ CWI:* $  & ,"@J&&& (]Q574=4LM)MEN+Z<0Q-(L2L0
M3EF.%&!SDFHM,US3=9DO8]/N1.UE.;:X 1ALD'5>0,_AD4 : &!@4444 %%9
M6O\ B32/#%@M]K-X+6W9Q&',;/ECT&%!-5[WQEX>T[0K?6KS4XH-/N5#0RNK
M R C/"XW$^V,T ;M%9VBZ[I?B'3UOM)O8[NV8XWIG@^A!Y!^M5?$/BW0_"L<
M#ZU?"U6=BL?[IWW$?[H- &W28&<X&?6N2TOXG^#M:U2WTW3]8\^\N"1%$+:9
M=V 3U* =C2ZK\3O!VB:I<:9J&LB&\MR%EC%O*^TD ]54CH1WH ZVBJNG:A:Z
MMIUOJ%E+YMK<()(GVE=RGD'! (_&K5  1D8-(  , 8%+10 445BZEXMT/1YY
M8;^_6&2+R_,7RW;;YA(3. >I!_*@#:HI 0R@CH1D4M !1110 FU0<A1GUQ2T
M4C,J(S,0%49)/84 +16;HFOZ7XCLY+O2+Q;JWCE:%G52 '7J.0,_7I4EKK.G
MWVI7NG6UP'N[$J+F/:1Y98;AR1@Y![4 7J*QO$/BK1/"EK'<ZW?"TAE;8C&-
MWR<9Z*":TK.[@O[*&[M7\R"9 \;X(W*>AP>: )Z*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CJ&J1::
M]J)E8BXE$2D=B0<9_*K4[^7;R/\ W5)'X4KPQRLC21JQ0Y7<,X-*Z[XV3.-P
M(H \Q3Q;X@DLY[M)X/+A=5(*<\_C7:WWB"+2-&M;RZ1Y#+@80<Y(S68?A]IQ
M#@7=V%8Y*AAC/TQ]/RKI38V[V:6LL2RQ(  '&>E $L$RW%O',GW9%##/O4E(
M    , = *6@"MJ%A;:KIUQ87D0EMKA#'(A[@UX;HGVC6/%"?#6^UF*XT729W
MD$@;Y[V-<%8">F%SS]*]8\9R:[_89M/#UMOOKMQ")R0%MT/WI#SV'3'<US^J
M_#2WM_!UG:Z&QCUG2F-S:7C??DF/+[CWW\_I0!1^)VC1ZQXA\,Z2%"K-%>)&
M /N,(&VD?0@5+?\ B"77OAEI-G ^W4=:>/3Y K?,ASB?\E5_SK0DL];UGQ%X
M,UBZTM[9[43&_C9U(A8QE?7D$],>O:LSPYX,U73_ (DW\]Q$!H5K)-=:=TXE
MFQO]\CG\Z +/P@L;:+PCJ%J(8VABU:X1%*@@ ;15CPI;0-X_\9*T,143PX!0
M8_U8J]\.M'O]$T74(-0MS!)+J=Q.BD@Y1B,'BI/#NDWUEXS\47UQ 4M[R6)H
M)"1\X5 #].: .B:_L('\AKNVC=>/+,B@CVQ7 ?%?PT-2\.ZEJEWJ%R]O:VVZ
MWLD;;&),_?;NQP>!T'I73WW@/PMJ>JMJE[HEK/?,P=IW!W$C&#U]A2^.-.NM
M4\$ZI86,1EN)H"D<8.,GTH R?&<&H7GPIFL],LY;NZNK2*%8XCAL,!D_3%8\
M&K^(_"-[I"^(])T?^R+N6.TBDL%;S+5VP$WEN&[9( KJ]:TS6;KP;#:Z/>M8
MZI#'$T;9X9E RC>QZ&N9N;7Q7XXO=+L]7T1=%TVQN8[J[<W"R-<O&<JB =%)
M&3F@#+TK6-"\,?$+Q;_PEDD5O=W<R2VEQ<IE9(-N J'GOGBG>!M(T[QAI.L6
M%Q'<QZ38^(&GMK4@*I3:KB-U(/R$DMCWK=UR7Q78Z_<G_A'+7Q%ISX?3V)CC
M>S;&"&W EAGG(YK-GT;Q=X;\ SQ:3:_:M?U6]>YOY+>0+Y6_[Q0MW"A5'OS0
M!:UI;+5_B=X?L=%@B-UI#-<7]Q"H AB*D+&2.['^$UW.LZE'HVBWNI2C*6T+
M2D>N!TKB/"5WJ^D-#ID/@&\LK>67,]Y+?1R.Q/61SC+&NL\7:7+K7A'5=-A_
MUMQ;.B?[V./UH \LM['5+K5=-MH/LK^+-8MSJ%]J5U'YRV%N?NI&AXSR /H>
MO431^'=6USQM<>%M?N;6ZBT^P-Q#?06JPR,[D"-SCE64Y^Z0#WJ72-0U2?5K
M#Q/H.FC49DT]=,U336F$4UM,AX//;.?J.:5+;Q]8ZYXAO+FQL89=4CB_XF;7
M&(;&()@J!]XE<GG@$@GO0!W?@'5[C6_!ME=79W7*[H97QC>R,5+?CC-8.EQP
MZO\ &77Y;N(2MIMG!#;^8,A VYF('J<CGVKI/!?]ECPG8QZ-*\UA&FR.=T*^
M:0>6Y SDY.>]86N:?KV@^-7\2Z'IHU6"\M5M[RS$HC<,A)5U8\=\$4 0^#$7
M3?B3XTT>V18[)'M[M(U^ZKR1_-@=NF:?XU6/4/'G@_2+E/,M'FEN7B/W7*+\
MNX=\$YY]*D\,:5K>DV^O^)]2T])M<U)_-6Q@D *HBXCBWGOQUZ<U)XJTS6M5
ML]"U_3+%$UC39?/:PFD'SJRD/'NZ9YX/K0!GZ_:0:=\7O#+6D:P'5K*[M;DQ
M?*2J*K*?J">#1XETCP]X0^'<N@Q6PNY[I&@M8I KSW,S9PQ( R03G/M3["Q\
M1:[XO7Q3K.D"PBTRTDBT^P,JR2/*^-S%N@&% _&L+1)?%MKJDVM:QX%O-1UB
M1FV3-?1A+=">$B7!VC&,GJ: +/B/0/$QL/ .E6>GI?SZ=LDN9IF/D++'%M!<
M]<;CGU.,=ZWO#6N:Q:^*6\-^);#38K^6W-S;7.G*5CEC4X8$-R",CO4NM/XN
M==&U[2;1E>)3]NT228#S PZ!^FY3^']8]!T[7=:\8#Q/KNGIID=M:M:V=EYP
MD<;B"[N1QV&,4 2?%#6]4T#PK'>:1-Y5V;R",< [@S@%>0>#],USM_=^/] \
M3Z7ICZ]8WSZ[O1!):[$LF4;B5 .7 &<9(SQTKJ/B-I%_K6@6EOIT!FFCU"WF
M900,*K@D\^@I/$VCWU]XZ\(W]O;M):V,L[7#@C"!HR!W]?2@#G+3Q3K?@_6?
M$&E>(M376(K#2QJ4-UY(A8_-MV$+D<G_ ":S==O/B-I?@>3Q6WB"U#31+(^G
MK: "V1L8*.226&1G(QUK;\1^%Y-2\9^(;O42MKHMUX>^QF\=P%1_,W<YZ <'
MM7+^*]1\7-\*Y=*O=+M([:WAC2358[H/'<Q@@+Y2CG<W'7CK0!W&JRRZUXA\
M(Z42715_M.[..#L4;,_5R#T[5PV@>*Y+#Q!XE\-Z2T?]O:KKTZV[2_<@4#)D
M;UP <#N17H_AS1[N'Q)J&IWD155M8+.U8G[R*H+'';+?RKE++X?WEW9>+3<6
MHM-1FU=[[2[K@L&'*-GK@\@@GN: -76;GQ)-K.F^#M&UKR;I;0W-_JLT"R2
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MFN:#I.N)IMC;00R^>UL)6C)S\J@D<GN23P.*[/PEH7_"->%['2FE\V2%,RR
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MY5'8<'N?2L%;_P ?:QX9N_&5AK5I;6IAEFM=+-KN5H1G#%R<AR!D=LXKH_[
MNM$\8M<Z?:YT35[<IJ,<9"B"4+@2@>A'!Q]:Y*&X\4Z-\/M0T&PL;"\TN&UG
M6UUM+L&$6^&/S*.=P7(ZXSB@#T/P)J-WJW@G2K^^F,UU/ KR2$ ;CCVKDIKO
MQ?K_ ,0/$6A:5KB:;8V<<$BSM;B5D++]U1P.<'))^E=/\.8C#\.M!1NOV-#T
MQU&:AT'2+^S\?^*-1G@*VMXMN+>3(^;:I!_4^U '%:=JGC[Q!X8U'4%U^SL&
MT1YH7,=KO-Z\6=Q;) 0''85OZOXNGN_A)8ZF62WU#6HHK>$*V )9>."?0;F_
M"I/"_A_5+#P=XILKFU:.YO+R^D@0L/G63.P]>^:QM'\#7VK0^$]*\1Z;_P 2
M?2=++302,"LETV%"D \[5R?J: +/A8V/A+XAG0+2X@>QU2PCD@\MU/[^)0CY
MQW8 '\#5*&P\1ZG\4/&-IHFKQZ3"'MWFNC;^<Y/E+A5!.,=<D^U:'BOX9Z?8
M6-IJO@[18+?6+"ZCG00_*94'#)R<<@TQ(_%^@^.?$.MV7AX:A8:AY&(1.L<F
MY8U&X9R" <@@X]: (;C7K[6/AQXRTO6EADU31DDMIIHUPDORY5P.Q(ZUW/@O
M_D2=%_Z\XO\ T$5Q,_A[4-)^&_C/5-8,8U75XY;FXCB.4B 7"J#WP.IKMO!?
M_(DZ+QC_ $.+_P!!% &[1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% '+:YX T/7=2_M-XY[34MNTWEE,T,I'N5Z
M_C5!/A;HTLB-JM]J^L1H0PAU&]>6/(_V>A_&NXHH ;'&D,2Q1(J1H JJHP !
MV IU%% !1110 4444 %%%% !1110!#=VL%]:36MS&)()D*2(>A!ZUQEG\*M
MLYH 9]2N+&W??#I]Q=L]O&1R,(>.*[FB@ HHHH YSQ'X,TWQ+<V]Y--=VE];
M*5BN[*<Q2JIZC([5/X<\)Z9X8CN/L2RR7%RV^XNKB0R32D=-S'DXK<HH Q/$
M_ABT\56$-I=SW, AF6>.2VDV.KKT(-:5A:"PT^"T$TTXA0)YL[[W?'=CW-6:
M* "BBB@ HHHH **** "N?\2^#M,\4-:S79N(+RT)-O=VLICECSUPP]:Z"B@#
M!\.>$=-\,FXEM3<7%Y<D>?>7<IEFDQT!8\X%;U%% "$ @@C(/!%<*WPG\/\
MF2(EQJ<=A+(9)-.2\<6[L3DY3/K7=T4 1P016UO'!#&L<4:A411@ #H *DHH
MH **** "BBB@##\4>&+?Q7IHL+N]OK:#)WBTF,9D!&-K>H]JTM-L(=*TRVL+
H?=Y-O&L:;NN ,"K5% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mrsn-20201231_g6.jpg
<TEXT>
begin 644 mrsn-20201231_g6.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X4 D17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(Q.C R.C$X(#(Q.C(Y.C P   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,T,0  DI(  @    ,T,0  H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,3HP,CHQ." R,3HR-CHU-@ R,#(Q.C R.C$X(#(Q.C(V.C4V      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  +G<         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@!  #N P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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M]/7V]_CY^O_:  P# 0 "$0,1 #\ ]HU?7X=+:.".%KR]E8*EK%+&KG.>3O8
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M_P#(H:Q_UY2_^@&K6B_\@+3_ /KVC_\ 010!>HH ** "B@ HH ** "B@ HH
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M_P#Z]H__ $$4 7J* "B@ J&[_P"/.?\ ZYM_*@!\/^HC_P!T?RI] !10 44
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MG'CBTU[6O&^@6>B:HUG%9G[1=@.0IR?E4X'4A9 .O&?Q /1AG SU[TM !10
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MC\/^&5T^^^WG5=0NI(T>T1)S'M$:OP,*B],>O<^M=-0 44 %% !10 44 %%
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MU8=:O:1&([$*-2?4?F/[]V4GZ?* .* +]% &/XK_ .10UC_KRE_] -6M%_Y
M6G_]>T?_ *"* +U>8_$6ZTWQ#X<O&U*=8O#EE("\P?:;J89 5" > 3V')XZ
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M0!JZ)XF&M7TL":?=PQ*K-'<21,$?:VTC<0!GN ">,^E;] !10 44 %% !10
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MP\2ZN\>HS7$P+QPFX2)"K"/;*5,;84%21T!)SR<BO0 <J#ZB@!:* "B@ HH
M*@ELK2:3S);:&1_[S1@G\Z )\#&.U1^1"0H,2?(,+\H^4>WY"@!1%&N=L:#.
M<X4=^33@     !P * &&"%MFZ)#L.5RH^4^WI2?9X/WG[F/]Y]_Y1\WU]: &
MSV=O<VX@EC!C5E90.-I4@J1CI@@4J6EM&SLEO$K/PQ" %OKZT 2E5*;2H*XQ
MC'%)L7=NVC)&,X[4 -DMX98Q')%&\8Z*R@@?A33:V[",&"(B/_5Y0?+]/2@
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M+:[D\'26K18O&L#'Y:MGY]F,9^M<T+#4DB6?3=+NM/V6<<-P$\M))CYD98H
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MU*,F>-DC4VY.PF1'&[Y\, 4Q@!>#0!;U7PN=5O[.[DN(=T40BE1H6*N P;*
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MT]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M/#<&6\OIVFFDQ<R@;G8DG@ <GM7TE7S!_P $T?\ DRCX;?\ 7"Y_]*I:^GZ
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M8;4EGV%2[;RV!M YS0!]'4444 %%%% !1110 5X_^V'_ ,FH_&'_ +%+5/\
MTEDKV"O'_P!L/_DU'XP_]BEJG_I+)0!P'_!-'_DRCX;?]<+G_P!*I:^GZ^8/
M^":/_)E'PV_ZX7/_ *52U]/T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%?%7[?_[$OB_]J37/"VO>$O$6F:=<Z';302Z7JCSPQW09P^1+%DJ>
M,8QWSD4 ?:'V>+=N\M-_][:,U+7X;>(O#/PP_9_UFVT3XV?#'7HKOHUYX/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M44 %%%% !44DR01O)(RI&H+,S'  '4FI:^5/V^?B9K%AX'T/X2^"Y?\ BO\
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MRCKTK\\O ]Q\2OA]X5T[P[HO[;WPKBTC3H5M[2&>>TG,42C"H'<EB , 9)X
MK]#/@S=:A??"OPQ/J_BC3_&NI262-/X@TG9]EOVYS+'L^7:?;B@#MJ**P/#?
MC?P[XSDU%- UW3=:DTRY:SOET^[CG-K.OWHI-I.QQW4X- &_17(ZA\6/!.E>
M+H/"UYXPT&S\3SX\K1I]3A2\?(R,0EMYR.G%:_B;Q5HO@O2)M5\0:Q8Z'I<(
M_>WNI7*6\*?5W( _.@#7HK&\+^+M#\;Z/%JWAW6=/U[2YLB.]TVZ2XA?'7#H
M2#^=9>G_ !8\%:MXLN/"UEXOT&\\309\W18-2A>\CQUW0AMXQWXXH ZVO'_V
MP_\ DU'XP_\ 8I:I_P"DLE>P5X_^V'_R:C\8?^Q2U3_TEDH X#_@FC_R91\-
MO^N%S_Z52U]/U\P?\$T?^3*/AM_UPN?_ $JEKZ?H **** "BBB@ HHHH ***
M* "BBB@ KS2SU*UT7XQ_$'4+Z>.UL[3PYI$\]Q*<+'&LNI,S,>P !/X5T'Q.
M^(&G_"GX>^)/&6K075QIF@V$VHW,5FJM,\<:%F"!F4%L#C) ]Z_)O]I__@I-
MX5^,^F^*-!\&6/B/0[3Q=!I.DZG?7UM LT-E#-=/<B-4F8,SB>-0"0"-X)&0
M: /K_P#8QTZZ^/OQ8\=?M*:W;R+9:K(V@^#+>9<&WTN%BKS $9!E=>?<2=C7
MVA7-?#OPMI'@?P+X?T#P];?8]$TVQAMK* @96)4 7..^.2>Y)KI: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZOJMGH.E7FI:A<1VEA9PO<
MW%Q*<)%&BEF8GL  3^%7J^1?^"@?C#4]?\/^$_@9X6N#%XJ^)NH+82R1C<UK
MID9#W4Q'IM&WW&^@"A^PGI-Y\7O%_P 0_P!H_7;>2.X\97;:;X<AN!AK71[=
MMB8&./,903ZF//?)](^-GC+6U\9?#J"'P)KMS%8^+0\=S'+9A+H"PO5_=YG!
M&0V[Y@O /? KV'P-X-TSX>>#]%\,:);K:Z1I%I%96L*C[L<:A1GWXR3W)-<Y
M\5_^1@^&/_8T#_TWWM '6^'=6NM9TF&\N]*NM%GD+!K*]:-I4P2!DQLR\XSP
M3UK6HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *YGXC7&A6GP]\43^*8_.\,Q:7=/JL91G#6@A8S#:OS'*;N!S
MZ5TU> ?M*1_M"S:II,7P9C\&2Z0]M(NJ)XJ60LTA8!0@7@KMSG- 'P1\7O'G
M[ NL?#/Q%:>%/#%S_P )/+92II;:7I]]#.MT4(B8-(0F V,[LC&>#7Z0_LMV
MFH6/[.?PVAU;1[?P_J:Z#:?:--M8! D+F)21Y8 "$]2H P21VKY6M[/]LBTU
MM+&"U^!L.KH/,2VCC9;A1C.X*#N''>OM7X9_\)7_ ,(#H7_"=?V?_P )=]F7
M^U/[*S]E\_\ B\O/.WZT <%^TUX1^*OCSPEI7A_X6>);3P=<7U^(M8UR9=T]
MM8[&WFW&/]:6V@8QW^9>M?*7_!*.$^"?AQ\=H4GEOCI'B>X03S\O-Y4)&YO<
M[<GZU^B=?(_["/[/?C#X,Z7\7;7QOIL=C'XD\37%_9K'<QS>;;."-QV$[2<]
M#S0!\'>&?@?X=^+7_!/[XJ?'77(IKOXH-KTVHQZ]-<2M+"$G@W1K\V"&#R<D
M$@D>@KV+XG:Q+^T]\1?V+_!GC>2;4/#WB'1!K6KV7F,JWMPL!RSLI!.[R2#Z
M"1L8S5*^_9/_ &E/!_PP\7_LX^&?#6CZE\-O$&MB\M_&;ZC'$;6U,L<A1XM_
MF?\ +)-P"MU8#(((]P_:&_9/\=^$Y/@3XU^#=I:^(O$?PKM5TW^Q;Z98!J-M
MY:HS*S$*&/SY!8<29'*X(!XSX%O&_95^,/[8_A/P*\VE>'-'\+?V[IEBLC.M
MG<>2FUD+$D%3.<<]%7.<"O*/%'P(\._"G]@/X5?'CP^)[+XG1:Y;ZI/KJ3R>
M;/YD\N(VRV %VIR!D[3G.XU]<_ 7]D_Q_P"/-2^._COXQV5KX6\1?$[3VT:+
M1;&=;D:?;>7L#,RL02-L6 &YV$G&[ \6L_V5?VF/&_P[\#_L[^*O#ND:7\-O
M#>M"ZN?&4&H12?;+1)'=8UB#;^!(VW**20FXC!) /L;]H+]MWP1^S#9^#V\:
M:?KMW-XDLWN;?^Q;2.<)L$>\/ND3',JXQGH:^8/C_P#\%4OA%\2O@;X^\)Z5
MI'C"+4]<T&]TZUDN],A2%998612["8D+EAD@'Z5^D5K:Q6=K#;Q+MBA18T7T
M4# %>3?MA*!^RC\8< ?\BEJG_I+)0!P/_!-'_DRCX;?]<+G_ -*I:^GZ^8/^
M":/_ "91\-O^N%S_ .E4M?3] !1110 4444 %%%% !1110 4444 >5?M2>%=
M2\;?LX?$O0-'A6ZU34O#][;6T+RI&KR-"P +N0JC/<D 5^#GP:_8]^+GQPM9
M-2\%^$6UBPM71I+C[9;PKM,DB!E\R1=PW0RC*Y'RGVK]FO\ @H+\3=2\&? A
M_"OAMF;QI\0+V+PKH\41(DW7!VRN-O/$989'0NM=5^SW\--.^#?B"\\$Z6H^
MQZ'X2T&S$@'^M=9=1WR'W9RS'W:@#V;1K=[71[&"1=LD<$:,N<X(4 BKU%%
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MXITWQ+X4AN'U_P &7^G7J7,9M93OGM-RDX:-FSMZ\2'N"?ON@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@_CMJ
M^O\ A[X+^.]4\*Q--XDL]$O)]/5%W-YZPL4*K_$P(R!W( KO*^=OVG/%WQ_\
M!Z[H6M?"3PEH_CKPW%;R+K.AWDPBO'?<"KPMN7^'(_BY/W30!^?EGX"_9EN/
MV3F^)5U\4)U^.ATHZJVHGQ$_]KKJ^-PB%MNR1YN%SMSM^;?_ !5^HW[.VN>)
M/%'P)^'^K^+XC#XEOM$M+B_5AAC*T2DLP[,W#$=B2*^'_!7QS_94OOB2EY\5
M/@K%\'OB,9A-)_PDVBD6K3Y!\Q6"[,[LG>\:^N:_130]=TWQ+H]IJNCWUOJ>
MEW<8EM[RSE66&5#T964D$?2@#2HHHH **** "BBB@ KQ_P#;#_Y-1^,/_8I:
MI_Z2R5[!7C_[8?\ R:C\8?\ L4M4_P#262@#@/\ @FC_ ,F4?#;_ *X7/_I5
M+7T_7S!_P31_Y,H^&W_7"Y_]*I:^GZ "BBB@ HHHH **** "BBB@ HHKS7]H
MWXP6GP%^"/B_QU=%6.DV3/;1/TEN6PD$?_ I&0?C0!\\:+(/VC/^"@&K:S(3
M-X*^#%B;"UD?/DR:S<K^^<<X)C0%3W!C4]P:^A?#^K67_"\O&K?;+?:="T8
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M7?Z=X_\ &&MZG!<:C-M,>E:9/=RW$MR2C%@PBF"Y( !#[22%S^CGP7^$.@?
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M-Z_*,$@\GJ<#TKV>@#SOX"_\DW@_["6I_P#I?/7HE>=_ 7_DF\'_ &$M3_\
M2^>O1* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *Q/&&GZIJWA'6['0]1&D:U=64\-CJ!C#BUN&C8
M1RE3PVUBK8[XK;KP[XL_%RR;XO>'?@9<V%]%)X^T/4V&N6-V(GL5CA<,5&TG
M?C.&R,'!P: /F?XE_!G]L;X>_#_Q!XFA_:0L-4_L>QFOI+5M'M[<R)&A=E#M
M$0#@'&<#WKZ\_9L\33^-/@'X"U^YUZ;Q-=:EI%O=2ZM<VZ6\L[NH9B\:?*K
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*^XOC)^SY\?(;[XBZ/8V.J>++?Q?J3ZAKTM]X,.^2XC9C#]GG43G:H9MI1U
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M:0Y_T2_NXGA?C&&"Q G\^U=S110 4444 %%%% !1110 4444 %%%% !1110
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MYBLED8'&FI'@[T\W!<MG'S; .#P<Y'%?\.6?C)_T,_@[_P "KG_XQ7[2*P8
MCD&G4 ?#/_!/']B?XE?LD^(?%,_B?Q1H]]H&L6T:?V7I9EDS<(V5F+.J[2%+
MK@ YW#IBON:BB@ HHHH **** "BBB@#Q;]KWX]6?[-_P#\3^,9FB?44A-II=
MM+@B>\D!6)<'J <NW^RC5_/E\,_BEK?PK^)^B>.]&GV:WI5^M\A^ZLAW9=&
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M'_!)OXZ_$3Q5-=ZC\6K'QE9VN8-/OO%&H7DMV(,D@$%) G))VJQ&353X<_\
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M_$;3;*>[NOVO/B-;VMO&TLLTEQ<!411EF)^U\  $U^0GQA\;:IXV\=:A+?\
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M@7X,> _A?>7-WX0\':)X9N;J,13RZ38QV[2H#D*Q0#(!YYKXYUS]G&]\??\
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M07Q_^,'A[4+@_8+^\.M>&XG(!2UC"V[1 '!R46"3&.ID)Q0!]^4444 %<O\
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M):?XAN_"VK>='>6&J6LCKY4\><!PA!9&#,I&>^>H%?.WP_\ V1?C=\1_B_\
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M+\2OC)X5^$4WARW\27[6MSXBU*+2=+MXX6D>XN'( 48& !G))( % '=4444
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M)_&L/QZL_P"S_#-Q\9_ &C^&[6P@\&Z+XKDT_4=(*!4-PT$3^8[-C(<JP.X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !117!^ _C)X:^(OB[QGX:TF6Y76O"-XEEJEK=0&)D9U+(R9^\C 9
M##@T =Y17"_$_P",'AOX2CPZ/$$\XG\0:M#HNFVMI"9II[F7.T!!SM !+-T
MZUW5 !17$?%+XN>'?@]I.D:CXDFG@M=4U:VT6V:WA,I-S<,5C! Z#(.3VKMZ
M "BN1\*_$K2/&'BKQ7X?T]+U;_PS<0VU\UQ:O'$7DC\Q?*<C$@V]2O0\5UU
M!17&^ ?BKH'Q,U#Q79Z'--+/X8U>31-1\Z$QA+E$1V52?O##KR*[*@ HHHH
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MZPVGZ7\3/ASI>I6_B3P1X%U_^SM!\0V\$<?VR.1#)+&[1@+*\;'!EZMOR>U
M'&_&3Q9^T_\ "_Q%X-\*Z?\ %/PEXG\9^++W[-IVBV_A?RBL*#,]U*YD;9%$
MO).#GH >:^Y]-CNH=/M8[V9+B\6)1/-&NU7D &Y@.P)R<5\M?LQ1-\8/VBOC
M-\7[_;/!INI-X'\.9(9;>TM<&Y9.X,LS!B?;'(KOOB?:_M%R>,[MOA]>?#>'
MPILC^SKXB2^-Z&VCS-_E#9C=G&.V,T 4/#_Q4\2ZA^V]XN^'DUZK^$]/\'6F
MK6]GY*!DN7N-C/OQN.5XP3BJO[9'Q>\4?".'X1-X8ODLCX@\?:7H6H;X4D\V
MTF+^8@W [2=H^8<BO%_$GP0\/_'#_@H-XJTKQI]N8VG@#3KD_P!C:E<6/[[[
M05;YHG5F7DX#>W>N8_:R_9;\"?!#6O@1K/A@:V+ZX^)FBVDAU+7+N^C\LR,Q
MPDTC*#E!\P&>H[T ?8W[0/QL3X+^#8Y['3VU[QAK$W]G^'O#\;8DU"\8$A?:
M-!EW?HJJ>>E9?['?Q1U_XS_LX^#?&/B>2"37=4AF>Z:UB$<>Y9Y$&U0>!A17
M@VN1_'71_P!HCQKX]OO@DOCF*W2;2/"ET/%5K9PZ;IO.^1(65SYTY 9W.#@!
M  !ST'_!+_Q%XGU;]F/P]I^K^$O[%T2PB<:9K']HQS_VF&N)C(?*50T6QOE^
M8G/44 =?^W9\4/&7PM^%_A6Y\#:U'H&LZQXKT[1&OI+6.Y$<4YD5CL<8."%/
M;IU%8'BOP%^U'\./#]]XBT;XP:'\0[G34-TWAW5?"L5@M[&GS-&LT<I*.P!
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MQ)(0Z@CA64C)YR ,DXK$^#/[6'PO^/FM7^B>#?$C7VLV,0N)M/O+*>SN/))
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MGPRF\*V;>!GR?['R_EJQD\W<K;MP;>=P(.0:E\%? /P'\/;SP]=Z'X?6VO\
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M\):KX:L)_#-C-#/:Z3#'Y%M"\3;H]J1E0 IYV]/:NV QP!@4M% 'F-]^S?\
M#75-)\8:9=>$[.73O%UXFH:Y:EY!'?7"N'65E#8#;@#E<9P,YKTF&%((DCC7
M:B*%51V Z"I:* .-^'_PE\(?"IM:_P"$1T&WT)=:O6U"_CM-P2:X;[TFTDA2
M?]D <5/\1/AEX3^+7AR;0/&7A^P\1:1(0QM=0A$BJPZ,IZJPR?F4@C/6NKHH
M X/X5_ _P'\$=*N-.\"^%=/\-6MRXDG6RBP\S#H7<DLV,G&2<9.*XOX*_#/6
MH_B?\0OBCXOM?L6O>(IX],TS3VD$AL-(M25@0D$@/*Y>9@#P74=00/<** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCJFJ6>A
MZ;=ZA?W4-E86L33W%S.X2.*-02SLQX  !))]*\Y^,G[3GPR_9_O-,M?B!XKM
M_#EQJ4;RVB3032&54(#$>6C8P6'7UKY0_:0_:/\ #?[:3>%/@/\ !KQ1_:__
M  EU]N\2:K:V\J+I^EPX>7_6*N68@8['&T_>H ^^K6ZAO+>*XMY4F@E421RQ
ML&5U(R&!'4$=ZLU\#?LS_MD^%?V>/!VI?![XX^*5\/\ B_P'?OHT%Q=6\\G]
MH6*_-;3*41N/+*CD_="GO7UE\'?V@_A_\?['4KSX?^(X?$=KILJ0W4D,,L8B
M=@64?O%7.0#TH ]'KEK'XE^%]2\=7_@JWURTD\66-LEY<Z1OQ<)"V-LFT]5.
M1R,CFNIKY/\ V\/!:^&?"NG_ !W\.ZI;>'?'OP[_ -*M[JYDV1:G9LV)=/EQ
M]\29P@_O-@8W9 !]%>)/B+X:\(Z[H&BZQK5KI^KZ].UOIEC*_P"^O)%&6"*.
M3@<D]!WK-\._&CP/XN\>:SX+T?Q-I^H^*]'#-J&DPRYGM@K*K%E]F91^(KYQ
M_8AC_P"&A-4U;]I#Q/=VM]XEU9I='T;1[>3S(_#5A$Y!MN0/WSGYW; )##&
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MB@#]'J*YOX>^-++XD> _#_BK30Z6&M6$&H0))]Y5D0.%;W&<'Z5TE !1110
M4444 8OB+2=)O+5[O4M*M]4^RQ.ZK):K/)@#)" @DDXZ#J<5^:7[/?QTU3X;
M_%[XF_$SQ7\ OB5<^)O$]X+;3HM'\,,L&GZ5&%\J$9V_.=J[N.=BGO7ZCT4
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MM8=.0>U=[\'=8\7:[\-] O/'NA+X<\8M;A-3T^.>.:-9E^5G1HV9=K8W 9R
MV#TKMJ* /E;XA?#/XD?"?]I+5?B[\,/"MAX\L?%.EP:;XA\/S:C'I]TDL!_<
MW,,LG[LC;\K*W/''MM?LW?"WQU#\4/B)\7?B1IMCX;\2>+4L[&U\-V%V+I=/
ML[92J>;,ORO*Y.3MR!CCK@?1]9NNZ6-=T:_TUKFXLA>6\EN;FS<)-$'4KO1B
M#AAG(.#@@4 ?+'P(U;4[OQI^TQ\8](T]=<M+[5(]+T2R\]+5;Y-+@:*1Q,YV
MJCRM(H=L >63TKZ2^&_B_P#X6!\/?#7BC[&^GC6M.M]0%I(X=HA+&KA2P'.-
MW6H?#OPP\,^%_AS9^!++2H#X7MK+^SQITR[TDAQA@^?OELDL3]XL2>M=+;6T
M5G;Q001+##"H2..-0JHH&  !T ':@#YG^*7P^^)?PX_:(;XN?#+PU:^.;;7=
M'BT7Q#X;GU..PGS"[-!<P2R?)P&*LI/TZY%_]G[X;_$&W\>?$3XO?$72;72_
M&'B2WM[#3O"UC>I<)IUC;*YCB:<?*TDCL68@[1D=.@^D:* /"?B&OQE^('P7
MTK6/"5M#\.?B39WL>H2^'=0NX;RWNXHW8/92SH&4+*N#O3!!P,CDCS3Q#X/^
M-7[47B[P-IOCSP%9_"SP+X;U>V\0:C_Q.X-3NM4N8"6A@B$0PD>_EF;!QC'I
M7V#10!\??%3]F+Q;^U?\3O$VI>/GNO!WA?PW;O9^ [>QOE:87YPW]L2>4QP0
MRJ$C)!VCD \GWGX!ZAX_OOACI4?Q/TF'2?&=GNL[UK:XCFAO?+.U;J,H3M$@
MPVTX()(P.*](HH ^5_BWX;^(?P:_:&N_C!X$\'R?$31->T2'1_$'A^RN8X+Z
M*6!V:WN82_#C:Y1D'/?Z<IX%^"OQ*^,7Q4^,OB+XH^$X?!GA[QWX0@T&PLX=
M0BNYK2,&5?+EV-S*-WF' V_.%!)!K[3HH ^'/#?BK]I+P#\(;;X,V_P?_M7Q
M/8:8=#T_QQ'JT"Z,8%3RHKJ0'YPRI@F,C)*].<5K>)OA-X^^!GPJ^&'@[2O
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MC@ "V0DD]A6E\3/ASHOQ;\!ZSX/\1PRSZ)K$!MKN.&4Q.R$@X##D<@5X0O\
MP3K^$4EHMA?/XNU/2O+$1TV\\5W[6S(!@*4$HX [=* /E?Q%XDO]0_9Y_:^\
M>^&)YH/#'B;QG%9V^K6IQYUFLD4%W-&1_ 5=ANZ')]Z]Z_;"^"_PK\&_L2ZY
M?:%H^DZ+'X<TVWO_  YK%C#'#<172LAMY(YE 8M(Q4$Y^;>:^H;3X6^$M/\
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M27R8"AB'F#G(\M,GOB@#M-%F>XT>QED8O(\$;,QZDE02:^3?V4_^3T/VK_\
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M!>VRW(.R\C28!<LVWS"NW@+Z$9YWX&_!KQA\2_B=^TC>>%_BYXB^'1@^(%_
M+32;>WF@EDV(1+()$+$\@8##A:^S?'OP6\+_ !&\8>#/%.KVTXU[PC=/=Z5>
M6LYB>-G 5T;'WT8  J>#4_P]^$?ASX8:GXNO]!MYK>Y\4ZM)K>IM-,T@>Z<
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M?>(!8\ 5]J^']63Q!H=AJB6UU9I>6\=P+>^A:&>(,H;9(C<JPS@J>A!KPO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2EH ****
M"BBDH 6BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BDI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** &-7S]^V#\=_%OP8\*^'[3X>:3IWB#Q[X@O9+?3M-U))'B:&"WDN+F0JC
MHQVI'@88<NM?0/UKX>UCX@>-/%W[9_B?Q5X.^%U]\2]%\ Z9_P (I;R6^L6-
MC'::C,5GO)%^TR*6;88HCMZ!2#UK-ZR45Z_=_5OF-:*[5_Z_IGT[\(_BK;?&
M#X*>'/'>FF-5UC2TO"L1W"&8K^\C[\I(&4Y[K7S7)^T/\05_X)V^'/B<-?\
M^*XNY+-9=4^Q6_SB35%@?]UY?EC,1*\+[]>:?^Q+XEUOPKKWQ@^$OB;PU/X+
MO--O)/$ND:)=74-RT&GWQ=VC62%FC=8Y0>5/_+3!P017FTN?^'2'A'T\[3__
M $]I6T;2FI6T;AIONW=?HS%WBG&^J3_2Q^CQ'%?*G[9W[5WB[X!ZMH6G>!M
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MQ$T3QU\0?V\O&5EI7A_P#XJGT'PU8-H]C\0I)Q#;VTQ8SSVD<4,@+M*-CR$
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MZ!;KX(6UDLAH]Q(\\9AD+,Z%I&9B"68Y)R.V,"N[/2@'Y:++EMT"_O>9Y_\
M![X%^"O@)H=UH_@?1Y-'TZYD666*6^N;P[E0(H#SR.P4*H 4$ =AS5/XN?LW
M_#CXZ2Z=/XV\,0ZM>Z<3]DOH[B:TNX0<Y59X'20*<GY=V/:O3!2K1+WG[P+3
M8X#X>_ KP'\*?"5]X9\,>&+'3M$U R/?V\@:X:^:0$.;B24L\Q8$@F1FXXZ5
M\S?M$?\ !/\ \$V?P5\1VGPA^'5L?&=U<6AM%DU!W^SQB]CEG%N;J8QVX*AR
M1'LW#C!X%?:X&:"*:;4E+KI^ ^ECS[XJ_ OP/\<O#]EI/CKP_#KEK:3+<VS-
M+)!/;2C'SQ31,LD9X&=K#..<UF_#?]F?X9_"'Q"NO>#O"EOH>L?V>=+>[AGF
M=YH#+YK>;O<^;(7Y,KYD. "V!BO4UI*.K:)Z),Y?P/\ #7P[\-[75H?#FG_V
M=%JVI7&L7B^?)+YMW.P:63YV;;N('RKA1V K$^'7P%\!_";Q/XJ\0^%/#L.C
M:QXIN1=ZQ<Q32O\ :90SMNVNQ5!ND<X0*"6Z5Z(:.M"TV] WO?KJ>*>,_P!C
M7X-_$+QO=>+O$'@>UU#7+QHWO)/M5Q%!>M']PW%NDBPSD>LB-G SFNA;]G7X
M>M\([/X8'P_CP-9F-H-*%Y< (8YQ.G[WS/,XD ;EO;IQ7I='>DM%;^M-ON&]
M=3@/BU\#_ OQST.#2/'/ARVU^RMY?/@,K/%-;R<?/%-&RR1G@9*,,XYJG\*_
MV=?AW\%(=5'@[PW%I<VJ8%]>2W$UU=W*@857N)G>4J!T7=@=@*]*[T>M+34.
MUSAM%^"_@[P[\)V^&FGZ1]G\$M93Z<=,^U3/_H\V_P U/-9S)SYC\[LC/!&!
M4/B?X%^!O&?PJB^&^M^'X=2\%Q6L-G%IL\LA\N.$*(MLN[S RA1APV[CK7?T
M4;N_?] 6FW0Y'X:_#'PY\)/"L'ASPM82:=I$4DDJPRW<UT^]V+,S2S.[L23W
M8^G05\\VG['6A?$CXY?&77?B7X-CO=(U74=-N/#VIQWS07)1+$0W&R6WE6:)
M2PVLK%0V!P0 :^M1WI/6G>S<GVL):;=SAM"^"G@3PS\,V^'VF^%=-M?!;6[6
MLFBB$-!*C#Y]X.2[-U+,2Q/).>:\]\)_L-?!#P/J^D:KI'@:.#4M(NX;S3[R
M?4KVYFM9(MWEB-Y9F*QC<?W0^0G!*D@8][]:,<47][S"VG+T/F[]L[X(ZK^T
M1I_PY\'6^@Q:EX='BBWU'7M3EN(X_L5E KEU12P=GEW>6-@;&3G'4>R^/?AC
MX:^*'A&7POXETW^T=!D>&1K-9I(!NAD62+#1LK#:Z*< X.,'(XKJZ.E$=%;S
MO\_Z0/WFF_0X7XK?!+P1\<-%M]*\;^'K?7;2VF%Q;M(SQ3VT@Q\\,T;+)$W
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GJKW%:P4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>mrsn-20201231_g7.jpg
<TEXT>
begin 644 mrsn-20201231_g7.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" .& UX# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:V/CSPOX9OVN7LE*0WD+VDQBN%0D[&RC*Z@D9 (P'"KR_P#P1%M8D^%OQ+N
MBB>36;:-Y.Y58"5'X%V_,T >M_\ !.O]M[5OVH--\0>%_&]C!8>/_#@66>2W
MC\J.\@+%"_EDY21& 5QT^92,9('C?[2'[<OQP^('[2VJ_!G]G"PMVOM%>6VN
M;U8+::>>XB_X^#NN3Y,44;?)\PR6!YY 'GG[#TC:1_P58^+UE:'R;:2^\2VS
M(O ,:W^X+CTRBG\!47_!)&1M:_;$^*^KWO[_ %&32+UVF;KNDU"!G/U) _R:
M /<?V'/VZ/B/XM^-^J_ _P".-A;VWC6W686E\L,=O*T\*[Y+>5(_W;9C#2*Z
M #"'[P8$?H77Y(_'*,:-_P %F?"-Q9DP37>H:0TS)QNW6JQ-^:#!KZK_ ."A
M'[6'Q/\ V8/^$!_X5QX6TWQ-_;G]H?;_ .T-.NKOR/)^S>5M\B5-N[SI,[LY
MVC&,'(!]AT5^/7_#V#]I[_HE?AO_ ,)[5/\ Y*KG_&G_  5E_:6@TJ)KGPKX
M?\(IYX O8]!ND+G:W[O-Q,Z<]>!GY>N,Y /VEHKQ3]B_XIZ_\:_V9? _C;Q1
M-#<:]JT$\EU);Q")"4N98QA1P/E1:]KH **** "BBB@ HHHH **** "BBB@
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MN=WD6&G:U;7$\NU2S;8T<LV%5B<#@ GM7<5\<_ 7_@EW\,?V>?BSH/Q!\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB'1KD7U@K;6ND9"GE*?X6<L%#=B0>U?E'^S+^U7^UCX+^%]EI/PR^&=_XR\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQUXQ^-<W\5?^0?X=_P"Q@T[_ -*%KMJ $I:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#G!QU
MH 6BO.!H7Q=_Z'?P5_X1MW_\M:R-#;XNZQJ?B"T_X3#P5#_9-\MGO_X1"[;S
M<VT$^[']J#;_ *_;CG[N>^  >O45RGA'3O&]G?3-XG\0Z!J]H8\11:3H,]A(
MKY'S,\EY.&&,_*%!Y!SQ@]70 4444 %%%% !1110 4444 %%%% 'Y$?M3_\
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M:0D^8?NYP,5^C= !1110 4444 %%%% !1110 4444 %? '_!:O\ Y-9\+?\
M8YVO_I#?5]_U\ ?\%J_^36?"W_8YVO\ Z0WU 'LO_!-7_DR'X7?]>MU_Z6W%
M?35?,O\ P35_Y,A^%W_7K=?^EMQ7TU0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <3\5?\ D'^'?^Q@T[_TH6NVKB?BK_R#_#O_
M &,&G?\ I0M=M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5R/@G_D9?'_\ V&XO_3;9
M5UU<CX)_Y&7Q_P#]AN+_ --ME0!UU%%% !1110 4444 %%%% !1110 4444
M?)?C3_@G#^SU\4O'WB#Q#JVEW=[XAU6\FO[_ .SZU,I\UW+.=BM\HW-T[5F?
M\.F/V<>G_"-ZM_X.KC_XJO#/V'/^4HG[2/\ N:O_ .G2WK:_8YU:^NO^"GW[
M15I->7$MK%;7WEP22L43_3K8<*3@<9H ]P^%O[$O[.?[/_QL\.:CX<=-+^(5
MO'-<:9IUYK[/<RQR0RQ.ZV[ON==GG<@$#:Q_A-?6%?G[\:O^4Q_P(_[$Z?\
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M6K_Y-9\+?]CG:_\ I#?5]_U\ ?\ !:O_ )-9\+?]CG:_^D-]0![+_P $U?\
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MUKBO%?\ R4?P+_O7W_HB@#M:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M^U-XV_:6_;X^$'BC6(+SPYHEUX@TN'1]&2:00K8B]P&SP)69P^YP,$J1P%
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M-XS_ ,"V53_8*\O_ (=C:<9,>7_96O[\],?:KS.?PKZ$_:I^"Q_:&_9^\9^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?GO\ \%@_A+\/KOX&Q?$/58/L'CJSO+?3=+O;5!OOO,8EK>;^
M\BQK+(">5*8'WB#\!_L=?L&^,OVFOB%+9ZG:WGA7PAI)BDUC5+JW:.3#JLB0
M0*P^:5T96!/RJC!CG*J_VA^VY))^U5^WA\*/@):O++X?\/E=3UY8R2GSJ)Y0
MX' (MXT56/1KDCOS^@O@=%C\1>/E50JKK<0"@8 _XEMC0!9^''PX\._"7P7I
M/A/PII<.CZ#ID(AM[6 8 '=F/5G8Y9F.2Q))))KIJ** "BBB@ HHHH ****
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MKX;\'Z':>']#M<F.SLTVKN/5F/5F/=F))[FNFH **** "BBB@ HHHH ****
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M@!X_UOQ;I@UOP[;:/<"\TLG;]L1T*"#/\.\L%W=MV>U?D_\ LN_'C]L'P?\
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M,O\ P35_Y,A^%W_7K=?^EMQ7TU0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !5/6-5M="TF]U*^F6WLK.%[B>9NB1HI9F/L ":N5\U?\%&/B<?
MA;^Q]\0+V"YCM]0U2U71+4.>9&N6$4@7_:$)F8>FW/:@#YR_X)*Z5-\1O&OQ
MR^-M^K?:?$6MM9V^\Y:/>[74ZD^G[VW  Z;/I7Z15\V?\$Z_ABWPK_8_^'UC
M/;QV]_J=HVM710<NUTYEC+?[0A:)3Z;,=J^DZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***K:EJ5KH^GW5_>SI;6=K$T\\TAPL<:@LS$]@
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M2E"/](?HB]%].0#]1:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKBM>_P"2N>#_ /L&:I_Z'9UVM<5KW_)6_"'_ &#-4_\ 0[.@#/\ VB/BY:_
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M: /4:*R-'\7Z%XBN'@TK6M/U.:-=[QV=U'*RKG&2%)P.1S6O0 4444 %%%%
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M0![+_P $U?\ DR'X7?\ 7K=?^EMQ7TU7S+_P35_Y,A^%W_7K=?\ I;<5]-4
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M&Q+2:;':NTHQT;SX91@?[(!KDKKX1:E?:E8W\_Q)\5O=V)D-O)Y&E#9O7:W
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MEV=C(7M[2"W<C!:*-5)'IP*M444 %%%% !1110 4444 %%%% !1110!\G?M
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MZGX]\6[KG2$O$R;.VD'^O (^1G3"QA<!(< </@?H#2(BQJJJ JJ, #H/:G4
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M]/\ J%>3?MY?MH6G[+G@N#2-"1=5^)OB%#%HFF(OF&$$[/M4B=U#9"+CYW&
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ML#.* ->BBD)P"<9H 6N%^&O_ "'OB+_V,?\ [86=7?\ A-M8_P"A!\1?]_\
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M"KOQ2C\6^+Q>^$?@!H5VPT_2XV*/>LIP50]'E.,/+R$R43G- &!J7@GXD_\
M!7CXH/XB 'PY^$/AP3VFDZA>6GVF1F8KN 0.GG2N50OAPD8  +'[\NC?\$6_
M[7\4>(M'_P"%Q>5_9#6Z^=_PC&[S?-CW_=^V?+CIU.?:NB_X*6_M77O[/L&C
M? +X/NO@NPLM.BEU*YT<F"6WC8DQ6L3#YDRH$CN#N;>!GE\_F;X9^)GBWP;X
MF/B+0O$NK:3KK/YC:C9WLD<[MG.6<'+9/4'.: /Z*/V6/@;=?LV_!70?AU-X
M@B\2V^C>>(+]-/-FSB6XEF.Y3+(.#*0,$<"O6Z_/_P#9?_X*N?#G7OA#8/\
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M!Q/Q5_Y!_AW_ +&#3O\ TH6NVKB?BK_R#_#O_8P:=_Z4+7;4 %%%% !24M%
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MM_V.=K_Z0WU??]? '_!:O_DUGPM_V.=K_P"D-]0![+_P35_Y,A^%W_7K=?\
MI;<5]-5\R_\ !-7_ ),A^%W_ %ZW7_I;<5]-4 %%%% !1110 444GUH ^?/V
MC_VYOAG^RSXFTO0?&SZO_:&HV?VZ%=-LA.OE;V3))88.5;CVKY]\/?\ !6KX
M&:)JWC.]D7Q/*FI:DM[:QQ:8FYD6QM8<',H .^%^^,8.:^6/^"Q]YI6I?'WP
MI=Z992VDDWA\&YDGTZ6SDFD%Q*H8^8BE_E"C=SP ,\5\"4 ?JK\._AG\0/\
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ML;&VTRS@M;.WBM;6%!'%!"@1(U P%51P !V%6*** "N'^,W_ "(C?]A/3/\
MTOMZVO%E_P")+&W@;PWHVFZQ.S$3)J6IO9*BXX*LL$NXY[8'UKSSQO'\5/%O
MA\Z='X.\*V[?:K6X\QO%-PPQ#<1S$8_L_N(\?C0![#17GG_"0_%'_H1_"_\
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MBBB@ HHHH *^ /\ @M7_ ,FL^%O^QSM?_2&^K[_KX _X+5_\FL^%O^QSM?\
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M);++-?0PG[/J-N"%\XE1B.0$@,IP"2"O4JOVS0 4444 %%%% !1110 4444
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M&#3I]#L0IGL;6!Y6@DB<XWR*9Y2P8@/O(^7"[?18K?XG_P#!6CXD)-<"_P#
M7[/&B73%%R ]ZZD#W66X([\QP@D#+']X 6O'WQ2^)?\ P5'^(=S\/?AC]J\)
M? S3;A!K&OW$90W@!SF09&[.,QVX/.%>0CC9^A7P#_9]\&?LV_#^T\)>"M-%
MG91_O+FZEPUS>S$8::9\?,Q_ *,!0  *W_AG\,?#/P=\%Z;X4\(Z1;Z+H6GQ
M^7#;0+U/=W8\N['EG8DD\DUU- '"6ME;GXZ:I=^1%]J7PY9Q"?8-X0W5R2N[
MKC(!Q[5WE<3:?\EHU;_L7[/_ -*;JNUH 6BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\<_;"^(&L_"W]F/XC>*/#TC0:W8:3(;2XC&6@D<B,2CW3?O&>/EYXK\:]8_9
M-UMOA;\&/B?KGQ,:XTWXE:Y'I5Y<^6]PVE-+(X61W:8><0(Y2Z_(5*$9/6OW
M?\8>%-+\=>%=7\.:Y:+?:/JUI+8WELQ($D4B%'7(Y'!/(Y'6OB37_P!BWX(?
M"_\ 9]\4_ [Q#\4;'2!XFUS^V="NO$-[:QWUA<;(XX5CC9E\X JX;:$++,Z_
M*3NH \-_9S_93M/V2?\ @HQX"\,>*?$5UXLU#4-&N]1\.ZG8A;=!)Y%S'+'=
M0.7;;Y:S%2C_ 'MO7+ ?K+7PE^R3_P $S_\ A0/QGM_B/XG^(<OC?6M+AEM]
M.A2U:(0EXC$7D9Y'+8B=E"# &[.3BONV@ HHHH **** "BBB@ HHHH ****
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M%3@E76(JPXX()!ZBNTHH \0T?XB6]K\7O%6M2^'O%BZ;>Z-I5K!-_P (S?\
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M_P :O^"M7P6\$>$]0D\$:M+X[\3^619V4%E<06WFG@&665$^0=3LW$XQQG(
M/5/VSOVS/#7[(W@3[7<B+5O&&H(RZ/H/F8:5NAFEQRL*GJ>K'Y1W*R?L;_MD
M>&/VN/ /V^R\O2?%FGJJZQH+29:!CP)8\\M$QZ-V/!YZ_@7\5/BIXF^-'CK5
M/%_B[4Y=5UO49/,EFD/RH/X8T7HJ*.%4< "L+1?$&J^'IIY=)U&\TV6X@DM9
MGLYWB:6&0;7C8J1E&'!4\$=: /Z _C]_P4*^#'[/;7%CJOB,>(?$,)VMH?AW
M;=7"-Z2-N$<1'&0[!N>AKY2O/C9^UW^W=8SV'PY\(6_PG^'FH1-$^L:DQ4SQ
MD$,/M+Q[W4]/W$7'(+=:]@_8*_8>^%WAGX3>$/'6M_#FZ7QU?6J74P\7%+J6
MVD#95XHL!(@=JNI*"10P!.<U]PXH _"W]KS_ ()B^+_V9? ]EXOTG6?^$ZT.
M&/&LS6UD;>33W)X?9O<M#SC?D8/4 &J7[ 7[ >J?M2:\GB7Q,EQI/PST^;$U
MRH*2ZG(IY@@/9?[\@Z=!S]W]V;RRM]0M9K6ZACN;:9&CEAE4,CJ1@JP/!!!(
M(/K53P[X<TOPCH5CHNB:?;Z5I-C$L%K96<8CBAC48"JHX % ">&O#>E^#] T
M_1-%L(-+TG3X%M[6SM4"1PQJ,*J@= !6G110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%9VD^(M,UVXU.#3[^WO9M-N?L=ZD
M$@<V\^Q)/+?'W6V2(V#SAA0!HT444 )6/H?B_1O$FI:W8:9J=O?7FBW2V6H0
MPN&:VF,22A']#LD0_CCJ"!QW[1OQIT[]GOX+^*/'FI;)!I5HS6ULS8-S<MA(
M8A_O.R@XZ#)[5^0W_!-K]KO4_ _[55_%XOU,SZ9\2KMHM4N9FV(FHR.SP7!
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M;X.T+6+2VN5N-/U+7[2WN(2;N=@'C>0,N5(/(Z$&OH;_ (:Q^"'_ $63X?\
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M /\ "HL?_CM 'H9\-Z2?^879?^ Z?X4'PWI)_P"879_^ Z?X5YY_PUC\$/\
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M]IIK9/\ $PMYT#GW8&@#QKP__P %7/BQX?LY+[QK\!)-0TF'/G:QX?FGCM%
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M"/['WP1\#V<-OI'PK\)QB$Y2:ZTJ*ZGSZF:4,Y_%C6#_ ,-\_L]?]%9\/?\
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MA.G]Q98E/Y>M3K^R3X%\0+_Q5G[?.BZNC#YX%UV!QSU^:34&S_WSVH _2?\
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M$X Y K^@*OQJ_P""/_\ R>=\0?\ L6-0_P#3C94 ?0O_  Y-^$W_ $._C/\
M[^VG_P 8H_X<F_";_H=_&?\ W]M/_C%?HA10!^=__#DWX3?]#OXS_P"_MI_\
M8H_X<F_";_H=_&?_ ']M/_C%?HA10!^=_P#PY-^$W_0[^,_^_MI_\8H_X<F_
M";_H=_&?_?VT_P#C%?HA10!^=_\ PY-^$W_0[^,_^_MI_P#&*/\ AR;\)O\
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M6>?56C,JR/>3Q%1Y:*-N(%/3.2>:_?BOQM_X*^?\GI?#O_L6M._].-[7[)4
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MB\VY@FW[_.?./)VXP,[LYXQ7V5/J%K:OLFN887QG;)(%./QJ/^V+#_G^MO\
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M:QX@TO2;B;_50WU['"\G^Z&8$_A0!N44R.19HUD1@Z, 593D$'N*?0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'/,EO#)+(P2-%+,QZ
M #DFOQ5^#7PMU'_@JA^TU\1O$GC#Q1JFF>'-+B,EFMLB,]M \K+:6J*WRHH1
M79B 2S*Q/+EJ_9?QA;S7GA/6H+?/GRV4R1XSG<8V Z>]?EI_P0YF1=:^,,6X
M"1K?2F5>Y :[R?H,C\Z #_@G-XH\2?LW_MD^-OV<]6U*;4]!FEO%M%)Q&ES
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M1X9\5VGAO6K/4YX-)M_-WB&99/+W+*P4G81S7ZO5^)'[0?PCU?\ X):?M">
M?%?P_P#%-]J^DZE').;6^98Y)XXG5;BUGV+L>-TD3#;<@DD ,BM7[:0S">&.
M5<A74,,CGD9H ?1110 4444 8WC'QAHW@'PKJOB/Q!J$6EZ)I=N]U>7DQ.V*
M-1DGCDGT R2<  DU^#OQG_:&\3_M0?M6>"?'6K6EUIWAB;7;6T\-V,PPD5I'
M=H#C'#.6.789^;*@X0 ?2O\ P5/_ &G(O&'QDTSX"W>I7GA;P1H]U:7?BC4X
MHC(]RTD23((T0DR)''(I"M@-*02 (U:O!/VJ?CU\(?%7Q.^"#?"Y+VV\$^!;
M.ULY(I[-HI$6.Z\UB 3EV*Y8L>68DGDF@#]._P#@HI;_ !>UOX$CP[\'=)U*
M_P!9UB]6#4KG2IDBF@L0C,X5BRL"[!%^7G;O'>O@SXA?\$K[?X;_ +(-U\3M
M6\5ZA8>.-/TB/5[[1;JWC2VB+!6:UZ[A(N[;NW$%AC:,YK]4OA)\?_!GQH^%
M:_$30=0:#PH?/+WNII]E$2PL5D9]Q^51M/)[#-?GA\:OB_X\_P""G7Q*?X2?
M!^.YTKX0:;<++K?B>YA=(;K8V5DDS@[<C,4'#N1O8 )F, ^F_P#@EO\ %?Q1
M\6_V4["]\67UQJFH:5J=QI,.H7;%YKB"-8V0NQY8KYA3<<D[!DDYKZ[KA/@A
M\'?#_P  _A?H/@7PS$Z:5I,'EB27!EN)"2TDTA  +NY9C@8YP   *[N@ HHH
MH ***\2_;(_: E_9G_9_\1^.+2Q&H:G ([2PA?\ U8N96V1O)R/D4G<0.3C'
M&<@ ^1/^"JG[6FH0V-Y\"_A^9;S6+JQDOO%5U9G+6EBD9E:W.!QNC4O(<C"
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MH^$_[4OPQ^.7BO7O#7@CQ-_;>M:$"=1M?L%U;^1B0QGYI8E5OF!'RD_E7J]
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MWP.T+]HWX5ZQX \2W>HV6C:HT#33:5)''<*8IDF7:SHZC+1@'*GC/3K7HE%
M'P"G_!%?X()(K'Q/X^< Y*MJ-E@^W%G7U!^S]^RE\-/V8]-N[;P'X?6PN;P*
M+O4KF5KB[N ,8#2.20N1G8N%SSC->O44 ?/G[3G[#/PP_:ON;&_\7VNH6&N6
M47V>'6=%N%@NO)W%O*;>CHZ@DD;E)&3@C)KS74/^"3?P-DTKPW;:1_PD7AF_
MT.Y>\36-+OXC>74I\O#3/-#(I"F)2JHJJI9R!\QS]FT4 ?+/[;G[6WPQ^!'@
M7Q#X*\:&ZU;7=>\/3BUT**WEQ?QS"2##3J D8W!MQR"!DJ"<"O!O^"-?[/E]
MX-^'_B3XGZW8R6EUXF,=EI*W$6US8Q_,TJD\[)9" /7R >00:_0;6O!OA_Q)
M=6]UJ^A:;JES;_ZF:]M(YGCYS\I8$CGGBMA5"*%4!0.  * /,/CS^S7\/OVE
M?#=OHWC[0DU:&TD:6SNHY&AN;1V&&,<JD, 0!E3E6VKD':,?/WP]_P""2?P$
M\!^)XM:GM=>\5F"99X+#Q!?1R6L;*VX QQ11^8O !60LI'!!R<_:-% "*-HQ
MT%8_C#P=HGQ \,ZCX=\1Z7;:SHFHQ&"ZL;R,/'*A[$'N" 01R" 000#6S10!
M\2-_P2 _9^/BL:N+?Q(MAG/]A#5O]#^F[9Y__D6OK;1_AUH'AOP#'X,T33H=
M$\.PV36$%G8*$6&)E*G;P>>2<G))))R2:Z6B@#PC]E?]CGP9^R'IOB&Q\':G
MKNI0ZY-#-<G7+B&5E:-65=GE0QX&'.<Y[=*A^'O[%_@GX;?M&>)_C1IFJ:]/
MXI\0K<+=6EW<0-9)YSH[^6BPJXP8QC+GC.<U[[10 5\T?M$?\$\_@[^TKX@G
M\0^(M+OM'\37"HD^LZ#="WGF"C"[U=7C8XP-Q3=@ 9P!CZ7HH ^=?V<OV"?A
M'^S#K']M^%=)N[_Q&(6@76M;N?M-RB, &V *L<9/0LB X)&<$BKO[4'[$WPV
M_:T&E3>,HM2L=5TQ&BMM6T6X6&Y6(MN,3;T=&7//S*2,G!&3GWVB@#PBZ_8K
M^%^J?L\Z3\&-3TNZU7P?I.Y[*2ZN3]L@E,CR><LR@8?=*_08PQ4@KQ7CNB_\
M$B/@-HOAK6=+V^([^\U*+R5UF\OXGN[)=ZL?( A$2D[=NYHV.UF (S7VS10!
MY_\ !OX)Z!\$OA%H_P .-(DNM4\/:9!-;I_;#1S2S))(\CK)M1589D88V@8X
M.:^<+[_@DC^S[?>.F\0_V9KEO9,^]O#L&IE=.)SD_P 'G 9_A$H Z  5]GT4
M >!? /\ 8K\!?LW_ !(\8^,O"%QJT=WXG+_:--N'MQ8VB-,91';QQPH412=J
M@LV% 'O7Y_?\%+/VB/!7[6>K>!/AK\,-,U#Q5XUT_5YHVG6QDA:)V!B>U17
M9B7169L;0(E.3SC]?JQM+\&>']$U*XU#3M"TVPO[@DS75K:1QRR9Z[F4 GKW
MH Y;]GWX3VGP-^"O@WP+9A=NBZ=';S.A)$EP1OGD&?[\K2-_P*O0J** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ***2@!:**3- "T444 %%)N%+0
M 44E% "T44F: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% "$XK\E/VLO\ @F+\9?C+^T5X
MY\:^'6\.G1=9O1<6WVK46CEV^6B_,OEG!RI[U^ME% 'XB:/_ ,$?_CY::O8S
MRMX66**>-W;^U7. &!)_U5?MT*6B@ HHHH *^=?V_O@?_P +Z_9=\7:-;0K)
MKFEP_P!MZ4WE&1Q<VX+[$ YW21^;$/\ KKWKZ*I* /S"_9"\;WW[=G[57A/X
M@ZW:2G1_A7X1L[9TNCYD=QK4RL'N%0\+EA*P/7_1XCUZ?=G[47PKN?C;^SUX
M\\$6)C_M'5]+DBLO.?8AN5Q)"&;!POF(F3V&:[_0_#&C>&8I8M'TFQTF.5MT
MB6-LD(<],D*!DUIT ?F#^R/^U/\  #P1\*]/^'_QM\+Z1X*^(7A56TR]76O#
M)E:Z6,G8Y986(?;M5E?!)!(SGCU_]G#]IKP1\=OVE;S0?A1\'M(E\$Z+:?:+
MCX@+8+826TI1@ B>1DF0E45&:-B%E;!"XKZG\=? [X=_$Z\BN_%_@3PWXGNX
MAMCN=6TJ"YE1?0.ZD@>V:Z+PQX2T/P3I$6E>'M&T_0=+A_U=CIEK';0)_NH@
M"C\!0!\"_LO_ /*5S]HD_P#4'/\ Z,L:W/\ @KD<_#GX2?\ 8]6G_HF:ON*U
M\-Z18ZM<ZI;:596^IW(VSWL5NBS2CCAG W,.!U/84[6/#^E^(8X8]5TVSU..
M&02QK>0)*$<=&4,#@^XH ^'/^"EG_)6/V5#_ -3W#_Z/M*R/VMM4NOV6?VY/
M /[0&HZ5=WOP\U+23X>UN\LU,C6<I\Q0[#' VM"P'5O*D YQG[ZU/P_I>M36
MDNHZ;9W\MI)YMO)=0)(T+Y!W(6!VG@<CT%2ZII5EK>GSV&HV=O?V5PACFMKJ
M)9(Y%/565@01[&@#X;_:"_X*C>!8O L6G? [5G\=?$O5Y[>WTK3X=(NF1"\B
MY+JZ(68J&41KEMS+P!6!^UE-XCN/VC/V()O%\-C;^*I-49]5ATT,+:.Z+V)E
M2+<S':&) R3P*^U/!?P)^&_PYU234_"O@#PQX;U&0$->:3I%O;2D'J-Z(#CV
MSBNJO_#^EZK>6=W>Z;9WEW9-OM9[B!'D@8X)*,1E3P.1Z"@#\W_VHX]._99_
M;WM_C)XZ\(1^*/A9XYTN+2=0O)+%;Q-/NDCBC#;&! <+;1,!P61I=N2I%=+\
M7?VZOV5_"O@\S_#_ ,)^&_B)XNN_+33M#M/#1@$C.P \QWMQMP"?E +DX&.<
MC[_U;1[#7]-GT_4[&VU&PN%V36MW"LL4B^C*P((^HKBO"/[//PN\ :P-6\,_
M#CPIX?U1?NWNF:+;6\RYZA71 5'L#0!;^"TUW=_"OPU=W_A"U\ WEW9K=3>&
MK-@4T]I,N8CB./#?-EAL&&+#G&3VU%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 444E "T4@YI: "BBB@ HI*\Q^&?[2_PW^,'C+Q'X2\*^(Q?^)?
M#S,NIZ7/9SVL]N5D,;?+-&FX*XVDKG!*YZC(!Z?14%]?6VEV5Q>7EQ%:6EO&
MTLT\[A(XT4$LS,>   22>!BO.OA;^T?\/?C1X4UOQ-X-UU]9T#1I'BO-0%A<
MPQ*R)O<*9(U\PA2"=F<;E]10!Z917B_P6_;&^$'[0WB6[\/^ /&$>NZQ:VK7
MLMJ;&YMF$(=4+@S1H#AG08!)^85[10 45XO9_MC?"#4/C(WPJMO&$<_CQ;N2
MP.EQV5RP$Z*6=/-\OR\J%;/S<$$=>*Q/B1^WU\"?A'XVU3PCXL\<C2O$.F.J
M7=G_ &7>R^6S(KJ-\<+*?E=3P3UH ^@Z*^5_^'H/[,__ $4E?_!+J'_R/7HW
MP3_:Z^$_[16M:AI/P]\5#Q!J%A;BZN8187-OLC+!=V98T!Y(& 2: /8J**2@
M!:*Y>'XG^%;CXC3^ HM<M)/&,%@-4ET=&S-';%P@D8#@#++P3GY@<8(KI\T
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M\U?8%?S/_ ?XK>,_A=XV@/@WQQ+X!GU=H]/N]6WL((X6D7YY@%8E%/S$A20
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MI6N6NC$W'0&(1OM'0N?>OUOUKX.^ ?$FJ3ZEJ_@CPYJNHW!!FO+W2;>::0@
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M"\U;PO\ "?1]%^+WPNGO'N].M=5NTAN[ /G*_-+%M).-VW>A(+ (785^CM%
M'Q'\ /A#^TI\1/CY9_%;XXZ^O@S3-+MO(LO OAO466UN#M8#SDBE=&4,Y<[W
MD9F !PJ@5UOB3]GOQEJ7_!1;PK\7X+2V/@G3_##Z7/<&Y43"<K<@ 1_>(S*G
M/O7U?10!\_\ [=WP>\2_'K]F'Q5X)\(V\%UKVH2V;P17$ZPH1'=Q2OEFX'RH
MU>B? /PCJ/P_^!?PY\+ZQ&D6K:)X;TW3;R.-PZK-#:QQR ,."-RGD=:[RB@#
M@_CYX1U'X@? OXC>%]'C275];\.:CIMG'(X16FFM9(XP6/ !9AR>E?"7P%\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKN[#*QJ3ECR3TZ4 >V44FX4M !129HS0 M%%% !112;J %HKDOBU\0H/A/\
M"_Q7XTNK234+;0-,N-2DM86"O,L49<H"> 3C&:X#X0_'C4?BE^RM:?%9M,M=
M-U&\TB\U./3PS20Q&)I?+0G@MQ&N2,9YQCL >V45\\?L)_M#>(OVG?@':^./
M%-EI=AJTVH7-H8='BDC@VQL I"R2.V>>?FKZ'H ***2@!:**3- "T444 %%?
M!GQ;_:X_:(D_:\\9_!GX/>#_  7XB&@Z=;ZF#KBS1SF%X;9I&:3[7&AQ)<J
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M/[,OB3]E_P"+&K>'-7L9AHLEQ))HNJ;6\F]M=V4*L1@NJLH=>JMGJ,$@'._
MG]H#QI^SIXZL?%/@S5I+*YAD4W%F[,;6^C!R89XP0&0C([$9RI! (_=7P?\
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M^%6B?$/XK_&CQEXRO=9TZ/5+J]AUF..QAC=/,*9E60[4R5+;E'RGY5Z#F?\
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M_P"TA_RE5_9R_P"P+<_^@WM>_?M\?\F;_%C_ + LG_H2T >(_M-1^*/VG_\
M@G?I'Q M/&5]X)N(?#3>(=9LM+601:NHLW\ZS<+*F(G?)^8., ?*:X_]@SX)
M^*O"?[*.K>/M1^)^L>(/#6O>#-0BL?!ET)?L>DL&DR\1:=DR=C?=C3[Y_'T+
MP^"?^"1<N!G_ (MM=?\ I-)6Y^R',DW_  32T QNK@>%=34E3G!#7((^H(H
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MGXJT;XA:K;+?V&G:+*8=+T;S%#QVXB#;FVY +*RG(Y+$;FQ_^"B6@^'O#/\
MP3;\%Z9X1EO)_"]O=:2NF2Z@C)</;&&0QM(K*K!BI&054^PK] /!0'_"&Z#_
M ->%O_Z+6@#Y4_X)>_''Q=\8O@7K-CXZU"XU?Q'X5UJ71WO[O)GFA$:,GFL>
M6=274L>2%4DDY-?8U? O_!)/_D6_C9_V.UQ_Z *^^J /@?X3_P#*8SXT?]B1
M;_\ H&DU]\5\"?"N5(?^"Q7QG9W5%_X0BW&6./X-)K[6\:?$KPG\.M%EU?Q1
MXETKP]ID7WKK4KR.!/H"Q&220 !R21B@#X,\-V?_  JO_@L9J^G:'MMM.\:^
M'WNM0M8T"1[_ +/YK, .-QEM0Y;KF1_4UZ[_ ,%//C!<_#C]FB_\-Z.&G\4>
M.YU\.6%I"GF2RQR_\?&U!R<QYCX_BF2O&?V/Y7_:N_;U^)'[0=G;W:^!=$MO
M[%T&XN4*>;-Y,<7R@X_Y9"64J>5-PF>:S_C9X)B_;\_X*!W/P[N=4UC3O 'P
MSTAQ>WFD3QQR+?N5+-$[(ZJYD:%""I.+5\8ZT 7?VQOV:K[X#?L??![Q+X0<
MKXL^#-Q:WK75O&"LAE=&NI=G.0;D1R8.0%+YR,FOO?X2_$?3?B_\,_#/C72"
MPT[7=/AOHHV(+1;U!:-L'&Y6RI]U-?(5U_P2"^%]Y;R03?$3XGS12*5:.76K
M5E8>A!M.16)_P2M\=7_@>;XE?L[^)[B+_A(/ NJSS62B0GS;9I2DWE@C[BR[
M7SW^TC@4 ?._P[_:T\(?LC_MZ?M$ZYXPTW6]2M-5U6^LH4T."&5U<7A?+"66
M, 8!Z$G/:OHJ;_@LU\+]446?ACP!X\US79SY=II[V=K'Y\AZ)F.XD;D^B,?:
ML#]A;G_@HU^U%_U\WG_I?7O_ .W/^R;'\?/ A\2>$E?1_BWX97[;H&L6,GD3
MRLAW&V=P,D, =AR-K[3D*6# 'G/_  35^!OCOPWKGQ6^+WQ"T27PKJ_Q"U-K
MRWT&X1HI;=#/--([QMRH+S;55@& 0GHPK[IKY3_X)[_M:S_M,_"N:Q\2LMO\
M1_#$GV'7+9HO):89(CN1'G(+!2KC Q(C\*"HKZLH \OC_9S\%P_'V3XQK:71
M\:RZ:=+>9[EG@\HA "L;9",%3&4V@AWR"6S7SC_P4^^-6CVWPCF^"^CVZ^)O
MB/XYDMK2QT*T7SIH8_/1Q,ZCD$E-J9P2QR,A&KH_VR/VM/$?@CQ1I/P9^#UB
MNM_&3Q)&&BD9%>#1K=L_Z1)N^3> K, WRJ%WN"-JOJ?LF_L7Z%\!KZZ\;^+M
M;_X3SXOZN&DU/Q/?2E_*9_O1VX8Y QA2Y^9L?PJ=@ /:?@%X!O/A7\$? ?@[
M49X[G4-"T2TT^YEA)*-+'"JN5SSMW X]L5WU-5@R@J0P/0@YIU !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M6/XJ\'Z#XYT>;2?$FBZ=X@TJ;'F6.J6D=S ^#D91P5/([BMBB@#FO!/PS\(_
M#6SEM/"/A?1O"]K,_F2PZ/816JR-TW,(U&X\=3S72T44 %%%% !7QYXZ_P""
M5?P/^(?C;Q#XJU9?$?\ :NN:C<:G=^1J82/SII6D?:OEG W,<#/ K[#HH ^-
M?#?_  26_9XT#4H[NXT/6-<6,AA;:EJTAB)!SR(]A(]B<&OKCPYX;TKP?H=C
MHNAZ=;:3I%C$L%K8V<0BAAC48"JHX K2HH \OA_9S\(P_M 3_&3%^_C&;3/[
M)^>XS;+!A1\L>.&^7KGN:]0HHH *X?XU?!WP_P#'SX:ZOX%\4BZ.A:IY7VC[
M%+Y4O[N5)5PV#CYHU[=*[BB@##\"^#]/^'?@GP]X5TGS1I6AZ=;Z9:>>^^3R
M88EC3<V!D[5&3W-<K\?/@+X7_:0^'TW@SQ>+PZ-+<173?8)_)DWQDE?FP>.?
M2O1J* ,[PWH-KX6\/Z9HUCO^QZ=:Q6<'F'<WEQH$7)[G %8/Q<^%NB?&KX<Z
MWX)\1_:#HFL1+#<_9)?+EVAU<;6P<<J.U=?10!SWP]\#Z9\,_ N@>$M&\[^R
M=$L8=/M/M#[Y/*C0(NYL#)P!DXKH:** "O#_ -I;]CWX?_M7_P#".?\ "=#5
M#_8'VG['_9MV(/\ 7^5YF[Y3G_4ICTYKW"B@#XDM_P#@C_\ L^03I(]MXDN%
M4Y,4FKX5O8[4!_(BOI;X,_L\_#O]GW1YM-^'_A6Q\.PW&W[3-"&DN+G;G;YL
MSDR/C<V S$#<<8R:]%HH XGXP?!GP?\ 'CP1=^$_&^C0ZUHUP1((W)5X9 "%
MEC<?,CC)PP/0D="0?E71O^"/_P #--U>"ZN[_P 8ZW80R!QI&H:M']E('\)\
MN%),?1\^]?<%% '+ZE\-= U#X:WO@**Q73?#%UI4FBBSL (A#:O$8BD>!A<(
M<#CBN-\+_LN_#[PQ\ E^#3:7)K'@/RIH7LM4E\UW$DS3$EP 0RR-N5A@J0I!
MR,UZU10!\.Z9_P $??@;I^J+<2ZGXTO].$@<Z/<:O&MJPSG8?+A63!]GSSUK
MWCX:_L@_#?X/_%O4?B%X-TVX\/:IJ&FQZ3/I]E,$L# BQ*N(=O#?N$.X').X
MGECGVJB@#Y7^._\ P3;^#WQ\\:7/BW4(]:\+^(KL[KR^\,WB6YNFX^=TDCD3
M<0.6"@GJ<GFNA_9Q_83^%G[,.L76N>&;74M6\27$1@.M:]="YN4C.-RIM1$3
M..2%!/3..*^AZ2@#Y)_;H_:R^&'P]^$OQ'\":GJUGJ_C>\TJ33(?"H222:26
MZA B+ +PH619,Y'3 .[ KL?V"?@))^SO^S)X5\.W]N+?Q!?(=7U=3%Y;BZG
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M*'Q>_P"":'P=^-WQ'UOQOXF/B*37-7D66Y:WU()'E8UC4*I0X 5%&,]JX_\
MX<]_L_\ ]SQ1_P"#8?\ QNOM^B@#FOAK\/\ 2OA3X!T'P?H8F&CZ+:1V5K]I
MDWR>6@PNYL#)]\5TM%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG1=;^'?PHO;ZUU?1;>#4O%WB/2IS$^CV\DT44%NLBD%999)HR=I#!<#D,VT
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M/CE;_MI?M-'X(6WAJXU ^)M1_M(>)"P01?VC<;/+VL.<[LU^Q%?CM\"?VM/
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M?('[;G_!-_X._ /]F#QIX[\+0ZXNO:3]B^S&\U'S8OWM[!"^Y=HS\DC=^N*
M/O']D.XCE_98^#Z)(KLGA#2 P5@2I^QQ=?2O7:^5?^"=_P"SCX/^"_P-\/\
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M^VQ^TY\:_C=XPT/3_%?@V&X3P_X<LM:TR.XM7B7!63RI58+(L,<)/&<W3]*
M.#_X* ?M0?L__&+X,^%3\+_'MO!XX\"ZE;WN@6\&A7T#"%=J-#%)) J1[=L4
M@W''^C@8R17Z.?L[?&"Q^/?P5\(>/+!EVZQ8I+<1(I AN5RD\7//R2K(N>X
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M-^'WPZ\/_";P=8>'?"VAZ1X;T#2XA#9Z;I=G':6EH@_ACBC 51[ "@#\5O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117GG[
M3_[6'PY_8P^$E]XY^*'B[2/!WAG3QA[N^EPT[X)$4,:@R32M@XCC5G.#@<4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?S-?\ !['X%U'3_P#@H;\+O$TD6W2=7^'46F6TG/SSVNIW
M\LR],<+>0'@Y^;D#C/\ 3+7R7_P5^_X)%>!/^"O7[/5KX3\37<OAWQ/X<FEO
M/#'B6VMEGGT>>10LB,A(\RWEVQ^9$&3<8HR&5D4@ ^3OVQ?%WPG_ ."IO_!L
M]XPM_A/K6D:S'\// ^G:J=/LPBWGANZTJ&&YDM9K<<POY-O/&!C#*Q*%E()\
MV_X-2/\ @J]\+-$_X)V7GPE^)7Q$\'^"=>^%^IWDUG'XBUB'3X[K2+ES="9)
M)RB,(YY+E7568HHC+8#K7UI_P0;_ ."0.L?\$L/V1OB#\.?B!J7A?Q??>-/%
M-W?R7&EK*UK=:8UI;V\,4BRHK!R$F9TP5'FE0S ;C^+_ /P4"_X-*/VC/@I\
M;=:D^"^@V?Q3^'%]>R2Z-);:M;6FJ:;;,=R07<5S)'N=,E/,B9U<('(C+&-0
M#)^%'[4W@CX7?\'56B^+/V=[N$_#GQC\3K'P[%]B=HK'4(-4,%EJ)1<8: W,
M]Q-$,;/DB9< *1_5A7X*_P#!O;_P;+_$K]FK]I[1?CE^T)::;X;N/!IDG\-^
M$X+^&_NY+YE>-;J[DA9X4CC5M\:)([M(5+>6(RDG[U4 %%%% !1110 4444
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MVI:3K%K%>V-Y;N)(;J"5 \<B,.&5E8$$=015^@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X@_X+)_\ !#;X:_\
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MK:S.QU#3M%.D0M&<;5\@SS_,.?FW\\<#'/4444 %%%% !1110 4444 %%%%
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M10 4444 %%%% '#?M(?LU^!OVNO@WK7P_P#B-X;T_P 5>$]?A\J[L;M,C/\
M#(C##1RH?F61"'1@""",U_*Y_P %OO\ @WO\>?\ !*;Q7/XT\(OJ?C3X)W=R
M#9ZZJ9O?#KLPV07X0 *=Q"I<* CG (C=@A_K<K^=7_@Y[_X. =8\;>*O%G[+
M_P )VU+0O#^DSRZ3X[UN6%[:ZUB5"5ET^!6 9+4$%9), S$%5_=9,P!\1_%[
M_@XV_:2^-?\ P3WLO@!K7B16M\O9ZMXK1W&N:]IFU1'8W$N>1]X22C#S)L5R
M?WAE^%?#_B"^\)Z[9ZII=Y=:?J6GS)<6MU;R&.:WD0AE=&'*L" 01R"*IT4
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M9(_X.9_V0?VM/LMJOQ&7X<ZY=8']F>-[?^R2A/&#=;FL^O  GR?2OA/]N?\
MX,J])U<WFL?L[_$B72)F)D3PWXR!GMLGG;%?0IYB*.@62&0GC,@ZU^.G[:W_
M  2?_:#_ .">]])_PM3X9>(-"TE9/+CURWC%]H\Y/W=MW"6B#-U",ROZJ.:
M/[9O#OB33O%^AVNIZ3?V6J:;>H);>[M)UG@G0]&1U)5A[@U\.?\ !</_ (+A
M^#?^"2'P<^R6GV'Q+\8O$ULQ\.>'&DRMNIROVZ\VG<ENK X7(:9E*J0 [Q_R
MB_LU?MO?&#]CG7!J'PM^)7C+P-,7#R1:3JDL-M<GTF@SY4PX'RR*PX'%<Y\>
M?CYXR_:?^+6M>._B!XBU'Q5XN\13_:-0U*]<-+.V     J(J@*J( J*H50
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MA4CC10 JJH  %:E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1A4B@R<O0!^J]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\G/_!R
M]^TU\2/A[_P6U^-6CZ!\0?'&AZ39_P!A^19:?KMU;6\&[0=.=ML:.%7+,S'
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M:C_Z=]'K^GZOY@?^#*G_ )2F^/O^R5:C_P"G?1Z_I^H **** "BBB@ HHHH
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MO=2?ZV]\-:]!>6</^Y8W</FMU_BONP'J: /ZVO@K_P %_P#]CCX]B$:+\?O
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M^&O#6DV.A^']#M4LM/T^RA$-O:0H,*B*.  !6Q0 4444 %%%% !17Y1?'O\
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M@W_@GE^V=H?_  4$_8T\!?%K0O*AA\6::LM[:(Q/]G7R$QW5M\P#8CF215)
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MUCIOB+XX_$2QNG,5Q8^%+*>ST= >,31V*1VP4=,R].YR: /ZHOVE_P#@I3\
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MHSY^Q2#IGR=KVY"C"I%!DY>OU7H **** "BBB@ HHHH **** "BBB@ HHHH
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M>3(8REU(2 @.0OS  @@'T?\ \&5/_*4WQ]_V2K4?_3OH]?T_5_$G_P $O_\
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M@#^GZBOY@?\ B-6_:F_Z$']G_P#\$>K_ /RSH_XC5OVIO^A!_9__ /!'J_\
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MQ^-=#HG_  8_?#VWA<:E\>_&5U(6^1K;P];6ZJ/0AI7R??(KXM_XC)/VN/\
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MTO4EM6E<R2!'NK:6159RS; VT,S$ %B3Z5_Q%&_MV?\ 1<O_ "S/#_\ \@T
M?U^T5_''+_P<C?MMS2,S?'O7LL23MTC3%'X 6V!]!4-[_P '&W[;&H6<D$GQ
M]\2JDJE6,>G:?$X!]&6W#*?<$&@#^R*OG7_@JW^WII?_  3;_83\=?%2]>V?
M5-,M#9^'[28C_B8:K."EM%M)&Y0W[QP#GRXI".E?RF?\/]_VR?\ HX3X@?\
M@1%_\17F'[4?_!2?X\?MK>%].T/XJ_%+Q9XWT?2;DWMI9:C<AH(IRI3S-B@
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MGWQ^%<U?_P#!WW^QS9V<DL>I?$:ZD09$,7AE@\GL-TBK^9%?RD44 ?U*:O\
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MEY\2M0^.6F:#H=KI]MI.@:(_AQYCI-K&@:1#()QYC/<//(6P.) N,**^5_\
MB!YU_P#Z."T?_P ):3_Y(KQ?_B-6_:F_Z$']G_\ \$>K_P#RSH_XC5OVIO\
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MH_XC5OVIO^A!_9__ /!'J_\ \LZ /Z?J*_F!_P"(U;]J;_H0?V?_ /P1ZO\
M_+.C_B-6_:F_Z$']G_\ \$>K_P#RSH _I^HK^8'_ (C5OVIO^A!_9_\ _!'J
M_P#\LZ/^(U;]J;_H0?V?_P#P1ZO_ /+.@#^GZBOS!_X-O?\ @M7\5/\ @L'_
M ,+F_P"%F:!\/]#_ .%=_P!B?V;_ ,(Q8W=KY_VW^T/-\[[1<S[L?9(]NW;C
M<^=V1C]/J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH _+C_@HO_P &M/PW_P""C?[9/C'XS:_\3O''
MAW5O&7V+S]/T^TM9+>W^S6-O9KM+J6.Y;=6.>['M7B7_ !!&?!__ *+1\2O_
M  !LO_B:_;2B@#\2_P#B",^#_P#T6CXE?^ -E_\ $T?\01GP?_Z+1\2O_ &R
M_P#B:_;2B@#\@?V:/^#/KX5_LS?M'?#_ .)&G?%OX@ZEJ'P^\2:=XEMK2YLK
M-8;J6SNH[E(W*KD*S1@$CG!.*_7ZBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K^?_ /X/D?"4WG?LVZ\BNUOM\16$S<;8W_XEKQCURP\SV^3WK^@"OS3_
M .#JS]A_6OVQO^"7-]J?A;3[K5?$WPIU>'Q9%9VL?F3W=FL<D%XBC/\ !#-Y
MY RQ%M@ D@$ ^2_^#'36K6?X8?M%:<LFZ\M=4T*YECVGY8Y(KY4.<8.3%(,
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M@J?V6?\ H?OV@/\ P>:1_P#*ROS_ /\ @RI_Y2F^/O\ LE6H_P#IWT>OZ?J
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M_E91_P 05/[+/_0_?M ?^#S2/_E97Z_44 ?D#_Q!4_LL_P#0_?M ?^#S2/\
MY64?\05/[+/_ $/W[0'_ (/-(_\ E97Z_44 ?D#_ ,05/[+/_0_?M ?^#S2/
M_E91_P 05/[+/_0_?M ?^#S2/_E97Z_44 ?D#_Q!4_LL_P#0_?M ?^#S2/\
MY64?\05/[+/_ $/W[0'_ (/-(_\ E97Z_44 ?D#_ ,05/[+/_0_?M ?^#S2/
M_E91_P 05/[+/_0_?M ?^#S2/_E97Z_44 ?D#_Q!4_LL_P#0_?M ?^#S2/\
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MO=$_X-LOVUXW#+\$=85E.01JMAD'_O\ T ?LM_Q!4_LL_P#0_?M ?^#S2/\
MY64?\05/[+/_ $/W[0'_ (/-(_\ E97W;_P23UGXPW_[ _@/3_CQX7U#PO\
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M ?D#_P 05/[+/_0_?M ?^#S2/_E91_Q!4_LL_P#0_?M ?^#S2/\ Y65^OU%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "AE#J5894\$'O110!^37[?O_  :(? ?]K3XBZIXP^'_B+6O@MKFL,TUU
M9:;8Q:AH33L2QF2S9HWB+$\I',L> -J)R3PG[)O_  9;?![X2>.;+6?BE\3/
M$WQ6MM/F\Y=(M=+3P_I]YCHD^V:>9D[D1RQDD#)QD']H** ,WP;X-TGX=>$-
M+\/^'],L-%T+0[2*PT[3[&!;>UL;>) D<,4:@*B(BA550   !6E110 4444
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MU_7Y_P %8O\ E%E^TM_V2KQ1_P"FBZK^0/\ X)._\I3?V:?^RJ^%_P#T[VM
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M_P"FBZK^0/\ X)._\I3?V:?^RJ^%_P#T[VM ']OE%%% !1110 4444 %%%%
M!1110 4444 %%%% !7X _P#!\Y_S:[_W-?\ [A:_?ZOP!_X/G/\ FUW_ +FO
M_P!PM !_P8Q_\W1?]RI_[FJ_?ZOP!_X,8_\ FZ+_ +E3_P!S5?O]0 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?R!?\'1W_ "G7^.?_ ' /_4?TROW^
M_P"#7'_E!1\#/^X__P"I!J=?@#_P='?\IU_CG_W /_4?TROW^_X-<?\ E!1\
M#/\ N/\ _J0:G0!]_P!%%% !1110 4444 %%%% !1110 4444 %%%% 'S_\
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M'PMX)\,^'_!_AG2_,^QZ1HFG0Z?86GF2-+)Y<$*K&FZ1W<[0,L[$\DFN@HH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,_Q9X3TOQ[X5U+0M=TS3]:T
M36K26PU#3[^W2YM;^WE0I+#+$X*21NC,K(P(8$@@@UX_X3_X)E?LV^ O%6FZ
M[H7[/?P/T76]%NXK_3]0L/ NEVUU87$3AXIHI4@#QR(ZJRNI!4@$$$5[A10
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M@^:F"Z!AE98D/8@@']KU%0Z;J4&L:=;WEK*EQ:W4:S0RH<K(C %6!]""#4U
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M_;2^,=VL;&VA\$PPR2=E=[Z$J/Q".?\ @)H _I.HHHH **** "BBB@ HHHH
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MA2'QWX*UC0[BXNK2#6;*:QDGM659X5EC9"Z%@P#@-D$@C(&0>E?C_P#MD_\
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M+^+-GX?T_P 47_@>ZEO[/3;Z9XK>6X,$D<+N4^;$<CI)@8+>7C*YR/T(T/\
MX/*?VLM.\7?VA>:/\(=0T]F^;3&T&YCA"\9"NMT)0< X+.V,\@]*^X/V-?\
M@RY^'_PD^-TFM?&+XCS?%GPA90@V6B6.F2Z"+R?<<FZ=+B1_+"@82)U+,W+
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M_@I7XJ^)OPWN]0OO">J:;IMK;S7MFUI,SP6D<<F8VY #*0">M?MQ_P $$?\
M@N=^S]J/[-7[//[-T6L>(C\4ETB#0#:'191:_:D5W8>?]S;M4G=0!^C'QO\
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MM#N)H6OO%UAH-_&C$+=6-_.EG<1L,X;]W,S*#P'5&ZJ"/[5J "BBB@ HHHH
M**** "BBB@#^?'_@^*^(-Q+XJ_9W\*I,RVMO::YJTT0!VR.[V44;'L2HCD X
MXWMUSQ\2_P#!(3_@M[9_\$=?V4?B9#X/\&V7BSXN_$C6[98IM49X]+TFPM+=
M_)EF$>V2=FFN9@(D=.%9BZ_*'^P/^#X70YK?XV?L^ZDVW[/=Z'K%LG7.^*>U
M9NV.DR=_7IQGYO\ ^#7K_@D/X _X*??M"^.]=^*4=QJW@GX4VMC++H$4[VZZ
MS=WIN1 )I(V$@AC6UF8JA4LWEY;:&1P#LOA/_P 'FG[3OA/QQ%>>*_#/PO\
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M@W2;;0_"_A6QCT[3;& 82WAC& ,]68\DL<EF)))))H ZBBBB@ HHHH ****
M"BBB@ HHHH **** "OC'_@X3^/TW[.'_  1R^.>N6DLD5]JFAKX<MC&2KAM1
MGBL7((Z%8YY&SQ]WCG%?9U?)7_!:C_@G3X@_X*E?L37'PG\.^+--\&W%YK=E
MJ5Q?7UFUU%)#!O;RMJD,"7*'((^Z1T.* /Y]/^#1?X'VWQ>_X+%:-JUU"DR_
M#GPOJGB9%<_*)"(K!&QW*M?AAZ$ ]LU_6!7Y??\ !!;_ (-^O$'_  1]^,_C
MKQ=X@^(&A>-I/%FBQ:1;)I]A-:M:!9Q*Y;>Q#;MJ>XV^]?J#0 4444 %%%%
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M;/ __!YW\!?AGX-TKP[X=^ 7CK0]!T.TCL=.TZQGT^WM;&WC4)'%'&K!415
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M^S7_ ,$VO@AX'\10/:Z_X=\':=!J5L_WK6Y:%7EA/NCNR'_=KZ HHH ****
M"BBB@ HHHH *^6?^"U6C_$_4?^"8WQ8O/@WX@U_PU\1?#^F)KFF7>BRO'>R)
M:31W%S#'L^9FDMHYD51RS,HYZ5]344 ?R-_\$<O^"\_C[]D#]OO1_&OQL^(?
MQ.^(W@36-/GT#6QK&O7FLRZ=#.T+K=Q1SRMEHY+>'=M^8Q>8%R2 ?W#_ &T?
M^#H']EOX"?LUZMXD\!_$33?B5XTO-/<^'= TFVG,L]TRXB-R9(U6VB5F5G\T
MA]JL%1V&T_,G_!6+_@T%TO\ :'^)>K?$#]G/Q'X?\!ZKKEPUWJ'A+6HY(M%,
MSMNDDM)H4=[8$[CY)B=,MA6B4!1\2>!_^#-G]J_Q%XHAM-7U;X4>'M-\T">_
MEUR>XVQY^9DCCMRS-CD*VP$X!9>2 #X0_P""9/[,VN?M?_M]_"?X?Z#:7%U<
M:UXELVNVB4M]DLHI5ENKAL=%C@21R?\ 9QU(K^IK_@X[B^+&D_\ !*OQIXJ^
M#?B[Q9X/\4^ [FWU^[N/#M_)8WESIJ;XKQ/,C*L$CAF:X.""/LP(Y J3_@C3
M_P $'OAI_P $A/#%]J6GWLOC?XH>(+<6VJ^*[VU6!HX,JQM+2$%O(@+*K-EF
M>1@"S$+&B?<6H:?;ZM83VMU!#=6MU&T4T,J!XY488964\%2"00>"#0!_)G_P
M1-_X+Z^-?V,OVYX?$7QR\??$CX@_#SQ98/H>MR:MK5WK,VC[Y8Y(]0CCF=V<
MQNF'5/F,<LI4.X5#^R7_  4B_P"#G#]FGX-_LD>(YOAG\0M-^)'Q \2://:^
M'M+TB"9EMYY8]B3W;NBK"D1<.8W(D;:5"YW%?E'_ (*6?\&:L_CWXHZEXL_9
MJ\7>&_#NEZO,;B7P?XE,\-MIKL27%I=Q)*WE<C;#)'\F#^]((5?E[X7?\&:?
M[4WBWQ3!;^)-=^%OA+2=Z_:+UM7GOI50YR8X8H?G88Z,Z Y^]UH ^3/^"$_[
M(VL?MF_\%4?@_P"'=-M6FT_P_KUMXJUV4Q>9';:=I\T=Q-OSP!(52 $Y&^=.
M#T/]H5?(G_!(C_@C?\-_^"0_P9N=%\*RS>)/&7B!8G\2>*KV!8KG570?+''&
M"1!;*Q8I$&8C<2SNWS5]=T %%%% !1110 4444 %%%% 'XL_\%:?^#6#QI_P
M4?\ ^"@GQ ^-&D_%KPOX9T_QE_9WE:9=Z1//-;?9=-M;-MSJX!W-;EA@<!@.
MU?./_$$!\1O^B\>"?_!#=?\ QROZ-** /XA_^"H'_!/S5?\ @F+^V!K?PAUG
MQ%I_BJ^T6SL[QM1LK=[>&47$"S !')(*[L'GG%?K%_P0%_X-T/%FE>-?V>_V
ML&^)7AU]$98_$O\ PCXTV;[5Y<D4D8B\W=MW#=G.,<5]#?\ !8S_ (-A/&7_
M  4[_;L\0_%[1_BKX9\*V&M6%A9IIUYI4]Q-&;>W2$L75P/F*Y'' -?I9_P3
MU_9AO?V+?V)_AK\*=1U6UUR^\!Z)#I,U_;1-%%=LF?G56)*@YZ$T ?FM_P '
M6_\ P6=UK]C/X9Z;\!_A?K$FD_$+XA6#7NOZM:R,MUH.CLS1JD+J1Y=Q<NKK
MOR6CBC<@!I(Y%_!K_@F%\=O@G^S-^U#I_CKXY> ]>^)GA_P[%]ITOP]8- MM
M<WX=3'+=^:P$D,8#'RL$.Y3<=JLC_N)_P52_X-:?B7_P4B_;O\=?& _&GPOH
M]EXHEMDL-,NM)N9WTZV@MHH$BW"3;_RS+': "SL<9)KYY_X@@/B-_P!%X\$_
M^"&Z_P#CE 'T O\ P>X_!U%"K\%OB4%'  OK+C_QZOMK_@CI_P %NO!__!9#
M_A8W_")^"_$OA#_A7/\ 9GVK^UIX)?M?VW[7LV>63C;]D;.?[XQWK\I?^((#
MXC?]%X\$_P#@ANO_ (Y7Z-?\$ /^"('B/_@C5_PMK_A(/'FB^-O^%C_V/Y']
MGV$MK]B^P_;]V[>QW;_MBXQC&P^M 'Z-4444 %%%% !1110 4444 <?^T-\,
MYOC5\ ?'/@VVNHK&X\6^'[_1HKF52R6[W-M)"'8#DA2X) ZXK^?O_B" ^(W_
M $7CP3_X(;K_ ..5_1I10!_-G\0_^#*_XA?#[P!KFOR?'+P9<QZ'I]QJ#PKH
M5RK2B*-I"H/F<$[<9]Z_)G]CC]FR\_;%_:H\ _"W3]4M=%OO'NM6^BPW]Q$T
MD5HTSA0[*N"P'7 /-?W*?%/PA)\0?ACXCT&&9+>;7-+N=/25P2L32Q-&&('4
M MFOQ&_8(_X-%/'?['7[:'PS^*5_\9/"6MV?@+Q!:ZS-86^C7$4MVD3ABBLS
MD*3ZD4 ?:?\ P0/_ .",?B+_ ((Z> _B3H^O>.-%\:2>.KZRO();"QEM5M!;
MQS(0P=CNSY@/!'0U^5GQ3_X.]?VJ?A-^TGJ7A+Q=X(^$>CVO@SQ/)I/B#3])
MTN\:\9+6\,=S DT]TZ^85C= YC R<[1T']*]?DK_ ,%Q?^#872?^"C_Q.NOB
MM\*/$&C^ _B?J2!=:M=3CD_LCQ$Z($2=VB5GMY]JJK.L;JX )4-N9@#V3XD?
M\'/7['O@K]G*;Q]IOQ,A\2:@]D9[+PK9V<Z:U=7&TE;9XF0"$[AM,DA$8ZAF
M!7=_+W\,_A]XV_X*I_\ !0VWTBPA5O&WQO\ &4][=/!$TD5G)>7+W-U<%<Y\
MJ%&EE;G(2-CGBON[PQ_P9N?M::SXG6ROM2^$NCV(<A]0FU^>6+:#C*I';-(2
M1R 57W*U^T?_  1@_P"" OPX_P""16E7FO)J4GCSXK:U:FTO_$US;"WCM+=B
MK-;6<&YO*C)52SLS.Y7JJX0 'W+X)\(6/P]\&:1H&EQ>1IFAV4.GVD>?]7#$
MBQHOX*H%:E%% !1110 4444 %%%% !7C?_!0KP3XZ^(G[#_Q2TGX8:QJN@_$
M2?PY=R^&[S39S!=+?QH98$1QRID=%CSZ.>U>R44 ?QJ_L/?\%KOCE^RQ^W#X
M"^(WQ ^)7Q:^(FC>$]39=:T+7/%-]?\ VRTDCDMKA/*N)2AE6.5VC#X"R(AR
M,9']%/Q'_P"#G3]CGP3^S[-XZT_XHV_B2Z:T,UGX9L;&X76KN?:2+<PNB^2Q
M8;2\I6,==Q!&?G3_ (+)_P#!J%H/[;GQ5UCXI?!'Q%HWP[\=>()7N];T35(7
M&AZS=.<O=+)"K26LKDLTFV.1)&.[:C%V?\[=#_X,X/VM]2\1K9W5_P#"73;/
M?M:_E\03O"%R!N"I;&0\<@%1T[4 ?!*Z5XP_X*:?M_7B:+I>_P :?''QO<7D
M=I"&ECM[C4;QYG+$#/E1>:S,Y "HC,< '']8G_!8S]@63]I?_@C7X]^#_A.U
M:ZU;P[X;M+CPW!%$OF3SZ68IX8(UX >9+<PC& /.["O/?^"*/_!O'X!_X)+/
M/XPU+6/^%A?%W4K9K2779+7[/9Z/ WWX;*$EF4L,*\KL7<+@"-69#^B5 '\4
MW_!&S_@H/%_P3'_X*">"_BMJ&GWFK>'++S],UZSM-OVB:PN8S'(T6X@&2-BD
MJJ2H8Q!2RAB1_1W^U+_P<_\ [*OPM_9/UCQIX'^)6G^-O%UYIDI\.^'+.TN(
M[ZXOC&WDI<))$/LT:O@N\H&%!VAR55O _P#@L3_P:::'^V+\4-8^)WP'\0:+
M\/\ QCK\SW>L>']5CD70]3N7;<]Q%)$KR6LCDLS*(W1F.0(\L3\!>"O^#-G]
MJ_7_ !;#9:MJWPHT#2_- GU&37)[A5CS\S)'';EV;&2JML!. 67J #Y(_P""
M'G[-NL_M3?\ !5SX'>'='AN&33/%5GXBU*>.,LMI9:?*MY.['HF5A\M6;C?(
M@Y) /]IU?$O_  1J_P""'?PY_P""/_@'4I-'O;CQA\1_$\$<&O>*;N$0M+$A
MW"VM8<L(+<-\Q&YGD8*78A(U3[:H **** "BBB@ HHHH **** /R)_X/'/V.
MM2^//_!/;PU\2M$L/MVH?!S7&NK\)&6EATJ]18;B1< G"SQV3,. $5W) 2OR
MH_X-F_\ @L#X+_X)6?M'>-+'XF?;K/X>_$^QM+>^U6TMGNGT>ZLWF:WF>&,&
M1XBMQ.K>6K."R$*0#7]7_BCPOIOC?PUJ&C:Q86>J:3JUM)9WMG=1+-!=PR*4
M>-T8$,K*2"",$$U^ ?\ P4/_ .#,+5[WQY?>(/V:?&&@VWA^\?S1X4\67,\<
MFG9SE+>]5)3*N=H59@K 9S*YZ@'L7_!PG_P<#_ 'QK_P3N\8?"WX1^/--^(7
MC3XF6T6F$Z7!)+::59-*CW$LTKJJ!FB1XU127#2*Q4 9/PO_ ,&;W[.FL?$S
M_@IWJWCZ&WG7P_\ #+PO=27ETN/+%U??Z-;V[=\O']JD&./]&;)' .I\"_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HK/MO%FEWGBJ\T*'4M/EUO3;2"_N]/2X1KJUMYWF
M2":2('>L<CVUPJ.0 Q@E )*-C0H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW?\ @W1_Y0J? '_L"7'_ *7W- 'VM1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ?\ [%O4O_2J*OLG_@S.\'6.@?\ !*7Q!J<"'[9KWQ U&:ZD8#)\NTL8D0$
M': F0"3AG<]\  _#S]O7_@GQ^TO_ ,$+_CIX=U+Q%XHGT76/%"RWVD>+O!NO
MW0BOY8G4S)YY6&<2H9(V8.@R)5(+<X_HD_X-L_\ @J#XH_X*=?L'7&I?$"2&
MZ^('P_U=O#VK:A$BQ_VS'Y,<L%XR* J2.KLCA1@M"S *'VK\S_\ ![5HT,_[
M"'PEU!@WVBU\>_9T/;9)I]TS?K$E<7_P8\_\D5_:"_[#>C_^B+J@#]UJ***
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:?9^';6QFEU2>^D6.UAM51C*TK-\HC";BQ/ &<T ?P]>!/VV/&7P^_8G\?\
MP)L;@KX/^(GB#2_$&H*7^X]DDX,87'(E=[5V)/!LH\#DU_0?_P &:?[%;?!S
M]A?Q5\8M4LTCU;XO:P;?39#DM_96GL\*'G[I>Z:[R!]Y8HCD\ ?SK7GPML/C
M;^US+X)^%,-S>:7XN\7G1/!T5WN$T\-S>^38K)D;MQ5X@<C.2>,U_;W^S%\
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M'_[%O4O_ $JBK[>_X,Z?^40TW_8]:K_Z*M*[S_@M_P#\$ /^'ROQ&\!^(/\
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M^UTJRTO3_"UEX).I1V:P1!&D-P;^)I'E?=([,NYG=BS,Q+']</@-\,/^%)?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEG95WW!C9XU5!L179MSLR^7^R%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 445\"_"O\ X.0OV=?BG^VE:_ 18_'V@_$"Z\1S^$S'J^CQP6L&
MI12/"8'D69L%IHS&N 0691T.: /OJBBB@ HHKX3_ &9_^#B+]GW]KW]LJW^!
MO@"/QYKOBZZO[VQBO(M(C_LIUM%E>6Y^T><?W&V)F5]OS!E &6 H ^[****
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M?O\ L"6__I?;5^ _P\^+W[4'_!K7^WQIOA+Q-J$UYX-NYHM1U/0K2\:Z\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M37XP_P#![_\ \G&? ?\ [%O4O_2J*OVT_P""3O\ RBR_9I_[)5X7_P#31:T
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M0U+P[_P4?\?>%(F+:1XF\!3W=S'N(_?VM[:>3)[X6>=<?]-,YXP?Z<Z^._\
M@G?;?L,^(OB'<ZS^S+#\ ?\ A,ETR1;G_A#H[&#6(K%I(]_F11@3K"9/*!+*
M%W;!UQ7V)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\%:/X=T.Q@TW1- LH=-T^S@7;':V\,:QQ1J.RJBJ /05J444 ?E[_P ''O\
MP0BO/^"IW@'1_'WPV:QM/C-X&M'LX;>ZD6"W\4:=N:06;RD?NYHY&=H78B/,
MTJO@.LD?Y'_LU?\ !=/]M3_@B5HEK\'_ !YX1:^T302UGINC?$32+Q+G3H8L
M*(K*Z62-GMU^4)S+$J%1'A2M?U95!J6EVVL6C6]Y;P74#$%HYHQ(AQR,@\4
M?RF?M0_\%U/VSO\ @MEH-Y\(/!?A'[+H.O&.WU'0OA[HMW-<ZA"QQY=W<,\K
MK QSNP8HRH(?*@Y_73_@VS_X(6ZC_P $N?ASK'Q"^):V;_&3Q]8QV<]C"R31
M^%=/#"4V8F7(DFDD$;3,K&/,,2H2$+O^G^FZ7;:/:+;V=O!:P*25CAC$:#/)
MP!Q4] 'X!_\ !Y+^S)\2OCY\?_@G<^!?A[XX\:6^G>']0BNY=!T*ZU)+5VN8
MRJN848*2 2 <9Q7[%?\ !,'PYJ'@[_@FG^SQI&KV%[I6K:5\,_#=G>V5Y T%
MQ9SQZ5;))%)&P#(ZL"K*P!!!! (KW*B@#S']MK1[SQ#^QE\7-/T^UN+Z^OO!
M>LV]M;6\1EFN)'L9E1$102S,Q   ))(%?BC_ ,&;7[,GQ*^ ?Q_^-ESXZ^'O
MCCP7;ZCX?T^*TEU[0KK34NG6YD+*AF10Q () SC-?OY10!^._P#P>-_ ?QQ\
M>OV4OA#8^!?!GBSQI>V/BRXGN;?0M(N-1EMXS9NH=UA1BJY(&2 ,\5]C_P#!
M CP)KGPR_P""/WP-T'Q)HVK>']<TW1YX[O3M3M)+2[M6-[<L%DBD =3@@X('
M!!K[!HH _GU_X."O^" 7Q4\#_M77G[4G[+^GZUJEQJFI#Q%KFB^'_EUC0-60
M^:VHV2)AYEED7S&2/=,LSLP#(^(O"_!__!XE^UA\&O!K>%?%W@OX:Z]XLTF-
M;5]3UO1KRROC(H +75O#/%&9#U(1(AS]VOZ?JIW_ (<T_5;R*XNK"SN;B#'E
MRRP*[QX.1@D9&#SQ0!_+#^SA_P $[/VL_P#@X^_;%L_B=\9?^$BT7P#,\:7_
M (HO[#^SK.STU'W"QTB!EQ(VUV"%59 Q9Y79R=_[G?\ !:W]G]M-_P""'/Q3
M^&OPW\+W]Y%I/A:PT;0="T>SDNIQ!;W-JD<,448+MMCC' !.%S7VY10!^.__
M  9R? ?QQ\!?V4OB]8^.O!GBSP7>WWBRWGMK?7=(N-.EN(Q9HI=%F12RY!&0
M",\5UW_!R5_P03U'_@IKX;TSXH_"N.S7XR>$; V$NG3SK;P^*M/4O(D =L(E
MS&[MY;.51A(RNP 0K^K5% '\J?[-G_!?C]M+_@C1X>M/@_\ $'PB-6TOP_OM
M=.TSXBZ3>QZAIT$?RK#:W2R1L]NAV[-WFHJ;5C*ILQD?M0_\%K?VT/\ @N=I
ML_PC\(>$Y%\.ZM)'%J'AWX?:+=2-?(SC8+ZX9Y76$,I)RT46 2X(7(_J[U/2
M;76K7R+RUM[N$D,8YHQ(N1T.#Q3M/TVWTBS2WM;>&UMX\[8HD"(N3DX X&22
M?QH _-G_ (-Q?^"(M]_P2D^"^N>)OB!)I]U\7_B$D2:C%9OYT/A^QC):.Q27
MI)(S'S)77"%@B+N$0D?]+*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<Z#(UKK.O:G,[:'HUTK8>V2.)E>ZF3!#D21I&XVYD8.J_!^J_P#!QS_P4?\
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M/^$_Q=\/Z1X#^)VJ@KHVH:9*RZ-XAE ),"I*S26]P0/D0O(LA! 96VHWZY4
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M6'QXL/#_ .T=I&N^)M'ED$ESH7C'1(]/O+FWW?O);*^BC0N><!B9H@1C:.:
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M  <K_P#!3[]H;]F#_@K+XR\(?#WXQ>/O!_A>STG29H-,TO59+>VB>2SC=V5
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MO_BA^Q[^R]\*-6^%OCSQ-X#U+5O%,]I>W.C7K6LES"+1G".5ZJ& ./6OI?\
MX-W?CAXO_:0_X(Z_!_QIX\\1:MXL\6:U_;7V[5=3G,]U=>5K>H0Q[W/)VQQH
M@] @':@#[5HHHH **** "BBB@ HHHH **** "BBB@ HHK^3O]L/_ (*4?ME>
M-/\ @K7\7OA'\+?C+\4'NKCXJ:[X;\,:#8Z\;>)%35+B&WMHM[*B*JJJC)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?\'5?[7'_#,/_!([Q7H]G>/:Z[\6+ZW\'V?E_>\B4F:\R/[C6L,L1/K.H[T
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M%R7$TL\BIKD0:1RQ")KVHHBY/954*!V  ' H ^^J*** /QS_ .#Q?_@H#=?
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MOB)\1+$S^(+^U?$VA:,Y9/+5P?DGNBK(#RRQ+(?E+QO7ZL?M'_'KP_\ LM_
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M +,M)KY;_2]9=%9S'#<[(V68HK,(Y(P#C:KNV ?T*\9_LX?#WXC>$IM \0>
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M8:TK>+/@7X(U;3BRYCTC6;K3YE'.[YI5G4GICY1T]^/V4_X):_\ !6_X4?\
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M=_ SPW\2/A[K=OXB\'^*[7[7I]]""N\!BCHZG#))'(KHZ, R.C*0""*_,?\
MX.KO^"8OPS^)'_!.GQ5\9M%\'Z+HOQ*^&LUG?+JNF6L5G-JEE+=16]Q;W)4
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M_!5WX8_\%9O@5<>,?A[+?:?J&C3BSU_P]J81=1T2=@2F\*2KQ2*"T<J$JP#
M[722--O]N3_@FC\(_P!O7]G?7O /C#P;X=Q?V,L.EZI#IT*7V@7)C98KJVD"
M[D>-B#@?*P!5@RL5/\_O_!G7XXUOX7?\%8_%O@J=IH;;7O!NH6FHV8D#1BYM
M+JW='.#@LF)D!!(Q*WKF@#^H":=+:%I)&6..-2S,QPJ@=23Z5^-__!1/_@\0
M^%G[.'CN^\)_!;PF?C)J&FRF"ZU]]2^PZ"'&0WV=U1Y+H C&]0D9SN1W&,^@
M?\';W[=^K_LF_P#!.BS\$>&;Z73?$'QHU)]#FN(9?+FBTJ*/S+W8>O[S=! W
M3Y+A^>E>>?\ !M!_P0F^%O@/]D'PA\=OB9X4T7QQ\0OB':+K&DQ:S:QWMEX<
ML&8FV,,+@H9Y(PDK2L"R;U1=N'+@'S%\,O\ @]Y^(MCXEA;QE\#O!>J:.SJ)
M4T75[FQN47/S,K2B96('12%SC&1G(_9__@FC_P %6OA#_P %6/A+=>)OAAJ]
MQ]NT=TAUSP_J<8M]6T.1P2@FC#,K1N VR6-FC;:ZAMZ.J][^T'^PS\'?VJOA
M[<^%OB%\-?!WBC1;B-HQ%=Z9%YEMD8WPRJ!)#(!T>-E8=B*_FM\'Z-JW_!NI
M_P '&-AX7T/5M2N/A_<ZS9:=*]S*H;5/#>J>42)L##/;,^<X7=+99&U6H _I
MN_:C^.,/[,?[,WQ%^)5SI\NK6_P]\,:EXFEL8I1$]ZEE:2W)B5R"%+B,J&((
M&<X-?F[^RU_P=G_!GXT_L]?%CXC>-O">L?#G3?AD^EVUKIYU*+4M0\4W5^+T
MQVUI$%B'F*+)B2Q"!6W,R*I-?;G_  5B_P"467[2W_9*O%'_ *:+JOYC?^#:
M_P#X)B^&_P#@IG^WW+I_CZQN-0^'?P_T=_$.L6B.T<>J2^;'%;6;NI#*KN[2
M-MP62W=<C<#0!]B?$W_@]Z\?W7C&9O!OP.\'V/A^.9A$FM:O<W=Y-&&^5F:(
M1)&Q7JH#@$XRV,G[J_X(^_\ !S_\.?\ @I?\4+'X9^*_"]Q\+?B9J@8:5;O?
M"^TO7'1"[1PS[$:.;:K,(I%P0,+(S$*?T"TO]DKX5Z+\-_\ A#;3X:> ;?PC
MY/V8Z+'X?M%T]H\!=A@\O85P ,$=!7\J_P#P7(_9CT7_ ()$?\%IX;OX86*Z
M/X?L;C1_B#X<TV*4A=,<2AVA1R6(075M,R9 V*RJ 0H) /ZZJ*** "OY*_A!
M_P K8UW_ -G'ZM_Z?+FOZU*_DK^$'_*V-=_]G'ZM_P"GRYH _K4HHHH _ #_
M (/"O^"4'A_PSX6TK]J#P+H\&EW\^I1Z-X[M[2)4BO#,"+74F ("R"11!(0"
M9#-">"KLWW'_ ,&M_P"W9J7[:W_!+?1;+Q%=2WGBGX3W[^#KRXF;=+>6T,44
MEG,3DD_N)4B+'EFMW)ZY/=?\'(^AVOB#_@B5\>H;R'SHXM+L;E!N*[9(M3LY
M(VR"#PZ*<=#C!R"17YV_\&-&M74^B_M-:<\S-8VL_ABYBA_A221=65V'NPBC
M'_ !0!^^E?S;_P#!W9^U)JW[67_!0CX:?LS^"FDU23P>+>.:QMY#_IFO:JT:
MPP,N,%DMS;[3DD&[D''.?Z&OC]\;-!_9L^!WB_XA>*+AK7P[X)T>ZUO49%&Y
MQ!;Q-*X4=6<A<*HY9B ,DBOYLO\ @VX^#>M?\%0?^"W?C#]H+QK;M>6O@N[O
M/'-_YC^="FJWLLB6%N-P)VQ;I98\8V_8D P %(!V?_!TY_P2=L/V1/V6_P!F
MCQEX5MFN+'P'X<M?A=X@O$!_TAX(FGM+EP !NED-^7? Y:-?[H'[,?\ !$G]
MN]?^"BG_  39^'/Q"NKL77BB"S_L+Q1E@9%U6T BG=P.%,P"7 '9+A*ZO_@J
MS^QA;_\ !0'_ ()\_%#X5O%')J7B#1Y)M%=V*"'4[<BXLF+#D+]HBC#8ZHSC
MD$BOPZ_X,VOVX+GX+?M9>./V=_$LTUC9_$&!]5T>TN5\MK;6;)#]HAVD!@\E
MJKE@>GV)1C)- '])5?SS_P#!\=_R4/\ 9Q_[!VO_ /HW3Z_H8K^>?_@^._Y*
M'^SC_P!@[7__ $;I] 'ZQ_\ !!__ )0\?L\?]B=:_P#LU?6M?RO_ +&__!VA
M\7OV,?V7/ _PKT7X9_#?5M)\"Z7'I5K>7KWHN+B-,X9]DH7=SV %>E_\1MGQ
MR_Z)#\*/^_FH?_'J /WS_P""@_PW\"_%C]A[XKZ)\2H=/D\#S>%M0FU:6\5?
M+LHHK=Y?M()QL>$H)%<$%616!! -?SG_ /!F?XDUG3/^"K.O:?I[3-I>J> -
M1_M2(/B,)'=631R%>A99-J@]0)6[$Y\__:0_X+-?MM_\%S-*;X3>'_#[W&B:
MHT46I^&_AQX>N5AO]SCRS>3/)/*L(922'F2'@EP0H*_LI_P;9_\ !#S5/^"6
M?PGUSQM\25LS\8?B%;16]W9V\B3Q^&=/5A(+(3(2LDKR;7F9&,>8XE4L$WN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4RS,Q))/))H _+.Q_P"#WCP)IEE#;6W[._B2WM[=%BBBB\36Z)&BC 50+?
M   '2OR=_P""V_\ P4\TW_@K1^V'8_%#2O"-]X+M;/PW::";"[OEO)&:&:XE
M,F]408/G@8QQMZ\U_5'_ ,.8?V2_^C</@S_X2EG_ /$5_.9_P=:?LW> /V6O
M^"F>D^&_AOX-\-^!O#\W@73KY].T2PCLK9IWNKU6E*1@#<51 3U(4>E 'Z_?
M\$M?^#H'PU_P4]_;%T/X0Z9\(M<\(W>M6=Y>+J5UKL5U'$+>!IBIC6%2=VW'
M7C-?J=7B7P4_X)L_L_\ [-WQ MO%GP_^#/PW\&^)K..2*#5-'T"WL[N))%*.
MJR(H8!E)!&>0:]MH *^*?^#B[_E"I\?O^P);_P#I?;5]K5\4_P#!Q=_RA4^/
MW_8$M_\ TOMJ /S7_P"#&/\ YNB_[E3_ -S5?O\ 5_,M_P &DO\ P47^"G[
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MK4EU3PWXMUYDAL5#1*DMA,Z(L5JBF)9(V?:A,LH)4[ X!^=-W^Q?_P %!/\
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MD?\ M:OZLZ /BG_@XN_Y0J?'[_L"6_\ Z7VU?$/_  9&?\F??&C_ +'&V_\
M2)*^WO\ @XN_Y0J?'[_L"6__ *7VU?$/_!D9_P F??&C_L<;;_TB2@#MO^#U
M;_E%EX!_[*KIW_IHUBO9O^#4G_E"'\+_ /L(ZY_Z=;JO)O\ @] \/76M?\$H
M_"ES;H&ATCXF:;=W))^Y&=.U2$'_ +[F0?C3_P#@U/\ VX?A'IW_  2C\)^
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M\'EW_*6G1?\ LG>F?^EFH5_4O7\M'_!Y=_REIT7_ +)WIG_I9J% ']2]%%%
M!7\E?P@_Y6QKO_LX_5O_ $^7-?UJ5_(*_P 8/#?P _X.=?%'C3QAJD6B>%_#
M/[0FLW^IW\L;R)9P)KER6D8(&; ZG - ']?5%?%/_$1=^Q3_ -%^\+_^ -__
M /&*X?XS_P#!TU^Q7\(] NKFS^)U]XUU&WA,T6F>'O#]]-/='!PB2S116X8D
M8P\JXR,X'- &3_P==_M!6/P6_P""-OCC19+R.WU?XD:EIOAW38SM9Y2+N.[G
MPI!X^SVLP+=BZ\@D5\U?\&1_P+NO"W[*GQH^(L\,D,'C+Q-9:);%U9?.33K>
M20NN>"N[467('WD89)7 _-S]O#]MWXV?\',_[?OA?P7X!\*WEEX?LI&M/"OA
MM9&EATBW=T%QJFHS*I56/R&1PNR)%2-0[9>7^GC_ ()]_L8>'_\ @GQ^QWX%
M^$7AIOM%CX1T\0W%X4V/J5Y(QEN;EADX,LSR.%R=H(4'"B@#\W_^#QK]N9O@
M7^PMX?\ @[I%XT.O?&+4M]^(V9632+%DEE!(Z>9<-;+@G#(LPP1G'Y2?L%_\
M$_?^"D?PT^#-IXH_9_\ #_Q(\+^#OB-:VVM17.B^(['3DUB$H3!.R/<(^"CD
MKN4</D<&N@_X*G>/]3_X+>_\'"\'P]\-W,EUX?7Q%:_#G1I[8AOLVG6DS_;K
MT$Y5E#F^N P',8488CG^JWP7X.TWX=^#M)\/Z+9PZ?H^AV<.GV%K$,1VT$2"
M..-1Z*J@#V% '\T?_#-__!9K_H(_'#_PN=/_ /DNOA7XP_#/]HS_ ()-_MR^
M"_B%\4_#>M>%?B:NK1>.K.:^O(IO[8=;QGE9YK>1T822)(LJ;LE9/F7:XS_:
MQ7Y,?\'?_P"PX?VC/^"=NG_%#2;-KCQ%\$]2^W2LBEG?2;LI#=J /[LBVLQ8
MYVI#)TR30!^FO[//QRT']IOX$>#_ (B>%YS<>'O&VCVNM:>[##B&>)9%5A_"
MZ[MK*>0P(/(K\&?^#X[_ )*'^SC_ -@[7_\ T;I]>]?\&:/[=W_"V_V1/%?P
M)UB\5]9^%=\=3T6-OO2:3>R,[J.>?*NS*2>,"YB':O!?^#X[_DH?[./_ &#M
M?_\ 1NGT ?J=_P $*_ NAZC_ ,$@OV>Y[C1M*GFD\'VK/)):1LSGYN22,FMS
M_@I7_P $<?@O_P %,?@EJ7ASQ-X9T?0O%'DL=%\6:;IT4>J:-/CY6#@ RPD@
M!X7.UUZ;6"NL'_!!_P#Y0\?L\?\ 8G6O_LU?6M '\IO[#G_!2KX^?\&X'[<^
MI?!+XGMJ.N?#/0]5:TU[PO),TMM';S.'75M)=AF,LC"8(-J3*[+(J2$21?U*
M_##XFZ#\:/ASH?B[PMJEKK?AOQ+8PZEIE_;/NAN[>5 \;J?0J1P>1T/-?E]_
MP=._\$@5_;D_9>/Q@\#Z3]H^*WPGLGEFBMH=]QXAT52TDUJ .6D@+//$.2?W
MR %I5Q\C?\&@'_!7+_A&=;D_93\=:@J:?J4D^I^ +F9@JP7#%IKK3<D])#OG
MC&/O^>,DNBT ?T+T444 ?B3_ ,'NG@6;4/V0O@KXF59/L^D>,+G3'('R!KJR
M:5<\=<6;8Y['KV]J_P"#07X.>&_ 7_!([3_%&E6UO_PD'CKQ'J5UKET #,[V
M\[6L$3-UV)%&&5>@,SD#+DGZB_X+3?\ !/\ D_X*6?\ !.SQU\,]/^RQ^*7C
MCU?PU-.=J1ZE:MYD2EN=HE7S("W\*SL>U?@G_P $#O\ @N!=_P#!%WQ_XP^"
M?QP\-^(K7P'?:R\UY&EJW]J>$-54+#,7MV(+1,L:"1!\ZF,,H8EE8 _J6K^5
M7_@ZS\(6/[,W_!;2/Q=X,A&C:WK.A:/XPGEA) &IQS31"=1T4D6<+'&,ON8\
ML2?V8^+?_!T[^Q;\-OAI)KVF?$Z\\:7SV[RV>B:/X?U!;Z[9<?NS]HABCA))
M _?.@ZD9P:_%O]C;PM\0_P#@Y)_X+H1?$3Q-HQL/"&F:G::[XABAW7%AX?T6
MS9?LNFB1@ TD_EB+.%,CR3S! JN% /ZMJP?BK%#/\+_$D=TL3VSZ7=+*LH!C
M9#$VX,#QC&<YXQ6]7@?_  5/^-4?[/'_  3;^.?C%YHX9M'\$ZH;1G.%-U);
M/%;K_P "FDC7\: /P'_X,I)+P?\ !3;XBJC7/V!OAA>&8*6\DRC5=*\O=VW;
M3+MSS@OCO7].E?S]_P#!D#\![@ZA\>/B=<0[;58]-\+V$O\ ST<F6YN5_P"
M@6A_X'[5_0)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!^<7_!2'_@VQ^&__  4\_:BU+XI>//B9\3+;4+JSMM.L]-LI;3[%
MI-M#& (8 T)8*TAEE.23OF<]\5X-_P 04O[/O_13/BO_ -_++_XQ7[+44 ?C
M3_Q!2_L^_P#13/BO_P!_++_XQ1_Q!2_L^_\ 13/BO_W\LO\ XQ7[+44 ?F3^
MP;_P:^?"W_@GG^U/X7^+/@?XG_% ZYX9DE_T6YDLS:ZA#+$\4L$P$.3&RN>A
M!! (((!'Z;444 %%%% !1110 5^7/Q\_X-4OA!^UC^U;JWQ<^*'Q0^+WC+6_
M$&K)J6J64]Y96]I=1*R[;)3';K)%;B-5A41NKJ@&&##=7ZC44 4_#_A^Q\)Z
M#8Z5I=G:Z;IFF6\=I:6EM$L4-K#&H5(T10 JJH "@    5<HHH \U_:^_9/\
M&_MP_LX^*OA?X^T\:AX9\66AMIPH'G6L@(:*XA8@A9HI KHV#AE'!&0?CG_@
MF?\ \&Z/@/\ X)6?M#+\0OAS\6?BQ<R75G)I^JZ+J<UA)INM6[ [4G1+9&S'
M)MD1T965EQDJSJWZ(44 ?#O_  5F_P""#_PV_P""OOCGP?KWCKQ=XX\-W'@R
MQGL+2/09+54F2:19&+^=#(<@J ,$"OJ_]G+X)Z?^S1^SUX#^'&D75[?:3\/_
M  [I_ANRN;PJ;BX@L[:.WC>0J%7>RQ@MM &2< #BNSHH ^5_^"KO_!)/X>_\
M%=OA#X;\(^/=5\1^'U\*ZO\ VO8ZCH;P)=J6A>*2$F:.1?+<,K$  [HDYP"#
MO?\ !,+_ ()G^!?^"4_[-DGPT\ WFLZII]UJUQK5[J.K-$UY>W$JQIN<QHB8
M6.*)  HX0=223]%44 >;_M@?LRZ1^V9^S%XV^%>OW^I:7HOCK2Y-*O+O3R@N
MH(WQEHRZLN[C^)2/:OGO_@D;_P $3?A[_P $=O\ A8/_  @?BGQGXF_X6+_9
MWV[^WY+9OLWV+[7Y?E>3#'][[6^[=G[JXQSG[,HH *JZ[I*:]HEY8R,R1WL#
MP,R_>4,I4D>_-6J* /SK_P""9G_!MG\)?^"6_P"T[%\5/!OCCXBZ_K4.EW.E
M"TUJ6S:U,<^W<V(H$;<-@Q\V.O%?HI110 4444 %%%% !7Y]Z!_P;J_"OP]_
MP4\D_:HA\:?$!_&DGB:?Q0=*>6S_ ++\^8.&CQY'F[!O./WF>!S7Z"44 %%%
M% 'Q?_P4)_X(#_LT_P#!2;Q#<^(O&W@^YT'QM>*%G\4>%[E=-U.YP% :;Y'@
MN'"JJAYXI&"@*"  *^5?A]_P9>_LP^%O%5O?ZUXP^,'BBQMWW'3;G5+*V@N!
MS\LCPVJRX_W'0Y'7'%?KU10!PO[./[,O@']D/X2Z;X%^&GA72/!OA/2@?L^G
MZ?%M4L<;I)&)+RR-@;I)&9V(R6)KNJ** /E__@H-_P $<OV??^"FMO#<?%+P
M/!<^([2#[/:>)-+E-AK-M&-VU//3_6QJ68K',)(U+$A<DU\,Z-_P96?LSZ?X
MDCN;KX@?&S4-.BE#_8GU+38S*H(.QY%L@<'H2H4X/!4\U^PU% 'D'[%_[!GP
MF_X)\_"O_A#OA'X-TWPGI$CB:[>(M->:E*!CS;BXD+2S/R<;V(4'"A5P*]?H
MHH \3_;A_P""=GP=_P""C/PWB\+_ !=\%V'BBSLW,EA=;WMK_3'."6M[F,K)
M'G:NY0VUP &##BOSCOO^#*C]F>Y\0//%\0_C?;Z<[%OLJZEIC.@/\*R-8G@'
MIE2<#DD\U^Q%% 'SW^P%_P $MO@C_P $R_!MYI/PC\&P:+<:L$_M35[J9[S5
M-4V_=$MQ(2VP<D1IMC!)(0$DGZ$HHH **** /Q;_ .#RO]@";XQ?LM^$_CUH
M-G)-K'PLN#I6O"),M)I%VXV2L<9(@NMH ' 6[E8\+7WA_P $._VW(/V_/^"8
MWPO\<27OVSQ%8Z:OA[Q+O<-,FJ60$$SR8)VM,%2X Z[+A"<9Q7TQ\2_AOH?Q
MB^'>N^$_$VFVVL>'?$UA/I>IV-PNZ*\MID,<D;#T96(]>:_%_P#X(T? [XP_
M\$0?^"K'CK]F_7/"WCCQ7\ ?BA,-0\,>,K71YKK3;.Y"'[+/<SQ+Y<#R1JUK
M.K 'SHK=@!$0[ 'Z9_\ !3S_ ()N>$_^"J'[-"_"_P ::YXB\/Z.NKV^L_:M
M%:%;KS(5D55S+&Z[3YIS\N>!S7YX?\03?[/7_14OC-_X$:;_ /(E?LQ10!^,
M_P#Q!-_L]?\ 14OC-_X$:;_\B5[!^S7_ ,&DO[(?P \00:IJ^D^-/BA=6TJ3
MQ1^+=85[2-UQU@M(K=)$R,[)A(IR0<CBOTXHH H^&/"^F>"?#MCH^BZ=8Z1I
M.F0);6=E96Z6]O:1(,+''&@"HJ@ !5   J]110!^>?QV_P"#<7X3_M"?\%+(
M?VGM<\;?$0>+HO$>D>)#I,4]I_9CR:<MLL,)#0&7RF6UC# 2 X)P5XQ^AE%%
M !1110 4444 ?F[_ ,%'_P#@V6^$/_!3']JO6/BWXO\ '7Q(T+7-9M+6TEL]
M'ELEM$6WA6)2HEMW?)"@G+=?2OTBHHH *\/_ ."BW["'AO\ X*3_ +)WB#X0
M^+=6US0]"\13VD\]YI#1+=QFWN([A IE1TP6C .5/!.,'FO<** /E'_@D[_P
M2,\#_P#!(?X9>*O"W@7Q)XL\267BS5(]5N9==>W:6&1(A$%3R8HQMP >03GO
M7U=110 5^>O_  5%_P"#<OX4_P#!5K]I"U^)OC;QM\0O#^L6>B6^A+:Z)+9K
M;&*&6:17(F@D;>3.P/S8P!QUS^A5% !1110 5Y3^W!^R3H?[=W[*GC+X2>)-
M2U;2=#\;6B6EW>:88UNX%2:.4&,R*R9S&!RIX)KU:B@#\9_^()O]GK_HJ7QF
M_P# C3?_ )$H_P"()O\ 9Z_Z*E\9O_ C3?\ Y$K]F** /S%_9P_X-(?V0?@-
MK<6I:QI/C;XH74,BRQQ^*]:#6L;C'_+&SBMT=<C.V7S <X.17Z2> _ .A_"S
MP;IOAWPSHNE>'?#^C0+:V&F:9:):6=E$O"QQ11@(BCL% %:U% !7QO\ \%2/
M^"&7P-_X*P6UKJ'CC3=0\/\ CG3(/LUCXLT&1+?44A!W"&8,K1W$0/02*63<
M^QDWMG[(HH _GYU3_@QMNF\0R"Q_:4MTTEG)1I_ I:XC3)P"!?A6(&!G*@]<
M#I7Z"?\ !+G_ (-P?@'_ ,$Q/%UKXTL8]6^(?Q+LT9;;Q'X@*;=++J%<V=J@
M$<)(R/,;S)0&<"0*Q4_H%10 5^?>O_\ !NK\*_$/_!3R/]JB;QI\0$\:1^)H
M/% TI);/^R_/A"!8\>1YNP[!G]YGD\U^@E% &#\4OA?X>^-GPYUOPCXLT>RU
M[PSXDLY-/U/3KN/?#>02*5=&'N#U&"#@@@@&OQ/_ &E?^#)/P1XN\;7.I?"G
MXT:UX+T>ZF>4:-KNB+K(M0QR$BN$F@?8GW5$BNY&-SD@EOW.HH _%?\ 9 _X
M,M?A+\*_%=IK'Q>^)7B'XI1V<PF71M.T\:#ITXQCRYV$LT\BYYS')"3P#QG=
M]0?\%'?^#;;X$_\ !1KQ1X%U+4+[Q)\.8_A_X=3PMIECX12SM;-;".626&+R
MY('"B-I9=H7 _>'BOT(HH Q?AQX3F\!?#W0M#N-5O==N-%T^"QDU*\"+<Z@T
M4:H9I0@5/,?;N;:JKDG  P!^7/\ P4._X-'_ (&_MC_$?5/&?@/Q%J_P7\1Z
MU*UQ?6^G6$>HZ+-,QRTJV;/$T;,<DB.94R<A <Y_6"B@#^?[P5_P8Y2)K\+>
M(_VC4DTM#F:+3?!FRXF']U7DO"J?[Q5_I7ZT_P#!-'_@DM\&_P#@E-\-KW0O
MA?H]VVI:T4;6?$.JS+<ZMK#(/D$D@556-<G;%&J("2=I9F8_3%% !7Y._P#!
MXS\5_!_A#_@E79>%]>L(=2\4>,/%MB/#.<>9ILUL'EN+U0>PMS);DC)_TU>,
M$D>R?\'!OQU_:D_9K_9Y\$^,/V7+/Q%K&M6NOR6OB+3-(\+Q^('FL9+65EFD
MA,,DB)')&OSQ[<%QN)!Q7X]_ +_@FA^VM_P7[_;"\/>*/VFH?'GASP#X?<1Z
MAJ_B/1O["C@LQ('>STRR\N(-++]PRK&57;ND=F148 _33_@TA_8:D_9<_P""
M:0\?:M9?9?$WQNOQKK%XPLJZ7"&BL$)ZE6!GN%Y^[=C@'.?U.K-\&>#M+^'?
M@_2?#^AV-OI>BZ%9PZ?I]E;ILAL[>%!'%$@[*J*J@=@!6E0!^=?_  4S_P"#
M;/X2_P#!4C]IV7XJ>,O''Q%T#6IM+MM*-IHLMFMJ(X-VUL2P.VX[SGYL=.*_
M12BB@#RG]N#]DG0_V[OV5/&7PD\2:EJVDZ'XVM$M+N\TPQK=P*DT<H,9D5DS
MF,#E3P37D_\ P2=_X)&>!_\ @D/\,O%7A;P+XD\6>)++Q9JD>JW,NNO;M+#(
MD0B"IY,48VX /()SWKZNHH \C_;I_8G\$_\ !0W]E_Q-\)OB!#?/X=\31Q[I
M[&80WEA/$ZR0W$+D$"2.158!E96 *LK*S*?QA'_!D+J&B?$!+[0_VF(['3[6
M[%S92S^!O.N[;:VZ/<!?*CLI"@M\H.,[1]VOWZHH ^3_ /@J[_P2+\$_\%=_
MA=X3\*^//$GBKP[:^$M2?58)M :".2>5XC$0WG1R#;@DX'.>]>E?\$^OV)O#
MW_!.G]D/PC\&_"NJ:UK6@>#OMGV6]U9HVO)OM-[/>/O,:(G#W#*,*/E SDY)
M]FHH *_/O_@GQ_P;J_"O_@G/^V/??&KPIXT^(&M>(+^VOK:2RU:6S:S5;MP[
MD".!'R"!CYOKFOT$HH &4.I5AE3P0>]?E/\ \%"?^#27X!_MA^-M0\6> M6U
M+X(^)-4=IKN'1[&.]T.:5NL@L6:/RCZK#+&G).W))K]6** /Y_?"7_!CA,NO
M1-KW[2$;:6C R1V'@DK<3+GE0SWI5"1_$5?'H:_53_@F+_P1I^"?_!*'PI>6
M_P .='O+[Q-J\0AU7Q3K4B7&K7Z9#>5O552*'< ?+C502JEMS -7U=10!QG[
M1OP3T_\ :7_9Z\>?#C5[J]L=)^('AW4/#=[<V947%O!>6TEO(\98,N]5D)7<
M",@9!'%?*'_!)G_@@_\ #;_@D%XY\8:]X%\7>./$EQXSL8+"[CUZ2U9(4AD:
M12GDPQG)+$')(K[BHH *_/7_ (*B_P#!N7\*?^"K7[2%K\3?&WC;XA>']8L]
M$M]"6UT26S6V,4,LTBN1-!(V\F=@?FQ@#CKG]"J* "BBB@ K\FOVC?\ @T'^
M!?[2_P"T+X\^(^K_ !(^+5CJWQ \1:AXDO;:SGT\6]O/>7,EQ(D8:U9MBM(0
MNXDX R2>:_66B@#\9_\ B";_ &>O^BI?&;_P(TW_ .1*Z'X=?\&8'[+OA36X
M[S6_%OQB\4PQMG[%<:M96MM*/1S#:++^*R+7Z[T4 >.?L<_\$_/@S^P#X+FT
M+X0_#_0?!=I=!1=SVT;37VH;<[?M%U*6GFVY.!([!=QQC->G>.O#L_C#P1K&
MDVNJ7NAW6J6,]G#J-F$-QI[R1LBSQ[PR[T)#+N!&5&01Q6K10!^=/_!,[_@V
MF^"__!,+]IZ#XK^&/%'CSQ9XAL=,N=.L8M?DM&@L6G"H\Z>3!&WF>5YD?)(V
MS/QG!'Z+444 %<[\7/A;HOQQ^%7B7P7XDM%OO#_BW2[G1]2MC_RWMKB)HI5_
M%'(S7144 ?G#_P $V_\ @VK^&?\ P2^_:CT_XJ> ?B=\5+W4[6RN=-N].U*:
MP:QU2UG3#13".V1RJR+%*-K#YX4)R 0?2/\ @K9_P0W^'/\ P6#UOP-?>//%
M?C;PW)X#@O(+-=!DM56X%TT+.9/.ADY'D+C;CJ<YXQ]K44 >;_L?_LRZ1^QG
M^S%X)^%>@7^I:IHO@72X]*L[O4"ANIXTSAI"BJN[G^%0/:O2*** !E#J5894
M\$'O7Y3_ !$_X-&O@)XC_:6U#XG>%?'7Q2^'&IS:X/$.G6/AVXL8K30KH2B9
M3:B2V=HU24;D7<0G &  !^K%% %?2+6:QTJU@N+J2^N(8D26Y=%1KA@ "Y50
M%!8\X4 #/  JQ110 5\C_P#!1'_@A_\ LZ_\%.+EM4^(W@^2S\8+!]GC\4Z!
M<?V?JZ)C"[W"M'/MXVBXCD"XP  2#]<44 ?C_P"$?^#+3]F/0O%$=YJ7CCXS
M:YI\+%AI\VIV$*3#/"R/'9JY&.NPH2><CH?TS_9-_8V^&/[#/PEM_ _PH\&Z
M1X+\-PR>>\%DA,MY-M5#/<3.3+/,515,DK,Q"J,X  ]-HH *_&;_ (/,?VSD
M^&_[&O@WX':5,SZ[\5M834=1MT4L?[,L7615(!X,EX;8KP<_9Y!UP:_9#6=6
MAT#1[J^N3(+>RA>>4QQ-*X15+'"("S' .%4$GH 37X@?L*?L7?$3_@L3_P %
MJ_%G[5_QQ\"^+/!7PP^%]]#:^ _#WB;2Y+"XOVMB6L4,$RA_+BW&\E.-IN)E
M12RB0* ?H9_P0O\ V S_ ,$XO^":_@/P'J%DMEXNU.(^(_%2X&_^U+M5:2-R
M."T,:PV^1G(MQR>M?7E%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !117E_[5O[:OPI_8<^'O\ PE'Q8\=:#X'T9B5A>_F)GO&7&4@@0--.PR"5
MB1F .<8H ]0HK\O;_P#X.]/V.;/QF-*CU3XA75IDC^UHO#3"R&&(Z-()N<9S
MY70CH<@?;W['7_!0?X,?M^^$9M:^$/Q"T'QG;V@!N[>W=H;ZQ!) ,UK*J3Q
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MXQ>'(]8\(^)-!\5:1-_J[[2-0BOK9^_$D3,I_.MZ@#X?_P""I/\ P7T^#O\
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MI-T-T%[IUTEU;S#U61"5;\#6I0 445SGQ1^,7A'X'>%9==\:^*?#G@_0X/\
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MVUBYT'QQ\6C=-?:O:/LNM(TB (LGDN&#133R2JBR*"52*?&URCCXA_X)"?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(K>5XF=719 DC%2R, 0,J1P0#^@7_B*-_83_ .BY?^69X@_^0:/^(HW]A/\
MZ+E_Y9GB#_Y!KP#_ (@J?V6?^A^_: _\'FD?_*RC_B"I_99_Z'[]H#_P>:1_
M\K* /DS_ (.B_P#@L1^SC_P46_8W\ ^%?@W\1?\ A,=?T7QFFK7MK_8&IZ?Y
M-L+&[B,F^ZMHD;YY4&U6+?-G& 2/OW_@T=_Y0Q>%_P#L9-9_]*37Y:_\'#W_
M  ;_ /P;_P""2G[+'@OQQ\./$OQ,UK5O$7BM-#N8O$FHV-S;I ;2YG+(L%I
MP?="HR6(P3QG!'ZE?\&CO_*&+PO_ -C)K/\ Z4F@#]$OBY\6O#GP'^&&O>-/
M%^K6F@^&/#%C+J.IZA<MMBM8(U+,Q[DX& H!+$@ $D"OYT_@UX,\9?\ !V-_
MP5KNO&WBRQUW0?V9_A:1"EBTYC$%EOW16*E&P+Z]9=\\D9)CC7 ?]W!GN_\
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M"O'+W/AF[O%M+3Q7X>\R.UGDP6%GJ=E)N0;\.51S+$P7(;>"%_H<_P""-O\
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M>/2OT:_X.MO^4(?Q0_[".A_^G6UH _"C_@F/:_M.?\%+_@%8_L:_!2Z7PO\
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M"./P+\<KG4?#.F[M9N[/1-+:&^U*9FFNY49]2#LAFD<(6 .Q4&U<!0 >%?\
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MOAC4])^'-A?-+I>B/*5M;2(,RG6-9G0,B%8S]T;ECW>7%YLCYE_H'_X)(_\
M!+CP=_P2=_9/L/A]X<E_M?7;YQJ/B?7Y(]DNMWY4!G _@A0#9%'D[4&26=G=
M@#ZAHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2/AQX#\9_$#5K'QY'>7-EX;T2YU6XMX!I]XAE>.!'94W,J[B ,L!G)%>K_\
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MCOXT36[V]I/:0'^R_"L4B!95M#( \D[@NC7+*A\MS&J*#(TGZB4 ?RG_ /!
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M^90I7.Y?WQ^$G_!N=^Q=\&DC_L_X$>&=5F7):77KJ[UDR$[<DK=2R(/NC@*
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M72K3Q?H%KJ:Z=K=K,)/( N(W6)WC2Y3(*[G6-.2RBOZ/O^'3O[+/_1M/[/\
M_P"&\TC_ .1Z_([_ (."?^#;WX@>*_VB=4_:,_9CL9+[4M7NEUGQ!X7TR;[+
MJEMJBN9'U+3V!7>TC 2/&I$HFW.F_P S;'\O>#_^#IK]N7]B[PS:^"_B%X9\
M,:UK&GH85NOB#X3OK36&5> )/)GM1(R@@%W0N>"S,Q)(!^Y7[57[+/["/[$7
MPED\=?%3X)_LY>#_  K%>6^GF_N?AQILH:>=PD<:I%:N[$G).%(55=VPJLP]
M0_8"UG]FWQ+\,]4U']F>#X1P^%9[X)JA\ V-E9VQNUC4@7"6R+B41LG^L&[:
M1VK^:GQGX1_;[_X.0?C%H:ZYX?UZZ\-V$K&PGNM+?0?!WAU6PLD@D9,2/W/,
M]P5R%! "C^DK_@EY_P $\_#/_!,#]C7PS\)_#=Q_:DFF[[W6=7:#R7UO4I<&
M>Y9,MM!VJB+N8K''&I9BNX@'\Z'_  >!?\IA[S_L3M(_]K5_5G7\T?\ P=1?
ML(?'']H7_@JM=>(O 'P9^*WCCP^WA32[8:GX?\):AJ=F94\[?'YL,3)N7(RN
M<C(S7]+E 'Q3_P '%W_*%3X_?]@2W_\ 2^VKXA_X,C/^3/OC1_V.-M_Z1)7W
MQ_P7I^&OB/XP_P#!(GXW>&O"/A_6_%/B/5M'@BL=*TBQEOKV\<7MNQ6.&)6=
MR%5CA0> 3VKX]_X,^OV:/B1^S-^RM\6].^)'P_\ &WP^U#4O%<%S:6WB70KK
M29KJ(6:*9(TN$0LH8$;@",\4 ?K]1110!^5/_!XM_P HAH?^QZTK_P!%7=<O
M_P &5/\ RBR\??\ 95=1_P#31H]>I_\ !UG\"?''[1/_  2UB\/_  _\&^*_
M'6OCQGIMT=-\/:3<:I>"%(KD-)Y4",^Q2R@MC W#UK\3?V*O&_\ P4Z_X)W?
M"S4/!/P=^&/[0'@_PSJFJR:W=6?_  IQ]0\V\DAAA>7S+K3I9!F.WA7:&"C9
MD#))(!_6[7#_ +27[2'@O]D;X(>(OB+\0M>L_#?A'PO:F[O[VX;H.BQHO626
M1BJ)&H+.[*J@D@5_-O<_\%)/^"R%U;R1-X=_:""R*5)3X&6Z, >.&7200?<$
M$5FW?_!'[_@I5_P5Z\>:=+\:)?%6FZ';R^8M]X]UB.RT_3"3AFATV$EUD*LW
M,=NH(&"XXH \[_8>\+^(_P#@O%_P<(P^.+S39H]#U/Q8/&NNJR!TTO1+!X_L
M]M*<X):.*UM,C.6E#8P#C^L#Q[XXTOX8^!M:\2:Y>0Z?HGAZPGU/4+J4XCMK
M>&-I)9&/HJ*Q/L*^7?\ @D%_P1^^'_\ P2(^ UQX<\,S2>(O%WB$Q7'B;Q/=
M0+%<:M,BX6-$&?*MHRSF.+<Q&]B69F)KRO\ X.9_&OQ4C_X)GZQX!^#_ ,/_
M !]X\\3_ !2OHM!O1X7T&ZU:73-,&9KJ2001R;5D6-;?YL9%PY!RM 'X@_\
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M["STO2=+MX[2RLK2%8;>TAC4*D<:* JHJ@ *    !0!>HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ_D3\.S>+/\ @VS_ ."ZJV3ZE=7GA_PGJ\=K>W&U@/$7A>]V.2ZJ,-((&5L
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MTI<64:3%(OM MOM'!5?F\W<<<DU^]%?RZ_##_E<6N?\ LKVI_P#HNXK^HJ@
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M\6>*-4L]$\.>&[&74=2O[I]D-I;Q(7>1CZ!03[T ;E?G?_P<4?M ?M6?L^_
M;X?7W[*-AXVO_$VH:_+!K:^&O!L?B:9;,6[,IDB>UN!&OF8^<*N3QGM5[_@G
M9_P<:?"'_@I_^T>GPS^&/P\^-3:C':3:A>ZKJ>D:;!I>EVT7'G3R)?O(JN[1
MQJ%C9BTB\ ;BOKW_  5+_P""MOPX_P""1OPV\,>*/B1HOC;6]/\ %FIOI5I'
MX:L[6YFCE2(RDR"XN( %V@C().>W>@#>_P""47C_ .*GQ2_X)Z?#'Q!\;K?6
M[7XJ:EITLGB&+5]&71[U)A<S*OF6BQ1"$^6(^!&N1@XYR?H:O+_V+OVM/#G[
M=7[+_A#XM>$;+6].\.>-+5[NQMM7ABAO8D6:2(B18I)$!W1L?E=N".>P^8/#
M/_!PS\$O$W_!26]_9>70/B18^.=/UB_T6XU>[L;"+08I+.":>:0S?;#*(MD+
MX8P@YQD 9( /N^BOQW_;6_X/)?@G^S]X\U'P[\+_  3KOQEFTN8V\VJQZDFC
M:/<.K[6\B=HII)5&"0XA"-P59E.ZIOV)?^#R#X&_M!^-=/\ #OQ1\&Z_\%[S
M5)_(BU.6_36=$@).$\^X6.&6($D98P&-.2SJH+4 ?L%13+:YCO+>.:&1)895
M#HZ-N5U/(((X(([T^@ HHHH *_)__@ZD_P""EOQL_P"";WPP^#NH_!?QK_PA
MEYXJU34K;5)/['L-1^U1PQ6[1C%W!*%P78Y0 G/.>*_6"OPI_P"#X;_DBO[/
MO_8;UC_T1:T ?&_PM_X+"?\ !6CXX^!+'Q3X);XP>,/#.J>9]CU?1/@U8:A8
M7?ER-%)Y<\.EM&^V1'0[2<,C \@BN@_X>A_\%B- 9+R]\-_'5K6V=7E6Y^!M
MO'"Z@CY78:4I"GH<,#SP0>:_7_\ X-<?^4%'P,_[C_\ ZD&IU]_T ?S;_LS?
M\'A_QZ^ ?Q03P[^T5\-](\2:;:R)#J8LM.DT'Q%89P2YB<^2[!2&$31Q;LC]
MXH.:_H _9*_:V\ _MP? ;0_B1\-=>M_$'A?7H]T4J?+-;2C'F6\\?6.9#PR-
MR.O(()\/_P""O_\ P2)^'_\ P5B_9OU#P]KEC8Z7X_TN!YO"?BI80+O2+H E
M8W<#=):R'"RQ'((.Y0)$1U_#C_@U'_;3\3_L7?\ !3+5OV>O%GVRQT/XE3W6
MCW>FSRY31M?L5E9),;BH9Q%+;/L!+LT&3B,8 /Z?Z**\3_X*.?M>V/[!G[#?
MQ-^+5[]G:3P=H<UQI\,[;8[R_?$5G 3Z27,D*$C) 8G!QB@#\,?^"Y7_  <@
M?M#?"/\ X*/>/O G[/WQ"7PSX$^&L<6B7XM] TO5%NM0B;%Y.\ES;2O'LGE%
MKM#!<VX. SG/[!?\$/?^"A#?\%+?^"<O@?XA:G?6]YXTLT?0?%HBC2/;JMMM
M61V1 $0S1M#<!5 4"X   &!^(7_!M;_P3'N/^"EOA3]JWQQXZDN+J/Q5X7N_
M!6GZM>A9EDUK46%Y->\\F:V>&UDR< _:NYY7I?\ @T)_;"U/]EK]O'Q]^S;X
MT:;28_':S_9;&Y?_ (\=?TW>)8,=%:2W6<,<\M:Q*,DC !_2A7C_ /P4)^*6
MO? []@7XX>-O"U]_9?B;P?\ #_7M;TB\\F.?[)>6VG7$T$OER*T;[9$5MKJR
MG&"",BO8*^?_ /@K%_RBR_:6_P"R5>*/_31=4 ?S;_!'_@OW_P %,/VF-<O-
M+^&_C3QK\0-2T^#[5=6GAKX8:1JT]M#N"^8Z0::[*FX@;B ,D#O7I7_#RS_@
MLE_T+G[0'_AB;;_Y4UU/_!DG_P GQ_%[_L15_P#3A;U_2K0!_+GK_P#P6<_X
M*P?L]Z;-XE\=:3\4+'P_81M+<R^)?@Y;Z=I\:+@LSRKI\)4 =3O  /T(^X/^
M"*?_  ==-^V'\;=%^$OQ\T+P[X5\4>)IELO#_B31O,@T[4;QV"Q6D\$C.8I)
M"0J2*Y5G*KL3()_:QE#J5894\$'O7\F/_!TU^SCX-_8]_P""N$K_  SMK7PR
MOB7P_8>+;JTTG_1H]+U.2XN8W:()CRF;[/'/\N,-,2,9H _K.HKC_P!GGQI?
M_$CX ^!_$6JPM;:IKWA^PU&\A88:*::VCD=2/4,Q'X5V% !117Q/_P %N/\
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MKX\Z]#\6/C5\,'N9)O"]QI%KXHAMV?Y+6\CF6VD=%[&6.2,,>_V>/TK^B"@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[AF+>9UW><,8]#7Z8T %%%% !7X _P#!\Y_S:[_W-?\ [A:_?ZOP!_X/G/\
MFUW_ +FO_P!PM 'BG_!.C_@[:_X8"_8I\ ?![_AG_P#X2S_A!K*2S_M?_A.?
ML'VW?/+-N\G^SY=F/,QCS&^[G/.![)J?_!\Q=2V,BV?[,<%O<D#9)-\0S-&O
M/=1IJD\9_B']*^RO^""W_!.C]GOXP_\ !(GX(^)?%WP)^#?BGQ'JVCSRWVJZ
MOX*TV^O;QQ>W"AI)I86=R%51EB3@ =J^M[O_ ()*?LKWMM)"_P"S5\ U612I
M,?@#2HV ]F6 $'W!!H _FNU_]J7Q9_P<L_\ !0KP9I7QR^*7PX^"?@W12]MI
M=K-,;2WLX)I4\R&S\XL)KZ?9"I:61%8HN  JQG^J[X*?"'P[^S_\(/#'@?PE
M8QZ;X8\(Z7;Z3I=JAW"&WAC6.,%NK-M4$L>6)).237X>?\')W_!O/\'?@U^R
M%K_Q\^"?AV'P#JW@N>WG\0:'8S.=,U2SFFCMS)%"[%;>6)G1\1;49/,RA<@U
M[E_P: ?\%!?%7[6/[&OC+X:^,;^\UK4O@I>6-MINHW+F25M*O4G^S6[.Q)8P
MO:7"J3TC,2CA* /UXKY5_P""T/\ P4.M_P#@F1_P3Y\:?$J&2T;Q5)&NB^%+
M:<@K=:M<!EA^0D;UB423NH.3';OBOJJOYM?^#R?]K+5/C9^VO\.?V?O#S37M
MKX)TZ/4KNRMI"SW>L:DP6*)HQP7CMDA,9//^FR# !R0#I/\ @T!_X)QW7QQ^
M-/BS]J[X@QW>K?\ "/WL^F^&+C46::34=7F4O>Z@S/S(T:2A Y+;I+B4Y#Q9
MK^B:O$/^";O['>G_ + O[#GPU^$M@MNTOA'18H=2G@7"7NHR?O;R<=\27#RL
M 2<*0,\5[?0 45^'7_!<#]M7_@H]\%O^"A?B3P_^SCHWQ:O/A7;Z=I\EA+H/
MPK@U^R,SVR-/MNVT^8L1(6R/,.T\8&,5\C?\/+/^"R7_ $+G[0'_ (8FV_\
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M"YJ?M-:#I/BRS\!KXK\,:X;"_M;>/5_(TRVTZ*=?+2=X=[-:2%!YV"&3)7)
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M=*_X(I?LCZ-X$7P[#^SE\'WT]8O)$L_AJVGO]N,9-XZFX+?[1DW9YSFOS_\
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M?^V'\ ?%/PS\?:3#K7A/Q=9-97ULX^9>0T<L9_@ECD5)$<<JZ*PY K^89/\
M@WZ_X*+?$S]HWP_X\^(7@#Q1XJURUU.QGN]<UOXC:/J6H"*"1-I,TFH/*VQ5
M^4 D@  5_5M0!_*S^R3\7O'G_!K?_P %D]9\"^/IKJ^^&>O/%9Z]-#;MY>NZ
M'([FRU>",9_>P,7)5=Q!6ZA!).X>]_\ !T[_ ,%@I/VKO'^C_LH_!'4?^$FT
M2:\M'\3SZ/\ Z4OB34I'B>QTVW9"1*D;F-V"YW3&-1@PD'Z!_P"#TEO@[_PR
M3\/QXB63_A=/]L-_PAYLO+\X6/'V_P"U;N?LF/+VX^;S_*V_)YU?G=_P:52_
M!V/_ (*GZ>OQ)61O&$FF2K\/C<!3IXU3K)OSR+CR _DY^7)?_EIY5 '[M_\
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MC?7%K;#)))VV\4*DGJ5/ &*^YJ_.?_@U)_Y0A_"__L(ZY_Z=;JOT8H ****
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MJ1ZEXL\87UJUG;ZI;Q%4_L_3L!0[F.,0J8LI HW,<A4?H_\ @KQ_P2^\7?\
M!O7^V'X9^,7PE72]>^%VO:BRZ!)XBT>VUJ/1+K!D?3+E;A'5MT:.8IUVRM&L
M@#!XV=OWB_X(Q_\ !7#P7_P5K_9B3Q'HMO:^'_&GAGRK'Q5X964,VDSLIV2Q
M#JUK*%<QN1_ Z'+1M0!]>65E#IMG#;V\:0V]N@CCC0;5C4#  '8 #%2444 %
M><?'/]D+X8_M-^)_"6L?$+P1X?\ &=[X%N9;S0AJ]L+J#3YY0@:40MF-G_=H
M0SJ2I7*X/->CT4 ?)/\ P7;C6'_@CI^T,B*JHO@VZ5548  V\"OS?_X,>?\
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M0"!<R.&4=#'#$XX<5^R],MK:.SMXX88TBAB4(B(NU44<  #@ #M3Z "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OP4_X.0O^#;Y?$::[
M^T%^S[H074%#W_B_PA818%P.6DOK.-?XNK21*.>649R*_>NB@#^ 1T:)V5E*
MLIP01@@U^Y/_  ;>_P#!MZWQD?0OV@OV@M"*^#U*7_A#PA?Q<Z^>&COKR-O^
M73HT<+#]_P ,P\K F_2+Q]_P;/\ [.OQ$_X*+V?Q\O-)VZ:NZ_U#P,MLG]BZ
MIJV]62\D&?\ 5CYF>W"[)'VDG:'CD_0]$6- JJ%51@ #@"@ 1%C0*JA548
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M/27O42&Y#M$+B1"X4LH)7(&X9ZU^S7_!4?\ 88_X>4?L)^.O@I_PE'_"%_\
M":?8/^)S_9O]H_8_LNH6U[_J/-BW[OL^S_6+C?NYQM/Y _\ $#'_ -71?^8W
M_P#OI0!^OS?\%9/V6%4G_AI;X \<\?$+2#_[<5\N_M\?\'1'[,/[)'PXU*3P
M9XPT_P",/CEK=_[+T?PU(;BS>;;\C7%Z!Y,<0;&[8SR8SA#7Q'_Q Q_]71?^
M8W_^^E>W_LY?\&7/P!^'&MVM_P#$3QYX^^)0MR&?3XO*T.PNO42"+?/M/^Q.
MA]Z /SJ_X(4?L2>/_P#@M3_P59U#X]_$ZWFU+P;X7\0CQ9XJU26/;::EJ8<2
MVFEP@DY7<(V:,96.WAVL5,D0;^CS_@HK^RXW[:W[#'Q4^%<,L-O>^-O#EU86
M$TW^JAO-F^V=_P#96=8R?8&N\^"'P*\&_LU_"_2O!7@'PSHWA'PIHD9CLM+T
MNV6WMX-S%F;:O5F9F9G.6=F9F)))/64 ?RU?\&T?_!572/\ @DW^U=X^^$?Q
ML:\\)^$_&UZFGWUW=QG9X5UNS>6'_25'S)$^YXI'&=C1Q%@$#NO].NE?%GPK
MKO@1?%%CXF\/WGAEXO/75X-1ADL&CQG>)PQCVXYSG&*_/O\ X+!?\&U7PI_X
M*B^*)_'FBZM)\+/BO<(JW>MV5B+NRUP* %^V6N^/=(%&T3(ZO@C>)0B*/R]N
M/^#)S]HA?%[0P_%#X+R:!YF%O'N=36\*8ZFW%F4SGC'G8QSGM0 [_@ZP_P""
MPO@_]O3QAX-^!OP>U:'QEX5\&ZHVK:KK&FG[19ZQJK1M!;Q6;H2)DBCEG!D4
M%7:?"$A<M^WO_!%+]C?4OV"_^"87PE^&NN1-!XDT[2WU'6HG(+6]]>SR7DT!
M(X)B:?RLCC]T.3U/S%_P24_X-<_A/_P3H\=:7\0O&6M3?%CXFZ2PFTZYNK-;
M72-$F&=LMO;;G+3*",2RNVTJ&1(V (_42@#^77X8?\KBUS_V5[4__1=Q7Z$?
M\'IB:T__  3+\"FQ6].DK\1+0ZF80?+"_8+\1>;C^'>1C/R[MG?;7>^&/^#;
M+_A&_P#@L7)^UG_PNCSO,\7W/BK_ (17_A$=N/.60>1]L^VG[N_[_D\X^Z,U
M^@O[4_[+_@O]L[X ^)?AG\0M'CUOPGXJM?LU[;EMKH0P>.6-^J2QR*KHXY5D
M!H _+W_@SV^-GP;/_!/.3P7H>H^'=.^+5OKMW<^*;&1TAU/4@\I^R3J&^::$
M0;(QMRJ,K@@%LM^D'[7_ .WY\'_V#OAY>>)/BIX\\/\ A6UM8V>*TGNE;4+]
M@NX16]LI,LTA'144^IP 2/PK_:-_X,DOB5IOBVX?X1_&#P/K.@RSEK>'Q?#=
M:9=VT)R0K26L-PDKC@%@D8;D[5^[7>?L9?\ !D\VE^++'5/CY\5K#4M+M762
M?P_X,@E47I!!V-?7"HRQG!4A( Y!R'0\T ?F%\>_VX9/^"B'_!;"Q^,TUC)H
MMCXK\?Z*UC9SN"]E8V\UK;6RR$';O\F&,O@XWER">M?V;U^2W_!1_P#X-0?
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M/VXV_8Q_X)4>++'2[P6OBKXL2CP7I>T_.D-PC->RXR" +1)D#C[KS1&OE/\
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MWGA]I/#9T>70XY<M-; _:K@21-*3(H^4HSR<L&4)]:4 %%%% 'R5_P %X/\
ME#Q^T/\ ]B==?^RU^;W_  8\_P#)%?V@O^PWH_\ Z(NJ_7S]O#]EO_AMG]CO
MXB?"?^W?^$9_X3W1I=)_M7[%]M^P[\?O/)\R/S,8^[O7/K7S?_P0\_X(K?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>mrsn-20201231_g8.jpg
<TEXT>
begin 644 mrsn-20201231_g8.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +; ^\# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ9-Q)/M7)?\ !'#_ )-%N?\ L9;W_P!%05\U_P#!;[_DIOPR_P"P/=?^CEH
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MY-%\16ME=Z;-*C&"18;:*"6+/3(>(EE!R!(I_B!/VC\'?^"B?[.7[1'@_3O
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M5DA&!%(#*Q8%%<[ANSA< 'L=%%% !1110 4444 %%%% !1110 4444 %%%%
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M1(\T,K.3Y\I8Y@4#IU/6@#&_X+'_ /)HMM_V,ME_Z*GK@/\ @B)_R27XD?\
M8;@_]$"OKC]L']F2']K/X0GP/-XAD\,%=0AU"/4$M!=8:-77:8RZ9!#G^(=!
M7/\ [$O[',/[&_@S7]#3Q7)XMFUB^6\DNFT\6:Q[4"!0GF2?GN_"@#\9-4DG
M_9=_;CDNM4MI(8O"/C87<L6W+26B70D!4')P\)!'?#"OZ +7XK>#;[P&OC6#
MQ1I,GA%H/M(UK[8@M1'C))DS@8[@\CIUKYN_;0_X)T>$OVLM03Q-:ZF_A'QU
M% MN=4B@$T%Y&OW%GBRI) X#@@@8!W!5 ^'D_P"")_Q>.J"-_&G@E=.W<W"S
MWAFQCKY?V?&<]M_XT ?.OQ.OI/VQ/VVM7;PY'/<0>,/$RVM@RKB3[+O6))2#
M]W$*!SG[H!STK]/O^"Q__)HMM_V,ME_Z*GKL?V,/^"=GA#]DRZD\17.HMXO\
M=S1&'^UIK<0PV<;#YTMX\L5)Z,Y8D@8 4%@?2?VP/V9;?]K+X/MX&G\02>&6
M6_AU"+4([07(5XPXVM&73<"';HPYQ]* /C#_ ((=_P#(H_%K_K^T[_T7/7Z>
MU\S_ +$/[%=O^QGX=\3Z>GBZ3Q=<Z[<PSR7#:>+)(EB5E553S)"3\[9);TX'
M?Z8H *_!;_@JYX&NO!_[9_BF^FC9+/Q#:66J6C$'#+Y"0/S_ -=8)/TK]Z:\
M _; _8W\)?M?>"[;3=9F?1O$.FEGTK7K>,226Q;&]'0D>9&V!E<@Y (([@&]
M^R_\>/#/QO\ @3X7\4Z7J]G*ZZ; FJ0><H>QN4C"S1RCC;A@V"0 1AAP170>
M$_C!X#^-%UXO\.>$/%>G^(+[152UU7^S7\Y+5IED"#>/D8_NY.%8X*$'!K\J
M;O\ X(F_%A-8,=KXW\&S:5NP+J:2[CGV^OE"!ESTX\S\:^]?V%?V(;;]C/P]
MXEC?Q*_B?6_$3VS7LZ6WV>")8!+Y:1J68GF:3+$\\<#% 'XL_!+P[X-\%_M-
M:-X=^-6F^9X3L=5GTKQ!:R330B%@)(=[/$RR!8Y=KG:1PASD9!_8JU_X)P_L
MD7^AKK-MX)L+C1V3S!J$7BC4&MRIZ-Y@NMN.1SGO7/?MD?\ !+_PO^TKXFN?
M&GAK6O\ A"_&=T%^VLUOYUE?L %#N@(9), 9=<YQRI/-?(-M_P $3_B^VI!+
MCQGX)BT_=@SQW%X\NWU\LVX&?;?^- 'WE^RO\+/V5O"GQ-\2/\#[?2KKQ;I%
MI'!J5UIVIWFHI!#,QPJRRR219)B.?+)8;<-C(S^8?_!6+_D]CQ9_UXZ=_P"D
ML=?J%^P_^PKIG[&NGZ_,OB>Y\4:[KR0)>3M;+;6\:Q;RJQQ[F;K(V69N<#A>
M:\X_:T_X);VO[47QHO?B"GQ'F\,/>V]O!/I[:*+P9B0(&1_/CQE5'!4\YY[4
M =E\=O\ E&#J/_9/['_TGAKX0_X(J?\ )TWBG_L3+K_TNL:_5;QU\!;+QM^S
M?>?"(ZK<6=C-H,>A)J?E*\J+'&J+(4R 3\@)&1GD9'6O!/V)_P#@G#;_ +'O
MQ&UGQ@WC^7Q==W^DOI*6XT@6,<2/-%*SD^=*6.85 Z8R>O& #V7QUXN^!GQM
M\1:]\(/%^H^&O$.M:<\8O/#FK%5FC=XE=6AWX)8)(OSPDE2V"0<BORI_X*8?
ML8_#?]EZX\.:KX$UR6W;6KB6.7PM>W0N);=%4,)HF/S^6#\I\PL<LN&/('U7
M^VA_P2KU+]H+XM:U\1?!OC*QTK4]8$37>DZS X@$L<21!TFCW, P0$J4.#D@
MX.!XK\//^")/C>YUJ ^.O'WA_3M(60&5?#JSW=Q(@ZJIFCB5">FXAL=<'I0!
M]=_\$H?&&N>+OV.M"_MR>:Z&EZA=:;8S3L68VJ,I1<GJ%+L@] @'0"OL.N4^
M%GPQ\/?!GX?:)X+\+6?V'0M(@$%O$3N8\DL[G^)V8LS'N6)KJZ /@W_@L9\*
M?^$T_9FL?%MO"7OO"&JQSNX7)%K<8AE'M^\-NV?1#]1^3FI?'C4]1_9IT3X0
MOYC:?I_B6YU\2,WR@/;I''&!WPQN7.?^>G?M_15\5OASIOQ>^&GB?P5JY9-.
MU[3YK"62, O%O0@2+GC<IPPSW45^>'A/_@B/I6A^,-*U+5/BO+K&CVEW'<3Z
M8OAT0M<1JP;RC*;I@,@8)V'J>* .._;R_9E_X0/_ ()]? V\ALECU'P9'#!J
M.P8\O[?&)+DGU_TH(.?[Y]37PY\6/CIJ?Q;^''PB\'7"22#P3I-QIL9Y)E>6
MZ=EVCVA2V3W*&OZ$/CS\'],^/OPA\3^ -7G>UL=<M?(-S&@=H)%=9(Y IX)5
MT1L?[/45\+_";_@C'I?P]^)OAKQ1JWQ0D\1V&C:A#J!TE?#XMOM)B<.J-(;E
M\*2HS\O(R.* /M_]G'X6I\%?@1X%\$JBI-H^E0P7.W&&N2N^=AC^]*TA_&OP
M@_YO_P#^ZG?^Y6OZ)J_/C_AT?I__  T?_P +0_X6=<_8?^$F_P"$C_L7^Q5\
MS/VG[1Y/VCS\8W<;O*Z=J /HS]O.-I/V.OBT$5G/]AS-A1G@%23^ !K\V_\
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M[07[67C7Q+X%MI[S2M;O[>WTY(X&$EVR010;UCQNS*Z%@"-WSC(SQ7W#;_\
M!#.)9D,WQI>2$'YUC\+!6(] 3>'!_ U]0?LS_P#!-7X3_LV:];^)(([WQ?XL
MMSNMM4UPHRVC?WH(54*K<<,VYASAAF@"I^V/X?O/"?\ P35\1:'J&W[?IGAC
M3+*XVG(\R.2V1L'ORIKX_P#^"(/_ "4WXF_]@>U_]'-7Z;_M#?!V'X_?!GQ3
M\/[C4Y-%BURW6 W\<(F:$K(D@;82-W*#C(X/6O"_V'_^"?\ !^QKKGB?5?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?!__  4X_:T\
M3_"FT\-?"?X:S20_$#QCM#7-HP^TVUL\GE1K#S\LLTFY5?\ A"-C!(90#Z\\
M8?&SX=_#R\%IXJ\>^&/#-T<8@UC6+>T<YZ?+(X/:NA\/>)M'\7::FHZ%JUCK
M6GN<+=Z?<I/$Q] Z$@]1W[U\)_!G_@D+\-]/\,PWOQ7N]4\;^-;Y?/U&1-1D
MAMHIF.YA&4VR.03@N['=C.%SBM[P)_P3GN_V=/CUX8\;?!CQOJ&D>&7NQ'XD
M\-:O.TD=Q9[3D1LH&\@XPL@)!.X/Q@@'UQ8_%;P3JGC.Y\(6?C#0+OQ9:AC/
MH,&IP/?Q!0"Q: -O7 ()R.XKJ:_,W_@IQ\&=:^#?Q&\+?M2?#E!:ZQI-Y!%K
MBH@V%AA(;AP,95U/V>3GD&,=R:^I?$'[;7@W2_V0%^.]M(DMC<6 -IIKO^\;
M46R@LVQSN64,K$=%5FZ#- 'LR?%'P9)XV;P8GB[0F\8*N]O#ZZE"=0"[-^3;
M[O,QL^;.WISTKIF8*I). .237Y]?\$N?@+K&H)XB_:+^(6^]\:>-I97TZ2X!
MW16CONDF /W?-8 *!P(XUP</BO.?VJOBMX__ &V/VKI/V;OAIKCZ!X-TAY(=
M?U&W<@3M%Q=/,5(+1QDB)8L@-)]X\J4 /T*NOVB?A38ZS_9%S\3?!UOJV[9]
M@EU^T6?=R,>69-V>#V[5WUO<174$<\$B30R*'22-@RLI&001U!'>OBK1?^"0
M?[/VG^&TTZ\L=>U74-F'U>;57CG+'^((@$8]AL/OGK77?L@?LC>+/V3/&WBO
M2+3QU/XF^$U]:QRZ3IFHD_:K*[W_ #\ ; "G5DV[B1E1MR0#Z'MOB5X1O/&=
MQX0M_%6BS^++>/SIM!CU&%K^), [V@#;PN&4Y(Q\P]:Z2OS$^$W_ "FB^(O_
M %X3?^D5K7Z=T %<OXD^*7@OP=KNFZ)K_B[0=#UG4V"6.G:EJ<-O<7;%@H$4
M;L&<EB!\H/) KS3]K37OC3I_@[2-*^!^B6=]XFUF]-I<:OJ#)Y.D0;"3<$.<
M$Y  R&'^RQ(%?EI\<_V:_$?[/?[57P'N/&GCBY\>^,_$^M6-_JNH3;V1)%OH
M4$<;N2[J!P&(7@#"J!B@#]OJBNKJ"QMI;BYFCM[>)2\DLK!411U))X J6OS%
M_:TUSQ!^VA^V]I'[-FE:Y>:+X T.,7/B&2Q?!G=8A/*S=FVAHHD# A9&9B#V
M /OG2/VAOA7X@UD:1I?Q,\'ZEJS-M%A9Z]:2SDYQCRUD+9R0.G>O0:^'_B/_
M ,$C?@9KWP]O],\)Z1?>&?%"VS?8M;_M2XN"9P,H9HY'9"A( 8*JG!."#@UC
M?\$E?V@/$?Q!^'WBSX;^,KFXN]?\#74<4,]Y(7F-K(77R68DDF*2)USG[KH/
MX: /OFN9\<?%#P;\,;>UN/&/BW0_"<%T[1V\NN:E#9+,P&2J&5E#$ C('K73
M5^7G_!:FSBU#Q'^S]:W">9!/=ZM%(N2,JSZ<",CGH: /N[_AK'X(?]%D^'__
M (5%C_\ ':[#P/\ $SP?\3;2YNO!_BO0_%=K:N(IYM#U&&\2)R,A6:)F"G'.
M#7SU_P .N/V8O^B9_P#E?U3_ .2:]=^!_P"S9\-_V;].U2Q^'7AM?#MMJDJ3
MWB_;+BY:5T!526FD<@ $\ @<F@#J;;XE>$;SQG<>$+?Q5HL_BRWC\Z;08]1A
M:_B3 .]H V\+AE.2,?,/6NDK\Q/A-_RFB^(O_7A-_P"D5K7Z=T <_P"-/B%X
M5^&^F1ZEXM\2Z/X6TZ240I=ZU?Q6<32$$A \C*"V 3C.>#6Y;W$5U!'/!(DT
M,BATDC8,K*1D$$=01WK\\/\ @MG_ ,F_^!O^QG7_ -))Z^D/C%\4-4^#'[$.
MI>,]$4'6-+\*6S6;% XCF>*.-)"IX(0N&P>/EH ]4\:?&+P%\-YHX?%OC?PY
MX6FDY2/6M6M[-FSTP)'7/0_E6OX7\9:!XXTQ=1\.:YIOB#3V.!=Z7=QW,1/^
M^A(_6OS/_8!_89^&?[2/P<;XK_%<:A\0/$WB#4+KSENM5N(A 8Y63+M$ZN\C
M;=Q+,1AEP!U/U%\#_P#@GQX)_9Q^.3>/_ &M:QI6FSZ=-8W7AJXF-Q;R%RA5
MED)W@+M)VOO.3D$8P0#ZFKC_ !#\8O /A'Q-:^'==\<>&]%\076S[/I.H:M;
MP7<V\[4V1.X9MQX&!R>E=9<7$5K!)//(D,,:EWDD8*JJ!DDD] !WK\%/C-X7
M\2?M:?\ "_/VD;&6Y&B^'=;M(+! IS)9EC$NWNK11"U=L=/,8^I !^]]%>1?
MLF?&:/X_?L\>"/&IE66_OK!8M0QQMO(OW<_'8&1&(]F%>NT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>1P3CN*_4:OS"_X+._\ (W?L[_\ 7]JG_HS3J .^_P"%R?\ !0S_ *(3\/\
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MI+)8P><\9E2- Y7(^5<Y.,G . 3@$ ^"KK]EG]IS_@G_ .)-6USX%ZBWQ!\
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M&RL7.21P-H)_:.&:.YACFAD66*10Z2(0592,@@CJ"* 'T444 %%%% !1110
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M".WR_* ?F ![1??%+P9I?C*U\(WGB[0K3Q7=@-;Z%/J4*7TP()!2 MO;(!/
MZ UT]?B[X?\ V?;W]F__ (*8?![PYJWBN[\:ZY?&WU?4M8O%8/-<2_: ^"S,
MQ \L?,S$DY/&<#]HJ "N7TGXI>"]>\67OA;3/%V@ZCXGL59[K1;34X9;VW48
M!,D*L74#<N<@?>'K7S3^U9X<_:3^-'Q%7X<_#6\M?AW\.&LXIM4\;-*1=3LY
M8/!#M.\%0!P@0D]9%4XKY)_X)^?"R#X)?\%*/'W@:WU&;5XM#T2\M1?7"!'G
M.^U8N5!.,ECQD_4T ?KI1110 45YQKG[1/P\\-_&'1_A9J7B-+7QYJ]M]KLM
M):UG;S8L2-N\T(8EXBDX9P?EZ<C/GWB;_@H5^SOX1\3/H&I?%'2_[123RG^Q
MP7%U C X(:>&-HA@]<MQ0!]$5QOC7XS_  ^^&NH6]AXN\=>&O"M]<Q^=!:ZU
MJ]O9RRIDKO59'4LN01D<9!KHO#_B#3/%>BV6L:+J%KJVDWT2SVM]93++#-&1
MD,CJ2&!]17Y*?\%$_A>/C5_P46\'^!_/-K+KGARWM(9\\1S'[88F/^R'"Y'<
M9H _72QOK;5+*"\LKB*[M+A!+#<0.'CD0C(96'!!'<5/7P5_P2+^,EWXD^#N
MO?"W7S)#XD\ W[6XMYR?,6UE=RJG/>.59D('0;!Z5]ZT <KXX^*W@GX8K:MX
MQ\8Z!X36Z)%N=<U2"R$V.NSS67=CVK=T76].\2:3::II%_:ZIIEW&)K>]LIE
MFAF0\AD=258'U!Q7XB_M@:G=_M;>._V@?BM%<22>"OAK:V&BZ)-&<QS.^HPV
MX(/0JX>\FR.1NB!K]-/^"<7_ "9/\+/^O&?_ -*IJ /I.BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\L_P#@L5/J
M5K\7_@#-HUO'=ZQ'+=/96\QPDLXN+4QJQRO!; /(Z]1UKTW_ (7)_P %#/\
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M^65??5Q&TUO+&DC0NZE1(N,J2.HSW%? K_\ !./XWL[$?MG_ !  )SC9>_\
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MP-R%AR.>17JM 'YB?M)?\I@O@U_UX6/_ *%=U^G=?F)^TE_RF"^#7_7A8_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y\_:J_8A
M\!?M?3^'9_&.HZ_IL^A+.EM)H=S#$664H6#B6*0'F-<8 /6O _\ ARI\$/\
MH:?B!_X,;'_Y#K[_ ** /$OV6?V2?!_[(WAO6M$\'ZEKFI6NK7:WD[ZY<0RN
MKJ@0!?*BC &!W!/O6[\=/V9_AO\ M(:+#IWC[PS;ZP;<'[->JS0W=MDY/ES(
M0P!(&5SM..0:]0HH ^$M/_X(T_ :SU87DVH^,K^WSG^S[C5(!"?;*6ZR?^/]
MZ^L_AS\$/!'PA\#2^$?!7A^U\-Z)*K"2*R7YY&9=ID>1LM(^ !N<D\#L*[JL
M3QMIVM:QX0UFR\.:NGA_7[BTDCL-4DMEN5M)RI"2F)N'"M@[3UQ0!\AVO_!.
M/5/AGX$33OA7\?OBEX<U'38I)-,T^ZUM)-'$Q+/M:T2-%"-(Q+=>6)P37@7Q
MI^/OB3]I;_@DO>>*]="-KMGK5KIVKW$,8C2Y\JZC"RA0,*6\R'(&!N#8P.!]
M-^(O '[8WC32+SPM>^._A7X?T:\C:VF\2Z+IU^VK")AABL,A\E6()&001@$$
M'FO0-%_8V\#Z+^RG<? >,W,OANYLG@GO9"#<27#/YOVGTWB4*X'0;5'04 >O
M^%[B!O!NDSM+&;4V$+F4L-FSRP=V>F,=Z^0?^"0=K>6_['-D]R<PS:W?26O!
M&(]R*>W/SK)Z_P!!%9?L\?M86?PR3X1K\3O /_"#)9'2%\5?V?>?\) +'9Y8
M01Y\D,(_E#;MPQG?GYJ^J/@S\)="^!?PP\/>!?#<;IH^BV_D1-+@R2L6+22N
M0 "[NS,< #+&@#M:*** "BBB@ KP#]H[]AKX3?M1746H^+]&GM?$$<8A77-'
MF%M=E!T5R59) .V]6QVQ7O\ 10!\;_"G_@E!\!OA;XBM]:DL=9\975L_FP1>
M)[R.:!&'0F***-7QZ.&'/3IC['50J@ 8 X %+10!\\?LV_L+_#?]E?QCXC\2
M>"Y-:DOM;B^SO%J=VDL5K#Y@D\N)5C4XR%Y<LV%'/7-S]JS]C'P3^V!;^&H?
M&6J>(-,70'N'M?["NH8=YF$8?S!+%(#CREQ@ C+>M>]T4 ? '_#E3X(?]#3\
M0/\ P8V/_P AU[S^RK^P_P"!?V0;SQ)<^#=6\1:E)KT<$=R-<N8)0@B,A79Y
M4,>"?,;.<]!C'.?H:B@#Y;_::_X)V_#C]JSX@6WC#Q;K?BK3M3M["/3EBT:\
MMXX#&CNX.V6"0[LR-G! X'%>2?\ #E3X(?\ 0T_$#_P8V/\ \AU]_P!% 'D'
M[,/[,/A;]D[X?WWA#PC?ZQJ.FWFI2:I)+K<\4LPE>**,J#''&H7$*\;<Y)YY
MX];N&E6WD,")),%)1)'**S8X!8 X&>^#]#4E% UN?*7C;]G>S^(G[1OA;XU7
M7A'Q):^*]$ACL].MCJUM%9-+'YG-V@BD=(QYK[9(G;=L^Z,IO]Q_X3CQ5-_J
M? EU'YW[FW^U7T2;)A]_S]N[9%UVR)YF[:?E&4W=Y16'LY_SO\/\CU/KF'_Z
M!H_?/_Y/^M?E\H_LT_L[6?[+E]XRN_!7A'Q)<S>,+B%ICXBU:V80SPF4[7$,
M0\J &>7;(/-9MO093>OC3]G>S^(/[1_AGXUW?A'Q)!XKT6".RTVU;5K:*R\V
M/S,F[01.ZQCS7VR1NV[9]T93?]6T4>SG_._P_P @^N8?_H&C]\__ )/^M?EY
MWJ/BCQ#KNGW5C-\/9IK/4(FLQ!?7D2J7(*RK<A=VR$@L!(GF;MI^493=X-^R
M]^RSHG[)^I>([_P-X(\17-YXB$=LLWB/5K9VM6C+,T3&*(>5;Y8D2#S6?RQD
M#Y-_U[11[.?\[_#_ "#ZYA_^@:/WS_\ D_ZU^7@WQU\'WO[1?PIUSX?Z_P""
M]8L]$UX0P^;;ZE!!<13PSQS9E;9*L<6^(8D59=P5OE&Y-UWX(^';SX*?#?PW
MX"\/^#-8&@:9%]AL[C5K^![E9-[/*]SY8"JF6<J\88-M(VKE-WME%'LY_P [
M_#_('B\/;3#1^^?_ ,E_7Y%%%%;GE!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3Q^&O[0'[+NI>+/&MG=W'B'6[J[MM*U"WNI8?[-CC B61(U8)(WF"1CO#*0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=S=:7;-!"'FCB5E"-T^9&/'8B@#WBBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKFH/B9X/NM<;18?%
M>ARZPK;&T^/486N W'!C#;L\CMWH Z6BBB@ HKB;CXX?#BSN)8)_'_A>">)B
MDD<FLVRLC X((+\$'M6SX7\>>&?&WVG_ (1WQ%I.O_9=OG_V7?17/E;L[=^Q
MCMSM;&>NT^E &[1110!^5?[ O_*4W]HW_N8__3Y;U^JE?E7^P+_RE-_:-_[F
M/_T^6]?JI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 445#>7D&GVD]U=3QVUK C2RS3.$2-%&69F/   ))- $U<
MG\2/BQX-^#^@MK7C7Q-IGAG3>0LVHW"QF5@,E8U/S2-C^%03[5\V^(/VGO'?
M[1WB2]\'?LVV=M_9%K*UOJWQ3UF OI=HP'S)9)_R\R\C!P4Z<%6#CK/AG^P?
M\/\ PIK47BGQM+?_ !=\>X!E\1>,Y3>;7SG]S;L3'$H/W1AF7C#4 <U<?\%#
M-+\:74MI\'/A?XX^+SHY3^TM.TUK+2@VUB UU,/E)('5,8)()Q@SMXR_;*\9
M*\ND_#OX8_#R-\[;?Q3K=SJ4\8QW:S&PGISC'M7U;#"EO$D42+'$BA51!@*!
MP !V%/H ^4E^#_[6>N[4U#]H+PSX751GS=#\&0WCN>X(N& Q[BC_ (9#^+>K
M9DU[]JCQM<7$S9N&T?3;738R.XC1-PCX]*^K:* /E0_L,ZY=D1WW[2WQI>WS
MEEM/$*6\A],.(B1S[4O_  P+_P!7&_M ?^%S_P#:*^JJ* /E ?\ !.GPGJ%R
M]QXB^*?Q=\83;%CBDUSQA)(T*@DD(41#@D]#GIQCG,G_  [>^&'_ $,'Q _\
M*RZ_QKZKHH ^5/\ AV]\,/\ H8/B!_X5EU_C1_P[>^&'_0P?$#_PK+K_ !KZ
MKHH _-W]N;]B'P'\*/V5?'GBO1]9\8W6HZ=%:M##J?B&>YMVWW<,9WQL<-PY
MQGH<'M7W9I/PH\$-I=F3X.\/DF%"2=+@_NC_ &*XW]LKX1ZU\=OV9_'7@?PZ
MT UO5+6(VJW#[$=XKB*;9NZ L(RH)P,L,D#)KYCM_%__  4'M;>*%/ /@?9&
MH09EM\X Q_S^T -M_P!E_P %_&+]NSXWZ5J!U7P_8:3I.A2VT'AB_?3%W26[
M;MPBP&^Z#]2?6O6_^';WPP_Z&#X@?^%9=?XU2_8U^%GQGT[XJ_$WXF?&G3](
MT?7O$\&GV,5CI4J.NVV1E$F$DD !# <MG*G@#%?7% 'RI_P[>^&'_0P?$#_P
MK+K_ !H_X=O?##_H8/B!_P"%9=?XU]5T4 ?*G_#M[X8?]#!\0/\ PK+K_&C_
M (=O?##_ *&#X@?^%9=?XU]5T4 ?*G_#M[X8?]#!\0/_  K+K_&O.?VBOV%/
MA_\ #CX(^,?$VF:UXTN+_3+%IX8M0\1W%Q S!@,/&QPPYZ&OO&OGG]LKXA>%
M?^&??B/H?_"3:/\ VU_9S1?V;]OB^T[]RG;Y>[=GVQ0!P7@W_@GC\-=:\'Z'
MJ$^O>/$GN[&"=UA\4W*(&:-6(50>!D\#M6Q_P[>^&'_0P?$#_P *RZ_QKV?X
M0_$3PIKGA'PQI6F^)]'U#4QI=N#96M_%+,-L2[OD5BW&.>.*]$H ^5/^';WP
MP_Z&#X@?^%9=?XT?\.WOAA_T,'Q _P#"LNO\:^JZ* /E3_AV]\,/^A@^('_A
M677^-'_#M[X8?]#!\0/_  K+K_&OJNB@#Y4_X=O?##_H8/B!_P"%9=?XUXSX
M[_9L@_90^+@\5^!_V@+?X:/K>D?V=Y/C*R;6[B=4E#R%9)6X7)CXQQSSS7Z(
MUB>(O _ASQ@\#Z]X?TO6W@!$3:C91W!C!QD+O4XS@=/2@#\Q[/XN?$;XY^!_
M&'AGQC^U'X2T+3+Z>\T)[.?PI%OO[-E">>C(0460.V.XQUKZ3\)_\$S/AYH_
MA71K#4/$_C>YO[6SA@N)K/Q)<V\$DBH%9HX@Q$:D@D+G@8':OHU?@M\/58,O
M@3PR"#D$:/;_ /Q%=G0!\J?\.WOAA_T,'Q _\*RZ_P :/^';WPP_Z&#X@?\
MA677^-?5=% 'RI_P[>^&'_0P?$#_ ,*RZ_QH_P"';WPP_P"A@^('_A677^-?
M5=% 'RI_P[>^&'_0P?$#_P *RZ_QH_X=O?##_H8/B!_X5EU_C7U710!YY\$_
M@;H'P%\-WNB>'KW6;ZTN[LWDDFMZC)>RARB)A7?D+A!QZDGO7H=%% !1110
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MS[6)OXY 8?EP/^>BQ@G RN:^T?A_\:O!_P 2OA/9_$C1=7B;PC<64E\U]/\
MNQ!'&&\T2Y^Z8RCAAV*F@#N:*_/M_P#@I)\3OB1>:QJOP;_9ZUKQMX#TN5D_
MMR>25'O0OWC%&L9^;AOD4R-RI(!.VOI;]E#]J_PQ^UAX#N-;T2WFT?6--F%K
MK&@WC!I["8YP"<#<C8.U\#.U@0"K  'MU%?$'QF_;J^)N@_M*>)_A+\*_A-#
M\1+SP_9P75W*MXT3J'CB=CC&W ,R+USG/I74_ W]HK]HOQU\4M$T/QU\ ?\
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M1=S')Y8L2<#:J_2]% !1110!^5?[ O\ RE-_:-_[F/\ ]/EO7ZJ5^5?[ O\
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M1110 4444 9?B#PKHOBVTCM=<T>PUFUC?S4AU"V2=%?!&X*X(!P2,^YKG_\
MA2OP\_Z$/PS_ .">W_\ B*[2B@""QL;?3;.WL[.WBM+2WC6*&W@0)'&BC"JJ
MC@    #IBIZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ***^8M<_8S\2:SK6H7\?[1GQ8TZ.ZN))UL[35HEA@#,6$:#R^%7. /0"@#V
MSXS>-;KX:_!_QUXNL8(;J]T#0K[58(+C/ER206[RJK8(.TE #@@X-?,GP[^+
MG[7GQ.\!^'O%VC^#_A.NE:Y80ZC:K<ZA?I*(I4#KN49 .",C)K#_ &@?V/?$
M?AGX"_$G5Y_VAOBIK4.G^&M2NWTW4-5C>VNUCM9&,,JB,91P-K#/()KT_P#9
M*^.7PXT7]E_X46&H?$#PM87UMX8TZ&>UN=:MHY8G6W0,K*S@J0>"#R* *'P?
M^/7QFF_::3X4?%7P]X-TU[CPO+XC@N?"\]S,2JW*0*K&4X')<D8[+S7U17Y_
M_%/1=,_:2_X*":%9>#/BI?Z#%;?#>2277/ FJ0M-N743F!Y%W@ B16*]>%->
MK?\ #$/B?_HYCXP?^#B+_P"-T ?55%>8_ _X-:E\';'5;?4?B+XL^(;7TB2)
M-XJNUN'M@H(*QE5& <Y/T%>G4 %-=%D1D=0Z,,%6&01Z4ZL[Q%X@TWPGH.HZ
MWK%[#IVDZ=;R75W>7#;8X8D4L[L>P !- 'Y;?%?4->_X)3_M%:QXE\*Z8VL?
M"+Q]:W,MOH(<QP6=^B[DCS_"$=A@]XI&7#-'D?1O_!/7]G76= TW5OCC\2I&
MU+XI_$$?;WEN%._3[*3#I  ?N%AL)7C:JQH -ASX#X=^&.K?\%7/BUXK\>^*
M9+_PY\'_  _;W.C>$8D^5Y[A@0+@CN5.R63L2(H\L$:O2_\ @G;\=/$'P]\3
MZQ^R]\5Y8[/QGX49H] FDD)%]9JN_P F-B!O"IB2/N8CT C- &3_ ,%)K6&^
M_:S_ &1[:XC66";Q-'')&W1E-_8@@_4&NJ_X)JW4_P *?%GQJ^ .I33//X-\
M0/?:7Y[ F2QGX4J.P^1)#[W%<W_P4;_Y.^_9 _[&F+_TX6%:W[0C1_LZ?\%(
M/A/\3@5LO#_Q"LG\+ZU/Y>%,XVQQL[C@9)LOO=%@8YP/E .B_:-8_'/]O+X*
M?"I T^A^#H)?'.MQC[AD1MMJ&'<K(L>1P"MP<YZ5S'_!%G_DV/Q?_P!CG=?^
MD5E75?L LWQ?^)'QQ^/=RCO#XHU[^Q]$DD7'_$MM%"QLOLP,8/\ M1&N5_X(
ML_\ )L?B_P#['.Z_](K*@"__ ,%5/]1\!?\ L>K7_P!EK[N3[J_2OA'_ (*J
M?ZCX"_\ 8]6O_LM?=R?=7Z4 .KS/XB_L[^"_BI\1?!7C7Q'9W%YK7@^5I])
MN"((I&96+-'T8Y1#D]-H]*^9-5_X;Y_M2\_L_P#X5S]A\Y_L_FXW^7N.W/OC
M%>[>(_CRW[.'[.-AXT^.-]9VOB&WMEBO;?20&^VWQ#%8+5<C<S;3CH  S,0J
MD@ Z+]ICXD>%OA3\"O&>O^,#!)HJ:;/;M9SX/VYY(V1+95/WFD)VX]"2> 37
MYRZ19^(?@_\ \$:=<EO))K"Y\57JRV<; ADL[F[B7&#T66*-V'8K-GJ:]@^&
M_P #_'_[>WC[2OBM\=M.;PY\,--<S^%_AVQ;_2022)[L'!*D!<Y ,GHL?#^M
M_P#!3?P9)X@_8C\<6^FVF]M*%G?1V\(VA(HKB/>0!QA8R[8]%H ]=_9=\#VG
MPW_9U^'/AZS@2W2ST*T\T1J!OF:)7E<XXRTC.Q/<DU\J_!VW'P__ ."LWQ>T
M'2@D&C^(_#46KW-K&FQ1<@6K%_<EI)VSQ_K3^/U7^R]XXM/B-^SM\.?$-G<1
MW*7FA6GFM&P(298E25#CC*R*ZD=BIKY.^$>I1^.O^"KGQD\2Z3B]T;PQX832
MKFXMF$FZY ME:(8Z,'BG7&>L1_  \#_9[_:0\9Z9^TI^T)XL^'?PIU;XJ^)/
M$>MM#:26K&&RT^QBEG*F6?:V68>2 GR ["0W1:^NOV<_V_Y_B%\5C\*OBKX!
MOOA/\0I5WV%I?.[07XP3M4NBE6(5BOWE;:<-G /M7[-OQL^&_P =O!-[KOPR
M$2:/!?/:7,260M'6=40G='@=59<'N/I7RI_P4@2QO?VD/V5K32U67QF/%$<B
MK:Y^T+:?:;4[FQT3<KD%N!MD[!J /.[WXY^ O __  4*^-GQ5^)5ZUS;>"+2
MVT+P[IMO$D]R]RZ!"MM&2"9/W=QR2%'G/N89%>DWG_!1SX'?&C4(/AY\7_AY
MKWA;0M7EC:"7QC8(+)L./+DEPVZ,;L?/@JO.Y@,FN/\ @K\/?#NC_P#!7;XI
MQ>)[.-M4:RDUGP\+Q04>:58)&EBR.75'E QTQ)W7CWW_ (*B:'X:U3]C7QI=
M^((+5[K3S;3:5/,H\V*[:XC1?*/7+*SJ<?PEL\#( /J30])L=!T6PTS3($MM
M-LX([>VAC)*QQ(H5%'L  *O5Y+^R3<:E=_LO?"B;5WGEU%_#&GM,]R296/V=
M,%B>22,9)Y/?FO6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSL(YP?8T ?HE2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQC^T.R_%[]LCP9X/5&N]'^'?AG4O%VIH!^Z6\FC,%F'/]],>8H']XGL:]?\
MV)O^35_AW_UX-_Z.DKYA^!?_  MGXG^-/CE\4/A[I'A?5-&\::]<:/;ZIXCN
MIXYGL;,&WA, C&!'M)Z]64Y' KV[]GGP?\?/A3H/A'P9JFE>!Y/"6EX@N+R"
M]N7O?)+LS,H*A"WS<<8H ^GZ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M5\JW(]_-D2O6J^3?V^F?QJ?@Y\)8!F3QOXQM6N]W*_8+/_2+GCN?]6?3CG%
M'K'[)GPSC^#_ .S7\.?":V[6L]EHT$EW$P((NI1YUQD=OWLDE>M444 %%%%
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M\'?$#]G'PCK_ (!\+_\ "&>$KO[9]BT/Y?\ 1MEY.DGW21\TBN_']^O9ZP?
MO@/P]\,O"MCX:\*Z1;:%H-CO^S:?9IMBBWR-(^T>[NS?4FMZ@#XU_P""G&G_
M !B\:?"72_ GPE\-:IK$>OS2_P!O7>FNJ-':QA=MN26'$K.<XZK$RGAB#\<?
M .Q_;5_9J\$CPOX'^#MK9633-/<7,^EP27-U(6)#2R>:"^T':N>B@"OV1HH
M^5OAKX^_:*U+]D?Q=KWBGPO'9_&6W>Y&DZ2MFBK*%$?D_NPY!R2_\0Z5?^#.
M@_$G]HW]EGQ5X8^/VD?\(YXBU[[;I<D5M;I$T5L\2B*95#,NY6+,,GJHR*^F
MJ* /QV\*_ _]MS]E/2_%/PQ^'NE?VOX5U>XD>#5=/-K+'EU"--"\CA[=F4*"
M' P5RO\ >/VG_P $Y?V/-0_9-^%NJ_\ "326TGC3Q)<1W&HI:/YD=M%&&$$
M?^,KOD9B.,R$#(4,?K:B@ HHHH _*O\ 8%_Y2F_M&_\ <Q_^GRWK]5*_*O\
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MFOSR_8E\>ZU\.?V2OVC_ (TZ9IK)'?ZQJ.KZ)%?)E9"D?RNP!^95=\'!Y,;
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MF[DV^K;1M)'3I7U?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!\JZI_RD^T7_LE$W_IU%?55?*NJ?\I/M%_[)1-_Z=17U50 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?A9H?[
M05O^R3_P4:^+'C;7?#U]JMHWB'7K<VD+"&4QS7KE95WC## !'0$'K7[IUB>+
M/ _ASQYIQT_Q-X?TOQ%8-UM=6LH[J(_\!D4B@#\>/V!?%'PG^*G[>GC?4?$^
MB/K,GBVYO]1\+QZ_9)/Y5Q),URZRH"Z"41[\2$X^1NA8"OH3_@K)JWP*\,?"
M6Y\*7NB:7#\6+B*WO-!73].$-S!#]H DE>94VB(JDR[&/S$<#*[E^KO"'[$_
MP6^'OQ2TWXA^%O UGX=\4Z>)1!/ITTL4"B2)XG_<!_*'R2.,A0>:^>?%WA?]
MF_\ ;>_;.DTW6;S7M7\:^![*?2[O03 UOI\ZV=XX?S7(RX$L[ !2NX'G(XH
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M(/LMU)JMH\T7ER$NFUV9=K$L,8)R*_7^@ HHHH **** "BBB@ HHHH ****
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M*NJ?\I/M%_[)1-_Z=17U50 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ5]'Z+KFG>)-)M=4TC4+75=,ND$EO>64RS0S(>C(ZDAA[@T 7J*** "BBB@
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M /(*NN3MW'@?^"3>C6MK^Q/X=D6)3_:.H:C/<*RC#M]H>+GU^6-1SZ5\U?\
M!&4?V1\7OC9H]J62P2&VQ$3G_5W$ZIS[!V_.@#]7J*^ /VI/^"K7_#-?QV\3
M?#C_ (5=_P )'_8OV7_B9_\ "0_9?.\ZUBG_ -5]E?;CS=OWCG;GC.!Y5_P_
M._ZHG_Y=?_W%0 ?L"_\ *4W]HW_N8_\ T^6]?JI7Y ?\$K?'7_"T/V^OBWXR
M^P_V9_PD6C:OJ_V+S?-^S_:-5M)?+W[5W;=^-VT9QG Z5^O] !1110 4444
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M:I_RD^T7_LE$W_IU%?55?*NJ?\I/M%_[)1-_Z=17U50 4444 %%%% !1110
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MUQSS7U=7SC_P3Q\&W?@S]C_X>KJ!#ZCJ]M+KMQ(!R_VR9[A"??RY(Q^%?1U
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MVWBK5UV:WX^U:^\8WRA<#?=RY0C/4&)(CGWH ^FZ*** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ><_M%?%2#X(_ WQOXXFE6)]'TR6:W++D-
M<L-ENF/]J5HU_P"!5RO[%?PIN/@_^S7X,T;45F77KNU_M;5S<?ZW[;<GSIE?
MW4OL_P" 5YK^UXR_&SXW?"'X#6J_:K.>_7QCXJBR=BZ7:,1'%*!U6:8[?JJU
M]<T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^5?[ O_*4W
M]HW_ +F/_P!/EO7ZJ5^5?[ O_*4W]HW_ +F/_P!/EO7ZJ4 %%%% !1110 44
M44 %%%% !1110 4444 %%%<#^T!(\/P'^)$D;,CKX:U)E93@@BUDP0: .^KY
M ^',(_:4_;9\6^.[E&N?!OPF#^%M $BKY4FL.,ZA,!S\T8VQYXX*$=ZX?]F7
M]@/X0?$K]GOX=^*M?L=>NM:UC1+6]O)H_$-[&KRO&&8A5E ')Z 5)\./V>_!
MG[-/_!0#P;X>\!6M[IFCZEX+U&^N;6XOYKE7F$Z+O_>,<' '2@#[SHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGK&KV7A_2;W5-2
MNH[+3K&![FYNIFVI#$BEG=CV 4$D^U7*^3?VV/%6I?$C5?#'[.?A"YEC\0^.
MF$^OW=OUTO04;_296." 9,&-<\-\R_Q#( S]B"QNOBEXF^)G[0.K6]S&WC;4
MC8^'!>*%>/0K4[("%_@\QMS$=]@;OD_6M9?A?PWI_@WPSI.@:3 +72]+M(K&
MT@7I'#&@1%_!5 K4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /RK_8%_Y2F_M&_P#<Q_\ I\MZ_52ORK_8%_Y2F_M&_P#<Q_\ I\MZ_52@
M HHHH **** "BBB@ HHHH **** "BBB@ KSC]I*_MM,_9Y^)MS=W$5K OAK4
M099G"*";:0 9)QR2 /<BNN\8>,-$^'_AG4?$/B35+71=$T^(S75]>2!(XE'<
MD]R2  .22 ,DU\>6&E^(?^"B7B2QUC6[*_\ "_[-^EW"W%AI-P?+N?&4T<@*
M3SI@%+0;>$/+=>O,8!SG[*_[27QBT3]G3X>:9HO[-'B+Q!I5CHUM:VVK?VY;
M6BWB(@ F2.50P1@-P/0@@@D'-=E\.4^*WQ6_;.\,_$/Q7\(=2^'&@Z1X6O=(
M:6]U6VO!)+)*KKCRR",\CIVZU]DV]O%9V\4$$2001*$CCC4*J*!@  <  =JD
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJEI>M:?KD=
MP^G7]KJ"6]Q):S-:S+((IHV*R1L5)PZL""IY!&#7FWQ__:6\%_LZ:!!=^([J
M2\UF_80Z3X<TU1-J6J3$A5C@A!R<L0-QPHR!G) (!=_:!^.WA_\ 9W^&][XK
MUXR7#AA;:=IENI:XU&\<'RK:)0"2S$>G !)Z5YW^R#\#=:\(V>M_$[XBC[3\
M7/';+>ZNT@S_ &9;]8-/BR3M2-=H(!Y*@'.Q37-?!GX#^,_B]\3+'XV_'6W%
MEK%@[MX2\ K(LMKX>B;&)I3C]Y=G:IW?PG!X(58_K*@ HHHH **** "BBB@
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MB[Z\T2TM_A[X/N+O7-O]E01:)J+/J&Z9H%\A1=YES-&\8V9RZ,O4$5J^!?\
M@JE^U/\ %#[=_P (;\)/#_BW[#L^U_V%X:U6]^S[]VSS/*NFV[MCXSC.UL=#
M0!],_P##G7X%?]!'QG_X-HO_ (Q7TM^SK^SKX5_9A\ R^#_!\FH2Z5)>R7[-
MJ<ZS2^8ZHK?,JJ,81>WK7Y]_\-]?MO?]&Y?^6-KG_P ?H_X;Z_;>_P"C<O\
MRQM<_P#C] 'ZJ45^5?\ PWU^V]_T;E_Y8VN?_'ZXK3?^"M'[3.M>,G\(Z?\
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M;;6_#?P+T_Q!HMUN\C4=+\(:Q<V\NUBC;)$N"K8964X/!4CJ* /UJHK\J_\
MAOK]M[_HW+_RQM<_^/URF@?\%4OVI_%?BK4O#&B?"3P_K'B33?,^W:/I_AK5
M9[RU\MQ')YL*71=-KL%;<!AB >30!^O]%?E!JW_!1#]M#0=+O-3U/]GZWT[3
M;*%[FZO+OP7K44,$2*6>1W:X 554$EB<  DUE>"?^"GG[6GQ*TN74_"'P7T?
MQ5IL,QMI+S1/"NK7D*2A58QEX[E@&"NIVYSA@>XH _72BOR _P"'J7[4_P#P
MG?\ PA/_  J3P_\ \)G_ -"[_P (UJO]H_ZKSO\ CW^U>9_JOWGW?N_-TYH_
MX>I?M3_\)U_PA/\ PJ3P_P#\)G_T+O\ PC6J_P!H_P"J\[_CW^U>9_J_WGW?
MN_-TYH _7^BOR _X>I?M3_\ "=?\(3_PJ3P__P )G_T+O_"-:K_:/^J\[_CW
M^U>9_J_WGW?N_-TYK*T[_@K]^T7K&A:OK=A\//!][HVC^3_:6HV^B:C);V/F
ML4B\Z07>V/>P*KN(W$8&30!^RE%?C7:_\%?_ -HN]O-$M+?X>^#Y[K7-O]E0
M1:)J+/J&Z9H%\A1=YES+&\8V9RZ,O4$5Z!_PWU^V]_T;E_Y8VN?_ !^@#]5*
M*_*O_AOK]M[_ *-R_P#+&US_ ./T?\-]?MO?]&Y?^6-KG_Q^@#]5**_(#QU_
MP52_:G^%_P!B_P"$R^$?A_PE]NW_ &3^W?#6JV7VC9MW^7YMTN[;O3.,XW#/
M45U?_#?7[;W_ $;E_P"6-KG_ ,?H _52BOR@U;_@HA^VCH.EWFIZG^S];Z=I
MME"]S=7EWX+UJ*&")%+/([M< *JJ"2Q.  2:RO!/_!3W]K3XE:7+J?A#X+Z/
MXJTV&8VTEYHGA75KR%)0JL8R\=RP#!74[2<X8'N* /UTHK\B_&O_  4\_:U^
M&NE1:GXN^"^C^%=-EF%M'>:UX5U:SA>4JS",/)<J"Q5&.W.<*3V-:ND_\%$/
MVT-?TJSU/2_V?K?4M-O84N;6\M/!>M2PSQ.H9)$=;@AE92"&!P0010!^K]%?
MD!X%_P""J7[4_P 4/MP\&_"3P_XM-CL^U_V%X:U6]^S[]VSS/*NFV[MCXSC.
MTXZ&JO@K_@K1^TS\2M6ETOPC\,/"_BG4XH3<R6>B^']3O)DB#*ID*1W3$*&=
M1NQC+ =Q0!^Q-%?C7IW_  5^_:+UC0]7UNP^'G@^]T;1_)_M+4;?1-1DM['S
M6*1>=(+O;'O8%5W$;B,#)HU#_@K]^T7I&@Z1K=_\/?!]EHNL>=_9NI7&B:C'
M;WOE,$E\F0W>V38Q"MM)VDX.#0!^RE%?D!H'_!5/]J;Q7XJU'PQHGPD\/ZQX
MDTWS/MNCZ?X:U6>\M?+<1R>;"ET73:[!6W 88@'DUU?_  WU^V]_T;E_Y8VN
M?_'Z /U4HK\J_P#AOK]M[_HW+_RQM<_^/T?\-]?MO?\ 1N7_ )8VN?\ Q^@#
M]5**_(#_ (>I?M3CQU_PA)^$GA__ (3/_H7?^$:U7^T?]5YO_'O]J\S_ %?S
M_=^[\W3FNK_X;Z_;>_Z-R_\ +&US_P"/T ?JI17Y%^-?^"GG[6OPUTJ+4_%W
MP7T?PKILLPMH[S6O"NK6<+RE681AY+E06*HQVYSA2>QK5TG_ (*(?MH:_I5G
MJ>E_L_6^I:;>PI<VMY:>"]:EAGB=0R2(ZW!#*RD$,#@@@B@#]7Z*_(#Q!_P5
M2_:G\)^*--\,ZY\)/#^C>(]2\O[#H^H>&M5@O+KS',<?E0O=!WW."J[0<L"!
MS6MXH_X*3?MA^!]"NM;\1_ K3_#^C6NW[1J.J>$-8MK>'<P1=\CW 5<LRJ,G
MDL!U- 'ZTT5^1>E_\%//VM=;\&OXNT[X+Z/?^%$AEN&UVU\*ZM)8K%$6$LAG
M6Y*!4*/N;.%VMG&#659?\%:/VF=2\&W_ (NM/AAX7NO"FGS"WO-=A\/ZF]C;
M2DH!').+K8C$RQ_*2#^\7^\* /V)HK\:]0_X*_?M%Z1H.D:W??#WP?9:+K'G
M?V;J5QHFHQV][Y3!)?)D-WMDV,0K;2=I.#BK>K?\%:/VF=!\37?AS4_AAX7T
M[Q#9PO<W.DW?A_4XKN")(3.\CQ-=!U58092Q& @+'CF@#]B:*^7O^">?[47B
MK]K/X,ZWXM\7Z?H^G:E8Z_-I4<6B0RQ0F)+>WE#$22R'=NF;D$# ''4GZAH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *^ /^"K7[+?Q/_:4_P"%7?\ "N/#/_"1_P!B_P!J?;_]/M;7R?.^
MQ^5_KY4W9\J3[N<;><9&?O\ HH \_P#VA/"VJ>./@%\2_#>B6OVW6M8\,ZGI
M]C;>8L?G3RVLD<:;G(5<LP&6( SR0*^?_P#@E_\  7QW^SM\ M?\-_$+0O\
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M^%W_  KCPS_PD?\ 8O\ :GV__3[6U\GSOLGE?Z^5-V?*D^[G&WG&1G[_ **
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MWSO]=\GW/?[O-??]% 'P W[+?Q//_!6 ?&3_ (1G_BV__0:^WVO_ $ OLO\
MJ?-\[_7?)]SW^[S7@'P:_8+^.WA3]E+]HOP=JO@;[+XD\6?\([_8ME_:]@_V
MK[+?O+<?.LY1-J,#\[+G.!D\5^OU% 'X53?"WQ1\%OVF?V.O!OC+3/[&\2:;
M_9?VJR^T13^7YGBK4)4^>)F0Y21#PQQG!Y!%?NK7P!^U]^RW\3_BC^WO\%?B
M-X8\,_VGX,\._P!B_P!J:E]OM8OL_D:K-/-^ZDE61ML3JWRJ<YP,GBOO^@ H
MHHH ^ /^"K7[+GQ._:47X7?\*X\,_P#"1_V+_:GV_P#T^UM?)\[[)Y?^OE3=
MGRI/NYQMYQD9^_E^Z*6B@#@/V@O"^I^./@)\2O#FB6WVW6=8\,ZEI]C;>8L?
MFSRVLD<:;G(5<LP&6( SR0*^??\ @E_\!/'?[.WP$\0>'/B%H7_"/ZS=>)I]
M0AMOMD%SN@:UM8U?=#(ZC+1.,$Y^7I@BOL&B@#Y _P""G_P%\=_M$? '0?#?
MP^T+_A(-:M?$UOJ$MK]K@MML"VMU&S[II$4X:5!@'/S=, X]^_9Y\*ZIX%^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#X;^+?%W[77P3U/0O"VM:UIME%:?:KS3M/FN(8,7Y8[W12%PO/)Z<T >Y_\
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M[MFOBC]MZ6^;]BO]D$.9FM3HU_YA8$KN"68B!/\ N[\#TSCI73_$K5OVK_\
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MR?%WP=-X*\->%WMY(;:[L9K-9!;N9;>W@CF/F2 RN7=S\GWQZ+0!'XZW3?\
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M89$<B6)EPR?,F" WZ?>#?%5AXZ\(Z'XETJ0RZ7K-C!J-I(PP6AEC61#^*L*
M-BBJUUJ=G8NB7-W!;NWW5ED52?IDU9H **KPZA:W-Q)!#<PRS1YWQI("RX.#
MD \<U.2%!).!0 M%?,'_  4:\87V@_L3_$;6O#.MW&G:C;'3EBU#2;MHIHBV
MHVJL%DC(*DJQ!P>C$=Z[']B;6=0\0_LG_"[4M5OKG4]1N=%ADGO+R9I9I6.<
MLSL26/N30![=14%U?6]A&)+F>*WC)VAI7"@GTR?H:F5@ZAE(92,@CH: %HHJ
MM)J=G#=+;27<"7#8VPM(H<YZ8&<T 6:**;)(L:,[L$11DLQP /4T .HKP[]L
M[Q%<Z7^R5\4-7T/4Y;.\M]%FDM[[3[@I)$XQ\R2(<@CU!KEO^";'B35O%W[%
M?P[U;7=4O=:U2X_M'SK[4+AYYY-NHW2KN=R6.%50,G@ #M0!]-445^57Q8\,
M>./CY_P4^\?_  PT_P"+'BSP)H<6GVM[$NCZA.(XBNFVC%5B$J*-S.S$CN2>
M] 'ZJT5QGPS\*GX3_#3P]X;U;Q+<:_/IELMJ^M:M)B>\89.]RS'+'ZGI767=
M];6"![FXBMD8X#3.%!/IS0!/117Y)_\ !3+Q)\2KS]L33?"?@;QCXAT/S?!Y
MU!+#2M4N+>.5X$O9W 2-P"[+!M!QDG;0!^ME%>#?L-?&23XZ?LM^!/$UW</=
M:NED-.U.24@R/=6Y,,DCX[OL$GTD'3I6K^V#\7A\#/V:_'WB^.?[/J%KIKV^
MGN,Y%W-B& @#KB216/LI- 'LE%?DC_P3/\2?$NS_ &QM0\)^.?&7B'7!'X/&
MHO8:IJEQ<1Q/.EE.@*2.0'59]IXR#NJI_P %(OA3\0/V9X[;QQI'QQ\;WT?B
MG7KH#2%U&XMX;%'W3!(RLQ^5<[0,#@"@#]>:*SO#LC2^'],=V+NUK$69CDD[
M!R:T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?'B6Z7FH6/ARVAT^VD^[)=2N(XMPR,JK-O8 @[4;'.*[#_@J(H7]A/XF #
MTP#_ ,&=I7S/\>/#M[KW_!&_P'/9B1ETNTTN^N$C!.8O-,9R!V!E5O;;GM0!
M-^SS_P $];C]K/P/IGQ=_:$\;^)M?UWQ+"+W3]/MKM(EM[1^8V8E& #KM=8X
MPBJK 8)R!CZQ8^,/^"5/Q[\$6UCXOU'Q1\!O%]Q]DGL=:ES_ &=M=5E;(&Q'
M02K*&0()0KJ5&S</O/\ 8]\8:7XZ_9;^%FJ:1);M:CP[96CQVV-D,T,*PRQ
M=MDD;KC_ &:^-?\ @LU?P^)M/^$'P]TUUN?%.K:S)-;V2L"VU@L"%AU :23
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M])VH _0_PS_R+>E?]>D7_H K3K,\,_\ (MZ5_P!>D7_H K3H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#\][/_@G3\6_@3K>K']GOXYS>$_#6IS_ &A]#UNW\Y86QC(;:Z.V HW>6K8
M!)V@GO/V>?\ @G>O@/XK)\5_BOX[O_BO\187,EE<WJLMM9-@@,%=F+LN6V?=
M1,C:@*JP^S** /E_]M#]B&R_:K_X1S7=+\2W/@GQ[X;8MIFMVR%QC>KJK[65
MU*NNY'5@4+,<'->40_L1_M(?$:Q_X1WXI?M*W4_@QP([JR\.VOEW-Y#T:-YB
MB$ CKO\ ,!YRIK[WHH ^./V7_P!@VX_98_:5\7^+?#.I:>?AUJ^E#3[32)9)
MGOK=@8'W,[ AAOCE_BZ..F,59_:G_8!B^,GQ(L/BI\._&%S\,OBG9E-VK6J,
MT5YM0HI?:RLC[,(7!8,@VLA!R/KZB@#\]/$W_!.GXN_'#0=2_P"%U?&U_&E[
M:V4ZZ!I-K&UOIT-ZT3I%<S[%7=L+9PJ;CT+%<JWU/^Q_\$=3_9S_ &=?"?P\
MUC4+35-1T?[7YMW8AA"_G7<TZ[=P!X64 Y'4&O9** "OS<\#_P#*:[XA_P#8
M!B_]-EC7Z1U\#?&K]A;XT:[^UMXJ^-/PO^).A^#+O5H+>VA-S \L\<:6D$$B
ML#$Z?,T.?H10![)^WU^RWKG[6_P=T?P?X?U?3]%O++7H=6>XU(2&-HTM[B(J
M-BD[LSJ?3 ->_P#A/2)/#_A71M+F=9)K&RAMG>/.UF1 I(SVR*R?A/HOBCP[
M\.?#^F^-=9A\1>*[:U6/4M5@0(ES,,Y<*%7 /^Z*ZR@#Y5\ ?LB^(?"/[=GC
MGXYW&M:9-H.OZ:;*'38A)]JC;9:KN;*[<?Z.W0_Q"CXA?LB^(?&'[=7@7XY6
M^M:9!H/A_3A93Z;*)/M4K!+I=RX7;C_2%ZG^$U]544 >$_MJ?LU_\-5? G4/
M!5M=VNG:RMW;W^FWUZC-%!-&^&)V@GYHGE3(_OT?L6_LVO\ LL? VQ\&WE[:
MZIKDEY<:AJFH6:L([B>1\!AN&XXB6),GKLKW:B@#Y5\ ?LB^(?"/[=GCGXYW
M&M:9/H.OZ:;*'38A)]JC;9:KN;*[<?Z.W0_Q"O!_^"W/_)'?AW_V'9?_ $G:
MOTBK\X?VEOV ?VBOVE-:O8?$/Q>\/7_A2#5;B^T;2[JU=&LHW9A&A:. %BL9
M"\D]/QH _0OPS_R+>E?]>D7_ * *TZJ:39MI^E6=J[!G@A2)F7H2J@9'Y5;H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>mrsn-20201231_g9.jpg
<TEXT>
begin 644 mrsn-20201231_g9.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '" F4# 2(  A$! Q$!_\0
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M7CWXDP?MB?$3]F+P+;,+NR^Q+K>M0CD>6&$89_<&$G!_O>]=C\'O#^F^*_\
M@I5\;=&U>R@U'3+S1S%/:7"[XY4+IE2.XKT']B[_ ()UW7[+OQ/U?QAJ_B>U
M\0O):M9Z;#! Z&UB9B6!+$YXVXQZ'UKTGX;_ +)^H^!OVLO&_P 7YM>MKJQ\
M068MHM,2!EEA;<I)9LX(X- 'RM_P31^ W@#QH?B=?ZOX3TJ^U+2?$=U;Z;>3
MVX:2T4$A1&>V.U>=>!?BJ_[(OPT_::^#]_<2";3'ECT2"5OGF@FF%N67UW++
MO]>*^N?A/^Q!XT^"'QXU'Q+X-^)(T[X>ZMJ0U+4O#,EF));@Y)*>8P.T$L?N
MX/OTKYJ_;N^#>E?$7_@H1\-M$T:1'U?7E@EUBV7)'EP;7Y7WB1CS]: /M[]@
M_P"%?_"H_P!E_P &:3*BK?W-M]ONV48WR2DL#_WQL'X5] U5TNQBTO3[:R@7
M9!;Q+%&H[*H  _(5:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **@N)TMH9)I6V(BEBS<  =Z^=9_VN;L>%W\<6O@:^O/AHERL+
M>($NHPQA+A!<B'[YCR5Y Z'/04 ?2-%4M-U.WUC3+34+.42VEU"D\,HZ.C*&
M4CV((KP35/VJM1GA\4ZSX9\"7GB/P?X9NI+2_P!8M[R)&D:-L3&&,_,X3J<
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M"[8R'*D@*,#&>U<EXT^%?Q$^(5KJ6@:IXSL[+PM?2?O?[/M +QH=P)A+,NT
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MN-R*H;)89&0.:N^)OBIX.\':Q#I>N>)])TK4)@I2UO+R..0AC@':QS@DX!H
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M7OA+Q?;>+?#G]C^%M6\2)K6A^&6< :='&D>PA4.(]TB/)L'3?R,YH Y+5O\
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M** "BBB@ HHHH **** "BBB@ HHI"<=>* %HI-P]:,B@!:*3</6C(H 6BDW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%]_Z):H/V'/^30OA'_V+MK_Z!0![E1110 4444 %%%% !1110 4444 %%%%
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M=<^.DNJ>%X=0\<Z3JS*1J=Y=HTL#9Y60NP) !)R,]*^^/@K^R3K'@7X5^&]
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MR =/W:CYAGU(KA/V1?&O[0>J_$NSMFT:\U[X5#[OB#Q5IL5EJ.S'!PKN<^U
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M&UALX!TBMXPB_D!BK*C%+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M&N-/N;B0-N,RD LY ^\Q&2:^O+:XCNK>*:%@\4BAT8="",@T 2T444 %%%%
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MV'/^30OA'_V+MK_Z!4_[:W_)I/Q>_P"Q8OO_ $2U0?L.?\FA?"/_ +%VU_\
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MP2-Q/-?4FF?:S8P&_6%;S8/.6W),8;'.TD X^HJQM/K2JNV@!U%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#;*(HU3<5R<9VYQSUJM=_"/P;>VTMN_AS3PDB%&VP '!]#VKL-O.>M&WWXH
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M?^)/V;_'5Q#XK\1:#)K$FO7=KX6>QA7<DT]P\<9#KO'FJXSGD;Z />H_VN?
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MCN&<4ZJEC;SVT+)<7+7;F1F#LBKA2Q(7 XX&!GJ<5;H **** "BBB@ HHHH
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M9:ZE IW+'=1+( ?49'%:-K:PV-ND-O$D$,8VI'&H55 [ #H*EI: /$_VUO\
MDTGXN'O_ ,(S??\ HEJ^4?V8?^"CGPQ^&/[/?@#PKJVB^,I]1TC2(+2XDL=$
M,L+.JX)1]XW+[U]7_MJ_\FD_%W_L6;[_ -$M4'[#O_)H?PD_[%VU_P#0* /)
MO^'JWPA_Z /CW_PGC_\ '*/^'JWPA_Z /CW_ ,)X_P#QROLNB@#XNF_X*M?!
MZUADFFT7QU%$@+/(^@%551W),G%2K_P58^$#*"-!\>8/(QX?)'_HRO;?VMV(
M_9=^+>?^A7U+I_U[O7I'A'_D5-&_Z\H?_1:T ?)?_#U;X0_] 'Q[_P"$\?\
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M6>"*?2?&T,TQVQ1OH6&D([*#)S^%6?\ AZM\(?\ H ^/?_">/_QRF?MGD_\
M#5W[)'_8QW__ *!;U]G4 ?&G_#U;X0_] 'Q[_P"$\?\ XY1_P]6^$/\ T ?'
MO_A/'_XY7V710!\677_!63X,6LD,4VD^-X99FVQ)+H6TR'T4&3D_2I_^'JGP
MAW9.@^//P\/G_P"+IW[<!Q^T=^R7_P!C?/\ R@K[&7[PYH ^./\ AZM\(?\
MH ^/?_">/_QRC_AZM\(?^@#X]_\ ">/_ ,<K[+HH ^*W_P""L7P82]6U.D>-
MQ=NN]8&T+#L!W"^9G%61_P %5?A O_,!\>?^$\?_ (Y1\0FV_P#!5'X7\?\
M,A7G_HZXK[)6@#XV_P"'JWPA_P"@#X]_\)X__'*/^'JWPA_Z /CW_P )X_\
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MHH **** .5USX5^#_$VH-?:MX:TS4;QA@SW-LKN1Z9(J+2_A!X)T.^BO=/\
M"VE6=W$=T<\-JBNI]00.*Z^B@!*6BB@ HHHH **** ,3QIX=T7Q?X7U30O$5
MK#>Z'J5N]K>6UPQ5)8G&&0D$'!![&D\%^%]&\$^%],T#P[9PZ?H>G0+;V=K
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MYP!BOA[]DN;Q!X!_::^.=OX]\93>(9M*TVWO;[5+H[88\QQR2;%Z+&@) X&
M!7 >$/C5J'Q2_;7\ >-[WQ-:VOA'5H[ZUTC2/MJ8B@B:(++(N<*TC,W!Y(C%
M 'Z6#FD9MM*O2N*^-&@^)O%'PP\0Z5X/U2'1/$=Y:M#9ZC.2%MV/\60">F:
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MZG9B20D6]RF0D@VL.1D]>.:ZNWOH+EF6&>.1E^\$<-CZXZ5^<'PC\)ZG\/\
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M?]D/XK:;X>\3WGB'Q3:^+_-U.31[DS7LUB8T,P@"G<1DX&/2O5?^">'C=_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <3\:OB-!\(?A/XL\:7%HU_%H6FSW[6B2"-IO+0ML#$'!./0U_,]KFKW
M'B#6+S4;N:6XN;J5II)IW+N[,<Y9CR3[U^QG_!8#Q+XFU/X<^&/ 'A;3=0U;
M^U+DWNJ6]CI<UP5AC(\EO,1"J_.'RN<X'(QBOR8_X4S\0L_\B+XFQ_V"+C_X
MB@#]X_V /C-%\:OV7_!VH27-@^KZ;;#2;^UL&.+9H"4B5P22&:%8G//\>1@&
MOH^ORB_X)!>+O&OP[\9:_P##?Q!X2UW3M$UK=J5M=7&E/#%%<I& YDE<# 9$
M4*!GFOU=H **** "BBB@ HHHH **** "BBB@ J"Z8K#*0VUMIP1]*GJ&Y5FA
MD ZE2 /PH _.;P/X9^/WQ>\/^//''A[XU7VCOHVKWT5GHLUC#)"ZP.?W9.W.
M"%QU[U[KX3_:M\::Q^S?X2\9Z=\.[WQ?XFOO.MK^RT^7RXX)(9&B=RY4\$IG
M'O7D'@[P;^TW\,['QIX,\+>!M'.CZ]JE[<0:]?:@%:!9V8[RB@G@&M3QU^R?
M\3O!_P -?A7X7\*Q:;XYL-*-Q_PD.DZK,8[2]FFD,C2.I!W*K.0.,\9QS0!W
MW@7]O)/%VE^ M1O/!UUH5KX@UZ;P[?"ZN 6T^Z2-V4'Y1NW&,CMBI_$O[>6F
M^&/"/Q3\4OX;NK_1?!>L1Z%"UK,-VH7;)&=H^4[ &?;GG&*\.U[]GWQ#\*?V
M)?B)IGBP:;H6NZ+KA\0:-?6C@6_F"8;&B'W@,$J 0#\U>N?!3X0^(;']A^QL
M8= T;Q7XG\112ZQJ>G:\2EO?-<R/*P8A6^8HZ@9'XB@#U_\ 9U^-OB7XQZ/>
M77B/P%?>"I(]KV[33":*YC;/*L%&"../>N9^/_[6%Y\+?'>F^!/!W@?4_B'X
MRN[0W[V&GMM6"#)&YFVGGY3Q7G_[#_P!\>_#'QOXKU_Q#H-CX$\/W]O'#:^%
M=-NS/ )0V6G'  R./QK;^/?PN^*WA#XY6WQ9^$MEIWB&YN=,_LK4]#U"7RC(
M S%)$<C QN''?% %3Q)_P4(TG2_@+IGQ$M/">H3WDOB*+PW>^'Y7V7-K<LDC
M$9V_-R@ XYS[5V?[-O[6,_QP\<>+_!FN>#;_ ,#>*?#BQW$VG:C)ND,$@!C<
MC:-I(8<5XG=?LB_$)?@WH,6HFTU?QMJ/C^U\5:W':L$A@C6.96"[L9VEQT]:
M]>^%_P &_%'AO]M[XP?$.]LUC\+^(=)TZUT^X\Q29)(HXE<%0<C!4T 5OCQ^
MV5?_  P^,5A\,_"_@"_\:>));%=2G$-R(4BA9MH RIW,<'Z8]Z\^^-G[5GQ.
M\/?M%?"/PWH/@_4(M*UVV%S>Z6X'FRLRG>A8K_RRY8XQG9[UM?MN?!GQK\4-
M6LCH7PQ\,>-+=;<Q0:I>79@OK"1NK E/N\*1AL\=*Y:^_9K^,'@Z\^ /B&R>
MT\7^(/"<#6&K?:KDJ%CEW!G#,,L$5\>^V@#U/5?VRAI/@'XJ^(Y/#,F? U^M
MBUJ;C!N20I)SCY?O=/:N:^*G[<NI:3>6/AOP9\/=8\8:_=>'H];U+^S9!_Q*
MX980ZL?E.[&\?7I7COQ>_9P_:!DU+XO^&?#.C:/J7A'QM?1:G]NDN@DR8 #1
M!2/O'&>>,#KS78:[^S]\9OA;\1K7QK\-=,TS5;_Q!X/L_#FLV^I7&S[%)!;Q
MQB1>#D QCIU- &M^RQ^UIKC>%/AAI_C6.?49/&5QJ$46L7#JCQ2PM&1$R@ =
M)/\ QTU]"_ /XX-\<K'Q/J<&DG3M)TW6;G2K&Z:7?]M2&1HS*..,E>GO7Q?\
M5/A#XJ^$O[!>CR:U<VWA_P"(7AK6VU.SD616+22$@HA!_BR/RK[(_9+^&[_"
MK]GOP7H%PFW4%T^.XO@>IN9%#RD^Y<F@#V 4M)2T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U@3T.*-OYTZB@!NW
MY@<_A3J** "BBB@ HHHH **** "BBB@ HHHH *:R[J=10 W;_P#7HVD#KDTZ
MB@#F/&WPT\-?$:SM[3Q+I<>KVD$@E2"9W$>X=-R@@,/9LBN@M;.&QMXK>WC6
M&WB01I%&,*J@8  [ "IZ* &[?RHV\=<TZB@!NVC;^5.HH 9L]Z79R#3J* &;
M.,?K1LZ\X/K3Z* .5\9?"_PO\0I-.?Q)I$.KG3Y#-;)<,QC1SCYB@.UCP/O
MXKI_+Q@#@#L!3Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;^ _$G@G5QKGASQ3X1U(:?K&C7/EO$_ER%6!22.1T="I#*>U>\5G^+O%FE^
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M ^"S\#]3TNPU"XL-/T^/3(([X1M$3!%&ER9_M"3KR7<H-TF3_25Y=&S/^>M
M'XS?%CX0Z]%_P5?\,_LWP:7?#X;_ !W\5^&/CQJ,\<:_8HHM&T^9=3LY0>#]
MHOM.TEC@9_?8)&Y"/V948(ZUY/X?_8U\*Z+^USJOQMN;SQ!K'CF^T+_A&;-[
M^]WV>B::9EN)+>U@555!),BNSOOD) &\* H]8"8- #J*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>mrsn-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrsn="http://www.mersana.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrsn-20201231.xsd" xlink:type="simple"/>
    <context id="ia8f204faa7704411a0850b074d255000_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc81d87920df4d46804f62d14d1675af_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i93de83dcf0d640bda59d5ec464074a69_I20210223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2021-02-23</instant>
        </period>
    </context>
    <context id="i02a979a8932342d78dec04dc805709b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7a39af3ac91431f9135e7905754c66c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iec68d7798d0041aaa3817b210b456dc3_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i3dd854fec4ed47cb8bffad52078aa3ea_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i5bdd4a73857d40c8a50ac539b3fe1443_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6d2fd67c849e42de89b7f83df7efdddd_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia4dd90b55c3d4405a31378f2cf6c85a5_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i1666e43922144352b571dcc6dc54780c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6957e6107783414c86d7d038c4de0d0d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie629a06a7eb44ce7b948b0a2eac6c15a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifb028a17d03043db910b31d93f01ebd6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibdd4c70c35274a40bc12395e93b9c793_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i248321357d504cd6b2392e62a156b394_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i646b21abf1f34c91ad1c6c0474853466_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2b30519d48b44dce8f3ebc341927841e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i90519fa5579c4a0a830381b5fb35398f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id85be7739be4471886b92107ad654c16_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7763b300d146495ba1f6d378fcf527d4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i820a1679d0844c67ad4f922202689e57_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4018a4aefc7144ef90a07daed7e35438_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3d51cce334c24c3384bbf0988c25c72b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i568856ae452c43d9a8f78d6db3cd490b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifaf2a7f80adb41dba4f4492c90a549b8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0c5ee7c8c32f480aaa50a43deb934371_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1f1bc12c003c4e57a5f7a90f50d8d476_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4f7e8965da448198116af6c110f7faf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i524d5f48af734daa921b6b627766b439_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie6fd43849d3e4363a46139030c95a116_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie8130fe63e6246718c8b705ebba7e9b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ee2fd134e6b4b6abbb327c32e4f4ded_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e5bfe19343142b3906779afeba94ec7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5d693db8b41458bb34eba574b8b961b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a6d0e47a36447d293b93e7ae49266ad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib1b597f23a2c4b7ebe27542604c170b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i08c6e587f4aa4d3a87ad5a5bd3f7ef47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a63ce8628a6420f8f56fbf95c67ba5c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c8a68e376b84047b4655bd24fe4098b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d033197c1ce4359a4e3f0b33dee0964_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad9d949fa3384c24aed7832550cba9f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id3b785dd5a254889b46e8f92526bbb8a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic822eefabb4d4deb9631ece7d64d45df_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7587cbccc6c4451e9d3b098bfd5bc320_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia4e03a06a83b45da881a991b3fa64a37_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i35ae40d344cb48109420ed8b520d73e7_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i20d32d9d39084d6a842551c406380048_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i32e7573ef8fe419aa60a3e7c2573e532_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6249b32c3a3472199c99217268325e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a4bce75e9484c55ab4f169eabc82fde_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2bc5954c2df24836829d0bdf041a7dc2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="idf326ed84a184b69aac5f187571380da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc059b98c5e4406eb2f908459f254117_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id4e7d49b91dd454c97384848857e7904_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibbf381469b4d49adacff9769db1f0076_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icef7477d01eb42fa93cb54ff9d6cbd4f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9972585559044d9bb7fe57fd33d4126d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2ca1a08f33fc491daa2aa0165f719267_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:ComputerEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i67f598299c7a417cbd523207c78e819a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff1a309483c5420db7794218d82c68a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83018382077d46b8aefa5023352430ad_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i4df390ba859c457b82608a3b20950c08_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="ic742200b058d41098d52ab5f0e3428b8_D20140601-20140630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-06-01</startDate>
            <endDate>2014-06-30</endDate>
        </period>
    </context>
    <context id="if4257918738749a69d4891f5d50d9d76_I20140630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-06-30</instant>
        </period>
    </context>
    <context id="i7a9c0faaca2d45558f08d2d44e3bcb4f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iff84fe17ddac4d30aa64382852adc5e5_D20150101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="if5291b03335245c7aa553dda74e5ae19_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc3fca032b454351a178597d5f40733b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i907e240893884fc3b84988f45bb0e42c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib969f2c036c54b3aa4e16d5cd4467eca_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5fa45b03b28a4c988f4645fd9a126190_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="icbdaeaae5ace468d9fc696fd63746c47_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5f3c590e11e5409186c16c2b7663f9fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c28bca56c544eb188d401c14dce4279_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60c254ebe9d141308dc815c9e53ae58d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a0a25cb274a4de5addf0a574c9ee5aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87ac3e6acdfe4d5297fd46e985220155_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:RightsToFutureTechnologicalImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf1def552aea421892138747772fc31f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:JointResearchCommitteeServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb6492dc61484f73b5b8d09644054672_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:RightsToFutureTechnologicalImprovementsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4931e025e0654175a346486558f333d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:JointResearchCommitteeServicesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idaed771792aa4f45820e1bdf461f9acc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6e9a106d068b45588dee4fc2c9191449_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:SupplyAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5b8df85e3b534d9680740bcea14c3648_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:SupplyAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99dca4a69ab24c5a872dd3a7062b04b4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:SupplyAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3ad77cfaea7c4367aa41179d395dd1fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61c929a4e2c64380af7083035353ca9b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5cfc255c5b5348df8b706ecee6e18fc5_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="i753b8ff92fff46fea6569a01931d0c30_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i26c601317048494e845d1196c42e27fb_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="i50edd11bfb47457a9112b1ae5cb86665_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="icbf321584c2242ad97228b78ab55de05_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i084338c0a80d483dad529458b1964134_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6f7873d325a04701833b6ce4c01cf715_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4ff6fad6dff742daae99d7c13a13b3a3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i68908ae9c5064baa964d04f85fc17eaa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7dd109ee0cb84c998131f728a303e54f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i23577b731ce742d9a2dc95f75f3ed39e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LimitedServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9427fc34fbbb4872be93f51ea1a98758_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LimitedServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4bf844a9201846c6b8d71ce0fc4564a6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LimitedServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib2c25c7d679e4207b7260e4df1988cd6_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:ServiceMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7f85c6dbea4e41f68ef9f77064c9488c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7c0a8934a1c6426dbdc36c02ecbace70_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c164faee42044c6bd0efd3f8e822986_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id1ad11b4ad384e07aadaac9fb23dd498_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if421bb6d4ade4aa7875850e2e9e7ce5e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8269462beefc49e0bf40ee05af372ef6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i32fd9e9a94794fe3a2242b4ca9bc78d0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6341208859442f9b6ef8af77034d83d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i352d06ba5fb848548eb58f8027ff894b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8fc9df98ef2d477ba1138bc3dd081e76_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia12bcd4d127345a18bc09a7631d0e9ae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c176c12317e495abdb2f03744b1bffa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i32e2e3e778ca460194f0dffe0a2edf27_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icbc4ff85c1d24045ab6977cd50a5b2e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic52340d210a24378ae895de1817cdca3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id50ec1eca088483b9329538c98b03e04_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8f480eeb670e4a4e820469036816203f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if61098ade0e347d582c1a9c5ca600ca2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i09af4016cf924f80913d431c2607ec67_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if3e5c95050104eaa8d8078a5e789e74b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i47ab6eccf1b6445f80bc756361d8cff7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id53d0e5e5e574f9ea3bfac8d17355c76_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9fc584d33c9d43799da46631af3ada8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0a28d50b8e94ad8a3d5ce0e83bf2a8c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i856895a9ae3d498cbd7a6e7e6aea88cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:ComputerEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd1dfdef8c0c4efbb4a9ef235c35a801_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:ComputerEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0af0080ba1dc4a0cb75af59f74d83190_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentLeasedAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic7699dd1563a4628924b1afe47e1a4dd_D20190508-20190508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-08</startDate>
            <endDate>2019-05-08</endDate>
        </period>
    </context>
    <context id="i631efc7ffeaf4f04ac0f4957eaba56a9_I20190508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-08</instant>
        </period>
    </context>
    <context id="i163836ee7b6f4ffa9c0cb574b727c47f_D20190508-20190508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-08</startDate>
            <endDate>2019-05-08</endDate>
        </period>
    </context>
    <context id="i6bc12f9880564eaaaf5cd6c44d035584_I20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-28</instant>
        </period>
    </context>
    <context id="i90749e47b83a4ed7a4168ba3c7be4fbc_I20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-28</instant>
        </period>
    </context>
    <context id="ie14bf80516a946eab284cdc6fa94ee65_I20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-28</instant>
        </period>
    </context>
    <context id="i7e2dcf3cdc3748e483ed1c6403bb6a16_I20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityTrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-28</instant>
        </period>
    </context>
    <context id="iec2d0197c15d41c8a6bdc407bc838c19_I20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-28</instant>
        </period>
    </context>
    <context id="icfaa9f81105a42f396f57538ca9bca0e_I20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-28</instant>
        </period>
    </context>
    <context id="ie6d2f0012515488e88c88d4beea20fbd_I20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityTrancheSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-28</instant>
        </period>
    </context>
    <context id="iaa8dbb46bbe744e985b2e0216ba5ac51_I20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-28</instant>
        </period>
    </context>
    <context id="i5b7d7299ce1c41e0b7319ee9be889c78_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i078da7f737c349af8b0fe34900888817_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i21f9feecd548415ea57bfadff8075528_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrsn:DebtCovenantPeriodAxis">mrsn:PrepaymentOccursPriorToAugust282021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i1d95ffd29d8a42f09d5833c466360f5c_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrsn:DebtCovenantPeriodAxis">mrsn:PrepaymentOccursBetweenAugust282021AndAugust282022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i3c584ca6ee79452785e1ad58cd890611_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrsn:DebtCovenantPeriodAxis">mrsn:PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i4b8290917b104724b022253cb68344a8_I20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-28</instant>
        </period>
    </context>
    <context id="iab9b2892056c4107bc99217b78b467ca_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="ia64de5de74d14ba6a2d99ac7e5b576e6_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram559PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i12e103ce06ac4a6899e2b020312d0789_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram774PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="if180f69d9ce245cf99704eb7f6351a59_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram559PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i41a996208e274d7a8e321ab0940d2cd2_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram774PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i13f8a6424f0a4cf9be7614ce49041c63_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i308407f9760646139e65cbbff6cda013_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia651b5389b414e8d9e7497b27b28db57_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i06524015ee73497b86e333130cd09189_D20130101-20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="id811a98ebc9446e780342c9c938b83b6_I20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2013-12-31</instant>
        </period>
    </context>
    <context id="i317cfb0a66ce420aba39052cc61dd3f7_D20191126-20191126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-26</startDate>
            <endDate>2019-11-26</endDate>
        </period>
    </context>
    <context id="i455788b289d34014a736e72b5a36e693_I20191126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-26</instant>
        </period>
    </context>
    <context id="i87d8789f035d4fd5a4df293bbf1c1d7e_D20200302-20200302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-02</startDate>
            <endDate>2020-03-02</endDate>
        </period>
    </context>
    <context id="ib6469fe4541e48b89a7a078c0ed5ffcf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:WarrantsAndShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i535686c256b94372ae4ce5f38fcb0825_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:WarrantsAndShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic5e733a950fa45a997c912a1f02d01a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i140f6ca2a4144d20a6d857ac59d04d54_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie75edfebdd6e45ba9f9bfbf6f784bf06_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if65e9cab919646faac147bc5c615a4ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i303a7a474d1f41a5a7a7433b5d46bcc1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i659d9c80d2bc46cdb8692d3fccee5dd2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iecb87f2b399c4ebca9aa9663b640aed4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a5864a7879b4087ac73cb3bfcccd0e8_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="i61566b4dae604295b9e10906b8b19b74_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="ic9335c4c8a544f7784ac7050e6f8525a_D20170601-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="idc230768a013428dbfb0b0e0a1cf01d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i20cea58d91fe4a02bb07ac2b8a1f0791_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="i90de0efc2a4f4539a8da0eb8a4f579dd_D20200902-20200902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-02</startDate>
            <endDate>2020-09-02</endDate>
        </period>
    </context>
    <context id="id1c52f697f3447aca0d47be353863ce4_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i1aec4bf8702f430b91a2277849a9a314_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie39e122b84984208a83a60f26cebb72b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6d84e8019e7f46ad999a65d511d99d20_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i23c524872861491cbbc5e13e4cf5d051_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="id980ee2ed8d34feca1762482a2e75df0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i920acb3427774292827daa9726c45873_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15699193709b4c5198a5f460762ea356_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b2ee45dc2784fc396ead6a8bfd4ecb5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f6ea660b40844fe84f66bd5e5fe9ea5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i79fb9930f6094104a456730528f5bc99_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9f4688b8c44640b09f240cd0e1c92161_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iad5bc870fab4400884a565359cfdf9a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0fd03e26fc404cd7886d527bbebe9cee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i25c2d7125bea4d40a3c4bd88341d03b4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0ebb056de9f546e0a119ca21f8308e0c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i95e58426df2940999d78200d99d5eba5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icf67d48970814a13815d8dec946856d1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i95fd51f717da4b488c652bf7d8674730_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e5593e7a34742298584e0cea80c0c50_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3f6b9959fd5242cba1fd04a96cea57d3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3e12adb838364036838eba86fa043b68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f8aac06008a4724ae9284b7cc253a25_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i05268d4f6e994edd8ddff9186d1b7540_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7df3a8881d504e549decddca8cac8c76_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="if3d5650f067549778be0f063470fcbca_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6686ed562d224356b9709fed401426e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:OfficeSpaceCambridgeMaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib85365aea4d54cff875208fefeee96ef_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i90755edba69e44b6969f908dafac0389_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:OfficeSpaceCambridgeMaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic059f7a3532745518966900be47d1c47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82697de2ab144693bec9626ce8bdb92c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1a16dd07ee341a0b4a2267c3b6bd737_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibacf6c67e9b24271b096b036df23e4a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2f999c2f67b946f6a6d1493212350a0f_D20190101-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i6132787d773e482cbb6d82895b63d717_D20190801-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4114a3ad19d943caa2f08b5649e9e275_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementUpfrontPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a071cec119846ab9055589216a2b776_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementUpfrontPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1094fe6fc0a54ffaa7e6425e002d5fd9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementUpfrontPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i480e629817294830afafe0f1a51084b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4abde9e6537849859c77bdc8d4176754_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i65bb47754a65456c89056c19e9b6a48d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="target">
        <measure>mrsn:target</measure>
    </unit>
    <unit id="milestone">
        <measure>mrsn:milestone</measure>
    </unit>
    <unit id="agreement">
        <measure>mrsn:agreement</measure>
    </unit>
    <unit id="security">
        <measure>mrsn:security</measure>
    </unit>
    <unit id="vote">
        <measure>mrsn:vote</measure>
    </unit>
    <unit id="jurisdiction">
        <measure>mrsn:jurisdiction</measure>
    </unit>
    <unit id="audit">
        <measure>mrsn:audit</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV80L2ZyYWc6ODc3ZDA5ZGJmYTQwNDI1ZmFkMDI1ZDc5MTE0ZDkyYTQvdGFibGU6M2ExNjYxM2Q4NWJkNGJhNGJkYzg3MTU4NGNlMTdhYzkvdGFibGVyYW5nZTozYTE2NjEzZDg1YmQ0YmE0YmRjODcxNTg0Y2UxN2FjOV8xNi0xLTEtMS0w_e9b44339-ada2-4935-859e-7a49ace95b6b">0001442836</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV80L2ZyYWc6ODc3ZDA5ZGJmYTQwNDI1ZmFkMDI1ZDc5MTE0ZDkyYTQvdGFibGU6M2ExNjYxM2Q4NWJkNGJhNGJkYzg3MTU4NGNlMTdhYzkvdGFibGVyYW5nZTozYTE2NjEzZDg1YmQ0YmE0YmRjODcxNTg0Y2UxN2FjOV8xOC0xLTEtMS0w_59bff244-88c2-4891-969e-78510115dae5">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV80L2ZyYWc6ODc3ZDA5ZGJmYTQwNDI1ZmFkMDI1ZDc5MTE0ZDkyYTQvdGFibGU6M2ExNjYxM2Q4NWJkNGJhNGJkYzg3MTU4NGNlMTdhYzkvdGFibGVyYW5nZTozYTE2NjEzZDg1YmQ0YmE0YmRjODcxNTg0Y2UxN2FjOV8xOS0xLTEtMS0w_14382aa7-b874-44bb-90e6-5c7c945cdf14">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV80L2ZyYWc6ODc3ZDA5ZGJmYTQwNDI1ZmFkMDI1ZDc5MTE0ZDkyYTQvdGFibGU6M2ExNjYxM2Q4NWJkNGJhNGJkYzg3MTU4NGNlMTdhYzkvdGFibGVyYW5nZTozYTE2NjEzZDg1YmQ0YmE0YmRjODcxNTg0Y2UxN2FjOV8yMC0xLTEtMS0w_c9c23db8-a1ee-41b3-86b1-cb071664044d">false</dei:AmendmentFlag>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xODk2L2ZyYWc6MDA1OGM3ZTBhOWQzNGNkZjk2MjE0M2ViMmM3Y2VkNjIvdGFibGU6NTRhNzg2MmU4NGYwNDJkYmFmMDNkYjkwMzcyNzZkNjQvdGFibGVyYW5nZTo1NGE3ODYyZTg0ZjA0MmRiYWYwM2RiOTAzNzI3NmQ2NF8yLTEtMS0xLTk2MzU_ca5868e3-45f4-4c03-b737-afa8296e37ae">mrsn:CollaborationMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xODk2L2ZyYWc6MDA1OGM3ZTBhOWQzNGNkZjk2MjE0M2ViMmM3Y2VkNjIvdGFibGU6NTRhNzg2MmU4NGYwNDJkYmFmMDNkYjkwMzcyNzZkNjQvdGFibGVyYW5nZTo1NGE3ODYyZTg0ZjA0MmRiYWYwM2RiOTAzNzI3NmQ2NF8yLTMtMS0xLTk2Mzc_e5d579e2-e0e3-4c3f-967d-42e52fdb1f5f">mrsn:CollaborationMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xODk2L2ZyYWc6MDA1OGM3ZTBhOWQzNGNkZjk2MjE0M2ViMmM3Y2VkNjIvdGFibGU6NTRhNzg2MmU4NGYwNDJkYmFmMDNkYjkwMzcyNzZkNjQvdGFibGVyYW5nZTo1NGE3ODYyZTg0ZjA0MmRiYWYwM2RiOTAzNzI3NmQ2NF8yLTUtMS0xLTk2Mzk_c90a21b1-f9fa-4812-916c-265bb8f37742">mrsn:CollaborationMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMy0wLTEtMS0xMjY3_a627f6f4-0dcd-4d57-a53d-d933bbc3fbaf">us-gaap:AccountingStandardsUpdate201409Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="i83018382077d46b8aefa5023352430ad_I20200101"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDYvZnJhZzphZjI4YmIxYjIwMjQ0MzJhOTIwYTBiYThjZmYwMzAwNy90YWJsZTpiZDllMmFmM2YxYjM0N2M2OWU2Y2QxNjZkZWU4ZGQxYi90YWJsZXJhbmdlOmJkOWUyYWYzZjFiMzQ3YzY5ZTZjZDE2NmRlZThkZDFiXzQtNC0xLTEtMA_90bd2b64-add4-4097-9685-ce4e5321468f">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="i4df390ba859c457b82608a3b20950c08_I20200101"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDYvZnJhZzphZjI4YmIxYjIwMjQ0MzJhOTIwYTBiYThjZmYwMzAwNy90YWJsZTpiZDllMmFmM2YxYjM0N2M2OWU2Y2QxNjZkZWU4ZGQxYi90YWJsZXJhbmdlOmJkOWUyYWYzZjFiMzQ3YzY5ZTZjZDE2NmRlZThkZDFiXzUtNC0xLTEtNzQxMQ_e56fd037-5fed-45d1-b499-0ffb0ca66f72">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMC0xLTEtMTkwMQ_def9574d-e21a-4369-9aec-5ccd94c4b5a5">us-gaap:OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTAtMS0xLTE5MDM_e1131034-fc7f-40a3-8087-977f8547a400">us-gaap:OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="i90755edba69e44b6969f908dafac0389_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDgvZnJhZzo0NjRhZjJhZDIzYmM0MDA5ODFjNDdkZjMwMTZiYTYwZC90YWJsZTpjMGQxYjMxMjhiMGU0NDY3OTJiYWFlMGExM2MyNjc3Mi90YWJsZXJhbmdlOmMwZDFiMzEyOGIwZTQ0Njc5MmJhYWUwYTEzYzI2NzcyXzYtMS0xLTEtMA_65334f8c-b5a9-405a-a46b-71559cc2c13d">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <dei:DocumentType
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDU2_68c3ae68-d884-4b3d-a26d-e81dd7276257">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDUx_b0ff835e-bac6-4a86-89db-bd6e33f3b01b">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8yMTk5MDIzMjU4NjU2_03f4c5fc-9ca3-464a-b6ac-9a6c57a77630">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8yMTk5MDIzMjU4NjU2_211c405e-44eb-496b-a4e9-156738d665d1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDU5_a0c7206f-5818-4606-ad73-2069fca99b6d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDY0_71ebdf02-c5c1-418e-b550-e9b2d2cfca14">001-38129</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDUz_9c6573b1-855e-4564-8d84-190ef0ed6906">Mersana Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6NjU4ZmExMzg3NDJmNDEzY2EzNDNjZWIyOGVjN2Y0MjIvdGFibGVyYW5nZTo2NThmYTEzODc0MmY0MTNjYTM0M2NlYjI4ZWM3ZjQyMl8wLTAtMS0xLTA_45d3379c-764d-4c7a-b90e-728272b0e185">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6NjU4ZmExMzg3NDJmNDEzY2EzNDNjZWIyOGVjN2Y0MjIvdGFibGVyYW5nZTo2NThmYTEzODc0MmY0MTNjYTM0M2NlYjI4ZWM3ZjQyMl8wLTItMS0xLTA_45f11b38-783e-49cc-a411-0045dbb717d5">04-3562403</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6NjU4ZmExMzg3NDJmNDEzY2EzNDNjZWIyOGVjN2Y0MjIvdGFibGVyYW5nZTo2NThmYTEzODc0MmY0MTNjYTM0M2NlYjI4ZWM3ZjQyMl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YjAwZDVlYWQ4MmQ0ZDAzOWUwYWQyMTg3MDAyMjhhNF80_afecccd3-db04-4352-b61a-911e8c996a2a">840 Memorial Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6NjU4ZmExMzg3NDJmNDEzY2EzNDNjZWIyOGVjN2Y0MjIvdGFibGVyYW5nZTo2NThmYTEzODc0MmY0MTNjYTM0M2NlYjI4ZWM3ZjQyMl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YjAwZDVlYWQ4MmQ0ZDAzOWUwYWQyMTg3MDAyMjhhNF83_02e7df54-0b82-4e03-8ad7-70663219aa93">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6NjU4ZmExMzg3NDJmNDEzY2EzNDNjZWIyOGVjN2Y0MjIvdGFibGVyYW5nZTo2NThmYTEzODc0MmY0MTNjYTM0M2NlYjI4ZWM3ZjQyMl8zLTAtMS0xLTAvdGV4dHJlZ2lvbjo1YjAwZDVlYWQ4MmQ0ZDAzOWUwYWQyMTg3MDAyMjhhNF8xMQ_298f3447-d63c-4c29-92ab-9d436b0fce3b">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6NjU4ZmExMzg3NDJmNDEzY2EzNDNjZWIyOGVjN2Y0MjIvdGFibGVyYW5nZTo2NThmYTEzODc0MmY0MTNjYTM0M2NlYjI4ZWM3ZjQyMl8zLTItMS0xLTA_505508f5-a699-4ef7-9dd0-6595f7de55bc">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDQ5_aa2c4800-9374-4c85-86c6-9dc0abd74ee7">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDU0_37267912-9644-4d2f-9a95-2d19ce7e740c">498-0020</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6YmVhNWMzNTJlMDQwNDI0ODhjYjUyN2I1NmYxNmFiMTAvdGFibGVyYW5nZTpiZWE1YzM1MmUwNDA0MjQ4OGNiNTI3YjU2ZjE2YWIxMF8xLTAtMS0xLTA_3f9c8d26-9eae-4d42-9dfc-f9fc21cf054d">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6YmVhNWMzNTJlMDQwNDI0ODhjYjUyN2I1NmYxNmFiMTAvdGFibGVyYW5nZTpiZWE1YzM1MmUwNDA0MjQ4OGNiNTI3YjU2ZjE2YWIxMF8xLTEtMS0xLTA_42cfe384-6134-4c7a-a5f8-4a304161737f">MRSN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6YmVhNWMzNTJlMDQwNDI0ODhjYjUyN2I1NmYxNmFiMTAvdGFibGVyYW5nZTpiZWE1YzM1MmUwNDA0MjQ4OGNiNTI3YjU2ZjE2YWIxMF8xLTItMS0xLTA_f42947cc-d22d-444e-bd72-ace4e8a4f6dc">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8yNzQ4Nzc5MDc0MDQy_b0aeb2ba-2133-4bbb-8884-6053f6f1bf3b">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDY1_68059b1d-a573-4167-a085-ab7418a73ae5">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDUw_83c78d7c-fc1c-4881-a4dd-55f48e7bdcb1">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDYy_2e4b433f-5d9d-401c-aabb-97e9d6325a64">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6MzIxYjhiNWRkZjI5NGYwNzg3MzZmYWQzM2NkNzc3MzAvdGFibGVyYW5nZTozMjFiOGI1ZGRmMjk0ZjA3ODczNmZhZDMzY2Q3NzczMF8wLTAtMS0xLTEzNjE_84428ac2-0d1a-40df-9a23-587c0572c6bb">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6MzIxYjhiNWRkZjI5NGYwNzg3MzZmYWQzM2NkNzc3MzAvdGFibGVyYW5nZTozMjFiOGI1ZGRmMjk0ZjA3ODczNmZhZDMzY2Q3NzczMF8xLTMtMS0xLTA_a8231a52-922b-41b8-83a9-1ea04eace66f">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGFibGU6MzIxYjhiNWRkZjI5NGYwNzg3MzZmYWQzM2NkNzc3MzAvdGFibGVyYW5nZTozMjFiOGI1ZGRmMjk0ZjA3ODczNmZhZDMzY2Q3NzczMF8yLTMtMS0xLTA_f590057b-1246-42c7-94b0-c1099310fa96">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8yNzQ4Nzc5MDczNjEw_6a391c1b-99a8-4760-81ab-32836162f42e">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMDYx_ab54f76b-d890-48f8-a6c7-761544df9290">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="idc81d87920df4d46804f62d14d1675af_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8yNjQx_fd3013ed-b006-4a11-8803-cadc1f830fe0"
      unitRef="usd">1147647431</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i93de83dcf0d640bda59d5ec464074a69_I20210223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8yNzc4_5bfc73d1-6bec-4345-9790-ff3a98fb4c7f"
      unitRef="shares">69042942</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xL2ZyYWc6NWM2NTg2YTk1ZjJiNGM4Mjg2OGE2YjViMjg5OGYzZjQvdGV4dHJlZ2lvbjo1YzY1ODZhOTVmMmI0YzgyODY4YTZiNWIyODk4ZjNmNF8zMjk4NTM0ODg2Mzk0_30249dae-6cc0-4cc6-9dc9-71b32729207b">Portions of the registrant&#x2019;s definitive proxy statement that will be filed for the 2021 Annual Meeting of Stockholders are incorporated by reference in Part III.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMy0xLTEtMS0w_397b906e-ffe8-490d-bef5-cf558891cee4"
      unitRef="usd">255094000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMy0zLTEtMS0w_2b5dbf07-eeab-466a-967e-352355a51499"
      unitRef="usd">62351000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfNC0xLTEtMS0w_469b7b7a-84f2-4cdb-97fa-456ce5cb2f82"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfNC0zLTEtMS0w_1bc0d1b5-44e9-4bdd-85d7-376623d9a0d6"
      unitRef="usd">37439000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfNi0xLTEtMS0w_716cb704-48c9-4312-9c25-cf62203002d9"
      unitRef="usd">3486000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfNi0zLTEtMS0w_11f9cdbc-5cdb-43bf-9045-de4c75a1c473"
      unitRef="usd">1536000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfNy0xLTEtMS0w_2cea4faf-0480-467d-a232-f6ca3de6e1ed"
      unitRef="usd">258580000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfNy0zLTEtMS0w_c116f3eb-0437-4aa5-809e-04c22f7a70c8"
      unitRef="usd">101326000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfOC0xLTEtMS0w_f68bc53c-766b-409e-9901-6f0e14c01ab3"
      unitRef="usd">1730000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfOC0zLTEtMS0w_eba99c4e-c1f0-4cfc-9f81-5a874ee17d2e"
      unitRef="usd">2164000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfOS0xLTEtMS0w_6c6ad973-921a-4332-a840-dde8351a995b"
      unitRef="usd">10936000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfOS0zLTEtMS0w_7e7f83e1-bbd7-4bb3-bf54-29fbbd1211f7"
      unitRef="usd">2598000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTAtMS0xLTEtMA_0302bd55-a959-4330-8ece-20ad4f011f95"
      unitRef="usd">2153000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTAtMy0xLTEtMA_9ffacb72-a1c2-48de-bf63-054c8cb31955"
      unitRef="usd">1453000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTEtMS0xLTEtMA_79f22742-6ef3-4cef-b53a-e504ec73ffeb"
      unitRef="usd">273399000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTEtMy0xLTEtMA_c1576349-5652-4157-93f5-552a14d468a9"
      unitRef="usd">107541000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTQtMS0xLTEtMA_1bdcf7db-53c0-4b41-8ee0-ef4432cda1b9"
      unitRef="usd">8340000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTQtMy0xLTEtMA_885881fc-c9c5-4fc9-87b8-7cc0e735d3ca"
      unitRef="usd">7296000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTUtMS0xLTEtMA_67e95e1c-cbe8-45c3-aa83-c2e388d8f9d3"
      unitRef="usd">16146000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTUtMy0xLTEtMA_c5ec44c4-8e86-405e-975d-8920a083f553"
      unitRef="usd">8986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTYtMS0xLTEtMA_30e868e7-e13d-4058-ad0d-c407ac397bd0"
      unitRef="usd">3987000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTYtMy0xLTEtMA_4fff1323-de4a-4a51-96e9-6a6a010dec82"
      unitRef="usd">4815000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTctMS0xLTEtMA_a58ab0db-10e3-4647-92d8-701edbbb60ba"
      unitRef="usd">1437000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTctMy0xLTEtMA_7eb441b0-06bd-49c2-b5bd-baeaea5c9be7"
      unitRef="usd">2219000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTgtMS0xLTEtMA_07810ece-e9f0-4efc-837f-cace4bc0ed71"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTgtMy0xLTEtMA_5c727d6a-18e7-4f36-8508-add2883092d4"
      unitRef="usd">667000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTktMS0xLTEtMA_a467565b-4e95-4b4e-8fae-05a59738d96b"
      unitRef="usd">93000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMTktMy0xLTEtMA_f989d3c5-a969-482f-89b8-a1fb4ac1c4c1"
      unitRef="usd">87000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjAtMS0xLTEtMA_54518462-cff5-4386-949c-c969b2daec07"
      unitRef="usd">30003000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjAtMy0xLTEtMA_ad6078b0-ac2c-43a1-96aa-f47bacf9652c"
      unitRef="usd">24070000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjEtMS0xLTEtMA_367f5ea6-fe1a-47c6-ab33-44775cbf0220"
      unitRef="usd">10158000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjEtMy0xLTEtMA_9d54b997-629f-49c1-a327-4cfad4568482"
      unitRef="usd">677000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjItMS0xLTEtMA_6223fb32-8888-4913-8c76-bf8c71ac671c"
      unitRef="usd">4977000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjItMy0xLTEtMA_640e0225-aa56-4d61-bcb3-4ce4f01e08bc"
      unitRef="usd">4201000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjMtMS0xLTEtMA_81c35f54-ffa4-432d-9f4b-16e0d45c8e0f"
      unitRef="usd">174000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjMtMy0xLTEtMA_b3a47996-3117-4ad0-9266-deba15d39f7c"
      unitRef="usd">275000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjQtMS0xLTEtMA_c9b1f0c7-d596-4077-bfa5-f89915a6f041"
      unitRef="usd">45312000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjQtMy0xLTEtMA_3c269f2a-656f-40d9-a76e-5ce379d9f80a"
      unitRef="usd">29223000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjUtMS0xLTEtMA_555b1f9c-5b86-4c9e-b376-4d26a0d1db14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjUtMy0xLTEtMA_6fd4cca6-313e-448c-9c9b-fb31c557e739"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NDE_4a496eaa-47a4-4939-9b5a-e490d80e177d"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NDE_cb34589c-be3d-4b2b-81f2-7b0e0492a621"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NTQ_8df6ab6b-b791-404b-9aef-4f22dc1e9fbe"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NTQ_af12a50a-e8f2-4972-bc59-ea2e835c40de"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NTg_c592db1b-419a-4b4e-93ad-c9c3c759707a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NTg_ea4ba233-60f3-4956-a5a6-4952ae67ae2d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NTg_f0392792-a464-40a3-b769-8ff325c49672"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMC0xLTEtMTM2NC90ZXh0cmVnaW9uOmQxY2I1NjhiYzczMDQ1YTk4MDdhOWY4MDQyZDE2NWJjXzEwOTk1MTE2Mjc5NTg_ff171ddd-b2d9-4a18-8ae5-445152809ea8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMS0xLTEtMA_0977ccb6-99bb-43c5-89fa-070bd3a255d8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjctMy0xLTEtMA_426b5b48-4d7e-4836-a490-5e73f4657c92"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyMTk_20775a18-c636-4185-8b66-3ac39a14f4b3"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyMTk_2fe0355d-87f7-47ec-94cd-b339c9677f79"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyMzM_04b884c4-8713-405a-801c-867245c9747b"
      unitRef="shares">175000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyMzM_93463672-45fd-46ac-a66a-7c6d82409192"
      unitRef="shares">175000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyNDY_1a307504-d77c-473c-9d80-9ce0bd821149"
      unitRef="shares">68841288</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyNDY_37009d98-7f93-428b-bf19-dd8905809113"
      unitRef="shares">68841288</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyNTk_08d08fd9-bbaf-4a87-a1b8-25d92bf71216"
      unitRef="shares">45388023</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMC0xLTEtMTQyOC90ZXh0cmVnaW9uOjNkN2Y0NDM0MTdjMzRkMDViMzZkY2YyYWI1N2QyMzlhXzQ5NDc4MDIzMjUyNTk_26a9b5e9-5cb1-4e7e-97fc-b26ef0213e97"
      unitRef="shares">45388023</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMS0xLTEtMA_65a39135-9672-4334-98f8-b7f398b13be9"
      unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjgtMy0xLTEtMA_619d4473-273e-4d16-a7d3-8806fb59dcd8"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjktMS0xLTEtMA_8225c0ce-22f0-422c-abbc-e4a37004ab73"
      unitRef="usd">508499000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMjktMy0xLTEtMA_74d45e6b-a062-47a7-b43d-a93dc09659ba"
      unitRef="usd">270662000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzAtMS0xLTEtMA_f9e4d836-a33d-459f-869b-47aa319b6cb4"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzAtMy0xLTEtMA_1858cb8b-a6e2-4412-94e4-8b4412f57700"
      unitRef="usd">25000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzEtMS0xLTEtMA_69f98de1-4274-4652-be9b-f49b5bb7ab99"
      unitRef="usd">-280419000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzEtMy0xLTEtMA_941ecc06-a726-4b9d-921e-4d317c7e44fd"
      unitRef="usd">-192374000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzItMS0xLTEtMA_ca9a6b9d-2ae3-48f4-888e-b2e033fc336d"
      unitRef="usd">228087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzItMy0xLTEtMA_2f96a947-5784-45af-a1e3-e6cbd999c464"
      unitRef="usd">78318000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzMtMS0xLTEtMA_e6a37a01-9de3-48b6-a559-ef4f6929e2f6"
      unitRef="usd">273399000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV83Ni9mcmFnOmFjYmQ1MzU3OWQ3NzRjYWY4MWI2ZTU1NGQ2MDk0MjNjL3RhYmxlOjAzMDYxNGFkNTZiNTRjYmQ5ZTI5NjliYWVmZGM3Nzg3L3RhYmxlcmFuZ2U6MDMwNjE0YWQ1NmI1NGNiZDllMjk2OWJhZWZkYzc3ODdfMzMtMy0xLTEtMA_4decd5aa-84bb-4d75-998e-9486921b53f7"
      unitRef="usd">107541000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMy0xLTEtMS0w_2934b57a-13b9-44f0-aaf4-0803eeab415f"
      unitRef="usd">828000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMy0zLTEtMS0w_514b8cc3-be51-4d8c-82e1-170aa4c26c94"
      unitRef="usd">42123000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMy01LTEtMS0w_f171fa6b-e941-4029-b527-30e1a8ad8cf2"
      unitRef="usd">10594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNS0xLTEtMS0w_c24163c3-fd4a-493b-b4f9-2c17d92dd64c"
      unitRef="usd">67036000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNS0zLTEtMS0w_98c3e726-be26-4cd1-9a45-49da9597c929"
      unitRef="usd">55040000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNS01LTEtMS0w_93d7e373-724a-4f8e-91ba-ec314e8d8db0"
      unitRef="usd">59915000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNi0xLTEtMS0w_ddb6edf8-56e0-4f29-be54-f475ff0e5e89"
      unitRef="usd">21902000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNi0zLTEtMS0w_51cfb76c-3483-4ad6-83e2-fb7690c544dc"
      unitRef="usd">17283000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNi01LTEtMS0w_4db375aa-9ff3-4333-b901-921b2db08494"
      unitRef="usd">16334000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNy0xLTEtMS0w_a955a95e-1c11-47d4-af4d-004dade37cdb"
      unitRef="usd">88938000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNy0zLTEtMS0w_aebc18c4-173a-4597-a40e-7f472add6cbd"
      unitRef="usd">72323000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfNy01LTEtMS0w_d7c3c3ce-e63f-4384-b19d-e08434ceaba0"
      unitRef="usd">76249000</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfOS0xLTEtMS0w_f10b5885-834f-4263-a228-2b3cac386fc7"
      unitRef="usd">424000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfOS0zLTEtMS0w_beaab818-27ab-44ad-a56a-6aad8a682e8a"
      unitRef="usd">2226000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfOS01LTEtMS0w_dc2a02da-4e21-4878-b5b1-5213ef9aa5d3"
      unitRef="usd">1398000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTAtMS0xLTEtMA_7d421056-18c0-4e7b-b0e0-04d9dd93de37"
      unitRef="usd">359000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTAtMy0xLTEtMA_c186571e-5064-4961-9f98-58ecf3e9fd68"
      unitRef="usd">234000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTAtNS0xLTEtMA_3099b994-34e9-44d1-a564-dc75a10684d0"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTEtMS0xLTEtMA_64953a36-884f-42ae-9176-43f50150a867"
      unitRef="usd">65000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTEtMy0xLTEtMA_f4147e2d-00a4-4c3c-a9ba-a8c30557051f"
      unitRef="usd">1992000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTEtNS0xLTEtMA_ec729c48-c0d6-453b-ae69-0b57e3854c8b"
      unitRef="usd">1398000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTItMS0xLTEtMA_17161cb7-205f-446f-ace3-cf0668283708"
      unitRef="usd">-88045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTItMy0xLTEtMA_283a4b33-998d-4716-a5d2-501eb218bfbd"
      unitRef="usd">-28208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTItNS0xLTEtMA_609f3089-0564-4cbd-8a7d-c450fa504b6f"
      unitRef="usd">-64257000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTQtMS0xLTEtMA_42841011-73b2-4f72-a7b3-e9942ecbcfc8"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTQtMy0xLTEtMA_f5afdc6f-0d3c-43e1-a9e7-5a63bb89924d"
      unitRef="usd">33000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTQtNS0xLTEtMA_4b39ce9f-800d-4666-93f1-d232689e8a23"
      unitRef="usd">141000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTUtMS0xLTEtMA_7e5622e2-2ea6-455a-92c2-d418930511c8"
      unitRef="usd">-88070000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTUtMy0xLTEtMA_452b047c-cb6b-423b-9816-0efcae384732"
      unitRef="usd">-28175000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTUtNS0xLTEtMA_6ef44be1-e5cd-4f5d-999a-fdee280db1dd"
      unitRef="usd">-64116000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTYtMS0xLTEtMA_4fefbec9-9f58-4f83-a860-3cce38a92fc2"
      unitRef="usd">-88045000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTYtMS0xLTEtMA_da11df87-9f5d-4815-b4f8-a60a8cdf82cf"
      unitRef="usd">-88045000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTYtMy0xLTEtMA_9c50153f-d8ae-44a3-b07f-894a2e3bac5e"
      unitRef="usd">-28208000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTYtMy0xLTEtMA_e267b2ad-c2d1-4d41-8f9a-39da94136155"
      unitRef="usd">-28208000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTYtNS0xLTEtMA_72226ed4-d7f6-44e5-8e25-b9bb2d24178c"
      unitRef="usd">-64257000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTYtNS0xLTEtMA_eb45d924-d4e8-401d-8708-1c2254951935"
      unitRef="usd">-64257000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTctMS0xLTEtMA_797167d9-1132-4e39-86b3-c05529cfebff"
      unitRef="usdPerShare">-1.43</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTctMy0xLTEtMA_c8c86b27-95f7-4da3-a4e9-1fa9b3f02a7a"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTctNS0xLTEtMA_69332cfd-8935-40a6-91a1-42ac1b399c71"
      unitRef="usdPerShare">-2.79</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTgtMS0xLTEtMA_6620217c-4379-47e5-8d1c-82982e55d3c9"
      unitRef="shares">61485205</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTgtMy0xLTEtMA_57856849-2449-43c2-bcd7-fb18717cdf8c"
      unitRef="shares">43492113</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84Mi9mcmFnOmY3NDlkZTM1ODVjZTQyODliOGFlY2I4ZGNkNjBmZTgwL3RhYmxlOmM4NDRiZjNmYjA2YzQ4MWFhZWNkYzlmZjg4NDc1OGQ2L3RhYmxlcmFuZ2U6Yzg0NGJmM2ZiMDZjNDgxYWFlY2RjOWZmODg0NzU4ZDZfMTgtNS0xLTEtMA_52c15fa8-d028-4f63-95d1-d8919f190b20"
      unitRef="shares">23032250</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="iec68d7798d0041aaa3817b210b456dc3_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMi0xNC0xLTEtMA_397c36c8-8b53-4724-b0ad-c9b593aafab3"
      unitRef="shares">22765017</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iec68d7798d0041aaa3817b210b456dc3_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMi0xNi0xLTEtMA_27182357-007e-45e1-9fee-806699770953"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3dd854fec4ed47cb8bffad52078aa3ea_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMi0xOC0xLTEtMA_e69f1352-e0d4-48f3-9d70-e9d1ee41ab03"
      unitRef="usd">168018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5bdd4a73857d40c8a50ac539b3fe1443_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMi0yMC0xLTEtMA_f0e8e665-9da2-4ec0-86ca-831ede3821bf"
      unitRef="usd">-149000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6d2fd67c849e42de89b7f83df7efdddd_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMi0yMi0xLTEtMA_38c8681d-c8d1-47ba-8fad-cf9e712b2553"
      unitRef="usd">-97878000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4dd90b55c3d4405a31378f2cf6c85a5_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMi0yNC0xLTEtMA_fbcef075-565a-48cc-96c5-5bce4d12b90c"
      unitRef="usd">69994000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1666e43922144352b571dcc6dc54780c_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNS05LTEtMS0xMjQz_4a536200-85e4-411f-97a2-60e2aa9c5402"
      unitRef="usd">-2031000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6957e6107783414c86d7d038c4de0d0d_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNS0xMS0xLTEtMTI0Mw_cf94fcff-7c0a-4fd1-8131-350fadf68372"
      unitRef="usd">-2031000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie629a06a7eb44ce7b948b0a2eac6c15a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNi0xNC0xLTEtMA_06700e6a-a3bd-462a-8a65-60b13d5da59e"
      unitRef="shares">427269</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifb028a17d03043db910b31d93f01ebd6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNi0xOC0xLTEtMA_c13b868b-ba33-4603-856c-fa377206c5a4"
      unitRef="usd">918000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNi0yNC0xLTEtMA_0a3d26c7-55bf-4cb7-9c5c-2e453d0a7d76"
      unitRef="usd">918000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie629a06a7eb44ce7b948b0a2eac6c15a_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNS0xLTEtMS0xMjYw_38bac3f8-65bb-4b24-839b-1cab614cdb21"
      unitRef="shares">42186</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="ifb028a17d03043db910b31d93f01ebd6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNS01LTEtMS0xMjYw_e2d33f4d-60d6-4a75-baf1-72e4fff4a4f9"
      unitRef="usd">146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNS0xMS0xLTEtMTI2MA_935d17e3-9b50-45d4-9d1a-def079f0bfb6"
      unitRef="usd">146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifb028a17d03043db910b31d93f01ebd6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNy0xOC0xLTEtMA_0f01ccf0-62e5-4af6-b8c5-c1040c98f11c"
      unitRef="usd">3884000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfNy0yNC0xLTEtMA_2beb0078-121b-4132-946d-ce3cccc3008b"
      unitRef="usd">3884000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibdd4c70c35274a40bc12395e93b9c793_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfOC0yMC0xLTEtMA_a625604d-9b6e-4a45-8908-b66ddb6f8eb4"
      unitRef="usd">141000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfOC0yNC0xLTEtMA_22728f53-06bc-441f-9c12-6edc05bc8768"
      unitRef="usd">141000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i248321357d504cd6b2392e62a156b394_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfOS0yMi0xLTEtMA_ee645848-a9d8-4eb9-9a0d-ab4e098a5dd3"
      unitRef="usd">-64257000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfOS0yNC0xLTEtMA_34e84fc5-7458-4988-861a-7567fb378073"
      unitRef="usd">-64257000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i646b21abf1f34c91ad1c6c0474853466_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMTQtMS0xLTA_183f3634-2525-438d-b280-ee1c7b3a4ed6"
      unitRef="shares">23234472</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i646b21abf1f34c91ad1c6c0474853466_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMTYtMS0xLTA_22c2a04d-7d51-4e58-a236-044189705498"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b30519d48b44dce8f3ebc341927841e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMTgtMS0xLTA_0bb9c8f3-37c8-4028-bf22-ad8b1efda02f"
      unitRef="usd">172966000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90519fa5579c4a0a830381b5fb35398f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMjAtMS0xLTA_41930f4b-2c42-4ca9-8dde-747520d1f0fb"
      unitRef="usd">-8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id85be7739be4471886b92107ad654c16_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMjItMS0xLTA_4c982d0c-7ca2-4ea9-bec2-1b56f0ea3009"
      unitRef="usd">-164166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMjQtMS0xLTA_96d161f6-c4b8-455e-b1cf-5de8a5031568"
      unitRef="usd">8795000</us-gaap:StockholdersEquity>
    <mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMC0xLTEtMTMwNi90ZXh0cmVnaW9uOmNhNDMzZDQ1NTAxMTQ0OWZhMjQ5NTBlYWIzYjZhNzNiXzEwOTk1MTE2Mjc4NjU_91ea28bb-9c7b-44c0-a678-aa6ec8886db2"
      unitRef="usd">5587000</mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7763b300d146495ba1f6d378fcf527d4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMS0xLTEtMTI3OQ_e9939700-acdc-44f6-8b37-3e0e00f0add8"
      unitRef="shares">24437500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7763b300d146495ba1f6d378fcf527d4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMy0xLTEtMTI3OQ_ade2ab05-996e-49b1-bc53-abe641a2f0ee"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtNS0xLTEtMTI3OQ_679592e2-dd34-4552-9ed1-5e3c9983b002"
      unitRef="usd">92160000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTAtMTEtMS0xLTEyNzk_a19c81f6-dfe6-4163-a15d-3f75ebdf9de9"
      unitRef="usd">92162000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mrsn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised
      contextRef="i7763b300d146495ba1f6d378fcf527d4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTItMTQtMS0xLTA_a6946407-6511-4ee9-8271-931034211c2a"
      unitRef="shares">150978</mrsn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
    <mrsn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTItMTgtMS0xLTA_361cc9d7-a3bc-4a8b-ab36-004471ddace7"
      unitRef="usd">175000</mrsn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
    <mrsn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTItMjQtMS0xLTA_addbe289-835e-4635-bcc7-190da84276b9"
      unitRef="usd">175000</mrsn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i7763b300d146495ba1f6d378fcf527d4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTMtMTQtMS0xLTA_a9fe16f6-06f2-4e84-a941-4c070b4ef8c1"
      unitRef="shares">140073</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTMtMTgtMS0xLTA_b3080a56-a039-4565-be68-faf24e6fae89"
      unitRef="usd">489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTMtMjQtMS0xLTA_35eae489-f876-4939-baee-e1282f30fff8"
      unitRef="usd">489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantShares
      contextRef="i7763b300d146495ba1f6d378fcf527d4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTMtMS0xLTEtMTI4NA_f99eb669-328f-49ed-91ca-e78257ae3f72"
      unitRef="shares">2575000</mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantShares>
    <mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantValue
      contextRef="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTMtNS0xLTEtMTI4NA_cb6bdf41-e745-4a55-a661-b56729219e31"
      unitRef="usd">8986000</mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantValue>
    <mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantValue
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTMtMTEtMS0xLTEyODQ_871b29d3-3568-4e3a-b274-a5c08b45e714"
      unitRef="usd">8986000</mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTQtNS0xLTEtMTI4OQ_084a347b-87cd-4b05-9617-1bb0cc0ca9d2"
      unitRef="usd">8986000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTQtMTEtMS0xLTEyODk_25df6c10-5167-416f-9784-4d68de4951cf"
      unitRef="usd">8986000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibde5db038b3c4b8caf6a0db00f790ff8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTQtMTgtMS0xLTA_0f25585c-39f1-4406-b805-624249d1fdcc"
      unitRef="usd">4872000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTQtMjQtMS0xLTA_b68a9d4b-61b5-4035-bd33-3ee577e60893"
      unitRef="usd">4872000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i820a1679d0844c67ad4f922202689e57_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTUtMjAtMS0xLTA_492fa8b2-b4ae-402f-a4a3-06216e6061da"
      unitRef="usd">33000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTUtMjQtMS0xLTA_b4862353-e60f-4246-8052-6cc4dd98d5f4"
      unitRef="usd">33000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i4018a4aefc7144ef90a07daed7e35438_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTYtMjItMS0xLTA_b1c72efc-b206-4e9e-ae62-10082d476030"
      unitRef="usd">-28208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTYtMjQtMS0xLTA_6c5b9f79-388a-4c91-a975-df75649215ab"
      unitRef="usd">-28208000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3d51cce334c24c3384bbf0988c25c72b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTctMTQtMS0xLTA_0bdc6e67-174c-4635-aa9d-155e323f7d8a"
      unitRef="shares">45388023</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3d51cce334c24c3384bbf0988c25c72b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTctMTYtMS0xLTA_b8b4b6ce-7b5f-40c9-9551-c6a431a06560"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i568856ae452c43d9a8f78d6db3cd490b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTctMTgtMS0xLTA_bbbe5a15-20b6-4828-9f23-0cca02c3947b"
      unitRef="usd">270662000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifaf2a7f80adb41dba4f4492c90a549b8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTctMjAtMS0xLTA_72722719-7523-40b3-a257-35f0b5f1a9b6"
      unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c5ee7c8c32f480aaa50a43deb934371_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTctMjItMS0xLTA_61f8abe0-988a-4343-9017-c9cc4b5e127b"
      unitRef="usd">-192374000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTctMjQtMS0xLTA_42e50cc2-ded5-4e79-84f2-8e69eb2e6004"
      unitRef="usd">78318000</us-gaap:StockholdersEquity>
    <mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction
      contextRef="i1f1bc12c003c4e57a5f7a90f50d8d476_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMC0xLTEtMTMxNy90ZXh0cmVnaW9uOmFmY2U3YzhhMzk5ZDQ5N2I4MzkzODNmNDA4Y2RlZDg0XzEwOTk1MTE2Mjc4NzU_c3d613f4-5059-4595-953b-0a3844203012"
      unitRef="usd">2176000</mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia4f7e8965da448198116af6c110f7faf_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMS0xLTEtMTMxNw_c71e49b5-dc87-4298-9269-fe0f96642ca7"
      unitRef="shares">10900599</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia4f7e8965da448198116af6c110f7faf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMy0xLTEtMTMxNw_9b67ce55-dfac-4468-a710-431019015e55"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i524d5f48af734daa921b6b627766b439_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktNS0xLTEtMTMxNw_2f3b6eb3-5488-4592-8e87-a36027d3df8f"
      unitRef="usd">62976000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1f1bc12c003c4e57a5f7a90f50d8d476_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMTEtMS0xLTEzMTc_42782688-bab3-42a9-9528-efdac30e4bd5"
      unitRef="usd">62977000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction
      contextRef="ie6fd43849d3e4363a46139030c95a116_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMC0xLTEtMTMxNy90ZXh0cmVnaW9uOmMxN2IxODhlNzJmMjQwZWM5ZmYxODg3MDRlODY5MmI1XzEwOTk1MTE2Mjc4Njc_02220df8-a5c3-4453-ac39-12870102c163"
      unitRef="usd">10809000</mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie8130fe63e6246718c8b705ebba7e9b6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMS0xLTEtMTMxNw_db668d04-4e77-4472-bd87-5ac4e6f23341"
      unitRef="shares">9200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie8130fe63e6246718c8b705ebba7e9b6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMy0xLTEtMTMxNw_556c997e-ce88-4ebb-a7f9-d013dba24017"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0ee2fd134e6b4b6abbb327c32e4f4ded_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtNS0xLTEtMTMxNw_71ebf8a0-d0fe-479f-986b-39cafb2b2e6e"
      unitRef="usd">163990000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie6fd43849d3e4363a46139030c95a116_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMTEtMS0xLTEzMTc_60b87019-77d7-4f65-9414-dc0130da529d"
      unitRef="usd">163991000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mrsn:StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised
      contextRef="i6e5bfe19343142b3906779afeba94ec7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjEtMS0xLTEtNDczNw_c7f6f2b3-d2e4-47a1-8434-0fa0b46a586a"
      unitRef="shares">2574971</mrsn:StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6e5bfe19343142b3906779afeba94ec7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMTQtMS0xLTA_42c65cb1-eb7f-4e12-982d-325e624b1ae5"
      unitRef="shares">697428</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie5d693db8b41458bb34eba574b8b961b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMTgtMS0xLTA_db8869a7-8e46-4443-8361-31928d2b12ca"
      unitRef="usd">3138000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMTktMjQtMS0xLTA_3459b1ce-03f8-41ae-a9cd-ef2a21285577"
      unitRef="usd">3138000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i6e5bfe19343142b3906779afeba94ec7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMTQtMS0xLTA_fa978c78-701e-458e-8cc1-feae85d3aaf1"
      unitRef="shares">80267</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="ie5d693db8b41458bb34eba574b8b961b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMTgtMS0xLTA_7735c943-8674-42ed-8f81-4c65c021050d"
      unitRef="usd">561000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjAtMjQtMS0xLTA_4d26fac7-a76b-4b63-8ce3-a413383f45cc"
      unitRef="usd">561000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie5d693db8b41458bb34eba574b8b961b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjMtMTgtMS0xLTA_d63a5fa5-37e5-4e1a-9104-350918169903"
      unitRef="usd">7172000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjMtMjQtMS0xLTA_8dacc272-1723-40ee-a86c-4fb12a8b8215"
      unitRef="usd">7172000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7a6d0e47a36447d293b93e7ae49266ad_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjQtMjAtMS0xLTA_d6ca5ea6-4d8e-4d54-a35a-1d3bb13ff5ed"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjQtMjQtMS0xLTA_dcd19b99-aa94-45ae-a65e-077e13a2d08c"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ib1b597f23a2c4b7ebe27542604c170b4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjUtMjItMS0xLTA_48a244c8-bde2-4c3c-83b2-d9b7d0b30511"
      unitRef="usd">-88045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjUtMjQtMS0xLTA_3b9c7222-0482-4dc4-8d46-ef355d32e0d8"
      unitRef="usd">-88045000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i08c6e587f4aa4d3a87ad5a5bd3f7ef47_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjYtMTQtMS0xLTA_37a265b2-285c-4266-9fdd-9fdc20d4364c"
      unitRef="shares">68841288</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i08c6e587f4aa4d3a87ad5a5bd3f7ef47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjYtMTYtMS0xLTA_9ff36b1f-7fa2-4d73-9385-73bfb79e6442"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a63ce8628a6420f8f56fbf95c67ba5c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjYtMTgtMS0xLTA_d00a768c-b853-4499-a50b-1f23e1b9e00b"
      unitRef="usd">508499000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c8a68e376b84047b4655bd24fe4098b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjYtMjAtMS0xLTA_12b3eb6b-e3dc-486c-873b-1711e9f8a20e"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3d033197c1ce4359a4e3f0b33dee0964_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjYtMjItMS0xLTA_ac8dfa9a-6123-4306-8bf3-f3e6401075ab"
      unitRef="usd">-280419000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV84OC9mcmFnOmUxMGJlNmIzNTViNjQxNzk4ZDcwMDNlYThiYjM1NjY2L3RhYmxlOmQ2ZGJkM2E5NThlMTRjMWJiYjZlMzkyMzI4YjQ2NGVmL3RhYmxlcmFuZ2U6ZDZkYmQzYTk1OGUxNGMxYmJiNmUzOTIzMjhiNDY0ZWZfMjYtMjQtMS0xLTA_65568de9-7988-486c-af01-0465b0d2b04c"
      unitRef="usd">228087000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMy0xLTEtMS0w_049c112d-fa33-4c64-8c2d-87acd5e4bd7f"
      unitRef="usd">-88045000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMy0zLTEtMS0w_fbd940f2-9a9b-475f-a8ab-641e634f1da6"
      unitRef="usd">-28208000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMy01LTEtMS0w_42305e81-3ce3-4cda-b737-317f9b0903c0"
      unitRef="usd">-64257000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNS0xLTEtMS0w_5f19e4cb-b814-4d1b-8337-4e3b74211d4d"
      unitRef="usd">1010000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNS0zLTEtMS0w_792443f0-5b0d-409b-b593-fb6637a791a5"
      unitRef="usd">1245000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNS01LTEtMS0w_e98489fc-c353-453e-a72c-5d19aee12a82"
      unitRef="usd">1257000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNi0xLTEtMS0w_7e8b3576-aa54-4cad-939c-cb25f185cbf7"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNi0zLTEtMS0w_3ac09d43-d9e8-4cdf-94e1-2ed4df6778f6"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNi01LTEtMS0w_6a9d7f81-349f-4aba-8d35-7241f1715325"
      unitRef="usd">-20000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNy0xLTEtMS0w_176dcf22-8bd2-423c-bba3-265032e619f1"
      unitRef="usd">86000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNy0zLTEtMS0w_7dfd3638-f6c0-40a9-ac27-899ad30ccf9f"
      unitRef="usd">222000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNy01LTEtMS0w_38923ce2-0286-4462-b77e-61a660f61370"
      unitRef="usd">296000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfOC0xLTEtMS0w_719af26a-2505-4920-b6d1-94441fd417df"
      unitRef="usd">7172000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfOC0zLTEtMS0w_38f30105-bd30-4fb5-8568-7153cb8a49b8"
      unitRef="usd">4872000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfOC01LTEtMS0w_22fd9378-ccb8-49c0-b910-abba8011a1b3"
      unitRef="usd">3884000</us-gaap:ShareBasedCompensation>
    <mrsn:ChangeInDeferredRent
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfOS0xLTEtMS0w_88f0d6d8-3ee7-4c45-b27b-1c71e83b56ad"
      unitRef="usd">0</mrsn:ChangeInDeferredRent>
    <mrsn:ChangeInDeferredRent
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfOS0zLTEtMS0w_e7c69d57-7d7e-4223-a23a-731bb88c7553"
      unitRef="usd">0</mrsn:ChangeInDeferredRent>
    <mrsn:ChangeInDeferredRent
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfOS01LTEtMS0w_bae8bd95-632e-4ad9-8add-adbed41837c6"
      unitRef="usd">110000</mrsn:ChangeInDeferredRent>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTAtMS0xLTEtMA_ab0c6583-3f06-4e8c-87f2-409cb69aa7db"
      unitRef="usd">-148000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTAtMy0xLTEtMA_5278acbe-d2fc-4d41-b679-b99d711af8ff"
      unitRef="usd">-103000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTAtNS0xLTEtMA_8dac751f-f9f0-42c8-ab15-cc74946d2bdb"
      unitRef="usd">0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTItMS0xLTEtMA_50c3ccb4-7c8f-4a38-8496-ef6407af9427"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTItMy0xLTEtMA_97add20b-1acc-4cef-a6ab-e04a96f9fc1b"
      unitRef="usd">-459000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTItNS0xLTEtMA_3795139c-f6f9-4042-85c3-0b6a5ddaa4d7"
      unitRef="usd">-325000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTMtMS0xLTEtMA_e148f0f4-596f-4ddd-8c1d-cd1891996d2b"
      unitRef="usd">1950000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTMtMy0xLTEtMA_c4453125-156f-494d-8505-93410b1d32cb"
      unitRef="usd">-2179000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTMtNS0xLTEtMA_0c3afe5e-c585-475b-87d6-85d503c94acf"
      unitRef="usd">1690000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTQtMS0xLTEtMA_7df6d328-e7b9-4878-8694-80a759eda946"
      unitRef="usd">700000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTQtMy0xLTEtMA_024ee368-ec64-49e5-817a-e7db8acfdd7c"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTQtNS0xLTEtMA_8d01c592-e953-419c-b2e6-eb11b8a82bde"
      unitRef="usd">1132000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTUtMS0xLTEtMA_bd1514ad-52c9-499e-9c0f-0ec1669a4563"
      unitRef="usd">942000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTUtMy0xLTEtMA_2cd1893e-924a-478e-8a16-ea793e589c18"
      unitRef="usd">-3110000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTUtNS0xLTEtMA_e0fa1f26-2500-4100-8717-09440506930b"
      unitRef="usd">7375000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTYtMS0xLTEtMA_24b06f70-a869-4864-96a1-ffa5bbbdcca5"
      unitRef="usd">7280000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTYtMy0xLTEtMA_7ba7852e-4700-43a6-a8b0-0f57dc211c41"
      unitRef="usd">-3569000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTYtNS0xLTEtMA_265df0a1-d8ee-47c8-8e24-3825ca57b09b"
      unitRef="usd">5431000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <mrsn:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTctMS0xLTEtMA_9ae975b3-814a-44c1-8bf0-3afd85609b6d"
      unitRef="usd">-1642000</mrsn:IncreaseDecreaseInOperatingLeaseAssets>
    <mrsn:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTctMy0xLTEtMA_5d6f33f9-8c92-4da8-adaf-cd26c3ad43b3"
      unitRef="usd">-1771000</mrsn:IncreaseDecreaseInOperatingLeaseAssets>
    <mrsn:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTctNS0xLTEtMA_e02dec5b-fa4a-40bb-abda-540649f466bc"
      unitRef="usd">0</mrsn:IncreaseDecreaseInOperatingLeaseAssets>
    <mrsn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTgtMS0xLTEtMA_c9d8f926-6667-43be-bd81-7b6fe225209a"
      unitRef="usd">-1281000</mrsn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <mrsn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTgtMy0xLTEtMA_1e12f55b-bca6-42d7-bf1c-14dfee5717e4"
      unitRef="usd">-1883000</mrsn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <mrsn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTgtNS0xLTEtMA_d6e1b3b4-04c0-482e-a0ee-f11269ec1d07"
      unitRef="usd">0</mrsn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTktMS0xLTEtMA_9833f83f-8680-48e2-a249-625ad2e4988b"
      unitRef="usd">-828000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTktMy0xLTEtMA_573fd2c1-74c9-45e8-a520-d714dabdeb9c"
      unitRef="usd">-41381000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMTktNS0xLTEtMA_1678dd38-a016-41d7-865a-7cd44ec859a3"
      unitRef="usd">-6243000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjAtMS0xLTEtMA_fa8871ec-44ac-4166-81fb-80f66cc14454"
      unitRef="usd">-74696000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjAtMy0xLTEtMA_239e5845-f773-43ef-b381-56a970b74640"
      unitRef="usd">-67744000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjAtNS0xLTEtMA_80df4c7d-a830-49a3-938b-0b3471c4c8ff"
      unitRef="usd">-55216000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjMtMS0xLTEtMA_2add0451-6464-4111-bb9e-156d45028e5e"
      unitRef="usd">37500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjMtMy0xLTEtMA_36ca8ca5-23af-4b01-a38c-0dd0b49e15d1"
      unitRef="usd">27000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjMtNS0xLTEtMA_25752e22-aad6-435a-855c-91afd3f00da3"
      unitRef="usd">88565000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjQtMS0xLTEtMA_e3fd6c31-a567-4840-8853-6eed9df6fd64"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjQtMy0xLTEtMA_4c1c9a5a-1194-461c-a16f-b734673241a0"
      unitRef="usd">53688000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjQtNS0xLTEtMA_22aa3b16-bfb0-4012-841d-a8a7c9d8ef02"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjUtMS0xLTEtMA_c02e0dd4-fdf0-4a14-a9c2-9baa6f814f01"
      unitRef="usd">473000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjUtMy0xLTEtMA_c9100b94-b6c7-4c8b-a633-5c1a02f949ed"
      unitRef="usd">605000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjUtNS0xLTEtMA_05f39e92-b7ba-4601-a93f-892c9a5d76a2"
      unitRef="usd">1370000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjYtMS0xLTEtMA_5fd46126-16ff-4e8e-9e35-7801b0cc9f7f"
      unitRef="usd">37027000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjYtMy0xLTEtMA_06fab1e9-1078-4ef8-b059-4a772a2c64b7"
      unitRef="usd">-27293000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjYtNS0xLTEtMA_74c6c311-c9b5-4c05-b124-0d1c7ac28680"
      unitRef="usd">87195000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie6fd43849d3e4363a46139030c95a116_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjktMS0xLTEtMA_223f6bbe-60b7-42b8-b373-3b29afdd86b0"
      unitRef="usd">163990000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iad9d949fa3384c24aed7832550cba9f3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjktMy0xLTEtMA_37e68094-c948-4677-8ebd-970c29ee83aa"
      unitRef="usd">92162000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id3b785dd5a254889b46e8f92526bbb8a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMjktNS0xLTEtMA_d38182c9-263c-4dd2-98a0-6e863594bded"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1f1bc12c003c4e57a5f7a90f50d8d476_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzAtMS0xLTEtMA_00f5e768-9622-4b7e-a4ae-92fe605f3a9e"
      unitRef="usd">63036000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic822eefabb4d4deb9631ece7d64d45df_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzAtMy0xLTEtMA_f22cef49-10dc-4876-9cc6-51b4828bfeab"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7587cbccc6c4451e9d3b098bfd5bc320_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzAtNS0xLTEtMA_d9995ac8-86b0-4d3e-b15a-6dfb535c411e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzItMS0xLTEtMA_02e15d39-a4ab-4135-a7b7-b5a89863d5a4"
      unitRef="usd">3138000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzItMy0xLTEtMA_cd211479-1d67-4e6d-b68f-222ba4f5fcb2"
      unitRef="usd">175000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzItNS0xLTEtMA_aa4eff63-1288-4116-ace8-671da827483c"
      unitRef="usd">918000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzMtMS0xLTEtMA_dcc08f80-54d8-4fe6-9129-a0bafc16cb20"
      unitRef="usd">561000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzMtMy0xLTEtMA_1931d47a-533b-439d-bdbf-0379190b07c9"
      unitRef="usd">489000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzMtNS0xLTEtMA_0b59dcff-7dd8-46fb-933f-4ab11ba42fe0"
      unitRef="usd">146000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <mrsn:ProceedsFromDebtNetIssuanceCosts
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzQtMS0xLTEtMA_87d5738e-d23d-44db-8497-84598868517d"
      unitRef="usd">-197000</mrsn:ProceedsFromDebtNetIssuanceCosts>
    <mrsn:ProceedsFromDebtNetIssuanceCosts
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzQtMy0xLTEtMA_348d8e9c-4fa1-4da9-880d-dc3684718dd8"
      unitRef="usd">4965000</mrsn:ProceedsFromDebtNetIssuanceCosts>
    <mrsn:ProceedsFromDebtNetIssuanceCosts
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzQtNS0xLTEtMA_4c8d7ef9-9d94-48e5-9f9b-120819572241"
      unitRef="usd">0</mrsn:ProceedsFromDebtNetIssuanceCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzUtMS0xLTEtMA_823fef5f-9781-4604-970e-c56a9f33e025"
      unitRef="usd">116000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzUtMy0xLTEtMA_811253ee-dfec-4293-9b7a-e7a047472be2"
      unitRef="usd">87000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzUtNS0xLTEtMA_a4d05385-3b65-4f24-9533-6ceca11d5ab1"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzYtMS0xLTEtMA_35caeab8-a8b3-4cbf-9976-c6405717dcc0"
      unitRef="usd">230412000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzYtMy0xLTEtMA_6a228e53-7643-4e7d-a884-72c937aa677c"
      unitRef="usd">97704000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzYtNS0xLTEtMA_fb6d62d8-6c39-4c5a-a60d-b0be3d682f6d"
      unitRef="usd">1064000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzgtMS0xLTEtMA_891d4e09-a9a0-4909-a6f5-efecf6b6c373"
      unitRef="usd">192743000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzgtMy0xLTEtMA_9c52ea8f-bf80-4dc8-bd8e-bbf1be903b18"
      unitRef="usd">2667000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzgtNS0xLTEtMA_d3696c53-d402-45ac-84c2-d876577bf7f1"
      unitRef="usd">33043000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzktMS0xLTEtMA_2bac1b5b-7196-471f-bbcc-f2b4c1d2a17f"
      unitRef="usd">62672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzktMy0xLTEtMA_caaf17e8-7a00-46b6-89f6-10d280c12043"
      unitRef="usd">60005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia4dd90b55c3d4405a31378f2cf6c85a5_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfMzktNS0xLTEtMA_c81e6179-30eb-4c7b-ae42-36683981235a"
      unitRef="usd">26962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDAtMS0xLTEtMA_e08d9a8a-d81d-4c17-a867-096cc6963752"
      unitRef="usd">255415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDAtMy0xLTEtMA_d62a4882-0243-4dc4-a71f-6606d748c4c5"
      unitRef="usd">62672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDAtNS0xLTEtMA_cef9a415-90d1-47cf-bc35-e8dcffc242d3"
      unitRef="usd">60005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDMtMS0xLTEtMA_8520cfcd-a756-43af-9fcf-72151e49f8bc"
      unitRef="usd">0</mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant>
    <mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDMtMy0xLTEtMA_22604557-3029-4dc2-910c-c3062d313f54"
      unitRef="usd">8986000</mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant>
    <mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDMtNS0xLTEtMA_51232025-d869-4d6a-a0bf-f650db9e8d66"
      unitRef="usd">0</mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDUtMS0xLTEtMA_3347f690-74dc-48af-b563-86b1f089f68a"
      unitRef="usd">102000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDUtMy0xLTEtMA_df46cf87-d10d-48d5-a2d5-ce96e48d3824"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDUtNS0xLTEtMA_415ea4f0-836e-4ae6-b258-9c2e52789682"
      unitRef="usd">317000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDYtMS0xLTEtMA_496b288b-756d-40c4-8f6d-8a8d96ed83b7"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDYtMy0xLTEtMA_91039759-4fea-422c-b337-81495403c519"
      unitRef="usd">180000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDYtNS0xLTEtMA_0aec3520-1dc0-4222-914d-d43e7221f585"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:InterestPaidNet
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDctMS0xLTEtMA_d25d81a3-47ff-42c8-a96c-8c9827e5cdce"
      unitRef="usd">234000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDctMy0xLTEtMA_65db3ea6-6ac5-4733-8d06-7d1ec230f85d"
      unitRef="usd">132000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDctNS0xLTEtMA_f6c6d5d2-97e3-445e-aa66-a083ee667976"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDgtMS0xLTEtMA_9a651351-6140-4946-9de4-db7a32eb9256"
      unitRef="usd">9980000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDgtMy0xLTEtMA_1e3c8a31-d01a-4db6-b03d-cdbf113cb623"
      unitRef="usd">4369000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDgtNS0xLTEtMA_efa3f95d-700b-4b79-ad35-3995d0352ba6"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDktMS0xLTEtMA_6411baf5-340a-4536-935c-21b6cb7afd27"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDktMy0xLTEtMA_8e32069c-efa4-4b1a-9476-d6ed42ecf6c5"
      unitRef="usd">429000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNDktNS0xLTEtMA_090894e1-9db0-45e6-b6ec-402c367f5dfb"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <mrsn:AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNTAtMS0xLTEtMA_b4b07ac4-bb5e-4c2b-857e-8b371fd9a8f7"
      unitRef="usd">0</mrsn:AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard>
    <mrsn:AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNTAtMy0xLTEtMA_d5994ac1-b754-42b9-9bf9-73a87e736986"
      unitRef="usd">0</mrsn:AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard>
    <mrsn:AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV85NC9mcmFnOjI3OGQ0NmQzMmYyOTRlNGE4MjkzNWYyYmM2NjJhNDRlL3RhYmxlOmFiZjQ1MTVmMGM1NTQ0NTU5ZDEzYWRjN2NmOTQwYmEyL3RhYmxlcmFuZ2U6YWJmNDUxNWYwYzU1NDQ1NTlkMTNhZGM3Y2Y5NDBiYTJfNTAtNS0xLTEtMA_b4fd13b3-b36c-40bf-91e7-fee2baad9959"
      unitRef="usd">-2031000</mrsn:AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzU3MzQ_6642e7d0-b6fe-40f2-8af4-22653f337753">Nature of Business and Basis of Presentation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with significant unmet need. The Company has leveraged 20 years of industry learning in the ADC field to develop proprietary and differentiated technology platforms that enable it to design ADCs to have improved efficacy, safety and tolerability relative to existing ADC therapies. The Company&#x2019;s innovative platforms, which include Dolaflexin and Dolasynthen, each delivering its DolaLock payload, as well as Immunosynthen, delivering a novel stimulator of interferon genes (STING) agonist, provide an efficient product engine that has enabled a robust discovery pipeline for the Company and its partners. The Company&#x2019;s product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company's early stage programs include a potentially first-in-class B7-H4-targeted DolaLock ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform, the most advanced of which is XMT-2056.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UpRi, an ADC utilizing the Company&#x2019;s Dolaflexin platform and targeting NaPi2b, an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma, is currently in the expansion portion of a Phase 1 study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592 uses one of the Company&#x2019;s new platforms, Dolasynthen, and also targets NaPi2b. In the first half of 2020, the Company initiated the Phase 1 dose escalation study of XMT-1592 .&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, the need for additional capital, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and reimbursement for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on third party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net losses since inception. The Company&#x2019;s net loss was $88,045, $28,208 and $64,257 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The Company expects to continue to incur operating losses for at least the next several years.&#160;As of December&#160;31, 2020, the Company had an accumulated deficit of $280,419. The future success of the Company is dependent on, among other factors, its ability to identify and develop its product candidates and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative operating cash flows have had, and will continue to have, an adverse effect on the Company&#x2019;s stockholders&#x2019; equity and working capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company sold 10,900,599 shares of common stock and received net proceeds of $62,976. In addition, in June 2020, the Company sold 9,200,000 shares of common stock and received net proceeds of $163,990. The Company believes that its currently available funds will be sufficient to fund the Company&#x2019;s operations through at least the next twelve months from the issuance of this Annual Report on Form 10-K. Management&#x2019;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management&#x2019;s estimates, the Company may need to seek additional funding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). All dollar amounts, except per share data in the text and tables herein, are stated in thousands unless otherwise indicated.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIzMjA_d33962b0-1104-4de7-b728-e0da4d79fdbb"
      unitRef="usd">-88045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIzMjQ_93f6c0b2-5797-4db5-b757-70a576643127"
      unitRef="usd">-28208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIzMzE_385e3260-3057-4a17-99c7-cb29af35bf91"
      unitRef="usd">-64257000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzI1MzE_02917592-2f66-4fa0-8ffd-764745cf5a75"
      unitRef="usd">-280419000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia4e03a06a83b45da881a991b3fa64a37_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIxOTkwMjMyNjQ5Njk_7e94b48b-dca8-4a83-bcd6-5d0ee4cd8d49"
      unitRef="shares">10900599</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts
      contextRef="ia4e03a06a83b45da881a991b3fa64a37_D20200401-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIxOTkwMjMyNjQ5OTE_643964b3-1a9a-4c31-b4e8-06cfc3f041ff"
      unitRef="usd">62976000</mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i35ae40d344cb48109420ed8b520d73e7_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIxOTkwMjMyNjUwMzk_771c5c1c-7751-4a70-ab31-bccf9f074b78"
      unitRef="shares">9200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts
      contextRef="i35ae40d344cb48109420ed8b520d73e7_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDAvZnJhZzo3ZmE1ZmQwM2FlY2Y0OWE1OTE4YzQyMDE4ZWQzYmZjYi90ZXh0cmVnaW9uOjdmYTVmZDAzYWVjZjQ5YTU5MThjNDIwMThlZDNiZmNiXzIxOTkwMjMyNjUwMTQ_7624e36d-b11f-4d83-9364-aab745055c5f"
      unitRef="usd">163990000</mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTY0_00db374b-c73b-49af-a9b6-c5374c67aba4">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include those of the Company and its wholly owned subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company's management evaluates its estimates which include, but are not limited to, management's judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess performance. The Company views its operations and manages its business as a single operating segment, which is the business of discovering and developing ADCs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;employee-related expenses, including salaries, bonuses, benefits, travel and stock-based compensation expense;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of preclinical and clinical studies and related services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the cost of acquiring, developing and manufacturing ADC product candidates, clinical study materials and other research and development materials;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;fees and costs related to regulatory filings and activities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs associated with collaboration agreements and license fees and milestone payments related to license agreements;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs associated with creating and obtaining approval for the NaPi2b companion or complementary diagnostic biomarker;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities, maintenance of facilities, insurance and other supplies; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;other costs associated with clinical, preclinical, discovery and other research activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs for certain development activities, such as clinical studies and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued preclinical, manufacturing and clinical expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration agreements which are within the scope of Accounting Standards Update (ASU) No. 2014-9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606), under which the Company licenses rights to its technology and certain of the Company&#x2019;s product candidates and performs research and development services for third parties.&#160;The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;research and development costs; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promised good or services in the Company&#x2019;s arrangement typically consist of license rights to the Company&#x2019;s intellectual property and research and development services.&#160;The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#160;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.&#160;Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.&#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.&#160;The consideration may include both fixed consideration and variable consideration.&#160;At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received.&#160;The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method better predicts the amount expected to be received.&#160;If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not included in the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;To date, the Company has not recognized any royalty revenue resulting from any of the Company&#x2019;s collaboration arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.&#160;The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contract.&#160;The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.&#160;Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance&#160;and related revenue recognition.&#160;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have 30-day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, the Company adopted the provisions of Topic 606, using the modified retrospective transition method. Under this method, the Company recorded the cumulative effect of initially applying the new standard to all contracts in process as of the date of adoption. This standard applied to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The adoption of the new revenue recognition guidance resulted in increases of $2,031 in deferred revenue and accumulated deficit as of January 1, 2018. For the years ended December 31, 2019 and 2018, revenue was not materially impacted as compared to the Company&#x2019;s prior revenue recognition methodology under ASC 605 Revenue Recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(ASC&#160;808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company considers the guidance in ASC Topic 606 in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(ASC&#160;820) establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash included in other assets, noncurrent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash per statement of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term marketable securities consist of investments in debt securities with maturities greater than three months and less than one year from the balance sheet date. The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Amortization and accretion of discounts and premiums are recorded as interest income within other income. Prior to the adoption of ASU 2016-13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, unrealized gains and losses on available-for-sale securities were included in other accumulated comprehensive loss as a component of stockholders&#x2019; equity until realized. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net, based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis. Fair value is determined based on quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the adoption of ASU 2016-13, the Company is required to determine whether any portion of the unrealized loss for any available-for-sale debt security is due to a credit loss, and if so, to measure the amount of the credit loss. The Company reviews each of its available-for-sale marketable securities for unrealized losses (declines in fair value below its amortized cost basis) at each balance sheet date presented in its financial statements and whenever events or changes in circumstances indicate that the amortized cost basis of an asset may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded other assets of $2,153 and $1,453 as of December&#160;31, 2020 and 2019, respectively, comprised of $1,832 and $1,132, respectively, held by a service provider, and restricted cash of $321 and $321 at the end of each period held as a security deposit for a standby letter of credit related to a facility lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting for Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(ASC 718). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the initial public offering and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption.&#160;The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of each restricted stock unit, or RSU, at its grant date based on the closing market price of the Company&#x2019;s common stock on that date. For stock-based compensation subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based compensation on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records forfeitures as a cumulative adjustment in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding and 2,575,000 Exchange Warrants (as defined in footnote 9) outstanding during the period, without further consideration for potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the diluted net loss per share calculation, stock options, unvested restricted stock units (RSUs) and warrants to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,720,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,746,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,207,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,856,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment, office equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the statement of operations. There were no material sales of assets during the&#160;years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If an impairment review is performed to evaluate an asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the asset to its carrying value. If the carrying amount of the asset exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not recognize impairment charges during the&#160;years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with ASC 842, the Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use lease assets (ROU assets), current portion of lease obligations and long-term lease obligations on the Company&#x2019;s consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#x2019;s consolidated balance sheets. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheets for leases with an original term of twelve months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&#160;Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes in accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides for deferred taxes using an asset and liability approach.&#160;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.&#160;The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160;Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is more likely than not to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) comprises net loss and other comprehensive loss. For the years ended December&#160;31, 2020, 2019 and 2018, other comprehensive income (loss) consisted of changes in unrealized income and loss on marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Off-balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company has not experienced any credit losses and does not believe this it is subject to any significant concentrations of credit risk from these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. This guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The guidance per ASU 2018-18 is to be adopted retrospectively to the date of initial application of Topic 606. The Company adopted the new standard effective January 1, 2020. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. Historically, U.S. GAAP delayed recognition of the full amount of credit losses until the loss was probable of occurring. Under this ASU, the income statement will reflect an entity&#x2019;s current estimate of all expected credit losses. The measurement of expected credit losses will be based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down of the security. This ASU is effective for annual periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company adopted the new standard effective January 1, 2020 using the modified retrospective method. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as part of its initiative to reduce complexity in the accounting standards. The amendments in ASU 2019-12 eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes. The amendments in ASU 2019-12 are effective for the fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTUy_08305847-7449-4073-b5bf-0718003bef61">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include those of the Company and its wholly owned subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTYw_c275427c-c9a8-4a57-ac66-63fa2e4030ba">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company's management evaluates its estimates which include, but are not limited to, management's judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTY1_658f4aec-d363-457a-8fb2-ac075329d648">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess performance. The Company views its operations and manages its business as a single operating segment, which is the business of discovering and developing ADCs.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTYx_45bf10d6-de2c-4e8e-b020-a2a98f8a9640">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;employee-related expenses, including salaries, bonuses, benefits, travel and stock-based compensation expense;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of preclinical and clinical studies and related services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the cost of acquiring, developing and manufacturing ADC product candidates, clinical study materials and other research and development materials;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;fees and costs related to regulatory filings and activities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs associated with collaboration agreements and license fees and milestone payments related to license agreements;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs associated with creating and obtaining approval for the NaPi2b companion or complementary diagnostic biomarker;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities, maintenance of facilities, insurance and other supplies; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;other costs associated with clinical, preclinical, discovery and other research activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs for certain development activities, such as clinical studies and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued preclinical, manufacturing and clinical expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTY4_352a6a82-9041-4e8d-87ee-af3cdddab82a">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration agreements which are within the scope of Accounting Standards Update (ASU) No. 2014-9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606), under which the Company licenses rights to its technology and certain of the Company&#x2019;s product candidates and performs research and development services for third parties.&#160;The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;research and development costs; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promised good or services in the Company&#x2019;s arrangement typically consist of license rights to the Company&#x2019;s intellectual property and research and development services.&#160;The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#160;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.&#160;Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.&#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.&#160;The consideration may include both fixed consideration and variable consideration.&#160;At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received.&#160;The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method better predicts the amount expected to be received.&#160;If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not included in the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;To date, the Company has not recognized any royalty revenue resulting from any of the Company&#x2019;s collaboration arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.&#160;The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contract.&#160;The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.&#160;Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance&#160;and related revenue recognition.&#160;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have 30-day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2018, the Company adopted the provisions of Topic 606, using the modified retrospective transition method. Under this method, the Company recorded the cumulative effect of initially applying the new standard to all contracts in process as of the date of adoption. This standard applied to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The adoption of the new revenue recognition guidance resulted in increases of $2,031 in deferred revenue and accumulated deficit as of January 1, 2018. For the years ended December 31, 2019 and 2018, revenue was not materially impacted as compared to the Company&#x2019;s prior revenue recognition methodology under ASC 605 Revenue Recognition.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <mrsn:RevenueCollectionPeriod
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzEwOTk3_2b328fb5-76ee-4bb2-818f-2cfefced88f5">P30D</mrsn:RevenueCollectionPeriod>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i20d32d9d39084d6a842551c406380048_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzEwOTk1MTE3MDEyNTg_ce5e19cf-1118-4e2c-9acd-9f2cba08ef96"
      unitRef="usd">-2031000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i20d32d9d39084d6a842551c406380048_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzEwOTk1MTE3MDEyNTg_f4bfe9d0-5dc7-43fa-b14a-ef99df54246e"
      unitRef="usd">2031000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTY5_7da5da03-476d-4322-9ce5-810a9d524b77">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(ASC&#160;808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company considers the guidance in ASC Topic 606 in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTUz_d1a4ddab-85eb-4cb0-bdc1-a178d808a914">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(ASC&#160;820) establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/div&gt;Level&#160;3&#x2014;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTQ3_07aa6c1b-ef6c-471a-9776-582812451cf8">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzI3NDg3NzkxMTYzNTI_262fb467-eaee-438d-a5c9-0b545572fc20">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash included in other assets, noncurrent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash per statement of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTU0_68c9165e-a97c-42af-a2e4-e17e232f49bd">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash included in other assets, noncurrent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash per statement of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzItMS0xLTEtMA_e4187f8f-d2cd-4c12-9b0c-02477d80a0e0"
      unitRef="usd">62351000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzItMy0xLTEtMA_49bbe73a-98e3-45b1-97e4-096968706c0c"
      unitRef="usd">255094000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzItNS0xLTEtMA_576901ca-d20b-4e56-b8fe-820f9840379f"
      unitRef="usd">59634000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzItNy0xLTEtMA_9d214014-31da-467f-ac67-0861e06bdb80"
      unitRef="usd">62351000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzMtMS0xLTEtMA_49553b36-34f8-4a12-9775-1c3600ab1327"
      unitRef="usd">321000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzMtMy0xLTEtMA_a67fc646-7f24-4d0a-b6e8-75d63facb526"
      unitRef="usd">321000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzMtNS0xLTEtMA_c4fa0523-8931-4820-8ef8-84f17526b468"
      unitRef="usd">371000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzMtNy0xLTEtMA_0d10f18d-4152-46cf-b0ed-79c0c99d64ad"
      unitRef="usd">321000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzQtMS0xLTEtMA_946e6e95-d1bd-48fb-8d46-445672e971fc"
      unitRef="usd">62672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzQtMy0xLTEtMA_237a725c-39e9-402f-88cb-6fd9f2380402"
      unitRef="usd">255415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzQtNS0xLTEtMA_630f8067-999b-45c0-b1ab-e90e6c3370fb"
      unitRef="usd">60005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo1ZDBlZWZkMjk5NTU0ZjQwOWUzYzEyNzM4MzI1Nzg3Ni90YWJsZXJhbmdlOjVkMGVlZmQyOTk1NTRmNDA5ZTNjMTI3MzgzMjU3ODc2XzQtNy0xLTEtMA_49df72f7-aaa4-45be-be8f-8828fb8cac18"
      unitRef="usd">62672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTU1_f3b91ec8-5f81-44f2-ac67-bddee5d4b4d1">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term marketable securities consist of investments in debt securities with maturities greater than three months and less than one year from the balance sheet date. The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Amortization and accretion of discounts and premiums are recorded as interest income within other income. Prior to the adoption of ASU 2016-13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, unrealized gains and losses on available-for-sale securities were included in other accumulated comprehensive loss as a component of stockholders&#x2019; equity until realized. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net, based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis. Fair value is determined based on quoted market prices.&lt;/span&gt;&lt;/div&gt;In accordance with the adoption of ASU 2016-13, the Company is required to determine whether any portion of the unrealized loss for any available-for-sale debt security is due to a credit loss, and if so, to measure the amount of the credit loss. The Company reviews each of its available-for-sale marketable securities for unrealized losses (declines in fair value below its amortized cost basis) at each balance sheet date presented in its financial statements and whenever events or changes in circumstances indicate that the amortized cost basis of an asset may not be recoverable.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTU2_7c729b69-2d76-4b2d-9471-8d384885a05e">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded other assets of $2,153 and $1,453 as of December&#160;31, 2020 and 2019, respectively, comprised of $1,832 and $1,132, respectively, held by a service provider, and restricted cash of $321 and $321 at the end of each period held as a security deposit for a standby letter of credit related to a facility lease.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzE1NTQ0_253b1a35-05e4-4b9a-9eb5-c5ddd819476c"
      unitRef="usd">2153000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzE1NTUx_19412005-b6e3-4f06-bc3b-bf97ffad3633"
      unitRef="usd">1453000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RetainageDeposit
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzIxOTkwMjMyOTEyOTA_41b617a4-9421-4e4f-85a8-98ffb49d48f0"
      unitRef="usd">1832000</us-gaap:RetainageDeposit>
    <us-gaap:RetainageDeposit
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzIxOTkwMjMyOTEyOTg_3c89851c-db92-4d62-96a4-45324fe11251"
      unitRef="usd">1132000</us-gaap:RetainageDeposit>
    <us-gaap:SecurityDeposit
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzE1NjQz_bcc43262-56c6-4e14-a2bd-c876919f9d6d"
      unitRef="usd">321000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzE1NjUw_e60f1e99-4b2a-4e6d-918f-422ac60db6e3"
      unitRef="usd">321000</us-gaap:SecurityDeposit>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTQ4_70e94979-d81e-4449-8263-81fbfab92faa">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting for Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(ASC 718). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the initial public offering and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption.&#160;The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of each restricted stock unit, or RSU, at its grant date based on the closing market price of the Company&#x2019;s common stock on that date. For stock-based compensation subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based compensation on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records forfeitures as a cumulative adjustment in the period in which they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzE3OTMw_4b7bf8c8-3edd-4908-a5c5-2386f4a83267"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTU3_47b775f2-4a6e-4359-a191-b105cac45d4f">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding and 2,575,000 Exchange Warrants (as defined in footnote 9) outstanding during the period, without further consideration for potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For purposes of the diluted net loss per share calculation, stock options, unvested restricted stock units (RSUs) and warrants to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i32e7573ef8fe419aa60a3e7c2573e532_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzE4NzE4_7d03c01b-8fb1-41b9-a11c-8a53714649a2"
      unitRef="shares">2575000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTQ5_a63330c0-410f-4dc5-934f-a72e9d18b636">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,720,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,746,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,207,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,856,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie6249b32c3a3472199c99217268325e2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzItMS0xLTEtMA_39948aa8-453c-4b2c-bc5c-4173eaaa7083"
      unitRef="shares">6112948</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6a4bce75e9484c55ab4f169eabc82fde_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzItMy0xLTEtMA_045b1f33-bd9e-46ac-9df6-b62fe1d20289"
      unitRef="shares">4720772</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2bc5954c2df24836829d0bdf041a7dc2_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzItNS0xLTEtMA_b225f70f-5614-440d-9a42-5794ffbf20dd"
      unitRef="shares">3746567</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idf326ed84a184b69aac5f187571380da_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzMtMS0xLTEtMA_eb569eec-4306-42b5-9bfe-e4a2d65d27de"
      unitRef="shares">716767</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idc059b98c5e4406eb2f908459f254117_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzMtMy0xLTEtMA_5c072ace-32df-445a-af6c-4b22f0d247ae"
      unitRef="shares">447336</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id4e7d49b91dd454c97384848857e7904_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzMtNS0xLTEtMA_ece8c530-cefb-4899-951f-45001b541c42"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibbf381469b4d49adacff9769db1f0076_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzQtMS0xLTEtMA_a9513788-7865-44a7-b915-337d74d845e5"
      unitRef="shares">39474</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icef7477d01eb42fa93cb54ff9d6cbd4f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzQtMy0xLTEtMA_cee28e86-ca8b-434c-90f1-91b148fde6fb"
      unitRef="shares">39474</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9972585559044d9bb7fe57fd33d4126d_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzQtNS0xLTEtMA_f52e0dcb-346e-4314-8ba6-786e44c154d1"
      unitRef="shares">110365</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzUtMS0xLTEtMA_a2e930b2-e452-4be4-ba78-0f3a3c24afce"
      unitRef="shares">6869189</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzUtMy0xLTEtMA_7538765d-9962-4a7f-add5-bc34eda4fa15"
      unitRef="shares">5207582</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZTo0ZTg5ZmRjZTMwMjY0MmVjOGYwMWEzYTc1Y2M3YjFhZS90YWJsZXJhbmdlOjRlODlmZGNlMzAyNjQyZWM4ZjAxYTNhNzVjYzdiMWFlXzUtNS0xLTEtMA_891fa20c-5fc4-4caa-924a-fc79f153e1bf"
      unitRef="shares">3856932</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTU4_2d274e95-d06f-42ce-b284-361d2e211de7">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment, office equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the statement of operations. There were no material sales of assets during the&#160;years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If an impairment review is performed to evaluate an asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the asset to its carrying value. If the carrying amount of the asset exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not recognize impairment charges during the&#160;years ended December&#160;31, 2020, 2019 and 2018.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <mrsn:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTY2_8aa8546e-9a23-4a3e-b75f-b09ff3bdeb20">Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment, office equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrsn:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2ca1a08f33fc491daa2aa0165f719267_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZToyZGU3MDA0YWM2NjY0ZmM2YmQ1MzUzMWRjMmE2ZWU3My90YWJsZXJhbmdlOjJkZTcwMDRhYzY2NjRmYzZiZDUzNTMxZGMyYTZlZTczXzAtMS0xLTEtMA_590a1b41-3610-4baa-a7ae-a2b1d54fc23e">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i67f598299c7a417cbd523207c78e819a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZToyZGU3MDA0YWM2NjY0ZmM2YmQ1MzUzMWRjMmE2ZWU3My90YWJsZXJhbmdlOjJkZTcwMDRhYzY2NjRmYzZiZDUzNTMxZGMyYTZlZTczXzEtMS0xLTEtMA_2445719e-26dc-4bfb-88a3-b98c2ea8295f">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="iff1a309483c5420db7794218d82c68a9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90YWJsZToyZGU3MDA0YWM2NjY0ZmM2YmQ1MzUzMWRjMmE2ZWU3My90YWJsZXJhbmdlOjJkZTcwMDRhYzY2NjRmYzZiZDUzNTMxZGMyYTZlZTczXzItMS0xLTEtMA_f409363b-512f-4916-9820-e7e3f296a34a">Shorter of useful life or life of lease</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTUw_d678a4bc-9527-47c6-85b7-c6abc5d775f0">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with ASC 842, the Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use lease assets (ROU assets), current portion of lease obligations and long-term lease obligations on the Company&#x2019;s consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#x2019;s consolidated balance sheets. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheets for leases with an original term of twelve months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&#160;Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <mrsn:PatentCostsPolicyTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTY3_d0db52ef-75c4-4c92-8955-b2a57b40593b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</mrsn:PatentCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTYz_4350717d-a1ca-4df1-95dc-1901c56f101e">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes in accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides for deferred taxes using an asset and liability approach.&#160;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.&#160;The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160;Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is more likely than not to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTU5_099eeec3-b7fe-4c10-b676-c6a8f5ffbcde">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) comprises net loss and other comprehensive loss. For the years ended December&#160;31, 2020, 2019 and 2018, other comprehensive income (loss) consisted of changes in unrealized income and loss on marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTYy_143179f6-5623-47dc-b682-f5991a4a5dea">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Off-balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company has not experienced any credit losses and does not believe this it is subject to any significant concentrations of credit risk from these financial instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzI1NTU1_ef7bcf64-e265-4d05-b9d1-4077207b1971"
      unitRef="usd">0</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDMvZnJhZzoxNmVhYmRjM2ViNTk0NzljYTk5ZTg3YTc0YmUzNTY4Ny90ZXh0cmVnaW9uOjE2ZWFiZGMzZWI1OTQ3OWNhOTllODdhNzRiZTM1Njg3XzMxMTUx_4a68fde6-c400-44f8-95ef-eb25304c908d">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. This guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The guidance per ASU 2018-18 is to be adopted retrospectively to the date of initial application of Topic 606. The Company adopted the new standard effective January 1, 2020. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. Historically, U.S. GAAP delayed recognition of the full amount of credit losses until the loss was probable of occurring. Under this ASU, the income statement will reflect an entity&#x2019;s current estimate of all expected credit losses. The measurement of expected credit losses will be based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down of the security. This ASU is effective for annual periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company adopted the new standard effective January 1, 2020 using the modified retrospective method. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as part of its initiative to reduce complexity in the accounting standards. The amendments in ASU 2019-12 eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes. The amendments in ASU 2019-12 are effective for the fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE3NDMx_411c2d8b-15ad-4b71-bbb8-b0423385165a">Collaboration Agreements&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merck KGaA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2014, the Company entered into a Collaboration and Commercial License Agreement with Merck KGaA (the Merck KGaA Agreement). Upon the execution of the Merck KGaA Agreement, Merck KGaA paid the Company a nonrefundable technology access fee of $12,000 for the right to develop ADCs directed to six exclusive targets over a specified period of time. No additional fees are due when a target is designated and the commercial license to the target is granted. Merck KGaA will be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;responsible for the product development and marketing of any products resulting from this collaboration. All six targets were designated prior to 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Merck KGaA Agreement, the Company and Merck KGaA develop research plans to evaluate Merck KGaA's antibodies as ADCs incorporating the Company's technology. The Company receives reimbursement for its efforts under the research plans. The goal of the research plans is to provide Merck KGaA with sufficient information to formally nominate a development candidate and begin IND-enabling studies or cease development on the designated target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the payments received for research and development activities performed on behalf of Merck KGaA, the Company could be eligible to receive up to a total of $780,000 in future milestones related to all targets under the Merck KGaA Agreement, plus low to mid single digit royalties on the commercial sales of any resulting products during the applicable royalty term. The total milestones are categorized as follows: development milestones $84,000; regulatory milestones $264,000; and sales milestones $432,000. There are six individual development milestones per target, payable upon the completion of various activities from the delivery of ADCs meeting defined specifications, through the dosing in a Phase&#160;3 clinical trial. There are five regulatory milestones, which are payable upon regulatory approvals for a first indication in each of the U.S., European Union and Japanese markets and regulatory approvals for both a second and a third indication in the United States. There are three individual commercial milestones, which are payable upon the attainment of certain defined thresholds for annual net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2018, the Company had received $3,000 related to development milestones under the Merck KGaA Agreement. There have been no additional milestone payments in the years ended December&#160;31, 2019 or 2020. The next potential milestone payment the Company will be eligible to receive will be a development milestone of $500 on Merck KGaA's designation of a preclinical development candidate for any target. Revenue will be recognized when achievement of the milestone is considered probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the Merck KGaA Agreement will expire upon the expiration of the last royalty term for a product under the Merck KGaA Agreement, after which time, Merck KGaA will have a perpetual, royalty-free license, or if Merck KGaA does not designate any ADC product candidates produced by the Company under the Merck KGaA Agreement as preclinical development candidates, upon the expiration of the last to expire research program. Merck KGaA may terminate the Merck KGaA Agreement in its entirety or with respect to any target for convenience upon 60 days' prior written notice. Each party may terminate the Merck KGaA Agreement in its entirety upon bankruptcy or similar proceedings of the other party or upon an uncured material breach of the Merck KGaA Agreement by the other party. However, if such breach only relates to one target, the agreement may only be terminated with respect to such target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company entered into a Supply Agreement with Merck KGaA (the Merck KGaA Supply Agreement). Under the terms of the Merck KGaA Supply Agreement, the Company will provide Merck KGaA preclinical non-GMP ADC Drug Substance and clinical GMP Drug Substance for use in clinical trials associated with one of the antibodies designated under the Merck KGaA Agreement. The Company receives fees for its efforts under the Merck KGaA Supply Agreement and reimbursement equal to the supply cost. The Company may also enter into future supply agreements to provide clinical supply material should Merck KGaA pursue clinical development of any other candidates nominated under the Merck KGaA Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified the following performance obligations under the Merck KGaA Agreement: (i)&#160;exclusive license and research services for six designated targets, (ii)&#160;rights to future technological improvements and (iii)&#160;participation of project team leaders and providing joint research committee services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has concluded that each license for a designated target is not distinct from the research services performed related to the designated target as Merck KGaA cannot obtain the benefit of the license without the related research services.&#160;Each license for a designated target and the related services performance obligation is considered distinct from every other license for a designated target and related services performance obligation as each research plan is pursued independent of every other research plans for other designated targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the expected value approach to estimate the amount of consideration related to the payment of fees associated with development and research services.&#160;The Company utilizes the most likely amount approach to estimate any development and regulatory milestone payments to be received.&#160;As of the date of initial application of Topic 606, there were no milestones payments that had not already been received, included in the estimated transaction price.&#160;The Company considered the stage of development and the remaining risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Merck KGaA.&#160;The milestone payment amounts were fully constrained, as a result of the uncertainty whether any of the associated milestones would be achieved.&#160;The Company has determined that any commercial milestones and sales based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation or in the case of certain variable consideration to one or more performance obligations.&#160;The estimated standalone selling prices for performance obligations, that include a license and research services, were developed using the estimated selling price of the license and an estimate of the overall effort to perform the research service and an estimated market rate for research services. The estimated standalone selling price of the licenses was established based on comparable transactions.&#160;The estimated standalone selling price for the rights to future technological improvements was developed based on the estimated selling prices of a license or rights received, as well as considering the probability that additional technology would be made available or the probability the counterpart would utilize the technology. The estimated standalone selling price for the joint research committee services was developed using an estimate of the time and costs incurred to participate in the committees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. As of December&#160;31, 2019, the total transaction price for the Merck KGaA Agreement was $21,500. During 2020, the Company revised its estimate for fees associated with research and development activities under the Merck KGaA Agreement to $6,325, a decrease of $175. The revised total transaction price for the Merck KGaA Agreement is $21,325. The transaction price of $21,325 was allocated to the performance obligations as follows: approximately $3,941 for each of the license and corresponding research and development services units of account for the first and second designated targets; $3,439 for each of the license and corresponding research and development services units of account for the third and sixth designated target; $3,152 for the license and corresponding research and development services unit of account for the fourth designated target; $2,746 for the license and corresponding research and development services unit of account for the fifth designated target; $425 for rights to future technological improvements; and $242 for joint research committee services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is recognizing revenue related to the exclusive license and research and development services performance obligation over the estimated period of the research and development services using a proportional performance model.&#160;The Company measures proportional performance based on the costs incurred relative to the total costs expected to be incurred.&#160;To the extent that the Company receives fees for the research services as they are preformed, these amounts are recorded as deferred revenue. Revenue related to future technological improvements and joint research committee services will be recognized ratably over the performance period (which in the case of the joint research committee services approximate the time and cost incurred each period), which are 10 and 5 years, respectively.&#160;The Company is continuing to reassess the estimated remaining term at each subsequent reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the Company has completed its research service obligations associated with four of the six designated targets. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded collaboration revenue of $828, $853 and $2,444, respectively, related to its efforts under the Merck KGaA Agreement. During the year ended December&#160;31, 2019, the Company recognized collaboration revenue and corresponding research and development expense of $1,280 related to the Merck KGaA Supply Agreement. There were no amounts recognized during the years ended December&#160;31, 2020 and 2018 related to the Merck KGaA Supply Agreement.&#160;There was no balance in accounts receivable related to the Merck KGaA Agreement and Merck KGaA Supply Agreement as of either December&#160;31, 2020 or December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, the Company had recorded $3,987 and $4,815, respectively, in deferred revenue related to the Merck KGaA Agreement and Merck KGaA Supply Agreement that will be recognized over the remaining performance period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda XMT-1522 Strategic Partnership&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2016, the Company entered into a Development Collaboration and Commercial License Agreement with Takeda&#x2019;s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. for the development and commercialization of XMT-1522 (the XMT-1522 Agreement). Under the XMT-1522 Agreement, Takeda was granted the exclusive right to commercialize XMT-1522 outside of the United States and Canada. Under the XMT-1522 Agreement, the Company was responsible for conducting certain Phase 1 development activities for XMT-1522, including the ongoing Phase 1 clinical trial, at its own expense. The parties agreed to collaborate on the further development of XMT-1522 in accordance with a global development plan (Post-Phase 1 Development). On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the XMT-1522 Agreement upon 30 days&#x2019; prior written notice. The XMT-1522 Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the XMT-1522 Agreement as of March 31, 2019. Under the XMT-1522 Agreement, the Company and Takeda shared equally all agreed Post-Phase 1 Development costs through the date of termination and for a period of 30 days after the effective termination date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Strategic Research and Development Partnership&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2014, the Company entered into a Research Collaboration and Commercial License Agreement with Takeda&#x2019;s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (the 2014 Agreement). The 2014 Agreement was amended in January 2015 and amended and restated in January 2016 (the 2016 Restated Agreement). The agreements provided Takeda with the right to develop ADCs directed to a total of seven exclusive targets, designated by Takeda, over a specified period of time. On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the 2016 Restated Agreement upon 45 days&#x2019; prior written notice. The 2016 Restated Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the 2016 Restated Agreement as of March 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration agreements with Takeda were terminated following receipt of written notices during the first quarter of 2019. As there are no further performance obligation, the Company recognized the remaining deferred revenue of $39,965 related to the termination of the Takeda agreements in the first quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the termination of the agreements, the Company had identified 14 performance obligations in the agreements. The Company concluded that the license related to each of the designated targets was not distinct from the research services performed related to each of the designated targets as Takeda could not have obtain the benefit of the license without the related research services. Each license to a designated target and the related service performance obligation was considered distinct from every other license to a designated target and related services performance obligation as each research plan was pursued independent of the any other research plans for other designated targets. Further, the material rights provided were determined to be distinct from the other performance obligations in the arrangement as they were options in the contract Takeda agreements and not required for Takeda to obtain the benefit of the other promised goods or services in the arrangement. Similarly, the Company concluded that the XMT-1522 license and the related research and development services, including the Phase 1 development and the transfer of certain materials and know-how related to the Company's manufacturing processes, were one performance obligation. The license to the Company's intellectual property was not determined to be distinct from the research and related development services that the Company was obligated to perform. For the years ended December&#160;31, 2019 and 2018, the Company recorded total revenue of $39,965 and $5,868, respectively, related to its efforts under the 2016 Restated Agreement and the XMT-1522 Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the Post-Phase 1 Development activities under the XMT-1522 Agreement represented joint operating activities in which both parties were active participants and of which both parties were exposed to significant risks and rewards that are dependent on the commercial success of the activities. Accordingly, the Company accounted for the Post-Phase 1 Development activities in accordance with ASC 808. For the years ended December&#160;31, 2019 and 2018, the Company was billed approximately $200 and $8,046, respectively, from Takeda representing Post-Phase 1 Development costs incurred by Takeda. These amounts have been reflected as research and development costs in the consolidated statement of operations. The Company did not perform any Post-Phase 1 Development activities or incur any associated costs prior to January 1, 2018. During the years ended December&#160;31, 2019 and 2018, the Company billed Takeda $195 and $3,746, respectively, related to ASC 808 costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Contract Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the balances of our contract assets and liabilities during the years ended December&#160;31, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue recognized in the period from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts included in the contract liability at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance obligations satisfied in previous periods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has provided limited services for a collaboration partner, Asana BioSciences. For the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded revenue of $0, $25 and $782, respectively, related to these services. In addition, during the year ended December&#160;31, 2018, the Company recognized revenue of $1,500 related to a milestone achieved upon the completion of a GLP toxicology study by Asana BioSciences. The next potential milestone the Company is eligible to receive is $2,500 upon dosing the fifth patient in a Phase 1 clinical study by Asana BioSciences. As of December&#160;31, 2020, the Company considered this next milestone to be fully constrained as there is considerable judgment involved in determining whether it is probable that a significant revenue reversal would occur. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestone is outside the control of the Company and there is a high level of uncertainty in achieving this milestone, as this would require initiation of clinical trials by the collaboration partner. The Company reevaluates the probability of achievement of a milestone subject to constraint at each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <mrsn:CollaborativeArrangementsUpfrontPayment
      contextRef="ic742200b058d41098d52ab5f0e3428b8_D20140601-20140630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI5Mw_b11ab5b5-84e2-4244-bf57-8c4393e3dc4a"
      unitRef="usd">12000000</mrsn:CollaborativeArrangementsUpfrontPayment>
    <mrsn:CollaborativeArrangementsExclusiveTargetsNumber
      contextRef="if4257918738749a69d4891f5d50d9d76_I20140630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI3NDg3NzkwODgwMjU_24768b4e-a8fa-4c03-bcaf-e18f48dbafa3"
      unitRef="target">6</mrsn:CollaborativeArrangementsExclusiveTargetsNumber>
    <mrsn:CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense
      contextRef="if4257918738749a69d4891f5d50d9d76_I20140630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzM5Mw_07ffabb0-ae04-4b0a-b286-108bda8440eb"
      unitRef="usd">0</mrsn:CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense>
    <mrsn:CollaborationArrangementsTargetsDesignatedNumber
      contextRef="i7a9c0faaca2d45558f08d2d44e3bcb4f_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzYyOQ_a9063808-a9e3-4823-8471-8dabe2f5bda5"
      unitRef="target">6</mrsn:CollaborationArrangementsTargetsDesignatedNumber>
    <mrsn:CollaborationArrangementsMaximumAggregateMilestones
      contextRef="if4257918738749a69d4891f5d50d9d76_I20140630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEzMDM_7693a0b7-510f-41bc-adaa-128dc5300b53"
      unitRef="usd">780000000</mrsn:CollaborationArrangementsMaximumAggregateMilestones>
    <mrsn:CollaborationArrangementsDevelopmentMilestones
      contextRef="if4257918738749a69d4891f5d50d9d76_I20140630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE1Nzk_193ecf41-03a8-487a-9f8f-ee45aaa60ef8"
      unitRef="usd">84000000</mrsn:CollaborationArrangementsDevelopmentMilestones>
    <mrsn:CollaborationArrangementsRegulatoryMilestones
      contextRef="if4257918738749a69d4891f5d50d9d76_I20140630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2MDU_3017be48-d8a4-48c8-b777-fb8e4dfc341c"
      unitRef="usd">264000000</mrsn:CollaborationArrangementsRegulatoryMilestones>
    <mrsn:CollaborationArrangementsSalesMilestones
      contextRef="if4257918738749a69d4891f5d50d9d76_I20140630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2MzA_f90532be-8ad5-4d97-b0e3-4c1e6d8a17f6"
      unitRef="usd">432000000</mrsn:CollaborationArrangementsSalesMilestones>
    <mrsn:CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber
      contextRef="if4257918738749a69d4891f5d50d9d76_I20140630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2NDQ_f4deca6e-c1bc-47bd-bec8-7e272cfba055"
      unitRef="milestone">6</mrsn:CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber>
    <mrsn:CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber
      contextRef="if4257918738749a69d4891f5d50d9d76_I20140630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE4NTk_6801086c-dfdc-4326-8820-6b3a22aa2774"
      unitRef="milestone">5</mrsn:CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber>
    <mrsn:CollaborationArrangementIndividualCommercialMilestonesTargetNumber
      contextRef="if4257918738749a69d4891f5d50d9d76_I20140630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzIxMDc_c010eedd-3ce9-4d0d-b2b2-11e8752292d6"
      unitRef="milestone">3</mrsn:CollaborationArrangementIndividualCommercialMilestonesTargetNumber>
    <mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived
      contextRef="iff84fe17ddac4d30aa64382852adc5e5_D20150101-20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzIyNzQ_f9a6006a-1249-45cf-a924-868d8983b889"
      unitRef="usd">3000000</mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived>
    <mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived
      contextRef="if5291b03335245c7aa553dda74e5ae19_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzIzNTk_7207dcba-c74f-4895-a049-815cf6920cfd"
      unitRef="usd">0</mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived>
    <mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived
      contextRef="icc3fca032b454351a178597d5f40733b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzIzNTk_9ebca646-f932-498f-834c-01b687c4836a"
      unitRef="usd">0</mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived>
    <mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone
      contextRef="i907e240893884fc3b84988f45bb0e42c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI1MzM_3aa0a45b-07cb-4b3f-bd7e-b779eba5f474"
      unitRef="usd">500000</mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone>
    <mrsn:CollaborationArrangementsPriorWrittenTerminationNoticeDuration
      contextRef="if5291b03335245c7aa553dda74e5ae19_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzMyNjc_613a94d1-14a4-49e6-9970-305682e663e2">P60D</mrsn:CollaborationArrangementsPriorWrittenTerminationNoticeDuration>
    <mrsn:CollaborationArrangementsTargetsDesignatedNumber
      contextRef="ib969f2c036c54b3aa4e16d5cd4467eca_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzQ0ODM_37852444-aa91-4453-9cc8-2300f04cef4d"
      unitRef="target">6</mrsn:CollaborationArrangementsTargetsDesignatedNumber>
    <mrsn:MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice
      contextRef="i5fa45b03b28a4c988f4645fd9a126190_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzU1NzQ_8db1d302-673b-44c4-8cf9-991d2fdab491"
      unitRef="usd">0</mrsn:MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="icbdaeaae5ace468d9fc696fd63746c47_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzc3MzI_57a8edb0-02f1-47a3-8cd6-c265df250637"
      unitRef="usd">21500000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:ReimbursableExpenseResearchAndDevelopmentEstimated
      contextRef="i907e240893884fc3b84988f45bb0e42c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzc4OTQ_2ab12ef9-f6f5-4bc5-8779-87139bd89934"
      unitRef="usd">6325000</mrsn:ReimbursableExpenseResearchAndDevelopmentEstimated>
    <mrsn:RevenueTransactionPriceIncreaseDecrease
      contextRef="if5291b03335245c7aa553dda74e5ae19_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzc5MTI_963e7205-e29a-4f80-ae34-8a9beede51c6"
      unitRef="usd">-175000</mrsn:RevenueTransactionPriceIncreaseDecrease>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="i907e240893884fc3b84988f45bb0e42c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzc5ODQ_d941b058-48e9-4f2d-a75f-96928538a101"
      unitRef="usd">21325000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="i907e240893884fc3b84988f45bb0e42c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzgwMTM_37d816a7-d49a-4689-aae5-71444411c774"
      unitRef="usd">21325000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="i5f3c590e11e5409186c16c2b7663f9fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzgwODc_396e0d59-1d8e-47f1-84e6-cbc39f05a5f1"
      unitRef="usd">3941000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="i1c28bca56c544eb188d401c14dce4279_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzgyMjg_946cc233-fb0a-4d4b-8998-ad00ba19b776"
      unitRef="usd">3439000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="i60c254ebe9d141308dc815c9e53ae58d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzgzNjc_174406a7-5ab6-43be-979f-82a4fe02f284"
      unitRef="usd">3152000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="i2a0a25cb274a4de5addf0a574c9ee5aa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzg0ODg_93bc15a5-0304-4655-b7bb-e136ca8b346a"
      unitRef="usd">2746000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="i87ac3e6acdfe4d5297fd46e985220155_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzg2MDg_eaa0383c-dde2-45f3-b078-b70b7581104f"
      unitRef="usd">425000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="iaf1def552aea421892138747772fc31f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzg2NjQ_a482a80b-a415-46ae-8cb3-a31eb035aab9"
      unitRef="usd">242000</mrsn:RevenueTransactionPriceAmount>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ieb6492dc61484f73b5b8d09644054672_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk0ODI_95aa9262-5e41-48f0-b177-b271b0fa6103">P10Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i4931e025e0654175a346486558f333d9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk0ODk_a0d3867f-1a35-4887-b181-512ae4930e5a">P5Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <mrsn:CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber
      contextRef="i907e240893884fc3b84988f45bb0e42c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI3NDg3NzkwODc5ODY_998496f5-a9ab-44a1-9351-5ea6bc978a78"
      unitRef="target">4</mrsn:CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber>
    <mrsn:CollaborationArrangementsTargetsDesignatedNumber
      contextRef="i907e240893884fc3b84988f45bb0e42c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI3NDg3NzkwODc5OTQ_df7b0e2a-60f1-4cab-b8a9-553d611033ec"
      unitRef="target">6</mrsn:CollaborationArrangementsTargetsDesignatedNumber>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5291b03335245c7aa553dda74e5ae19_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk2OTc_d7e49ed7-21c4-4aec-8091-c4b6bfb858d8"
      unitRef="usd">828000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc3fca032b454351a178597d5f40733b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk3MDE_9cb552b0-01b3-475a-a67f-764cba35d3cb"
      unitRef="usd">853000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idaed771792aa4f45820e1bdf461f9acc_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk3MDg_d3c8e32b-68c3-4ebc-a3d6-ceef47f74b20"
      unitRef="usd">2444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e9a106d068b45588dee4fc2c9191449_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk5MDY_d0afa709-2677-4ec5-9fe4-9c8fe9bf4b4c"
      unitRef="usd">1280000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b8df85e3b534d9680740bcea14c3648_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk5NjQ_0f5b5743-e72d-4765-aca2-b783ca726451"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99dca4a69ab24c5a872dd3a7062b04b4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzk5NjQ_9bdc25e8-fba5-400e-a295-a665de89d993"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNet
      contextRef="i3ad77cfaea7c4367aa41179d395dd1fc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI3NDg3NzkwODgwNTQ_09dd17d2-c6d6-4340-8d70-1c197a5923d0"
      unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i61c929a4e2c64380af7083035353ca9b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzI3NDg3NzkwODgwNTQ_ce2709f0-934a-4f13-9e05-075882f5cd95"
      unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3ad77cfaea7c4367aa41179d395dd1fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEwMjUz_b7a244f6-b087-4423-8a8a-50ca9fedbad8"
      unitRef="usd">3987000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i61c929a4e2c64380af7083035353ca9b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEwMjYw_c98b2252-86ef-48e6-ac4c-341a5a3815f3"
      unitRef="usd">4815000</us-gaap:ContractWithCustomerLiability>
    <mrsn:CollaborationArrangementsDurationToTermination
      contextRef="i5cfc255c5b5348df8b706ecee6e18fc5_D20190102-20190102"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzExMzQy_72901367-fb35-4ccb-91a1-9e27b415ab2e">P30D</mrsn:CollaborationArrangementsDurationToTermination>
    <mrsn:CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod
      contextRef="i5cfc255c5b5348df8b706ecee6e18fc5_D20190102-20190102"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzExNzA0_b18d9d03-8d84-4388-ba1a-408252dff85b">P30D</mrsn:CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod>
    <mrsn:CollaborativeArrangementsExclusiveTargetsNumber
      contextRef="i753b8ff92fff46fea6569a01931d0c30_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEyMTk1_d560d95f-74c6-46ba-9aa8-204f3b2f6314"
      unitRef="target">7</mrsn:CollaborativeArrangementsExclusiveTargetsNumber>
    <mrsn:CollaborationArrangementsDurationToTermination
      contextRef="i26c601317048494e845d1196c42e27fb_D20190102-20190102"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEyNDIz_e0ca131a-f96b-45a4-8f93-23fe1228783e">P45D</mrsn:CollaborationArrangementsDurationToTermination>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i50edd11bfb47457a9112b1ae5cb86665_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEyODk2_8db1a47a-ab71-4053-b0b5-652cf9c1639c"
      unitRef="usd">39965000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <mrsn:RevenueRemainingPerformanceObligationNumber
      contextRef="icbf321584c2242ad97228b78ab55de05_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzEzMDUy_366b1273-21ee-424e-89af-8a3398d927e3"
      unitRef="agreement">14</mrsn:RevenueRemainingPerformanceObligationNumber>
    <mrsn:RevenueRemainingPerformanceObligationNumber
      contextRef="i084338c0a80d483dad529458b1964134_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE0MjIy_c0c54887-b057-4678-a683-7310d14be4cf"
      unitRef="agreement">1</mrsn:RevenueRemainingPerformanceObligationNumber>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f7873d325a04701833b6ce4c01cf715_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE0NTA1_04c326c5-bff7-4377-8606-1a23261526f2"
      unitRef="usd">39965000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ff6fad6dff742daae99d7c13a13b3a3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE0NTEy_56805ace-0506-4796-ba31-f5cdb132c3d6"
      unitRef="usd">5868000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i68908ae9c5064baa964d04f85fc17eaa_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE1MzM2_08baf852-9a48-4194-8b41-b272e3ecaab9"
      unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7dd109ee0cb84c998131f728a303e54f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE1MzQz_4156d651-dbfe-4280-a735-9089c0c0bb89"
      unitRef="usd">8046000</us-gaap:ResearchAndDevelopmentExpense>
    <mrsn:CollaborationArrangementsCostsBilled
      contextRef="i68908ae9c5064baa964d04f85fc17eaa_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE1NzQy_e25b87c7-8cbd-4705-8af8-962ba609df77"
      unitRef="usd">195000</mrsn:CollaborationArrangementsCostsBilled>
    <mrsn:CollaborationArrangementsCostsBilled
      contextRef="i7dd109ee0cb84c998131f728a303e54f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE1NzQ5_6d1f5797-89d1-40c9-9d51-3eb6bcfa0108"
      unitRef="usd">3746000</mrsn:CollaborationArrangementsCostsBilled>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE3NDMy_da197391-941c-4596-86ea-c5318f219977">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the balances of our contract assets and liabilities during the years ended December&#160;31, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue recognized in the period from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts included in the contract liability at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance obligations satisfied in previous periods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTo4YWE3ODViZDE1MDk0YThkODljZTFiNDU2YjM5N2UxZS90YWJsZXJhbmdlOjhhYTc4NWJkMTUwOTRhOGQ4OWNlMWI0NTZiMzk3ZTFlXzItMS0xLTEtMA_ff0a8257-b2f5-4105-9189-2641b7819975"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTo4YWE3ODViZDE1MDk0YThkODljZTFiNDU2YjM5N2UxZS90YWJsZXJhbmdlOjhhYTc4NWJkMTUwOTRhOGQ4OWNlMWI0NTZiMzk3ZTFlXzItNy0xLTEtMA_8129ac9d-2535-456a-a28f-0c97be2ae35f"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTo4YWE3ODViZDE1MDk0YThkODljZTFiNDU2YjM5N2UxZS90YWJsZXJhbmdlOjhhYTc4NWJkMTUwOTRhOGQ4OWNlMWI0NTZiMzk3ZTFlXzQtMS0xLTEtMA_a11d06c0-602b-47ed-a98c-6a2678f758c0"
      unitRef="usd">4815000</us-gaap:ContractWithCustomerLiability>
    <mrsn:ContractWithCustomerLiabilityIncrease
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTo4YWE3ODViZDE1MDk0YThkODljZTFiNDU2YjM5N2UxZS90YWJsZXJhbmdlOjhhYTc4NWJkMTUwOTRhOGQ4OWNlMWI0NTZiMzk3ZTFlXzQtMy0xLTEtMA_5d208387-0557-4553-b328-3383d2927e13"
      unitRef="usd">0</mrsn:ContractWithCustomerLiabilityIncrease>
    <mrsn:ContractWithCustomerLiabilityDecrease
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTo4YWE3ODViZDE1MDk0YThkODljZTFiNDU2YjM5N2UxZS90YWJsZXJhbmdlOjhhYTc4NWJkMTUwOTRhOGQ4OWNlMWI0NTZiMzk3ZTFlXzQtNS0xLTEtMA_92c9f8f7-78bf-4612-b0bc-b5843d68a10c"
      unitRef="usd">828000</mrsn:ContractWithCustomerLiabilityDecrease>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTo4YWE3ODViZDE1MDk0YThkODljZTFiNDU2YjM5N2UxZS90YWJsZXJhbmdlOjhhYTc4NWJkMTUwOTRhOGQ4OWNlMWI0NTZiMzk3ZTFlXzQtNy0xLTEtMA_f2b79b1d-7b5f-484d-bc34-a43b47154347"
      unitRef="usd">3987000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplOGU3NmFiNjRhNWE0MmUxODVmYTA5MzNlNjZkNjk3Yy90YWJsZXJhbmdlOmU4ZTc2YWI2NGE1YTQyZTE4NWZhMDkzM2U2NmQ2OTdjXzItMS0xLTEtMA_29863b2b-0755-495c-9e34-7c3c586907e9"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplOGU3NmFiNjRhNWE0MmUxODVmYTA5MzNlNjZkNjk3Yy90YWJsZXJhbmdlOmU4ZTc2YWI2NGE1YTQyZTE4NWZhMDkzM2U2NmQ2OTdjXzItNy0xLTEtMA_91a9039f-d232-43f9-a4cc-33f00398249e"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplOGU3NmFiNjRhNWE0MmUxODVmYTA5MzNlNjZkNjk3Yy90YWJsZXJhbmdlOmU4ZTc2YWI2NGE1YTQyZTE4NWZhMDkzM2U2NmQ2OTdjXzQtMS0xLTEtMA_1ccfd1cf-3e89-4391-b6b4-c910a888ad08"
      unitRef="usd">46196000</us-gaap:ContractWithCustomerLiability>
    <mrsn:ContractWithCustomerLiabilityIncrease
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplOGU3NmFiNjRhNWE0MmUxODVmYTA5MzNlNjZkNjk3Yy90YWJsZXJhbmdlOmU4ZTc2YWI2NGE1YTQyZTE4NWZhMDkzM2U2NmQ2OTdjXzQtMy0xLTEtMA_cfdd45be-a979-49ff-a71d-cf183d6c74ca"
      unitRef="usd">210000</mrsn:ContractWithCustomerLiabilityIncrease>
    <mrsn:ContractWithCustomerLiabilityDecrease
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplOGU3NmFiNjRhNWE0MmUxODVmYTA5MzNlNjZkNjk3Yy90YWJsZXJhbmdlOmU4ZTc2YWI2NGE1YTQyZTE4NWZhMDkzM2U2NmQ2OTdjXzQtNS0xLTEtMA_8715d932-c205-4863-8ab6-de4b37d6f0b1"
      unitRef="usd">41591000</mrsn:ContractWithCustomerLiabilityDecrease>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplOGU3NmFiNjRhNWE0MmUxODVmYTA5MzNlNjZkNjk3Yy90YWJsZXJhbmdlOmU4ZTc2YWI2NGE1YTQyZTE4NWZhMDkzM2U2NmQ2OTdjXzQtNy0xLTEtMA_0ff86efc-f987-442f-ae0c-b50fb8788bb1"
      unitRef="usd">4815000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplYzU1ZWMyYmY3YjI0OGRiYmZhNzE3ZDJmMDc2MmIwYi90YWJsZXJhbmdlOmVjNTVlYzJiZjdiMjQ4ZGJiZmE3MTdkMmYwNzYyYjBiXzMtMS0xLTEtMA_2d6dafd9-4530-48d9-b1d6-330171b51840"
      unitRef="usd">828000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplYzU1ZWMyYmY3YjI0OGRiYmZhNzE3ZDJmMDc2MmIwYi90YWJsZXJhbmdlOmVjNTVlYzJiZjdiMjQ4ZGJiZmE3MTdkMmYwNzYyYjBiXzMtMy0xLTEtMA_2308572c-2760-4b4e-92da-15d7ef100d7c"
      unitRef="usd">41591000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplYzU1ZWMyYmY3YjI0OGRiYmZhNzE3ZDJmMDc2MmIwYi90YWJsZXJhbmdlOmVjNTVlYzJiZjdiMjQ4ZGJiZmE3MTdkMmYwNzYyYjBiXzQtMS0xLTEtMA_1b71e2e3-c1f2-4069-ad7c-e540c7222afb"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90YWJsZTplYzU1ZWMyYmY3YjI0OGRiYmZhNzE3ZDJmMDc2MmIwYi90YWJsZXJhbmdlOmVjNTVlYzJiZjdiMjQ4ZGJiZmE3MTdkMmYwNzYyYjBiXzQtMy0xLTEtMA_64b3d8de-44c8-41ea-a3ff-972ebf355414"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23577b731ce742d9a2dc95f75f3ed39e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2MzIw_e57e701c-043c-4407-b56e-32e0b18dfb87"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9427fc34fbbb4872be93f51ea1a98758_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2MzI0_d68f884c-7f52-4bcb-84a4-96fa62b137f3"
      unitRef="usd">25000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bf844a9201846c6b8d71ce0fc4564a6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2MzMx_5a538a7d-4865-4cbe-9b83-7982f1fb3c7b"
      unitRef="usd">782000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2c25c7d679e4207b7260e4df1988cd6_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2NDQ5_b53a5a96-48a3-400b-8874-616adcdf3035"
      unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mrsn:CollaborationArrangementsMilestonePaymentReceivableNextMilestone
      contextRef="i7f85c6dbea4e41f68ef9f77064c9488c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMDkvZnJhZzo2M2YyMDIxZTNhNGU0ODkyYjhiZjgxNGQ4NzU5MDhlYi90ZXh0cmVnaW9uOjYzZjIwMjFlM2E0ZTQ4OTJiOGJmODE0ZDg3NTkwOGViXzE2NjE5_8b24e752-0b96-42fe-ac14-e0371401b0d4"
      unitRef="usd">2500000</mrsn:CollaborationArrangementsMilestonePaymentReceivableNextMilestone>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90ZXh0cmVnaW9uOjZkNWUzZWQ1YTRmZjRmYjFiOGFhYmYxZTRiMzRjY2YzXzkyMA_be7cbfa1-b2bd-4cf5-a9b5-f736ce4626de">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents information about the Company's assets and liabilities regularly measured and carried at a fair value and indicates the level within fair value hierarchy of the valuation techniques utilized to determine such value as of December&#160;31, 2019. The Company had no marketable securities as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in&#160;Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no changes in valuation techniques or transfers between fair value measurement levels during the&#160;years ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in the consolidated balance sheets for prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the carrying value of the Company&#x2019;s outstanding borrowing under the Credit Facility (as defined below) approximated fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. The Credit Facility is discussed more detail in Note 8, &#x201c;Debt&#x201d;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90ZXh0cmVnaW9uOjZkNWUzZWQ1YTRmZjRmYjFiOGFhYmYxZTRiMzRjY2YzXzkyMQ_e4111f83-68ea-4659-abdc-e7c6362569ec">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents information about the Company's assets and liabilities regularly measured and carried at a fair value and indicates the level within fair value hierarchy of the valuation techniques utilized to determine such value as of December&#160;31, 2019. The Company had no marketable securities as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in&#160;Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7c0a8934a1c6426dbdc36c02ecbace70_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtMS0xLTEtMjM5Mg_99d5a03a-2066-425b-a32b-5b50540f86c3"
      unitRef="usd">11940000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c164faee42044c6bd0efd3f8e822986_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtMy0xLTEtMjM5Mg_271d37bb-65c7-4a7a-88d4-58193b0fb099"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id1ad11b4ad384e07aadaac9fb23dd498_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtNS0xLTEtMjM5Mg_c6775e1b-c4c3-4010-a097-905bf1650827"
      unitRef="usd">11940000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if421bb6d4ade4aa7875850e2e9e7ce5e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtNy0xLTEtMjM5Mg_8abc9dbb-2c25-4d2f-91f4-84e978e7dee5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8269462beefc49e0bf40ee05af372ef6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtMS0xLTEtMjM5Mg_58ebef5f-1726-4008-bd73-a9defc89666e"
      unitRef="usd">12010000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32fd9e9a94794fe3a2242b4ca9bc78d0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtMy0xLTEtMjM5Mg_fa868cc7-ddc8-4382-8b66-a3f62393415c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6341208859442f9b6ef8af77034d83d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtNS0xLTEtMjM5Mg_7c7560d3-61e7-443e-a7b5-8a879b03bbf8"
      unitRef="usd">12010000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i352d06ba5fb848548eb58f8027ff894b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtNy0xLTEtMjM5Mg_fad453c9-c016-4fa5-b3b3-541bfd8606ab"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8fc9df98ef2d477ba1138bc3dd081e76_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtMS0xLTEtMA_6481c3ba-104a-490e-b96e-f03c0406fd5d"
      unitRef="usd">13489000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia12bcd4d127345a18bc09a7631d0e9ae_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtMy0xLTEtMA_656ca187-60e4-4b9c-a76c-80e3682d4e3f"
      unitRef="usd">13489000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c176c12317e495abdb2f03744b1bffa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtNS0xLTEtMA_5018afe9-cf76-4999-9bd2-bd8cb31796bf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i32e2e3e778ca460194f0dffe0a2edf27_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzMtNy0xLTEtMA_9731f3e8-ffe1-4fbb-abd6-b340c7f61bfb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icbc4ff85c1d24045ab6977cd50a5b2e9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtMS0xLTEtMA_4a0af7cc-fe6c-410a-9b22-78e8df163e23"
      unitRef="usd">37439000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic52340d210a24378ae895de1817cdca3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtMy0xLTEtMA_123e5d03-be14-4d67-a1cd-c1d967cf788c"
      unitRef="usd">13489000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id50ec1eca088483b9329538c98b03e04_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtNS0xLTEtMA_fbc88610-c26c-470f-8c15-b6a56597c32a"
      unitRef="usd">23950000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8f480eeb670e4a4e820469036816203f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMTUvZnJhZzo2ZDVlM2VkNWE0ZmY0ZmIxYjhhYWJmMWU0YjM0Y2NmMy90YWJsZToxMWQ3YzEzZmY1MTg0YmI3OWFhZmY3NmM0ZGNmMjNhZS90YWJsZXJhbmdlOjExZDdjMTNmZjUxODRiYjc5YWFmZjc2YzRkY2YyM2FlXzQtNy0xLTEtMA_0187ea21-7bf6-45fc-90ae-c1fadd0042fa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90ZXh0cmVnaW9uOjYxNjA5ZGRlMTUzOTQyZDE5NzhjMDEzNGZkYWNjZTBiXzcwNA_bfcb501f-ba21-41de-9ca5-185c0443fa31">Marketable Securities&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes marketable securities held at December&#160;31, 2019. The Company had no marketable securities as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90ZXh0cmVnaW9uOjYxNjA5ZGRlMTUzOTQyZDE5NzhjMDEzNGZkYWNjZTBiXzcwNQ_fe429c53-5156-45cd-b037-53ddbedcd385">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes marketable securities held at December&#160;31, 2019. The Company had no marketable securities as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90ZXh0cmVnaW9uOjYxNjA5ZGRlMTUzOTQyZDE5NzhjMDEzNGZkYWNjZTBiXzI3NDg3NzkwNzA4ODM_5c33644e-6d87-48d2-bccf-707b7a6713d4"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if61098ade0e347d582c1a9c5ca600ca2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItMS0xLTEtMjQxMQ_a2c22dd8-e1b1-4203-91bb-016ffde1a1e5"
      unitRef="usd">11940000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if61098ade0e347d582c1a9c5ca600ca2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItMy0xLTEtMjQxMQ_e891bc38-5056-4ffe-85b6-537cac8762a6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if61098ade0e347d582c1a9c5ca600ca2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItNS0xLTEtMjQxMQ_44c8a3f2-32d1-4668-b75d-f0f24fe6f081"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if61098ade0e347d582c1a9c5ca600ca2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItNy0xLTEtMjQxMQ_0d700def-2b81-471f-b32b-d7e81d3d268c"
      unitRef="usd">11940000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i09af4016cf924f80913d431c2607ec67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtMS0xLTEtMjQxMQ_8450b1a3-c3b6-4e5a-9882-b9c608849754"
      unitRef="usd">11990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i09af4016cf924f80913d431c2607ec67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtMy0xLTEtMjQxMQ_8eb10710-836a-497a-bd9a-1b7e98933572"
      unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i09af4016cf924f80913d431c2607ec67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtNS0xLTEtMjQxMQ_a2996fdb-b777-4791-bd4c-4bc4c7d0bb74"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i09af4016cf924f80913d431c2607ec67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtNy0xLTEtMjQxMQ_22761fbf-72fd-4cb5-8a4e-9ae022b1aef8"
      unitRef="usd">12010000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if3e5c95050104eaa8d8078a5e789e74b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItMS0xLTEtMA_4350601d-2e24-47f1-bd13-e8c11b04f24a"
      unitRef="usd">13484000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if3e5c95050104eaa8d8078a5e789e74b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItMy0xLTEtMA_60f9e5ef-632d-476a-ae52-30caec249d8a"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if3e5c95050104eaa8d8078a5e789e74b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItNS0xLTEtMA_b6ea261b-49b1-43c3-a7ce-2ca671774377"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3e5c95050104eaa8d8078a5e789e74b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzItNy0xLTEtMA_a8ccf4d2-be96-44b9-8d13-fae174ab926f"
      unitRef="usd">13489000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtMS0xLTEtMA_73cbdee1-9208-4f0b-ae7a-e59273f14acb"
      unitRef="usd">37414000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtMy0xLTEtMA_1b8f58cc-d03e-4f4a-94eb-b105aafef63d"
      unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtNS0xLTEtMA_5cd01bba-df30-4df1-8ac6-8fdceacebe70"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjEvZnJhZzo2MTYwOWRkZTE1Mzk0MmQxOTc4YzAxMzRmZGFjY2UwYi90YWJsZTo3ZDViNDE0MmMyYmI0MTQ2OTdhMjQ4NTAxNWU5ZWYwNi90YWJsZXJhbmdlOjdkNWI0MTQyYzJiYjQxNDY5N2EyNDg1MDE1ZTllZjA2XzMtNy0xLTEtMA_226b2bf3-5f1c-4321-9cae-18d5fdb0d846"
      unitRef="usd">37439000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90ZXh0cmVnaW9uOjcxZTI3ZjZkYTYzYTQzYjFhMzJhMDY2YTUwZjlkYzdjXzM1Nw_4e28ac1f-9356-488a-826d-9577dec46165">Property and Equipment&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following as of December&#160;31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company recorded assets under finance leases of $429 as laboratory equipment during the year ended December&#160;31, 2019. Financing leases are discussed in more detail in Note 11 &#x201c;Leases&#x201d;. Depreciation expense for the&#160;years ended December&#160;31, 2020, 2019 and 2018 was $1,010, $1,245 and $1,257, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90ZXh0cmVnaW9uOjcxZTI3ZjZkYTYzYTQzYjFhMzJhMDY2YTUwZjlkYzdjXzM1OA_e1250a25-adff-42db-9a85-ad3f441d6cf9">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following as of December&#160;31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i47ab6eccf1b6445f80bc756361d8cff7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzEtMS0xLTEtMA_64f8c98f-cd85-487e-82d7-db97b551cfeb"
      unitRef="usd">6520000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="id53d0e5e5e574f9ea3bfac8d17355c76_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzEtMy0xLTEtMA_c1bf44f1-46d5-4770-82c0-fa641f76b56c"
      unitRef="usd">6419000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9fc584d33c9d43799da46631af3ada8e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzItMS0xLTEtOTk2Mw_9f994b6b-45fe-4570-ba04-9f36e7fc5462"
      unitRef="usd">1886000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id0a28d50b8e94ad8a3d5ce0e83bf2a8c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzItMy0xLTEtOTk2Mw_8f291f4d-c67d-482d-af70-0c0f7e5d2d56"
      unitRef="usd">1886000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i856895a9ae3d498cbd7a6e7e6aea88cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzItMS0xLTEtMA_c25065ed-5fe9-4415-9d0a-d63e74e233e7"
      unitRef="usd">959000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibd1dfdef8c0c4efbb4a9ef235c35a801_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzItMy0xLTEtMA_c52c4c02-8b4a-48da-8a72-56ca6a9bc2c5"
      unitRef="usd">1068000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzQtMS0xLTEtMA_10ff1a8b-0481-4cef-9619-a7dd9ee2169d"
      unitRef="usd">9365000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzQtMy0xLTEtMA_01b2a37a-25a8-49b8-a199-809aca0e3869"
      unitRef="usd">9373000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzUtMS0xLTEtMA_b28c4b3f-f28f-48a8-b4f3-7107f755573c"
      unitRef="usd">7635000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzUtMy0xLTEtMA_77c68546-c05a-42bf-8490-fe57b6043564"
      unitRef="usd">7209000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzYtMS0xLTEtMA_0dd7cc56-126f-40df-a274-9bf8e4f2e4d6"
      unitRef="usd">1730000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90YWJsZTphZjk3MDA2OGQzOTU0MDZhYWFkMTU1YTlhMDEzMzU2MC90YWJsZXJhbmdlOmFmOTcwMDY4ZDM5NTQwNmFhYWQxNTVhOWEwMTMzNTYwXzYtMy0xLTEtMA_54a67d31-5752-4969-947c-f91c8f7b0197"
      unitRef="usd">2164000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0af0080ba1dc4a0cb75af59f74d83190_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90ZXh0cmVnaW9uOjcxZTI3ZjZkYTYzYTQzYjFhMzJhMDY2YTUwZjlkYzdjXzE1MQ_dfd53fc1-4b30-46ae-85f2-debd28cd6bd4"
      unitRef="usd">429000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:Depreciation
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90ZXh0cmVnaW9uOjcxZTI3ZjZkYTYzYTQzYjFhMzJhMDY2YTUwZjlkYzdjXzMzMA_c9721486-32dd-48c7-969c-de18b80f85c0"
      unitRef="usd">1010000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90ZXh0cmVnaW9uOjcxZTI3ZjZkYTYzYTQzYjFhMzJhMDY2YTUwZjlkYzdjXzMzNA_4e0391eb-8145-42bb-a7f4-93fed4d6c320"
      unitRef="usd">1245000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMjcvZnJhZzo3MWUyN2Y2ZGE2M2E0M2IxYTMyYTA2NmE1MGY5ZGM3Yy90ZXh0cmVnaW9uOjcxZTI3ZjZkYTYzYTQzYjFhMzJhMDY2YTUwZjlkYzdjXzM0MQ_99bb81e7-cc49-4bce-a2bf-5e7851645c80"
      unitRef="usd">1257000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90ZXh0cmVnaW9uOjc0YjlkNGI3MDk2MTRhOGQ4Y2QyMDFkZGM4MjAzMjczXzg1_1bf1de78-52df-4d4c-845a-d22917f45d15">Accrued Expenses&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following as of December&#160;31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical, manufacturing and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90ZXh0cmVnaW9uOjc0YjlkNGI3MDk2MTRhOGQ4Y2QyMDFkZGM4MjAzMjczXzg2_7c2440c6-4f7c-4580-a889-acca76aad102">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following as of December&#160;31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical, manufacturing and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <mrsn:AccruedPreclinicalAndClinicalExpensesCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzEtMS0xLTEtOTk0NQ_90a4afa8-1eae-41b0-ab8e-adf900d78f68"
      unitRef="usd">9902000</mrsn:AccruedPreclinicalAndClinicalExpensesCurrent>
    <mrsn:AccruedPreclinicalAndClinicalExpensesCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzEtMy0xLTEtOTk0NQ_1a5a5d45-1e00-41d4-a2ff-75c37659175e"
      unitRef="usd">4230000</mrsn:AccruedPreclinicalAndClinicalExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzEtMS0xLTEtMA_93fe9cb7-9b3e-4c52-9b04-f1648b488ca6"
      unitRef="usd">5412000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzEtMy0xLTEtMA_816a4221-f8c3-4e23-b763-710a98d51eb0"
      unitRef="usd">4037000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzMtMS0xLTEtMA_9185b452-15f5-406b-abc3-ecc0e9da46a7"
      unitRef="usd">757000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzMtMy0xLTEtMA_105916b9-24a6-4427-8559-2824bafe49b7"
      unitRef="usd">675000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzQtMS0xLTEtMA_1f4f23b9-73bb-4944-9483-4648a86f9c44"
      unitRef="usd">75000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzQtMy0xLTEtMA_102a2bd2-4fdf-4165-8fa9-58fb8322d683"
      unitRef="usd">44000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzUtMS0xLTEtMA_b5825ec0-d2d4-419c-ac77-c58d0f6321d3"
      unitRef="usd">16146000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzAvZnJhZzo3NGI5ZDRiNzA5NjE0YThkOGNkMjAxZGRjODIwMzI3My90YWJsZTo2ZGQ1MGE1MTEzNjE0ZWY0YWE3YTg2OGQ5ZjVhMmZlYi90YWJsZXJhbmdlOjZkZDUwYTUxMTM2MTRlZjRhYTdhODY4ZDlmNWEyZmViXzUtMy0xLTEtMA_dc1fb010-3820-4c01-a05b-5214509b0770"
      unitRef="usd">8986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQ2NzY_38154782-22a9-48c7-9043-b5baaf7bfdd9">Debt&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 8, 2019, the Company entered into a loan and security agreement (the Original Agreement) with Silicon Valley Bank (SVB) pursuant to which the Company borrowed $5,000. The Original Agreement accrued interest at a floating per annum rate equal to the greater of (i) 4.0% and (ii) 1.50% below the Prime Rate. The Original Agreement had an interest-only period through August 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 28, 2020 (the Effective Date), the Company entered into a second amendment (the Amendment) to its existing loan and security agreement (as amended prior to the Amendment, the Existing Credit Facility) with SVB. Pursuant to the Amendment, the Company can borrow term loans in an aggregate amount of $30,000 (the Amended Credit Facility), at its option, (i) up to $25,000 in up to five principal advances through April 30, 2022, and (ii) an additional $5,000 in one principal advance, if the Company reaches certain development milestone events, as described in the Amendment, through April 30, 2022. The Company drew $5,200 upon execution of the Amendment, the proceeds of which were used to repay the Company&#x2019;s existing balance and satisfy its obligations to SVB, including the final payment obligation under the Existing Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Facility bears interest at a floating per annum rate equal to the greater of (i) 4.25% and (ii) 1.00% above the Prime Rate, as defined. The Company is obligated to make monthly interest-only payments on each outstanding term loan commencing on the first calendar day of the month following the funding date of such term loan, and continuing on the first calendar day of each month thereafter through May 31, 2022. The interest only period may be extended through January 31, 2023 upon the achievement of a regulatory milestone, as described in the Amendment. Following the interest-only period, the Company will be required to repay the outstanding principal balance under the term loans in equal monthly payments plus interest in arrears to SVB through November 1, 2024 (the Maturity Date).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also required to make a final payment to SVB equal to 5.5% of the principal amount of the Term Loans then extended to the Company. This final payment is accreted under the effective interest method over the life of each term loan. The term loans are secured by substantially all of the Company&#x2019;s assets, except for its intellectual property which is subject to a negative pledge, and certain other customary exclusions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Company&#x2019;s option, it may prepay the outstanding principal balance of any term loans in whole but not in part, subject to a prepayment fee of: (a) 3.0% of the term loans then extended to the Company if the prepayment occurs on or prior to August 28, 2021, (b) 2.0% of the term loans then extended to the Company if the prepayment occurs after August 28, 2021 but on or prior to August 28, 2022, or (c) 1.0% of the term loans then extended to the Company if the prepayment occurs after August 28, 2022 but before November 1, 2024. The Amended Credit Facility includes customary affirmative and restrictive covenants applicable to the Company. Affirmative covenants include, among others, covenants requiring the Company to maintain its corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The Amendment removed the requirement for the Company to maintain a minimum liquidity ratio. The restrictive covenants include, among others, requirements relating to the Company&#x2019;s ability to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets and agree to a change in control, in each case subject to certain customary exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s payment obligations under the Amended Credit Facility are subject to acceleration upon the occurrence of specified events of default, which include, but are not limited to, the occurrence of a material adverse change in the Company&#x2019;s business, operations, or financial or other condition. Amounts outstanding upon the occurrence of an event of default are payable upon SVB&#x2019;s demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount outstanding. As of December&#160;31, 2020, the Company was in compliance with all covenants under the Credit Facility. As such, as of December&#160;31, 2020, the classification of the loan balance as stated on the balance sheet was based on the timing of defined future payment obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unamortized issuance costs under the Existing Credit Facility were $139 as of the date of the Amendment. The Company incurred debt issuance costs paid to the lender in connection with the Amended Credit Facility of $17. The Company recorded such costs, including the settlement of the final payment obligation under the Existing Credit Facility as a discount from the carrying value of the term loans which are amortized as interest expense using the effective-interest method over the term of the Amended Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was $5,200 outstanding under the Amended Credit Facility and the debt consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term-debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt financing costs, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion related to final payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the estimated future principal payments due are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020 and 2019, the Company recognized $340 and $214, respectively, of interest expense related to the Existing Credit Facility and Amended Credit Facility, as applicable.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="ic7699dd1563a4628924b1afe47e1a4dd_D20190508-20190508"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzM0OQ_deff9dea-9aec-4e1f-a8f9-0e6d5a6d8b20"
      unitRef="usd">5000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i631efc7ffeaf4f04ac0f4957eaba56a9_I20190508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQ5NA_ea3f85cf-608a-49e1-b569-7d5cef73a817"
      unitRef="number">0.040</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i163836ee7b6f4ffa9c0cb574b727c47f_D20190508-20190508"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzUwNg_0e28cf32-3876-44e3-a0f4-3db8217a9589"
      unitRef="number">-0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i6bc12f9880564eaaaf5cd6c44d035584_I20200828"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyMTk_c71511a9-a2fc-4638-a156-64aca4386178"
      unitRef="usd">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i90749e47b83a4ed7a4168ba3c7be4fbc_I20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyMzE_3865a729-f943-421f-b465-a2db561783f6"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie14bf80516a946eab284cdc6fa94ee65_I20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyMzE_6468deb8-7865-41e6-9867-c79f4f5b5906"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7e2dcf3cdc3748e483ed1c6403bb6a16_I20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyMzE_c13eb810-263d-4b86-86d8-ea83cf8d5925"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iec2d0197c15d41c8a6bdc407bc838c19_I20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyMzE_f0c86795-eed1-460c-b330-f14eb7cfe7d0"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icfaa9f81105a42f396f57538ca9bca0e_I20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyMzE_f72fcc4d-6011-4a3f-a6fa-629f29b87e67"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <mrsn:LineOfCreditFacilityAccordianFeatureIncreaseLimit
      contextRef="ie6d2f0012515488e88c88d4beea20fbd_I20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyNDM_a2d2d967-212c-40a7-b21a-ed79a7c2f277"
      unitRef="usd">5000000</mrsn:LineOfCreditFacilityAccordianFeatureIncreaseLimit>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6bc12f9880564eaaaf5cd6c44d035584_I20200828"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzYyNjA_7ed8928a-1294-4120-b5bc-612857228fde"
      unitRef="usd">5200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaa8dbb46bbe744e985b2e0216ba5ac51_I20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2Mzg3NDM_624c5dfd-a095-4494-b01e-a7f5aac8bbd6"
      unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i5b7d7299ce1c41e0b7319ee9be889c78_D20200828-20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2Mzg3NTA_d40a9fef-6abe-487a-ab53-ce57ace389fb"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <mrsn:FinalPaymentAsPercentageOfOriginalPrincipalAmount
      contextRef="i078da7f737c349af8b0fe34900888817_D20200828-20200828"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEyOTQ_e479e020-aa65-4cbc-8d52-6f010d796a64"
      unitRef="number">0.055</mrsn:FinalPaymentAsPercentageOfOriginalPrincipalAmount>
    <mrsn:DebtInstrumentPrepaymentFeePercent
      contextRef="i21f9feecd548415ea57bfadff8075528_D20200828-20200828"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzE4MDY_6f74f7c1-565e-4e9e-b8b4-48e82afa02c3"
      unitRef="number">0.030</mrsn:DebtInstrumentPrepaymentFeePercent>
    <mrsn:DebtInstrumentPrepaymentFeePercent
      contextRef="i1d95ffd29d8a42f09d5833c466360f5c_D20200828-20200828"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzE5MTM_9505049f-bf75-49bf-adf4-74b8e04941d2"
      unitRef="number">0.020</mrsn:DebtInstrumentPrepaymentFeePercent>
    <mrsn:DebtInstrumentPrepaymentFeePercent
      contextRef="i3c584ca6ee79452785e1ad58cd890611_D20200828-20200828"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzIwNDU_37f181ad-761e-4d21-bca9-9caaa34aa8f5"
      unitRef="number">0.010</mrsn:DebtInstrumentPrepaymentFeePercent>
    <mrsn:DebtInstrumentAdditionalRateInEventOfDefault
      contextRef="i078da7f737c349af8b0fe34900888817_D20200828-20200828"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzM4MDc_6c0254f4-583f-4a89-b3ee-0468e1af89f3"
      unitRef="number">0.050</mrsn:DebtInstrumentAdditionalRateInEventOfDefault>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i4b8290917b104724b022253cb68344a8_I20200828"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzI3NDg3NzkwODk2MDQ_2cd1f404-deb0-4eaa-b7f5-37d083c40d6e"
      unitRef="usd">139000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i6bc12f9880564eaaaf5cd6c44d035584_I20200828"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQxMTU_16ea74ec-fef9-4ad1-a4b0-c1e5026f2171"
      unitRef="usd">17000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQ2Nzc_bc1eae38-65d4-4936-aaaf-1735632cde8d">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was $5,200 outstanding under the Amended Credit Facility and the debt consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term-debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt financing costs, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion related to final payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6bc12f9880564eaaaf5cd6c44d035584_I20200828"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQ0NTQ_7ed8928a-1294-4120-b5bc-612857228fde"
      unitRef="usd">5200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo1OTgzMDdjMzhlZTM0YThmODE0ZmQ1YzAwNDk4NmNhNi90YWJsZXJhbmdlOjU5ODMwN2MzOGVlMzRhOGY4MTRmZDVjMDA0OTg2Y2E2XzEtMS0xLTEtMA_d254a229-e9bc-4cce-9308-fbf41392e95f"
      unitRef="usd">5200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo1OTgzMDdjMzhlZTM0YThmODE0ZmQ1YzAwNDk4NmNhNi90YWJsZXJhbmdlOjU5ODMwN2MzOGVlMzRhOGY4MTRmZDVjMDA0OTg2Y2E2XzItMS0xLTEtMA_81961f97-9f50-4b28-98a1-cadd3a4ab150"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <mrsn:DebtInstrumentCarryingAmountNoncurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo1OTgzMDdjMzhlZTM0YThmODE0ZmQ1YzAwNDk4NmNhNi90YWJsZXJhbmdlOjU5ODMwN2MzOGVlMzRhOGY4MTRmZDVjMDA0OTg2Y2E2XzMtMS0xLTEtMA_2e0636e0-03a1-4b79-ad97-09c03cca7ca9"
      unitRef="usd">5200000</mrsn:DebtInstrumentCarryingAmountNoncurrent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo1OTgzMDdjMzhlZTM0YThmODE0ZmQ1YzAwNDk4NmNhNi90YWJsZXJhbmdlOjU5ODMwN2MzOGVlMzRhOGY4MTRmZDVjMDA0OTg2Y2E2XzQtMS0xLTEtMA_e063e3de-98cf-4e16-a5d7-22c7ed9da948"
      unitRef="usd">246000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo1OTgzMDdjMzhlZTM0YThmODE0ZmQ1YzAwNDk4NmNhNi90YWJsZXJhbmdlOjU5ODMwN2MzOGVlMzRhOGY4MTRmZDVjMDA0OTg2Y2E2XzUtMS0xLTEtMA_b12bbe98-12ac-49b1-9f31-6d60194de022"
      unitRef="usd">23000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo1OTgzMDdjMzhlZTM0YThmODE0ZmQ1YzAwNDk4NmNhNi90YWJsZXJhbmdlOjU5ODMwN2MzOGVlMzRhOGY4MTRmZDVjMDA0OTg2Y2E2XzYtMS0xLTEtMA_16f920aa-7cd7-40b3-bc22-e9601a1b5f60"
      unitRef="usd">4977000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQ2Nzg_bf1197f3-c45b-4663-8187-9e0163069d1d">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the estimated future principal payments due are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo2NWY5MzJkYjI1N2E0MzAwYTA5M2ZlYzcxMWM3YTVjZS90YWJsZXJhbmdlOjY1ZjkzMmRiMjU3YTQzMDBhMDkzZmVjNzExYzdhNWNlXzAtMS0xLTEtMA_00778e70-7cca-403f-a812-260abd09eca6"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo2NWY5MzJkYjI1N2E0MzAwYTA5M2ZlYzcxMWM3YTVjZS90YWJsZXJhbmdlOjY1ZjkzMmRiMjU3YTQzMDBhMDkzZmVjNzExYzdhNWNlXzEtMS0xLTEtMA_346d5a09-c042-4686-abca-21b371333c63"
      unitRef="usd">1213000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo2NWY5MzJkYjI1N2E0MzAwYTA5M2ZlYzcxMWM3YTVjZS90YWJsZXJhbmdlOjY1ZjkzMmRiMjU3YTQzMDBhMDkzZmVjNzExYzdhNWNlXzItMS0xLTEtMA_183fbe2f-c16c-43d7-9ad5-77d7ea6742f0"
      unitRef="usd">2080000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo2NWY5MzJkYjI1N2E0MzAwYTA5M2ZlYzcxMWM3YTVjZS90YWJsZXJhbmdlOjY1ZjkzMmRiMjU3YTQzMDBhMDkzZmVjNzExYzdhNWNlXzMtMS0xLTEtMA_0e1d102b-63eb-45d2-a824-eaadd100e555"
      unitRef="usd">1907000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90YWJsZTo2NWY5MzJkYjI1N2E0MzAwYTA5M2ZlYzcxMWM3YTVjZS90YWJsZXJhbmdlOjY1ZjkzMmRiMjU3YTQzMDBhMDkzZmVjNzExYzdhNWNlXzQtMS0xLTEtMA_b01776db-c342-426e-a7b5-26e5a64894f1"
      unitRef="usd">5200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestExpenseDebt
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzQ2MjM_db40e32c-99d0-4a5a-85e4-562f500af9cb"
      unitRef="usd">340000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzMvZnJhZzpkZTExMGEzMjI4YmE0M2Q3OGZmODY1OTMxOGFhNTdmMi90ZXh0cmVnaW9uOmRlMTEwYTMyMjhiYTQzZDc4ZmY4NjU5MzE4YWE1N2YyXzEwOTk1MTE2MzI1NzY_285c7ad0-2a85-4140-88a8-afa9518fb4df"
      unitRef="usd">214000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzI3NzI_6fab9757-ab5b-4937-a47f-c01f0a3d971e">Stockholders&#x2019; Equity&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the Company has 25,000,000 shares of authorized preferred stock. No shares of preferred stock have been issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At-the-market equity offering program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, the Company established an at-the-market (ATM) equity offering program (the 2018 ATM) pursuant to which it could offer and sell up to $75,000 of its common stock from time to time at prevailing market prices. In April 2020, the Company sold 8,938,599 and 1,962,000 shares of common stock at $5.59 per share and $7.74 per share, respectively, to raise &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;aggregate gross proceeds of $65,153 through the 2018 ATM facility. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering were approximately $62,976.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company terminated the 2018 ATM and established a new ATM equity offering program (the 2020 ATM) pursuant to which it is able to sell up to $100,000 of its common stock from time to time at prevailing market prices. As of December&#160;31, 2020, the Company had not sold any shares under the 2020 ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Follow-on offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company sold 9,200,000 shares of common stock, in an underwritten public offering price to the public of $19.00 per share. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering were $163,990.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with a 2013 Series&#160;A-1 Preferred Stock issuance, the Company granted to certain investors warrants to purchase 129,491 shares of common stock. The warrants have a $0.05 per share exercise price and a contractual life of 10 years. The fair value of these warrants was recorded as a component of equity at the time of issuance. As of December&#160;31, 2020 and 2019 there were warrants to purchase 39,474 shares of common stock. During the year ended December&#160;31, 2020, there were no exercises of warrants in exchange for shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exchange warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 26, 2019, the Company entered into an exchange agreement with entities affiliated with Biotechnology Value Fund, L.P. (the Exchanging Stockholders), pursuant to which the Exchanging Stockholders exchanged an aggregate of 2,575,000 shares of common stock for warrants (the Exchange Warrants) to purchase an aggregate of 2,575,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, merger or consolidation, change of control, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.0001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Codification Topic 505, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. While outstanding, the Exchange Warrants were classified as equity in accordance with Accounting Standards Codification Topic 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. On March 2, 2020, the Exchanging Stockholders exercised the Exchange Warrants in full on a net cashless exercise basis, resulting in the issuance of 2,574,971 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of the common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors (the Board).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019 there were 6,869,189 and 7,782,582, respectively, shares of common stock reserved for the exercise of outstanding stock options and warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,720,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,782,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzkwMDg_7d1fe851-c55d-44ca-93e8-866f1b7a4060"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzkwMTI_beba5002-8267-4acb-99b7-dbe921363515"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <mrsn:StockIssuanceProgramAuthorizedAmount
      contextRef="iab9b2892056c4107bc99217b78b467ca_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMyNTY_9420ea46-347d-49ff-b275-f59491d3704f"
      unitRef="usd">75000000</mrsn:StockIssuanceProgramAuthorizedAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia64de5de74d14ba6a2d99ac7e5b576e6_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMyNjg_1b77f4bf-9e5d-418b-ab3e-14799e60b60f"
      unitRef="shares">8938599</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i12e103ce06ac4a6899e2b020312d0789_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMyNzk_02406985-736a-4f87-94fe-b7b304934014"
      unitRef="shares">1962000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="if180f69d9ce245cf99704eb7f6351a59_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMyOTA_d7bd0bf1-48a2-40d0-901c-8930e35edcea"
      unitRef="usdPerShare">5.59</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i41a996208e274d7a8e321ab0940d2cd2_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMyOTc_16f90fa7-3aea-4dcc-a494-b77a53b31074"
      unitRef="usdPerShare">7.74</us-gaap:SharesIssuedPricePerShare>
    <mrsn:ProceedsFromIssuanceOfCommonStockGross
      contextRef="ia4e03a06a83b45da881a991b3fa64a37_D20200401-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMzMDQ_fb177ff2-7009-42fa-87b2-30b7f2ba2d31"
      unitRef="usd">65153000</mrsn:ProceedsFromIssuanceOfCommonStockGross>
    <mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts
      contextRef="ia4e03a06a83b45da881a991b3fa64a37_D20200401-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMzMTY_ec1ff238-990a-447b-8f87-10a417f9cd43"
      unitRef="usd">62976000</mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts>
    <mrsn:StockIssuanceProgramAuthorizedAmount
      contextRef="i13f8a6424f0a4cf9be7614ce49041c63_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMzMjg_0cc83433-15e2-4179-80d9-4efb82b43e9d"
      unitRef="usd">100000000</mrsn:StockIssuanceProgramAuthorizedAmount>
    <us-gaap:SharesIssued
      contextRef="i308407f9760646139e65cbbff6cda013_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzgwMTM_79f43833-13df-418b-9d57-a387cc3e0b1a"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i35ae40d344cb48109420ed8b520d73e7_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMzNjM_96fc0899-3279-4695-b60c-a5b618a67e3e"
      unitRef="shares">9200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ia651b5389b414e8d9e7497b27b28db57_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMzNzQ_0809e642-bbae-41b5-8a94-c547d9761e08"
      unitRef="usdPerShare">19.00</us-gaap:SharesIssuedPricePerShare>
    <mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts
      contextRef="i35ae40d344cb48109420ed8b520d73e7_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzMzOTU_63588bb1-53bc-45c8-bd19-8fd2030c4bcd"
      unitRef="usd">163990000</mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts>
    <mrsn:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued
      contextRef="i06524015ee73497b86e333130cd09189_D20130101-20131231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzQwNDM_5e26d2a4-002a-4ab5-b7a3-881bddc6c62b"
      unitRef="shares">129491</mrsn:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id811a98ebc9446e780342c9c938b83b6_I20131231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzQwOTE_b11f4329-ba94-4b09-b844-da1f2b3f61ad"
      unitRef="usdPerShare">0.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mrsn:ContractualLifeOfWarrants
      contextRef="i06524015ee73497b86e333130cd09189_D20130101-20131231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzQxNDY_2e5ff118-4a48-4ed0-b7c2-03892426dc19">P10Y</mrsn:ContractualLifeOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzQyOTA_1fb03d57-b99e-466d-8e99-3e27cac65aad"
      unitRef="shares">39474</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzQyOTA_410e7d40-d55d-4bab-ad9f-21fa6d5b7329"
      unitRef="shares">39474</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mrsn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2Mzg0NTQ_97521a81-d919-4b67-8e1e-49f5d90633c6"
      unitRef="shares">0</mrsn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <mrsn:ClassOfWarrantOrRightSharesExchangedForWarrants
      contextRef="i317cfb0a66ce420aba39052cc61dd3f7_D20191126-20191126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzYwODY_7f7715e3-9603-4fcd-b4e6-be1d21ac8105"
      unitRef="shares">2575000</mrsn:ClassOfWarrantOrRightSharesExchangedForWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i455788b289d34014a736e72b5a36e693_I20191126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzYwOTc_929e6a3d-2b52-472c-94ec-0a26aa549328"
      unitRef="shares">2575000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i455788b289d34014a736e72b5a36e693_I20191126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzYxMDg_5beec896-57a2-49e6-a412-2f612afec5d1"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mrsn:WarrantsExercisedInPeriod
      contextRef="i87d8789f035d4fd5a4df293bbf1c1d7e_D20200302-20200302"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzYxMTc_ac1e3871-41d2-4f19-a5ad-2ae1d3746817"
      unitRef="shares">2574971</mrsn:WarrantsExercisedInPeriod>
    <mrsn:NumberOfVotesPerCommonShare
      contextRef="i6e5bfe19343142b3906779afeba94ec7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzEwOTk1MTE2MzgwMDY_1fb9348e-075d-4d0e-aae3-c862dc357e47"
      unitRef="vote">1</mrsn:NumberOfVotesPerCommonShare>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib6469fe4541e48b89a7a078c0ed5ffcf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzI3MQ_ad609bab-211f-4b0f-a106-a153978214bb"
      unitRef="shares">6869189</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i535686c256b94372ae4ce5f38fcb0825_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzI3OA_3edd7a2d-d33c-4057-906a-4b89f350d596"
      unitRef="shares">7782582</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90ZXh0cmVnaW9uOjA5NGY2ZWVjNGQ2MzQyNWM5NmM0NDAzNThkMTU4YzkyXzI3NzM_007ff899-e751-47fb-8eab-a042f21786ea">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,720,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,782,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic5e733a950fa45a997c912a1f02d01a3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzEtMS0xLTEtMA_45e4c7dd-8d2d-4284-b7f1-f21d6aafbbf1"
      unitRef="shares">6112948</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i140f6ca2a4144d20a6d857ac59d04d54_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzEtMy0xLTEtMA_0477efca-048a-4436-a2c4-96afdf3418e9"
      unitRef="shares">4720772</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie75edfebdd6e45ba9f9bfbf6f784bf06_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzItMS0xLTEtMA_f29f7aa6-75d4-4a9e-bc29-b32b0bdd675a"
      unitRef="shares">716767</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if65e9cab919646faac147bc5c615a4ad_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzItMy0xLTEtMA_4f73774b-5296-40bf-a468-7425e727adcb"
      unitRef="shares">447336</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i303a7a474d1f41a5a7a7433b5d46bcc1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzQtMS0xLTEtMA_4bc34b8c-0267-4834-9e22-ae52525194aa"
      unitRef="shares">39474</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i659d9c80d2bc46cdb8692d3fccee5dd2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzQtMy0xLTEtMA_13537a23-7c30-44ca-a986-98bf8d702245"
      unitRef="shares">39474</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i32e7573ef8fe419aa60a3e7c2573e532_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzUtMS0xLTEtMjkyMQ_0722d0f7-fdf4-40a9-821a-2df80c9fbe8e"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iecb87f2b399c4ebca9aa9663b640aed4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzUtMy0xLTEtMjkyMQ_92964fa2-ceaf-44ac-a40c-65aba61c742e"
      unitRef="shares">2575000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzUtMS0xLTEtMA_4c26605b-71a6-49f4-81f7-cc5c247dc85e"
      unitRef="shares">6869189</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xMzkvZnJhZzowOTRmNmVlYzRkNjM0MjVjOTZjNDQwMzU4ZDE1OGM5Mi90YWJsZTo0OGRhYjk5ODg0ZDQ0ZWY0OGI5NTA0ZjQ3ZGU4NTc0YS90YWJsZXJhbmdlOjQ4ZGFiOTk4ODRkNDRlZjQ4Yjk1MDRmNDdkZTg1NzRhXzUtMy0xLTEtMA_31e89c53-d1a8-4410-a490-eaa001478b21"
      unitRef="shares">7782582</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDA0Njg_e8c0aefb-4c0e-43cd-8767-6e4cbc4a7d98">Stock Options&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2017, there were 3,141,625 options outstanding under the Company&#x2019;s 2007 Stock Incentive Plan.&#160;The 2007 Plan expired in June 2017. Any cancellations under the 2007 Stock Incentive Plan will increase the options available under the 2017 Stock Incentive Plan as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017 the Company&#x2019;s shareholders approved the 2017 Stock Incentive Plan (the 2017 Plan or the Plan).&#160;Under the 2017 Plan initially, up to 2,255,000 shares of common stock may be granted to the Company's employees, officers, directors, consultants and advisors in the form of options, restricted stock units (RSUs) or other stock-based awards. The number of shares of common stock issuable under the Plan will be cumulatively increased annually by 4% of the outstanding shares or such lesser amount specified by the Board. The terms of the awards are determined by the Board, subject to the provisions of the Plan. As of December&#160;31, 2020 there were 1,288,072 shares available for future issuance under the Plan, including 1,815,520 shares automatically added to the Plan on January 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inducement awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted its senior vice president of regulatory affairs an option to purchase up to 120,000 and its senior vice president and chief medical officer an option to purchase 200,000 shares of common stock on September 2, 2020 and November 30, 2020, respectively, as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). No underwriters were involved in this issuance of securities. The securities were issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, relating to transactions by an issuer not involving any public offering. These options are subject to terms substantially the same as the 2017 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to incentive stock options, the exercise price per share will equal the fair market value of the common stock on the date of grant, as determined by the Board, and the vesting period is generally four years. Nonqualified stock options will be granted at an exercise price established by the Board at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Options granted under the Plan expire no later than 10 years from the date of grant. The Board may accelerate vesting or extend the expiration of granted options in the case of a merger, consolidation, dissolution, or liquidation of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity under the Plan is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,720,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,359,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(697,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,147,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2020, 2019 and 2018, was $7.99, $2.47 and $8.78 per share, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received from the exercise of stock options was $3,138, $175 and $918 for the&#160;years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2019, the Company issued RSUs with service conditions to employees. The awards cliff-vest two years after the grant date. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2020, the Company issued 324,932 RSUs with a service condition to employees for which the vesting term is annually over four years.&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Vesting of these awards is contingent on the fulfillment of the service conditions during the vesting term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of the RSU activity under the 2017 Plan is as follow:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the provisions of ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to account for all stock-based awards to employees and non-employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The measurement date for employee awards is generally the date of grant. Stock-based compensation expense is recognized over the requisite service period, which is generally the vesting period, using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock-based compensation expense by award type included within the Company&#x2019;s consolidated statement of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included in Total operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock-based compensation expense as reflected in the Company&#x2019;s consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense included in Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was $19,487 and $2,699 of unrecognized compensation expense related to unvested stock options and unvested RSUs, respectively, that is expected to be recognized over a weighted average period of 2.8 years and 2.3 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black&#x2013;Scholes option pricing model with the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility for the Company&#x2019;s common stock is determined based on the historical volatility of comparable publicly traded companies. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected term of the option. No dividend yield was assumed as the Company has not historically and does not expect to pay dividends on its common stock. The expected term of the options granted is based on the use of the simplified method, in which the expected term is presumed to be the mid-point between the vesting date and the end of the contractual term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs is determined based on the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2017, the Board adopted and the Company's stockholders approved the 2017 employee stock purchase plan (the 2017 ESPP). The Company initially reserved 225,000 shares of common stock for issuance under the 2017 ESPP. During the years ended December&#160;31, 2020 and 2019 the Company issued 80,267 and 140,073 shares, respectively, under the 2017 ESPP. As of December&#160;31, 2020, there were 644,818 shares available for issuance, including 450,000 shares automatically added to the 2017 ESPP on January 1, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7a5864a7879b4087ac73cb3bfcccd0e8_I20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2Xzc0_deae96ea-267c-438f-8c64-9936d036bf54"
      unitRef="shares">3141625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i61566b4dae604295b9e10906b8b19b74_I20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzQ3Mw_a0897695-15c1-4acf-9c40-fab6dd763086"
      unitRef="shares">2255000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease
      contextRef="ic9335c4c8a544f7784ac7050e6f8525a_D20170601-20170630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2Xzc3NQ_49fed797-c4d1-4172-a698-58f00cd2c7f5"
      unitRef="number">0.04</mrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="idc230768a013428dbfb0b0e0a1cf01d9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2Xzk2Mg_26055e30-5013-4de6-beea-4ada838d49a6"
      unitRef="shares">1288072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i20cea58d91fe4a02bb07ac2b8a1f0791_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwMjg_f6f3dda5-2163-4bd7-bfb2-8aa05563db60"
      unitRef="shares">1815520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i90de0efc2a4f4539a8da0eb8a4f579dd_D20200902-20200902"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2Mzk5MzY_4847fb9e-353c-4352-8e97-7dc7f9307f48"
      unitRef="shares">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id1c52f697f3447aca0d47be353863ce4_D20201130-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDM1MTc_eae36241-d8c0-419b-8ee3-26b454978b7f"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1aec4bf8702f430b91a2277849a9a314_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDAzNjc_43c8be6c-2c9a-4f0e-af7f-08ab69426253">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ie39e122b84984208a83a60f26cebb72b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDA0MDM_d402661f-291c-4baa-9d53-ba6478b6cbc6">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUzMzM_91a220a3-5c80-45d2-915b-872d2de94a86">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity under the Plan is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,720,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,359,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(697,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,147,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzEtMS0xLTEtMA_4b0a6901-6063-454a-9bc7-ba817acf36b8"
      unitRef="shares">4720772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzEtMy0xLTEtMA_3d713b54-b9ab-490b-98de-1b9c333cdf1d"
      unitRef="usdPerShare">5.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzEtNS0xLTEtMA_0e370cde-7be4-409f-b016-3ed72f7fa331">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzEtNy0xLTEtMA_aff5f378-65b5-46f6-bf46-6f6ff94e238f"
      unitRef="usd">9836000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzItMS0xLTEtMA_9281e346-5141-4af8-9767-c4d5c4cd19c5"
      unitRef="shares">2359074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzItMy0xLTEtMA_413c46a4-e7c0-4832-8007-ba031f3bef5e"
      unitRef="usdPerShare">11.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzMtMS0xLTEtMA_feb8a6d9-2f74-429f-bedd-533037a705c6"
      unitRef="shares">697428</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzMtMy0xLTEtMA_3777704d-d574-42f5-bc68-9ce587a1be5a"
      unitRef="usdPerShare">4.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzQtMS0xLTEtMA_91ce5c8c-73a6-49f3-b3e8-bc1ff9c2a31a"
      unitRef="shares">269470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzQtMy0xLTEtMA_38435f48-eca2-40eb-9c86-5a43360fd0ef"
      unitRef="usdPerShare">7.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzUtMS0xLTEtMA_6cf85b33-00dc-4d73-bed5-4daae24c7e10"
      unitRef="shares">6112948</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzUtMy0xLTEtMA_19624c62-7e06-443d-a160-b3f967921bb7"
      unitRef="usdPerShare">7.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzUtNS0xLTEtMA_89020839-e028-429d-8ac8-f92e419ced16">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzUtNy0xLTEtMA_81c6224d-521f-4eed-b79e-dc56d96195de"
      unitRef="usd">114729000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzctMS0xLTEtMA_32b2726a-a8e8-45db-85f4-219d0917fc93"
      unitRef="shares">3147379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzctMy0xLTEtMA_ed9f5328-b6d5-40b7-b7ba-7d1746bdca66"
      unitRef="usdPerShare">5.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzctNS0xLTEtMA_2652d27a-9e38-43ac-921a-9431c4fa0a23">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpmOGMyMTM5NTI5NDQ0NmZjYjcyMDlmZWY3ZTE1MzI0OC90YWJsZXJhbmdlOmY4YzIxMzk1Mjk0NDQ2ZmNiNzIwOWZlZjdlMTUzMjQ4XzctNy0xLTEtMA_45696417-101d-46c7-9dbe-e2610988e8ee"
      unitRef="usd">67562000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzE5NDM_a90862ca-9d13-40b9-a464-b37fd5aa1d52"
      unitRef="usdPerShare">7.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzE5NDc_f646ed90-8147-4796-9100-e1186d51a041"
      unitRef="usdPerShare">2.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzE5NTQ_40336abe-cf15-4c6f-8f7b-63dd16a843c7"
      unitRef="usdPerShare">8.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzIwMzU_5cb4afb0-0270-4604-acc3-5a43fe785a94"
      unitRef="usd">3138000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzIwMzk_d11ab878-1652-4ed8-a9b9-bd1c0c8c93d1"
      unitRef="usd">175000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzIwNDY_1d1d82d1-2d38-485c-8462-7476143e703c"
      unitRef="usd">918000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6d84e8019e7f46ad999a65d511d99d20_D20190701-20190731"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDA0MzQ_5455a285-64c7-4454-80f7-28b0d14a99a8">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i23c524872861491cbbc5e13e4cf5d051_D20200101-20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDA4NTk_9b1ce19f-7990-47fc-b96b-2c271ab8bab6"
      unitRef="shares">324932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i23c524872861491cbbc5e13e4cf5d051_D20200101-20200131"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzI3NDg3NzkwODY3MDc_04420e4a-9b85-4ba4-a83a-1fea6491550c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUzMzQ_4ec488ee-77d2-48a9-bcca-da19c78f161a">&lt;div&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of the RSU activity under the 2017 Plan is as follow:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id980ee2ed8d34feca1762482a2e75df0_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzEtMS0xLTEtMA_d4020e76-901d-4edb-9ec6-1103f83c5507"
      unitRef="shares">447336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i920acb3427774292827daa9726c45873_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzEtMy0xLTEtMA_96fd78d5-c537-41c6-b980-758543f2e745">P1Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="id980ee2ed8d34feca1762482a2e75df0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzEtNS0xLTEtMA_a9cd5af7-dd71-4bcf-8526-fce193948d73"
      unitRef="usd">2564000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id980ee2ed8d34feca1762482a2e75df0_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzEtNy0xLTEtMA_6ca54ac7-e59b-4552-8034-29f625015c31"
      unitRef="usdPerShare">4.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzItMS0xLTEtMA_704e2125-bf70-44db-82d1-2da9e185e7b3"
      unitRef="shares">361932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzItNy0xLTEtMA_f0728717-46a4-4824-9b12-1bb4f9045653"
      unitRef="usdPerShare">8.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzMtMS0xLTEtMA_b91a3c55-a7d2-4ce2-9382-8c28db75dfc9"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzMtNy0xLTEtMA_16fe5b08-6629-442e-9a8b-69e4b72f3794"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzQtMS0xLTEtMA_3280f831-8889-40c3-b341-819260fdc8f6"
      unitRef="shares">92501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzQtNy0xLTEtMA_6ef0c4fa-e65f-4f4d-b885-68d5e59600c9"
      unitRef="usdPerShare">4.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i15699193709b4c5198a5f460762ea356_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzUtMS0xLTEtMA_5accc3ca-5923-4b16-9042-a3d52c8bcf12"
      unitRef="shares">716767</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzUtMy0xLTEtMA_978a3574-b6d7-493e-9bad-f377b5458142">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i15699193709b4c5198a5f460762ea356_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzUtNS0xLTEtMA_c7601e83-6ded-41cd-9bcb-d1056f191362"
      unitRef="usd">19073000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i15699193709b4c5198a5f460762ea356_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTpjMjJlOGNjZTEwYjk0ZjhjYTRiMmZhYjEzMTYzM2I5My90YWJsZXJhbmdlOmMyMmU4Y2NlMTBiOTRmOGNhNGIyZmFiMTMxNjMzYjkzXzUtNy0xLTEtMA_8e974a5b-64ac-45ad-b227-203f1f5439c2"
      unitRef="usdPerShare">6.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUzMzU_4aa4c116-d932-4fbc-9b65-a21a13b29e4b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock-based compensation expense by award type included within the Company&#x2019;s consolidated statement of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included in Total operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b2ee45dc2784fc396ead6a8bfd4ecb5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzItMS0xLTEtMA_0a650dd2-d0b2-4063-adc0-6723a7e099de"
      unitRef="usd">5725000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f6ea660b40844fe84f66bd5e5fe9ea5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzItMy0xLTEtMA_bf46bf1f-2efc-4be1-abb3-20fa8edbddbc"
      unitRef="usd">4230000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i79fb9930f6094104a456730528f5bc99_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzItNS0xLTEtMA_affbb04c-5e2b-481f-8954-629434cd776a"
      unitRef="usd">3754000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzMtMS0xLTEtMA_6b06778e-1079-4b03-88d0-6c9ecfa71e74"
      unitRef="usd">1187000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i920acb3427774292827daa9726c45873_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzMtMy0xLTEtMA_92da8cbb-ac08-4c5a-b95e-3be5c0b9b4a7"
      unitRef="usd">410000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f4688b8c44640b09f240cd0e1c92161_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzMtNS0xLTEtMA_5bd47072-c1ab-46ef-802c-c6369de369b2"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iad5bc870fab4400884a565359cfdf9a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzQtMS0xLTEtMA_5bc4301c-ba14-4862-bc77-a1e93c56d391"
      unitRef="usd">260000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0fd03e26fc404cd7886d527bbebe9cee_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzQtMy0xLTEtMA_4723b473-85c5-43fe-86a9-2caf281ef372"
      unitRef="usd">232000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i25c2d7125bea4d40a3c4bd88341d03b4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzQtNS0xLTEtMA_fd6a9e4a-5944-4e89-886c-ff1ca7673bab"
      unitRef="usd">130000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzUtMS0xLTEtMA_fb72395d-09bf-40eb-ac47-c0717ab522a7"
      unitRef="usd">7172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzUtMy0xLTEtMA_a4d4bfad-a201-4ced-a92d-4c0eff9be989"
      unitRef="usd">4872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo2ZjNjMzdkYTJkYmE0ZTliODI5N2ZlMDM1ODhiOGFlYi90YWJsZXJhbmdlOjZmM2MzN2RhMmRiYTRlOWI4Mjk3ZmUwMzU4OGI4YWViXzUtNS0xLTEtMA_fffed89b-f031-4685-b500-588a8d5524cf"
      unitRef="usd">3884000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUzMzA_7595cc98-99d1-443b-9297-416f26cd9cc4">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock-based compensation expense as reflected in the Company&#x2019;s consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense included in Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0ebb056de9f546e0a119ca21f8308e0c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzItMS0xLTEtMA_c8c47da3-14c7-4002-bb21-3de72f8b395d"
      unitRef="usd">3841000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i95e58426df2940999d78200d99d5eba5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzItMy0xLTEtMA_b3010e27-0ec3-45f8-9f37-5b62f007cfcd"
      unitRef="usd">2245000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icf67d48970814a13815d8dec946856d1_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzItNS0xLTEtMA_180836ee-5bb0-488e-9bd1-97cdb20a1ccd"
      unitRef="usd">1788000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i95fd51f717da4b488c652bf7d8674730_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzMtMS0xLTEtMA_5c9a0057-fc97-4dc7-b373-404fe281f1bd"
      unitRef="usd">3331000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1e5593e7a34742298584e0cea80c0c50_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzMtMy0xLTEtMA_c8c6cf8f-5631-4e74-8cbc-474d980c921d"
      unitRef="usd">2627000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f6b9959fd5242cba1fd04a96cea57d3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzMtNS0xLTEtMA_b7d57c60-a140-4d93-bc2e-c39c5a8c693f"
      unitRef="usd">2096000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzQtMS0xLTEtMA_6bf42767-4b67-43ea-b876-e1f984de8a09"
      unitRef="usd">7172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzQtMy0xLTEtMA_4f2827ac-4654-4841-a95b-552edd74ab57"
      unitRef="usd">4872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo4OWU4ODkwYmJjZTc0NjJjODAyMGVmNDRhZGY3ZDI4My90YWJsZXJhbmdlOjg5ZTg4OTBiYmNlNzQ2MmM4MDIwZWY0NGFkZjdkMjgzXzQtNS0xLTEtMA_65865d20-a7e3-4f5d-8b4a-84d7f1cc2d82"
      unitRef="usd">3884000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i3e12adb838364036838eba86fa043b68_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzMwOTE_840e2ce8-e80e-4bf0-9dad-0d85fb822ca3"
      unitRef="usd">19487000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i15699193709b4c5198a5f460762ea356_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzMwOTg_2ab33739-a470-4255-9ba5-7eef0208a61c"
      unitRef="usd">2699000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4b2ee45dc2784fc396ead6a8bfd4ecb5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzMyNzM_cdef84ff-976e-4f5a-a43e-cfe3c8ee1671">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if8a36e198f294ba6a53d99aa6f67b8ce_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzMyODA_dc93618f-ea1c-4174-83b1-9b6777213c88">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUzMzE_26a1c5fd-179a-4a28-863d-418cdf60eb8c">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black&#x2013;Scholes option pricing model with the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzItMS0xLTEtMA_be92030b-5d6f-4be2-9a91-379f156788f4"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzItMy0xLTEtMA_51ae310e-2803-4480-b1c8-04a50dcb0890"
      unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzItNS0xLTEtMA_116075cb-da1a-468e-99b0-52c80f5cb8b5"
      unitRef="number">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzMtMS0xLTEtMA_2771388c-830c-41af-b510-93c729dc93e6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzMtMy0xLTEtMA_cfcebf60-b6eb-4708-83a0-5a3fffb12ece"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzMtNS0xLTEtMA_ea44508d-341f-4ebf-a24d-58e42cb9c094"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzQtMS0xLTEtMA_6e0568c0-b640-42f3-88a4-faa6db5d1fb6">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzQtMy0xLTEtMA_63a775ff-ff29-4657-997b-43f96b09bcb5">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzQtNS0xLTEtMA_fd25a718-e479-4dcd-b672-6cdf29e9e857">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzUtMS0xLTEtMA_1d301375-2e58-4111-b5b5-869bc5f06aed"
      unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzUtMy0xLTEtMA_1ee98d5e-5217-44e9-a01b-ee1f1988f736"
      unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90YWJsZTo5Y2E0ZTU5MGExOWY0ODliYTIzZTI0MGUwZGEzYjJmYy90YWJsZXJhbmdlOjljYTRlNTkwYTE5ZjQ4OWJhMjNlMjQwZTBkYTNiMmZjXzUtNS0xLTEtMA_90030ede-bd7c-4736-947f-cd3285b9db7d"
      unitRef="number">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzI3NDg3NzkwODY4NDQ_624dcd3e-9736-47d7-b546-5e70cbf4c1be"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6f8aac06008a4724ae9284b7cc253a25_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzEwOTk1MTE2NDA5MDY_48739e36-fa3e-47d1-a759-e4226a8f206b"
      unitRef="shares">225000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iad5bc870fab4400884a565359cfdf9a1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUxNTQ_5e430825-b931-443a-a447-1dbc931855a4"
      unitRef="shares">80267</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0fd03e26fc404cd7886d527bbebe9cee_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUxNjE_d3b6989d-cd38-4435-b5f7-f0fabe2836c0"
      unitRef="shares">140073</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i05268d4f6e994edd8ddff9186d1b7540_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUyMjg_5228a16c-0317-459b-94f6-d5ccba4e8e0a"
      unitRef="shares">644818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i7df3a8881d504e549decddca8cac8c76_D20200101-20200101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDIvZnJhZzoxNzlmYjcyODcxYmM0MTNlODEzMmQyOWIxNmUwMzMzNi90ZXh0cmVnaW9uOjE3OWZiNzI4NzFiYzQxM2U4MTMyZDI5YjE2ZTAzMzM2XzUyNjU_b4ce882e-a8bc-404c-8174-1f15c582af9f"
      unitRef="shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEzMDk_55eaafae-8f65-437d-83ef-8f57f06229fe">Leases&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an operating lease for its office space in Cambridge, MA and operating and finance leases for certain equipment. In March 2020, the Company entered into the Seventh Amendment to the office space lease to extend the term of the lease through March 2026 and to provide the Company with a tenant improvement allowance of $172. The current rate per square foot that is in place through March 2021 (the original expiration date of the lease) did not change. After March 2021, there are predetermined fixed escalations of the rate as outlined in the amendment. The Company has an option to extend the lease term for an additional five years. The Company&#x2019;s exercise of this option was not considered reasonably certain as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extension is accounted for as a lease modification. The Company assessed the lease classification of the amended office space lease at the modification date and determined that the amended office space lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been remeasured based on the present value of remaining lease payments over the remaining extended lease term, using the incremental borrowing rate applicable as of the lease modification date. The Company determined the appropriate incremental borrowing rate by using a synthetic credit rating which was estimated based on an analysis of outstanding debt of companies with similar credit and financial profiles. Since the operating lease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred, such non-lease components were not included in the right-of-use asset and liability and are reflected as an expense in the period incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the modification in March 2020, the Company recorded an increase of $9,980 to its right-of-use (ROU) asset and lease liabilities in the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the office lease, the Company had a letter of credit agreement for the benefit of its landlord in the amount of $321 as of each December&#160;31, 2020 and 2019, collateralized by a money market account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2019, the Company entered into finance leases for certain equipment. The Company recorded assets under finance leases of $429 as property and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMC0xLTEtMTkwMQ_def9574d-e21a-4369-9aec-5ccd94c4b5a5"&gt;Other liabilities, current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTAtMS0xLTE5MDM_e1131034-fc7f-40a3-8087-977f8547a400"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense was $2,644, $2,160 and $1,994 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEzMDk_64e75a3e-feb7-481f-9843-7f2e7ce58f4f">Leases&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an operating lease for its office space in Cambridge, MA and operating and finance leases for certain equipment. In March 2020, the Company entered into the Seventh Amendment to the office space lease to extend the term of the lease through March 2026 and to provide the Company with a tenant improvement allowance of $172. The current rate per square foot that is in place through March 2021 (the original expiration date of the lease) did not change. After March 2021, there are predetermined fixed escalations of the rate as outlined in the amendment. The Company has an option to extend the lease term for an additional five years. The Company&#x2019;s exercise of this option was not considered reasonably certain as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extension is accounted for as a lease modification. The Company assessed the lease classification of the amended office space lease at the modification date and determined that the amended office space lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been remeasured based on the present value of remaining lease payments over the remaining extended lease term, using the incremental borrowing rate applicable as of the lease modification date. The Company determined the appropriate incremental borrowing rate by using a synthetic credit rating which was estimated based on an analysis of outstanding debt of companies with similar credit and financial profiles. Since the operating lease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred, such non-lease components were not included in the right-of-use asset and liability and are reflected as an expense in the period incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the modification in March 2020, the Company recorded an increase of $9,980 to its right-of-use (ROU) asset and lease liabilities in the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the office lease, the Company had a letter of credit agreement for the benefit of its landlord in the amount of $321 as of each December&#160;31, 2020 and 2019, collateralized by a money market account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2019, the Company entered into finance leases for certain equipment. The Company recorded assets under finance leases of $429 as property and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMC0xLTEtMTkwMQ_def9574d-e21a-4369-9aec-5ccd94c4b5a5"&gt;Other liabilities, current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTAtMS0xLTE5MDM_e1131034-fc7f-40a3-8087-977f8547a400"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense was $2,644, $2,160 and $1,994 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <mrsn:TenantImprovementAllowance
      contextRef="if3d5650f067549778be0f063470fcbca_D20200301-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEwOTk1MTE2MzExMDY_4191d81b-78fb-4b12-994d-579f39b852e0"
      unitRef="usd">172000</mrsn:TenantImprovementAllowance>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i6686ed562d224356b9709fed401426e2_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEwOTk1MTE2MzExMTY_1ee1b0b7-7413-4426-b322-4afdb4333046">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mrsn:LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEwOTk1MTE2MzM0MjA_41f0dbd9-854b-479f-8479-b292946c157b"
      unitRef="usd">9980000</mrsn:LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets>
    <mrsn:LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEwOTk1MTE2MzM0MjA_b63eb185-668c-4294-9647-7198c14a41ca"
      unitRef="usd">9980000</mrsn:LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:SecurityDeposit
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzcwMA_2e17b439-78f7-44fa-8c27-2fe3093d801b"
      unitRef="usd">321000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzcwMA_7dbec876-98f5-40a8-b899-3261b0f49540"
      unitRef="usd">321000</us-gaap:SecurityDeposit>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="ib85365aea4d54cff875208fefeee96ef_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzkxNg_8c3e142b-c959-4b69-9797-45e79ee8c2ec"
      unitRef="usd">429000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEzMTA_b33d9777-00aa-4ed2-b0c7-025bd2c2e353">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzEtMS0xLTEtMA_0d04072d-0eaf-4d86-aa01-3a7d3a341dee"
      unitRef="usd">2755000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzItMy0xLTEtMzU3MQ_f31b959a-55f8-4074-8c05-41f31145b889"
      unitRef="usd">2160000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzQtMS0xLTEtMA_aa9406e7-ed39-431e-b14b-62ba1a259420"
      unitRef="usd">176000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzUtMy0xLTEtMzU3MQ_a99feb67-a65e-45db-bfb2-ab979e3094a2"
      unitRef="usd">75000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzUtMS0xLTEtMA_b11c4638-5030-4cbf-b2d2-dd36e374df40"
      unitRef="usd">21000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzYtMy0xLTEtMzU3MQ_0a1ac474-29b5-43c6-a035-1b4ddaedbbf2"
      unitRef="usd">20000</us-gaap:FinanceLeaseInterestExpense>
    <mrsn:FinanceLeaseCost
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzYtMS0xLTEtMA_769b88ea-226f-4146-8913-6d046f2210c9"
      unitRef="usd">197000</mrsn:FinanceLeaseCost>
    <mrsn:FinanceLeaseCost
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpjZjE1ZWIwMjUwMGU0ZjgwYmE5ODM0NWZiN2VhNmFiOS90YWJsZXJhbmdlOmNmMTVlYjAyNTAwZTRmODBiYTk4MzQ1ZmI3ZWE2YWI5XzctMy0xLTEtMzU3MQ_da832422-74f2-46a8-b6cf-94cceb62c2c1"
      unitRef="usd">95000</mrsn:FinanceLeaseCost>
    <mrsn:LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEzMTE_35bac52c-369a-49cb-944a-f8eb8678ab76">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMC0xLTEtMTkwMQ_def9574d-e21a-4369-9aec-5ccd94c4b5a5"&gt;Other liabilities, current&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTAtMS0xLTE5MDM_e1131034-fc7f-40a3-8087-977f8547a400"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mrsn:LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzItMS0xLTEtMA_0314e3d1-9430-4004-b2a0-c3acd95898b0"
      unitRef="usd">10936000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzMtMy0xLTEtMzYxNw_c2efb34d-978a-499c-8bd8-15acc9d523e8"
      unitRef="usd">2598000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzMtMS0xLTEtMA_aa3838fe-fa3e-495a-9927-d94f13419409"
      unitRef="usd">1437000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzQtMy0xLTEtMzYxNw_ef813497-8143-48a3-8d74-a6c0fbd46edd"
      unitRef="usd">2219000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzQtMS0xLTEtMA_9dcc0ea1-5bc5-45db-a796-f024eec551ed"
      unitRef="usd">10158000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzUtMy0xLTEtMzYxNw_d664ce3f-c38a-4e33-a197-0d2cbfb8363a"
      unitRef="usd">677000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzctMS0xLTEtMA_e0985af8-38c0-4577-94e1-c04d1cf8cd28"
      unitRef="usd">429000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzgtMy0xLTEtMzYxNw_b9572e06-190d-4546-90b8-2198b492aaaa"
      unitRef="usd">429000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzgtMS0xLTEtMA_52ffc5fd-3e04-4628-bfe7-c5537c1aa582"
      unitRef="usd">176000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMy0xLTEtMzYxNw_825d4a74-45a5-4b2f-9c2d-f9ed2bdba86a"
      unitRef="usd">75000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMS0xLTEtMA_ffcde58d-7d6d-4966-9f32-ab04995a2c3d"
      unitRef="usd">93000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTMtMS0xLTM2MTc_421bcc04-0a5e-4321-839e-b6ff72ab62d6"
      unitRef="usd">87000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTEtMS0xLTA_ebe0c502-698c-4cff-9109-18ce906d691a"
      unitRef="usd">174000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzExLTMtMS0xLTM2MTc_6949e5c7-1943-4dd8-a1b7-9751422f2e3f"
      unitRef="usd">275000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEzLTEtMS0xLTA_934dd616-5479-4fc5-87d5-fc78feccadc0">P5Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE0LTMtMS0xLTM2MTc_ca5b4113-0647-4571-a556-bdd5a84fb2b5">P1Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE0LTEtMS0xLTA_20c62bc3-3965-4e89-bab1-18a90c492cc4">P2Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE1LTMtMS0xLTM2MTc_29383c9b-6a03-4bdd-9116-f947684f5d2e">P3Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE3LTEtMS0xLTA_e13f5a5b-17b5-4ebc-b80f-afbeaac9e908"
      unitRef="number">0.108</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE4LTMtMS0xLTM2MTc_3ef0b83a-c342-4ea2-9dba-5afc9de64037"
      unitRef="number">0.103</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE4LTEtMS0xLTA_47129f92-276d-4de5-96ff-b02066178ac8"
      unitRef="number">0.069</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzE5LTMtMS0xLTM2MTc_2cfd960d-3df1-4ffb-b8c0-4fed1cf290f3"
      unitRef="number">0.069</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <mrsn:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEzMTI_52ed4b6f-af1d-4d67-a369-64e993ecfc2b">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mrsn:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpiMjcwYTU5MDYyOWU0ZGE5YTJjYjFjNzRmNDliNzU4Yy90YWJsZXJhbmdlOmIyNzBhNTkwNjI5ZTRkYTlhMmNiMWM3NGY0OWI3NThjXzItMS0xLTEtMA_faa73348-0d6a-4463-86ff-d4f441e96b85"
      unitRef="usd">2394000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpiMjcwYTU5MDYyOWU0ZGE5YTJjYjFjNzRmNDliNzU4Yy90YWJsZXJhbmdlOmIyNzBhNTkwNjI5ZTRkYTlhMmNiMWM3NGY0OWI3NThjXzMtMy0xLTEtMzYzMw_5403cf56-84eb-4698-9d20-e261740ccdfc"
      unitRef="usd">2271000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpiMjcwYTU5MDYyOWU0ZGE5YTJjYjFjNzRmNDliNzU4Yy90YWJsZXJhbmdlOmIyNzBhNTkwNjI5ZTRkYTlhMmNiMWM3NGY0OWI3NThjXzMtMS0xLTEtMA_7724fe4c-1c16-4a03-bd9c-21ed3c132b2e"
      unitRef="usd">21000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpiMjcwYTU5MDYyOWU0ZGE5YTJjYjFjNzRmNDliNzU4Yy90YWJsZXJhbmdlOmIyNzBhNTkwNjI5ZTRkYTlhMmNiMWM3NGY0OWI3NThjXzQtMy0xLTEtMzYzMw_790eb70d-cddf-439e-b6d0-cef50cd5db70"
      unitRef="usd">20000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpiMjcwYTU5MDYyOWU0ZGE5YTJjYjFjNzRmNDliNzU4Yy90YWJsZXJhbmdlOmIyNzBhNTkwNjI5ZTRkYTlhMmNiMWM3NGY0OWI3NThjXzQtMS0xLTEtMA_6f9ad9af-9996-442d-8281-90fb23f4fe3f"
      unitRef="usd">116000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpiMjcwYTU5MDYyOWU0ZGE5YTJjYjFjNzRmNDliNzU4Yy90YWJsZXJhbmdlOmIyNzBhNTkwNjI5ZTRkYTlhMmNiMWM3NGY0OWI3NThjXzUtMy0xLTEtMzYzMw_3a83463f-6ff8-47d8-84ae-84fb2c8c2b5e"
      unitRef="usd">87000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:LeaseCost
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzExNjA_2dd8ccd2-ac4e-4f4f-860b-c72cbe0293a7"
      unitRef="usd">2644000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzExNjQ_eb8622bb-a43d-4ac0-bf9e-f6fc5a1020a7"
      unitRef="usd">2160000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzExNzE_ede04e51-6d64-47b2-9592-29bbe964c705"
      unitRef="usd">1994000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzEzMTM_35e6d661-51da-4e5f-8e1f-5f0de42bdfe2">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90ZXh0cmVnaW9uOmRiYjJiNjE2NzE4ODRhNGZiZmY5OWExYzdlZGRjMTQ1XzI3NDg3NzkwNzUxNDI_e3cfbd66-8938-460e-8bed-ca86f52748c3">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzEtMS0xLTEtMA_d2e2c8df-1063-4ab1-ab03-cbeaacdfc4a0"
      unitRef="usd">2772000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzEtMy0xLTEtMA_adc36016-0c9d-4c37-8be6-9320fc2149b3"
      unitRef="usd">116000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzItMS0xLTEtMA_bfbaf7f8-f96c-40aa-8c57-4ba9813c762e"
      unitRef="usd">2843000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzItMy0xLTEtMA_8a956c62-2373-45c7-950b-f79b835f1bca"
      unitRef="usd">84000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzMtMS0xLTEtMA_7a6e3a5e-b1f6-41cb-8063-04a3fa909b01"
      unitRef="usd">2928000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzMtMy0xLTEtMA_ce7015b3-5987-4e32-be80-ac64fe16c76f"
      unitRef="usd">74000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzQtMS0xLTEtMA_cbcf834d-3c1d-462a-9afd-1e4bbd20b33f"
      unitRef="usd">3016000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzQtMy0xLTEtMA_527b7e7f-dd2a-41b6-8dd6-3752518eb798"
      unitRef="usd">18000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzUtMS0xLTEtMA_bfaf6923-871d-4c0f-b917-0cd1f691130e"
      unitRef="usd">3888000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzUtMy0xLTEtMA_16150950-7cf7-4cad-b375-11f6051d1df3"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzYtMS0xLTEtMA_3bf31fab-0622-4dda-b908-9bad4ef3b45c"
      unitRef="usd">15447000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzYtMy0xLTEtMA_8c27b3d2-5103-4ae2-ac59-c1228e6d0298"
      unitRef="usd">292000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzctMS0xLTEtMA_c3b704c1-7943-4fd5-aebe-0f3fc276bb36"
      unitRef="usd">3854000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzctMy0xLTEtMA_c88f3761-aa5a-415a-9f3f-85e86c7c09ae"
      unitRef="usd">25000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzgtMS0xLTEtMA_f1f44037-322b-4779-960c-bac3b9aca7ce"
      unitRef="usd">11593000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTo1OTUyZTRkMTczOGI0Y2YzODI4OGYwNDU5ZDA0Y2E3MC90YWJsZXJhbmdlOjU5NTJlNGQxNzM4YjRjZjM4Mjg4ZjA0NTlkMDRjYTcwXzgtMy0xLTEtMA_bb370b8f-75de-4e70-a764-551206d287ba"
      unitRef="usd">267000</us-gaap:FinanceLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzUyOTY_ec4dd1f6-9409-4331-9e9f-30c0872df186">Income Taxes&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded no income tax benefit for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations as of December&#160;31, 2020, 2019 and 2018 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax computed at federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of ownership shift&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s net deferred tax assets as of December&#160;31, 2020 and 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net operating losses (NOL) since inception. At December&#160;31, 2020, the Company had Federal and State net operating loss carryforwards of approximately $250,367 and $184,781, respectively. Of the $250,367 of Federal net operating loss carryforwards, $34,149 expire at various dates through 2037. The remaining $216,218 of Federal net operating loss carryforwards do not expire. The State net operating loss carryforwards expire at various dates through 2040. At December&#160;31, 2020, the Company had Federal and State research and development tax credit carryforwards of approximately $4,582 and $1,482, respectively, which expire at various dates through 2040.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by ASC 740, management of the Company has evaluated the evidence bearing upon the reliability of its deferred tax assets. Based on the weight of available evidence, both positive and negative, management has determined that it is more likely than not that the Company will not realize the benefits of all of these assets. Accordingly, the Company recorded a valuation allowance of $77,375 and $48,889 at December&#160;31, 2020 and December&#160;31, 2019, respectively. The valuation allowance increased by $28,468 and decreased by $5,051 during the years ended December&#160;31, 2020 and 2019, respectively, primarily as a result of the Company&#x2019;s 382 limitation and net operating losses generated during the periods, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of the NOLs and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&#160;382 due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section&#160;382, as well as similar state provisions. These ownership changes may limit the amount of NOLs and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. If a change in control as defined by Section&#160;382 has occurred at any time since the Company&#x2019;s formation, utilization of its NOLs or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could then be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOLs or research and development tax carryforwards before their utilization. The Company has determined that ownership changes have occurred through November 4, 2019 and that certain NOLs and research and development tax credit carryforwards will be subject to limitation. The amounts presented do not include NOLs or research and development tax credit carryforwards that will expire unused due to ownership changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the accounting guidance in ASC 740 related to accounting for uncertainty in income taxes. The Company&#x2019;s reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. As of December&#160;31, 2020 and 2019, the Company had no unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalties related to uncertain tax positions would be classified as income tax expense in the accompanying statements of operations. As of December&#160;31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the United States federal tax jurisdiction and two state jurisdiction. The Company did not have any foreign operations during the&#160;years ended December&#160;31, 2020, 2019 and 2018. The statute of limitations for assessment by the Internal Revenue Service and state tax authorities is closed for tax&#160;years prior to 2016, although carryforward attributes that were generated prior to tax&#160;year 2015 may still be adjusted upon examination to the extent utilized in a future period. There are no federal or state audits currently in progress.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzUyOTQ_16f8ce5c-b776-4a08-8773-4410d2d940b3">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations as of December&#160;31, 2020, 2019 and 2018 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax computed at federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of ownership shift&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzEtMS0xLTEtMA_91a2e3fb-ced6-4b12-885d-b46adf525f9c"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzEtMy0xLTEtMA_2d816d60-3df2-4c03-9b3f-0f1cccd84be1"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzEtNS0xLTEtMA_a00d2b59-8300-4ad0-a03e-efa7a3b23361"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzItMS0xLTEtMA_bafd8184-df70-4760-b1ff-fac7fcdecee3"
      unitRef="number">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzItMy0xLTEtMA_d1ed3f83-223f-46e8-88db-b95295d32b6b"
      unitRef="number">0.061</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzItNS0xLTEtMA_764ae225-39af-4f11-93ba-fbd0523a5bc1"
      unitRef="number">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzMtMS0xLTEtMA_4f166475-f25e-4466-b987-9fd26162e255"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzMtMy0xLTEtMA_06852f6e-49ae-4284-82ae-5c25e0dd5316"
      unitRef="number">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzMtNS0xLTEtMA_2e77973c-38e7-4ccf-825d-16513b508fb3"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzUtMS0xLTEtMA_76985d85-d5e2-4ea3-89e1-9208b02373bf"
      unitRef="number">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzUtMy0xLTEtMA_aefec750-dae8-4a71-a44c-b85015ec2106"
      unitRef="number">0.103</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzUtNS0xLTEtMA_5fe6d889-cd8b-4dff-a7ea-60333958ce22"
      unitRef="number">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzctMS0xLTEtMA_6d3289bf-43ae-4737-b023-013e0423c2e9"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzctMy0xLTEtMA_915ad3bd-4c1f-44f1-8cc6-cf4119e176ad"
      unitRef="number">-0.533</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzctNS0xLTEtMA_699af40e-4387-49bf-a0ce-52fd9e04cb99"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzgtMS0xLTEtMA_680730d2-1509-4040-be76-9f845ab1d168"
      unitRef="number">-0.323</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzgtMy0xLTEtMA_d1c6f3bb-59a0-49c4-b315-c6f41e1da6b3"
      unitRef="number">0.179</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzgtNS0xLTEtMA_a1a14acd-12b7-45ef-b07f-1351c25883aa"
      unitRef="number">-0.323</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzktMS0xLTEtMA_10367bca-a368-477d-b176-aad56ecbfd30"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzktMy0xLTEtMA_653571e2-33cf-4b6b-a5c5-a8ef36172b8c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTozOWM2Nzc2MzM3YmU0NTJlOTMxMmQwNDU1YjJiMjg2Yi90YWJsZXJhbmdlOjM5YzY3NzYzMzdiZTQ1MmU5MzEyZDA0NTViMmIyODZiXzktNS0xLTEtMA_aef2f091-40ed-472e-b4c2-9e4f869e6ab4"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzUyOTU_7edc8060-f11c-482e-8961-18eb654edad3">Significant components of the Company&#x2019;s net deferred tax assets as of December&#160;31, 2020 and 2019 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzItMS0xLTEtMA_2a96eb46-14aa-43ed-8eae-2fdc013866e2"
      unitRef="usd">64259000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzItMy0xLTEtMA_24b3cd6d-4b81-43d5-a230-b4cde96b3c49"
      unitRef="usd">40554000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzMtMS0xLTEtOTA1NQ_1ff7c594-0344-460c-80f1-ea7a45bb8477"
      unitRef="usd">5670000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzMtMy0xLTEtOTA1NQ_7d132c55-1f5c-4479-b3c4-ea9f8e6e3bd5"
      unitRef="usd">2448000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzMtMS0xLTEtMA_b6a588bb-8707-4789-ac30-f96b6f7cd9c4"
      unitRef="usd">4058000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzMtMy0xLTEtMA_3e52cacf-99fe-498f-aa20-6f2c4c22f19e"
      unitRef="usd">2520000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <mrsn:DeferredTaxAssetsLeaseLiabilities
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzQtMS0xLTEtMA_7ee65625-b345-4c64-9bd3-1f217e3884dd"
      unitRef="usd">3166000</mrsn:DeferredTaxAssetsLeaseLiabilities>
    <mrsn:DeferredTaxAssetsLeaseLiabilities
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzQtMy0xLTEtMA_ee3bc1f4-06ed-41df-8a6f-c83604a0862a"
      unitRef="usd">791000</mrsn:DeferredTaxAssetsLeaseLiabilities>
    <mrsn:DeferredTaxAssetsLicensedTechnology
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzUtMS0xLTEtMA_eb3ceaef-08d2-468e-ad02-b8a906d70340"
      unitRef="usd">1534000</mrsn:DeferredTaxAssetsLicensedTechnology>
    <mrsn:DeferredTaxAssetsLicensedTechnology
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzUtMy0xLTEtMA_b3ca37fe-945b-4546-ac17-50d343865866"
      unitRef="usd">1402000</mrsn:DeferredTaxAssetsLicensedTechnology>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzYtMS0xLTEtMA_5e839349-818f-440c-95fb-d53b9f124f1d"
      unitRef="usd">1088000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzYtMy0xLTEtMA_a2062309-5a05-4291-b7e5-2ffc42e0eb4c"
      unitRef="usd">1315000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <mrsn:DeferredTaxAssetsDepreciation
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzgtMS0xLTEtMA_35de98e6-e3c3-4352-9253-32b8d19845e7"
      unitRef="usd">502000</mrsn:DeferredTaxAssetsDepreciation>
    <mrsn:DeferredTaxAssetsDepreciation
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzgtMy0xLTEtMA_c03bb0aa-0235-438a-b5c1-109b36c35bec"
      unitRef="usd">492000</mrsn:DeferredTaxAssetsDepreciation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzEwLTEtMS0xLTA_78a70890-7501-4144-954a-79d14ebc2bd6"
      unitRef="usd">84000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzEwLTMtMS0xLTA_a0a0b73c-5736-471c-a872-96d8bd31ea85"
      unitRef="usd">77000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzExLTEtMS0xLTA_cb2d0d52-7bcc-49cd-a581-9b7bda14919e"
      unitRef="usd">80361000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzExLTMtMS0xLTA_2b4b086c-e951-42e6-b59b-5846d6a5a2b4"
      unitRef="usd">49599000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzEyLTEtMS0xLTA_3d49ffe2-73c1-45b8-8e25-30ace11619b2"
      unitRef="usd">77375000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzEyLTMtMS0xLTA_23b0e30d-c043-4e6b-95d0-d8c6dca15a3f"
      unitRef="usd">48889000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzEzLTEtMS0xLTA_4aa58354-63a0-4b17-a5df-43c155cda54b"
      unitRef="usd">2986000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzEzLTMtMS0xLTA_09141fff-05af-435b-b41a-229bc6cfcf52"
      unitRef="usd">710000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzE1LTEtMS0xLTA_2e5299b8-bfc9-400b-a2c8-29535d077c9e"
      unitRef="usd">2986000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzE1LTMtMS0xLTA_174db9f1-544f-4fc2-b818-5715192ef819"
      unitRef="usd">710000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzE2LTEtMS0xLTA_df674b5f-1f72-4747-bd71-7b5da7d1fe95"
      unitRef="usd">2986000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzE2LTMtMS0xLTA_8ed65a59-2db2-4dd6-81e6-4ba1a2931227"
      unitRef="usd">710000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzE3LTEtMS0xLTA_f6fec491-cfae-4581-bf44-bacb55e835d6"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90YWJsZTo5NGI4M2EwZGUxMGI0NDE2OTdlMTk0YTllZjk3ZDBiMy90YWJsZXJhbmdlOjk0YjgzYTBkZTEwYjQ0MTY5N2UxOTRhOWVmOTdkMGIzXzE3LTMtMS0xLTA_bae7778c-8726-4acd-a9bd-1f368da91ba6"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic059f7a3532745518966900be47d1c47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzgzMw_21912ffa-374c-4641-a6fc-60f113d9bd67"
      unitRef="usd">250367000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i82697de2ab144693bec9626ce8bdb92c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzg0MA_fdb0456b-f10a-4cb1-90dc-644a519e7f75"
      unitRef="usd">184781000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic059f7a3532745518966900be47d1c47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzg2NQ_09311830-0e95-4caa-b9bb-8e007529ea9b"
      unitRef="usd">250367000</us-gaap:OperatingLossCarryforwards>
    <mrsn:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="ic059f7a3532745518966900be47d1c47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzkxMw_cddcc1d6-6df4-408e-b2d5-60407f9a0976"
      unitRef="usd">34149000</mrsn:OperatingLossCarryforwardsSubjectToExpiration>
    <mrsn:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="ic059f7a3532745518966900be47d1c47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzk2OQ_b3b8ba86-4879-4416-b663-42c0a5220921"
      unitRef="usd">216218000</mrsn:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ia1a16dd07ee341a0b4a2267c3b6bd737_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzEyMjA_8503cf4f-1de2-4a1e-8df5-645967389058"
      unitRef="usd">4582000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ibacf6c67e9b24271b096b036df23e4a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzEyMjc_c0e8a528-da73-4bf8-92ae-1598b7ff190c"
      unitRef="usd">1482000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzE2ODI_88ab5ab7-e72c-4cf1-a9ba-6b031023f725"
      unitRef="usd">77375000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzE2ODk_63849cda-75f5-412f-acd7-a4c4d27e90d2"
      unitRef="usd">48889000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzE3NTc_64137311-a8b2-4d63-ba97-edf153e768ff"
      unitRef="usd">28468000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzE3NzQ_830723ac-fa1f-4432-8de0-b3198ab4da4a"
      unitRef="usd">-5051000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzM4MzM_42af5a13-1214-4c7e-b048-941d2d266524"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzM4MzM_a42ea398-5e79-4db1-a279-242cf375330f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzQ2NzQ_5e6e2355-319f-4b4d-ad4f-7d04bc44f909"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ie7a39af3ac91431f9135e7905754c66c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzQ2NzQ_d3afdf2f-bb0c-4df9-a14a-c2832539f1de"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <mrsn:IncomeTaxesNumberOfStateJurisdictions
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzQ4MzA_af92174d-4327-4817-82c4-0d1d882007cc"
      unitRef="jurisdiction">2</mrsn:IncomeTaxesNumberOfStateJurisdictions>
    <mrsn:IncomeTaxesNumberOfAuditsInProgress
      contextRef="i02a979a8932342d78dec04dc805709b8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTEvZnJhZzplOTBlOTk1MDE3YWM0Y2I5YTk0MzkwZmZhYTJkOTZjZC90ZXh0cmVnaW9uOmU5MGU5OTUwMTdhYzRjYjlhOTQzOTBmZmFhMmQ5NmNkXzUyNDY_b0b1c915-5552-4f3b-a1fd-9318f1eba1a1"
      unitRef="audit">0</mrsn:IncomeTaxesNumberOfAuditsInProgress>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzg0NA_8ab2045b-b440-4ef6-a5b6-e02371da7007">Employee Benefit PlanThe Company has a defined contribution plan established under Section&#160;401(k)&#160;of the Internal Revenue Code (401(k)&#160;Plan), which covers substantially all employees. Employees who have attained the age of 21 are eligible to participate in the 401(k)&#160;Plan with no service requirement. Employees may contribute up to 75% of eligible pay on a pre&#x2013;tax basis up to the federal annual limits. For the year ended December&#160;31, 2018 and the period from January 1, 2019 to July 31, 2019, the Company matched the employees&#x2019; contributions at 50% on the first 6% up to $6. For the period from August 1, 2019 to December&#160;31, 2019 and for the year ended December&#160;31, 2020, the Company matched the employees&#x2019; contributions at 100% on the first 4% up to $7. For the&#160;years ended December&#160;31, 2020, 2019 and 2018, the Company recorded expense of $486, $404 and $332, respectively, related to its contribution to its 401(k)&#160;Plan.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <mrsn:DefinedContributionPlanEligibleAgeToParticipate
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzEwOTk1MTE2Mjg2NjM_92e53b3d-1b70-453c-a59e-7b4a22979b67">P21Y</mrsn:DefinedContributionPlanEligibleAgeToParticipate>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzEwOTk1MTE2Mjg2Nzg_54697ab4-cdc3-47f8-919f-cabd78ed0775"
      unitRef="number">0.75</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzU1MA_2f5bef14-a40e-406b-8029-92ba20fac1f0"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i2f999c2f67b946f6a6d1493212350a0f_D20190101-20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzU1MA_484961b8-ff24-4fcb-8f68-454637ddec25"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i2f999c2f67b946f6a6d1493212350a0f_D20190101-20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzU2Ng_255c23d0-da2d-426b-9435-d99a8cd60f87"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzU2Ng_e6a9b497-0a5e-461e-8166-01e2323d3d84"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount
      contextRef="i2f999c2f67b946f6a6d1493212350a0f_D20190101-20190731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzU3NQ_b0fafd8c-a2dd-402d-b8fb-0beb94fcdc20"
      unitRef="usd">6000</mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount>
    <mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzU3NQ_e54cd50c-812d-4dde-b529-89dd86639394"
      unitRef="usd">6000</mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i6132787d773e482cbb6d82895b63d717_D20190801-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzEwOTk1MTE2Mjg3MTc_1fbb44c7-f445-448b-bfd7-587e2bbd01dc"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i6132787d773e482cbb6d82895b63d717_D20190801-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzEwOTk1MTE2Mjg3Mjg_74611bc6-5f27-4a9c-8b3e-b7898e0ff4c5"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount
      contextRef="i6132787d773e482cbb6d82895b63d717_D20190801-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzEwOTk1MTE2Mjg3Mzc_a6d9d190-772b-4c9c-8428-213b2d1f69fd"
      unitRef="usd">7000</mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzc2OQ_77d84b1a-589f-4396-809b-c0e914d275e7"
      unitRef="usd">486000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzc3Mw_544654b6-24ed-4fad-8a59-793d9ee32e53"
      unitRef="usd">404000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i015a9ec2242a41419b8f887080a604ce_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNTcvZnJhZzpjNzdkM2Y3MzdjMWI0YmMxOWI4NzZlZjQ5MjcxMzhjYS90ZXh0cmVnaW9uOmM3N2QzZjczN2MxYjRiYzE5Yjg3NmVmNDkyNzEzOGNhXzc4MA_fd3e20ea-e3bb-4795-8647-ba81e085ad2b"
      unitRef="usd">332000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzU5Mw_9d790256-f27a-404c-b569-55c4f26bbfe8">Commitments&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded research and development expense related to non-refundable upfront payments of $250, $750, and $0, respectively. Further milestone payments of $750, $600 and $0, respectively, were also recorded as research and development expense during the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 11 for the Company&#x2019;s future obligations related to leases as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i4114a3ad19d943caa2f08b5649e9e275_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzEwOTk1MTE2MzA3NTU_df68e3b1-6893-4bf7-a604-1a529440112e"
      unitRef="usd">250000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i6a071cec119846ab9055589216a2b776_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzEwOTk1MTE2MzA3NjI_ab1ef77b-d78a-469b-a3a6-b4def556fbe4"
      unitRef="usd">750000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i1094fe6fc0a54ffaa7e6425e002d5fd9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzEwOTk1MTE2MzA3Njc_117f5b42-8b7b-487c-ab76-1a5516fe06be"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i480e629817294830afafe0f1a51084b4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzQ2MA_49a4ec26-d263-47fa-b868-2ad27af2f4ef"
      unitRef="usd">750000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i4abde9e6537849859c77bdc8d4176754_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzQ2NA_c5a3c767-364d-40c2-adc1-b0678074e80b"
      unitRef="usd">600000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i65bb47754a65456c89056c19e9b6a48d_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNjMvZnJhZzoxMjE3MzIxNTQyZjM0YmM3YWYzNjIxODdmNWRhYjAzYS90ZXh0cmVnaW9uOjEyMTczMjE1NDJmMzRiYzdhZjM2MjE4N2Y1ZGFiMDNhXzQ3MQ_05deef8f-8a67-4117-a5e0-1bf4f7d56028"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90ZXh0cmVnaW9uOmJiYWJmYWNlOWIwYjQwMmM5ZDc3YjVhZjBlZmJiNDQ0XzQxOA_35271693-9936-4380-9580-114faa2411ea">Selected Quarterly Financial Data (unaudited)The following table contains selected quarterly financial information for 2020 and 2019. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.232%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,844)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share&#160;attributable to common stockholders &#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares used in net loss per share attributable to common stockholders &#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,988,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,748,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,419,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,630,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.232%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share&#160;attributable to common stockholders &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share&#160;attributable to common stockholders &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares used in net income (loss) per share attributable to common stockholders &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,299,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,708,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,833,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,886,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares used in net income (loss) per share attributable to common stockholders &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,461,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,708,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,833,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,886,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="ia8f204faa7704411a0850b074d255000_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90ZXh0cmVnaW9uOmJiYWJmYWNlOWIwYjQwMmM5ZDc3YjVhZjBlZmJiNDQ0XzQxOQ_c8908743-5317-4a30-a0f8-8bc3dd9dcfd7">The following table contains selected quarterly financial information for 2020 and 2019. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.232%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,844)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share&#160;attributable to common stockholders &#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares used in net loss per share attributable to common stockholders &#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,988,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,748,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,419,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,630,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.232%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three months ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share&#160;attributable to common stockholders &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share&#160;attributable to common stockholders &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares used in net income (loss) per share attributable to common stockholders &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,299,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,708,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,833,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,886,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares used in net income (loss) per share attributable to common stockholders &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,461,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,708,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,833,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,886,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzItMS0xLTEtMA_d6c2d97d-64cc-44c0-9212-f58307666258"
      unitRef="usd">11000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzItMy0xLTEtMA_2575a3cb-13e6-468e-b7c9-336299c595ac"
      unitRef="usd">796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzItNS0xLTEtMA_dbd2d01c-0b86-4ed9-99c9-c0085c3a0308"
      unitRef="usd">11000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzItNy0xLTEtMA_d82eb61a-2a9a-4d7d-abe4-a1b2c6e5930d"
      unitRef="usd">10000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzQtMS0xLTEtMA_da473221-3134-4ba8-9efb-a12b0d6d396c"
      unitRef="usd">12219000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzQtMy0xLTEtMA_617aea2b-d4e1-4cf8-9c5b-24f4876298ec"
      unitRef="usd">15413000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzQtNS0xLTEtMA_c96e0cb1-6d23-44db-95b8-25783a12111a"
      unitRef="usd">16546000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzQtNy0xLTEtMA_2167672d-efd7-4d08-844a-59570224c0e1"
      unitRef="usd">22858000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzUtMS0xLTEtMA_976a3f5d-c1f5-4cf1-a9f2-bb6bce436fb7"
      unitRef="usd">4936000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzUtMy0xLTEtMA_06739b95-fd65-4da1-8df8-f4d0dc73a5ac"
      unitRef="usd">5171000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzUtNS0xLTEtMA_0b2daf9e-c274-4894-827e-94d956bccca3"
      unitRef="usd">5881000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzUtNy0xLTEtMA_49fbbcc7-17d2-4e09-a6c6-9fc11e05efe4"
      unitRef="usd">5914000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzYtMS0xLTEtMA_1a29cd15-f7ef-47af-ac1a-02935bc5d36d"
      unitRef="usd">17155000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzYtMy0xLTEtMA_a55e562d-48ab-4dcb-a396-8291516b1350"
      unitRef="usd">20584000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzYtNS0xLTEtMA_3478ece6-e9e9-437a-bba7-0afd89abd137"
      unitRef="usd">22427000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzYtNy0xLTEtMA_f809f4cc-d4e4-421d-aa65-6bedae338e7d"
      unitRef="usd">28772000</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzgtMS0xLTEtMA_b0da3bf2-b22e-4f29-9290-be59105882df"
      unitRef="usd">306000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzgtMy0xLTEtMA_15ac2f8c-9c77-4ebf-8141-c319e42e6d6d"
      unitRef="usd">89000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzgtNS0xLTEtMA_f8c9aa55-7e56-416f-b72c-b45b37916bcf"
      unitRef="usd">19000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzgtNy0xLTEtMA_35286672-e1be-4469-8e8b-78bccc016c05"
      unitRef="usd">10000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzktMS0xLTEtMA_c2d62c84-4b32-45bc-b654-5408198111e8"
      unitRef="usd">88000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzktMy0xLTEtMA_4d51eb6d-db0c-4b99-8f39-e61fd5770833"
      unitRef="usd">87000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzktNS0xLTEtMA_16ab3239-b80f-400f-a111-94334237f521"
      unitRef="usd">92000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzktNy0xLTEtMA_76c444e4-cb9b-4b0b-bd80-4e62d8f99d39"
      unitRef="usd">92000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEwLTEtMS0xLTA_66e32295-6e10-4801-b358-3cfc481a4d69"
      unitRef="usd">218000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEwLTMtMS0xLTA_bc9d4f64-890c-44a7-83cc-494e722c5f0c"
      unitRef="usd">2000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEwLTUtMS0xLTA_dff8d3f4-4238-4e6f-8247-7410f0987099"
      unitRef="usd">-73000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEwLTctMS0xLTA_ef5fdf75-a0ba-4c03-868b-2f9606344084"
      unitRef="usd">-82000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzExLTEtMS0xLTA_81cd85b4-c3a3-42e1-a3f9-c8e51bdc5507"
      unitRef="usd">-16926000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzExLTMtMS0xLTA_0c3e672d-e554-47d8-8676-5dd750e3fb29"
      unitRef="usd">-19786000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzExLTUtMS0xLTA_94eac668-36a4-4097-b294-08f387227704"
      unitRef="usd">-22489000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzExLTctMS0xLTA_0e071e15-1424-48fc-b77e-0cd915a7ca2d"
      unitRef="usd">-28844000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTEtMS0xLTA_84a383a7-e0d3-4da0-af12-3ec028787908"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTEtMS0xLTA_8a197d38-a37e-4eed-a887-18ed2de69bd5"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTMtMS0xLTA_117d7c0e-949a-496a-8fa8-7710ed891591"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTMtMS0xLTA_6e045b78-3ee1-4fb4-9891-2a4b0897eaf9"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTUtMS0xLTA_48f9304e-9240-4051-9ba3-27132d2549cc"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTUtMS0xLTA_4a73b6a2-2cd5-4191-b1fe-b3897e05a1d2"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTctMS0xLTA_180bfda3-5f95-4fa6-876f-4b1d6fa2229a"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzEyLTctMS0xLTA_589a38d6-4691-4ede-9f57-b445304a9e9d"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i38901776c10c4c5aac660dbc202f1cd5_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzE0LTEtMS0xLTA_96cd2b07-5ba6-469d-9265-80590f8afe5f"
      unitRef="shares">47988630</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iead5c18dcdb14cae9b098182ac3586b5_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzE0LTMtMS0xLTA_73ae3563-cbbb-40f9-b693-a32779faae32"
      unitRef="shares">60748225</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i794800a551a9426caf3efd53342dfb1e_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzE0LTUtMS0xLTA_c10fdfcf-3c6c-432d-ac15-23ab38af3d65"
      unitRef="shares">68419192</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo2YzYxNjY0MTA3MzM0YzEyOGU1M2EzMDFlOTU2MzdiZC90YWJsZXJhbmdlOjZjNjE2NjQxMDczMzRjMTI4ZTUzYTMwMWU5NTYzN2JkXzE0LTctMS0xLTA_46a4d361-f546-4112-9b6f-d1b73fdf54db"
      unitRef="shares">68630078</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzItMS0xLTEtMA_3b33072c-59af-41ab-9fd1-d58ecee9a431"
      unitRef="usd">41035000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzItMy0xLTEtMA_2603a8a4-df9d-4d22-aca0-7d0411eb45a9"
      unitRef="usd">202000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzItNS0xLTEtMA_a3cf249d-38bf-4e7d-84f4-090b49a57e80"
      unitRef="usd">844000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzItNy0xLTEtMA_1a770c62-c615-4b00-877b-66c337a6bf7a"
      unitRef="usd">42000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzQtMS0xLTEtMA_8735421c-e11f-4751-ab2c-81d0829d230b"
      unitRef="usd">15143000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzQtMy0xLTEtMA_8cda0394-74c3-407c-8d89-0bd0b845727f"
      unitRef="usd">13766000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzQtNS0xLTEtMA_e22c99c9-5972-415f-9d91-ab309883b219"
      unitRef="usd">13701000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzQtNy0xLTEtMA_ef0ecd48-2b1f-40f7-977d-16459790fb30"
      unitRef="usd">12430000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzUtMS0xLTEtMA_76644ec3-b8db-41b8-9148-a4d926066d23"
      unitRef="usd">4443000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzUtMy0xLTEtMA_1e9d1d65-75da-4489-9465-95f5a8354cfb"
      unitRef="usd">4192000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzUtNS0xLTEtMA_801f0bfa-67e2-41d5-8094-af8075e40b01"
      unitRef="usd">4436000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzUtNy0xLTEtMA_41b4a25f-bd20-4932-8dfd-3b91fcd83395"
      unitRef="usd">4212000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzYtMS0xLTEtMA_369878ab-929f-4373-b39d-82eeb93f0485"
      unitRef="usd">19586000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzYtMy0xLTEtMA_72a00342-2617-4347-986b-2079f5693f30"
      unitRef="usd">17958000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzYtNS0xLTEtMA_d1984f4c-c080-4844-bc68-e09481376894"
      unitRef="usd">18137000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzYtNy0xLTEtMA_8e479d30-fb00-477c-bc8b-fee4b4281ffe"
      unitRef="usd">16642000</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzgtMS0xLTEtMA_a53e81ad-f034-4901-a901-e2911aadd322"
      unitRef="usd">452000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzgtMy0xLTEtMA_b7cc49e7-0fbf-45e2-aebd-563bcf0f0cb7"
      unitRef="usd">725000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzgtNS0xLTEtMA_1ed81ad8-2dab-4052-9147-57154ed0cca3"
      unitRef="usd">608000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzgtNy0xLTEtMA_e4473318-63c4-4cf8-b728-c68ac33a3fe6"
      unitRef="usd">441000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzktMS0xLTEtMA_5460374a-6cce-4af2-853e-286dbb2cb03a"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzktMy0xLTEtMA_c0c77a2d-9486-4b99-a75d-34535215b703"
      unitRef="usd">40000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzktNS0xLTEtMA_763b074f-790f-49fd-895e-2aeb7b3d365c"
      unitRef="usd">107000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzktNy0xLTEtMA_8a481093-e884-4de8-8627-9fd2f5fbfef5"
      unitRef="usd">87000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEwLTEtMS0xLTA_b0b08799-1cae-4684-83cd-d739ef15815a"
      unitRef="usd">452000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEwLTMtMS0xLTA_40b9d884-08de-42c2-9f31-818684beb7ca"
      unitRef="usd">685000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEwLTUtMS0xLTA_bc3cdee2-68f1-4267-887b-19771831187c"
      unitRef="usd">501000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEwLTctMS0xLTA_1c822946-6be5-4615-af86-efa482e7134f"
      unitRef="usd">354000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzExLTEtMS0xLTA_0a622733-5316-47a6-bbfe-24f66a410b18"
      unitRef="usd">21901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzExLTMtMS0xLTA_c30a4ab2-a8d4-413c-9c03-6efa700608f4"
      unitRef="usd">-17071000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzExLTUtMS0xLTA_f8474488-cc5e-43dd-8a79-ebe1a5c0dbab"
      unitRef="usd">-16792000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzExLTctMS0xLTA_29f2eadd-f56c-4ab6-8f95-3430060150f4"
      unitRef="usd">-16246000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTEtMS0xLTM5MDE_18f1298c-9653-400b-8d67-2dcf05489615"
      unitRef="usdPerShare">0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTMtMS0xLTM5MDE_2fe6706b-cfaf-4069-83bf-61b55cea03ee"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTUtMS0xLTM5MDE_1151aca8-3eda-457c-9f72-3da0ef0b3fc9"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTctMS0xLTM5MDE_7e45bbe5-56a3-476c-8f7c-0e84e64d4a7f"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEzLTEtMS0xLTM5MjU_9279dcbd-0e38-4465-96c9-8d3116461a23"
      unitRef="usdPerShare">0.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEzLTMtMS0xLTM5MjU_81222265-720e-4e95-b95f-e0cd06395182"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEzLTUtMS0xLTM5MjU_90cac7b3-60db-4b16-b32c-9675e583ea80"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEzLTctMS0xLTM5MjU_51811e06-5946-45fe-be28-95ebb3c9c07f"
      unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTEtMS0xLTA_f369487b-4687-4211-b817-fe31a4111bf7"
      unitRef="shares">30299650</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTMtMS0xLTA_c2925879-e315-4da2-94ce-073e7aa80155"
      unitRef="shares">47708085</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTUtMS0xLTA_c75b34a5-5a34-4e53-98cd-d50892ec705b"
      unitRef="shares">47833607</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzEyLTctMS0xLTA_5ef5e447-8442-4147-8bfd-8e25da196a0a"
      unitRef="shares">47886144</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i60b4aa948d3f48d192d75301259a0120_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzE1LTEtMS0xLTM5Mjg_fc859e63-005d-47d6-9b98-2993d29a0c95"
      unitRef="shares">31461696</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i86bbc3a7f9654fe7a060a234e4f2471f_D20190401-20190630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzE1LTMtMS0xLTM5Mjg_1397243e-973c-4b30-a61f-a2ff8ec65bc3"
      unitRef="shares">47708085</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2230807b40294554b203da69a2a9b2d5_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzE1LTUtMS0xLTM5Mjg_eb5bbff9-6664-432b-965f-b099d8641cff"
      unitRef="shares">47833607</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6a29ff99e41943de82107edbd828a83a_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNzIvZnJhZzpiYmFiZmFjZTliMGI0MDJjOWQ3N2I1YWYwZWZiYjQ0NC90YWJsZTo3OTRjNjRhOGQ1N2I0NWE5YmIyN2E4NGEyNjU2MWYzYS90YWJsZXJhbmdlOjc5NGM2NGE4ZDU3YjQ1YTliYjI3YTg0YTI2NTYxZjNhXzE1LTctMS0xLTM5Mjg_f1b07f56-efe6-41ff-8cbb-2854e779872d"
      unitRef="shares">47886144</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438409823608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 23, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Mersana Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3562403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">840 Memorial Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">498-0020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRSN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,147,647,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,042,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement that will be filed for the 2021 Annual Meeting of Stockholders are incorporated by reference in Part III.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001442836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438409836152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 255,094<span></span>
</td>
<td class="nump">$ 62,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,486<span></span>
</td>
<td class="nump">1,536<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">258,580<span></span>
</td>
<td class="nump">101,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,730<span></span>
</td>
<td class="nump">2,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">10,936<span></span>
</td>
<td class="nump">2,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,153<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">273,399<span></span>
</td>
<td class="nump">107,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,340<span></span>
</td>
<td class="nump">7,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">16,146<span></span>
</td>
<td class="nump">8,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">3,987<span></span>
</td>
<td class="nump">4,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">2,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">30,003<span></span>
</td>
<td class="nump">24,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">10,158<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">4,977<span></span>
</td>
<td class="nump">4,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">45,312<span></span>
</td>
<td class="nump">29,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note&#160;14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at December&#160;31, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 175,000,000 shares authorized; 68,841,288 and 45,388,023&#160;shares issued and outstanding at December&#160;31, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">508,499<span></span>
</td>
<td class="nump">270,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(280,419)<span></span>
</td>
<td class="num">(192,374)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">228,087<span></span>
</td>
<td class="nump">78,318<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 273,399<span></span>
</td>
<td class="nump">$ 107,541<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333676248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">68,841,288<span></span>
</td>
<td class="nump">45,388,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">68,841,288<span></span>
</td>
<td class="nump">45,388,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438409812216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 828<span></span>
</td>
<td class="nump">$ 42,123<span></span>
</td>
<td class="nump">$ 10,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Type of revenue</a></td>
<td class="text">mrsn:CollaborationMember<span></span>
</td>
<td class="text">mrsn:CollaborationMember<span></span>
</td>
<td class="text">mrsn:CollaborationMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 67,036<span></span>
</td>
<td class="nump">$ 55,040<span></span>
</td>
<td class="nump">$ 59,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">21,902<span></span>
</td>
<td class="nump">17,283<span></span>
</td>
<td class="nump">16,334<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">88,938<span></span>
</td>
<td class="nump">72,323<span></span>
</td>
<td class="nump">76,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">2,226<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(359)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(88,045)<span></span>
</td>
<td class="num">(28,208)<span></span>
</td>
<td class="num">(64,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(88,070)<span></span>
</td>
<td class="num">(28,175)<span></span>
</td>
<td class="num">(64,116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders - basic</a></td>
<td class="num">(88,045)<span></span>
</td>
<td class="num">(28,208)<span></span>
</td>
<td class="num">(64,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders - diluted</a></td>
<td class="num">$ (88,045)<span></span>
</td>
<td class="num">$ (28,208)<span></span>
</td>
<td class="num">$ (64,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders &#8212; basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (2.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used in net loss per share attributable to common stockholders &#8212; basic and diluted (in shares)</a></td>
<td class="nump">61,485,205<span></span>
</td>
<td class="nump">43,492,113<span></span>
</td>
<td class="nump">23,032,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121551570&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438336818872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect adjustment for adoption of ASC 606</div></th>
<th class="th"><div>At market equity offering program (2018 ATM)</div></th>
<th class="th"><div>Public Stock Offering</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th">
<div>Common&#160;Stock </div>
<div>At market equity offering program (2018 ATM)</div>
</th>
<th class="th">
<div>Common&#160;Stock </div>
<div>Public Stock Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>At market equity offering program (2018 ATM)</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Public Stock Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative effect adjustment for adoption of ASC 606</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,765,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2017</a></td>
<td class="nump">$ 69,994<span></span>
</td>
<td class="num">$ (2,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (149)<span></span>
</td>
<td class="num">$ (97,878)<span></span>
</td>
<td class="num">$ (2,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">427,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Purchase of common stock under ESPP</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(64,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,234,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2018</a></td>
<td class="nump">$ 8,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(164,166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201409Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Purchase of common stock under ESPP</a></td>
<td class="nump">$ 489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="nump">92,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised', window );">Exercise of stock options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised', window );">Exercise of stock options and warrants</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares', window );">Retirement of common stock in exchange for common stock warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,575,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue', window );">Retirement of common stock in exchange for common stock warrant</a></td>
<td class="num">(8,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrant in exchange for retirement of common stock</a></td>
<td class="nump">8,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,388,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2019</a></td>
<td class="nump">78,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="num">(192,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction', window );">Stock issuance, Discounts And Commissions On Transaction</a></td>
<td class="nump">$ 5,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">697,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 3,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Purchase of common stock under ESPP</a></td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900,599<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,977<span></span>
</td>
<td class="nump">$ 163,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,976<span></span>
</td>
<td class="nump">$ 163,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised', window );">Exercise of common stock warrant in exchange for common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,574,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(88,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,841,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">$ 228,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 508,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (280,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction', window );">Stock issuance, Discounts And Commissions On Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,176<span></span>
</td>
<td class="nump">$ 10,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discounts and commissions deducted from cash proceeds received on stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period and exercise of common stock warrant in exchange for common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued as a result of the exercise of stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock that have been retired in exchange for common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been retired in exchange for common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331341400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember', window );">At market equity offering program (2018 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction', window );">Issuance costs</a></td>
<td class="nump">$ 2,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction', window );">Issuance costs</a></td>
<td class="nump">$ 10,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discounts and commissions deducted from cash proceeds received on stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333458824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (88,045)<span></span>
</td>
<td class="num">$ (28,208)<span></span>
</td>
<td class="num">$ (64,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premiums and discounts on investments</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,172<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
<td class="nump">3,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ChangeInDeferredRent', window );">Change in deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,950)<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
<td class="num">(1,690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">942<span></span>
</td>
<td class="num">(3,110)<span></span>
</td>
<td class="nump">7,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">7,280<span></span>
</td>
<td class="num">(3,569)<span></span>
</td>
<td class="nump">5,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_IncreaseDecreaseInOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">1,642<span></span>
</td>
<td class="nump">1,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(1,281)<span></span>
</td>
<td class="num">(1,883)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(828)<span></span>
</td>
<td class="num">(41,381)<span></span>
</td>
<td class="num">(6,243)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(74,696)<span></span>
</td>
<td class="num">(67,744)<span></span>
</td>
<td class="num">(55,216)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">88,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(53,688)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(473)<span></span>
</td>
<td class="num">(605)<span></span>
</td>
<td class="num">(1,370)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">37,027<span></span>
</td>
<td class="num">(27,293)<span></span>
</td>
<td class="nump">87,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">3,138<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from purchases of common stock under ESPP</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ProceedsFromDebtNetIssuanceCosts', window );">Proceeds from issuance of debt, net of issuance costs</a></td>
<td class="num">(197)<span></span>
</td>
<td class="nump">4,965<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments under capital lease obligations</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">230,412<span></span>
</td>
<td class="nump">97,704<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">192,743<span></span>
</td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">33,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">62,672<span></span>
</td>
<td class="nump">60,005<span></span>
</td>
<td class="nump">26,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">255,415<span></span>
</td>
<td class="nump">62,672<span></span>
</td>
<td class="nump">60,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant', window );">Fair value of common stock retired in exchange for issuance of common stock warrant</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,986<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Debt financing costs in accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">9,980<span></span>
</td>
<td class="nump">4,369<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for financing lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard', window );">Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offering of common stock</a></td>
<td class="nump">163,990<span></span>
</td>
<td class="nump">92,162<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember', window );">At market equity offering program (2018 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from public offering of common stock</a></td>
<td class="nump">$ 63,036<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Retained Earnings, Deferred Revenue Upon Adoption Of New Accounting Standard</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ChangeInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in deferred rent during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ChangeInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of common stock retired in exchange for issuance of common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_IncreaseDecreaseInOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_IncreaseDecreaseInOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ProceedsFromDebtNetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Debt, Net Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ProceedsFromDebtNetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331571112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">Nature of Business and Basis of Presentation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with significant unmet need. The Company has leveraged 20 years of industry learning in the ADC field to develop proprietary and differentiated technology platforms that enable it to design ADCs to have improved efficacy, safety and tolerability relative to existing ADC therapies. The Company&#8217;s innovative platforms, which include Dolaflexin and Dolasynthen, each delivering its DolaLock payload, as well as Immunosynthen, delivering a novel stimulator of interferon genes (STING) agonist, provide an efficient product engine that has enabled a robust discovery pipeline for the Company and its partners. The Company&#8217;s product candidates include upifitamab rilsodotin (UpRi, XMT-1536) and XMT-1592. The Company's early stage programs include a potentially first-in-class B7-H4-targeted DolaLock ADC, XMT-1660, as well as candidates leveraging the Immunosynthen platform, the most advanced of which is XMT-2056.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UpRi, an ADC utilizing the Company&#8217;s Dolaflexin platform and targeting NaPi2b, an antigen broadly expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma, is currently in the expansion portion of a Phase 1 study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592 uses one of the Company&#8217;s new platforms, Dolasynthen, and also targets NaPi2b. In the first half of 2020, the Company initiated the Phase 1 dose escalation study of XMT-1592 .</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, the need for additional capital, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and reimbursement for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on third party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since inception. The Company&#8217;s net loss was $88,045, $28,208 and $64,257 for the years ended December&#160;31, 2020, 2019 and 2018, respectively. The Company expects to continue to incur operating losses for at least the next several years.&#160;As of December&#160;31, 2020, the Company had an accumulated deficit of $280,419. The future success of the Company is dependent on, among other factors, its ability to identify and develop its product candidates and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative operating cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company sold 10,900,599 shares of common stock and received net proceeds of $62,976. In addition, in June 2020, the Company sold 9,200,000 shares of common stock and received net proceeds of $163,990. The Company believes that its currently available funds will be sufficient to fund the Company&#8217;s operations through at least the next twelve months from the issuance of this Annual Report on Form 10-K. Management&#8217;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management&#8217;s estimates, the Company may need to seek additional funding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). All dollar amounts, except per share data in the text and tables herein, are stated in thousands unless otherwise indicated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438330213208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include those of the Company and its wholly owned subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company's management evaluates its estimates which include, but are not limited to, management's judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess performance. The Company views its operations and manages its business as a single operating segment, which is the business of discovering and developing ADCs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, bonuses, benefits, travel and stock-based compensation expense;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of preclinical and clinical studies and related services;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of acquiring, developing and manufacturing ADC product candidates, clinical study materials and other research and development materials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees and costs related to regulatory filings and activities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with collaboration agreements and license fees and milestone payments related to license agreements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with creating and obtaining approval for the NaPi2b companion or complementary diagnostic biomarker;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities, maintenance of facilities, insurance and other supplies; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other costs associated with clinical, preclinical, discovery and other research activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for certain development activities, such as clinical studies and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued preclinical, manufacturing and clinical expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements which are within the scope of Accounting Standards Update (ASU) No. 2014-9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606), under which the Company licenses rights to its technology and certain of the Company&#8217;s product candidates and performs research and development services for third parties.&#160;The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development costs; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised good or services in the Company&#8217;s arrangement typically consist of license rights to the Company&#8217;s intellectual property and research and development services.&#160;The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#160;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.&#160;Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.&#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.&#160;The consideration may include both fixed consideration and variable consideration.&#160;At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received.&#160;The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method better predicts the amount expected to be received.&#160;If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not included in the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.&#160;The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract.&#160;The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.&#160;Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance&#160;and related revenue recognition.&#160;If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have 30-day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company adopted the provisions of Topic 606, using the modified retrospective transition method. Under this method, the Company recorded the cumulative effect of initially applying the new standard to all contracts in process as of the date of adoption. This standard applied to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The adoption of the new revenue recognition guidance resulted in increases of $2,031 in deferred revenue and accumulated deficit as of January 1, 2018. For the years ended December 31, 2019 and 2018, revenue was not materially impacted as compared to the Company&#8217;s prior revenue recognition methodology under ASC 605 Revenue Recognition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company considers the guidance in ASC Topic 606 in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;820) establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash included in other assets, noncurrent</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term marketable securities consist of investments in debt securities with maturities greater than three months and less than one year from the balance sheet date. The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Amortization and accretion of discounts and premiums are recorded as interest income within other income. Prior to the adoption of ASU 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, unrealized gains and losses on available-for-sale securities were included in other accumulated comprehensive loss as a component of stockholders&#8217; equity until realized. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net, based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis. Fair value is determined based on quoted market prices.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the adoption of ASU 2016-13, the Company is required to determine whether any portion of the unrealized loss for any available-for-sale debt security is due to a credit loss, and if so, to measure the amount of the credit loss. The Company reviews each of its available-for-sale marketable securities for unrealized losses (declines in fair value below its amortized cost basis) at each balance sheet date presented in its financial statements and whenever events or changes in circumstances indicate that the amortized cost basis of an asset may not be recoverable. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded other assets of $2,153 and $1,453 as of December&#160;31, 2020 and 2019, respectively, comprised of $1,832 and $1,132, respectively, held by a service provider, and restricted cash of $321 and $321 at the end of each period held as a security deposit for a standby letter of credit related to a facility lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Stock-based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC 718). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the initial public offering and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption.&#160;The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of each restricted stock unit, or RSU, at its grant date based on the closing market price of the Company&#8217;s common stock on that date. For stock-based compensation subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based compensation on a straight-line basis over the requisite service period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records forfeitures as a cumulative adjustment in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding and 2,575,000 Exchange Warrants (as defined in footnote 9) outstanding during the period, without further consideration for potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, stock options, unvested restricted stock units (RSUs) and warrants to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,720,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,746,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,767&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869,189&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,207,582&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,856,932&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment, office equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or life of lease</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the statement of operations. There were no material sales of assets during the&#160;years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If an impairment review is performed to evaluate an asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the asset to its carrying value. If the carrying amount of the asset exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not recognize impairment charges during the&#160;years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with ASC 842, the Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use lease assets (ROU assets), current portion of lease obligations and long-term lease obligations on the Company&#8217;s consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#8217;s consolidated balance sheets. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheets for leases with an original term of twelve months or less.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&#160;Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides for deferred taxes using an asset and liability approach.&#160;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.&#160;The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160;Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is more likely than not to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) comprises net loss and other comprehensive loss. For the years ended December&#160;31, 2020, 2019 and 2018, other comprehensive income (loss) consisted of changes in unrealized income and loss on marketable securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-balance Sheet Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company has not experienced any credit losses and does not believe this it is subject to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. This guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The guidance per ASU 2018-18 is to be adopted retrospectively to the date of initial application of Topic 606. The Company adopted the new standard effective January 1, 2020. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. Historically, U.S. GAAP delayed recognition of the full amount of credit losses until the loss was probable of occurring. Under this ASU, the income statement will reflect an entity&#8217;s current estimate of all expected credit losses. The measurement of expected credit losses will be based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down of the security. This ASU is effective for annual periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company adopted the new standard effective January 1, 2020 using the modified retrospective method. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as part of its initiative to reduce complexity in the accounting standards. The amendments in ASU 2019-12 eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes. The amendments in ASU 2019-12 are effective for the fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333534712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationAgreementsAbstract', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck KGaA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Company entered into a Collaboration and Commercial License Agreement with Merck KGaA (the Merck KGaA Agreement). Upon the execution of the Merck KGaA Agreement, Merck KGaA paid the Company a nonrefundable technology access fee of $12,000 for the right to develop ADCs directed to six exclusive targets over a specified period of time. No additional fees are due when a target is designated and the commercial license to the target is granted. Merck KGaA will be </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsible for the product development and marketing of any products resulting from this collaboration. All six targets were designated prior to 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merck KGaA Agreement, the Company and Merck KGaA develop research plans to evaluate Merck KGaA's antibodies as ADCs incorporating the Company's technology. The Company receives reimbursement for its efforts under the research plans. The goal of the research plans is to provide Merck KGaA with sufficient information to formally nominate a development candidate and begin IND-enabling studies or cease development on the designated target.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the payments received for research and development activities performed on behalf of Merck KGaA, the Company could be eligible to receive up to a total of $780,000 in future milestones related to all targets under the Merck KGaA Agreement, plus low to mid single digit royalties on the commercial sales of any resulting products during the applicable royalty term. The total milestones are categorized as follows: development milestones $84,000; regulatory milestones $264,000; and sales milestones $432,000. There are six individual development milestones per target, payable upon the completion of various activities from the delivery of ADCs meeting defined specifications, through the dosing in a Phase&#160;3 clinical trial. There are five regulatory milestones, which are payable upon regulatory approvals for a first indication in each of the U.S., European Union and Japanese markets and regulatory approvals for both a second and a third indication in the United States. There are three individual commercial milestones, which are payable upon the attainment of certain defined thresholds for annual net sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2018, the Company had received $3,000 related to development milestones under the Merck KGaA Agreement. There have been no additional milestone payments in the years ended December&#160;31, 2019 or 2020. The next potential milestone payment the Company will be eligible to receive will be a development milestone of $500 on Merck KGaA's designation of a preclinical development candidate for any target. Revenue will be recognized when achievement of the milestone is considered probable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Merck KGaA Agreement will expire upon the expiration of the last royalty term for a product under the Merck KGaA Agreement, after which time, Merck KGaA will have a perpetual, royalty-free license, or if Merck KGaA does not designate any ADC product candidates produced by the Company under the Merck KGaA Agreement as preclinical development candidates, upon the expiration of the last to expire research program. Merck KGaA may terminate the Merck KGaA Agreement in its entirety or with respect to any target for convenience upon 60 days' prior written notice. Each party may terminate the Merck KGaA Agreement in its entirety upon bankruptcy or similar proceedings of the other party or upon an uncured material breach of the Merck KGaA Agreement by the other party. However, if such breach only relates to one target, the agreement may only be terminated with respect to such target.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a Supply Agreement with Merck KGaA (the Merck KGaA Supply Agreement). Under the terms of the Merck KGaA Supply Agreement, the Company will provide Merck KGaA preclinical non-GMP ADC Drug Substance and clinical GMP Drug Substance for use in clinical trials associated with one of the antibodies designated under the Merck KGaA Agreement. The Company receives fees for its efforts under the Merck KGaA Supply Agreement and reimbursement equal to the supply cost. The Company may also enter into future supply agreements to provide clinical supply material should Merck KGaA pursue clinical development of any other candidates nominated under the Merck KGaA Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Analysis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following performance obligations under the Merck KGaA Agreement: (i)&#160;exclusive license and research services for six designated targets, (ii)&#160;rights to future technological improvements and (iii)&#160;participation of project team leaders and providing joint research committee services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded that each license for a designated target is not distinct from the research services performed related to the designated target as Merck KGaA cannot obtain the benefit of the license without the related research services.&#160;Each license for a designated target and the related services performance obligation is considered distinct from every other license for a designated target and related services performance obligation as each research plan is pursued independent of every other research plans for other designated targets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the expected value approach to estimate the amount of consideration related to the payment of fees associated with development and research services.&#160;The Company utilizes the most likely amount approach to estimate any development and regulatory milestone payments to be received.&#160;As of the date of initial application of Topic 606, there were no milestones payments that had not already been received, included in the estimated transaction price.&#160;The Company considered the stage of development and the remaining risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Merck KGaA.&#160;The milestone payment amounts were fully constrained, as a result of the uncertainty whether any of the associated milestones would be achieved.&#160;The Company has determined that any commercial milestones and sales based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation or in the case of certain variable consideration to one or more performance obligations.&#160;The estimated standalone selling prices for performance obligations, that include a license and research services, were developed using the estimated selling price of the license and an estimate of the overall effort to perform the research service and an estimated market rate for research services. The estimated standalone selling price of the licenses was established based on comparable transactions.&#160;The estimated standalone selling price for the rights to future technological improvements was developed based on the estimated selling prices of a license or rights received, as well as considering the probability that additional technology would be made available or the probability the counterpart would utilize the technology. The estimated standalone selling price for the joint research committee services was developed using an estimate of the time and costs incurred to participate in the committees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. As of December&#160;31, 2019, the total transaction price for the Merck KGaA Agreement was $21,500. During 2020, the Company revised its estimate for fees associated with research and development activities under the Merck KGaA Agreement to $6,325, a decrease of $175. The revised total transaction price for the Merck KGaA Agreement is $21,325. The transaction price of $21,325 was allocated to the performance obligations as follows: approximately $3,941 for each of the license and corresponding research and development services units of account for the first and second designated targets; $3,439 for each of the license and corresponding research and development services units of account for the third and sixth designated target; $3,152 for the license and corresponding research and development services unit of account for the fourth designated target; $2,746 for the license and corresponding research and development services unit of account for the fifth designated target; $425 for rights to future technological improvements; and $242 for joint research committee services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is recognizing revenue related to the exclusive license and research and development services performance obligation over the estimated period of the research and development services using a proportional performance model.&#160;The Company measures proportional performance based on the costs incurred relative to the total costs expected to be incurred.&#160;To the extent that the Company receives fees for the research services as they are preformed, these amounts are recorded as deferred revenue. Revenue related to future technological improvements and joint research committee services will be recognized ratably over the performance period (which in the case of the joint research committee services approximate the time and cost incurred each period), which are 10 and 5 years, respectively.&#160;The Company is continuing to reassess the estimated remaining term at each subsequent reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company has completed its research service obligations associated with four of the six designated targets. During the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded collaboration revenue of $828, $853 and $2,444, respectively, related to its efforts under the Merck KGaA Agreement. During the year ended December&#160;31, 2019, the Company recognized collaboration revenue and corresponding research and development expense of $1,280 related to the Merck KGaA Supply Agreement. There were no amounts recognized during the years ended December&#160;31, 2020 and 2018 related to the Merck KGaA Supply Agreement.&#160;There was no balance in accounts receivable related to the Merck KGaA Agreement and Merck KGaA Supply Agreement as of either December&#160;31, 2020 or December&#160;31, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company had recorded $3,987 and $4,815, respectively, in deferred revenue related to the Merck KGaA Agreement and Merck KGaA Supply Agreement that will be recognized over the remaining performance period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda XMT-1522 Strategic Partnership</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the Company entered into a Development Collaboration and Commercial License Agreement with Takeda&#8217;s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. for the development and commercialization of XMT-1522 (the XMT-1522 Agreement). Under the XMT-1522 Agreement, Takeda was granted the exclusive right to commercialize XMT-1522 outside of the United States and Canada. Under the XMT-1522 Agreement, the Company was responsible for conducting certain Phase 1 development activities for XMT-1522, including the ongoing Phase 1 clinical trial, at its own expense. The parties agreed to collaborate on the further development of XMT-1522 in accordance with a global development plan (Post-Phase 1 Development). On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the XMT-1522 Agreement upon 30 days&#8217; prior written notice. The XMT-1522 Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the XMT-1522 Agreement as of March 31, 2019. Under the XMT-1522 Agreement, the Company and Takeda shared equally all agreed Post-Phase 1 Development costs through the date of termination and for a period of 30 days after the effective termination date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Strategic Research and Development Partnership</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Company entered into a Research Collaboration and Commercial License Agreement with Takeda&#8217;s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (the 2014 Agreement). The 2014 Agreement was amended in January 2015 and amended and restated in January 2016 (the 2016 Restated Agreement). The agreements provided Takeda with the right to develop ADCs directed to a total of seven exclusive targets, designated by Takeda, over a specified period of time. On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the 2016 Restated Agreement upon 45 days&#8217; prior written notice. The 2016 Restated Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the 2016 Restated Agreement as of March 31, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Analysis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaboration agreements with Takeda were terminated following receipt of written notices during the first quarter of 2019. As there are no further performance obligation, the Company recognized the remaining deferred revenue of $39,965 related to the termination of the Takeda agreements in the first quarter of 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the termination of the agreements, the Company had identified 14 performance obligations in the agreements. The Company concluded that the license related to each of the designated targets was not distinct from the research services performed related to each of the designated targets as Takeda could not have obtain the benefit of the license without the related research services. Each license to a designated target and the related service performance obligation was considered distinct from every other license to a designated target and related services performance obligation as each research plan was pursued independent of the any other research plans for other designated targets. Further, the material rights provided were determined to be distinct from the other performance obligations in the arrangement as they were options in the contract Takeda agreements and not required for Takeda to obtain the benefit of the other promised goods or services in the arrangement. Similarly, the Company concluded that the XMT-1522 license and the related research and development services, including the Phase 1 development and the transfer of certain materials and know-how related to the Company's manufacturing processes, were one performance obligation. The license to the Company's intellectual property was not determined to be distinct from the research and related development services that the Company was obligated to perform. For the years ended December&#160;31, 2019 and 2018, the Company recorded total revenue of $39,965 and $5,868, respectively, related to its efforts under the 2016 Restated Agreement and the XMT-1522 Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the Post-Phase 1 Development activities under the XMT-1522 Agreement represented joint operating activities in which both parties were active participants and of which both parties were exposed to significant risks and rewards that are dependent on the commercial success of the activities. Accordingly, the Company accounted for the Post-Phase 1 Development activities in accordance with ASC 808. For the years ended December&#160;31, 2019 and 2018, the Company was billed approximately $200 and $8,046, respectively, from Takeda representing Post-Phase 1 Development costs incurred by Takeda. These amounts have been reflected as research and development costs in the consolidated statement of operations. The Company did not perform any Post-Phase 1 Development activities or incur any associated costs prior to January 1, 2018. During the years ended December&#160;31, 2019 and 2018, the Company billed Takeda $195 and $3,746, respectively, related to ASC 808 costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contract Assets and Liabilities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our contract assets and liabilities during the years ended December&#160;31, 2020 and December&#160;31, 2019:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,591&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue recognized in the period from:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in the contract liability at the beginning of the period</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,591&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided limited services for a collaboration partner, Asana BioSciences. For the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded revenue of $0, $25 and $782, respectively, related to these services. In addition, during the year ended December&#160;31, 2018, the Company recognized revenue of $1,500 related to a milestone achieved upon the completion of a GLP toxicology study by Asana BioSciences. The next potential milestone the Company is eligible to receive is $2,500 upon dosing the fifth patient in a Phase 1 clinical study by Asana BioSciences. As of December&#160;31, 2020, the Company considered this next milestone to be fully constrained as there is considerable judgment involved in determining whether it is probable that a significant revenue reversal would occur. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestone is outside the control of the Company and there is a high level of uncertainty in achieving this milestone, as this would require initiation of clinical trials by the collaboration partner. The Company reevaluates the probability of achievement of a milestone subject to constraint at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331359288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents information about the Company's assets and liabilities regularly measured and carried at a fair value and indicates the level within fair value hierarchy of the valuation techniques utilized to determine such value as of December&#160;31, 2019. The Company had no marketable securities as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in&#160;Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,439&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,950&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in valuation techniques or transfers between fair value measurement levels during the&#160;years ended December&#160;31, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the consolidated balance sheets for prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the carrying value of the Company&#8217;s outstanding borrowing under the Credit Facility (as defined below) approximated fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. The Credit Facility is discussed more detail in Note 8, &#8220;Debt&#8221;.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331594392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes marketable securities held at December&#160;31, 2019. The Company had no marketable securities as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331618696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following as of December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,365&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company recorded assets under finance leases of $429 as laboratory equipment during the year ended December&#160;31, 2019. Financing leases are discussed in more detail in Note 11 &#8220;Leases&#8221;. Depreciation expense for the&#160;years ended December&#160;31, 2020, 2019 and 2018 was $1,010, $1,245 and $1,257, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331550968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following as of December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical, manufacturing and clinical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331317912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2019, the Company entered into a loan and security agreement (the Original Agreement) with Silicon Valley Bank (SVB) pursuant to which the Company borrowed $5,000. The Original Agreement accrued interest at a floating per annum rate equal to the greater of (i) 4.0% and (ii) 1.50% below the Prime Rate. The Original Agreement had an interest-only period through August 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2020 (the Effective Date), the Company entered into a second amendment (the Amendment) to its existing loan and security agreement (as amended prior to the Amendment, the Existing Credit Facility) with SVB. Pursuant to the Amendment, the Company can borrow term loans in an aggregate amount of $30,000 (the Amended Credit Facility), at its option, (i) up to $25,000 in up to five principal advances through April 30, 2022, and (ii) an additional $5,000 in one principal advance, if the Company reaches certain development milestone events, as described in the Amendment, through April 30, 2022. The Company drew $5,200 upon execution of the Amendment, the proceeds of which were used to repay the Company&#8217;s existing balance and satisfy its obligations to SVB, including the final payment obligation under the Existing Credit Facility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Facility bears interest at a floating per annum rate equal to the greater of (i) 4.25% and (ii) 1.00% above the Prime Rate, as defined. The Company is obligated to make monthly interest-only payments on each outstanding term loan commencing on the first calendar day of the month following the funding date of such term loan, and continuing on the first calendar day of each month thereafter through May 31, 2022. The interest only period may be extended through January 31, 2023 upon the achievement of a regulatory milestone, as described in the Amendment. Following the interest-only period, the Company will be required to repay the outstanding principal balance under the term loans in equal monthly payments plus interest in arrears to SVB through November 1, 2024 (the Maturity Date).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to make a final payment to SVB equal to 5.5% of the principal amount of the Term Loans then extended to the Company. This final payment is accreted under the effective interest method over the life of each term loan. The term loans are secured by substantially all of the Company&#8217;s assets, except for its intellectual property which is subject to a negative pledge, and certain other customary exclusions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Company&#8217;s option, it may prepay the outstanding principal balance of any term loans in whole but not in part, subject to a prepayment fee of: (a) 3.0% of the term loans then extended to the Company if the prepayment occurs on or prior to August 28, 2021, (b) 2.0% of the term loans then extended to the Company if the prepayment occurs after August 28, 2021 but on or prior to August 28, 2022, or (c) 1.0% of the term loans then extended to the Company if the prepayment occurs after August 28, 2022 but before November 1, 2024. The Amended Credit Facility includes customary affirmative and restrictive covenants applicable to the Company. Affirmative covenants include, among others, covenants requiring the Company to maintain its corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The Amendment removed the requirement for the Company to maintain a minimum liquidity ratio. The restrictive covenants include, among others, requirements relating to the Company&#8217;s ability to </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets and agree to a change in control, in each case subject to certain customary exceptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s payment obligations under the Amended Credit Facility are subject to acceleration upon the occurrence of specified events of default, which include, but are not limited to, the occurrence of a material adverse change in the Company&#8217;s business, operations, or financial or other condition. Amounts outstanding upon the occurrence of an event of default are payable upon SVB&#8217;s demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount outstanding. As of December&#160;31, 2020, the Company was in compliance with all covenants under the Credit Facility. As such, as of December&#160;31, 2020, the classification of the loan balance as stated on the balance sheet was based on the timing of defined future payment obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unamortized issuance costs under the Existing Credit Facility were $139 as of the date of the Amendment. The Company incurred debt issuance costs paid to the lender in connection with the Amended Credit Facility of $17. The Company recorded such costs, including the settlement of the final payment obligation under the Existing Credit Facility as a discount from the carrying value of the term loans which are amortized as interest expense using the effective-interest method over the term of the Amended Credit Facility.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $5,200 outstanding under the Amended Credit Facility and the debt consisted of the following:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term-debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt financing costs, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion related to final payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the estimated future principal payments due are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,907&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020 and 2019, the Company recognized $340 and $214, respectively, of interest expense related to the Existing Credit Facility and Amended Credit Facility, as applicable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333386328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company has 25,000,000 shares of authorized preferred stock. No shares of preferred stock have been issued.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At-the-market equity offering program</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company established an at-the-market (ATM) equity offering program (the 2018 ATM) pursuant to which it could offer and sell up to $75,000 of its common stock from time to time at prevailing market prices. In April 2020, the Company sold 8,938,599 and 1,962,000 shares of common stock at $5.59 per share and $7.74 per share, respectively, to raise </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aggregate gross proceeds of $65,153 through the 2018 ATM facility. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering were approximately $62,976.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company terminated the 2018 ATM and established a new ATM equity offering program (the 2020 ATM) pursuant to which it is able to sell up to $100,000 of its common stock from time to time at prevailing market prices. As of December&#160;31, 2020, the Company had not sold any shares under the 2020 ATM.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Follow-on offering</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company sold 9,200,000 shares of common stock, in an underwritten public offering price to the public of $19.00 per share. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering were $163,990.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a 2013 Series&#160;A-1 Preferred Stock issuance, the Company granted to certain investors warrants to purchase 129,491 shares of common stock. The warrants have a $0.05 per share exercise price and a contractual life of 10 years. The fair value of these warrants was recorded as a component of equity at the time of issuance. As of December&#160;31, 2020 and 2019 there were warrants to purchase 39,474 shares of common stock. During the year ended December&#160;31, 2020, there were no exercises of warrants in exchange for shares of common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange warrants</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 26, 2019, the Company entered into an exchange agreement with entities affiliated with Biotechnology Value Fund, L.P. (the Exchanging Stockholders), pursuant to which the Exchanging Stockholders exchanged an aggregate of 2,575,000 shares of common stock for warrants (the Exchange Warrants) to purchase an aggregate of 2,575,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, merger or consolidation, change of control, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.0001 per share.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification Topic 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. While outstanding, the Exchange Warrants were classified as equity in accordance with Accounting Standards Codification Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. On March 2, 2020, the Exchanging Stockholders exercised the Exchange Warrants in full on a net cashless exercise basis, resulting in the issuance of 2,574,971 shares of common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors (the Board).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019 there were 6,869,189 and 7,782,582, respectively, shares of common stock reserved for the exercise of outstanding stock options and warrants.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,720,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,782,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438329933304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Options</a></td>
<td class="text">Stock Options<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2017, there were 3,141,625 options outstanding under the Company&#8217;s 2007 Stock Incentive Plan.&#160;The 2007 Plan expired in June 2017. Any cancellations under the 2007 Stock Incentive Plan will increase the options available under the 2017 Stock Incentive Plan as described below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017 the Company&#8217;s shareholders approved the 2017 Stock Incentive Plan (the 2017 Plan or the Plan).&#160;Under the 2017 Plan initially, up to 2,255,000 shares of common stock may be granted to the Company's employees, officers, directors, consultants and advisors in the form of options, restricted stock units (RSUs) or other stock-based awards. The number of shares of common stock issuable under the Plan will be cumulatively increased annually by 4% of the outstanding shares or such lesser amount specified by the Board. The terms of the awards are determined by the Board, subject to the provisions of the Plan. As of December&#160;31, 2020 there were 1,288,072 shares available for future issuance under the Plan, including 1,815,520 shares automatically added to the Plan on January 1, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement awards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted its senior vice president of regulatory affairs an option to purchase up to 120,000 and its senior vice president and chief medical officer an option to purchase 200,000 shares of common stock on September 2, 2020 and November 30, 2020, respectively, as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). No underwriters were involved in this issuance of securities. The securities were issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, relating to transactions by an issuer not involving any public offering. These options are subject to terms substantially the same as the 2017 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to incentive stock options, the exercise price per share will equal the fair market value of the common stock on the date of grant, as determined by the Board, and the vesting period is generally four years. Nonqualified stock options will be granted at an exercise price established by the Board at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Options granted under the Plan expire no later than 10 years from the date of grant. The Board may accelerate vesting or extend the expiration of granted options in the case of a merger, consolidation, dissolution, or liquidation of the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option activity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity under the Plan is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,720,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,359,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(697,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,147,379&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2020, 2019 and 2018, was $7.99, $2.47 and $8.78 per share, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from the exercise of stock options was $3,138, $175 and $918 for the&#160;years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2019, the Company issued RSUs with service conditions to employees. The awards cliff-vest two years after the grant date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the Company issued 324,932 RSUs with a service condition to employees for which the vesting term is annually over four years.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Vesting of these awards is contingent on the fulfillment of the service conditions during the vesting term.</span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of the RSU activity under the 2017 Plan is as follow:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,932&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,501)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,767&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the provisions of ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to account for all stock-based awards to employees and non-employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement date for employee awards is generally the date of grant. Stock-based compensation expense is recognized over the requisite service period, which is generally the vesting period, using the straight-line method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense by award type included within the Company&#8217;s consolidated statement of operations and comprehensive loss:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in Total operating expenses</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,172&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,872&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,884&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense as reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in Total operating expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,884&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $19,487 and $2,699 of unrecognized compensation expense related to unvested stock options and unvested RSUs, respectively, that is expected to be recognized over a weighted average period of 2.8 years and 2.3 years, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black&#8211;Scholes option pricing model with the following weighted average assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility for the Company&#8217;s common stock is determined based on the historical volatility of comparable publicly traded companies. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected term of the option. No dividend yield was assumed as the Company has not historically and does not expect to pay dividends on its common stock. The expected term of the options granted is based on the use of the simplified method, in which the expected term is presumed to be the mid-point between the vesting date and the end of the contractual term.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs is determined based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2017, the Board adopted and the Company's stockholders approved the 2017 employee stock purchase plan (the 2017 ESPP). The Company initially reserved 225,000 shares of common stock for issuance under the 2017 ESPP. During the years ended December&#160;31, 2020 and 2019 the Company issued 80,267 and 140,073 shares, respectively, under the 2017 ESPP. As of December&#160;31, 2020, there were 644,818 shares available for issuance, including 450,000 shares automatically added to the 2017 ESPP on January 1, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438330299112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for its office space in Cambridge, MA and operating and finance leases for certain equipment. In March 2020, the Company entered into the Seventh Amendment to the office space lease to extend the term of the lease through March 2026 and to provide the Company with a tenant improvement allowance of $172. The current rate per square foot that is in place through March 2021 (the original expiration date of the lease) did not change. After March 2021, there are predetermined fixed escalations of the rate as outlined in the amendment. The Company has an option to extend the lease term for an additional five years. The Company&#8217;s exercise of this option was not considered reasonably certain as of December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extension is accounted for as a lease modification. The Company assessed the lease classification of the amended office space lease at the modification date and determined that the amended office space lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been remeasured based on the present value of remaining lease payments over the remaining extended lease term, using the incremental borrowing rate applicable as of the lease modification date. The Company determined the appropriate incremental borrowing rate by using a synthetic credit rating which was estimated based on an analysis of outstanding debt of companies with similar credit and financial profiles. Since the operating lease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred, such non-lease components were not included in the right-of-use asset and liability and are reflected as an expense in the period incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the modification in March 2020, the Company recorded an increase of $9,980 to its right-of-use (ROU) asset and lease liabilities in the first quarter of 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the office lease, the Company had a letter of credit agreement for the benefit of its landlord in the amount of $321 as of each December&#160;31, 2020 and 2019, collateralized by a money market account.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2019, the Company entered into finance leases for certain equipment. The Company recorded assets under finance leases of $429 as property and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMC0xLTEtMTkwMQ_def9574d-e21a-4369-9aec-5ccd94c4b5a5">Other liabilities, current</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTAtMS0xLTE5MDM_e1131034-fc7f-40a3-8087-977f8547a400">Other liabilities</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 years</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense was $2,644, $2,160 and $1,994 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2020 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,447&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for its office space in Cambridge, MA and operating and finance leases for certain equipment. In March 2020, the Company entered into the Seventh Amendment to the office space lease to extend the term of the lease through March 2026 and to provide the Company with a tenant improvement allowance of $172. The current rate per square foot that is in place through March 2021 (the original expiration date of the lease) did not change. After March 2021, there are predetermined fixed escalations of the rate as outlined in the amendment. The Company has an option to extend the lease term for an additional five years. The Company&#8217;s exercise of this option was not considered reasonably certain as of December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extension is accounted for as a lease modification. The Company assessed the lease classification of the amended office space lease at the modification date and determined that the amended office space lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been remeasured based on the present value of remaining lease payments over the remaining extended lease term, using the incremental borrowing rate applicable as of the lease modification date. The Company determined the appropriate incremental borrowing rate by using a synthetic credit rating which was estimated based on an analysis of outstanding debt of companies with similar credit and financial profiles. Since the operating lease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred, such non-lease components were not included in the right-of-use asset and liability and are reflected as an expense in the period incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the modification in March 2020, the Company recorded an increase of $9,980 to its right-of-use (ROU) asset and lease liabilities in the first quarter of 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the office lease, the Company had a letter of credit agreement for the benefit of its landlord in the amount of $321 as of each December&#160;31, 2020 and 2019, collateralized by a money market account.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2019, the Company entered into finance leases for certain equipment. The Company recorded assets under finance leases of $429 as property and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMC0xLTEtMTkwMQ_def9574d-e21a-4369-9aec-5ccd94c4b5a5">Other liabilities, current</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTAtMS0xLTE5MDM_e1131034-fc7f-40a3-8087-977f8547a400">Other liabilities</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 years</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense was $2,644, $2,160 and $1,994 for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2020 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,447&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438330153208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded no income tax benefit for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations as of December&#160;31, 2020, 2019 and 2018 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax computed at federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of ownership shift</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2020 and 2019 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,599&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,375)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,889)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,986)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net operating losses (NOL) since inception. At December&#160;31, 2020, the Company had Federal and State net operating loss carryforwards of approximately $250,367 and $184,781, respectively. Of the $250,367 of Federal net operating loss carryforwards, $34,149 expire at various dates through 2037. The remaining $216,218 of Federal net operating loss carryforwards do not expire. The State net operating loss carryforwards expire at various dates through 2040. At December&#160;31, 2020, the Company had Federal and State research and development tax credit carryforwards of approximately $4,582 and $1,482, respectively, which expire at various dates through 2040.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC 740, management of the Company has evaluated the evidence bearing upon the reliability of its deferred tax assets. Based on the weight of available evidence, both positive and negative, management has determined that it is more likely than not that the Company will not realize the benefits of all of these assets. Accordingly, the Company recorded a valuation allowance of $77,375 and $48,889 at December&#160;31, 2020 and December&#160;31, 2019, respectively. The valuation allowance increased by $28,468 and decreased by $5,051 during the years ended December&#160;31, 2020 and 2019, respectively, primarily as a result of the Company&#8217;s 382 limitation and net operating losses generated during the periods, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the NOLs and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&#160;382 due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section&#160;382, as well as similar state provisions. These ownership changes may limit the amount of NOLs and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. If a change in control as defined by Section&#160;382 has occurred at any time since the Company&#8217;s formation, utilization of its NOLs or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could then be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOLs or research and development tax carryforwards before their utilization. The Company has determined that ownership changes have occurred through November 4, 2019 and that certain NOLs and research and development tax credit carryforwards will be subject to limitation. The amounts presented do not include NOLs or research and development tax credit carryforwards that will expire unused due to ownership changes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the accounting guidance in ASC 740 related to accounting for uncertainty in income taxes. The Company&#8217;s reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. As of December&#160;31, 2020 and 2019, the Company had no unrecognized tax benefits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to uncertain tax positions would be classified as income tax expense in the accompanying statements of operations. As of December&#160;31, 2020 and 2019, the Company had no accrued interest or penalties related to uncertain tax positions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States federal tax jurisdiction and two state jurisdiction. The Company did not have any foreign operations during the&#160;years ended December&#160;31, 2020, 2019 and 2018. The statute of limitations for assessment by the Internal Revenue Service and state tax authorities is closed for tax&#160;years prior to 2016, although carryforward attributes that were generated prior to tax&#160;year 2015 may still be adjusted upon examination to the extent utilized in a future period. There are no federal or state audits currently in progress.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333975720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit PlanThe Company has a defined contribution plan established under Section&#160;401(k)&#160;of the Internal Revenue Code (401(k)&#160;Plan), which covers substantially all employees. Employees who have attained the age of 21 are eligible to participate in the 401(k)&#160;Plan with no service requirement. Employees may contribute up to 75% of eligible pay on a pre&#8211;tax basis up to the federal annual limits. For the year ended December&#160;31, 2018 and the period from January 1, 2019 to July 31, 2019, the Company matched the employees&#8217; contributions at 50% on the first 6% up to $6. For the period from August 1, 2019 to December&#160;31, 2019 and for the year ended December&#160;31, 2020, the Company matched the employees&#8217; contributions at 100% on the first 4% up to $7. For the&#160;years ended December&#160;31, 2020, 2019 and 2018, the Company recorded expense of $486, $404 and $332, respectively, related to its contribution to its 401(k)&#160;Plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438330244664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text">Commitments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2020, 2019 and 2018, the Company recorded research and development expense related to non-refundable upfront payments of $250, $750, and $0, respectively. Further milestone payments of $750, $600 and $0, respectively, were also recorded as research and development expense during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 11 for the Company&#8217;s future obligations related to leases as of December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438329946904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data (Unaudited)</a></td>
<td class="text">Selected Quarterly Financial Data (unaudited)The following table contains selected quarterly financial information for 2020 and 2019. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.<div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,926)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,786)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,489)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,844)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share&#160;attributable to common stockholders &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.33)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.33)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in net loss per share attributable to common stockholders &#8212; basic and diluted</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,988,630&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,748,225&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,419,192&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,630,078&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,443&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,901&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,071)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,792)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,246)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share&#160;attributable to common stockholders &#8212; basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share&#160;attributable to common stockholders &#8212; diluted</span></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in net income (loss) per share attributable to common stockholders &#8212; basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,299,650&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,708,085&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,833,607&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,886,144&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in net income (loss) per share attributable to common stockholders &#8212; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,461,696&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,708,085&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,833,607&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,886,144&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438332540008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include those of the Company and its wholly owned subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company's management evaluates its estimates which include, but are not limited to, management's judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess performance. The Company views its operations and manages its business as a single operating segment, which is the business of discovering and developing ADCs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, bonuses, benefits, travel and stock-based compensation expense;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of preclinical and clinical studies and related services;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of acquiring, developing and manufacturing ADC product candidates, clinical study materials and other research and development materials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees and costs related to regulatory filings and activities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with collaboration agreements and license fees and milestone payments related to license agreements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with creating and obtaining approval for the NaPi2b companion or complementary diagnostic biomarker;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities, maintenance of facilities, insurance and other supplies; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other costs associated with clinical, preclinical, discovery and other research activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for certain development activities, such as clinical studies and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued preclinical, manufacturing and clinical expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements which are within the scope of Accounting Standards Update (ASU) No. 2014-9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606), under which the Company licenses rights to its technology and certain of the Company&#8217;s product candidates and performs research and development services for third parties.&#160;The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development costs; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised good or services in the Company&#8217;s arrangement typically consist of license rights to the Company&#8217;s intellectual property and research and development services.&#160;The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#160;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.&#160;Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.&#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.&#160;The consideration may include both fixed consideration and variable consideration.&#160;At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received.&#160;The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method better predicts the amount expected to be received.&#160;If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not included in the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.&#160;The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract.&#160;The Company utilizes key assumptions to determine the stand-alone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.&#160;Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance&#160;and related revenue recognition.&#160;If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have 30-day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2018, the Company adopted the provisions of Topic 606, using the modified retrospective transition method. Under this method, the Company recorded the cumulative effect of initially applying the new standard to all contracts in process as of the date of adoption. This standard applied to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The adoption of the new revenue recognition guidance resulted in increases of $2,031 in deferred revenue and accumulated deficit as of January 1, 2018. For the years ended December 31, 2019 and 2018, revenue was not materially impacted as compared to the Company&#8217;s prior revenue recognition methodology under ASC 605 Revenue Recognition.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company considers the guidance in ASC Topic 606 in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;820) establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></div>Level&#160;3&#8212;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term marketable securities consist of investments in debt securities with maturities greater than three months and less than one year from the balance sheet date. The Company classifies all of its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value. Amortization and accretion of discounts and premiums are recorded as interest income within other income. Prior to the adoption of ASU 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, unrealized gains and losses on available-for-sale securities were included in other accumulated comprehensive loss as a component of stockholders&#8217; equity until realized. Realized gains and losses and declines in value judged to be other than temporary are included as a component of other income (expense), net, based on the specific identification method. When determining whether a decline in value is other than temporary, the Company considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis. Fair value is determined based on quoted market prices.</span></div>In accordance with the adoption of ASU 2016-13, the Company is required to determine whether any portion of the unrealized loss for any available-for-sale debt security is due to a credit loss, and if so, to measure the amount of the credit loss. The Company reviews each of its available-for-sale marketable securities for unrealized losses (declines in fair value below its amortized cost basis) at each balance sheet date presented in its financial statements and whenever events or changes in circumstances indicate that the amortized cost basis of an asset may not be recoverable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Other Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded other assets of $2,153 and $1,453 as of December&#160;31, 2020 and 2019, respectively, comprised of $1,832 and $1,132, respectively, held by a service provider, and restricted cash of $321 and $321 at the end of each period held as a security deposit for a standby letter of credit related to a facility lease.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for Stock-based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Stock-based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC 718). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the initial public offering and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption.&#160;The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of each restricted stock unit, or RSU, at its grant date based on the closing market price of the Company&#8217;s common stock on that date. For stock-based compensation subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based compensation on a straight-line basis over the requisite service period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records forfeitures as a cumulative adjustment in the period in which they occur.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding and 2,575,000 Exchange Warrants (as defined in footnote 9) outstanding during the period, without further consideration for potentially dilutive securities. In accordance with Accounting Standards Codification Topic 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the diluted net loss per share calculation, stock options, unvested restricted stock units (RSUs) and warrants to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment, office equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or life of lease</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the statement of operations. There were no material sales of assets during the&#160;years ended December&#160;31, 2020, 2019 and 2018.</span></div>The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If an impairment review is performed to evaluate an asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the asset to its carrying value. If the carrying amount of the asset exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not recognize impairment charges during the&#160;years ended December&#160;31, 2020, 2019 and 2018.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with ASC 842, the Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use lease assets (ROU assets), current portion of lease obligations and long-term lease obligations on the Company&#8217;s consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#8217;s consolidated balance sheets. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheets for leases with an original term of twelve months or less.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&#160;Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides for deferred taxes using an asset and liability approach.&#160;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.&#160;The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160;Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is more likely than not to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) comprises net loss and other comprehensive loss. For the years ended December&#160;31, 2020, 2019 and 2018, other comprehensive income (loss) consisted of changes in unrealized income and loss on marketable securities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Off-balance Sheet Risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-balance Sheet Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company has not experienced any credit losses and does not believe this it is subject to any significant concentrations of credit risk from these financial instruments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The main provisions of ASU 2018-18 include: (i) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and (ii) precluding the presentation of transactions with collaborative arrangement participants that are not directly related to sales to third parties together with revenue. This guidance is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The guidance per ASU 2018-18 is to be adopted retrospectively to the date of initial application of Topic 606. The Company adopted the new standard effective January 1, 2020. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. Historically, U.S. GAAP delayed recognition of the full amount of credit losses until the loss was probable of occurring. Under this ASU, the income statement will reflect an entity&#8217;s current estimate of all expected credit losses. The measurement of expected credit losses will be based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down of the security. This ASU is effective for annual periods beginning after December 15, 2019, including interim periods within those annual reporting periods, and early adoption is permitted. The Company adopted the new standard effective January 1, 2020 using the modified retrospective method. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as part of its initiative to reduce complexity in the accounting standards. The amendments in ASU 2019-12 eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes. The amendments in ASU 2019-12 are effective for the fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the potential impact ASU 2019-12 may have on its financial position and results of operations upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333008936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash and cash equivalents</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash included in other assets, noncurrent</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of restricted cash</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash included in other assets, noncurrent</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,720,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,746,567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,767&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869,189&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,207,582&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,856,932&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of estimated useful life of property and equipment</a></td>
<td class="text">Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment, office equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or life of lease</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438330244664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationAgreementsAbstract', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of changes in the balances of our contract assets and liabilities and recognized revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our contract assets and liabilities during the years ended December&#160;31, 2020 and December&#160;31, 2019:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,591&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue recognized in the period from:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in the contract liability at the beginning of the period</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,591&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438329946904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured and carried at fair value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents information about the Company's assets and liabilities regularly measured and carried at a fair value and indicates the level within fair value hierarchy of the valuation techniques utilized to determine such value as of December&#160;31, 2019. The Company had no marketable securities as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in&#160;Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,010&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,439&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,950&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438330203192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of reconciliation of marketable securities from cost basis to fair value</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes marketable securities held at December&#160;31, 2019. The Company had no marketable securities as of December&#160;31, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gains</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438330228040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following as of December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,365&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331981576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following as of December&#160;31, 2020 and 2019:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical, manufacturing and clinical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438330238920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of debt</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $5,200 outstanding under the Amended Credit Facility and the debt consisted of the following:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term-debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt financing costs, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion related to final payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of estimated future payments</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the estimated future principal payments due are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,907&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438330251544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule for number of common stock reserved for exercise of outstanding stock options and warrants</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,720,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,782,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334457944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity under the Plan is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,720,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,359,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(697,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,147,379&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock unit activity</a></td>
<td class="text"><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of the RSU activity under the 2017 Plan is as follow:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,932&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,501)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,767&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expense by award type</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense by award type included within the Company&#8217;s consolidated statement of operations and comprehensive loss:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in Total operating expenses</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,172&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,872&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,884&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense as reflected in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense as reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in Total operating expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,884&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for estimating fair value of option awards</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black&#8211;Scholes option pricing model with the following weighted average assumptions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333493288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock', window );">Schedule of supplemental balance sheet information related to leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzktMC0xLTEtMTkwMQ_def9574d-e21a-4369-9aec-5ccd94c4b5a5">Other liabilities, current</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjcxNTdjNWVhY2ZlOTQxZGU5NTA1ZmVlZWU5MjA3OTFlL3NlYzo3MTU3YzVlYWNmZTk0MWRlOTUwNWZlZWVlOTIwNzkxZV8xNDUvZnJhZzpkYmIyYjYxNjcxODg0YTRmYmZmOTlhMWM3ZWRkYzE0NS90YWJsZTpkNjg0Y2E4OTA3Zjk0ZDAwODJlNzAzMmYwNDBlYWJhMS90YWJsZXJhbmdlOmQ2ODRjYTg5MDdmOTRkMDA4MmU3MDMyZjA0MGVhYmExXzEwLTAtMS0xLTE5MDM_e1131034-fc7f-40a3-8087-977f8547a400">Other liabilities</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 years</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock', window );">Schedule of supplemental cash flow information related to leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under operating leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2020 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,447&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments on finance leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2020 were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,447&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,593&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental cash flows information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331576120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax rates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations as of December&#160;31, 2020, 2019 and 2018 are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax computed at federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of ownership shift</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of net deferred tax assets</a></td>
<td class="text">Significant components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2020 and 2019 are as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,599&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,375)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,889)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,986)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(710)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331571112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Selected quarterly financial data (unaudited)</a></td>
<td class="text">The following table contains selected quarterly financial information for 2020 and 2019. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.<div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,881&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,926)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,786)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,489)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,844)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share&#160;attributable to common stockholders &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.33)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.33)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in net loss per share attributable to common stockholders &#8212; basic and diluted</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,988,630&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,748,225&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,419,192&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,630,078&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,701&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,443&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,901&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,071)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,792)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,246)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share&#160;attributable to common stockholders &#8212; basic</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share&#160;attributable to common stockholders &#8212; diluted</span></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in net income (loss) per share attributable to common stockholders &#8212; basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,299,650&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,708,085&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,833,607&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,886,144&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in net income (loss) per share attributable to common stockholders &#8212; diluted</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,461,696&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,708,085&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,833,607&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,886,144&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334894024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,844<span></span>
</td>
<td class="nump">$ 22,489<span></span>
</td>
<td class="nump">$ 19,786<span></span>
</td>
<td class="nump">$ 16,926<span></span>
</td>
<td class="nump">$ 16,246<span></span>
</td>
<td class="nump">$ 16,792<span></span>
</td>
<td class="nump">$ 17,071<span></span>
</td>
<td class="num">$ (21,901)<span></span>
</td>
<td class="nump">$ 88,045<span></span>
</td>
<td class="nump">$ 28,208<span></span>
</td>
<td class="nump">$ 64,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,419<span></span>
</td>
<td class="nump">$ 192,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember', window );">At market equity offering program (2018 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts', window );">Proceeds from stock issuance, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold (in shares)</a></td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts', window );">Proceeds from stock issuance, net of issuance costs</a></td>
<td class="nump">$ 163,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net proceeds from the additional capital contribution to the entity after deducting fees, commissions and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438409453448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Revenue Recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueCollectionPeriod', window );">Billing term</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 3,987<span></span>
</td>
<td class="nump">$ 4,815<span></span>
</td>
<td class="nump">$ 46,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 280,419<span></span>
</td>
<td class="nump">$ 192,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative effect adjustment for adoption of ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,031<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_RevenueCollectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which entity receives payment upon billing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_RevenueCollectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438330032712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 255,094<span></span>
</td>
<td class="nump">$ 62,351<span></span>
</td>
<td class="nump">$ 59,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in other assets, noncurrent</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash per statement of cash flows</a></td>
<td class="nump">$ 255,415<span></span>
</td>
<td class="nump">$ 62,672<span></span>
</td>
<td class="nump">$ 60,005<span></span>
</td>
<td class="nump">$ 26,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334593592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 2,153<span></span>
</td>
<td class="nump">$ 1,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainageDeposit', window );">Held by service provider</a></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Letter of credit for security deposit</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainageDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets, typically cash, provided to suppliers of goods in advance of receipt and acceptance, or services (such as research facilities, lawyers or consultants), which is held by such parties until the entity either effects full payment (including applying the retainer) or obtains release from liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainageDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331398024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Stock Based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334381688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Net loss per share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">39,474<span></span>
</td>
<td class="nump">39,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">6,869,189<span></span>
</td>
<td class="nump">5,207,582<span></span>
</td>
<td class="nump">3,856,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">6,112,948<span></span>
</td>
<td class="nump">4,720,772<span></span>
</td>
<td class="nump">3,746,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">716,767<span></span>
</td>
<td class="nump">447,336<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">39,474<span></span>
</td>
<td class="nump">39,474<span></span>
</td>
<td class="nump">110,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember', window );">Exchange warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">2,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334654184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember', window );">Computer equipment, office equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements, estimated useful lives</a></td>
<td class="text">Shorter of useful life or life of lease<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331413480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Risks (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Concentration of Credit Risk and Off-balance Sheet Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure', window );">Financial instruments with off-balance sheet risk</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334671224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Recently Issued Accounting Pronouncement (Details)<br></strong></div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member', window );">Accounting Standards Update 2018-18</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member', window );">Accounting Standards Update 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438409863768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Merck KGaA (Detail) - Merck KGaA<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>target</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>target</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborativeArrangementsUpfrontPayment', window );">Upfront payment received</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense', window );">Amount of additional fees receivable when target is designated and commercial license to target is granted</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborativeArrangementsExclusiveTargetsNumber', window );">Number of targets | target</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsTargetsDesignatedNumber', window );">Number of targets designated | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsMaximumAggregateMilestones', window );">Aggregate milestones</a></td>
<td class="nump">$ 780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsDevelopmentMilestones', window );">Development milestones</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsRegulatoryMilestones', window );">Regulatory milestones</a></td>
<td class="nump">264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsSalesMilestones', window );">Sales milestones</a></td>
<td class="nump">$ 432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber', window );">Number of individual development milestones per target | milestone</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber', window );">Number of individual regulatory milestones per target | milestone</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber', window );">Number of individual commercial milestones | milestone</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived', window );">Amount of development milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone', window );">Next potential development milestone payment eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration', window );">Prior written notice for termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of individual commercial milestones per target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of individual development milestones per target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of individual regulatory milestones per target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional fees receivable when a target is designated and the commercial license to the target is granted under terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum development milestone amount the company is entitled to receive under terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the next potential development milestone the company will be eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the development milestone payment received by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsMaximumAggregateMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate milestone the Company is entitled to receive under terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsMaximumAggregateMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time before which prior written notice needs to be served for termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum regulatory milestone amount the company is entitled to receive under terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum sales milestone amount the company is entitled to receive under terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsTargetsDesignatedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets designated as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsTargetsDesignatedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborativeArrangementsExclusiveTargetsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of exclusive targets entity provided right to develop under terms of agreement as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborativeArrangementsExclusiveTargetsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborativeArrangementsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payment received during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborativeArrangementsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438325329080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Merck KGaA - Accounting Analysis (Details)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>target</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">$ 796,000<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="nump">$ 844,000<span></span>
</td>
<td class="nump">$ 202,000<span></span>
</td>
<td class="nump">$ 41,035,000<span></span>
</td>
<td class="nump">$ 828,000<span></span>
</td>
<td class="nump">$ 42,123,000<span></span>
</td>
<td class="nump">$ 10,594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">3,987,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,987,000<span></span>
</td>
<td class="nump">4,815,000<span></span>
</td>
<td class="nump">$ 46,196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember', window );">Merck KGaA Agreement and Merck KGaA supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 3,987,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,987,000<span></span>
</td>
<td class="nump">4,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsTargetsDesignatedNumber', window );">Number of targets designated | target</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice', window );">Amount of milestone payments, which had not been received, included in the estimated transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Transaction price</a></td>
<td class="nump">$ 21,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,325,000<span></span>
</td>
<td class="nump">21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber', window );">Number of service obligations completed of designated targets | target</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated', window );">Amount of research and development fees expected to be received</a></td>
<td class="nump">$ 6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceIncreaseDecrease', window );">Decrease in fees expected to be received for research and development activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,000<span></span>
</td>
<td class="nump">853,000<span></span>
</td>
<td class="nump">$ 2,444,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | License and corresponding research and development services, first and second targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Transaction price</a></td>
<td class="nump">3,941,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,941,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | License and corresponding research and development services, third and sixth target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Transaction price</a></td>
<td class="nump">3,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | License and corresponding research and development services, fourth target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Transaction price</a></td>
<td class="nump">3,152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | License and corresponding research and development services, fifth target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Transaction price</a></td>
<td class="nump">2,746,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,746,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | Rights to future technological improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Transaction price</a></td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | Joint research committee services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Transaction price</a></td>
<td class="nump">$ 242,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_SupplyAgreementMerckKgaaMember', window );">Merck KGaA supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,280,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Merck KGaA | Rights to future technological improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Expected recognition period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01 | Merck KGaA | Joint research committee services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Expected recognition period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsTargetsDesignatedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets designated as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsTargetsDesignatedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangements, Targets Designated, Service Obligations Completed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payments, which had not been received, included in the estimated transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of research and development expenses received or expected to be received included in transaction price (performance obligation).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_RevenueTransactionPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price which represents the amount of consideration the entity expects to receive for transfer of goods and services. Amount is net of estimated fees associated with research and development activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_RevenueTransactionPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_RevenueTransactionPriceIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in transaction price during the period due to change in fees expected to be received for research and development activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_RevenueTransactionPriceIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_RightsToFutureTechnologicalImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_RightsToFutureTechnologicalImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_JointResearchCommitteeServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_JointResearchCommitteeServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_SupplyAgreementMerckKgaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_SupplyAgreementMerckKgaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333975720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Takeda XMT-1522 Strategic Partnership (Details) - XMT-1522 agreement<br></strong></div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsDurationToTermination', window );">Period of time until agreement terminated</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod', window );">Period of shared development costs following effective termination date</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsDurationToTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time before which agreement will be terminated due to counter party serving prior written notice, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsDurationToTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time following effective termination date in which development costs were equally shared with counterparty under the terms of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334412904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Takeda strategic R &amp; D partnership (Details) - 2016 Restated Tokeda agreement - target<br></strong></div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborativeArrangementsExclusiveTargetsNumber', window );">Number of targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsDurationToTermination', window );">Period of time until agreement terminated</a></td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsDurationToTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time before which agreement will be terminated due to counter party serving prior written notice, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsDurationToTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborativeArrangementsExclusiveTargetsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of exclusive targets entity provided right to develop under terms of agreement as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborativeArrangementsExclusiveTargetsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438332983672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Takeda - Accounting Analysis (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 828<span></span>
</td>
<td class="nump">$ 41,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 796<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 844<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 41,035<span></span>
</td>
<td class="nump">828<span></span>
</td>
<td class="nump">42,123<span></span>
</td>
<td class="nump">$ 10,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 22,858<span></span>
</td>
<td class="nump">$ 16,546<span></span>
</td>
<td class="nump">$ 15,413<span></span>
</td>
<td class="nump">$ 12,219<span></span>
</td>
<td class="nump">$ 12,430<span></span>
</td>
<td class="nump">$ 13,701<span></span>
</td>
<td class="nump">$ 13,766<span></span>
</td>
<td class="nump">15,143<span></span>
</td>
<td class="nump">$ 67,036<span></span>
</td>
<td class="nump">55,040<span></span>
</td>
<td class="nump">$ 59,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember', window );">2016 Restated Tokeda agreement and XMT-1522 agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueRemainingPerformanceObligationNumber', window );">Number of performance obligations | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,965<span></span>
</td>
<td class="nump">$ 5,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember', window );">2016 Restated Tokeda agreement and XMT-1522 agreement | License and related research and development services, including phase 1 development and transfer certain materials and know how</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueRemainingPerformanceObligationNumber', window );">Number of performance obligations | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember', window );">XMT-1522 agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 8,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsCostsBilled', window );">ASC 808 costs billed to Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">$ 3,746<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsCostsBilled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs billed during the period under terms of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsCostsBilled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_RevenueRemainingPerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_RevenueRemainingPerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438409936712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationAgreementsAbstract', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward', window );"><strong>Contract liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, balance at beginning of period</a></td>
<td class="nump">4,815<span></span>
</td>
<td class="nump">46,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ContractWithCustomerLiabilityIncrease', window );">Deferred revenue, additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ContractWithCustomerLiabilityDecrease', window );">Deferred revenue, deductions</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">41,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, balance at end of period</a></td>
<td class="nump">3,987<span></span>
</td>
<td class="nump">4,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract', window );"><strong>Revenue recognized in the period from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts included in the contract liability at the beginning of the period</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">41,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Performance obligations satisfied in previous periods</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract Assets And Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ChangeInContractAssetsAndLiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ContractWithCustomerLiabilityDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ContractWithCustomerLiabilityDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ContractWithCustomerLiabilityIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ContractWithCustomerLiabilityIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438332562424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Other Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 796<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 844<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 41,035<span></span>
</td>
<td class="nump">$ 828<span></span>
</td>
<td class="nump">$ 42,123<span></span>
</td>
<td class="nump">$ 10,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember', window );">Asana BioSciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone', window );">Next potential milestone payment eligible to receive</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember', window );">Asana BioSciences | Limited services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember', window );">Asana BioSciences | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the next potential milestone the company will be eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_LimitedServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_LimitedServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_ServiceMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_ServiceMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438325314760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 37,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets regularly measured and carried at fair value</a></td>
<td class="nump">37,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">11,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">12,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">13,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets regularly measured and carried at fair value</a></td>
<td class="nump">13,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets (Level&#160;1) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets (Level&#160;1) | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets (Level&#160;1) | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">13,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets regularly measured and carried at fair value</a></td>
<td class="nump">23,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">11,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">12,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets regularly measured and carried at fair value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438336748936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in an unrealized loss position | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333351128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment at cost</a></td>
<td class="nump">$ 9,365<span></span>
</td>
<td class="nump">$ 9,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation</a></td>
<td class="num">(7,635)<span></span>
</td>
<td class="num">(7,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment</a></td>
<td class="nump">1,730<span></span>
</td>
<td class="nump">2,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">$ 1,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment at cost</a></td>
<td class="nump">6,520<span></span>
</td>
<td class="nump">6,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment at cost</a></td>
<td class="nump">1,886<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember', window );">Computer equipment, office equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment at cost</a></td>
<td class="nump">$ 959<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentLeasedAssetMember', window );">Laboratory equipment , under finance lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentLeasedAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentLeasedAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334476552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent', window );">Accrued preclinical, manufacturing and clinical expenses</a></td>
<td class="nump">$ 9,902<span></span>
</td>
<td class="nump">$ 4,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">5,412<span></span>
</td>
<td class="nump">4,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 16,146<span></span>
</td>
<td class="nump">$ 8,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_AccruedPreclinicalAndClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for preclinical, manufacturing and clinical expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_AccruedPreclinicalAndClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333935592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th"><div>May 08, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_ExistingCreditFacilityMember', window );">Existing Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized issuance costs</a></td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_ExistingCreditFacilityMember', window );">Existing Credit Facility | Minimum | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_ExistingCreditFacilityMember', window );">Existing Credit Facility | Prime rate | Minimum | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember', window );">Amended Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount', window );">Final payment as percentage of original principal amount</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DebtInstrumentAdditionalRateInEventOfDefault', window );">Additional rate in event of default</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Incurred debt issuance costs</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt outstanding</a></td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember', window );">Amended Credit Facility | Line of Credit | Prepayment occurs prior to August 28, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember', window );">Amended Credit Facility | Line of Credit | Prepayment occurs between August 28, 2021 and August 28, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember', window );">Amended Credit Facility | Line of Credit | Prepayment occurs after August 28, 2022 but on or prior to August 28, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember', window );">Amended Credit Facility | Minimum | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate percentage</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember', window );">Amended Credit Facility | Prime rate | Minimum | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Spread (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheOneMember', window );">Amended Credit Facility, Tranche One | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheTwoMember', window );">Amended Credit Facility, Tranche Two | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheThreeMember', window );">Amended Credit Facility, Tranche Three | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheFourMember', window );">Amended Credit Facility, Tranche Four | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheFiveMember', window );">Amended Credit Facility, Tranche Five | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheSixMember', window );">Amended Credit Facility, Tranche Six | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit', window );">Line of credit, increase limit</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DebtInstrumentAdditionalRateInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional percentage of rate in event of default under debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DebtInstrumentAdditionalRateInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DebtInstrumentPrepaymentFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of prepayment fee under debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DebtInstrumentPrepaymentFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the final payment as percentage of original principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Accordian Feature, Increase Limit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_ExistingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_ExistingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DebtCovenantPeriodAxis=mrsn_PrepaymentOccursPriorToAugust282021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DebtCovenantPeriodAxis=mrsn_PrepaymentOccursPriorToAugust282021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DebtCovenantPeriodAxis=mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DebtCovenantPeriodAxis=mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DebtCovenantPeriodAxis=mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DebtCovenantPeriodAxis=mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityTrancheSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438332142024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term-debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DebtInstrumentCarryingAmountNoncurrent', window );">Total debt, net of current portion</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt financing costs, net of accretion</a></td>
<td class="num">(246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Accretion related to final payment</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">$ 4,977<span></span>
</td>
<td class="nump">$ 4,201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DebtInstrumentCarryingAmountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, classified as noncurrent. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DebtInstrumentCarryingAmountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333081240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Future payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Estimated future principal payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">2,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">1,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 340<span></span>
</td>
<td class="nump">$ 214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331540232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity Preferred Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438332656456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity At-the-market Equity and Follow On Offering Programs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember', window );">At market equity offering program (2018 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceProgramAuthorizedAmount', window );">Amount of shares authorized to be offered and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts', window );">Proceeds from stock issuance, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram559PerShareMember', window );">At Market Equity Offering Program, 5.59 per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,938,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares sold, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram774PerShareMember', window );">At Market Equity Offering Program, 7.74 per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares sold, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember', window );">At Market Equity Offering Program (2020 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceProgramAuthorizedAmount', window );">Amount of shares authorized to be offered and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares sold to date (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold (in shares)</a></td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares sold, price per share (in dollars per share)</a></td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts', window );">Proceeds from stock issuance, net of issuance costs</a></td>
<td class="nump">$ 163,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross proceeds from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net proceeds from the additional capital contribution to the entity after deducting fees, commissions and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuanceProgramAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock shares authorized to be issued under the program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuanceProgramAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram559PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram559PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram774PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram774PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333445848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued', window );">Number of shares into which warrant issued during period may be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ContractualLifeOfWarrants', window );">Contractual life of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">39,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued upon exercise of warrant (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right issued during the period may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ContractualLifeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The contractual life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ContractualLifeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331935752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Exchange Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 02, 2020</div></th>
<th class="th"><div>Nov. 26, 2019</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember', window );">Exchange warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants', window );">Number of common shares exchanged for warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock into which warrants may be converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_WarrantsExercisedInPeriod', window );">Issuance of common upon exercise of warrant (in shares)</a></td>
<td class="nump">2,574,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares exchanged for warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_WarrantsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_WarrantsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334686232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Common stock (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">6,869,189<span></span>
</td>
<td class="nump">7,782,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_NumberOfVotesPerCommonShare', window );">Number of votes per common share | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrsn_WarrantsAndShareBasedPaymentsMember', window );">Warrants and share-based payment awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">6,869,189<span></span>
</td>
<td class="nump">7,782,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_DeferredCompensationShareBasedPaymentsMember', window );">Share-based payments | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">6,112,948<span></span>
</td>
<td class="nump">4,720,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_DeferredCompensationShareBasedPaymentsMember', window );">Share-based payments | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">716,767<span></span>
</td>
<td class="nump">447,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">39,474<span></span>
</td>
<td class="nump">39,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember', window );">Exchange warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,575,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_NumberOfVotesPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes for each shares held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_NumberOfVotesPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrsn_WarrantsAndShareBasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrsn_WarrantsAndShareBasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_DeferredCompensationShareBasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_DeferredCompensationShareBasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438419562536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Plans Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,112,948<span></span>
</td>
<td class="nump">4,720,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2007Member', window );">2007 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,141,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2017Member', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease', window );">Cumulative annual increase in number of shares issuable, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,288,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="nump">1,815,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be cumulatively issued annually in accordance with the plan, as a percentage of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333648504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Inducement Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Sep. 02, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,359,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_InducementAwardProgramMember', window );">Inducement Award Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_InducementAwardProgramMember', window );">Inducement Award Program | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_InducementAwardProgramMember', window );">Inducement Award Program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrsn_InducementAwardProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrsn_InducementAwardProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438429225256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Activity Under Stock Option Plan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">4,720,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,359,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(697,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(269,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">6,112,948<span></span>
</td>
<td class="nump">4,720,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, at end of period (in shares)</a></td>
<td class="nump">3,147,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">11.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share)</a></td>
<td class="nump">7.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">7.84<span></span>
</td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, at end of period (in dollars per share)</a></td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Options outstanding</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Options exercisable</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding</a></td>
<td class="nump">$ 114,729<span></span>
</td>
<td class="nump">$ 9,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable</a></td>
<td class="nump">$ 67,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 7.99<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="nump">$ 8.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from the exercise of stock options (in dollars)</a></td>
<td class="nump">$ 3,138<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438446818888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Restricted Stock Units (Details) - Unvested restricted stock units - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares)</a></td>
<td class="nump">447,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">324,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,501)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,767<span></span>
</td>
<td class="nump">447,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,073<span></span>
</td>
<td class="nump">$ 2,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333858296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in Total operating expenses</a></td>
<td class="nump">$ 7,172<span></span>
</td>
<td class="nump">$ 4,872<span></span>
</td>
<td class="nump">$ 3,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in Total operating expenses</a></td>
<td class="nump">5,725<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
<td class="nump">3,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock compensation cost</a></td>
<td class="nump">$ 19,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period of unrecognized stock compensation cost</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in Total operating expenses</a></td>
<td class="nump">$ 1,187<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock compensation cost</a></td>
<td class="nump">$ 2,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period of unrecognized stock compensation cost</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in Total operating expenses</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in Total operating expenses</a></td>
<td class="nump">3,841<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in Total operating expenses</a></td>
<td class="nump">$ 3,331<span></span>
</td>
<td class="nump">$ 2,627<span></span>
</td>
<td class="nump">$ 2,096<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438333123064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334073640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Employee Stock Purchase Plan (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,869,189<span></span>
</td>
<td class="nump">7,782,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,267<span></span>
</td>
<td class="nump">140,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334555912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Description (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LeasesLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_TenantImprovementAllowance', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability', window );">Increase in lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets', window );">Increase in right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Letter of credit for security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Assets under finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_OfficeSpaceCambridgeMaMember', window );">Office space, Cambridge, MA, Leased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LeasesLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, operating lease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in present value of lessee's discounted obligation for lease payments from operating lease due to lease modification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in lessee's right to use underlying asset under operating lease due to lease modification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_TenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of allowance granted and reimbursable by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_TenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_OfficeSpaceCambridgeMaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_OfficeSpaceCambridgeMaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438330156328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,755<span></span>
</td>
<td class="nump">$ 2,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_FinanceLeaseTotalCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_FinanceLeaseCost', window );">Finance lease cost</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of finance lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_FinanceLeaseTotalCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Total Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_FinanceLeaseTotalCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334595400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental balance sheet information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LesseeOperatingLeasesAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 10,936<span></span>
</td>
<td class="nump">$ 2,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">2,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">10,158<span></span>
</td>
<td class="nump">677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LesseeFinanceLeasesAbstract', window );"><strong>Finance leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Less: Accumulated depreciation</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Other liabilities, current</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Other liabilities</a></td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">10.80%<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance lease, liability, current, statement of financial position</a></td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance lease, liability, noncurrent, statement of financial position</a></td>
<td class="text">us-gaap:OtherLiabilitiesNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LesseeFinanceLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LesseeFinanceLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LesseeOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LesseeOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334610680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental cash flow information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LeasesSupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 2,394<span></span>
</td>
<td class="nump">$ 2,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LeasesSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases, Supplemental Cash Flow Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LeasesSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438446817960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Future minimum lease payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Rent expense</a></td>
<td class="nump">$ 2,644<span></span>
</td>
<td class="nump">$ 2,160<span></span>
</td>
<td class="nump">$ 1,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">2,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">2,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">3,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025 and thereafter</a></td>
<td class="nump">3,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">15,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(3,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">11,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2025 and thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438331391416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">General business credits</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Impact of ownership shift</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(53.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(32.30%)<span></span>
</td>
<td class="nump">17.90%<span></span>
</td>
<td class="num">(32.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438502532712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of deferred tax assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 64,259<span></span>
</td>
<td class="nump">$ 40,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">5,670<span></span>
</td>
<td class="nump">2,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">4,058<span></span>
</td>
<td class="nump">2,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">3,166<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DeferredTaxAssetsLicensedTechnology', window );">Licensed technology</a></td>
<td class="nump">1,534<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">1,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DeferredTaxAssetsDepreciation', window );">Depreciation</a></td>
<td class="nump">502<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">80,361<span></span>
</td>
<td class="nump">49,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(77,375)<span></span>
</td>
<td class="num">(48,889)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets less valuation allowance</a></td>
<td class="nump">2,986<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(2,986)<span></span>
</td>
<td class="num">(710)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liabilities</a></td>
<td class="num">(2,986)<span></span>
</td>
<td class="num">(710)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DeferredTaxAssetsDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DeferredTaxAssetsDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DeferredTaxAssetsLicensedTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from licensed technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DeferredTaxAssetsLicensedTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334477112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Net operating loss carryforwards (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carry-forwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 250,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_OperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards subject to expiration</a></td>
<td class="nump">34,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards not subject to expiration</a></td>
<td class="nump">216,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carry-forwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 184,781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438409591336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Tax credit carryforward (Details) - Research and Development<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 4,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438419599576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Valuation allowance (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>audit </div>
<div>jurisdiction</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Valuation allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 77,375,000<span></span>
</td>
<td class="nump">$ 48,889,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">28,468,000<span></span>
</td>
<td class="num">(5,051,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax position</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_IncomeTaxesNumberOfStateJurisdictions', window );">Number of state jurisdictions in which entity files income tax returns | jurisdiction</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_IncomeTaxesNumberOfAuditsInProgress', window );">Number of federal or state audits in progress | audit</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_IncomeTaxesNumberOfAuditsInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of federal and (or) state audits in progress.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_IncomeTaxesNumberOfAuditsInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_IncomeTaxesNumberOfStateJurisdictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of state jurisdictions in which entity files income tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_IncomeTaxesNumberOfStateJurisdictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438334274344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DefinedContributionPlanEligibleAgeToParticipate', window );">Eligible age to participate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum contribution by employee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage employer matches of the employee's percentage contribution matched</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution (as a percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount', window );">Maximum annual amount employer contributes per employee</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employee benefit expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DefinedContributionPlanEligibleAgeToParticipate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum age for employees to be eligible to participate in defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DefinedContributionPlanEligibleAgeToParticipate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum annual amount the employer contributes per employee to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438332994200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments - License agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrsn_LicenseAgreementUpfrontPaymentsMember', window );">License Agreement, Upfront Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and development expense</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrsn_LicenseAgreementMilestonePaymentsMember', window );">License Agreement, Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and development expense</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrsn_LicenseAgreementUpfrontPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrsn_LicenseAgreementUpfrontPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrsn_LicenseAgreementMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrsn_LicenseAgreementMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140438325235416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 796<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 844<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 41,035<span></span>
</td>
<td class="nump">$ 828<span></span>
</td>
<td class="nump">$ 42,123<span></span>
</td>
<td class="nump">$ 10,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">22,858<span></span>
</td>
<td class="nump">16,546<span></span>
</td>
<td class="nump">15,413<span></span>
</td>
<td class="nump">12,219<span></span>
</td>
<td class="nump">12,430<span></span>
</td>
<td class="nump">13,701<span></span>
</td>
<td class="nump">13,766<span></span>
</td>
<td class="nump">15,143<span></span>
</td>
<td class="nump">67,036<span></span>
</td>
<td class="nump">55,040<span></span>
</td>
<td class="nump">59,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,914<span></span>
</td>
<td class="nump">5,881<span></span>
</td>
<td class="nump">5,171<span></span>
</td>
<td class="nump">4,936<span></span>
</td>
<td class="nump">4,212<span></span>
</td>
<td class="nump">4,436<span></span>
</td>
<td class="nump">4,192<span></span>
</td>
<td class="nump">4,443<span></span>
</td>
<td class="nump">21,902<span></span>
</td>
<td class="nump">17,283<span></span>
</td>
<td class="nump">16,334<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">28,772<span></span>
</td>
<td class="nump">22,427<span></span>
</td>
<td class="nump">20,584<span></span>
</td>
<td class="nump">17,155<span></span>
</td>
<td class="nump">16,642<span></span>
</td>
<td class="nump">18,137<span></span>
</td>
<td class="nump">17,958<span></span>
</td>
<td class="nump">19,586<span></span>
</td>
<td class="nump">88,938<span></span>
</td>
<td class="nump">72,323<span></span>
</td>
<td class="nump">76,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="nump">725<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">2,226<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(359)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">685<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,844)<span></span>
</td>
<td class="num">$ (22,489)<span></span>
</td>
<td class="num">$ (19,786)<span></span>
</td>
<td class="num">$ (16,926)<span></span>
</td>
<td class="num">$ (16,246)<span></span>
</td>
<td class="num">$ (16,792)<span></span>
</td>
<td class="num">$ (17,071)<span></span>
</td>
<td class="nump">$ 21,901<span></span>
</td>
<td class="num">$ (88,045)<span></span>
</td>
<td class="num">$ (28,208)<span></span>
</td>
<td class="num">$ (64,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares of common stock used in net income (loss) per share attributable to common stockholders &#8212; basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,886,144<span></span>
</td>
<td class="nump">47,833,607<span></span>
</td>
<td class="nump">47,708,085<span></span>
</td>
<td class="nump">30,299,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares of common stock used in net income (loss) per share attributable to common stockholders &#8212; diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,886,144<span></span>
</td>
<td class="nump">47,833,607<span></span>
</td>
<td class="nump">47,708,085<span></span>
</td>
<td class="nump">31,461,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used in net loss per share attributable to common stockholders &#8212; basic and diluted (in shares)</a></td>
<td class="nump">68,630,078<span></span>
</td>
<td class="nump">68,419,192<span></span>
</td>
<td class="nump">60,748,225<span></span>
</td>
<td class="nump">47,988,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,485,205<span></span>
</td>
<td class="nump">43,492,113<span></span>
</td>
<td class="nump">23,032,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M2)M9/AYF02.SW-+T'& X!\A#GL/]YM7N,#EV7^A\VZ11FS2JX^&QI"LA:*D
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M$@W>&.CG&ZZEM1F80]KV4'[U#U!+ P04    "  J1UI2*, 7G,4"  "K"0
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M0-H <W\AA'Z=V/VZ.Y^E?P%02P,$%     @ *D=:4GW!$!85!0  D1,  !@
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M&!>62N>I(9[;IM3%X" @;4H&5']DFI:+AWON;VJF3]40933>Z?K:]RVG0\"
M(SZQ_#8% \YSB#OM(='T6^Q>4'_KL\E0DQJLP*8[86_01:]4[632Y!\UF6[5
M#@9=:=772(TH:HOR!C)<I8 $K'.>R,2\AE5?./=0QXU=D-U>P P8[. >_S6=
M$@^WRD7'<T824V,Z3*TV#P..^'CJMKD8<)Z#L==#I^F5>+A9'G,:A5+R9)67
M$9),9TBFPJ9V,^NWF*41<+UY4/NU9&TDW.U]YOPWX(SY;\ -Y7_33?%P._V/
MA*,DS65[=U-1#CK3BYFR 6>D;, -4"9-RR769935#(%$''*XB/SWW_EJ%_!#
M&?-R,BR=@:Y494=ZO.4G.J]-/JHL\T\YX;'3*M6%"6:-VZO_T@0CXVG/3$*:
MN8$,SPU?BJ,&B&["O9JRMH!HKL=UO2\Y.D8S%"@7BKTB3_\/CY;?,+NQ.VIX
MV/%=8K63S8!T;"<@&+>71P.2V)9-B-MN_Y.3LXH,^+8X\Q&*84YEN;NOW];G
M2I^*TY36^WM\NRQ/AQHUY6'58\BW"14HA8U2:8VGJ@IX>?Y3/DBV*TY$5DQ*
MEA6W,83*JQJ@_M\P)H\/^@/U*=S\7U!+ P04    "  J1UI21=3.G0D(  !2
M*0  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;+V:67/;-A#'OPI&[;3)
M3!3AXI7:GK%\)&[LQ!,G[4.G#S )26PH4B&IV/WV!0^+(B[*LIL76Y1V@3]V
M ?P6D [NLOQKL>"\!/?+)"T.1XNR7+V93(IPP9>L>)VM>"H^F67YDI7B,9]/
MBE7.650[+9,)AM"=+%F<CHX.ZO>N\Z.#;%TF<<JO<U"LETN6_SOE279W.$*C
MAS<^Q?-%6;TQ.3I8L3F_X>67U74NGB:;5J)XR=,BSE*0\]GAZ!B]^4"=RJ&V
M^"/F=\76:U -Y3;+OE8/%]'A"%:*>,+#LFJ"B7_?^0E/DJHEH>-;V^AHTV?E
MN/WZH?7S>O!B,+>LX"=9\F<<E8O#D3\"$9^Q=5)^RN[>\79 M< P2XKZ+[AK
M;#UW!,)U46;+UEDH6,9I\Y_=MX'8<J F!]PZ8,G!(08'TCH0N0?'X$!;!RHY
M8&QP<%H'1W) )DENZ^#*8_ ,#E[KX$D.A!H<_-;!E\=@ZB%H'0+)P4.FQ,&'
MS$$YL+[)99-L.=O$) L]I!O)^<;0Y/*0<"1GW#,E$#VD'-4YGS33MY[[IZQD
M1P=Y=@?RREZT5[VH%U#M+Z9\G%9K_:;,Q:>Q\"N/3K*TR)(X8B6/P$TI_HF%
M7!8@FXFG+/RZR)*(Y\6OX.S;.B[_!6/PY>84O/CY)?@9Q"GXO,C6!4NCXF!2
M"C55FY.P[7G:](P-/7_.2I9HW$[L;B?KY3IAU08!^&PF=@S HG]$I"K90.Q]
MXC%;U=N(&,+QS0EPH:OIY=3>RW$IHIQ_%7LM;\:=B;[R.)V#59[-<[8$+S!$
M/CC^?/52T_J9O?7K]6T2ATV P<>V94TSYP.AR);++/WE)^3"W^JV-$V\?603
M3QSXNT=VMVLD+@;2%45QE7.6@&L61V,Q,T_8*M9/L-_W;>N)L7F_;[^[!NER
MH(,P;-:.6.D?RP7/@4B'*! 6%;G%<KK,"MTROMJ]U5,^B\.XU#3RX=&-/'V=
M3\16N-D/\68_Q+42:E R90E+0PY8"6[Y/$[3*KVBAY4(>A:!%R(KQ8+EO'A9
MF9SR\#4@Z!40>?=T"[CIS*T[J\JN[T<8>ZY36W_7R"0;F>0I,G>0-FTZ<+:D
MN4$0T(VN9C-6K<88$M2W.E>M2-_B0K5 KB\62]_L4M,=HD'?Z$IC%'B^)[7U
M84AZ+_!T$WA:NQ%#X"_24)34!0<O1(#K5R\K#NI8:9F-SJ8WQYKFLWN>A['H
M3:2VJ)=_,^>+[8FHFW>.,N\H]K ;Z ?O;N2X^\G1S2]7D1#(Z;ZPV_0T>AN-
MGE7C]3H/%ZS1&-:X::6N4Y$<<'9S?3T4/$\3/.2[>EW^1I?_5%VZ*/J*%D1=
M*8IVFY[:8*,VL*JMY_.X.D1%E5IQLBQ8O=GR^^HUUTD-%!G$]Z7]Y&+ J"<6
MP:Z(A5:Y#<["'L[B5#R+=9H(K.G2/&W;[,=-VMDN!XSZ>K>*;F35^T'4$(D>
MM]/6=;O'L4NQXTF[X+!=7UQ'0+0S GD:[08_7UN]:NA',*'4PP:-'?[0SOSK
M:]Q!UQ2I9/"]P)&8IK&2H=::]":'AP/7E2>1:C?VY71J;)!+D6M8R:@C%OH1
MR$(=LY =6J*8R]9I654DXD"91BR/"O!E51TQP5]G]V6U/F\346_&1?FW-C_V
M]M?%>,[8ZDW7SZ:;IA>1=PJ#*[Z\Y;EM1!WVD)U[S\ 4I*).B(0>,62WPQUZ
M,N^T,?:4V4W]0)[?&A+ZAAH"=2!$=A+NPQ:D,H[Z6]M(JW? JB^X8R&RP_"B
M*-;U;K,I>X:2K5(.4TH\!T*]%MR1#MM)IVC110NKT HP<J5PG;=FVW- CJBA
M)=,P.@!B.P#-A:U8R>".Y3FK;J$&XHQ5!"('!IZAA,1;AT [ G>3IPV]RCSD
M.7)4[49]T1T3L9V)GW@9Y_7UG;(7Q-7B$MM$.N?UV;GW83N<P6!K "6J#3&G
M3;.A(Q2F_Z=R;1ZH!KF!+Y?.@V;]$74,Q'9&;2]3;;#E<>7&$&A'IY[O=(,;
ML.J/K:,AMM-PKV(;J_PC4CEU:;?IJ^WXB.U\M)7:6.7;&/L8RK79L%U?7(="
M;$?A/J5VH%V<&O(YXF0%L2F '?VPG7Z[EMHZ75.LDM#SB7P/<-Z:;9-(V3,U
M3/6@*T/M4F?GR/E4;<8HP,0S'$1)AV<"?T"M33J.$CM'FSOAN-UM7H'3N*B+
MX@(<BUQ5U^WBLQI<'U/P6>P\!:N_8]5>""(U"8YONJCL6$KV9:D=.%.B4M(-
M/(KER3-LUU>^=<=J!^JCKKN(YKB(B'SA152(]JSZ2CN $CM G^& 0E02BMW#
M-:6_(R&QDW#/\PE1V>6X2(ZFW:BON.,;L?-MG_,)4='E(>5\,F35%]PACM@1
M]]CSR5NB\@S! $(GD$Z [S26 8;06/.1#GW$CKY=#C*G;1N]+REPX$E786<:
M,^22()#FRUN=G3S@09/?#:*DZNN]290I<AV0B1W(V]O23K5ESVAH&]#ATZ.!
M9_K>I$,C_1_N:*EZ_AS+.+\<,.KK[=!*][^CI9J[5U%L4;G0&+;KB^N@2I_]
MCA9#7;ZI!IZ^3Q'V#5"B'3[IL]S1:G5-J8I3C'WH2TO_7&,GF5QH3!SH4WFO
MN]3803F?NN\413Z1X5*,;GVM^",N:6F'96K'\C,6CJ=M5[U<(7D_/--8(>A#
M.7*3K=\R5;\VO&+Y/!8R$CX3?O"U)QK(FQ_P-0]EMJI_WG2;E66VK%\N.!,!
MJPS$Y[,L*Q\>JE],;7Y&>?0?4$L#!!0    ( "I'6E(79F@1@0(  %0&   8
M    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULI55=;]HP%/TK5U&EM=+6?$ (
MK0(2T$[K0S54VNW9)#?$PK&I[93VW\]V0L9:0)/Z@GWM>\Z]QW8.Z5;(M2H1
M-;Q6C*N15VJ]N?9]E958$74I-LC-3B%D1;0)Y<I7&XDD=Z"*^5$0#/R*4.Z-
M4[<VE^-4U)I1CG,)JJXJ(M^FR,1VY(7>;N&!KDIM%_QQNB$K7*!^VLREB?R.
M):<5<D4%!XG%R)N$U[/$YKN$7Q2W:F\.5LE2B+4-[O*1%]B&D&&F+0,QPPO.
MD#%+9-IX;CF]KJ0%[L]W[-^==J-E213.!/M-<UV.O*$'.1:D9OI!;']@JR>V
M?)E@ROW"MLT-/,AJI475@DT'%>7-2%[;<]@#A(,C@*@%1.\!_2. 7@OH.:%-
M9T[6#=%DG$JQ!6FS#9N=N+-Q:*.&<GN+"RW-+C4X/9X)K@2C.=&8PT*;P5R1
M5B *$XEL70J6HU1?X/:YIOH-SN=$FH02-<T(NX!O\+2X@?.S"S@#RN&Q%+4B
M/%>IKTUWMH:?M9U,FTZB(YV$$=P+PZS@EN>8_TO@&UF=MFBG;1J=9+S![!)Z
MX5>(@B@XT-#LO^'AU8EV>MU1]QQ?_PC?G5(UX1E")I0^=$"S!A\[O/W\7L9Q
M/$Q2_^5 U7Y7M7^RZD2;YR+7Q@^PN4%1%"@I7\%&BI4D%9P;?4.8/-Y?G! 9
M=^7BSXF<QA]$1F$R."QRT%4=G*PZKY>,9LV+A9^MP!-JDHXW^:2:Y(.:,!@&
M5^_D^'L?:(5RY7Q+&=::Z^8]=ZN=-4Z<([Q;GQK+;!SN+TWCM_=$KBA7P+ P
ME,%E8GJ2C8<U@18;9P-+H8VIN&EI;!^E33#[A1!Z%]@"W1_)^ ]02P,$%
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MJ@V^[_C0T;;L+M>]'(/J:5U,[_L\O@\OO _AX"MO^UT7_-J6K#SN8"T'/S/
M/QE\QMX>-ZSX&!#T(< A#H$!W9[='.5 \\WYS3,/&S+/!]']D:7Y4$;?:J-O
M!6\"N< %[:OV<5PA55^QSO.::'Y-I%\3+;SF=QE1:MZ!$SBVC'5+%3:>KE=9
M%D;QY?KIT*P #&<XS(YA&P"61#A.9]C1^.-Y_+'73#?EO^3:&%VUYS( %;PM
MJIH%[41,?:L^%\J>0R>=6_HM9,Q/'FLF\V@2KS4W3,;<HJ(JDD$6'5LG!S9
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M=:G;);ACG(CI[\$9[\,_IQ2RV&D^^=CG3;/!6?@0<]D!;:[GF8$]$3CT!<F
M'IQA\"::@T 2&8A/243N"C;;-!.77%-;C$H;X5+,U&79<W?7A'#JU@P&>#XO
MC@[.LJU5S]/J /:O6(^X9$0M]A+%@4:0*)IT!"6.04. 7X/"MM+Z3E'P$ISN
M# Y_"!^Z-S#RE3B9F "PF1H[37%#Z(#?;V$"?9X<!@6B@X]]FMK/4)G5=+Q
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M>.CDC IN6O2,:TF/:%C9+GD>K"EL;+%3LD *620!R98S?E1:P).0<'!,)V^
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MW86^EV<L[Z-QKCBE"W#,:AJHV).>#MY,Y4G3:JR@:P$;M[$R2&J1/?AJ'QK
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MM<%; M<UC:+-)=9V?3Y(!]N##WI5>3D8+^:M6N$=^H_M+?%NO+-2Z@:-T]8
MX?)\<)&>7DY%/@A\TKAV>VN02')K[V7S<WD^2 00UEAXL:#X[P&OL*[%$,/X
MW-L<[%R*XOYZ:_U]B)UCR97#*UO_H4M?G0]F RAQJ;K:?[#KG["/YTCL%;9V
MX1?6478R'4#1.6^;7ID1--K$?_78YV%/89:\H)#U"EG '1T%E-?*J\6<[!I(
MI-F:+$*H09O!:2-%N?/$MYKU_.*]T@2?5-TAW*!R'2%GW+OYV+-Q$1D7O:'+
M:"A[P5":P8TUOG+PHRFQ?&Y@S*AVT+(MM,OL58O76(Q@D@XA2[+D%7N37:B3
M8&_R[Z%>:U?45J)U\.=%[CPQ._YZQ<=TYV,:?$S_?SK_DR'XO4)8VII[29L5
M>)77"-R-+EQJ$[LTT#WG%@3/XE>V:979?.= .8<LIDP)M5:YKK77G '"55<K
MJC?01%=E$"D4D9:U!P5+P?,0\,B=-J4NE&=E\5#C PIQ?:7-OF2ED105U0;L
M,@C*<83GL:B,_MRQA<XSD+_9D;?<3QZ):8X\)8IJZ]")/M,!FQRIIT1Z,@K)
MZ*.#2I5@++<&W6-,B\.BHQCA00M9<@HAS;]UUK/[6](%R][IE=%+CL[X9^NO
M_,/-(5^G@JA!*K2JH54M*[R!-!V>3!->?/O-+$NSLT-'5Y9:2YQ3R*TI':39
M,$F3W?47VX^C.XZ?0KTDPG0RG,Y.MG];J2=WD^/A='(B?J/$&\@FPY.C?0"<
M34)8RP\GLJB46:%PZG#5+ %WC7%+) <Y^C7BL]HW3ZR-_'!0,E0A+5=M@XK5
M4";%UV4)#'NJL/!P(XJJL9W0G.>V#'44&@9KA37.UKI4<I:K6IF"2R(ST7&S
MD#1(JW0)^,AOF</8 98UB4<LD4",K3'D5Z*(3EJU"94543ZD#O?UVY;LHVZD
M6FR&@WZ*7.)$X7*\<)4E_[VP&HSRG)$17!QFXS#&LHTVIK%OG)[EH53'9ZS?
M>><9F@CFEBB.@X[S25&>FUA[IG<A3;Z!M]P!_%9Q8W&"Y"5^MQ]#N5^XMPI^
M"?V<O5#.=\-M!<2G-AP;.@\4QD&?3YXEZD'I.J0PYF(;0]^V7P#4C(^'<L=E
M**&QS$$>!6Q 2OPKMR?,AH&H67)VC;D/R_1L=&ADC_=>0V[$57CS&9G4-3Z,
MN]/=9\5%?$V?Q.,W"7?X2AO'!%ZR:C(Z/AH Q7<^;KQMP]N:6\\O=5A6_&F$
M) )\O[2,O=^(@]W'UN(?4$L#!!0    ( "I'6E()&1O_IP(   T&   9
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M843[%7CQ;"9^</ANCF#0)&A",C<L8[!>@.'3,,;O"'71_W<+SAQ+=,>&5 >
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M>U/PSX62*"@9X#F]^VXN:(+MWXON?P=02P,$%     @ *D=:4G&FVX.Z"@
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M*DNMQD]+ZNVH70"]SQ6Y[Q8N0?^W6/P%4$L#!!0    ( "I'6E(E"F[#%P4
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MM1(M0-%*%=)/KRY+T"$D*)?9>X^IL!$\!*--V[TY7K:@Q:.^/Y(PA9,<.XD
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M2M=3."2E_ED;$6^AW>=Q$ZJ<"MW''>CHEB-W:%MS?'@BL$6-<J19QC<W5()
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M3-N&"]6*+1_6U9+O1#FBSL2(6'KYD<+^KU9$7/3=F#;3Y1,#:@;5(;[/T=R
M^8AQVE:XB'V.D5LX!8XY&'9O)6,_?%>)[^ =EA17=HO).VLXVECVH LQAE7T
M PF$,T,D-X#$2"E1*;7@;O"V:.PF]D[=OKW!3N=MTOK\NJ^0/6IJ=EY=?;D
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M 92=@..5Q-T]?%@'XW^.Y5]02P,$%     @ *D=:4FF1M^!$ P  S@@  !D
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M*11>&[!M73/S<(92K^=1&FT7;L2J<GXA7LP:ML(ENB_-M:%9W$<I1(W*"JW
M8#F/3M/IV=C;!X.O M=V9PQ>2:[UG9]\*N91X@FA1.Y\!$:_>SQ'*7T@HO%S
M$S/J(;WC[G@;_3)H)RTYLWBNY3=1N&H>G4108,E:Z6[T^B-N]!SY>%Q+&[ZP
M[FR/DPAX:YVN-\[$H!:J^[-?FSSL.)P<<L@V#EG@W0$%EA?,L<7,Z#48;TW1
M_"!(#=Y$3BA_*$MG:%>0GUM<,F'@*Y,MPA4RVQJDC#L+;VY9+M&^G<6.4+QM
MS#<1S[J(V8&(:0976KG*P@=58/$T0$ST>H[9EN-9]FS$"^1#&*4#R)(L>2;>
MJ-<\"O%&_]=\(2R7VLNV\/TTM\[0-?GQ#,:XQQ@'C/$!C"553]%*!%T"LQ8I
MI4P5( 7+A11.$%[=Y;L(&YP9(_S80>GIW7MZ^Y+_+*POX:EM&,=Y1#5JT=QC
MM+BM$$HMJ?Z$6H'S!PMAUQ^T4%UEAQ+)J6S!D?FYKANF'E[;0^0-KEK)C'PX
M*(/M" E[0A6",T?.'D'B/?K+[BJA=BTK@8897CWXS'E#O]S1<\@K)7ZV%*%U
M1.0W 3E-->C04&D@=19>;0&M]Z>;@W6.9G-[TLD0;A_50<4*4)K*R=QAEQ:+
MO#6=PKT1LF0*X?I\;K4C^&LC.-DNQ4J)DM0I]V3\#SY<[<.:>D8U&BZ8A(8U
MY/ 2TG0P&2<T>/7B)$NS]_N6SK5IM*&<0JY582'-!DF:]-M_3;\,EZ3?A//R
M"M/18'PRV?ZV5H]PH^/!>#3QN)W%2\A&@\G1+H%]E1+O=",2M0H]UP+7K7)=
M8^I7^[9^VG6S1_/N3:!LK82R=%E*<DV&QT<1F*[/=A.GF]#;<NVH4X9A14\3
M&F] ^Z6F8]I,/$#_V"W^ %!+ P04    "  J1UI2.=?0[M0"   \!@  &0
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MO'N(KKG>"FJXP@VEQB?9. #=B;LSK&J\H-;*DCS]MJ3W$+4+H/.-HNO4&Z[
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;,57;6_;-A#^*P>O&&Q
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M+W=O<FMS:&5E=',O<VAE970T,RYX;6Q]5%%OVC 0_BM6M(=66DD(M)NJ$*G
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MHS@0_BL6V@^[TEW!D)"T2B*E27NW=^JI:K=[GQV8$*N <[9)6FE__(V!$MJ
MDWY)P'B>>>;%,Y[)7LAGM0'0Y"5+<S5U-EIOKUQ711O(F+H06\CQRUK(C&E\
ME8FKMA)87 IEJ>M[7NAFC.?.;%*NW<O91!0ZY3G<2Z**+&/R]1I2L9\ZU'E;
M>.#)1IL%=S;9L@0>03]M[R6^N0U*S#/(%1<YD;">.G-Z=4M'1J#<\9/#7K6>
MB3%E)<2S>?D>3QW/,((4(FT@&/[M8 %I:I"0QW\UJ-/H-(+MYS?TV])X-&;%
M%"Q$^B^/]6;JC!T2PYH5J7X0^S^A-FAH\"*1JO*7[.N]GD.B0FF1U<+((.-Y
M]<]>:D>T!(*P1\"O!?P/ OZH1R"H!8*/ K1'8% +#,[5,*P%AA\%^HP.:X&P
M]'WEK-+32Z;9;"+%GDBS&]',0QFN4AH=S'.368]:XE>.<GJ&$4G92DA6QGF>
M2 #,&ZW([^0.9/1,_OZ#S<G7)6C&TV_O5[\0GI,?&U$HEL=JXFKD8U#=J-9]
M7>GV>W13<B=RO5'D)H\A[I!?G)#W3P'<V &"T +@HB<;=_IO[KSVK8A_%?D%
M";S?B._1P=/CDGS]\BWC*6 <<W2A3$!WV6D'74*$H-2 ^EX-VHNU/!N+7M98
M78X['V5TBM'M^5CC+I!W@0B:O Y*U."LO&9-7EN@!PWTH(0>]$ _;=<2LX9L
MV:N!Q/H: 5;'KOR[KI"&)9(I\CM,6L_S)NZN@\"P(3"T$IAGHD"]8DU8''-C
M($O)&D#55-@J!;+?0$XJ=Q*NL-@JGN1,0TSPL))(9!D>9(Z"*8^P40#1HK4]
MD2S7W28-CTSJ,2=LS FMYOQ39"N0QIQ*OR*_2&\R75=884M]V*U^U*@??5)]
MRU<6)HN1A4EUB$[NN+7M>&?-N+%F;,^-!%,]0>ZD*3N=E7E\%,71V.O-S,M&
M^Z55^Q)V>%?9EL?"KO_RR/#QH%<]]0[=S+,2>("D2)D6\O6$_AJG3< /+0Q:
M_91:&3PR5'M*.3WR_B#HKPO4/RCWS\QEGL=\Q^,"#WC<&12RQ8WU@?]U6.^D
MZY^;I?10GFGP>::R*WJ?(1H<$1WV$#T4>VJO]IU$6^6S1?04N\$1NZ"'W:$3
MT'-;06>4S^E1"VJKZ-6=XO26FXXM07]&'WH#/=$<X 4[K=!H!._+Y<9*2'G"
M3?/#7E9;W&EP>$1UV,OTT$:HO8_<2RXDV4NND2S)A<:^2G#T(QHD7MRKBPCF
M,A?=4;"CAQZ)V6OG]<5MW?XQ*Y-R3E.8HY@9U<VU66UFP7DY 7U87]"K9371
M'6"J ?,.CQ_/%4EAC9#>Q0A])ZN9K7K18EO.&"NA<6(I'S<XYX(T&_#[6F (
MZQ>CH)F<9_\#4$L#!!0    ( "I'6E)-;#M[%P<  +LE   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0V+GAM;,5:6V_;-A3^*X2QAQ;(:E&2;T$2(*F3-LYE
M0=)N#\,>9/G8)BJ)'DGG O3'CY1DT;)HFFLUK"A:2S[GX[F?0YHG+Y1]XTL
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M' T'E.P!E7C!)R]4:BM[D8QA(F?AG%/Q-A1V?"BR-T(+0I&:$Z,5Q5C,,<[
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MV]$\T7?B_">K!A05\6*1J/(O.%?WAB,0YTJ+M.IL*DAY=OFE/RLA&AT0[.B
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MMTP6-YCK.V'<5-4H-C;J?:G5OU!+ P04    "  J1UI2G;X,(),#  ",#@
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M%]:"(DT3)3=$V=7&FFVXO7%J$PT3]A0?4)E99G28+F")9$#FLJJE (&:G"X
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M:Y;F#0-E%YCY0DK<=FR9[%[%]#]02P,$%     @ *D=:4CR0-%V2 @  *P<
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MS<)>9Z!=@HUOE,*#XT[,<$&FOP!02P,$%     @ *D=:4O>U5S!*!   -!$
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MD1LIM4>I[?(FSD)P3Q,I1? Y Y\W&\+B; N6C&X93CFX6A"!XX1?@QOP;;4
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M965T<R]S:&5E=#8R+GAM;+U676_3,!3]*U9 L$G0..GG1EN)M4-,@FG:!'M
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M>:/*@L&-0+*I*BJ>+J'DFYF#G><7M\4J5^:%.Y_6= 5WH/ZI;X0>N3U*5E3
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MN?;)':^ENM4EI0;=5USHB5<:4[_R?9V7M")Z(&LJX,U2JHH8Z*J5KVM%2>%
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MF:G_!N#:0,VO&9,O'5UH[)](_ ]02P,$%     @ *D=:4L0)4TJM!   )!(
M !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULK5A;<YLX%/XK&D\?DIG4
M(''/.)Y)[.YN'[K-)$W[+(-L:P+(*\EQ\N\K 09L0"$[S4,,XER^<X[T'4FS
M ^//8DN(!*]9FHN;R5;*W;5EB7A+,BRF;$=R]67->(:E>N4;2^PXP4FAE*46
MLFW?RC#-)_-9,7;/YS.VERG-R3T'8I]EF+_=D90=;B9P<AQXH)NMU /6?+;#
M&_)(Y-/NGJLWJ[:2T(SD@K(<<+*^F=S"ZR5RM$(A\9.2@V@] QW*BK%G_?(U
MN9G8&A%)22RU":Q^7LB"I*FVI'#\5QF=U#ZU8OOY:/VO(G@5S H+LF#I+YK(
M[<TDG("$K/$^E0_L\ ^I O*TO9BEHO@/#I6L/0'Q7DB65<H*04;S\A>_5HEH
M*2!O0 %5"FBL@E,I.&<*T!U0<"L%M\A,&4J1AR66>#[C[ "XEE;6]$.1S$);
MA4]S7?='R=57JO3D_%&R^!E\W^DB"/ 9W.HZ4/D&GO*$<-#^#.Y3G(.+)9&8
MIN)2"3\]+L'%ITOP"5A ;#$G M!<:5(IKM2@>OZQ97N!\T3,+*G0:I]67"&[
M*Y&A 600@6\LEUL!OB@HR:D!2X59QXJ.L=XAH\4EB:? @5< V<CN ;08K0ZC
M'O7E>/70$(U35\XI[#D#]O[=9RM5(;8&CT7J#2;=VJ1;F'0'3'[?2R%5M6B^
M 5B"%=G0/-<ORLF.<,H2<*&*6I;ZLJ^DI7V_L*\IYV7N!L@. C2S7GJ >34P
MSPCL;XYS2=[U[G6\(\>+[,#M]^[7WGVC]R^OA,=4O._?[_C_[$>!B\)^_T'M
M/S#Z7^ \5L3XOO^@ZQ_YD1O8_?[#VG_XD6E!\F3\A @[D'P(4>0V*2F77E?.
M.'&B&GIDAEX1&RE+B%<IN?IP#%$'FP/=P FB?FS0;KC7-B[A7T57(HFBW1?"
M59L%QZD&[CF-B6%)PQ;!PS^QJ!.6II@+/53FHC<5E:^PE0MOB@;6%T0-1C1Z
M?8\$4AJ,6D @G$;^ )*&5*'S@;4^$HO3P>).O0$D#1=#,QF?KOJ12-P.DF!J
M#T%IV!>:Z?== AB)SNM!%[IG3%!)C9QB#8=#,XF/9X*1P?@],.$0S(;J86"D
MA-LDH1HH3L&2BCAE8F_N[;!A<6BF\2/;U&3S0/3!0!=UH39:7&W!]\KM#\*S
MJWI'R)K2]V;![#( ;T2GT@%9N96#(4CP6]]N</%'3)VFIND2T-PF_E=J6C.I
M-S5FEWX5#RSC ?Y[T:"FK2#;:/IVL^%D@R4!7Q5VJLYH,?B)TST97=;*@7?"
MKJHA1V=KM4<N"IT!$D9-RT+FEC4B@'>27SEH _,#SQ_83:"F42%SHZH[-JXF
MRD9W+E4ZA76-*0<O&J8F%%8!W7RXM540PA.:C#JI[TJAJ1N<2BU[I,)I$$3M
MOX&<-"T3F5OF HLMX"0FZ@"?@#5G&9!;<JQ0D0Q1'"./*6FEHC\!3J=X#G3.
M=XP]4C#PSN/O"D7P?#MNM8[/&>&;XAI"@)CM<UF>+NO1^JKCMCC@GXW?P>ME
M>6'1F"GO3[YAKK9= J1DK4S:TT AXN651/DBV:XXI*^85$?^XG%+L#J":P'U
M?<V8/+YH!_7%T/PW4$L#!!0    ( "I'6E)F.^O20 0  ,0/   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;*5746_B.!#^*Q;:AU;:DC@) 2J*U$+W
M;D_:NZK==I]=8L!J8K.V [O__L9.2 ($$VG[4!)GOF^^F8QGXLE.R ^UIE2C
M7UG*U5UOK?7FUO/48DTSHOIB0SD\60J9$0VW<N6IC:0DL: L]0+?C[V,,-Z;
M3NS:DYQ.1*Y3QNF31"K/,B)_/]!4[.YZN+=?>&:KM38+WG2R(2OZ0O7KYDG"
MG5>Q)"RC7#'!D:3+N]X]OGW$8P.P%F^,[E3C&IE0WH7X,#=?D[N>;Q31E"ZT
MH2#PLZ4SFJ:&"73\+$E[E4\#;%[OV;_8X"&8=Z+H3*0_6*+7=[U1#R5T2?)4
M/XO=W[0,:&#X%B)5]C_:E;9^#RURI456@D%!QGCQ2WZ5B6@ @*<=$)2 X!@0
MG0&$)2 \!L1G %$)B+H"!B7 ANX5L=O$S8DFTXD4.R2--;"9"YM]BX9\,6X*
MY45+>,H IZ<O6BP^T'\;\]84ND'/5&G)%IHFJ'CTRIE6Z&I.-6&IN@:35[X%
M(S"0M:VRMKFU!8N7.;KZ=(T^(0^I-0$[Q'C!]!D6X?K[6N2*\$1-/ U1&"W>
MHE3\4"@.SBC&Z)O@>JW0(T]HTH*?7\ '#@(/TE?E,-CG\"%P,OY#>!^%^#,*
M_,!O$32[ ,_3/1R/V^)QP^=TX?3^V!E^[/T@&6%54*'E"\\5E'G?-V;O)HCL
MB#Q^Q0>D444:6=+H#.D;5!KC*[2ADHFV=_[@QD?H-R6RK=AF;F#0!CP(85"%
M,'#FY=\\>Z<2B26R&7)1QA5E[!17;42BT3M=,<Y-CL!#D29T!1NMV'[7;2DK
MR&-+;N;)=AI%PS",)]ZV67T7S0ZT#ROM0Z?VOR3A1OH%C<,3YV$0C</@2&.+
M68R;9@<:1Y7&T<6JNRAQ/CKQ[;>['5=NQTZW, "7E'7P/#[Q?#,.!CYN=X_]
M>B3XG>N*\J1S1<U+WJ:B(8Z'\?#P=3VVV+EJ"C>&&79NLA_VNP"4WV^IA.\<
M&&?F8\ELBQGT? F?)3E)T7<J,P33!]VO5I*NB*;H*SQE\/FS0&\DS:EC=^*@
M5A,X\[A7<T-*-;)2LVBHT:"F-9MN=FQ;4UO#[P1$,<KL&'2%6C=]'#HYZT2R
M*I%;DTA;,HE(4^BB[353$ \:M8#'_C \+IE3LV 01V<*IIXK..I4,#?[@K%]
M"<U-)%\(DY>KH>[_>/#'W;I,E%DJ]EEK4RP=-7,1'35$I\EA /6TP>YQTVS9
MG83.2\)Q0\6HCR._\7>N6=5S!+L'2:-)=Q1U.BS.-&Q<#PKLGA2'+;NCCM%)
M<J)^/#HCI1X>V#T]W,V[H[3Q2?7$Q_OQU.2XP+S&J22C<F6/@PI:7\YU\3U9
MK59'SGM[T#I:?\"W,]RR/C='5'L*JNF+\^TW(F&#*932);CR^T/0*8LC8W&C
MQ<:>B=Z%AA.6O5S#,9M*8P#/ET+H_8UQ4!W<I_\#4$L#!!0    ( "I'6E*P
M*/??#00  /<0   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;,586V^C
M.!3^*U8T#S/2MF!#$C)*(DV;[N5AM%6[W7EVP0E6P69MD[3SZ_=@"!!":'>5
MJB\)-N?VG<_')R?SG51/.F;,H.<T$7HQBHW)OCJ.#F.64GTI,R;@S5JJE!I8
MJHVC,\5H9)72Q"&N.W%2RL5H.;=[MVHYE[E)N&"W"ND\3:EZN6*)W"U&>+3?
MN..;V!0;SG*>T0V[9^8ANU6P<FHK$4^9T%P*I-AZ,?J&OZZ(5RA8B;\YV^G6
M,RJ@/$KY5"S^B!8CMXB()2PTA0D*7UMVS9*DL 1Q_%,9'=4^"\7V\][ZKQ8\
M@'FDFEW+Y >/3+P8!2,4L37-$W,G=[^S"M"XL!?*1-M/M*MDW1$*<VUD6BE#
M!"D7Y3=]KA+14B#C$PJD4B =!>R?4/ J!>^M"GZEX-O,E%!L'E;4T.5<R1U2
MA318*QYL,JTVP.>BX/W>*'C+0<\L[XT,G]"?64&"1A>H7%]!)B-T+5,X7II:
M@FZ>BV>&/J^8H3S17T#XX7Z%/G_Z@CXA+M!?L<PU%9&>.P8"*\P[817$51D$
M.1$$)NB[%";6Z$9$+#HTX "B&A;9P[HB@Q97++Q$'OX%$9>X/0%=OUD=SWK4
M5V]7#P;0>#5)GK7G#9(D2Y(&[/FU/=_:\X?L73Q:DL,VR:PBF8LPR8$)RZLT
M- 'G3(&,V.QE>FDNW8ZMV^+&V2ZG>$KFSK:=^F,A/^@*K8Z%O"#P:Z$#V.,:
M]OAUV&](XZ2V-SD++=/:WO1C:"G=3EK)'$_)N$/+L9!//+=#R[&0-QV?H"6H
M80>#L!^$8J'<"/X3D&F;TP/TH=2F#U5P=$3P#$Y2?S"S.IC98# _;*-@T07=
M0F8W#-%4*L-_EJ% MKF,D%RC_'\&/>R=H!=&E48SE);W(0Y01%^&#A=VFYO>
M?27/6Z8!&K1K;10/31UY+K@9]-'J)O@L)8%)8Y%\3%%4?@_.#VX=G[(J*JF#
MLL#=JN@1<ON/(6ZN?.R]2U549MNPR&0V.Q%.TS'P<,MX[[IXQ?V^,+S_4!A-
M6\##?>$FS1+YPE@5;Y:K,(;SAK*$BB$'39_ YVD4N.D4^(-:1>7W\/BXW:(X
M;@/$ZW;P'B'LG2J+IE?@X69QQS0<A#!&\$L3?M]O87#)8 PQ0UEM[GX\.PM/
MI+ESR?"=^VX\57X/.G'@XPY1/5*$^)W.O^J1PM,@Z*>*-+V X$'LOS$!2!++
M%(U@=N'0=F@QY@VEMFD,A)R'K.;*)<-7[ON1=7PG>YYW1%;?S4VF7;)ZI-S9
MI$.6TYH(4Z8V=K+6@"H7IIRBZMUZ>O]F9];._A5,]>4,WI@I_Q+X3M6&P\R8
ML#68="^G$)(JI^QR861FY\Y':6"*M8\QHQ%3A0"\7TMI]HO"0?U?Q_)?4$L#
M!!0    ( "I'6E*X50DUSP(   P)   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8Y+GAM;)U6R6[;,!#]E8&  BG06)N7)+ -V%&"]A#42-#T4/1 2V.+,"6J
M)!W'?U^2DE4[D!0W%XG;>S-OAN1PO.-B(U-$!:\9R^7$294J;EQ7QBEF1/9X
M@;F>67&1$:6[8NW*0B!)+"AC;N!Y0S<C-'>F8SNV$-,QWRI&<UP(D-LL(V(_
M1\9W$\=W#@./=)TJ,^!.QP59XQ.J'\5"Z)Y;LR0TPUQ2GH/ U<29^3?1R*RW
M"YXI[N11&XR2)><;T_F63!S/.(0,8V48B/Z]X"TR9HBT&W\J3J<V:8#'[0/[
MO=6NM2R)Q%O.?M)$I1/GRH$$5V3+U"/??<5*S\#PQ9Q)^X5=N;9_[4"\E8IG
M%5A[D-&\_)/7*@Y' '_8 @@J0/ &$+0!P@H0GFNA7P'Z-C*E%!N'B"@R'0N^
M V%6:S;3L,&T:"V?YB;M3TKH6:IQ:OJD>+R![X5)@H1+N"=4P#-A6X29U'NA
MFKB(4!'*Y.>QJ[15@W7CRL*\M!"T6/ #>."Y2B7<Y0DFIP2N=K?V.3CX/ \Z
M&2.,>Q#Z7R#P J_!H=NSX?YU SPZ'W[5H2:L,Q!:OK M RD1>&GV;@(+LM='
M2L%,")*OT;9_S992"7T^?G<8Z]?&^M98O\78(Y6;RY5 !)HK%"@5"**P*:O=
M1'XO\#XUQ;X;%O3"1ECT'FST%G8B?U#+'W3RW+T6^K[1@4[H"TTP3V!/D25-
M\KN)O)[7+/]CL.B_82?RA[7\X7GR=>HSN-@C$<TGNIMF"!8)_A4D9"^;PM!-
M,#@0^)"55T,P;*.*SO,E&#00G 1I5 =I=%Z0I+T:"T%CA!?.B**,JGU3N+H)
M1_VVS?)!7/0.+FS;+NY1G<A0K&V]E1#S;:[*Z[<>K4OZS%:R-^-S7>K+ROR/
MIGPG/!"QIKI@,%QI2J\WTCM;E+6W["A>V&JTY$K7-MM,]7,%A5F@YU><JT/'
M&*@?0-._4$L#!!0    ( "I'6E*%K/[LT0(  +D(   9    >&PO=V]R:W-H
M965T<R]S:&5E=#<P+GAM;+U676_:,!3]*U:>5FDE'X0D5(#4%J9MTC94M.W9
M)!=BU8DSVX%VOW[72;!H^1B;IKV '=]S?.[QS75&6R$?50Z@R5/!2S5V<JVK
M&]=5:0X%53U108DK*R$+JG$JUZZJ)-"L 17<#3PO<@O*2F<R:I[-Y60D:LU9
M"7-)5%T45#[? 1?;L>,[NP</;)UK\\"=C"JZA@7HK]5<XLRU+!DKH%1,E$3"
M:NS<^C>SH8EO KXQV*J],3&9+(5X-),/V=CQC"#@D&K#0/%O _? N2%"&3\Z
M3L=N:8#[XQW[NR9WS&5)%=P+_IUE.A\[B4,R6-&:ZP>Q?0]=/@/#EPJNFE^R
M;6.CT"%IK;0H.C J*%C9_M.GSH<]@'\*$'2 X%) OP/T+P6$'2"\%##H $WJ
M;IM[8]R4:CH92;$ETD0CFQDT[C=H](N5IDX66N(J0YR>++1('\F7RIR:(M=D
M5E1</ .0=F%>RS3'<R!S3DOR9@J:,JZN,%#E5((:N1I%&"HW[3:\:S<,3FSX
MD98]XOEO2> %WA'X_7GX%-(>Z9^&3R^&^\,C\-GE\/@EW$7CK?N!=3]H^/JG
MW#<F7IM"SPC=4IFI,Z1]2]IO2,,3I)_K8@F2B%5W1O@Z*Y ;W +;"EG5NI9
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M%B!- *ZOA-"[B;E<[-?*Y!=02P,$%     @ *D=:4CWU4JY4 P   0L  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S$N>&ULI5;;3N,P$/T5*^(!)""7-KV@
MMA(0T*X$6@1[>7:326MM8F=MA\+?[]@)H91@NMJ7Q';FG#DSGM@SVPCY6ZT!
M-'DJ"Z[FWEKKZLSW5;J&DJI340''+[F0)=4XE2M?51)H9D%EX4=!,/)+RKBW
MF-FU.[F8B5H7C,.=)*HN2RJ?+Z 0F[D7>B\+]VRUUF;!7\PJNH('T#^J.XDS
MOV/)6 E<,<&)A'SNG8=GUV%D -;B)X.-VAH3$\I2B-]F\C6;>X%1! 6DVE!0
M?#W")12%84(=?UI2K_-I@-OC%_9K&SP&LZ0*+D7QBV5Z/?<F'LD@IW6A[\7F
M"[0!Q88O%86R3[)I;..11])::5&V8%10,MZ\Z5.;B"T \O0#HA80[0L8M(#!
M+N C2<,6,-P%##\ Q"T@WA<P:@$CF_LF63;3"=5T,9-B0Z2Q1C8SL-MET9A@
MQDUE/6B)7QGB].(&<%L4.2$)J%2RRF[W80*:LD(=X?J/AX0<'AR1 \(X^;X6
MM:(\4S-?HW-#X:>MHXO&4?2!HY#<"J[7BESQ#+(>_*4;/_@,GWSB/W(0^)BU
M+G712^HN(B?C+96G9! >DRB(@KZ _@^>N.$)I$[XU=[P<-H#O]Y;_"[\32X'
M71D.+-_ 688.HF%'-+1$PP^(O@.G7!-65E(\ AZ!FM "CT_*4^@KVH8MMFSF
M%'Y<A.-HYC_V2(@[";%3PE>>2A..^6$*.R@87;*":;8;8E,G\3L-T^DDZ!<Q
MZD2,]A8AS>EZ(O*3&N=4*=!]*D;_H&+<J1@[5=R UB")R FJR9@F>!42!6DM
MF7[&"Z 2BO6)2<;OQ RBL-/2%+C;YHW>2:=WXM1[;I*C2(TGA"0YXZ9JFCWL
MV[AD\D[!,)KNJ-S#YMIM\R:2:1?)U!G)MSQGJ%U5-(5C<DG+I639"H>WY\?$
M_FVN(S ,7J^/X/]^W'#K)@J=DN^!PX86!"NF[#W?W?"8/ .53BG1JY3HD[K%
M0L!D80,GJ69\U13!,8$GIC28JL":%LUMJ04NXV+_I>1VI&4-?8K]K1N]!+FR
MO9<BJ:BY;B[W;K7K[\YM5^._FC?-(1[5*\851I C-#@=8YW)IM]J)EI4MC]8
M"HW=AAVNL4<%:0SP>RZ$?ID8!UW7N_@+4$L#!!0    ( "I'6E*+3Q1_N0(
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M_58^Q9O$LJ;9:;-V.A&TTMN71RKD9D@?[N4&%S,5(.]O*14O)VI'U&Z95[\
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MK&" 70K!OC>SA1 <I=!97.A2R;-;HQ9):!A)YT(!=9FDZ=OCWB()#2/I-4A
M72Q=H+ G@Q9*Z#50.A<(==#CS<8I(-V#K6U.Q+8\(DBPY@53U<:P&6V.(5?E
MYOMD_%H?3ZK#1!NF.MO<8;&E3.JD-SJD=QGIC$1U7*AN%-^5&^@55WH[7EZF
M^HA%A)F@?]]PKEYNC$%S:%O\ 5!+ P04    "  J1UI288K%T4D#   ?#
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M[0*:+Y7"AXXU,/P3K'X 4$L#!!0    ( "I'6E)!:3.\I@,  "\-   9
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M+Y9<NU^RKFP#C\2%-C*OG)$@9Z+\IYLJ#SL.[>B,0U@YA <.8>N,0[MR:+M
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MG&+.](4L4-#-3*J<&=JJN:\+A2QQH#SSPR#H^#GCPAOVW=E4#?MR83(N<*I
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MO#_\X_CE68^NGY[SV?(/_9M?4$L! A0#%     @ *D=:4@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  J1UI2G8RTC.\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  J1UI2F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "I'6E*^
M=X2+,08  %<9   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  J1UI2<;FR*<P%  "@%P  &
M    @(%U#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M*D=:4BC %YS% @  JPD  !@              ("!=Q0  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "I'6E)]P1 6%04  )$3   8
M          " @7(7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  J1UI21=3.G0D(  !2*0  &               @(&]'   >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ *D=:4A=F:!&! @  5 8
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M965T,3 N>&UL4$L! A0#%     @ *D=:4GEJZ.@[!   > D  !D
M     ("!BG<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "I'6E))# 8.QP<  )L4   9              "
M@7V.  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ *D=:
M4IEY'^;U"P  *R   !D              ("!>Y8  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  J1UI2M$G^JQ4(  !J)   &0
M        @(&GH@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( "I'6E)QIMN#N@H  (@=   9              " @?.J  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ *D=:4GC",#B  P  +0@
M !D              ("!Y+4  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  J1UI2=RTAA;8"   Y!@  &0              @(&;N0
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "I'6E(E"F[#
M%P4  'X-   9              " @8B\  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ *D=:4L_[1D_0)0  %((  !D
M ("!UL$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  J
M1UI22;)-VFH$  !_#   &0              @('=YP  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "I'6E)ID;?@1 ,  ,X(   9
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M970R.2YX;6Q02P$"% ,4    "  J1UI2EV<-T  #  #^!@  &0
M    @($/_   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M "I'6E*''Y0]E (  &T%   9              " @4;_  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ *D=:4C"C%)B=!0  = \  !D
M             ("!$0(! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  J1UI2W$36/:P$  #0#@  &0              @('E!P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "I'6E+U('=J0 0
M -T)   9              " @<@, 0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ *D=:4A1+H>$D!0  6@T  !D              ("!
M/Q$! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  J1UI2
M,\,SN4,$   +$0  &0              @(&:%@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( "I'6E*/Q ?K_P(  !H)   9
M      " @10; 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ *D=:4NFEL@RU @  O0<  !D              ("!2AX! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  J1UI2,1A.&58"  #&!0
M&0              @($V(0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( "I'6E*=CB\(2 (  /$%   9              " @<,C 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ *D=:4I>OU_A5
M P  'PP  !D              ("!0B8! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  J1UI2@_4=$YX"  #E!P  &0
M@('.*0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( "I'
M6E*0)6$;,0(  )T$   9              " @:,L 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ *D=:4C^E^1PR @  (@8  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( "I'6E+3G9[)ZP0  / 4   9
M  " @<]! 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M*D=:4A'> 6Y: P  T0H  !D              ("!\48! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    "  J1UI2F_3YAJ0#  #D#@  &0
M            @(&"2@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( "I'6E+L>53.9P0  *,:   9              " @5U. 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ *D=:4IV^#""3 P
MC X  !D              ("!^U(! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    "  J1UI2=B9<Q84#  "4#0  &0              @('%
M5@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( "I'6E+<
MOG!=D0(   T'   9              " @8%: 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ *D=:4M;7@1=(!0  0!P  !D
M     ("!25T! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "I'6E(A"<4H]@(  !8(   9              "
M@3AO 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ *D=:
M4K?OZ'WP @  YP@  !D              ("!97(! 'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    "  J1UI2%HZ)>) #   J#@  &0
M        @(&,=0$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( "I'6E(',M))0@,  *D+   9              " @5-Y 0!X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ *D=:4K0?NZF? @  E0@
M !D              ("!S'P! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    "  J1UI2Q E32JT$   D$@  &0              @(&B?P$
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( "I'6E)F.^O2
M0 0  ,0/   9              " @8:$ 0!X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ *D=:4K H]]\-!   ]Q   !D
M ("!_8@! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    "  J
M1UI2N%4)-<\"   ,"0  &0              @(%!C0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( "I'6E*%K/[LT0(  +D(   9
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M970W-"YX;6Q02P$"% ,4    "  J1UI2O,E?TZ4#  # #0  &0
M    @('<H $ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (
M "I'6E)ABL7120,  !\,   9              " @;BD 0!X;"]W;W)K<VAE
M971S+W-H965T-S8N>&UL4$L! A0#%     @ *D=:4D%I,[RF P  +PT  !D
M             ("!.*@! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"
M% ,4    "  J1UI2&!-B*%\"  "W!@  &0              @($5K $ >&PO
M=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( "I'6E("_N92'@(
M &8%   9              " @:NN 0!X;"]W;W)K<VAE971S+W-H965T-SDN
M>&UL4$L! A0#%     @ *D=:4L_VSP0. P  E @  !D              ("!
M +$! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4    "  J1UI2
MRFO\?E,#  !T"P  &0              @(%%M $ >&PO=V]R:W-H965T<R]S
M:&5E=#@Q+GAM;%!+ 0(4 Q0    ( "I'6E*>)\'JN0(  !4(   9
M      " @<^W 0!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%
M  @ *D=:4LO?=N4*!P  FB$  !D              ("!O[H! 'AL+W=O<FMS
M:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    "  J1UI2JJS!TCH"  """@
M#0              @ $ P@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "I'
M6E*7BKL<P    !,"   +              "  67$ 0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( "I'6E)O7";D5 8  (PV   /              "  4[% 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  J1UI2-$X[?7H"    ,0  &@
M            @ '/RP$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  J1UI2(' .V20"  "I+P  $P              @ &!S@$ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     6P!; /08  #6T $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>227</ContextCount>
  <ElementCount>463</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/NatureofBusinessandBasisofPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2114103 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2123104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2126105 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2129106 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132107 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135108 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2140109 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2147110 - Disclosure - Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptions</Role>
      <ShortName>Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2156111 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2163112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2170113 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2172114 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2174115 - Disclosure - Selected Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnaudited</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.mersana.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2315302 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/CollaborationAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2324303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2327304 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/MarketableSecurities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/PropertyandEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/AccruedexpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/Debt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2341308 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/StockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2348309 - Disclosure - Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsTables</Role>
      <ShortName>Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/StockOptions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2357310 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2364311 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2375312 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/NatureofBusinessandBasisofPresentation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of significant accounting policies - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails</Role>
      <ShortName>Summary of significant accounting policies - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of significant accounting policies - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails</Role>
      <ShortName>Summary of significant accounting policies - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of significant accounting policies - Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails</Role>
      <ShortName>Summary of significant accounting policies - Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Stock Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Stock Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of significant accounting policies - Net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails</Role>
      <ShortName>Summary of significant accounting policies - Net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Summary of significant accounting policies - Risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRisksDetails</Role>
      <ShortName>Summary of significant accounting policies - Risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2413409 - Disclosure - Summary of significant accounting policies - Recently Issued Accounting Pronouncement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails</Role>
      <ShortName>Summary of significant accounting policies - Recently Issued Accounting Pronouncement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Collaboration Agreements - Merck KGaA (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail</Role>
      <ShortName>Collaboration Agreements - Merck KGaA (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Collaboration Agreements - Merck KGaA - Accounting Analysis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails</Role>
      <ShortName>Collaboration Agreements - Merck KGaA - Accounting Analysis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2418412 - Disclosure - Collaboration Agreements - Takeda XMT-1522 Strategic Partnership (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails</Role>
      <ShortName>Collaboration Agreements - Takeda XMT-1522 Strategic Partnership (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2419413 - Disclosure - Collaboration Agreements - Takeda strategic R &amp; D partnership (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails</Role>
      <ShortName>Collaboration Agreements - Takeda strategic R &amp; D partnership (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2420414 - Disclosure - Collaboration Agreements - Takeda - Accounting Analysis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails</Role>
      <ShortName>Collaboration Agreements - Takeda - Accounting Analysis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2421415 - Disclosure - Collaboration Agreements - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Collaboration Agreements - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2422416 - Disclosure - Collaboration Agreements - Other Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails</Role>
      <ShortName>Collaboration Agreements - Other Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2425417 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2428418 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2431419 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/AccruedExpenses</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Debt - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/DebtComponentsDetails</Role>
      <ShortName>Debt - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2439423 - Disclosure - Debt - Future payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/DebtFuturepaymentsDetails</Role>
      <ShortName>Debt - Future payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Stockholders' Equity Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2443425 - Disclosure - Stockholders' Equity At-the-market Equity and Follow On Offering Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails</Role>
      <ShortName>Stockholders' Equity At-the-market Equity and Follow On Offering Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2444426 - Disclosure - Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockholdersEquityWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - Stockholders' Equity - Exchange Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Exchange Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2446428 - Disclosure - Stockholders' Equity - Common stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockholdersEquityCommonstockDetails</Role>
      <ShortName>Stockholders' Equity - Common stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - Stock Options - Plans Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsPlansNarrativeDetails</Role>
      <ShortName>Stock Options - Plans Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2450430 - Disclosure - Stock Options - Inducement Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsInducementNarrativeDetails</Role>
      <ShortName>Stock Options - Inducement Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2451431 - Disclosure - Stock Options - Activity Under Stock Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails</Role>
      <ShortName>Stock Options - Activity Under Stock Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2452432 - Disclosure - Stock Options - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails</Role>
      <ShortName>Stock Options - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2453433 - Disclosure - Stock Options - Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Options - Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2454434 - Disclosure - Stock Options - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails</Role>
      <ShortName>Stock Options - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2455435 - Disclosure - Stock Options - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock Options - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2458436 - Disclosure - Leases - Description (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/LeasesDescriptionDetails</Role>
      <ShortName>Leases - Description (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2459437 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2460438 - Disclosure - Leases - Supplemental balance sheet information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails</Role>
      <ShortName>Leases - Supplemental balance sheet information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2461439 - Disclosure - Leases - Supplemental cash flow information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails</Role>
      <ShortName>Leases - Supplemental cash flow information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2462440 - Disclosure - Leases - Future minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails</Role>
      <ShortName>Leases - Future minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2465441 - Disclosure - Income Taxes - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesReconciliationDetails</Role>
      <ShortName>Income Taxes - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2466442 - Disclosure - Income Taxes - Components of deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails</Role>
      <ShortName>Income Taxes - Components of deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2467443 - Disclosure - Income Taxes - Net operating loss carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails</Role>
      <ShortName>Income Taxes - Net operating loss carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2468444 - Disclosure - Income Taxes - Tax credit carryforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails</Role>
      <ShortName>Income Taxes - Tax credit carryforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2469445 - Disclosure - Income Taxes - Valuation allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails</Role>
      <ShortName>Income Taxes - Valuation allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2471446 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2473447 - Disclosure - Commitments - License agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CommitmentsLicenseagreementsDetails</Role>
      <ShortName>Commitments - License agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="mrsn-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2476448 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="mrsn-20201231.htm">mrsn-20201231.htm</File>
    <File>exhibit21110kfy2020q4.htm</File>
    <File>exhibit23110kfy2020q4.htm</File>
    <File>exhibit31110kfy2020q4.htm</File>
    <File>exhibit31210kfy2020q4.htm</File>
    <File>exhibit32110kfy2020q4.htm</File>
    <File>mrsn-20201231.xsd</File>
    <File>mrsn-20201231_cal.xml</File>
    <File>mrsn-20201231_def.xml</File>
    <File>mrsn-20201231_lab.xml</File>
    <File>mrsn-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrsn-20201231_g1.jpg</File>
    <File>mrsn-20201231_g10.jpg</File>
    <File>mrsn-20201231_g2.jpg</File>
    <File>mrsn-20201231_g3.jpg</File>
    <File>mrsn-20201231_g4.jpg</File>
    <File>mrsn-20201231_g5.jpg</File>
    <File>mrsn-20201231_g6.jpg</File>
    <File>mrsn-20201231_g7.jpg</File>
    <File>mrsn-20201231_g8.jpg</File>
    <File>mrsn-20201231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>112
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrsn-20201231.htm": {
   "axisCustom": 1,
   "axisStandard": 23,
   "contextCount": 227,
   "dts": {
    "calculationLink": {
     "local": [
      "mrsn-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrsn-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mrsn-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrsn-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrsn-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mrsn-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 618,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 9,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 13
   },
   "keyCustom": 72,
   "keyStandard": 391,
   "memberCustom": 43,
   "memberStandard": 30,
   "nsprefix": "mrsn",
   "nsuri": "http://www.mersana.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.mersana.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114103 - Disclosure - Collaboration Agreements",
     "role": "http://www.mersana.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123104 - Disclosure - Fair Value Measurements",
     "role": "http://www.mersana.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126105 - Disclosure - Marketable Securities",
     "role": "http://www.mersana.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129106 - Disclosure - Property and Equipment",
     "role": "http://www.mersana.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132107 - Disclosure - Accrued Expenses",
     "role": "http://www.mersana.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135108 - Disclosure - Debt",
     "role": "http://www.mersana.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140109 - Disclosure - Stockholders' Equity",
     "role": "http://www.mersana.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147110 - Disclosure - Stock Options",
     "role": "http://www.mersana.com/role/StockOptions",
     "shortName": "Stock Options",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156111 - Disclosure - Leases",
     "role": "http://www.mersana.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163112 - Disclosure - Income Taxes",
     "role": "http://www.mersana.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.mersana.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170113 - Disclosure - Employee Benefit Plan",
     "role": "http://www.mersana.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2172114 - Disclosure - Commitments",
     "role": "http://www.mersana.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2174115 - Disclosure - Selected Quarterly Financial Data (Unaudited)",
     "role": "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnaudited",
     "shortName": "Selected Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315302 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://www.mersana.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.mersana.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327304 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.mersana.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.mersana.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Accrued expenses (Tables)",
     "role": "http://www.mersana.com/role/AccruedexpensesTables",
     "shortName": "Accrued expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Debt (Tables)",
     "role": "http://www.mersana.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341308 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.mersana.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348309 - Disclosure - Stock Options (Tables)",
     "role": "http://www.mersana.com/role/StockOptionsTables",
     "shortName": "Stock Options (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357310 - Disclosure - Leases (Tables)",
     "role": "http://www.mersana.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364311 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.mersana.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2375312 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedTables",
     "shortName": "Selected Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)",
     "role": "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails",
     "shortName": "Nature of Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrsn:RevenueCollectionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of significant accounting policies - Revenue Recognition (Details)",
     "role": "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails",
     "shortName": "Summary of significant accounting policies - Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrsn:RevenueCollectionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of significant accounting policies - Cash and Cash Equivalents (Details)",
     "role": "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails",
     "shortName": "Summary of significant accounting policies - Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i0c4249c91c854c66a6b84b2a99e5fa0a_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of significant accounting policies - Other Assets (Details)",
     "role": "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails",
     "shortName": "Summary of significant accounting policies - Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RetainageDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Stock Based Compensation (Details)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails",
     "shortName": "Summary of Significant Accounting Policies - Stock Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of significant accounting policies - Net loss per share (Details)",
     "role": "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails",
     "shortName": "Summary of significant accounting policies - Net loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i2ca1a08f33fc491daa2aa0165f719267_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i2ca1a08f33fc491daa2aa0165f719267_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412408 - Disclosure - Summary of significant accounting policies - Risks (Details)",
     "role": "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRisksDetails",
     "shortName": "Summary of significant accounting policies - Risks (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413409 - Disclosure - Summary of significant accounting policies - Recently Issued Accounting Pronouncement (Details)",
     "role": "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails",
     "shortName": "Summary of significant accounting policies - Recently Issued Accounting Pronouncement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ic742200b058d41098d52ab5f0e3428b8_D20140601-20140630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:CollaborativeArrangementsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Collaboration Agreements - Merck KGaA (Detail)",
     "role": "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail",
     "shortName": "Collaboration Agreements - Merck KGaA (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ic742200b058d41098d52ab5f0e3428b8_D20140601-20140630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:CollaborativeArrangementsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Collaboration Agreements - Merck KGaA - Accounting Analysis (Details)",
     "role": "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails",
     "shortName": "Collaboration Agreements - Merck KGaA - Accounting Analysis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i5fa45b03b28a4c988f4645fd9a126190_I20180101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "mrsn:MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i5cfc255c5b5348df8b706ecee6e18fc5_D20190102-20190102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrsn:CollaborationArrangementsDurationToTermination",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418412 - Disclosure - Collaboration Agreements - Takeda XMT-1522 Strategic Partnership (Details)",
     "role": "http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails",
     "shortName": "Collaboration Agreements - Takeda XMT-1522 Strategic Partnership (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i5cfc255c5b5348df8b706ecee6e18fc5_D20190102-20190102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrsn:CollaborationArrangementsDurationToTermination",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i753b8ff92fff46fea6569a01931d0c30_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:CollaborativeArrangementsExclusiveTargetsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "target",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419413 - Disclosure - Collaboration Agreements - Takeda strategic R & D partnership (Details)",
     "role": "http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails",
     "shortName": "Collaboration Agreements - Takeda strategic R & D partnership (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i753b8ff92fff46fea6569a01931d0c30_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:CollaborativeArrangementsExclusiveTargetsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "target",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420414 - Disclosure - Collaboration Agreements - Takeda - Accounting Analysis (Details)",
     "role": "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails",
     "shortName": "Collaboration Agreements - Takeda - Accounting Analysis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i50edd11bfb47457a9112b1ae5cb86665_D20190101-20190331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "iec68d7798d0041aaa3817b210b456dc3_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "iec68d7798d0041aaa3817b210b456dc3_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421415 - Disclosure - Collaboration Agreements - Contract Assets and Liabilities (Details)",
     "role": "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails",
     "shortName": "Collaboration Agreements - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422416 - Disclosure - Collaboration Agreements - Other Revenue (Details)",
     "role": "http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails",
     "shortName": "Collaboration Agreements - Other Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i23577b731ce742d9a2dc95f75f3ed39e_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ie7a39af3ac91431f9135e7905754c66c_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425417 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.mersana.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "icbc4ff85c1d24045ab6977cd50a5b2e9_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428418 - Disclosure - Marketable Securities (Details)",
     "role": "http://www.mersana.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431419 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.mersana.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:AccruedPreclinicalAndClinicalExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.mersana.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:AccruedPreclinicalAndClinicalExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.mersana.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ic7699dd1563a4628924b1afe47e1a4dd_D20190508-20190508",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Debt - Components (Details)",
     "role": "http://www.mersana.com/role/DebtComponentsDetails",
     "shortName": "Debt - Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "mrsn:DebtInstrumentCarryingAmountNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439423 - Disclosure - Debt - Future payments (Details)",
     "role": "http://www.mersana.com/role/DebtFuturepaymentsDetails",
     "shortName": "Debt - Future payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Stockholders' Equity Preferred Stock (Details)",
     "role": "http://www.mersana.com/role/StockholdersEquityPreferredStockDetails",
     "shortName": "Stockholders' Equity Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "idbfd3b132fb84bca9aadac495eeb85eb_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "iab9b2892056c4107bc99217b78b467ca_I20180731",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:StockIssuanceProgramAuthorizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443425 - Disclosure - Stockholders' Equity At-the-market Equity and Follow On Offering Programs (Details)",
     "role": "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails",
     "shortName": "Stockholders' Equity At-the-market Equity and Follow On Offering Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "iab9b2892056c4107bc99217b78b467ca_I20180731",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:StockIssuanceProgramAuthorizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i06524015ee73497b86e333130cd09189_D20130101-20131231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444426 - Disclosure - Stockholders' Equity - Warrants (Details)",
     "role": "http://www.mersana.com/role/StockholdersEquityWarrantsDetails",
     "shortName": "Stockholders' Equity - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i06524015ee73497b86e333130cd09189_D20130101-20131231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "id811a98ebc9446e780342c9c938b83b6_I20131231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - Stockholders' Equity - Exchange Warrants (Details)",
     "role": "http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails",
     "shortName": "Stockholders' Equity - Exchange Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i317cfb0a66ce420aba39052cc61dd3f7_D20191126-20191126",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mrsn:ClassOfWarrantOrRightSharesExchangedForWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446428 - Disclosure - Stockholders' Equity - Common stock (Details)",
     "role": "http://www.mersana.com/role/StockholdersEquityCommonstockDetails",
     "shortName": "Stockholders' Equity - Common stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i6e5bfe19343142b3906779afeba94ec7_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mrsn:NumberOfVotesPerCommonShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - Stock Options - Plans Narrative (Details)",
     "role": "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails",
     "shortName": "Stock Options - Plans Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i7a5864a7879b4087ac73cb3bfcccd0e8_I20170630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450430 - Disclosure - Stock Options - Inducement Narrative (Details)",
     "role": "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails",
     "shortName": "Stock Options - Inducement Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "id1c52f697f3447aca0d47be353863ce4_D20201130-20201130",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ie7a39af3ac91431f9135e7905754c66c_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451431 - Disclosure - Stock Options - Activity Under Stock Option Plan (Details)",
     "role": "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails",
     "shortName": "Stock Options - Activity Under Stock Option Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i23c524872861491cbbc5e13e4cf5d051_D20200101-20200131",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452432 - Disclosure - Stock Options - Restricted Stock Units (Details)",
     "role": "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails",
     "shortName": "Stock Options - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i23c524872861491cbbc5e13e4cf5d051_D20200101-20200131",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453433 - Disclosure - Stock Options - Stock Based Compensation Expense (Details)",
     "role": "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails",
     "shortName": "Stock Options - Stock Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454434 - Disclosure - Stock Options - Fair Value Assumptions (Details)",
     "role": "http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails",
     "shortName": "Stock Options - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455435 - Disclosure - Stock Options - Employee Stock Purchase Plan (Details)",
     "role": "http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails",
     "shortName": "Stock Options - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i6f8aac06008a4724ae9284b7cc253a25_I20171231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "if3d5650f067549778be0f063470fcbca_D20200301-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:TenantImprovementAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458436 - Disclosure - Leases - Description (Details)",
     "role": "http://www.mersana.com/role/LeasesDescriptionDetails",
     "shortName": "Leases - Description (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "if3d5650f067549778be0f063470fcbca_D20200301-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:TenantImprovementAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459437 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrsn:LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460438 - Disclosure - Leases - Supplemental balance sheet information (Details)",
     "role": "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails",
     "shortName": "Leases - Supplemental balance sheet information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrsn:LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrsn:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461439 - Disclosure - Leases - Supplemental cash flow information (Details)",
     "role": "http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails",
     "shortName": "Leases - Supplemental cash flow information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mrsn:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462440 - Disclosure - Leases - Future minimum lease payments (Details)",
     "role": "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails",
     "shortName": "Leases - Future minimum lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465441 - Disclosure - Income Taxes - Reconciliation (Details)",
     "role": "http://www.mersana.com/role/IncomeTaxesReconciliationDetails",
     "shortName": "Income Taxes - Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466442 - Disclosure - Income Taxes - Components of deferred tax assets (Details)",
     "role": "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails",
     "shortName": "Income Taxes - Components of deferred tax assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ic059f7a3532745518966900be47d1c47_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467443 - Disclosure - Income Taxes - Net operating loss carryforwards (Details)",
     "role": "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails",
     "shortName": "Income Taxes - Net operating loss carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ic059f7a3532745518966900be47d1c47_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia1a16dd07ee341a0b4a2267c3b6bd737_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468444 - Disclosure - Income Taxes - Tax credit carryforward (Details)",
     "role": "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails",
     "shortName": "Income Taxes - Tax credit carryforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia1a16dd07ee341a0b4a2267c3b6bd737_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Business and Basis of Presentation",
     "role": "http://www.mersana.com/role/NatureofBusinessandBasisofPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i02a979a8932342d78dec04dc805709b8_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469445 - Disclosure - Income Taxes - Valuation allowance (Details)",
     "role": "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails",
     "shortName": "Income Taxes - Valuation allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrsn:DefinedContributionPlanEligibleAgeToParticipate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471446 - Disclosure - Employee Benefit Plan (Details)",
     "role": "http://www.mersana.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrsn:DefinedContributionPlanEligibleAgeToParticipate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i4114a3ad19d943caa2f08b5649e9e275_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473447 - Disclosure - Commitments - License agreements (Details)",
     "role": "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails",
     "shortName": "Commitments - License agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i4114a3ad19d943caa2f08b5649e9e275_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476448 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Details)",
     "role": "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails",
     "shortName": "Selected Quarterly Financial Data (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "i880c596025ba42f3929eb3b9e553c9f8_D20201001-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20201231.htm",
      "contextRef": "ia8f204faa7704411a0850b074d255000_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 79,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrsn_AccruedPreclinicalAndClinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for preclinical, manufacturing and clinical expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Preclinical And Clinical Expenses Current",
        "terseLabel": "Accrued preclinical, manufacturing and clinical expenses"
       }
      }
     },
     "localname": "AccruedPreclinicalAndClinicalExpensesCurrent",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment To Retained Earnings, Deferred Revenue Upon Adoption Of New Accounting Standard",
        "label": "Adjustment To Retained Earnings, Deferred Revenue Upon Adoption Of New Accounting Standard",
        "negatedLabel": "Adjustment to accumulated deficit and deferred revenue upon adoption of Topic 606"
       }
      }
     },
     "localname": "AdjustmentToRetainedEarningsDeferredRevenueUponAdoptionOfNewAccountingStandard",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_AmendedCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Facility",
        "label": "Amended Credit Facility [Member]",
        "terseLabel": "Amended Credit Facility"
       }
      }
     },
     "localname": "AmendedCreditFacilityMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AmendedCreditFacilityTrancheFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Facility, Tranche Five",
        "label": "Amended Credit Facility, Tranche Five [Member]",
        "terseLabel": "Amended Credit Facility, Tranche Five"
       }
      }
     },
     "localname": "AmendedCreditFacilityTrancheFiveMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AmendedCreditFacilityTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Facility, Tranche Four",
        "label": "Amended Credit Facility, Tranche Four [Member]",
        "terseLabel": "Amended Credit Facility, Tranche Four"
       }
      }
     },
     "localname": "AmendedCreditFacilityTrancheFourMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AmendedCreditFacilityTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Facility, Tranche One",
        "label": "Amended Credit Facility, Tranche One [Member]",
        "terseLabel": "Amended Credit Facility, Tranche One"
       }
      }
     },
     "localname": "AmendedCreditFacilityTrancheOneMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AmendedCreditFacilityTrancheSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Facility, Tranche Six",
        "label": "Amended Credit Facility, Tranche Six [Member]",
        "terseLabel": "Amended Credit Facility, Tranche Six"
       }
      }
     },
     "localname": "AmendedCreditFacilityTrancheSixMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AmendedCreditFacilityTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Facility, Tranche Three",
        "label": "Amended Credit Facility, Tranche Three [Member]",
        "terseLabel": "Amended Credit Facility, Tranche Three"
       }
      }
     },
     "localname": "AmendedCreditFacilityTrancheThreeMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AmendedCreditFacilityTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Facility, Tranche Two",
        "label": "Amended Credit Facility, Tranche Two [Member]",
        "terseLabel": "Amended Credit Facility, Tranche Two"
       }
      }
     },
     "localname": "AmendedCreditFacilityTrancheTwoMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AtMarketEquityOfferingProgram2018ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market equity offering program to offer and sell common stock from time to time at prevailing market prices.",
        "label": "At Market Equity Offering Program (2018 ATM) [Member]",
        "terseLabel": "At market equity offering program (2018 ATM)"
       }
      }
     },
     "localname": "AtMarketEquityOfferingProgram2018ATMMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AtMarketEquityOfferingProgram2020ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At Market Equity Offering Program (2020 ATM)",
        "label": "At Market Equity Offering Program (2020 ATM) [Member]",
        "terseLabel": "At Market Equity Offering Program (2020 ATM)"
       }
      }
     },
     "localname": "AtMarketEquityOfferingProgram2020ATMMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AtMarketEquityOfferingProgram559PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At Market Equity Offering Program, 5.59 per Share",
        "label": "At Market Equity Offering Program, 5.59 per Share [Member]",
        "terseLabel": "At Market Equity Offering Program, 5.59 per Share"
       }
      }
     },
     "localname": "AtMarketEquityOfferingProgram559PerShareMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AtMarketEquityOfferingProgram774PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At Market Equity Offering Program, 7.74 per Share",
        "label": "At Market Equity Offering Program, 7.74 per Share [Member]",
        "terseLabel": "At Market Equity Offering Program, 7.74 per Share"
       }
      }
     },
     "localname": "AtMarketEquityOfferingProgram774PerShareMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ChangeInContractAssetsAndLiabilitiesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract Assets And Liabilities",
        "label": "Change In Contract Assets And Liabilities [Roll Forward]",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ChangeInContractAssetsAndLiabilitiesRollForward",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_ChangeInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of change in deferred rent during the reporting period.",
        "label": "Change in Deferred Rent",
        "terseLabel": "Change in deferred rent"
       }
      }
     },
     "localname": "ChangeInDeferredRent",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right issued during the period may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Securities Called by Warrants or Rights, Number Issued",
        "terseLabel": "Number of shares into which warrant issued during period may be converted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares exchanged for warrants.",
        "label": "Class of Warrant or Right, Shares Exchanged for Warrants",
        "terseLabel": "Number of common shares exchanged for warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightSharesExchangedForWarrants",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_CollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Collaboration agreements",
        "terseLabel": "Collaboration agreements"
       }
      }
     },
     "localname": "CollaborationAgreementsAbstract",
     "nsuri": "http://www.mersana.com/20201231",
     "xbrltype": "stringItemType"
    },
    "mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Collaboration and Commercial License Agreement with Merck KGaA and the Supply Agreement with Merck KGaA.",
        "label": "Collaboration And Commercial License Agreement And Supply Agreement Merck Kgaa [Member]",
        "terseLabel": "Merck KGaA Agreement and Merck KGaA supply agreement"
       }
      }
     },
     "localname": "CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Collaboration and Commercial License Agreement with Asana BioSciences, an existing partner.",
        "label": "Collaboration And Commercial License Agreement Asana Bio Sciences [Member]",
        "terseLabel": "Asana BioSciences"
       }
      }
     },
     "localname": "CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Collaboration and Commercial License Agreement with Merck KGaA.",
        "label": "Collaboration And Commercial License Agreement Merck Kgaa [Member]",
        "terseLabel": "Merck KGaA"
       }
      }
     },
     "localname": "CollaborationAndCommercialLicenseAgreementMerckKgaaMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails",
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of individual commercial milestones per target.",
        "label": "Collaboration Arrangement Individual Commercial Milestones Target Number",
        "terseLabel": "Number of individual commercial milestones"
       }
      }
     },
     "localname": "CollaborationArrangementIndividualCommercialMilestonesTargetNumber",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of individual development milestones per target.",
        "label": "Collaboration Arrangement Individual Development Milestones Target Number",
        "terseLabel": "Number of individual development milestones per target"
       }
      }
     },
     "localname": "CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of individual regulatory milestones per target.",
        "label": "Collaboration Arrangement Individual Regulatory Milestones Target Number",
        "terseLabel": "Number of individual regulatory milestones per target"
       }
      }
     },
     "localname": "CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional fees receivable when a target is designated and the commercial license to the target is granted under terms of the agreement.",
        "label": "Collaboration Arrangements, Additional Payment to Obtain a Development and Commercial License",
        "terseLabel": "Amount of additional fees receivable when target is designated and commercial license to target is granted"
       }
      }
     },
     "localname": "CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsCostsBilled": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs billed during the period under terms of agreement.",
        "label": "Collaboration Arrangements, Costs Billed",
        "terseLabel": "ASC 808 costs billed to Takeda"
       }
      }
     },
     "localname": "CollaborationArrangementsCostsBilled",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsDevelopmentMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail": {
       "order": 1.0,
       "parentTag": "mrsn_CollaborationArrangementsMaximumAggregateMilestones",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum development milestone amount the company is entitled to receive under terms of the agreement.",
        "label": "Collaboration Arrangements, Development Milestones",
        "terseLabel": "Development milestones"
       }
      }
     },
     "localname": "CollaborationArrangementsDevelopmentMilestones",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the next potential development milestone the company will be eligible to receive.",
        "label": "Collaboration Arrangements, Development Milestones Payment Receivable, Next Milestone",
        "terseLabel": "Next potential development milestone payment eligible to receive"
       }
      }
     },
     "localname": "CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the development milestone payment received by the entity.",
        "label": "Collaboration Arrangements, Development Milestones Payment Received",
        "terseLabel": "Amount of development milestone payment received"
       }
      }
     },
     "localname": "CollaborationArrangementsDevelopmentMilestonesPaymentReceived",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsDurationToTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time before which agreement will be terminated due to counter party serving prior written notice, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Collaboration Arrangements, Duration to Termination",
        "terseLabel": "Period of time until agreement terminated"
       }
      }
     },
     "localname": "CollaborationArrangementsDurationToTermination",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_CollaborationArrangementsMaximumAggregateMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate milestone the Company is entitled to receive under terms of the agreement.",
        "label": "Collaboration Arrangements, Maximum Aggregate Milestones",
        "totalLabel": "Aggregate milestones"
       }
      }
     },
     "localname": "CollaborationArrangementsMaximumAggregateMilestones",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the next potential milestone the company will be eligible to receive.",
        "label": "Collaboration Arrangements, Milestone Payment Receivable, Next Milestone",
        "terseLabel": "Next potential milestone payment eligible to receive"
       }
      }
     },
     "localname": "CollaborationArrangementsMilestonePaymentReceivableNextMilestone",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time before which prior written notice needs to be served for termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Collaboration Arrangements, Prior Written Termination Notice, Duration",
        "terseLabel": "Prior written notice for termination period"
       }
      }
     },
     "localname": "CollaborationArrangementsPriorWrittenTerminationNoticeDuration",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_CollaborationArrangementsRegulatoryMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail": {
       "order": 2.0,
       "parentTag": "mrsn_CollaborationArrangementsMaximumAggregateMilestones",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum regulatory milestone amount the company is entitled to receive under terms of the agreement.",
        "label": "Collaboration Arrangements, Regulatory Milestones",
        "terseLabel": "Regulatory milestones"
       }
      }
     },
     "localname": "CollaborationArrangementsRegulatoryMilestones",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsSalesMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail": {
       "order": 3.0,
       "parentTag": "mrsn_CollaborationArrangementsMaximumAggregateMilestones",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum sales milestone amount the company is entitled to receive under terms of the agreement.",
        "label": "Collaboration Arrangements, Sales Milestones",
        "terseLabel": "Sales milestones"
       }
      }
     },
     "localname": "CollaborationArrangementsSalesMilestones",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time following effective termination date in which development costs were equally shared with counterparty under the terms of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Collaboration Arrangements, Shared Development Costs Effective Following Termination Date, Period",
        "terseLabel": "Period of shared development costs following effective termination date"
       }
      }
     },
     "localname": "CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_CollaborationArrangementsTargetsDesignatedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of targets designated as of balance sheet date.",
        "label": "Collaboration Arrangements, Targets Designated, Number",
        "terseLabel": "Number of targets designated"
       }
      }
     },
     "localname": "CollaborationArrangementsTargetsDesignatedNumber",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails",
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangements, Targets Designated, Service Obligations Completed, Number",
        "label": "Collaboration Arrangements, Targets Designated, Service Obligations Completed, Number",
        "terseLabel": "Number of service obligations completed of designated targets"
       }
      }
     },
     "localname": "CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_CollaborativeArrangementsExclusiveTargetsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of exclusive targets entity provided right to develop under terms of agreement as of balance sheet date.",
        "label": "Collaborative Arrangements, Exclusive Targets, Number",
        "terseLabel": "Number of targets"
       }
      }
     },
     "localname": "CollaborativeArrangementsExclusiveTargetsNumber",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail",
      "http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_CollaborativeArrangementsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payment received during the period.",
        "label": "Collaborative Arrangements, Upfront Payment",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeArrangementsUpfrontPayment",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_ComputerEquipmentOfficeEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to computer equipment, office equipment and software.",
        "label": "Computer Equipment Office Equipment And Software [Member]",
        "terseLabel": "Computer equipment, office equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentOfficeEquipmentAndSoftwareMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ContractWithCustomerLiabilityDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability, Decrease",
        "terseLabel": "Deferred revenue, deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDecrease",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_ContractWithCustomerLiabilityIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability, Increase",
        "terseLabel": "Deferred revenue, additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncrease",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_ContractualLifeOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contractual life of warrants.",
        "label": "Contractual Life of Warrants",
        "terseLabel": "Contractual life of warrants"
       }
      }
     },
     "localname": "ContractualLifeOfWarrants",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_DebtCovenantPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Period",
        "label": "Debt Covenant, Period [Axis]",
        "terseLabel": "Debt Covenant, Period [Axis]"
       }
      }
     },
     "localname": "DebtCovenantPeriodAxis",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_DebtCovenantPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Period",
        "label": "Debt Covenant, Period [Domain]",
        "terseLabel": "Debt Covenant, Period [Domain]"
       }
      }
     },
     "localname": "DebtCovenantPeriodDomain",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_DebtInstrumentAdditionalRateInEventOfDefault": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the additional percentage of rate in event of default under debt instrument.",
        "label": "Debt Instrument Additional Rate in Event of Default",
        "terseLabel": "Additional rate in event of default"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalRateInEventOfDefault",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrsn_DebtInstrumentCarryingAmountNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/DebtComponentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, classified as noncurrent. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Debt Instrument Carrying Amount, Noncurrent",
        "terseLabel": "Total debt, net of current portion"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmountNoncurrent",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_DebtInstrumentPrepaymentFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of prepayment fee under debt instrument.",
        "label": "Debt Instrument Prepayment Fee Percent",
        "terseLabel": "Prepayment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercent",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrsn_DeferredTaxAssetsDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation.",
        "label": "Deferred Tax Assets, Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsDepreciation",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_DeferredTaxAssetsLicensedTechnology": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from licensed technology.",
        "label": "Deferred Tax Assets, Licensed Technology",
        "terseLabel": "Licensed technology"
       }
      }
     },
     "localname": "DeferredTaxAssetsLicensedTechnology",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_DefinedContributionPlanEligibleAgeToParticipate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum age for employees to be eligible to participate in defined contribution plan.",
        "label": "Defined Contribution Plan, Eligible Age to Participate",
        "terseLabel": "Eligible age to participate"
       }
      }
     },
     "localname": "DefinedContributionPlanEligibleAgeToParticipate",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum annual amount the employer contributes per employee to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Employer Contribution Per Employee, Amount",
        "terseLabel": "Maximum annual amount employer contributes per employee"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Development Collaboration and Commercial License Agreement for the development and commercialization of XMT-1522 with Takeda Pharmaceutical Company Limited.",
        "label": "Development Collaboration And Commercial License Agreement Takeda [Member]",
        "terseLabel": "XMT-1522 agreement"
       }
      }
     },
     "localname": "DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ExchangeWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security, two, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount with an exercise price of $0.0001 per share. Referred to as the \"Exchange Warrants\".",
        "label": "Exchange Warrants [Member]",
        "terseLabel": "Exchange warrants"
       }
      }
     },
     "localname": "ExchangeWarrantsMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails",
      "http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ExistingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Existing Credit Facility",
        "label": "Existing Credit Facility [Member]",
        "terseLabel": "Existing Credit Facility"
       }
      }
     },
     "localname": "ExistingCreditFacilityMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of common stock retired in exchange for issuance of common stock warrant.",
        "label": "Fair Value of Common Stock Retired in Exchange For Issuance of Common Stock Warrant",
        "terseLabel": "Fair value of common stock retired in exchange for issuance of common stock warrant"
       }
      }
     },
     "localname": "FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the final payment as percentage of original principal amount.",
        "label": "Final Payment as Percentage of Original Principal Amount",
        "terseLabel": "Final payment as percentage of original principal amount"
       }
      }
     },
     "localname": "FinalPaymentAsPercentageOfOriginalPrincipalAmount",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrsn_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of finance lease cost recognized by lessee for lease contract.",
        "label": "Finance Lease, Cost",
        "totalLabel": "Finance lease cost"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_FinanceLeaseTotalCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Total Cost",
        "label": "Finance Lease, Total Cost [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "localname": "FinanceLeaseTotalCostAbstract",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_IncomeTaxesNumberOfAuditsInProgress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of federal and (or) state audits in progress.",
        "label": "Income Taxes, Number of Audits in Progress",
        "terseLabel": "Number of federal or state audits in progress"
       }
      }
     },
     "localname": "IncomeTaxesNumberOfAuditsInProgress",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_IncomeTaxesNumberOfStateJurisdictions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of state jurisdictions in which entity files income tax returns.",
        "label": "Income Taxes, Number of State Jurisdictions",
        "verboseLabel": "Number of state jurisdictions in which entity files income tax returns"
       }
      }
     },
     "localname": "IncomeTaxesNumberOfStateJurisdictions",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_IncreaseDecreaseInOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in operating lease assets.",
        "label": "Increase (Decrease) in Operating Lease Assets",
        "negatedLabel": "Operating lease assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseAssets",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in operating lease liabilities.",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_InducementAwardProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Award Program",
        "label": "Inducement Award Program [Member]",
        "terseLabel": "Inducement Award Program"
       }
      }
     },
     "localname": "InducementAwardProgramMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_JointResearchCommitteeServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents joint research committee services.",
        "label": "Joint Research Committee Services [Member]",
        "terseLabel": "Joint research committee services"
       }
      }
     },
     "localname": "JointResearchCommitteeServicesMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LaboratoryEquipmentLeasedAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to laboratory equipment under finance leases.",
        "label": "Laboratory Equipment Leased Asset [Member]",
        "terseLabel": "Laboratory equipment , under finance lease"
       }
      }
     },
     "localname": "LaboratoryEquipmentLeasedAssetMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Leases [Line Items]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesLineItems",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesDescriptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_LeasesSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases, Supplemental Cash Flow Information",
        "label": "Leases, Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "LeasesSupplementalCashFlowInformationAbstract",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_LeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about leases.",
        "label": "Leases [Table]",
        "terseLabel": "Leases [Table]"
       }
      }
     },
     "localname": "LeasesTable",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesDescriptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_LesseeFinanceLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Lessee, Finance Leases [Abstract]",
        "terseLabel": "Finance leases:"
       }
      }
     },
     "localname": "LesseeFinanceLeasesAbstract",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of supplemental balance sheet information related to leases.",
        "label": "Lessee, Operating And Finance Lease, Supplemental Balance Sheet Information [Table Text Block]",
        "terseLabel": "Schedule of supplemental balance sheet information related to leases"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of supplemental cash flows information related to leases.",
        "label": "Lessee, Operating And Finance Lease, Supplemental Cash Flow Information [Table Text Block]",
        "terseLabel": "Schedule of supplemental cash flow information related to leases"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in present value of lessee's discounted obligation for lease payments from operating lease due to lease modification",
        "label": "Lessee, Operating Lease Modification, Increase (Decrease) In Operating Lease Liability",
        "terseLabel": "Increase in lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseModificationIncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesDescriptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in lessee's right to use underlying asset under operating lease due to lease modification",
        "label": "Lessee, Operating Lease Modification, Increase (Decrease) In Right-of-use Assets",
        "terseLabel": "Increase in right-of-use asset"
       }
      }
     },
     "localname": "LesseeOperatingLeaseModificationIncreaseDecreaseInRightOfUseAssets",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesDescriptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_LesseeOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Lessee Operating Leases [Abstract]",
        "terseLabel": "Operating leases:"
       }
      }
     },
     "localname": "LesseeOperatingLeasesAbstract",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_LicenseAgreementMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Payments",
        "label": "License Agreement, Milestone Payments [Member]",
        "terseLabel": "License Agreement, Milestone Payments"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentsMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LicenseAgreementUpfrontPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Upfront Payments",
        "label": "License Agreement, Upfront Payments [Member]",
        "terseLabel": "License Agreement, Upfront Payments"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPaymentsMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and related research and development services, including Phase 1 development and transfer certain materials and know how related to the Company's manufacturing processes.",
        "label": "License And Related Research And Development Services And Development And Transfer [Member]",
        "terseLabel": "License and related research and development services, including phase 1 development and transfer certain materials and know how"
       }
      }
     },
     "localname": "LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the license and corresponding research and development services for fifth target.",
        "label": "License And Related Research And Development Services Target Five [Member]",
        "terseLabel": "License and corresponding research and development services, fifth target"
       }
      }
     },
     "localname": "LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the license and corresponding research and development services for fourth target.",
        "label": "License And Related Research And Development Services Target Four [Member]",
        "terseLabel": "License and corresponding research and development services, fourth target"
       }
      }
     },
     "localname": "LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the license and corresponding research and development services for third and sixth designated target.",
        "label": "License And Related Research And Development Services Target Three And Six [Member]",
        "terseLabel": "License and corresponding research and development services, third and sixth target"
       }
      }
     },
     "localname": "LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the license and corresponding research and development services for the first and second designated targets.",
        "label": "License And Related Research And Development Services Targets One And Two [Member]",
        "terseLabel": "License and corresponding research and development services, first and second targets"
       }
      }
     },
     "localname": "LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LimitedServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limited services.",
        "label": "Limited Services [Member]",
        "terseLabel": "Limited services"
       }
      }
     },
     "localname": "LimitedServicesMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LineOfCreditFacilityAccordianFeatureIncreaseLimit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Accordian Feature, Increase Limit",
        "label": "Line Of Credit Facility, Accordian Feature, Increase Limit",
        "terseLabel": "Line of credit, increase limit"
       }
      }
     },
     "localname": "LineOfCreditFacilityAccordianFeatureIncreaseLimit",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payments, which had not been received, included in the estimated transaction price.",
        "label": "Milestone Payment Not Received, Included in Estimated Transaction Price",
        "verboseLabel": "Amount of milestone payments, which had not been received, included in the estimated transaction price"
       }
      }
     },
     "localname": "MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_NumberOfVotesPerCommonShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes for each shares held.",
        "label": "Number of Votes Per Common Share",
        "terseLabel": "Number of votes per common share"
       }
      }
     },
     "localname": "NumberOfVotesPerCommonShare",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_OfficeSpaceCambridgeMaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space in Cambridge, MA under operating lease.",
        "label": "Office Space Cambridge Ma [Member]",
        "terseLabel": "Office space, Cambridge, MA, Leased"
       }
      }
     },
     "localname": "OfficeSpaceCambridgeMaMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesDescriptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws not subject to expiration dates.",
        "label": "Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws subject to expiration dates.",
        "label": "Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for patent costs.",
        "label": "Patent Costs [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrsn_PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the prepayment occurs after August 28, 2022 but before November 1, 2024",
        "label": "Prepayment Occurs After August 28, 2022 But Before November 1, 2024 [Member]",
        "terseLabel": "Prepayment occurs after August 28, 2022 but on or prior to August 28, 2022"
       }
      }
     },
     "localname": "PrepaymentOccursAfterAugust282022ButBeforeNovember12024Member",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_PrepaymentOccursBetweenAugust282021AndAugust282022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the prepayment occurs between August 28, 2021 and August 28, 2022.",
        "label": "Prepayment Occurs Between August 28, 2021 And August 28, 2022 [Member]",
        "terseLabel": "Prepayment occurs between August 28, 2021 and August 28, 2022"
       }
      }
     },
     "localname": "PrepaymentOccursBetweenAugust282021AndAugust282022Member",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_PrepaymentOccursPriorToAugust282021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the prepayment occurs prior to August 28, 2021",
        "label": "Prepayment Occurs Prior To August 28, 2021 [Member]",
        "terseLabel": "Prepayment occurs prior to August 28, 2020"
       }
      }
     },
     "localname": "PrepaymentOccursPriorToAugust282021Member",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ProceedsFromDebtNetIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Debt, Net Issuance Costs",
        "label": "Proceeds From Debt, Net Issuance Costs",
        "terseLabel": "Proceeds from issuance of debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetIssuanceCosts",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross proceeds from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock, Gross",
        "terseLabel": "Proceeds from issuance of common stock, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net proceeds from the additional capital contribution to the entity after deducting fees, commissions and other expenses.",
        "label": "Proceeds From Issuance Of Common Stock, Net Of Stock Issuance Costs",
        "terseLabel": "Proceeds from stock issuance, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ReimbursableExpenseResearchAndDevelopmentEstimated": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated amount of research and development expenses received or expected to be received included in transaction price (performance obligation).",
        "label": "Reimbursable Expense, Research and Development, Estimated",
        "terseLabel": "Amount of research and development fees expected to be received"
       }
      }
     },
     "localname": "ReimbursableExpenseResearchAndDevelopmentEstimated",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2016 Restated Research Collaboration and Commercial License Agreement with Takeda Pharmaceutical Company Limited. Also includes the Development Collaboration and Commercial License Agreement for the development and commercialization of XMT-1522 with Takeda Pharmaceutical Company Limited.",
        "label": "Research Collaboration And Commercial License Agreement Takeda2016 Restated Agreement And Development Collaboration And Commercial License Agreement Takeda [Member]",
        "terseLabel": "2016 Restated Tokeda agreement and XMT-1522 agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2016 Restated Research Collaboration and Commercial License Agreement with Takeda Pharmaceutical Company Limited.",
        "label": "Research Collaboration And Commercial License Agreement Takeda2016 Restated Agreement [Member]",
        "terseLabel": "2016 Restated Tokeda agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_RevenueCollectionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which entity receives payment upon billing.",
        "label": "Revenue, Collection Period",
        "terseLabel": "Billing term"
       }
      }
     },
     "localname": "RevenueCollectionPeriod",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_RevenueRemainingPerformanceObligationNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of performance obligations.",
        "label": "Revenue, Remaining Performance Obligation, Number",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationNumber",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_RevenueTransactionPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price which represents the amount of consideration the entity expects to receive for transfer of goods and services. Amount is net of estimated fees associated with research and development activities.",
        "label": "Revenue, Transaction Price, Amount",
        "verboseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueTransactionPriceAmount",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_RevenueTransactionPriceIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in transaction price during the period due to change in fees expected to be received for research and development activities.",
        "label": "Revenue, Transaction Price, Increase (Decrease)",
        "negatedLabel": "Decrease in fees expected to be received for research and development activities"
       }
      }
     },
     "localname": "RevenueTransactionPriceIncreaseDecrease",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_RightsToFutureTechnologicalImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents rights to future technological improvements.",
        "label": "Rights To Future Technological Improvements [Member]",
        "terseLabel": "Rights to future technological improvements"
       }
      }
     },
     "localname": "RightsToFutureTechnologicalImprovementsMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]",
        "terseLabel": "Schedule of estimated useful life of property and equipment"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrsn_ServiceMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service milestones represented by the achievement of specific activities as defined in the agreement.",
        "label": "Service Milestone [Member]",
        "terseLabel": "Milestone"
       }
      }
     },
     "localname": "ServiceMilestoneMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be cumulatively issued annually in accordance with the plan, as a percentage of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Percentage Of Outstanding Stock Maximum, Cumulative Annual Increase",
        "terseLabel": "Cumulative annual increase in number of shares issuable, percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrsn_StockIncentivePlan2007Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2007 Stock incentive plan.",
        "label": "Stock Incentive Plan 2007 [Member]",
        "terseLabel": "2007 Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2007Member",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_StockIncentivePlan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2017 Stock incentive plan.",
        "label": "Stock Incentive Plan 2017 [Member]",
        "terseLabel": "2017 Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2017Member",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounts and commissions deducted from cash proceeds received on stock transaction.",
        "label": "Stock issuance, Discounts And Commissions On Transaction",
        "terseLabel": "Stock issuance, Discounts And Commissions On Transaction",
        "verboseLabel": "Issuance costs"
       }
      }
     },
     "localname": "StockIssuanceDiscountsAndCommissionsOnTransaction",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_StockIssuanceProgramAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock shares authorized to be issued under the program.",
        "label": "Stock Issuance Program, Authorized Amount",
        "terseLabel": "Amount of shares authorized to be offered and sold"
       }
      }
     },
     "localname": "StockIssuanceProgramAuthorizedAmount",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period and exercise of common stock warrant in exchange for common stock",
        "label": "Stock Issued During Period, Shares Of Common Stock Warrants In Exchange For Common Stock Exercised",
        "terseLabel": "Exercise of common stock warrant in exchange for common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock issued as a result of the exercise of stock options and warrants.",
        "label": "Stock Issued During Period, Shares, Stock Options and Warrants Exercised",
        "terseLabel": "Exercise of stock options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Shares, Warrants Exercised",
        "terseLabel": "Common stock issued upon exercise of warrant (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options and warrants.",
        "label": "Stock Issued During Period, Value, Stock Options and Warrants Exercised",
        "terseLabel": "Exercise of stock options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock that have been retired in exchange for common stock warrant.",
        "label": "Stock Retired During Period, Exchanged For Common Stock Warrant, Shares",
        "negatedLabel": "Retirement of common stock in exchange for common stock warrant (in shares)"
       }
      }
     },
     "localname": "StockRetiredDuringPeriodExchangedForCommonStockWarrantShares",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been retired in exchange for common stock warrant.",
        "label": "Stock Retired During Period, Exchanged for Common Stock Warrant, Value",
        "negatedLabel": "Retirement of common stock in exchange for common stock warrant"
       }
      }
     },
     "localname": "StockRetiredDuringPeriodExchangedForCommonStockWarrantValue",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_SupplyAgreementMerckKgaaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Supply Agreement with Merck KGaA.",
        "label": "Supply Agreement Merck Kgaa [Member]",
        "terseLabel": "Merck KGaA supply agreement"
       }
      }
     },
     "localname": "SupplyAgreementMerckKgaaMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_TenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of allowance granted and reimbursable by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Tenant Improvement Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovementAllowance",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesDescriptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_WarrantsAndShareBasedPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and share-based payment awards.",
        "label": "Warrants And Share Based Payments [Member]",
        "terseLabel": "Warrants and share-based payment awards"
       }
      }
     },
     "localname": "WarrantsAndShareBasedPaymentsMember",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_WarrantsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Warrants, Exercised In Period",
        "terseLabel": "Issuance of common upon exercise of warrant (in shares)"
       }
      }
     },
     "localname": "WarrantsExercisedInPeriod",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Discount Rate",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted-average discount rate:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Lease Term",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted-average remaining lease term:"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.mersana.com/20201231",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r109",
      "r118",
      "r196",
      "r318",
      "r319",
      "r320",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect adjustment for adoption of ASC 606"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r109",
      "r118",
      "r196",
      "r318",
      "r319",
      "r320",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r109",
      "r118",
      "r196",
      "r318",
      "r319",
      "r320",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r276",
      "r277",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r460",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r276",
      "r277",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r460",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r173",
      "r252",
      "r255",
      "r461",
      "r497",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails",
      "http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r173",
      "r252",
      "r255",
      "r461",
      "r497",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails",
      "http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r257",
      "r276",
      "r277",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r460",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r257",
      "r276",
      "r277",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r460",
      "r498",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "Accounting Standards Update 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201818Member": {
     "auth_ref": [
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.",
        "label": "Accounting Standards Update 2018-18 [Member]",
        "terseLabel": "Accounting Standards Update 2018-18"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201818Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r354",
      "r355",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r22",
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of premiums and discounts on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.mersana.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpensesDetails",
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r41"
     ],
     "calculation": {
      "http://www.mersana.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r54",
      "r55",
      "r56",
      "r488",
      "r508",
      "r512"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r53",
      "r56",
      "r57",
      "r106",
      "r107",
      "r108",
      "r377",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r352",
      "r353",
      "r354",
      "r355",
      "r462",
      "r463",
      "r464",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition",
        "terseLabel": "Purchase of common stock under ESPP"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r279",
      "r281",
      "r324",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r220",
      "r228",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock warrant in exchange for retirement of common stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r281",
      "r310",
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense included in Total operating expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails",
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail",
      "http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r101",
      "r156",
      "r165",
      "r171",
      "r188",
      "r371",
      "r378",
      "r395",
      "r466",
      "r486"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r51",
      "r101",
      "r188",
      "r371",
      "r378",
      "r395"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.mersana.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets regularly measured and carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.mersana.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.mersana.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r180",
      "r204"
     ],
     "calculation": {
      "http://www.mersana.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r177",
      "r181",
      "r204",
      "r471"
     ],
     "calculation": {
      "http://www.mersana.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.mersana.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails",
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r179",
      "r204"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r282",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails",
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails",
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails",
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r105",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r31",
      "r90"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r91",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r91",
      "r97",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Other Assets"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r84",
      "r90",
      "r96"
     ],
     "calculation": {
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash per statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r84",
      "r397"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r110",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r314",
      "r315",
      "r316",
      "r352",
      "r382",
      "r396",
      "r410",
      "r462",
      "r463",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Asset and Liability [Abstract]",
        "terseLabel": "Revenue recognized in the period from:"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetAndLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails",
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails",
      "http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails",
      "http://www.mersana.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares of common stock into which warrants may be converted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityWarrantsDetails",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r362",
      "r363",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails",
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail",
      "http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r258",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails",
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r218",
      "r472",
      "r492"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments (Note\u00a014)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails",
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails",
      "http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 175,000,000 shares authorized; 68,841,288 and 45,388,023\u00a0shares issued and outstanding at December\u00a031, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails",
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r60",
      "r62",
      "r63",
      "r69",
      "r475",
      "r495"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r144",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Off-balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.",
        "label": "Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure",
        "terseLabel": "Financial instruments with off-balance sheet risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRisksDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of changes in the balances of our contract assets and liabilities and recognized revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r237",
      "r239",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r237",
      "r238",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Deferred revenue, balance at end of period",
        "periodStartLabel": "Deferred revenue, balance at beginning of period",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails",
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r237",
      "r238",
      "r253"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amounts included in the contract liability at the beginning of the period",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r258",
      "r272",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails",
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r467",
      "r469",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Spread (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r16",
      "r221",
      "r469",
      "r484"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mersana.com/role/DebtFuturepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Debt outstanding",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtComponentsDetails",
      "http://www.mersana.com/role/DebtFuturepaymentsDetails",
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r102",
      "r229",
      "r232",
      "r233",
      "r234",
      "r406",
      "r407",
      "r409",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r406",
      "r409"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "terseLabel": "Accretion related to final payment"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Debt financing costs in accrued expenses"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r186",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredCompensationShareBasedPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary.",
        "label": "Deferred Compensation, Share-based Payments [Member]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedPaymentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Incurred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r35",
      "r408"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Debt financing costs, net of accretion",
        "terseLabel": "Unamortized issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtComponentsDetails",
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r17",
      "r18",
      "r341",
      "r468",
      "r483"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r342"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r347",
      "r349",
      "r350"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r343"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails",
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r349",
      "r350"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employee benefit expenses"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Percentage employer matches of the employee's percentage contribution matched"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum contribution by employee (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r88",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r88",
      "r155"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails",
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r70",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r124",
      "r127",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r476",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net income (loss) per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders \u2014 basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "verboseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r70",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r127",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r476",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net income (loss) per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r334",
      "r357"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax computed at federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r334",
      "r357"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r334",
      "r357"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r334",
      "r357"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Impact of ownership shift"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r334",
      "r357"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r334",
      "r357"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "General business credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.mersana.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average amortization period of unrecognized stock compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails",
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails",
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r112",
      "r121",
      "r123",
      "r139",
      "r196",
      "r228",
      "r235",
      "r318",
      "r319",
      "r320",
      "r354",
      "r355",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails",
      "http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured and carried at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r383",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r272",
      "r384",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r383",
      "r384",
      "r386",
      "r387",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r258",
      "r260",
      "r265",
      "r272",
      "r384",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Prices in\u00a0Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r258",
      "r260",
      "r265",
      "r272",
      "r384",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r272",
      "r384",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r272",
      "r433",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r389",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r414",
      "r420",
      "r428"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "mrsn_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r416",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r412",
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Other liabilities, current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Finance lease, liability, current, statement of financial position"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum payments on finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]",
        "terseLabel": "Finance lease, liability, noncurrent, statement of financial position"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r415",
      "r422"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payments under capital lease obligations",
        "terseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r414",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r414",
      "r420",
      "r428"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "mrsn_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Assets under finance leases",
        "verboseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesDescriptionDetails",
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r425",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r424",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r208",
      "r209",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails",
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails",
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r335",
      "r339",
      "r346",
      "r356",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r97",
      "r332",
      "r333",
      "r339",
      "r340",
      "r345",
      "r351",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r66",
      "r154",
      "r405",
      "r408",
      "r477"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r75",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r82",
      "r85",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r73",
      "r153"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r426",
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lessee, operating lease, existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesDescriptionDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum payments under operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesDescriptionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r101",
      "r166",
      "r188",
      "r372",
      "r378",
      "r379",
      "r395"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r101",
      "r188",
      "r395",
      "r470",
      "r490"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r101",
      "r188",
      "r372",
      "r378",
      "r379",
      "r395"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.mersana.com/role/DebtComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less: Current portion of long-term-debt",
        "terseLabel": "Short-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/DebtComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r104",
      "r219"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtFuturepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r104",
      "r219"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtFuturepaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r104",
      "r219"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtFuturepaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r104",
      "r219"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtFuturepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.mersana.com/role/DebtComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "totalLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/DebtComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]",
        "terseLabel": "Marketable Securities [Abstract]"
       }
      }
     },
     "localname": "MarketableSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-term Debt [Abstract]",
        "terseLabel": "Estimated future principal payments"
       }
      }
     },
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r84",
      "r86",
      "r89"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r58",
      "r61",
      "r67",
      "r89",
      "r101",
      "r111",
      "r116",
      "r117",
      "r118",
      "r119",
      "r122",
      "r123",
      "r128",
      "r156",
      "r164",
      "r167",
      "r170",
      "r172",
      "r188",
      "r395",
      "r473",
      "r493"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r124",
      "r125",
      "r129",
      "r132",
      "r156",
      "r164",
      "r167",
      "r170",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r126",
      "r129",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to common stockholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r118",
      "r135",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r352",
      "r353",
      "r354",
      "r355",
      "r462",
      "r463",
      "r464",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):",
        "verboseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r421",
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r417",
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r425",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r424",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating loss carry-forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r41"
     ],
     "calculation": {
      "http://www.mersana.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r369",
      "r370",
      "r376"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r59",
      "r62",
      "r65",
      "r68",
      "r228",
      "r398",
      "r403",
      "r404",
      "r474",
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r41"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r76",
      "r78",
      "r178"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r257",
      "r259",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r282",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.mersana.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.mersana.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at December\u00a031, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from public offering of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r80",
      "r313"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from purchases of common stock under ESPP"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r81",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from line of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r76",
      "r77",
      "r178"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r80",
      "r313"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received from the exercise of stock options (in dollars)",
        "verboseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r58",
      "r61",
      "r83",
      "r101",
      "r111",
      "r122",
      "r123",
      "r156",
      "r164",
      "r167",
      "r170",
      "r172",
      "r188",
      "r369",
      "r374",
      "r375",
      "r380",
      "r381",
      "r395",
      "r478"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r213",
      "r414",
      "r420"
     ],
     "calculation": {
      "http://www.mersana.com/role/PropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r52",
      "r214",
      "r420"
     ],
     "calculation": {
      "http://www.mersana.com/role/PropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "totalLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r11",
      "r212",
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Total property and equipment at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesDescriptionDetails",
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r216",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r97",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Leasehold improvements, estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r212"
     ],
     "calculation": {
      "http://www.mersana.com/role/PropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r214",
      "r491"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r97",
      "r214",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesDescriptionDetails",
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialDataAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Data [Abstract]",
        "terseLabel": "Quarterly Financial Data"
       }
      }
     },
     "localname": "QuarterlyFinancialDataAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Selected Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r328",
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "verboseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r327",
      "r519"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails",
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r97",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Investments [Abstract]",
        "verboseLabel": "Other Assets"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r5",
      "r13",
      "r96",
      "r514"
     ],
     "calculation": {
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash included in other assets, noncurrent"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails",
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails",
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainageDeposit": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of assets, typically cash, provided to suppliers of goods in advance of receipt and acceptance, or services (such as research facilities, lawyers or consultants), which is held by such parties until the entity either effects full payment (including applying the retainer) or obtains release from liability.",
        "label": "Retainage Deposit",
        "verboseLabel": "Held by service provider"
       }
      }
     },
     "localname": "RetainageDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r235",
      "r321",
      "r489",
      "r507",
      "r512"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r112",
      "r121",
      "r123",
      "r196",
      "r318",
      "r319",
      "r320",
      "r354",
      "r355",
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r151",
      "r152",
      "r163",
      "r168",
      "r169",
      "r173",
      "r174",
      "r175",
      "r251",
      "r252",
      "r461"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails",
      "http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails",
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible List]",
        "terseLabel": "Type of revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Expected recognition period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r423",
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for financing lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r423",
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]",
        "terseLabel": "Concentration of Credit Risk and Off-balance Sheet Risk"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/AccruedexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of outstanding potentially dilutive securities excluded from calculation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of marketable securities from cost basis to fair value"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails",
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail",
      "http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense by award type"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of significant components of net deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of income tax rates"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r281",
      "r309",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r281",
      "r309",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense as reflected in the Company\u2019s condensed consolidated statements of operations and comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of estimated future payments"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Selected quarterly financial data (unaudited)"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "verboseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r10",
      "r96",
      "r465",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of restricted cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r282",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails",
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r288",
      "r299",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted average assumptions for estimating fair value of option awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r47",
      "r99",
      "r140",
      "r141",
      "r224",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails",
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails",
      "http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule for number of common stock reserved for exercise of outstanding stock options and warrants"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Letter of credit for security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesDescriptionDetails",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested at end of period (in shares)",
        "periodStartLabel": "Unvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested at end of period (in dollars per share)",
        "periodStartLabel": "Unvested at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted-average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails",
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails",
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails",
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails",
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r290",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "terseLabel": "Number of shares outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails",
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r280",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails",
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsPlansNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails",
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails",
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r97",
      "r282",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Accounting for Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Aggregate intrinsic value (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsInducementNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r304",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares sold to date (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares sold, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails",
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r49",
      "r106",
      "r107",
      "r108",
      "r112",
      "r121",
      "r123",
      "r139",
      "r196",
      "r228",
      "r235",
      "r318",
      "r319",
      "r320",
      "r354",
      "r355",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r404",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails",
      "http://www.mersana.com/role/StockholdersEquityExchangeWarrantsDetails",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r139",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r20",
      "r21",
      "r228",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Purchase of common stock under ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/StockOptionsEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r228",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares sold (in shares)",
        "verboseLabel": "Issuance of stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r228",
      "r235",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r228",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r228",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r26",
      "r27",
      "r101",
      "r176",
      "r188",
      "r395"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary or Equity Method Investee [Line Items]",
        "verboseLabel": "Subsidiary or Equity Method Investee [Line Items]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "verboseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.mersana.com/role/StockholdersEquityAtthemarketEquityandFollowOnOfferingProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r352",
      "r353",
      "r354",
      "r355",
      "r462",
      "r463",
      "r464",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesRecentlyIssuedAccountingPronouncementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaAAccountingAnalysisDetails",
      "http://www.mersana.com/role/CollaborationAgreementsMerckKGaADetail",
      "http://www.mersana.com/role/CollaborationAgreementsOtherRevenueDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedaAccountingAnalysisDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedaXMT1522StrategicPartnershipDetails",
      "http://www.mersana.com/role/CollaborationAgreementsTakedastrategicRDpartnershipDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r258",
      "r272",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurementsDetails",
      "http://www.mersana.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r331",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax position"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Abstract]",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityCommonstockDetails",
      "http://www.mersana.com/role/SummaryofsignificantaccountingpoliciesNetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r126",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted-average number of shares of common stock used in net income (loss) per share attributable to common stockholders \u2014 diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Weighted-average number of common shares used in net loss per share attributable to common stockholders \u2014 basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r124",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted-average number of shares of common stock used in net income (loss) per share attributable to common stockholders \u2014 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.mersana.com/role/SelectedQuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL82887624-210437"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r521": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r522": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r523": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r524": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r525": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r526": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r527": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r528": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>113
<FILENAME>0001628280-21-003370-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-003370-xbrl.zip
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MUF]UP^J&2+5EY_/5)K6\?T78@LI::6Z+[#3BQEB_OE7O@)-_ %!+ P04
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MX7>4% (^@9NE!%:!.662&<N1=D(L(3E)%I LT6 ?#0W4"U]K5<FB2&  '&J
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M:&EB:70S,3(Q,&MF>3(P,C!Q-"YH=&W=6FMOVS@6_;Z_@N-@TP2PY7?L.&F
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MUDS&(&.6PS!-"Y+ )<VXD("F*1<K<&SC-^ 1O*8"%R7@QU20C!:2!7D=SM+
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M]4S/[CS*K:7+6Y88H<JQ<U[4O-IV0M4;/3>[ 6=_5ZC:Y0/X?7U2T/OR,;Y
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M:QLC8:RDE .$E<8E+1+"BL/,8^Y-X&MO$@ SP_8#]-_S*W0?B.[V-70QHXH
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MJAS6\T\1/Z8U3GLK$7'_@D\T1D>%,>*&D4BUB%RFE+RTA]R@L*0$L=D;3NT
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M-"K0F81%9!@PF U28.8"TXAA)^@8,+ZTQ@U!3VS<)+#XE(K@(<60C%H*))C
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MH8C+=,?U)=*=K:1BND!O2:+GO7;6 W5SC0ROC-OB#,U+8F.(_68OJ6W;Y-9
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M[=6->>BTNJ5;\WY[RKZ)W4I@3J.TY-J;9F*8K!>S=7@@$&3_'O:ZS2\=DQ\
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M-2G./>R/6UYC"3\4IQFMY65^55@@<XEC4S==3A( D8FZ:>UIB[SG*TY>[S@
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M>;F&CQ71"2PNJP+Y-$1G+-Q[?4D>$T*T"."RQ*=S@+"5Q$;((MW-LG6Y*3M
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M+,^90WI>U0V,XN,YN,]S\*+I+X("V@UCR_"'<T6$?62\?G&"2$6_,=-#D [
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M%@6S2ODSS]?L?LR+[KHHJ@@+&D)3N7=@6_CQR);D\)4+$5K'S.GG<6%^PFV
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M5#\SP[W09^G\3W"_6:!IXE-[CC+;?_1)(@N@'2M; EE_JWH*0#$D7^+^'@7
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MYE*_8WC:62C2M?@#6A7@;.,.I7LLLB%7DH8<@0PQ05:>I$]0N(9ZK=V3V=P
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M+[0-L)RBF=.WQ8E2]-$<< !&1_U4(-3E9K :T=V%0>3R+C2@&G-)EDO]9%A
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M&-\<+GSX!DOXV;-'?YXB3!I2(@7LUL,SB8'WDQA4"^RGZ.1\TZI/5SBLW:=
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M2V$6%QH!J5O1C&\CE9$%=@'5F&)=?O/5?TR H4(:NMMM%:X.=W?;^KYH-O"
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M=&"ZOI-3^%SLJ[?>:G(BA&1&^B0G!MCW%B\XQI]<@>DM6^$;@HR6S^<[ P;
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M25FJ&TNR*8.$6Z$M2I!?+$ NHGEBJ0[^AH"I3=E>U,U%B"(S:7 GA</D@O/
M%DV)Z-8:O@5^>^%4%(U4@L2':81^<LW#54G/9E2DZ:4IF^ @YWI;\F_") WT
MAQ-D1T+F;-'+:)I8K/#5BW, $^:EL/2KN85/S=IT?W01Z5=B_V:O:D0\7S3]
MA=B\S^MV4X T^QSI"CIVKUX\/Q?C]$T_I_W+?N06Q=F[HKE"]-2^]^;'=_+?
MO&UM6Y/N9U=UH]@59^X)6SD&NMIO^+@7RZ.=<G9&$;>8^'>RC,ST<1OLK" C
M5_\D&^@&0^L3C2$G7D,<^W^@F 6A<(]R'G\+M47IBP)SLU?\%^3-0KI6O_CE
MO_A_94WC>,%I"MSQP<KO&V7:>9 O?$40S)N;M1Y#5:DS)UDV)7],^Z?%%36J
M^F*+[\#Q0U:F#.U(['3AK?,B[< 6G87)]TM!)L(YVJ7^[BRQ6R3%JXN3=;'J
M_OSDV>1.R$<E=WW_\\G9-]ON,^T-<!R/GWWW^4*\Z7*=/3W]"FLQZ'#J AI*
M9  OF_:IXUKX<N.)#RO>X(VI05?F,_3O]1@%+,L%J3K_@BU$A-W-'WYZ,_/J
MZ;OC@;C' R%51O--*5U"%'X!J2KJ[+67Q70:,!2Q66CK7O_UA5>'FHS9](QT
M^5 80$!%B-;X#<O$1(A<"!9T)#".I^$^3T,PN4#XC@V1GC+0J%:"*L= '87O
MZ[Q9RE%X^SU:RT@+I,#1'C<;58-Z#@9_X:I"U232AHIV_[CM][GM2M5JUFB^
M)*/>8O.< 6.SKEZC/&MT?Y,,O*275D4G\!\2 /3=Q<X &@ UUAY<$H TVM.7
MC46MW-0.JPN$SZ-N85T2!I%JDN=O9HE#<CQ%]WJ*&MC?D5IXOUH!AX#ZQ3\I
MNN\\JA'>R^]_.C_NWGWN'CM2"ZZYL:97C0AYO;NT(P:WV#"A@AKP4!3GRZNR
MA67WO-YL4(=0Z(^/>WB?>]C2_6F1C,16I*:^]A7CAF38ZK(2:*KU6$N@20XJ
MQ6#!")M"B$?.@ OL\(5U2  XV46]FFF?9^7 1"@%><AVY"XP9"L-)%7V_;[1
M_D*<.@[C0%>S[K*.'0&@GK0!B6DOK@8E>Z119B =;?!*!'" \I2V:XKJHKN<
M.88@TE$]6CP>3_"!G&"F/1N>W";+R0KIPAG64*!+W =NN=HC\^38I#8H;-36
M';OA,27S8N*47G*/RN+"VH$R*"K0N>9=?CQ ]VJ$1&*(OD77F +"PL#_*PZK
MGX\UVW?[D\W'7?J#C WS-?TNX$H==^*^ X(>FE.!2+.E5;3M\2(OX0;*WI;M
MA^PE6I)%H__GTH)%F=(E"I/RVY<_OS.T7\PA2<XJ?9_YE:%")\VWY>P>QK2*
M_NP!AN_?<YU3&[!=HTR8KD [@C/-E$-H'ZQI%E03,ZEL.R6>D68LH<I=\[M(
M"B@3U&&NXMXD]O2ZOAG#] YR6I\ZB>!PN4AZ$6]?#+&DJ>P9;@VB./C?/UC\
M?.).E55V59+E_CF!\'+UTE1'=%5X14.WQYLC6^FR>]9"CGQKWMUHR0;IE[#'
MK4<=*%9V!(S<)Y/1U6J4Z2>QT*^CB3R)8NWJBX)SH]+!._$$RXJ#@Q*:R:M\
MO>N"<3L361(P]HGE"[E/WA10]58&+44[C# ?C6$*FJLH#(XI+'T8*6\#=3:R
M%']]<9J=QYI9/T<5L3,E@FNE[1>L=8?AW<5J'P$?X#U(;\A^R/OW2\?_D8#$
MKXZ Q",@\4%9!L\?O%DPG$$H=V+ NL,[W6 00(Q*+E8UC4>GM?T6\#*#!<5J
ML C*J:4.;)B8&89'3L<!$S5@ID6]ZP?  ^&8S,1[\D!U SZFFE8> KP,%+:C
MB(P\2;15K'\0K59P\+ MK*NU1H)L71*S7.@0N.)H$$"07TG.]/7;[P_3BKX%
M2F2+&5-R@_"8V$D[7]<1?I/3_BYECSG[/[]=:ZN");5="8Z@)T68LV7!C#LH
M>F\500#TWA-'IJ0ZVIR;Z"#.Z"1S(RE--4OD&'!$&T&3ERUW*('+(Q%$FDLK
MII7AZJ0ACN4J!^L "-TZ7U@MG7Q6I>@^+GH5>X/N'7I4F#UA6$5ST# F7C(X
M;[C(6&*0>G:YP W#2,.4BN&(0$W/"(H'>/!& @T67[?;ZCE(4L'=)3H0Z>%C
M @#P#[=*@!6@FL!>:IX*!$Y7I CS+;9MSC'=.8UA^?NBS@Y&P?G6M7_^K%Z5
M#.+]I/XI6P5Z" RPLPP1DS!=,LAY-]10W(J-_@TJ#-PH8%Q)6L0V"LP:(R1%
M2[KBJ/C^HCB].)W)2(1:_,M,&\^44CA+M]0OV6R/PD1+BW DX4\HUE'\P5FV
MK%LR<^D$HCD"4^K BF^V6L%7=.2PK\MV,ZSM*SXNFL)"9QRE)HG#E?5,)H6^
M.DQ\GC>\4(:0@/AD/@\3CI4T'UD* Y60<132_A:N&(_N[K+AH9[XQP=]XLTX
MB]VCUN6F5-KYDK5IO35LI:0NUXR';E#%KG$>+7;<$WO@(VDL87(7Z/%Z&Z2;
ME!99[\)!DRK4UK!Z<HPTSM&4[8>)<S4\[6(8_0\[;$\>UF%C"OV<F=#'QVWF
M4-ED+UT4:!RYO51Y1^<'#")C0XCSI2R5[X(1"YUXBHKY3#A !%8(M&-LS>Z;
M/N?N3$X<^:CU1U T*'^T],1)/IG3"%;2]V)5KHOAH_2<2W,!!R-PX:_ ;&!%
MW(-G/$#[RQWII_NPN<X*$\-;M7=:&"QIF-!5*%IS?2N'4-19#-(Y;IG E9LT
M!0D*7H'!\.KX",-OS+=<[^[5HDFJ>M$+)4&<D.V]/@D61$(''TH8Q!,.C8X*
MY__Y("P(5\%"$NEJX>B*9>#R5<864@N[,">Z9-%2QU@9-\I./.>'=XS&9GRG
M!,*7NM2^^,M5JRC&HUBF=/HPZ=CXV3G6,&,)PYWG]O&GV:N^P0X UC2+3J"X
MX3./",FL(0W$SJ:F UPWXEXI8$U  BXS*55GJ)%:\H\#Q5D^\HQ=V1L=0U2@
MU3W(WFHZ38.<Z:JLE+%",4T!GQ*##@V@TLJ^5+=!@O>5XO.@ML5,9L$6"P^9
M!BE:JHJ42;!?"2+[-K3+W0 N=PF0/Z @X;L(6U6ZN0GV Q?4.,@YWQSLH1W?
M*!.B7KD!UBKDWH=9E(26P^>@NCLEFL:PJXGL$UF:>;EF?S!J7LFDX.+4DV ^
MYF%JF7$Q862)T$ F<-&0CB-A^:U))^!53.A[#2@<9BSBAX:*OX=1;1VHN/_$
M6X/5('U]>9T_P(YXO^PO [=P9J#%O"KS; A?DL,@IL,[P2:JE_#5F=T&*Z56
M=E%AU>3?+@LZ@R%J'Q2#;T-%MN\,>%1-HG)"^C3[A9TO?G>LYF05H?$),G/Y
MD(_K\03WP77M4LCSTWEK2A>A=1I1=QENLCPG"VEM#D[F342(-TPW??./.$H'
M'2(_LMPT/\ 0+[PD>#_(D)D+C(GIF,II*::5P/?XVDDBV5F47F!(Y_<F$(I%
M+0G%WA0K(XA-A3HJN W,'FP#?H\,=>8A%Y**%R+BI7[$JTJVH4J4] 7M);.L
MN9K9.*RR%9L(1H/9D(.':X7Y:'RS;-ZC69KSXU;DB=77K02AT\<<J,"Y6;QH
M%3*OFF5YN"*A\[:/63PI6#P%K4_4,9>M5QK2PHF?APVQ^G]_)S7+X%ZSPT,B
M[6C M;<>E[#>#<9[5UO-X9.5G6_25AO9:6J>,;$H*_PQ@.4(:DA #<^.H(8C
MJ.& !>&+2*LRQ(M&V<+-IUG Q*AM4$EU(,Y+<;<!)Q7=U9N#0U+CUUP5]"*6
M15OT_,ZEQ;FZV!;'*P3Q%KDF0@%@@%OMV.X>=LY+.B4DLG-B:DZZIY3 .>./
MI>-F6E*D@:%V& VL^X[W@1,M' BWI*(0I1H6<U.$\--%7RXY+W6Y:\$R(RT*
M^LK^+M@W9-?71>APH=XW!#,"91&E!OJ4IEQH!#\DC:SN*:2_$);BOQ<)9R*@
MV8@!;XR_M:O)"WJ FO^7@;T\M&7'"%C8PPQ66&BOZ1&(,24.';BML;[HQL(X
M<5P3XX.VD@Z[<.,[)B _+N:W?ZXQ+W1P1G2JR'YB(I^9NKXVL"6=S 4"I(Y3
MU1756G3&]PI19Y3[TWOG6=UYL6.!>"F7Q:"Y03133[.75T456#Q=-$0Z1$T:
MW'$Q:#%+4"ROI:R?!#CBZ>'&>7MX61=B]4K=EQF]@>]ST91,U9S$^1_@(7Z]
MBK)91&";]":1D"@G!)UHYQ!("!,$0+$E(<+/(Q%J;@Q,[G<S8Y=JI659L<A[
M>2 3+K 8"V1!)OYB@"1Y^&2EQITUQBS-)0#?+.';!&T]".R8R9I0@KEAN;C4
MG9112/?P R=::3="W%4$!F)%"PR+7[2@A55"7@52<>301-^EV'&-"6D8BE1.
M/M?ZVC2%E+BIM%M7VLY"#H<M6 Q*^BXW:8<B)]=\XL'4-S<?F5@P<E@&:[WA
MZ+81D2TNT62HM;A8.*KA.)H&D\QN5M$52HYC*D[M<2RQHV0)&3;N\A*#<@$9
MKPMA^S\JS'1E?A[%=YC"XQ.#;:_0DAT\:Q]FW"SE@S6)D,28EB^G\1;?8>H!
M E]=E$1)H/]9*"Y!NY6%;O8AJ<=(QH];LM @;G09RE4T-F-"L<;9:P1&0]X]
M&5EJV:WI_$;QF*0GR1TJ)-/#UW-5G "@ADY$'/=2$%(*.)+L:)!-&,0J;*;?
MHCT;Z]N$W;+)AWG2;S[7:)(6#0FQ'FQ[\R26SN64-):P>/S!V7=NF\M.D&:Z
MQZ8V_\4]E$!+YZ*VQ;!,R)VF\5%R;9^FC\@K)EP(9R*V.M%,IF3EN5?'!0^U
MX3DR$0ZTNF=@BX6 MI[&L.00S*WC@<@G7AU4,0Q8AT+UAIP%O\BJU7:OND%
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MY,8MC'?*P'A%-\[H926:CPJNA68THL[=YCL64VXBS,J4?J$UXG(_9C.+TN1
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M/6&V'.8,=VZ^5KL.:3=:#D,?#\GGU)!I5?(P2)0> #;/F#3(C#'ZSD)IM2W
MHL%Y([J/6B<X-T7X.4I*$-W4(.;<4@O3,$--:+!\,H4+/PHE3AQEBNW5&#/K
M@YKBGHQ,M3M::O\C@5*/CT"I(U#J*(/_*!G<UB>:WE5WP81RVU<M*>O">FVZ
M6%/@CAB(:0& )%1^2?D&V0%EQQC6Y5""HSM*Q34L#+K)/=*D0VT4EY/5[19&
M,>)9E[L6-2_6],"> R;8\#>M#&$Z2-(;I@QLACY:RH+_)-86VG>W_9QL\.P[
MO.1H']SCV51(.R?'\G5]T1<!2"P40MYX<-TIDS 28\A<4%\LC>ANA/8Z)6?^
M8YQQ&'QAH- 0#C\ >XT<EIG#YG/4IUZ8L6.N+Q<LNO-N;$0WVC_<6V8B$##3
MBZDLU7:28>%B=?9<,7:JJJ4,Q@/"@G$5"\# G[U$->0LD#S)8GKB(69-$6M_
M4&<!E2S1"C&6FD+HGIL"Q.*RTNFV=I=]JP-8Y(HV"Z,1)-^!)H1OSI<6KO-N
M1-&V7)SB>,JE$)[%*HFPG:MO8VL9&<I0!>=SY%:I5_[_[+UKD]O(M2WX5QAG
MSIWHCD"5)?7[.F8BJM4/Z_KHM*XDNR?N-Y!,LF"!  T054W_^LG]S)V)!(NE
MEDHL-[_8+1:)1SYV[L?::P$B H .KI_J(+N.*M&CJNCE[.]I7V#/WUP$$N[9
M0+E1;N0JN$Q&$,.HR<6/&J^[L'?&U;1"FA2U+<VOYW7;T>L5MI)0;?S6Z]M&
M,0/<H"\5-L)Y5%LE*DAJ9"[=2XSC/%@F*"PFR[+T)HPXR!&+_1D5=O,Q@L2*
M1P U+RA?[0A8LJ:>8H")2;2B]!+Z(:&>B(K,']WK,#UP_"W&#9L\986<O,-.
M45#>S@"*5-X&:CFA9S BSQW '-2B/]D-:(YP#7)O'RZ7EVWGX+7Q,J1A/1/I
MK(Z7/6!&JH88Y><NU\F468F8$" :8NYG%TAC(7 X  (PZ1<\%D$<S=,1J(<W
MS&F:C??'D71 S+DYR9<Z: M_&3I% >.>"=.U4-$X1&30 4'H7:S[F(V+IE/E
MGZ"^J?0<":\@F CO$=S"<KR<_>H4V(&0)T!NF:P4LM/[X>DH&PTX+=I(%CB"
M-'3<@2T]#(2=A._C8>N/N%W8I0J=SE[+7,(4I,R[VA;%PC!0D[I$76$MR@ #
M$(H8V;AQ[QR/]9@]SYXQ1;J7@DL1)!\>WPJ<5%WKG.TCH*Y]:[A*8-.8$W>"
M]7-J$!V@E(R*2MPX88E#IRK%)E[.?AI90=OU8._,=I"6>NF/?KU?*[0\6L3T
M)L&LB561K(O"U@HEO),D?/+HC!*T;?OA+3*(7K)-L^?PCJ_I2:ZHZ[ TQ^Z,
MQX 1[;OK#MMHY*2EK_>"_4)J$+'\$<>Z<0G(G75FW1N4;P3KYS==JE&YNU>9
M^TW"+CHFI0?J<2(A^+8;-MO(+0)<1;K:VF:-E CLXU+TO 2>)CQ_MPY62DV*
MEK8BW5L"A_P,I%-5_B8+Q:ZC6^_[2 6=VXX=>NY03/^&3ES'!7E'$P-7(A=N
M'Q0X_-]HA":6PXJ!)$+2 AIN+ .CS58\H<L#LXGZ1@VSWO@G_(YX.B9NBLJ<
MT(R$8VW<,;7C"AR\I.(:MC<!:\5I5?[>^FGL9S?>@_M7V7W* J#*(LBX]4+7
MJPU,I86;YR<FCJAU.:N$T]#D3T1>OT KBTH;NG![[NT_?%-8Z_YP D55IC>'
M;[\90 W/S9[[(Q!;P/[;+S8T]\^>/'MR.7O%'@>ZXH.U174EY) %;=)#M\>G
MGK!@<,P,^_&R%X$>X"A%U^@1GKK?NWW+%GUJ7J:,HCTY>.K93D;$">9T[I =
MDQEY>NZ_X0_'ZTB,+K4%PGE$L=IR"=!Y-;AC'5QD>?WE[R]^N'CZW0R/N4VU
MB)ZI,0<:+ M7.WD;,65D+J.XLUPL_!>I/P[RI\L;6 ;+\"6%,$U@1"YGOV!"
M)GE!1CH+S#[Q&:-S+G/ ZQG] WSQ-=;-@-8,B_K:\F1%I%"!MF5GVC0%R_&K
MBCU<D)MEQ&W\J.EKOX+-_<-LWJ%S#CQIU+S!TI3<N]6.?X (!&_HL?N*J0>C
M@W]=;BE_\-63_P%7^.;)_T"A,;.B@M-^2U2/*,F,<' _#F C*-C #A/_SZ?)
M$ 9*M__E7[ $Y2#_K6<%LH3WP@>58N0TM\EROBSW@(H^SI)J(4-B5VJ:(AT#
M4_2$W!V#S.ZHN[[Z_J7-/U*>D[>39H=D-F/?&3LO8__9+ W(8MA3-QZJ!9A@
M_P D$MY5(+7=_*/%SLL2HRPN7FS ,<6.$K?D5B^I7RA<M/7^,&L/HH0L+1F<
M>756XL'ZGL']3&8#PJJ.>P0:F;S94YR^IP3ZQSFAGE>Y[[SLB;T1 T)M0^--
M5BV8JM?_8>!=3^1]ZF9']HYCVUMX%I&B!28WJCMK#VW.V915]3TPUJ5_DY-%
MJ7R  M3U2&['OX"=;6?"SQD&RB.W'.:%N.9D;VPV2%;I$.]NR,+-HW-[T1(]
MP+W;S4B:BL?[LSA"L29^/$C]YVBUJ<L(W68KE M/%[\\):\"F6TQ>G66(W5+
MN0,QMOG];^91#0ITFR]*4(5<-TI8NN5++AYIJYT<R,%]EL/$).]S,2R8&?2M
M28>80XVV$\J_VD4-ZA1Q4A9&.RWC\VF"Y,F>MS:BX=8^4?ZD&7^-/D"]#\X&
M'UM"R4OJ8%0%A-<R+]0O.L"\[;.$4Z$;F<)U)K(4'X*Y++'E>TG]@A)4QY?J
MA4KXC JQJ) OSJB0,RKDA"UE8B,YU!">MI >-/D=,0UHI# I*$%UH%?'RR*?
MB?@2TG5,9RCP 30 G>Z\:[<TET*;"_X(%H?#6?4(#R%+>0*'^#A^LU:?<U=R
M,K6=)<OCK#>'03Y:8]*9PI(68-9TR/ GH'SFB'4-:PK^.US9!M*48G;M?00L
MBL&S .OJ!IF]::$74.;E^$O\RE4*FLZ\6MMQ0%L(HXCD[(%TH$AQ GP%+I,)
M"ZNI%C))#_OJ/LCT3K^KHWY8+JF%HG-4!*#VVA-=4_>LK-W9B7!2+W<7VF#$
M 9M]-:J[<F@!^EC Z1M3_Z@*SJT6SH3%F_86DM\PCS14D9 5>U6A;3?<W!3L
M6$N8I 1\8+GL%^76,7= >-J4/5J"2J+_186N0C()UJ,K(W-)I%#(-#)]:<[P
M*.]Q()<&>QVVQ6G7E-^S=3^N[,L2LJ58D[M[H;G)5^!<&_[4JP6F&>2C*[)N
M3[_[[FO$:VT<%H/2JP42][>!;@96@G*.P[6?2Z<=_PXNCG4=LH6!L"O"$8BD
M )0YBZ@C2ZC'6^_N*ZJBT80?)QDD52#@;\DP?)8'9<4->[%-1G%S_X#7+<BA
M?QY!&2FLKSJY;3"Z3!FNT$SDX/"&'X*I5%E/&>P-0RNL]R)FL$?OP6B A61T
MNHDU&6WVLDK_(<:EKMP-(Y1 )C0P# '>2_6+<H.YES=J6O.5Z1<?M*IFSD6>
MTI3*88PK]0; QS^0V8*BDY8AS<QRB[(E&]=G0#X8U :GV]&M>D8H6FZ=/O0)
M8%<40?.<M)5F1A2^-@#VBFTP\P0Q?]Z-BSHF.$8V<QL;]=# &MT"O].FHQ0H
MV .FARI@44+.SVM"UX&I;U"2:;NF*L&')W[[5_Q(F- '[;CGKZX8L).3MHBS
M:4_HF(#?S-98AS:W$ K]?O;9TJTJKGEK:JBN[9<ED>/WF.POY.GO4]D"8N]'
ML9]W,7I9YPTS5OLMTYF(9H(=6[8P $T*;$Z58[:H[#<192HL3"S=YJ=UW7;,
MF]+[Z8$+8&Z/K!5BU.S5($-I[@T7"2SY0X>V;852]F0!R>?T3EX=$N TJ$K0
MEWL_/5Z31XP!A[C'4+@C,-_UUR7BQC,7-5,=BU: XPR>>V*3[=1(JA^T-1:8
M7<ZNDR  ,B8BG)8$2>%QNR-6Y!TKR=4.,,''C3:?:*1IU$>T2FV3>1/#60,S
M.S&#2:%U*1HL]/QE>'H@&&N''37*U8K"KKK\+#X^#^B7*6WU@E',RZE0("H"
M*9X\9R^9=FU2FN@.$2+.'?_XXU5.<.A(6:&=JJ4P'U[;OI-XLV)1H410B(/$
M/MI\J8>1*DQ&RI+ZV(*G17K .BI$:*4?66#+*E)QHBW=%TAD!L XD>^102 S
M;GI*+#-3+*X34LHMP^C5FS40E,*R*OC '0X[E1!L$:W(<WY=;;-0ZTA "4;R
M0AR+>-;AC>',===EO1J)]NC@8YN.Y)J)*(*JS2S=TX_7DQ: _-A;QBKBO8P%
M1/MJYWHS5Y_'RC\*OC@@4O<<5%-[X6ZNJ?4BL#%3KD6TCD)\%5;%:._%S+;G
M-,\YS?-!=),3:/PQEIUE#*DO&8J)0;H+D#_DE!F+8?#)%A</%(HB>)WH^8SD
ML(CY$!^*.BVXQ _#'K<P7)"7M!2Q*^9/$G)V\NHX#B/68UKB+)A42%^4U86:
M[V.]JL*F92+I6T93P^G/0L^R4 ,"BH;5@&-I^5$]ELK![%&:=B+>K[FEJ:D6
MI6SF6 0VXM*[5=U&0@&,E$C6BA"*V@9ABGC)"_DHL>6O<O+'>_I@+.N8H1>U
M,[Q7* U6Y@7-JH!Z(1-;*[2:BXF(W;9O"U6_!&V=@5<7LOO@KB8[0UWM>":?
MZ,:\9_[URC;8/%YFS!=C]00 &"*.+6*ZMU0((4YQS4W547,35;BMC;@N_^6_
MAOD!:AE;N%$X^\MB,6P%:_*F7#G.]X2$&1U6KWG18N#NNINP=R-R+8G[WK:_
M>>?TC=X6:W; BXP7S&[7M[BI E<1OBEM1#HN0=S3VZAE+85S'W!CX1R6NF2C
MA9+76ZYK -<QV !P3FU)680P&*1(77&\ZH-C.,P#T_Q\7T0F^L4JS7D&DXNX
M?6(?"SA/,SMXJ/^& 78B79F?I5L7NEOJ2K3<U ;'2 ,1,_0VSUN@&^]]0),!
MC)^!6(&[1#ZWJ"8D/ASG-J6=S+CTTP;C#XDM^/*,+3AC"T[B3,D?C2_\*V#^
M;J SP=NK1UJ6++D*0S*FB<(N*>=09[#1'%!_EL-1P7-17VSL0)DDU]#U _Y'
MN2.@-+6,@K@K_.;JA^>08-M![%1$MP9/G6T8R8 #HUA!/QB'BD2! =UX)#W;
MRV$6H+1R-(-T>91K0!>88=H^;BW9.VV"JPW-SM"$$-X@"<S]PVX@34)E&SLP
M"*L."D/H/D;G\Z^,5^E@/L!;\6<JRAQW#F( 8##$;(CI@\,WD9G!LUCTY\G;
MX?OQ^W,S#\?8.K[4AY59T3,9]M/T9^]L:@US 6D.S 5A]S-K4)J0@08\Y1L7
M17HS=K)X@Q=E1S(%?T.90O=-<7 M';F?6 1CZ5:.B=CYB0JBJ.YNI#]PI(<-
M7XZ6E&GVI6@<DLQ5LX+]H;5*\[[V33GGEY8<+F<P[M+]RV2JL6&Y_^I#-]%2
MV/'VAO ,7550XRP25/=G5)E\A<_O#QWU*6=O@1-VCZF<5\_?4L57'#9Z76%G
M$!=4NTO29S]V<D<6D]#W!\U#U&*O3N\CQSJ\Q1W1;>("MZXRVI@^:MBR4 HU
M)> OB&B=OL>ITN!>*RC&?TQE;MJ\H/3C T!L2C#Z'0=UTL.RIQO[9?SLR6SO
M2F$^Q,"C[( M>"=+$)O%4.\'^8\DGZ[O9I<4/E+FQB5_5^M(>'M&?4!3AO]-
MPUTBYOG*)<PIT7)(.H,%QUVO%W6L8Q.3@2S]VM[WDDW^VYM7;W_!EC;5B\4P
MJ"L;9A;E^[(&SAPEV[H=/E6U"G^OZ-DK0B!AV;;TRXCH.+ %"X>O@]&#G#S^
MBM+OLCKT6L%-@)=!X*2_O42A 75.N53">T)?[+J2D,X.%FM:0*469"%0U)@E
MD4ABOB0^"ZYG+J<[IF*JD0XI '1F*7U;1!(4L'4)#AJ<%9$<TV<P8LO^R3/B
MXI%&L2'X:)E*:?*%L5;);2"RCW!8:1M 8(I]. 7O0OC8[$-8?:I4).4+$<."
MFR+I$+Y?.!M7!(D1 #WD<>>0)P0,!X.56#A23RBY=<X2X^&-KT#5-#*JS.-#
MC+:X05'C(3OI,*:J=A,VCO9YP==[*0K($]%@/4)K>\6U,9H,OV6L<!@<Z!-"
M,$7J":G[0Y"5NJ(^^/N?Y$@.F]D'Z-:H'^MB/XT],W'AP(-%X\[=^0Q=X0GG
M='I(BX?ES7_R>Y*W^>7L+U(NNF/IL5AC6%?1NI252/S)Q@"@?2/@]P(4J^3\
M,!Y3H6),(=6%O<A^F>,&(? 0KD"-$.*J%Z%,O%>SI"W*[ZEJ.G.JFMQ2ZRH7
M"S!/99<WUD<2^V!?+*#(@$C=O!,?!F+*X@'@^VM;X1(=);\YD$X :*JZQ;"Y
M018AN!*FTZC<RJUWA'3@=VK*KH,72;H3;[40.'<)>F]F!4Z-CR;UX/E>YSW,
M2W::,3T9EYG]!&RE0QBG.K<ZLB0X9/9P+E'3Q>Q,"ARZ<HO[$DV3 GYQ> 0V
MQ1-#0]8:GBV<!'2'H:VT63#RP<%;AN?!PQYC"2[9Y(<JKI&$16I)TJBBA)"Y
M8N:X*H1N$EP$3($/+4BZS:IH\@\8^-D+]<_0\,*&+R5B;(+XD_RO2E0A3YNR
M92'$2DZIU*N.#G%L2$1_([9),KK\XP+P/_X16>6*SJU"R K,:9%:-C[S0BCJ
M[?>2BFT26/"B@;OYTQSJ6U2:PPYWM)DL0D@JE^1S =R@:N%-86LS+Y_>PG*:
M^!6N?2><U9$@E9B[Z?:W4J%O.ZHP,,"$!.M8,XN-H!6SPU;X'71LVZO!R[ /
M17L5-5DMIBJ46 BJU;\;A5K9P\3[9C46U(W PFO_:W$VT'M^AA\==\%+QK(^
MRO/=KSH!;'[!_<]H&+R-)ELK]!?!U,\@Z/3+IFK]WGOV5&P^!-$AF?#TF9K%
M-* Q7XP-G4&Y@!"OG#D3W_^\0&!A$X[=(^Y1S+[[2AXXCMDQ&P!+E:_F0_OL
M0\(2?OHDO-VAR-^\T.ZVU1<Z\)//B<,L]$3+=Z,>#A. %D@^0MJ4<'[A3L4%
M6\RNNC6"YTO_G\" YI><_\_ON_)?55W,GI=-N?3_?GZ-WR D$/Y_V</W?A[J
M593W>.[CWP7\\B^02?EK"S=_T7>E\Q^]\(-1XO_YF<.?O_ N4N'7UA;^[Z7[
MK5KX)WI9>NM;S%Z5[RJP_04NY/_C2F@5*6:OAQY_^L8;^VM_ P3.T3^N5IT?
M(O*BWI;5;=E0INCID]SR"W$)K-J?:G]W #+;#/&,(?[_4#E/-IU(/O3%LX)8
M*)GR8V_9(I-L0AI$<Y-S+H+Z,^70_%*X\Z%_:.MR!0_>W.>QO\0!\O_Q[4=\
M?G.I!D[]W+M,/::PX_I'?"+/^LU'>M;$XU9WE@) ]*2MUX[/'SM>_5WO\ V_
MPY?/T%1B" L<4Q_EC1)/1KPY9DLEQK]&O&JP,G!@Y>8&0R*=-X4 \ETE\?S?
MY:OJV1P92^;MD@6WH=E^NRL%"V#O9V\U3HE.+PE<N<^^^TA#]JL3#B!_OG=H
M(BEG9*YGV\7HO-,L,+M[](^XCP[I)U6[1"X@\9)(<8\GC9S"!?/:E/,2;.;$
M'7.'2N"WHD2EQJ(_50;>CI\:MQU)*V%YZHW01XSO4_748D=QLXLO$#BW:]"M
M]L]^QAQ8S,%79\S!&7-PPLZ^WU!#R"BPKI,U+!NBN6:U\MC8(9/T:N@#<EP+
MW&!$E'PHSBY?0TJ#[1/\#O.(<(Z1J8'LA8^W=Q3="G-0R!ZWMDKC[9H@R#"U
MTX?$5L;^RDWY$E"H']?Z,5.B>9-'F)]]>^TF$Z8<HDGH%J,C]),\_ $!$PUG
M\/PIUZ[TX[*!4?;._KII>TPO41?AQ@\29":@>;2]3?G$0L2(7_=K#/&(1*S6
M[Q0P!P!8E*%KB:0*V:-:RDQ@+I-+<9*:FTZX NE5N!:L-JY![*6MHQ"2)RW\
M13E#S?8BA2Z4H?IA[F.K'?L.5.(JN;YL,F*\ B73./L,MM,.IST"#'PN/\/,
M$Q[GZ$(5G/L21Q7S?#5Z,DK&3I7Q.9?J(9F1MO3<50HA=51RQ&C*3G+YWQ-R
MG WU3O+%?O>^EDI(/KKU"X24G9GY/R"@^@"!4E??7B-NGIH 0KWCM%L/Q3AJ
MSVG^,:RI#'W@9GHCIK61'P4N.?D,*ZQ"VJ Q""H/:3Q2KC4E:YXS/)W@L\2B
MY9]I5(6"@P\ $]2AVJ(*^V=PD?G>5@*3GT' _E_MXMULY9#_[W.!6<DKBB7]
MS%VN+U%N6T?#?_-/^&J'W_3SR]E=&;N)A$B! =\]$W+%[,MO)W-E!"/OG#LJ
M$?9^6:U1/NOH)-9TADH24I2(DKQ4-O-D<TU0V\)A,D5U#9H(EJC0#M4QL"-@
M*N5N>L\^=$+JW\+H3Z3*3O+5/IC9G\H/WL_PQU?YJ*;?W.KAC/\1!G,B&UMH
MFNS>5O.++_)6DR[Y]+C2P<,93,KV'VTY(Q.9MY^4K/](]O/ PC^0%P_XBP]G
MQ8-DBUEUR>,=?*J/DZ3_M[#I?]N^KF  3_)=/I@1YQ1[-A(O9C &Q3T,.ER1
M3#)<4,FJI^H#:7Z_9#RX6<$A87#@7"CN.A3,#Q*JZLFDPA%V>V4CW(]78O[B
MFV/,]?BT@/*Q^48TAY34RO2DX#32M!\Z?2FLR6=CY JX!N W^(]EVS.'FE_J
MC0&"P4JEC@#,G>.C287@3Z$\<%T&R,SA KGM7CRUP\KZ_#@V]KCZD&<4COE!
MT__-ASZ0\);Y)?$)SJ"/<=SF%O+A=_ON-(_"8[O-/WZ)EVSUH4*O@.OXG^;6
M\*7_&I:WU1J8(U$AB$!FSP%UVD$[NBN[Q?4QI>+D^3Y5K5A>TK\-8)YN$?(>
MEB99I:K,G0!357,#3B1[QR/ [(!7$_O!?_W@W0XM^V<'EOT?LC#[];DP>R[,
M/JKH!USP?M] N]8?**5%IY%]]_?,:M&%^@5@D6O2&H;LEF3@?V>6BWI8^.+'
M1"KOE41Z^O7[QQVYCL%?W?OX^E,@V',ZWWJFAQ?ND1#"+SZ25W.2-N.>]O#_
M>_GVXNE7WSW[]\\( 9/CA1(.'\X/R:A\HAQ1NM9_3Y*(PL4X.:3@D?3+'\OD
MVA_9'T1?.K[F^8@L\^9T+/,'-,UJ-0Y%2U\^/9O=@V;WZZ^?H*TXR1?Z2';W
M^V\N_O+E[*#=]</R >QN^)AN^:@-[:3-_,!;&E;DP2U]QDI,$X]M-D/3_E%C
MR_CM?U=T^>;MB__^>5:N6]A(QP G<A@%W7/;<E^WY<>+)J/.QN/Z) $7<:R;
M8[\[Y9@D&MOYJ3A[0Q\X3KTS_OQ2VO#^4([0?0A_%1!TZXA9#TEMAH9ID989
M3C1@VKOX4$Q[ME=>^?1@G]Q%C):(A2"_0T$@5L3%8\M_S/)6KGUTPWQR2/PR
MD-),.8>$K4@N] N0(D)/J5QZ4R*?@SG2IX6;P@? ]K)@N9-B?$.D?&&F"&#U
M\=-/N*[,D[C-MF[W3IL4&J"2*(78).AUTOOYF3$7"6SJYB8QHP?>AQ3%W?1+
M1L-!E%.'1M&Q$4-6<BAK+1W<GG;C$3,W$[YF<U'DI@ 6BZ->"TM-HUM3?R#H
MY_E3I0,=#+2EED)'V2EY:2(#>X<B8:F&1D#K&=('[-MQ'?*A6*T%T#*#[AP7
MJ2T8+B:N>?(DDL!$LAR@29,-'50"1BM#Q-0*)7JBXS:Z#ER#Z"I@@$3JPC03
M<>],WLE(&0TC;@ID6/$OG71E(-'.4-72D9E.O #._?DS[TKH>8I(_Z8-#76#
MT.6J#3U.CJIB]G;Z&LPTLJQ Y1M(6L(*Q2Y6XH<9ZK(C];!&V6)H]D;OBBQN
M2DL3PA>:B@-O@U.#5&_8&X,/U?<.^VW\BK@-@H=5LX33>:\KTS:OIKPMK &.
M/)>-"##Y3;'HJGD,ZJ.&L.-Y1U12;AFL5<*^^H%)1_@'S^\PX/'&B,F'A#?*
MCP<8"W^D<?<>M'&Q5!J+(V1H/W<I=ZF5D+J+$>4/68?^YER'/M>A3\+OS><&
MG@?7[?$Y[>"'C0D*_2<)1R$?&-B?+*Y5VRSH)T!)YL >%\3*[7_JS;/CQM;]
MK"NWU1(%B@?-G!F/">)LURW<S#C!Y##O.H@,D729@M:)TQGBO4Q/KGA'S&"X
M&I 5U00,$3N8<:(XF^&8G]D[554O/%[P,GPN@#A7^,3P_B'EFG)9Q-1\WKO!
M_NY4,#;U:6R2:10_0$>K/XUZE=L%5XRD77,484AR>PM?@UYP)TQS!#]+@OF9
M=U36+K,$#$TE9GS+VE\G7COF*SYB7X),";@V"&B#!G5_@FX4:,=N12F:3SL7
MOAL_&U+]"6$^SQ]F9$24NHZIT7@IC.DM!50G7X;@A%11X!(K\(Z-DV0HWDH1
M^_R?I[S%\_8)+K,@<.$.*+AQ!O0]/H71F9%.Y$O(EJSK=DYIJ8FU%F4(E]6P
MH;VP@<F:7GT A!3A@R8W ,!#@[X876G3>JLRU/!;H3C&@!$ ,&1?--UOKD'<
MC$@XSJ%$/R _8&!!K/>&P!Q7Y4FG=B8DJ:PM.H6EH[+;H>NBB(H^<D;!W(>$
M-7(2[%"\5C#"Z,'<EL0)Q$28$,H!@>>.0I,D8H5246-6FV2J'(DP@Z@:\8!J
MFHKM"8RB/^E(G)"-+3X?9;$A.>&C-;\"<<&:GCYDJ28A3SUVP$CCD;1I_6.1
M6*]=I?9=:9D*_5 9!@0/'B",T&7+9RK+]?IERTT/'>>(RMN20IL-B#SZX,R,
M YX_\)+C=(C0T1HC+;M"EI4]@GXHJVIQ7<W>E,V[?5MPUOMGYR?YYPK?XS/Z
M""S"HO^\F+U:^47447>"*_TWK:FGQU-%<SB&&A2H#W>\ZL&Q*/UG5Y"U_C_^
M4 #>O*OY_.^5*U!HMH'7^M/K=G'M.-G\SD$RV["5YIP00PV_4U< B56 B%_+
M 3TE#8GLEXC B,EW?,F(TR)X*K#0-JS5Z2 705KW0?ELYVU<)^S2."Y,9*%!
M:8[4I%I%ULLH#F[\@^^ 478?U@^]7Z\)K3YS(U44M72[RO'%;,)"5"MOIX33
M]6-DG'EIF&J-\U',7$5#4D-]RH\?)5.AQ.S6D'/1I4IL;('[UP_Z&@XB)/-G
ML<2"=IYJPUT/&U3P%%5&OQ4;TO3UQF+A@SA8^L!\ECR6;%?,X03GF7X_)$S@
M2J&/A;YP-F+%W&]B=X-D,=[Y[+? E>TOWKUS()B)70/^6 9E1[#"PN%H+M)"
MEL(1Y5"4)K]Q^ JN9D4[[\:O>?^7BW\.%;>(L9:YTH/?+]1A?FUA7D;65!R3
M,*3$(.J-->1(Z%%(,:4DQ\(_4ZBC)<,\-E%$3&TCCX%UHQ?=0$S"Q',G@__/
M 338JR3O3J)+WN_'%![I(S=05?-'D]]757^-#VW5!/8LAHQGG;=)+F6HBIB=
M17] A[N+RS2.MCUKJ$":L<6,LC>J?BG!!ZNV4]'A=5=N_&"\X?%"30,E.#*C
MHT(3D<,5":R:G172KG5(<X8J!,9'70?*L";O1[$/DMC+4+EE> 0B3S7R1NT6
M:N9#0Q:550WC72HE45Z!E#/4B,_NNNG(5(VOUA9P&:I-)#/O1Q0_]JO1WP2G
M$.CB@;L?15N)KQOVL-RY)#YP]4PA7;UV,"';ZU@!&[C)4#B[E1\G"D_%R(#@
M5+&6DQ728'NAC(Q#+]*NL(B2ZAU<3#/_I60$V(1H)RC4JR'6)=I^>URQI@M4
MDSJJIH2@VTD66:G8E0.!)0_"Q7"-BN0%3>2=1VS\*/8 /^4#+!\!_!@EQ/^"
M!\OS<@L FE-^F7OS=U_[ ^KITR<SR!51%45+ =9=_.9KLA<O+W^X],[GM?\_
ME*"FPYR6XM(O*R@K@-40KSQ[V6^_P3WFFK6W=TNR]YP'@<%.RS'/ODB_SBF,
M$4CMQLD!B+;KO]''6*4U83S/N+A#^;IRAD;2QT85:;<8T882;2B7*N=^AL4-
MD H*E2RE]I:O>,9/0(9\W;;+D]X8DUJ.HS0>>^YB1?!0P<R54=DB(T>!X])J
MOI0[+,*:@U["TOZ=-S_@W,O(X5!+ C >TU$NL"_KLI,S>]XV T::]OQ"=C[@
ME=R'XG81K3ZU@_BFKL'#([R$#\PZ(U[5WNZNN:%YUK5S/TO\?'2M<O$.CG>\
ME+_PIL5@R0=A(+'FUVW7PO]AXH<""=4DJ2&HM;OQ&B6=%V6'KN2.U:$@M&P:
MA">15U,M:>NUJ]7E2>-R)TCZR@4L$C^'I_SLAU0ANVV+FH=^OI;><^UVJ"WF
M=TK=+DKVD9Z7FWE7+=<.4%_>5UQ<^Y6Z8ZQ*"YK>[$+\5FW\;_RV^.*KPC_\
MK(<K>@OK'$E\PO%,KISB3OP6\LM.ZNZ@KE7V&I)C0N-BYU>U7SKJ<BCE:WO4
M&QA$C=_B6P$I(:Z+$E)T3P6&E8W%BR'>D!3OL.D.2YF)UU(RD>6A%ZP@HP-_
M1R<0A*1P5$R"H7%N*<5M?\7>;WO6YM*'H4N)RQ.J&27]#K75X#+N@-G^0Q:L
MOST7K,\%ZY,PQE,%:S%C+P+VY/&=*;]"#15!1FJ7E]3)\.0I&JG9#][*W)).
M-'T!(:"_$-JK 1!6+:#.&\<&-3Z0O&G\]LLGLY?.!]80[/[08;1M#ZFKF8\=
MH M5>D_\H>2VU^!K<^;'6^.OGWYS\>5WWUX\>?+L"3T!J>9ZJPQY%_C*[>WM
MI8^I_8B4E]YQ0ZO?M8 WA4-N4[Z+*LJJ8&LA5BOHL0,ANFOP.*V'M&BQ1"VD
MUDT#]?/7#BZ"^I0_037@Z9.+OQ:S_TW'FK]GYN__V[\[GR#I7[^]^"LY>][W
M6AIQQQ:3P?1=DI  4/;@/47,K6"5CJ5XWS!^\.D7GY6?P]>>?O79\G,!J__X
MFW^OQKN,5XL=E@7[%K&O_NIEWS:8A]Z"Z\S@1C2K!(.4^V/<!,%+UTIQCAX)
MW.4B?C!(6<%MW_SXG.;"&Y%U ]D8&,);-\>)PW7VSNUAS"''!@^[A/"KF@]R
M^G<H(,'E;BH0"2H6?[YQ)75,,'@,JSJ0V845A[T*\M,PU9P9]R^@ 96%GOGO
MK[FR0'K,_BW\C&$2!G[^TP^7=O.C$X^RO=)=)>_77Z.N!^7DEQ#A+=,-Q[D]
MBN(@Z\;JU'V\SI)E)D1'<B,DU@:R\E!AH(8&X=KV0P+2'YS((SC ['J_17/^
M+I=3J9;_SW_<;=V??O<?1UB]+3A&S?JB=BMO5O-VD#ZJ$$3Y/R_@2Y_(P+]X
M^^-+JI,^O;JD_QC_[^L7;_XZ^^GJ^=M?7K\Y2>,_V:(UC60*B(W.@$0-\-)N
M(;*.DID]N%Q!^H^3NQ!E$I!(<AS@];\-D%9_KZ%A+4RLHS)25CC^=7D3A IT
M/1NJ1_O'A:I&\,"GKLCH4TC8^)\#_+=AN+J1YPVZH1H[L/BYVA;-TI9+D'F&
M<Z;$E'(L=P[ZFZ76EI-![C$HXV2^_*0(-2D8)N'EHBPO'4,BC];;6B<E#5#.
M0(J'/.SRS/6>LUSQ Q^*04[ @<EOTQ%J.<WT:6G-BE&,LLDG^>+W%2#PC@UC
MIDL\R%H4NN"$TZS-9-%Q]>+:F[&2-=6+0-[$G]52JIH0),4#R,B:#IWZ;UQS
M537XT>/TX:N9DCFUTT82'<<^$L;\)+HA ;*_"&3_O.E"BP;->#Q4&(-C8=0\
M-*/3H3F$TH\V0;PC"L ;UXB.&SI'F??+C?=I5RVFTTXT$]ZS\,-4KJ/"I]BC
M0!\*0XGXDDS_>IN]F)U8>SUE41 D$OW4F$ TJ7@J25*F[:9!'X6>&U)$K=#?
M1<%>"E^DD4AM[ #2M>L6Z^IZZ?QTIZ5=U('95,P:29>$7CCSMK8(?,0@Y[1^
M#=XC?I.^\JNA[.RMP4IV%[3'<X]!X!.$//0B43-^JY<Q=(MS?PD"@'$!!BE@
M, $,Q$"$V#(J/_=N-R\7[_1I^6'' X:!2<!&4(KKQMFWQ0'E"T0V(L1T]BOI
M/0HQ#V-Y[JAE#'7](,TG R[O,,(F2"%57Q+'80[=L&A"H3A4,/:!5C7@:-=0
MB#>3M:H:$L-&9YZ$KD;C@U&]XO+\O'*!%>H37'0%8(CK;D2!"RYV8'6.1R>,
M(G3Q@#H6ZE]3G.C4OZ!J_6.T?( %'(U%)"OOW3*P,+(%%<ZUB\O;A+:E"0CP
MC=VARCXFG*E"/U'_CL4=]3EWZ)5:*VHJEIFSEKJ[#58@ "7\3JZK?R'K,Z_L
ML)L)LM>5%:YO\*S!"YVWPXZQ>>/5MHHQ<KW %+;5UL'@LT;]$>9WO$ YA=4P
ME52F(=#%3S(Y&-6*T%TXH9CR1\ILN:,/IK?^:03K@F(]/5F\8,86CJ]$S@BJ
ME-& Z%"U7;(_LGU\N2.,UQZ9^QNJ-_NK+;VSLR=/)>#*: 6-$&93*^HM/B[W
M8EJK#!T/4EX%D;[Q[,J<27>_PG_'D\6'[(0NWI(PP,VP<1T([JVDF=8DXC"%
MA>N'8%>HJN:/*Y Y<T@QO+LF6];N6F\M0&^-GV<1#BPP!>19[(/RFN"VMNV6
M\SR R@DWI,#IFBZEA.HQ"DQOJWX+6@1(3G7M%K8(F?CT9PBVJK;45?ZR[5R+
M_<G6(D>6V(]7.2,H\<X/>3_T@ :L&/3IYVQ/U3=HA(8J> @52Q\9[WLYXA(H
M-EHXCG>7 O<=[Q4??$(> ,YOV ,T3Q61N!U[B$!F#CH($%\%3CE#7,DL_O3#
ME:[;QWA\U)"=Y@BD(.0C69=IL\_=Z+I;>:>OT#$+2&>BO$@7:H":@>TJ_6;L
M !)?]B$+B(:BKSKZ3X)F O300?T3K/":+L)YG4@V<(9!7A>G9OV>\_]8Z&.Q
M:;@E% -5G#5%@DJ>>#NB(* 59.NE")@)W=V9%1.61XCL.T8,_H.MO;F@]PMW
M%\$,^H7+$1P^AJ;8E?4B,R?)26N_$11'\27!;B^[\I8WC4T]E+J%8"J!Y,<E
M8^<7QZZ/!K=@_@&U6#A:>#$,9)V_]A"8&C;^0;C9@<'/^]EGKW]\^>9SB5(H
MQR;!;QA)0'1@7#5V0S#LSL11IEDPC"["-,,2#>\L ^,O>(O9J,:M)33W@U$F
MV;*#6:YQ4NQ<.H]*Y]^=2^?GTOFCRER^@.U2 3M'N[V /W.[F .#TD"LA*X.
MIML0@!,%.R$F@SA]8.\;ZWW]-7-4H<QM2_^/D1M50:$?$N#3<ICB;4:MQ^@Q
M=?$)XP\CRB\#.^!*M!&,(XK/1*GWT/V@50/C4:)AKQKVYQZAG_-3.L(:H\@<
M5#*_S#XBT\Q4'90JO7.R0U9-<CVC'TWGPN @Q=6B*6ELN/_GP#E#<+6A2LL'
M#YSY^,SF8:96'64"H%-CY])U(C0MC&NE_B1<<JKT+ GM80?+CAP)4ZD)*U46
MJ6NZMJZQP"&X43H:[U[*D)$,0^8?96)"*+( E\W[2. AW'_IQVT_\2+GCA_S
MEB%<#)QRZ>3>.IMHXK4%A<,K2O;#O0I9:WD+$DJ0-Y6[E4A[49(O._C!K--'
MQ:[-,'Y7'+3;>%)BWFT\MI5=0>*Z\%7),$2:W#/(GT9N4*CAG:95N*>5_]76
M4S'SB95;('#,%^5(A@Z'+O I-QF#<*4^;:M5UHD,C_V]+1626WJPALNQ<@B9
M!@P=L!; S<OVBIKOFA"[5R)>38:$[-IISO?!4V \50@:TPFG3%X=,JKCQ'R^
M35>(/G#%2 )>,HDAS:"%&!!Y36K MY;84SK$IAIV;:9).7_EQ9X]^>IK_X4=
M9?YW""@+P2;ADO2V>"9"Z(ZG3P#^"YHI21UQX=4\?!)YRB!,MAI+WQ>7PB2Q
M&O("XS5GV%'Z\7;#E"RWUXY3=;#IQN,=C+'L1G)Z]\S_ZLWHQF0X0^LZ<@Z$
M[*;-%!S88W14Y&EK\J\<DYF\P(P,EDN.O"..DJE.%ISL33^GB_IKP3C1K"\<
ME:@R<78W^CH5MYQ%H6?:?I&DCP^UD! F[ZE+3AB3(S:5LZY= 7 =L[NG:7CN
M>=#\2 EU=4/PM=G)Q,Y1TXZ-39A^(*DP:%PKKHEXIX[9EG)Y[(E#)G7[O4$!
M?"5VP?8[I<4,I"PE/Z--WA.4,LW5%/FL(3PM@C#H3.J''MJD$,J$39FP7<O$
M@RV45H$(6)B)KV=OUS3/2E-YKF("+,></_);K2+62]A[]6/,V6:80CF2.U#^
MM$6J5T -S;C!>9KAI]1[2&Z:HV.TNH[#4PB()KK][.ELV?I+N-Y?4!*"<'^_
M8H/1DJ84+F(Z3!1CNQ<EAR6D0>/9+[RG/=2 AU[)[,9NEXUM1B\#):4\S(@3
MLH7!%W(]#,,JLZ9W#O#:!-F O>S7==F0;[' ?J R&>[+66H(,ON_[63UOH<E
ML <#9\RC\OT]F*XB;.P77Q^!C7WZ[0-@8_.[!,/$K__\Z3B,XN%Z^N7E5S 6
M:$-[:+ 5Q@<XY;#G'7"FKNF%X,W:T+6?](HL&>T2HBJ>)A ]3]U'FSHS:7K\
M8=F&7>8BM$CCR4-^$!8\7;?AR96H&7F@#8**NL';;ETVU;^DM NBL:]_X4)H
MCLWCO X>=!T( 30#RP*409WS%X'6$('FD,F9?=^6W1)G\\7K[_'_?]Q= _W<
M<V_5JQT2?L.'SXO@<D/[-81AF5D_3_I#3OH"^F.<Y,,3GAXZB!&$)/VUG.+L
M22&A4RKP3&Z(SWZ%\705IAQ-X(A(#158B=?">1D\Y#*H5/J&:MPZ%]>@I#K?
MYT]MW/$];>Z>V\'WW,YFG?0< (LPI!"?T8&1N'>F\@RA]/E,^#3K0H(,OP+H
MJ%9HK"&4!^!(3]B/:\ZC)';=0C[.$_@I)M! ?C #!>1Y")94!8^??KC2^AQP
MV<Q,>A>;4AVY;#\_?T5YAB##88S#>JB6F/@D%X+: T 0!+#GYZE_4)O>J+;)
M/Z%#N2+8*%+N$;M7F4DL*PN45 C[&#8MN.L#29F"J'A^*R%P+V8AOH!EIDD'
M[P;"'3&[[M]_ ! C=3T0HK;"'H\#6>84_WGX=/@CPI&^>'*&(YWA2&?K^C&L
MJP9"D+"6'"64=#0H$F)'20!W^-7.[09B&4-=/8#(*E\LMR9?#%OK/2=5/6J[
MII3S\U_^_N*'BZ??^;LVJ%9P/F$?-'C.,= &?'B//0=;*E-01?8<VS[\+''T
M"<*92>UH0=5Z8EV%.[8H"&=;@]#5?7/U(_YP(L6!,*6D@^BNTCACH)".=H>O
M)-T>H@DRF[O&K2K2_1N ]\'U@'2*7D=@!V(0,LT?Y\7VP/FTD$S3J"AJ>?#3
M"5$21E^X'@33A,Q#[ #WPQQRIRK_8: VU-\$R,WSS#[@S-;E OD+-*A:#31;
M%!2Q@L8HC_D("_$_8,!F+26'<-HHC>]9SH'%7'L$N7414!9,<K)(VTT,L,\0
MQ@;\[JB(3 "AE")"NZRXVRZ2Q]*KC0-4NI1_]'UH'C=*#0<:@A'(EOE)S'(^
MW=AJ'U\:T0_!$HF&[;01B?<$!EV!,VQFG6H+%F!%;'/$-B(.E*#J1J"&.U ^
MR"KJ#T77Q2!'...7_:%&W),<ZX/;]7DZ.'*>F+$=X]<%@81L+=Z4:0H>.U+'
MG;]G.,5#'C91CW13[H;N0)?TV<-[\*D!@B).HL*_EU6/,"CB*B0H,O>#GB?G
MH2>'MPNKD&Q!7"W,5,P2$-'1^'&N1%Q*:M52FSZ'[9]F*E5Z:%+LAP/MWZ#]
M>1_Y#LK>>JX;/WS.9>?GINR6.'5,*6<,97^VE)]ZAC!218"6]%;H%@NS N2C
M( J)2O.K/=M( P,ZS]F#)I>(* H0-8$TCCIB_PS&\#P9#Y[\K_Q5):(WVG,A
MR@=A\*UJ9'+1.B1Y@\0U">80(RU[E4 V2.VZ--^LK50KA3;K-6FWO(IY1_6C
M9H\Y1+A<+&>J0I;BYEB>FUO'U%YJHIOU8XR.3P/@.)'!D+R%25N$I 9GW42R
MCCL+HWQ&739'=JMH9QRC](YF[CS-.;]__S.L^=ZY=[-R]CV '82)_2WNF?WL
M!VP]H*WEA^.GLM_-WG:0]+5_X=PGT&,)WO$@N;$26?*6&YJ0K93\9AFIE!)K
M_]+<4Y@5 "!#DHRJA+SR3YGDN-HNKCP@1KLUC$C(%M#SDU4[ZE<BOGI>C*CS
M4[WSI_TU ,&H:.7?-/N*W+XM#99CVKO37$ 'C<:+9G8UK$'QZ]F39T\*G?(U
MMJ4MIQ:'[$2UIZ&R;P,3ZI0 *^[CFPN_WRN4VT2BY M_BR4D&)" KT7ROT;4
MWV^O6^I"YL%>SH8M'2D@G+%% 6/"WD$]<^^7QJ9:\*&PCPK3XRNM*!]Z^!)^
M87FGOF9I27D%Z"C;#8%O[-A=9@Q7)UL$?_L[]F=$71QOT%R'^\15Y'P,>B46
M+%<94K?L3)=:3,;17+D+F"%_QX;%=I>5,H=-$FL#545*:AK\!F):ZX@:P5N5
MC8.3:(D_!5$K?K"J-U1=LZO9W(ZLS&H%'/\K5,^@?ECP.XB*+KQI$32>X2AL
M-_.*!XOZR2V]"AXMZ&X4N#SAW>\8%,F@8<.?$NZG1"*!"A0D Z& RAZ+',;J
M-E'O<1@]HVDK*N,T6S?A%*SWJ;0W]Z;E^BN!'=WP\RDW:2".L[<,R^,,4+0
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M#GZ,+[P_,KLMH7N(=!I^'+IVZ^[WV*6I/(8'#ZZ]IO;\.L7@G86,>T3;@.&
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M9(<J-W:<V A2CI3EGQAUI!D,;?\L4J%\ 74)X=4U!YQ-U%"KC2F"6MBG=YY
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M@KIEPUPTPLN1$FW H^*CJZNYPO)W\O#D&$A5/&#RDJ+E ?FIRF"_-P!0QV4
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MG5D*7SXY(^[.B+L3ME4J8PJ6!UKKL4L,6A"88H6S6*7EZBXPP;CNI/P$?=;
M/@C!(I&G"S4!<JQ46Z*;)7JFG8-&^<O95>UM'V2^.+HN6&Q0,I=I6TIQ,$>>
MTT'F)NQL>DM3I4S:N(7.#K;21/5)=M"_M[ *3F3YJMZT_R-!.)C78+^A%Y03
M!\R\R(X]D-2@H@@,2KO@U@]IT0Q-#>,6JEPK"RDX3O#U&!4*K/(*G[3TX9J4
M7N_LM^?#+C2Q=ZP%,6AM6@?N\6HQO\AF$J4T$HM]0WH9<\N4\%D.Q&\A1(W^
MH\ YC^@$V#*&"H'VU$+2TG1FXAKEB@FNI8U?#YL*2#-8QD.:V10)7RZQ.1^6
M_X@*!%=2KTBVB7XDZBZF6VOZ/!N3'K@!PJ:HCPP>UI7+FN ZF*P^'LX@%22\
MWL0C4\X4O"I&^/3@\T3.D=(N^870+I%X*H P4R]F/\.5BRE<'THT8*3L_FP[
M\;;PNY7I,&7  Z;4<T-F&CC](YK^P<G9B,8+%P49#,,B.QI.K9W[BP - -H'
MK,V/L]\"ZL#V5N1JB'CG#9=!X$@.2"O$8!F\%>2"!6ZE\*J"VUY=EE3$6)1<
M)IF? ]L"D1.?D\I *X 4991?UH3KD@2*;'V'F*:)OO7^9<E#(D&IOI'!D9RD
MM;M_ 3KT2!X2;TB+,E%QC@,&/'V*XU/66-D5S0;\ZD2M5VAA%$<OSZ<U;*Y4
ME[U:)-P)L@'N:'(>@P_R#U+HSIPAL&UPP>Z89GQE>RMB_9/\<RB&Y237TUT5
M;0+=B$*66TXMHFGO+HAN'BT>0H=;LMZF8"31 M,59'@.<PONUY$H -(LSSEX
M2/DJ7OI[OIO]]>?R2JN5Q^V""5K,2Y"A2XBL4?J"2HBY!F<K)!B5_I?J)9,G
MD=K?/+MG8CS-)<QSR-X/W?],!HYUT'[AU\-0NY@E!*8>_'#B6=34C]D;1K-&
M&W2#0%8"WZN2DT"' .8%:[* 90*B(YX8^_C,T='V!E<:;UEXEDK<NT1GQ>2*
M]>#D@*H8LW!.'# +*?&/C(,_YQZ?1?C%KL)<F=3(,N'.8?9*9FI%7UJ6_:+J
M%L,&$EX+)^<N+GKXFWP'V3)+HD17JP+7XC/&B@:-5?284$RB((-IP+B7F7E6
M%GJ0OJ!?%.U.&&!I!?G @%'+B)L4<0*IS8>3XG+VLNU<BZ@8YE@9)4U']P/A
M@EW$Y*6H Z;TXE?O$2F*)*Q8\C-$P-0$X\H-9_XH]QA LX91-\1Z@<IY S7#
M;6VH!<G,J(6\P4T&;B7'K]$KB-L\C2\+[/<39K>WW)'W(7% 7P(R%OZ0QJP$
ML9[M;H%9-1ILY-<2"3:RTPR<W(-'2]=FRR<="CO5]J1]C<B9U-NH #Q$1F0(
M,HSLYEBHLUKSH/K4J<[!,-Y+@-1.7(XH0G&Z"P^/40&LLXJ; ;C2SGO\)*+A
MV'%ASF*E%I;D+/6[^7W R]_5&"MH7CD0\UK26FKM-BX4L[3 2"J!$.9M5%V&
M_J@2O)#8KC9S(*E2J)4QUZBY7%C0 E'+U!*,!6$1WM"FG4_DL\B'60R=2#@G
MS#M$@8U0&MX6T8F18R;P!_W0P6P!J6\AG%\C]Y:K7?]RZDI4.XL&CXG6E9XY
M>;ZI&*=+=EF^@T BWV@K1]C^V/G2LW9\+=,JDMTAJ9>-;\U%OL#)_>]P//:@
M.4Y4ULR/S\6O@),G$]256V1!I:"UI-;$1 /40*IWP)Y.ID$=4F\/\+0D.FQB
M_QOZ=%H1-31Z E?MC.@N_1:WL[P,99R4;3_\ 6V()(Z)5%M8S^%[XJ91%,Z_
MBGRV*7#3CRQ3&ZW)$%B0KPL'N^C?"*E4/LS@=#'YHG#$7CO"A3HROY1%AE!@
MP6X:3UCJ[&<5^*::(/I42"A](;X)0'5<1]+R@7PW(F.48T3/@BJ[V^=6L3L$
M1\E:"DUWG%HY?-%#9&(Y.A9UD'J__8&#/7+3"!-]9=UZ,\!R-VT"R<D@LLD^
M31-QSQS-VW:FK/1$#^@D*P9'=[^!=N5 7J1+A_A+C:C:# N\UJ=#ZTK)56$P
M0 >D<9F(*A4M,/)(+.$CZ4JY\$F._E$9C4.IB!P=KB;&D.6,L?E'C+V_6\]#
M"B2=@!5F[2LX'Y82$J6>GG4<PR-J54O8W9#@=.K.&$K91 QA:)"F,?OVF742
M&RN5T9)BQ<B1/<KGST:)%N[@1PA5&-DQC)DP$S=1A[,(OB*93N,M^C^><0L6
MM_#TC%LXXQ9.V$PO@B1*1J1O,D8EVT/,BJ_$S)+=B<H+)CD\E<[N6$_55,]L
M2F95#X#DU0C;&X-KVT%$6::XQY5R8-9$HVP1$M."]@]Q9X)E+[6J::3:$<W5
M:Y@*I4PI8]*5(9#G?FL^ITF"#[GW3_.L?C\%,LY=A^H]O*^6&60*I"L6_QV"
M_:GH(*^O?I@T=UR1"!'5*.$MZ<&@O,S)Y-.<FKO<*.M9Z)@B-%<UFZQO($4B
MS-$81M["^C-Q^\Q=<R8AIG#(&@?"]+9PW]D_(+56M<:1H \2!1+CY_V*=-FQ
MIH(@5\'=@GY]Y]XI>04S#$?N^51WM?0.^D72 NDE9V4P)U;UF*V[ #;:(6E)
M_ U3W$0N$?)K<5,OA]A3MS:Z99JH &4"$#"8S.E@X=4_4+OA.5:Y+&S=!':>
M7GH!)9QF09 =-CU ^@\X)K#CC?$QV#NN':?83BKCJ4BIH">BV7=X[Z"W-1_U
M$X;,@5PULA-X$'#"[XCJ9)%[5)3-Q79,8XY6Y4W;2:IL",YZIMJF#?M$^#ZQ
MNE>$^76_E3#U19J$L.B&"1D+T[W7E[5COWY,)0*CM*QZ_WE;P:Y>BXXLTWKB
MKN3$9YM_7NO2)^I<D_D$NO[1Q50<K(0GA:%ND@WBW>GG'W:2XW6 "Y/2ZE3-
MA/5J2150=([G9I2;#/[#5-!X[1H^E$?P0'([[)G>9<_YJEGZ30B8%3[E&=X@
MD=;B@/X?T^K[8V;CEFB#QHX2+N*.NOPFQ7H?X4%$<RA5D+"9K0-PQ$F2K-C#
M3?)64*#L1,>>\+/].UZ_?;P/1DE$"K#SLGRQZ6!T%]A&^R;L]@((Y;KJXGI&
MU.4=BD7BMJ@<4!!V,9E&\]=("(0E7W9,_<\P+>E6C^&4T>$X]<S)'\-3MYJ(
M3K\2'@W7;NEGV@?Y#4IMCT0M4*CKEC.7/ T@D-[OW);K4HJ3Q0OD*CAVUB!!
M4DTG0R?F^.!B.NDM=Z0"XV'\UVC[G.0;WS,0@3J/$&Y85AVJ:E+^MB</P3M
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M^FBLS]&$]9FP/ENLD+4/K]12K)@?T'VC<$<?1'B1K=C"R:'+3TC2P?8F*HN
M^V.3;])AY2:V7/C7[ZU=L$5F NO3\XY@2$!Q02IN#BQ,@IAFSW /F2:]OX Q
MD$=XOX8%/J/XS:#9R5";/+9!T'G0+@.B2ZV7QZA^YC:QPM%HOGRX:-27HBN[
M![TF3E3F5M=8W[4)08$Q/+S<#_;V]^B-(]_T+X&2(7L=7EPE:U=O]_KEB;^X
MD=XE!S2XG98=+ C$7(A6,#9H;?0K8 F,U@8F@25OYK.UA>OL4IKF5 J\[EHZ
M0$SJ_8O3$T2NH8!]YD4FST>83!T8BC=!A]FXK8P=\FX4FA(*;$-A6WL#L_T$
M9[3I1%CW#W9@_/V1!G-!J]5>^;[BT)H9_ 2:"^XAP&%@L#Z&!U_ ))T]:2,
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M58/-#4A9[3^-F:$'EO=GDURL=\Z66*:^A)U.K'*\1$'%H@Q6&<'W</T3*J1
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MLWN^RVV'RI7#@*O??L\STX^39O<2HK5#+N<\/>3PS+E?$#:>M%>[4#!K'(+
M'1(,=WEFN:*TCHL]AIS5$4^LD3Y(0X@1<&\YV\],/7BZ"'<N8H^^D%(4G4PI
M'1+LIND1T\"7.E MIB,E:DXQGCT'71G/\FG@M0-UD(A+E,>YNE<F5L8G\FTI
MQQI4<&URG_>A/Y/$V=7#9*+ 4(?.$5*C:*U*Z4?R[""/CC4/G:7LK.2 RL79
M4UP_A^:?"71-3>H&7\)=@4UUD:SPWH@WP(8*LL"9*7J\U$KRUQ=_LM_[M84-
M[E0A)8@*79")";U9S@JPYE07W(&<VHN'"^Q\/V-?!3/6$WD%</UDF9R[N).3
MJ(UU4XYD.<07*$YFI5;$P1EVE[=S%Z]C&X:")1?#A/BDWQ0%:@DZ</K=<*&>
MPG#-$9=9^2@N/XV#/0SJ4H63 ; ?5!J&MV]1.LGAR3[S]M5 %&K#^,8*&C">
M[_X*\ -NR88E IS8=/X^S !8 7V-E%:9&T412B1"N)I]+V-$V% D)O A)D2<
MZJJM "8EAXEBV@KX2'R%YN9#TNLHI5@1<T4@1SBE*,9'Q!IT$(2'%&\ \DE;
M@0YEUEFUX@O&P0H43X>=5]A['9_N];@?^R"Z:#+3JRAR(\5IVHG/#<..B$HO
M4<%*+TH03>>:#WO-@:6D"FIDW0#-Q!3J8&SVY'!L4W9NL"E@:X,41HK<G4X-
MC7R9?"+8X8KJ%!-LGM2T5>&;%5[:+4-GX/'IK+ /35NI7J_N**,H!,I+72#>
MJ_+6$I.%?C#853[ZN]0U1F>[)[OH=_!'9+D-[X\+@H&!\C9YGQW,D$/9^@_8
M)[=75QE'#G >#.-L722+1?8Y^OONO_#E\H<;O1V$MBS8=$;7PJ'67Y9Y4J\+
M^Y^%@U_&W$S%1XDY,"C+V;D(ZJ%KF< ROG2^TA ->;YTA0A@0KTC&V,K&83'
M6>FQ<FKG$C/A]!K('*T,&JK91$(A4KRPK8RKC,>2G)TT$LU!&R;834:P/Q I
MPUHS#13V7\9]:6M)W@[M2 ?<2! 5JP,HV WM.ZA [J8V3>-N&M9'J%WAKZ@9
M4(<B.B[A;JKN)G<B'[OZA<0GT-PV!H<@UH]P$"_607<0]:1(;_!R+^DW>7L@
MZJ,2KM'>Z-Y2@^&N<]H*DMZK:9943?C.T"(@ 0[Y 2E:%< +O0#X6@8L.J'J
M1GV]0$8;+1,J:V?W<> !N]'+K%ZUC<0RJ@S[ 4CI[; D"@H2@1CJS(1*<M#<
M=J(S<13>)P])4$[,8H]A'RS:3KG\V=7QND/DK?1.+;3 ?S%;/K$3W?MF(E07
M3R!%:X9+G.#P8ZAQ ?J-VHX,GFC69NXZD!0Y!)'4:6\"Y\2)R;3]]WZ6E:VB
M0D[^N/(9;UV3)J6;+T-N(4IE6AL$2(BFK;Q72CB[,<X"'0AJC2OE*[01P&U&
M7S2J[>_J!=@)$*,:?.:TM?=]2G6],)W-*Q>+7'B()IGCGPKK<E_8_R43$@ZV
MRU?]9BW,)@)DG%A6W"-G6)MSXSD7N:>4@^+KX:#HQ ?W$%*!N19.XGB8KE/B
MH7G^R ,J6.;CW7K2:KYPA=!#N?-MQZR3P+8AN%Z_5E82_$!S0_ZAY+X4YMEE
M__R@V%6NVQH<U8Q]-=<D+S1\I9N(02R/*@6<$$0:0?1L0A!-"*(M5E* I4"&
MZHY;FV:UM[-<^TN*BE" A_FYKCB5X1I"E%3GW&'M\@%\C#=Y4,JU:B[6C*XC
MKPO[<PS&(+T=Z5[N)A@+]=E#P=NC-V5E2BPJS1:P]A2(PD3.\!))!@F'Z"LY
MA>.A&B%;<!R-NN_'2*="3-=+$!F*/.<8OU39NJ%,8,#^(1T_>EVKZ#[$932#
M'"2/\KK'DO-Y5LW;)53!S$W8(+0?5L;35^9<NV$ OLVA>BQD=U*B,%Z#!>(4
MZ'2;ZX$<F&10(>5N*TE%X-*W(SI$,)@%33R.J.^/A6'NG]OT*CN/3KF)-$6;
M7U"'X0^<F2;@T\]-NAMCW'8''0.)P@R*?LQ$^K5;O9*99+P7R 1TU.-\(PJH
M#AGY0MX-KD[3%7^RQMP%C%,?*='S4=J!,KJU@^$1RX2I6<>:VC/O^=*.TT7'
M4Q' AR?#==N+DQU9&\B9ED'"=-.W5>R_ITO$1])\,RZ9@J72&'.'<O8B:=0/
MG'2/GW[56+8?[%=A-D(3R8A<EH*K)U@=YVNG21ZAVO":/[PF*9_<+](?Y8T$
M>!F2]N*%IH$G*'8[JIE[<$?2G:2CF)"O::Z$^)5<;G+8W5&[Q<A(MD,$&3XC
M>#!E!2%^(^(Z-.*!L7;7[;;#<P0/?6$*80W6,,B-4B;>9_/D&1TR!SA=E%\-
M3!$'S!O(2[H.9=#R,"@DJ7U-HG^-=]I\"30Y9GX8:!S1HP9'$S;0ZMP2E%T<
MLD"ND#HS(J]2'>$K<T,;0.83*&OAT;KQ4]3R#)DC5JC03M3ZDUJ^L56T,8EY
M,P-0HW#$18TWFX7U(\8OWJ!J*^1S#S92FG^X ^M/P(V!.E5HZCB@RL9?\07G
MQ(2L,2LA,[OFX/%HXMM%Z"FLJ,GL(+6:N_?^N!_ 4E>W0&JUG9M_2_"JJUA%
M9#@3DZ?$*G]5MUE(O^Z)(S<0Q9.M2Q5KKL1O!+J#U0<AS06P#7@R:*21<030
MC$CW\KJ=>[#Q +[0[>I=%JQ/F.A3H2'M]M(Z_@K@%K  7F8E4C][)B&Z'OQE
MN^D$6CU?2K6C>[V A@+X3@O8&E6TZ(R5T?YUKC*"+P"/.E;EGE+BGMYQ G$@
MJY!G5@T':B>8VA@(:AV"@ @P^EVGY;BDW_5$D$\6C/?ERI!PI8(Z$2("<P+O
M2,^C#NFY8[[C@ATZ*Q N+C^IDM6:T9E0\=6I/>.#V 9 P&YAFA@(3O@(FZK$
M;],^BQC]VG&I05]FV&5\* CDH:Z(CB9.S1QQMZC(ZXU+N!N]4<[*<*=477KO
M?'P5=$D-=J\RFCC)#D!0M\$ >2#7H^L+-D4CZMU@WXK&]3)Q6"I/_C%R;,JJ
M691Y5M8=0HS4U*N,C[D!XK*F'FM\(@&G4+\0!SKM,0*_5K2N@6X1H.C@X#P+
M%R88^,Y 2S:Y+*N[:H<N-$TS61&C!BY<ILBS5+]ZH+HK'.K1;5N7VPHH6)4Y
M@%_V<LEFP".\6<)V]5B4-+ )?KDIHL.$!9W2O]_:])P$*C5SJNO#.@$A_AFG
MLMQ0\DXE^?Q.XO5=()*4*9@]O1$9F8J+N>OU-,R,R@Z15,*Z;L>BL=)2<7-W
M'F*7Z/<6R/JP18JGJ]7,:NMKUE 4<=L,%F&):PM-4FHL526DI>(IC@<XJX.6
M'D9"^=B=1)-52DN9+K</.$+.NX0F\##[M3?DD:@"ZU0S:0$T!N0-B+&ZDZ]5
M@Y2$9NB*89U&ULR@NL3567N@G>U&9S5)%(PW+^O65^-9W65W=DU7LRXH?=FZ
MN"G(%*V$8@&]1O%<=SIH;FZ<KHUK40+=#\?@Q1%QOL.%22I:FZK-4:G9YR]+
M[TTHE&*V#+2?K[_R??F A=O8:RUC9J$D7]<-D\5#,0/<:82"Y6AI.+ZD=CW6
M'4,C5GNDG;XN@X34Z%2Y!C-#T'M>&VD8 T&9X*I2W#;V4IDKL8#R=CCV\T^B
M9D"C_0G>_A?UZ[_)'/GS*4<^Y<@?55CCHPI5>9+C8276]71#(QB4-U08^L0M
M,N*BIKF^"H^M\T=H3+YK=?>+H;:#0PT'I5I'T8K Q_TJY[$BD]BQ W>*3;J%
MKVCWT,75;TD(5R68-< R[]V<>,"_Z4=/'%6?3DL,^OB=7.Q';PH-6V+>WK"F
MFWTM#I%[,VKZC [W$P7E=#NKP(@8+ZLET[C?JC"S?G6-W.TZ%"!\W/HT2 PP
MY-J E(YCPL +-:#O^,)(QE%-,"S'FDSDX3"6?_EOQUJBN$DH2N$X0IDA7%N$
M/1HY4C,5L&V41"LYW MQ-WHK+$'(89NHKHF=+@G$-#'>,,WY>F$, 8/Z(F2+
MS/HP*'(.,DGYSH!-@.P\RA.-<E34UTHMA,LH)I:2MZ5[/4H# <J<6X]$D$G:
M.>RK% >M=*EM?6WH"R*@X1A3!H]/WP^P!5$8D4.",<?7K,5NY0JXE\CM-]P+
MBGX'>.HEY#E)8EK:$[-<Y>6:%6LVHK/73F-+H-FY9MQ5A78AQ6A51Y<3UJ$7
M"$_YA:.)"EV"$G?HB^FG0.'==( V/H_9EQ>)H%)?8A=A\S+#;7"QNRF20J[6
M!,@8D25F#&?1I:4TTIAB8!&LL+7YN9LZ.-S&_:ZJ 6Z^?_QC/S0^YJC+Q<8S
MUDE %18>;(L#@059EM*Y;40"M!2*XQB(JB_*M.9@GBLW!5.,/\$R6(C&^C(@
MST7=UIP]5C\==VIU^TWN*\D-.#N;'#:-Q"^S-GY;7BKZ]X/G0%J\MQ?@N =^
M3"T8\/4IU2DGS%#,(5OZVJ@A(*U2@GW235-T,\OHU6< >>'"R9@,_HF6W%_[
MC&R;4S1+?^=6G6%,7ILKQU#G"<0Q:(+\&$@ 38L A%89L3FY?A$HQI^S)<7^
M]Y_1XBZMWKJHW=H9Y@BOFUXGF0:5(7;Z]?PD EH8FDK(W'F#EDPJ!D&]3$DF
MUL+M(NH+?@XE,O93;+CE*%<@'K+IHJ6KT[_ KYT=11SH&MY2;%4BQPBZ0V"^
M @G%.I WU5)UH(];/#9GSG'=YH@]PKOOE<>T"&PY8/QBG5E'O5P:2KML/%X5
M*JB^X,03;+0FE1-)*O.4XZ4MMAOHO\_WR,%PL>J5EQLV!9$ +FP7/*3VP@-_
M2U4<_)U"D!G=2X,*.O9V(! >Q+WY>725I*EF.<0!.UCH:\#)='0([:Q9!OH
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M$(X9E,T0G;D#:(?[UM_D>"/Z?##_ANVT':2<=MP;"2/XS=M["%\"O;FUVGB
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M#5H8SK7W06]40#)('-N,0[MH-PF!R)!YG2FCR LVJ'9YN^W<HVN!E@,[TJE
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M_7#$T')0\=3\WA+01"R?GBVC[Y*AMG)A][C@5"AI1=OI<S:W_Q?X@\@'TLZ
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M2SWL648+QF5E6<6]/2'$[BXU<,4N(*K+R1ZO;G]U01MRNUJ$\]OWP860Y]0
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ME3<4'Z%Q\.YN@G [(9 ;=N5ET-V5 Y:XMHUO9&4'!G$'(](QY?&]O; >,.I
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M9@UZ9?C,F;&WPZ7SZ+-ZX_2PB%3[\$M<$Q52@8N,823$OMMF=)FIT="S)"C
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M2"N3U<1AW,(^_'5_;P^?0!0JW#"D.SR&50A[=)A-A_ J1AI=*TU)=>=E34"
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MN=5Y->85ETGUR7#,Q<S;*FNR?M_+@2D_;KS (TK\'QP=Q7O/-W>!^7+1WFN
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M(.:)FRWT=XW9]I#<\:C.*MBL@D1 PF']2"@@A4AQK,I4R!$E9%$#$:),Z)7
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M[.C9SVURU#/RXUQP-D8[-Q\=LZ9AZ?F\X3/,QFY=&DHK!U+!RESQ^G/,Z9K
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M0""O/W.!$R]%J^P(QZ;40PKEORY_Y[-SZALY'-G]'ADH!2C:FG.!3]!6KB\
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ME8<]4;A6XO9 M08K*%Q+7K<Z_!Y>'>]%6YET=K7[H6T],ZNZ"Y?:6[1=9FB
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MVK%:$@OF6@R&Y5):JB=OL&\#PBO0]QK@1P?HMX [;VB])F5Q9R/1]^LO1:K
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M4>YA'SQN)@ZW7#=/73< $>0XD6%%MY47,,#I/RJ>OX=(Q<#SW\_SG=KAY''
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M6N&GD7(IC@]"*T31))U <G@IM0Y(:BUH .*[P#EP/'?MU]:!O?:[JX:UK8/
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M56K(N@T8O]DR+18?24&9J+4UD1!!G7/<4.T9)5Y(%0-_OU.6]VYAD2DES01
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M+=4UE1DK,]:EK4O;-KN^'CIK<>C,IDNPW:WWELM(=>)@O20@9!1@(W402\V
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M&T@&D@)5RCHA%=_8M.+.K7*JE[&].D1+8@H5UG>$]85YP)IX($<P,^% :)/
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MA]3QO>'1@4,3)30OQ<=/]3$T7,+Q&"D+UR>BY=$?'A45S>&R^6$\Z<31<>D
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M<P\Y1D1HLTAL?Q"W-STW[.=T![G;;^L^/5]O,\Y>F]'4>8)]9]8(='J@YW;
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M'_&LS+*DBA@7J68\3@HFPB)D91@D4DB>*%[])*&H0VW2<:A.'M' W3N@H'3
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M.QZ.;VRQQ7KK9XU@:A-IHG?0$_;"]R0/'54G0O7.L!LIUE7.*QUF2@G)51R
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M>6EJ@RAT.A'$*5?,ZO?@)L/SJ6'Y,8#,Z<=8:)>6][I4'RL_I1IHU9RG? /
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MB^2VOXI1OFBU:^64T4B%T\JK7&P\E]K  FE 7V0D=59B$Y)2:Z^)N0=7XS'
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M,9?+8]>>0@T7MX>+X%)@N:53RC#AK;$V6,^-B-%I$=UMVQ^\G,3X1T2(J8L
M^!"X<!'E9$3$34K(*@*,)A'-@O2*>[OVFI++;6IJ>*CAX4G@X:;M,UY.OOSC
M(<=,OKQ61 3#*/(4"\2U9$A;)U&(W#$59,*. +<@Z\*0&CQJ\%B9*&3MBCP>
M7$R)!DY)RY@\2D8KQ#D%HA%Q/EZ#P10HK5T!%T]S<'=YROQ"5OSJ%>!?:'1V
M;8W\RUV8#[KPJ+(CZK2*?Q6Q&>1^<+GMW&#4*7J[+93SGR_?/^FL.OGS.-!Y
M/BW\7WUSVG(I]X-K]\)B>Z4G.(X 0/0*EV!TV_,(BK]22CU$(KHPXD&RYJ]^
MZ$\-5C]*UKRY2<"T:F;S*$;NAUF:UV4HSB':_1THN%$BV[.8MYO6.[ZO],)?
M:.(64E]?0AYPU9E]UKA51J>T-$5'U3_JC. 'WILZ:8?0B4_D36Q4+6[;XX;H
MBX1ERDRJ1NEN?!1HW";\=#Z7OG81G_P5GJ+HPHT<P@IQ/DX YY?Q$'<O/I.]
MK\WSW9-=MGOT#F^__=C>/=D[;%ULL;W-?TZ:FYXV3]Z=3;XS\1"_'+5V8(P7
M_\#]0[MY]('OO86?3[9@_.&X>;(+8]R%Y__5_N]%<R[W-<A@4S"( TE%7,-/
MC@2)&,-$$2>(YK@NP%!#Q7,*1=<H\C@H,HTS40:(KZA'5$E $<<C,C181$10
M,8&0!.6?+BS]2#3\22G8^]@O]"(?H.PY&$_1I770&,!_!ZE=<K+3?OS6[HT&
MXR#0%7-^HPEYWN!ZLU?\95#W@<OI70>X,X*Y/9'+3V.I?-=]7\ED>9BV!N%;
M@?!\WI%3)-+(D">)(HZE019P%T7!L5>44IO<'1./;PJ1]\CS;NVMU^#UBX+7
M/5/&&KQ6![RF#%)RQX(.$7'N->(D6F192L@H&EUB0G#"5Q&\EFQB_F>N"?RJ
M;6HNKVBQ/3R,_<;'99GCJS7\JYNBCW=9#RWPVW[O6SL'(COMD_80_@OW_=;.
M&Z*@S@W;*+8L7:]?Z'/CU/:'W=A?;VS &&SCKW;ODV_'O'_ZJO$&KK]9/_2R
M]$6Q*YMSLR]O_?;#-#D_ASW_]RTPD#*AE%.,^*@X#<;2X(U(2B06 S/QUA&V
M:JG?]'LGRX!OZWN.Y()RY!-A\/]AQWY_]O"V]]]#[$^^=.U7,]H^VKW8.WIW
MUCQZTVG2+;RW\X%O[_S3WG[[S\GV)OR^><!:.\=GVV^_ %1MT>;%N[/]*%14
MF'B$.?. 5%@A)V1$C$;LB XYIV+M]>6LS?5;K;7A5"7/>'+.<:VHBX8E 8A(
MK-%*Z!LG\]9K?>>UQOM!ZJ0U]T@E 6S:>8<TMQP9F:RD0$=48FNOZ>6\F0(!
M;K/>W"7-N349-;CTTNF@0,]Q\EQ(;F6QWGJ\WDL/?=3K_7/KW?R^+ZQ@VJJ0
MDRH%XMY%9)QF2!E-$TF.>07>D])TB79/TVLZY_FWCLTV9]C+)F 0)\;G5>-=
MMV&KHFGKC7#C1*)EUJ3::[VC/7'44^%5D,I$3C&8%BIQY"$1H[4/-Y&Y&X=A
M:W&\G3BV-C^(?2>8%=9($$?+P)G' #]:<22)M,&'Q# 3:Z_)NL"7S<VL!-H&
MT*T(,]V-#>L/V[ 6H3$Z[8TW:$]..[$0%A @VWC[[WOXTO=VYFT'Y\#B1N&\
MX<Z7$:-,N;H@3XW3WC!VAVW;F7G2K+"V@38!16SG##(8$,ANS'EH\.?;"*Q*
M6G@97+0\<I*DCLDDI;#DWG 0V9\HW%QEKL\PPHU^/R?>G<![#9KCEWIOS_,?
M/A;CSWR_!8.;?/JR)?9H2^QK1WE48"NQRV)+4T36$XXB9HIP3!P.X,'1Y1);
M2&3H#<: F-II> C$? CB-LRA:]MX#\0^-DC# _W/[MBUTKDQR )]DZ1,D+(!
MN K](BD3A+*0Z1E)[C4<#&?4Z927 GR!]Q%RIF9VF0HY'M^B2)(\&H6#DW+0
MWWJ=;V7@/<1A[)^TBX2'L\-8.%OM8?XN>"JN^-[PT [A+0?@3+43O!_<H3])
MK0$7= !O?-8;=4*CY_VH7[QB=ESR>[:'H&/?;&=DQZI<95^4PQU>^<;=[*/F
M#8$$"]'K#]:K%([),N3DC7)D)784;U;=?SI)\!Z]T3#?=)KVT>N,KQL_M\I7
M+>?,-@[!?VMTX)[%A2-8M_XP#_:\6.[B<>4PX.K)H];+B8<_E7/1C_\S:N<[
M G*T)V\_$9%A'W!ID&6D'-<2KZ]$LJEEK>8Q#LJTE&)YRM25C)#SLS +KH.1
M.XIYMGHS$Y_372)\">Y[VNL/\_M465%Y,N!5)J_=R&L-RVC[1;9N*3G@>_8*
M69E)!/;MOA^=#(9E?F\I"PM'O4&Y\A*TNZ4\S+GPE=O,!?C5IZ!O^8(_"GL!
MH#S-S/T_\Z?<JV1@//V*=3#&T?#JKSQXJ<X;A@;R&=NYV9GY=QYN =:*".4%
MK%2*AI,0C< B1?@'2+DR).X3(M;&WSKL3S<G#R)R_6B/D4WPBG_8SID]'ZS]
M9SYJTNZ.AZ1SR'EQQJXM$G_EI*7T8)-6QG5"#ED4 O3'")AI/U\% [8K,Y;&
M83]3@__UX]4#IWRG %G0V4Q!LZ;]O__8R[.])-!%EV:=%G]IPU"ZPS\D>X2:
M#\O#=LUL%\#V 83U[6D<#=M^L%Y:NW==?W6._\J^4*M7(&^)H3F'LN"QJ=T%
MN&L7-A_^<%*NWW-[M]\J4([A]V60=.41C"+4N@*AU^5OQ5\U_M]<P/L>=I[G
M_<<WMMW_ D8Y-J,=C/K%\K_KG@+AV&P/?*>7_[8##_RKT_/'3\V^=SY/V/?>
MYA=@SU^.\UFOO9-=^-^[[[NY_<G7?TZ:7S_CW:,FWJ6MD^;Y(OO>@^]\OMC[
M^H'L[GP\V3OZ>+)[] ;8]YO#W9-=8/,?V\V+CT>[=/?BOQ?'Y\V-?1>5=\D2
MY*@+B/LDD#5.H*28])%+*D,L':I"_C:R.^2=2TD&; RC7!CX#X?)]])$*8U/
M;JT1P:4YS1K5'P'RYV5H%.O0F%F(P:7MCCG17J BY>+\\,FO'TNBBGIG@XUN
M^'=:(ZIZN;#=!5=OU,\Q&KB@U>OVQ[_^90?M06%07K38?=@'3YR0I!D"=]PB
M+H5!U@6/0!HEDU3 BOI%,7J2@F!$5)M$TS-WY9&V4^#:L4Q=+^,$64C!1Q@-
M9UV7_SNHBC,7M'VFGAA0]8-1Q_;!.3RIQ*:XQ%L0E/QS=NE25IQOA>+DS\ 0
M@6\R=C!*!^BL#3Y-=_9*\#/ZMN\/S\=>U-2]&T9_V&W_3SXO" :_4YXG[$U\
MS.R*@,=1/?!*/YB8><_GT(([V&N G3F.U7&_+._E:UY]&XK_>/*3A'5CHWJP
M*SO8%6ILM'HGYK(A+OS>PAK?X)#8KSH1'T;@^(026-_W\V91,2WM;OFGC6)S
MJ?A3LP#H\N/?_LW6H[R$_/Z"I^_3-&I:3$R1SE+^Y/+N6[8?Q:^EWW!I\F@]
M>=/)^]SMW6C2V.\/?=BU\FQ7ZKQKW>RF'N1S."3\M+JS/.FWN<RYN,G9\#M
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MQC<KK6GCC?79*3X?\XDO?[UJO)^A#DMN,7X=#Z,I>40#WNND&-X@U]3*HSR
MD1UD8V%/<NF%VY9KD\X3FHS66$@>+5!8H(_2<QXP$T+S,KZ*-9UG&/(6#".S
MBC&I&,]"TWYOGXQ._BK>"F;I;WL*GPS/7S#IV#K;WCG.D07:O-@];^X<[WMP
M5L%C,_F@"S 0P'9D@1,B">;;<J8E47KM-<-+*<B,D(.D+@KA>B8>6>9[I_GJ
M]8)2C$ZS(-Y&>@PXD@9HJ=- 5&-0EA.IG65>N<B3\\NEIZ 5M?@\J/A<;(&G
M*H55U*!DP#_E% BLXU* - 7@(2 [+,G;A1 )=PF @@!AY!*H(]7<!R^!9_ 8
MI:A7^PE76W*I0W0:*5AVQ$F4R&BID%<&J*!PPN#;K;:*- "3@05FBNO(-8N!
M>,DQ<TY:(NO5?L+5]H3!6A.,J&0!<:<ETN"2HF@U\TD'8:BXG6Y[&G*Y=4]$
MX,1K*UWP'"OG-=.>F'JUGW"U$_:@RD:@""H(1 ![Y!C#*!$>G?(IJH!OM=H^
M66N2)@0+RVEB1B:A!"QT[CUN<:Q7^RE76P'=\SP@B0FLMF4)6;"Q2%*3J'%:
M19F[(BR//-W''[)K47+!E!TL\'*ZOGT*SJ<-WW)EZ,'4OX3/.@U6E-ZE='T:
MMLB>20A%IP'XWFTH992!)HP)%41PK:/67NO 78R6XN3"SXAF<6A_F5SFNG7]
MT+;=-]$.1_WXKNO[N4#QO^V3%QT(G1?.UF9S'\@C#09X!244?!)L%7*46 3D
MWUCE::)*7145S7+5ZRX1J/5&.\UYO##Y_C#7CXO]H85OA?@M=GIEG>J3=B<.
MAOD^\,?N<+">B\F%./#]MBLK3U]RI9<):QE7&3\P]./98_C-MRLN.QMS^]OV
M^^< F1N%FU_+Y%@FCS;V50S:4&T1H2;G&E&<=^,\DH1JH2C5*<0LDW293(Y.
MBXKCT8^*):\J%2Y$8DZK39+\<;G'<Q;[L3'*I<X!)OOQU)[/"G"N:T[4GS,A
M)6<[15'](JIDA^U!.B_];]=I'Q1[>$6OA4]?_@)EZ/K.*(R+L:<B[@</**1_
M>GU5K?^Z6-,SC/?M7!VT:+BB!/QC;YU8JX,#Q]FYJ#B/1@M'(Z9$.BNL%^0:
M@U1OG?R<>A^P;'(DY5Z$%)#%0($Y!QUWF,1<0EQ8Z[5SN6T??T4O'X&X\T:*
M<"HH:HR/Q(,OC9UBQ,1H'/ 1XY6NTB9@T=&=5K_>0;G!VN]L[ =@&";%A*1U
M$7&M++).,.2C4-9'IDUR>3ME";+#VKL>T-?Y[92*+0"HQC!/ =H3,"Y!_<0>
MQ\8)",5AYWQQEZ4$8_@"F Y@*HW>:#@8@J@5F#T.T8-$G<!E19.,7K?"\CX
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MML+C'<PMRU79264.U6V2[KC3U&!#E".8*\H=II0*YIW4C(/(7IUTMYB+ <P
M!O.F -3X=QYP*[[DI+IWK+5YP.#Y9]NY@_'FAWWJ TD<<_"$'$8YQ1$YE01B
M*F#-/,=!@G-&F+F<4E=J6U[Z<>;"PG[^W*YQM[!,H9&9V*(0G=KV))Z5\QE
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MH?EY9/J9!JL_1REKD+JFP,5UO*K5Z_H:N>Z 7'/=66G$DLF($6: 5]PI@VP
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M:5 HRA.LE$_&124)]Y$;S(F7K/)#11T7?Q15.CK8Q]YKQAE#1$2*0'L,TCB
M'8C):>HXBR:LO297;;O>0V#\-MO\MXV),JPY!D!0$DLN"3-1"N]<2M('BPF[
MEQW<>L_VDFP=G#5WFOO*),YTEBT64AD$-R$G#C&MO&<1.P)$N'MYSW98;HD4
M>R-ET'/:6VF,42L-X\L=B3=%A1I4=#HHX7>5W^&:G=ENO)]=+"9LY#@PSKWC
MFN!BDRYH)R@.BL4QZY)CUB7K+8M',P[PG'TCD\?:&,0HV 4NC4!.8H^L<)*
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MTY0_!7_7']J\N7:[#%$I*,?@.D7%LDG1,C+&" A5P(:4.1?P6W52A]TMG[A
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M$Q93H1B]5GO(:O(%.M&W#ULPNE!*X^;+=")L.-U&;R@P>E:<.:_V!79O?.]
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MN,2E2R0A&I-'W$6"K',,IBY9'8,+P?F5=;Y*V=(H@%705T'??*!/F>2,88"
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MUG?] :?$>8!.A&U6S624(,U,1$ZFI*AUD@:YLJX7*>7RS098*@;VK(6],=B
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M,(/_F6M IX*.IYX/5M#QTM#!)VDPBPD[S2SR /D 'Y8B$YQ%PB9O0I0<,U7
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M'#A[BG"M^_5QGE%),-S^QXH)QL6#Z[9WWH'_K8H&=NL'3$0@!I(@08)%0!2
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M<=P08LE2:'<*4"MR#!Z+-7CDVV^'4D!5R'# ^;%ZQSJ94,-Z31&=;HY.H\X
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M9#\3N<N42Y%CEB'.!$49%0PQ:E1.,L5!:6QLB;5R7&+X86ULA2BB=R6B(UO
M8F8,UAIARH1O,J21$98@ NC)4LN$<6 +\&R=1/31-:Y]9L&0T  L1D#NRF99
M?$+.TSV"X5)@N',>@##8+-M?I=(2JPPC*3!!G'".,L$UDEE.N#.6FCS=V%*W
MWBZ)L8WU%<_;VBM1/%<LGGM#\=188R.914*R%'%)+-)*@E.1YLKDC#BMQ,:6
ME&LDGBN*6JRUOC_J]'0K@6ETN_.*AMTF>O%L"DVOQT;)'WX-(T0M!U$_QRT(
M:VB.<T&1--;ZGF0YTD(1E!EI<DUX%A+'%6ZP]-998,O*R",*B3QCN7^(O94H
M]S>3^Y%I0@TW6*46N4R YT!=BHS(#!**IWFJA::^B#S/&B);5:&?.Y?[YU!]
M[U\W:JE\N[IVCPBW%G=57 ^#Y9*&B1'%KH5B%^/6"\MY5A0.K!=F <6$44@Y
M*A##VCI"4I(9ZAVL!I.S6\.+6B;>7E@>46SD.0/ 0U@N$0!6  !C9@PSV#$,
M7(TY0]RE!F4BQRA7-LVM)D*S LP8U5!JUHQ9/P!X#M&7_06EVENNVTU^K,B\
MB6[90U@WL+01S99#LU_CY@S76B@F.$J9;Q!OB$1:Y 7B8-T(87,MN/&G^#-U
MZX.S,1;S%(7^SO:"HF3?1+)'=@J&]2# G @+[>59&&0XT8C2S-C4%K80WE$A
MJZK.L7Z6RB.,M4QT.KA.V8Y[:D9P9\]X9BG+G_SOJ%.@?M>M8._O$:J6]0V7
MC55X\!4?@*[;9:G;QU7ONJB+EM-%9-S*I$[0#!8,F<)F"!C#($VM0C03#'QG
M*6U5*VJ>E7E]ESFF.*^Q+-^!G1@%=L4".S(>B>2Y/ZV(!.=@/!;6ET0@"@E)
M!,FH*Q3)YAN/#R*NS\$T7)A"M*+J;D_-AUU30V/8J#X6E+HQ5-%QVR(O4LF-
M*! I)$5<<HE,+@F21N1:YJ1PF;B];1'WXYZDX*_:*HG2O1+I'ADBRN6IT")#
M-#<@W7F>(D5<BKC11-.,$4KE;0V1N-5V=UMMR[=DK)>A[G#,@-9YI^\;%0\&
M?SN\6CN*+=TO;84$6F\@OW<#[I<K.[GNGERY-S&&[G&;8FF 9^/F6Y$6SO*,
M(%MHA[A/!#<%YPC8WPA?2T?X\V2AZSI]M=JMBA5(T)IWCXQ8&K'T@;+K(Y;>
M%Y:.C&6CG9126:0D!1-9^Y,UF<G!,V:IRG5&C'Z"6!K,ZA<]#2_="I/RW-QL
M5TE=\$G>_+'U#_@QF,JI+H^;[6I =!+0OO6[O69Q<?\R2D.$[\0E;SJG\.:+
MY$1WDV;;]H,=W9[3Z3SY;?_@_>])%RYR_DIWYJ>[F6SWDK?.NE/CRFI!&6DD
MWOAI)+V)Y^?).P<+HUN);N?)84_WW)P733;33#I%HL_.RLY/D/J>:UTD_[T$
ML%@LL@+ 13 JN1!$96F:86P<ESFQ7*X@RO:$.^#^_>\3;$__U=9_9?V#4Q@#
MC,F_8^\H/_GRZ].W+]]:)S#67_#,T[]/WYWLG7X4^Z?[W__]Z_C7WOE7ZB&[
M*#1BDEO$4TZ03@N+4EP0PG* B10<:2K\L;O9T\&!1Y99:T733.:.:D,X3S-F
MG,U2FEJG3&XR:N-:W]%:XSVPJ7.#N4@-*@C6B%M#4(9S6&O.M2"9DX44&UM$
M\894LT<L&TGINF<._O@!$KZ9'!0!.:*D/X+5I_L?O^*,$:(81MAEOA>*ULAD
MOBN;PU@*FCFP"2Z1=(#X@6*X2ATTUH4I0@&LQ1QQV#??@)^/.CL_SYKETRB(
M=7,F^?X3U('-<VM)GJ(T+SCB6#ED:"Y '7 LBTSC3(*IR'B#\-E3#+[E9;-T
MB>XE/W39[/2[20[F0!=P DS$XQ.P-YC<3+P]4[I3W6Q[]GD<K++?Z45NF> 6
M>O#QJV%&&:W IU R0YR3%)DT98A3B[6@%&>4 *20M$');%7C92 %O(>DW>G5
M'%;QT#5MTZN9DN-;VL>@&)TN[4GX*'>@'SMG/MDD[,//ZSY_.X-9$TW2/,?2
M.<:)QH9K2E-IF4E-+MDJU.C<_LW;I^#H/7Y7_.9,OW,!X_VJ!&:VX 4B8,B"
M.TT<4GD!&,E%EDJF,BR4[V<JU&SIOZ4-9G"PB]2FTF6&<BJ)P5EJ, -XILQQ
MS>-:W^%:VZ\6.P5(IE"N)>":*13*J':(B$P9610DPZ'@,Y^SUI,&<R,Y/VD"
M1%P+CH;1ED<3I-CNPFS_TV_ZN(2Y2+8/WR22 WC"@W65>><QKS<5RG#5*3N_
M)PC?N!_-W/FXA0$T]6C>/P/AZ 5S89#-=.$?T^S-+9>TF;S6OD%5?5,UW@"U
M/W2SY0-!PU<T$M/IG21GG6[3+T\0R[8[UOZ/B4'[4>:NY\I3F+(?)BP<H'FS
MFYQV2M]"\[M';_BX'?13^'Y\EN?-5BM\4SI8IE\N?&E<VQ5^$GYL\'U%F6'J
M-V@C:SNECX!YOAE_7.G\%S 0/>^ HG_0,N 2ZPX\-,C0@[>[7Y721F@CD9/4
M@F=6$!^?U<@#/<&4%9**A;4#EM8H\:SY&BSZ]Z\I4[[&E492@.W "2V0MKE$
MFEN>4]#W.*<+SXM[]3'?7 WL,.\KDDT'<+P-/0]$FFTP60.0FB7M4E6 ]BJT
MEA*#,P"6*9A*!DN8CQ"@?KZ^]2/$!!-T:UR9Y:AIIGMSXG.^=]O1DF'[1_9K
MR@F3C "TJ) Q!6Z: ?1'+B^(8$ZFJBC 5U,-GLYQU2K'YH9\D9LB9X8P6AC%
MC=69UKFV/!/.&26<\7P!AE3%%_.AIPL6#OP6&>2.&.37QZ^*84E!*X!]2'R#
M(D;!K7$8&48R4% \UUQO;(D&%K.QX23O!X/-FRH78+R!9=?V5LHE&#6+2(WD
MK(25+,$X!4,(+!SXLM^:MAO#-J5\U4V8HF!^G39[-7ZU%VR('8.Q508;<VR0
M<%&SXR.5$Y#X^,SNSSTPBG]5%*CIM'_POANHL7Q4XE1?@&V:=*M(5]+KP"+
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M:FQ9*B76J:(I>+<;CT.Y#A2KUX-@H7B=5( %UCX.]LA /W07[T-TO.U3[SD
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MF(D^#O;!R@5[6K6!2>-U]X1>>UO1[LT8Z?S\=H!!FJ;EMH_=4>>#]E5-FF<
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M>(,K:9$V,O5((4A:.)P:0(IY3#%9Z>Y=O_3D3D[]F:5>I^UNKF84=BG-%)$
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MGC_0JK'AE'A?W<GRFFMTVLSSEEO3-7KKNK9LGO5"GQ4O\9VB#L/,6[Q;<O#
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M/V-\C_^N4>O ]CK>!F/X$>!6<:V,@&=1N.!Z3$58!/&[!7$90?R)@_BES4@
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MA(@($0 19!(B]COM__1AK8HF".,=HL3EC>\>.4J\Z&G3<H.1C$E"/0!.-Z4
MACCK=)MAH4O7TIZ*K\Z;>>^D[MPR?J/I]'J=TY=X=(LVW4ZKWUM\RP0C=_NG
MI[J\&!==OW"N?"@$&NLU7RW7V,^3<D3B8X=,Z?1WI L8[4O=.M<7W8T7$S,]
M;;;1%&6GB5+-<NL?IGPQQ2=74"PBU<V0ZK^:D@AIA=.V<!DGN<L$%H6#_S**
M94;<5[FQ=>3EQ,/.&W@A\&-WCAQ/KQ*LRC$L>"T1*8RV_@3T#@RNDNWPW*'L
ME# X9'V;Y[.N>SGXY57>[)ZU],7+9CO,+]PT1YG5S)1EFTHPST^U$5 _OF:U
MS<!J [B8_$YLTDPM_!K<JL6W7O)813<%IM=Z[!.S762T71X?(MS.=N%8X,IV
MX40,;!<ZW ^[M3UR>2\[L$=>;%_/(DG7TR1Y.L*OHO!'X0?A9TO'-FZ/$BRB
MQ"-!B2RB1$0)0 E^D_#&[8&"1Z!X'$#!< 2*"!0 %&+,E]@Y/6MU+MS E/C0
MAT?K[M(@("((/!(0B,5N(PAX$$C'0."-[IXDKSOM?G=9N9\N0!OE_BZ$XTY!
M@9)-\O_.H?C#3SMBPF684(^'$D+P]^+"YQK^IW8!#ONFV\R;NFS"<, 56'SD
M,4K;?4L;B]+VF*6-S4K;FTZ[ZUM"@:#ME.UNKRH0_S_Z].Q5\J73;Q_7%>/?
M?XCB=M_BQJ)R>\SBQN8HMS=^$0I8AA#+.NN7W;X&Z0,[]-#9\!G#U OCH2Z-
M;L.8#WZVW$6R;8.(4@S?@DG[YJ3I0&!_.ML/4:^# I[IRBBB#R"B-(KH(Q91
M>E<B^J$$/[1YIEO@0;8U_ J_13%]*#&EH$FCG#Y>.:57J5*0O#,80B=OVJ08
M"EQ9-3J=)\093F^L9T.MG2<NX&L8_R5W&/:]]SD1 7,Z.G%)T6FU.N<PYC&^
M]?P5<HU=GC3;1:<\K;B\*#NGEP1$A@',[7:[#X\9]?D=G(_^/WA=M7MZX729
M5,?*WCH;*N17KAX+R=H4-Y+JO=48X/E^^(G[=\^UNTV?MOFZWX5/NMWZ-2&5
M\[UN'_?UL4M^:_[[]:?WO\.=MM7/7?<E?/)['6QM=SNM9E5GYK5N:1^9/3QQ
MKO<*KIEWT:'O8G9:>ZD'(.:!&-U )1^Z+=V)'Q/(Y_M.MQN><N5CWIS 2&$A
M869A\^BDTP+HZ?YOLO.??K-WX1_RX\IG^,CS.U@\>">,I9'\!K?L=WKP6 ":
MB?M&$#%\0G=S,4(\#7GE3U)>;0?&E/B,]TH<YVT@W)W\>:E*?K,P4@U_AF]&
M6QKD]X4\M?"HPU12]JMZ0=#_W][5-B6.!.&_,N6G]<Y#>=/3JMNJ:.)""4@%
MU+J/ YDU4QL3;V:RKO_^>B;A12$86"!@]1>Q0IC,=+J?IU^F$RW]B^KI?"4S
MASA,/E07?^F3"M*Q/])TU<S?:U.@ 8!D+USYI<Q6@OU:;?9R8Q%RZ7^^):?U
MWJQU-T-/.X!P/4K@6F"3!INU>6AWEH"M#<$T@1VHBL0K>0:V^222^3-+)EV
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M1.Q'[%]OS=IVG0=BE<AUB32LJQLD "0 )("""LZ>@)%26Z3#'PD+')&NCV2
M9+!Y,FA9#Z[3N7) [8C5:CGW6#= -D V*$:=6O0E>6:V-L8@8#^Q$H ,L&D&
M>&BV6I9KDT:)V([K;" ,11) $D 2R*M.#SP(J/",/3*!::$]XX'YICA6N$*A
MOFVY_69':U;C[M)QWZG6-@$KX\%IA2+6#(XC@N\&@N^621G9M"G,)326% ^8
M6*LE?8A5,SW6N5[@OLUG-^T*EY;+9]F/:3H>1-XK?/CJ*?CZ/U!+ P04
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MH][ Q CUQP<G1T<'_S4]'=N'@^'A<-P;HX'9L\S)I'>,S7[O^ B=.!,+/CS
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M!<&V2JN?)EEGG[N1!AVE%8Y$8=$W@8AD,*J(=91GSJUUK$TT?)>2 QU$\IU
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MM.L83X.GWHIK"*KU.U(OUYVHMKXG-3(F!,:0?QI]+*_<(_8U2R@=)HTVN-U
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MHN%*L*"3[<?GUGF'D!@X"39NWY9HIYM*-V8>(O M?"P*FLVO-NCS7.G$K"!
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M46(MU\Q2#U0UJ:S;1DRM7J#?QOS'?-9UHVR#"SEJPA)U&(Y[29QDBACCLE*
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M#6DE;;5;,_B/Z\_6Z<>WT,'\,W1GTW06X_S23[KE_R%MKGAP%!C3@5C-@,B
M4O)H6_"+M#J+Z)")DV#M2 :&='1W"B">0L]-4;I*&=U>0IQ989PW)"1I44(<
MB-<:/7;/@HC1\F;=T?>B;T@G<"?"6%\M]8;0NMGY/3\H%LBG]Q _36>3V<>K
MD94^>J,Y850%(C/^RU/)";J\PGL=HW=WW(0'.\P_.MF0#K\J J&)K-L9D=L>
M[$@'&H/7EFAE*)'&:N)8U$0'I[BTZ!++)G4GC] UI&.J4QB-'EII92PV*X[+
M'NAR5A8M%0G1XQYHC"4.@B(Z>AE-*3J6_DA3<6>J(9T8M3<4?>3<2/<OX6(.
M<75.-6(<7'80"<^TO$!"/;)J/?&"1NV4EI*IX_2^.<T^.C=_%)T?+=]VV\+R
M !RW*& R^R49&(WE%$@(R1+@ ;T41SVHTZ0=E^3L@PG[_6&BH@Y.DW%D0@K*
M093K[DB60Q4&4)$(]&2U49)9WZ3.8/^,8Z\%L#%J,<:EUW3I/OD15I4@+*JH
M+92.TY03Z7TF5I3'20./5$<+8%IGTG93.,1L4F\<[5@L%?5UHFJ*WV QNTZ!
M3=!LQ,W(L$XUQ5Y3U*VF.)RKNI>MOL9EF+TY;1U9[ARZ]L6L?;FH*;MO)[[^
M^L2WCN >'K>NU/:DO[?(KGN5_0A3R.-%Z5)VC(2V#5-!((]2UX+_'D#9,5H;
M:;0!1>FU/%X7TQXAA<T_K\#V@]34Y'.=S/(?YP!]6V_L,VQ=N>Q'??^FC3"!
MTJ_T?U_Z^0+FDZO5U>VQG[ST"_]AZB_1S$,Z1F;[#EVC5>,Q7)Q*=CW:<1\T
MP>GDV*:)]WYS]VD@>M@,IY/GHTM[[>*7+\%W\/<__3]02P,$%     @ *T=:
M4A]* F.X<   I20% !4   !M<G-N+3(P,C Q,C,Q7V1E9BYX;6SLO6MW6[ER
M-OC]_14]G:^#-.Z7LW+R+O<MXYGNMI?MSLE\XBH !9MS)-(A*;>=7S\%DKJ8
M(J5-<H.D)6:=N"51VGA0]6R@JE!5^+?__?GRXKM/.)D.QZ._?R_^E7__'8[2
M. ]'[__^_9_O?F7^^__][__K?_W;_\'8?_WXYK?O?AZGJTL<S;[[:8(PP_S=
M7\/9A^_^D7'ZS^_*9'SYW3_&DW\./P%C_S[_HY_&'[],AN\_S+Z37(K53R=_
MDQE<B4ZRD()ANBC-P$=@4B  CR8X9_[/]W^+R4IE5601I&!:E,(\"LZ\@Y"+
MIE\T.'_HQ7#TS[_5?R),\3N:W&@Z__;OWW^8S3[^[8<?_OKKKW_]'"<7_SJ>
MO/]!<JY^N/[M[Y>__OG>[_^EYK\M0@@_S#^]^=7I<-TOTF/%#__U^V]OTP>\
M!#8<36<P2K<#T/!Y=O.'=]&8'Q8?TJ].AW^;SO_^MW&"V5P]CT[ANXV_4;]C
MU[_&ZH^8D$R)?_T\S=__^__Z[KN%Y&"2)N,+?(/EN^67?[YY>1_I<#3[(0\O
M?UC^S@]P<4&(YT^8??F(?_]^.KS\>('7/_LPP;(1_?64*RA3X?Q+?=H/>V/Z
M0$ FZ2HBHY_BJ!*\1XSKGKX_YIMGL8P%KBYF/2*^_^Q>\8XO8=BG@.\]N@>T
M\P>Q2[R,..D3ZE?/O8/S&N0JPOK(2UIS803_FL:7/\S1_33^U 75Y60ZHJ$E
M%W+Q]O[+X@_O#$OZ'8Z&=<GXC;Y=_G4=8VL ^'F&HXSY^^^&^>_?#V60B1MO
M@LQ:"Y^#0XTAN!R-M5+GP3TH6TI@-!U?#'/=5WZ$B[IDOOV .)ON)I5-#^M#
M4IV KDA/0/:AR)!X1"TQ>&UUL$H81R)5H0PZ0>Y'HJ]A0IOX!YP-$W18NK<0
M[]=/;BCK!Z:P(GC4RL5,U T^:*4*0)+"(5AEN"@Z;A;\QLGLK(6W,_JW&E#3
M<7E%6\A\9Z=?SS^-+S].\$-=\S[A;^/IWJ3?8J1^M;3K%%>T%K,%J864@%K[
M*,!X4-X+[PI/0N!@_\GVHL6WLW'ZYX?Q1:8_^.6_KX:S+WUJ;LW3VVGKL:FL
M:(CS)(M-,=&[I66(T>88-9GY9%T& +M10VO&J7.ZGM7%.'TU[$4U@,<W6],%
M1+R8_W1P-67O 3X.;AY.8L"7].5T0*NMCA$34P4ST\86%K7,+'I.BX!UX$U>
MN]_/]_H"TSC?\)<C_%"5]0->S*;7/YFKCW&QM*'_93.4A<)VG]S+42)?:XH_
MX^*_+T?WY?=F?''QZWCR%TSR0$>A=0F"%:L5TS)F!MHX9FCOX1(32*]:S'Q+
MG%^+Y9;)+R;7 EK:;3L:=M4;[94EL_'A]++@!LWO^^_&$WK<W[_G^]+H[0?:
MS*:OKF;5&:W^_<!A5L$)QT)(-'E'#F$4TC-RIXL0!DDXL<DKLHKD\%1HJKMQ
MGX*_SP2Q-Q/N37400M1*<\.XSIQIY(0M)63.*P,0@2.VH<*&[>W)<F$_T=\G
M@^R%#"^GTRO,/U]-B)VO<3(<YP5IYQ^^^C@WIG[YC),TG&(>D#7-N:5%,_AD
MF!8U>N<5,$0K \84$5(SLFP%]1F0J9WJ[I---2+;?\+%%:X'+&(6R0MD >@?
M'8)C,:%A.0:NM0-A3;N%:1NDSY)J/2GN/M-TTV7M%_+(QE]P@?SUU21](/&]
M)K]_.DBZE!ABJ4(23,<L&<1<F C@!"\9G14'7]LVXWV6K.M5B?>Y9_;EWHO\
M_UU-9W-?]]WX1<YSC<#%:QCFEZ.?X.-P!A?S.?Q(B.<1"AQ-YQ&+]7.:C-]/
MX/(-DFRGPQF^Q<FG8<*%+-Y@&K]?Z'R0C0&M9&(I2LDTS9.%@I9E99#>NJ)-
M6A_BWI.[1YKOT^;^MT"B^^^./=B[$U>G_>C4YIO5 '()42G!C V%U@9RNSQ9
M/BQ:I GKA"F:H[XD.T[L_#8<C!;W:>^:FBM_X%_SCZ8#$T0D4RJQ&FYE.@=@
M47G!>)+9\>2T4OS@ULD-O*=-P08JND\DW]+#N@6I(6?DFO 9$6L 2K$0O&80
M!+@,R=AR2 _^:W3/DD9[*.@^B\*N+*KG4MW#"B]&^1\PF0 MRK=^'V@,$MW<
MT7-D/QC%8B'X5@KC)= LXHH#=?\P;'\83Y-#!U;/FM#SSJ<0#T&_%T58CUQQ
M!R)S)J/,3-L:NK*TL :0&!4W*7NW#[$ZH7A^O.I?.6MHM?.1QBWR-S@;3KZ&
M_LMG<GU&[S&3;,@DO!PO1+=$OWAA!MI$Y;P+]02&#+]L(_/>*MJOHX!2%&W:
MICNM=D3QU&EU".6LH=7.AR-[(%^X$TAK+*VEG %PSC3Y#PQR1":U BQ*%KEZ
M1-(KJYZP1WA0U:SAU,YG((]OWJ_*?<S3EZ/K27T]I]NUETN+6EO-O!.&:;2%
M@2AD,.I SBP9BBJ4_2VNW< ]=0X>495KN+GWJ4F7,,MR-HN9#U0!%)I;QK%(
MIGW@+"8?6"(?6!2;3,8FYR5;(WV:3#R,XM90;>]#DE>S#SCY*CN3Y#6^G.=H
M_H&S5^4=?!Y8E,J#+LPXH/=!Z\R\)C(4HRVW!2,ZV8)=7< ];4+UKIXU'-K[
ML(" W*(:>.ZXJN?,WB?-M*'=G:Q'P9+UTB&MH.2AM"#+5RB>-BMV%_@:]>\?
M-+^76%>TPE)H1D60JG1 8#$(<A]X-#H+Q[-MD_3[<$9C+REZ1@$I+I/*<@*F
M00*];&2WVJ)MBEQ'E]K%_A](T=O5 JY5%C\/IVE\19O6BWFF_N5P6BN^IJ]&
M[VBGFD*:GTB*E%5*SC-GT#&M:+T)03O:N"+WQ5B1MK5ONP[]-%_F ZAA39[B
MWOG++](<([U<;^M+1K.?_OFQEA;\4JL2IL-X@;\-I[.!T"H[3(:AK:%S'R+S
M1=,_*NAD;5#1-[$9.N+[YM/>6^BA29+S<M;O@! -4J*)2>^8<O5%*<'2C+'0
MMQ"<)WE8WVCUO NC1^7?*;ENKO(]9+E.L]\M"FC_EB[&Y/3^_?O9Y IO?S@>
MS?#S[)>+^8!__WZ*[^L7O=%AL896RW8\JN[2B\_#Z<""2;'0WFIX+(SH27MK
M"(&V6EI;L]8\8EMVK$/5(UD>J(5_@#P[:'L3<?:6>H,58@73S_/5M!.HP4IU
M?I^46(NJSTUC4XN!!XBPO_;&K41_,%X82Z^!X)XE<F_(M8B)S!_R>JT U"4+
M'K7]QOGP50N'X]-A&XDWH,&= .WO<PMKP(VU":.F/=,FIEVIYU(ZD>W-K982
M$F"3PLI[2 YO0_:@H7&?XFU0'[DA:KH$9Z*&4O-@+4V+Z,V! 21?0Q]1^(0A
M1-\FSOT JJ? @_[$WF -(%_GZO+JHM:O;PJ(+H%*[2%ZU,3;>JIH3&+>.,5J
M47R(Y F1B=W(Z^R&\$EPI8DZ&A15OL$9S17S+S 9D:,\7:)"D"8JGYGUD4SI
M) H#[B,S.>>H(G@AFZ1=KH?S%!C1@Z!;E#E>Q>DP#V'RY2U<X*M%OXNYE52\
M$>1!.68-[6Q:J<@"3XYE;U :JZ3F38)3&Q$]!2>S%VFW**V^A?,'7-*7=\*I
M2^YW0=C2VWP<XI%<SWYTNLJ4-@II$;U\'*D6TM(>1WN:YLBTC8$<+FE83"9I
MZU5QI3PERCSFG1Z+,=OHH4>FS$]Q7LQ^A\D_<>F1OR)+>9Z(M*CUDUSX%^]^
M7VZ)VB1)3I0C$RC'>C0JF>=!,&^-"DK);%+H=(K6?<PC''7TK*YQ>UGWZ,G.
M8;Z^BA?#M$C87F)<HE(QJ8!:L)(4[;'&!18B[=8\6LC.8"+3N!,#-@[QM!3>
MCR1[?.6GD]G@IX4#1/[.+X0IS19)AZ_*BSR>I^?/5[SDP&D)@463:<7+D!DD
M6LESRCX%H3PY0!VV!AKOSK9 WZUN"5T!?<-&9A.9]^AR=,&W?!&Z(-S"UNR%
M'<>P,=NH= N^[*&/ Z\F2Z1!.BV*# QC1<J+9*!T) ^=/JC=;&F-?0J,V6!B
MG@IAME'#H;>=F_SCY189K"\IU1 ^63RTZQ:HM:O(#!G=2:,OKE->>#];T JX
MPYDIK92[S>:TCV8V&J?_]L.*['ZC;YLWUNVU:_4V0QVRY6[WOM:" Q>*=&DU
MZ@(E>N*.)I\CH4P^^RWZ[WX]:._->-%@1!X3(X)I6AB1;'!._UA,$B$883H9
MI+OGU_RV;S/>'9,FE<LV:/"T!7##:G8R\XC ! DCT&?"K?;5_'9S5_?4^Y[I
MJ=M(ND5WW:]=#8A99&$U<_05TU%)L@DX+>DR"2^M-HDW.2X^F73#733?@RQ/
M)MUP8S22)B(MTCZ?"@#3-4$6(&16:%XE%1U$F^[<IWX"M)66.Y\ ;2/MXX3Q
MNR \GP#MK-/MX_F[*.0XU#'T6OALD6DIR64 ;5E0.C/A<H[>Y61C>$J4V?D$
MJ#%CMM'#$4^ .'CK:GEF*HJD8)5FWAA3&STF4X(2_GF< &VEKAU/@+:1]>%.
M@+PIF)3(S!:RC+6N ?!L)$'+GDLRGKGH5DGW;9T [:SP?B2Y\94_1!#E)YA^
M^/5B_%>OUTG=/K1=8&0#\)40B/.%8PS*<B>U\,5;GWQR\TM%O5";+XFZ?7SO
MP0Y;>%2"_$\N:P==4ZOBT7LFA#("G<Z$\[2#'7?*O:N<:(7[-"29__CE3W*@
M7HZ6%VR-WK^@M^P3J1RG+^)T-J&7;N#!";"9_+[DZ,6@]8[Y8H$Y5(#"R,A5
MDP2W[:&>1(!D&ZZL*<9OJ9T&01*"6H:S>>\ 02]IT!B9,+1L:AD<>7H&&((S
M(G".Q33AR2V$P^N_M<+&O4B[11K]W>XTM?7R* TO\*MF$N_&VXI&!05*.&3>
ME?FKDYA70I#BM5$\*V4MM*G(Z'\R3YZ+1V= @_3>G_'C!--PWF6<OK[ N<9&
M^<7E>#(;_@\LNB8 )ATBO6]:.!*:YRS6&B>;@.>8E:,/6["T"[C#L^[X-!@W
MUF&#U?,_2+)5,J]&"U^'9$/2F'VI=YW,?=&/5: #7KBPY.:P8*"B5#7/#33C
M)667M$^Y30U[-WAGKK708X-5[45*D\5;<.<5>%7NGL&]GN#E\.IR^G+T"9<2
M'G"I2K*!'&*4U2$F'SN"22S7V^VRRC(WNGMF)[AG-AY"SRTJJ];>>#/@V=;;
M$^N1D0UDWY(;%269)DAO3 3)D]?M^G[=@W-F5Q]ZZO%2N'DP[Z=YY]67M,T7
MG$PPOZF+;>11(AFVS,BDF ZTO].&'AF?-XL+UN'JIKDA(KKNZ<^8!_U(O,'=
M;/.ZX3](+B2$A5!^^5SYB0/I1>1"&0(6D?;=X!GD[%G-Z?=9&BY-DY2-C8B>
M,7WZU5:#:\KN]^F[$<&R@<'-_(/FWB<AZXY)2%T2+'#NF=/"%M0^>-DD'-P=
MXIEHK?39X*:P^TB7#?FF)$<<?EHDTW@1DBNUN7.LV5<YL:A$8;4K*T)VT><#
M<>X^N%-HJMF/<A_ET)Z::1!+N(^1C/R/,,S7>_1R?27K?[[VOIA.D:Q^R*B,
M@<C UN0LDA#ST5M63(3D50D^-&FMO!O<9\2PWK77(**P1C@5W.U2OD#I@C!>
MT4N1=:JWY\G(0C+ ZB72P4D99&@2S^\&[QEQ:F_M-/#[-Z^MK^'+?&'UP(U!
M*U@A5Y)I!,X\UMX_L=YLGV)0J]7-K;>\);)GQ)Q]=-+@#OBU "=7F'\;0AQ>
MS*W' 2HI?,% 3%:T.&:I:9FD_3DD--F05  .9RJM@'M>U-E',SU&"N:ABP?D
M\%O]?KDJ&N>X-XJL.:<<$5QQ%HK2C$AN@HP^)%B).VX('W4;[\GQH96L>_3X
M.T&\2UO:$1.YHKH>DPNF$]2^'V1W253!10$QF&XE7UL,^CR)L:O4#^*5_S0>
MS:?_C^'LPT]7T]GX$B?7@+\,8HFQI% 8#\1H#46P*()E*?)B+,B(I4E!Y)8X
MGQRO#J&O!K=Z=\_6&?#$?2BH6)IG)ELU/V*)+&?P65HCR/\[;@+F.=S82I^'
M8][B2'A#GI@-*6E3.QD47OM_>Q9!.V8"-\E92\";'*1L#_6II@#WI9T& 4B"
MFA#S]%<2S>\PNYK,T<W#6%_F+VBM\8:+B^FK\N(3#"^J'_GK>%(S9MYB6O[Z
M(-,"+U2J;;<\[?86D,5";X9Q7$3A?(ZY2;9)+^A/)MFS-YK<3SP^L(Y;$'6)
M]=WX1?KOJ^$$-T/]&2,)C'NPZ!-#5333Q2L&*I*CHH'<U^ RA";I=UOB?/KD
M:ZBW!L'Q>W"_R@JD%^4V,3 GT($KQ0+4_.M ?@[X1,"]T=R):#AO8MEUA_C\
MR-6/MAH$S+L+9H#2@]32UGX+GFE1:DI?RDSE7')1CCSH5O>F=H3XY'G52%L-
M8NH;D/XZ' $Y56L%8]%)Y"$Q4:I@:@B/=O3 %&#(.O/D59.#O>VA/E5_H"_M
MM-C_[MB*U_V>7I4[EP,-'(94BK!,^EP!NL( ;6)6*VY*,22O)N[DH\A.9E7J
M3;T/V/'[ZZ:Q,[FHTI^W/)S^\ADG:4BR&=CHI2\<:(UT!! +[<?%);+N; )I
MO'>\2;>E1Y$]*_+LKYN#K3R+F[S_'-$8+^D'H]I8D^RZ]?GLU>J;#I1)R=6.
MTF:>TL5)5"'9P'(VH*621:\> K9<H+:?P+.BXL$TW:--O^A%<F<2U7&MT>OE
M7'X:3V?3 <G >BD5LX),3QU+KK>D(?,%8BQ6A;R:/[6IN<LC(SU9OO0OYP8&
M^&+2.#\ ?3T9TOP_UJOS%G[IH 1GE"C(2M"6:4\T!0ZI5J[Z>@MGU*9)-LN#
MJ)XL8?K728.*E^ZR&(20'3@A68!:W)>59SX9K!NT(W-.)\>/[*D]>2HUTE:#
M$I@*L_Y_#7E]@@N<Y[F3!(9I1GLG?4";Z=<_N/.;BR[E]T_AT\55IEG^\CG-
M:\?>D'>\:&L^0.261^?IM:$55PL@5Z,HSBPO1KAHI?=-\CL/.\UO/@)QPJQH
M$&7=:[8#46( $/3&<E^;TT51CQX"R1ERS%"\S4T"KWNA?MX,W4IG#:R_/<$G
MAR58Q4J)M8-/BK1C8&1@4!A/[Y',39K1]$BX[47V]NKCQT5W;[BX[OKW<E3&
MD\NY9W>S:[L<C=9)UB:QA6F09-);6Q@9])A+""7F1E>S=L+WS;]W+?30=Y[O
MKS"<_"=<7'T=YGR#L^&D6F'7&]"OX\G:>.@_8#*!$1F V5N9<V#9EE([91D6
M+2T74B1.NY),/'5SQ?O!<P3JM-#U^+B*:A"_7F:TSJOV\G!V-<$I&3M7M9+O
MQZO9'^/9_XNSUS#, ^<LHO.<Y>+IO4O&L)" /$KADZ1%';AHM'!W _BT&-94
M/4T:T<6O8U37*'^^JBV+E_T37DU>PV0VA(OE]W<O3]$R@]($FUX'PW0-R@?D
MD1E.5@&WQC5*1]\;^=,DWF$5VJ1<<X;TMLS?CC]P-O"D_Y(1&0U,5C.OG;)%
M22S(^F,+2=A&Q9E?X7B:;-E'V U<E#?#]Q]FK\J?R\*M5W%&@EK9E-?7\7P9
M<)\#>2B*/))8+]:E)=7[XICPVG+I7':QB4>\!^:GR:E#*;%!O+L+]+L!^UO@
M(@<C5-+,+@I.T3+@5C*5H^<*0W11'XM]:Q$_7^[MK\"^7<?;&J-:8K2 _ M,
M1O1^3&\;H'W"T17^^;%>R[FXGO-5^0/_6M;-TZ^2SSW*,,F#B#EG+VC5SB$R
MK8QFH"Q]:VGK!AE"D**3"]DOKJ?%N&,KKD$AZLJM:B*A\J4(ECVO#BY(%GU,
MS(:HBTPE1]GD1.]D[B'<*V*UNRQ/_Q["E&/1@B,)1EBFG:2U4F)B42@!])%4
M8-N$.T_['L*MM-SY'L)MI'V<R^2Z(#S?0[BS3K>_56X7A1R'.CY&16^'9])I
M35NO#[3U>MIZP>IL3;+%F*=$F9WO(6S,F&WTT/<]A ]<E9:C$S(#RZ'&V,%Z
M!C87)I+)F8QU&<.C%Y%]@Y?.;:6,CI?.;2')OB\5W.+NPPS@BPJ:%27( O9
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M>W5Y22O?N+P=OA\-RS#5KIPW.7JOQS2/VD1BAP./CD_>_Z1CERFL'G'$9!Q
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M+?;Z5^6Z\'$>2S862N!EWL2TKMRR,##"LV*YBMXH\+R+L4GCW6$J?;?*TJZ
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MRUU<"3Z>?+E!=MUSL*@:D^/DE&9?40GF=0*6G=3!>&D5KIC(FV[,W33$"1G
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M4[U$;JQ'B"4Q(2PQ/5C/HG.:R6A0ZYC(_NR6D;(7C"?'G'9*V)C-T&?3YH6
M+C^.1[4+_9[]/N\_J)^&GX\ 7.GXR4'J2 Z9$<EI<"(4+$YG'CP&5 X'CT+=
M6H*_7M7V14M>["O%]0_K1Y(=@*[V3R6+2P0MDP?0TNM0NSFK8EWT K(.@TZ0
MMY+HV]DX_;->D$ ?U ;HLR^[B'+-4_:7X6/05AOV1JMR-LZ6@AIB),>RY"!
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M7!?  0!XA'A_VX#_L>%=N921B/CJM>LDEP?44@)7\/#QKQ#@_R'UY=Z R_T
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ME=W9E<QPOVXX\F4=T,-CF";X+G;Y?NAM+SR-+]?:>Z]1;/,6^B0M]78ND/J
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M!Q)%I33_#_:^.ZK):,LWB()(1WJ+2I4J76D!E2;2!.E%!*0)$6D! J%WB("
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M5J4!V#S5Y8N&<DVN##<*N$AW6GETM*(5(]K$8IQ!=]6)EP#!>?]9IME,MS-
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M!,G4J:B&T?RZM3%%?YVI2PX]&SO%\W(NH%2!=!44?P;8U]^$X;Q9 K\SDZT
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MB0NY6V08,8]4S]SPR-WR5691CFA!\DU"[4N(=PGC.=2XW_%"N,XX)PS!=^V
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M ;=LY)<>I-X49+OD2+/+]6:%B56Z@:DY5=];BRA'V39T3&T-6Z19(.H!<>-
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MSYVW4]< V?R5:<CH*0D6<G,4+/P$QNQTWENV;+;L-&'RI)P)H!^PM*C0^2X
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MVE0_;@"*>WKZYY+72&0]$P2I5T^Q&QF[K:J/VP%$#'4ZF:F^DYK!TB2T<;>
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M, L_L/L:0(*]M^K?>D@&UG\ZQOUC_'>Z919IC:M-41I?0:CN;993X=RJU!A
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M"T??Y36@S>=5,IM6!:GN-2#\QH:>TWI#L8#8OUU?193"FJ ("XS^57@6VS4
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MPV=[F$9I3;:#:!K&?U72FTJ.S$9)?F0\>=Y27UGK.SY*?-#_W<YA_A8 _R>
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M-[$67CJ3%*_&/Y#H:(WGW?N4@*2V^\FP1>!I109U'I%90W1@N:Z +35CV&L
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MM6FX:U[H^?19=5*3RFIGW,UFRM6U)"B\FDJU%+W,;65:U2;CZIAK+H[^[-*
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M=G*V*=0(F5#X,=I5_N<BL,I=IMYLBDE9UX+!XITO_C-[?OSWX7WP@OM[JM<
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MP;L-9-XZ!7E<CDDQFJ@=-OL<%^OHY4Q:N,O\ILD [-#X^,6J/\NC$4U$1TS
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MU(YZFAPL?PX;.$:0%FXZ)<OF9^\NUQ!95]M1W6;VB=-X>7E+I26*;,XP_O6
MT:+W;71!/Q3UE3#$'N-?U(]\''_?I\69KB=NAO\5MU,1U?"I)GJHP@;'-L;
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MK!_FF=R719S-J+Z/KA!IV6RIMEDN5#^64V\I7T F[IGEZS. R!$%]>!F&>7
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M=,UO$\]UX_.Y;CK>[/Q>I.8A$ %Z1$!?Q=9](=(U!.X9@HD(&-/0)@(0$T0
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M=_*B"GB.?@K\GA4@5#A\S5@1R-#VD\2O 1&;*X^!OVJ7J-Q&CK[ZK8/77'N
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M>>4YM]JERZ&6_!$/'+Q&W/9=@,I%PWXEUIT9CL?LYG9VTE8?@M0&:UYKLSV
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M-T=@]Z.A5N[52PO.FX7%\9$IS]VK5BS:QP;8 ZWXTT=^/M5[H4:B7?:O/O.
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M>ZL?<JI[/[L&N1*D5-RFG/-I>' ?3D5P/.BYNN:9%(*8Y2)CZ-:,3[G-PW(
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MW-O:W]ZT-TS^Z-TW)USA44(L:J\*R^[F>6WK?V/OO8.B^KIVP4801'+.06A
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M]DKRU,BT4;7?M\P2.#SC[6Z?A+* YBSI;4EOA,(5HQ(W"*FY%?,K:_8:H.=
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MK60CEGO&]<'JQU9D' H7M']/V 8*1#;O"*?3>0F&)2Q.2K827Q[<^W$GU,4
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M-*"_8;=JQN"7TH^'F;<+S43IHP1)9+1-<:MK;4RV6(]DWW*Y1;A T37 ?:^
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M*B:CD1H"@6081?W-=&^XA^*P5%*V=A86XYQ6J_OU,%0*M/],$Q#HSK!I.7?
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M D/WN[ .O9RB8,^[N"XT53Q<Z;M28AEP(+\S*RG;'4S7?)LODY;[^"$;62J
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M+K#6W>1N_I=(0L);=9<V&*Z?*_)PK/Y*<_Y5RWKW^=- QLIK #A7I7Y!:W2
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M[$\B'9[!J?6[)HJA]=/!9I""GDJ=UE[*YD''G7VY5[\['.S4!?9#,8,B@M<
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MS(@!RA%O;&II!2CGEZTDS<J,$Y-5" ^)RLKJ%YR]S'FZM)0FV[R/+6;*9YF
MBUW9JXHB5)D;J8Q:L\J7WI OW16)O?_P#$$_NL/]*D)Y Y41_^))><A@)Y_2
ME=%+?O&Z][*,1R\/2^;J3S;RJIF/40 &R'^FO\6K717G,M[1*E7>YI_J7.Q[
M[8'1="I".X/5^O!DPMYNBCO*5PWO%'3SK2&CA)5_.E/[<E]::\<3$1' W_J>
M#J4Z'"OK&,IY#7IMY1B&C(#.(O3S8_^S*4=@<8V#;J8@H9>T=6GY-[60+_MI
M(B/? >QL&R*N1X"S6B</E)G&"]?GSZ$[B2&7&7TQ15K2N)&=OC3& ZM!K[V
M[,!0GY+3]>?UJYV-N$%Q_.^9-6@<*RE$V'KFUY];O_::LOT+AT)]2V<0MC(3
M\DY-R;NFX&GI;I\XC4FHBB;@X6N V4[??XS5KML]:2L\3FM\$6B4\QOR<E)#
MI\Q-6/D/5^(-BQLNV4LOQ\NNC:BEWI8^F:(M@=S77)F[.MKQ#[JO)SU-0GH4
M _++TC2'C6+<*<9@N%EM,P+TYFG5)=I$=]/;RVH-W[23G)YT]8P? 2Y 1XXS
M*"ILRWA3S[L G4:6U12U2?/QV%O3]PB^'BRZDW@\NEQM$'IWHZ4?C]CKCHEB
M(W]>XT>=S>.HZBD!1WMX5@8H8T+XM9F/H$##F<REX]RHO$RY//T+:\N-9? V
M".B5_=[[-/%CS.E3IG3:E#>7L-"6Q 50Q,&@=!0Y+P:@FAA],ZMFNG61,TU7
MJ29BYV_QP\^/$?+#M[8Y$A3<NP]XO"DPCL->(&^(TK&2]#("VJF]N%'G#VY6
M.Q.S.<6\Q!\!B4]WD5(1A^NF^UTY7LF:^UN9>RI=(3P3F!-E=BNV0*:ORFY'
M=;1^!04E""N;EVG L-*6EBA&/^_ ;O4)&)U5N*U^-T4V$\/%2B]A&B]"3ED
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MOIFM O&$[$2%=_\&C"%#_R_M>@;3/1BADL:ES=#AR62J7LQ]97GR_.W,Z!:
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ML!>VGMV),[EZ99/GK8ZUA]SS)CW=)>T_+IW5BQ8NNZF8Q,VN*WUW'H,<URD
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M4MCB+5FIUWZ)]B?;A.A.5/I9 E6_&1>S \_P4?A=6(0*N%1571WC_BO3PD&
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MD )M>U(M0Q#TF!GP8\QJQKYO[8-.2UB?[_[.]Q,%1VS>/V[L2L3._D7PQOK
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M<GP1K[,]<@7>!0N*_JN0@_\,9#0),XJLL0\GN&/W>>L'CS]_FSMW3-9]L-%
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M=HM7EDY=FIVFN+?C,*U1B\D37YV3IRW#[>5^.M?P"HH]IIL(LZUCR2UT-E0
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M2Y<T@: "R _IRD PK19P98D/_V)]&5Z=UW<TK98*F>Y!7_]Y5[^S+>IBPJQ
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M)QE!@[R(:S$*D(:D%56O=Y'.QYX6*1J<AG!!PB$'$3$89R"-IL_,90FN7%0
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MZUSWHVU=*IR.=7@N88!"- 210]NI2$]P+AX&D(VI]1.T($"$- .SEK(76GI
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M+[?[POXN1QI//_>?&W3R*!!&%^\T"9,D3_"%U]U0]'VN:"#PX":'Z/%V01C
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M. &IL]"7HXRW(+.Y_JJ<U"!PX^)_V>"ZI9M"\CV<Q@.A<T?5R7!4C?G-)=A
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M,-LM^._,[M1-%;T':WX? "ID!NOS818$O3/ S,X98"N@#Y9$U,/^R<4@T6>
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M.(1EKZ3G1=8Q:[R([PRM7A?1H]4VPZEP5MNI;,YZ"_?8;:BI,=XQZ9;^'3,
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M.L!"!=&8LD</)G*$]>5SXL4PRMT$4\S1TU>A6?6K*KFZL30 #BM>2SH])XM
M,5RVX^>*5*6P8R+;2O=34!+8X1O](RQ=4OG._V#O/:.:>K\VX2 ETGL7@H*"
M%!'IQ01$FJ@@(B (44'I1)H$" FH@/0F(*@$I4N3KK30BXA(D1*DA*)2(HE(
M"*0PX3>S9LV\,^N9=V8]:SW_]2P_7-]R3LZ][[.OO?>Y=VD.]\J-\KYR:5+_
M:<K6[%L=V3_5-08G%V'<9. 5/52, :0('M"1VC=E41L_J1P)T)>U5H\$7IU@
MVF:L@7(<TSLR3>K'_7C\Y955YZCCK9]V)1X4BX:H?#X!..M2"'.J]N:(>+4,
M[3EJL:2=E0#K=M;O. !(.MT@0)(1*G[--Z:P?UKB3*;26X3C^Q*)0]%,F1/<
MWQX_CMH_>0N=T,Y/%NW?/8(2@JMVS\OE^,=I1BAR%HOUZ:;Q7N;]& E11:K"
M,8<A=3ER-(^'@(FL]S7E?8(4?#E8MI']Y7G:X]J<0I^(2;=$N6L__.5J.#A]
M][/I'*>7MY+0K :0Q05IJG)KKA7[SZ90(C@)YLG5[G-\V2/G>=^8\D5VV8 G
MKF%H_YW)V'S//+'QX^-!$5KC%N.OQ>+'^EACY X P4( ")-],R&4H>@Q:(;G
M>)OVTL!H,:OM:T/;A;[?WH$_R ^W3=[G/I1#C/ZZZ.%DD.P&V.V%5U,%,+C)
MDB75%+0(6,NS72*[<X$GN+ZY]LN?F1/\!153GCK\3)T.Z3)/JH=RSF*"HG:_
M3FWN$*IV;URQ6<:5//XQD9:@LM+,77ZY(BSUN\$*S;LM1J@I[D2<B$[:A;<R
M'0R/C:<K$J(%67P!^1T&:K"GQ?BA_BP'N@0&$YLL:(FHQ=(%X5:K90JWC11G
MCXB ,6OOJW=IN;K#%8.*CTQ7YIB/*UX5XT_F1E:MM8N/_G&:;1F&6-34M+3X
M3HF*3 X>RQ"P.#ECJ!Q@\>/#6Q=%<B@.*A4*[,D3'Z5>\-U>.0!X39L$KOZH
MFEOW1WL!J+1_.DKH$U639G% O!,A_N.&4_.7S8JM^5Y?ZB"RNP6?M2TV)?=V
M+UTYGKWC 9PI*0P6#5FL@M;1:Q;?-_BZVG\U@%3N27[_(C?V(^^.O.[%+ VU
MLP.XG&R9Q&A=YLT-):4(K<^2EN8G&AJB6/R-.%C,)_[;(=ZM^V4$$*[X0_F9
MLE*J/J'X=5G9?=$FQY/U&4<6X%MN\O(8#:;?O)O7B4/+:/QUXE8OB.],%0RA
M29" J&G,B7S_^"VA[,C3I:23:GNQS$&UY\!SBZ?,%R.(UV9G>]UA0GP74XT$
MGB3K3"B^B8H$,/[0*SU2\?^4I08M^?3ZV:-SO"P2G[Y0E=Z0G>\[2YJ]&[.[
MRU7NZI,:*ZNC4L^U+%]="4#"4)UG#P K6Q#/+0K[\ &@A#-W?XI$9?CX6N2:
M \!M=P8[CK7561+:DU[/.SNO84V2T<%!(;>LO'W26OOE5F<,50;ET8X?2CU)
MS0TO)T,FO\P[7FYQ:WJ?:"&98FIS]C#@.2Q8"R.+]"^%4 7=S0@QQ9>FO1MS
M)U^HEPZ:9/U:Y>3U;Y']9C\"J07BE1<(5A ^>,&B>[^W)%[0,IFVPRWOTE0?
MNJA(MKO-)P*_)7//C<L89@=845W/RRB8]M!2F_',LML/?AEZ&N8IT"NQDO[@
M+4!<#MU79W"'< #H.@#P5=@,];I(CAE8WA-7SMKO3;3W+Y-EB4XS%S]F#5S!
M,'B--'F8E!Y[ " D4%5J)X*AS![:#]8==^-.U8?#'4U/*7FDFC,#'$TA9[G,
MQ<3L-'<]R>H@/#N#2G<(4]VD#R(!&V"V,3LL+L9._RD^/TOD#FWAG,9GW3[_
MX?#&%X2I+@GM6&#L'X9_]S-+C^.=?]&LYY=^+[$@L+7U!ZH2<G)24M*C$H]+
MGI\7XN__K]4-UD  4Q\K 'D;V8=J$D%33L&OT8'(+WH/RQ9?7>^^;JY!NV#)
M?LJT*?T"1<K5+C FQ"V-6>F4KJ0IWBH%2K"&BM*_Y!D0FKI39LY$F&[9A=?X
MHY:TQB]TN3(S7;IE^O""^H?YB]#F?'<YT)<#@"A"GU"=@I_D%22[FQ'E.(I8
MPMJ>V%\2VA%+LV(K)* CJ>J+DMIUA/[8(#2/H[D17..%6*6K#Q=7A1=31SXO
M*ZT:XL5"2SX N)=[TZQL4WH@?&?P]E?'$HEROJ@PV2.6)7& &TD6VV(*G.FE
M:N_M1]"UO%3!I?Y^4-U6 M6$&"]>30TF7IBK<OF]%N*\EMH2.GI)?>Q^AL_P
M)O]1L=LHPYT1X$_PJ71QS23!JU\+G_!++CB:J1F&12OS0#BF\GF'061Y=#\W
MBA1.KJFD?\0(NU/._T*'R!"^_OETT<]J9$46M.>NB-92WKWO4O$68EDNS8@V
ML&SE;[O+YG^&^7XO8K\NO-I;"#OGJ^M<96K**PN,G\X_$J_P%_\>^*\ALM-A
MB-R4PQ5@K!AC9G/6]O!P55-%B.D[P\>IW>T<.N\<; X6))^2,G$P;[I&#OMB
M7L5^O/,WV0?=JKLV<J1-[7_TSZ[^W[83KW)?BOD0@D/'M*M,:NRQV.\CTT)"
M8+(*MVO-.)O3>8$L/-R H G[008%7(&FS&O0"NB =:0"<;Z IZ2B<XDS@257
MT@$_<2'5J;EJ N >E#+BXKW! 5"HSCD ^&W-,JC =2&FV:_&%;=#9/M0>:LM
M\TF(P-[#+\W%RW+O]Y[S@&_TH5K;O,<. )[5DNL' &Z4.^9IGN(7>2=G;[/1
M,]4^W^&3)A8VYSY>>B?S6X_?4/J%"6*.P2][Y-$E3,I"W=6T95X)J$GIQI3H
MU ,+ ZVU(\^2;=YJR3!'GE<Z[(C\W[L\8^01-Q@^@@$YFA!+FB2JQB!NH&!E
MB#-CK6:!Q5:NPD\L#43>7$@X8?Y6*A<LR?*JTWP]  "Q-3#&5<KV8F_EWF\I
M<MAP](F^N;G#&90GHAA06/"(YRB+/[9D+.B%%/!*XWC]D%*$OE6CT3&1QC3E
M:Q<+WKQ58#)[)]3L4N9>Y?DP+ L=*(R/7CGM#PMD!B8[S!G+EAWC,V(!&4.E
M4)U6$$\K:?HGQOH1H HXL^UC2\Q$<$C]A_1P\RIFT^/N ':AJ(%C\0 *.'Z
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M"CV\W]G566YE-!V3CBT*M:>*;-,MW+NM*%S?4#^CH% Z=N$W@S]%,9LWVP\
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MQ\JV(90HWO2A<@H Q(.X1Q9>\K7O2M,J$<D)*; (&C=U3K?@6TUV>_KTN4:
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M%,9.RV]5*2-?'>]=. KFAH==_K9N$0Y&:ZZ+7#^[( X]9V_-?\-2^7:ZU:?
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M7T@:" 2AO8[Q/K/ZDRW*.PNA5XJ,BV>5FT9G]0V?<'Z*>:"57%#V2^E/3#Q
M:3N<SFZ)BW!GQ&YB&(_!ABLG*%=B-FP:/>1:&^%9UF=4XQ0<N+_QCT_8KW$S
M1/.*.(5S[\%,HTEU7P\ 'KPQ2-%F8E.4P64W&+_'I,^(ALUEW ^NMYRLYQ0R
M3W)T.F3>9M/V(._2.:HCB.K=VO-"9%5">5\VFF]KR=L<2QHT'Y][]EBQ4'ES
M,S]&\A$@U( +-,:AP+R")LOS;F:\I0]!V1M.&]BZ@K6)Y[M<O![T+!EY2[#Q
M=;B)SP^UF][ET38W')!,B4=U:C(D\Q/5$(L_'5*Z)CHITN3XK!)V_FM=7P9O
MT[=C!6>9WLL0-Z"%&M; 'RGX-@H$84J^1S'Q@-8SI#E\RHK?JU'M#3G6)"$H
M_7):S_'YFNI//PEWM6R'SO0^X#WI]!;5"55NX!:N1W,ACA%?_>C)N3LC$A?L
M4WGDZC<>UU.>0EIP_M,^KJN?S7Y&,YRVIL,SQ&O$ZF[GZWU0,;!BN1$1V)?8
MOZE^>\27*WUOK/X]I5KN!6\V]81:GL6-18R'ZA.4,,H-A&VR(=,(L"YU^&S7
M_"F&G7^2TMW(/RCWR$QQ.^/8[?<\&]_C;CBY9G_32I7\DXLQ0*K1OX D4*ZJ
MV)0>Z1-$)'J)%X1@GLPLK!?AKR@O4L_T 2IJZ9TS?Z/]H"(E-4 'T$FNI#@C
MO&CE[:(;[=SD8(*]"T$EFO[J@>:(,#RI,'Y^\JMUSE(<M8AU)J!58%J.A7YR
M#;(8K_:.EMMZ>_5J]]):I-^,R,,<NNMVE>LRB"I\9(H41>"I(VPM0KL7Q+SG
MSQ*E,M:^>Y<K3-SL/>>3;N+@EIK%E!,P>\-J^'W4XQWM34&*+I3^"5*7EX9S
M]F&\=.Q2JSW-56^S-L5EWS]3^-W-(U;HWQ<=RU+69ZK _!FU6(YF6R&G4-1&
MEI(TQ1D:QNQ<7 ?3N&6N\EM@\?3FD<QG!X I)I<(AL.%)N35$-FVEU!X]J7%
M.GALGU[&C-.5.@^':T\R]EPIT9\\@+"ZI=814B[M@P&4<LO)"UTWT@V)U:M"
M+ZE<OT8?_NKG_M+<1JQ8LH\?%2)^CW7E+L"P&Z0-*H0<H0NN+1RA\Y&O=X0Y
ML:L$Z0LU>C;BMU<I8Q_-[OY6QU Y(O6;%0[#B%85G+,?A*PBTE:IE5)Z)OG+
M>V=#[/LF"/%4$CQ#$KDK%49T1(,,5"OF49VWD )>!$_1<4_KM<8AE3\//W\Y
M?F3[^$ON@M+U\'^B$@[J/,,^V)"A-PD'@#Y5[#G?Z^;MXW>:)RISV555\DX^
MXTQ8NB3"',(2M".\;\S@$S=$*#F0*$B2I%7N6&&9<5LQ9UKO$79[YEWA*9=J
MN$;\QMZ%=D>SO,D1NI2^6'KW1DU:,RQ^@6#-RT^?@O+NI,0L'$%*PM^<MW=H
M2!^Y.:4)M]'1: DH&=E[XPYX]JWE>=F/59L>#IH:@_0E&$]VGHRR)2QL-E5@
MU[&^W[.#YA5;4HW#F;M6KS24<C=$Z@P84"2([@1T3PKYE#9>< DM!(=U-F<G
M(X'PQMOC3FOA15D#?F>BWK%;G% ]48;*,O$1X?Y(+V'X^CDH,<QBD8L,[8V!
M<#AC\8O ;IBD=L).H3?[CM*+>W%_=@PNW3T[0''@2E'#GL^9F^#8]\9QESQ%
MN:)F^'=4X["_/BQO"3L8GZ1MWO\5<2GD%>'=C).H\JSMT?&49U);':?:<QF[
MI0.Y#8K*4R'/$3-ZH/6[?4KLKR?]_ ICNYN=-Y4?+8@;*\K^+A.@KQMLIVZ&
M,J6H$,,[7 [;F8?1IR<A@G1I#XFL.D)=7_JY#3WI#+_?3]EOC_?P&W'8HO4$
M'H"I" 5=FOF;R-,>S;TE3^O#I>RZKFLF_6$/9(D6YS1=%[>P SQ^I"/#/U\U
M:@(0NO87?_'_AG,Z-L)*$LJW:^X*N<J]S-B1R[!B. L>23=R'D4.?ZT9[-7[
M%VCM_1=_\1=_\1=_\1=_\1=_\1=_\1=_\1=_\1?_?[!$5T2X$=P[H3R#%>2A
MGMS[4;ZUIE&JOY9C+(MO#"8+W^7$7!65SP7@%:HY:#D' )_J6$@#;RS^5ZM^
MN=-:\V:Q\[SXA!].XIE7HNDVQX>3YI)-7(G\+^V;OS"9A"(_4*Y1CQ$^O]_7
MJB1>[VQ^6"Y9;X.]M=$X0'B_7GOD '"<Y&-?X!E6F?6AQ&E=(GBU_?6=@$?F
M9RKOW3R1R6MJ9V/,O*YPY*MP[%*U%!S6T4BX!<_HD;"/S7_UR=_R[7RO3^U9
M<<6BZ2/^T_;:!P!N=D(=/1[Z^ ! B/ ^ /0K,']1J* !>_3LX^N?:UX1O%XW
MJ3&4-'\%_V3-X)SOW<J&+YDZ]V06"492Y:G$)CP3H1_76)$+C:<?A[MVY[XX
M5SV]<\6%,S0&EWI3O/-&)] ?$*#[/5)_7S$YH<JS_>08?N>\K'7#UZ#9Z#GN
MU6=#&N>JS#\VIXNY\7?B[4O_!;;V+_ZSH+H;)G58O36-(5A7@SQ0?)H;E=J7
MQZHT$RPY39[)[MEQ*L1,RG0\45V%(;A>#IC):U(RH+F0IBFJH+H-.6J9VWMI
MJHMV::S[1HZD]=<_3A^XCEBD!8S/#C QS4KF. $:';2N*C!_Q\S\H+.O+:,3
M44?!XE0[LM62]WG.G@7?5N^U!N]!&<N;E;_,&W.9A:[.=*5V_,@$OM:A4.@<
MXJ6(>Z!:4C9NA,FC.:]IB1:\5#?U@]!0G[%GM\3FG2;-MG-3CB-_4: HEF7J
M>]-F)R40<9>61E7##5Q]AAWI:IF-*VQX-^%#+2WI>7(K(NOG&>-8>9ELCK!J
M _H*0HM(SR!>QQT 8EOOO![X[2FQFFA/ZC.*93\1@^VNXUI,[I$ 4#MH>0>
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MSOS3#XT'NI1-S5 514U+;S,VM@W$B5K)@9O1.TBH_9,*9(9MDAOJ72 !6P\
MHZIF70M[IP[GV[X[CZ;'70*L_T?76OS%?VZLTD^C!L\10VA16Y _EJ.$)KI%
M]A/4)J_[ >"-34H\]/?E5N<#P.WP$9K 'X3* 2#]'@Y$89XY /Q\EL_SYC^Z
ML>Y?_*?&7^K\BW]=_*7.O_B7Q5_J_(M_7?RESK_XE\5?ZOR+?Q\HR?;.*X]2
M@;A75CTN,A/'Q^J=S\W]JMHZPR.@,.%6\POY.!U^;+(-<9T"\[)'@>C*5##M
M^1_).($%QQP#HV7]A(>=C6.W(X;$95^G3<F>%S.>*67>&&&##YF0HW'.JCWM
MQR;N?*T_?Y7U0WW;8_V32<W2AC(DF4@C%KZCE6_):))*^WO:*Z0FU8B6$YRS
MHN?[+&4)RG+E0<\>UNW7Y=33YR_[67VXH_M3"?_ON^R_[/X7_PY0>D6.6QZ6
MQZ&B- \ HMYC%B(I;VY:HH)&3^W^7K;I4=QU361:-P% ^N>UQY 29/E;1)>V
M!RH:$1*?G3;*PI\R?L(TEWP6&&"X!95'=>H$A9"3BN$;I,=3OWQA"">BX(U4
MY0=7ZZ34K:(:C3U3KXYI)9;]\.I-2X.R4(-HE>WG4)VF!H&BW58 CQ M:='F
M5 ,7R9I4V/N+MR_NCK\\\U7?B>7I!)[RB=E^37L32)&>0PY N!K.:]M/"3H2
M13X$2GW/5S$2R>J][M4O\LM)7#> +8"-31?0?0!X% T'VH\9G,=!4Z2Y'J.2
MD"+S!P!//7FV;<N[K-]XS$Y>6$UY$_I^M7P-'0L&CX%/DWD-B<@H"#8HPNNC
MTJS[5L.$5(7^N9=E4D]E&_R@#K/K6=HB(:EF@9[^DL8:YTK=TL3X/G;LL @<
MW:U.P-R=W4B9F5J&]H!FLF_F&1?/F--/$BY.<5F]*KZZ,G@D8Z)OA9(EF/<H
M$CS]YM\OSX Y^]\VE.!_@R(B]>+_HT^]_N(_'DIIY-=$[\X# "M"WG\))DE^
M--*=*R=W_$.+:W;@J*P):V$ D[ZUP /X4NM63^[W!(H[\A/R5"S./2FZH>EI
M1?$XOF'@1);6HZO:_2?.VM]*28MAPJXD$E-YT0< GQ2R(NH)'=BP%8T\E@"1
MA"\9]&M._M[W>[FX&'M/9EB&OL3'1/ET5#'"BB1,+EL^ &"=2"'-DV!5LE>?
M6NFW86\?Z:&/L3?&L9I[\\ !14OSG+[)&VO?R-6;*0< EDS"2)<3V<"2Z/B]
MN]]%+FIWUO/A^DB14]KH<_.WXTV4=2%4T$O^?=YCWD)>3U_SFPK;WF;ZJ<"\
M"A- =:H> -Q!@EXI*/G(Y+Q?KR_K^14%PGBENI2? ]=N0@EK!X"9)GHTM_$!
M !B"H@:T=[R)!$,. +%6]&','P4O$%F_Y0"PG#E-E64P33B5CPQ:IJGWY0D0
MAN>RGP8MJ&\VJ7LUJ2O?-\=JZ8M_?%GP;D6Z_7UUP<__%X9>A,Y:TCF"?0F6
M?<VQW9!8NA1,&/Y9F')^;OO219'K>D=J^DHY+17^"WMO'@_U^_>+OY&]LF\5
MHPA9(R+;D&SY6$K9F2+KA%26&#.6;-D)4:$HLC1D&5O&OE:V(H094L(P(\:;
M69SI/K_[C_MQ?N?[N^]SON><WWG<GS^>_\W,XSWOZ[J>K^?S=;VNZ_5-3>V%
M%;NL)!"Y8XPT1@Y"B7;5\$[2BIL0.'@SN-HW[QZ&:F=B2WXRMBRIFYG3D_EB
M*.LA+R^QYP;]*=43Q.-5HJ'<.RH28(D-W\KY((47C0K2>0$+JXL/;[&'$@;$
MS269#=@CC9%7X!"BLQ)RZ6IS\Z@^GY%L BXC]O2/5U*7;4$+->-&M?"E'VLI
MA0WD]/5@2D"8$;F+2*/\LLL.0_7L.Y7X:1_Y5BEE4IUQ^I$!^U,)$TW_JT>9
MKN1(LZP,*?R S>J0"<2\]8C7ON2I D2[# GYNC X-S90,T,W8_:O\:'K;?4#
MDH@JAQB@0QK10,32N:_#48MK.CR)14</ +SX:* TA*0YH>(6VI#:OE:O)*J&
M_NO=6:U!KOY'  WZ\IT7R2L]$&]/4BS(J2'N.XI?6G6[<9;V1#;_Q\8OC/?'
MHLO4,3"3L13>QD_UAN:B>.C'#X" E?-W^34LK^[ALU9/=FO%>>C;C%S\8*6:
M<P@'(%]>@9VG]V$QL@]1MY6.TNY3SB N+'Y4NE00'WWO[)/2VU\=W1_+[[UY
MQASRYJJ!%*M%Y.E_:;-S MNKPN!IY3\\_9.>%*XO?  ,JA'3:='K!\#VY2LD
M"P93)V/7>1XPF-HM/0[+$'-2?\0<E,;_F.GS%6-!X&_\9X4G^+1GWS2&"HU\
M"Y_)>9M>\K7'JZ7]_6/CPW+:=:HXU,X*R]6V.G(Q. )=WR5">A=XE>Z'3KV]
M#[\?5G4MHVI3_E+5][M\%O'N%V9>8[6P< @H_S.Q_93?SPYL'55D,F17@/OF
MHB@AOX%[5Y9)Z62G3[=$BNF3NV=YTU"&J%OB.HLNT+JB>*5VM<M3[>I98OJ3
MF @WU.GG;:5%+&R&8C9SUKM)MT?9OR]$(0]3D7\ZFB$N22B2],N4\N).YKS4
MGOO^5T'PXXAV'\7B0P]2=*+"HW_H6UFORZZ3B.S=D#K3+AJT@R[H.-,U/?]@
MX^U7]=U[[9K#)X'#SYBB *9K(6A3#.;1N& \1Y:HQ_&K6I_ER[>!^V_^)ZLU
MN])%P[I0TR)T+C&2@C.I/2&HPB@RHDKWJO*$YO0.Z^/.8&$SNY.>0,H!$!DF
ME3X7#E(6R:T45?I,8_C/.-G/]U%B85BC\8#-:LNF NYAC90CO3)<S4Q#7GH]
M$JMW?%@ZL;@B[%%] #D.K;..UI5:6JFWY@^;ZK9W>MI9XN*GYCQ_,?O3)[,D
M:9,<K@I-$^ZT?HV=,L(5RO$5;/W/KLTC84>HAI%X)1[#IK3%&7']T_G.PW$O
MDAPN#')4!8W<VT'WSMF20[[H<E,4019R[&B;:5"@!AES_JE&_85XN-A25J",
MCZ?=R"F60B;;&$[V]-E AE1]&99--B:B>@X <3\^WTI:#*:@O>2.;OT'@])L
M/OK8Q:_BH0"[I U+^W&J"E%V/92B6G1T3:0Q$*_$U?<@./+R_IR4\]QR2KK\
MK7CO;[S*YE#Y%*+";RB=@X"GS'F3WY*\$]63?=>IFAXOYJ3[Q8P%7(R_&WRD
M+?(]"=^3J4-J(QZ ?_KCZ(-COL0%?'M1D"?.V9&Z%G'!/$WUV//7=%J? 0M4
M_A[FSO7#A%R:!2W[ /!<.$(?/ "X"%39%SJPA;\. +\OP4DVTGE3TH"SF(X-
M(&0K"P1+U_'R#*7/Z$TLY5&% F8-)KOF5KI[G>SB)^L0 _[N9ZMJ:2?VRE9_
MM+]A3,X)D.>O%I )-R+0[\GO%VZ%E2@Z,2C*JO0:DY^OQL[=+EJC'00[0S7
MP-@/@$Z8$OT;XC$*\FMB(R#*1??HPR+K>?2H_32$Z'3$34%EVMOPG3=,?[?W
M?*= \[7&9B]H] ST&$"R&$DI*$%UBBCE$:X>WVV6$/'=/=+U#<8O\(L<S+<T
M_MZ9SH'%6<K/DN^2 A.EZS!/KTP&[U65Y9>P%L[(G9P6\*[8R+5-*])#[#S
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M!S\[$^@/#XB6BI>V*7]4$E4, .)QB&C*-=3@+GT0NC/K=@",^U1,475^NQP
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M3MR39&_I*0M\X;ZNOP-$\KW^U5B@_-2W[*NSL;>'+[]A8" 7:YK<EXL5<B<
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M;!?SJ(\? +@T5/VA\R_I2AY=QX(7(V=1!'C<LULW\%G?RG'/J'/I3B_>^!P
MC9AU_?%5_]!%6WRKW>_3A3J95;]T=.I>*)]B%U4<2IW([$4N7E6+O\HQH,OK
MP_)[BGR=0;HM81:+<<ME"?KRCK-A/+ \OOXJXY/:U[OW56\W-$,)PFY'7>XH
M;)\2*VF*O^ >G'M&4,WLH9"GE&2,]B/0F3S ^ 7G,,VEX.H#((DNW@W'H27\
MU9Z&V9B6^5G_DO:#WO])#Y?LO/"MR@J_!5W/HP2!%+(L:1@A#0Z7K9IVV=DF
M^RJA!1OF$[*[NQ[\5AHXV7A&,K;EW'04U%>N:I,G+.$ODE?"S:H5#'G_=3:*
MZYO3O-. ]".?KYZ.#G<,A4K^8Y,U+(^00#'W/0#>+73,P?L$GKR>=(E,-GZ7
M<0#T?UQ[L]4I_L5 >6']A;@9&A[J\"7_B7SYH)<6$#Z%/P (KB0CV)_;/9%?
M"S2C=+E5FX@?4R=\G<Z]=>*/^K%F@T!Q<CC3F_N>#PZPAS(F727M:3!/Z@$@
M$HQ*F]?F7PUQLJ1F.WX,4PO<"=7W^!1YR1F#:O^5WF2,[)Z"$!/P7G%$:SPZ
M@<J';])-E3)I< Y[Q[;G7#D$KFXL/T^O/+;^KZ7#1,:;+FK\V3$2NU^Z[_T(
M*;U"+LAI%2P<&OG07BC,SGK+XGYF9O-*QS%@ETMA0%^ /@5CU]>"G4Z(H4NN
M[+>_DOP0'M'J[&JF6I0KEB->HXVWTIE"C_XS_>;?*=G_M!#J1MP"IW +46[L
M+23OU)TG]_U/,?-9>+YJROAY^XJ)OO>]V YQ)EF 7U,W>'$8Q10FU:,OTQH#
MKW05L6KZ[!DS%VIQRNBXV5!L*V\ITRJ<)-,WLL1#%4H@QSPHRZ9(=<WX'O\:
MX \UK/?8O1;TPPHD>TL]+\=*LK'WJ\S8=F&/07UXDD;\J_PD)$#?I37:J;5K
MV(BK@?K#-WT_</-O')^_T7HW)/Z2XL4-J5Y]8 5U5->(%&N>O.B=^)U8UKWR
M&I[\ZX/ MQ'URW<;U[Z;?&P&KU(,6(+6HB)+R&N@-;$;/]('XT%(@1=>NKJM
MM=PZ^W5U/W;>_-[Y%^67KTF?M+A]5*VU43YUW+]C^A&-"[1ET$ JJ%I*U2;2
M,&GJ$1_O]0[[I%:X=5=\,SKN<O;;ZJ,T$;_L^A-W!04&BX^.&#'8)0<YY"8V
M=OM^JNSB(>V0/ ]F9Z?IV;!06S-\DJ#\R_*&#H:.0T=C?562BKB1I^@S,)XV
M:V)Z'XOC&,)RT?48I>>8G^^N7;+P"_\[I](0EOPL[1>*-KYO_.:D=+63_MNC
M9)5X:U!&97T7AQ7TE9"<T#T=5I";$RJT4VE1Y:I=-=9T__1?3VZ(&7;BE@J
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MQO\D'F (K R^[H+5P;KA!X!86/OOP;K8W9#)(-X %6_)]?C3LKE:^AW,_8"
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MQ) $M#CWM2_U>_5@@ZC# 5 R,#Q&WA*,;:C]-*E5S/,!-<L8:9)*'T]BR '
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M=R!A14_V\Z+HXB ,CTK CU*E\#2=[H)+NM6OG]ZN>:'WE0 Y)[%^U_J>JQ"
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M4SALV/+S=JK5M#^AWE]X<=$B)$,;,W/+4<K@':MKB4^ >/,OV%W&TD7$,LB
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MU\9>9DQ*.8<$RS=T3;-$0AG4T[AF7"59-$K=O";.#_<0Y\K3<\KG<OD'#0"
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M(OF;6SS&SNP$E+NX# 7))KZPDPV]V)(4>ST:VG=3[@.IF'R%(D^:JG38:M/
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M]T9XM+7@1^*#4<PDA.7H@:[>RO5Q%9+-\O37Z<OIAB(I)ZUDF=;-:"KPV6,
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ME_H!"HY"D6_#AR,@."5\&X3+:7GP[79H&-M[KXCO-6?]M(YT_CQ^?T+LL2'
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M_'6:1-*>70=L_8=;".AI7M:+8*+PXO>WX9H$/22F2H>I!G6N.Y-GZD&*^WH
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M4*I)YF0!&R"EFCF*D="K=+G4W&H7'($1_EJXL3Q,R?P0GI&T-CXNPK;O885
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MRHDPC<3[5PW8EG['!Y$\(U;M'FLJR/)[7U%C[*A-8&ZA >6I/@=QHG(\!47
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MWLR*&)I5HD@Q[*M.Y:X$HE:<\BB^X]=9P!7I,-2Z^W;J#CLG9P@S47,TN50
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MTJ?4$2 %08M0CH"BQJ!HB?QS8Q'-(1R4PF65SU&AZH+/OQBP3=64"MQE/#P
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MI11-2 N5;\^/3UN^#^35:-,Y=K;C>YK=#4I>3-=2VOY8'(\:%A,4^O ^AB1
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M^$&[CQ &/#Y4SYAIX.=5B5A#JL:WZ'#U;+Y/D?U<=B=DY'B^$-M!SN3M%$S
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M4]'I9>2RQ(C6"C W)TS7:NR-?STM0F7YP49^]FG*<P,VM1V;8EH0]5_E52>
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M:.#^E W>\[%2@-E8A?F7;.-A ^ZH>.:P=I9V&F@O9)?)&X\_B3\RCH]J^(?
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MPV1]$+4D#42_=@!*02"G2U@L-C>[US!WKUF+T4P4;U[7B;X3$_YEI1KZPC\
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M5 UT*TVH/<S?ACB9J&/L3P3C)F.%?-[C0E<XI5).4O-F]-*ZSA<F-^LS6;)
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M@?ET8:SG\=PV^2$NIE_U4)>:9+,C&&4I:KF>I!>ZKB$.J0'_2EN^.]*B!.G
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M\I/VJ"\B8BQB>K*;O#&'/>-E&8YU,]IBJ3(ST/E4<S9\K@! Q&( 1527 _<
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M&!,-ZVW3+OZ8%+C<#Z&?XMOVXD=BH!H@MC$UJY5)/#?Y 7):@PX2TW%=@K'
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MNUVD;=:]HX/")]>'\$M$(YH >"N;*&8?#SMS&*9>VZS*(S;8=)K%]>#V*13
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MHS.+6_[$,6M G:@Y,(JX^.[AF4&<=N'ST;KCEQ6F=8(MN#\,C$G:/0OW)YO
M<A<)=W>F>FF"J"@8;B?JD290:=#04^-UA#))8H=.W ](Y\W8</[2-_6F#H7-
MI(/J(RFN!#F$"M$;0(D!@7-<8@DQO_>U!=K89'=,CG<T^#7;I8N'@S%_]R[Y
M3R=9Q&4:ESI1$"6">$S0[ R[$##F,0'Q"(4GFSC,?SGR%MK"=S:6#JIHW2=S
MO_:#"P )!'M4Y_T_+[9=B&(I]1ZIF[M>3F8M&*<JX=JA*A6[<Q"\.=L6M!T5
M$T@'<>CQ MKM6>V(S^ ;]1_=8,MI4DR+&P.-*8T5H_\"9TK_;'WQ_VR?\?\+
MP/O7I<S[(M?;V0HJNRMGETEVDR@G.BC)UJS'['FTMWS'@6UL<WWZ=Z2#)!TD
MDWCTZ2\7L?IG/5P]UT#S9%/8GRYZEKD9)#$B;4*^R5M-7+*0?'DQ'K2G/$4F
M%0_305[@J'M(V8^_RO9GO>N;%M(KLVJ:F%\S]R41&\4^?2%_;0O-1%VB@X3U
M0/UD*<J3D2WD27@ Q0Z;\SE[HMD]?3K 1+ GT$2$Y8S^E%3^?0X6:_>]@R48
MA1]#N@$,8"7$>ASYAY7K%,%WHTR/%MHU'RLIO+;Y$U%1QEF=%\6K#PD8@4'H
MH,Z2/Q+AAR?4P12)>3J(^+6+X8T<US3RN$>0EP!GDUVGD:=FL8>9SY-:TFOS
M+%6B#$6<C+7O^H6\]M>'>(_\AQSW_LN!"0>K1W?[ G<@U3M=9OR]FFEADB](
M@4K@;TH^[)%G)(MM]1<-U0FK?W1CC>U0L6@^GP=D/#AFR[7WK>PG$8HW1LH.
M0K SBZ>#IFG<!'!G@F>54G'0F8:0^,=7'[^//Q[VLO@OJE-E&>8^^/F_-8)P
M0<?,7/T8?"D)'SNA[/>',^Q^7,3+79*E' G7B_X7\ ;_O_?XG^*W/(WS/1UT
MYN+RSB'^+1VT'O8YS LF@VJ_"UWIU0FC@QQJ%ZG*#?D\=-#RY-;04N5,(98;
M'16P+SCIY<[=DUUZFC6K8^WJD2^M'T)4W7]:A(CS_GY"EJ<-.ZHR;/0Q;?C2
M4"<L+O" %Z[W<\OHP\P[3\'YY*,ASQL.TK)]GO3+>G\!44L(:$I\DR8U^ IC
M(B=:'__IZNR4)$^J!<)6/3=9T42P45R.T3CZATW,'2^5'3')&$!XY;'U>;:Q
M2WI5SCC%,_V6HSNGQM5FIRQP,]O3G=UJCYCE2WG83T:R[U>FHK"O%W\)4(LP
M6^\WZ*!#OLE>-,$,,FMWC_H*\42S'9P0O7R#,-4::N)9IU"ZIOF<,&*,;F;6
M\)\6WB:7];1V,(;A]]'[#BGMY HDWK853.'P8-YJ^KO7[3\%%9#EE*Y2U#,,
M6XOKLE=ZLYJN4FB7T;KTAYBO*1M#C*S-D@G8)]^ZQ<C=-"DG9L"LL\WVZX*'
MGS'15IZRKN7O%4,ZUSK6HZ&'^^2 8^=\^0SY%)Z<?FYI$)[_&"3Q'*G#"#ZB
M2-$Y^.)R21+RS$9!17*,R_UDG&-Y*'REYME<[/)?D,,-74-DU_#?39/__Z+A
MOPL"2^CZWG:)(%(<]17%"@OE-G/U+M]0])1IWN!3>YPA,&[QT>VND^J[ML?!
MO1.?!^-!P*)9"[6Q=EYO9E 1C$TP].7K*EX9[SNESPS]O-EM39NF-F'6F E0
M&NTABA+8VO8F'"H-]=J9BB%E4POJ.!#!.# [13.A2S0L0V$3VYSP:7M?39]3
M7OI;OW0\$U=DF0%75D>$'8V#BVSN 07K&%12I(C.$LJWB9)OE9\.7%Z/+VO(
M$=2LRX &S#IM#2UX]X^_@U8*_/YS3?LR-5*2\! BAA2=4@N)$FDBGLEP^Z3*
MU-<:"UZ6<&%^)W88+<V\SQ</7*!Q%)*#*WN'>+H).[V:&WJGU\^CWBS<FKHT
M4 W&Y.WFDY=+F3!HM._"?]35LW\=6*T.403=<0>4TS#0'N2(G6GU0?>KU/2G
M;!F>7O77CH9^G0#HH*>3:^I(6=IB4_<J_NZ?]\ZC2-%U_N89SP,-I.#SPA_.
M::]UQS_M7TMKUTM-N0$B#]$X'A 2*8K4- 0TV!^<^1ZH"%;__>OBKY4.N]VU
M!\F:O:6O#DGOUD(4T3%J#E#CL7P[;[V.!6T[#_XBAK\QE&P#03D___VEFO\%
MB&/^8;WQ]C\^<AS_N[?#_PXL5&,LRIC/"9_<4ZLU9UMVIYS0)*E\IX-<Z2#(
M+,(;,%E==Q3UVFO.TM7R]F8]"+P[S-3%,Z\M+Q$3?1L6BNR U0=FDNT0FMQ/
MAZWA!T9)4A.UM5K@/,&?O NR4B4$#4L&]_4M1!@L436[0R1H2676[>\];:/
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M@Q^7?("4P  <%WT^S(T?QPUZ\6^9/);?'?#IA,JD*VN+GE QJ9O.]8-,XV<
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M@99>M!>Q;>BQ#82<!=HE3N]N_^U[D&SE/1]R,AE ^(K)F^!X".1>"7/0]S,
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MPXFA67B(H-OX"$:FN+@SW_:KJTBQ;X!61]S*BRN3'"838*4IP)H-;+Y6GF4
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MXP4%#6H'J@?.?'#L-?=35)\SEW/.][ZGMY>=?7?@P]]].?B?2\K_;2)\QF'
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MC_*K?S_ER3CQG:@,Z9+1&&B&(+P80(>,PI<R37V!+MCQN9T=*RDKC(7IB@7
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M:>Q&%TP"V'+_^QV./YXF7DMN1,[%S\W*B%GC^K?KFI/'=45J8GNM?CPYH,(
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MR9T9?#*/)3NLF$&Y*RLWJ-[^#F3;]1:M1UJ[8EYX7719@0'LYAQ$.4['0%5
MU"R&>VDT\(W[W>FKABX2<OD?XZ4RA^/%SU]U#7_/8S3_?H:58N;@/0L?J\-9
M=B3[>#@<!/UP(?=MOHEC,!N/G;//\P K-JK \I@0RS:* ;"]!"WQ?(GPZOFX
MYA,>.L@W;CI!3?4)FP_B"C][]2K+.R4=O?K]<2U?;X,>;9$6]UI")O(5 FY:
M.U3MJ3-L,D2P<1*Q/JIRM./M)WZAW5;I"-8F^.]?/OA/^0>0LJ+%X]E0M!\*
MY<?[*+G47'-+>Z_ B;P+9KKJ,P>!=$N BYI->PF;>2,QB>GF/005.>/M2V0
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M2H3(K>4SJ6++4,&%P.FF+Z\Q[=G7FNNRQ7]T1HF.LD=U:@P\>$A_"(Y$XJW
MT6!!;5\?[+V\N>A?6CNO>#A])OK2';\,,@-SA5(YYO'T#SEU+YB<Z1I&#"J0
M9%KVUO#?,9LU& 0WZ4KO8"^ZK$T"[^R9YRU[O35>7&[TJ?Q95Q[THN[9K!MC
M.-@]D(>P@_T<TF,UMCTG?C0%X43RMRC\O?EX[*=JHUMN E7,W*)-A6[[WW,T
MSA=/GE G<TX!]5O=-VT&VJT3@S[?'T_MG92X$;5B%W(NST]/L5*8-_MQ=3KS
M0[I#5=+K$QD2(PK<HK[_>6TQ+;EESN:9<8[-[!\9QZ:&995GLE[^;<8/:U%D
M)OU'RN]D;+9;]K1.GH:^)+;@0Q8.M%,$<:RY3)J?$@591#'A9:M2<APWOJR_
MOZ%QSJY+G]*(Q!0@.3HE"7FP9" =)PYG6KVZK_'\JQ),^L2\4Z(QHR=#?>!K
M9J-0U/HYF0GZ,1I#0N(MX*S4K^VL!00N[,PQ3Q=OZV=3EJ\"N\&Y>YMN[JG&
M)4\:#(/9]3F[,5%ZO\-7J<QQ?ZOV/Y-2;I;W*B1H)CF%)HB)Z\W)PQ4@B4J^
M98^A7K>BK-I;[[&-TL&N-Y!,3YRA*_;EL1 90M3L22^,K;&ZL7U&_M=%S9NJ
M&S)9'K91L=F/D[%02SY9DX$P+ A3!KR@@EB8(W;B$0E=PDQ'7RVL4E>=G)3&
MH_W#A7LLQ:YJG#$T>!+RD-H)@*+_2U!:R?G?#9<R0':E+A^4-+=DN$6!/E^V
MDKAZ?&-P#:P-704UJ=6<7"%SI?6A>6+SNAHJP64Y'JH37VM*4@2'-N_075B5
M]8WA&]HUO!X$<UE=9.E%-@VB"%5>;BKC7/-590U%)E=<F])/ 0(AH6^CFV@,
M(XJIB&TTC22%Z$&<HR["A77$?>#\B'(":[.XF:4*HMGDB7^A'9_9-<7ZKB]U
MG#'6@+ J38 TG'S)A\@_#7,MN(^BJN)9WX>PQ:@ZC#<8>6GOS0GXHBM?:[=!
M?UYFZN/Z><W<Y(OJ#JQQCLPUCD-V@U,N$HR(P:D_MLQ]FC\WUT^N _VF7!_E
M)!NN?G\O47M>'5+N<TVH.2>JBX4Z@VP!]HV?788$UK?C$1':BD'"Y-J5^;+"
MN0M,$I)=ZHV?+EWSH+,T&6!&=XO0XMC9<0KR$U3+'H$"Q:M7*Z3)/E3R0I>\
MHJ_NCI9%?-=D-0&&Z_E5]5$CYW A^X_PJQ:4?%JD+M6YD(.='O3^4UA:^CVA
M;.&=7&G?L9E0]HD>%OS(]]W%A@B&)9O]E/](O("OP'KTD4]\0XCZ>*E8A+8Z
MEA3D"W;J\KQW0.+R>/+Z28C-^9[<9=NJ"%V QO@P'>"/%&XPX5";"]\RX"PV
MC557_V.8$E;AT,O[-,.X*(S[Z:JD;C]4']:C"G-'QH&;&1.@$J0XW->O<XF=
M^O[:(< %!$RRXQ\/)946O\GZC@(,*Q_ 8I1U S&=MI!&?(<'[X?AD2?^^E=S
M+I]K;BARK/7ZZ.8F6IR&2XG=1R1?'[_%;[1Y/ ";EUJ#[>40WE-%H>-)E=[M
ME_-,/L:FWI[+5JP;:BID&(<#'Z%BSZL#GJ:S*=#H4P1TT(,H0TK#(CE"!>T^
M)Z'L1S,L2K]XR(25.=VRS ,I!A@+?GM-/3XK8O,,&@GK43\%^*V=F)'<_1E)
M YYKI,P/W1)AW0^<[.?9NUY4='->$]6,3-5G9;;"GP*B5^E@7L!%^K662'+(
MB2[:%'O(2)+?4?!]/C)BNR^P^< MW3"[VX-U!_CV!UW6O:J7;(+?J$ T='25
M1F18/$%LDK9'0V2#\OVZ)@@E%7TDMK18*\SMDGV+;CM&^;LNL&GFOWK$K@.;
MMOI2'+# O7$"5W\[E\J+L?Q2X]EG8O[7A]<-Z]<H42=M:QN;G2Y$/*5+_F_G
M*(Y0<>-:/)QXU(X27%Q,JKP0D*027F_ 0D]M71=ZW62X%+L\V$92'UAE0_J<
M B+G>%]8#7_O8B/()3?S-F\TF_$<+<IR1CP32A2<FXP4C=(%*2$Q[U9KYWI/
M >AR+#A1VV5MW]1J5O44L!_VQ!X]2^J=17:8G!T-L%L>30Y< .>\UT"<HY1W
M,9#^CD8[,?#*"#7JYTU,8?^F<C%0U@B4U5ILH)26E6LLC1)TLN4L?FJYFU>^
MASTQH]&'FUURWIKCO1UR#OTB0JTW3)=%^@_W#^6BA5^O.%R5=-+['AEE/K@^
MUT0=1S8@!M)HF_*KI1^&-D+MEY!<[DR73]= ;E;,YX,:$\2?_\A>0(:^3M-8
M5P*-VEX]N[8!^(,@<E/JCY#H[]B&I24CUMRU<"$)S=D<_M\FXANMKS@MWI"T
M1:PB[Q?R=[U%]*_.'_;^I(Z#\%8LB+@N(63&R6V'S_>-L[*.^67[&W,X/KX*
ML!.XT0)KC"N%3OY7^A'/N_]WD"0(' 55R\>.]U(XY_I7U)O?Z(4'!2/D2C^6
MP ;;C;@8LQ\:?[EP!IZSJ7&>[A?;_E.<W+->6 -;_T47E+^$YK><N(/-J-#0
MT*?\R]*%_;S/Z.=KH(]A/7(P=W@4K#$D5AOFLT:Y\7U%L2GW+$_:2Y6+_J[;
M@,++@I\V?X8P/&9=DC(C_U'?6Z6]B.MLI\7:-A1(#L6OO'8I\T90\J]4^OL1
MD6XAP]P=L=9NBLV8CRCW"1/1Y+6M<;0R)JX/2+HROL_OL@8[X[AD@+4[R'-B
M>Z!5DE#LDC-],$A@+XIB6[TK;/PP&&!V<A<Z!.. 80I!7,_'X^%L036W8.<'
M P7-"!=$PV8#@;^#.^ZJI:.27]?KI>MJV%-T*'&TZ"1.;">YSVW>:!SG]Q(4
MG3TJ\<]R3,L.K7^V81([$':/WSR OX(Z!F\"HM@6I[%FU+@*>QKK]W:R%PQ_
MV=,>'1=TOR?T9[1$6(\=;Y;6LZ8(Q+C"?(>9?P0<_X %3A<*LO;U1Z6]K-S.
M-!.*[/Q^.\KDC0;]N>)0ER7=D\EFQ3P I?J_4I>(=TC,!Q&QN4ZY$WZR&1*_
MGH&JH"0*!N<QH F+(T\OW:\%_1I:_W/&POOW.+'U;T-EIU!&W+DMU'BT#K")
MX!__L>REP_*]']?DY6;=&"'6A-L]I:ZB&PGH\Z^;XE1'H*.G /S]1X3O?>I
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M15I04)+H(-F<A(<V=#L#O\%:(,H2+\KRGX:QN,O$^[I>82F\,705($Y]\2[
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MS\)ZW#K=/I'\B>Z3S[_*V]4T+C\#)T[?SQ8SRN5$R5:SO%3^T$*I_S.719T
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M=)K^9/W?-WIX%+HU*,"+ C/M=ETEJ)4SI!7M! @F=2Q&OTIA%&Z3R !89I@
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M8,Q8#9X1XQ';R5%#*OS>GY>:SRK1V:IAW##^FM7P\ JHO:,^ /3JT0/ZKZ>
MQ^!Y$ I<1\R$A2J< K"2A.9*OMAC^U!(:2J[?AC[%9,'2W02[^KNF@, X0;_
M5ASG:WJO<?+YXF?]N^VQP[U34H6X76ROT07OTMS_YW830/JK?I@'PWNOFS4S
MBDN+YBF7:H??9]Q^%&O-&,4DP>Y)OU43LC:0=F(*'09S!XU'_WF3]WE/T[FF
MS,$W(0/6),'*ZQV.<;K3&=9S>4Y4*)+00N9@[1?S3VA1(CW>-A-M,H883T#7
MO ]7/25N F53K9ZETSUY]"P'VY&$($D>[@^I)87(UD&X";\9^$M=-AP,P4PT
M6@I%&UU='KWG)R[;] =1M/W")N[Y3,/D\Y.;ZA8K/V5YKG^T] N6W^/6Y7=_
MW'<LD0<@>]"<NH#DCL*4[R]@P;PD;PZW\$J'':I$@0L?N'DP2(P7\'Q);LUE
MMS_M!<69\EZ'#7*3] T_=W>"*FEO#XJ;"4/ZM>7ZKO2:1WEN@G;G/1#Z[]CU
M1*EVM-#F*C\&I^WS^8. @2D@R\*7 .5C_T,6EU4^BHPZ,9M2VB7Z-W7==7V>
M?)5DZ1($C)Q:>ZZV_S8&H__U%Y;*E%GU?N=U3V 1($1'FO:64J%=(WTVXCVG
M ,ZCE@GW889O#_-82I,++?OTL@C?LQB%SX5_/1& ]D-Y*6F=XF$^Y<O-GW$I
M][V^J2Y\X."_M?7$LLPB1R##7,E$(N,%W0Z,3H=_%\@(90\%][27)_A#G,)+
M[&HZ\YJHVD/&0VBM5X[[=_O2JXHR$P__M3+Y3&I;S7RHA\&,:LJ]72UA98N6
MC(/=79=7L7PS#1TBW5<E*#)K(#0],74*Y*U DOI[AL])OM;>D;O_.*-WD__R
M0F"Z9!\TS/5L>H9]3@"LG8R)I=_W20K]5)3!O&;R_O4=[<"K;FXT5OXB2LMF
MO87&O?'_P!:#?5A:%[K.D0WN)6?*DRY'YO,]#)5[\H-=;^CZT.X2X 7-D!S,
MIAF[5_D=:6I&5;6LYDI3LU.@SV-Q9(NBJ''QF[2WAB/RZT+7TD5JP.J0V_@5
M.)Z1>IZ [0 QVO>7>AT[7YTZO]#=(1[C/WOUP!* N?9SX[(10 W0C5BP8-G6
M!,60M<J]G$7J&J:?FQKSR&@Y,,W>$(]G>R.& +A,(05AOFG<.\YTM"W[Z-EU
M9:[$)YS7Z%OGS0KG?RK&7&(E6T("BK/1E]ZQFE^E/YHF?J2\H0I39YS9XLP(
M):;EN];[&SLO*!VR(=89;726=JU![MV*A7QK?$\X?D\_I<5'-U)_F;<-VB^-
M((Z2ZCT.E/XJD;GB,*+M'5AFZI:0_GKF6GKR\2<0KGP D?BW#N<0S?(//@VU
M+7]DP>05(K9E$?%E<O!QXCQULO/YCNCX,$/PNIA;@MR).L:)\2X>&?W<3-QJ
M3AYB6CF_T.__[*.S6$E+AG3$5'U%MZPA+%<J@VX#7@_:>X^%+P"QE?C9..V\
MLO(PT;9O3;D3$CF9=)$Q9_=2#&^5_<_,+%K_;\?*/U#/2?<B-C@Y60@W-5YU
MS?9Z)V98Y-J@B %H#'UBZX4U2O4>QHN(9J)6!$D)V'"8O6 <$9K_44]E/S(;
MG;A>2U_IN/89 'T*":!4ZZA3%\! U;17R(;^7P,QV&7^4J[=6?4K8SY9R:\R
M< [O#E+EMKRE'S;K:4B<&Z%D(3W9TI -H'W?]Q N4G_E;AX1_FG)P%7TVZ'9
M3X/-J.9CM;D+IGS'@-(0WP%LHQ)A$\HQ1?U; *.(]#(+--/JX2V4GU ]]Y+)
MU<'.?M&JR8O^UN17@>:A2):L]2A;=CV&XHFC4T *'']_%>U@12B/*ZO#<Q_&
M[+UO-EUORSLW);9Z+5;R-5U6F8?78@ ]B;H-N,NX\G=+_1?,+=+ C'/]A8+-
M_B0+L@#BI>LL)N%3C=%7%4"JZ86PA-7 =)W?GQJHS(<G5D8GEI +C:TSGZS(
MOEA\7G";B.&.H\+!0=V.=*54\Z]T5@#BZS;T&G4"AC<#I^5!L];"0RP)"G'R
M=GY2]9EWLW^@K!KE$B1:O,)2+;_'/.P).5,.+U.!1:RH4PI/ ?XT"D1:Q*PD
MR=?A4;@'9D&5#OH_[!<<AII-"_:/79CLKB25/=N0#SM+?U16W5..1B\[+J%\
M+ZBK&]B'%2?+#%L%5P8R.   RA,7K/ZU8J:RRGO67J3@:86W3?:?\)AV_BOM
M[5F/$R6%[7+C 2_S (4XG):M1)Z'[?L4TXZZ;BMZB<R=1'(L*??$$SH);U;O
M-X.AP T%7>4N6.&K6:EFPBY1N- 6;H>$ S?Q87D]Z<C,2/)M+G )GNQ,\B)\
M-R0 HSO%"4!4WDKERT?/W">V_S0J+QD*J.F+52D^Y@T. 1A]AOX#[4$VMI"O
MVPR,"X8RXK*S=')H?LEAMYO#T>>:8]86T6H2C%"Z-2+CX6=^OGXK75==AP?6
M8]*E#1T%<@CV@@2?GQQR[A!_2(-M?=AE-4NK./K21P&<%R H* 95+!]B,P%N
MV4*%\Q*+2,)8)-H"LU),7(;U3M9L+:J0:_JRGW81+VB6S([GH -T?VH6-&V
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M#18/J_\[>H[^/AR[^580,YCXL:1S!C+X8_]C\9 8W:#2H"(%'4G]=$N)@0@
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M>I9:-SY.J%K:S8^U)R<A=U]7?]#->$%8MJ=OH_!.D8H[@5>$'S_7G%)E<[G
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MC4U'L./W<.84JO#BXN!G8WNE5,94ICM2^'QJ6EW@VD%?*!M<@3"&282#B^>
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M3+]71%TB*;^;2"L@B WF(=EFA(B?1:-'*Y4:(I\\OXA4CA()#YUCED1_N2A
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MTNZF]*O#(NQC>"%XX4N[1B^3S]VUUHT7KR!=+$I.,@&S(:966Z!)_\K6T>2
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ME8+PA@$B#]"+\7H2O[J![7,0IXVQB/;9_;=;ECQLJ6/3!6IKEO".!_<U>P%
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MW;J$P4\\*V!'<."%?,ZW=K)SEGJN3F.O $,2GS<?,L_!>F6ICK;N[N:M!0K
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M1&7LR6"D34@5W2SXE)Y[G:1787S/[ZV]8%G(-XDPO"+RA5Y_R*;IF]<GK60
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M_F+.,C6BW"1^CM]D_X*$;?(56FPENG+7$/L+IXB?!Z5WG^NO]D?2FHHOZ:4
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MD\/JH&'G!T=S-GD1"Z<OQ/P=T1]?%#%>?K@3LG_EW)-_8@O^?S-D)Z'7H5-
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MG(S\1!Y!6#21JGO%VD\$  <?YS*RG/A&>[YWQU  ">70+^#?UJ##9]6P0U4
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M"$8ZD9DTRR!:+;EOFYH_S.I<J^/?T!GF7$$(STVLER Z<*7L[-1A(,MCWH1
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M$[DL!BB )E ?GBSA!#%L7KB9.W=MY::_OV0JIBNM]1[OD2"4$;BJ(8%K0%
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M/RK^JUKY"S>OFU7V /;T3^60!5YR<H_&W9>M?7O93"@B.:])<S:L4/F;EDZ
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M]]1MT*U-RB=R,PPLPX6'-T6#Q5*L.M,UW3K:"F[<,/U4G)KRX?QJYI+[D"8
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M5-$T130.MQL,.H2[S1N/;F5"#PI;+@L7>_#Q>^@+20];G)B)40!+^M,4P._
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M8\PHO+W1KI]V[B*['_$.=2F8X0NV#4BM.JH>+*E9_O?"7[MKI6Y,!Y:LTU(
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M0.8U,7@8 414P5M?*>P3H<4<)P3%PV9V57Z4%VUK?NF,**E\=P 6I7J+N[#
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M"$0)0*^%@="0&+]6*VQD($IOW/<'6#.B=G#C>HJJI;W1]>O63'@+79^.BF/
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M5Z9I0L=0_+@(!_)M4M7Y'0R/S&#EPK+3TJTDBWD,#P/?)<.]=^(<:Y>E9Y=
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M7;97'.3,K5\Z[TS'Y4^1H^AC /OF"C,^.V&U4OP<I,ASYIK7C'^MP&5.I8J
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MH[EAT;Z\NTCJT3V/$_7!^6]CAB.DM*UEOTS?>;TJRAKUC+^(D7Y9=+6I+7@
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MC6G&WSI:^<^^BLSJ 3Y0Q*EGR>F;AJ1A7&>ROJS6N6('.UOJV:Z''U\G/,O
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MVCEDR4F1(?>I\+K!U9\>%^+"\9I]/-KYD<?M/_*/R7M5KZA*U[?0LNA'85"
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MSX8U2:=9D:7>)M5LZ/&0.Z#U+F-<;[NDC O+;30^2]U=%;^;/K\:H@_2I@U
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M<<C^]8#3Q1@I HOK%35!!8:5]43\C,RV".%7%!VIDAT5>JU_[M9UMZ:LK1,
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M:L?"0][Y'Q5GCKI4+SQU=BIT)-L)8G2?\PVK_6K^K^K(M\=.1UAWVIHT]J]
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M"@<#?[M?\6KV.0$4!1D8POKDU?5<K5GF[&U&'1JF"XR;.]O:?6E'??(?(75
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MC^M3IP,)OA5ELUE\*<[KKM(.C^.81UGZZMD-SLBA?BNRK.QV*G:9::P"&N%
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M+^]E!/9\W58QZ35KX[KQ6M(4(+FS8H7Q[#\!$'<G&.#*<?UYARB@U.1EI;K
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M+EPYL:3GH:F24[E%&,_^;FFSS*M5V!3A2/?,G^R+C#+4!6:G0)RN],SC8*8
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MJ4 &\(\D"+S5.*_VAYZ?$^UJ3U63,6_DO36I[*-^>;)@")$I,J?D2QEG*.;
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M)2=FK@G,5V]+\A QU-NY>M4 BV]?(.R0[&4RM_)S\OU^<#=&1?E\HFY:..U
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M^,-X2(J<W+O'_$7.O334>$W ]NS/AH9O\3YLNM_BHB-6;R=QG>K@*(62UH^
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MV,F^8YL[1X!NYD4L8XF8J,?>*/T!'LZFH%-I6+8,G4/,T6JVB7JEXJ()#(*
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M'GGOU^!H'K+0T&-R0?V6O 913P#ZZSJG'?XNG(U= 7RJ3I!%[SI>B&ZKV]1
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MD9*H9[<%'WI/-SSR1%SOGZ>_B>7JNLA&A[N_NJ.'4N;*"SAT:YNREB<C.EM
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MA M'MX$@U]-97$E&[13\=GF:$8BQXD>.03\'#04HS]4L,'IBZJ\Y<-JH5[U
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M( S#C:3TG]<X$4FOP*BYO6,-HLI[G$W_< P+)?\]EOGK4WN;7,;[ ,800?_
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MZ:+^#_=1*NUBE12P^9]PK8X4$X]" ,-\R0+AYK$X/(D6=%O7?&?YB@&LY"Y
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MG_*E!2RYMK8##(%Z"BL9BWG\6^U+^'-=4%(PSG*LLD?)_U:_X/C1%R;U)Z#
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M'0CW!DZ'>&@>RU#ELPNDB<92RAOBC. 1X&Z.$X-DU0A;!Y\(S#QYPK='3SY
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MW1/\7?>=^XDF-2F&DY5Y[HSETE(\E8I-R_$S-\*CV,PK%+F?=2F1?HB4;7[
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MT^1;NNXQJMO3&O!ARC)?]T-JDT.X?C0^_AUY%,Q]&/ZJCK]NG\Q#/R\>NX0
MYX97VVJ_7*N@6<F-VL:<&Y>:MB/Q6P>*04RNPEIMM0_56&MN@?.+4Y@JU\)[
M6T'\@OS:9J(V:J=,:4 6+]8N'*T)#CIK,_8'2WS*)8BZ>@:FFG\[PS[&\A@
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MG=O>231J7=_ZROZK_%EZUL*O*.LF2@:3CE-.UZT^ #77Q.::Z7D'4"5N'&M
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M_UXY ,M"-D(O-N( GUB@K9[Z%.JAJPQ;GEO6:\NZPX;H@L$4-:YU%TM_B#4
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M2=WNP_VXYG;DBIE4_X3N204D ;#<9H*?F= 3O-(@IA=0"C. ?UK9'K(D'#A
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MNA]Y@Y;Z9=*M?0W9]&#3PT5%8#Z"X?#A>Q&%/5TK2+_CTMTX^@)FH9"6"\3
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MN&,>- R<XSQ1$54KYM!P<\Z[E$OS*_03;HJJ0/;U:FS*'K_)RZKZ*^HU_:>
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MHGTKJQ>(K'3&'?\(ALIQYP!6$[X>PNP:"7[R53IMHL0GD>B7MK$!(TR^4,Z
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MQ:A&5+^9AX/ZM0N2.3".L?Q9R^Q*.Y\EG(GO;*:)GG^HC(F>-F#E0 ?[#$K
M)FPL10*#U=9*=Y,8'@WFZ&0__];-F(YF&3U4OKH#ENSW2KF@;GQGRT/3,D.
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MX%'C7/<"( # (<#YUP#^;>#@WJSQ%B$1,0GIS1_JJ0!<'#P\7'R\OU9]\VO
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MR*'.9G.$!]AQ?D5(^>%/5-5+& GP,[?:LX/>P:BAI<2!OM'264F;R,7B9^=
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M&$91EQ7NEUGDZE4!=C=^=I8:7O$F;'/.C<(B$7DG3GX\_5S+H.BW>1:,)G4
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M&;9O-9YLD]*B!%*I6M\1OP=7]P>E?[X&:.PXLUX8L[-BPD)1I+H>.6"9P'I
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M/[F\8.T?(7O7725U9_6(L![*A*!<&.IM;HRLTRQ=B"5\,>Z5$7^WSE1B]D6
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M,7$1'Y=S3&TG\0[<2UQ_VC3V3/*W>4DZ?V^JC'QRK;46%W5+6+\/'?X:$UL
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MKKQVEW3L[-5#X1\V87H^$($T_)J\^B.F>P<B?G[^HHQ7(/XWF_QLM\/:DHH
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MPI8&4,N85V#D#/_&4I_0=(JNZ!_$'\3RZ@5M%H2IHIQEVO).OD@D^\58.DW
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MUM\(AL+J<0:X69=]!BA<LVFWT3H1#.G]2A8Y U3]CUH6LRZ^).8 3DL2-)E
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M+V<EW7 LB?JP[32+;DL=] ;EAX?TDD%NI<X3%HK9+R"UA2=\FP,K/[H$/QT
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MQIQ4!S^%PCK6(=;O$T@ O?#+6[6A0\(E-;'F6_G/BF[VE^8OM5GWTS(\#SA
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M= 8XU!Y]09A'NQC>'S[P1YG@OI/5>>N^3C XIT\*V(%_X1X_]6RK88FO[/<
M/[\995Q^L_!Y+"W,X"ME7$!\+%@$]C!+OZ76D&'*\2N63:M3+27HZP6!I3=D
M4?TT=MW.5FX-H0T!813)#10K]@S3Y6ZNB[_VF<%3*$AC]-<7[G;5;3[J7W1\
M]BUOD@[ODBPAY<X\:241%5(E*$R6?K*+V8_'##>1/SAYS=F,N3SEC.Z=").8
M!2]4OF$+*+_=;*U]\EA!_TVPP].[9DI4Y,ZWB?+M;HVA1K3B'2!L;B>!?(D@
MT$KDM$:.^F1[=@Z*6O[HNR5#7?W6M*V7WS @#E?2]8=4P4Q.RVL'M#NP7YTG
M?"D7$&'/6"4N0TY;<%511@$L-LL+?P[SM9SS?TF7ISQCSYPL8)(TJ(N&W\/S
MA@+V]-7. )W_Z$7XBU*%JN?\+7M(7 ,4SN:\5^J_ .<Y T1^(YR#W<]MJ^ZM
MU,+S>LXY#^%.?B[<-=9Z/SARH>N9X(:2RU$>\#&1?YF2FS]O[90^<91!O&O#
M&]B45-.UJ2J?9>EXA(4L#46!N-5T3VR@:)3L5ZB7P9_?-TI-]<O@<9]38WNK
MY1?I8KE"Y5U;+./7%.K!)7Y:")+42SRWMZ@42GZ*"Z'N%<@M''">.&I1''NE
MV!B4F5.L3"_@<-*;QK<T.00FZ)T!PGSGF< ]F86@2_)P5CWIV>Z,T]3"N?+2
M,IKV>.OW=&_$^C_[F0D@J([%&2&,^CS7GFC5/O$&^):L?%!Y3KE=#F*%SM\G
M)*6=EGFZH.8;=B_GN-.="U7:LY(>BE73%>PZ/_P9LYDYJ._7=+FVG6E9*C8J
MH3GX13>DJK8E]GA I@#6MNA9==Z#--EK(T;Z#=<FCD(LJ9V6=54=1QY^%3PR
M5"'_WO;,.S:B&P[A5) E%1P$B77VUT_ *W)X+0.#[:1TJ#;:CN TIQEJ-'A>
M$)^S6>9VEF=Z';&7PS7K&I)J[$9W,&&E)6V8K/H*5^_0D G6V#;,Q!^O56]M
MI8[H/K_--PDBU)A^&Q,C\OE.ID^R\MNL&U4]J'R0@?L&- P [(0EYRQ,<A/U
M]28/=H!U607/GLUR%R8LI:S_ZJRQBUT$B#BH>DQ7^);I:[(AD*C,#LY69.SH
M9M*<-F/Q4YL 6B&'W3+$_QR%^?_\R#6F&I9.5QI6 &!/B:N=Q[FQ+5?)NH2C
M",J\7\G&N6X0*YHY5J8PH67H$H.;<K9:]3 -A;:3[\3LYS'_UZE?=1QM*N6F
MQ.XR\3G -2X-LA?X$F4X1S0*=]2](P#1$"+ $VJ;Q1[;'1YA&9$>EM/==2.2
MU,N7"MT8]04^';(?T<:X9UBHOQV)-%]&)HQ;I6A>O]"K_HOJ.+'(I=!\*-#_
MIJ6%%J^>U*CB^#UJT=3]2DL*IWB82>=&!3*F'%2=Z59S6JJW^SMW]F!03H^8
M:C2*:(T4N-HTX>VD=J^XTU8J94W.\B.6<%[TSB7JE'D_NHD6X/"6A0M0ATB!
MY\U''Q@\.CC@Y\#<K9<H0;SKX2\/-DJ2?L/[JDW(@3L/V%I(2L9!?>*8KAY,
MRY6NL\1(NY#[$3]TM,"E%8:7/7!!5@'/_NXT(/_\0^!"N!QE<2&,SBH<%8(Q
M,M,=M];V3E-T$R]("]<J1=L#RLW-BXS+._U$/DU."[(6DGJ172):X6TEG7_H
MF;;S99LXN&R?\@S+1=?! #[O//J0?VDX.%C\@_9.0KHER:(]@D1]IYF0Z4:S
M;W^(/3NO8ALZD<Y8;\&(.@O^<%)]45; ,9AJ%/QX8F>Q.A3X7KFO8?\I7RJ8
M.A@S3W@\Q U3.?TL!0,N6-_L-!MA_QQFV=SBWI!,<BG/.^WPBMC_\XH3!"-?
MC2E<4#/T*%ZWD2-:E58GF%B A>?0T2=U1 VU;RJN"<&O[8;I.BG<I IB)_H,
M@.2,MI'<&&)PM AU+/J#>7;"NNPZJ[R.>B_2ZFW8U)P8!+<'BY'0!6MFF3!!
MPON-E$=P]:/H@]R:&2V \N[D:ZE"I'KDS.(GNVD"<',#_@?*UHIJ2(P)3<1'
M&26O9 U\K(C&_EQW-\M1]88/"ZYI\NFVAUSH6Q",".8D;!Z_JDS0R++E;S+_
MV6\?R?J9]^EWFJ@6&I]4ISKD(QZ(HWUPUMR-1QJUGO&!1N?$^6GIG/\OINK_
M>!ZFUFID;B45 6!E)\8VEI!6-A0()VV!$QK-O1^D&93>6^E*'I%XY+Y1)XUR
M^(3D6FD^P7G>$^P\97J9J1\],>_<*W6.5HA56?/1_" J]? M29W(B<Y1&24_
M^S-\34<0@4WJU_5Y8Q08FCZ()C-&:N8V\C[8!REI6\]OSN,#=[A@EPG%\"\S
M/?ZE5IJ4H*Y'F_%KDOE"K?W!.R::_"5Q(IE@!@C]N7Y,[?L^GG;*MRKMT);?
M:V Z+-2LB^.84<Z*%/ATC,SN4*DEM;R)E9PRCU&2?'-E+MK=C]&A?PT=_'9T
MF&ZU-B-4#0)YM6"I7P$TI\R[W+IC?=U!*J1F5#+.#)5H.MOIKW=#F4YM#_P$
MIDWT0V<Q-#M/:Y,\\M>QPG?[:/.]\.$N4C$UZ3=.T^K>><K5[Q_!G_?4&D^"
MEAC^0_<7/4W@I<CIXCATN$CVG7\3%H,_A,7A?W?K_X.P&"O-RBL]^-UT^(M$
M]#L!D<4-+SFU2$5U6I3='\%V7HV=#:HZC->AEK2E:^5WI$X_+4 %%4-U#R,)
M&LG^Q"@KPB>>XM7FD2UX?B+[$T ^5?Y+);[PU*'79J 3%]C#<8ID\!#ERG +
M'];&P&Z'S4Q +%/;S;7M]DPRW^4K:E] ,LIJDSTV*@29F!.]/V/L/+&[=3$M
M]^'$G()3/Z]HYFWW]J[G+Z@O)Q2>4UXP6P.ARYZA'A,Z5GIT",N#K?GF:#[%
M0X[="Z^:)"-H]-D[9*@&=3QFC.AZ6@D/0R(H8J/!0!*FBR,.4@XM+-0OF+:Q
M8HL50A_9WZE WMY4#9R<F*_:>1,L1E8@5);DD4X,1C:W*//^(1"QCZ4*O?;U
M#2F^IK0*W8QO'3[A2RF=-K1C*"I"NK2D.2%M*.+ ,4VD7DF)X5JC4 -SGAR6
M=ON3#[S03.U_JGB-!5SG#=O@BV!3=;GZY)/=(7?I3E%]XJ!#;8)]_1,Q>=\V
M^TUZ.#?)D/BY6^#&),K2#6_(:.$8 (X2,*^4R6_8>Y:MW&9DR,48<A&0@>OI
MWF&#SN.3HE'B00OF^X$NS.#K&T8\\.P^G6K=:'+:2?LDJ7XHH.\4CK"<4J.F
MK7F!EX;<::IIC 3(-XS*)[]*>XH\5Y$"6%R'#&IP!(]2@*,4!>CTDPD[%($2
MAR_[/IA:!N'PQ%K,^"M6Z2P.^# <?7[M-<1NMCC9C2.6H8W(J@2S:'E):?77
MHA.N/@;/]=E<"?HL]_&>36#5I#L!1G05P9A+%E"30P>B1I9&*<8_P"Y95S%?
MY7<U[L+2@BM(R\PGB=\ #P=.027;YTP_E]DXC?0$!F4?3EQ2"]27HUOQ^O[D
MO+=H<KS@1[+3(HB=_&B8+$[4[LFEWT_B(3%H4H8Y,X-0AQCY^(+[;_'*/R4>
MQL?#YL;W,S93%[@I@F3I0'^R N=;RGRI0:EVT=T7&@^-S_\L['K@39>?!U0D
M<1)L=O1(O:6_CG/C?;*]]$C.A\..Z6;2@ND%+AKJZ%"K3_07^/;/M2 MB/"(
M^C^(,/0O 1=LX4#)RH/;_\,A]:_+C7^3 _&?W[J,9VB]" ,2*ZM>E.H5V3Q;
M2^ECW_3P3V"@.@I;LCNQ;V8)_E6IM"@;M:GVE%#3=:Q35E$2B=CHX[Y2/[YD
M]Q1Q1_E=QF\=$!9?(_W:/W<35W0&<-C@3)1OY5KKAJCOG 'HV=[)TR#AL[LC
MGG.K=9#YC47X%+BS"BJ^.$Y)*H19-)'*"O1Q7UQY7N5P;Y4O6WY@-T(\?*(J
M*4=]DE^VJ3.(2:S'OXF[!TO"YV)E>^:HB),Q^_I3B&9WK..N\\VK\0[V:2)6
M[4RH1R3>C^GVK^6&MH>:[1U!B(PN XAY$^&R]<][>&@MR1L]R3'#U2]K"_'6
M2W)5 B+>KXUHY0&KR[JW_NOFPH@L?%J(4L<;AL\Q$0T3U+3R228F$YM_=1JN
M\[PU[1-AI).+X;([IVMH\8, 3B"K+L*Q&\^:""NM1:2P"4%JBWNB6.LEOVM)
MAR?A",1KS=M""\?#=,/_R%/=/BJTWP!?"&F_>P9PD;T<W)\C1\A)Q57HZ/LK
M\'IX>0%_OOC ];9(CW'QRC=FN@> $]UN&_E1,D-![Y?UU.@"PS01&QM3=79=
M+W!J %W[/!OLP6D+V)0HUN1E6V#C[ :;F&1],'CE,FOZHSP \&*1IR;W!OBS
M(#59P8](K3<<+ +M.#IQ,&^L>U8NW:]S6^K)T?WO7.^.7CO,LV]],J*%J:@G
MM&2?YO(G-/[<G#H$2\-0 ;9<:-UBJ-O]X:G$[*(IIRUQ1A>74>'9WUA:B.[V
M8LENH12MY5X>#?=J4A%L[\089IS1P:EBFLP4KV3CI%^7\NC!;T_)B&,^LXIY
M:-VJ*2I(M3.YHNO+[D"0$,@AZM=\]US?)S^X(JF!L/$HI;M_9LVO16S" FJC
M/Q#Q7>OZ1UJZBXK;'8G7J+\0;)W![&I*)<['Y7$O"F=UF^6GM8^Z[ZO.UR_F
M40O4IGJ4D%3Z%J]^ MO7)'S&6,LMY\BH_3KT.MVDMLG'9>GK\S/_8.#5MG5,
MQJMZ-CU@7.4JJWCQ&D-O@+('[[SG)O^BVNU(U1GY_F:DF]OPSO7$K#PG[-V!
MJVGO%0=_,X[(T.]8>+\'7+3X-^[N_S]/-4JOC(E.:]P')#L(47WF"JOV:'K)
MT1WHP%[VY,! @\G$L+&ZT?IP4@YQ\PO(G_N^R*X\%3'R"W%T>G'US:@>1>@9
MR:%3XRI&1'^6Q;M!K"'BZEOZ1<ND&XR?6G@=N/EX3B3OU$9B=*O"9C]N+2(3
M1.S7GUP#Y'I*?G>A7'-J97(K(@4N[-!L: @A"2B.PU293R/G:VG9H(MBNE:Y
MTN^).;5;'-59T;;O/M^UIN::_KKD#7H 2,Y_Q@EAZINY,>@4YW"N&!VI -;\
MS*[ !NADO15U78DY(1&BA+Y(%^D3<KS_5W&&0DGKB@C[1WSD4.3_UJ5Q!A"L
MAG?<.@,8_R.!\ 0F>_+8J46,2)OU7-YIR\6'(:,V;&O59$\J0>"9W#MZD[D6
M/=*5,P"-&,$LG'*1K$;R*7(*2"]:M'0YU_.P+N&I6D;3;HJ"-;JU><-&G9!Q
M2$U"^A#QAJP;G2<JV'6\_I1B_P^&)H[=GW#"WN UZFT@MO.00O#;A/L7.!T%
MP%K$Q@Y$&BHV79_>90FCOJ4XL9K#V5JAJD\TBP$Y&:ATD)"'X @?KKL3Q_QO
M>X;2#(FS5K;+VIB^IW3A>WL]8>0GI^D(07Z9+ ?."'E5U5F0.ZK:KK8J11G)
MF"X*S^1-1=D)VD"V!</F+L6UG0&8O*4E7(00*;?I,M.7'Z0.>Z($;MS:TA3P
MGJ]:C=A1")0V7==)W)WY?&&KX%["@\.'89K'*4$;<UL5$]@+>' 3SWGNC5")
MDV:)IZ54OK%R.CO._^_N 9>HP&"S'P;W- -@CW$??(82/:'I&^A6QJ1$4!7Y
M7IF3*4_X!L;IQ,6V.<T8)*/03O6$,<4K]AB#.\S)!(7+9RD,XPE8[4M/1_.S
M!BR##7_P4OM5>LS5RT9K:!#3LX@W.]MMSH\@N-UDO"?'MV5]?A>'S3N^[ZEB
M?( N%/]D6VP0X! Q;>%R[CLI1DID(M9^S1OI5P=,/6(([;+EU\QC"O@_13T;
M/0K^;>\8UVD"5TCG-=A_:N(!03WQ\I+6]M+"00Z&4:;O[56Y99(=0MS?;H/2
M ,X?;_R$RYT6MEP#M9\!PC./8A?'-_>57PO/\X^?IMKH-E7_UA=]%?-+XX6-
MY8E],)9'=W.+L+Y[!NBL?D;*0(N]0B9VTZN-(<5%4>A;" "SDH^HV4  N'LK
M\'#J](//+*2["NN$#2KZA3'I/-QK;EP'UEIN,0F'+C"1L V"$GE L],4D(L;
M[Q^,2=\:Z"(SA Z6>,;"_=K[M_PTD_RE^8UB?WN91S<!#.^*ZP5)UQPZ^"UM
M2);%UM!5HW$U,/[CZKNUN@!&B-N+Y^U:H":7S:YX"1?R8JADS1D@S!_JNH@S
M[#QUZ[00C]Q<&;N:(R&C(.F?95?"J/0 3!>_0#-D8H,CIB[XQ6B(.:5+R]2R
M37[[/G 8E"44SS("75WWSP-&:_"0J4=K]04O:H3C5#<@CAUHP%A1_\G[I#_'
MH$ V #Z6"_PIDYVW=E@@QYGJPA>H^_H:%UR)9$L0U"+ (\JW:K,%#<85S.?[
ME;PL15J@;8PZ4+BI,;LF-<"=!B S@I:14(I5N@CP8<N*$-M&&5&7%N_PAUQD
MH-)D+OBXXO')8T._WH'_%]68J4[5(A-#9W4/1UF%T[%="F.!C;4NRXMU:I9,
MWQ)\MJ0N@8S=FMV7<R1TN(JBYAA?WKC5)%**!CBYJE;I-\42^V2Q9;B>>)@J
M7G_G(K1ZTB)+MP;R9;%F>1C@[OZ3K@BJVQ&"A>!!$61PL3XQH>0; 1DM;>/"
M8_[:Y5/+C4XH4NKW=,X8U2$B@UZ 6J5,<(?/+)XR.L];.Q_62)/XY?-:IFD)
M6W4/6TQ0:5!VNS\+6\&6:M1 2N#+%C_2_*+MB0[,@L<M#&5$X?Y&6$F&?)F9
M@7 J'8.FZ>L_R,MU?V]J?R*( AQT0\NEM9\0=:.]#:/. !PP%P)&C^@6CNDT
M*+)8.P,X6S9\SES'3_=E&B(NT5^]P:T'DOLSQ-9;HT/XKQ $VRW/ *S.&<<&
M4=$M[5+I=<,S0<7B]8#-I]-A4[?WX1^">=9M5(F<24*$[02BK/;8"^)RVD1)
M17-E"L4G_%SL8_H/$;8KR>ET^?CFHT./TQR$8 2(V>6 R:\CW;=%PLM?NL]?
MWT-*3L]#*N;<S=7E"S\4OW1[6:UN(@-QOS5$8?<H X2@E2A_GT#I@8CQE3CI
M GGN[A$1(8#=E^F<V=MYS"$+?UU%KVM$JO+'P5E([TEQG6#FRF3O:88R>6$3
M!83;1_KOHMSJJF:!)]9D)4+S:B=;2Q#S@.N6FW1^I'EJGYWN1Z72Z41FNF5+
M$$.+ /D18;X;R F- [O1UX7CZ2?,D@QRUBKS=W'W/[=!.SY%CR'5[/"-H(1Y
MZJ'N"HW!#C<VYP"F3\ 5>17_MK1P20E7W3NM%0"O>41=6A%4_]"1:)]5TNE6
M/*5;\O";9?[%S\NB;W(##L",,_2HJ\5ZSB.#\[9)KH++XL\7A1M:6<DLA*$D
ME'B)H\VMFB1TU3-@NLLC.1&Y;@:^U4]F!C@0G9,&S; +PN5B-[_20R17[-SY
MB]'JH7G *R037&N,!:C;C7=C3GAX/\Z H<M$^UH*QNAF'V?JZW=Y4]\<_-*!
M-K=L",T23<QR:&5/NG_<3?;_[K8ELU#*"!:86+L3 V; $P*F@^(H8I"OBD6O
M)Q4M>6XK2HU$6BU%=AM6!.Z>CEB)]X1P.X.!P4!H4U?F;:1*\<>27B^WPY(G
M<0&)#!P+P I[BY\_2(9_?D .DN63)I5UJ"DO]XL.\:C]<(<KJ2(TT_W/.WGK
M>TH4UAF;WL<OBG##.4CL>/K: 0N_C$6;5**4>N['TZP2[-1= G_?"6:)G\0]
MO<<(FZN'.^<Y#%&X3M_M)P'%X_.SNAHG2ESP2'_XZ/*B_1Y#E)GIU#NCI/?>
M I$I\X>JPU(PC6%+:"HXKLO@BUCIG.AE]&'W1^%$]M[=0]L?D5>[YW'P/+G?
M <9&=)=QX/!@%@(\?!_,A"[ @M>P:N>PF),[%U9];,C5!^K$V 64:IY3,/\I
MO#;:NT)EZ&$$F<%QB_\3 VM-B*-5_+L\NX6+1PJ+L;]S%X$Q!R :LB,I ?ZK
M3;&B&"9MV:3YY,;-HF6,+!U<R$-34'_;K4>!;])C^L[N@/#_P]F;1[/]??_"
M44JIH=0\MRBMJ>9J$:JFJBIJGEHS06H.0K2FFJ>B144I:DP-08EYKJI9:B:F
M&D)B# D>G\]W_>[S>]9][KKKWC_>65DG:V6?O<_>K[WW^YR]3S<G;4W3:]5C
M.4),\:7":\)<P>^#P+&UV<%U+2X'QVG^*46]8!]0C#VOBTN;?3RV[?P8Z;]0
MU9H =)%,M*AL*MJJ N4^&/:P,W<:(ZE]TP=[B+*U:SH)!)WV]@E\6PL#/O4#
MQW(N=.GV'X"CAI_\3;1OQ,MM9M36*7=IWW>$$9C>]EKL\\7:XO2'HB[7"R$[
MJ-6C(HR7/9U [/+N/2(P%F<JSJIW_"'/(R<'. NGU3MB)).RG.!@^V*HXK!L
MV0,C!Y.C^OXJ9E]CB@,$/%34G!#7LW 3&4%H+K4A*)8?\#W2UA/G?))KO;XJ
MSNOMLZ7*EY?+,_H:=QYM7]RNE,EZ]+W\KFRWKO3;,$L7<J"JZ."=L])S'C5,
MOY+BG9H:P\2_4]7I7$^^U*7DG*)C20*$ 'QOSP)=+<<NRM2^P%S7G5/RWMI?
MJP_] !T.U;!EJHK .?AVYK(F;C:4.;/-7XH0 [69[H1J=1<\'8:YAA2'CLX[
M05OD&1/G1,BW^&)A[&+N*"J$?MZ\GMP!ZW:_'XAW)>*=BI-P'D+H+)ODA9&,
MFQ><D&V]04C=).K7(_>G*1P,UR%63 7\/A9\W"U7239HE1N0M*=CYW=F"9_7
MD->R:%S\Y:-P5(9V-QW<^ZAR8E?.N4E"^-]I^-"0@*7CSO?G]"X7@#]ZSC[T
M]>(Y(PM6(5^LW]15ZR9]",%<!80D.;[V*)H6;R[7I97"E8:S2']WOP#DH!/.
MBI?GLU0\@&U!.>J(S,  [H64]Q) SCT^'I(%(?P"<%WUKXHDGJ>U(^0A#XTE
M,;""(N!NR)OJ_$A:4B+[HM]1'D.53'VAQ(Z,[7VHP-F7%H%-6P;?N*;+>,A&
M!"]0W<=GA42-O4[<,#$U3K<#1;Z1?SNAAE"9!+J!N;26AI@(0^=,/(]T.$UC
M3'5MR68[W:<CDL]^B/<M9D@B!]YH]VW% HCA7ICD5GT;Y'Y]8JL''RT$V,'9
M4GK*%F/?6EOO^AKY8UCRB7<#GU\AH[L:'.-$/I^@<)0Y01)>GA-0)7PN_GO.
MA9PXZ/?C>C0C^DE(/V79L-J33Y(AYP 3IA)KZ#K1X7H!X&GAWE0-5%'"S6@'
M[F4;O[4*>=FBA1%EZ('7HM^BN,K,7.W./0(,FNM3=T1#:*A:7]-(ES4%WJH+
ML]9Z\,^E?!H^+63XG12\:(>_C<#P:FJ(_'9#PM>$@C=]6*X2$\ [#C/O1\;6
MZACTVX.05QL*YU+#8GXO,#+V/J5JW$LQ;=;Q2S6Y?_+HJV,]E^(3M9!</5Y9
ME\'(<-LYI.!-'I6!WKS(O C9N#$(^YA._B=F9Y54!H),FSL(1!I3I)W0X).B
M@'7%[4/QN0_ UR!:W5NEA+<F6O)PNX:X"'[@;WPI3GM7E7=)K_^@X,UME/-1
MUEF>(.'J4HC*Z9!& YZW#";0ZU%DH28V.E![UZ.,,ZUG:>BY"_E4'.^'7&?R
ME!QT"I3I[$NM;2R< 8.G+Y"KC_;4Z*H[9K4(SS;G3V%_5UZ-?051UH!(]NS&
M\PJA6X3<ZN?)Q^7^N7"5O6:A?#!OTZ2#-M?TE0Q=%^UZTE, \;5EP.AG<QNV
MB0(T%%B\*066FE--17Q4<6?,#=DR^?]OT/N_>Q(:<PY*[MWEL#=QZGC;+[A(
M R H+%\ NBI@2[N]23RS!$-K-W::KFE$9KG%E&7@]XV16:8XH?+XWCZ#WSLH
MNY8UW-F8&^>=S[Y=:7*UWHX?;^Z+*"53PNX1[(]RTKH:CWM<!6J&#^ W7+QW
MY/F$<K[KWILB]]RO:5#4;7N8R**&:)2]^MG76LGZGE#OU#*3F.T;^9%DJ1E9
MLB\:S"^H(B"[1U^1.&"WCI*X</1JXVCYSG:YG+*#=011J'NMW?T=3T0?>U_8
MYTZ.W=@C!F98'[*,_@)@_V_*NG_<A9B"6>-;>[CFW.B,].(Z&GL*"C>S4I^-
MAM0IEM/JT3R^PGQOD&9'K!.0X]0$C+$E*U?2;N&?=, G)98+YE(+@90?=:%-
MCDK>]TTGEWD8+^<=RI)=Y@[;EVZ!8H-@7@(17=+J=G6>_*<N,DU[#&GD62]U
MECTD); SL[JS=3X1&G8!N*%$'HN7G%)XDGA\Y$H0AZ(54IJ+H\0X7D<MI0H/
MEE8*JG62Y<0?\/-.; PNSL"JXL!8GI>(Z>[UC^"OD@TPRNWU@4N&"@&!;#WZ
MT8VY5?A[XM[HCAN$HOX#G?*GV6/NP[]&!01PQ?XL9J%RPIV[UZ$..'!$[99D
M/<%[[9IQK.N^Q>#1^Y=-]TW@OSMQ7I_#"X-(\ZSO5I%1"HVQ=-JW^YBPO>E5
M7A]_G,T'8[<,.Y<(7U!1JYZ(ZUJ>XA$>;[IIXDG=/N]FSW9JR?9L$U7D( @-
M/%7LF T^B&!K/>98PPF.*G_ZK/[G-CE62+HK_N!V\W+G!:!6.&)GN08Y4;F&
M.RH1 YW'E#_QF/OS[?>P3TK6%I;$!@+11U]K&9]UE3ZIDJVO')3ZTQ^3"(/<
M7UEJZ*-"&D^T<&UD'24$%&ZR<49B"P>'?_CEXO^LV!^_2NOP.G[X@I(^D_@$
M(F""KJAM\M#)U<V.0KY;=MX13+[R!I'#2U89W@-G5>+#8;%I72VWJT9R5V[2
MS.G6-O!XV2A? &C+0OP*-VRX&_ &^M<V&N-LV^V=W<77;%/&[_U$Q8,K+)/"
M'O9&0!V+(>'MG*5#LJP)KF(J0BVYBQZ*)Q^P[KPNY-.R?#<V6D1&*N0\[ASQ
MJ.LUJ0FRO9!?2=%_3.<]+T98762XLCE42 COSO),^W8["A3\J:[ZG33U0255
M&["&-I0'EYCY[X:<W8)E\:YF)N;Z1_'TDZ$/80EE0^17OI,TB J$.AY@;Y9"
M-$H-'/B54#U142FAI!6H/+AMF<=X$U7FV<;!H?(N3'FAZ_S!L!+;EP1GJXD*
MWV:Q= ._-\07&1P&\#?W)"FACW&7408U BI7/@TR^=Z_JB->MD-#^#VV&[NG
MSQ@Z&)"R<<I]2A7KUU1AJ=L8M7H;3XGT\G&88?QPOKW3?M+P %.(6]_>+YD#
MY=Y&D_0Q"88#+R<J[7/:ESSLUD:G'G=5)?R4WW&7M I^054,F<%D1K1PG25#
MX+;5(W3SRX"F--<T3P5[-%?TNJGO O=?SM[([*X,"V3%[W=52MAOFB?O-<,R
M[4(HZ4/3ET\1VV>5?WD51DCZ2WQ,-FX*_G4*_C)J&*PA!N__:X2[1]OC:Z#5
M<J56H=/T>?^^'@YM/;(+M:SL+G>KFC^IVC@=_!7T)M5[Q8F7[%GK+ZDA)1]5
MWJ;%A?A<:D(T3"XSBJ17O*7PIOB3H'SUCJ.M59#)4"S),1_"I9EF@CY\%"*L
M%U_:/#B 534+HPSI)\<C6,?. 82"+I4[8WX,K)!PXD,ZA>=$"CY<[*8":QIP
MCL.?Y@>?R/*=8GSO]J!\8=$?G2^0^BZ937^VNN,ZW-;IZN#$)ZD^1+1Z4W7*
M6 4@J#X\5!!BC^').;;A0HL=9D/X'*HM^AL$[!_(I=GCQY;."S$P@I8'U+)(
MOS)P"'S$G"T=&/-Y(,D@_,24+/]\Z&%=!88.9H/7CSD45[D &#ETMT;Z!<=I
M7_G&SPJ06.['6ITAMH<PDS6C*$4_#/O-3LY0A$HASVHAMBLH6[0FF?:+UN"^
M=X#/("!$*!AVF2(-^/E)JX%I,E.U'A@;C&>M0#GP96VMC')LWW$+L;)8)[S=
M?CQK]8[')W)_96FM=2OP^U:G)F5+]>::\)Y0N?VB]_DA95V9AD\8/'Y:IF"M
MCC*)*I!B*[22L@\&<4,"#LIWK7CM/L\Z+B'NR9V*JHFTN<_ D<>@C]?OE01
MA,T]A&TND[5"MZ=?LJ8Q'I5D?[4KYP1UF*6_.[Y.UBJ$HC%\4\7=+SJ7E654
M\10*%OHQV SJ'26U8"^?8%9*:M-[4\O%<O,6Y[^/[K=]FY?%3_I'>K0(-P+.
MN;Z1AS(D+C!4HO3YHNWPGI_N_!#$3+B;@.<Y=-I4E7VF:U$>>/T.6WJ5P0L
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MD4L(V1T/FRL_<T%@>KBN%"OS?H6I>MJF)[HW[\ALY)B.FEP .* *O.F%/1<
M)A3CT4$C7=!6F65$*MU@NG[VKCW8RE=.;($#)0&K?P9D(K'3OF^=RD8&P^;D
M?_')K*VOK[=>XH=_Q2*";6M>/MR*4(];,"*DT:$CW?/&5G"'.4L>SG0RP"S6
M9X'100ZXAV]$2R\#UA.\V_*1T:ALTP*+FTXP?9*[5J3%'.. R&./P@!:?4#)
MKJV6!KZL Q12+$/2P;G66'K7OY>+"QF2IZ3Y/"OA8TS5 V:X #A% F]";QXM
M^9OUGU6 :[:)>VQ<+4?S,ENJ? \)DHN)7_!-/;C^9<GPWJ7YI**_=NV&C]K*
M H&#,0P?4M:YWTQQH\V)*N<#N?(X6-<U.5M>MYA*5TZ])O6"&5WII^)J;=<3
M"H 2@0A'^/+E]+:,7<Z%(%(>*Y$:J74(\,>5=:%S3RU]"[-068B5E>L=_9C0
MZR[V\7&'UC8+TBH/[NZ_D3G(HU<_>G^6GK8,?R^K]YS.559X+$.HRY\8_T70
MF49;8'6 5WG0KW%A>V$1Q@714AV&FA94(L$%EN6LF_4W+7NDPC]7/4S,8\Q9
M9F$@2?S#L>//<$S N]!YSWI!^/0D42G^;*'YN&J^$MB#N'8!<'$3@S-!.<5M
M '7?_()#^B7HS1-W-+U4>=#14+EB@KX:<E3V&^>"/M(ZN6L45:BI0_RMRZNS
M"=)UG;.QI.J!7T_:ME7 V+X;RN B:GDBP,2QI,R!DX9UE726WAXPO7QVR5?@
M327F>H1?XT_-">R1%N727L/<@,>LS*8&(.CG<J%X()PDT4H%\]3E)R0L[A=F
M&[^,(]HM_+JYHV@7$#+7@"FQ)+G@-LU<XH!="U=U KGS-I\W-C>8&]&E\ VV
M_UYX'A6F[)2!2EU?UHKF1%N:A=XAW'5.J2F6<9LDVEN'V>E?.BP5E#&"8&W#
M=(Z.O,SI'0@*VU?&RWK/$.#6W\NT]+M-DV'*FK%[#T)E(%#S/^7PFR@FS]05
MY*]PD_IIG.<#XY,&CP:2FRX\@9?S==G[4"&"6& VK.;8[>@"T'BXL.]S.DQ5
M;F U%!'*#P'W\/V=UHHY\ @Z94_?$1C=S<]!J)I%V*D.5?B. R:W_L]N)K*2
M[+56L)I482#4]78:S P@K%SWM)PRGU9P)"<J4%(P'K+,2<ZQ8/B0Q=U)  +Y
M4G-/^#*<HW\13GC*G]O3<\[ENI865)IQ[[8F?]@ F@<D/=G[*;2?C^ZP]2K)
M'$\Q=!3WF6K;U$ <^].BQ%]!2I9&Z>.+E2=\_L]E$D6WI@F91S?&2+=S'Z"=
M<>C8"C^UH^"IY3'9"LZ]GZ,/*B7R,_TW\A)T'G]AT7P^J5R&+:5D685SJPB"
M0JG!=!LJ7,C:!C22V GR$#J"?GP79O[Q"O4B?C#H<R"B!QQQ#&,J&-ZI_?R&
M$&PSXMF"MH<=.388"Y-]*'BC!J =IH!3G$M:0%\2#)80;+."#]4W)\L4D1FO
M]Q3P@.?25!7>&?6L%L78@/+2?G" Y_R56AW*55\!XN-U_J.-Z8H-6#6X4Y*@
M!A5?@C%"='7P$;P\M?)U 9P3'P+H\Q;K%,@3NM7X@VCPU^DL%]';)T1C2-GC
M,=2#%L[1=5QD13,V,7HIN^1VUF44RS1 0<L=Z!X.$^V97;D!4*FJPH$C:V?>
MRF5$%UB@-HU"FK]JCY+_EJ822,R=*+!W+G3!][DOUE3K+0"38]CG=N-];!A
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MT_8BIF>IHEI'N7BM.!1/$<'9"+>#Y,VT\S,31^3)8[0:3-_(1PFOL@\]7:X
MNF"U+,^J/:!7:1=>XP:1Y74]=^U?'6<^!LK\,HIWYWJW%[J7*S4(",XDW;T
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M6"L%=VA;O_0B9 &ZAD,Y9PBF1[D/ZV*6RCP$'L.HD%_K+4*RU*];G2&M;HD
M)+\[YTY@=4]-UX]C+@ @?2Z"PF(SLKD'P8&WAR1/6]D^S7>HJ]$=+%?J.Q:5
MX9]!\V<1>SN/!TI=@D+^I W>;.?.;O;.6PN3_9]V6^85+/[7==@08:PSCJT'
MR%,+8YB"Z':?.D<,QH\IS[@]5 J*GF;L )0U?<37KI10K 29-B/FF%FH_JG'
M. D^TC]+(ZD1@9!6LTDYQ V7TZ5Q]\$?(2J3F]1*G;<5A1P:(!VDXD@-Q1YZ
M:8;QEV]53T>'[^?'BI!5["6FK[.V7)L0.,M'H%X9 K?-4>+@KV6!8:W33#NN
M9AX',[?WM[(.N#:>R5<W)OS^UJTIDTH)6DZ:2NJU.$?B9=10+7C6PE)=# /V
MR[<_<]:UR3-G6:>;(C0]SP4>W=8X[@:$P/]M-:JK ;C%P;*V@(O<U#J*M65[
M2ST2'=E:K1L8_FO_?%*H9T&O>6MD+5Z'ZU8?[7VO;B@:E]U941(Z%BJ+&I/#
M^NLS$.QDQ^9_[IRLU3<T9<FEYXCROJ\T95^L (2(:X@S PP-1SD!FCUCN:*#
ME4HW2P:(ZJ[S4M>Y7)(A%NLZ ?M4G]:;YU!E>Z<>"3\J:WJOE^LLZ1G[BGYS
M/S0B/V&[6>*84-7).-]""U_>C9.U_5,T.G/.=+GR2S*37"^HNM@,7V.7(QYE
M4BF;Y<4#O&G#CO(81GA1HV@N7+3%P\L4NY7*-AM1U^]5,*TCU.[1HR4E@='W
M:5*L['[^DMLNC(9!?3HCI65C5Y5Q!6'4$YJ^]A =YF>M?A2/*X[':%NJCZ'D
M2C9\^AQ.NO9GS?O9K\]ZO'N6^X<7.0RUL@Q4X22$8UL$X>U'CW^KJ]2[SSC6
M)KG._FU;N<_3*\"R)PW)[#WFJX8E0O67=IG<@OQ3I].L-A2"?F&5+P!'H8<O
MC&.$%)CN4U, (&MA*ELV&BR#))FFK$O>6B,E/!U<*^^,>CBDZM";_^GXFAJB
M(S<Z3*9SN5A/GLO\WMP'LT"XC"=5E"%4W75;C",''L(F-4WV_/2"#2#U&]=G
M0U?W@KVVK&$)'Q3"_=JF.R&A,H[R9R8JG"/^W+_H-6F2LE4F<)J%RPCF^D[=
MN 4&2&:715(D$LQJ^6>#<=;M6594X;4H>ZE$)_"<P/?'7][S"83R\^5[Y:Q]
MMM$BBA#"7^ 5VN"T\YN-'Z:+\E]+#8EW?A+2,@KG^D'<_CAMYL!$38&N'/Y7
MMS0#[41_HYP7/^M;$$9PZUV3'0*%+B:GY:;QHX"?G@*1]M./]KF<1YL86-TO
M_1[8F,E-2TNS+ED^[RNYIWS*FK.2QQ;<C3"@=OECF>6(4N#B#-][0]?13@R7
MHN]60H")?RIF<.E91(,>40G-]%I-T&]7E<]+<R9&D2+X9?H*L'HHEJ_;EN9U
MADM1[.;OHV7]!NFYYN% NY#*D9^+;(__>2?8'/1_=ZS^OS\KH<)0A=&6NQ P
MD<_8]<N33Q*O?M2_$JK_Y%/W1) Q)6V<%XDV"7@OEPVD_WN<54C"SYA/=>SK
MRB;>N/>M7U&0[!+[,*%L<'((Y1XXJI$2Z2K?7-A^]@56A.Q [@B]LEA[R9VP
MW;8.<&Q :! [1UMISZG/IY(N  S7,S%Z.V45DI$HG=+!5[A??P59I3-TS0JO
M'KW'V#,*>-$(+#] S'Z\H_M^U.RS8TR;HZ][V17I:\K= *UO9D4%]EZ@6_?2
M>D9J)%^PW] ^7JM"D2^& )?0$=M08.$ND:[XT^K)Q]F OE&I!^1-67^_Y5%P
M&SG&ZW'=^ML63AC[F\=P)>U(B.#HASO6QZ7/P_W\/%Z3U=4U*WAK>7$[/4G)
M%%'EKP4EJVW83.7]-9GG&A'S+>,?<'6\8MG!$W>C%, AG-96P2ERI:BDN+*D
M:&X*E?JD_@;JCO9O'O6['%3C3JBX);[M]GP2#VX>N70F8S6Q6QMB+&3NL4LK
M#.K[-:K[PY[6*D.I2@Y[Z2+%+2ZAR-1T?,DXT$/<X;-Q(U.I]M"J*G,H)^&Z
M'L%T48^K(TO]Z;1G.J N[%=[SC?!/=6M_LH/=:L'I^A?+8"S/))[?2YY(]XO
M,5,B&D-TM9G74U[ LHX6WRN4!_Q\J:"X^+97*2"4[ZQ$Z3I&W-=E(\#+M41\
MXWNJ: --H.')8V/:(+J?IGP&JAQU"]6PZ%?XW5CHB^GY&MGY.\+$Y[]=;[LX
M6KWB?Z10&I]ZY3LWVA*7N1@:C8O&CKJB%1HCYZ:[K\_9]G%T2=WN9;9W(7?+
M+TV4Z17,!7'IGWTC49=N<=)_<@[T\O(K[W*N4Z.F&J"K#Z3B9F)X=E 9CK'M
M0=!"1;(FZ=Q<I_<V>%VPY=AY5UKMPJ_)D50T7\S.V3EDR>9%9K9L7/%LBVS1
MYW<@[\9>3D@<,FO'VX2D-_>S'C]6-'E)7_R@,S^GDH$;;]6=A/V$ZS1"LSVK
MF5C[(>YUM:HQ<>H7S3ZEU+L_NU6]=?1NQUA%?)P%X=%2,^N^5G5]&E&38*$/
M"V[=/N(ON;?G;L(O _C40_;J.94L6?$2;&JW,Y<#WV4C'+5E@,I #[*R!F12
MFHE!A]^ILX:"LP?T4<_E\8F@\0![A T!D:$$)'JY3K9(X^\D82ID_[B>WDE[
M'7BGQ.$<*JVKE"9ZE3]D:*YH;#:#G7U]%#DTG=UFPXOVXV'"G"X=@L0U?.NJ
MHZ964G5^Z4DPBRA>D752^>E"7D0HQMEVP#ED_X@KZ1?+K4]-&M=GW5V)7-J_
M$CUM$/VB#*TL.G@ _-/:T<*"CXXF:>2#IG<^^>2;J159=-1H25\3H*$YQ[,G
M$#4Q7V\./2W#@8]:+S/H!!+-=&[3PRD08]UZ=0S],G>F3"?EL&H_^!;A"%%
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M.[2ZPM/Z[.V)2=0L_=WQ%Y1./Y8&'W5EC,QL^J?8J'.727\MX'^8$W4:;NR
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M$C3Q1*^%LB\-9\SO-TU;3X*XI^I_>+0QQ#]+02U5 '#W(F4D<!J"=]4GY8B
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M[7SO5)3)D[3HK/>$O$WS09+_,H7CKT2B\ZM:[.O_6T0&*<R<*=T DO0Q&C<
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MK6B2::#H2G8,!?VC)7"1/\A<\M(F<*02^V_R.4C1B^*R]/(MB7ZDC?+>Q@W
MX_7./SQ@7@ANTWKFJW<OMP>]W2UM+J5T/ZK_+ ZI@E0^.)#Q'\H;7PYH&(.$
M.%[+0#K!9,;?IR#\S]*8@7OB@_ER65$VRLL&#.[7@ZN/QZ 6&ZQP\KX<GJNN
MJG9FA+\8L_"K.<%*J.Q5TYG#J,DR(;=W^MVUKH@W=V4OV[<CKQZ@XCZ>3.!A
M B;4IP6OQVR=@E]ZT]J="@QQIYUR926IL*A>:CD$B,S6K]W;S2%!U3J=7;C6
MV9=I7L=75VCBVK#=@W? 5)M;6J=!/.V-ES3+"?Q:X&;IE/[W+2S)/FZ1#W$<
M_M=#*SS;\@XC__"?#6$L0*7.B9"FUVC7W"^.37+29PK5:R.US[ZL'O(#DX;2
M$'.ZG!_-G?<]+[^T_][P[EXCQ'JA8&?*D1YIDESA[L#Z@1O NVT&R_JXQ_-U
M@BX^:P>IZX?DO=[F"DE]&3F9W@46%O\/:>\9UE3;;0L'$4%!4'H/2+'0I"LM
M($H5*2I5B$KO'0($0I'>! 0>02G218CT'CH107J1T$,O@802(@GAX]E[G[._
M7=[WVN?:O];?=:UUWV...>>88W;+L#:+7*FNX[)82TCZYIVQY*4X_15J0# I
M@)J/N-0FNOS".UL^6C1*Z" R9-/N/27:U[TDZ&.]N\%7,,=<#%<=1[8XQ<8+
MJW[/9MQ+8(YZ^%9?<+UE^PHDIXPH!&$SQ5F55<PC@Z46ZWHPK]WT9[XT?=3I
M]THY,M.RXXH&27[UNP"C_8C=(^#WV6WS(_/4^=X WOKFB.!FN2296$!FJ4'*
MK941DT)X+YRJ'[TS?#69V1&$33/O<+L]%C*1ZQC'/XE26F4('+C(H4()+@BV
M5AP;Z78@S8B+FTJ_=UDP G3K;ACRP_"G*UN=ZZ'RK5Q+/ P="*:Q5L7"WYJL
MF<5=8I@OOG0O-=LK I([V*> "4#@J !-1*\<Y.7?VRH8XWDG,>9N^>Y??W<&
M.'KR3'[;YKW[Y?7/[< ;FN:XW-#V ]-V!PDBI\LYX&C46I5W^7\25<#\YX#.
M9Z+'^HSDX=CE8,H7J0-F$\<TL[O?4SG1\S<'PZK&[NO8' TMFI^.G>YQ<06X
MB0N9\D4^3=7!U!EJ"J9M@:6<68V@C[#ZR2JWMPVK>[U?X\WII.G81;LOC5',
M%/%+GP->]0)\P-_;NW.9H))GV5"A0DB)L9[Y605YG$MC<(!9BA&'; J]?>VG
M@H?&%>=-SC45YEQ"/2_#Q3V6S27'Z&S_WWM["7%Q-'G90,?][2GPNV=IL-50
M"/B,.'PFFM-F87 .2*;-/5U=_#']@=S??J"J)$$^VR!GZ*ORMOVO+!JLDX*>
M?Q4FBWO<H42WHZ8[Y%7$"9W,*%KPXG;T4]:3]Q:.57-<6J8K'O;I%#] 'K[#
MYJ>SRWLY*/WP(PMI?$*W2TS(1+[M#V /!1_PM1ZTC*CEK" ?B7BXX)0CF//D
M.QF9="=KL6=T2UA4;GTA>Z)QYY![R61R@;HY_*3+_&5OC;1%O]NWR)+#?J,'
M?SK_(&HIVEL."N<))BRX-*0)Z#J9<X=\JR9J(6B UBZ5IO+J[P-KFL;+K .O
M7:TL\E:GAQ2 F(@5\$V(?O> ZY?-]X1J\C9)[_K$<^2U3H>,8?&WXH)Q1N*9
MM/R;T@DW58%O6!^B:Z &WLN)8'+K^@407(?BEN&H&A.<?0^MJ:A/_,UEH%37
MU+:V_%FMOJ]# \WS]=DZ72J^RJ!I2_0P:GRI#9%<8=J/>]YU-?"]'JW%9SL
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MJGQ:@_=R%"U X\7Q#KCPUVR#3/ >K ( _85]-+Q"'=9NWQYU:A_=*KE\]NA
M[/[U1Q*,3N,SNFYS+D]N=HKO71W2ZJ,V'SW[X-:J[K^RGS1&J$3JC_NNX_3@
M*#&?\I*F>GU"NIGKC, 7:6B+]L\$1LVVX!L%7K@.E3HTF.(%K M]EJ</(^C\
M'\:Q\L]CZ0= '8>7]-:KZ&2$-(1IV<(<G@ %?R%85E:_MC0_5?3FX]'9%Y"Y
M(#I0W5$94/0)KWC2*>T\GZIP./HJI::':62" #W]^KTKR@Z4L81.;XD>?4;'
M1;K=5V<YIZ#:G0/DJ*B46DRNF4=_4F?-6"5YE%%W&18:(F!Y[R<'?T/- 2G#
M*TR G8.=.@7)XKV4&>8NH\Q[TJ.PMX[3CUDC^AX^6&?AH\FC_)YT/TYU^T5.
M<0W,:?[1BCZ!">W@*O-9W:RI-6*WW[UXMG;OZL.YEVI=B6W!%\0&1NDNX8Y@
M)"A8[#A@"EUOC7Q%\GLV]#]EZEA-X#8)L'(G*NU([8"IH;?LQ_:/8C&U+<YF
M8L<B?N%ZHSVESZ8H(QHBMJQ2+D#9R"Z4->[IF!L^C\:7@8!M.@=4ZI$2 _1W
ML\\!@I1=YX#]!=B6S?&6E<#D[I$E(WZ/O"ZBJ(5V/1Q:-O2Z+Z7?Q+*:6[48
M4_O+>@D4O5R%:&A)G=_K&:#+'[29'U1]L/5>+8_!_7_CPE5:^%ZC$M-5VJ\R
M*::F-$#GI?3N\DO!M-_^>0Q_A<B1G**M7$T>C>PK22@G3G[+\)K;'IV_^L7/
MJ.*=A=UENG- T">3$1##[G-]K$J\,\O&[)BBC:'7#?A'I $#G\E/,-?4,-H_
M5G863EN<C_X-JEJM&RW&AI0.L!07LB<VT%*&TH04ZW_PD3U.#G6M4Y2XLCEU
M.B"RG8+J:Z!2I81P'^51(GFOCJOP0ZR(JE-O'44EF*D/LIT+*--ME3]J708:
MB Q4@FR EX>7@RS9K9S?M\JG+LJ5\9 E[%)?)MHPZC:L&YN^O?S:A@_N^254
MJ1(XT] YM:!2C;-M]<^8]BN_8<%>TIM=:_!'4@NWDF&*S=NH\T7<P2Y\@,J7
M-XWMGIRE6J>Y?21&YZ2/3X'C8*MFD^> G2'W,\ (]4<RLOW Z1Q ,WRF\R\Z
MJ""J .K_RH+^W5GT:1Q7D0WDRXI)S<C>VD@%/V*2!>1-U;VKZ>Z=$@>8IF-0
MMS(DZD,.+0@!6.<>A=S(#([6%U,8UG1W<5U=CVX:%M4_V8*>'<<"%3;0VX2S
M8+3^.TG(?A^G966DNQ_+MPJ,T"'O4KVJJI3V6]6EH-,755LG?E@KJ YNDIR;
M/Z]&R:-RW<@@(_ Q]W*N(,/])+/8'T,/* &4&^T$P4(K.7!$B%!N;^!;E.,)
M9]ROXOD'/0V _4.U<X#ML_GV_0LN*@=5F H1@%HY'L4*!%E\-$9QV+Q_)Z5Y
M0US!AUT 6W8.L(;%WH34+ &CCWB8+,>.75]^Z+WE.%;>]BXHVULOW"_GKU.B
M217AG414ZY-E$9'K @9-=>,VZ6LY7"8IVI"X/5%JP:I^E2.*K4"HF.L;5Z9/
MS1JEGN-\KR>_QLDMQ'7<H!EB,#S^!]$2SG%6HN2[DAQ%9HBVPH9ON3,_?T+U
MTXFK^FF-H),)X&CQ5Y L9!CC?7'C]"_R"?@9Z!R@RY_'\!R+<O+<K"\PD\-\
MO0 [+>=7?VQ;,,-.X_\6GN["P_J7GG]]^%XKDMWF?F<>0W*(E'FWYTIVOY(2
MU%*N]32QLM,=#_[>L+]R*/4TOWYW,2TAJ>,(7GE$6+7@@LE?4N/< VQ\HION
M =[(.5$CU'WKM5[6,'/QC6?WP0BBYG^BODGUW\CRO/<)&C9/>&"9*P^8GI-+
M,)^Z87V0U/N'X<&2I^KUB3H+9=8^BP%BJ0OF%D= B4=,P5Q6_NU$*.B:J>*.
M,4U6-"E0^A4?TSF@:?@7P20M9#KG)NYV@@H+DCIJ=V6B4LQ71+<E4<4AH<R3
MSKM X2^D.. R9N-!G\@&D O*CVN(;04N'\$HXD6(\_26\CKUX\ON(D]:Y.G(
M?A9B %O;U90$ZSI \+P]VE7 8%)<9L#UV52PQIQ;UM3#],($GWX#KX=PL;-J
M!M+;Q9YV(J7>F<B "A5)&@>,)BMNGY@G1PO7-$8_GW+;:WVTR>)>42G^$;/"
MD-#^\^>LEQ\&R5X2,F5(L@6'MM]\5N*]9(R=&5\_-!Y;.++\P\%]UWZFG7TU
MP2Y4I3KZS!S6?$\GG)+82/YK"_/\OZVW7G+C]C8[7:][LSPOM6(X45E04]U@
M>?!+X#45<)!(KQ<@7D9\0;!0)X25$O0-Q^O*1<HOFY6TY.I]=)V2^V%&F]YA
M]"+4._R)^;A/T' \YSL5(9QE^1:"O<H=I#<JWO=KU4M<_,4)<K!T3N)R8K<,
M!0Z(.5X&TY(<<&P1)/65ZYY*MSG:PX>0SQPX]M;'YZI2UY]Z1-P#6 5[#U'/
MMP-((B6;YP"&(Y$*Y2P+UO&\"+U#+F]-F](O0K>;[C'G!A[D)N5>V25+[ISJ
MQPC'L8M:.?ADN]=:B"B&O_H3>K/CZ-1D-(06NQO"B"U._O)X=F6\XE:=!B7@
MG4&;HD_>M3+L?G?5SN*L<Z&%<'GCP^9K_GO'0\[_C'O]OY6+(.T^)HDA(V @
M]"&V$KG+EL/_?=0WXW$S$)5APF010WM?U/S!C-K/G)*Z(*!AW)]L?!\AO\A!
MP34Y6E8D:/-+4I"KN>.>6*&>^"FS/Z/9+Q_-#]FA'/3=X2)24WWMN]EH5P8T
MRW0BU+J04/,,]Z2OPM.I 30C5]WKZKZF\3-,]^N>(*,V92D\OWPC>>9*KWT5
MSCYFETU[' JJM-)4^9RWV3!B.>N(^_J=3^DR,E.06X*2Y4B94HG^$/\E"L@"
MR5J0N#YO"?'NQOB[!GSMEG)/0L^8_BB^I3:3CN)22FWUYQ[Z3+1]M9TRZ_@>
M(J>&QJ@MI3T;*VR^]!!3G"B8]%Q\,7/-,Z5V*6*ZX@TA#2\RY3L<DT7.=T5S
M!2L^FI3E47^1H?4T?-N^.>J%W ' 3T9GC)J2XZ>86A&YO_V&S&==79R.,^?E
M'-%1E0'[DD>CO_#:HDMQ#\X! 4/0[JHD-<H45: .29B07$(R)_CG0UJ>)IF*
M'EO8-FK9 90"R*R= @([5L%8EFB2^+]W9B9AM.3^'*XZPINEQ6L[65%-GA+1
M+HG5<XZ<:WM9U1F=;P?<[[FMTKD-*?I^:Y]1[\3S4N).D*X,ND$SHJY00R<!
MUT=XY_XAS+W^I"T[.[^UY 7K,*2:*E!C])]($XSD=<PUME1Y!8@O33M]ET$T
MK=@G(K N< %@*"SF"D9**HA3-X:A]QP0-W7JHJ89 >7>$=V../$W#Z,R5+[6
MA[#3+.?'@%5@G<]ACM>]E^!1)+9BAV8;Z6'_,O6R^-E0G8+9'SPWZ-^EMFY4
MP4M =HJ/(Y9,WKFI='H7SX/-A-8F3#X>#NY)]3T*$ U:#U5^X;-C94U4)Q (
MU,ND3%T["?-MV[K?8+L1M8=##" )G:. /8&:<.T2WZ0[$RTMGZ@ 7GH![CW7
MZ4&Q(5R(M@FT[:BK2?#G%MNG\/$A%^\$&XH];U2HK HEY(CT"'O],ZZ&5<]-
M97"T?)_Z-8KF 8_JKT!E+Q@=5+*88-)Y:EOYT4GL3>KECQ\D78=^7E7*69TV
M4Z7B'W8R5\>H\EK@O%?VTK$P@[%O=7K4X(FA8K1(@$^+PYHZ_P,:7:U&4&2@
MQF=?_ Z[^&4CM0T^F+@!9:6F!B 'QHEK1[VVVU_NTP1B4RW. 9)6#6C@#=._
MC70GZT0BZZIJ8P9$*ST S!1H<'WJG#.0AJT[R[)6(3/&5\SD61"/L".=L_^J
ME;I2Z2#%O9Q7^AF='</41=ZY5;G1LFV/5L"$Z*#E-K8N3LV8O*B% <U1>,ZJ
MANOZ9T%_,>;7C/IJ.52!P.X*>F+O=.8YX&;K$R?\=.;48)9*KL?]*58;6^WG
M)S:>X3-_HG2P#TK^4SVN68%^XO_%8^._J B:?G9+WPNHJ$5+A9SPW.N5;%<R
MH.[)$3G[B\P'M<'99%4@HI<7(^P48R^;3V4J9:(28AM):W(],;^FRZV5]8+3
MEH.%@QE4QX^(%8\LC=91+'&Z,WV\=I3[P, _-2L-& FT>QB8G?>J3/_?%.2S
MK)#<E$>T\U7*Y9+/$W9WOM.;/V(V&<OAF4QJRO_M1,4JX'MMH$Z0OD! Z;X@
ML#3ONL[=(L2KH]-)#MD!&M>>,?"L)BTHH[KV*W/#B7<.8H(BWRSD[CD@Q=[D
M@F$\;#^B-.9Z46>Q5B,O25MON>/>ZBZRS5;&8M'+<0YX!S89)OWY=0[(XP0<
M@O^SG/Z?T,CBJHX\*O=FYY_MCO#8YN'.<T 8613G%O$V*ZFBV$Q;YL8/J?SP
M5/9D-&7E:#_<:"X GH.X"^DF,\%O6JF[%X.=%QBQT-$Y)^-F%S$1)_EN^HQM
M@.*D5$*'#7?ZPTYFBF40]JFR=0^( P%$5*P$/XPLB5Q0U&>@Y$BZ8DQO\_XN
M<>A^@7\!T/QT=J7WUS;T(:)V[$2[;)XECH9%77KUX'YP^0#(NCWFNCT1M!EH
MNQ'MJ\Q[#M"/%?M2W]I@(_]LMBG&>MTP26MKH0TQ_'@";78<E'QKP]*FQ_"'
M?MJE<X"GY^)DR^'0'4IDNS7L^K;"LS0T;9NZ/E'01'AQ=RS *7_BJKPU[ZK)
M:)MS"L$Z?X>7"SMG;O=-3-<"QX3*^!,F^&F]>1M@_M\MW[M[CS;^!^9UJN,K
M368'RYEF*DK!,RJ Z05SK(2MQFX#C\\!)>> +1O9*8C\BGVX"K^SB8)^-%2W
MQ F56 _="7*<G)><YN,^@C.=?5?2KMC)N35"YMQ"U<<N$Y6?:S=-%T_(1O&Q
MU335W66T3JA* V$Y :=9<4LA5(0#(AK<=<;5HQ W6X$92;<A"D.+[XH@F[Q_
M8X97+(__=1""Y8=Q9/==7Y1703O//7/GHXV+B"!G05(B1'BNE,))?*F0VX]U
MOXS#7%Z=E6JU',R*74IPX^@.F+-_\* W&$AC&WLY@5/U_F !Q_$##%C""<Q)
MTL6>K%QIR=-# ^D7M^3-$T1N(I@VGAU>"J.KAN^MB Y>NL*7^I/:$&R@SN]@
MF#2F$Z[CLX4*O?VE\1P0#V04#6&"JDR1GI>6Z]+G4BIYW%YH_(#CUMT>6GL1
M]!U.-0%RY1J 46\&DJRXU+D<D%938FOORV<M BK87W"L'22^_WOBYRN<\ZP:
MM#I%%CH'_.9TWS);O$@7'7:&@5"-MM'%QTG3JD$8]6?CQU29/JF_'*4UA8^'
M*>JEZ95%TLXJ592A<I/M]NTQ*)[D'@8ZRQVCK1H+X>PK<+>3ZW*J!SUO3EB'
MV?L<*+<(?^M>O^0:=,PDJH07_^=97?8E T!@H EH18+;485R=-%P<@]:&C;+
MK26O*YW#<C.HZ@'ESA 5].+&4@'.FI3TB#(7N#\<W2HAU2^[:Q4\P>"4"OC8
MT6E[6_ TT&04?%7IH42,C#(3VB3)E^98S.GP6=3>C"WXWNS3.*WN9>L'M,)<
MZU[R7AJ>O8"0$ A#5_-&TCE@J: ?K>??4X^O!SDFG1#E-@=M',BO,[ZUR$6Q
MBVIH<7!_PIUZ=9("(*KSP.B*66INKC+FHW. QTT"&O%Z[+@"W NJI13,>#=C
M-2\J-<"3U?<+T ]\8*"J=)A%5*&Q;HB\%<OZ8,3UA5IHGM^ET(<P5@B+DB&>
MBCS>,EY0DV*7I&@$F&MC6$ZS%/LDO$!3X,AI%,<6=+:^4G92UA6F,?IIY-*_
M!WQYT)D3P/?^)Z;A+2L.HG;(^'OR</7FS0''XOGZ,M_KW]FRVMJR;W\4[B#:
M^BI2K.7NE0YI]9HU$/HKH$91/(K+F*+6FMK7BX1P;597E1\YY<QQ.D/G@#U6
M2J"\H2HOJ^_^I6343Q!;<O0I8=0<O=B] CXPV8VP"*I/M &U#ZDX3/LMS(M@
M?O<QG .L$#=&5'@=S.4Q$M;+M&U!?0K%R==[ZQMWQ!*[4+H58C.9GKZJ80\T
M=FIMXH@]]^>3_Q:B___F/,W_Q_Z?:;G=+*M@=@0GH0;-VT35:J6<W!5"[^P;
M96'AS.+<OR$Z(Z*(8&9! 7X'7&D+>_&:V]OJ*M'!,;,9V54AHC_FJ^UCZ;;3
MPRKI.(W[HM#M9=9:GP;ATV!X;I91K[ 8!JK9CX39SPL8?L=.S]JF&7UZM3 /
M?BJ8$0  2?(!%'( < -X;KLMB!&RC=]'JG 18M%U./\8DG+0]=9,/_Q]"XL[
M/F\O6QF)>S=\GN'#]093J/X@*,/.?)HVO7NAM+AD_%^MB+/\8ZTC"0Z4^>_-
M+!5XR>PF=I$J0_=WFNB!>LLZ7_X=K:W&N VH8KFS0DD<5!I+AK$2(DG2:/9O
MLLJ/,+[E85Z93!:]@BE%/V!2LJ(]N\: *QWL>0RC:Z>K)C$DJG- :B]1#?9[
MW/X<4!S/N4JF)8]IYX<,GP/H??79S0C9YI.^KO*#SA5 U=:)AMT.,?YPN6O/
M-*03EE;R*QAF='NG<A0NJ*>E6]>B06U=,^Y)F9:O+H=+)9M;NDV)C]37YH,2
M#NX$WJA0E81_5*0JEOQ3=7;W"-FQ<6H 4-FO\.95PDUFAM;*(YJO*P\TI#G:
M<PQF2@.;0X,#<SJ8P"J.YFZ?L?OX9!P"7@XIMR+WCM66RM[9=?-UCG7MJ>[G
M>UW%QE]3^T;U]-HQC()@1>SCY4M&YHC42UHQBQ0Z&ATT0\5(3P(#"JW%)NC"
M0I^I*JFO3$>= ZJ4I)?;&2$HX8E6_:^$$LU4K=9\03EC]!9-?;)RZ,[9NF@0
M&E$_OO<E^VFX#UCX2L)]NA:_!!^D$XX!-=Z%N(?SBU@NMZ1\.>;S@V_:17Q5
M(5Q149M[NS^QO?N]M.5>KES9"I>63__&N]G9K\@R*[,UHP#J%_%*F)7<@3:
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MG+N4?:5ZG'-GMR><<7U;&[]2O7^;,B>\8;KDJ0&@P%7L'S1V7CR-V7X9*I+
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M<Q8OA)4B!*F-\K5-B?G,RU'7YM"XF;B2Z(B#S]>T;2]_LN;1"Z9N-&PTH,Z
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MK]@]1\Z*RD(<7?.L#G?IT,/>U]#7A(+EY*B0FQ/N2FJ^=AN[>Z..W@H?W6F
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M:\L^(!G8IO/_.%N*WBT02_+; YJ?+K2"\;]2WIREDV\K?KJU62,-?!,'P-/
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M5^[V)$[#HQ772(E192.!B%*;60S)8B0U7KC,8:?DQS=ISHQ:2DR$Z0:_E>1
M N43K'M/^7R0:A@_SBX>QT1FM)8KJ*3MKY0IK#DH_&&ZZIK0$O?Z)@KQT3T\
M1&XRAG.Q%^.V*Z\HZI)7A?PN^?H<8 [8A,(N/B5P.:->)OG&SEW[4O8GG:$"
M#TW[.^R0JAXP 4OCCRNNE,:CN\<BKF]_ZHK\8%SG@!X;C%9'&:\>\<5A=?=G
M3'JR@+&R%?I=.0^;;:=E5L?W+[B<0([N'YU*LF'AW(LWPS_O4_GD7#]+)+-#
M_+N:Y=++"$[('C96.8]97<_2'N'#.+[GZ:\UZ*63/HU<-@J9":&M0\1CS#5C
MQ62T925VTW&"4]=DNCW#/==CK_91;+@Z_R*:DN12K5FSO^G"Y^YV1NO6![ #
MGZFN-YW=QDMC*Y/]2]2NE(7D<'R?O%+AOES'[V+]X1* AAZPBHL[(09!7%^;
MYB>^B;QRZ=820UX>0R*9/V1"A7^2+ AV;/:K/P?0R2CJ\4NXKN(THO:%\R4=
MU6[N_@5HOY5<)ON;)#2)4(0Z$*R7Q0*)9A> '9XW*5/NW(08MA::'.Q=,18M
M_!'.Z/VY4$7!YAA> *\-XM&>K-RMV+,,Y+"^GCQ4H<[XZ&M*WF/#NI>J  8G
M ('<C9?&Z8UMGE+'^/ZBML 6Y<983^W9N(I]F1 /K[+F>EJ-I==70R$^8_>[
M8;008^9XG1%1L4O!TZ84,.+F6O*&Y1-FBO0RB+WV5)'FA$^+R(9:'>?ZO. ]
M90J^2:*%Z3?,&,TM+?X$5ZT5@Z\%WP$^+++_6/4S]3_W\ME/NB 3L1>GDZ1/
MU'%2\/MHZPQ;IES.OLO)8^(_$S(A[M; @M(<;K +KI\>CS]Y$B"!D5[1,^D@
M4XY7UE:\E+GI_\W<=,$IF;,?K^O('BMT;8X1P,[RT=G:?ND<$"GK?M6Q 8^J
M_%BP5:S]$FTI9$J]M">N+?AI.M\DB\0R(79,RZ.=A\/AELQN< QZELP00!+]
M2.6 ([A.GGW7(JN2/)SD0)A!!TN2@%\=4!H1SL&LD3+&.K<FZNZ*K296VF0J
M"?>EJ';VO_?N]2(#L1)QM<-L!&ND-('-DA,4C1X_:IF7=/DP-Z?-TJHM.(IL
MH0\+XXJE7H./<MZA7'=_!Z(EBQ,TET#=OZC5<.+1RXH8D/Y,*6K'7#0KGN,J
MUZ,/C?%VHY_"Z;UG6;SQAM731^< (-0WHI>S**.FLB1.+&0\H,1,MI 1N%LN
M5?3645 D$J6"Z[^,^V0RFGX(C"0+.RS2D"R)FI!,JX#GS^IQ+^-2+NL)M,BE
MO65Y^8)16\F >KS6Y#U4Y*Q$B1^G^V+"I_'71O1Q_.4X;9FSP/EOZS;O)8V?
MO+_[YB!'PWE<H[U8#H2V=]PBM\'Z0F5*2\UM3+.,M@4,<Z4%V(]_!> CB(](
M<CCAHO(M/*_LJ&WS&-@67;=]^X/:AE#,9;\?Z%!EWK@#2W=\+L&[T,W4=VJZ
MD)H"JNPH5T* %8A,_P#7@3$SN/C.]AO0N[;8Q0[SVD"A4:JAHL*'KJI[R RI
MH@+V4]XCBE,),U1E2XF#ITQSY%G;)QTI\X!+YP!I*^5B"'B%.KEV0/<SK!<%
M"U]JC!0,8F PCRWDX+@W]C3__>&DGFDTWHW@6_0S,^?>(=3"BQXG$0_/^D-)
MOUE3<\_Z+.<#Q0&<Q%R.S\<Z0^7'9?;I+6!=9E_/JCXLF@\H>6XMN<ZQY[_*
MW'Q(9K(:P-*[Q[1SJC 1G$[TDA:7@1%N8@;(-TY6AX:I2G12>OR71(\I4@BR
M\427Q=\[[0P^H*L0$].JJK'B+'7OZY\_L$DNRS'/-MYH%$)@ J<[]3D@L[U
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M-'^/PL4_P&H%G_.&1+4>KH ZAEDV3\62D\;1PD45D,RN$^L78;XL,S8] OE
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M84,_O3^>(TUW",=Q#9Z%J&ESKN=X1+ .OG"#JSH3=H30?_3:A(3]Y<?%%6:
M$C^&-!5P9B.D!UJFV&GM5VFRN(B"F-?4$>2CMD[#P@^@B!V?!;N9/FI%"HZ^
M%5V2^7?ZRX*^[IYV3PM:LBA-34<4'P.>5+4A_Y]CG;\MO)];=!59P4"LQ%AN
M1(9OQEA(K+S$[W=* .\2T0VET\^#EI4^:?HDD7CIN,RRZJ S36)==P=7<[2:
MS==^9Z?J",=O=MWT%8#M&:QB3+#B@'8  (.VJW]2W ?A>XJG//*]QE:.)4#3
M42\W^V?CBTU)P@YC$U,RK&0O#>YUQWN>6V',OT52_&M)*:--D_MI!_#.2--6
M$:^ IIT[UR"6%1#1G:?P\+4)^5J,E.MVW&!^I?E;",>7E96U&]/+N_95?F%1
M)2+-^-(RJ"MU;<8OIV^DWQUB H'IR.PSX3^G_RRPOFHTE#I[4C&,%*OCRQ6>
M*T[>$MY;>*[[J[YE'V1ULZ;4(N-G%F.90J1"I*R^!G6E*0^-MWP%-E -<E1*
M$'G_E?@2O01C0XSJXR%;/6S8K:<BSGNY,;,A/0,@DTEBB%]W&%(SCXC1*A\_
M\)_RYI79$TZ=WZ283<BF*Q+]2W6[H>BHP 9B2O3-1Z ?Q^[^)K"5N>7,/I_N
M^CTQI 3WY>9E/WZI=P5P:;1_-.S:H)HS[>SG7>F3S'8OM['A9BF;TOB#PJ I
M ""+]DR+6TN2!9"F]1 N9YX\,B@7Q7)?%/YA@%6#4^CLV6$WTA:?CHEMXB1&
M/6HXTZNNJXB7F?XU7+_H3IVT4L3$$KOX83Y0*8I[D,:93W&R2=%PF5?Z\B8O
MY$'Y\,A*M8!V]<\ZA\3^ 2K)^\_MWX<EIAZY_6)7+]K;Q[$'-_A*;T,6C6BL
MSD$$UBM V,&6>'U$]NB$T/W9J&GD!PFI+5&J[+?8F/C#4^=O\\]=K-73Q_NC
ML:ZCCTJ/+,CIXLMXLEF%WZF\U3W.HJ>C48BDU-37H'>5=MG'1(#4\ $+,Y>\
M=HC\)R/GAIB-?2QVVDADU^CS+:G%=,*7935<(^NIYV@C$DKHLQY5,SPS<+JD
M4&'M"LZ3J\;F5>!TY2"?(::I]]KFI^]$WB%U]A'^%*BPK#9$.8*F*SUPH]0:
M5:-T*\%N^DV&5O;IJ_:\Y%?Y)\)8V2#]:UD\]:Y-U["=U.5@,R-C$-H%'3WH
M]C* +=.?-Z?7UX<WI/VCZ4+#RWVF=THB !)LT[<L4J=LI]QO@6*;\*.Z)^F>
M_OXJUM,S72/]<F$TX=E"B7\ &*J)!G_\EC5A/:1)&M-AR RF)Z*Z389R$U&F
M>G\SIEL6,FBB[+L8X#Z=?IF=]7/BAD1'G'\)3 MV<\-X8[_7(T<'=A3:H/'/
MIT>(DRC&%-Y]NXQ]R#QQLM5G7EG?3?_1I/3A>,;9=BKY##TS"5DO>6T0[JD"
M_)Y$5LAR*N!";%0>(@DUK!Z3D!*L+_\9X1"*2'NG&RU3S/A6DQ5VHZ'^R&D$
M)B<=!*+YT3B:.U):<C!EGX!UZ O^@>P>RJC=^6)1$/L1X,;BH:^+5@&LGFL1
MP&VV-R</&AFM)K>]YNR>J;H6_Q6F%5K/8X%CE(B,N#@R!,/ Z))\<\Q!([2S
MSB#E#FY@=N<C+'V]U>#+"X-L3+/?(MB5K'+<.P:H786?S[[3*+^6K@:OQL+2
M^;)9+'[\<K->>O>2ID=8^ =C2O3^,Q3;"=:QNT_<B,J*V*ZK_WU7A."05-I0
M/M4Q(\#41WO__INFMVKE1KW[]J3\0%OI.9ZU_QJ'_[?VE%LU+!?T,S/"5F&T
MB0?!:$L 8?Q2?=)RIWL]Y<?"?Y>%\#"S,/MV:VKPD4COV$-A9[YQP34)L]96
MU4'5TP"+T+63ZEF8$%W>E*G62KS>AIWQ7^Y0L,KE:WEPY/SMB2;)00+?&NX6
M+L(;ME.=9-^!=MY'SOZS40/''W2S7O"=<Q%#WA @2[ 0)"1_OKL <CV,?KN_
MBO[6\&E&BB50@X$#Q4(R\^\6$/Y1!27-$_H\CP[V.>@NO5\U65_D(,&+1K=0
M0W:,$JC;FMFSB(#*K:[[6^Y1%/BXRM4>SH&[I)MW/ZFL/K$HXQ4]/%DN1(VD
M3K8N!->9903AQ-/<=&ULC/(L^_,ZW]:D>KU[D'V<J.(&T/6H\>2YF*4Y8J2]
M',I0G@1).($H/[;R8-LA4"8;R0*Q.I/*6%_%TUL""?S:OH ARO$QB]_ "G#W
M-?X8Q<&CD,++T-44BS*^@,:JF,8BJQS5<'*14','=:4DXU/2?D^_XQWIY31&
M/MN+C+]=NB\)5$.3;>*N]-,U4DSS)V&43I2_!;E]WLL8L9 <\<HW;BW;38\>
MQ1+#<%< (()AM-.Z,3D[EUBA/_;7=![;^@+J[)8?P[Y.N4;^>GT4UNC5S-RD
MB.AK U>NI2^)IUMY+5!O%B;702VQUG,][GS 1I7*/AG NJ"+3#R%;F\68\&'
MI!^:/8<4:4)!SY+=@L\Z)M=WV\#86UT9 'Q^\.(X$O+FNY4+&A^OYPWWIWNE
M6\J/: BWJF'F7K</?O^0)%9<L'.A$AYS*8+D##MS[.2R"$M TVZ<?IP8L;H;
M8.O<D( 3'+^1 O945V[I!0"S-6ND_.)</EKT-I."E!#_NER[TB[TN U8Z52F
MABU9K 'HO7+;P0XG\M*6U1H<7HP'O/Z?"V;]=],^[[?X65'S<\HA5-G \=VN
M1J=1P:!?V<2_P#RQ&$1]SDB(BV%U6ZL;J3QQJ*ZIS>R]]9ME)UKQ..(/Q;63
M5X'T5P"W?M)N8%5-#(H./+T#+M<,>U+_.=K4QJ;#9W;F'Z%=0;K-OKADA<7)
M,?GS":0P\01SKG2156D4F6)1X>(WUY0'@[F7:F1 @^ZLUHIX<*=_6"#+R.&Z
MC$/*8A[B,/0;*N/EO;S5N<ZL*R:_*%:MF)0HR:*70IU(K;^FSBOGQ,RQ?F8P
M^ZPI%J#S]?NS5<W<+(KOO9=>FP8DV.1 &LR14\,^J)/Y0V4/BZ.[9_2I6>3=
M&QP"D>0O69PY?"1: 9PB/X_S9<D7OZ#DUB[$UXSB)LT5P7QJRKG0>?'QAOM+
M&W+*:[YR,R>2GO>< <JVQ0".W9% 4-IRKFF<7EE-G>)]JYG.M[.?DX49/"?7
M2-4F6VV%+@I!0D1@*YC!U/Y[=8GPI]JF&VW*9#V.-XL,1E3*T_/!_/:SR]&G
MYBF$>ISD8'B3",)';X1[EWR#JV3+5L_%5N%SJOD/TT)JUP=#/P$\B\=R)(<?
MV89GPFYJEU&XQD=%9ZSEL^X-M@!C;=4(CMN'R]),4)\$%[Z[PW_70L=*ZKJD
MF'1NB0.H*<F_'.Y$+J4MIW34-W(-7H],.[;OZFNY.6W836=-\F8LF2W2UO:M
MKM0<L8OA+NG.VLZSI_JC2W70W(IJ2*B07)L\@]Y6<I<>1IDHB\,P(1(7QZSC
MPJ7-ER'1-EJ2*\:^_I&JY&^#\P$H,P(L]-QL61W:<EI5LA#GK9]<36"+\3JM
M%TIAV^L4*F-@,RRAO?]BEV]6E,PQ>HCRSV%C,9NNZ3S5HJD^:\R#Z(QU5H6E
MVNC%8TR$T$5! ]S1'N9LKS3A?0:Q\8.D29<O?9HI^5DE\F/PLT"7;RG$B+B_
MW$RV::M"\"0.P#C_I-X<O=/PNNR^CDJ?T_")QR/9'R=[C_1X/32 64USZH4W
M'2F_[%.9.+ZLRIDBO7<@,O)S, 1N79J+W]5LG!3>/U2M?^DI[CH==R_%K-M5
M_.ZY>%$6S5'U6ZO2&81]$+6$N3P-M;J?6>IC:X!826=2X^_6M??*5L\*9/A%
MG+MTU&N!2=8Y633)7&\R4J.K?7Y8%_%\H'NI"<IG=0UPRLTB*Q"JCM3_F(33
M_L 2XO/\!R4GX/)&L:DQN;^_DL1X,H=]D%74O9@;[XV$"//%--9W 3G7H(%;
M;^S%0?Z(,;^U]6-KBO_[HK5!Y -"5Q)^M.5T-_*P]W68[G#Q:E,=(M$_?-FT
MO\K_"VD09,<N'8VW8HQ5 /$0]7*1,N&=H!(<YW)S.JU* ]NP7I+'WLZ+@>)/
M ]JR&GQ+5P"R_8M<Z69GZ?>>FUQKWYT+$&F/FQ,&MGI)'/9D/PDEZ9!\H?@#
M4'U"R7HHCV)'MXJ"5$3:,-@'ZJ1/Q]Q+#H"L$/F(&N9"2$ QJ].;-$^2O<)?
M67N>=P!KS5[_3J^ )&:2-1V&HU? $;9Q337^E<(&XORS5)M4AR5L0 7H_G6[
MQS<VAR']OUMA'UX!:$$+N.@]YWV(1C]*X'**S]DT6Q4T\'K0+2<2<,&UJ05J
M5M^Y D!A$2J#,6HV[&%I3QM'*B]$JZ"/QKQZ7BK2TR5(E'69:BL):)"TU7!V
M48D4$3)W;A)N[R^A/A. #\:^U>#[C\H\/5DK%?X<IW"91M!1""=]T+\WU<%&
M^9["B70'*[Z.B0*SR\_ J)&*/X>KE-44G7&*T0M;[,D@>VN!1ZYJ 2S5.-DO
M=!8#$PN5W5TV?@&N=ZKK7G,!PZ0.S>IL>.Z--T35(T:TM 7[F'.B/<:,*?^H
MKW;XQ%>.ZI8]:JA0;B'=,JAJ>K]CC[@3:[EBTV.\_O:0<J0)1;R0;.Z 3<<]
MJIVH,ANR,X][4N><7^,K^7N@$"<Z3-)A *'O FS9"2#LNS+$\9.1)?+2M+.9
M--TY1.BSJO(1MR7?8G>AT+_]=MNK;0FQN3EV'YD$U8PI-[7,JAK>;^M.[$E\
M%;K;R:WT<@R(=B$^V3HJ)$S\7*8^Z =WW'=.9<%\F^DKX57[58WR>^3.3?D>
MKKJG2QMKQ-I]+D*<61X,)6Q:N\4L')WSW2-(Y5,DH=SH'L.2<3/*3X\?MKGS
M^%Q,-@)0";$?J\BCW[4[DGGJK1N$%^[9<W]B,%K^CX4+_C\Q,WE#L3[(CXQN
MD\KWI[^\126K?D.%WHEN<NKRQ]F;_\EB$+]DB6MO6+]D M-= 18S9JX X:7Y
MCX>WY21!M/0*OQ:>E 6Z14Y,"$?>[?(,,0,PZ&UL6?P/4LQE:EJ+: 9B;8?W
M'*7!1 /F$(U5\)AU/84]C6NK_I-%1__PNII"Y2VWEQOQ?Q,1R2]*RF<M.W
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MW7Z# [/K0WD)(ZXK/V,'](/<I7@8D\'W0K&6BXZ4F(>V[IG AH!LQ-I,6X8
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MEW<:*+-(%)F2<1-<=IY-9A!_5B"(RBVSAZYH[LX_T&QY!!CKTI\ ,Y+D8=-
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MC^/:!00Z;6;U_93NN(HQNOPWQZPA2MF:SC)^(B#$PE*G"^7 @7KT6/N-9",
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M.]$=5B2^,ZHB(4M6Q)E7/;R.58KEL(^<GU?\.8Y:[E)SR%#4:;Q-1UP7W^\
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M\'981B080,CH1^4AX91C);^X[']4^K*6)M1R.<;09)J^8/A<)F9\C>*6(Z=
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MB6:6 5V+E/KLR3TC<JS:;M]:5.6ON8[_]Q&M,WK^=EU'#-:^)PGBX(GBC1<
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M )0KW&)Z>!*(JV6'3;,!6<^_J%S!J?X^BY90T46?+1O7LK&*WJPPKYX&9=*
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MQ_:.?$ZC],PN*JLIRE3-D>E)AT!"*95F2C^?#P))SH5F!3F.-_\'#-E[F<K
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MR7^W>^9?^I?^7XGE8/;? %!+ P04    "  K1UI2'IETE-&*  "[K   %
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M5>@E'M7=J/22%GPV8:U]:G.7(0(:=I$E#OA/TWZQ[-\S+/!_9-G?#?N'7=,
M$=HQ,<@QR0$(<!@5(74YU)4-'*T?9Z. &P&4F,,1,ER9^VF8D2JW9+@0Z#]@
M^6?3+[7FH\Q(%0@!A  0/\K$'(YLC6P-()'A6OZU1D2J@F[>__\[_Y_O' K@
M->\,GJ  V5'-R5 NPH 3$7^S<,RJD6TD= "660AP"$"R.5?1%^<_-# .+S0'
M-I7E 70;$S(V]M]N4&5RXGO'9&LPNZ3M=J/N#$FC1ES/J3M1OG,;ID-4>5"I
M;S41)<<"'=A4A&0[GJ6V>B"I&R,(YR*)VEZ(D3-E!37*=#'YC#61>?(LRP_Q
MN7WR^;9W=)F.K&3G74UI>8D"I#5P!7[I;.]IT::7PCTVWCJ"WV+#\>2@,[/F
MBW=#K*3[9V<K)\^$J-9+Z;,)@G:W#N#1^E%FZG MF/#L&2DY8Z240?F(;]+C
M62B+GP3UF/Q^B%5E_!J8:G/X#MGW:)Y5O2W7#L K]Z=5<5-VC=@50^4AQ1GP
MV\G>\&6RNPIKW9@1=F%IV+_HC X%3*$J$E?<7/^J(95(P6;Y+1/MX[2+I[ &
MENTE=G<AO%V$3NX=-N(62Y.LR'01T%H],M;U0B]=K$V*6JNMT_!.LS0.$PI8
M'EL?YE*FOX=#H/1MPQHD<<6U?I25$4";.AP!55'A GG]#QOR+VY$.A?;W9XV
M^:PILE.ARH*#HXP(MO?,;R7S?$;W;8)?(-?F@1,1YEK8RY@4:\P/O]A1L%FI
M]MDV/IYGB6'MZ5M!>J $$U+HC3W0:FV?>\O$L^Q!H(9PZ9URY/U!W$^N/QW!
M9#QWO_5D1OF3YHBHE(PN%TB(O^0\ ).S9F"X6N7/LU:%D%JR\;UGF6_<Y?*^
M*-G1ZG%O,H(RTC$6%/3+8G,._V6B4QGH.90.P[_C^)<#\S]O\4([&JD_M7J_
MHHDQSFZ))^=Z:I)F5>%Z!/PRNUJ:<H2_J.*@^@\:L*E8WFS* \S!5/Y^W% &
M0(7K.'-;CK"KD,E[6//?_3U*(S1T0"2:YCI *10.C+ZQZ\1:*K-D#A=L722C
M@%"W*0%'C6X/ER5=KM$D=X+,(HE-[6N!1I_>[BPJ>#U]_/:+D+(TR#29R5"]
MM8XC<<>B$2X-WXVXF6^/M^6' A[)D?O>U1NN)UYJ(#AQ$G[TEI[=>.7+8ACE
M3#3NDDXCXUD@ON\>GAWAVF;B:]UKK@<2/V2$.V7PBFBU1G<K_!3LMB^#1+_G
MWFQ'!@WJ99XIJE7LZ[U>@4>4L#BN:M7ZE1%1IKR!+V]P84 I^QSVE]O"EPHY
MOB<F[PNXNE41L?7C+H>!SB9B)HH[I*'4]6#^^AQ1^(TDL71,EL<H '-D<B*J
ME[&-MX.5ZH5Y0<&M.\QWTG >LV1"#(_!6" 40/"I8]9B)2:M"U%&O;J0[1WY
M\NQ,';9W"D8!\J' 82'+-&^AQ\/*CYCRHK.:M1%"V<UL;"D?"R-9-MT-Q<)%
M"8EEP3?&63^QS1K1RW-&*V^I>_<.&CQJ-WP$KJWZ2GET2%-K%CI^* \G.)^C
M(PP.AZ$ :P?"+A@QP!E2+B.FO@]^+<IKY'3SX @RS3[?Y8^;+@X.*(HQ&I0F
M7?K$S*LQ:N]XPR??;<:2Z+M8$D9_>]+QM<=D$E],9<M2VI8&@G8<,P6_OSS-
M?*['0PI)O@=_)*L>W#+  %UMA1YO8"J@@#86/ ;FU'>Q)D8V+C=''K-SK+P_
MTFA?>2&Q7J'1-.3+#R/%VF)8>/,C=Z1(9.3C$R_ZMF($7FI;KHK_5[PSV@R2
M-SN]S1<R>ON.D"6#L^\1< 'U;$!OO^NUB#5"6"S45XT]5]V 2,.H_?G(UV]=
M3,='70_&<U*S/'F[,'R(2?J7E<;(B=Z?QXB\XV)6Y(,^T#)3O%&\KZCF0]?[
MB3#FY%78TP!"C';_:TB)38,%O!]%-Z5MF&=MU1H*'@QW3[F(=Z?A(B#[.1\+
MNF&,#BXW=$M#W+\Q!>'WXK#A8B$:#G@9VQ.05+7EKR&D&Z<TKFS)!WW"MX^[
MTCEQI2?TTDTX>A J-2_[)\K=%9C YS9]7NY<&#X"YWB&*&#B*0H8#/:A;2_&
MM&MDG]C9/9K1SPYV&,/WBI,8D&: SPB<H8 *%%#4C0+2"8XBP\1.=1NY*U5]
M:M+!EEJZ$@01N5]%0"_=]NLZ;KO'& ]8.);<#YX+;F7!Y6RJT-\G^;B$ LCY
MYT/R9O".)=Y7Q$U&M?0+AUG9(&J?U=P8J\#5*LPS+HT*)/I^!YSL>$;8=FIX
M&E*(^,B"YV!@E;+DR?7%M>58O -PLD82E0R^\%,U@@=_]GS\+'!ZXOM3H6KQ
M;]-W.KU=M]7VU5^_@)"=^9@TC X:^J5H] I)^<-N8=X"DEB$A.X4O>D:P(U
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M?BXNPUL_4I1>?W;ILM^X<O\%9_%U!6=3 QCI.;VHT\55*@I08  ^M2X<W-Y
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MOQ175HJ[BP?5;+AKHG%'&9$J@*_CD"K3N_!O+6_\[_1Y%,.#VEW(3$>4S'%
M=KJ02QFO*RK0/ IHG87CD-B_L(=.I*, V#;)1*=A<GQ4GDU\R?3=A-T^Z6[R
MPX</E8CK<AV3B5U'W3L !T_7#H:$X*+5ZI%IMO4;W6P?5=DBG^.MU45B;GG0
MS./"G^7:5<XO<5#DQE9KVV,VL\-_N)H:Z3E4^-WM;X5U3N\J%19!)Q2JVZZL
M,7/KSM)A4G42_!,_=!MM=[P<TJ;8B* ^G.=ZO+E;>HDZ1Q[CPN5B@M&Z\MM[
MJ18Z_K$:N"]0 (VOTK<9BQ&M9W1B^/;W4XUWMXUCO1O3:8I$M>MBS?"E!Z0K
MC3R\L^4!#RO81 C>PHK-Z\>W;EP*SI/(>%@<%6FIV6DF&"(G?&J(3S^NX4?.
M?^ODA2QP%GMS8595G^7#C-X2.9Q0?<A9*,^NVO-/6P=GF]NF\(ZZA>OV:M61
M^64,D;--O[&9=L''2DKQ(==_ 4T]1$(O%AD2D75>,#5#-95S<\K:8%8.GFJ6
M]L2FI3W&;5.&EX4%V:]5%25NGY+OR?F\%Y+93LH(D QW[9I>:\J]"EPJ+-S!
M[[UGP]+A?V<])G%U(R- Y$@&JK6_<]8PPGF0W4EGX5)]Q(8X+HI8A^6^7:^*
MYFILLWY*9^/@<"*!\  ?V(5D;\LQ>),T>2W-/1%5A?#OZNC[7ZEBIF0=2'P1
M\Q R-9TUZ:WJ2]&-.XD0:H^)=+1EX,+H"%^I];MJ6+GN.^-%HSTK))3+QC9<
MY!ED5@^_63 ==]!:5HK%2LU3#=;R\[,3R*8"/(K>M:7<'O<5P*H\$;K'49[+
MC]WN,R+SC9[9+N5"RV<0UP$%$#YJ[_4@@HLF\=*H1U%AF[L&RCY)2NW_ZG"T
M8];A73AZX9_R+'GET-+([5RCI-^+$U.BP'MP^+A!73[:0*1WRL%4!V]-.+#M
M:QK).JSH,T].^-+43:QA?:-,DUN8']U?IEJ$(=VZK%,XF@;YW1A]1 .R$3CX
M86^5"0-EC<F#N@NZUQ.W8*HAJUZ6455U)=T6VYK>WAHX76\0:E_.S%?71CCQ
MF "XY*ZRX!:OG<;9)QCO)3<_U=145@W)^/,/4V\F;E1/<V':M35RCTD+N+%?
MV'^3'@JQB/)@NWCJC$ !%Y<QB$=P]AQAVDD'C&IS_IV3O9:-A=O.(Z$_4</O
M47O"1>[;A[5K4CZPGIF=%@V","NLE-9:-KA9^[R2%A]1B_M5U@SR=#MY<F#)
M6)0*5 93I]QBX6Z(V-,@"V$+4Y#.YL%CJ>%,[$)(:OEH)OZ*P"J_83+7;RB=
M\2L<1X?^[K:RO(",-7 $BTYHQ!7Q9[8&R>1E5E 1:NPHRECOS(PG'*<]F75'
M WUF!< TC-1V5I0] ORU_;5=]_Z;&B09X+0U2\O*WO+C DEIJNXIR^'2;\H+
MC, S-X@!#BK7X82F0H#Y7,1/#1UIM)#:29IRA#N*N;;<7$!&9*XA%P +Y?IY
M'&D:ZT^5S 5D[\RC!PZ)8SGR%VDHD\/OH/(9OH0%$*AP>VW*X4<TCFJJ[LCA
MJYZY9>TH'J1AKT6'BJ=A5EIGAAH"*MQ02=F:/H!S&1VY6.9C@931IB)NV=AR
M(%FV_-=N5]P0!BX@<Q_!#2WD ,#%XZ&RY1H@>991J"3 ;0WI#T,!/S=K'JB?
MFRM['?W ,_2(8YM4  @/U_I\A-\&D('^6I\/(/BGER"NKD(!$?, T$[2L%M&
M*""EJ>B$K*#"'LA!LW!/*3IDA_KE%2<*H%9$\()QH8/4D#U$$T+'K5P#EP.=
MR?2V+!QA_T-" "U! _GUTL2!"M0-;2W9][@"/4*B &44T*&)[M+5TH5\_!D%
M0+/0X)Q?F!$@(7"F*TN" M)XH N;D+,OD"7],REDP/\-$;2%?Q4Q_2G"#CV]
M4$?R1/ZQQ[9U&HDJDCHAJ&F#(/5O J:_"9Q#_RX0^0<!V=\IK$7OQ6@4$&RY
MN'>!D7N%C$$!H9E_UX@T^XL$"DCXER(6?U5""/[ULJ@R%%AI^M7 $A3P9WM7
M_\F4_!S_[V9M]<]3\GN17_P"!0C\DW7N_6V=?^\:O\F4_MD7_I6,!0IH&H;"
MM?_D/GI&\H"+V7Z!+S,*D--&RQR@@)]"O^^C,SXDQY3PTUDMP)-_LR/O'Y/U
MZWS^-CU_,/9?"?W!2?+^M'9_5O0GF?]:D<6_JZCKWW/T/ZYJ)Z3D]^O1]>M<
M_\>+]I<-W/M/%/VKE?VWGO9O"$7^R0/J?WJ $@K8.TI%Z(!_N];^LP?\"E>_
M2OC^$PF!7R3P_RT/^>/"@H^F_[*9?VW[.R XHP"UO\#*WUO_+ZCZ$SK\ADG(
M?RV1$%2& JYI+R,__7&SA4'-?Q/*0/<$,D+_OUV*G#I-A;_N.\8Z%L4K%S$S
M%^YD:/5=UQ >2:.GE\G/*H#0S2B[+>Z8<[$*&<LD?6;(ZZ702[L8Q*%)7S[G
M\V?4/\O\H?GITQ!9Q%16Z][[1>+YE*,)^'ANEJ<""C"%XR38,;3VQ _IS^'7
MGYA3$9V<1QX7^5_>KW=Z-4\;N-P6^:4P(7;"'7N*G4!<7#.@W9NAV0S'=J*1
M 7[_XD:(<\YDGY>31^ZFZY+QATE:*==.N46K2B[,X7KN9<8=,X.&(=$&=IO$
M['+NYVP&OAW1-S;N=)D+F@1[#;S*''4;>,N0$+(^['C4*YS;8<E@DF? _))/
MB0D^8%CGNG_A?IC#(@R_:^4:;"(7()E$:@OL6A<I+H4?SV?OKRO4-];$KZWI
M*T<;Z)<)SGK'F+@!5)KR_Z\HU,Q="!]5Y!)2AT,1O:E8AE% -30.<&["0P$K
M\1MFQ\TH8$.ASA;F3XX"NOD'F[9?HH#!</=10%.>ZC\KVA7,AKTJ]WVZZRM<
M[B91)OGQAH\C_/@;#G+B'R?.IG$DDWAX,*-9WI$>>9KGCN.#93W/QX21?!DI
MWNL3T[4SQ'=GM*H.=]@/6?O%+*A MJ'V;TL[ARK=O[:TM""V^Z7G=!<,G$ =
M!0)Q7(>9C39EKLPU$!$3%[.AVAV)'3F6&'DO_YK/\YY0F-\[>1^AC9-*,HY9
M8C:A'2\&R*V5%.T=CMI%AH3VVOY,5SCX;GEY33RST/2QP^Y=V;'JJ&7W:><)
M:U/%R[L!,@(B>JFV#-BQ4+(C.ZSH,\-9_3E5/G.DKS#O?:HKY$SDNDF2F*3?
MQTAUU;RQ02S]:9.!'Q(2(B#OL F<83M-A.%(9L,H=<%:68V@X5T\>1W>UTY[
M@@-+TV5["1J1!A/'#F;WQZQ&,C[>U[KG:X[O^/GP5K@QS4JTYSH5:#-6+WG6
MV- 6*9 H8Z114SFLD$PU_3AT5XE&8VK^7(OPUKD"_O)P:IHX'/*:[UC-0KLF
MHK4O5QGXT'QC<E57T9+'N:KJP7$:Z9V,&C- S<LY;8!O[_E)H9? ),/J.Z7Q
M67OV%'5?RI@P33EF':J?+T3_EXJKAZSD(#]"F>3E266,1O0=<J7,9]KF0IBW
MZ'!G)(JBZZ7:^](-/'/@/Z2]<#XL.!EU[UB5"YU[$ A6BS'7L7!A3KV8TQK0
MJ[1[Q_VJ)"N2DDQ2*+H (JC'&WWF1A)#&IQPR:8MF>7RX$#=4X_%/FLU0LIU
MNG8:X$)G]#Q2D6<G"5=MB"\J$<M(F6P4\!P%\ #+?W+FL78$&PJ(-DJ'3F"B
M@'2&G;P_@%Y!WT._N^-B*9CVYB9IO/F.*R^W]PS=^L_>M#,X%#PR4'6N7*3F
M<-XE-<L&'&8(T\)/<EY5>AZ\Q 2'JVN7SQD.Z(:LE"5\UW8H>*Y ;)*&@290
M_ZK@2#OW"++R@D:>][EZ+P3QNWU:<K&RQI.KT\011P''$^H*UIBI@[[<=NGE
M*TJ.TH,@BFO++*G)3CP\1*S!+ 'FR?* O$N93'F^XU8,]77FUW=3NJA[4S$,
MJMXPM!0]10[9^(^Z"2+K=IBS!BJ!K@=$>KJ[)9E2[ZD5E&6"%:K<!VQ.LE.$
MG<JK$ND<FO<2@;7<?>?1XEW'"M78U!UOI9$B\D>@&G-]Z(()#Z$ IDQ%RMOH
M+1R[3X3+?M(_DF8EM.HOGBNNFAA[Q ]_*^ERIE3ZQJPMWOUHEE3=^T4567-/
M:1^#<!+7,Z#DY#B-:":9<H>%9^2X&.(TQ9\3U-,U?TC M#YCM6V(TS^6>]A7
MK^!TOJ'AB-CZ"*<)8[09XVLCZ;3LLY;G<VTO;=^"5_>4)@7*Y&'>6+\KQL+_
M=4(:0:AJ\_B@\FIG]:'K3F79GJ]HOG%.YK/$[7#)JY 7T;>&[Q;<^A:^H5C\
M($E/9:2]+(N8%=^81ILS&O=1:+YSP69\S(>; CL9L42Q7@#;?AK1NR:BN2YI
M7.4F)7Y8I9%;90HYJV)55LC&Y/+@HJXE"@A8CV=F[9^^8GSX%7NEHN:N[I:Y
M:^,#\A1E\<W$[2(W7D9!\'3QM:#OERGV+SW\A-6KZRLJWO175X=RA31[/ <A
MU #Y7$4?ZA+5]2HOT+GO*YXT[\=#NM=2&#_H6G,HFS^)>_&X^0HO(X#]-R\$
MX0,4#X&51+@/Y&UBZEM9$8-)@P>;2XANHL>D\4NQOGVI19#N8KFS8(?B!4_9
MW=XVVYR+97(:@:]?6!AQ)YC\19=;?.]D^"KN^X6>V<[C_]@Q%>?OF'02?>@A
M\5A<1KT!<*^:+G[K:P8GU1]\$6YY](Z?94Z_FTJECZ] 2#BE;=!;]RF$RBUH
MW^M80?^3L5'3C\55A9'KX@L1R=P.;G803%]CN'S7VZ>73 S)!:XS*LL\EXK?
MTTZED7$]1IY033 FQVAP;'-E4>V;N*KU6Z\[?_BC:?IN0843V1D$1A*<83O=
MNS5N^)VX)B=<)^,#T>ISX:I*TN(*33^/]D;!T7HCGVR[PNRI#?8.!X*[!1QN
MN,XQ$M_$(=GR?GGZ9Z>PXE?L@ZN7EI7)^-5UB:)2YLL!ZD7/!0TN'N9:+1JE
MOO5^V'"KLK8A7GD'$_/R^/GDU/9I,&"_94;I9M04/ ]N&O&MK@A_YOSL*6^[
M(UU^-5BS:[S\2$;/>'^A?;*>^\O6WI=I,X/S?34AGGI'R>(>"6:[5_7[NYEI
M")9]O^.^@NJOH_([T]A2F>%)7]G=FSL]8;7Y1C,0>H3+2(4,@UF%ODT\;G]-
MF._+&7'CBT,YEOJG<L]-%$>'O4K66<R1;BV>,8M[P8A'1;-V#&]F9,=DYY#&
M,WH!P#)+8/UR)X3X2 #3,Z$E9A-L*^":WQY-GS5[BQYO9UL.?&_H/PS!>L1?
M%LY"1!FS@IKC/>*7OAFLU(4_"!H-S*E+A/N9R<$5\F'Y5S=A YIVA WRCC=O
MCMLKC%NG%2CWW^%\#C$$]AK!UK41P4LO'3YGD:NS'SRX%A3[2OCI-=FIHB\U
MD#>Z#"G)2_??:"MGN(J$$U%V-RJ9\ZEDLJR0NII8_J_D&D^-Y^S(YKH(Y!_K
M6K$*]2\N$AUV '9#FD;G:]272F&JB+M"*L@*?H!Z99Z_,N6RO6K$4)X=WJG)
MO*S5\A#H8MZN&:_@WG54>)>=-->-K-4<QCJ6/>:;MF=0?Y,X/?N<7E5P:Z?Z
M::HWT+Z/XT!QT+IJR)BVA,BE<ZAF.NQS'XLIM&[3U*ZN@K(B,6OIWQ2G'^-\
MRMB^<=20//N,^"X+Q]M3\#Q+1L#MGX'G7Y7,SV;JYF\')_O<]=_KWLPWK@HS
M>V0BN:!3$0\;<RZU5K5P] 9OFC3(NSI1S]6U2.*&=]*K.\LQ3002(Q)]1Q8^
MQ7LQOG 0N-LX-C@UV^U**1T_+'>/C/HB:OM1!I]S@76ZCAP![F/N4> 5#A;Y
M>T_6^@REHU&X=B*!Z8-&RNAM^Z$O,.KZQ:O4[P-X4T1Z.0^%^WE'=Y_0WAZ6
M,QE4RE:]WD9TP= G2S=,^KH_P$%[<Y7@P^$ IU39A+O70"'@M?<. M.!R\HX
MSJGD1&6WB7RF:[Z$)&Y?ZRJ-;O8NO-G :V=&?L2LI,32.O#(B/=Q35M-R+2"
M;/4Y #'<R]QO3*I26-/D.ZAX7^+^\=3IK5707O=:1OF^>Y2E1?;T/:9 &2$+
M:7K?Y!4R5>]C&6M,QD<C!;@=Q!B0KS,.#I+[I>>\@1[W!E0VF\J7 L]?')75
M F3IPU/U)2@  Y/N\XUA!ZMQ!S<]W4N=<JU[]'.=$SQ&D6= _BAHO=1&V0+^
M3K5:3(R6 IVL"0K+NA-W!VN( U8C*2LC B+)=JIU<-JW8^5&WQC,I.\Y8RIS
MQC%<-5]^S0V:/#0IGY;)NI@K*MI:L*L,@87M+O):2/MCE.7N.\9)GSH@HYC$
MHKVJ;L._]U+US<:=[H59-0"/:DLJ)EZTY>O;C"<P!,]%\RAZMQ=8MUVSJ#*=
M['-FH*L=$S4CL8D/IQHRL!%"3 ?2DULI/W!T#Q1CN47ZQ#3&8^D=X:>%2@6K
M\NI;;^EWL@3WPEYHX>8\E H;A@2+-)49=#A1SHB^9YW79\J_!O%).=]+6@L0
M1A +O?/3;9YN<7*V]!WJYW])+D6M.QL04TZFV)M"8EW8QZE8-N1@2BCRF/U]
M+UN=HQ?3\3/.SXN:<K0;O_DFSXV**I]7R8OA.7>"WZ?Q-=V;SLX(N%Y=7EE'
M<-,!]H&[)X3LMNS'S^XW^SXIS%HXBG?P4X&(:.+'ZQH'G*BD(HQZY6H0GV^4
M5=1$L:=,TYO(+DOB\![UJ<L#;#RE5);82BU:XJP95155Y7?C!^4)8J+9Y-)2
M6W,R @@.H&'0 Y9],A20UX-& &73$E-U>"3R7B,&$_@LJ9BE24@#M^ _I1MZ
M8;:'GE_07%[LXGJ,0:A4LI+P $44E2Y7&G+G#>C#+NZL7M;9@+8?;2M#?%9,
M/;$3OC/K-9<F.26<$M9AA,EGHQ8_.]C&4B",/5[$CIH=(RT,^0+DNC0T-M/J
MG&P\YW28=2E>CP*,K\\=.*$ .^I\&(32QI]Z>!X%:-?H6P _C,.'R82#F?O4
M,@QM=759=#_GO;L,;S]OO<ZBF(/]] P%/"AKV'_]V54FZ='LC('ZBE3:L[#2
MPZK!) + <B+RJ Z".WD6JN_XP&-)OO#+-9OL9QMI3XF0HMC%[0T44!);PXYV
M/7>SJ5(O,=TJ\I="2@^IG^-C12M([/7S!C<&^D#?F)$<NU?&&YG<A'$7C>GQ
MA02*.9Q<Z#XKMO. ,8,[4ZZ-\.4D=CHHC.O?"0N2O-_FBLT6%0'%[ "\NX(1
M#I8PN_Q/HJ6-(WN%<4]]["8#)10NBVZIX]3^+:'.[_/E]*$-\>?:JMU-C$Z6
ME+G)J"ZSS,5@TO&6?CO EK$)UU?=QI$C$D:DC/_,4KU4H*=!;E..<>'?@GH=
MPH5SO,V%XR$4<(2IMQ5\BGCU8K=I&XP"[HB _$M$&TQ5G6YVMOCV*2R_G2@E
MW1-+HY:MRB^*L\\0$3;Y[MY"</P,!1!$WA^:_B:SNHSO1G\>K[Z+ DH; S2P
MIF]'L<38]];W.G,OB/2-36?5#3L(&)=O_5 WEL HUI0C,S*4MPXK<6QC2OZN
M?EAP9:> '"2?G5%>66CY+A1YA77),)$1("3B8+5SN>/XOBWO7GL)>$U&WFY<
MH2+3K[[+PXXS*N_.=ZT(%/ C55,AO  %6.-6U:BS(BE#GD"^>X<"$__;9S+%
M7&==*.#Z L@Y%;U;D*_BMHY74 #=^40]EA0*L$>WQ(*V_^49@!8%KA;N>,QW
M];WB=3F2C$]KG*<3A[D:('FJ/Q1<03CEP_HQ!*A@4O_NB(FZHZ[X:%C)T=I7
MD:9@2<]AON#^[**NY]?416D?Q6([9%X#/.F+%8I%R\Y*LC>1[!/EQ11F'?8.
M-T\,RY\KM60V+[XG_4[B*L=<&93>LG0E]4/W<.[AIW=.-1]Z$"B@W*M0").(
M#$_F3L$.J=F(M'+N59UR+>WMNE"OE_1>S)Z/B6TT,.Q-/MT.K^X4[ #IZ%EK
MT Z2<%NG86EKT^D0R  =0O\@>]&9U2@@T@8Z"^D)$%]X!3U0?2%PL0@]8C.I
M<(;\R1M_@4'>@0H!9KQC>;,2JQ^EU0,?3ZM9&[ .>'LJ((0FJK"8IYRO>MT:
MGTP$=V_+,7L$+TG&[_C_V*M)B@OWN1\41K"Y+= V;5_[,)PXJ;^8U8K#VZU0
MY>_1GQ=L.!2^VULG=N"&)Q&AB3#[D:IA9QX*= ]5O,SC>S_+&>5'2GG7QR=2
MP\ZPI**0OIA!:H:3;.N6*U/R!^B+2^W$VZ6U84Y4&X\;@D*6'+_X*58 MO]I
M#OA?8F8,P@(%O-\+>*V(>/TH\HQ"K^"/36'0\O_"E\P]:S[Z"GAKOW=WPV7>
M[D*.0!"G"<A+T6WD+10097AY-;!M*B''X,W?WF58BF.#)U2,/5#H8^GI'H)V
MWUZ!BQ]-_0V= 01<&7\L!U-.%4V4GC&&06I-0R\\1>HBKV7W9?2*[ 1XW%9J
M36G7^ZP7:W>X8<H.)]Z/;*:5G*T4\DOTJ3Y)NRD8MQ*V+ *:.,,TB6F7I3.J
M*=Q)_W@C&I\XKUU+Z#9A[B5G\2,3>?,S0[5I)A41L2$M(4V^!4=M$A0@0%WQ
MZ]G%[Q)59<U9:%=YTRYX58[)J15RSE%+>_4<<D%>-%V=^@>_^C79[6SMW(,1
M5='WW'GG!MG'6.BOHY'23KV3N(R0S5Z-."HB'D,4"5\-5H/' Z08_FQSYWBY
M5>W3QJ]03LTWN^(;RY>%1B(:.*;A!3=S*;.B/CA=EWH6',D#;:W@I30:>EH;
M)7!TBO:3@\+I.U?CGX\<GLEH<2H\HI[EM!\4TX8LR3'$_@^/!^]Y>#@]L>&?
M&^TF(N?VB.K'>-DMVF\#)I<6*+)5S9W<LCVE<*6H%<)7_$)Q:R'8:<O0(:4X
MM^])GEP531EQZ?TK.K>68C#<F#0+H;P?EEB8).GQAL_JEDWIM.]WXV7;[IB#
M""ETPN2M^%;:>6F/R+C+X8M9@1Y)7;M2]J3 Z5OZYM/\31CS#37<2P>G)4FK
MA#6_7(_>JFU3IR41(Q00SB(6O4/S[#5=^MWMI.NX;$?%XE6)NF>\-U,\",W.
ME&B(6#;KV$GMK[P'<9LV6"3W]T**4B94FRB,>9P.DNGIBO.P7"3 R8J%OG?V
M!]X<LSW)VU)E[@D8YDF'\K$$PY.;PI^G"!+F^IKN4U6^?^4>GOXX""M',#(-
M)\^3F?91U5FZJW>^=+&SR(/=M.@O8,S4-$0>YL2>VY7 PZ&')6X^5-[^S3"7
M!6[<'!E7[7K(L@QN^X$:39PW1SP98>>&9H ,"1Z37N"[CQ6DK^9!Y77/HO%%
MH1QQM9)\6:!=0!S!.RBJP==D[4<THT"Y(^G:=7LH+*]?.#(MC=2@F/,WP">*
M/"?*I4,!-KSJ[2B 0K0!MYV6P2'WY3&Q"E[E3NUK+>H#T/**C'!$0WY_O=&R
MR:,._QO[]F)(ZH:A>&+#&WK5YJUW#<3I[XS TT@S\OX%96F%OT&$3BSL0@WA
M"\7G*$!ZHL2S#2EOMW<**?3<W$/Z66,@_[Z!!U# A.F2*3@#!7QSZ476"1P6
M/__+*1=FA>?]"<,7IF+P>[8IUR;*NQE.R8L^$;[-D@L%B6L1NM]H6,A^?I&3
M#.,6V#6=Z-*-=Z:5-29]%KD:T1P].XB3&WBC_),<J>7G+88P4PM_Y)52C&Q2
M@+,)APN81-1GQZJ-6#;3.R%!<TZ5L)<!^U[%U]O+>9TD?MO%OP[@'_$@*V\7
MLCQM=DIZD$8BM@1&1,\1(JO!5W@3#L;J?]C? 4)N^>+SP\J'7.^I@8)7%E'3
MQ8;3\K99\DVX,34A2+>U%*FZ:G5R90IC%;:#T1]ZUZ"2LV<>KC(=#>NI(M$[
MEITGG$P:N#H%QH1J# <NSJ4TURZ7(\>_EK]U@HV(O(_GZP5NZO>D52[Z76T-
MA#V%3 9.>=E]7'Y+@O@*&:[*4+])%7GY!1M@YV=K+^3S-XKJ61?__&? ^%G:
MQ\MM.#^Z\4N\,@QC"YK606[KSE&!$C+M!&V_EI9^*(*=6[VLS80&V^JR5&2I
MLF<^&C&^EW=7<CE$[[+0>/$LM+?B:04HX'HS,Q["&K,I(]_F].ZE>N *!E8>
M(Y9YP>"?4X+_KN X-N0:;TWS]\7EI-].=6:%27WP/V *NA(TIO3$;+^XF@^G
M?>?VCK$0HASW[(X#(_Y-)B*,%?BY7NZ0'(M7@2?8M!(>OOX6P?G98$8M[RYK
MW>N#VY;?Z$BJ]X[S8&?J#N"V&_OI#4[EY:DV8A_6!_KO^4GI9:*[>F1Y,IK6
MP!U3B\^*M<IJ_(0PJ;-N6[>HD@?NU#6A ,,O6V"2XVW^1\90PBWWVY62BWVC
M>H(EUA\"\>_*N'A?3.1JHA__Q9>_HOH,FN/IH5YW*=,?WRM3V"O \ER"K]F=
M/>9L=!Z\_ZP"!>!'P=5#C@E5/TT6(OL<B!.%NAA.(6*N)COH4!KK:T$_X8O=
MA>A\A +NJAQ[_\9R:*]>ZZ$CZ[]F-*#@9=)SZN*F663%<I-Z&P*I\\/T'_%3
M"@E-10%F!VF$TYR(-WQ-VZ4H (("='S"/?W?_7T7HCOM_E7Q@.>Z0>W^:>"Q
MFF%O[Z5: <?R(2UOJK.I?P(43_1MQFB%3SAS!6^LLJ/RQY>'!.%S9VL-X(Y:
M2L]/K;6OPV+>,NRRT<46[30%J^9:T]!(6F9G3ALI#=Z-^DC$>TBM(3PR'<"Z
M7XX$?[K_UM.R\.$G>JY42_ UMN)E(QVF6_<</UT+857?S0@&9RO+T2<B&YXL
M%;*JJ6M%#4\+?5&Y_HP]"0!6DL9-(B/+I>983G46W!RL+",E5>NLWA0_<,24
M."E0?Y<Q;(*I%H@\V>H<5E-@X^BKOXXH8 ILCRJW:H*H',Y9:(WN(< P.](=
MY>,KL%I3N6?QI*/0C>.;-4SB9J;6F%.^8LO\C!WFSME]W-$8TM]R0C+=<-.G
MV\1E*ZK^$>6]JEX7VQ^GAC$4I6<]2*#1W"2[>]CVW?\9S'WE^4-!PP1UN #E
MCZ#6-? GQ\W<_GGGU(0B+A *^.]X#:C-L[%G^M2T//SQ(RYUH:7+6"R =%T/
MP>_ $OG9ED$Y#)=XK?-J7GCD8%,AU=*A<#LQ>^>[O[T2;)X/?NJ-;.H)]V\1
M@9;9Z9(_*02?]N3N=7JR)0*IQAA[[8;\4=V:; ^7I^ZT(+8SBR /1U% 1?VS
MD2X[L03LIKA#JG-"%^7SF@U)[_&*V=.2^38*6S+LN,G':3V L!RCMK;N)2)N
M@2NNKC0,4PN]R:D-'>[VS_6HN5+92[Y^SH711TTE1C;[V9K#@(J)(I=-E/\/
M"8)HB^!79B7Q8OKJ03?2BN[+%/K)H%2HX4DH%V;B?G\A@^&=;)-,(]/[ 5C.
MD;<LOEQ,J&J+FK!.Z%4=[%(2U6>]:[M^C%-Z?4S@!?WP@,'WRN_N;;ZXS-[B
M/ZPQ<S(2(Z*OO7C<HW 'MU#RKVCWS\K=%@7EYNP",ZHSVXD.;_9$R]G3VUO?
MZ9]5QEBD,[=<<6&,)Q39)/9ESME,1,W*18L\V/*<;5"4C;N1_$5_:U_ZPF_4
M@YP]G%':ZMHM<;8MWK5N:='%0D*ET1PTGC0\'T]H>L;:$D>C]R0UEFF=;K4L
M;*+*]U;E('\]X3-?,;X1_6_?UU0CC\/.SZN>2WSKRJ4"3?XY._][.OT&5[('
M[708*L>A!Y%A%I)[ >BP]*$'NJ$LQU+\KP"5-@RRHMN( EPO)M#\,G4='6P1
MVY.()RB M>+T,G6\WG7S#)K:$R"PD7K A :&HEXTFQI81P=DY@SH;_$8!1SK
M5?\5RTUE;U8DF[4CV4(:61M#B..&(A@-GKR[_IQD[Q/XYD-<T[BMQ.R&N?F/
MSMC!FZ5U+UAY7])!^1O<4TB'ZR^U]M>:1(<'"JSG:>%L]V]Q1$/*^M73.5V.
M3JA ;Q:+*3U?F6T(S9U%'7N*JGXL-,7G'[M%1G$C+$+E:$MJHGP"DF9D--?F
MY.>Z=";2NVUI;1&Y8D'!9&5C>LMSTP0;D'=VP)XEQ?XNV$<8)N+"90G1L)7R
MD^T9'_D1?_)>WE&!2)F.,#(-5C D1UU0OLU_^T9H9S^A]>0N+]$3D&R]=A48
MOB-P^>9<.^YOI\_:H,X_ON[;.E8ML<B>G2T!UX5%Q<S70%[UER"XAY@G>?AK
M^+H"<);[#. WJW+FIV8,[N09B5=7W[EN "((BE9'TZ\STZ%"$4*G6^#;FFO?
MU(VK1%6[(KJ70MQ+Z%_@XM+34P]UE'6K\P6Q#)5'?-C16)B^*AU*/UB,86<N
M*UI%YXO?I(7YWL%X^4MO$7,1!TT4VIWE*UK -G8*9N/KVC])G--%0W+L<I%]
M:ACTQXQO10[>=FKH4M!1-NM(+"?I9%<WUOLP[OUXK6!<Y[N=1'V-=#R 251-
MJBT?)P&2]([)@I**0_EB?,/R&ID"J;IW..[T=1Q/C)@Q,'%H_N=-YZWG[ XB
M^T+,W_8;AXD!LX(Y1Q%)^P)-54L<)11@_2CS]4&;*C=CQ7&KWP@W@=%DE+%>
MB+1RD5RGA+U:8=VB^?U^?=<V#W1>D_Z%E8CUR_J@>;)Q4W"]ZE4N01?4#7>&
MW:*4G>X:Z6'B7*KVUXK4;RD'>-G-4LS-XK*C(,?0)W$8^;2 V(.4\L6>WNI;
M;*,,@"$W"#<==U/U%^*%>R=&^Y/>R%AEQ3#.9I">-U%B3XT^I/*'OSY\M3<%
M]U($E!-1REK+E$\4M*V62%=TW3HGW/0VG>63EMPBP8-EEM%R4&]#]NEKD^P2
M8K<<*]<9%E/PBV.6L;K<+=W:Y"^SACW,ZIISZNG4CE]%B7'T=R,R,Y5/?.K7
MT*:O)LVWN\L>@9KD+389C@Q?A=L]?SV-A!R_EUC?DI&W_^]S'R6%.\S"FZI*
MKD$1#7F8ZY<".)Z)71V"AO.&4S>3L^9,;&\/U_<BX]B#N*HYI<DD9"2*'YR9
M9?5FGMUO<W-V$/TQH37@4CF,HY0\(R4D]3(43O]"C6=IPA3.O#.) D)V.E(*
MI-L^: >:BW=ALAT7/SZ[Q9_0[&,/8YURLB)_T!PDB7O=>+V&#AP,>#/_^56\
M%Z13,-FCV9@2!5#&HB-3=(-Y?>HR77_=XDU\M.Y?\:?D/\&?_,GZ?^"/!QIO
M(,BF=3G:([-S$@/HA"42NGY0_+R8= BR(F&) DP2T PBM;^A]:_8#2>^ISK(
M+VT&HY?66[HRM7%T5)WJMJ(J51ARH&LQ#5.2Z//Q\Q(X25XKAC61&9F=K6QD
M]&SW! Z3TWWWQ)+@3UI)!'KV'=_X9&TAZ>W4A#5+:ZH3/6H/"1UN!TE)S[><
M@PM]_,S/3$4CE:9KE^T@$BA Q:_FPK?>V4C[%VC6]O@G2-&,D$0C!2?:0E,*
M%/!CK,5CO0J=0S:P+?'P(G@&AV*I[5SPV/)FT7NT=;@L]<<E]')1 VO:"A%8
M@ *V Z$;K!GCQ8XB.SQV==98!_<QJ3C!-[T@<2Y(D<:Q(YNTQ)[EWC*W22JN
MUJ@9.+5%F^M9**ROJ +;H-#2+%X(B"KK5)3#/4PCJ%5_5R1]+T\QMSN[>0C2
M=YU/"7!-'3@/W?4F(ECU%<OLSIPW$2QYSAFSXM)[P)EK9KCUZW\P%$123-WQ
MR2SM_Q0H*73)W%JQS6E8:U:J[,CZ,8M#:8J>;8\$%B#09>6 _XB)//]:Z_O,
M:WZV4LE"G0?J0K!A>C.ZV6_XG_F+HC<-HIYJD,B^X$5L>0.?O7(,S&8*&\9J
ME2F8OJ0$1L^HEI>5^:A:U^>92>BPNVWK<:41]1+C#*A5"QN5GU\++^:V7)\<
MX1Q$[,C-%:5[L2C=$(7&7EH,5^2E$>VHJM?63YTX*!C=30LJN3-WG$MHM'$4
MXUA5MW<;[LSJ,9"6?X1F$A]Q"DD_B#)6WZ2Z&N"_G=I9?ZBYGSP%UW;/$=4O
M6KE9$'1=3QK)AN =LQ-:N\\P%S(OB$8)Z%P:3K*>RG#N.U6O^+DX0/Y)@.*=
M 951+#(\"=ST/$<'_F+S*6<BU^L_MJ-TW*0(Z_)@M\4ZAY7*7GX5:GJ(A^#"
M5 CMM\L/EU*B7"A.%B*=]TM6!FL0J^;:NM=FW3 R(.1)NG4MD+0Z#<_-@69&
M1][JNY[@(=5FVW440-!7/NY8_GGYZP2@U64O9BNK+ ,Z$AW6%M-];V943BO(
M%R6F\T2.(A /BREH,-1PM7+AS."@T7(M:M8M&G0E_T+7H_+TI-?9@;6;D00O
M#7_COWBER)L(3ZDHMHZ_/6+-0#^6$VU2JEC'2(NUBX";^BPO4'GF&Y^]<UHL
MQIN[BLJXP_']?"9F(I[^NMP6KO%$AN>,^D2% )[)M*?WCH.;@L[4S8.LQX%W
MOVXH89$6 EZK7:'2#F[4HWI@0H<5U0+ZL6^L6KB,#6K>M"]W*PB+23A/(H)8
M0M@=+2+Z!8-UF/&ZBM1<FO!\G?(]0YE5%> $**!]0?5YJ:"Q,#>[[^3RM3"]
MGP?+EIX1)N;,.#M'C-9%;K=2JR/T"++6:SA'$@]]=J"=+/AC]9)N<\^(E=V\
MVBFG^'C",9E<PF3WZ3O5 .\=ZC6&R+?2:C S\%8CR_YN)DF"0Y9<,=\.7ESV
M^[#@ED4!)U->67#H]#M?#@?GPDSDM%'J5RPDYDWGNLT(_W+0]I%>O+[GN_9Y
M.OC\NW3/H$>1VA7CC_FBW^K>#M00DNO2V1DHU$[M,.6&*V3#WD62VK[?/&$
M"1:H ZZNK.ON,/^-<W45X'B+M[M"(%2L%"$R>.PG1-=96/"@,@\<%Z$VHW\9
MH$@-O3M1+Y_A*Q_9:GIM-'.,K:[\4KYA,-C\<=O>3=J\[3[ 6^=_#X>O(*2'
MYWJ_.Y+9.T="KZ#H)-#Z=TG@E<ZNZ-*%P-\9([I+]5]UZXN9XN]W'(\FB!D2
MOQKY-I.B?!VKY/A&55X:@;=C7.[&2:KEB/UB>16N1P(!MO'%HDX/U[]]IF)7
M[1W97QWY:J@@E>"%TIQ+H>,]4@W]<;S]^N5.\%2J8(#8QR9PR_85%^;7QD$G
MM][>(.CSQ^7&?(**KP?\NF2VW?OG5:WO.TG$<H'\Y=+E=CH>OBWIS LB2 -D
ML/\;=I V?3-IH*&0K$HZZ12-)IB:-%SC(AI?,@&2UN2?P/\,KT?I2[KT0/VW
M6^I-XUD9 4)'.T+;ZLE5MD*S1N0'65\(N5& S_"'Q /B!Y.ST\9WV&0GYQ)X
MD&B6+@]PXD;(QO7/;R0PO-B#II-%= E-@X]=KF2(C4=%Z/8$L'^(Z=%4R3DL
M4":129$/YXSN"8B<F?O8T=9K(JLL@&:+/.8-4*)NC<,7WAM$8IIP/HKGWZ!M
M\^4'PF&A*]):\:>&P#@LPL[N&[SD7)%I&:?:B-E)RVC;Q7$W"T/^:O)]\FP$
MA $X^<*;@@)>9:6W3\MFLTB5&R"U5^'^GU  /\66<-A2X0(:R_Q#.UCXAI1;
MZO&1%W%(\UQULDT*OSF%V2MV*E"NO(Z:2H]ZG0>:R58&YA@L.=7Q@#,)@.A?
M3NSR/?*F)N-H]<A;S7;W'@NK58P5"&0)3L]U\+Z,SEM,TL#N0<^R-&_':0Q"
M[.Q[(U]->;0?6#- D;=32'L10S83>#E?6]<4T8A356(#:TJ!:=3H4^ 0/91T
M?7DQKAB!9-VF85@]"49S:(TQ>[9F"F5&H6]X P_(3:'@$(="3K$W2]35O+TT
M!OJDS8$0%6 /23"UQ9!2"!-@,#/Z0*D3BT?VF5Y#F=WG!?V)Z ^=#E\).#)Y
M.?F&;GG%;3V:5^SCN1E6.>*;+8C\BC2B2"K/T('6%.;Z<:>0@\*1Z[AZ%JUY
M%]'8G@M!L@/+8)H[RTZTV].^CN$H@&).>(?WPWESSWJ$CQMGH4\<VOL_SS#:
M7>H[IK%34GUC5F86%XU/(=RO=^$+69KC-V%T*9V^QN.G2 5:E]3-M%I2#VL4
M<'"$28GO%6:FS"M'C+D!ZUC',CXG13P+B@UF+TNW4BT_]4KVS/_@/:0+LG#G
MW2B\IS B^CA(<V3'L=V*>[VUN&HS2C>XGM?IQ)G(G+G.]VNFHXS@"!5HV7ML
M-?5=(_\9_PN[5W41_30UU9Y&WIW5WV85[R61=I8A9/QLENAEV3<3YUH-C?OX
M8IJCF>@UVQRFKO;J)?7*-Z=OQ&71DWS*F3;X* %EI59;,"80>"'#J54=X;,C
M-+QFW;C<1U G,!@E!X886U?5"K228BW,&55'3#RB]0 $!#L/:+2@1/YN4WXY
M(^TH@.4HO^&&6VWER-&:S?K;77G^)*((X0&5X\_\2XESA:LA+#0FA8Q</(HY
M/)7)F9N)]QU8/N5.3V4R?0WDD%-OQ :>SW.>J8%#?.^XYH,IML:?^=4$SNV_
M"\:,\&LR/"RF0<BJXWBFMI3=K,FSA=B,99HDJ+W_\%2"V6ZC%LV<?;<;,<#'
M] \AB_\Y<?Y]XOH_)LY_*YK&<T931LJN;B+/6^AF#Y1F=!0_B_)[+70^0P&A
MMZ<E" F511DM:[O4!;[3#U0ZRS$7Q15N)J[6&=MX#)JTY]J)J"6![^G^#3R+
MQ?<+="L7Z*05<>*CNJRNDAV'V0$O?T>_NIT.ZSD[,S*H[^<E0IQW:P3KCS3C
MUG%SF:"20,SO\=:F1&QON@X>/KE.O;Q (FK&:(2 #,%&I 4MW)Y=E]7>R^.A
M98S4Z:(>10&.O@IH&BSV$ 6TI*%3%V WKXCVTA4FB (^BCT$FVA"6R-W!MXN
M'-W81 %G(F;[:21;H4N0*EDVZ."G7'^&#!00+'"RWFZ_C"2;D]H2E?]-!R5:
MA]@5?BT424R+X(;^)@]='(*V!DA]X0U&SIZ%AZ& 5L9?V\HJBID\E^5*5>O0
M2*"?)2#R'*/V/:=KY=B&C+,<2X+\\Z:95/*F#;61)N;?1M2%?#HG[N<F_[LQ
M_^-Y?QP?X/%"C_"J!LXHCH9)L8<7X6@5,;^7Y\*LRZ@V^\W,A9]69J)OWQ9&
MC\4Q&04$_?DA'C\[\5(<PL3"['TUGRQU(SB>BO)NA'WE/ G@T;:2L'_L-R+'
MDO]/1OU_>AXC?V]$&DG/0<__P]Y[AC69K8W"#Z*@(B!(;Y$F*@(6FK2 2HF(
M*$AOHRB]B+10@R(@741@!"G26T!JZ+T(2(<$Z2%(%4BH 4)R@L[L<6:7L_=[
MWG/.=WW7^;%^\+">=?>VUKJ?3-U#2.[</\$G)*CQS)/U15KQL.A<U7T!M9$R
MD=W O9"@'^N/DDFBQNNZQH77.,/R;#CL>!@^2LEX\8U3YIRZX#I>(3T? JS8
MN1S<'5WSWBLQ5NHQA_J!$T76;<ULNM\5VSH3KKZ@KY?HAI&UJ9T07/5]M?N'
M+">^7)$E 53^9!YG#M7U'ZNQM\UHALZB!WF=-KMOQ"('%^'.'A_2G44A?A=+
MN#P9C$D F0N.>V=*UP@<]-_E( 7&J5I/3N'$06A%#@Z?I.=Y:OWA=+;N-!6[
M']^"?I6WH1[T%MI>*[[42]MVD, PX;&YF3M%9CR,S'@2@+6J1]^QUYNAK)O#
MWHW5YYI=4D_^JLB!X.$<6$F_?Y#C:C?_FK;G&I[CG;>\C&H5K>_6@X@3OR@[
MQ\4I2 VY'90T>#X883NV)2A]<.%<!6ZB+7F;"JOSP@A#H:U+@\ =\;N GT,N
M=7V#V0[%KQBY(5TIN:5GHM&#POB SL21Y\_;'53Q#Z0X8&'I@X(ER4WERY27
M7W_:JW!FD0V+[$56]0:YQ9HW(??"<^BWAS>D5MJY 9XA"F3_X4D #&-VRMK]
MC<'4\IYKV6=+>B;$R?SZ>QK:<3.J+V:"$VLT,S[>@YQXE@\#Z#0L;,FZZBT\
M8V*#T1UZ5&6;\TE4RXZ.2N919:(96J]IBNZ6T/!JTA=5V2?57^NGSSXF,E&H
M3]?T+=6!<;$E60WF@T*N#-X51V.%=IWQ* 0JD2"!4WTI-E_=Y\UK+L!2;B7H
M<=*>#M(^E.QL&OSW=_S)"2UXEPY/XT\">&/^EM"""$$UQTC PQ@,\>B_N#CP
M\.^RU]K0-M"ZL!FL\L"V'=9+]KW+1!<*&-DB7G^-.W SFR?"+NZ<Q!Z<(=Z,
M-=OZ DO>)2R/__,;,KFC@<G6N2,:YC!'[M;\KG*U=/93%[N9*&(^X!W5L..,
M-]-'6NV*RQ=/;CFO:DID7(P+[G-]<M8BV=BQ1=Y6>_"2>!<WSQ-$W7!A6K%Z
MH,GDW55XQ)R?&)[^9A5VZD5I-]]6FFV"57EEV%?G-U#IG8*("D<*F[V2I:J=
MH++07D1OQIT7LKV7>&/8'CM0^BF[B_]Y1_@*!GYDH\63B457A9?/S&A<ZM>G
M)],"P1''7+;FILZ $>()UA*A]"PF!L+?7HS=#1SFZKHB#5RY/E^? 7AJ,$>B
M;4T,>YO=[BW'U=L-O;#PN#'M(#?]5,:%(/SHSUDPVK7PN(U,4&LB90NVAJ^M
MZ<M,C$'=L[M$?]#*210N,R]_T9!IP"H>6EEUI7+#5#$'H$EL1XWHZ@76F&P[
M!K#P"*(*XE7WQ=X)3SM$E?@!;!U"?N<I*U)K-M".KR16/ @W7->UH&+,6F.4
MIR\8KQQU74'6TOT9@[E2>:JUN[C(8%>#^&N..7*T@'9LDPK3_&#\G)R/6&A^
MQM 6M SO8L_3-&$XK"L159!!Q!R!S@/FR(297A9\<1<ZIB[#,O.X6,9@[,SJ
MXLC%,4FJ::9UHR1JQR8_>9F0#Q]Z19#^6;W76&+5H1,C.X(J-@<_Z9G:EU&W
ML')I*C^^ZN#,DB2!MOGPMY9#(6U8E7!G]-JQ14,-]$UG6R#B)GOG_ @J>7+)
M5Z;/^V9J=[;M:0WG7)MS9U*5CS]1]WY?X3W/J^(<=@JIB\ DGS'$(XG'M[)G
M:A!#:66E?74]QZN"ZU_50:7%*5;?:ET05'H8V,X7 NS.SV2U1#+KXY&8YFW$
M<H;U0F<JVISWU5G&UDHYYX&*-2:\T:V@IM/+?=#:LHG;1ND19@D4.L^%+C[[
M@D%A"W/+-#CO(%=\NW/UC29OOG^9=+D!=#\I:%PO#AJZ[8U=3>4PX9BQO^J;
M^VZ#OQ?SB;! V2<GA)[@5^J'![[+:K09: A446Z^/BJ35%9OZH2=NH&K#RI<
MLY-3SPY=D>"[;WDVVOWL:\_PYC#70M6_[TSY8<G>1Z7!N.NFY$S+M,CT/B[,
MT@3+"MI@USPX<9YR^*\[%,)@;>0WETBQE1(/7PLWW'MDP%,S!D7KS6'Y$?_-
M3RFT4W@-<;%=<I;5KF$\6*.495-2*JF]&Y%7$<;0JLM#UT=./LZ24Y.Z!()M
M M;[RAB^5^<%TPFNAS%Z?0XI='%_> >%Y*#=?[@)^561M53S]TU(8NX.!_:
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M84I9TO18J_<C;8:G3CUL']E7E06# KPAN= \390<Q"FKQ:7B<0A2^')W[7O
M!.&RV*<G4T]3-H\3@:^ZY)VA'1U7S]9GYWOC0IL8>.D;>PJM#V6[9UT&SLP
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MN)=";Y5:8T9D3'0DOM #[0R#R!"3?T!<^(<0I[Y#S/T;1!3X!\#^?PBP_CO
M!V2 !;!#>/O_"-[?46C\ ][./X+W9PHK?P!<_0< _XY"Y^\0)_XAQ/^M/'7
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MC:JL!@T4$31]7!W1R[(^DR;#7_3'"SE5%&S2?\%ZLR1_Z16I?"\Z>.$KPKQ
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MXJVRN%9[(#DB,;X&WU[TOI]J8O.H9T/3Q6B9W?M3K-)ZA1PS^+Y.2F0+JBH
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MI5U* V:IS$=)-<\-90L;PRTSN+/&AA/JOQZ=.Y.?MP=D?R](IB+QPHC0?(_
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M?N[C%O 9Q'3[6\%Q7,R=JT^M/%3-S)W+>Q;HO6WF\.]=XENAJU#YT40!9&N
M=!;T!N?88$/]V!&,*]KMR"!!PI<W+YP3-D6NQ?#BPVYR1WO73F?.=EUPMU[_
MUSD%;3=?_PM02P,$%     @ *T=:4NO(G] +LP  5M$  !0   !M<G-N+3(P
M,C Q,C,Q7V<U+FIP9^R[#3R3_?L_?&IJ*5E*18U5E)XERK.37+6DK.<'B4J%
M5,CSL),4$5MRE8A-*>H2JY"',"*C!Y/)1!ZG9I9L;&RSA_O4]WKH^[NO[WW_
M_K__[W[]?Z_7_5VOCW;R.3_G^SB.]_$^CF-%V:[L!>;NW.ZX'5!140$^PW\
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M"+UJ1(O![2;P)F=HOMC(('!(K48)@'$<L:&=N900">Z"R(<' P:Q,/)!RPG
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MI1)J([8Q&6&("=B>E>'"P4@ZJ* U3 YP;),H#0+Y,1GG5RF"7(WR552!J',
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MU$%MU<XXP>E\)@=S^P'_=O].<A?MCA(P3)F@U&8$2P*4P',*9V= 2G(,!5<
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MM'W+__;]EY"E6-7Z;6NOUC0A1PO>1,U:=?^O-0KJ*H'&(#YF\CGD(GKS3Y>
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M*$)C'A<3OBM=\:H#9=;GF5T6RU^9L71PMI^PHN2SD,=W'7_# )RU2A<5>)@
M K6VT$RUVP,_^?85N&">4J=H&("A;@B^V$6M/Y$.J.M$M>H9&Q#T#MV&[7UW
M_'Z;+3O_T0_[$8@])J8S,E:_1V$OJU#O!B/N8;&^QJ\?@1AFP&'_\B9I-$>5
MZT9<].J)>0(=CUG3@+QK!_%)13VT\?GO\EY7TZEA9R:Y:7;^(15J(1!5M+N
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MAZGV^H&?+V(OO$,,=D7^RI_M1?>?KKCW;=6E0Q-OF9\%*BB([!U&[!W7<Q.
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M2N/]>:UGP&Y#5.AWQN4>*)7C=B&XGT30T&@;W&3U@K]XL>8[E?\Y9CG@.3A
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M4[U ,Z: #%K)_:VK/D[*X>Z&#M87,%OVW%(<9WH^?MXNC?P85QD:"Y(!FT>
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M0B9[YQ3'28/F_[^]_ZV)8NL"#$D/MXY;C5E B(W:A@X]*+D'3+T,_86J+TP
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M/4SSKAT,+/!,,/> I>:N53#"(%;1]O?"TO95H$;($\C.69)!&R5^%3Z#P,L
M0@+ Z3]6P!='=Q4+$S(3N=4?PKH>U]=#C"G;]3"Y5E>I[PE^WG@Y25V%^W2#
M-=\CC<7^;502NGT * 9P@/%I1<HR2D$:3 ZDV6>"]'A@\Y.IP:4(,,5EHU#?
MN]JDL3<1"B&1Y?)VZ+_8[="GYD5$&'"MN<G@PUR7A9\D6>TL.VY=D1P<'*PE
MM)0+&]<$EU.:>5=# >=Y,H5[RG4KI#S=39@W&2+[?:^H3E*3X/JD8.G7[UI!
M2GF0A@^G?!6GRDS1 &]S8B3YFY/>PL(61:'T"/L,@4=.C]G'$9W"XQN;?&'_
MSMH*_+9@]<!XCE1F!;+E%-19]D"ET30]/8GNUSGLU3?YV9+&QG"K]C@KW5!!
MC)H)LZ@FR4(8Z&R(K+<46C2V BL?_42-C+=.4,J?H,(6Z[&+,W\BPZ\0JS\=
MNN11&'JR).HO6)PN^E(G<I;Y5(:N"$B#8/S0^_ !P,."J#2#A\^ C)4%8KP;
M@TI*7G>\+GLRA5(B$UM1N)MND]2UW?Y.N0+ EUOXER/,3#" _U42.NN.Y9HR
M0]1.-3<QRS2:T>CP0!.:J=2Q$.11MS3<:;P_/$&@'!DV.OD0C'R$7S5AT->B
M^O=)OJ)?D@;Y.W/!&$T% 1)K3N 82'5;1V8(W$_2EUJ%J!VV9>E.4;570CT)
ML_#_[3&F\'A2WE>:+B;P'D!MW)/>T3;3ZL@SZ_=6*($V[@^GUN]YA6L_M.HA
M3:N:R>BFX_2V'6'3*J2C &=<,:A0TJ ,0?:6#D$7K:=9C#--_ $'+6$0S4L+
M4D4G\SY6C!.Z]?6'7?'C.GZXF0F##N-NZJ2JK/4MJ%4F>ELP)4I^:05/\-<=
MO]/_>6HL?330'-Y!7!8^Y[72JPF0  B:-L3?\-5@C L*:TO D(J-U;$9(4\%
MVPA;#AD!6T^2 ,#NS<O:U*=!=O/"G#!>GJ.45)K$HT=:ZT%3O:VG..)C'L@V
MZ9>AXZ)R]X#&W4JFDU>S)_W1O$*)?]<M].="6WT2YW4S[%*_*6V;QR4N.>19
M/(,Z_ZO'\K#>Z!W]')%%CW5%MJ8<TPHEO'^?VI=FA2+5!+7:3HYZ1T<CUN3W
MS"R&G<^$E,<)PN5^3Y)PE#M=LUJ<5,WNS()D&%84P;1Y.E)U59.A\<NY(?8<
M#3IFD"C1QU:XFSTZ9E&X1JQJ-1-KX2MUT5HSLC><N(7I-:O@ %N)Z-RTU>\"
M,4K+](RHL.>=H7CR;"%LV'CH,A##J9N>E,KM73\-> @8* .0R=)*.0(SKDOH
MOYULFJ0(.?A&XNC:%LK;W+R),!+J?U3GH;3J8V(]J%M0#%Q<"N::B1L?_,S,
M6":$LW_'TYBC=1U9MEKLSC[K]IQ7,)J[!O^LWO*Z#R**@BW^BY":LL^JI"C<
M,;K;WXZ"=._W)]Z)GGWAGYEO6H:PTNX8W31WA>##21/4?OSN[.:;G#&B%Q&_
M%=;=\C-)Q3EMI]27B_%.1LC-UJ]YITM.A2:>F8T/'_].Z3-.K:*?VC;%GMA<
M1R*DQ?K:R ;KC-;D>'/=1Z+)'JR?,V\!?X*7(3PL3:TQ"WA/*/CCI@,X:2A%
M'GJE:!@#3F&J!CV]C!38SMGC9>^%PDV=EA0RY!O3!_9/DM((]L.G$R(V1TBA
M1=NNX7X.8"_*3P$^0Z,\(PJ"HJ"T.L$PZ(Z!%[J?V (,MO/ZC$$ZY45_2&9S
MI0[R?$CSZO#34W?I+-7A#>(^^.+JB#3SO('V_#L9A\BOB5\3'GWY0M )RIR;
MQNLGV_8/8<1@QY)^S@ H%91_1UL%O8DP:#VQR"%,W<5D[T:P2"IL5")[V<(4
M'DV\P!F3W2X'N#.^[)3P&PGFT'$L*&E%-K!9URAM 5.K1VVA7JB"T<NXKN1?
M<<+=].LZH@;N)FL0V:E)_G\X>V&-@\'Y@SRGH<!!43_=/) A!AEM?6'M+#1[
MA2+*;[X'U,<H/)!EMMS:E[%P7E\$O>5(/N^5&6JCDRYC+#X;<@OZ:_^N5=?.
MGGT*OY)F$KR@$CD'+')^+?B), ]P-GP/8+\(_4D0>LY_%VA0:D!=<:UJD(AF
M7XR_X%%?0;\(/X)M)9#%B'VS\_3TE,4H")J5_]?^R-$737"%@YE(ULT=&Q%2
M/Y_L/;(]>)[:@]\GF##0<YUN=0]XI%8!K^1;<7.+BT&.,Q74D^C*'!=6(L,D
M$[@F@ZRVD_T&+U>H\^W ?EY>Y+V86LI'I'Z=&L53%BJ'%\DAJ\HGO0M=2E#K
M=D'FJ3]#BE_+;M&R_VCC8FG/X7#?2ZQ?X@W+;5G%RD%;5X0%B&Q84F14'MBQ
M+RZLJKYXQ^8<,%E=(4\5T>+T/9Y+4'J!NY,&'2:EDM!@==G_\V]H^V\+E]/%
MJ=/XY?YG1U,NBQS;_7%4?62-V9+0O#.]Y5Z>,FU?7H_>\;\UG,#6TD;AWN#6
M5*#I85V-;<QWC?8F%V#J]P7&:/_MOZNURGS]C=GS;? 1]_$Q79TY&YJ'89)=
M7%.N(!-TLIOY7-T-:Z7A-Z?R_DRIT9_E[Y#;[.1,V1H!31RIQTQ#I,Y4>:K?
MZE1]+G&LNJ,ZB5ICW(Y3.L__L2U= QP[="KE@?3S6>]-2J>%YYNZ-@R]HTG1
M/9VRDV-XW@.@A%]__J4!9X/40A^SQ1>IN1"ZYI;LA8GO?L;E-W=ZS:\Q-:'Q
MT0YR6)(1.MM&M5H3)[K"?(%<PC_RD[]9Y:[RK7:S O]%1#TA!HFA/Q1SA7TV
M8LD%EE6CPG^ 4Q=[-.JGT/8GOZ)=CNR[VL,T_#U\=VWBGAUII=1Y_-;$A\A[
MF1-AA>Y86KH3->$F:@8:GU;-99,[WP(>O0J,>/2\%;X>,#S<Y66.(?N0*JFE
MZ^I$<ZX'S- H!SC-F/:'@S2\T!-4VYJ=K2))[=IO&MLW]'3&?EWV@HM[^^&S
MQ>1FDVECALP.EC@VTR%".-8)7]NQ(K'^4M]%5N ?FDUP9U^I5UHR*.^':Q\$
M'&?!%-GR[&Y[5]ZY[]$"(=+7Q40$7%0:U->^+X^9@YU'5%V>O"\,V 4<%@;J
MFK,MVLVVUHI[SZ<$YA]^M&Q;OU*_I'65?/#EAA,8DK!SPX/N%#91"SC4?FTR
M6($1-'DL:N7[XO5(H> $9*K!2;_+V-F/^A)KV/%UBBU<KV46[V("X#ACM$!W
MEUFCSM(XQU-ORQ\O&R.[R2)&A'")D"$8Q5[%"?.1.%%I'_ /7/D9S!@S%TDJ
MG"JH<P)K2SN.+/2P45P5!UWF66"/:C72P.YJ4UBKV)A[0(;7P*CRUCV PIFN
M]PY6>JCOONK\1Z>X:-QSIJOK6$'G6%(3WT3>J^\UEKN0'HD.5+5H<Q;5X>DM
M;_OIEIY*>_DL([B620DK$\\=I HNA;9HM,3#\>Q;.EO2FJG,C>A9(R,1]9S
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MNC$9'A:R]'0V-<68:8OUH^T7:6+&F#^^PM]@]_3?(GO\2Y9A,\PG,-EML,W
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M_FI.NW"[\ EU0!Q,S""\@U$FJ-3O906#GA+;8L4D;T]>E/G50CE4^OL^3OB
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M?ARSQ;,!!Z0Z(V==6)"MW\!/@C?4>L!TKH=AKU_-_]];J-\O_S=02P,$%
M  @ *T=:4E"G[5E*' $ 9W,! !0   !M<G-N+3(P,C Q,C,Q7V<V+FIP9^R]
M!5A<R[8N.IO&W=V"!(*[:Q(L! GNKL'=/;B3 $&"! \6@KM#",%=@Q,@0..-
M]F6MO;:<M??9]YS[OO?.][W+Z*Z:8Q8UZZ]156/4J#F97;!9V J _4):3AH
M@4" Y_T'@*U*T$EY6EL @(("P 0  #* "* !</?<X_L3$Q N +[G0?<? ,3Y
MM_0($-?O//X]7Q%N#<#_G@= [MHE!Y#NC^CWYQH @"--OOM[F0_T0 _T0 _T
M0 _T?REI6MN;.7BX4"M;.;@Z4$N96;LZ.%-S<K!QL'%R<'!RLG'R<0OP_!=S
M<7%P<0IQ< EQ"E#?,UR"0AP< ("8 /ZK5X)#G@#_-YXC*?%W'LS#"0!)27_G
M<T!_]V[^[KF@8/]6VP?/Y8$>Z($>Z($>Z/]N^I.WP2?$R_<OT^X)$03^PZ=
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M-*^V4?I4^2^>ZQ!W@EFJ6NYF'D6D"T3N$5]OTKW* ^.HM3$#B0+S1<E??+6
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MB]\W/_7_!_0 \@#R /( \@#R /( \@#R /( \@#R /( \@#R /( \@#R /(
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M2/Q*G=5/W) CH),G8..;&%G #%KV+5-*6W8.7!3C_TQH$(]+]6[+AACV>^B
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MS357 XT/&,$;#B'M=?W=AX0V!GP39Y54.Q<7 9!D/5VHO2!KAK@%9P\U\O.
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MRY\P(?/8H ?6_G&U?7$!GIVQYXS@.L7JLW2*2BIQ7K\2<$F!S^G7$;&P<^*
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M3.:TAU^#16<YN 495)<96>.MX.6;W%^-GS/";3.TS(C,?+V1^HOF26CVUE.
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M(C]+J250Q]+7-.\!1S3F-#4T3L=5 ;##<JJ&F+GYG>L,"4W5O[3AX+P;'IF
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M+_H_JP;TC#TTV6]$2.3^$*=KQ<AZX\UWDY.R!7++/5$S(H!0\.1J1<R)31S
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M' )Y][=E#X2X[1F+_>,/X43O4$^TLM3(201= 7*/08:O2#*T8] L8M<.%*!
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MN-F-;$?5;K_-*'YH-/6<GR>A/_TQG\_"QY-3AN(&.9.0(G CZ+8(XJ]X&-3
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M+3NEMYG4$P:U^))74FJ]AG&?_QBB:3V-Z=H;THYA$7)E4>9: TD346_^/65
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M9\ TB[TC$.VX-;E:A="^*4A>WX^9\%-!0X%W$SVJ,Q\LRQ9LTSS9O\U16BI
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M<R2T#[''A[UV^!3CCCF).DMI3J<KTYPI/+D5M,N4B^?FM')B?1257$'/;-S
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M9-LNV[[F!0FMF;M-+9D<SS=(F2#^$[=3?QZ!*@,F<G;QDB[K\_R'14<@[Q[
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MQ ^Z"OTK Y2QVDBH!;DP4<,JSR9=YO&JU;N!J:S5C>3&J\K/9V([^J^!Q3E
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M?:6#-WG=0;)0,IOG?2E"Z&3S+=SIC--YMQ^-<_'GR/D/KN3] .RI<BA-!G.
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M;>L-(_'^=,;?($BYL;YMFJ1AO@F7T:U(?GN7,XLZNBPA-N#B8VP;B"3 C*J
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MYL5]\G8QEOC=]3'HV5,M9E_0DO]+KN7/9X1OLF7I3'N?CKTC$?GKG(,\<RJ
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M[>Y$$ O_S91)T/3+'9$A_>T\1Z#QJJWJ!S,G2]V'$P/_^O_I>=$%V=9BU7X
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M5^R[SDC!YGJN]"/'Z%PW#7I)\ !&9 (IY42Y0XME-N(JIIUHDH(X1U[DF+K
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MZ?H."FVV+?*$B%$AM&B2/^)]^0>$%#YB"U5%MUNDH:6[%Z[H;658#H5';M&
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M+[;4SO)(;6(FKJ:-AHLB$=)BOLO]&95FM"S7[PNOZG8D=KZ:"MZ.J$',2A'
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M<0E)A<.*2D>.:FJ=U#YU^LRY\T;&)J9F%ZY<M;&%V=D[N-YT<_>XY>EU[WY
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M1Q%8 IHJK$'^2()V)N\#9]&<H%#7JY_'5;]F7#\^95IE=N^0<==0T+/V2]U
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M#%7_2L<-_JU<G*1V=DTEZN,+]/PIJO+/7% )]@C*1%0BZ$Y6!L!#TW_-,<D
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M23[K>]=0#&R6=]BOX0(NQ.%8/M>OVP_9PNW>)?  %:VD[1+6+&);]!\GIA@
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MP 6'YH>M!I]G'4'#G63S^6\F0\H:B2VI=X25>#/QJ.'"HC_R,VBRB=W=.\D
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M=\:#\'.R/U!'6]*FS%M"8@NLU#.8KL6=HO'DTIE4 YF_#=*NW$R]81QT/:9
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MXGNN\\W,=]Z9;][KG#/S9WXD/W+MO;.OO=9S/_>]U_/<Z[PF*?40>).Z"*-
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ML;&X'0AAFQHO'$A[H1@P\H_2J1LWOAN(6G? _O A<)NP\K^N@.L?;/&TXX?
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M;F*C8-7*;=C(>VK#+18+VTQK!Y;1FU<BAW;&\)=2](BUB*=.DB\"Q72R]N5
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MC$?M$#CN<7VBO0@9-F;-<3$K,BK04X!12\5,N$0_4W?<^K]&(0;!MNR)DK=
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M>C_=(F!$U*,,+LGAT=&.4,K"N-C0;6+(F\^=\;XK\?7GDKS6TZJ&G:ZC7,'
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MC^;\ZY^/"='BMSO%UX)7JX*'10"_3@WK>9B8^-BOG'C4I.&C"!%%:>+;E]R
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M3%>-B(RVMB(@!A SB P!0JGZC)J.( 16*D4:M8#R4R4,E2;!8'NQ>H)63UU
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MCD$U?@?-53R.& ^S%YQ%3^^(OM 0U+J_XD\#";-?1_:"9S-6%+&<?XXY(I^
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M$&=IJ/W*J6@J+7Z1.6Y;D7EE'#SE3<W)7+!A3+(/H6<VU63B"=?;:;G8 &N
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M&,BNCDNE*_?KN5>Y+AP"GHNCWQI/M*>3>D<P]M=Z#'V8?^HI?\."]R";XX>
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M5\CW<,_Q(U1+,)+8_PLA@G9&K2&$:>V.N*8MUR\&L:*W/<LN9EW$0C#-&W^
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MM:0FWM-%\:K.:7@IEC>@&;F4Y";2-I?SR+7P<G,VS<.U1HU'R9/%/:ZS5?C
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M4X]TD(82:IHZ:':J%_"?;LV>R#;3?M]_YL0Y_L8AJ!80Q6M\=PEB</[NZC@
M(ETZS<HZIO^,.B]D Y?\?E^JZSDO%Y.K.PQW(C',)/=.XCS@B8'KQ=Y)=J2
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M2<&2=[O1/ PLC ,A2&(6/3T_H-)+U34[1+3:W%7:MOX96OYIZW2!V&]%3YX
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MJ(F7,1R4N?0TP_6QST8&7RC\&BDJP>W=:GC0UZQBNZ[/#E/373+Q8F/WSG[
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MPO<]4->A6X.]V%)J\<LP "Q[0ES<BB]53=SL9*PA>NP Q,ML="<:_(.71-
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MH\K35KGXR<T+#T<<RYUZX?68EU_X&^Y4"US6?^/Y_E^IXA:8%.\I'8W<##H
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M3#FRJX<]T:SG9V@!=KGH:,RO3^IF?>9MCTNBH9\P@ QZ,XEL03E,+X@ M)@
MT+TM8;$(%O;^X*+-:>]&&B\_&^;@%)#N:?=X04?NW+8*9[J&POI^(=-IWO/:
MI)Z\"J_=K]CLK$\.W1%N87X$,[^WKUA[9<[C7[V*.1IT].[^_W7(."".P:W
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MGL_#BZ-/T3O6<_UJI?A+\\5<M91MA_5.R2E7'=&YZ;/__?\,F.L'L4H,P7@
M3/@+/,C50QAFF==G=);:_-/M)OS;Q$9<_I34INFI9*+>U\74I6#F\-C90"/;
M"U"U@\F: S\L;I%%.ZAS1C?SM_S\%":WW#/#3J2H5VL<K18PEWN3Z?.+"9%P
MVG')14^:0!W.)HO,33!FNL"OYI*;2T+G9_F,#P/^V@W9\[_P%DI7H^4'[-4"
MWKQ:+(!6]=-BF,TTCED6<6&Z_4MY*7*MR.XMN T)R.?0!(T(8)JPQ6)E!6D7
MWS*80 SZ 3',Z[K=6A5((4EZ5:I43"F=U5%M7=?G<6-I6$35(PF\2&P=(P["
M!26%, %!=@)#$V<RMS.6Y%UZ9H7I >C&_B6DU1C+#I3&KTYY!(Q33T1U2$ Z
M#D#IHO.2XYIH-N>!^X7S:Q)/ZPJ"LYZ&"CQX(920-F_WDB=&R)_O LSIWZFL
M'R_4)&Q.XN#8#=Q\+>D 1-"*_W, $@ZU@B7T-U4U76<*$Y[$3EZI#U$>+XX%
MWCMV,G5RARGNV%J9SHF@'4JY$K(30X.4LAZE 2B$/.$M:"S+6^!K.C_-!EP^
MDM]UUDGQV HH<2X6LO$$DP\#=+89?"P3^KX$M$C4P &(<\9ZJ!E:/'@N:['%
MS\X%NV'WBM,^$!".=J\]*IQYG?4"F^VNO3H(84J.8/!=I!<?!B]KO[39"O)Q
MD;.I&YA>GU<R]:_TP3X8YY^:M2@PG1>X=OZW?/<39*@'8-O).-E**FCR_.@=
MDN,0];[T>XY(G<V.V*^Z%\<\ N_W?SYYW/1D<JDQ"'ES@>0W29.R<*,&K3K
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M(([A("%'6,/%K$J.9#7CNHL^5@&TH0W]"/)JO'$.& LMGI _VHC/-PD@L@X
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M-CC/-W56<G6:-@\:A"S+#_#-D_:/NMWSXG\;2!/Q&._$M-Z>XNO%MY$\847
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M$_1:B4U<]B#E^-NAX[Z>!VVD5O@_-&N<4U QDQ'.]C;EW6YNGTQ^TCF8M;&
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M3&)CZ'V'H_K+[KV)(0[5-EO036Z[+'STO<]6F\L#!NE$"?#S?2@"1\U 5P3
MZ'0++S?>: O+X]C"F^CF5/?VD-N/K9;]%\05^BJ_\MPXDGCRHLF/-PX[KILH
M=O\KM7?29@="HY1ML/9>D7EHX /6@?-5)5UW]>(TQ23+8\[Z&*WH1JZ**WLG
MZ&A\V^K0'G[V39I@:"8YF0 :>D&"YNN B /[7B,3WU@5G4XEAY,\(SN?K2;\
ML4]"WG&.Z$PJUZR[_CPH3XDVR;/VM(04?>E#U/CP[6+-.=%;L;:O#$YOI&6D
MAO,K)91K8F&+J'^+9EY$@'?(H.H,"J$W/8]J1?)RTL6L]D,+\Q;7L/7:)JB
M_.4QK8!"T>0CB>0+^?]]_> 380?'C1G86'&+Q1=G=.!-V1W1J#?O3#W*8^>
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M'A+R;@M4#PE@Q)B$&0HSZQ@3]6!1'2$29-5H7>":Y];O5J$>U'ITP>[E(Y>
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MU1,8'1^G!PLG6BF7N 2XJ/S+F?>E:DCD/CSH1T%E2.!+,*,S&BF+L=2/QNX
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M^*45BLK+5O[N RK5+6O[_&,_1Q/C/F [TIX6]$Z '<8M*T,%E:+F@;2RD\/
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M[YU0MP7M*-)7I*_,FAAKJLK951EZ9Q<\?>FO?3 GZ\6-C]\_6J<'/?FCC=<
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M=YJ](E"_# \3[]_]0Q; 1_H_"3$OG>@$Q<9SN\\GQW+X\KV+NGA?VR=EO9@
M8ZUP66Q+Q0@:L("?CMJL%K1!RLSC "X6!/@Z/K=UO^?NAWW]1*I#M4TWL?)@
MQK6@UA67>^=0LMS767^JT\Q@-6W .N/'E3MH[P3B.!+TA:8=SB>WW:>8&N--
M7+T1GCGWY==#]1R<$D4$35F>8O*M_ZX,/J1')-=/ V>\/"'.::IYZQL2!0>:
M-?+,?O!VZJLY5T4_,"AL]X2QY#[+VUUOZ99E;[U#L=+W$YU1Y,^H<7K[M,PV
MX@9:- 1%/3 W7$CD_/FVM-HS)Y8W430W8'>JLGU[JN4AN1SOH*O^IR(-$!Q+
M0W^Q@BR..4'MQ '=+;;$6%W#8IOO[_C#G+5>%GN(I<:4+7L]-Y2O,EZ(/'/6
M11Y : +X91C2<!S#?$15;Y%\>!@G@.A87:M@"GJOAZ_[R5MF,]TQ^[+O2WHX
MC_*]-O?K)Y[$DE?PH*H0F&/9P$S'2"SVT*2UW.; V%>V==V^)RG&U068)?$Q
M^0GLW(M\I_#4@G_4#A4@SJFCJHJ8.%L?*%&$A?G:J@</7$:!RN?>PP[X  SA
M?PK$RQSRU#.W.O=0V6# JV>>\#KR\X4[Q2P6LC@MRR2]:35&LO)4LUS0:MM,
M8-M*</MX2?4#=+3_4N)%ZJ!3Z6&C_GKD60MTAV('+G8;(4(D5TX#EYV;WZ6:
M69"FQ1I-^;,*;,V.:9:G2PUPKI2EA^=F#%/?L-<",9_'=&(1S,%*6!/&]?_H
MHJ"49F=0'=^KGVXC2)\<+Z8N('^V?WW]FSIO]2-S&8:9[,*@(?R.!"VGU,!S
ME"74;IOQ2M(KFZ,Y#\\9IU?%K'I-"QE='!YOO_TP_^5A<4(G,@$%..5.1=!/
MF-TG$Q.%/*=%2E7-6MX0^S)&C(><N$UJ8]L3Y=F>LJ=LA9]3"JO$I\,09&UB
MH0,+G"=,]+;IGXRL,>5#71S<E38K+9[R,GA%LX KT$?>+&*^D.?9S?0,>;T8
M6>3XSSW\.<6G2MV'MS(J"SK*!CTUCC[_^"&!Q9+C2SB?V9_S#.+0%!)PP(^-
M0%QMU Y]:8;Y2.,I1\J]@9M#(;DHHXS?&N&6 6:?G^[2MY,N>BKX8+>#^C9B
M]QVH$[6I$02C%B[/;(8X++1DZ!BV=66G9QGC3E/2;&_5EY\Z6/Z)5_0WS*A^
M'O=+V(F@><5)W&VK-^YXP,UU)?*U>^V6:1%#)])[O\V9NR#N=NQ;UB@9*S;7
ME"4#9 T>]KW?T6/*M%"P>P;) OJTYZGCVQVTADLW^=1.-&K[BMRUM[^8?+IT
M(=)"/HY'!C%/-"SY]9*Y<S9O:&V<0'O ?-O,"VXCVBV) B-M$ =U.);"=V$B
M*+KGB>TXND6W0;A;,L?)*RPE+0Q-)-9-KW@50*VH"GR[3WQV]9VO=B 2'CN/
MN_/Z,&V9HFQW=[)Q(G8_3NYIUWO%.,2&#WAP@2'J2$8RA";,ZG 4;%P^5AAM
MQWQ-:AU7V4^W;8R?YY&-OEMZN4I.J4NG,^'C^R-*OL!%6"4Y*AFL#52EME<A
MA\!ZU_PJQQ5?-;S&Q^/?.FB1,DU2FVOH1_!%^GL9=K L>[ MI\O\T2LVNF>I
MQRB=!-4>6DGQ^4Y)YZON![)/LQQB$S0Z_2)!R2CE!5""+D;6(1GB=>K+VPBZ
M!!C1.<T/'?+4/TX=B= HUO1<$5TPM+XYXABIVS5;99T[9U*K_&16WSTEO/!J
M+9F%7D&7@B;0/-L('T*$):0+FE.Z!42#[KF;5?=RNBV\><M=.KPE^%;(\*"E
M1<W[ S;6SC8F/ST@9RQY& F'[.JBY3#8&,0KHJ^ )ZB!)J -=7^KEUS[R!:T
MAUC3OR)S,"]8IRC#^-'-_NM&7#<?-:1)WX>R_WRTF "S)/)+%. [LCP&A]Q)
MZN1(1,"*HQV5E+3,:;?"T7JO;\JT( V?,>\NG\3YU6M>_?#'^BN7=K$U0/Q'
M8'GA%G?:Y8$*4$U9D"6U5!<[6_*!H3K3G;^-L"GJ/JJ;9D]X>9;M[F/O>.4S
M%\]Q_((C63ALQ2T'0W;*0&0QBS7-^48]MQ&C)_736(9UK2CQW_-^KEB:<%XJ
MKK\P(FSR-O3SLT<I\2%O99&UT[M0Y$WSL5Z2P[&:@1![,BZVF7U@]>F^H6^U
M=8-E7JB)K'UIGV$#N3Z;4GFN>Q WC(W$[]'5IA)GIG"4-4[/!SZQNL<H/,Z-
M S7*7.W#6[[:1I92#\)/AG,>EXV#W%'D-T3 (ZF>SL'8/1#R$,"VYRF!52Z:
M>S5Z+$Z?5&!:LFI9ZL2<;5[30AWS.,KVM?#LB9MO":-(P'6RB+06EFW53HS$
M"C>+,RX"^%#Y**00Z$UOSY-I&KA-?G>4T[N,G#JSQZ['0B1'./1FRKMZ>5::
M'R6Z0YT_1!@,+@&K.L:G<F:(O-^U>@)?+3YXM,1>\]1T*'<B;)1E,!71)6OU
M#7:+ZJ#N$LT3#*9T;4YS@*84=+ND:> $LX3]J817[GMH\S3EU F9_K/BA#PL
M^:?Z>%%GFB>:'\/G1LN3K0&D:W", S+[FN+&1BX.^LBGDZOK[ANTN(D>DC^2
MEC!YIEVHI&YA&MP_PI"8#(#G1HZ9=1LZ''(*#'M(1G.#<:8Q(:@B]P=WKZ/1
M^4>?V"Z:R-^H(,V?4WK-YG*GH>Y@)UE@1!U4'&%(K=&/0=/Z^@,,B7=)]4!O
M9W;U#_<B]V;5*.4@39,<EEOABR=DA);;]^=':=_;=\TZ6>![ 58$QMLH4"%J
M9_O],V:EID#D@Z(8+UTKC_&'S57YBU\F<ER:JIZ\*TZ5[ITSKCRKE#[5-L?+
MOY>%>1;;TH2O%8O91GCU@O+;B#:46%#KO)=AAVU(H#YRD%!PJ]]#P%FG16JU
M/;5?5WGW/=WJR-X'"+KE?V5_^[_+&BXH0P(8:GOF3N>O]SB^C,SN_A#-8@\/
MSE\L]>_BCB4]V$:\X 5.\IO[Y&/)7?;<P],T8;"^N/2&@T,08-NM>"])57\H
M&;/+78#!W6RWL^U.0[QL&W%;(/SWR[U0[WWR4LY55IV(C@?+8[-[V[N2'C[P
MQ9<0R5W%5V$KT\<H*<Q-$06_W:K_QEHX=@,ZCDIYQH,&@CFBGK_;.07'.#8L
MZ8-WI"I,]>@[W.LI6%3[NI!TP^%(K_21WBZ8T#NAXLMO$SUZ$\>Y8?7+*YC1
MT?EEA)TK:%K(>/I0S6F!X;E$ /4\KT2I@PJ*;0U:C@N]U-,?G:X'7.T/N$1"
M6:$_-VO#SRRW^6..6=U\9++TMM=SX,+A+D7GP.9'KQBG3VPC0K,14-JK?YN9
M*?$\V4&(K@XN._T[:.5VZ<W@^-A\G2M[^TR/"8\BN%#G$0PW^ 9-L!=[;86J
M&GEOIDT+ %P*:#XB(5>J/8DB9CR8]6[#KQ]4U_FO3AJ7%@T?=+YR1%:S&]N2
MAP1,E=$LC(.#* \!,?>&QK.47M0YP/9S-)/CHM&87]"SS?MSEK%VXKM;P0,N
MFB"3?IYQF7J.(4J N#>P#XNZ?&EK"0X:=7T:>]QLS9=[3A2:VIEUY8E*.I]+
M#G^I+"==+X]UVD9PZHM\Q_Z!$0%]6AS$*W$7@;5'F]T/Y<QJ#8[P->XN]24@
M_&J,S/W2#*2E_]W.A,\^#*%XB)=.=4UL-"P*(M'RLU&\H(M0E6*XQL2,0G$Q
M-;G.ZG"%J5NON'5N@6Y"NX$B&0T>=WT_KMZF#JJ8=Z+YP4"3@4T]#D/\^8J!
MZB6>@+J:BG"]_1V.<<<'V<]<0\ _W%"W,O@#EN5CXIPV7H:X+%>$_?'Z8RBJ
M$ G*;B,8SV=I03"G.PDS/!="F4WX(9?CE[L4:T)@PLF&W$8\UL7T(FF*MMN(
MY:%U*X;T<]B%G*$BER_3%;^CN1E"(]D^L<U:Y^Y[!I2UMUS,+3@UISKH^_2;
M&2HO)8IU+N'C*?[+H1SS:(94[$ZKIR$BN1A;LYH)G)M1V9)8:#/G\.0J=+_T
MHR7?9^]2^=2IMP:H8:/2^;T(CGL_I(0.7&JT8H@A(:XC!;#2*Q =\6/F;5N7
MQQQ"3*G1#/GQHL0 8\1-U0_VDA^K$ZD9X6/V?<?:CO7(\LP+*L$?:$!53R\3
MZ-P,_R'](R$A(YHD:D:41'?+;[.\"-6?3;$I'#FO&EZ1<JNK+Q. 7>DQ\IU6
M?5@8*X'*N!8LJ!3(.+@&7CU96%>,;>5A-C'+F,\+3!WGF 2Z=M<$<<UUN7]!
M^K">&^LF*\2; POJ0<B5;41EK#J4<]N3=HN8O09JQ4,\@8# 3B9C/[C4LHT0
MU<0)NK^;:J)L#7O)O>DK:$HLZTDOE<VXR#(M3/W.LH;NOYA6W%'F;EF7['UX
MLCW-R/K&R@W.#[\E$!7_FF3-9=QC)C<+0X-&GQCG0<>=PARL[A^H8\08AI[[
M:[ULXM1NC;X*G!XMI3^?F0OSH:CI2E1D#9_ #"Y<5YNLA[S6?#)],B/>*2-C
MX_J3V9B/EQ&2<6?WDK$"PTU_$!6P,%D&C[?MI!I"OML6M2(CMFJS2235TRS2
M\\_V*%8!NE?40KI8/G8]N!HAI<)=.".?Q7+K,6L[EKR. @]9199B^-VFJQ2C
M"64_U?=ZV*838G2OIB0NO;1I+Z5]T?&W*4Q)O?0LPYK"'BKT7)? $#]'W^TI
MX?*2BJ)%#96NJFPVG6X/DFOK/^XL$7KL;,##_1&A'W#L+Y03PJ?N?A.YB=Z#
M;9%"D:-1,"VIQHLO@+E4X2LCU=N(2#^/7C^*NJB'L&YV9ISKE*W;[:D+64ZN
M'[MTG.4.--,)F>@AUQ:?"'TQ9BXDXB;# 5C&N\ZL<8,./2H:/?I#QDGC(E*\
M3S-NW;5YDN%R(%8^U0"E0R3/^X *11TX\- VHE4]8HH+M,BW1J/=H4-Y6Q9-
M@^JIG[M-:K5*\_Q+[W[SOJ'5GK2@>PB1LKZVPKZ-V 6%Z,%"-('UD6\;X::^
MVV'*<'8M08(0?2-\J[UR_-?A'V]JF.5+GGMC'25VAZZGS9M$;(G\<MSRV#EL
M&!%/G./&(XG+7#[;B +:( MC&=M2CEK/Q8;AMY [.] L"$LT8K+ZSB8T"\)_
MVX2&6PQ@8K[\*4WHP$Y%05Q6]&,,E^$:/HOV;00"([#XN[9,)5-L/*%9N-)N
MH@N]UB6_M#?EZ8).O'">7Y[GM*<Z2>9X7[,XJ'V-*A938X\R_.*O8Z)>(VWT
M>\?9U"6:=JFD'N&.><VE8HS@1@1T?$X#-EJ%S#0R;/6CGX]EIII(WZRKJ(T]
M:GJD]<5^-9/CL$.")=J$KFN&C89]IS=S+IC6D<=5][89J,W90WS4>)CZ?@I3
MYN/]F6U&G[JQD.&::,PWUWCCU8VS#P_ 'X&I440L8X<R*E+/X#D@#C.".YK#
MUM=5IXTW>=%!]^D;;IDC](X:U3#I>I9\>8WXW H2#<^0A*/KKOY)3$_S_CY(
M#_-E_#H*R+5YW C@'LGKWP(# .ZIJ:3$H&/TM_>MCS3%9KJ%LFYZ0IQ5=/%%
M]!MUAC!R!M6FY^N $G+/=ER4^'IQIJ?FY[=^^]Y=5G/Z%I]O?01"2K\M* )(
MB-\/'I-ZT #-A%G,\*(NM9V\GDUH68L9;_/4SGRC-0_,%]]7^$%^>\64<^ZM
M:] WUAL;9T+VV$\/SAX^JT+B/B%/(\RB(>X.>(""8"3\OK.V&S%UMFC1-N_Y
MC%W9PQ ]8*O-](2=CIO$31^?_1U;F+X[[2;RB1F?PK1O)VE>$N@7>(0%@G6"
M?&CN%6^HKBTY*\&4C)P;&02L5UE!<]KKSZ_$5JZPBJ=*DU3Z#OKFL;Y"J;<2
M 5,8J*EW"(#JR)7),H8!]4")(5ER;4]W.<.0*JA_@4]^0[*XU"MJ9=[=,/U2
MO6!)R9'WEZ;+D;QPB/XT/39BQLQ3W42)!J61?A>UFRP/3@5EM%U.FI(,;GH9
M.+9BNS_/X,:=RM6[^0QR2ATP8CO2? 3;PH8E%S8K].LJ4@HKJ9EMJM='>WP1
M 0.,<TXM"HEJ7ELAM(W6OA.QL4K6>VY\+T>@JE_=-'6S/-[GF*3)_?HE]S-_
MQ .+DEZ4$WY<\0*S'+M3*6<;(:(1)#-PD4H+<RT_Z[$J8WI,5UG.8/FXJJ2H
MD5S"<X+AG[ <+]/P0O^R3XYM?4VE:8E.H,6#+X1<$?3]*(8WSWJXP7$*,0L)
MJBPPI/5V\/->YI.?/A%$ 7WIJ2"YUF9%3[_RQ7?E+^HD(K]=OI 6[_8R]O29
M*..7*G-?WZV:O>92_.U!)47NHTZ'UR3R4RB+_7PN'SW%%6N<;69L')W4(B,0
M9*U3L@EAR0^L8--=28.5]"Z#F\JQO%2JWI)KV*DO!:85C)GJIR@4E<1/2-^:
ML3C$WE_)%[]/,N1#W++ZVY*P-Z'W40R)G4--EM3,5K1TT<HIJLX%>_ZI#:-@
MGS_<TPY[=O7_N-?SZF/330M^QT3K55_=TFM7]Z7]I$/<%M0\\[%9B&N-6M7Y
MY4.?0Y!/R\F:N9Q=XYA^57E!7MJG@EW!+L2,7E![ ^+NF<6!BH$K!>1I@6V$
MM\-DB )UOLXK/RCSU-NW+E6AUS\D)YZ6/[&[E\OI[D>6%+F#)'8X?%R&T>85
MU.A;;(LA]M:T!$,JK4/;@2>B,V7"4*O,RZ7N[OOD2<,[5XT^AT7\TA'XI&^E
MP<)P@UK1-0])R]ITVR!U2@\^>A.>530HLVA'U]/Z[1HW91?!EM*Z:C'??O>D
M25CXE,/1^@],SB^P(J[CQ[LO4@-ID?,X(/K2P%BSUY%JR2<S/)VGWTURG7I_
M7&4E85W@/#V"ME.?60V#9,B#DPHUU'B*[K1HR#YG3BW; TE9:N'JBE_O>N>J
MR6-5#NXUSC4]=O>]&O*[^LY*A:0B_5B('S.S\2*1'Y+Y@>+#R'Y_9];1&_W3
M7N)^V4SPDUEU*:O+HFYS<4;7+.\9[H\Z8"T5SO)C&C 2 -5(;010>2OBIZ2D
MI"B [A#@LRO[7#5C5Y*>E1^:;G'?58$E^ZMQR]YTJ\0LUE 9+>P[91#VD>''
MH7[;WF48 K'K@0<H*S+4,C%(J%M:\0KRB%VB_KIS34-B.H9V,_W#A^-W$L.O
M6M&Z_@0UI7 D0A)&C)F%X0W*H7 DUEC[FW,'&9IG6@RN.;$W/G&\GOOZ657#
MG==Q/#I'7X<;<_PZ"G93%2DP[>N#[^M?-5!MO::B\G,IH_)+Z8*%9E%X-:>)
M:Y[74R<UIY1*W:Y\SJ+YQ'-#TT"0&&./<CMJ]S;"G0OKW,2G7HWE9.AZJIJW
MX^9WTA#1E]Y6QZU.WLF?G^+TEMMG)UGH>@ ;*'F-"&J70-R!])W^D8I85].5
M<QUY<M2S"YT^,E[8W9,M,PU9E '5ERZ'K0V86C#RD#:8EKN18?WR/4<;K&!W
M4,MIY.E11XC[V*L054 ZM )8B]0]\GS"Z%/)PE0WC3.A[M@>A$9_O>N]]]U'
MWK,BL&9$X-0VXI<A:9FZC;@50(!ZT)^T&6*]M!$ R1 1AKBM*(18(M_J3YXU
MKL5L[QQ/'\V5'-L+O>SYOEU/)I)9#R'R:N@[B3=XI.$+F-YQW/(071?JZ?.4
MV8\2R32.,-"*/OO8EEF\9S(:OZ6U<B7P$L=W4N<V E3<>H\?MVL?\,0+-O.%
MJ%%KFWQ%[JU[O!N)7"8$[$I"O<6[I1Y3&_J^:QEA_-WL'IY=GS/(D'8'="X$
MU=]CI/I#%&?T)'OH_.F%=C&J7B%C#NY:^P%M$[GZGVKF#Q9+ %.(7P%6[B<C
M!KCK(!]="PQW'K(\]X:*3JK^4<O$(97'?E06]V8]+<WD27RB+*X2^(RC%PD$
M;C%$TEJW$356*Z=FD!$0%[%V:),8H0!ZOHNL%Q#)[F@S2ATO<<17R;-8%Y.R
M-&*,' E].%!#FW9@F.BB#BHJ/)\E[![O<2P.<1NRN%Y1E[8O\WS</NG\R&!Q
M4_.#>K.I<NA<>*9\S!F2SJ\Q([^3(JA5L[5IO@4,.?O,WV+1JX9G V;5$J4J
MU7?IL [*2/@F$AMNK#"/N?]^V)QVD[VL5'!\?+RSPI#76.AXBM&>:^=8#!"(
MXXA+;(/_FH.')U!*$E;:1Y7PU%A 71>RV8"O(=?!T,H?4R+5O^SHNNSMXX]?
M8^>>ZCP^*+N6/GM]C] >NA^EMST8&8'G9IA15J[H9%5/<_^PLNWX>F]1PC5J
M2BRK]0\#E6O\++*N4G&0*LS3\1,X"_C[BS'3ZR'&8%.YR8P>3[M$>E-\CG7^
MH%AKMI))NQ8U5,(E3NM>IUA/>E92S[=0@7(L.8P(G%M:FQ@VCT57:W?$ZS39
MS:R%:S#/+W[PP!-A R'9TW4K19.;+U08M)O*:0N=[RN_SO4XI 96-7V89#1"
MG_$T/7?B;PVK5;%(%'E68%2;]I 9^PW4 P8N4^^E/?L.[:W_LAF, HV\=\T'
M21M^^!;2;R*7>5\R(]!%-PT=A@(N8'$8:68FBOQLFJ-Y?U"M9PF6%]3NT+(M
M+U)MW'7?,?P$R]U7)VYQW.QZ)K",A[BE@:7+()&.8-P%,G"29B5!+V=HQ'P;
MHY>^J<&))RD'WTNO?V;'RN !8X%QGK:=.L4,D04R'J=[[4XM1O)+R&4O9L&]
MGAJ59YF']=KPJV<.;$A*K1@F>?Z>@@48B&VYIB^(;;E<+2#B@>7\J>IZI1IX
MV-%4GC\>E74@]ER6??)!;%.[5^I)7W04%G"8!K7L*.JPIB;IRX-5='T09J8D
MI #C<H!6R:L@'^/HST.ZFKYR8NG[ZM!YP;?:*SDC=&\\/E1C^(9C,X""CM<7
M P+;E'LE%F$8Z+^-X!BUUBKQ+3.[+S%ZUDWX_M.>W#R'Z9Q[OG&0!/8V,O:!
M3R=N?(22F>!OF6J&[,A3&ZK)$?4_V,/>\:W*Z'PRI\[U.P;[FTQGD,N[Z;;0
M%Q]7H*$-S0MI>MABQYO-1!?,FZKZ50I52"&%L\YEQ)[&M<?/NG2_C:1#P^@J
M3!E=%M,WI08Z$M#N[S(:R#FS!8L6/^;&![^^(&2G5+VN4CKA]/6J]T3RX;,(
MK"L:..\C-16RT]O<"=.;/5^@DBF1]!)8.YVZZLXYJ=O:NN<^/T+<A?T-AS@!
M0W@*!\-D";Z1*"PY'5V5GOO-B^\3EE]#+&A4L&_M361KLL&^T!N<RWYHH_^9
M(UQVF.HH'#/SU2F],_'21"XOYIE3VN8>53^T.(-%NP,7,:4"E#47*<3[4NPE
M-L['7T[:=VQ4 ] ]?>-1: >/-[<QQ]X/SP1FNBF9I 9L'+X6&0,=]#QI3ILD
MQ.HZ^U%R5HZNF^%]3-9LYXWE;TA*MNVYQ=))N4_H6Q/&MLQA:[R+9V,#I+7/
M@*8%/_3=#_]0/%.?=T3FXE"J9;W0L1NA-N?_,#I=[HNVW>FM$R&GJS.#Q]D:
M/:>L)8GEJ8!^GG<VIMVU\F2@CX.$2TXDCG']/J77&9U;5WFO'KX4&:$XB1+%
MDL?61D<H/BWNC9*N0"JI]8HJ(<6Y_/M(W>Y%FIH8CS9>COBTK5Q12#EP5Z@N
M">*$\22'2M YB#N,\K99 MPX6P$&4A\8V]I)!@='/51N?RY2'3Y8KR[U\?F3
M]W.Q!C;V0(L[',)FB$+? $6&$$OUVV]*S1K4VK27QG^D-5U6\ZD82;H=UM5[
M(4 6-Y]#X0^CX$9Y:$,CU8GJ-H)@-YF4J'9;M<;TVOB+K0M-0>T?^#$6\CJA
M)V8CLB&8"I!7[.^:XZ8!F/Q$3AT?&-:H;*0F15!,Q 36V_SR%[F?WSVV5>Y(
M'YW5 S@Y*&N,W<<@;M1,+W@ O;)O5B#>=B1JGHJIXHCPKL;R_CC2_4WE77K'
MT',ATT.6ZS.F0:O:>]B[G"X=_M2]"<#R_;B-\&29=1DD5F $<P]W-= 5Z=Q+
M'[CP#?,/2WH^ZZPM3=2$X/]9+B,\Q!T+6)B#!PD1D#@8MSY/:G51SG5T"+8)
M:<BZO?)2[68,>28_N4/<^W7YIQ.7!#9/_:.#Z1MDY4(G?LS"$JB#W4:T%E(@
MQ+W0O1+)MS1N_VG%/],=N9KQO5ONX6MMYVM8;?6:)R4OD\FLM?#]#F%; D-8
M82>/!;R?%Y**8%Z^AVK5IM6Z9 .TC^QWSIN^8UYKTQ7J'.&W_ZV2A&* Y0>W
M20@@4(H@SERZH2=^IQZ1'1D=4ZT3^]QS3<S:39OZ4K#.4GNC(+?]]K$HYM=/
M'P58AB1?AZ-J//ZT>@F%8,D@(49;""RA!0*O+W1[^KB7>PR<89F0:Q@[*RG3
M_BK)X/AL<$ O4@@>Y3X4N:X6"YQ#CYVC..D+ %Z9\?IJ#./AE8Q#-49!FTT*
MK?V3C"R7W2NI]]S+7?Z0]Y^QB2=\1"X+@/IBAMG3LZ[+]&*MZ:K)[P\Z*@,^
M@T4U+BM):8I8AZ>N\S"<T%R"N 3( N"AK16>V:9 RN- B;IPC,CX:+=:F,B:
M][N>R1_U@ESYB8_"]PX/NRA%FFIG9HR+2[%6@N8[10LP \W"U':K/&6@%_:I
M8F[J"M[^HYMCFV/A?NMM)R],2*9L&*<F\&?-$Y\)@ J!#)&&F6G&'FV:5PT8
M"_R&(X>2HV/I]Y&)L[3HH-?BSQ\?DBUF.VI,5"[FB.(M^?42OL7.EMMFU!^Z
M>^BL8,,L1PNL,:,,/9CM!0?5\,1[*5@EM5E7""M=3#7X=-DI4=Y=] QWS]R*
MU_ORZ6@L^3-ZG,<6W.D2;S2HR^?C>^0+[/4=5I673N%4RU5(XUX+>EO[XQ_)
MC/"1[K PSYMQ7V_M^Q O?_>0I:6X)<<KN?[FG616([;%/F2G#X0UJ#?#9W<9
MT-N*S>RH&]$ZZ9V9W\L7UTDES3=4..^[5!5ZOOA$"'ED?,_Z-$,D&.+B *(A
M[H+703(^\9Z4^&YS1!DX4.K?8[&LM5ZS,,8@97J(N:"KC,3XGWF'1.0A4)GX
M<0X*L7,:/#X!<7O1U@3 BU,^>\#LO9M,N3-5F:+Z4OTK+2W9<^^9XV+WY=.I
M[TQBSDJ^C,%>V^G!C1YU-=M9O,>TY?T!HHJFRHO5(Y<G:Z1/77JQ*#;P8>/K
MIV?K@MURC]A27PG>(\QO0?P2.YLU?L"(PCP&PTXEMD[O#HI;>M]\N"%757_Z
M+GY<7VKPAO+1_69[C?R=O/K>VG^_<>.3B:7/B "HB8:X7U)ZP8/FRSB*#R?#
M:*A<]]3LVB-MR^'*)3&S=TN6 ^49%I[R/6'S%Z*X7KC.95W1NFL??YACT>OO
M#O3]%[Z0L=/ @][ELE<AIYB/(=&0ZP-E"WFHJ-]#PRFO?P5-\)7GOUG.HJ_8
MK-Q*N/&S7DKJ6X@CS)T+L"UHC#2L<JB0 *K S'1'SP,43Y I:<6]V-VVI_TB
M+4/B$<MLT/S!_!<]DH7241U:H+QW#]84N[=9,,B3%@I:4038P.YS-2.-JI1X
M<?])<_-Z-E( 6]RU3#EV\Q.\^4>3.65#SVWTT&]C6S*V$4*-.K/T[FU$:-Y)
M@!BK>\!/65<"':<F_V;(_^?Q=LQM7UUMA-\&7GY34C+-0.H<0WJGO6\LZ$7'
M+.$%],49LB,#'1@Q0*]CF%"Z=-C@A^O]A_M++W6P'K]".=C>\?2/!%?[TGO9
M=%:(MY#Y.$  #D>5(QWJ\>/IC5\ZJ)+6M7V;N,.\IIY%*E-.75!W[UTJ'/CW
M%#,P7LP$(KD;%Y=W$ QSOD\=(#GL 8H>><U9U;\!AMJSD\I"GC>[I4_)AR.Z
M^R]\-,(.C6SJ 5;DWBBL*_91LPR@'>&?XR70"NVIP%T<N'UCKVF0XUY6/1N<
M?$67BWRJB4+HR;A_=S@=)$'\PB!3>WD&MKB[X$*YK:F\U7AA5+-4[9'4<LG+
M><IBLDF1CGE&O<C )%^TJU47&K#%@8KF,2AR,;I"D]2*Y0>KS "OCODZY^+K
M:+1-S> 5PUVT]=IB7JZ[T;*X=^<,81_\$$7NPX;1IL6(Y I;K;( [@M$_A#U
MUT%9>WH_RN]79KL=J#0R$_T<0>O!6N_Y]1!^%E$XJ&$:X7#%]A#LG26(!450
M=D7.NNO:O.C(MU/ W]0LL65_>GZNKH*OP2,XL?GG[XA_KZ!8:11P-Y-1N#$[
MPGSDO\;4M+&BJ:)CT<!5+*BIW#D-7$)/C% 4.U75*6N1(=HW9SU+W&<&O*MC
M%[('S[JRU_,NDJ6>F-XYJ75P)W_P+UO"2MI0Y&;8(YS&[\0/1X89T$DWH$+1
MY,< 7_E+MNY7[NN3DE7^M$_<RS?K?)+]GB[<V214H,AYQ"J^M64[NC!#$[1X
MM5C[;FXK=-/8/XNP\L+M18-3[^?7[>D<>EP$IV<""^J0;"B8N(TX.]N" O>]
MVT;,I@/3#-%@B#.,@@+EK!C*6-!8]_X+< (21='P*4S\357":',;36^BKF*2
MN!*?X"@I4(9UW/-K9TOQ/QH-R ;A(![E;01W)@0[?1FW9BX8IO@R*Q:V$6[6
MI@&TZ;J'$=Z3"5K+=$G7$Y^I/PR0D3M%UF'JG].!!JRFPV0.4(<CJ')M$&\M
M,-4XSIM1]_OVR)4+E"EQQOL/[UEB0UL6E#Q_?P6:4\<YHOR7Q)Q3ELMNA66=
MX[WVQS?,-2J:(8B%N(Z58UMDB2Z]8D%B#M2HM%D=G%!0>LWWU665;S7&E\8G
M6N;2[YJ<>/0T@G%M:\^?-AB&P$/A$,"V7,=#7!9TR?SFO:F3D%+(V50OQ=8N
MA6'H,W?H5P^5Q*UA]J#6<,ZC/:)DJSN$.6VR6+L VR*RFI9)(2353AVECCQ:
M&/PV%&+J5>0A&> C^*$CWSDXR^[.AK-<3UK@DVMX3^7DV=_6L-"6L2W->$$B
M^0VRNC<JQ+& 80UCKT<A.C,^_(6)[OEH]ZJOE9^]%;(]$THB=QD S]__^&.D
M'4UEXVCW^:TNP[635AC91D@]$[@-H!@R@8#8##["G\ /!I+%DJKU. RKDT@7
M!TI=!U96;GO-7DKID/)HN;S' ";/+&A+;,LAF$&N[1S"MD:Y-Q"C]/>"@;,"
MW(M:#_9TOAO)+NBI3JZ^T\WFC$C(^'IA\=SM0X3/6#"<E:+-%,.QP7 T:@GF
M85:C,"!= [66.J8!$\+$?CH%4T_5:<L[_'^P]YY13;SONG 0!00A@-)+4$"4
M(HH4D1(;341L"$B)%*D"TD%"1D'IB(# #Q!BH:@($6D*2*0K19 J(*2@('VB
M$D:2#._PVV>=L\]_[[776?L][]GO.NO_X1[XD)EGGG;?U_7,7:H:P>&I&/7K
M(6_+BVWS?+VWYA<DO/_)UX%-N'F.=R$4C_!G7@F@2\P8"WP1I6R@+)?*EGS
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M/:?(>P&WM+'7OYCMG!>&W&"=];!&B,.*_,+E=76]-1'M]"O:GW89J%)?R=U
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MSODZBO#GN@"VM#(XR\R*ITWE@^3.?KP42+D5LG= ^D.$ \M_UKY@62EWQ?^
MU;<= [5@:5#MEF?;+JF2?A#9.Y\RC390<5LX27@N, H6U80LL32>UQE]+-PB
MYBK+_\_W_/#,&<LJ>8]#[YJ6@S^A>#MQ8"AIT1SPQ4#*<37T5-VA7CHN5L^M
MO;9]RTI&^Z5V0$KE"9],G\+53"_R2?9'*( YRHA'-JU+VBX\5^V;,2IY%U3?
MV;[&Y5BV?6FIY#9=$:-E43_\R5K0$^/X$/"G2*VF\4, C3<I !\<6O(%.C!J
M49_I3$3TF;=80F+C+S71@X7.B\0SH^ D6$:]1*PF+=D^9NM#-^OO#D"#;9]_
MY'$[F]5338S>WY-2X3O(_Y3W_C/4-K?WN[@XRLB0%Y(K<>Q]&$C%N)AQ\D+5
MP06*M(Y'P]VBA,X]<V%6RN]>/_P5E[,4%'M+2OGDAV9L>5876P R> +W8;<U
M*E,U!9N9T=S--XTJ$DL["#^; _C;\M_9O=AB'611\>)_3^'[?\K_+/#U?TGS
M;V8-[<<M<;%.XR]]KH[J2RC4@@[3K25\PO.44V?;+0,6[PY>(^=9GAO1D^A^
MI6YZ^-7)G[^Y%;G7SR"@5AR@WL:"UXW)+'Y\5!4TS!B\!,*/I]'HHMA6>?G/
MLU%ET5KVBH=J)GO:;9ROF:5?T-F19&?1^.8<L7KH_Z5'2<_*TC2"7*YLAMT2
M^LDR^"A:S1OH[C1PYV9GXLJ!D&2KB_3BE^,G[&H6/E[O]30"Q[Z79D^<TK_P
MU.O#EJ;- J, ECJVY EOGV,4&&OC?8:K!1TZQT.K1Z9D^W_'^^9;"7?E*]5G
MA]E0;KAYIMKPM-EZ?%WL_@Y_^*]WI_FG_%/^*?^4?\K_";%]3^9'3.4WS;%1
M.G&IV!<4<6,P8QE;%MJ"H3.=93\8S;X\Q;O2MM_^9I^_K22EX\U6\6MR0E[<
M*R_^-K4DA.%[ -"19&8TAP1<+P-N-Z'2.O-6DBM(*]==&Y/-TUC[1SY?B_0G
M?)[%?/5+S,4%]$@=D[JZCWNYZ[][O'[3A/9[LL5'J62V:$Z'O$0_O+]SFJ>1
M$?IP=(37=%"48?BFX'Q==I;NPU?OFTE%\%:\&P)HO8BW84'H-HT1IHV6\PIS
MWCUH,N2JWUXS6>]H,K-/26TQ/8CKB+Z4-M?PWRZ!N,VZ?*>QU!>;)8BH65@T
M6Y^.2[*@>PSBSS\SSKW&2;U:E[$]^_#N*>E3+4N\#PM]!\CNV'%BRP:JMF^1
M0L,E$02<+/":TP*>]8,=CU$QLZY=#+D?4C$%G^N"._9Q#_Q+H$4CA=G(><[6
M9.TD],*J4.FTR5!^"XRNM2P_Y@UN7P[3?B[\Y>Z#0Y-[UF0];AGM2?I3!V\G
M(>3D H1#KI<A@(X596M8[SR03XL^KMU-6<K?5G6_YW,BS_O7QK;>LM^"<1;_
M]8[\_]>+"]NZ/J.;1DHHB;/8G2>G]7TZ7;),D>^O&+YOPE&C8.\+>)BRZ^G0
MLAA!&7^LI>L]T&X2.0_,%:. L&I;,'X#)>C"L(:3;-O0['W^&RCH.P8<P>S:
M0/THQA_;0+7$(73TWCG>M4B32#1[YZQ](T-B400\>6[H0$5 C< *RDM/0D]/
MM+K*\?1ZR([EY;9L#U<+I0P+I5'2OPJFZ":SY:)9!^;)E2ILL8!6HHPA1KM>
M%6^5A!:=&[TO6.Y6X5W.?_8#7X>I^NS'3\YA'SH.<T[9SN+8<H(LD0U4JQO0
MO(_M]&QNI"R0GG;G-5K:NPB=^[C.U.''3RX#JZ>]>S^O%4K^&E3@7@2^=#+_
M&B!?)XUA:2OM1KO4PXR/]I>'!B@)6Q6]-C7\(;,U];-ED^ZWG_&9SOFX9"QX
M;6WIZ09*0)-IPNAKECL]&_84[+.1;KJ?VA$R\;/G1U.3T\"9M@W4X,!F5B%\
M+++P)SBU&RA:#)::0]S)]O3$CP.)-9;<-++@1YD7/?59/PYV*D4J2-S=42<Y
MFQQT(S")W8Y@W/UDE\IM.6U]XXIV52Y*;1$JK0%[#O[AS0D&5&.;MS5]E*[_
M%I-98=:CEH3\N ?PS5])P52/MI#'.EM6@I_IQ=&DEY^[^&R-6[G49&SU8!MA
M+5^6:^Q8APDT'Y@V083VIBT&NK"X""W$'?!.>W7G\#N_O08OYAUJGWIZP*,Q
M_SEM62GKUL>6+"F$)2YG=;/-H0DJ.?;^2<UDMA,-X&\/A)^OIEX6$,M\B"^Y
M[/CSV/0(>=-9\OL*=*"P'$'W_>"!-+"3YM?>B)4T#'4=77EN(7VF26(P7-N5
M=OYU>:!:4;+DU:XG^R53%GE_!3 MD$Y<WD!YIT'[2N_2H#)&/ET+$EIHOU^^
M*$A/J_$M5'YG*F7O[Q9^4?R[ZK$,-X6/7Y-O\?'^?@>RZ*5W80UOP6<1MFUY
MZ,278K7Y!2KGDIC"T7H=/8>AD55 #5%RMFSAD\P7"..0-D/F;I3FV:8R^ALG
ML)2QUB8ODA&-O33@,E6<M]R?C?8Z70+*7U(T]MFZE3C>!^FMP0)H#%NLCGFQ
ML8&Q53</:,?&_VPMC:@8&0L[&3ZC)A,%Y4!N#\T4]K.U3!2X_5N.8361@5C;
M0/TYTG=K \74F,>MVX@11H!FC=!\+!IH5B%[RBR=F!_OZ!JE8>.4\NATFZ1]
ME[S%WWIX**",+$CM6,AH P6?/4S%<I)OYL!9)LYFK+W(3-7,LF6M0=S[L'#"
MODH(8!GA%3^'4'B]B..B9^I#6^=&#EVI9C(#4R:_9MSZJ'WW_)DT:8N?DN]Y
M?]> FZXY4###S2[S+$A*8^^D^YV0=Z\9J.EV^)A)NI3ZY5[\LT7?6M+WDS"_
M[P:*IPGONOF5E"V:/\T;AX\LP9\"5^ZX)ZW8O!E8G!E8]1..?%8YJ>3P;5):
M?UN!DJ D%W-IQ\=UTK^D8KR$=T$6/8J396A#)28>;1]-: P$XZ(,0D<JOKR;
M*2]Q?$GV](TW[#;T"U#5+IT)_9F<'?3I/>8&80H K0+N8,$+E&T_G#%0,VV"
M+.+M+//.S[1EGXYE/O>N7JF42B\Y 7Q1BJA).+E*<W&"AAGCI5K'$V0@M'6^
M!9AV5\'73W? X?F!0KYQL_NQ2BF?*(<KNW>.D)61.5G%2,Q/H3GI38*]13YY
M]W*TIS3?F$49Y-PN(+3-;GV^-85)J@&H4W[.*YO?+[7P/(U-]6\:&X@F;[Q5
M"D\J96#J'%.R72W87MR+\U0VCG41?PB*IN,6G:+H>K=^&[G=L'[E(\TIKOE$
MO\&;_9/GHZ&;&(388UYNH-FO21,>)M>&/66I$CY)QY&O/9F[26(K2B=#@85&
MMNWKKVYD.J@_C[>,*!+<?DE524U-WZOK=B8(P#ORH;?TOKBP]9R4)LT(M69X
M[YOX7KB]=G#OL%NMJY9B]C<+Z659GD-%24(W>E!*W.NG!D*CG**LXGYVS$_]
M_$0[V6XHNETQR_K$R[=;HY(VLS0>^/NXC+!Y7$:&<R9LJ=C6OF1*#2];>I2%
M]VX29>@^UIF-]9])/C_T6\VRHQY9.RG5=<&R.>*/6_[8*BC>S?0QSS!]W&IZ
M&KL\RY:(IQ](8\3"?!*,J/8I^<:T<_V&YVD:!K:#!Y[J6^;[)I?IN]['F)I=
M,*[F8JRPI:0V4'NC&4_A3ID SI[3G&I2&QG2.@R?84V;<>[I4M9/9?W @,&V
M;(E,Q\T\X5[C <U]=\+3Q]AV#(]"'0TS^X.) $UZL*#P2,_QV]8UIS^P++F_
M/UGN<-9%89[C1(V/0HK4\9:I@XR<NWC5 SRN1SO* ]QFA,RZ9^IG'\_-V39N
M8^BU F+: 4N: E#L2<;>PK/&P\44DT@A@)*:"UR!O;'N%$A[A9G!:62KDW<9
M'\:?J(/"GT<T:0^)8D4Z0\NAO)6(#QE,W9"?N3DN DJ]^[X=-;45^T#X@@5/
M68]W(R,11)9MDL2?R+0%EV-5!<@BT&F+<DWM']T5QA1W5E:Y/3-N6TD"J(02
MN8^>STN"XF$^ V3#!&U64ZR#/VC0!<^.]%E Z=2).P-XIU(']V,>US0$ORED
M7)8:=KRKLH_1E7OU\<32_/\/(F__[Q-V+F*)7F"I)3@9,C6_"04=B@9Q'10P
MSBFBZMSPU6$<2[[U/.O"2;FR4X?"MS[6S<4\:#9X^XD'*XVE[Z-,5,').;!]
M(68#]4T:)F\Z12X@9BVV$/"W"CY=7UD/46;&ITZ!9XA@W ^!=Y)B+NFN?!]4
MTGOQ8MJ]@8?-.X/UU3N'\F!FD_H&ZJ,:0X\34T'^;3D*VKX$/EQ9@!NPO[2Y
MG#>]SM\29!#(_Q&H+6W!QM]$WV$;,8@L[#&PHR"@:"Z;#";\N!B=-\*7O>_I
M%//,4HV(Z8QKIY12H:\OO">5TX#]\1;XGDM#K,QQTKPMO+UY [6/L:FKW!=:
M*>O7ZTC(FW<0_\X77,=8@_E-IA$EP,1*&T9MH+87D.[\YJA&[\=6:B\9+)*T
M<RSW]Q8WFJSQ#<9_D(GH. M<>_;?R$_\A4&_U8*C]$_+DA5^_D^]/.)L=F0\
MW2)E)\^G</_X0EY>$@J^ KB<Q+*%B;#0M7P:\\DO>TC/9K0$=,F^  !/YDOT
MM<?L/W:(GKSZ\Y 2>N_QH4#.B8C!CJ,!K7V\/E,*(Z3=@[^CA3[YG8#G+R8L
M/4K<D6'>^=G&PKB%S$.FKFI^N?O96)+P.4_N9;=.Y0;JSN&VBR=DODEES%K_
MM<1ZXQ8J=7]58\OL<M+29H@( -I;&.]'1O4U@&;;N#W?Q^A<XO7VHR[9+-U*
M?9)'"5KPJWQK-UE^+5ZV(.?9<87X1^C[ #51GFN83*W"@C=R$F&CB"<CEFF"
MT$7;>@9GR#;]9<S7LC]'=>Z9<3TV/KE?O\M.3]^@;)U Z@8@;1)3 C?F"6_/
M]YN>O-#F$$&:]IMELI=_;'U>8E*O8:QE&H0@0H&ER)0M:JM[;F'3R9"ZQ))3
MR1P !O:E$G9'M)YZR\B)@^4B%JSB_+8M-V8UU@P,C.O67FC.$AGG==6EI:18
MJUL1XH&V&U,("WX:S3"#Q0X"/XWP*HBV,037[B+3C8/T6]ND<]JMT7:^%"'-
MQM#2B'B[ZF$_D^&"Y2Q 5LO1W.W:'I,42[WNV%\MML]Z@5,W ;9()_/D\$N%
M^AI. ;Q]\LJDZ>M6;6>)UQ'?3:4N7]Z^Z3XB*^S%_;.ODPC>!%J!Q$*>D4:]
M"L(G8\4A;9RP75\)9;R;[AMV;V;*:UQ?\:H?>%+QH (C%J<.-.<116O0F_E-
M+ZWV\FQ7\M-K=]Y&CIN7^[87.J#A<<\Q_-KXO-'6<ER3]"A;9(6)!6?2PI_Y
M8*I&FV5D!/B<9V9F@!WV9F*-YL4%DTDN-I=$+:A<C@C>^4)H;E*%"NO)BZ,2
MB^N&(7DAI+J60+L)W\"QC++]7I<T6MHS;B>>XU(K?'(+N_??PV]]0+.T(;KD
M[[IN9^#>=4*FKUQ!>6=K ?IBQI&A?;[)#?LJEC$H(6?OHJ";&6T/,ZP(!_^=
M0 !.-7+_V0U4ESK9@\A2=I9 F()).2H :#X5(H/=+(2#A?6]Z^^H!;I%(Y;W
M_V'OS<.A_/__T1%E;Y!]&Z%42$H4,DI(WJ4-(::2;$F2C$PSHNQ+%$),MHB8
MRA9A[$N(+-EB%OL^TS)NYI[;[Y[/Y_RN<YWO[_N[?N>O\SOG7-\_[AK79=S/
MU^OU7!Z/^WXN+J'8*+5'^IG'U-3X[CT*%5@\3H(Y.Z +V:'*T>V%Z_IMC-57
MK?Z-JK-W%(-O0;?)#[<0OJ@-W=Y8"DMUB;#IFT46(%,[D/!:$E L[07RIJTV
MXC$L#G\U[&"(./CV']OFMA!GLNKK8,&D@'J;" K#=[WI,7Z/PYX^4.F=E\#[
M<=M8>X,DA,TQE([CAC"$]-]"O# !8)3K&M<+)9YXS"UJV,V( 6'V%\J'4^MS
M3?.9_@&J%8YHO3>YVEUEGQANTOS0@Y=)@406@!N>S&)(Z-V4CC(VD5Q101(
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MOG_Z7I5XBXV:YF=WON%?J6P]6(./DCW)8U_H!DWH)Y-J@"_3MWER1T3K9>/
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MC"GWYF(W&9+6D]M,_72!,W\1M;=/:WVTB05G#8[]#DT8&$/L(W6A@.,QD'"
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M%*(T/<,)*EHPUW8#OIH>WHAKJ0;F5N(A_E^^@7ZFJ$$IJ0WN7,Q3\(UR] C
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M78)M3#%^8^V6-MJH8"OW21<SD/]OE;#_;0;K/K?AAPW9PW<T#!+JFM(1P)T
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MB.@WXJZX%.*H](_U0BMH>[BKD2L_1](5_2 $_Q6G 63D@EZ $XTLA\4OZ#Q
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MS:#KM!1GFC@[4FAKX4=U=EF[2N9HU%EK6MW]Y^RT6'Z+FYF8Z;=[WC7O*;(
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M"/'5C&NB89F?OKF>:MBU?EM]CO?X&V0!P0.&-/K"].&F-4!S!Y'YA77K,Q!
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MW ,;_C(OK!E"\(<&43-:/(FNN8+S- \H#"A<R0[!G)L1:?FN:V1(S"!Z,5#
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MQ']O+[*>;9>JR*AY_K5TM5__I[1UX+6XAC[^$>(N G6=A)K MMUF^#:L\8\
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M()$DAN6S<LV)RY<X^4=C1 W./5DM+2TUWL]W;_QTM,/T0P.LK2U?$A8A#PH
MF6_G#0U:?![U-M4\8Y%HQ4X;M/ZU-9_6NM:_GSJ:]N=%2HN7O1&Y<,1'0^Y8
M)Y1%H*Y0@/T:X&'B\G'^)M3.167+.).C02F!+O^\2NDZ'9M0H=OX=6/Y$D]B
MA,5G)3MR2A'BP&1(RF'O2N]W=8./O,^'+JR\U.N4IM6^N<ESO;I!781>!.]
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MWM*Y]+ME;.KU)@R3"1!RGC6CR6;:[B8V:=WB94=DV+HSO=7U3<XB+'U^RY,
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M'V[C8_&P;?/2\+2IGT:TDZ/Y?;&$ZA,OI*?2E*I[WAP1,&9<H)\ L_/HGF!
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M^[R?L./<JO,)D$"*EPB>"9S.L?XTQ?-XL$^FW;MZ@=%ME#(A:;<Z)L36QAQ
MUJB% Z[()XU^CS'B(79F9+\G6WF8P=(5BJ]UMT112JR:<N+C1G.QG)C>6SZ-
M!7&POP!S/\MM>H^!!8@E]>29,&NRGJB!3&WD&C57=OB[MGA_K<O]T=\CC-O>
MU^*Z3Z1J*9M=3T,?6(;:YK$V6 JFZF;C8A 26KQGCALQ8O^H:&LH1O!UI]Q^
M3%B^\/24GK#>Q)J6$-LBH@I8$R-G,_?])N.8_!M/,+PC8?)%9B2?AIC:B:SG
M>2[][]\_JZU!RDM\A4"F\%VEB65(&%%4"&!&W \[#-T3Z#KQT"(4#1.]28K7
MU5&W=_)[Z,,X.;#/Y^&+3[U2]RN^\]:ULD7R*?U.HC$/O&:\_!5F^+N3 E]X
MU/)JS7&M[(U7PC*<7)YX*X2KY.HK/G.H8=#L_)Y;XX2Z7P_*0/<^LN^/-'(R
MH=*S0;P2M6[A_-.C>4S+ A]XT?^(2N6]\U[U)\R/L,EB\_\K.1\20O3$3?S7
M/7X)Z.JY)TQ]3^U[%N5ARN_/V#8?O52;93R=F%K591:QZ@F[*_++5D_E$:M6
MA2ZC09J!1Q)?S/'0_8]M3.L9NY3@HILO?FR_E%7\C/_2YHV<=R>NOF>OZ'LB
M+];YZ"1%;;XEFA(_/]LTCQ3TJI_JC@ZSN&F0^>;KC.HR3J7$2#*E<LOMEG[H
M/Q&-,J:M&PE(\GD$J-B=A'=G!+3-GJ*@6Q%Q@KQ&[5+J=4,_&D=N_SJ'J!X,
MT+OXO773Y)W/F4JN@;AOX0?YU]AV/%@F AKL.R$HYOY\FJ8:-.+B/KE'R<RD
MQH\M-=1WPOF..'7A%)L Y3M-J*R S:7'_9@0H$,0J)E@"*LES($'2W9AF\<P
MGZT,$1",IG#,K?V!C,+%!1TFAQ>>'NM,H&E!<E"$KT:TPOG/OO7>024:*#@Y
M7DCK1,0'/7UH]LU_G,?LW?#YGH'>)W'WSO:0\)<5\O8;'"*WO"1B^;XN[ZCF
MN!1YG7'=Y^OAYG8G@TI-D6[KEO3<4_ :QFD)VX-C8;%0^GU6+0J,(/,+EFS=
M WBM!W3-'>2*+Z!(I9",BCKU2ZDNO:4JU>W[>-DR/[G5)9P08(^X:Y> B?JW
MTD.8.U [3:$)GF05H[V"F,+9@PVD7=CA,+,O=?WNP^/#COI2CL=JC1N>WK(N
M< P.>Y;WJ@%]@7&4%;\/:6-BP5QE-.LP0Q&+G\88\(,-MA.:^CP=5Z90^C^>
M#:G,N,^2=)_L=S.]))+ GJXGF"#E,Z.0!W\.$-,@T#H(\7S"$:982%G;+"=%
M/E[/W(W4;ZUO^\,I:'W*WM7LR=DKO7$G&V!29T]OH.V@]@K_A90<)T2&(^\Q
M63L^MG@O'G1LBS:EH4,-OBKRX%C+D_I&V7J?V[>BKA79'?64]5T<:*5_;94,
M&ERV^5<:,[OGS!E$]>5H6C#F4ZXZ:$ZRN&@['(B4<#A6_.W'"Q?']\)R298N
MZDIR 8<DWQ"S_G@KL%.P3.EL1BY^^4T89,5:$W5V82D*$).1VX5YX'84T6)X
ML@R$71<O,%Y \G(2\("#FM'4LR#ON\XW/N*HQ!8%)Z.C?9(8I?%(AZX%Q&;7
M@%)@4,_ 9%AK0&0*NBB7G<P73:XA-/I%AVD4K#@?)C,3]TQ]]<IR*W"X-GF^
M6=G?^!!WG"XGS+8.:GX7*YM>,G@DLW4.5.*LJ\A?2-2Q)._"D@)[#/I=2/U[
MSS>,6O,'<[L?>'>XPW!+X+CK#$U,IQ[3 S4-FW.%><"WT8^_1QGPNA@X?*W7
M!-M:7"%SZ=4>3M!6^H:'(OPZ7_K./E85(FB,[V+8H#$^J>?DLW#QT!^_&$!@
M;2ACN@,C?;SAHFK^]<FIO(-M9CV_)3X_WWM7=G\G:ED8:M_2+'X7MO<G78D"
MIPMM(J<*_,3##%'BIB1//4O-HHQ!FMK@$VE[RF)H$Q\!.^N1UH^)L#(\A!1J
M$04?+GBTY_BU&2@/K=5M' !3!RR05T8J%N9X%P6.VYE($?\<DB9&<._%"^["
MO-"@.HH@I4JI&R@FERZ8U!$_2OWT>.XY]2NFL:?NP#T!I2=97%^Q0>?C?IGH
MG);.8 Q W1?>A;G"0?6)>;4VO/"4#T*TY5A(-.GY_8!]F28CM92\E9$$E[Z<
M)S6HHTNONF5ER7"Q;W^XZ$+!3-YZ$/HFISC%]'&0RCE:!Y;/!03F1\GU+UWF
MA6KJ:ARYOZ?:W]I<?-P6,W7M_M-6QCP)?TXA[P Z6DHPNQ4-#U3A6[#Y.'%'
MT\F 1TQ+J34^X+6FU5NQ8FYAO>[I#_5O*\Q;V6&8Z]!@&^&)0[NPQ_AZ9,>C
M*UT8=HH(CHSN>##ZSO^17ZF]Z>OEFDO=*HJ3-1U#-9*I,B^OR!]A&P#L(8E:
MHA'09)?GL;BV61E&H;6%"I][O 79O2\V>MMFL5D1NR$,%&-JH2]H L34N;V0
MR#Z?X\4%JCW=T9_V=A@R&0\S>ONYX4Q]98_!6=G'-K9:O=-"WC'[Y+W<W9&7
M6-C@,NO,.U*8CIB'@\><,I_^6>4.4A,*:>^LEVD_W?VRI/^VE&/\&%=E@[IC
MJCHP8I<@8%H-$ CXPX W:A)'#26C$I!N?<B#/N)C%?ACN)C:?IDV"OCX1U7J
MN.VUHB?MLC$IO>)TRCK!__TS?W0R ,,3LQ#U#731#6H;>3L.Z?4Z+'1^$ 8^
MZG@0A2/I2]#VGU+N>#P[>*EZD\2KC+_[J2K=J:GHONO5&_ 1%$O^Q-.HK+K*
M7G"$]SC:C:+3M4JIJ II^]1X_4A!Y;D'Z3<\WCMCUK\2)9?^G*D)$R.NJ\W/
M16YAX<OWM7><X_.OM9>N4&U7JB5T0RQ-A<QT%0O>/O[*YG"5[>\$M!18B3]O
M,R$^1+!&>DUB%$/ZNA$' WF]?56G+VAG*=?[>,M$WA_OJ-2]HSN N1U(PANS
M<'<IE<A(#41.-U&O4C+;4 +>#O5I^>#4D(KJAF:[^+?6-YKW(L52KFF\:/V.
MXIA(@]XN#Q!3<B&2%V%$5Z?8/6WF(:%$0E+[.K.*'KS[W+@Z75O9D\(=49HF
MY'('IA<1,-M2 7TFF;K"B*6S5BPO(Y-N0<XF<>@,SL\)FDJMK+GSS]JC!,N?
MS9Q;Y)=-,K9E2T\/5_STZ7,IY0E >-88%4MA4ZM%3MW2/6PPOG9]\B+R<?-J
MD^^[1OU6M*+N\?T\87D+NJ;?<'-O%=@7(5/,@MIJ!"39#G@Z*TC&)>N9DW!\
M4^!%ZT>V^VKW1IR63R>=Y)\-O,?[7I88D/MG!4U&X;YFM\^1+V,GX6W(O72E
MMSX.XX^)&_6/,K9M/:<V_6IG!T-HGSUCVV?4$Q3^&@Y<-J=Z*\!P@WA0OILN
M408AJWV#-)>Y,&]R::*!M(^S-+Z^I3ZUSS:COWSLSHSN,YG'".G'R=FK60R.
M@O"]EC]MHJZ2SVZ@G[-2^V%!S4PB8CUZP=>H,W?/6)U:A('LV.&2IFC3JJ1M
MHRS;5>DJ]^1/!F4'JDIEUWOE\+8LP=IN@P3K21_N_-3V^A$)+\_6WL/1$1=F
M+GWX;J2_<E46.&C7G8\;0X%R:O2#I40L72"Z+1."WWR!#_LV!+TIW$%HH57K
M8UWO,"]YO_O97(T[W(I0U;*\\,;W,[O=&$0TQ6@F=,$12*4!DZO=6#ZMAV73
MA^5)7-%!<-[9F<ET41&RLZ.YGTR7O?J&S;/T&>X>,0Y_M ) D .($'7@Q1.?
M.9^F1'TDHD5#%CHRI32J(MI^Z3^X:&MF+29N?'RQ7:Q7^6SOT182!.?H$$R)
M*("6U0=@/T L0]<^Q77,281,DT2C_\3K"\R=<W02<-2J/VFD/*R4HBF@O>EQ
M W/[!M^9I2W%?Y4A4=KTH2:RG#M,3N8P1#'4D@UD(%HE8*!B_W..7\_X=4@J
M=6K@D9[C]&!HP+&.V$,^MKYQP_Q-L:?897-]_F1 +,7C?S*<RYC# .$%HGKC
MJ=;[#2V\"/T6Y=+)>DRG?]DUA^D+^I+MGM5,I:,3JQ^%V!:P58-TP=_$P35V
MXH=:M2=(^!:"<\J)4S1@VF0$[2T1T+ N:IV1Z_OAE( NYXQ_PD1IR&I[#=A.
M$.]*\WGKO!SL4)Q O?M3^R9O5^ZF24]-=[/ZQCDC5:+)5=>#G=Y#AH@<)/G2
M!JB=3<33!7FHN9$D?)2>U<*@2$A4]Z4/(^6W)A9K/94=[K[^79K&X?LCU-DU
M+%7[,]V# Q// B@#].N@8P'='[0AH3G!U"&_9B3IF^J2Z>B[9'I#_?O8@G1
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M8\7"3W<IL(\JX/H@4 #JCE!/UU!>#!>.&1QQ<G!-7O=LUFSKN1FS/+SO0U?
M]T"9_!Z$'Z8;3;8$(A$-&T_<QUOXZ>>^A'GX>;(U-33<C]KI$##4</CT1L_P
MF:&'H007!_$+5_6_M\VN!T&VP8,JZ+9!4&:)+HTFUVC"8\27Z,JH=?C:'&BB
M[*O:G%SU*+/_=\M0P-X91H5^4["'S]*=O1@\KA4!&@0P?8.9/_",MB]<7Q 4
M\8:UFEW8.?@ZZW"_/F3',X*.)=.E<FB*WV;;A7*YP3\^DDFO1R[F>QD?X2#6
M<(Z^K#R3DY=[BH-R?9!^,(#)2V.D #Y(\-AV&R(&RV\ <:NVLPMJ0EX!UW\^
MB*8?$Q_#3;DZ?EC@^A2Q?O3Z486VUY(>%1:/--X"A')\Y4=&6B><\#!>3*+H
M2TB?DP<J[V$7^K,X[ _P58/)XT/39M73T-I84XL"^*6S.^/WO0(?VM5E6HQ^
M,U3NTGS.B?7D:$@=]F679\_::<,_QX)J$_2#Q0 Q%BW1(D4W 4^3 $%6_)T
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M-H;B$*M\$QGJT@:RYD=.8=AE4(QR86#VU!\U?J^=S*@_I_<*?<I(YJ!^0'0
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M;R \<S59%MQT<U7.Q2&C[YZ0<*]N=>J6:]!39ONILV\[E K3KTM:?$ZV<D9
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MOCQ/[FH^_C-E^G.5Z?F"/53K)&ZPTY6VMT['_/G?/_Z^LU,I.?F5F]0?.<X
MT#R_?KH*5=O3DO,C:NOBW*=-"C?X9U+5!GV[^%?WH[FKWG]G>NBF1%$T-8\9
M5&_6?YJ&CXETO+3[OGODZ14K@? S=OD'#?A 3W@^,_ ZR)SKW(^ 3PAA5)[E
MFG/%9^?(!6"SEQII_MJ@*?9M@=1=^3P1_6^?S@TE_TAZ=-=&;5M$1@Y-CZ/
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MJA@.45432IB4S^7]/CLK:LZ86T]9Q!_\1+.8=9:;P5<7+3QD_&1M!W7>XBS
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M]YZ: R*(6XL8>SFA_7_2Z0<Y.]X8I6G;.=6F+C8-[EANC$JR?6;L(R:JR6_
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ML^819FAWGGJ$L''V Q='(ZY%A.2GRL*7+>J_VO)1QEVO^-=A\!H90KP.@-<
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MH'IMPK7!][0/M:F[:C\<4;^SXWO%'@4!%6ID-B(M?DT&$N.Y$'X 814C4#Q
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MTMAT4G+6%%=7.*<E;*^C14._;KB&:R#_O<R*[=KEVR,DIS<=M\*24D!#%&N
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MZ?MN"CY:^["JH.2@]%JKJK*W*XKUSP=!2!P\9XE0F>K^M8.:;9.S%%DD_E.
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MZYSSS^^>M>Y.WK6R)C-[]KOW^[[/\\Q,POS&7 0.G[9UL 4@$ @0S7H!S'G
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MJAR[\S?]8(/B0N]D2#*FQ?/7I'@7?ED<;WTP?B#W]E7><-*.F6:-BXWD:IE
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M$\!NV;&2K]M2#+.8BV!#RZ).TXM0#J_!]BXY<;)+!2PC-*2L8WH/B?R8=R3
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MVQ"@AR?KY/3NOE"\W_]SF)?CJBM;RYW<XA@VZ" 3N*D%JN"[8*(H-;)=7XG
MCR F ,/6WO3_HO"EJ:A<ZO*7#&G=LI.Z\280N_RFY42H'&P$3K+%2" +P[:T
MJJ,C/Q,OO@@N%/F-]PCX$TN,IKVV9Y T72WRI*9\0(6P?MQ6@B09FSA0T,ZQ
M[!2UNC7HH[9)O5/,@B:YKP<0JABZAR%.S][SMD5ZV_H(1;>[V&0S 8]"0:$'
M7Y:M^6),A<V>U:M;*BVJ G"G_\1G>/Y_^W\U%(NJL!O3:\V<2953O3[<#*DQ
M)<1A,]\F@[$R6-.\IUGQ)20,H=[H\/[?>JCHRY9R#H8UNT9N).![1[J#B%@Y
MT+?7R$XBR6U:8TMFM6I$,6FN#0Z++K(C1Q869B=7NVUXQ#[36"BYG=\W^.D$
M"]3P'U JI  &-R\)[TP:-<*);N\[2X/3?U%TVU-?_%+FCCW9OB;IU&#"MMA>
M_R.3<"=]@:1"$R[>H=P%]PDYTB@)<N>+\N@;VWUH)=(TUM1!MK]X*E=:57K(
MN&>(FVT;-L#%.2.&$.T0?A,]OMHCAM;^I$ES#Y:8*.U^W?6'S [4!T+#O YQ
M#VVKO<:.XL%C@]W/D8OXOC!>])<2@7,>&U).RX+(] >&8A+VH3)\-[R=9Y=7
M'_K*?L2^1EE10Z*-'.D/Q9<^-*5I9/7'&Q8B<3O2YV^6-MZ\\_X&7XV=C4MH
MDCYD\R/9KCLO>K9#HECS4]$ 3_M\[\;KDQ% N]'R_/9OG<:5\85G>W5/GQS/
M.PLLY_N4^) <2^+;!DJ+%>@O&4?"/I"KLBH>[:UI0GZ(EG6N*0-TO$$\#^<A
MXQE.6/KODKEJ8FL.$PC)F6MSGFTG5+X[X$RZFYHGBSG?>IMM2US<6><"KYVD
MPM$,>?V2Z-T* '&R#A=8DFQX8H)B,]&'Y_1<GV^)2_1&3P;\&!I\[/>C&!;Z
M%>_YW2:"[4ZW@A-?NJQ25I+:,4DVP2^""YW')S&+#S&-E!)"TQ16/6++]=QL
MZM>5KU=,1N!$KGA;\Y3>G>+F&?00O,$H ^$W(1V-M6\B?V$H@TYQ2)FVLT]?
MY5.JU3XP 01P$ZAR<6I/DSS?J@3]%1N6=D6P@_Q\\+X&[?++">)(-&VM26)?
MPH.AU&4Z!\SW$/Y9SD3U3K>=IO6!3DS@V,M_J_@58<R::"WZ^2>(%R[-XEBT
M5O?<=M%+)$/STUWS@(M7'Y^(K'C=&Q8>V9^8(!+:_>RQ/*ITUQ*K3Z\UV,DZ
M@4EJRE);1*<%Q!%#_/?FO((/DE3RRZW>YM^R?B;\$!BZQA@18D=[H.[0"VEV
M5'/&5Q_(MEG04D:)'#C1=_ UBU']RNE#KI+GKW-VTN\UUSDA#ZX /:\D2F'S
MZ^GKZ[S20:&:_MD+"T>UE!K>7K*1=5")/^Y!ZV>=>^(P>@[>0LFE&@9Y_%S)
M6.07T+E#E%3WX8ARN[_;&!GRXF4:])"8K;\\!:"NVM-?=(J"2>Y2M@5DO>Z#
MQS5C36[N&]-YXV?#<S3\-)X]/!&%M<*F,A3_O8R(YD#B86%[$]QKX@N2Y)/S
M1M^:<5N.&8D!4%7_;#L_57M(XIMGPHD"_+Z8[J.80)@@S0J,(TZD,'3?OVN?
MH?%'R)R;B#D2DU63///17RGO>IZ*U^IV&XQ0"NM$/B4/]L,X:#JMS>_(.1EW
M$=S==[=D.]I6*OCS1KO\WDBZ6Q_F&I)KGG+]N4H3JQS7L.[#-.[7]L0\=(ZJ
MME%8SJRV>,8UM/JB%-:.(]2@N3"3?B"&"23;L")7MJZWBPD(F\')AI]7-KH9
M:I]HKLA@XK&53_L284(JBD?<7_KSA(_SH_:9@, [^A/<KZ=,X"?F$A-8+MS'
M)S"!Q@"6?,>=_:J.EHT.09F&O#F=OZ UKZGIX6IYV2&H_#; 1N*2*0360SJ/
M1MO^'HB2.]Q*=LE 9&@L_:[\Y/OE&A+,!W9898 WY6*>SF^8QYK:;V&"$:TR
M@ZA%CV9%6[E+\T&4I0P3R+(X$NU*Z'PJ5T'$"_UBB$V5_W.RX-Y7FDNX_GVA
MPV:9I2T0X_%H@_=AX:)?!"?8TO1U5>_F&?+5E/L=MCMG=X]&8A&;62;P$0=*
M,P98!.RSP\8:+--'Q, Y"5XO4+%D+F@UK8_C\30H$A%0?$K,UG_X>O&^IC1G
MSN-X\XL#)1(=[*2%0 (Y+(MF0@@J_ZDXW8R,-;RYUY4[8P[[Z<$0)S].6,K2
MB8 +L##]@3[%6/R>]_<H'6'&@1#"@S9!C\=<*TG!-.5T#X!8LE<P_+"9$Y'_
MY,:X9ZT+\0@DV^5,^ZGU'<60[XXZ$C>Z9)V_^$#_?:!>CINE>TV,<FB06J24
M2Y'%<X.LF90Z92.Q77'5RX]/1L6W.\Q1Q\]:270#!X7OF,!AVG42[#[*"4GX
M$34H)SV)LHIHW#PX^Z+:LSO*\'>SX:EMR58Y#DZ5BH@"<4&/;J7?0P][I0IB
ME*Z^></AH+0'1&&[G3,7Q,DJ6RP&P_N;DEO_>#FP4W9Z2_ZM996N^V,=S87U
MR5,:WO53H[[KEIP[<:++/@T! X$,!'I"CHO\^M$-7.=;MV:^\)9=K1\3@U?]
M;!5GD^]M 2+G;?ZW-=&_E\FW#<CB-+'\[LA[&3&4:<QUY-V;U_5DD\;CXX[^
M[:S$74;NCC!X$A9+#M/XZ>6=THS/%C*-L=6\[K57OQAF'O>:'W(7L]UL/'DF
M9E#.?56)!Z [O>RH6L1N69%FEO#W0PQV>,#JLT5C:5>6SKY[;[^C_FW?X:7*
M[8?1$S_,+SVTJM$29\S!><VTR*8]); 0E!4L#>5-E+4U/V&..)FKV3G@P_#P
M,@ZI?S5DZK!@-71!UY*S.GJC]YY*)DJR+A!]-)&W!+8N=F'>9_#VR8&K?D<^
MJFPO^FUO95*PJT5=.%+..E[\+BRE#9_9K$A280@[R&H=O2BBI[R?L<6G>TBO
M3X%OECXWY"EK13=EY5 E>O+>XUS"#^E%NP2S$;PL2%YJ?9_R:<5M<SDNX_"@
M[7.&\Q^Q,_3%X-6^"5!Y)<=H4^T&:<2ZM?4=>2%)&ADY5Z@I]?O2L:+[$YQ^
M;\PJ../%%- _@;BQRJ"60LVBH*IOGC8!OD%"5F%A/,GV99=Y7I7> @# O'IW
M@L'%!*0V$'*=9LC6VM7UP9&+M[Y]/S5SL:.*'/B)(;K#!$B.$W/%SEEX+GBW
MQ=%WX4LX]C>SWS6Z%3RK=79[=3B?C^0<H_Z\E%_0CWI-P BUTH21#!Y)XBO:
M9?9^7*^/Q--"M5]$];0@LQXW_W,FOFSQ?8MWLI:AC]B@%([TY29,1C$G&9:Z
M-'-W0N*7T9Q:)?F5U>N3GY9^]%Z-V/G\#I&,:Y[IQ69AQ)IW(-'P2V%"7H%M
MT;B.:77+.,134;;S(R4+1J,"ET0'T->M "@1?Q^_6ZCU +=/,&+D>LRL_4#[
MH'0Z6Z=8>=]8(GBCK5@ML+-;];?RK8R2>L_P?)\*'.E1(&Y/_"T3Z/J'-1/
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M+H!&2J[)E/;5=9F)>TU$Z!NM>2(0B])YOMZFK/._+!591_DN_!]0B/VO;!"
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MRS?HBY-DXS"^F: W+':C^$3MD.*8SFN-@)II#:ML<]M:M\\'%)Q4A,44G=T
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M4K;)=VEX5PC/JC@NHWOK[>9?HN'WWT@46PLQ-;I(JT<62>MSP5S@&9%@P-+
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MA";-+8_83D_=MKRT8/Q=6O*G'H]T]\609'0$C!5XRR,"AW0].S*?_B2_2U=
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M$R1<5QLN-QNES@5$S?X<\V>VOX, [@[B AW]_#\T8E 1<RO)S9)5=(WXL,B
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M?;0M7CG!__[9^R;&\3PWA4$F-!A5,EI@G!W[#:<59P$I.IP]J>URVRJSWBW
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MQ10@/>)D4DF1RZ3X@-.@MS7=1MTXT,?0VU>M[:C=4%HXX&\$V+RK@>YFW*-
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MJ1>8P-J'I5]QK7UBY.50B%J@6Y3%86>+\A<%"OLA]Z1>4ID#%Z 6#'YF,$L
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M/*&P4BJY+0:=AG!L.EAZ=^+Z6$[BQ,CKA$;.,S=W?0" <]> +;Y5FB<X0K^
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MAEE>=SXJ[([ :$72J[+<MAPB3E+AI[2\.8>0V#.+Y=FC'&#3#K!?FL5S? >
MI9]AO_=3X@X09:% /4>DS8-=TV.]/*BN%KPF40>.ZJNGF3BKM!??:LD:CU-X
M] 7"78'Y08S$#$^5MV4L95-RT9[^6<;D$X>R#H9]7U[9?? -_V>W-NOW/:]7
M+X@1&4?J&MGJU(+]OLB6;YC.K1R;7^>6DVEAHQKT7U^]= DW:^*TY.=?>=]?
M:L;'X%28*9@S8YA^-KL^2Q48,$B^7#6,&:AL=GG>*YC@I<A]"N"6E9K0)C?
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MK.PJTK^D\M?R]$,,==0HRO)QYJEO!G956%OV\XJY:(DDX".IF$WC3]*S03O
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M%GW_)&:X$L/?_[ >"PU@:&86%J><+PZCO9Y]\YE)&O,\+&IZ[V">Z.O@WR(
M8Y+)5B=G2.2SY!@<ZPAXF[PGC21<[_$!]FZ;5F'O,1OZZ\K/RSPEH_:ON79W
M#K9G'D9Y#!$"$26KP:S]BR:H_+7?)M2Y5N0'F@W8U;JY9V&C;#-)LK50GLCA
MV]3DR$_-"R5,1SR+#6;HOD?6ZG4XE0P]&7N]JG3*CI+7?;3DD[TG*W50A9N"
M&P#-AH_RJ?CN"OA:4'YD?$8.F@; _CN8=,\4J&01I*R)"X0=I"I5U"<T92TZ
M*KR_H!^J'1X1YG$1?X8(*\YNN(]^RJS%"Z/8GJ*7F7B?'*F $UNTXDJ/E LC
MRBZ(OKV:K#W Z7K"0/]E0%%(Q^0NPM5Z,Y(-M$-"?% #>MBE<K0]^L.E>[4E
M]5$&1S\_"^5F!''PKV$2V+KPEIE6GL'_OFP'V$O[Z.LA%G2E;V7#TKYL][T
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M[**USBI^-^-4-#CS(P%19 86'9@J1RP1Z<YH)S"$LCG=$:ZCQZPH0IK?[/V
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MG1C:0\]'&"YDF!FY(E^U%:??%]A:5_-$_;#]5<F(HY?$CZ3=GM>[& G:G-^
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MDA;G]2V/G8J)OH-F[!ZUN ^5WI-G'( N>G=8V<U=/6SW22^.D)_R7[:>P0Z
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M,,*9^6HK^],B(VJDBC(/7](\F5^J<2FV9>?-6!@2V9I \V(#9U=;D32E6C9
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MV0 WE& */D Z-$H\\C;FRX:,OY;3R*@)CDB<LZV**H,V)'T#->W&TJB! (6
MO#Y .X"_!P_/68AXY4@+QLD9XFSJ#XQ4**8$??Q4JD,%8FMD9(GUPK0C^^.8
M]U@' 0U@& !O7_ 2/D"9:\/4;3+V8)M#)I*D;M5;'=TB*.[\KGZ\,YC'S=.>
M.EDXPJ%+6@=+@XWWS#*&<#'<A?G,()#HCW2AJ.[?M!E>KA@Z@*E&>%P_( DL
MU8SJM1XIY8@)YC:L])@3IAVPZ<+N=':D82]0S)H#)::B,B/E?*^ B/ /O>R\
M[X;9Z2.?I';PG:G+EM$5;F #'GA)'\1)9@Y+W#?O;,ZRKX&^IS=ETN.:EC%_
MFZK1[0FE !!9UYNT04O=!VLC^D,)/&W3VJ/S'2=KJY1&J>>::T<%=HC+&?DH
M-6^,S\1'&]YGOF^0H(P1XQ,(*!Z&7*.\_-"&2K&\(F5GV.O FX&!V7;F++=O
MYCYRM5?3<][LDKJ[9@&=O8_E":B^[%%/@=Y?"9VX&Q&:I.ZF.E1X^?YU$5YE
MY9U9 S,#VFAZ)&L8M8>A3C$CK#9C8\?LZZ!I<+<D@[H^7(6:6Z9]LD;<E^Q@
M]T=5_M<YN ??)W=@P*"OT^@=@U7P<\R2AE"B9#$$6UF9X_B,\\DKS8']<UEL
M0+7Y*\5H+W3VD:$&I2O>4(EQC:9 Q.ZQ(:;J-V_&J.FL?;_X7:/*0H!WK==>
MET\F<7U--NW%&!=12+^=#9!MD;BVKB:^]Y3K+PG8&$,@GY0UX1,@ABZ^+*T=
MS'=H5>E![X^5LCV[@6>/DVQH!W8E$+#\K&$\I-J&%S;P)MS#6L"K&.]R+K,[
M)%!N)#$SQ\3.K9E[YR%)Q;LN$(9(_R*$ Q[%+&+)^1UPH_QQIVZJI%!G($Q0
M:ZI+<;W;3K.]^>M\_\>E3(X!Q"CDK0$;>+?:G"X=7C2+36$8[TK03L)0H'$;
MS@_?8QJK@L6*_]A/-*?=>&#->37A"-X:!*,:&_C:82C%!J9LV(!U6.@$8GKF
MP#!<C;Z/8?]A9"5S5"65G]@J,I^;%[KVW$@_<X7G>Z2##(A+L&.S]FZKZTTH
M\\3T9YXOH;\^S")_686U0^E !QLH[I%F*J+[!CC9P">_)@50FKC5F3J.GWFV
MC[5[ U[L2,8RTVYCMXRC+O]>Y.B+8PVR^(=9"O!PREA*Z( \+:TO$"=C^?X9
M9BC34T1I3R?E/1<G8-2ZZVYX]Q!XP1=D=UDXC-6E#V,J-*%KF\!&=.N1T<R8
M<N3/<Y]YYL<8HM@KE/1F/*Z>&$B:J B/GV\OE/E,FMD\ETE($J?+"Q4Z9<)K
M,E7B5*.7[:U/9EZG+?-?0;:X-PF;'%'-P":TOM/[Z'9UY/3.L+W@XY!KC]7O
M0ZE (%.T9)#2QK)5( >RFE78P/-0?F!L^X5\/$V8?A8<K,**%VO+MZ;-_;:4
M!"T\;M O52JM_2'B^ 39V+WDC"*?7XH#2\?<67729@#K!D)A-+ZQPE@V[HJC
MD:S;W1%-M8GYZ*MRD==8N#U8$IT>R."C$0(?'?=WA]%,0G_I<B79)9EDVMA^
MZU]>8"4WZI,0/<F&IQ S>-FFH^;2+A*M/I#8XSHW)'L.MZ\D+ GH#BUAW78I
MSL+]A!GB^L2M_?=,R+_XWV@ NQ>F+H+C'X#\FL;09P-O2=@MZQ'L3C;P31,F
MB20!^"UEFQ=@JZ; 7I6CA6V_D43^+'C%^1/:!EU36X!M+$BPHE6LJPRTV,#^
MF6PVX)J!_+&C^L?_:3_Q/^U'OJ(GH=03%,CR,8HZ03?IEDN(Y9!_@]SM38GS
M^"3=?L'/%O?&7WCMSN@_F;PUNCU!E8M9";T6Q4EMHMWT)TS;7L@_\^764FQ8
ML2_Y[ &=-;$CGWZ8XV4$/8T/?WH]($O_LI>#+)Y"EV1]"7.Z@9 80_I*E3,.
M5B9*1QE^^3KBJM")/Q%CSB<;H)FU41YX#TNV>LE$07UAW(PSY%V8 +AR\4*Z
MSYN))9&>H\\B;BK9FBFUQ)!VKB:]U4G/CN>QW3RUER-AKES&G"(1 S_],CS:
M]);*LB%Q\OQZ915I54;UPX#_R])U&(L72[;7A]%L$(=Z#[RO\8$2Y :/>MWO
M'.!_FT=H%3$2A-]MT5/9U_V]*9Y9BO5$I6*K>9)KU+3:L%)9K1"!FGS'Y0TY
M0=SC@Y(N[W8>$7L,X;QUW8Y'==?I_4V)-#5R@A%-F(QM8^TD]P8?3"^:_'6L
M^QCWY2>90Y8*P(X5$EB#] 0!S4]W68)]=N U:Q!5A4Y!R'MOQ17GOEJ"7ENK
M6(V5M/U4'W][NEKT4[M1\Z*)$WA7'?6=B+Y"69H#L;V2(M18G,K,>/5<12;R
MQ1&[3DG.ZEB2WZCW4^&!2"A-V:8#>_?D3!G2"YL6$F[3Y@3:!N\H86?,>HYX
MIZ:,7U'MCM09IUI@9\'3PG5J!(CR,'0T2T6Y YG,TL?2T!1Q"<W+5V9*U6JR
MW*);7![5'W7VFC[[$1?]YBU=,QGXA:1^9B;>P/IB:6;:T^KM&$,^RFK\>.WC
M\DF%FZF+B^B:[)'2BJ^A;N>K9&7''AK3]["&('O*D 0YVDOZN6F;V:X=^J7J
MNW"_PG0?_/2><4\T4JQ@ QKRP<5-F\^C#?68N6S ;3)]PH.:34&FP+5>^\P3
M1M$OA0R'S7,L"K>F[][=U'JK$$_[QCJ:=M)#S(M:PHQV!R5E?QNQI TK>86A
M22NY;GN[W/?^H*O_F628GXHBJ56"*W8?[N/ICUM;R0#C)T67(5I"7.T2X@%%
M(.X+I8;A$^GG>?*'M%69?V")\9W!DR8AAATNDP)>_/GI9SJ"RS>@)-!YVS+!
MGO2"\3$,1K4%K&PO#++&OD^/Q^_&%H0=7\($\<0]Y,P8D::> UGQ+\H_MB '
M%Z*44L5I@Q6LT9DCM&$REFB=,-O3Z"00Z6W5*ZQ*Z<QY<'K_VV,GX7V[$/?.
M\[Q#X&'O9C[0G1ER@PP(@0FS&0Q4K?D1ZO5^Y%Z\3BIH^X_H'-:O.HGZ@].5
M#1!.[;<1ICF8#GT/S?23.>1?,-<_>LWHQ7WJQS+4O2WU9 -]\GS;5F!JZ".X
M";'>SR[]XA<WHZ00C?XKA^R:H2O)2X<XO\$ Q,<F!7+Z\L0<*BU,>O2Q3BQZ
MH?B3G(Z",J[(/Z?TP[OZFZRT:6$*OZ'"]C<I"<M?9F%I]ENCC[EC"4R]RS;%
MGY3HE\I$%L*.2@1 AR1>LT1A=A>,Y$7IOH@^)/D+;$>H,)>S"VX!]VEZ$K^
M&7O5MU?4E.9^.P;A77CI(XL)J0PDX< LWM4\">&><<4MYGW-S96.?_WJ<BGO
MBG(&63) )FV_8Y9RQ:=-W[\*V/#?!4Q&TM0&&!GX!"15#L27!0YK7KJ>0,UA
M1B.]T3A;I\:$=JA$PRDDP5S;.659QK*NYI;?H>E'IG%%T>(J4@+=IZ#2 %.
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M2S [FL"=[8(+,I6O&W=L?M3<Q%#\[B-'1@<U8=UXLET2-+I-2,^+V$7HEV#
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M-9E2CAE?H7M@E*+#>(O3E.+_CPR&FNR+93@I()G[3DK;>;)2DZ:4]\?^]VX
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MU$N6F*A4,JJ(3Q3>&WXL\'5:P5)"VZOK\Q(^8&;2[O,O4I9<EYT)J.\><L
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M<:V-UBC+*2H,,0YR8\>\^K\*L@3^BCNY#_H+YVC289<+:S*+E5^SNO(^^>M
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M"N8"J0ATYC-0ET2[GA:MC'A?+[_"X4(Q%W_V/J.;YK=?\'KE^-5\^F>'S2G
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M( Y7744@S<L(.B9=?<9[)U?X,I*E^_N9K(>:(0,Z-1:%1->]>Z0DLEBR8G2
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M2_ZNBSV"AS/$AJL.G<Q7VN%DJJBVS;BH-N/^]6F!0EK!M8?/MD]N_U",$![
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M.-6-KA2+:61KODS4(W8%95M_\W1_7I_6.# 9?-/8./:&;^V&ND!W#$S!ISA
M3#$$!O4QU2)Y?N>ULL@=Z]]K=DX033 7?F#]1O_MA]=+ EI6H#6I;ZTCN>9U
M)9QOY0 >(C_#ZI"=,"M@9ZTCT5.D*=GH!L4M+6Q9&=>LS^%+0]$<I2AC8E6C
M%$MZ5F[[(W?[4AWE:XVNPJXFKU =6ZO=JK[&<:<HW]#$>)^:#LHE,/\3*-O!
M.U!"^J-W,J$F7KT@.IOE16CX958&!@Z:2;(5N)S.-%+I0!9CC<?/H$U&LT:0
M'OMCXS.G=5N]9;_HJO-05DK0>B")H,: EX[!940T0X94Q9P*I_JEJK-L\9I>
MM-H/.)_X^92]F7GAZU$T%P$MMTEBGA48#^ '_5J3&5[+Z4\Y_5Q(THH<$W7(
MF9Y*G[U">,[=<AV?-0X#P!'\4H<KRQJ4HUB5X;.#Q>7[$BOC"B]F7@Y>G#5W
M>5! Z_C+79V/(@*NX/LU\4_F7E'X080&*;!LA-#<T-1(.EOQ8'8]R]2.;5/5
MOF#-"*5VE%NT"P%U+Z/\69/FF_QTFA7<S5L_RZ\C6]LE_^@::I+E!\TH@S82
MX#T2WWT20UNAS(F5>I?<AXDU"HKCURR -<DK#ZL+.,BYIF)OJZN:>2@#^^.\
M^5'R5("O%9<RQ^94@W%D=\2^^)ZXEKIADJ:8NM.*#U1RC<[@%P;C\89TH PN
MKN/Z#O*^2?-'Z2VI#4'36+FXYX#"CU[N-1,8+Y:L!2(/;SHTGR'I=)@WNN>L
M8NF/0*YS-V:R$IB0[\Z&._^Z[:]\:JM9/&"PO7O;47;%1K2>Z+_YUL/%N42N
M4%R6U9:Q-\SJRG6Q=&TGQ19,17HI+N[U.8KL>+/PFJ#T*-)C*D8!JW*HXI/
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M42B[-=L)08SVR6@_!M"^"@5E+S]A[<[')0F?WZ#EU-PS/TKUA <E!EP::S3
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M?AL!X69Y?@,9VHVE"T D[9GXH<]WV&ZGDC!LD.IC$REZ%(FQC6,.:,, .U0
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M+Q1%6W.08'O'%O%EEZ[*48'LR!?_^\WL=>*U<3BBHL_?^O>%7Z0-V10=D/L
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M61T;6>0H/Q02XF';=Z=?_=K6H,/.=,<AI!F ^L_>GOW_#*X;^QM02P,$%
M  @ *T=:4FWY1TOS. $ +K , !4   !M<G-N+3(P,C Q,C,Q7VQA8BYX;6S<
MO>MRY#B2+OC_/ 6V>VVZVDSHX@4DP>Z9.::\]>1.Y<4R55VG+6TM#,1%XE8H
MJ"$9F:EY^@5 ,H(1B@O  "GFF,UTI202</] ?' X'.[_^K^_WR_!5UY6>;'Z
MMS_X?_'^ /B*%BQ?W?[;'WZ]>0/Q'_[WO_^O__6O_Q>$_^?%IU_ JX*N[_FJ
M!B]+3FK.P+>\O@._,5[]#D19W(/?BO+W_"N!\-_U2R^+A\<RO[VK0> %_OY?
MR[\&C"0B2P*8TC2"2(0($IP1&/B<$"^+TB2)KF[_FM$X".,P@QD)?(A\(2#F
MO@=Q0E(FD'PPXKK19;[Z_:_J?S)2<2"56U7ZQW_[PUU=/_SUYY^_??OVE^]9
MN?Q+4=[^''A>^'/W]!_:Q[\_>?Y;J)_VTS3]6?]U\VB5'WI0-NO__'_>_?*9
MWO%[ O-559,551U4^5\K_<M?"DIJC?E9N<#1)]1/L'L,JE]!/X"A_Y?O%?O#
MO_\O !HXRF+)/W$!U']__?3V:)?IS^J)GU?\5HWL1U[F!?M<D[+^A61\*:77
MK=6/#_S?_E#E]P]+WOWNKN3B<+/+LMQI54F9*BG]6$GYQV.=_7R!^([DK9_*
MZD XK>Y[5S*>PO2],W%O)#_P\07N=7.QR,T']7K%IOIV-UU=+/KX$KOZ+(J:
M+"?X++;=]$1>JE_\(O_5=J,:.D&FNI^6NGNB\N\U7S'>L.5.TR!G__8'^:_%
MNH*WA#PL/M^1DK^01,M>%O</?%5I_KXN2[*ZY6I)?/&X?>0C>52_NOY&2O;Z
MO]9Y_?A6+@*E7CJK#_4=+V_NR.K#@VJB^KMLHJ[>KIH/:>%1*N*$^#!A"8(H
MB7V8$L^#S",QI[' &>.+>C-7%GP%?_W<J:5E?Q[!_V Q$O411BEY5:Q+NEV+
M[Y>'%EBYMJK5&/^\(O>\>B#M"U)[9;8T@/R[EDY:*#_E*U I!:L__^O/6Y!F
M-.++'W8<E^,.H=8'*NN&@;[2H*<UR!Y!_[E6<Z!5OP*-\J"G/=#J@UKJ#UH
MKD # 9"?2@/"T2^EH#O:+I4=5Y3[PU;09QNV';[50R9(E6G,6Y'D^ 7>SWQ9
M5]UOH/H-]/S6=OSCY++__&0V7I<=T*2D9S[%]HF?:2&M[(<:[GR5:E?RO"-2
M%\\[D9LO58+T!U"4C)=RGW< \ W],9XONFW>C7QUX:,XR3P60H$P@8AQ#$GL
MIW*CAFD29"A.A6^R(.TW/+<%8[.W5<*9+15/L#I-Y9<@,#+5FBEOS'['--VR
M4]714\7I7VZ+KS_+5QIFDO_8)Z0GS4U"&,>4Z";TT;_;3;C[LEHM7A9+^>^B
M;+A@I:CAGI<TEZ9O3B5'\.O;DFMV>"=__?M_2B9YQ^\S7BY0E@DAF =]C!.(
M,$YABGT.,9;_1JE /DE,IN=E8LQM,FOQP'_^G5R;S>0+!^'TO)\.VI%98D<'
M()4 6RU JP;8Z ':09":@"^-+O_O)*/!VDFIWYS!J.S(,][H?.(/LCG>&+*B
M*.^;87K@94WR5;ZZ!74A[5X.=H>1G!M&[>/=3JB_7+X\N(&^64Q46WJ]\(-V
MM;BP]4G6%C<(="N1H];L#<6W5)37:Y;+8;ZN:UXUG_B;);E=9,070< RR'P<
M011' F(4"NC[F1<%48)0$IN:C<>[F=NZ\_;EFT^@%17T9 5*6'.C\@2NYTU,
M-VB-O)0, \K* #V/PP7FZ(G&)S-.SRO8-U4-GK8C@(LWM.VV]<.Z5B=DZM#Q
M[:HN\U65TW^0Y9HO>)I)FN "AJG<=2+, I@Q'LM-:!AG?LI3PKQ)?*'G))T;
M#5W?2JY7[G.PD1-H0:\ZGQ<HMKI,Y!<].]PC.T)=#N+\/9\;WV9/WZO]SV$&
M?D[349F%8_.LL#^&)],4<V>N2^,.GV<%VG6<_KTLJFKA$R]*6,Q@YH4>1(F'
M818BY?9,XHAS1)&@4ZX]!V2<VZKS?$=N)\9QFD7EPM'Y@9:3_:,R]1NI[7Q6
MDA-#,:<UY)"8/]3J<0)GU^O&J:Z&K1@?I1"-FT0?HGTLJKKD=5XVTO 5%WE=
MO<HKNBRJ=<EO^/?ZA03O]X5 '$4^]B"G@=R()-B'&6(Q#%D<"S\)!$V-W!J7
M"C(W[G]]_[ L'CD'K<S@H_RS'?L/'A,SBI\"Z9%Y_--&W@[F"GQ1@@(MZ7'O
MNC4)7PJ62Z8=+,ND='HI8ON<>7%[$YO29Z,3_L$K:1QV)/X;5V'AG%U_Y26Y
MY9KA7Y&:OR%YV7@#,N;3C*8$XL17SA\B;>^,2_,DYCP-HX1&?!H#W+5F<Z/N
M1GQMM3-UAE!6ZLRHL>!G$S-G^_6,;/8_YS<Q_\V"8=1=^^'UMA(=3J %JMEM
M  454%C-QFLUUOC/8H?B7+D?8U\SUIA.%P X5,")387W:W7L_$%<,Y:K5\A2
M/U==K^N[HLS_F[.%.O;!3/A0;JLRN?C+#SS+_ !&OB\BC./(\X-)%O_SLLYM
M.=]*VCKA -G(^@RN.8/!'GFM=CN$\U]]&WU!(4#O4VA4!EN=9["(F@_,+)9%
M W%_C(7.''=G2Y=%E\,6H\VB]G;UL*ZK7_A7O@S;>$ >Q,@GF,J/(5)7JI(0
M8I1%T/>)(#R@411E-HO)B;[FMAA\SF]7N<BILJ)_7159Q<NO)%NJN  E.OA)
M"_\O?_1C[V^AY9)P"G(S2G<$Y,B4O-UX7+6P70$M*@C/Q[5:LZD!)B[9\%1W
MD[*9@=[[;&3RRI!8_#O%9F]7+XM571):7U<5KZOK%?LE)UF^E/S%JT_%<OFF
M*!6U+:((I4F"$ABD/((H\S-(PC2&?D!9&'DTSGQB'H%OU_G<^*83&RRWXMK$
M?%M"?YIFQ@9T9-YI))>4 S:H-L+KR/N>^."+4@"T&EC%V%OB;1-9/Q[N$\73
M&^/O*B!^&&*GP^ MVYPP^'V8MKLA[P/;&&9B_L)E\_P7+FW;ZF.QS.GC]@@R
M4U%!&6(0\U"N 4F 8)9&&62,>@%'Q(L9LS$Q3_0U-\IOA+0S'4]!:68Z.@)H
M9 IOI%3FHI(3?&DD!:,<V1H@XM)P/-7=I(:C@=[[AJ/)*\,XXA47O"PY>Y.O
M5,ZGET555TT<&N-Q@M.80$1]U%B)&(4)1![E/"0Q98'5)O1H3W/CA[<KNE:"
M L:S&N15M5;R JH$MF.-X^":<883R$9FC%<*I+<=2%I$YQ%V9W%PR1/'.YN4
M)<[JO,\1YU^P8XBJK!>?E+G2>DABGR0<^Q&D(4XA8K& !!$.PT@D@<\8BH51
MGI^]=N<V^[5HX,NKXI[D*\.MR3Y4IV?W!0",[<M7.Y2JSBE9@G=RL5FWL5MG
MT3">T4=T/S%_Y1N]N2M_VI^W^TU.,DN/Z-'-R6-_'FC';S<'<JOPN9:K_EVQ
ME.]7S0'K=5;IW<0B\&)$*4\ACK"0ZW;"8$I0"-4-5HX1"WVSS">V'<]M#O==
M#>JV>-63_%_^B ,_^1O@6@/+78#I0!AN"4: =^S]P1ZR;>#,ETY4E]L#2W2<
M[A5,^YYVXV")R)-=A.W[0^EJQ3^(E](4R>MV08P\+$3(,\@(EWL)+")(. X@
M]^1.(L(,!3BR(Z;]+N9'02NN3K0;&6UIY@F IH1R"2RC4T<?D1$.HHYK[Y8:
MGO0R,0D<T_+I=#_ZY,3Q4TJ2MS6_KQ8"HR!-PQARCCR(./*EK2((#%@B4(A$
MZ@FCY$_N1)H;<?3C9(B2U-+GX&"0S,AF6NC'WOE<&L4$OFA^TWHYY#1W(,\B
M(FDKU8\1>/0$16?Q14];'L;)G_+J=V7-_2J!T&FSM'77[4,$]R-)N1PFG@@A
M"J,,IC&5["M0$ =1EJ+(*C?SR=[FQJ0OU<>ASMGT1-Y:'DH)O7GY((2<RDOM
MN/Q\QWGS)SNZ/8V_&9,Z0W5DDM1R:N1V)!UE]V>$B4M..]WAI'1EI/L^$YF]
M-#!6L7$IZ_.G3RI&_X/XM>+Z\/KZOBCK_+^;^(HPPFG )+8$IS%$?LP@3J,$
M2JKAA":(^2BUBELTZW=NQ-.73?&.+B@#"P'7%0=$'_E;!BX:XF]&-R.@.C+Q
MM!(WI])7X%.'YZ\J[:.2^PKT)7<8VV@'E=,X1\.NIXUYM,/C2?RCY>L#8B&U
M5TL=1W+V:EWFJ]OF:I&.NM1_:V\>2:;\C90Z3</K[RKKI+3/%M)2BI''?>B%
M7@91E$00AQ&""2?,3T2 D(^, R,OD61NC-8)IMA,.]-!T69E4]; MU9\BSB^
MBX;I-,U-"O[H!W(*ZT8/T"BRN7K:!G@WCWSH#4>G$-AH--7 6$1;3C5 $X5>
M:KFWLR-O1HS( 0&RF_6R5G]3J8RYT4QRE;+8!<HGPS4OZF"ZV$T7..P$<CII
MT#Y]\6=.96_UX^OO5$>2OI>?Y (3'#$J#>[0Q]+JQGX,LS#@:I./,KEN11XV
MVN0?ZV!NBU$G(^B$!$I*\US%!T$\O::X@&;LI<(.%:O$Q*=4OR E\<%F)TM&
M?$JI?AKBD\\YWT^_X*(H^365J]9ZJ<K)[6SP,(ZB)$M3&!**(.)^! G-,IC1
M+$6<!E[&C6[N7"K(W"BAO>:P7LDQ *+=+2X'Q'D/'IDX8(3[JLH09W+KX,E=
M T8AAL3W>>@)(G<.X>(K+[-B3F/3%VB\T?E8%JJFPZ,V<53<S8.RR*[ [<DH
M4;?C<[%KQ!GFS^\KR;0JH*?+].X3(S@G\J><EF4N#A8CQ"P\+F;M71RQ^%+%
MTJ_J!<]"03(?09%$$424>3!%TE[U?40D18HXS;Q%O:F=:A,\UW9AM2@=J07K
M<B;J0K" -L+9WR\]@:49F5V&T,@TU1/N"K3BC1([N*?Z2%&"72_/%0^XI^6)
MR+_])P?X6']IJO84Y>/K;C'7!,,TK[01:QGF?I *I Z<Y7PGF,!,92>G413X
M44 ]C+"Q+]6DQ[G9I%N9MS8/N#IDHUJXYXR@-_"/N@9T;+;88KF1M[%P6&/4
M#*G79H2EA4O3-:9SJL*V//0Q']INN?)<VH!YTD-IU-!TGD@;O78\CE8O7ES0
M<QO 5+W+E[RJBQ5OPY<^<<ISG9/G/?]>;_ZZ(#SE-/,93.* 0B0HA9G (<QH
MC%,4(1*E1NEOG4@SM\5 "0<>BEI*K&H6WG=R@H<VB) O\]M<Y3F2DZW4.MDL
M"Q</GL&2,>60C+R<[)4%[>ER!3;R;N([M_I< 3V.FT>F'*'!-4+'':F)%BFY
M-UVO-H=HJV.S2?V1%O</9/4(ON7+)<CXH9DU3D70X4!;% 8=T,ESU0<=CL>)
M,J$7-#K,E=&E:ODMK^]>KF6+][QL(E:V65L>;U2OVXP@2" O1H1"N>%)Y5+(
MDB8G//.IX"@4S$N-XD@ND&%N"^!G>L?9>JG/O9MS%%V21TW8-@2W4G^2_<D)
MW"8O:D+EM-=XN7?O4$[DXG:E,\26_"M?G<BQ[6Q4S;PN(X_5Z"MCB[VNH=S)
M?[674*KW\T:E*STNVSD(OF@EQTD=<P'(+AU 0\28U$-T 4[[+J1+FAI8\JCD
M#R1GK[\_Z&+0;5V1YJBO\X0&0<2(B (8LM2#*";JQ TG,$J"*&(^(5D2V!V[
M&?0ZQQ,V+33@C=0-1Q:Z@D'G?QX2=VPR F:LZ!C5D5FP@[,5M[DLHM%L)![!
M8VT!D--210;=3EN5R!R')P6(+%Z=6ZVA]\7JJZZ%<+Y0#!8A9FD<0L$B7U)>
M3&!*&%67:3T?<Y9%*5L\Z'"TSS4I:S/:FX-J-@RPK^!X9/!K*SX@M=Q.WN8K
M[1.5MFHCPLS+$%E\6)1B2F(20750*S\GPF"6T!"&$<+8%VF(L[#]L%[+-?]_
M\&?5J3?-1\756OT_[W,R,PSF(.J,+(_I:EEMX/F?5,3*?LQG<2W>I5X_QL7Z
M$49RNJI5 V0;9F_^@Y2YVE%_DFTV*?@6H>#8CT4 8Q9QB!CQ(.940!:CS/>C
MU*.A503PTR[FYCGL) 1*1,O$C"> -%N>+H-GY,7"$AEKGCZNO$O6/-#+I!QV
M7,M]1CGQY+#Y?4UIN9;D4Q:"5Y6N,O2&;\/\:(K3-%"U9.,8R;DNMWL$!00&
M29QFD2<D#UA=IS_=W=SF?2LM>.B)"P2W#9\\@[$9#;A#;F1*Z$#K2PJ4J".X
MK,Q <4D59WJ<E#;,M-^G$,.W+C<7KK_GU0(E?A:J%.Y!$%.(?(ZA<HA#@1CU
M(T[2$%E5I-[O8&Z4L;<@*A$O,!0TA/9F@BTPTQH)IS&YR$3H*SZ6@:#[>#;S
MH*_A*>-@Y[FA80?W]WFMMQ_7*Z8.WW*Y;5G1G%>+A#&*HH!"ED8Q1,(/((XX
MA1ZCB;H'B"E-[ Z]3O0VO\.NGK#@I_=%S9MJ@#ZR])*=@MCTK-\);*.?Z6_Q
M4B=9.W*Z/),_"X;;L_?CW4U\QGY6[Z=GZ>=?&5S.)5]QW6299VOEKO@H/X9W
MY'M^O[Z_7JW69-G_8_61EZ_O'Y;%(^?RGRI?WL*/(AXGDD_" "<0$4$AQB2&
M,>(!E89$0%.K+/(.9)J;H='*WH0JM6(KMRQOQ08_Z=0?#XWTEKSD8@S-^&OB
MD1F9YUIM0%]BH/2Y MUX-2KM/%&IA#J@T^H*M'HY+5[C"F3'96XN%FOJ@CBN
M<#Q0.L=9T\-X^[40G-;Y5_YV18M[?D.^*SOR$U?8Y,M<NZZ[XH%=H1_Y4!/<
MH%S-C7-[N2R^J5C*!1+*1O0X3*GG090F J8\RV JDC!-$:7"MW(=.99O;GS>
M5L[,5^!K)RL@G;!V[.UZ),V8_!G'9V16WV@&&M6 %+O9R^YJ=P6V@]AIJ)]M
M<X-LE 0;+4<@^Y'&P27QNQ9QTD5@)'SW%X2QNKD\7= FU+8]L:Q>K?F")90D
M*<ZDB:Y."Z*(P<Q#TG:/* DX$AEED4UNA7,=6M'W9)D6] 74[D+=!7EE#D)L
M1L,N@1N95_?RQ/3B^%MYK\ KET$?IM",E?/E8)_/EMOE% *G<KB<?&_@(613
M@[I+69\F/$(LSB 6L2H,G2*89L2#/A&1($F<1K%1WH;#S<_-\+L>$!6_!YCA
M">)@&,8^,6S,HS%R^!_6V>F!X&X/TQX 'M3NR8'?X:<&QI^WE^@^B"ZEFMJF
MJALXFYP ^@;.@J@T@0GR(,<L@,A+$IBI:I HHSPBD9?$Q.H"HFG'<YO>G;17
MV@]4;TH6-ODKFAMJEB>$QF-@Q@MC(#LR8UP&JGVTJ"5"3B,Z3?N>-NK2$I$G
MD9&V[T]\6T;_SS]X56_R*ON+.$R$[\<A3#U!(4)I #'Q/)B(U ^B-!.<6560
M="G<W%BOE:Z]43#1U8%#@V9(@<\T%"/3I(-0_J:R7#><'T\/YW1A^"=PGT4X
M_2'Y?HRP^!/(.@MO/]7'X#!6E9U%M5<L<]HO@(8X]I-0I##R8N6/R@@D(O1A
MRK ?$)QYGK"B[>-=S8V$MY*"3E23398MP(:[3R>PC;T3'8;8D+C5,V XCED]
MUMO4\:IGM#X0JWKNC8&Q;:2Z4W$O\C_*X/Q*ELJ3]4E24IG3FK/#?]="/"[\
M@$>1GS$8TCB3AJ G8(J99!0O8$$@>))*P\,N^.T"<>87'=?/4V 9#W?)L)CQ
MT%10C\Q42KXFE$[]HR?I%=CJ DX\U6@$OK3_'2='C@.LG0;L72+/M!%]#I![
M$O+GHDW[@D&O)7_7C]>,R<^_^ER3FG\HY:;_:ZY""ZC'/"$M,9@EA$OCS,\@
MCO3 88RC-*!8A*:%@TYU-#?3K)$5M,*J$FHJG* H02>P>2VAD_B>YD27J(T=
M@S$8,*LR0R9H7%!NZ&3SDY4=,E&R7W[(Z/FYI;/YA[X>_7;5["\7*6<H#+"
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M/UPTV>\^UZ2L?X#AW9=V1/]H;TQ)+:GZ-E\I#[\:]D:*.0VU3TF0!$1.WRS
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M5&T6_3B(8^I'?AA87; TZ'-NZ_?+WDR]VL8NZ969%<LE*2O%! U%6&[[3(;
M;"/G&-B1E]+^\J<JAI?J+F0C<A-[I!;69E%UF''7'"*G^70-NITV6ZXY#D]R
MX5J\.F"[\K$L*.>L>B-E5E2IHH1WJ/$]KS^(#9.J/RN?>;4(THA3E?Z*>F$&
M$8L0Q&$6R/_Q698$""<^-]Z3#)5B;L35Z0'4)]":(WDK\!58\:8Z=/L+:9!4
MIC?"+QLK@WW$%",P,L-MP%<Z@$[*_0W"%9":J%]N]Q;ZL9=3#8:%R3_%H$QD
MU]_<<?W]/^S,$!7\1!C+5=]D"2AYR-5)$E6EMO-LO:F:+A^3(N;U(R!"SF/
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MB,#42WT8!5& ?$)C%!I5W+Q(BKG9EUL]0*$5 5FC"6AD!P'6B5M\?6"R^[O
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M,!B'7Y%ZVN1,;C\=U=7\8M/Q)AQ7)[J1^'<%79(PB&*.!.1^E$(D%PN849S
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MN;X(A>=S#OT,26,/12%,.5:<2<(PBCR:14;'C"/*.#<B;:12.U!]AL@ Z\6
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M@22C$8P\POP@P3Y+D=W6^%1WL^/>GK1_ZI(R*H$ON,MX$F[3?;,K$$??-E^
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M:[4/V58G>_V=+M>,LS<29*7%NMFE?A"O2:E.1RLI7*/$X^$&="XE'#"<Q4$
M(THRB"(DEP4_8E#$&>$D2L+8IS9KZXBRSFT=[4O:KR\X)+_5F$-LM@+.9.!&
M7NT&CIE]!-[X:#H-ZQM1W&EC!<?'_4D X@1=#ELW7K1);U[QBI:Y7KFN5^R%
MJDW[07QL+LPT*3RV98%1'(E 4.@)$4#D^Z%<#I@/"4NY[R4L27RK7-3V(LR-
MY=^3>EWJW5"GB[[)KU50O^TK8<?Y X;'C,K'!7UDAMZ@W)/^..+@RRA%1(8C
MZ)*5!T@Q*=D.1VF?0R]H:1@UOE0:KNJFR-ZGO/J]26&D_K7 GLB2V(\AQH)#
M%" ?ID(9QP2IV&^,0[-40@9]S8WL=D15<ZT1%2A9]23\( 3,R%*[CC_?<=[\
MR8[W3F%O1G".$!W]X+0/IA+NJH_G%?A8+'/Z"+ZT_QV%R0R@<DE9I[J;E)L,
M]-XG(9-7W)WQ/;Y3AH7\[UZ]+^+[B4@C!'G&I 66896ZT:/R?\(T3GG(+)W=
M%GW/C8WZ==;$6IMA]_DJOU_?=^?CE;HFZ>H.ZKF1&7X:Z #O9SL.?)-7E"R;
MZB"=&J,6<!L X-CG@\>Z?_8#PC.XF)P0GFOBLNBT':=J]9DL>?4NE_]3%]+<
M6P2)"%*>QC"C%$O[*LX@\3"#C" ?,QK@E!O5H;7J=78LI\23Q-;)-RR(ZC30
MIZEK-/A&-[!Z(N]%IC6HOAL5U6&Q:<[0G2@X[1WYKI?<:O<[[2J6JX@T5025
MK!Y5C7&N4F8M.>M7*6^2JZCD;'K_KC.TW):<N\RQ8@NP:1S;Z<:>)9#-2+]C
MD6QF+SNY1;U("4<>)BIN(_$A2E7<1N;%$,6)A%M@AI)DL>*W*G&BF3&[UX/1
M;$F;V=+O9[S)XO0&];#;TS,BZ/V;TZ/=F1[#$-SOXCGO2A\SZ(X]-FS^=LE+
MV_R^J9R\B4<)Y(&0DS; !&:<"'5_-4*4<)K%1M;9X>;G9H9]ZN?I[>5NM9O!
M>Q":3>#AP(P\?S>8;!/Y@Y>D+!]%4:IHB/-9IZTG]F$L7,[KO1XFG=:'M=N?
MU4>><KD3^UCF1?F;W/;5?'4C#3.Y,52/O"_JG/)7Z^:%11+&*,;,ARF*4HA4
M:;)4A/+'6-"89Q+?T"C[F0-9YD876FCPK9$:K+2L.I-WO=6@O:GA8NMA-EZ7
M;/.<C\(S;OZ:P6F5 3UM0*..BFW__\E[UR6Y<21=\%5@-F;356:!.;R )'CF
M5Y8NLSHFE322JGMGZT<8KIF<CHS((2-2RG[Z!4 R@G$'&""3O3LVUJ7,) GW
M#Z3#X7#_O'0XL?4Q-SXVB][G:&1F9;7W*QX%H$)]**+A6'XZ]2$MA>!5TYU8
M\^2K_>3AMW6XD9R9M-/E?RT_+=]^7_Y?ZC_?_J)O>B3KF;E9_"2/3PLU]W_Y
M$OY7\BF,W_Y%[5#W>$/5CZM29ZM*PDPYEM[GOBA;K)Z@-[*/J^7Z0;U?VD58
M/Q3J4B4R)R_5X+M8IYGOM[>U&V(".UXG+.SVP6Z/[.==O]7O&JM[YJA_+T1S
MRGWWJ-ZYXA^U76 9P12%:IW%/( HIA+2@ 20\RA* YFRA#FE8]H,.K6EM2NS
MF_=M!;&=3^X;N(%7PZZXFI^L$=A8JJ[(_AQU%X!\NN]6XX[JU+L@<>CJ.]WK
M9G>J<CW_4J[XAJT_ETT'$I,/'*121)A+F!"J]O5<F1?"D@R&*.8QXAG-A!4I
MP+D!IF9/&AG-M]"(Z92C?1;(RY;$!SP#6XT>R%C;B6OJ7[ )ZM:./5 _'=J"
ML\\>Y;N_IEG[C5^]KI\?T2GMG.L.X7$<4IABED 41!A2+ *8B8"$E J>)Z$+
M+7#GV4Y?\6C<P(N=@&ZN01<U.P^@)Q8#?[(?+0!P7LM/J.ISR>X^?M25^81>
MAPOPJ4OZM*\TN4<FA6(N2)JA(%-?84B5#T]P"+&0$N9YBE!&N:1A8-^*<O?@
MJ:VKM6A-+I!3X\$.6!8AJYX0#/TA^M#>I85B/Q1&BO"\+2JV6%5-I42QK ,O
M9@="5YMUDYOGK;'A,1:7FQ1VKA^QX>"QE/O- T_\W6-^:8?W02?OO2^>Q9RA
M.,TCY? G$<\A4C_"'&,)628QC44N0^QTI&<[\-1,EWI%DB:*)TI!Y/H"]^=M
MB-OY&D/@.+#].Y\Q6H=MOY""S^JT42WYP/FA%[ :/#GTU-BOGQEZ 1&KM-!+
M]_>S4N\>GQ:K%R&:K=#I&OPMDZDIMZ^,U]_]^YM5M?Y]M?XOL=9=R.^7Q3\$
MKX\7WJ_*YE?ZNG".9)K%*,\ACQ()U3\(Q#AA4.J,4\F"D+F5\8PK_M0LYA%I
M#.E$J%K>;4U@MRRWBH%JO6)_-]F!6U81I@!P,[4COS9V!GNZ+\/ 9O\D#<SN
M)*5#JMVRPV@M];DK>-'58EM%9PU'C#F;ZRCK;Z%XG3GRN=R,K,&HB];KS,[A
MTO=*4HS,N[8EHKFKJLUC36&C4P:9TNFOJX5ZC%[Q=9?%N5H88Q)A ?,PULUQ
M4PKS-(UAD&-*4)3$'.-1N-;L99[:4ME*V2Q_3Z4.JS]O11Z)+LUASNV6O(G-
MY(CK7$]:M!V_&>AH/@/;]V.GO&D-/ $6-/>IF@3SF8/8_QQL9^[SX(WAK,?0
M/<^Q1%4)L6TMN[_[_&/)BXKI B/!W_UDZM*:(WLN2!:*,(E@R#4Y T,,$I1B
M2&7(>9ARCFCN5E/22PXK2S5JY4G#DM&0=Q+^WYMJ[9Z_WF]2+ _4!@-ZK(B_
MEE_37;;=D(]C7UTU0*T'J!7Q>%IW"XY>S_5Z"3+N"> M6!V=%=[TL!ZGBF^%
M%&4I^'?RLVYS>LCM/*<I37F &=3L[Q!)&L$<!P***(TCPFDF[9J4V@TW-4_;
MR.>>$V")K<71I%?$!C9?K:RFF*>6=E9;,&"35- '08?C3:](CMNVHTEG)PMC
MNIO<=+T,-P>@ZO<_='S=%#_S=A;6:A9,IVM UNNRH)NUH=18K]0E.F6H,#^)
MQZ=52<H7P NI;A3F,=K,U2>JW7??U^&J]4Q</'*]_I3Q#F*M-=H[GK6_JZ?_
MNUK>ZUQSW=RVX>!0#_TJ6FH;37Q6+%GQ1!8?EOH(YON/U3Q.$Y'*/($TI RB
M)";*_14<8I8)$>9<1C1R"<_T$6)JJX!Z^2)'+[</])9.[L" #NWC*O&AEM_T
MN)YM&7^:DUPEK$<_]@:HO+JQ?>08UXN] :DC)_:69_7S88NECD(LZU5.+8E?
MU"O7L(K<+9<;LFBB\.7>1:)L@_/-+A/A/"<91I!IBX=B02$5<0C5CE]$.,YI
MGEJ%IOV*-35KV-*U$*-"R](B&E4 :W41=0N/Y@^61!6>9]3.PQY_GH;WQ+5.
MH"LOT%II>UO/7JT8:#4[N%3]HE5N=BV\,.3\N?GWX\_CR Q)^Y^<+BB]^MEI
M?Y_H38%Y(5AWEI_4&!Y]>K_H7_/]/8TVZA[!+T*'>PG/3^]Y@MPP:GZ6W_39
MY&\O;Q9J#[JCN,RC,(IRSB".L XG)0$D41S#A,8LY32/LBAU.OV]/-[4ULXM
MX:C.25F:5MIZS\Y6CX_J@ZR/<W68?5N0+GZ*DA55W2QKLZ[69,EU8+B^M&V?
MI1--?Y#2](QQ//V],E^6)[?^9F'H4]<.XZN151^Q&FD'I1RU!,CK6>>5(<<]
MI[33_^B,T?*VWA3MIEGAWXKUPYN-^J(>1;F-MG\5SV*Y$;M\FSEC04ZB+(:,
MY12BD"90O6,48I$*SO,L5B_?_%F4=.7 V^X@@,M7U!5CN(^I$1'L$C*=>=I=
M)B!F*,X2(:!F]X.(92&D <IAS@C-8A(R2:DC;?Y \(_2',HLU[H77MT'1K.3
MU%29M5;;R.T+(+6O2,5]L=2M85IJ$Q?VH)YS9K=^##<3 R\GK>#@AY(<M*+O
M'=BV'\G7ZQ])'^[]'KAYIN-WD6!LAOX>Z)P@[>_SE+Y+TN-C8;(JJKNE\>;5
MYRJ6K!#5K@!NVSTZI!*E<2X@1[HX6R8YI DB4$HFDC1/<<B<4BF=1I^:/>P(
M;_SA/?%!IWS0HN.TA[FQ-7P#(3ZXW?,'=@^KUP,TOT;/18"1;5X/;(Y-7I^'
M]+-X7\H5TUQLNHW=AZK:Z'-LY>[KS,'J#TWK_<'T3"F>A1+E=,ZA#G14\S@A
M:9+E(10T)A"1((!89A+*F. (TQ2ER(I*TK=@4[.3K5[U(?^3>NR#J3,_#$/4
MG.KOOGWYXF8FO4VHG05]C6D:V+BV*LU JY")5AB59J?SP;OU475C2.WFU[V$
MU2_J&))'Q],WZCZMLS?91C7<OA$]M.G>G]_/W/\NUFH@Y4-_7%75W3,I%J8I
MS.J-,3TFRO.P6JCG5;HW'YL3S/,D80B*),R5BQLSB(-$0LX91W&8ACQPBA<[
MCC\UXZW$!VKYK8Y2NKJFNU$ 0$"U#F[FVW6"[*ST@+ /;(PUXK7HX!<M_*]@
M*[[&O58 =#68F4:BYV%W-K8]P?-I4UU%&-5T]L3GT$+V?4Q/1I6V"N;#\FFC
M4_^>Q2)L2/U%%H:8JXD00MD[Q.( YAE)84!Y0-0.7[#<:5]_8:RI&;C_W*S6
M@O_KOX1I\.]?=%VC#G#6/]XQTU/]$RG_+M2V\Q>C1OVG\%='<I4+X-L9-$^0
M#FR\=@6"RI<T@NJ$;"4J" ?HK&"!B5>JE O#C<N.<EWO(T(4BUM\E'-TV5_G
M+&:1""2%4@.**$D@CO0I5A2@#/,L$IE5Z_7K0TW-JK@3/EO >=E0^ 5I8#MQ
MLG)C$-!N*=CH"][_'XHU> >;P>HT3DV 6XW&WA->L3[CE":7:S-.WG&CZU<_
M6>VW.S4?GP31T57^>?E5L$U9%LM[=<'O*\UZ5/]HFM;7[(XXE52(#$,L8PH1
M9@3B/"0PRB*$"4V3*+0JSO,NV=06@*XCM)7>G%QTY7?CVO0_G8ZNYYB3-**C
M>L/\]'=9?6$YB(-[LW"OXP[[PO2L\^QM@+[=2%FI*_;>BOJ_'Y9WS-1G5U_(
MB_F@:1RF+.=J9I/ M#>C,"="P)A':8*)E''J="9U=<2IV=U6//!4R^?:K?0:
MP'86TRML UO"5E;P2ROMKSJS:PODERM ]FAT:@F.W]:GUP8=N1FJ)0;'[5%M
M;QR9D.W=_VR*]<N'9;4N-W75G28B_OY EO6A8+6EG/NZ6BS>U]TVYXE(.8HE
M5@8J8Q %<0B)R=-G,@QIBF.:./F3XXH_->/W^S:_OSYF&XF7K=_4VUG2Z4[H
MP&;9 UM;#0'H8  ,"&"M4&C.ZJL.O:GZY\$+!/[4X( &'9_E":\RK9-@=NNG
MP3\'R=M-L^.-[^TV*?JMFW]MXVUW;;CM,*#SYD'+K=;KNM"4,2(%23F4:9I
M1$,*21@2*#,9Q7%.$A%D+BN?JP!36[MV;BCONJ$GXIANJYKSQ-BM2T/"/?#*
MLA4=;&77L??#@+P^P#O:&5RMS79>"?H"Z=.6.\LPJC7NB]"A/>W]G+[-8>EZ
M9X--=\$,TSA@)(.ZB1M$A')()<60,Y;0C#),8B>;=SS$U*R:EK#C@#DU:;P
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MN_WZ!&=Z8#?2J .IU@=T=>YZE#JUJGM=ZT<:S=7>O]9]KQYT!EK]00, :!$
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M!ZQ\CO,42<XR* E2^WP4QY $@D 22L'21&+"J%V/)>LQ73Z/<5HLM2(#/:E
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M\0:JQ1(6],QIAC//=83.)]>YFC HWW7$9Y_SNC[&3P+?_6*6\]=-8?IIHL*
M!6$(P\3(!P0BA%C%!$K%,X[B" >94VK*A?;&MF+QG8RW#Z\=:7D$K>]]CB/)
M=96UX%O]7V,V*.WN,8_N!$)]YLOM-_FF>7$G_+^4_W;JMN[E5+<UOQ\,A4W3
MD"&>!!R2@"<0F6,HK/0T"@E)<"H%P<2Q0,Q!&V/CD*_\28KUK)P7[1X,@%9%
M=/"M-+Y#<=5]B.TXY4K@>N813YAU*K5Z A7?=5;WFQF\R.H)/X]56#UUZ14Q
M4ET*/[_7\Z'5:^L%*!-T'Y[HO#Y,_T>9 ])4@]ZKGEC^\IU>"'V@^;)*Q8PI
M9I$@(4PX0Q!1%4'&I8D8Q4F6I2Q.A--Y^&@\&QL'EA9* 7[)YT L9C.ZK*94
M9:KNKQTBKL8 LDN UACL'1._7Q_/5:&S,QQ4F@TK#= VVJO"R @15B@=J9U;
M7@(,5,!@U4LDV)CZWWO@V"B<&S[.;!1NGPM+&Y6!'?=EET8Y=/5ZK^EC=3,O
MS7LQ=KTO5OFSV=7\O9!J/?N4?Y?%E"L2<20IQ%3IU448((A3&L(P4#*).94R
M<5I=.+4^MC&W/&=Z6LP$R)]-M9NRVS4CRL9VL"Z-!S-CO>/FK%.W6&[-]@5V
MWQNSM=T34%I>RHAL;-?CU ;NRGSPZ2S<[MNR76#SNBGK9,"P6[)=L#G8D.WT
MD [B'!_G?/$L'^A/650%PN[4S5KD)=D:)6Q9%%.9(1QPCJ!,$8<($;UBB<(,
MAIED$B=,A"&UENFP:'!LI+:M=J>D*5 ]*XM9K\S<C9:FFYG>2VV\@S*%#?;G
M::P/1'MFKLI:4)K;E&,TT-YLD+SO!TD'M0_/B Y>E+%Y3<VH\,MB^>O)E]67
M%(@#8&=%06R>,YP\B(-7.T(A+O=U#;>9Z;\NC+K]=]F:8&]#%+;'/3@F/!:A
MYNQ8!!!EC.OY*:,PR"+]7TWK*$5N0F_6;8^-R%NFFV6_[HEJ?NHJKF8/OMTL
MM"=(>V;R':MW-E&V=H-OO1R]=0#,;_B3??,#AS\YXW(8_N3^"*^U9#_.OYO5
M8KO(XR9T, V0*2&@8,K"$"*F$"29GHFJ" =A0B*,$J?BB^XFC([23.E3-5O\
M*(!Y'?3@7IONNZSLN6ZQ8[E^P>Z9["Z4F=TXT2HSVTO@9W<0!Z@\>\Z*,52@
MM4#)LA*MS9.N%NHM-TN+NG9I(F(E"-.LE_$8(FK4RR.6P9B)+&082Q63CGJ]
M[79&QV\[LKV[*KOF8*_Z%\?3O%,8V\[6KD:N]YE96RRW,K)7M=QC./0DFKO3
MU%MIYQ[S]XR$[M'+.]*#)J.;N3#_,7N"W^G,+&!NJDH+FH^J0^*0)#&+ PK3
M4H9*DAABAA,H,IR8<BN1C)QB#*Q:'1UUF.':;(%P\X/<VNU(%E:(6U*';QS[
M)I(&PO*'ELD3(VG>6.W[\-H)):\T8]7PL*3C@L4!!3G=W.'TH/.)[[W4;^A\
M11_EG;K;"N67;/E/^C-_7C_?KI_7LVH56JKX-=5HIS(+J%[I!1 C(2 BB?DI
M0)"F1&(9X2Q 5AM:;^;!Z(AR8Z?^UDLARKRI_*MG6//-MG)K]E4)&;UL,'#8
MJW^3=\;B&&7L;T+/5&\5'?7;V>BH+1#@3H$6%-5,%-1@&&F2S0M7*Y\V@(S]
M/7(X1!K[^S30J51M\2&-K)[T%.*9OIJ$<K[Q9_:ZK:%B/#-_GP/*N1Z3RIST
M'_GJ2=\KP8MN1D]#"D!;/&2>WRZ\PJOZS]7ZT==IUUOV[-GCLS<Q;+CSN+?$
M?>> [TT-Z;9N_"*_R_E:?M"(-G4,_M!?TNU:?QG/<GF_7(@U-Y$F=;WS]S]7
MVJ]<#_.?\F(U18QEBN$ AG&"])P+2SW=RC"4(4DS$E 1,>FRH+S.G+%-H![T
M$PWS+"NOW-:75_:,W<)S.+Q[GJ;4CE2''8TKU:#0.#,!M3OERK5V"'S;N@2,
M3Q[WY/V ZW,A>Z5%@ZYP_:"WO_3U]-1N9'NG)R34G [LRJY,4X952*6A34DA
M"D(%:2 5)#)-0\PYYE*Y52 ]T9++!SM,A=%[_3"S5"B+[942CN7Z<E9;['Q*
M>0IB.SKT %O//+>Q\$"$R1]O74#!)R&=:FI0IKG@[SZ%7+J\8R+BFA6YR.GR
M]6Y9Y3W\4ZZ>%J(Z4932J"W<J7)&J&>1!Q<WEU5IMS2FB4(T@X(9;5UAY-E)
MFL)4RB0-&=/$@MP(Q:=YXV.AK<$FA+?.YJH<!(WI$V!\-!15[5J8C+!CMS77
M=TNB]OH:V)'>6W5MWQM7;]&G[@EY/8#O-:?.IWW#IL7U@.Q!9EL?;5POL?Y9
M(U0K6 =8JBQ+]%R2),(4'HH@4TI!'J8!U1--$5'>565]V\S8%MY;F091:E[/
MY15BX"TTPS3B3* ,AHE16L,1AYA$,<0BSI2*5<3,=L=B16>#H;EI[,^'IMWP
M=#U&/0\T^P+K[W_RV;K<91Y*:OT0EK[4UELMO9G@^J&WYS37CUQ]5:&WXHOD
M,O]N&/NS7$V%"&)NY)2EV05%6:J9EN(4LI0(QF.58N6T 7JTE;'1:V,D6&ZL
M[%2X;0]+.SZX&J&>Z6 #SM; ":!*]PNXF<T6/\K3*J7GEK=+*?)*TLU[@;;C
MZ/10D&VOH;<HP';<UQ,%UTY<W"'&Y7ZYX%**PFPEED0C5R:2SW3O[:)8%5-&
M!$X82:#D)(4H403B*",P"L,PB5%&0V$?CW*IM;%11&-OG7U0FVI66ILYA/G+
MYA?<..%PRG\1?8O(#I^8]DPJ&SB-K?4\PZ0>-/:"6]_X.40T^,1QH.B#*_%T
MBPNPQ>?L&?[%APQWWF[KS\[9N/5-':CX4\[EO)";Q,W?7[3%\U6C7EO7@0T#
MQ&-,*%1QI/F8<0Y9Q"7$,0U(2DF0)593-?LFQT;*M=';#-<)J.UN0K9<*,0.
M=0L>]HYEWPN^RS!>+KW;%4\'7O:.ZT#D?,UKZL;,3@B=I6>[)PW'T4Z>[1"U
MVYW=UM)-\-([6?WWX_QP>CYE'"<:9P8)2S*(XB2 -.,",A+3E$N:AH%T*VM@
MTZS5]S!H+8.K5]M6:-LMOKTA.)BH3!6O_DMC\*\F;/3($MW?"MP%(I\+<JMV
M!UV?NR"QOUQWNM>')/BG?"X_KN1S,4VP1(CHA3K!6.IYHJF@R"6"6<CB!*LL
M(G9E%"^T,[;)X3OGBJFG +2C$@^P],P>>Q+?X)LQ$I16]B;S?8!#?U+?VZ;>
M4.[[P-_SDM^'EW>,MC%'LD:/4G]8U5GL-.8A3Y,TA@2%IKH(99 I1B B^C=)
M)"+!J,O9WF$38SO7>UAL4B!J.__Z%QR%V=_+I-@S$66VD(HDH3)1>M[&E( (
M"P1)R"/(19Q2EE">IN'TI=1N_;JBR]40P.XWUQ^\O]%9N95$5X#)QWQNJEN8
M/<_*@JO!39,L8RD.(4G"!*)4OZI4J!1&%$6*DR2(I:K!?3^WG"#[@+9I;!!@
MY5QXA-1NX+H.I)['K+9Q_Z,)7[I9K98Y6U<UT%8+O8HVYZ$>@YA.(N(U%.FP
ME6$#BDYZ>1 6=/K*+LG4YFEZ/JR[+/\NC?)K%(19O1V44$R22&$H:1!#E,02
M$I6D,!4BE#B4$FF*M4YZ/M/2V*:KQK)2Y-@E-?0<DA8;E;[P&8(#P,;.$B50
MXM5A5_(L9BYIKYZP&V@/\HM\J3(3C"ZJ6BR?JZ1G([Y,\W(DUSQ:8EJAG6_0
M-OFGWC)*+4 [G_EY[@$#9FA:^+&;26ES0\= R6UJB4GS.9P%) E221 &$,<L
MA0AI<J5,KPNDHF$4!1F+(N84Y'>AP7$N"UH9.&6^G*]EPD7X[29A/D'M_;AH
M%\GWYU%SCP2TA,)K3."E-H>-#K1$X"!.T/:^SA&#5=*V%&7A$I,4OI1/)I_P
MNZS$H$WPUV>YNE,/].=49F' :)#"@'&DYW+Z#\P5U3^%8:(8S6*2.<82NK0_
MMAE>RWRP**LI\;8#9LC5'C@''CIUB1T9]0ATS]S4QKBJ6+5C.ZA5^7\QYO]:
MA<CHY;;VP6O$8A?P/,<R.IDP=)1C%WR.Q#]V>DSG ]Y*ZOZ8^#G'"JD@B*",
M$#,[K7J"%2D%$14JIE3JI:O5FM6FL;&16KO,A?,I[FE(K4]OO0#5_ZEMC5'_
MBO$VD'@^I3W=WM"GLQ<]/W(J>_D>-\80,I^^UZN\U>N-$*8$QJW^\6[YL/@Q
MGP9,<B(I@BS$FAZ$G@M1%L<PRH*$9X+A%,<V1'&FC;'Q0V4FJ.V< &.I240U
MMMKQQ3E S].$)YAZ9H=."%GS@@4&6SHH&CXH)/_;X^+[O^F[*RK0/^PSP+DG
M#_+A6[C6?.\VEW:;&+Q_?IDM7J7\(LNI2&L%5B?+33E)&8N$^>A)IN<$ 8:8
M)@*F3$C!DIC+V"EC]6*+8Z, /5-;&J&[%_JJVZRJ-2TKXX'\:63%7*<.ET&W
MFS]XA;)OFJAMA0UT+6LG36:FOWF$-30^)Q.7&QUT1F&-P?ZTPO[&;J2S*0#[
MV^OFQ_^9RZ5^T-/K)_E=H_(S+Z8J3I.(RA2&" N(4A3JZ08A$.$LE8%*:18Y
M,8]=LV.CGVW9:; QMN2@SS?_";X9BQTE32S1MZ,@_YCVS$/7P.G,0F[H^*0B
MRY8'Y2,W-/9)R?'NKO*;Q6J9<TUZY>[S[_-\57SY^GM]O$IDB(*()S"+X_(D
M*H,L0]C4; @0)0BA+'53USS3VMAXZ/=*',7,?1JKJT,HL#9VNXIIGL-9!#$.
M&&50I2*"B 4*TE#H<4 0C"(6ZO\YRF5Y0WH8_:LOO4-LQ^[>8.N9U%MX5<?_
MI:7@%VUK\>OE*(L.2J(6N/@5"CW7X, ZH!:^'\I\VMSD0\73)*].,48LY@&'
M2@4!U)PM(<5"PI1(A0(2*8:L-JI.-S$V=M[J4%:"G29__QJESA)&.Y*X#IR>
MF>% G_/V'#!72G.V?>]/E;-LY0T%.=M>GM?BW+FR8W20+ HI3TA\-CF0[];R
M?TNZ_)!_EU/):)A&2$#&F#!SAP3B1,8FY#U#F2 Q=ULTNAHP-F+0KU12KF_,
M(:,L=6\< X1<>\".-?K$M6=.J4R?@-/:OQ,3C<@DN*>YF #C C ^>(PQZHB>
MUY@C5QN&C4'JB-!!3%+7YW32S7C.S12IDCIO% 98@J(X00F4 F.().:0L) 8
M1HOCD/(PSJR*!)YN8FR<51L)BMI*)]&&8Q">IR0_P/1-.C4FC8'=%"V.@>.D
M8'$E2(,I5NR^0+[BO\_Z?T&/XMB=0^I/G+%\3V_BW)7=9G'_D'/-G[.;N;@1
MS_D\-Q6832#Y^^KX;(H-8#)C,$5FPX=*/6GCA$(69B%.6<89H2Z3M@OMC8WO
M:G/+:1K=,=AMJG8)9KN9F4?P>N;$-FZ[MH+:6'\S+DM4?$ZP+C4YZ'S*TO_]
MZ9/M;5TE(Y1<+J5XH#_;L>-UA?=I*!1#+$X@R50"D6 8DE1)J A.<13R2'*G
M;:#SS8V-51IKP8K^[%[ Y0+$=I3B#[B>&66#F0EVW(E0^,=R4>A)5V.S5\$)
M&W#\ZDZ<;7%@^0D;[P]5**SNZAB>D,_IG.>FIE^C<U&>B',A<2"3&&KR2/5"
MC 80!R&#&65Z\I*D/ N=Z.1$.V/CD8V9.]HK70(/3N!JQR$>T.J9/+H Y1Y2
M<!X&KS$$)YH:-FC@O+\'40(7+N_&"*9PY)VZ$8L7LVZMU\T!CS'G^OO'(>$0
MQ0&!-* $*ARS)(Y9%D7$A0Z.-3(V+F@J:#96@F_O%L\TGSLRP5$\[6C@6I1Z
MYH!:%:TJIJW7)70I"O#[BZ K>1DK9S(X!X9/)CC:SJ T<,[3?0XX>VW'U%'=
MI2*?K<W2Y:OD=?60JK*(%%7URN>7=;6O=:?>TZ71)"CNY;(L,'SS;%Z**4H3
M'! 1P0 E>@(1Z94)CC(&)<E"+,)$_^%6G,*'56.C&.,4;+P"Q<8MQ\12+QUF
M1TF#=T/?'-;R!VP= HU'35'?C4]F1&B\ MHM4/HU 95G'E-3?0+M-6'5BV'#
MIK'ZQ/(@N=7KPZ]9Q<G= [MM]2$].J]*/>4[M9DSWB^*W%BT5[H[#EB6T30R
M B091$0%D*64PH3H-6 6D"1(.ZS[/%@V-NJN':M"D":;/:?7"9AOO)N HO'/
MT(;:K)E>:A>[K"E]]+++*G3@OAMDW2J/1#%\;G7;UW:W;9>ZC7=]%F[W#KK_
M5;(/X]Y@7>T1T^,K<9\-7#\._"'SQZ>5%#??Y9(^RB_RN1(/*W]I*M2%TX1%
MB@<Q@HC&FNP#$WN>:-JGF8P4"_62/U5=R?YR\Z-F=,<IN"/P[OSK%\YA2;:Q
M'=3&@XWUU17 V-\/@]K#UA=-6ECP9EQHC\XYPG-X2C=6^R==_DN6 K+;^?56
M?B32Y!403*$*D@0B'AC)?!;!C$@<TC#A&;<*&;-J;6R<M36VM7AUHZ[SZ-HQ
ME3?,>B:FHW#5A=5!+QHO5LCXY)[S#0Y*-5:^[S.+W4U7%&J;BSK5^XLLI$FH
MU/_RSJ14+E[,%*V)!7N@RT>Y*N[FYHZ''XMZXY['2)&$41@C&4(D(F2"[S-(
M$!(LU?,E@JT.0OR9-#9*:BIHF4 EOM#SW^)E,2]+4B]K[\I?B:U_F]#%B5XB
M+XM5I?DI]5MFXCE*GSN4,KNNG\_SWMOT7L_DN"E]IF&O/0*-2^4_MIS:AN;6
M;@'M5WF1]NR: G37]5J' G6#]=[PXM&K)[V8Z?XUEH6BS3,./DHAB_QQ7KX@
M]??I+^C88Z]8%<V[KJ7AB^IY0>9HT3T_3^Z8UVHRMLR&"2V>*J&W)HXW3F.:
MJ)C # D,49S%D!+)3;T1A%7$14:86R6^DVU9?<V#EM^K9%'GBSDTQH+<5!]R
MS'0]":S=S/XZL ;*>RU1JHW<R,;6=O[J,0'V$A9>\V!/-C9L.NPEGP^R8B_>
MT#&M@N9S(Q)[-_]*9_).W2\7IB#"J]'G7QG)[)*DIB@,F**<:;I(8X@R82II
MI4C/U-,DH#3 <4#=Z,*NX?%QA[$9+.9 Y'K(+^BL.H'ZJ<=L6A364VI'^.U(
MQ2.D R5?:(-K(6H#Z;L2TKP)!VC,+XN=K,#& 8\)&4Z ><W+L&MYV/0,)S0.
MLC3<[NXH-5EJ^)N#_\5</ZT*AIMBDH44(P%%G.BY3((%I GG,"(X"Q1.L@0E
M3O*2QUH9VWY 70=L8V7',,KCB-KQS=4X]4PO[A"Y:T2>@\"K+N31AH;5@CSG
MZX'^X]F+.^PSWBYF^N?%LESGWRR7NJ/+L]_B1HARR*"S.I7^87''3$6GUB)+
M+ZFT*<]R:8Z(ZX79% F49($@4!$5Z3D-T4N@2"*8\"A-,,4)BYGUGJ-W\\;&
M-U5 E1F7Z<8CH*1LUS '/Y[DO-Z[ 'G1WM"H-DH:'S?[)ZM%Z_)'C9J^UF%[
MR_]+8;%!^:9=W3-E[O@&VLY-P-8]4/MGNJ_R$-"=;4S3VULW0>WGFW:LPQ[F
MFW;P0/N9]I\S/?U!FUW,$Q^U_LW!APW6<TWV0+/5<V%:-A?1QZ4LP?6UU=E;
MYYW=]O3?ZG!;H+TAMK,=VE\K/O.^37!%/G]LVS<53(8R31CD"=;SA$!*2$D6
MP(2$3&0T1C+";GL?UFV/;_OCBPE*@0L%U^;TH\..ASWN=HL0OUB^=8IX;??.
MR-MWFO@9K/K/&#_6^ B2Q\]@8I='?NX!5Q/63?G=&?GJBDUGL\4/$S<VY0)G
M)G<4<H8RB&2*(4.(P2Q4(0TY386(.E/5J5;'1U(;&P%MC.Q,4B>Q9C%.98P2
M&""<F(*.1G HC"&C.$UX2C,AG7:=?"$]X)IP$)R=AP$?Z TY %3V3L 6S9N+
M:%Y#_9?PZ8GT3S;[5G1_"8<S1'_QUFX4O[-GKN>\FVWSSW(U)5+06*_-8*0P
M@BA$"&(9)9 (C/3_44'2P$W1_EQS+A_+,(+VF^,@L_*4C:D3,)>.*M5G4;9C
M&U_(]4PSC9F3^@BM*55=(_?Y#'+.!&,#B4]F.=O>H)1BX_D^EUC=T[7JHB:H
MCT(_*U<Y+_GI\[H,XXMBC$5BBB%Q1"&*PPQ2I)$-4AJ2E$@>$2OM@(LMC6V>
M4AE;#K:[YH+*7M<JC*< /D\>7F'K^^BL*V(=JC)>0./JVHRGGC]PA<8+;A[6
M:;QT0X=#M'9^45F>042<4AI%4"5&ZCXBH=G;"J&*..(\RA+&U'2U6-&9Q1G8
M_M.=:&#31G\O]4XFHD-YB^/069P470-(SQ_X7B[AV9(6-N^1_>G*-: ,?CBB
M#EX9<SZR>)SG_ZU7;^Q5_\)HNY<QW<TU\U) T-=YQBFXSAY''-PTW&G"*7MW
M#@-.7M2UY-IW.5_+2A2D@O^/?/5TNRY6BV>YO%_,<OZZ3;Y+@YBS  EH2DY#
ME$4$DD1F,,H$R6*J&,)6!__=FA_;Y*BV'GRIWFMW_0Q'].U66/UAVC.Q-G#6
M D>5Z>"'MATTQH-OE?G]I$9V0\YOI3$G"P8N/=8%G<-:9)V>TG'C/R_X;%&L
ME_).F8 J.2_*\:].*S'\692:1[]I-A5-/9'M!Z>RC(8XI5"BE$.D1 2)PAGD
M <-4)%@E"#EM5%]GS]CXKZKV=U<*_;F>95[9,Y9;V\/AW3,WEE9"9LS<A!"U
M3LC MUX(T1-^7K?%KS1IV"US/_@=;*=[>FPW4OTL5U4:C8E9GV)"A,CB"$94
MF&5P*""65$*].%9"L)1DA-LL@X\^?6S+8&T<T, [<MTN8 P%<4(Q@@D+3?I@
MD$!*40P#05 6X(#'2>8RIG0';( 1P@=@ B$L611#$F?Z#4,TA#@+$119F(:2
M24Y2Y78R[P[9H&?P/D"S&Q\[OSL]CW8&@29KLLIQNEFMECE;5THIJX4> Y=>
M\YF.(N%SW-IM8-!1Z*AO^V/*\8MZ$?^<2LDC'*8$1A''IC*,A$0D"&9A$-&4
MJ8BE3O$?%]H;&RE6V<&=:\)<0M?NT_>(V;#[K4<%,@=3N^R#&BXU.29ERE/T
M87M;-T+1S+0T3WXGJ_]^G&]*@M[2EUQ/_#8ED0@E"<\4@U',*$1,8$C")-"S
M+46IIALI(Z?IE7W38Z.9VR>S.BQ /@>+3:W<*NZX#&=H$="_NS&00W?8D5$_
M(/?,2XW1X)?&[%\-UMNZQ+7IO92M<D?,)V,YM#XH>;FCLL]C'9YPA;Y,*^KY
MMAZ]0T&B&(D0IFD:0F3.6D@L LA9++-41HFPDW.[T,[8R.K*.=$I-.WHQP-&
M/7--!<].OL.M[YG/!12\2\D<:6IX(9G3_AZ5D3ES><?2-M]I/C.+V@^+I5%_
MV$I,?J#YTH3)RH?%S?-BN3+'YF9G[S=:Y-L*D(IF62P5@H&* SW=B3AD$9)0
MH@2'&<NXBKE349OK[!D;K;3D53O7LKFRA^PH:$#<>Z:J=Y*M6EJV$[!Q#:K%
M$A;:N0DP3I51^^5FSL:O,IBFE_F2)WR]EJVYTJ1A"];XP>^@5(VGQW8(Z+NG
M*TW?Y5G)?IP%CE."!4UAE"%D%/X()"H3$(<LBD.6TB2Q(M4+[8R-+"M+RV_0
M1=[V#)#GN<\C/#US6AL9IQ 4)[0<(@']H#903.#VN+(43=C6:'RI@#01@"\5
MPB9,T)MTZV60SD8"GKE]N)C RS[L1 =:7'[%<M6<-2_EDZD.\UUN3PL^R]6=
M>J _IV%"J PE@SC@J=E[BZ&F4@8IQC%3DF(:8^>UZX5&QT:BU4J-MXT&>7V4
M90[U3JM_=L?=897K$<U!EKP[]NZ>"9996(91M-V>5\&6*'E?$E]J=_CUL242
M1Q?+MO=V3>IGJVV9Z=_UJU3/$N^7\CE?/T\#+D(5,0151O4LCB4*8A4C2*7$
M+!.QDL1I:7RIP;$QT0WG2UDF'BUK[7R]U#)1^3,]VKZ>E0/M!K@=#?F$<8BE
M[-;6"6A9"VIS?>:9VP'C-\G\0IL#9YC;(7"87FYY7X=EHGGV[>*[G-/YZEXN
M\X4P%>VG7$G,:1)!1"-BE(U,?=(4P2B*4IZ0@*+8*H3A3!MCXY/R:VC,G(#*
M4/#-F.JR #H!J,52\7J8AN"+WA!R6!Y>C]102\-CB'E:_IT'X>S2[\2MPRW[
MSMN^L^2[<*E/O=BZT,:[C91A78'CCLWRQ_+JPLSY9E+_JL[K#C$3,I%2$R..
M-4]B#DF ,YA)*@,J$-&_O%XIUMVPL9%K9959S=3%;L!B:WNYG"R--Q<<UKKQ
MH0[:H6\M*/N->JQGGC\G]=I4G]IZ-FE*4X&6<V#CW<1)2<%[)_H0=^VW,P<:
MBH;M5$_*K-V1[Z;)VJ&]$:BQ=D?)3H?UBN=WV_LHPRRW1\QAR,.8!2F,@]BD
M*88!Q$D8PT1D 9(LCC)L-<@>?_S8ALK*.IM38AOL[#8MNB/2\U!D#X;S?L1Q
MGWWN/NRU,.A>PW'O]G<63ES5]:LU@A>;>,+RV>_U7'TEM<5WJLJC?5B\_ZG_
M04PCC%42T<CHU1&(J$20X S!0*99F#(><D[=/FJ'UL?WS1OC)ZU YEF5#2 ;
M#\S,>%'Z8+8Y9>F%*S&X=(\M;_0$>N^T4N&]#6:NLR_>M_&^V^!=.0"^K99&
MOX'."NF5B#J Z)>G7 P8F,8Z8'/(<ET>TC'@L4Q :.)S,<*1(AF#-$U2B$@:
M0I:1$(8QCM)4"28"Z9(]O/-T)Q(;('OXP;0!ZHR83@KPN^#945!G2'JFF$:[
MUWL<\U&'O0;N[30P;!C>,=\.@NJ.7N0NB5D_X4-><#K[WY(NW\_%.[V\F1(:
MTDRIU$Q-8B.+DD&2(;W\$ FBD4@"GBA;-<Q3C8QM!E+;"2I#@;$4O#<ER+6M
M]B*8)R$]_RW[ JKO?;$N&#G)7EX"X0K%RY./'DSL\I)S;9W+B]=VV/?_NGYY
MF;W>-&6%_BF7_%__H1FE+F6/J,@D"SE,,FY4M)D>M0,CJIVEC-(P%CBP$D.R
M:&ML'W]I'OB/?] ;4)2&;XLO.6S;7L#78CO='VH],T%E*-A8"FH$M:W@6V6M
MRXGH!>0<]K#](3C0MO07^:(?9W8903Y7B^5SM3]M)+!I/C<KL[IFV 'DI7#>
M]LWU%55KA^#9[>4+CQANQ]C.EYU-8,M;.D;9-DNPND+Y=IN211ASRA(HXU#/
MNVBLJG-4I%=0*I%&ASQT"JT]U=+8J'>[ R%K2QV3U4]C:K=^\H)4SW2[!:DQ
MLI<=X8M0> V(/=G8L%&PEWP^"'V]>,.5W&!B:&_I<OFJ1X,?="F**5$1#Q,-
M(>4F(BV@&!*&*"1292J2(J&!D^;%Z:;&Q@YE!/AV3UB;"[BQ%S0&=^2*0XP=
MR>(JY 9C"V,EV#&S![(X"44O;''8VMO0Q4FO3_+%Z3NZ$<97_B3%>B;OU$'Y
MI9NY:&6R/Y@$S&T:6A3&<<03!16/8VBJ(T&&%889CD,]RPAY% @7-NEHQ]BH
MIG&CC-'*'^=E;8DR9:TNU%X6YIUK0A)-B;(5_=EIF[=KS]EQU #]T??JLM45
M1^K!E>I&+3_ M]*3?C3#KT33)P=V-650@KP2KWWVO/9Q'@4.IR2+923T#"P5
M46R47?4,+"2I[JXL"#.F]+S,L<S<T79</L2AZLN5.Q3@>RGHH#_*JIZ'7X7#
M:W0-1\1=I]0,>U8P[(-OCC?T]FJ%I[CB_,4=C[/GJUSDL_4J_]X2KWC_D\_6
M0HJJRL'SR[K:);Q3[^G2[-D5]W)9"G1_RN?RXTH^%U,DL4BIQ!!+AO6L*TL@
MHXI!F6&5,3TEX\Q-R,>386.;AAF_8.-8=U$?7]UF1TIOT1D]\UC;I9;<#VB<
M:JJX;-PRXT+CF$GT :5KX)MQ#I3>^93[\0RXU_ !7[8-&WG@&=&#H 7?S^]R
M &KJF7S4<,R-%:; J$8JJP^9L HBG*D(BH@$$&&1098%#%)%4AI(DF21U0[\
MQ9;&QKC&LK(*KLN!W3DD;0XZ/>'3]T*T+("SL;-$"91X=3GD/(>9RQ&G)^S&
M=,!98EJAG6_0?M'/\7:J:0':^3/-<P\8\$33PH_=\TR;&SS79-<_M^?B7_+'
MI]6=^KV0Y<+]-ZG? GG#]=NW+G4KWIDWA.=5VLU<U')PU9<@*$Y3%@:0*,0A
M$G$*B20,!ED6)TA0E(1.T^8!;!X;OU=AJ2]':\0#NG*H]CIDQ]M-O$?6G3T/
M1WM%ZR>[5>O+O^UL/X#2;;A04#M>;9Y. "M]!RWG0=O[\BEM__U-V@?L+)_S
M^2','G2J/V _[*\"AFRZVZ#V7BG)5QM!JP?Z\XMNT%2 G?-\5K7X5<^9I-E^
MUJ_\;'.=+*:*LC3%*(8L,O4D X:A_J89S!B.B8@1R[A3X9MKC!G;,%3::8[,
MC&;PO%)V4U)WC!Z<F)Q+E3N.0E?UE-WP,A3^/8\;&S<:@3USEF8\ ;NN3$#5
M2>7YFG&G=;WI-;T8YUY3.7S@ZY/JK[)G4 [W@=P^.7MYYO4';GO<WV+]G0DB
MIDF:!#R 7 EI,E449)E",(P9C5@<9T&*W,H&NAMA]8T/6EO0I/K]^\[D3K2&
MRN['=):=XGZ&YQ'H-SG@.S;%;L/?SU2Z.X)]'1!:6O%FIX=N*)T[6G1\4H=]
MZK*%XF'Q8;U:+^6#Y$_SQ6SQF!O*?=8+^>^5+$F]=9@E.,:!$) Q$9J3105Q
M'!,HLDC20"+!D94JLWO38YMB5L:7,JBE^6#5MA_D+0<<]FW=>L-B\[LWC'MF
MOAK>AP6H+ <[IH.V[5WVQ]UP=M@P[PWOX7?0E_9ON*^=\T[HG=U*=WOB<'OK
MG3S=V6SO]H2.X;]F8_]I,=-W%&8;9?6Z27R)0RQ$F"00!V8;@A()]928PBR.
M)0N(9#)UTND_W=381H"VI?^CW.8^$WGE"JO=Y-8/6$,<;&YPJLP\48.[ETRC
MRR!Y#9P]W=JPL;$7O3X(?[U\1S?VN)W1HKA3?U C<[>Z6Y;,56G7W:EM?,8M
MG<VD^.VUOJZH+RRF$>,)2ZB"B@D"41)3B 4.8!AD@7[E H&$5;*X)WO&QD,M
MN5<3O5*F#O#%\_-B#HKZE%M_8#^><OX$?M2^@&?Z"IC4U\V_RZ59._Z2S^O[
M':N*7-N[=DPW8)_U3(>E)Z:/:AOUIU0M[!N=3_.[5A!<Y1)@K\T-Q>8.CQE6
MGO#UR:37FC0HW7K";Y^3?3VV:UF4O30(_<.M_GN^VLUGC+,H(2J-()=8$S02
MILZPU"P=1 R%B7Z*=)(7M&QW;$1L3CIX:6:5.-HM;]06=#O>[ '*GOGQ2!+6
MI/RY,KNO%%-'H/P63K%K>N#Z*4YX')91<;N]X[K43%A^HX4IY_EL,N3WY91_
M>]U><E\5*KHQ#5<RA,7=>E6LZ%SD\\<OB]GL0V75E 8<29ED,(H%TA/.-(5$
M+V^A7M<**:,P3"*GH_5^S!P;_;5F+^4\TG$MW$]76JZCW[R#^EZ#&^LA,^:#
MMHMM;7HSQ6Q?5_L)2D<GM4"KYN*6L^";<1?4_OI<L_?:(5[7^_U8.NQ>0:]H
M'^PS]-N:NS;ENWIKO1+ J^K>?-#_5DQ)EF(1A0IF^B:(B%!F8IM!'@08413$
M'%E%!)]M96P\WAC:2"_6I:=*6^W5*4^#>IZ2O4'5]S2U"TI.^I074;A"H/+T
MLP=3J+SH7ENB\O+%@Z856,:54YS0- J1D5<S:5XI@DPF'$99PC.2(IYP[A8V
MU*N]_W='&/7;U7;SS+?OOC]1\L"?)VO@3Y<O\']1IL";Y @,DAWP19JD1?HH
M=1.+(E]-D]!L3" )%4TI1-2(]-&8Z'<B)2$*D@A1[*8)L]^$"X4,(P?S/^6L
M//MH*AF:P(9<V%:X.PFE'5U? T_/#+LQ#=2V^2/!4U[[Y*V#-@:EFE,>[K/#
MR>LZQ%E6U9\^;35::$9%A%.(%"/Z#QY#P@B&22@)#6(2)LR^F.G>P\>VHJS,
M<PC/VP?K_.=Z+00]?ZI-6;5/%N(DEZ%PB$6\ I*!H@U+2')C'%@V@8= E>-N
M;LK;5)^S2>:OA6!R/?L#9=#0W\##D[Y^>XT1@%F;?<O5 @B]3)SIP<D\58_'
M99!16Q" %L7"C-GZZE+97"R>]8<.GLM8N<*(+FK#RM86VL#%$CS3^2LPN2>-
M0GIE@Z>PQQ,==3:P<?^>X4(73UB[$YQXZIIN,Z'/<E6E_QA9TYOO-)^5 GR+
MVS+*I1VW],ZHOD@Q#:-4"90$$!-LZDO$*<1A$.D_.,49$TF@4I<3'&<+QD;!
M1MRXE#2F>X%W[4BAV@4 @:B\<)MEN7>3W32L5_![)G^#>YW8^(LQ_U>P<<"@
M7[D VCY,P+L+X#O/Z#H#Z'/*YV[$H'/"SACM3QJ[/ZCC&;@I(E&>F]#9+2V>
M/LP6/SYNQ[I-1'$04))A&D*>F-5C)"6DDB&8IB(($XE"&3@5]K5L=VQ$V#:[
MF2>LZZC)^6(.N78%4).:6D96.1:(L.T,RV-I_Q#W?<[<1M>8#(S-H&5T/R'>
M;D!Y/?^U;'K8 UTW/ Y.:!UO[T_]XO-BKJ?]:WV9YM"Z",:4!RI#) QTE] ,
M(H05I(0HF$4"JRQ42J21;^6+8X:,C=KNI>X@HQZO>4V[M#055QVC<#KWB1VA
M#8%TSPQGKV^QXTA33.>-A"W.@3JTJ,516T8G:'$.L2YB%F>?YY- ;Q?S53Y?
MY_/'NAK(8EX<M6A;#XSR*!$)AFFB_T L4A K%4#"L!($9S)R"W?T9-?8Z-7^
MRZ\_<9NI3J\=>PTI]]I=H^%HAY[RQ,N=<>V?IMU-&P%K=\;3CL2[/[[#&='M
MDPF!_#AO@N>_Z%=SRI3$@4(2HL0$HW,20A8H:G8V TYH3#-EQ<XG6Q@;SU8V
MFLWW3?&CLT7=+7&T.$.Z%IV>:6T+S"9'YHL'8!Q.E*X%:*!CI8<G">CS8CTO
MA?_X\?<)B/6R5(1^:HZ)S-]>RM!"7P<[Y_ Z>[IS],;ACGC.V;USSG/VPBNT
M)CX6Q5J*=V4/5=&>54[)^^>7V>)5RO*B>_V^/-&B%)HNI@D)4LR#"*:*:+(4
M7$#&0PDYS4(]@=437+<CGXYVC(U-&^,.LL+7>CVR!.^_WM]WS_WNVE>6VY_]
M]T#?VZ&5IG_I JA\J /%)W62U 0TCM22])O^*GWQK(+1'4SO$AD=3!E>/Z,[
M7D?%-:YXG'M6RWL]<5V]?LAG<GFK9ZN/B^7K-&4B#!.4P!A+"E$:28@#F4%!
MPC3 42A2957<]\3SQ\9]E8F@M!$T1MJGL!Q#\#QS><"E[Z6Q$R1.^2IG'+\B
M4^784P?+43GC4CL[Y=QEU];;W7!#%0![(GEN5G9-6<W(+$L?Y_E_2U%1S.VB
M6!7;NJYQ*E%&8@2S-"*: D(!:13'D"K-!I@$29JZY3;W9>G8R&2G9J\AZCI-
MEK?3:66UL0NH"6A3,\E751B96608&.C\]:]_T42;_;TPD6O"7&P>,2\6LUR4
M 6F%43U^;FH +S:[#F7:@VEL*9_T;69WRP3T=*T&[/N]LIS2C>%MZ7O2=RR'
M>IO=.FF.@D39H[?T)5_1F?%K8K):S*)UF!K#/?5 /U6(?1O[1G6*>\+\="7C
MOAKLJ 2WC8&JI55IIDPF9  19_H/&640ITD,L8@585DL*':2CSQH86S#2&7@
M7_^B)]Q_+\UT5%L[0-".>*_"I>]]S580Y&4Q7W=ILU.N>Q4K.VAD6/FQ4SX>
M"(J=O-#MBRZ6*Y,\9PZT37'TFEZ*=V4@_92'+!:<QS E')L,ET!_T%)_U7J&
M&84QDUEHM1=WMI6Q?=F-H>6PWI@*OE7&6IX GX?U_*?N#:R>/_?:QC9,EU&R
M_NJM4#CSY>O[6U^]_MO^%W^^@4&^>BL?FR_?[F+/\@F?-OE*7%)*D*!0BH1!
M_0.%3&3F)Q&&*(J%5'Z**GX::_;;-AE>[F3 %PNU^J&G8V6%*D]:!I\<BXG[
M1;-_XFBK"NR)"O13_-L>H$'2^C^]3<%N>Q2L$^P/[_1,00_Z>?6X&2F]NLB4
MA&F<IGJED820I"F&"24I)BI27#HM,BS:'"\)'?EV)L 8[CA5<>F *\FH&ZP]
ML]&GQ?P1?LJ_ETJE\\<RR+<4A_ XF>F S" TU&IV'#QTB(,U$1VYM4L9)9D_
ML_6RH-OHWB^RD/HA3[JQ=_*[G"W*YMX7J_S9;/1.19"DA*4!3"-)]'PH3"#C
M*()<2(*SD"29L$ICZ-C^V!CJ9A.PLZP-+TE*;$T'2NH%E=EB+[?55PNC8+^4
M7)J/T*7XCWM?G2>P 7J@9S)K&[]-5?C2[HB6!Q.P\:%?V%T*+_4*_T"!:QO;
M6N%K)[^&^JRIV'P"1JC@Q->QHZ"P6M)Y85(<%W/PLC3+[U\T-9;I74:1:\%F
M^6/IZ*_>ZCIU[ISSQ9W<'SM@A:?./N^6>>K^F [#6!WD/'\TR<L[2MV?%ZNO
M:_9?^N5Z6&@[\NI4<IK)1+(L59"S0$^M<28A2V@(6<K#3.G?260_B+FV/K8A
MS"3[+QH?*KF%G4( 8+Y8@:+RPWR@<N.) XTZ=Y'%V-4G\#V/7!O3@;%]MSJ
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M1K'^B<0")XHH9E<LRZ*ML9'1QE20MVQU8Z!ST-K1CB? >N::+59M,WN82UK
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M"YS*OS)-V/=BICO*@\7S'[=B/+']9U%RBO,__Z2N(;SSU5*O8O[(5T^W:TW
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M-#!5@BY 78Y>RVH27FF+FV6<O!?\)J+-LSAZ#'*_B,?%@/;S+4P;O'Y1DZ-
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MEQ>SLW,W_3Y"%&L90X <21%)\F"U15><R>0EU<;H_G)TMI+0#1T-AS;[$N_
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M[DE%-T@^ZWNUXVIJT$;Q!["Z=M@2'@:XZ1-PKA0'HH<&+OH$3'"7,F>9W;V
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M!94"2\Y**CNU^MO?@GZ[4RNC8W4]/LCX.4S*0^\ANP?.N([*(M@A!B*AW 2
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MQ74OV:]I>I%^.T?)QMGYNFWVN_3GIB4.OO73TDVCF\>13S%&0_%TB=:#X%*
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MQ#@FB+5WB])_V)CH$+#H% ?=14<- &W7L(CFV5CE%##+%0B9.'B5$E!).?[
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M>$2CHZ.#G7'(U35C9;"VQD!%4#AB8Z' 7-:ABRQY$UA.]JRN)YY'(_:]@#7
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MIS&V"Y<?K:T35 Z%AQUBY6.$TRG>EK?;=GU8*IAU2G$'5B$1INO8HH (V9;
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MD/3\NWJZ+#, = 9F;E]8>95)TZYZ;%<W\>WLM^\UFU=^Q1*N+BXGB=S&+'2
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M)ZMV;9*KVG9DC6U*DDPR2Q",#R!4$$%B\L'NEK9\_.014]_#P^!XWATN^$I
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MEA0NLVWR]KNA']YOMM\LYNOI_'8ZO]Z6G2WFJ[T6_4$T209G==&T3X2IL:T
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MG/$;H.W,9KQ>YKLQ.2=DL@_YV)X-UF'D#V+("D7P!$,$'BSAA$4#/C@%7.C
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M?;'0</N#^B7@*O_G?_P_4$L! A0#%     @ *T=:4GUH-TO4 @  :PT  !D
M             ( !     &5X:&EB:70R,3$Q,&MF>3(P,C!Q-"YH=&U02P$"
M% ,4    "  K1UI2&SJO,>L#  !B%   &0              @ $+ P  97AH
M:6)I=#(S,3$P:V9Y,C R,'$T+FAT;5!+ 0(4 Q0    ( "M'6E*<>[]U] <
M "<F   9              "  2T'  !E>&AI8FET,S$Q,3!K9GDR,#(P<30N
M:'1M4$L! A0#%     @ *T=:4BC?Y!@O"   5"<  !D              ( !
M6 \  &5X:&EB:70S,3(Q,&MF>3(P,C!Q-"YH=&U02P$"% ,4    "  K1UI2
M\ OXV6,%  !!&   &0              @ &^%P  97AH:6)I=#,R,3$P:V9Y
M,C R,'$T+FAT;5!+ 0(4 Q0    ( "M'6E*2:EO=[,P#  *:(@ 1
M      "  5@=  !M<G-N+3(P,C Q,C,Q+FAT;5!+ 0(4 Q0    ( "M'6E*9
MK,?1?A@  #@= 0 1              "  7/J P!M<G-N+3(P,C Q,C,Q+GAS
M9%!+ 0(4 Q0    ( "M'6E*H([V?O28  -*< 0 5              "  2 #
M! !M<G-N+3(P,C Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  K1UI2'TH"8[AP
M  "E) 4 %0              @ $0*@0 ;7)S;BTR,#(P,3(S,5]D968N>&UL
M4$L! A0#%     @ *T=:4@Z4S7;[80$ Z"L" !0              ( !^YH$
M &UR<VXM,C R,#$R,S%?9S$N:G!G4$L! A0#%     @ *T=:4L]SZL:+\@,
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M              "  7U!#0!M<G-N+3(P,C Q,C,Q7V<U+FIP9U!+ 0(4 Q0
M   ( "M'6E)0I^U92AP! &=S 0 4              "  ;KT#0!M<G-N+3(P
M,C Q,C,Q7V<V+FIP9U!+ 0(4 Q0    ( "M'6E(I, 7MA/T" '"' P 4
M          "  381#P!M<G-N+3(P,C Q,C,Q7V<W+FIP9U!+ 0(4 Q0    (
M "M'6E(L#Q"(7?P  -\J 0 4              "  >P.$@!M<G-N+3(P,C Q
M,C,Q7V<X+FIP9U!+ 0(4 Q0    ( "M'6E+W=S^]+(@  'R7   4
M      "  7L+$P!M<G-N+3(P,C Q,C,Q7V<Y+FIP9U!+ 0(4 Q0    ( "M'
M6E)M^4=+\S@! "ZP#  5              "  =F3$P!M<G-N+3(P,C Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    "  K1UI2%G",B.VR  #Z9@@ %0
M    @ '_S!0 ;7)S;BTR,#(P,3(S,5]P<F4N>&UL4$L%!@     5 !4 @@4
' !^ %0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
